<SEC-DOCUMENT>0000310158-21-000004.txt : 20210225
<SEC-HEADER>0000310158-21-000004.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225163456
ACCESSION NUMBER:		0000310158-21-000004
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		141
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merck & Co., Inc.
		CENTRAL INDEX KEY:			0000310158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221918501
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06571
		FILM NUMBER:		21680913

	BUSINESS ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033
		BUSINESS PHONE:		908-740-4000

	MAIL ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merck & Co. Inc.
		DATE OF NAME CHANGE:	20091103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SCHERING PLOUGH CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrk-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:3b02abbc-3b84-4f9a-9655-da3777b72964,g:4abc6098-1e3f-4748-b81f-d8be8057e101,d:ab6577be4c3840fd8181bdedf457fba5--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:mrk="http://www.merck.com/20201231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrk-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV80L2ZyYWc6MDFiMGI4MmNkNmU0NGIxYjlhMjdkMmMxYmMwYWNmMTcvdGFibGU6YjBkYjA0MWM1NjQwNDBkNDg0MDc3NjJhMThhMTQzYmYvdGFibGVyYW5nZTpiMGRiMDQxYzU2NDA0MGQ0ODQwNzc2MmExOGExNDNiZl80LTEtMS0xLTA_ceea1a96-b757-4abb-95a6-48689749c7f2">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV80L2ZyYWc6MDFiMGI4MmNkNmU0NGIxYjlhMjdkMmMxYmMwYWNmMTcvdGFibGU6YjBkYjA0MWM1NjQwNDBkNDg0MDc3NjJhMThhMTQzYmYvdGFibGVyYW5nZTpiMGRiMDQxYzU2NDA0MGQ0ODQwNzc2MmExOGExNDNiZl81LTEtMS0xLTA_39d56554-d2af-4c87-9aca-277655209051">2020</ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV80L2ZyYWc6MDFiMGI4MmNkNmU0NGIxYjlhMjdkMmMxYmMwYWNmMTcvdGFibGU6YjBkYjA0MWM1NjQwNDBkNDg0MDc3NjJhMThhMTQzYmYvdGFibGVyYW5nZTpiMGRiMDQxYzU2NDA0MGQ0ODQwNzc2MmExOGExNDNiZl82LTEtMS0xLTA_fd1b9e0e-616d-44eb-9194-a6d2d644344c">FY</ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV80L2ZyYWc6MDFiMGI4MmNkNmU0NGIxYjlhMjdkMmMxYmMwYWNmMTcvdGFibGU6YjBkYjA0MWM1NjQwNDBkNDg0MDc3NjJhMThhMTQzYmYvdGFibGVyYW5nZTpiMGRiMDQxYzU2NDA0MGQ0ODQwNzc2MmExOGExNDNiZl85LTEtMS0xLTA_10ee7f6f-07c8-49c6-b175-a3c2fe2acee6">0000310158</ix:nonNumeric><ix:nonNumeric contextRef="i72b8afe3fe844c02ab7183ab38cfe809_D20200101-20201231" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzU2_e83aaddf-6760-4d99-a679-17c8ad2698ac">P3M</ix:nonNumeric><ix:nonNumeric contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_50622f13-ac81-4492-afe1-5ad4feaf94c9">us-gaap:OtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_821d9613-2257-47a4-8e9e-6ec850c6c87e">us-gaap:OtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_36307b76-5525-434a-87a2-55d497163500">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_ff6866b2-78de-4484-8932-0849a2e904bc">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_8ad1ce04-1366-42d1-95f3-bf2b967b7e47">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_a770729c-7273-4447-83c4-49a31ce0554f">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTEvZnJhZzowZjg4NGRlMDhjNDY0Zjg3YmJhNjBlZjIxNmMwZGM5NS90YWJsZToyMDk1NDljMzg0MGE0NTc4OWUwMTQzYzk5ZDNkYjFkNi90YWJsZXJhbmdlOjIwOTU0OWMzODQwYTQ1Nzg5ZTAxNDNjOTlkM2RiMWQ2XzEtMS0xLTEtMA_d8d9a076-4f04-4d2f-bce3-9ba225e75d4f">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrk-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a69ae5ef81348d4b09b8c83b9741937_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.125Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib21d7c48408a40228dbaaa754ce181ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93e99ad3baf40e8aa1621b924a2b8b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42c8fd57f9e4140bb466d7b0aec1493_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce73055eb814c269b6620f3c2a24a2e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i525fed88e739475e9bdd2c20f8225d78_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia25c4a8026c741e390c5f222dcb409cf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i16ad2dca7dc9466c926cfba76668c892_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65645d9ce3443819f0f193e3bf67acc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i530838b57a7f40aea997c3c0d8eafce0_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65d876890752448da45fd177f909c525_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57393189447424cbdff690d6eb86857_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a0cf6a00f14978ae5b1e865e6c3e41_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93f33a2e859a4576a7e62ef19bff98f0_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c3f97c0c25247749fef8b6deb546624_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e100303069b40878e0e19c66282b95b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057a5c09a76d4467aa5c101819252a07_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0acb90ffdfa0455fa5f6bad3cc955686_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3e6a049ad240ddbcd87576b751ad64_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84af4bb4ea9e41b5a3bb5245f8f322f4_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4872f4e47894212bbb218c64e39c4a7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ccd612449647558e0d8cc5f0e5305c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb0a1d042d5e4a5ebb0664bb2c15ebf6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67131e7c55f84174b370dc31e7893725_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe17ea10ec2d46f9aac4bca5f67dd3f5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae2e6ec2ed8a4ed5964f5012a0361b21_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b4b127a8884ff190bb26aefa784be3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if472f36dd37249baacd8179c8220ecaa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f70c8d1831f4f1fa906b5a243db58b0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef6045954534437abb1993aa1937f07_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763fc5648968415f92f38b504b93bf09_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17941d3435994547bd0f648e9860112e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i009e5e7a34934b2c8895d34fdb93faad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c92792b11148c6966e23a7b3c4e4e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0896f4b9831541ae8488b94c4eae2335_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1000caf1ca924d2e859d474fe4e47375_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fcf60e98e4e4e8b96733cb145c00b95_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i090793285fc448169b5f2766fad90f7a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia612eb926af84202b6beec26340d18cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b305782607415cb6a709c71a39dc73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b68c915866b4394b86d1d387ad993a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07fa82e04dff4428aaae1017c07a4108_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96312e064b574ffaa9f1c3392694a627_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3e65989c80429e8fe99db11d1d76ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94362b387b441469ec50222fe704479_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0a54f787d549bab0a21ae47e9740ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433792a99d134359b4473b0754e16132_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09ace19fb574f50904349a9da836610_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice647f7217ff4273a045f1876ac8bbe8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b572de2338948dd96d08b22dd4171a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrk:segment</xbrli:measure></xbrli:unit><xbrli:context id="i72b8afe3fe844c02ab7183ab38cfe809_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953fcdd3d90e447480d218ef6e31883b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee629d83621d4a4cbfa8f64a6cda8b18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fddbf63ffa94c619baa9b05476b6c33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ffc6813f6914b38827655a976cc9e74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a28618800c243e9a9a56cb43ec76314_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7ae7baf3bf34777906747207fd9aa2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b12aa625c44405b0d39ee793eaf417_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1033319c2914559931cb908a21c6d0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58165389de634c2cb2c0d3e8bd443866_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff425d31a4c6439287e6017923a0069d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35717a97f0d5480bacc494c9ae0ae49a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i738d85dae80e42aaba01188d809878b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce1d972df3a4822ad7fad1e42f1b354_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d7b698e30044dfb6cffe1fc04d9813_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib3fa7c6d136f41a3b40cca31c266c6de_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib175c23599ed49f9b1a462f8b563aac4_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2ee89502b94cd49ce08e1e3c882c21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb9fe46e2d94d4ab49c1b03fea4519d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib773c56e9fab416e9e0d022601d5ce4c_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ddf3aa69a84aabaecb0a4d2ed8e2b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i528e4f9a522448139a618d9f8e9aa62c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0243fd5dacc84dfa85f4fceec13fbf65_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ca48bff51949d4bf90dd5e362d3f56_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34ed105cdff4df1a7d378c513d91380_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59fbc25bfc7641aca2fdbe80413efad3_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02313044742341b49e06fa6a758966bb_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209f5888fc6749a2931c1615385b0e25_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d37bdc4f354e69b8bcd53b246297ec_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7690d5c0cc347ed8b222d4300b23e30_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b12110871ee41ee9868a579e4bbf80e_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="idca8cca7b4e4487caad2c748e715f6e0_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4224acfa30774326b05925533ba77ee8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610b6867a103424f8f050100dff9795f_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1781ced27c45cbbbf893095d8cf6d6_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f3dc7254c8544e48303d0911c527606_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f79093ce234ffb8ea77c30f545b9db_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9ba64de11e407f98dad1bd9112b382_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54d078ec4ada42c9ad9804ab857bdb70_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9b918e005a49c58a372d8e08c8ca72_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945ab4055e164145a085c5b93e7c531b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b9bcefa984431da58d2e033612d715_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f84cb29fc604ca6b0af582a6e9be121_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dedf39dc8524bb497923e4bea2c9e1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e411be978c47beb7efc4b35966b7a8_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:IAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36680a86aa854fa98c2457cd53911551_D20200116-20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-16</xbrli:startDate><xbrli:endDate>2020-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8908727197fb4c19a64ffa96d563a2bc_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d2cb7efc4324a38981648aa89ddcc18_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07f15f684a9f4e1da581924f2c98bfb6_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347f3eb2160e4032b140b2fdf9799106_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i081c04d8d22d4e03a143a335398bd927_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:CommercialmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9f0c316ec4420c85c71329dbb4ad02_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8341e9d08ff14983a3ef4b4dcd949328_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4d11122b7294a4694e482424ef3b691_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida918a35a96d497a919b2f7b5fbb9713_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d04a426e1da4d6ca4a2b650e191b1fc_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb01ee2305f4539ab9c5f07db7173e7_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i996ba4f2c0984b8cb870df85ea16273f_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i485e704327b34e818bc08bad5c4a5d97_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2da5d31a2da043428a6be3a178933283_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SamsungMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="aud"><xbrli:measure>iso4217:AUD</xbrli:measure></xbrli:unit><xbrli:context id="i1f7489b20f5c48308b9bb04baf6a39d6_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ViralyticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26856c5ef4364f19bff668d3dfeed68e_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ViralyticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefeacd0e5f5842dbb109b127cdbe7f72_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ViralyticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a33fa403504dada396f58875c9157c_D20170701-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b6640d40ff4e1799c205b35e73ced7_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f6bb982b5943a1bbbe16a8ac755b27_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d63658c728d4ed98637396020df1f7b_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i620af11cbb8f4c91a858173de9d019db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c051937aae495b8e9e5625eae66971_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd91baf9509462f81a3d9ce3a0cc395_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6419d35ddb6b4e628eda2d42348e331a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26c0f3b7f0544268df9ca7c0d8af913_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a16518bdec4e709a2954f61afd02f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i878da9d0c0714be2bd5756cb5d5e834a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba602abb2d7549c19eab5306b4002102_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e966186f72a4b0ab58ea90de20ec66a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290e0168aaad4d8bbb291ae388c991a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7885d0aea044a2285bce8f3e73dfff2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32a30c39b1b49b5b51cfcea80332547_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d315dacfbde4501ba6c19d08de524d2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07de5c0f87bb4cbb837704628b2bd9e8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44cccbfd1aaa4196b45c4d6ecaf6cf96_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a073f8f7b1407aa63ab374b8f4b9a0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i330b41f19cde4e878a6b9d06b389bb53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i401735563ecd4f6e8f401746036baa9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ece84cc7606444390554357bcf90179_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fd756807e314175a880dd575077a4e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i697fb80f1e6e4a91ac61fbdcad18f9cc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica44f5e5fa844b15a4879fab9631e48e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a10731ee0b24e8db15d8038662bb511_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de09b10a2384c05b55e43c2f74660f9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5af579547c4a299bf5671d6d56b6c4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b51d3311034c3bac51a0de70567e64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be4fde20b284f118e551ecaa1276e5b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fc12f18f7224792ae5dcdbaf054352e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0326de13695545ddb2210521908c117c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4488c2e1f5c64819bf4b59fccdb0e9d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0adede01333549d8bc322abf9e22e84f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica3ea97cf2554f1d8815cc085464ebc4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11173b2b42d64d0cb11c1105fb2ca7d1_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2173fc8dee04c56aaeb475acb7c7018_D20180301-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i199ae1c6ff6e448eb1085cdc50ff93f1_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be5634cf9e3423d903fb59b51dfffc9_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302846733a5e4162a65e06b042b6c625_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884fede8f02b4207af70ce8ef3e7719a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8401099a9d4f1da0c09f5e4a845f53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie652d13a7772491b9988fe4ca0cfc66e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6bc081967747b58d1b8d8f5af214b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa940ebb76b40afa60a15a108b7af2f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic341c5bdad3f434ab0c54a2c5e63395e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4920692eee4e4d815006aacc7d78b3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f9356746cd4c6aa273dff749ec985b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4443e6b872f4ba8905276b85a6342e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i491d903bb49f4ed1a82e1b5a703ac09b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0400fa9e2d64e50917ba83f9b0256bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia245619b9e664a26b6753a23646c0b18_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454f432bff4c4574930a4219c0b5c005_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf4d70ed271480fa94afe6dd9a2000f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b505e290fea45b99717b674adac2691_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9d776541aa4ae082408d286b415f75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b435415c6274d44b0dd2ae2de7d186d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7fdf3938156482ab9562725eb331768_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab203463d1344f2b6b7b49ab329c80f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7570f8d4c86b4b70ae7e83bff83c5ff5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i440fbf44eff94d33beb60677f2144686_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a84ffaafac460fbd68e4328f87c599_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d2650552a454bfdac17540247c4ad9a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7041cdecd0cc482fb7f6996b7e09667d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7422cf6500bf43efb6beb9930ca4c6c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4df60e0c1ad4ea8abfda1ae6df07058_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283cb0fd0292451f9077f95aae1b4028_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i491ff105eeb74cc6979d2752383ad3e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61497bc7d49a49a8b98adf19ffa96211_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedff350d0421432989e5b4164f44779f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2cc693bd8114433a7e7cebbe0e1a220_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b17ae627674bfd9c3a3e606fc39a10_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50171610356846629bd94e414c848b8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13429c0926e34225b226ce3b2cdb7e1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897a73e11e48487f9d94d60f05fd9038_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b8080482a8f4179b87efe70700d453f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246836ba7661455ea504f59e31b98459_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1c052cc4f74b61be4c309541e38a86_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1516d5f6bccc4706bf9051b3e301dca3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6830421fe254ed988b3fe026bd6113c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805d69de042e4086a978510f436a9822_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6870f468772426088757f8a26d5a6e9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593c3840adcb47bfb516fe38bcd2f1dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78dbe2e542714ef7a4f706598fae075a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483c42968ecc45ce84311d03c17955f3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie47cee1fb9984770a9955c2c750b7a95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5318ed6e471f44528573063ca8254b68_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ac791388574e7691237e3081e536f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bdad4b05278451caa2c67b1fd87b02e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626dcc5c192746988b8441a68e30c032_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i191f68fbe0d14b05907bb1ab69c9f445_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i241eb84e414f48f9aacd4316e70bae28_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406f377346f2457ab0d54b35df3d1600_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5a50fbb06094261ad5ce78fa80bfdca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id525dc078af8495c9e5d272e8afdb6e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id75a71a6eed4446ca55443b556bc6d5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac627a818264bfea847b4e9fcf4bb06_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309b4bb1ac054ea4a6873ed465501a43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91f1c852ca6946b889085c1d2eac8943_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132c0ea6fd274dbcbbfe45e4bfa925ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2907e5468544c409931e7a4c508414f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie186fc5433844dd6ba21127222d4697e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d28d8d5240b476db71452abf822049e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f2d2fb55c0f461397ea5ac456124114_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a4dd366030a40c8942fc0ce87bb62fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fcec778c1341728db868452426a980_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44c2a7a188ae4476beca9dc90f2118fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c96cd074f44412a6ee38d6cfb5e054_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88114076b7514409b6d5d5c9d41eec3b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e4009b0313c49faafb6d57d35380369_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16991361b0704afcb1a08545a7ef9345_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0268c06921574bbdaf52522aad280467_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e9a2d3136f48c5b13b1e298ae8df45_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab50b716a604e0abfd1dc584019060e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1229966d621a49d0bdc08d199df3b425_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a7193bba0f545a0ba937a6de3f640ee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f5ce19e15f46aeaf70c9fbe7e2be87_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41552ef38afe4fba9be6c306a861bda0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e13eba63251417abb5c0ab7664c6e4d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83171e10413a49b188f9233c14af2273_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab6726b526241b7af9e46ef03b526d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d20764941a4d70a43d94185021fb3e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i303d422323e846809130057830f40fa1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i442a1ac9ec1d4a639edc93d1081da0b7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3185a39a2bf49e2ae8b3d6395304e98_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000067615c4c405d828fc57adc37155d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a6ba62d3268488b96375548230f0997_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85c8e6a868e4feba214cf64258745f8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc85f9026150482da03c6e8b08d5382f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56bac035ca3547929df24caa6baea983_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7a886b5f1384f9e93e1e2055f773282_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70612a50b7b04ed0ab9d05830ec20ad5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5007327f71f42658a82bd6f754e52b1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29303b1ae4084cc1a9f349ed8d5206fd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bb2d3506924e62bdb508461cb588a2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e3e97d3c08440fbd570966142c7671_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4dd7b1ee8f549d5afc0e7f66c436a5c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ea083b872444e39abc9269525384e0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9671977d7414c988b3c191e1c358988_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66a0f6babbd4e029e67a8693588a68c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0feec00e0c5476aab00efe202b2d98a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbecee173d84b5cbc3262dcf64fb42d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de74f34845e4ec4a02ce6ad4c118345_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31627d70cdc54331b46aac1bc8263b56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f9cc96dc0b44a9b57239198ed1c72b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a3afbed0fc48ef8a9dcbf1de6c8ca2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3da63b07e7034274b8cf4a20a267d380_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ee164ec487d47deab4a2cb367a6d6f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a8fa9009f24eeaa07743fda8f3cd94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4118cf8759442dba9e8fa1ea1b34d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i221ed400ff5c4bea9e2d3cf8e4a80a94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f699b1657a4cecb4b718174538872b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba11098240e441f8418597d2eaf880d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i430e6b977c1c4ef7a281ebd43d1dc672_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02369c098d4b43f2a421a2218e9d32f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06d5fda89074431f97565335e930712f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0720d84e024817b305c556282b7dcc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddec87a959fd4ae7a481edf7b41f776a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f7e3451c9c24858a05b98ed5defa565_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id885d560ad0848c6bb060989b08b75e9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f64eeff8ec43de9cc630344108c010_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibae253e40a0d426bbdb3f0cab3da9b51_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b418fc03a0e44ceac8e72b427273960_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>mrk:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="i44610560536947e69f16077e7abce690_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b47f492e4384e57a7069964eaabf6dd_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.85NotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88f884909c041e5a8334a8a11ec5b1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc6d538660a64a929760160006272b4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b41cb38aa34740b1a603947ccefc36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425ef8de5ab24cb2ae98743e10aff911_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2e005cb1174aa094650f2d67119a34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcba6eceb0784bbe830143aade4b1cb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb9d1e2142f94c22863ddaceb3677823_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c598196c7c4f32b1024f98052bb448_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94bc6f83a1ef4f3fb5f4a5ba0339bfbc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b90c404414f4e0a961177cdf72dce77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib018b37155eb42059b22223b5da9a50f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf93915f5e8748a5b702271482140b4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad3e974650b43728fcd799e35eef6a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3739cd95e2441d399690968d9f5734d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i074470fe2c264f67899fe067fe1d0df8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26449e4f0e6e4176aa31d97fbc42b586_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1f968bae9794c1fb41d0984eda03c04_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f98b3a13c41429d91995e92273e4703_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibefd44c960cd430e9696cd56751dc0b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i189cc2bba23447f08495ab8fd74daf9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b006db8f5ac4d31aa4182239c7ce684_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c27f7451db44bf808afb15b4e436ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f4e1f66a9354462a9d22b56d9240389_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7a599f496545fba9341a054b669c26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1a474906bd4f89bf006e7bc9fe12be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c22c5b30fa04d829f43ad58f4fe0781_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3168f8864f4f08853f9c776e12e5e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b004e801174cc4a3f896b5ed79a5e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686e5291737847fda61bb04fa2bb680a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2bc89ac3e3745259da485c0e123fdb6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60742cd64004ea490a84445a5be282c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab5c661a48b4562bbbc071a962b540e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab64708b390a456aa95dfe12bee43bbf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf6219e2385d4b37b8a73d0fea710bbf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f228e2c11eb477aa93be52424102e54_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a833d327f8451596b0800e5d644c7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a1659884f848f5aabd436539f2bf47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c1f1933cbe418ead09d219d10cabe4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96051c5103e4b92b51fcc3dabaec98d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9756dfe40bb4a4284b0062e05aefad9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98079bd7917c45ce82bcf778574127d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d9aaa6d14d47c08624bcb65746c4ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92ffc89462f2430192ac1ba5cb28f8cc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i157e712600dd4995a5373a06637c27fa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dedde47b1a347a0971fdd6194fcae67_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af59371761f403683996b2f9e8ed882_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248775075bc545c390593609d97824a4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b72497910f4f5b8362034975eafe4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac680b79731d4242af1965a13712ffcf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf79a13e56b4dacb00d6c54493be948_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c514e2dbdd434aaf832d950c66924a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4120124e4b9b4d7082f37a0ec3592298_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc62c243cd0e4d5686c1f797407cf679_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd51a21a4b0451281d898defd8ebb87_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a43afc3c18842a8bfb574432eb8396b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f107554e5944c88d03135cc0d5646e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bd171f0c0d4bf7ba9049b6fe49d4e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51875e63a23141e799f3c721b2e98c35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97372e9ec431481e8d2ad41c37299b60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9818f3ecec9d4b5da3c91600169a5ea9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5099d5a15b8741809c09bd89ce675d38_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i449d46bca2a640e3bf828a985bf5b6e7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f95efcbb854b47837ed0e30678717c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0eb091d5f2d4f76bfd8bf94afcd2d03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d003a9b64b24e768af4f068b938a189_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d6bc76e46da449c9f8e5b9c566ed471_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifca9ceeab0e241baa78dca85e021d03b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5979ae1b6734b4482a704ad0292fd9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4889e793f60e4d05b6ddd2f8025a83f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3019315f797d4f6da1bf695e1d0e2adb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f168f035dcb4b52b45a1f046f60c471_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678944a90428428ab1d1f74e0f90e565_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86760add50e540c9915bc96dfade2cd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic305af5c5eb64be5b8250cc700e82e3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9480f02ab9e4065aeae4c973801cd09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6378f9682e49e986ad883f181e19c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id61514cbea7e4ef19f040db41edfae2e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i581be677b2e04a02926271e7f77db17e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe2de3ba6564509844cdb877e313935_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f126cdd894e4acf97878c636bbdca1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8493f72d249346a0be32eddede66afca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01ab1f5da5bd49309c4078402b7bc49e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40443158b83241babddbc35d611fd36e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9e331ce86b43ab95f546a5ce865a32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a51ca67bac440cba8e01beb97c8d5f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7788d5f200f54b93a9c93e43368ebea2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f6c5c42bd2346b1abb083ce9edcfe4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6b30ab1c0a4434bbad28238f32d3d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf6232f74fa41139923e59a424dc61f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id12d18ccfca34d6bb8faff8660c8a76a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2128132540244319b6739b88b72e0cf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i403305af9ece44c9b22ee241dbf53d51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec3c8f6c78f649b2b6d8249918906936_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2903ba97df754b6ba63aa316be7a875b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b4a3504a044aa29ba5b89de4a75a7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02029bf2987943d7b527f9fbbfbaccac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7f02989f1094e35a4db4abadae73636_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83c58a9e62e44be893953a1c54696515_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e8a59217086413e83da0688d9c2171d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a6a626d7d64f7f815bfc2849d97a81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e33912988a248bc8246486df6397715_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabecd6bb38834f98b4af258e1624a7d1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8acf6daac21d4c88a48854a1221633c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i517c433fbeac4a0d877922b89aa5b92a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6584b76ba97e4e2d92b394330f179c16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c5289be2704fd3939c74e58673fcb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7496836c554c4c8e7d708f7cc69249_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3758cf682b409f8450b04bc57aa0b7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd74ed33e96944c3a04c8497e2aceddb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia72079f482c740f3946c8e6aa0108539_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba9bae92903b40b180b8db555d0dc4af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac0d630db304c5fbb6b0d1dd4b0fd96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b97df8525e24037aefcb485eb08406f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aaa816b38bd47f2a17d32d765b2fb2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831b4ecbf45d409481738e9647f09306_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4aa9ea67d9f463dbb092452343a4414_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00919146800d4139ac109a85dfb7d711_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8999a38e79d4363a379eff3d701a62b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9295a488115f4c68a8e8c1703fb43b33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240370941e09472fa67b09378158fe7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e355174746e40ccab1d3a022356179f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04293f756da241a999ca08cf5205814d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5454937046f471eb2aeccd5bdb66a94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512cc6f095a04b919b00809dc9264562_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860f8c1284824650bf9be85917582840_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3923a650ec254483b01b7e8e723eace4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic00bd05172e849cdb1c49805feb4ff31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52894ba21b534bdfb980886fec594cbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388f19daab3349fd94f8e901eebd7ad7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb53e8019d3444a183fd939d626283cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e91fa49f38046778d905adb20038b86_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a9ffaa8ff04b0db0e23fb174f64775_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6fe4bb91db47469413570dc5792607_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf40c6bc57a4a96acd2a20797b47feb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05886a9b13149dfaff74f75da70ff5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a073eb825fe4210b901ff8c5229ca73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732691c0edd54472919c517d2ba0ba90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7a41aa57ca40e6862b37e8bdcf31d5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc7c95447cb4b7394d986bbf3eb4737_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66640b35975948b1bb6102116f2f95c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c736b947a254ac49c79561ae499a87f_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9160300b5a4225a05fdc2ad5bf9b30_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b3b680e1b34262aaaf5bdb274dafa6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5ba2a7e59e4ea0bf92b13e77d6584e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0100533904ac46ef9b774bc1b666a843_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04309b24f07b4666a134a9d0f656e644_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i532617148a464d439523456b08377125_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5e6f127527444d84707fb30170819f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6e48a8195a4472b5f2937fd2336c6c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b686d23f6794c68a37ebff0a13d5324_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58799cd60f0b478798fb7372e4698074_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d31fc70051c4a68858b153d5a6e84d4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc97187f000b4d789b7229ce5f27da09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15819e1b053545a9bde3e98453b6f6db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a204be8a7764bf2bc2bc61353ea4e61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0372a4dd384371b56eddd9bf14f331_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if73dd2ac8807408f8a19eb712e8ff82e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd8d36d804a4f318d753989188298a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0929727611f46b9a4fabbb67f15cf52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1150b2b45f4f4e73994ea0b6ecf39132_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8e2e9cbed5405c909c9467c786afb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaad2db9e0af480e9820c25f8d39bf48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9ed711cabf40539749dacb49e1f568_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced3a5a3165a403dbf79ac1d619c977c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ce2a6386134b23bed761ddc429d6f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af2e1d785f64d9b9574fd6067247ae4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4e2529a81fe48e2af0847da14387edd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ece120a22b4a28ae57b244c672e267_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85308ed5ebab473ebc2ea2ac65fa9e3b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie066b7e11e1642829a90d72bfad73dbf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8737f47e0b428ea8e395b4b91b4140_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1173b6885a2f45998fdccfb8d45d893f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8b5fa2afe945b58cc7cc58540a4871_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c757b49a734e889c7b8814b17d27c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e4557c2c3774ac6bd1f5631a947887f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84352a69c7a940baa059487a008d720c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644295df1e6b4e9dbedf44a0e8a544f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c8541f7de64146a1d1b841885e43cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44dc8a8199b54644aaa379692dd53d6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db1bfb9494a4fe2a7e9ed0eaa5d201c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f574ea21943431ab05c0b6dbcdce88b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b02c94bdf4b498b8851fe2c79b417a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d85fef1ef64fa4b7ac0d3e28260cee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IOmetPharmaLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db9d51af09c4754abfbb7520bc64c24_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SmartCellsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a6d1399fe54a219de34e4fb8d4af00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00b85fd4d974a758d1b963871ea7a01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6bb25ba3f5e48d98f224bb95792c81b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc988053afe14f7b91f98a61bca385dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba347791c48433e925479fecdd16a54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieea8732c8c424a298f074a0d05b4f8e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i344abc1ac8df4e5fb7317baa25a573c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6416b36cb32d45d7972ecd5a8eb20bcd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83a3cf0b47ac4f21b67473d021c763ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dfc4e4a837d4b3d94e05f841194c53c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9099574c5f4032937d3bc2367b5b64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cca79113e2045d5b4e73f3784ef8022_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e429ebe7354c82b1294000a91d6238_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9960f291154518b7771a8367588623_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd58c6c117ea431ab0dfe66f19331376_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb84f0d208f541898a079de4407fbc4c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ab23cdcdc843a2917bbca28606754f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff98b9634eb4b8abec7f2929324acd8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78df5306478342eab229fdfa2b5ff46b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78222fc09fda4c99ad6c20c30a5771e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceecc1aac1de4bc0a9891ccd1446b5c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe272a16def41b5a009731435dffb9b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754a95212e81449592b1cdc907c41645_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732723d5fe6a4b868b89375b49d5fd8b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c412aa3064f462e946f0da6f2d9215d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i736b59648d614c0e97f2775844772478_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1555c8a744114e5db01a64b368754154_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6875a6efe8e744ff842540cb414f8f8a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0efc1bff14834532b53dc32625a888ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294d63d03b95427aab71e6571ccc09c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib13a5c56a92845b8ab48bcaf8bc19e9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41cef927a50d40dd94bf6b3639986635_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if245f9f1b17449e88cc2103efa045493_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0cb1fa4d45425fa7783c3a6ef3bc70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80623f99eb964250b8fc54ea685897f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e81d555abbb4c418adeed3f0d9d7565_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a01f80b4c246a2bf622369fdfa8f18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34867e87009e4b0e99e46b2f6cb4c092_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a46592892940408701fcf1a045d8f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i456e1ba1d4d048b8b9c8e3f642d03c44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ea05d6371640059821d1b96b78bcfb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65571cdb0e3545d08e1a78ce87482955_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291cfe0382bb4a1da525a53dd4bd56d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e47a06c17e443da59e214105dd3142_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe8e4e022a84cfea391ef6224221b96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2a2f31269d4bfbbaa9fb0d49f28117_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a29df5772da4572bbc2b0dc9d2a170b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e537b9b718849abb7a52b86436ee26c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6be4ea71456d4e0cb0df403c03f0803c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7f96dfc50594cc98edcf62d8b285b5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5f170dde14479cad14ff734e5b12f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eeb41177eb24d1d9df2236c98035186_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc08d1a074864992a264a4b6422ccf21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04a54f19f0a746b39d2b9025e8db43c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9978259f8d4b47488a313e4f6298d224_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22994b5296a4991ac4adf5979eadbd5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacb65bc336f4dc9bb0c0a000f8b3b2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a2ef6578e84496b80d826a8bd81fc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd3d72bbfff46e9b1dbe43d5ae389a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.125EuroNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5065e542a7804f1d9986df718c97d477_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.125EuroNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2431c7a6454b38ab36680e0e8d37e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1148b1b31242e48e86597a3d3f1701_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3949abad89e14fd38587a5c5fbfe1511_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01916148acd5472d9995c901f488ade4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288d6bcb95724509929f814f722c2cf6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.75notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894c10ae01644b8d9f041da769af6d71_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.45notesdue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c1f495cc6884078a83bcc4ce2ed06da_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35notesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7670e8fa924f52a3744367cf66477d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.45notesdue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf5a47fd424649b58844b8504c6890af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8e4e7cb13141119d6f1759b7717a08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="legalmatter"><xbrli:measure>mrk:legalmatter</xbrli:measure></xbrli:unit><xbrli:context id="if1ad8b2fd3e14ee9bddb13cd515e52a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93df136354cf4fa38c646e1cf689a82a_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a481dedbd2d4933a6677cd0e1edf178_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eaa63e5d47740128c127b437bacd031_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie55841cf14c74bd7b0e16fd09b652e33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:NewJerseyStateCourtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e56c0040ba4a169fefc5cf5549d74a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:CaliforniaStateCourtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i431f7512254c41a3ab21b8e40f090091_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4047d89366440f5864171ba3e8586b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c91e20a1c71440293d3d8d945468a75_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id52db59ac0fa4c2590483162033676b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb6a7b18f5c4976971de8a6461cfe40_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VioxxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7663bc55df4c4c659db0b11ccee9658d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd659ea6c05471da9fb04c882ed6666_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c8d1063fa24db98c2859bbb23cc25a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:PatentlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d206d30ad44f5780586176e7331c05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31aeae8af44247eca21b7f933034044c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19dc4d009aa34aeb9203985671a29f18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c2178f642f47caab789497db80c0bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0885861e3a0249f99de1e639684e4e6e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757d42734fe94bb68d3cf7cf12d0c493_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrk:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e330e646b54193bfa5012cd95c821c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">mrk:AcceleratedShareRepurchaseAgreementOctober292018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a59deaeb6ac41918736b40c0e87db06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrk:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f31986a93f04797badcd48bd6288494_D20181001-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrk:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic34f1f7cd09744c996b65b7244c26c66_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000733eb4d4149cd92245dbf45a48680_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2c8bbf6d144b1590bfc2f06989e5f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5824e3a83dad4afab742fd2ce8e74b3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc972870d3e469faf7b5829c17b665c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i471a8ae5a9eb4a88ba94d7f35162f55d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i537a35ed55a14a679dacba9b73800613_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b329e4def234bf9be62b33165383a04_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4874f46f9b2349859720b5a4665c75e5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ec46d52043488489055d11d93409d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8290bb9fd604f50bbd5b1c20107b822_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87b8ce0948a842ed9ef92b8f8846b1e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ad1d90c9eb49c08404e53143774bb6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c8adecec8442f49ba129f60935b000_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief783e1fed134fbe824b470778e1f671_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1966c1d9b34614a906164b1b847e14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079debce911f4d1385c9e937966e9b9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b5e7d4fb334cc49a3a07e272a89d54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02395d4a531f43ed837de7ae7e2f47bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c8164d243514c2d8cc997890ef95cab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762afa9f7a1a49199bcaa4c4777b52b7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i896c0ab5f6ee40249192bbeea55f6056_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb94a8956cd48ecbaecb94d4ffd9314_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97baa9bccd8e477aa4dbb884bbaca507_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04401bfc21e40589a67bb73d6d9e7e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dfc8f0a72a24b79a719822430bd3aba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e067be53a86451abe0e60ecbd4d1b2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff30bd3bec0342a79f37f6d47d61a152_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66284b3427a4a55b18a3d2307d2311d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492575ea226e4ef79e791f68f775cbcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaa9c1f8e8f14bc88b26db4f04818c63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05de118d42874d8a8b65d9fbbb8cd8c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43bae42e68b74c9ea2cef860a864df98_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4839f9e8f263483bb5a57380e0ac49d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f92475a0e644fbad104227d35a788c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b4d58ac72a4b6b9e8a4a3bd3534739_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie610ba127e0c486a927aaae038bb4c2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4f3b3b5ab84f1f88c1687777c06d94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2614fa71de8840c3916410fec8e4c6c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8493396c311a48c087c4da0df9e9e265_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia33c4c3964914ed192b098a7887db425_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i983bc4d845244c9a85c0ce012de520ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f904c273db45369ca533911c7fdafd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07aa6e44c4e64dc09a11f648c3aecf39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76599c7f104045fa9d3705ce55cae95d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a35eceae1749b2afc0e2adfbab500f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf07f551b9e54a50ac5e33ce5e447aaa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafbe4a56619b49ab892a56d15529c893_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb63fb418f534cf9a00bf9ce064c5f01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22427a43423b41ee97f6e223da5fc0c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fdcc0719b79428ba1c8942ab8420778_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29bf2bf658614113ba17d962e1e99dc1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0441dc72fcb54c48aa6e5a54486d62a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04061d95b9fb4f6692618bb6b2e163ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24ab217ecf2047ca82f61f394e3b2143_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a333a9d32a4a75939aaec5815b2ce7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3a588a2b1824cb39195f5f331917939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b412ecd46f4665a8377ecba5fa899f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6e39b65bae448395fac9f11f72bd1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdd6fe4acd1d43f89863a9719678632f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifffdb8aac16a488c88f1530e7c5839e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id031685155804a84ac3ff78aa32f7379_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fda6a6813da45e8b85ab5cc18158c65_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8e94062e6ca4f1e848b910410e66b4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7598124a95dd40e180dcd55e241004cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c46ea7c16f04e6f9077e7ada8dc3aee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i881d12a48fa145e29b963710be067d8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963fb897f1a84494b29bbd3cc88a5cde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d998e95188b43bea7ef9db2acaa7908_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5e8ce709424f55baf4ceb447892b4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if27f9b2b78804c56a1797bb83137c3b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iece7c24fe22a4365ac316e8f89696d65_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5510be169a403bb3a2fdf843a3ed07_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c15bfcb925489c83014b3d69b512e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607a874a41c14bfc92471a1eb2e4fc73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i738f3a9fb4864314980f11c6fc424c84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb154d7816ba4d54a0aa8908f07daee0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i845f426bf5684441b08a4d78f16a13f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0318028fba4d4d2ca13a6790d87c0bac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18cc995c2f4542db8ad348a6a80f3f7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339d812fd79a4559bef0ec19bfe98349_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc88b48898f04f409e0109283ed2987e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a508f5db8a4cada4798954c65d9223_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29a7f12c8e24256b2319a238659e1a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia882b52e228c4eabb69646abbee285bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if58a48d4bdd44296a817bc4d6ab8b57d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7dcb9e05394ef4b640628827cf587e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c09a641f9f4bc18e3972169da2930c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i470fbecd1a04428fb6e6a4caff23f1d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7046796fe24f1c868c09c2c0ec273f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9da7337a3242dfbff5100ce601af33_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3221566626c342a999e23dfe29877216_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c99d58a8ef4f18bbb9b810927e2266_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69b26112f2e43dfb981f625c4a50657_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idabd1fedb7e64d168d077d9c93085e62_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e1943c724246bb8b80b478f5c0736a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39cc1d86c43e45a5bc8a8a5055e74603_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i663cd110b4a94a17af138ccf8e74215a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29b60f8e53c4a6ab9ee426df0b5ae37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23692025eb79488d8a33a2716b0b4e30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8b282d6d4b46ffa0cd607de8b36a5f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f96273f8de344e0b556346389159cde_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2d21f8910346afa7a2eccbd54765f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6df641d6b2e4a7fb6f87a544978da43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51ad2bfb5d1643ac8704a1745e062147_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ec77bd07b245cdaaba698bb230ad64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dbe419490e34f4283f48203f8d00d4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59d367709184c039635ea8a9c404195_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86afa43f33044b8aafbe32dc59a25171_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i183768f390164f1794cac12bfbf64b84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db834c97ee14fab88d75f50f80223f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec7437b4bf19421b9a91bc99840e0acf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if74d1efb8d174c4f838e140f7fd23e52_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i549747388339440e9de44fc9bf5b409d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78824aa845834cc8a14b6fb34703097c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73d0fa26e4ae496ea46a709f7fe43c2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436bb533ef46402880b1b951670aabfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec0205bb40a4e4aa25f265fd1063854_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c9b892c37442a186be4817fc66f40f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5fe2d5dae24dd8abcf648861561996_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2c28218b2834e5ab51167cc6eb02eb6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40916875d4914c52a1de3c0cc928e327_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a5827af8cb4a649aac89e78df2a8ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86afe2a27ef042fa97134e39bf3b608b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d8855de2ab94dbaad3ea5df4e70bf44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i259684d6ca2747128dc9ad3d0b306636_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2c67f654184b1bae5acf068d5001f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcfdabfe8f44d56a22b24a80a126022_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeea9d67616a473aab6b59c7fb911c4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e43a005430483da4c326627defc690_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64370d94415e4d9cb45ff1cb008bc7f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e19c56a0f04e119dc0d2f946e31d30_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9750dfea550483aa010da7eea306529_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc4e566933f2436ba71c1f31ac45a19e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f3cf886e184967b21a73d9c69c8280_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d72a9e301de4cd0a1a1a7fc0b36c4a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39901cc34fd740158d36857127b01175_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154bf08968984b7c99f026a36c01c389_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040e5118b6d14454b71d08507239b29b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2938292f70e456cb6f95bd21bc78090_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5092f87e8ca34ffdae394fa1e9d5e453_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id457393c18e544d79b6943a75591c9f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ba248a0903c42bfa04628d1088a7603_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b23ae04674c46f6be8804520b0a170e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c07cfb24c14c908e52a77dd7f27872_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af75dad006d4960bcfe8d7100ff57f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6be20872a4dc4195a2a00b91c7bd9e53_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5fca2613e754dacb1d1358910525b05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb175a0e182a42959d20bd6d81e8811b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1dc802dfc0e4d8b943a8088b309a76c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc71c589efe74a8eafc71efb7fc704e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if758fbd200de40f9992c9a7b6d18d162_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d28cdebd3ef470d805bdfff3c328aba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4529abd8059b44efae78aa81e23a2069_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4ade71303f484886aed15962aba524_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a8ec52ff25456fbf0f605de1c62d83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7318c9a1044a450c8705fd6d1ea5e7ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37caa9d66c6c48c784567a49cd4dfcb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf01b81038dd4b0d8ac214954c67671a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd70b64d3e72405ba247566a7383f575_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i383c1e83a37649849826069e2ea30e70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ca88a53b7a422eab11e135ad001f09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0976228eb3844b76813b5ecd4ea518c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19223921be5a44f4b5b22d6e5d166870_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d99fc733314c5ba2bf5402ab0d6392_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd1a97c92462458c929c7092d0e8afef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84ab6be0c3e403bb9cd82e264108aab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9acb800bac97417e813ea16d4d5ededf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44275a244d0a4892be5505d09958c1a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51e79c06cea4cdfa2bf6a0d5be0124e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69f45e018d1747a68360c2feb30d6b84_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbbda6da3727484e81200d5caf50552f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd94dd271aa54f69a8baf12100b51778_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb967b896a4468fab08e88cae9df856_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86344444b47e4721b7a2fc0ea7cc11ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22038ea5b4744df99667fec848961056_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia40b98564996403db036113cd733924b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie48c9ebac6d74ee190face5ee60b51f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b013c8f53aa4ad0a92b472ab7fc6b81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib672d0934c6d49c19aca1d0a43b92a58_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349312ecbb7345d7ae0733d60b92c8e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i457ae5efb13d44ef94eb093fd86a744c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780ae83f21484b4f85c3d3e21ba5c7fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a46d5d13eec48b0ab6b5862c0d10927_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf91bf6b83d04def977d5ec5adea56d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f802b0b6548410683a7feb2a61f6ff9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4534e1b0f4594853b0b92171732984b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f034b282b3b45ae8315f6d3446c99ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic405b218f9744ab780ce9a8a7aab3fde_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0001ec828bc546a68b1b01be577c9472_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if840940eee764ea69eeee426ab4d3762_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07001dda2e5f4d7ca903f069b0abc178_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f673e87cb9d4be2a8a2fcce749d9a73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a21cac2295041bd8c7761632655bfe3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie982dbca87ff40549928cb1b655bf842_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d48af822b4482a9b7498a050ddfcc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d0c8c5170b4f6a80534e5ba634dc51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i622fafb065b347f886df4ed478a637b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i633bb8841df546c49ab62349cfd6e177_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5993c63f98347de90f6f8e4da9b444b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id334f615428b4033a167d3ecd93c0a56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee9f22f4e7c9422aa9d5aec3892f508f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d837922a8c34c35b598417be5b7179e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i357033ae6b9242f3a760e4ce6ef092bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6504027ab63f4de5b4bcaf9260f31835_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e6fd8f061154a30a819a163c8185ce5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09db396a1bc405585c8bd00bd42ee90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e9909fc72e4d14ab3b844920200857_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34620b194a57489abafae0caa71b1e81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i803b0a3f273448c6bd0082f93b43ceef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058faadf9b554518a3b689fa8335bd98_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3677204f7a3e41dfa2f70915e9c33438_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c48edd856d446fdaf20a830fb838512_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf61bbfdc384cc9be1bc920c1d76754_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied410f99d8eb4af592290310c06476b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d66850a0b7c440c99a213e0733986ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dc4d7beef254de9a0eba7eb5cccc084_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72fd7651ac6a4a2a94a953d682b650a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5161c382e704689bd21397306aea661_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6ecdff488f4420ba322ef0fedaaf2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06a9999d9324811b9a1be2dcab19ac4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77d538a77664954990b8a71d696a859_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813c30a7a82a437a930c6658dffd6bda_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21fb50eeb34a4114bc13c96d65cbd097_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8b1f9b69d540cc9ee48b788f947e86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5520bc81f9124c16a0f7c2a4ac6d32d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1ccc0110f849388ab267dc48f11d4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8158b6396da446795bd99eab428f39c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31cd5815632a49b2ba1c177fd6bc40b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ab5fd43cc1445d0af3c8df232ceb26c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6e35c9626041d98bbf692bd5a64946_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407cc8de7a564cd591d2cc8905f16ad3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402c71bfb56d475d822a8336e13e26c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a9ec48e8f84f82a1c47ec8330267d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3937995f915a48b5b2629bee83030604_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91ec2179722044d5a5d1eb812df66bc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c42749acb640bf9567f2c696835c1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d256b285e747878c834986bfa70aaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b83770c83d4ae3892d22a8c95183d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54869a5a706b498f8af31af979c71c44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7510a56e62d4a91a42048cfc19c7873_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea763b31b9e48d09c3f501947f1b1b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04238d138c34d0c9609f710057ea45a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49eded9c6aae423091e00e60b8b07d6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied9fcdadfe1b4674bfcaa0b730e4217d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74504e9a2e54432f8b030a4dbcf9ccec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bf9b49410e149e4988f1a1303a8002a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38efeb11d07d46c98df2083b9decac1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68339e93b1f64b1dbf950cf628cea274_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fc97e4e4d57436bb7f739eb609cf62e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf2a2c1e08e8478582cb66340b717486_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec2478b8f0e417d82d47d2e798bdf92_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i620692e3a36142a99469f7b3c1df10f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fbb0d61bcab437d8de63b52dd292d32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7e666cc10345cdb2262b32f0065fe8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e268cd703d845b29d850a21ed33546e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6d74a08d594448d9548a1eb92cbbf96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8dfaa78b8a242ddb57ebc4c9c31d5e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229c0c3633fc41e78ea30bb9ccd6a28e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i189642b9649f470d84f77e09dac85b67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a79dc129ba4160b0dbd0cde3962a9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5adeeac55b484b6f80dd2c5799f04e33_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5481e593b17d47b1aa1c93ac944e5897_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71a47f45b5b94684b166d8f428a29ac6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa08043c6f9b4f8ab940e92d8ff823e6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ae805d9fc1142e3b9ff8fbb8f056835_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie76048d496a9406bacee02b8f107dea0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d19186cf57479f8c9c9f80797a937c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i181e86400b884db2a06d3594319d4a0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f4bf6ebef94a2b9c96589c57b30e5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56b5dfd32194495790f2c8c81a479431_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i182aa63f2acb4acc82da9b87c7730e81_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a92dd071da943828df32be68c3aaeb4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa22d9c51f4484bba2b9f4934ac0a1a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8face53a5d81405290c2c762e2706f10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8993b7d37c36436185b4a48db374a7ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i197d5c37737145e4be8b85609364f159_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec259e3fe62049edbdab75f9a4208515_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5ae4a5fc4714d318fd513d240f6ee0c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee7f5c6f7f3431b9e2edc9b74fe47c6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d17ed2f94a04fa9aef9f8d5c15caa5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd81d119ee0498cbcaa47e8e4e04faa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6244f9b099ff4947aad981a8256ee577_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56379a346a34c328d1074093e2a301d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a8d5d4b6784223a646272a4e63a5a7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f0eeb607674c858416639d103ec85b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4103a039ab6c450b8e3fd2d3aec9b167_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248058aeee814ad1b7ccee7a89ac58dc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c14cccf97aa4e98bed9ab984d662ca6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c7eb5004e0643efaa0d767fd8811f55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc1fae753be47e5bd4c21587185b6fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df3a94dfc774b0e8194462a843091f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15952b0805294332b2734607d6a255b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f636340dc640479a5f05532e7d057c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39557d630df942dd86fd2bf4c39cf856_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i699edc2c96984870bd641e2007368c3a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib791d92b691f48e596977e133b7a160a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef24876a7764b5baf52ca7024d66e6c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ba9f69f2a94435d9d0a72322f3ae888_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e9da0b7f32d4b4b907aa341ebe4cb77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43cc1a499218442e95080f98c69c62d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60bf9bd5acfb401fa74b890b56b423f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie96f52556ae446d4a890b661e68c63e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b79dacdae14f1e977caf0b1f646c03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief56854f3aa241a0b9fa4ddfcfe5de10_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib62ecf568cb04ff1aacdc2f07c2ffeb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied08a22fe762423eb0853b09ffc68ba5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic57e6fb3e1414f279eb4e83bd905b61c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i755cbd5c13c24c81933f62cd6b4eda28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a189549221f4e24b423fd38671d9d54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0252b084de946b684173854befd400e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb1b2bee0774b4aa8d069b01b4b4a15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ef8d12db6e40848a3a69a5aff2a1e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a497acacff4f75ba6294cfa44db5bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15a714c12b94a1ab30adc88613b45ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd632257d3a49bbac09f1ac0c2bfb66_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a774411d90415084d7be23aba71361_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b6ad0ae1984ddb8dff1329153f9b50_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75c7902d5027446ea98179759ec35a86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85e0fb8780a4f668610145bb98e568d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23dea03aedd24af7bba7749747e2c448_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cbe0c4416b349fb9992bba23dd31615_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a6261bbf6434c1fbbb017c083ac826f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i099c7987308445478005041a2e2499e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7b979b8181471cbb2f4d6499c774b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9635dab5da6b4d86af14a4b3b3e3d17c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9accb5aa18f4478b540bfc23200dd1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d7560a3be3405aa45a2e8965d79a75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i991d3d8795e7450993baad6ac1542b2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe94f09fb8b44e858f391b3b456ea158_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03dcff373b2c4b2e99f9bc879d71f877_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4161dc5395848ec97371fb2973a6cf8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148dc14f164643bc9efe7b919ed342bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd0233a6f6343d6985c502db8bfff5f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79484360495649f0914e71275a2db5f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i952760f0a9e74c05b6d48ac685eb2961_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e0d1a44c2c42158b392f684f51f780_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9deec913ce4e429d807dd9d9ffb90a6b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17183f50f3f84a319239298ca400b998_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd9c6661e1d486f8658b5ab959fdfba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib753ab6b2404493bb7bb3e62d12eddca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ffe7e2d5821413da37bc4be396523dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib945d0e7dfa340bf87fc9b367dfeb236_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8163064b7e4a40249d86d66b673c237d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ced98f942344b8ab3c48acf6650470_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9b9a544637409b9b31bfd72192e634_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10fba196d5842819ca00cca1ed5d9bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae7bb63a321a4dbca2ff6d7d594a9842_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3515234e4c5489b8a5058fd44abad74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e22790d03c4f9b8ae9e600bf7d8610_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ac062f19214253a973f162cd6b7257_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d2514b5ecb4f079fe56b573db1a351_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i054b0d4c7dcf4dad93d6b261932d1c2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8b3ee4288f1434fba7a20a0cc9987ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe6a7bef2d8421da8fb84a3f0eb8f61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a9d170f4c6f48cdb4f7d2ceb8f17c94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93fb52f964bc44ef98075f84eb2f5ff3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf1c6eec00b45b1895cc6d33e8b5bc4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6482ac243747999a0cfa001203778b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349bae78403843118305b16989643e38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568c8abfe83946f99469ae90bb9eb5ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee961b99d48a42e294600feed306ca7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d6adfd31e845609eafb982fa870054_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a974d49102240d79181f4c266d17f3a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c1d58045034f7d978522ee23262647_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id45dfd155d034c4dac37d090ee18315d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3707009e777f46e0827af9a448af3671_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb206a1757a4824b9d626e0233b0fc0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe1114db0d24d3585c20ee5c36843de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd30b86dc69946c795758370be94e534_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if946e67d0b6c4774bc9f3f9e21193f23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if030402de9be4396ada7e2f22518b79b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7862913b018b4ac799b5977d1114dd64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3e27f1bf5849a283a049ebe88b1431_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e25808393b84cb8b8588f0b2ba8f09a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice86e24a0fbd45fdb549c788c2fae42a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933961f1977a41cab0929eb4211fdd05_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2701d8c81625454b892b42c08d22f20d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42cfd92c13d147b1aaef0650037a65e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60637f24b9c34907a65ab4eafa2af829_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d6e855b0100414ab5cb98a6a2b9c3f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d6988d2c895477a9dda50151b45b1bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bb985051a0e4022af522f73d07de54c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if670e72285554034b4161deaea318730_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb83591d5af44b1dbae73ab7ad1e4fba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c2e264dd3bb4e18b7d7a3a250729f3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ed9e9d5bef4e08bd9d56bcb3fe7dd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf43c3e9e35453580b96b6cc36256f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if51206021aaf4c96a2df71f22290016b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61232e501c3a45dd9ffc51e1a7b18638_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa31db245c334463830834bd6fdfcb7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43dbdf70f3f84f9bb800dc9b2bc789a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a185822a7fd4092bdcf42d8ed03b009_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DefinedBenefitPlanCashandOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafec61eba0f44b598174decf94362de9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d4c0e028b3f47a5a748c2576dd13eb8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac8719a9476464ca9bf1d1a240d1510_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7410576a916e42d4bcc349b678e87d26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i405bca874530481997ce79928dac111d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6481cbf5e20244beada5e16fb8e1c7db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9b18bf3f2b43149e469b0523aeec6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6314d5000824e4a8abc4c270f634a7a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fdabe48bf6945578d95ee1057e5b49e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:PatentlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553d83c3c5324495837bdbe11f4b2eca_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id83dfd7a1bb849e1b213bae11674e00c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mrk:CGRPreceptorantagonistsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b367730bb94d77b0694a73c6126ccb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b58a3ac34da4fe8ae1aff48a5e4e450_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:IncomeTaxesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ea8b16632d441e9fe3b895f38cce6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf552eeb0d424605ab9e87eb7385fe42_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic82df9d4f97443e485af19b6f535a820_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9efe0064ee4c049327821352c6c0bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae848d20b3c043e09bea70d1386a41c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mrk:ConsumercarebusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i942f16eff97546a5b0fedc3f590bc635_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2bfc40d64cf42fb9a74577988a596bf_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480e76dce93f4111adcabce9984765ce_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f8cc640b7474a98b853cd9c382a0cbd_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1354b93356c743609177591ddcc546e5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic550ba60e01a461a85b42e40d108acfb_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2352f0a4d1a4a9c99aae16eca9eb64f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice856820a83d4f64ba70affc98cad508_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ff4b660b424b82be57badc5035314b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d27b6850029421d9b74d51b9b3c2a91_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if578ac895a894796b44b038d0fb39402_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fcfb5df86d440c885a97df59dc74f88_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6f7feea16443b79fb74434abc31baa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3e4ef69c5d4f6897a3277c799164dd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4b8ee6455d4a9b89b308842da6473f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cce9deabde142dd99183ccb92bf0341_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c2b49e682e4caeb3bc52179ef40698_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i924abcecf31e46c1b8d02841a745163b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610c168f90e34562ba8f9dba8f33d1cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife933330c1ac424aa46ca468fd356d4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9afb706ed88c4a9c952412a1568ca05b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae4b953ffd8449bfa452e08fac76110b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f71d04bdcdc440cb39d626bbf39da82_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7110e61b679b41dfb55959ead2fa0d94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944bd7f6e96e4f45827bcfb3d2cee24b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1028ee01f9f443790787ed899f2bb2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbfbe344564a46048fb4ab43f38e7fa2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6efe006638854a89a541ce4a48c0e6e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ddc21fcecc54b61b50c3d29b99a74d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i914bdb16078940c8a02194e2230817a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944b92f0135f4cea93c996121cdf4250_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b82cc9ac9bc467aa2d1652a512c75ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i762e382a2fb74a4f8babd38337173a85_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487b197ad43f42b4912ad594d94ebd83_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea50166c87a84aebbe4b0e1f96819e9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib06a34e4d2ab44d5bf29fb6afb196f2e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33e663e5d3448369da90c6d1a069ec0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2abed73e41814781901f099d40ed7105_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3942b136244804978f116fbd64e6fa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e466932ee4e460ab0dd0bfb9b1ea289_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i913afbc19dee4cb2a26b17a5b2526f58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86a72289f7a4e82b9b4eb4aa37f655b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic980b87bd8b0418db9d06a8a487b8264_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd394238a2bd4fc599ea677dc8fc9177_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i705f2f1b42d3489389778770491f3701_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e95cee7306454cb048b4b3891df099_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idacbd259a14a4cc3b723aea685fe8402_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica27ecc79da8419a88633755deac6f27_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b34437d3a04710a586018aad577595_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b948ea353cd4ba2a534ccca93683bd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a60cb9fff2c4cc895d8bdf8605a165d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7ae51b0ccc49e49568440c6c4249ba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i568b7384fa7a46cfaca0984581c67866_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc913222658499b880f61b227164ce4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7e5ca7b90b402180e94a9e8706abf0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01ae12bf7fa44aab5d2eb12ee013b9f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e937a0914304e858eb868231dc9e5c8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62fb6e91ba434715b8251869bd7299e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8b090798424ac8aa3116f12d6083ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd47028645b14cdd8bc6a7f8356b4316_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9dcda80a2b744fdb022181fac4adddd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie561b863be38430bbd97eb1eb078fef6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea786310eb1d478086e32978d875173c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea00f3442984ed4a0f48e661b09bb6d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782fc528304543298cebb02d1190ac5b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1145ed6aec9d48c3a25ff2a988aa54d9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42905f2114b449e882139c3304e1e067_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b89ba8279e7484d8920197b705b8e22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f022f4e88e842849c6953bd007071a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386b32eac5004086999833832cf45f24_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bc8ca75e4db4e72a0644865c60bcc0d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930ed6885726482297a6b88617a1004e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a909c96c814060a10e2801793e0e6c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic440e28e121b44579dee80b8c5d681eb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de667927bd44a37a2bd00481afd12df_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id371c43a511c445bb4a2ffeaa7880af4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d2eda461ad492daf3a3842f708bc0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c67db88a3e4613b882d85cae7cf938_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b2d959e73643b7b560fc019573878c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i563016c582e24bb6a9faae151d3fbde3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc6b337a3ed481cb8f2d22309e2a645_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb152fb64524f35a5ac871ac508cfbd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc8a3df09604d98a7533cea6a7cc1a4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8d517618414005bbbe9f82e782a39f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie588ee62a35341cd8301ef54adb5166f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99baf06e598d4cc587b4eea203a0baa5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f59b103858d46878eedf45649386455_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4e6f22b3114161abfe58eb27fdd9b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3244ce2b91904b73b45793012b9deba1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee34845ecb84d00a4446c16e8283f06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac945c4f8f4d4171981befedd8042eb6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13aac18591694ed095c07e398d82a9a4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce7fe828cc94d6db92ef54014d5e83d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3082eeb63264d528664dcb84a196ffa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8ddb57daf4449b95d7f5842fbd9cd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c04273d563d43ac903ddf81cd8713df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7885796f74eb4f47aa093cd5153cdddb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76caa434d4545c2a41daf436667a0c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i698eb8ca231d455e8bd8025f25c5bafb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd5c6efee8b467ca3065e20772c0f16_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c82a481d0e4e5c9cb61cd60076fae7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51e714cd39394117b1cb6e8777bf32d8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eac079c11544e2cbf3daee151f7b5d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c795d67996d4d41850e0375598399a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic268fa475d8247a888383acd5008c4c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792a79580b224fee9d46fb4cfe23165b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bc19564465e4f5a972c56bb809a8f36_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b81e96d6791496eb43340c7203088f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9f73dcd0954e21b2a313db04ce7e1c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6471730c7cf14bb5a10b893fe2704d8a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c40f8fc0d443f0a7972029aa43014a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cfced3ea7ba40dc813084356a8e2a71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5c946bf5a44685a08ed2fe940530f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43a68e5100c460f9ae570bae3642222_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b08c6f8ff94c49933c0e1f8bdf1a79_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieea7542288c045289bbc1900530f6c6e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i712dd95c443d44bd97852acba774042c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7bd988df8be43ab8a578291ca6766e5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5e6a2873114b8ca3d699b684dfbeed_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a19fa1ef2549e48a8c798ff8cdcca2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia794776b17ba487d81e689c730a89a44_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if56def4d43604279ae1490a45ca12c8c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a57852d19f944bd80a118414f3fb03e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedb68ee70d874978a87dc2e09bd612fd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837a264760b94cbd823d589b3848eacf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i981d29244f2a41eeaca918a69762f31d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d4bf02785f34f25b07ca7068a5d28ca_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i622f7b5d6bd64049b5b32da99600ada9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63db189e7eec4a128a0d35126d4bd81f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fee648ff7994140af926011d3631567_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b60dd13bb14d32b824e1653e259c32_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631ae57e96054ee5afcb44dd7471b663_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a880330a694ef488f4f7c68d82cd1c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00da273161ef4edea36fdc16bb3586f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad4b5afd5b04abaa51621d6b0f67e32_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f990850d9594267a6e1caceafb75e22_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8408528418746d49007de7097987a4a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dcf25c15d3649238957a6c3c1922909_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95a6af99921b4ce385e45e7baf0ceb30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158a181d72de473e981382f4977cf6c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80beea5c84e343bd885ca3431e912104_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i982bda5b96d648869406352d49e6de87_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26fced3e231e4bdca37b63bce6e68d8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8fc37aa4da24c6fbb3ae07dec2598ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id86a4dddcb1b448daeff944a4e1e47f5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdb32068982447049d6b160c7f5328e3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic23472488bb44800886a04efdac600d6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00dc40a9ba5740df90cd396ff7e12f29_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i340d2c3e7cd4499c8922b0efb09a24e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c343bc0a184f35986855d72aef089d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80da1dcdb7dd4217893159cf5cfd10ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244975eafaea4f8981c83f70f314cf09_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32db1b78a5840528d295a594b2e7616_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743e39e016e44963826fff0f356a69f9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06b3400e18e404eb05b4445a2bc6313_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6083ea4bda474120b0f548d11216c6a5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af11e6de1ff462890478e6393a18b91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65c1d7b2f4f44342b7cb4177aafef6ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52759226e58746448d8a420c332f2381_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8efad0f18a4a45a2614ed77513463a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ecf2f6aada4757bd26858e97cfcd1c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34bf512eb4f541a2b071eb54fdb82c88_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3964e6a61c54a82afe378671d25a543_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a6bbc3767d4a6ca3952000f13d28c6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac4d80bdecb4bab833db37a8d18cb8c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbb92d1ba39b45128f93a4709dee1c15_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56b2370d6fbc401ab58d1068789e89e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593fe290ce72487993a67db241486f76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8cd853b60043e0b70f1bfec080a4d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f99c5231e7c4dc7a81d228fc3415f7b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfca6579a4ac42e4a4e603af62eb5c01_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c71abcc275f4683af8e0271a80096ab_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa50d7bd230485abf1e66bfe14032be_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42ee491dfce40f7aa8d266a46cf3543_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia213538c877d45ffbeda1c478dce239e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i021950f39f7d4ff5bdba80113c0e13a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id025bb2578734377984deb7afd65b7dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce0eede954143acadf9aaa2596ab83e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5f4f6a1ceb451d81c5435d7c937683_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e0ce6e85e94727947ac68e911896ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ab04a7c31974211af284155f6a7dfd4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic02b5b66b5be42709792b6f221415e99_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib03ebcd3ef9e48ce8bb69abc9273d951_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cbd149a97d401d971e534e429cb2ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b8228b2d5564ad0a725a3a7b79ca7b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6479fa964a3c49189f62b4bb3b39de1e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccdf4f20c8b84ecaa29c0e18c61129ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c18fa5bbcf1406fa004601033af85e2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb282931027048db8b47047f9082a80b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d6b32b4a6540428d17548fe7806b49_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id466d72c74484e4c9b0cb94ca903c707_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02732cb0bc4444dc90c11841a6721a88_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204bbdb330e744b0b3ec21cefec837e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac9ad937795f4b4dae6cdba2cea3e74d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e1b718c831f45e49a8fbf7722d13a2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8aab449a70046f4a0e3b44a0956bc11_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296ebee4da8b40bdbe6a589d85f3a4c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if41e158eb1c44c3aaaf6bdce81669ce4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ead8dfa8dc541b28d9320a858a459a7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee9488d170c4cfe8fe249373f7a0005_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588e0e2cfde5403d9d0ff73b1f9cb4d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fdcaf9b54604eb68c5312737d3846b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031b4271f5cc481aa8b8f2ccc0a1ba58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dfb2239d4d14352bd4a728fd7f880f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9231ea96e50a4020a32910e880f0b50c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5929161d3242ee9a55a4b589697d38_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f37ba6e7a148089b5c5d7be8a75edc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cae2150e5694f75822ed5dc50d0ef1e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33200ae436ee48ecb1d3c2bbc22ec28f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d52e6c1a9c4700a879d6f651d06973_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec78dc79b8ce4a3497112535b38ada92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1175a70af145bf8a80dd6f301e589e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a8fc8006e849fba47a9ef2942dbb3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia340a8ba6ebb4c029daea71176cbe2d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0227adf4c24296a707c703a304ac1c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78215076410d4611825d515c00ef799a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i969a6ffbcd4d46c0940c7138d634f818_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb8e77760bd942eca8efc4de9fe68e8e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d2aac33ad54ab59d96297ebc97d425_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica384a52be1a4278b12ee9bd5f583bf0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4578066b041421da1aa43b44e975cb9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6940bb247a4473bd0c443d685569d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c976d77fea4c3689cc0098063aad26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie370a43016b44af890fcfa0146cbf033_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa036d0f6774475a9fe49fd92e495644_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37abe5d72534dd093c0b9a1d4a419c0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492b22beaf094ed68eda935067df1fb5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i389e5536e60c49a5a0ceee0886fca045_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c7854b1a4640c3819cb580a9f6f419_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66a5487bfd8f452284fbe7d3ff2c5ff9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65b72cf07aa47b1973dfb9bb3a28323_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i358a98553f7943209f20f57502c434c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0fbc9b5596453f8b88b17db85f5aa9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbddcf663e174f7d911abb1df12ce84f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f563f809894d48ab7c89d2ee8f18f2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3769c8c30b424f33a150c2196196a059_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9bf768836345a986b10235dda945a9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic330260f1af24c978c806b2a3416c5e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ef50a789254301a24d80d4157ed09b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65bb28cfb3444cabded850e87bf4e90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9aff7abd7c74f4681631afcc4ec4dea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa6da700c404dd8a7694bfe82d5c830_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d3bb6b88b54cdd855c97a8e84eaaec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbfae44be544a3289c07e6254ad7066_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58961068953643e9a0d7276345f42e0c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26dff7caf3b24a61bb9d9d43432b1342_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02da2130a9c547e1b8cfd90b9810c602_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e9473f3032842009abc88dcbd4241bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9850a5dd51c243e993ed526a423fca5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ebce7e3847428bac65d9577590ffba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2992f734d65487ea3350732210cf724_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a61b67189614b05922be71c8c421962_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808dbd3f3e6e43ed9399f61bbb7b4055_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164de0f742494c9b8cd2d3f94f2923b9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5ffb4bcbf94ae0abcf664e4c6e1872_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i765e235347ca4df1873ed1248b331df8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817e3b1fea9f458fac0f6055c49641a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0433bcc5a7d7432f9bb4a1eb7ce37fd3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic50b4573044e4647ac213a16ebc379d6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec6cea25192742dab7d8f55c6193e913_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic118b67ceccb466faa220eb7ba62f56e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a086b497c64ebbb2509e91e103680e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db350f249ba416299a4392f33c42f88_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaaf6f8150b84a25a8315a1b493d2252_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ba25329bb24f2ebc68cfb217f3876e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff1a0642517447883a7677e44f19609_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65dbfd32d29c4a1298cc6b005e57d0b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe5e33fbfd9e47729ed353ad56f6955b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428851a5d25042ebb249a9a84028610d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471a2257c4e044cbb9b7a564c9ac71c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a09f1a3abd48109fbe59b3fb93d141_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1404f852ad8849619c48eee49eecb017_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c819bf8048847f3984282adbf7f9562_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib453c2cf19634dcb9f7c38e577527fce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a03414556c84b1f80a00b809a8ce3fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b493f99d5764db3a3587eb876ab87f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7650b81f2f948028475c26edc5c16eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifddd89c3eb0447f3be23aa56aa560afa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350c3286a7fe4a509add74cc2448733b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea6a755e6024199aadd27d792902ca8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d8c9e4810f4401bb73a64a044563400_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdc2a0905fa54560be844a4a5613db12_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08dc5fac7cd845a6bd3b00791e7e5b2f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2950cbfe843d45e68f856f33961cba31_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icebba189d4a3458198db7346f2a6e713_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24f803edfbc4167bb3299a898ee2e13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ddb314823aa47c6954a1f2feca8eebc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8ae0bf62de4457894eb884499173f85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb86dc9c584485fb7a5049e10ba046b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b7f8648b2f44883844130f1d90b85ca_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e1ba5291ab459dabb27adb7b97387a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26737262a3c3462b96de8ebe023d1021_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3daaadb2da99469f970536fbd9f589ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia40a7732f3a44955b312d4698d4c6026_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83be474e89ab4750bd00aebc5eb6ad68_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id315307ab2cb4c808c77a47abdcb132c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d95952196a41059a02aa8be7602540_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id961d5e81bdf4ce5b89fc5130610e285_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia103de5e6cbe4fb2a104961a19138f6d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie39a5cbe975a499289e9b0481f88571c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37ee02873134a16a7d2ac745f1f3efb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e9f2daaae4745d2ae55c4ff7963f472_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2a922a9abe43d5a57491ba600cf3d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bbaa3f0d655424f8b54cbdd948628ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d42283095d74b78ad5e947157ee6849_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i509aa0b5030e4f4e8b6a1b0424b3b2b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e10e6c25c3b4557a099fe326409b993_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7a07462ffa4e17bc9007b49e82bb59_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa9ecb4f9e4493aa7973a44ec374287_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218d611e83f64fffadaf940a7b0b4fb6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id76b73811b3549068b674f9ad76a7123_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95423e666a3b4e49b40bfdea87560d09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f702272ab94a368cb9cf9ce09c4a23_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5266d257b030492988eccda7eea5b5de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cdce5f66d1e44a484b2b6697296c809_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1b7ba9d9fb403ab62cdc18b6eb0b30_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9d8e4e0a1e40b5989ef83e9ec5eec8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11fc958fd5eb46b88f87a1d5fd077ea1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eafdbc1aa0149d59422d69d95d29318_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925822b570a24b5ca88a9c40184078f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df1b6b114284f41a95dbc2dad95ed8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966a056f15d24b6d807f7b9fcf634f8a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c7ec1f79b043b5b18d5e72d1499fdb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8352fe1a5ba54b86949f5c412a8f6d84_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fcf3dfb4b9a4b46a7e562cb5174729e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3b6478297d44108e0c4b7a552445ed_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba005e9d4424eb3975bed7e80cec408_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id46eaf3fcf0744889088ffbbc1e457c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2213ab4b32ee478b9b62e4101ed98e0d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3be092e6e874de493898709ec58bcd6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574e546b62164a8a9f5caddcf3c862e0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i976d902516444c31a4ac366db6d832da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccebb2ddc10e443c8537cc870f8ba888_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2839ccfa8fb44d8fa8ebd57a2d4c45a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca98a5ab938484c825c7201cf25965b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d15a37330f4dd78bdfeef167d3a769_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512a98056064477d978b1b7f932b53ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifae8562aa19d49e0880f0646e4267477_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de3ad1081d5496086b75ba3dfaa828e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i220331bcd9ca417b9f8990a1d20fde9e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibce7dbd95b264cac956659757d0b8dcb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c7919a2fdb48038043cef3080be5a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc3e04a9593148d0a9fbc6099bd71fcb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic63b0377678244a6b0daa177fa91da22_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51cccff8d27547a1a031e6d2ddfe47e1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0395da8cb60645ceb3126a26ed0ca226_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45440e929de74f10b63f714199cbcbe9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1082609c81ca485f837033633e3ff2ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb74f29937f40e19f43e122a3376b3f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3193b9aa442a468b835ac9e65c53542f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ffea7f6f1e4e4983ca7cd6779d45a7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef571096a444eea921f01711727d9bc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14375f6d274a48d9b9b162940b4d25dc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94fd88fa633844479351964383e1f158_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i962fd40d3ee6484299bd3c87f64af7d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic416aba94535424bbb9d655ecaf8bf86_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462d9a562b7d44599cf894438401f0f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7af0cf69df426784f6ec3b33bf0fc2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14dca43e6ead40a69e7edfc8b772ec1c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4054ed0640d4d4eb44198419c1c1fcb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e5cfb7bf144a1b85dbe4460106c525_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55dcf9079e34da1816b08c7ce38d62e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576b22bb76944f53a3d4648c3b0410c6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64789569b5264809a363eb25117c7863_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86793e8a3a894c159132ce9f8e6c1bb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4c9e4693f50403c8339af126a90a689_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e48594fc2d243a0a8f39b754d4d89c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49bc3f554ac349838de0563f48fcffe4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ed8c22a5e8422ab95386f092f05a22_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf30c9ce3ea34204891eeb2f7d539507_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72ec6b2d07874cabb0d1efdbf4e854df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ccff3c21c3473e96622780327f8b12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9210f70f2d443e5889ab66abde4d50f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72cf7144b3a4b4b8c1e9ca00c55b8f4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09dc1fc46d8f403fbb3dee2b1027efac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib820ec90c26a48c1b63f85dba3250264_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d198392ab6443c6b3cd53afafd9c428_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacae1b4908084fab9344e4706e647c20_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f8aa3dff7c84cbd81161181b2b08825_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6859c10e69f430d9106fa8705843e30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b389087e5b6434f8d9e6fddb68235bc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e7a6ff124a4cdabf9930385a1ebb81_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531cef5b6df84d26b7bf2ea92797ba73_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa6bd27f83f148fa904f54b109976d82_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a62c431e03427790bd62d76d11d85a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f63110b9c74d60afa7701608b4e568_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ae00b7d39b4af0b551da02254dc1fc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d960b8f6d74e02b74dbdf263f7040a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebadcf45558049f9945a6997f511f459_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d58d6fc48c42c586a14d29d0057c85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383680c7a3bf42a8acc1ed3448266a57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6da7dfe4fb3a43148b28617382d7d627_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14adb31336c4a369b484fe90e397510_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45187d95cd0942edb66dab8c766886f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd2491b77054229931de28963068e3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33fa4b2aac9444684437df21be88b83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e19eadf02e2447689f31531525302de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a2e88969d1400e802b86560797eb1f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb55cd05c52044ecac300d08fac63719_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19b5c015e07a4757829cb06ce4b2aa8b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058927efa4b7468ba0ad2de228285af8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b124f26fbc4ed6bfea843c38aef53c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c11152ee28442a6a313d7ee0d121638_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b8a326cbb045a2adba2e477e561ffb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic75220e6ebf14568819bd9a9b6188619_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia318474dcd744baa89624395a2172f09_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54197fbcf9eb44bfb6b566fc98512a15_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a981d56b4f645fe9eeeed274c7cba3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d10a58948e44c138c7d0466ca49b76c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed37ac5584840178c946fee09f7a1c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d9ba332d224e66a279d66f036bb8d5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c943b762ec4138807d933021b95604_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i729d5aea6d6f496f88811f7efeda63ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b0fceaafb44bd1aa406949729a0241_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d5bac46f7047728d72dfe5c070cbbf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b957d86897d4ded98362051c9b71b26_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5949335831d149739ca8f936d4b7a57c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaad2b34e87e0423a9ea15f4ae64ee1bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia16d15f92eef46998d5ead2a1b1771a9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0dd811805a64591b10c10d7d8c3a94e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5401793db14442e29e91d912fc6f3de8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id687c9edba674c009de90ff41d9177bb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9717f9d6b3c445492a8c653a191c33e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if83be0173217465a96cf353e15212445_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b092f6738974424a865248091f7861b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0fa67cf15634c3098a5ad2740b26a0e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db75135b55642678e951aa56e432e6d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36735be07e1646a08e5d2a7ed37255c9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37fd9b761d8b4af6bff239e1d9eb1a83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8e3f46fa37d451a8e35adb77e7ff6bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba30e2338734c24914a82cefe965a84_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df174afc3444428bb70e46b35047e30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716b88505d1e48bf95997e445c69d7e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bbf21a381224062a3ec08810f278afd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e5d06897a04de68392658f8d0f8904_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3310a35e6b0403a81733f2e2057d4ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4a6cec336e42db876f0c5690a9b6d4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c03523e781649d89f6ad179f060154a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7262343d9a65444c927cc6b62cffc5f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4370b43741f1402a91671b54edbf2db7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129f29a2040140c08baabf19b38dddd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184871e21ba348d1b81fad633a38d169_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib70ed1d184c44bd8ba1ed708cad91d61_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e575aafa15847fba6a21907ae53dd63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08c0043b99c4e2ba8e47c65a339ceb1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c346b2768fb40dd91ac6ebba9fb94d7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2f235c0c07d4506bd10df5031278985_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d1c311fbe544e15a962f0cdcb5479e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a7538040e541f19698e90ed9663cbf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f4efdd418f74b408cf00135e5d118c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b72e0433646475693a6cb7d2df40022_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6390040a02294303a155f1923472865c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee4add6d698c44de8cd75978f383e97c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2cad22821de46f29ac5d2e479eed81b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52040186e8344d189b9e280fb7fe1b2e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88687f58720d4395a2d6dfdd03bea675_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d0b0e5a61604c6e866e7abdc8b2f909_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dbc20679af844698cd41359e5fd718f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78313bb854a147e5a42efbba390205fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef9755b84b746e88b21161ca9f7a0f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i265675dad9e342e9b47878356a5b781d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iab6577be4c3840fd8181bdedf457fba5_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As filed with the Securities and Exchange Commission on February&#160;25, 2021 </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.985%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">WASHINGTON, D. C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:120%">_________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE2_6f1590ec-6703-44d9-911f-b42a0c28643e">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(MARK ONE)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.550%"><tr><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt:booleantrue" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6ZDZjMjI5ZTkwOTRlNDA2YWFmZmZlYjRlODc3ZmUxODUvdGFibGVyYW5nZTpkNmMyMjllOTA5NGU0MDZhYWZmZmViNGU4NzdmZTE4NV8wLTEtMS0xLTA_9959f17a-dc3f-4252-ada8-5e5d0b88db43">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Annual Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div></td></tr></table></div><div style="padding-left:144pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMjQ_35011d6a-2638-4b00-9b4d-eb8ca3ec95db"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMjQ_4fa96099-fef4-4dcd-af60-0671d2a9dc64">December 31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.550%"><tr><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NGY5ZjhlNmM4Y2MyNDM3Y2IxYWZiNzA2MWRlMjBmYTgvdGFibGVyYW5nZTo0ZjlmOGU2YzhjYzI0MzdjYjFhZmI3MDYxZGUyMGZhOF8wLTEtMS0xLTA_0f75622b-f66d-4b8c-839a-86cc5cde5bc6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="padding-left:144pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE3_bc73f54d-addf-40f5-a135-79dc7e3a5866">1-6571</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:120%">_________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzIx_c6d1016f-9d88-4266-8876-ffce639db101">Merck&#160;&amp; Co., Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.637%"><tr><td style="width:1.0%"></td><td style="width:20.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YjE0ZGVlZTc3N2I5NGMxZjkwM2FmZGNiMGNmOTQ2MTgvdGFibGVyYW5nZTpiMTRkZWVlNzc3Yjk0YzFmOTAzYWZkY2IwY2Y5NDYxOF8wLTAtMS0xLTA_70adda38-a311-4bd4-87b9-cadd3dfa3777">2000 Galloping Hill Road</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YjE0ZGVlZTc3N2I5NGMxZjkwM2FmZGNiMGNmOTQ2MTgvdGFibGVyYW5nZTpiMTRkZWVlNzc3Yjk0YzFmOTAzYWZkY2IwY2Y5NDYxOF8xLTAtMS0xLTA_315af606-c25b-45c5-8380-43cf21febd92">Kenilworth</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YjE0ZGVlZTc3N2I5NGMxZjkwM2FmZGNiMGNmOTQ2MTgvdGFibGVyYW5nZTpiMTRkZWVlNzc3Yjk0YzFmOTAzYWZkY2IwY2Y5NDYxOF8xLTItMS0xLTA_b85972e4-3268-46d5-a19a-c4a9f7529f82">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YjE0ZGVlZTc3N2I5NGMxZjkwM2FmZGNiMGNmOTQ2MTgvdGFibGVyYW5nZTpiMTRkZWVlNzc3Yjk0YzFmOTAzYWZkY2IwY2Y5NDYxOF8xLTMtMS0xLTA_d5f8f715-1b99-4116-a3d7-40be5913fd1b">07033</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzIy_dd8497c3-2078-4125-bb42-4d8fe0791316">908</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE4_974f7ff2-be69-4859-98a1-043192399eae">740-4000</ix:nonNumeric> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:48.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NGZjNDk5MTVjY2ZiNGMyMGIzZjQ1MDlhNzU5NTNiOTgvdGFibGVyYW5nZTo0ZmM0OTkxNWNjZmI0YzIwYjNmNDUwOWE3NTk1M2I5OF8wLTAtMS0xLTA_1a32ba1b-3b37-462e-94b0-f65188952ce3">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NGZjNDk5MTVjY2ZiNGMyMGIzZjQ1MDlhNzU5NTNiOTgvdGFibGVyYW5nZTo0ZmM0OTkxNWNjZmI0YzIwYjNmNDUwOWE3NTk1M2I5OF8wLTEtMS0xLTA_7978163a-135e-42c3-96d6-8fa52b2be135">22-1918501</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S Employer Identification No.)</span></div></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:35.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities Registered pursuant to Section&#160;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of Each Exchange on which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8yLTAtMS0xLTA_84348ad5-12e0-4a63-8716-df13b8de6cd6">Common Stock ($0.50&#160;par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8yLTEtMS0xLTA_a38b0bfd-ba56-432f-b67f-b508224bb97c">MRK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8yLTItMS0xLTA_d6a59bd7-e021-47d9-933c-736354d4836d">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a69ae5ef81348d4b09b8c83b9741937_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8zLTAtMS0xLTA_cfa6cdac-af2f-4f0a-8359-ae9187b7542b">1.125% Notes due 2021</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a69ae5ef81348d4b09b8c83b9741937_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8zLTEtMS0xLTA_d71a2f90-9e64-457f-bf8e-7d362c91af82">MRK/21</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a69ae5ef81348d4b09b8c83b9741937_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8zLTItMS0xLTA_ce875610-35fa-46df-8073-4172b76e9f89">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib21d7c48408a40228dbaaa754ce181ab_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl80LTAtMS0xLTA_8d0a44f2-4df6-4699-8b65-712b8abf9515">0.500% Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib21d7c48408a40228dbaaa754ce181ab_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl80LTEtMS0xLTA_bb63b8db-92db-440f-b7f7-7910dd9164af">MRK 24</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib21d7c48408a40228dbaaa754ce181ab_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl80LTItMS0xLTA_d987e9ec-d20e-4ad9-aee1-4ef4b76d9f09">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id93e99ad3baf40e8aa1621b924a2b8b8_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl81LTAtMS0xLTA_0d883439-bfbf-423b-a1f9-74b7b165783a">1.875% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id93e99ad3baf40e8aa1621b924a2b8b8_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl81LTEtMS0xLTA_351bbfde-5de5-45fe-8691-a0c30865f112">MRK/26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id93e99ad3baf40e8aa1621b924a2b8b8_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl81LTItMS0xLTA_6266efd8-cbc6-4e43-802c-e90000841863">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if42c8fd57f9e4140bb466d7b0aec1493_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl82LTAtMS0xLTA_64d610fe-2acc-47a6-9467-a2504abd0392">2.500% Notes due 2034</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if42c8fd57f9e4140bb466d7b0aec1493_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl82LTEtMS0xLTA_0dd00c93-3743-440f-88b2-ca94878f4f86">MRK/34</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if42c8fd57f9e4140bb466d7b0aec1493_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl82LTItMS0xLTA_b0c4cd65-4ef6-4f52-9e14-40a9bd3dd909">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ce73055eb814c269b6620f3c2a24a2e_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl83LTAtMS0xLTA_914b3e1b-51ca-4a13-a59c-e9cb35d7aebe">1.375% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ce73055eb814c269b6620f3c2a24a2e_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl83LTEtMS0xLTA_2ce21fe4-2cd5-4698-b086-c2dd543194f1">MRK 36A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ce73055eb814c269b6620f3c2a24a2e_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl83LTItMS0xLTA_5f9b897d-ef38-466e-a8bf-95c7be8e0260">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of shares of Common Stock ($0.50&#160;par value) outstanding as of January&#160;31, 2021: <ix:nonFraction unitRef="shares" contextRef="i525fed88e739475e9bdd2c20f8225d78_I20210131" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8zMjk4NTM0ODg2ODIz_42f7e0fa-b8e4-42da-9374-5e4f731b777f">2,530,315,668</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Aggregate market value of Common Stock ($0.50&#160;par value) held by non-affiliates on June&#160;30, 2020 based on closing price on June&#160;30, 2020: $<ix:nonFraction unitRef="usd" contextRef="ia25c4a8026c741e390c5f222dcb409cf_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8zMjk4NTM0ODg2ODg2_3e431ff6-47eb-4101-91f7-c49fb990e0f7">195,461,000,000</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.    &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzIz_667b1d0e-be1f-47ea-b604-bc4197fbf3fa">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No </span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes </span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE5_836afa71-d6ed-4c8e-9bb9-755b96b85158">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzIw_053dd703-2a3c-4c59-bc20-9e1539abe22d">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzI0_10295048-b5c9-4fbb-be58-b7313c59ea8b">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744; </span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check One):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.898%"><tr><td style="width:1.0%"></td><td style="width:20.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NWIwYmJkMGU0MjNlNDk0OGE0ZDY4YmMxZWE5ZGZlZTYvdGFibGVyYW5nZTo1YjBiYmQwZTQyM2U0OTQ4YTRkNjhiYzFlYTlkZmVlNl8wLTAtMS0xLTA_4cd8332f-fdb2-449f-8f6b-0d8294724ced">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NWIwYmJkMGU0MjNlNDk0OGE0ZDY4YmMxZWE5ZGZlZTYvdGFibGVyYW5nZTo1YjBiYmQwZTQyM2U0OTQ4YTRkNjhiYzFlYTlkZmVlNl8xLTMtMS0xLTA_e8cecc6c-2da4-4da2-adfc-13198135a8b0">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NWIwYmJkMGU0MjNlNDk0OGE0ZDY4YmMxZWE5ZGZlZTYvdGFibGVyYW5nZTo1YjBiYmQwZTQyM2U0OTQ4YTRkNjhiYzFlYTlkZmVlNl8yLTMtMS0xLTA_2773aee7-c757-41ae-8703-06c909256d97">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744; </span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV83Njk2NTgxMzk3NDk5_66944dc2-7c0c-4e7a-ade0-a41bad38acbc">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes&#160;&#160;</span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE0_694729f7-29fd-47e1-baa0-d2d8e1e2e8b6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> &#160;No&#160;&#160;</span><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Documents Incorporated by Reference:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Part of Form 10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YTJkYjM1NmI3MmNiNDAzMzk4ZTNlNjEzNzE3NzgyZjEvdGFibGVyYW5nZTphMmRiMzU2YjcyY2I0MDMzOThlM2U2MTM3MTc3ODJmMV8yLTAtMS0xLTA_a9a11893-f099-41de-9945-7a143c0dc1f8" escape="true">Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;25, 2021, to be filed with the <br/>Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Part&#160;III</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_10">Part&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_55">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_55">26</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_58">Cautionary Factors that May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_58">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_61">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_61">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_64">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_64">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_67">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_67">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_70">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_70">43</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_73">Executive Officers of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_73">44</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_76">Part&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_79">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_79">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_85">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_127">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_127">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_130">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_130">79</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_133">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_133">79</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_157">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_157">83</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_232">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_232">136</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_238">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_238">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_241">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_241">138</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_244">Management&#8217;s Report</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_244">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_247">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_247">139</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_247">Part&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_253">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_253">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_256">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_256">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_259">Security Ownership of Certain Beneficial Owners and Management and Related</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_259"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_259">Stockholder&#160;Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_259">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_262">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_262">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_265">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_265">141</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_268">Part&#160;IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_271">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_271">142</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#3030ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3030ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_283">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_283">146</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_286">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iab6577be4c3840fd8181bdedf457fba5_286">147</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_13"></div><div style="padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Business.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#8217;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had an Alliances segment that primarily included activity from the Company&#8217;s relationship with AstraZeneca LP related to sales of Nexium and Prilosec, which concluded in 2018. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned, licensed to, promoted or distributed by Merck, its subsidiaries or affiliates, except as noted. All other trademarks or services marks are those of their respective owners.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_2412"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Planned Spin-Off of Women&#8217;s Health, Biosimilars and Established Brands into a New Company&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, Merck announced its intention to spin-off (the Spin-Off) products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ezetimibe/simvastatin), as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management, and is expected over time to develop research capabilities in selected therapeutic areas. The Spin-Off is expected to be completed late in the second quarter of 2021, subject to market and certain other conditions. See &#8220;Risk Factors - Risks Related to the Proposed Spin-Off of Organon.&#8221;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Company sales, including sales of the Company&#8217;s top pharmaceutical products, as well as sales of animal health products, were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,380</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,276</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Zetia/Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,703</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,764</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"> Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Other revenues are primarily comprised of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. Certain of the products within the Company&#8217;s franchises are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), the Company&#8217;s anti-PD-1 (programmed death receptor-1) therapy, as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin Lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal cancer, gastric or gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, including MSI-H/dMMR colorectal cancer, primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer, and urothelial carcinoma, including non-muscle invasive bladder cancer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and non-squamous NSCLC, in combination with chemotherapy for HNSCC, in combination with chemotherapy for triple-negative breast cancer, in combination with axitinib for renal cell carcinoma, and in combination with lenvatinib for endometrial carcinoma; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (aprepitant) for the prevention of certain chemotherapy-induced nausea and vomiting. In addition, the Company recognizes alliance revenue related to sales of Lynparza (olaparib), an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor, for certain types of advanced ovarian, breast, pancreatic, and prostate cancers; and Lenvima (lenvatinib) for certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for certain patients with endometrial carcinoma.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccines</span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 (Human Papillomavirus 9-valent Vaccine, Recombinant), vaccines to help prevent certain diseases </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">caused by certain types of human papillomavirus (HPV);</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8722;M&#8722;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles, mumps and rubella; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaqta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (hepatitis A vaccine, inactivated) indicated for the prevention of disease caused by hepatitis A virus in persons 12 months of age and older.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection, a medication for the reversal of two types of neuromuscular blocking agents used during surgery; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (posaconazole), an antifungal agent for the prevention of certain invasive fungal infections; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(letermovir) for the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Primaxin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (imipenem and cilastatin) for injection, an antibiotic for the treatment of certain bacterial infections; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cancidas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (caspofungin acetate) for injection, an anti-fungal agent for the treatment of certain fungal infections; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invanz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ertapenem) for injection, an antibiotic for the treatment of certain bacterial infections; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cubicin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(daptomycin for injection), an antibiotic for the treatment of certain bacterial infections; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunology</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (infliximab), a treatment for inflammatory diseases, both of which the Company markets in Europe, Russia and Turkey.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Belsomra </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(suvorexant), an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virology</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zepatier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elbasvir and grazoprevir) for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection, with ribavirin in certain patient populations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe) (marketed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in most countries outside the United States); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe/simvastatin) (marketed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inegy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside the United States); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Atozet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe and atorvastatin) (marketed outside of the United States) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rosuzet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe and rosuvastatin) (marketed outside of the United States), cholesterol modifying medicines; and Adempas (riociguat), a cardiovascular drug for the treatment of pulmonary arterial hypertension.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diabetes</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin/metformin HCl) for the treatment of type 2 diabetes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Women&#8217;s Health</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etonogestrel implant), a single-rod subdermal contraceptive implant/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etonogestrel implant), a single, radiopaque, rod-shaped subdermal contraceptive implant; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etonogestrel/ethinyl estradiol vaginal ring), a vaginal contraceptive product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Animal Health</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services, as well as an extensive suite of digitally connected identification, traceability and monitoring products. Principal products in this segment include:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Livestock Products</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nuflor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Florfenicol) antibiotic range for use in cattle and swine; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bovilis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine lines for infectious diseases in cattle; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Banamine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Flunixin meglumine) bovine and swine anti-inflammatory; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estrumate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (cloprostenol sodium) for the treatment of fertility disorders in cattle; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Matrix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (altrenogest) fertility management for swine; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resflor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (florfenicol and flunixin meglumine)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a combination broad-spectrum antibiotic and non-steroidal anti-inflammatory </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug for bovine respiratory disease; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zuprevo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Tildipirosin) for bovine respiratory disease; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zilmax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (zilpaterol hydrochloride) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revalor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (trenbolone acetate and estradiol) to improve production efficiencies in beef cattle; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safe-Guard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fenbendazole) de-wormer for cattle; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M+Pac&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Mycoplasma Hyopneumoniae Bacterin) swine pneumonia vaccine; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Porcilis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Lawsonia intracellularis baterin) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Circumvent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Porcine Circovirus Vaccine, Type&#160;2, Killed Baculovirus Vector) vaccine lines for infectious diseases in swine; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nobilis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Innovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Live Marek&#8217;s Disease Vector)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine lines for poultry; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paracox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coccivac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> coccidiosis vaccines; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exzolt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a systemic treatment for poultry red mite infestations; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Slice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Emamectin benzoate) parasiticide for sea lice in salmon; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aquavac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Avirulent Live Culture)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Norvax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccines against bacterial and viral disease in fish; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact PD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine for salmon; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aquaflor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Florfenicol) antibiotic for farm-raised fish; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allflex Livestock Intelligence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> solutions for animal identification, monitoring and traceability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companion Animal Products</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a line of oral and topical parasitic control products, including the original </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluralaner) products for dogs and cats that last up to 12 weeks; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fluralaner)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> One-Month</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a monthly product for dogs, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluralaner/moxidectin), a two-month product for cats; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sentinel,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a line of oral parasitic products for dogs including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sentinel Spectrum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (milbemycin oxime, lufenuron, and praziquantel) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sentinel Flavor Tabs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (milbemycin oxime, lufenuron); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Optimmune </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(cyclosporine), an ophthalmic ointment;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Nobivac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine lines for flexible dog and cat vaccination; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otomax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Gentamicin sulfate, USP; Betamethasone valerate USP; and Clotrimazole USP ointment)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mometamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Gentamicin sulfate, USP, Mometasone Furoate Monohydrate and Clotrimazole, USP, Otic Suspension)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Posatex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Orbifloxacin, Mometasone Furoate Monohydrate and Posaconazole, Suspension) ear ointments for acute and chronic otitis; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caninsulin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vetsulin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (porcine insulin zinc suspension) diabetes mellitus treatment for dogs and cats; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Panacur</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fenbendazole)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safeguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fenbendazole) broad-spectrum anthelmintic (de-wormer) for use in many animals; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regumate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (altrenogest) fertility management for horses; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prestige</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine line for horses; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scalibor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Deltamethrin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/Exspot</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for protecting against bites from fleas, ticks, mosquitoes and sandflies; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sure Petcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products for companion animal identification and well-being, including the microchip and pet recovery system </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Again</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of sales of the Company&#8217;s products, see Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; below.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_22"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Product Approvals</span></div><div style="margin-bottom:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a summary of significant product approvals received by the Company in 2020.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approval</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2020</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. Food and Drug Administration (FDA) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dificid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as an oral suspension, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dificid</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea in children aged six months and older.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gardasil</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">China&#8217;s National Medical Products Administration (NMPA) granted expanded approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for use in girls and women from 9 to 45 years of age.</span></div></td></tr><tr style="height:69pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) approved additional indication, dosage and administrations of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Gardasil 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (marketed as  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Silgard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> 9) for the prevention of anal cancer (squamous cell cancer) and precursor lesions (anal intraepithelial neoplasia (AIN) grade 1/2/3) caused by HPV types 6, 11, 16 and 18 for individuals 9 years and older and for Genital Warts (condyloma acuminate) for men 9 years and older.</span></div></td></tr><tr style="height:50pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 9 for use in girls and women 9 years and older for the prevention of cervical cancer, certain cervical, vaginal and vulvar precancers, and genital warts caused by the HPV types covered by the vaccine.</span></div></td></tr><tr style="height:42pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA granted accelerated approval for an expanded indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Gardasil&#160;9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.</span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.927%"></td><td style="width:0.1%"></td></tr><tr style="height:60pt"><td colspan="3" rowspan="11" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2020</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NMPA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as monotherapy for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (Combined Positive Score CPS &#8805;20) as determined by a fully validated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">test.</span></div></td></tr><tr style="height:41pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA granted accelerated approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple&#8209;negative breast cancer whose tumors express PD-L1 (CPS &#8805;10).</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approved an expanded label for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, as monotherapy for the treatment of adult patients with relapsed or refractory cHL.</span></div></td></tr><tr style="height:51pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PMDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for use at an additional recommended dosage of 400 mg every six weeks (Q6W) administered as an intravenous infusion over 30 minutes across all adult indications, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> monotherapy and combination therapy.</span></div><div><span><br/></span></div></td></tr><tr style="height:50pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PMDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the treatment of patients whose tumors are PD-L1-positive, and have radically unresectable, advanced or recurrent esophageal squamous cell carcinoma (ESCC) who have progressed after chemotherapy.</span></div><div><span><br/></span></div></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as monotherapy for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as monotherapy for the treatment of patients with recurrent or metastatic cSCC that is not curable by surgery or radiation.</span></div></td></tr><tr style="height:54pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NMPA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as monotherapy for the treatment of patients with locally advanced or metastatic ESCC whose tumors express PD-L1 (CPS &#8805;10) as determined by a fully validated test, following failure of one prior line of systemic therapy.</span></div></td></tr><tr style="height:65pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA granted accelerated approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-H [&#8805;10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.</span></div></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA granted accelerated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for use at an additional recommended dose of 400 mg every six weeks (Q6W) for all approved adult indications.</span></div></td></tr><tr style="height:53pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2020</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Koselugo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approved the kinase inhibitor Koselugo for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lenvima</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NMPA approved Lenvima as a monotherapy for the treatment of differentiated thyroid cancer.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.927%"></td><td style="width:0.1%"></td></tr><tr style="height:41pt"><td colspan="3" rowspan="8" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PMDA approved Lynparza for the treatment of patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> gene-mutated (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">m) castration-resistant prostate cancer with distant metastasis.</span></div></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PMDA approved Lynparza as maintenance treatment after platinum-based chemotherapy for patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">m curatively unresectable pancreas cancer.</span></div></td></tr><tr style="height:48pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PMDA approved Lynparza as maintenance treatment after first-line chemotherapy containing bevacizumab (genetical recombination) in patients with homologous recombination repair deficient (HRD) ovarian cancer.</span></div></td></tr><tr style="height:98pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The European Commission (EC) approved Lynparza for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with HRD-positive status defined by either a breast cancer susceptibility gene 1/2 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1/2) mutation and/or genomic instability.</span></div></td></tr><tr style="height:53pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC approved Lynparza as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) who have progressed following a prior therapy that included a new hormonal agent.</span></td></tr><tr style="height:65pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approved Lynparza </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as a monotherapy for the maintenance treatment of adult patients with germline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BRCA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.</span></div></td></tr><tr style="height:65pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approved Lynparza </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC, as determined by an FDA-approved test, who have progressed following prior treatment with enzalutamide or abiraterone.</span></div></td></tr><tr style="height:84pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approved Lynparza </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in combination with bevacizumab as a first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with HRD positive status defined by either a deleterious or suspected deleterious </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BRCA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> mutation, and/or genomic instability, as determined by an FDA-approved test.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Recarbrio<br/></span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020<br/></span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recarbrio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Steglatro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NMPA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Steglatro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 5 mg tablets for the treatment of type 2 diabetes.</span></div></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Dificid in the U.S. and Canada is a trademark of Cubist Pharmaceuticals LLC, an indirect wholly-owned subsidiary of Merck Sharp &amp; Dohme Corp.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#1a1a1a;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In July 2017, Merck and AstraZeneca entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s </span><span style="color:#1a1a1a;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lynparza</span><span style="color:#1a1a1a;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> and </span><span style="color:#1a1a1a;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Koselugo</span><span style="color:#1a1a1a;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#1a1a1a;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#1a1a1a;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Being commercialized and promoted in a worldwide, except Japan, collaboration with Pfizer Inc. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition and the Health Care Environment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets in which the Company conducts its business and the pharmaceutical industry in general are highly competitive and highly regulated. The Company&#8217;s competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers, and animal health care companies. The Company&#8217;s operations may be adversely affected by generic and biosimilar competition as the Company&#8217;s products mature, as well as technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, the generic availability of competitors&#8217; branded products, and new information from clinical trials of marketed products or post-marketing surveillance. In addition, patent rights are increasingly being challenged by competitors, and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical competition involves a rigorous search for technological innovations and the ability to market these innovations effectively. With its long-standing emphasis on research and development, the Company is well-positioned to compete in the search for technological innovations. The Company is active in acquiring and marketing products through external alliances, such as licensing arrangements and collaborations and has been refining its sales and marketing efforts to address changing industry conditions. However, the introduction of new products and processes by competitors may result in price reductions and product displacements, even for products protected by patents. For example, the number of compounds available to treat a particular disease typically increases over time and can result in slowed sales growth or reduced sales for the Company&#8217;s products in that therapeutic category.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The highly competitive animal health business is affected by several factors including regulatory and legislative issues, scientific and technological advances, product innovation, the quality and price of the Company&#8217;s products as well as competitors&#8217; products, effective promotional efforts and the frequent introduction of generic products by competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Environment and Government Regulation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal and state governments for many years have pursued methods to reduce the cost of drugs and vaccines for which they pay. For example, federal and state laws require the Company to pay specified rebates for medicines reimbursed by Medicaid and to provide discounts for medicines purchased by certain state and federal entities such as the Department of Defense, Veterans Affairs, Public Health Service entities and hospitals serving a disproportionate share of low income or uninsured patients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Programs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States enacted major health care reform legislation in 2010 (the ACA). Various insurance market reforms have since advanced and state and federal insurance exchanges were launched in 2014. With respect to the effect of the law on the pharmaceutical industry, the law increased the mandated Medicaid rebate from 15.1% to 23.1%, expanded the rebate to Medicaid managed care utilization, and increased the types of entities eligible for the federal 340B drug discount program. The law also requires pharmaceutical manufacturers to pay 70% of the cost of the medicine, including biosimilar products, when Medicare Part D beneficiaries are in the Medicare Part D coverage gap (i.e., the so-called &#8220;donut hole&#8221;), which increased from 50% beginning in 2019 as a result of the Balanced Budget Act of 2018. Merck recorded approximately $700 million, $615 million and $365 million as a reduction to revenue in 2020, 2019, and 2018, respectively, related to the donut hole provision. Also, pharmaceutical manufacturers are required to pay an annual non-tax deductible health care reform fee. The total annual industry fee has been set at $2.8 billion. The fee is assessed on each company in proportion to its share of prior year branded pharmaceutical sales to certain government programs, such as Medicare and Medicaid. The Company recorded approximately $85 million, $112 million, and $124&#160;million of costs within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses in 2020, 2019 and 2018, respectively, for the annual health care reform fee. In February 2016, the Centers for Medicare &amp; Medicaid Services (CMS) issued the Medicaid rebate final rule that implemented provisions of the ACA effective April&#160;1, 2016. The rule provides comprehensive guidance on the calculation of Average Manufacturer Price and Best Price; two metrics utilized to determine the rebates drug manufacturers are required to pay to state Medicaid programs. More recently, although CMS previously declined to define what constitutes a product &#8220;line extension&#8221; (beyond the statutory definition), CMS issued a new rule on December 21, 2020 that will significantly expand the definition of the term &#8220;line extension&#8221; as of January 1, 2022 to include a broad range of products, including products reflecting new strengths, dosage forms, release mechanisms, and routes of administration. This expanded definition will increase the number of drugs subject to a higher Medicaid rebate. Effective January 1, 2023, this final rule also changes the way that manufacturers must calculate Best Price, in relation to certain patient support programs, including coupons, which also may result in an increase in the Company&#8217;s Medicaid rebates. The impact of these and other provisions in this final rule could adversely impact the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty about the future of the ACA in particular and health care laws in general in the United States. In December 2018, a Texas federal district court struck down the ACA on the grounds that the individual health insurance mandate is unconstitutional. The United States Supreme Court heard arguments in this case on November 10, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is participating in the health care debate and monitoring how any proposed changes could affect its business. The Company is unable to predict the likelihood of changes to the ACA. Depending on the nature of any changes to the ACA, such actions could have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legislative Changes</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. A number of states have passed pharmaceutical price and cost transparency laws. These laws typically require manufacturers to report certain product price information or other financial data to the state. Some laws also require manufacturers to provide advance notification of price increases. The Company expects that states will continue their focus on pharmaceutical price transparency and that this focus will continue to exert pressure on product pricing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Pricing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also faces increasing pricing pressure globally from managed care organizations, government agencies and programs that could negatively affect the Company&#8217;s sales and profit margins, including, in the United States (i)&#160;practices of managed care organizations, federal and state exchanges, and institutional and governmental purchasers, and (ii)&#160;federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and the ACA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Department of Health and Human Services Office of Inspector General (OIG) issued a Final Rule that would, effective January 1, 2023, eliminate the Anti-Kickback Statute safe harbor for rebates paid to Medicare Part D plans or to pharmacy benefit managers (PBMs) on behalf of such plans. While the Company cannot anticipate the effects of this change to the way it currently contracts, this new framework could significantly alter the way it does business with Part D Plan Sponsors and PBMs on behalf of such plans. This rulemaking also established, effective January 1, 2021, a new safe harbor for point of sale discounts at the pharmacy counter and a new safe harbor for certain services arrangements between pharmaceutical manufacturers and PBMs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS also recently issued an Interim Final Rule (the MFN Rule) that alters how physicians will be reimbursed under the Medicare program for physician administered drugs. Pursuant to the MFN Rule, which was intended to be effective January 1, 2021, rather than use the current Average Sales Price (ASP)-based payment framework for certain physician-administered drugs, the MFN Rule would institute a new pricing system for certain prescription drugs and biologic products covered by Medicare Part B in which Medicare would reimburse no more than the &#8220;most favored nation price,&#8221; meaning the lowest price after adjusting for volume and differences in gross domestic product, for the top 50 Part B reimbursed products, which includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, sold in 22 member countries of the Organisation for Economic Co-operation and Development (OECD). Several organizations, including two </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trade groups of which Merck is a member, have filed suit challenging this regulation. Those lawsuits remain pending with a preliminary injunction having been entered in one of the cases. At this time, the Company cannot predict with any certainty if or when the MFN Rule will go into effect. Implementation of the MFN Rule could have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also recently issued rulemaking allowing the commercial importation of certain prescription drugs from Canada through FDA-authorized, time-limited programs sponsored by states or Native American tribes recognized under the rule, and, in certain future circumstances, pharmacists and wholesalers. The FDA also recently released final guidance for industry detailing procedures for drug manufacturers to import FDA-approved prescription drug, biological, and combination products that were manufactured abroad and authorized and intended for sale in a foreign country. A trade organization, in which Merck is a member, brought suit, which remains pending in federal district court, challenging the commercial importation rule. These proposed changes could have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the health care system enacted as part of health care reform in the United States, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, could result in further pricing pressures. As an example, health care reform has contributed to an increase in the number of patients in the Medicaid program under which sales of pharmaceutical products are subject to substantial rebates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry also could be considered a potential source of savings via other legislative and administrative proposals that have been debated but not enacted. These types of revenue generating or cost saving proposals include additional direct price controls. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was active consideration of drug-pricing related legislation in the last Congress, and it remains very uncertain as to what proposals, if any, may be included as part of future federal legislative proposals that would directly or indirectly affect the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. private sector, consolidation and integration among health care providers is a major factor in the competitive marketplace for pharmaceutical products. Health plans and PBMs have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. Private third-party insurers, as well as governments, employ formularies to control costs by negotiating discounted prices in exchange for formulary inclusion. Failure to obtain timely or adequate pricing or formulary placement for Merck&#8217;s products or obtaining such placement at unfavorable pricing could adversely affect revenue. In addition to formulary tier co-pay differentials, private health insurance companies and self-insured employers have been raising co-payments required from beneficiaries, particularly for branded pharmaceuticals and biotechnology products. Private health insurance companies also are increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product if a generic product is available or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. These same management tools are also used in treatment areas in which the payor has taken the position that multiple branded products are therapeutically comparable. As the U.S. payor market concentrates further and as more drugs become available in generic form, pharmaceutical companies may face greater pricing pressure from private third-party payors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide information about the Company&#8217;s pricing practices, the Company annually posts on its website&#160;its Pricing Transparency Report for the United States. The report provides the Company&#8217;s average annual list price, net price increases, and average discounts across the Company&#8217;s U.S. portfolio dating back to 2010. In 2020, the Company&#8217;s gross U.S. sales were reduced by 45.5% as a result of rebates, discounts and returns.&#160; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">European Union</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts toward health care cost containment remain intense in the European Union (EU). The Company faces competitive pricing pressure resulting from generic and biosimilar drugs. In addition, a majority of countries in the EU attempt to contain drug costs by engaging in reference pricing in which authorities examine pre-determined markets for published prices of drugs. Reference pricing may either compare a product&#8217;s prices in other markets (external reference pricing), or compare a product&#8217;s price with those of other products in a national class (internal reference pricing). The authorities then use the price data to set new local prices for brand-name drugs, including the Company&#8217;s drugs. Guidelines for examining reference pricing are usually set in local markets and can be changed </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursuant to local regulations. Some EU Member States have established free-pricing systems, but regulate the pricing for drugs through profit control plans. Others seek to negotiate or set prices based on the cost-effectiveness of a product or an assessment of whether it offers a therapeutic benefit over other products in the relevant class. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In some EU Member States, cross-border imports from low-priced markets also exert competitive pressure that may reduce pricing within an EU Member State.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, EU Member States have the power to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement. In the EU, pricing and reimbursement plans vary widely from Member State to Member State. Some EU Member States provide that drug products may be marketed only after a reimbursement price has been agreed. Some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to already available therapies or so-called health technology assessments (HTA), in order to obtain reimbursement or pricing approval. The HTA of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in most EU Member States. The HTA process, which is governed by the national laws of these countries, involves the assessment of the cost-effectiveness, public health impact, therapeutic impact and/or the economic and social impact of use of a given pharmaceutical product in the national health care system of the individual country is conducted. Ultimately, HTA measures the added value of a new health technology compared to existing ones. The outcome of HTAs regarding specific pharmaceutical products will often influence the pricing and reimbursement status granted to these pharmaceutical products by the regulatory authorities of individual EU Member States. A negative HTA of one of the Company&#8217;s products may mean that the product is not reimbursable or may force the Company to reduce its reimbursement price or offer discounts or rebates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A negative HTA by a leading and recognized HTA body could also undermine the Company&#8217;s ability to obtain reimbursement for the relevant product outside a jurisdiction. For example, EU Member States that have not yet developed HTA mechanisms may rely to some extent on the HTA performed in other countries with a developed HTA framework, to inform their pricing and reimbursement decisions. HTA procedures require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining product reimbursement and exert downward pressure on available reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain reimbursement or pricing approval in some EU Member States, the Company may be required to conduct studies that compare the cost-effectiveness of the Company&#8217;s product candidates to other therapies that are considered the local standard of care. There can be no assurance that any EU Member State will allow favorable pricing, reimbursement and market access conditions for any of the Company&#8217;s products, or that it will be feasible to conduct additional cost-effectiveness studies, if required.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brexit</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the United Kingdom (UK) held a referendum in which voters approved an exit from the EU, commonly referred to as &#8220;Brexit.&#8221; As a result of that referendum and subsequent negotiations, the UK left the EU on January 31, 2020. A transitional period applied from January 31, 2020 until December 31, 2020, and during this period the EU and UK operated as if the UK was an EU Member State, and the UK continued to participate in the EU Customs Union allowing for the freedom of movement for people and goods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It was announced on December 24, 2020, that the EU and the UK agreed to a Trade and Cooperation Agreement (TCA). The TCA sets out the new arrangements for trade of goods, including medicines and vaccines, which allows goods to continue to flow between the EU and the UK. On December 29, 2020, the Council of the EU adopted the decision to sign the TCA and for the TCA to be provisionally applied from January 1, 2021. The UK and EU signed the TCA on December 30, 2020. In order for the TCA to be ratified and formally come into effect, the Council of the EU must unanimously approve the TCA and the European Parliament must consent to it, which the Company believes will occur. As a result of the TCA, the Company believes that its operations will not be materially adversely affected by Brexit. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Japan</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, the pharmaceutical industry is subject to government-mandated biennial price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricings for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules. The next government-mandated price reduction will occur in April 2021 and is expected to impact many Company products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">China</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business in China has grown rapidly in the past few years, and the importance of China to the Company&#8217;s overall pharmaceutical and vaccines business has increased accordingly. Continued growth of the Company&#8217;s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company&#8217;s current in-line products, and the absence of trade impediments or adverse pricing controls. In recent years, the Chinese government has introduced and implemented a number of structural reforms to accelerate the shift to innovative products and reduce costs. Since 2017, there have been multiple new policies introduced by the government to improve access to new innovation, reduce the complexity of regulatory filings, and accelerate the review and approval process. This has led to a significant increase in the number of new products being approved each year. Additionally, in 2017, the Chinese government updated the National Reimbursement Drug List (NRDL) for the first time in eight years. While the mechanism for drugs being added to the list evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2020, drugs were added to the NRDL through double-digit price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through volume based procurement (VBP). In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the first three rounds of VBP have had, on average, a price reduction of 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Emerging Markets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls and measures impacting intellectual property, including in exceptional cases, threats of compulsory licenses, that aim to put pressure on the price of innovative pharmaceuticals or result in constrained market access to innovative medicine. The Company anticipates that pricing pressures and market access challenges will continue in the future to varying degrees in the emerging markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond pricing and market access challenges, other conditions in emerging market countries can affect the Company&#8217;s efforts to continue to grow in these markets, including potential political instability, changes in trade sanctions and embargoes, significant currency fluctuation and controls, financial crises, limited or changing availability of funding for health care, credit worthiness of health care partners, such as hospitals, due to COVID-19, and other developments that may adversely impact the business environment for the Company. Further, the Company may engage third-party agents to assist in operating in emerging market countries, which may affect its ability to realize continued growth and may also increase the Company&#8217;s risk exposure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addressing cost containment pressures, the Company engages in public policy advocacy with policymakers and continues to work to demonstrate that its medicines provide value to patients and to those who pay for health care. The Company advocates with government policymakers to encourage a long-term approach to sustainable health care financing that ensures access to innovative medicines and does not disproportionately target pharmaceuticals as a source of budget savings. In markets with historically low rates of health care spending, the Company encourages those governments to increase their investments and adopt market reforms in order to improve their citizens&#8217; access to appropriate health care, including medicines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts. Although no one can predict the effect of these and other factors on the Company&#8217;s business, the Company continually takes measures to evaluate, adapt and improve the organization and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its business practices to better meet customer needs and believes that it is well-positioned to respond to the evolving health care environment and market forces.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is also subject to regulation by regional, country, state and local agencies around the world focused on standards and processes for determining drug safety and effectiveness, as well as conditions for sale or reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of particular importance is the FDA in the United States, which administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling, and marketing of prescription pharmaceuticals. In some cases, the FDA requirements and practices have increased the amount of time and resources necessary to develop new products and bring them to market in the United States. At the same time, the FDA has committed to expediting the development and review of products bearing the &#8220;breakthrough therapy&#8221; designation, which has accelerated the regulatory review process for medicines with this designation. The FDA has also undertaken efforts to bring generic competition to market more efficiently and in a more timely manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU has adopted directives and other legislation concerning the classification, approval for marketing, labeling, advertising, manufacturing, wholesale distribution, integrity of the supply chain, pharmacovigilance and safety monitoring of medicinal products for human use. These provide mandatory standards throughout the EU, which may be supplemented or implemented with additional regulations by the EU member states. In particular, EU regulators may approve products subject to a number of post-authorization conditions. Examples of typical post-authorization commitments include additional pharmacovigilance, the conduct of clinical trials, the establishment of patient registries, physician or patient education and controlled distribution and prescribing arrangements. Non-compliance with post-authorization conditions, pharmacovigilance and other obligations can lead to regulatory action, including the variation, suspension or withdrawal of the marketing authorizations, or other enforcement or regulatory actions, including the imposition of financial penalties. The Company&#8217;s policies and procedures are already consistent with the substance of these directives; consequently, it is believed that they will not have any material effect on the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it will continue to be able to conduct its operations, including launching new drugs, in this regulatory environment. (See &#8220;Research and Development&#8221; below for a discussion of the regulatory approval process.)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access to Medicines</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global health care company, Merck&#8217;s primary role is to discover and develop innovative medicines and vaccines. The Company also recognizes that it has an important role to play in helping to improve access to its medicines, vaccines, and to quality health care around the world. The Company&#8217;s efforts in this regard are wide-ranging and include a set of principles that the Company strives to embed into its operations and business strategies to guide the Company&#8217;s worldwide approach to expanding access to health care. In addition, through innovative social investments, including philanthropic programs and impact investing, Merck is also helping to strengthen health systems and build capacity, particularly in under-resourced communities. The Merck Patient Assistance Program provides medicines and adult vaccines for free to people in the United States who do not have prescription drug or health insurance coverage and who, without the Company&#8217;s assistance, cannot afford their Merck medicines and vaccines. Merck has funded &#8220;Merck for Mothers,&#8221; a long-term effort with global health partners to end preventable deaths from complications of pregnancy and childbirth. Merck has also provided funds to the Merck Foundation, an independent grantmaking organization, which has partnered with a variety of organizations dedicated to improving global health.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_28"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Privacy and Data Protection</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a significant number of privacy and data protection laws and regulations globally, many of which place restrictions on the Company&#8217;s ability to transfer, access and use personal data across its business. The legislative and regulatory landscape for privacy and data protection continues to evolve. There has been increased attention to privacy and data protection issues in both developed and emerging markets with the potential to affect directly the Company&#8217;s business, including the EU General Data Protection Regulation, (GDPR) which went into effect in May 2018 and imposes penalties of up to 4% of global revenue. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR and related implementing laws in individual EU Member States govern the collection and use of personal health data and other personal data in the EU. The GDPR increased responsibility and liability in relation to personal data that the Company processes. It also imposes a number of strict obligations and restrictions on the ability to process (which includes collection, analysis and transfer of) personal data, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities, and the security and confidentiality of the personal data. Further, the GDPR prohibits the transfer of personal data to countries outside of the EU that are not considered by the EC to provide an adequate level of data protection, including to the United States, except if the data controller meets very specific requirements. Following the Schrems II decision of the Court of Justice of the European Union on July 16, 2020, there is considerable uncertainty as to the permissibility of international data transfers under the GDPR. In light of the implications of this decision, the Company may face difficulties regarding the transfer of personal data from the EU to third countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines and other administrative penalties as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both EU level and at the national level in individual EU Member States concerning implementation and compliance practices is often updated or otherwise revised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is, moreover, a growing trend towards required public disclosure of clinical trial data in the EU which adds to the complexity of obligations relating to processing health data from clinical trials. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against the Company, harm to its reputation, and adversely impact its business and operating results. The uncertainty regarding the interplay between different regulatory frameworks further adds to the complexity that the Company faces with regard to data protection regulation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional laws and regulations enacted in the United States (such as the California Consumer Privacy Act), Europe, Asia and Latin America, have increased enforcement and litigation activity in the United States and other developed markets, as well as increased regulatory cooperation among privacy authorities globally. The Company has adopted a comprehensive global privacy program to manage these evolving risks and facilitate the transfer of personal information across international borders.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_31"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, PBMs and other institutions. Human health vaccines are sold primarily to physicians, wholesalers, physician distributors and government entities. The Company&#8217;s professional representatives communicate the effectiveness, safety and value of the Company&#8217;s pharmaceutical and vaccine products to health care professionals in private practice, group practices, hospitals and managed care organizations. The Company sells its animal health products to veterinarians, distributors and animal producers.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_37"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents, Trademarks and Licenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent protection is considered, in the aggregate, to be of material importance to the Company&#8217;s marketing of its products in the United States and in most major foreign markets. Patents may cover products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">per se</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pharmaceutical formulations, processes for, or intermediates useful in, the manufacture of products, or the uses of products. Protection for individual products extends for varying periods in accordance with the legal life of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent and its scope of coverage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Food and Drug Administration Modernization Act includes a Pediatric Exclusivity Provision that may provide an additional six months of market exclusivity in the United States for indications of new or currently marketed drugs if certain agreed upon pediatric studies are completed by the applicant. Current U.S. patent law </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides additional patent term for periods when the patented product was under regulatory review by the FDA. The EU also provides an additional six months of pediatric market exclusivity attached to a product&#8217;s Supplementary Protection Certificate (SPC). Japan provides the additional term for pediatric studies attached to market exclusivity unrelated to patent term.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent portfolios developed for products introduced by the Company normally provide market exclusivity. The Company has the following key patent protection in the United States, the EU, Japan and China (including the potential for patent term extensions (PTE) and SPCs where indicated) for the following marketed products:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Product</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (U.S.)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (EU)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (Japan)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">(China)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Janumet XR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Isentress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022-2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 (patents), 2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adempas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Nexplanon</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 (device)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 (device)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Bravecto</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 (patents), 2029 (SPCs)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gardasil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 (patents)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 (patents), 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032-2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (patents), 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028-2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 (patents), 2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sivextro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (patents), 2029 (SPCs)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (patents), 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segluromet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 (patents), 2034 (SPCs)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Steglatro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 (patents), 2034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Steglujan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(with pending PTE)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 (patents), 2034 (SPCs)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verquvo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Delstrigo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (patents), 2033 (SPCs)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pifeltro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (patents), 2033 (SPCs)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Recarbrio</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(with pending PTE)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="margin-top:2pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note:&#160;&#160;&#160;&#160;Compound patent unless otherwise noted.&#160;Certain of the products listed may be the subject of patent litigation. See Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note 10. &#8220;Contingencies and Environmental Liabilities&#8221; below.</span></div><div style="margin-top:2pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">N/A:&#160;&#160;&#160;&#160;Currently no marketing approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.44pt">The EU date represents the expiration date for the following five countries: France, Germany, Italy, Spain and the United Kingdom (Major EU Markets). If SPC applications have been filed but have not been granted in all Major EU Markets, both the patent expiry date and the SPC expiry date are listed.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The PTE system in Japan allows for a patent to be extended more than once provided the later approval is directed to a different indication from that of the previous approval. This may result in multiple PTE approvals for a given patent, each with its own expiration date.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Eligible for 6 months Pediatric Exclusivity.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company has no marketing rights in the U.S., Japan or China.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Expiration of the distribution agreement with Janssen Pharmaceuticals, Inc. </span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Part of a global strategic oncology collaboration with Eisai.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Being commercialized in a worldwide collaboration with Bayer AG.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Part of a global strategic oncology collaboration with AstraZeneca.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Being commercialized and promoted in a worldwide, except Japan, collaboration with Pfizer Inc.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Company has no marketing rights in Japan.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(11)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Company has no marketing rights in the EU, Japan or China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has the following key U.S. patent protection for drug candidates under review or in Phase 3 development:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Phase 3 Drug Candidate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currently Anticipated</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (in the U.S.)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MK-7264 (gefapixant)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">V114 (pneumoconjugate vaccine)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (vaccine composition)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MK-7110 (CD24Fc)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MK-8591A (islatravir/doravirine)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">MK-6482 (belzutifan)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2034</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, the patents in the above charts are compound patents. Each patent may be subject to a future patent term restoration of up to five years and six month pediatric market exclusivity, either or both of which may be available. In addition, depending on the circumstances surrounding any final regulatory approval of the compound, there may be other listed patents or patent applications pending that could have relevance to the product as finally approved; the relevance of any such application would depend upon the claims that ultimately may be granted and the nature of the final regulatory approval of the product. Also, regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a compound&#8217;s patent estate. In the United States, the data protection generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication and 12 years from first marketing approval of a biological product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the expiration of a product patent normally results in a loss of market exclusivity for the covered pharmaceutical product, commercial benefits may continue to be derived from: (i)&#160;later-granted patents on processes and intermediates related to the most economical method of manufacture of the active ingredient of such product; (ii)&#160;patents relating to the use of such product; (iii)&#160;patents relating to novel compositions and formulations; and (iv)&#160;in the United States and certain other countries, market exclusivity that may be available under relevant law. The effect of product patent expiration on pharmaceutical products also depends upon many other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient of the product and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions to market exclusivity are sought in the United States and other countries through all relevant laws, including laws increasing patent life. Some of the benefits of increases in patent life have been partially offset by an increase in the number of incentives for and use of generic products. Additionally, improvements in intellectual property laws are sought in the United States and other countries through reform of patent and other relevant laws and implementation of international treaties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information with respect to the Company&#8217;s patents, see Item&#160;1A. &#8220;Risk Factors&#8221; and Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;10. &#8220;Contingencies and Environmental Liabilities&#8221; below.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, all of the Company&#8217;s important products are sold under trademarks that are considered in the aggregate to be of material importance. Trademark protection continues in some countries as long as used; in other countries, as long as registered. Registration is for fixed terms and can be renewed indefinitely.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty income in 2020 on patent and know-how licenses and other rights amounted to $185 million. Merck also incurred royalty expenses amounting to $2.0 billion in 2020 under patent and know-how licenses it holds.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is characterized by the introduction of new products or new uses for existing products through a strong research and development program. At December 31, 2020, approximately 16,750 people were employed in the Company&#8217;s research activities. The Company prioritizes its research and development efforts and focuses on candidates that it believes represent breakthrough science that will make a difference for patients and payers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a number of long-term exploratory and fundamental research programs in biology and chemistry as well as research programs directed toward product development. The Company&#8217;s research and development model is designed to increase productivity and improve the probability of success by prioritizing the Company&#8217;s research and development resources on candidates the Company believes are capable of providing unambiguous, promotable advantages to patients and payers and delivering the maximum value of its approved medicines and vaccines through new indications and new formulations. Merck is pursuing emerging product opportunities independent of therapeutic area or modality (small molecule, biologics and vaccines) and is building its biologics capabilities. The Company is committed to ensuring that externally sourced programs remain an important component of its pipeline strategy, with a focus on supplementing its internal research with a licensing and external alliance strategy focused on the entire spectrum of collaborations from early research to late-stage compounds, as well as access to new technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s clinical pipeline includes candidates in multiple disease areas, including cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, respiratory diseases, and vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the development of human health products, industry practice and government regulations in the United States and most foreign countries provide for the determination of effectiveness and safety of new chemical compounds through pre-clinical tests and controlled clinical evaluation. Before a new drug or vaccine may be marketed in the United States, recorded data on pre-clinical and clinical experience are included in the New Drug Application (NDA) for a drug or the Biologics License Application (BLA) for a vaccine or biologic submitted to the FDA for the required approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the Company&#8217;s scientists discover a new small molecule compound or biologic that they believe has promise to treat a medical condition, the Company commences pre-clinical testing with that compound. Pre-clinical testing includes laboratory testing and animal safety studies to gather data on chemistry, pharmacology, immunogenicity and toxicology. Pending acceptable pre-clinical data, the Company will initiate clinical testing in accordance with established regulatory requirements. The clinical testing begins with Phase 1 studies, which are designed to assess safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic activity of the compound in humans. If favorable, additional, larger Phase&#160;2 studies are initiated to determine the efficacy of the compound in the affected population, define appropriate dosing for the compound, as well as identify any adverse effects that could limit the compound&#8217;s usefulness. In some situations, the clinical program incorporates adaptive design methodology to use accumulating data to decide how to modify aspects of the ongoing clinical study as it continues, without undermining the validity and integrity of the trial. One type of adaptive clinical trial is an adaptive Phase 2a/2b trial design, a two-stage trial design consisting of a Phase 2a proof-of-concept stage and a Phase 2b dose-optimization finding stage. If data from the Phase&#160;2 trials are satisfactory, the Company commences large-scale Phase&#160;3 trials to confirm the compound&#8217;s efficacy and safety. Another type of adaptive clinical trial is an adaptive Phase 2/3 trial design, a study that includes an interim analysis and an adaptation that changes the trial from having features common in a Phase 2 study (e.g. multiple dose groups) to a design similar to a Phase 3 trial. An adaptive Phase 2/3 trial design reduces timelines by eliminating activities which would be required to start a separate study. Upon completion of Phase 3 trials, if satisfactory, the Company submits regulatory filings with the appropriate regulatory agencies around the world to have the product candidate approved for marketing. There can </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be no assurance that a compound that is the result of any particular program will obtain the regulatory approvals necessary for it to be marketed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine development follows the same general pathway as for drugs. Pre-clinical testing focuses on the vaccine&#8217;s safety and ability to elicit a protective immune response (immunogenicity). Pre-marketing vaccine clinical trials are typically done in three phases. Initial Phase 1 clinical studies are conducted in normal subjects to evaluate the safety, tolerability and immunogenicity of the vaccine candidate. Phase&#160;2 studies are dose-ranging studies. Finally, Phase&#160;3 trials provide the necessary data on effectiveness and safety. If successful, the Company submits regulatory filings with the appropriate regulatory agencies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA review process begins once a complete NDA or BLA is submitted, received and accepted for review by the agency. Within 60 days after receipt, the FDA determines if the application is sufficiently complete to permit a substantive review. The FDA also assesses, at that time, whether the application will be granted a priority review or standard review. Pursuant to the Prescription Drug User Fee Act V (PDUFA), the FDA review period target for NDAs or original BLAs is either six months, for priority review, or ten months, for a standard review, from the time the application is deemed sufficiently complete. Once the review timelines are determined, the FDA will generally act upon the application within those timelines, unless a major amendment has been submitted (either at the Company&#8217;s own initiative or the FDA&#8217;s request) to the pending application. If this occurs, the FDA may extend the review period to allow for review of the new information, but by no more than three months. Extensions to the review period are communicated to the Company. The FDA can act on an application either by issuing an approval letter or by issuing a Complete Response Letter (CRL) stating that the application will not be approved in its present form and describing all deficiencies that the FDA has identified. Should the Company wish to pursue an application after receiving a CRL, it can resubmit the application with information that addresses the questions or issues identified by the FDA in order to support approval. Resubmissions are subject to review period targets, which vary depending on the underlying submission type and the content of the resubmission.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has four program designations &#8212; Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review &#8212; to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions. The Fast Track designation provides pharmaceutical manufacturers with opportunities for frequent interactions with FDA reviewers during the product&#8217;s development and the ability for the manufacturer to do a rolling submission of the NDA/BLA. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The Breakthrough Therapy designation provides manufacturers with all of the features of the Fast Track designation as well as intensive guidance on implementing an efficient development program for the product and a commitment by the FDA to involve senior managers and experienced staff in the review. The Accelerated Approval designation allows the FDA to approve a product based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict a product&#8217;s clinical benefit and generally requires the manufacturer to conduct required post-approval confirmatory trials to verify the clinical benefit. The Priority Review designation means that the FDA&#8217;s goal is to take action on the NDA/BLA within six months, compared to ten months under standard review. More than one of these special designations can be granted for a given application (i.e., a product designated as a Breakthrough Therapy may also be eligible for Priority Review).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 public health crisis, the United States Secretary of Health and Human Services has exercised statutory authority to determine that a public health emergency exists, and declare these circumstances justify the emergency use of drugs and biological products as authorized by the FDA. While in effect, this declaration enables the FDA to issue Emergency Use Authorizations (EUAs) permitting distribution and use of specific medical products absent NDA/BLA submission or approval, including products to treat or prevent diseases or conditions caused by the SARS-CoV-2 virus, subject to the terms of any such EUAs. The FDA must make certain findings to grant an EUA, including that it is reasonable to believe based on the totality of evidence that the drug or biologic may be effective, and that known or potential benefits when used under the terms of the EUA outweigh known or potential risks. Additionally, the FDA must find that there is no adequate, approved and available alternative to the emergency use. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary method the Company uses to obtain marketing authorization of pharmaceutical products in the EU is through the &#8220;centralized procedure.&#8221; This procedure is compulsory for certain pharmaceutical products, in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA). After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA. It is also possible for new chemical products to obtain marketing authorization in the EU through a &#8220;mutual recognition procedure&#8221; in which an application is made to a single member state and, if the member state approves the pharmaceutical product under a national procedure, the applicant may submit that approval to the mutual recognition procedure of some or all other EU member states.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States and the EU, the Company submits marketing applications to national regulatory authorities. Examples of such are the Ministry of Health, Labour and Welfare in Japan, the National Medical Products Administration in China, Health Canada, Ag&#234;ncia Nacional de Vigil&#226;ncia Sanat&#225;ria in Brazil, Korea Food and Drug Administration in South Korea, and the Therapeutic Goods Administration in Australia. Each country has a separate and independent review process and timeline. In many markets, approval times can be longer as the regulatory authority requires approval in a major market, such as the United States or the EU, and issuance of a Certificate of Pharmaceutical Product from that market before initiating their local review process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Update</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the United States and internationally or in late-stage clinical development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7655A is combination of relebactum, a beta-lactamase inhibitor, and imipenem/cilastatin (a carbapenem antibiotic) under review in Japan for the treatment of bacterial infection. MK-7655A was approved by the FDA in 2019 and is marketed in the United States as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recarbrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-1242, vericiguat, is an orally administered soluble guanylate cyclase (sGC) stimulator under review in the EU and in Japan to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction, in combination with other heart failure therapies. The applications are based on results from the Phase 3 VICTORIA trial. Vericiguat was approved by the FDA in January 2021 and will be marketed in the United States as Verquvo. Vericiguat is being jointly developed with Bayer. Bayer will commercialize vericiguat in territories outside the United States, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-5618, selumetinib, is under review in the EU for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) based on positive results from the National Cancer Institute Cancer Therapy Evaluation Program-sponsored Phase 2 SPRINT Stratum 1 trial. Selumetinib was approved by the FDA in April 2020 and is marketed in the United States as Koselugo. Selumetinib is being jointly developed and commercialized with AstraZeneca globally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">V114 is an investigational 15-valent pneumococcal conjugate vaccine under priority review by the FDA for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The FDA set a PDUFA date of July 18, 2021. The EMA is also reviewing an application for licensure of V114 in adults. Additionally, the Company has several ongoing Phase 3 trials evaluating V114 in pediatric patients. V114 previously received Breakthrough Therapy designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older. The Company is involved in litigation challenging the validity of several Pfizer Inc. patents that relate to pneumococcal vaccine technology in the United States and several foreign jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,400 clinical trials, including more than 1,000 trials that combine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with other cancer treatments. These studies encompass more than 30 cancer types including: biliary tract, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, estrogen receptor positive breast cancer, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy is under review in the EU for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) in adults whose tumors express PD-L1 with a CPS &#8805; 10 and who have not received prior chemotherapy for metastatic disease based on the results of the KEYNOTE-355 trial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved for this indication under accelerated approval based on progression-free survival (PFS) by the FDA in November 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy is also under review in Japan for the treatment of patients with locally recurrent unresectable or metastatic TNBC based on data from the KEYNOTE-355 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the FDA accepted for standard review a supplemental BLA for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with high-risk, early-stage TNBC in combination with chemotherapy as neoadjuvant (pre-operative) treatment, and then as a single agent as adjuvant (post-operative) treatment after surgery. The application was based on data from the first and second interim analyses of the KEYNOTE-522 trial. In February 2021, the FDA&#8217;s Oncologic Drugs Advisory Committee (ODAC), which discussed the Company&#8217;s supplemental BLA for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voted that a regulatory decision should be deferred until further data are available from the Phase 3 KEYNOTE-522 trial. The study met one of the dual primary endpoints of pathological complete response and is continuing to evaluate event-free survival. The ODAC provides the FDA with independent, expert advice and recommendations on marketed and investigational medicines for use in the treatment of cancer. The FDA is not bound by the committee&#8217;s guidance but takes its advice into consideration. The PDUFA date for this application is March 29, 2021. The next interim analysis is calendar-driven, and data is expected in the third quarter of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion recommending approval of an expanded label for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory cHL who have failed an earlier line of therapy. This recommendation is based on results from the pivotal Phase 3 KEYNOTE-204 trial, in which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monotherapy demonstrated a significant improvement in PFS compared with brentuximab vedotin, a commonly used treatment. The recommendation is also based on supportive data from an updated analysis of the KEYNOTE-087 trial, which supported EC approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of adult patients with relapsed or refractory cHL. The CHMP&#8217;s recommendation will now be reviewed by the EC for marketing authorization in the EU. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved for this indication by the FDA in October 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under review as monotherapy for the first-line treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer in Japan based on the result of the KEYNOTE-177 trial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved for this indication by the FDA in June 2020 and by the EU in January 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FDA accepted a supplemental BLA seeking use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with locally advanced cSCC that is not curable by surgery or radiation based on the results of the KEYNOTE-629 trial. The FDA set a PDUFA date of September 9, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the FDA accepted and granted priority review for a supplemental BLA for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction. This supplemental BLA is based on data from the pivotal Phase 3 KEYNOTE-590 trial, in which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus chemotherapy demonstrated significant improvements in the primary endpoints of overall survival (OS) and PFS versus chemotherapy in these patients regardless of PD-L1 expression status and tumor histology. These data were presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020. The FDA set a PDUFA date of April 13, 2021. In December 2020, the CHMP of the EMA announced the start of a procedure to extend the indication to include in combination with chemotherapy, first-line treatment of locally advanced unresectable or metastatic carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on the results from KEYNOTE-590. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under review for this indication in Japan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also received Breakthrough Therapy designation from the FDA in February 2020 for the combination of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Padcev (enfortumab vedotin-ejfv), in the first-line setting for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy. The FDA&#8217;s Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Merck announced first-time data from the Phase 3 KEYNOTE-598 study evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with ipilimumab (Yervoy) compared with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monotherapy as first-line treatment for patients with metastatic NSCLC without EGFR or ALK genomic tumor aberrations and whose tumors express PD-L1 (tumor proportion score &#8805;50%). Results of the study showed that the addition of ipilimumab to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> did not improve OS or PFS but added toxicity compared with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monotherapy in these patients. These results were presented in the Presidential Symposium at the IASLC 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in January 2021 and published in the Journal of Clinical Oncology. As previously announced in November 2020, the study was discontinued due to futility based on the recommendation of an independent Data Monitoring Committee (DMC), which determined the benefit/risk profile of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with ipilimumab did not support continuing the trial. The DMC also advised that patients in the study discontinue treatment with ipilimumab/placebo.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Merck&#8217;s announced that the Phase 3 KEYNOTE-122 trial evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> versus standard of care treatment (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer did not meet its primary endpoint of OS. Full results will be presented at a future medical meeting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and Eisai presented data from analyses of two Phase 2 trials evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting in which the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination demonstrated clinically meaningful objective response rates (ORR): the KEYNOTE-524/Study 116 trial in patients with unresectable HCC with no prior systemic therapy; and the KEYNOTE-146/Study 111 trial in patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck and Eisai announced that the FDA issued a CRL regarding Merck&#8217;s and Eisai&#8217;s applications seeking accelerated approval for the first-line treatment of patients with unresectable HCC based on this trial, which showed clinically meaningful efficacy in the single-arm setting. These data supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Merck&#8217;s and Eisai&#8217;s applications, another combination therapy was approved based on a randomized, controlled trial that demonstrated improvement in OS versus standard-of-care treatment. Consequently, the CRL stated that Merck&#8217;s and Eisai&#8217;s applications do not provide evidence that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lenvima represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for KEYNOTE-524/Study 116 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the current approved indications for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or for Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Merck and Eisai announced the first presentation of new investigational data from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) at the 2021 Genitourinary Cancers Symposium (ASCO GU) and published simultaneously in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The trial evaluated the combinations of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima, and Lenvima plus everolimus versus sunitinib for the first-line treatment of patients with advanced RCC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima demonstrated statistically significant and clinically meaningful improvements in PFS, OS and ORR versus sunitinib. Lenvima plus everolimus also showed significant improvements in PFS and ORR versus sunitinib. Merck and Eisai will discuss these data with regulatory authorities worldwide, with the intent to submit marketing authorization applications based on these results. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Merck and Eisai announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima met its dual primary endpoints of OS and PFS and its secondary efficacy endpoint of ORR in patients with advanced endometrial cancer following at least one prior platinum-based regimen. These positive results were observed in the mismatch repair proficient (pMMR) subgroup and the ITT study population, which includes both patients with endometrial carcinoma that is pMMR as well as patients whose disease is MSI-H/dMMR. Based on an analysis conducted by an independent DMC, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima demonstrated a statistically significant and clinically meaningful improvement in OS, PFS and ORR versus chemotherapy. Merck and Eisai will discuss these data with regulatory authorities worldwide, with the intent to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submit marketing authorization applications based on these results, and plan to present these results at an upcoming medical meeting. KEYNOTE-775/Study 309 is the confirmatory trial for KEYNOTE-146/Study 111, which supported accelerated approval by the FDA in 2019 of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and Eisai are continuing to study the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program across 19 trials in 13 different tumor types (endometrial carcinoma, HCC, melanoma, NSCLC, RCC, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer, and TNBC).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-6482, belzutifan, is an investigational hypoxia-inducible factor-2&#945; (HIF-2&#945;) inhibitor being evaluated</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">von Hippel-Lindau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (V</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HL) disease-associated RCC with nonmetastatic RCC tumors less than three centimeters in size, unless immediate surgery is required. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the FDA granted Breakthrough Therapy designation to belzutifan and </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has also granted orphan drug designation to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">belzutifan</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for VHL disease. These designations are based on data from a Phase 2 trial evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">belzutifan</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with VHL-associated ccRCC, which were presented at the 2020 ASCO Annual Meeting. Additionally, Phase 2 data showing anti-tumor responses in VHL disease patients with ccRCC and other tumors were presented at the </span><span style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESMO Virtual Congress 2020</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Merck and Eisai began a Phase 3 trial examining Lenvima in combination with belzutifan in previously treated patients with metastatic RCC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7119, Tukysa, is a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers. In September 2020, Seagen granted Merck an exclusive license and entered into a co-development agreement with Merck to accelerate the global reach of Tukysa. Merck and Seagen also announced a collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in TNBC, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7339, Lynparza, is an oral PARP inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough. In September 2020, Merck announced the results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant. In these studies, adult patients treated with gefapixant 45 mg twice daily demonstrated a statistically significant reduction in 24-hour cough frequency versus placebo at 12 weeks (COUGH-1) and 24 weeks (COUGH-2). The gefapixant 15 mg twice daily treatment arms did not meet the primary efficacy endpoint in either Phase 3 study. These results were presented at the Virtual European Respiratory Society International Congress 2020. Merck plans to share data from COUGH-1 and COUGH-2 with regulatory authorities worldwide.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7110 (also known as CD24Fc) is an investigational treatment for patients hospitalized with COVID-19. Merck obtained MK-7110 through the acquisition of OncoImmune. In September 2020, OncoImmune reported topline findings from an interim efficacy analysis of a Phase 3 study evaluating MK-7110. An interim analysis of data from 203 participants (75% of the planned enrollment) indicated that selected hospitalized patients with COVID-19 treated with a single dose of MK-7110 showed a 60% higher probability of improvement in clinical status compared to placebo, as defined by the protocol. The risk of death or respiratory failure was reduced by more than 50%. Full results from this Phase 3 study, which were consistent with the topline results, were received in February 2021 and will be submitted for publication in the future. MK-7110 is also being studied in a Phase 3 trial for the treatment of graft versus host disease.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molnupiravir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(also known as MK-4482) is an orally available antiviral candidate for the treatment of COVID-19 being developed in collaboration with Ridgeback Biotherapeutics LP. It is currently being evaluated in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2/3 clinical trials in both the hospital and outpatient settings. The primary completion date for the Phase 2/3 studies is June 2021. The Company anticipates interim efficacy data in the first quarter of 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-8591A is a combination of islatravir, the company&#8217;s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), and doravirine (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pifeltro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) being evaluated for the treatment of HIV-1 infection. In October 2020, Merck announced Week 96 data from the Phase 2b trial (NCT03272347) evaluating the efficacy and safety of MK-8591A in treatment-na&#239;ve adults with HIV-1 infection. Week 96 findings demonstrated that the combination of islatravir and doravirine maintained virologic suppression similar to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Delstrigo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (doravirine/lamivudine/tenofovir disoproxil fumarate), and the findings were consistent with Week 48 results. Additional Week 96 data from the study show low rates of participants meeting the definition of protocol-defined virologic failure in both the islatravir plus doravirine and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Delstrigo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment arms, and no participants in either arm met the criteria for resistance testing. These data were presented at the virtual 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Merck announced a collaboration with the Bill &amp; Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP) option in women and adolescent girls at high risk for acquiring HIV-1 infection in sub-Saharan Africa. The study, IMPOWER 22, will evaluate the efficacy and safety of once-monthly islatravir and is anticipated to begin in early 2021. Merck will be funding the IMPOWER 22 clinical trial in the United States. Merck also plans to conduct additional studies in HIV prevention with islatravir in once-monthly oral PrEP. These studies will include IMPOWER 24, a global Phase 3 clinical trial to evaluate islatravir as a once-monthly oral agent for PrEP at sites across the world and among other key populations impacted by the epidemic, including men who have sex with men and transgender women.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FDA accepted for standard review a supplemental NDA for Steglatro (ertugliflozin) to incorporate the results of the Phase 3 VERTIS cardiovascular (CV) outcomes trial in the product labeling. The VERTIS CV trial evaluated Steglatro, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in patients with type 2 diabetes and atherosclerotic CV disease. The study met the primary endpoint of non-inferiority on major adverse CV events (MACE), which is a composite of CV death, nonfatal myocardial infarction or nonfatal stroke, compared to placebo. The key secondary endpoints of superiority for Steglatro versus placebo for time to the first occurrence of the composite of CV death or hospitalization for heart failure, time to CV death alone and time to the first occurrence of the composite of renal death, dialysis/transplant or doubling of serum creatinine from baseline were not met. While not a pre-specified hypothesis for statistical testing, a reduction in hospitalization for heart failure was observed with Steglatro. A supplemental application was also submitted to the EMA and is currently under review.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced the discontinuation of the clinical development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#8217;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below reflects the Company&#8217;s research pipeline as of February&#160;22, 2021. Candidates shown in Phase&#160;3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase&#160;2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase&#160;1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 3 (Phase 3 entry date)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Under Review</span></td></tr><tr style="height:317pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4482 (molnupiravir)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1026 </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Hematological Malignancies</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1308 (quavonlimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Solid Tumors </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1454</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-2140</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Hematological Malignancies</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4830</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5890</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">MK-6440 (ladiratuzumab vedotin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7684 (vibostolimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary Tract</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Glioblastoma</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V937</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Solid Tumors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Chikungunya virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V184</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cytomegalovirus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V160</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Prevention</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591 (islatravir)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Nonalcoholic Steatohepatitis NASH</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3655</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Overgrowth Syndrome</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7075 (miransertib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V116</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Respiratory Syncytial Virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1654</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Schizophrenia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8189</span></div><div style="text-indent:9pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary Tract (September 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cervical (October 2018) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric (May 2015) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Mesothelioma (May 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Ovarian (December 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate (May 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung (May 2017) (EU)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-6482 (belzutifan)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Renal Cell (February 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast (October 2019)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (August 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(June 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (December 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Bladder (May 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial (June 2018) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric (December 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck (February 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma (March 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (March 2019)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cough</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7264 (gefapixant) (March 2018)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">COVID-19</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7110 (December 2020)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591A (doravirine/islatravir) (February 2020)</span></div><div><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">New Molecular Entities/Vaccines</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Bacterial Infection</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7655A (relebactam+imipenem/cilastatin) (JPN)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Heart Failure</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1242 (vericiguat)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (EU) (JPN)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pediatric Neurofibromatosis Type 1</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5618 (selumetinib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (EU)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pneumococcal Infection Adult</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V-114 (U.S.) (EU)</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Certain Supplemental Filings </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Metastatic Triple-Negative Breast Cancer </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-355) (EU) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Early-Stage Triple-Negative Breast Cancer </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-522) (U.S.)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Refractory Classical Hodgkin Lymphoma </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-204) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(KEYNOTE-177) (JPN)</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Cutaneous Squamous Cell Cancer</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-629) (U.S.)</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Advanced Unresectable Metastatic</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Esophageal Cancer (KEYNOTE-590)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(U.S.) (EU) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    First-Line Metastatic HER2+ Gastric Cancer </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-811) (U.S.)</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    First-Line Metastatic Hepatocellular Carcinoma </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(KEYNOTE-524) (U.S.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)(4)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Thymic Carcinoma (NCCH1508/REMORA) (JPN)</span></div></td></tr><tr style="height:200pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Footnotes:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Being developed in a collaboration.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">  Being developed in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">  Being developed as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">  In July 2020, the FDA issued a CRL for Merck&#8217;s and Eisai&#8217;s applications. Merck and Eisai intend to submit additional data when available to the FDA. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div></td></tr></table></div><div id="iab6577be4c3840fd8181bdedf457fba5_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company had approximately 74,000 employees worldwide, with approximately 27,000 employed in the United States, including Puerto Rico, and approximately 26,000 third-party contractors globally. Approximately 73,000 of the Company&#8217;s employees are full time-employees. Women and individuals with ethnically diverse backgrounds comprise approximately 50% and 31% of its workforce in the United States, respectively. Women comprise 46% of the members of the Board of Directors. Additionally, the Company&#8217;s executive team, which includes individuals up to two structural levels below the Chief Executive </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Officer, is made up of 34% women. Approximately 30% of the Company&#8217;s employees are represented by various collective bargaining groups.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes that its employees are critical to meet the needs of its patients and customers and that its ability to excel depends on the integrity, skill, and diversity of its employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a comprehensive approach to ensure recruiting, retention and leadership development goals are systematically executed throughout the Company and that it hires talented leaders to achieve improved gender parity and representation across all dimensions of diversity. The Company provides training to its managers and external recruiting organizations on strategies to mitigate unconscious bias in the candidate selection and hiring process. In addition, the Company utilizes a comprehensive communications strategy, marketing outreach, social media and strategic alliance partnerships to reach a broad pool of talent in its critical business areas. In 2020, the Company hired approximately 10,000 employees across the globe through various channels including the Company&#8217;s external career site, diversity partnerships, employee referrals, universities and other external sources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Diversity and Inclusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diversity and inclusion are fundamental to the Company&#8217;s success and core to future innovation. The Company fosters a globally diverse and inclusive workforce for its employees by creating an environment of belonging, engagement, equity, and empowerment. The Company is proactive and intentional about diversity hiring and development programs to advance talent. The Company creates competitive advantages by leveraging diversity and inclusion to accelerate business performance. This includes fostering global supplier diversity, integrating diversity and inclusion into the Company&#8217;s commercialization strategies and leveraging employee insights to improve performance. In addition to these efforts, the Company has ten Employee Business Resource Groups, that provide opportunities for employees to take an active part in contributing to the Company&#8217;s inclusive culture through their work in talent acquisition and development, business and customer insights and social and community outreach.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Gender and Ethnicity Performance Data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women in the workforce</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women in the workforce in the U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NR</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women on the Board of Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women in executive roles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women in management roles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups on the Board of Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in executive roles (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in the workforce (U.S.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in management roles (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New hires that were female</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New hires that were members of underrepresented ethnic groups (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36%</span></td></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NR: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Not reported.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As of 12/31.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8220;Executive&#8221; is defined as the chief executive officer and two structur</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">al levels below. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8220;Management role&#8221; is defined as all managers with direct reports other than executives defined in note 2.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a valuable total rewards package reflecting its commitment to attract, retain and motivate its talent, and to supporting its employees and their families in every stage of life. The Company continuously monitors and adjusts its compensation and benefit programs to ensure they are competitive, contemporary, helpful and engaging, and that they support strategic imperatives such as diversity and inclusion, equity, flexibility, quality, security and affordability. For example, in 2020, the Company added a personal health care concierge service to assist U.S. employees participating in the Company medical plan with their health care </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needs. Aligned with its business and in support of its cancer care strategy, the Company also improved cancer screening benefits, added resources and provided immediate access to a leading cancer center of excellence for U.S. employees. Globally, the Company implemented a minimum standard of 12 weeks of paid parental leave, which inclusively applies to all parents. In the United States, the Company&#8217;s benefits rank in the top quartile of Fortune 100 companies under the Aon Hewitt 2019 Benefits Index. The Company has been included in the Working Mother 100 Best Companies ranking for 34 consecutive years and was named a Working Mother Best Company for Dads in 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Wellbeing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is committed to helping its employees and their families improve their own health and wellbeing. The Company&#8217;s culture of wellbeing is referred to as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Live it</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, which includes programs to support preventive health, emotional and financial wellbeing, physical fitness and nutrition. It is designed to inspire all employees to pursue, enjoy, and share healthy lifestyles. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Live it</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the United States in 2011 and today is available in every country in which the Company has employees. In addition, many of the Company&#8217;s larger sites offer onsite health clinics that provide an array of services to help its employees stay or get well, including vaccinations, cancer and biometric screenings, travel medicine and advice, diagnosis and treatment of non-occupational illnesses or injuries, health counseling and referrals. The Company&#8217;s overall employee wellbeing program was recognized for excellence in health and wellbeing by receiving the highest-level awards from the Business Group on Health (2019 and 2020), and the American Heart Association (2018-2020).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Response</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes that it has a unique responsibility to help in response to the COVID-19 pandemic and is committed to supporting and protecting its employees and their families, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of antiviral approaches and supporting its health care providers and the communities in which they serve. The Company continues to provide employees with easy and regular access to information, including details regarding the Company&#8217;s tracking process, guidance around hygiene measures and travel and best practices for working from home. Examples of pandemic support resources and programs available to the Company&#8217;s employees include pay continuation for workers who have been sick or exposed, volunteer policy adjustment to enable employees with medical backgrounds to volunteer in SARS-CoV-2-related activities, resources to prioritize physical and mental wellness, adjustments to medical plans to cover 100% of a COVID-19-related diagnosis, testing and treatment, backup childcare and more.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engaging Employees</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company strives to foster employee engagement by promoting a safe, positive, diverse and inclusive work environment that provides numerous opportunities for two-way communication with employees. Some of the Company&#8217;s key programs and initiatives include promoting global employee engagement surveys, ongoing pulse checks to the organization for interim feedback on specific topics, fostering professional networking and collaboration, identifying and providing opportunities for volunteering and establishing positive, cooperative business relations with designated employee representatives. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Management and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company pursues its goal of becoming the world&#8217;s premier research-based biopharmaceutical company, it needs to continuously develop its diverse and talented people. The Company&#8217;s current talent management system supports company-wide performance management, development, talent reviews and succession planning. Annual performance reviews help further the professional development of the Company&#8217;s employees and ensure that the Company&#8217;s workforce is aligned with the Company&#8217;s objectives. The Company seeks to continuously build the skills and capabilities of its workforce to accelerate talent, improve performance and mitigate risk through relevant continuous learning experiences. This includes, but is not limited to, building leadership and management skills, as well as providing technical and functional training to all employees.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites. Expenditures for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remediation and environmental liabilities were $11 million in 2020 and are estimated at $46 million in the aggregate for the years 2021 through 2025. These amounts do not consider potential recoveries from other parties. The Company has taken an active role in identifying and accruing for these costs and, in management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $67 million at both December&#160;31, 2020 and 2019. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $65 million in the aggregate. Management also does not believe that these expenditures should have a material adverse effect on the Company&#8217;s financial condition, results of operations, liquidity or capital resources for any year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck believes that climate change could present risks to its business. Some of the potential impacts of climate change to its business include increased operating costs due to additional regulatory requirements, physical risks to the Company&#8217;s facilities, water limitations and disruptions to its supply chain. These potential risks are integrated into the Company&#8217;s business planning including investment in reducing energy usage, water use and greenhouse gas emissions. The Company does not believe these risks are material to its business at this time.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Area Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations outside the United States are conducted primarily through subsidiaries. Sales worldwide by subsidiaries outside the United States as a percentage of total Company sales were 56% in both 2020 and 2019 and were 57% in 2018.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s worldwide business is subject to risks of currency fluctuations, governmental actions and other governmental proceedings abroad. The Company does not regard these risks as a deterrent to further expansion of its operations abroad. However, the Company closely reviews its methods of operations and adopts strategies responsive to changing economic and political conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has operations in countries located in Latin America, the Middle East, Africa, Eastern Europe and Asia Pacific. Business in these developing areas, while sometimes less stable, offers important opportunities for growth over time.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.merck.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will make available, free of charge at the &#8220;Investors&#8221; portion of its website, its Annual Report on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, and all amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). The address of that website is www.sec.gov. In addition, the Company will provide without charge a copy of its Annual Report on Form 10-K, including financial statements and schedules, upon the written request of any shareholder to the Office of the Secretary, Merck &amp; Co., Inc., 2000&#160;Galloping Hill Road, K1-4157, Kenilworth, NJ 07033 U.S.A.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate governance guidelines and the charters of the Board of Directors&#8217; four standing committees are available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.merck.com/company-overview/leadership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and all such information is available in print to any shareholder who requests it from the Company.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_55"></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">Risk Factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks that if realized could materially adversely affect its business, results of operations, cash flow, financial condition or prospects. The following is a summary of the principal risk factors facing the Company:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As the Company&#8217;s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Key products generate a significant amount of the Company&#8217;s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company faces continued pricing pressure with respect to its products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The uncertainty in global economic conditions together with cost-reduction measures being taken by certain governments could negatively affect the Company&#8217;s operating results.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company faces intense competition from lower cost generic products.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company faces intense competition from competitors&#8217; products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The global COVID-19 pandemic is having an adverse impact on the Company&#8217;s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to attract and retain highly qualified personnel could affect the Company&#8217;s ability to successfully develop and commercialize products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the past, the Company has experienced difficulties and delays in manufacturing certain of its products, including vaccines.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company may not be able to realize the expected benefits of its investments in emerging markets.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical products can develop unexpected safety or efficacy concerns.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company&#8217;s business.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company&#8217;s future results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The health care industry in the United States has been, and will continue to be, subject to increasing regulation and political action.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developments following regulatory approval may adversely affect sales of the Company&#8217;s products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is subject to a variety of U.S. and international laws and regulations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability insurance for products may be limited, cost prohibitive or unavailable.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is increasingly dependent on sophisticated software applications, computing infrastructure and cloud service providers. In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. The Company could be a target of future cyber-attacks.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Social media platforms present risks and challenges.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The proposed Spin-Off of Organon may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The costs to complete the proposed Spin-Off will be significant. In addition, the Company may be unable to achieve some or all of the strategic and financial benefits that it expects to achieve from the Spin-Off of Organon.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following the Spin-Off, the price of shares of the Company&#8217;s common stock may fluctuate significantly.</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There could be significant income tax liability if the Spin-Off or certain related transactions are determined to be taxable for U.S. federal income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above list is not exhaustive, and the Company faces additional challenges and risks. Investors should carefully consider all of the information set forth in this Form 10-K, including the following risk factors, before deciding to invest in any of the Company&#8217;s securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks below are not the only ones the Company faces. Additional risks not currently known to the Company or that the Company presently deems immaterial may also impair its business operations. The Company&#8217;s business, financial condition, results of operations, cash flow or prospects could be materially adversely affected by any of these risks. This Form&#160;10-K also contains forward-looking statements that involve risks and uncertainties. The Company&#8217;s results could materially differ from those anticipated in these forward-looking statements as a result of certain factors, including the risks it faces described below and elsewhere. See &#8220;Cautionary Factors that May Affect Future Results&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to the Company&#8217;s Business</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent protection is considered, in the aggregate, to be of material importance to the Company&#8217;s marketing of human health and animal health products in the United States and in most major foreign markets. Patents covering products that it has introduced normally provide market exclusivity, which is important for the successful marketing and sale of its products. The Company seeks patents covering each of its products in each of the markets where it intends to sell the products and where meaningful patent protection is available.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the Company succeeds in obtaining patents covering its products, third parties or government authorities may challenge or seek to invalidate or circumvent its patents and patent applications. It is important for the Company&#8217;s business to defend successfully the patent rights that provide market exclusivity for its products. The Company is often involved in patent disputes relating to challenges to its patents or claims by third parties of infringement against the Company. The Company defends its patents both within and outside the United States, including by filing claims of infringement against other parties. See Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;10. &#8220;Contingencies and Environmental Liabilities&#8221; below. In particular, manufacturers of generic pharmaceutical products from time to time file abbreviated NDAs with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned or licensed by the Company. The Company normally responds by defending its patent, including by filing lawsuits alleging patent </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement. Patent litigation and other challenges to the Company&#8217;s patents are costly and unpredictable and may deprive the Company of market exclusivity for a patented product or, in some cases, third-party patents may prevent the Company from marketing and selling a product in a particular geographic area.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies or in other circumstances, which could diminish or eliminate sales and profits from those regions and negatively affect the Company&#8217;s results of operations. Further, court decisions relating to other companies&#8217; patents, potential legislation in both the United States and certain foreign markets relating to patents, as well as regulatory initiatives may result in a more general weakening of intellectual property protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more important products lose patent protection in profitable markets, sales of those products are likely to decline significantly as a result of generic versions of those products becoming available. The Company&#8217;s results of operations may be adversely affected by the lost sales unless and until the Company has launched commercially successful products that replace the lost sales. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively affect product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A chart listing the patent protection for certain of the Company&#8217;s marketed products, and U.S. patent protection for candidates in Phase 3 clinical development is set forth above in Item&#160;1. &#8220;Business &#8212; Patents, Trademarks and Licenses.&#8221;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As the Company&#8217;s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company depends upon patents to provide it with exclusive marketing rights for its products for some period of time. Loss of patent protection for one of the Company&#8217;s products typically leads to a significant and rapid loss of sales for that product as lower priced generic versions of that drug become available. In the case of products that contribute significantly to the Company&#8217;s sales, the loss of market exclusivity can have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects. For example, the patent that provided U.S. market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in April 2018 and generic competition began in December 2019. The Company experienced a rapid and substantial decline in U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales in 2020 as a result of this generic competition. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will lose market exclusivity in the United States in January 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will lose market exclusivity in the EU in September 2022. Finally, the SPC that provides market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU expires in April 2023. The Company anticipates sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in these markets will decline substantially after the loss of market exclusivity.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key products generate a significant amount of the Company&#8217;s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to generate profits and operating cash flow depends largely upon the continued profitability of the Company&#8217;s key products, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda, Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In particular, in 2020, the Company&#8217;s oncology portfolio, led by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represented the vast majority of the Company&#8217;s revenue growth. As a result of the Company&#8217;s dependence on key products, any event that adversely affects any of these products or the markets for any of these products could have a significant adverse impact on results of operations and cash flows. These events could include loss of patent protection, increased costs associated with manufacturing, generic or over-the-counter availability of the Company&#8217;s product or a competitive product, the discovery of previously unknown side effects, results of post-approval trials, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of the product for any reason. Such events could have a material adverse effect on the sales of any such products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to remain competitive, the Company, like other major pharmaceutical companies, must continue to launch new products. Expected declines in sales of products after the loss of market exclusivity mean that the Company&#8217;s future success is dependent on its pipeline of new products, including new products that it may develop through collaborations and joint ventures and products that it is able to obtain through license or acquisition. To accomplish this, the Company commits substantial effort, funds and other resources to research and development, both through its own dedicated resources and through various collaborations with third parties. There is a high rate of failure inherent in the research and development process for new drugs and vaccines. As a result, there is a high risk that funds invested by the Company in research programs will not generate financial returns. This risk profile is compounded by the fact that this research has a long investment cycle. To bring a pharmaceutical compound from the discovery phase to market may take a decade or more and failure can occur at any point in the process, including later in the process after significant funds have been invested.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the research and development process, see Item&#160;1. &#8220;Business &#8212; Research and Development&#8221; above. Each phase of testing is highly regulated and during each phase there is a substantial risk that the Company will encounter serious obstacles or will not achieve its goals. Therefore, the Company may abandon a product in which it has invested substantial amounts of time and resources. Some of the risks encountered in the research and development process include the following: pre-clinical testing of a new compound may yield disappointing results; competing products from other manufacturers may reach the market first; clinical trials of a new drug may not be successful; a new drug may not be effective or may have harmful side effects; a new drug may not be approved by the regulators for its intended use; it may not be possible to obtain a patent for a new drug; payers may refuse to cover or reimburse the new product; or sales of a new product may be disappointing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot state with certainty when or whether any of its products now under development will be approved or launched; whether it will be able to develop, license or otherwise acquire compounds, product candidates or products; or whether any products, once launched, will be commercially successful. The Company must maintain a continuous flow of successful new products and successful new indications for existing products sufficient both to cover its substantial research and development costs and to replace sales that are lost as profitable products lose market exclusivity or are displaced by competing products or therapies. Failure to do so in the short term or long term would have a material adverse effect on the Company&#8217;s business, results of operations, cash flow, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products that appear promising in development may fail to reach the market or fail to succeed for numerous reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">findings of ineffectiveness, superior safety or efficacy of competing products, or harmful side effects in clinical or pre-clinical testing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to receive the necessary regulatory approvals, including delays in the approval of new products and new indications, or the anticipated labeling, and uncertainties about the time required to obtain regulatory approvals and the benefit/risk standards applied by regulatory agencies in determining whether to grant approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure in certain markets to obtain reimbursement commensurate with the level of innovation and clinical benefit presented by the product;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of economic feasibility due to manufacturing costs or other factors; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclusion from commercialization by the proprietary rights of others.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, if certain pipeline programs are cancelled or if the Company believes that their commercial prospects have been reduced, the Company may recognize material non-cash impairment charges for those programs that were measured at fair value and capitalized in connection with acquisitions or certain collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully develop and market new products in the short term or long term would have a material adverse effect on the Company&#8217;s business, results of operations, cash flow, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company faces continued pricing pressure with respect to its products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces continued pricing pressure globally and, particularly in mature markets, from managed care organizations, government agencies and programs that could negatively affect the Company&#8217;s sales and profit margins. In the United States, these include (i)&#160;practices of managed care groups and institutional and governmental purchasers, (ii)&#160;U.S. federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug Improvement and Modernization Act of 2003 and the ACA, and (iii) state activities aimed at increasing price transparency, including new laws as noted above in Item 1. &#8220;Competition and the Health Care Environment.&#8221; Changes to the health care system enacted as part of health care reform in the United States, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, could result in further pricing pressures. In addition, in the United States, larger customers have received higher rebates on drugs in certain highly competitive categories. The Company must also compete to be placed on formularies of managed care organizations. Exclusion of a product from a formulary can lead to reduced usage in the managed care organization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide information about the Company&#8217;s pricing practices, the Company annually posts on its website&#160;its Pricing Transparency Report for the United States. The report provides the Company&#8217;s average annual list price and net price increases across the Company&#8217;s U.S. portfolio dating back to 2010. In 2020, the Company&#8217;s gross U.S. sales were reduced by 45.5% as a result of rebates, discounts and returns.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, numerous major markets, including the EU, Japan and China have pervasive government involvement in funding health care and, in that regard, fix the pricing and reimbursement of pharmaceutical and vaccine products. Consequently, in those markets, the Company is subject to government decision making and budgetary actions with respect to its products. In Japan, the pharmaceutical industry is subject to government-mandated biennial price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricing for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules. The next government-mandated price reduction will occur in April 2021 and is expected to impact many Company products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects pricing pressures to continue in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The uncertainty in global economic conditions together with cost-reduction measures being taken by certain governments could negatively affect the Company&#8217;s operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty in global economic and geopolitical conditions may result in a slowdown to the global economy that could affect the Company&#8217;s business by reducing the prices that drug wholesalers and retailers, hospitals, government agencies and managed health care providers may be able or willing to pay for the Company&#8217;s products or by reducing the demand for the Company&#8217;s products, which could in turn negatively impact the Company&#8217;s sales and result in a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed above in &#8220;Competition and the Health Care Environment,&#8221; global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s revenue performance in 2020 was negatively affected by other cost-reduction measures taken by governments and other third-parties to lower health care costs. The Company anticipates all of these actions, and additional actions in the future, will continue to negatively affect revenue performance.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If credit and economic conditions worsen, the resulting economic and currency impacts in the affected markets and globally could have a material adverse effect on the Company&#8217;s results.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company faces intense competition from lower cost generic products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the Company faces increasing competition from lower-cost generic products. The patent rights that protect its products are of varying strengths and durations. In addition, in some countries, patent protection is significantly weaker than in the United States or in the EU. In the United States and the EU, political pressure to reduce spending on prescription drugs has led to legislation and other measures that encourage the use of generic and biosimilar products. Although it is the Company&#8217;s policy to actively protect its patent rights, generic challenges to the Company&#8217;s products can arise at any time, and the Company&#8217;s patents may not prevent the emergence of generic competition for its products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of patent protection for a product typically is followed promptly by generic substitutes, reducing the Company&#8217;s sales of that product. Availability of generic substitutes for the Company&#8217;s drugs may adversely affect its results of operations and cash flow. In addition, proposals emerge from time to time in the United States and other countries for legislation to further encourage the early and rapid approval of generic drugs. Any such proposal that is enacted into law could worsen this substantial negative effect on the Company&#8217;s sales and, potentially, its business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company faces intense competition from competitors&#8217; products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products face intense competition from competitors&#8217; products. This competition may increase as new products enter the market. In such an event, the competitors&#8217; products may be safer or more effective, more convenient to use, have better insurance coverage or reimbursement levels or be more effectively marketed and sold than the Company&#8217;s products. Alternatively, in the case of generic competition, including the generic availability of competitors&#8217; branded products, they may be equally safe and effective products that are sold at a substantially lower price than the Company&#8217;s products. As a result, if the Company fails to maintain its competitive position, this could have a material adverse effect on its business, cash flow, results of operations, financial condition and prospects. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively impact product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The global COVID-19 pandemic is having an adverse impact on the Company&#8217;s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business and financial results were negatively impacted by the outbreak of COVID-19 in 2020. The continued duration and severity of the COVID-19 pandemic is uncertain, rapidly changing and difficult to predict. The degree to which COVID-19 impacts the Company&#8217;s results in 2021 will depend on future developments, beyond the Company&#8217;s knowledge or control, including, but not limited to, the duration of the outbreak, its severity, the success of actions taken to contain or prevent the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the COVID-19 pandemic impacted the Company&#8217;s business in numerous ways. As expected, within the Company&#8217;s human health business, revenue was negatively impacted by reduced access to health care providers given social distancing measures, which negatively affected vaccine and oncology sales in particular. The estimated overall negative impact of the COVID-19 pandemic to Merck&#8217;s revenue for the full year 2020 was approximately $2.5 billion, largely attributable to the Pharmaceutical segment, with approximately $50 million attributable to the Animal Health segment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roughly two-thirds of Merck&#8217;s Pharmaceutical segment revenue is comprised of physician-administered products, which, despite strong underlying demand, have been affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, have resulted in reduced administration of many of the Company&#8217;s human health products, in particular for its vaccines, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, as well as for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, declines in elective surgeries negatively affected the demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 have increased due to heightened awareness of pneumococcal vaccination. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck believes that global health systems and patients have largely adapted to the impacts of COVID-19, but the Company&#8217;s assumption is that ongoing residual negative impacts will persist, particularly during the first half of 2021 and most notably with respect to vaccine sales, with the impact expected to be more acute in the United States. For the full year of 2021, Merck assumes an unfavorable impact to revenue of approximately 2% due to the COVID-19 pandemic, all of which relates to Pharmaceutical segment sales. In addition, for the full year of 2021, with respect to the COVID-19 pandemic, Merck expects a net negative impact to operating expenses, as spending on the development of its COVID-19 antiviral programs is expected to exceed the favorable impact of lower spending in other areas due to the COVID-19 pandemic. Despite the Company&#8217;s efforts to manage these impacts, their ultimate impact will also depend on factors beyond the Company&#8217;s knowledge or control, including the duration of the COVID-19 virus as well as governmental and third-party actions taken to contain or prevent its spread, treat the virus and mitigate its public health and economic effects. In addition, any future pandemic, epidemic or similar public health threat could present similar risks to the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent of the Company&#8217;s operations outside the United States is significant. Risks inherent in conducting a global business include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in medical reimbursement policies and programs and pricing restrictions in key markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple regulatory requirements that could restrict the Company&#8217;s ability to manufacture and sell its products in key markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade protection measures and import or export licensing requirements, including the imposition of trade sanctions or similar restrictions by the United States or other governments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign exchange fluctuations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminished protection of intellectual property in some countries; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible nationalization and expropriation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there may be changes to the Company&#8217;s business and political position if there is instability, disruption or destruction in a significant geographic region, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest; and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to attract and retain highly qualified personnel could affect the Company&#8217;s ability to successfully develop and commercialize products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s success is largely dependent on its continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical research and development, governmental regulation and commercialization. Competition for qualified personnel in the pharmaceutical industry is intense. The Company cannot be sure that it will be able to attract and retain quality personnel or that the costs of doing so will not materially increase.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In the past, the Company has experienced difficulties and delays in manufacturing certain of its products, including vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has, in the past, experienced difficulties in manufacturing certain of its products, including vaccines. For example, in 2020 the Company issued a product recall for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following the identification of product sterility issues. The Company may, in the future, experience other difficulties and delays in manufacturing its products, such as (i)&#160;failure of the Company or any of its vendors or suppliers to comply with Current Good Manufacturing Practices and other applicable regulations and quality assurance guidelines that could lead to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing shutdowns, product shortages and delays in product manufacturing; (ii)&#160;delays related to the construction of new facilities or the expansion of existing facilities, including those intended to support future demand for the Company&#8217;s products; and (iii)&#160;other manufacturing or distribution problems including changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in types of products produced, or physical limitations that could impact continuous supply. In addition, the Company could experience difficulties or delays in manufacturing its products caused by natural disasters, such as hurricanes. Manufacturing difficulties can result in product shortages, leading to lost sales and reputational harm to the Company.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company may not be able to realize the expected benefits of its investments in emerging markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been taking steps to increase its sales in emerging markets. However, there is no guarantee that the Company&#8217;s efforts to expand sales in these markets will succeed. Some countries within emerging markets may be especially vulnerable to periods of global financial instability or may have very limited resources to spend on health care. In order for the Company to successfully implement its emerging markets strategy, it must attract and retain qualified personnel. The Company may also be required to increase its reliance on third-party agents within less developed markets. In addition, many of these countries have currencies that fluctuate substantially and, if such currencies devalue and the Company cannot offset the devaluations, the Company&#8217;s financial performance within such countries could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business in China has grown rapidly in the past few years, and the importance of China to the Company&#8217;s overall pharmaceutical and vaccines business outside the United States has increased accordingly. Continued growth of the Company&#8217;s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company&#8217;s currently marketed products, and the absence of trade impediments or adverse pricing controls. As noted above in &#8220;Competition and the Health Care Environment,&#8221; pricing pressure in China has increased as the Chinese government has been taking steps to reduce costs, including implementing health care reform that has led to the acceleration of generic substitution, where available. In 2017, the Chinese government updated the NRDL for the first time in eight years. While the mechanism for drugs being added to the list evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2020, drugs were added to the NRDL through double-digit price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through the government&#8217;s VBP program. In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the first three rounds of VBP had, on average, a price reduction of 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward. In addition, the Company anticipates that the reported inquiries made by various governmental authorities involving multinational pharmaceutical companies in China may continue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all these reasons, sales within emerging markets carry significant risks. However, at the same time macro-economic growth of selected emerging markets is expected to outpace Europe and even the United States, leading to significant increased headcount spending in those countries and access to innovative medicines for patients. A failure to maintain the Company&#8217;s presence in emerging markets could therefore have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in multiple jurisdictions and virtually all sales are denominated in currencies of the local jurisdiction. Additionally, the Company has entered and will enter into business development transactions, borrowings or other financial transactions that may give rise to currency and interest rate exposure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company cannot, with certainty, foresee and mitigate against such adverse fluctuations, fluctuations in currency exchange rates, interest rates and inflation could negatively affect the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate against the adverse impact of these market fluctuations, the Company will from time to time enter into hedging agreements. While hedging agreements, such as currency options and forwards and interest rate swaps, may limit some of the exposure to exchange rate and interest rate fluctuations, such attempts to mitigate these risks may be costly and not always successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s interest rate derivatives and investments are based on the London Interbank Offered Rate (LIBOR), and a portion of Merck&#8217;s indebtedness bears interest at variable interest rates, primarily based on LIBOR. LIBOR is the subject of recent national, international and other regulatory guidance and proposals for reform, which will cause LIBOR to cease to exist entirely in the future. While the Company expects that reasonable alternatives to LIBOR will be implemented prior to its termination, the Company cannot predict the consequences and timing of these developments, which could include an increase in interest expense and may also require the amendment of contracts that reference LIBOR.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical products can develop unexpected safety or efficacy concerns.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unexpected safety or efficacy concerns can arise with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, or declining sales, as well as product liability, consumer fraud and/or other claims, including potential civil or criminal governmental actions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company depends on third parties, including suppliers, alliances with other pharmaceutical and biotechnology companies, and third-party service providers, for key aspects of its business including development, manufacture and commercialization of its products and support for its information technology (IT) systems. Failure of these third parties to meet their contractual, regulatory and other obligations to the Company or the development of factors that materially disrupt the relationships between the Company and these third parties could have a material adverse effect on the Company&#8217;s business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales of key animal health products could be adversely affected by a number of risk factors including certain risks that are specific to the animal health business. For example, the outbreak of disease carried by animals, such as African Swine Fever, could lead to their widespread death and precautionary destruction as well as the reduced consumption and demand for animals, which could adversely affect the Company&#8217;s results of operations. Also, the outbreak of any highly contagious diseases near the Company&#8217;s main production sites could require the Company to immediately halt the manufacture of its animal health products at such sites or force the Company to incur substantial expenses in procuring raw materials or products elsewhere. Other risks specific to animal health include epidemics and pandemics, government procurement and pricing practices, weather and global agribusiness economic events. As the Animal Health segment of the Company&#8217;s business becomes more significant, the impact of any such events on future results of operations would also become more significant.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company&#8217;s future results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development, testing, manufacturing and commercialization of biologics and vaccines, particularly human and animal health vaccines, is a long, complex, expensive and uncertain process. There are unique risks and uncertainties related to biologics and vaccines, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There may be limited access to, and supply of, normal and diseased tissue samples, cell lines, pathogens, bacteria, viral strains and other biological materials. In addition, government regulations in multiple jurisdictions, such as the United States and the EU, could result in restricted access to, or transport or use of, such materials. If the Company loses access to sufficient sources of such materials, or if tighter restrictions are imposed on the use of such materials, the Company may not be able to conduct research activities as planned and may incur additional development costs.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The development, manufacturing and marketing of biologics and vaccines are subject to regulation by the FDA, the EMA and other regulatory bodies. These regulations are often more complex and extensive than the regulations applicable to other pharmaceutical products. For example, in the United States, a BLA, including both pre-clinical and clinical trial data and extensive data regarding the manufacturing procedures, is required for human vaccine candidates, and FDA approval is generally required for the release of each manufactured commercial lot.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing biologics and vaccines, especially in large quantities, is often complex and may require the use of innovative technologies to handle living micro-organisms. Each lot of an approved biologic and vaccine must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, the Company may be required to provide pre-clinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biologics and vaccines are frequently costly to manufacture because production ingredients are derived from living animal or plant material, and most biologics and vaccines cannot be made synthetically. In particular, keeping up with the demand for vaccines may be difficult due to the complexity of producing vaccines.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The use of biologically derived ingredients can lead to variability in the manufacturing process and could lead to allegations of harm, including infections or allergic reactions, which allegations would be reviewed through a standard investigation process that could lead to closure of product facilities due to possible contamination. Any of these events could result in substantial costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Government Regulation and Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The health care industry in the United States has been, and will continue to be, subject to increasing regulation and political action.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed above &#8220;Competition and the Health Care Environment,&#8221; the Company believes that the health care industry will continue to be subject to increasing regulation as well as political and legal action, as future proposals to reform the health care system are considered by the Executive branch, Congress and state legislatures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the United States enacted major health care reform legislation in the form of the ACA. Various insurance market reforms have advanced and state and federal insurance exchanges were launched in 2014. The ACA increased the mandated Medicaid rebate from 15.1% to 23.1%, expanded the rebate to Medicaid managed care utilization, and increased the types of entities eligible for the federal 340B drug discount program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA also requires pharmaceutical manufacturers to pay 70% of the cost of medicine, including biosimilar products, when Medicare Part D beneficiaries are in the Medicare Part D coverage gap (i.e., the so-called &#8220;donut hole&#8221;). In 2020, the Company&#8217;s revenue was reduced by approximately $700 million due to this requirement. Also, pharmaceutical manufacturers are required to pay an annual non-tax deductible health care reform fee. In 2020, the Company recorded $85 million of costs for this annual fee.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Centers for Medicare &amp; Medicaid Services (CMS) issued the Medicaid rebate final rule that implemented provisions of the ACA effective April 1, 2016. The rule provides comprehensive guidance on the calculation of Average Manufacturer Price and Best Price; two metrics utilized to determine the rebates drug manufacturers are required to pay to state Medicaid programs. More recently, although CMS previously declined to define what constitutes a product &#8220;line extension&#8221; (beyond the statutory definition), CMS issued a new rule on December 21, 2020 that will significantly expand the definition of the term &#8220;line extension&#8221; as of January 1, 2022 to include a broad range of products, including products reflecting new strengths, dosage forms, release mechanisms, and routes of administration. This expanded definition will increase the number of drugs subject to a higher Medicaid rebate. Effective January 1, 2023, this final rule also changes the way that manufacturers must calculate Best Price, in relation to certain patient support programs, including coupons, which also may result in an increase in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s Medicaid rebates. The impact of these and other provisions in this final rule could adversely impact the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above in &#8220;Competition and the Health Care Environment,&#8221; in November 2020, the Department of Health and Human Services Office of Inspector General (OIG) issued a Final Rule that would, effective January 1, 2023, eliminate the Anti-Kickback Statute safe harbor for rebates paid to Medicare Part D plans or to PBMs on behalf of such plans. While the Company cannot anticipate the effects of this change to the way it currently contracts, this new framework could significantly alter the way it does business with Part D Plan Sponsors and PBMs on behalf of such plans. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2020, CMS also issued the MFN Rule, which was intended to be effective January 1, 2021, to institute a new pricing system for certain prescription drugs and biologic products covered by Medicare Part B in which Medicare would reimburse no more than the &#8220;most favored nation price,&#8221; meaning the lowest price after adjusting for volume and differences in gross domestic product, for the top fifty Part B reimbursed products, which includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, sold in 22 member countries of the OECD, rather than use the current Average Sales Price (&#8220;ASP&#8221;)-based payment framework for certain physician-administered drugs. Implementation of the MFN Rule could have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also recently issued rulemaking allowing the commercial importation of certain prescription drugs from Canada through FDA-authorized, time-limited programs sponsored by states or Native American tribes recognized under the rule, and, in certain future circumstances, pharmacists and wholesalers. The FDA also recently released a final guidance for industry detailing procedures for drug manufacturers to import FDA-approved prescription drug, biological, and combination products that were manufactured abroad and authorized and intended for sale in a foreign country. These changes, if they become effective, could have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several organizations, including two trade groups of which Merck is a member, have filed suit challenging the MFN Rule. Those lawsuits remain pending with a preliminary injunction having been entered in one of the cases. A trade organization in which Merck is a member brought suit, which is pending, in federal district court challenging the commercial importation rule.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot predict the likelihood of these regulations becoming effective or what additional future changes in the health care industry in general, or the pharmaceutical industry in particular, will occur, however, these changes could have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities, including research, pre-clinical testing, clinical trials and the manufacturing and marketing of its products, are subject to extensive regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including in the EU, Japan and China. In the United States, the FDA administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling and marketing of prescription pharmaceuticals. In many cases, the FDA requirements have increased the amount of time and money necessary to develop new products and bring them to market in the United States. Regulation outside the United States also is primarily focused on drug safety and effectiveness and, in many cases, reduction in the cost of drugs. The FDA and foreign regulatory authorities, including in Japan and China, have substantial discretion to require additional testing, to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of a product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the Company is successful in developing new products, it will not be able to market any of those products unless and until it has obtained all required regulatory approvals in each jurisdiction where it proposes to market the new products. Once obtained, the Company must maintain approval as long as it plans to market its new products in each jurisdiction where approval is required. The Company&#8217;s failure to obtain approval, significant delays in the approval process, or its failure to maintain approval in any jurisdiction will prevent it from selling the products in that jurisdiction. The Company would not be able to realize revenues for those new products in any jurisdiction where it does not have approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Developments following regulatory approval may adversely affect sales of the Company&#8217;s products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a product reaches the market, certain developments following regulatory approval may decrease demand for the Company&#8217;s products, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results in post-approval Phase 4 trials or other studies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the re-review of products that are already marketed;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">the recall or loss of marketing approval of products that are already marketed;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changing government standards or public expectations regarding safety, efficacy, quality or labeling changes; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scrutiny of advertising and promotion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, clinical trials and post-marketing surveillance of certain marketed drugs of the Company and of competitors within the industry have raised concerns that have led to recalls, withdrawals or adverse labeling of marketed products. Clinical trials and post-marketing surveillance of certain marketed drugs also have raised concerns among some prescribers and patients relating to the safety or efficacy of pharmaceutical products in general that have negatively affected the sales of such products. In addition, increased scrutiny of the outcomes of clinical trials has led to increased volatility in market reaction. Further, these matters often attract litigation and, even where the basis for the litigation is groundless, considerable resources may be needed to respond.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, following in the wake of product withdrawals and other significant safety issues, health authorities such as the FDA, the EMA, Japan&#8217;s PMDA and China&#8217;s NMPA have increased their focus on safety when assessing the benefit/risk balance of drugs. Some health authorities appear to have become more cautious when making decisions about approvability of new products or indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of the Company&#8217;s products, it could significantly reduce demand for the product or require the Company to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes. Further, in the current environment in which all pharmaceutical companies operate, the Company is at risk for product liability and consumer protection claims and civil and criminal governmental actions related to its products, research and/or marketing activities. In addition, dissemination of promotional materials through evolving digital channels serves to increase visibility and scrutiny in the marketplace.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is subject to a variety of U.S. and international laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently subject to a number of government laws and regulations and, in the future, could become subject to new government laws and regulations. The costs of compliance with such laws and regulations, or the negative results of non-compliance, could adversely affect the business, cash flow, results of operations, financial condition and prospects of the Company; these laws and regulations include (i) additional health care reform initiatives in the United States or in other countries, including additional mandatory discounts or fees;  (ii) the U.S. Foreign Corrupt Practices Act or other anti-bribery and corruption laws; (iii) new laws, regulations and judicial or other governmental decisions affecting pricing, drug reimbursement, and access or marketing within or across jurisdictions; (iv) changes in intellectual property laws; (v) changes in accounting standards; (vi) new and increasing data privacy regulations and enforcement, particularly in the EU and the United States; (vii) legislative mandates or preferences for local manufacturing of pharmaceutical or vaccine products; (viii) emerging and new global regulatory requirements for reporting payments and other value transfers to health care professionals; (ix) environmental regulations; and (x) the potential impact of importation restrictions, embargoes, trade sanctions and legislative and/or other regulatory changes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to evolving and complex tax laws in the jurisdictions in which it operates. Significant judgment is required for determining the Company&#8217;s tax liabilities, and the Company&#8217;s tax returns are periodically examined by various tax authorities. The Company believes that its accrual for tax contingencies is adequate for all open years based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities; however, due to the complexity of tax contingencies, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued. In addition, the Company may be negatively affected by changes in tax laws, or new tax laws, affecting, for example, tax rates, and/or revised tax law interpretations in domestic or foreign jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product liability insurance for products may be limited, cost prohibitive or unavailable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of a number of factors, product liability insurance has become less available while the cost of such insurance has increased significantly. The Company is subject to a substantial number of product liability claims. See Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note 10. &#8220;Contingencies and Environmental Liabilities&#8221; below for more information on the Company&#8217;s current product liability litigation. With respect to product liability, the Company self-insures substantially all of its risk, as the availability of commercial insurance has become more restrictive. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities. The Company will continually assess the most efficient means to address its risk; however, there can be no guarantee that insurance coverage will be obtained or, if obtained, will be sufficient to fully cover product liabilities that may arise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Technology</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is increasingly dependent on sophisticated software applications and computing infrastructure. In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. The Company could be a target of future cyber-attacks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is increasingly dependent on sophisticated software applications, complex information technology systems, computing infrastructure, and cloud service providers (collectively, IT systems) to conduct critical operations. Certain of these systems are managed, hosted, provided or used by third parties to assist in conducting the Company&#8217;s business. Disruption, degradation, or manipulation of these IT systems through intentional or accidental means by the Company&#8217;s employees, third parties with authorized access or unauthorized third parties could adversely affect key business processes. Cyber-attacks against the Company&#8217;s IT systems or third-party providers&#8217; IT systems, such as cloud-based systems, could result in exposure of confidential information, the modification of critical data, and/or the failure of critical operations. Misuse of any of these IT systems could result in the disclosure of sensitive personal information or the theft of trade secrets, intellectual property, or other confidential business information. The Company continues to leverage new and innovative technologies across the enterprise to improve the efficacy and efficiency of its business processes; the use of which can create new risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations, and resulting losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has implemented a variety of measures to further enhance and modernize its systems to guard against similar attacks in the future, and also is pursuing an enterprise-wide effort to enhance the Company's resiliency against future cyber-attacks, including incidents similar to the 2017 attack. The objective of these efforts is not only to protect against future cyber-attacks, but also to improve the speed of the Company&#8217;s recovery from such attacks and enable continued business operations to the greatest extent possible during any recovery period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks and network disruptions, including the 2017 cyber-attack, on the Company&#8217;s operations and financial condition has not been material to date, the Company continues to be a target of events of this nature and expects them to continue. The Company monitors its data, information technology and personnel usage of Company IT systems to reduce these risks and continues to do so on an ongoing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis for any current or potential threats. There can be no assurance that the Company&#8217;s efforts to protect its data and IT systems or the efforts of third-party providers to protect their IT systems will be successful in preventing disruptions to the Company&#8217;s operations, including its manufacturing, research and sales operations. Such disruptions have in the past and could in the future result in loss of revenue, or the loss of critical or sensitive information from the Company&#8217;s or the Company&#8217;s third-party providers&#8217; databases or IT systems and have in the past and could in the future also result in financial, legal, business or reputational harm to the Company and substantial remediation costs.</span></div><div style="margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Social media platforms present risks and challenges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inappropriate and/or unauthorized use of certain social media channels could cause brand damage or information leakage or could lead to legal implications, including from the improper collection and/or dissemination of personally identifiable information. In addition, negative or inaccurate posts or comments about the Company or its products on any social networking platforms could damage the Company&#8217;s reputation, brand image and goodwill. Further, the disclosure of non-public Company-sensitive information by the Company&#8217;s workforce or others through external media channels could lead to information loss. Although there is an internal Company Social Media Policy that guides employees on appropriate personal and professional use of social media about the Company, the processes in place may not completely secure and protect information. Identifying new points of entry as social media continues to expand also presents new challenges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to the Proposed Spin-Off of Organon</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The proposed Spin-Off of Organon may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company announced its intention to Spin-Off products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company, which has been named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The transaction is expected to be completed late in the second quarter of 2021. Completion of the Spin-Off will be subject to a number of factors and conditions, and there can be no assurances that the Company will be able to complete the Spin-Off on the terms or on the timeline that was announced, if at all. Unanticipated developments could delay, prevent or otherwise adversely affect the proposed Spin-Off, including but not limited to disruptions in general or financial market conditions or potential problems or delays in obtaining various regulatory and tax approvals or clearances. In addition, consummation of the proposed Spin-Off will require final approval from the Company&#8217;s Board of Directors. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The costs to complete the proposed Spin-Off will be significant. In addition, the Company may be unable to achieve some or all of the strategic and financial benefits that it expects to achieve from the Spin-Off of Organon. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will incur significant expenses in connection with the Spin-Off. In addition, the Company may not be able to achieve the full strategic and financial benefits that are expected to result from the Spin-Off. The anticipated benefits of the Spin-Off are based on a number of assumptions, some of which may prove incorrect. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Following the Spin-Off, the price of shares of the Company&#8217;s common stock may fluctuate significantly. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot predict the effect of the Spin-Off on the trading price of shares of its common stock, and the market value of shares of its common stock may be less than, equal to or greater than the market value of shares of its common stock prior to the Spin-Off. In addition, the price of Merck&#8217;s common stock may be more volatile around the time of the Spin-Off. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">There could be significant income tax liability if the Spin-Off or certain related transactions are determined to be taxable for U.S. federal income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that prior to completion of the Spin-Off it will receive an opinion from its U.S. tax counsel that concludes, among other things, that the Spin-Off of all of the outstanding Organon shares to Merck </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders and certain related transactions will qualify as tax-free to Merck and its shareholders under Sections 355 and 368 of the U.S. Internal Revenue Code, except to the extent of any cash received in lieu of fractional shares of Organon common stock. Any such opinion is not binding on the Internal Revenue Service (IRS). Accordingly, while the Company believes the risk is low, the IRS may reach conclusions with respect to the Spin-Off that are different from the conclusions reached in the opinion. The opinion will rely on certain facts, assumptions, representations and undertakings from Merck and Organon regarding the past and future conduct of the companies&#8217; respective businesses and other matters, which, if incomplete, incorrect or not satisfied, could alter the conclusions of the party giving such opinion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the proposed Spin-Off ultimately is determined to be taxable, which the Company believes is unlikely, the Spin-Off could be treated as a taxable dividend to Merck&#8217;s shareholders for U.S. federal income tax purposes, and Merck&#8217;s shareholders could incur significant U.S. federal income tax liabilities. In addition, Merck would recognize a taxable gain to the extent that the fair market value of Organon common stock exceeds Merck&#8217;s tax basis in such stock on the date of the Spin-Off. </span></div><div id="iab6577be4c3840fd8181bdedf457fba5_58"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Factors that May Affect Future Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Cautionary Statements Under the Private Securities Litigation Reform Act of 1995)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product approvals, product potential, development programs and include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. The Company cautions you not to place undue reliance on these forward-looking statements. Although it is not possible to predict or identify all such factors, they may include the following:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Competition from generic and/or biosimilar products as the Company&#8217;s products lose patent protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Increased &#8220;brand&#8221; competition in therapeutic areas important to the Company&#8217;s long-term business performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The difficulties and uncertainties inherent in new product development. The outcome of the lengthy and complex process of new product development is inherently uncertain. A drug candidate can fail at any stage of the process and one or more late-stage product candidates could fail to receive regulatory approval. New product candidates may appear promising in development but fail to reach the market because of efficacy or safety concerns, the inability to obtain necessary regulatory approvals, the difficulty or excessive cost to manufacture and/or the infringement of patents or intellectual property rights of others. Furthermore, the sales of new products may prove to be disappointing and fail to reach anticipated levels.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pricing pressures, both in the United States and abroad, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The impact of the global COVID-19 pandemic and any future pandemic, epidemic, or similar public health threat, on the Company&#8217;s business, operations and financial performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Changes in government laws and regulations, including laws governing intellectual property, and the enforcement thereof affecting the Company&#8217;s business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Efficacy or safety concerns with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cyber-attacks on the Company&#8217;s or third-party providers&#8217; information technology systems, which could disrupt the Company&#8217;s operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Lost market opportunity resulting from delays and uncertainties in the approval process of the FDA and foreign regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Increased focus on privacy issues in countries around the world, including the United States and the EU. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect directly the Company&#8217;s business, including recently enacted laws in a majority of states in the United States requiring security breach notification.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Changes in tax laws including changes related to the taxation of foreign earnings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Changes in accounting pronouncements promulgated by standard-setting or regulatory bodies, including the Financial Accounting Standards Board and the SEC, that are adverse to the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Economic factors over which the Company has no control, including changes in inflation, interest rates and foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The proposed Spin-Off might be delayed or the costs to complete the Spin-Off might be more significant than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This list should not be considered an exhaustive statement of all potential risks and uncertainties. See &#8220;Risk Factors&#8221; above.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_61"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.36pt">Unresolved Staff Comments.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_64"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Properties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters is currently located in Kenilworth, New Jersey. The Company has previously announced that it intends to consolidate its New Jersey campuses into a single corporate headquarters location in Rahway, New Jersey by the end of 2023. The Company also maintains operational or divisional headquarters in Kenilworth, New Jersey; Madison, New Jersey and Upper Gwynedd, Pennsylvania. Principal U.S. research facilities are located in Rahway and Kenilworth, New Jersey; West Point, Pennsylvania; Boston, Massachusetts; South San Francisco, California; and Elkhorn, Nebraska (Animal Health). Principal research facilities outside the United States are located in the United Kingdom, Switzerland and China. Merck&#8217;s manufacturing operations are currently headquartered in Whitehouse Station, New Jersey. The Company also has production facilities for human health products at nine locations in the United States and Puerto Rico. Outside the United States, through subsidiaries, the Company owns or has an interest in manufacturing plants or other properties in Japan, Singapore, South Africa, and other countries in Western Europe, Central and South America, and Asia. A number of properties will be transferred to Organon in the Spin-Off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures were $4.7 billion in 2020, $3.5 billion in 2019 and $2.6 billion in 2018. In the United States, these amounted to $2.7 billion in 2020, $1.9 billion in 2019 and $1.5 billion in 2018. Abroad, such expenditures amounted to $2.0 billion in 2020, $1.6 billion in 2019, and $1.1 billion in 2018.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries own their principal facilities and manufacturing plants under titles that they consider to be satisfactory. The Company believes that its properties are in good operating condition and that its machinery and equipment have been well maintained. The Company believes that its plants for the manufacture of products are suitable for their intended purposes and have capacities and projected capacities, including previously-disclosed capital expansion projects, that will be adequate for current and projected needs for existing Company products. Some capacity of the plants is being converted, with any needed modification, to the requirements of newly introduced and future products.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_67"></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item is incorporated herein by reference to Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;10. &#8220;Contingencies and Environmental Liabilities&#8221;.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_70"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Mine Safety Disclosures.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers of the Registrant (ages as of February&#160;1, 2021)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All officers listed below serve at the pleasure of the Board of Directors. None of these officers was elected pursuant to any arrangement or understanding between the officer and any other person(s).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offices and Business Experience</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth C. Frazier</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President and Chief Executive Officer (since December 2011)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanat Chattopadhyay</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Merck Manufacturing Division (since March 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frank Clyburn</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Commercial Officer (since January 2019); President, Global Oncology Business Unit (October 2013-December 2018)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert M. Davis</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Global Services, and Chief Financial Officer (since April 2016); Executive Vice President and Chief Financial Officer (April 2014-April 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard R. DeLuca, Jr.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Merck Animal Health (since September 2011)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael W. Fleming</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Ethics and Compliance Officer (since March 2019); Senior Vice President, International Legal and Compliance (January 2017-March 2019); Vice President, International Legal and Compliance (July 2008-January 2017)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Julie L. Gerberding</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health (since July 2016); Executive Vice President for Strategic Communications, Global Public Policy and Population Health (January 2015-July 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rita A. Karachun</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance - Global Controller (since March 2014)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dean Li</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2020); Vice President, Translational Medicine (March 2017-November 2017); Prior to that, Chief Scientific Officer and Associate Vice President, University of Utah Health Sciences</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven C. Mizell<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Human Resources Officer (since December 2016); Executive Vice President, Human Resources, Monsanto Company (August 2011-December 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael T. Nally</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Marketing Officer (since January 2019); President, Global Vaccines, Global Human Health (September 2016-January 2019); Managing Director, United Kingdom and Ireland, Global Human Health (January 2014-September 2016)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary (since January 2020); Executive Vice President and General Counsel (April 2018-January 2020); Partner, Covington &amp; Burling LLP (January 2013-March 2018)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Merck announced that Kenneth C. Frazier, chairman and chief executive officer, will retire as chief executive officer, effective June 30, 2021. Mr. Frazier will continue to serve on Merck&#8217;s Board of Directors as executive chairman, for a transition period to be determined by the board. The Merck Board of Directors has unanimously elected Robert M. Davis, Merck&#8217;s current executive vice president, global services and chief financial officer, as chief executive officer, as well as a member of the board, effective July 1, 2021. Mr. Davis will become president of Merck, effective April 1, 2021, at which time the Company&#8217;s operating divisions&#8212;Human Health, Animal Health, Manufacturing, and Merck Research Laboratories&#8212;will begin reporting to Mr. Davis.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_79"></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal market for trading of the Company&#8217;s Common Stock is the New York Stock Exchange (NYSE) under the symbol MRK. </span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;31, 2021, there were approximately 104,900 shareholders of record of the Company&#8217;s Common Stock.</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuer purchases of equity securities for the three months ended December 31, 2020 were as follows:</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">($&#160;in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">of Shares</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average&#160;Price<br/>Paid Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Approximate&#160;Dollar&#160;Value&#160;of&#160;Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">That May Yet Be Purchased</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 &#8212; October 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,888</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 &#8212; November 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,888</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 &#8212; December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,888</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,888</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">The Company did not purchase any shares during the three months ended December 31, 2020 under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion in Merck shares for its treasury. </span></div><div><span><br/></span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph assumes a $100 investment on December&#160;31, 2015, and reinvestment of all dividends, in each of the Company&#8217;s Common Shares, the S&amp;P 500 Index, and a composite peer group of major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Johnson&#160;&amp; Johnson, Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Roche Holding AG, and Sanofi SA.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Five-Year Cumulative Total Return*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc., Composite Peer Group and S&amp;P 500 Index</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of<br/>Period&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020/2015<br/>CAGR*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$180</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PEER GRP.**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr></table></div><div style="text-align:center"><img src="mrk-20201231_g1.jpg" alt="mrk-20201231_g1.jpg" style="height:280px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.641%"><tr><td style="width:1.0%"></td><td style="width:27.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.1</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.4</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.3</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PEER GRP.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.2</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.4</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.4</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.4</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.0</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Compound Annual Growth Rate</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Peer group average was calculated on a market cap weighted basis. </span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Performance Graph will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference. In addition, the Performance Graph will not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC or subject to Regulation 14A or 14C, other than as provided in Regulation S-K, or to the liabilities of section 18 of the Securities Exchange Act of 1934, except to the extent that the Company specifically requests that such information be treated as soliciting material or specifically incorporates it by reference into a filing under the Securities Act or the Exchange Act.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following section of this Form 10-K generally discusses 2020 and 2019 results and year-to-year comparisons between 2020 and 2019. Discussion of 2018 results and year-to-year comparisons between 2019 and 2018 that are not included in this Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019 filed on February 26, 2020.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_88"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Merck&#8217;s Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#8217;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had an Alliances segment that primarily included activity from the Company&#8217;s relationship with AstraZeneca LP related to sales of Nexium and Prilosec, which concluded in 2018. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned Spin-Off of Women&#8217;s Health, Biosimilars and Established Brands into a New Company </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, Merck announced its intention to spin-off products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed late in the second quarter of 2021, subject to market and certain other conditions. </span></div><div id="iab6577be4c3840fd8181bdedf457fba5_91"></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Highlights</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:64.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">7,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-GAAP Net Income Attributable to Merck &amp; Co., Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">15,082</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$2.78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$3.81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-GAAP Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$5.94</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$5.19</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs and certain other items. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS (see &#8220;Non-GAAP Income and Non-GAAP EPS&#8221; below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Summary</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales were $48.0 billion in 2020, an increase of 2% compared with 2019, or 4% excluding the unfavorable effect from foreign exchange. The sales increase was driven primarily by oncology, certain hospital acute care products and animal health. Growth in these areas was largely offset by the negative effects of the coronavirus disease 2019 (COVID-19) pandemic as discussed below, the effects of generic competition, particularly in the diversified brands and women&#8217;s health franchises, competitive pressure in the virology franchise and pricing pressure in the diabetes franchise.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, Merck continued executing on its strategic priorities reporting year-over-year sales growth despite the business challenges posed by the COVID-19 pandemic. Roughly two-thirds of Merck&#8217;s Pharmaceutical segment revenue is comprised of physician-administered products, sales of which were negatively affected in 2020 by patients&#8217; inability to access health care providers, fewer well visits, and social distancing measures. However, in the latter part of the year, the Company experienced a partial recovery in the underlying demand for products across its key growth pillars. Despite the pandemic, Merck employees across the organization continued their important work, enrolling and maintaining clinical studies, progressing the pipeline and ensuring the supply of and patient access to the Company&#8217;s portfolio of medically important medicines and vaccines. The Company also executed on Merck&#8217;s capital allocation priorities by completing business development transactions and investing in its pipeline. Additionally, the Company remains on track to complete the spin-off of Organon late in the second quarter of 2021 thereby creating two companies, each focused on their strengths and portfolios allowing them to pursue their respective market opportunities and business strategies. In 2020, the products that will comprise Organon had total sales of $6.5 billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck actively monitors the business development landscape for growth opportunities that meet the Company&#8217;s strategic criteria. To expand its oncology presence, Merck completed the acquisitions of ArQule, Inc. (ArQule), a biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of cancer and other diseases; and VelosBio Inc. (VelosBio), a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. Additionally, Merck entered into strategic collaboration agreements with Seagen to gain access to ladiratuzumab vedotin, an investigational antibody-drug conjugate targeting LIV-1, and Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers. To augment Merck&#8217;s animal health business, the Company acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of industry-wide efforts to develop solutions to the pandemic, the Company acquired OncoImmune, a company developing a therapeutic candidate for the treatment of patients hospitalized with COVID-19; and Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases, including a COVID-19 vaccine candidate. Additionally, Merck entered into </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategic collaborations with Ridgeback Biotherapeutics LP (Ridgeback Bio) to develop an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19; and with the International AIDS Vaccine Initiative, Inc. (IAVI) to develop an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. In January 2021, the Company announced it was discontinuing development of the COVID-19 vaccine candidates (see Note 3 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company received numerous regulatory approvals within oncology. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received approval in the United States as monotherapy in the therapeutic areas of cutaneous squamous cell carcinoma (cSCC), metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, non-muscle invasive bladder cancer (NMIBC) and tumor mutational burden-high (TMB-H) solid tumors, as well as in combination with chemotherapy for the treatment of triple-negative breast cancer (TNBC). Merck also received approval in the United States for an every six weeks (Q6W) dosing regimen across all adult indications. Additionally, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received approval in China for the treatment of certain patients with head and neck squamous cell carcinoma (HNSCC) and in both China and Japan for the treatment of certain patients with </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">esophageal squamous cell carcinoma (ESCC). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza, which is being developed in collaboration with AstraZeneca PLC (AstraZeneca), received approval in the United States: in combination with bevacizumab as a first-line maintenance treatment of certain adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy; and for the treatment of certain adult patients with metastatic castration-resistant prostate cancer (mCRPC) following progression on prior treatment. Additionally, Lynparza was approved in the European Union (EU): as monotherapy for the treatment of adult patients with mCRPC and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/2 mutations who have progressed following a prior therapy; and for the maintenance treatment of certain adult patients with metastatic adenocarcinoma of the pancreas. Lynparza was also approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer. Lenvima, which is being developed in collaboration with Eisai Co., Ltd. (Eisai), received approval in China as monotherapy for the treatment of differentiated thyroid cancer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 was approved for use in women and girls in Japan where it is marketed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Silgard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9. Additionally, in 2020, the U.S. Food and Drug and Administration (FDA) granted accelerated approval for an expanded indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 for the prevention of oropharyngeal and other head and neck cancers caused by certain HPV types. In January 2021, the Company received FDA approval for Verquvo (vericiguat), to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults. Verquvo is being jointly developed with Bayer AG (Bayer). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the recent regulatory approvals discussed above, the Company advanced its late-stage pipeline with several regulatory submissions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review in United States and/or internationally for the treatment of certain patients with TNBC, classical Hodgkin Lymphoma (cHL), colorectal cancer, cSCC, esophageal and gastric cancer. Lenvima is under review in Japan as monotherapy for the treatment of thymic cancer. V114, an investigational 15-valent pneumococcal conjugate vaccine, is under priority review by the FDA for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The European Medicines Agency (EMA) is also reviewing an application for licensure of V114 in adults. The Company is involved in litigation challenging the validity of several Pfizer Inc. patents that relate to pneumococcal vaccine technology in the United States and several foreign jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Phase 3 oncology programs include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the therapeutic areas of biliary tract, cervical, cutaneous squamous cell, endometrial, gastric, hepatocellular, mesothelioma, ovarian, prostate and small-cell lung cancers; Lynparza as monotherapy for colorectal cancer and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for non-small-cell lung and small-cell lung cancers; and Lenvima in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for bladder, endometrial, gastric, head and neck, melanoma and non-small-cell lung cancers. Also within oncology, MK-6482, belzutifan, an investigational hypoxia-inducible factor-2 alpha (HIF-2&#945;) inhibitor being evaluated</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma (RCC), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received Breakthrough Therapy designation from the FDA</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has candidates in Phase 3 clinical development in several other therapeutic areas, including MK-7264, gefapixant, a selective, non-narcotic, orally-administered, investigational P2X3-receptor antagonist being developed for the treatment of refractory, chronic cough; MK-7110, an investigational treatment for patients hospitalized with COVID-19; MK-8591A, islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) in combination with doravirine for the treatment of HIV-1 infection; and V114, which is being evaluated for the prevention of pneumococcal disease in pediatric patients. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is allocating resources to support its commercial opportunities in the near term while making the necessary investments to support long-term growth. Research and development expenses in 2020 reflect higher costs related to business development activity, higher clinical development spending and increased investment in discovery research and early drug development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Merck&#8217;s Board of Directors approved an increase to the Company&#8217;s quarterly dividend, raising it to $0.65 per share from $0.61 per share on the Company&#8217;s outstanding common stock. During 2020, the Company returned $7.5 billion to shareholders through dividends and share repurchases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Merck announced that Kenneth C. Frazier, chairman and chief executive officer, will retire as chief executive officer, effective June 30, 2021. Mr. Frazier will continue to serve on Merck&#8217;s Board of Directors as executive chairman, for a transition period to be determined by the board. The Merck Board of Directors has unanimously elected Robert M. Davis, Merck&#8217;s current executive vice president, global services and chief financial officer, as chief executive officer, as well as a member of the board, effective July 1, 2021. Mr. Davis will become president of Merck, effective April 1, 2021, at which time the Company&#8217;s operating divisions&#8212;Human Health, Animal Health, Manufacturing, and Merck Research Laboratories (MRL)&#8212;will begin reporting to Mr. Davis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, in response to the COVID-19 pandemic, Merck remains focused on protecting the safety of its employees, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of antiviral approaches, and supporting health care providers and Merck&#8217;s communities. Although COVID-19-related disruptions to patients&#8217; ability to access health care providers negatively affected results in 2020, Merck remains confident in the fundamental underlying demand for its products and its prospects for long-term growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the estimated negative impact of the COVID-19 pandemic to Merck&#8217;s sales was approximately $2.5 billion, largely attributable to the Pharmaceutical segment, with approximately $50 million attributable to the Animal Health segment. Roughly two-thirds of Merck&#8217;s Pharmaceutical segment revenue is comprised of physician-administered products, which, despite strong underlying demand, have been affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, have resulted in reduced administration of many of the Company&#8217;s human health products, in particular for its vaccines, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, as well as for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, declines in elective surgeries negatively affected the demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 increased due to heightened awareness of pneumococcal vaccination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were positively affected in 2020 by approximately $600 million primarily due to lower promotional and selling costs, as well as lower research and development expenses, net of investments in COVID-19-related antiviral and vaccine research programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck believes that global health systems and patients have largely adapted to the impacts of COVID-19, but the Company&#8217;s assumption is that ongoing residual negative impacts will persist, particularly during the first half of 2021 and most notably with respect to vaccine sales, with the impact expected to be more acute in the United States. For the full year of 2021, Merck assumes an unfavorable impact to revenue of approximately 2% due to the COVID-19 pandemic, all of which relates to Pharmaceutical segment sales. In addition, for the full year of 2021, with respect to the COVID-19 pandemic, Merck expects a net negative impact to operating expenses, as spending on the development of its COVID-19 antiviral programs is expected to exceed the favorable impact of lower spending in other areas due to the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s revenue performance in 2020 was negatively </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affected by other cost-reduction measures taken by governments and other third-parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales grew 2% in 2020 due to higher sales in the oncology franchise reflecting strong growth of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as increased alliance revenue from Lynparza and Lenvima. Also contributing to revenue growth were higher sales of certain vaccines, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, as well as increased sales of certain hospital acute care products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Higher sales of animal health products also drove revenue growth in 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales growth in 2020 was partially offset by the effects of generic competition for certain products including women&#8217;s health product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, hospital acute care products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cubicin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, oncology products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Injection, cardiovascular products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and products within the diversified brands franchise, particularly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Singulair.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The diversified brands franchise includes certain products that are approaching the expiration of their marketing exclusivity or that are no longer protected by patents in developed markets. Lower sales of pediatric vaccines, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as lower sales of diabetes products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and virology products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zepatier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also partially offset revenue growth in 2020. As discussed above, the COVID-19 pandemic negatively affected sales in 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales in the United States grew 2% in 2020 primarily driven by higher sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, increased alliance revenue from Lynparza and Lenvima, and higher sales of animal health products. Revenue growth was largely offset by lower sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Emend/Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Injection, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales grew 2% in 2020. The increase in international sales primarily reflects growth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9, increased alliance revenue from Lynparza, as well as higher sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and animal health products. Sales growth was partially offset by lower sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zepatier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend/Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Injection and products within the diversified brands franchise, particularly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Singulair </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nasonex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. International sales represented 56% of total sales in both 2020 and 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 to the consolidated financial statements for details on sales of the Company&#8217;s products. A discussion of performance for select products in the franchises follows.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_97"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:29.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,380</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alliance Revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alliance Revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4 to the consolidated financial statements).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, cHL, cSCC, ESCC, gastric or gastroesophageal junction adenocarcinoma, HNSCC, hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), melanoma, Merkel cell carcinoma, MSI-H or dMMR cancer including MSI-H/dMMR colorectal cancer, primary mediastinal large B-cell lymphoma (PMBCL), TMB-H cancer, and urothelial carcinoma including NMIBC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for the treatment of certain patients: in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy for HNSCC, in combination with chemotherapy for TNBC, in combination with axitinib for RCC, and in combination with Lenvima for endometrial carcinoma. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical development program includes studies across a broad range of cancer types.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grew 30% in 2020 driven by higher demand as the Company continues to launch </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with multiple new indications globally, although the COVID-19 pandemic had a dampening effect on growing demand. Sales in the United States continue to build across the multiple approved indications, in particular for the treatment of advanced NSCLC as monotherapy, and in combination with chemotherapy for both nonsquamous and squamous metastatic NSCLC, along with uptake in the RCC, adjuvant melanoma, HNSCC, bladder cancer and endometrial carcinoma indications. Uptake of the every six weeks (Q6W) adult dosing regimen in the United States benefited sales in 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales growth in international markets was driven by continued uptake in approved indications, particularly in the EU. Sales growth was partially offset by declines in Japan due to pricing. Pursuant to a re-pricing rule, the Japanese government reduced the price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by 17.5% effective February 2020. Additionally, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was subject to another price reduction of 20.9% in April 2020 under a provision of the Japanese pricing rules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the treatment of certain patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, NMIBC based on the results of the KEYNOTE-057 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FDA granted accelerated approval for an additional recommended dosage of 400 mg every six weeks (Q6W) for </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">across all adult indications, </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including monotherapy and combination therapy. This new dosage option is available in addition to the current dose of 200 mg every three weeks (Q3W).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA granted accelerated approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-H solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options based in part on the results of the KEYNOTE-158 trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in June 2020, the FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the treatment of patients with recurrent or metastatic cSCC that is not curable by surgery or radiation based on data from the KEYNOTE-629 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in June 2020, the FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer based on results from the KEYNOTE-177 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FDA approved an expanded label for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the treatment of adult patients with relapsed or refractory cHL based on results from the KEYNOTE-204 trial. The FDA also approved an updated pediatric indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of pediatric patients with refractory cHL or cHL that has relapsed after two or more lines of therapy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was previously approved under the FDA&#8217;s accelerated approval process for the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after three or more prior lines of therapy based on data from the KEYNOTE-087 trial. In accordance with accelerated approval regulations, continued approval was contingent upon verification and description of clinical benefit; these accelerated approval requirements have been fulfilled with the data from KEYNOTE-204.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FDA granted accelerated approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Combined Positive Score [CPS] &#8805;10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as determined by an FDA-approved test. The approval is based on results from the KEYNOTE-355 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the National Medical Products Administration (NMPA) in China as monotherapy for the second-line treatment of patients with locally advanced or metastatic ESCC whose </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumors express PD-L1 (CPS &#8805;10). This indication was granted based on the KEYNOTE-181 trial, including data from an extension of the global study in Chinese patients. In December 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China&#8217;s NMPA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (CPS &#8805;20) as determined by a fully validated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA) as monotherapy for the treatment of patients whose tumors are PD-L1-positive, and have radically unresectable, advanced or recurrent ESCC who have progressed after chemotherapy. The approval was based on results from the KEYNOTE-181 trial. Additionally, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by Japan&#8217;s PMDA for use at an additional recommended dosage of 400 mg Q6W, including monotherapy and combination therapy. This new dosage option is available in addition to the current dose of 200 mg Q3W. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the European Commission (EC) as a first-line treatment in adult patients with MSI-H or dMMR colorectal cancer based on the results of the KEYNOTE-177 study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the terms of the more significant of these agreements, Merck pays a royalty of 6.5% on worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through 2023 to one third party; this royalty will decline to 2.5% for 2024 through 2026 and will terminate thereafter. The Company pays an additional 2% royalty on worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to another third party, the termination date of which varies by country; this royalty will expire in the United States in 2024 and in major European markets in 2025. The royalties are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza, an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca (see Note 4 to the consolidated financial statements), is approved for the treatment of certain types of advanced ovarian, breast, pancreatic and prostate cancers. Alliance revenue related to Lynparza grew 63% in 2020 due to continued uptake across the multiple approved indications in the United States, the EU, China and Japan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the FDA approved Lynparza in combination with bevacizumab as a first-line maintenance treatment of certain adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. In November 2020, Lynparza was approved in the EU for the maintenance treatment of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. These approvals were based on the results from the PAOLA-1 trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in May 2020, the FDA approved Lynparza for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC who have progressed following prior treatment. In November 2020, Lynparza was approved in the EU as monotherapy for the treatment of adult patients with mCRPC and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/2 mutations (germline and/or somatic) who have progressed following a prior therapy. These approvals were based on the results from the PROfound trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Lynparza was approved in the EU as a monotherapy for the maintenance treatment of adult patients with germline&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a first-line chemotherapy regimen. This approval was based on the results from the POLO trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Lynparza was approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer. The three approvals authorize Lynparza for use as maintenance treatment after first-line chemotherapy containing bevacizumab (genetical recombination) in patients with HRD ovarian cancer; the treatment of patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene-mutated (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m) mCRPC; and maintenance treatment after platinum-based chemotherapy for patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m curatively unresectable pancreas cancer. The concurrent approvals by the Japanese Ministry of Health, Labor, and Welfare are based on results from the PAOLA-1, PROfound and POLO trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenvima, an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai (see Note 4 to the consolidated financial statements), is approved for the treatment of certain types of thyroid cancer, HCC, in combination with everolimus for certain patients with RCC, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of certain patients with endometrial carcinoma. Alliance revenue related to Lenvima grew 44% in 2020 due to higher demand in the United States, China and the EU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, China&#8217;s NMPA approved Lenvima as a monotherapy for the treatment of differentiated thyroid cancer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the prevention of certain chemotherapy-induced nausea and vomiting, declined 63% in 2020 primarily due to lower demand and pricing in the United States due to generic competition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Injection following U.S. patent expiry in September 2019. Also contributing to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales decline was lower demand in the EU and Japan as a result of generic competition for the oral formulation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following loss of market exclusivity in May 2019 and December 2019, respectively. U.S. market exclusivity for the oral formulation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> previously expired in 2015. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FDA approved Koselugo (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA approval is based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase 2 SPRINT Stratum 1 trial coordinated by the NCI&#8217;s Center for Cancer Research, Pediatric Oncology Branch. This is the first regulatory approval of a medicine for the treatment of NF1 PN, a rare and debilitating genetic condition. Koselugo is being jointly developed and commercialized with AstraZeneca globally (see Note 4 to the consolidated financial statements).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ProQuad</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">678</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9, vaccines to help prevent certain cancers and other diseases caused by certain types of HPV, grew 5% in 2020 primarily due to higher volumes in China and the replenishment in 2020 of doses borrowed from the U.S. Centers for Disease Control and Prevention (CDC) Pediatric Vaccine Stockpile in 2019. The replenishment resulted in the recognition of sales of $120 million in 2020, which, when combined with the reduction of sales of $120 million in 2019 due to the borrowing, resulted in a favorable impact to sales of $240 million in 2020. Lower demand in the United States and Hong Kong, SAR, PRC attributable to the COVID-19 pandemic partially offset the increase in sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA approved an expanded indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. The oropharyngeal and head and neck cancer indication was approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 was approved by the PMDA in Japan for use in women and girls nine years and older for the prevention of cervical cancer, certain cervical, vaginal and vulvar precancers, and genital warts caused by the HPV types covered by the vaccine. In December 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Silgard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 was also approved in Japan for the prevention of anal cancer and precursor lesions caused by HPV types 6, 11, 16 and 18 for individuals nine years and older and for genital warts for men nine years and older. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 is marketed in Japan as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Silgard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 to one third party (royalty obligations under this agreement expire in December 2023) and an additional 7% royalty on sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 in the United States to another third party (these royalty obligations expire in December 2028). The royalties are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, declined 10% in 2020 driven primarily by lower demand in the United States resulting from fewer measles outbreaks in 2020 compared with 2019, coupled with the unfavorable impact of the COVID-19 pandemic, partially offset by higher pricing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II, a vaccine to help protect against measles, mumps and rubella, declined 31% in 2020 driven primarily by lower demand in the United States resulting from fewer measles outbreaks in 2020 compared with 2019, coupled with the unfavorable impact of the COVID-19 pandemic. Lower demand in Brazil also contributed to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II sales decline in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a vaccine to help prevent chickenpox (varicella), declined 15% in 2020 driven primarily by lower demand in the United States resulting from the COVID-19 pandemic, partially offset by higher pricing. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales decline was also attributable to lower government tenders in Brazil.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, a vaccine to help prevent pneumococcal disease, grew 17% in 2020 primarily due to higher volumes in the EU and in the United States attributable in part to heightened awareness of pneumococcal vaccination. Higher pricing in the United States also contributed to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 sales growth in 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 6% in 2020 due to higher demand globally, particularly in the United States. However, fewer elective surgeries as a result of the COVID-19 pandemic unfavorably affected demand in 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an antifungal agent for the prevention of certain invasive fungal infections, declined 50% in 2020 due to generic competition in the United States and in the EU. The patent that provided U.S.&#160;market exclusivity for certain forms of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> representing the majority of U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales expired in July 2019. Additionally, the patent for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in a number of major European markets in December 2019. As a result, the Company is experiencing volume and pricing declines in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales in these markets as a result of generic competition and expects the declines to continue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 70% in 2020 due to continued uptake since launch in the EU and in the United States. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the EC in January 2018 and by the FDA in November 2017.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cubicin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for injection, an antibiotic for the treatment of certain bacterial infections, declined 41% in 2020 primarily due to ongoing generic competition in the EU and in the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections, and subsequently issued a product recall, following the identification of product sterility issues. As a result, the Company recorded an intangible asset impairment charge related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 8 to the consolidated financial statements). The Company does not anticipate that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will return to the market before 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA approved a supplemental New Drug Application (NDA) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recarbrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bacterial pneumonia and ventilator-associated bacterial pneumonia caused by certain susceptible Gram-negative microorganisms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunology</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a once-monthly subcutaneous treatment for certain inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), were nearly flat in 2020. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are being unfavorably affected by the launch of biosimilars for a competing product. The Company expects this competition will continue to unfavorably affect sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a treatment for inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 20% in 2020 driven by ongoing biosimilar competition in the Company&#8217;s marketing territories in Europe. The Company lost market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in major European markets in 2015 and no longer has market exclusivity in any of its marketing territories. The Company is experiencing pricing and volume declines in these markets as a result of biosimilar competition and expects the declines to continue.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketing rights with respect to these products will revert to Janssen Pharmaceuticals, Inc. in the second half of 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Virology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 12% in 2020 primarily due to competitive pressure in the United States and in the EU. The Company expects competitive pressures for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to continue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zepatier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a treatment for adult patients with chronic hepatitis C virus genotype (GT) 1 or GT4 infection, declined 55% in 2020 driven by lower demand globally due to competition and declining patient volumes, coupled with the impact of the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zetia/Vytorin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rosuzet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Combined global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (marketed in most countries outside the United States as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(marketed outside the United States as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inegy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), medicines for lowering LDL cholesterol, declined 24% in 2020 driven primarily by lower sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inegy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU. The patent that provided market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan expired in September 2019 and generic competition began in June 2020. The </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EU patents for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inegy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in April 2018 and April 2019, respectively. Accordingly, the Company is experiencing sales declines in these markets as a result of generic competition and expects the declines to continue. The sales decline in 2020 was also attributable to lower pricing following loss of exclusivity in Australia. Higher demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China partially offset the sales decline in 2020. Merck lost market exclusivity in the United States for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2016 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2017 and subsequently lost nearly all U.S. sales of these products as a result of generic competition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Atozet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(marketed outside of the United States), a medicine for lowering LDL cholesterol, grew 16% in 2020, primarily driven by higher demand in most markets, particularly in the EU, Japan and other countries in the Asia Pacific region.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Atozet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rosuze</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t will be contributed to Organon in connection with the spin-off (see Note 1 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adempas, a cardiovascular drug for the treatment of pulmonary arterial hypertension, is part of a worldwide collaboration with Bayer to market and develop soluble guanylate cyclase (sGC) modulators including Adempas (see Note 4 to the consolidated financial statements). Revenue from Adempas includes Merck&#8217;s share of profits from the sale of Adempas in Bayer&#8217;s marketing territories, which grew 38% in 2020, as well as sales in Merck&#8217;s marketing territories, which grew 3% in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FDA approved Verquvo (vericiguat), an sGC stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. The approval was based on the results of the pivotal Phase 3 VICTORIA trial and follows a priority regulatory review. Verquvo is part of the same worldwide clinical development collaboration with Bayer that includes Adempas referenced above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diabetes</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,276</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 4% in 2020 as a result of continued pricing pressure in the United States, partially offset by higher demand in certain international markets, particularly in China. The Company expects U.S. pricing pressure to continue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will lose market exclusivity in the United States in January 2023. The supplementary patent certificates that provide market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU expire in September 2022 and April 2023, respectively. The Company anticipates sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in these markets will decline substantially after loss of market exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Women&#8217;s Health&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a single-rod subdermal contraceptive implant, declined 14% in 2020, primarily driven by lower demand in the United States and in the EU resulting from the COVID-19 pandemic. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a vaginal contraceptive product, declined 73% in 2020 due to generic competition in the United States. The patent that provided U.S. market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in April 2018 and generic competition began in December 2019. Accordingly, the Company is experiencing a rapid and substantial decline in U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales and expects the decline to continue. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will be contributed to Organon in connection with the spin-off (see Note 1 to the consolidated financial statements).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biosimilars</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Calculation not meaningful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar products are marketed by the Company pursuant to an agreement with Samsung Bioepis Co., Ltd. (Samsung) to develop and commercialize multiple pre-specified biosimilar candidates. Currently, the Company markets Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab) for the treatment of certain inflammatory diseases; Ontruzant (trastuzumab-dttb), a biosimilar to Herceptin (trastuzumab) for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer;  Brenzys (etanercept biosimilar), a biosimilar to Enbrel for the treatment of certain inflammatory diseases; and Aybintio (bevacizumab) for the treatment of certain types of cancer. Merck&#8217;s commercialization territories under the agreement vary by product. Sales growth of biosimilars in 2020 was primarily due to continued post-launch uptake of Renflexis in the United States and Canada and the launch of Ontruzant in Brazil in 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the EC granted marketing authorization for Aybintio for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, NSCLC, advanced and/or metastatic RCC, epithelial ovarian, fallopian tube and primary peritoneal cancer and cervical cancer. An application seeking approval of Aybintio in the United States was filed in September 2019. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above biosimilar products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be contributed to Organon in connection with the spin-off (see Note 1 to the consolidated financial statements).</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Animal Health Segment</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livestock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,764</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of livestock products grew 6% in 2020 predominantly due to an additional five months of sales in 2020 related to the April 2019 acquisition of Antelliq, a leader in digital animal identification, traceability and monitoring solutions (see Note 3 to the consolidated financial statements). Sales of companion animal products grew 10% in 2020 driven primarily by higher demand for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of products for parasitic control, as well as higher demand for companion animal vaccines. </span></div><div id="iab6577be4c3840fd8181bdedf457fba5_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs, Expenses and Other</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,485</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,558</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Calculation not meaningful.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $15.5 billion in 2020 compared with $14.1 billion in 2019. Cost of sales includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $1.8 billion in 2020 compared with $2.0 billion in 2019, respectively. Additionally, costs in 2020 and 2019 include intangible asset impairment charges of $1.6&#160;billion and $705 million related to marketed products and other intangibles (see Note 8 to the consolidated financial statements). The Company may recognize additional impairment charges in the future related to intangible assets that were measured at fair value and capitalized in connection with business acquisitions and such charges could be material. Costs in 2020 also include a charge of $260 million in connection with the discontinuation of COVID-19 vaccine development programs (see Note 3 to the consolidated financial statements) and inventory write-offs of $120 million related to a recall for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 8 to the consolidated financial statements). Also included in cost of sales are expenses associated with restructuring activities which amounted to $175 million in 2020 compared with $251 million in 2019, primarily reflecting accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin was 67.7% in 2020 compared with 69.9% in 2019. The gross margin decline in 2020 reflects the unfavorable effects of higher impairment charges (noted above), pricing pressure, a charge related to the discontinuation of COVID-19 vaccine development programs, and higher inventory write-offs related to the recall of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(noted above), partially offset by the favorable effects of product mix, lower amortization of intangible assets and lower restructuring costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses were $10.5 billion in 2020, a decline of 1% compared with 2019. The decline was driven primarily by lower administrative, selling and promotional costs, including lower travel and meeting expenses, due in part to the COVID-19 pandemic, and the favorable effect of foreign exchange, partially offset by higher costs related to the spin-off of Organon and a contribution to the Merck Foundation. SG&amp;A expenses in 2020 include $710 million of costs related to the spin-off of Organon. SG&amp;A expenses in 2020 and 2019 include restructuring costs of $47 million and $34 million, respectively, related primarily to accelerated depreciation for facilities to be closed or divested. Separation costs associated with sales force reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as discussed below.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses were $13.6 billion in 2020, an increase of 37% compared with 2019. The increase was driven primarily by higher upfront payments related to acquisitions and collaborations, including a $2.7 billion charge in 2020 related to the acquisition of VelosBio (see Note 3 to the consolidated financial statements), as well as higher expenses related to clinical development and increased investment in discovery research and early drug development. Higher restructuring costs also contributed to the increase in R&amp;D expenses in 2020. The increase in R&amp;D expenses in 2020 was partially offset by lower in-process research and development (IPR&amp;D) impairment charges and lower costs resulting from the COVID-19 pandemic, net of spending on COVID-19-related vaccine and antiviral research programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are comprised of the costs directly incurred by MRL, the Company&#8217;s research and development division that focuses on human health-related activities, which were $6.6 billion in 2020 compared with $6.1 billion in 2019. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were $2.7 billion in 2020 and $2.6 billion in 2019. Additionally, R&amp;D expenses in 2020 include a $2.7 billion charge for the acquisition of VelosBio (noted above), a $462 million charge for the acquisition of OncoImmune and charges of $826 million related to transactions with Seagen. R&amp;D expenses in 2019 include a $993 million charge for the acquisition of Peloton. See Note 3 to the consolidated financial statements for more information on these transactions. R&amp;D expenses also include IPR&amp;D impairment charges of $90 million and $172 million in 2020 and 2019, respectively (see Note 8 to the consolidated financial statements). The Company may recognize additional impairment charges in the future related to the cancellation or delay of other pipeline programs that were measured at fair value and capitalized in connection with business acquisitions and such </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charges could be material. In addition, R&amp;D expenses in 2020 include $83 million of costs associated with restructuring activities, primarily relating to accelerated depreciation. R&amp;D expenses also include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business acquisitions. During 2020 and 2019, the Company recorded a net reduction in expenses of $95 million and $39 million, respectively, related to changes in these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, Merck&#160;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program now estimated to be approximately $3.0 billion. The Company expects to record charges of approximately $700 million in 2021 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program to result in annual net cost savings of approximately $900 million by the end of 2023. Actions under previous global restructuring programs have been substantially completed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $578 million in 2020 and $638 million in 2019. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional costs associated with the Company&#8217;s restructuring activities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs. The Company recorded aggregate pretax costs of $883 million in 2020 and $927 million in 2019 related to restructuring program activities (see Note 5 to the consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, was $886 million of income in 2020 compared with $139 million of expense in 2019, primarily due to higher income from investments in equity securities, net, largely related to Moderna, Inc. For details on the components of Other (income) expense, net, see Note 14 to the consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Segment Profits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment profits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,722</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-reportable segment profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,932)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A and R&amp;D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of purchase accounting adjustments, intangible asset impairment charges, and changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in &#8220;Other&#8221; in the above table. Also included in &#8220;Other&#8221; are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits grew 5% in 2020 compared with 2019 driven primarily by higher sales, as well as lower selling and promotional costs. Animal Health segment profits grew 3% in 2020 driven primarily by higher sales and lower promotional and selling costs, partially offset by higher R&amp;D costs and the unfavorable effect of foreign exchange. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates of 19.4% in 2020 and 14.7% in 2019 reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings, including product mix. The effective income tax rate in 2020 reflects the unfavorable impact of a charge for the acquisition of VelosBio for which no tax benefit was recognized. The effective income tax rate in 2019 reflects the favorable impact of a $364 million net tax benefit related to the settlement of certain federal income tax matters (see Note 15 to the consolidated financial statements) and the reversal of tax reserves established in connection with the 2014 divestiture of Merck&#8217;s Consumer Care (MCC) business due to the lapse in the statute of limitations. In addition, the effective income tax rate in 2019 reflects the unfavorable impacts of a charge for the acquisition of Peloton for which no tax benefit was recognized and charges of $117 million related to the finalization of treasury regulations for the transition tax associated with the 2017 enactment of U.S. tax legislation known as the Tax Cuts and Jobs Act (TCJA) (see Note 15 to the consolidated financial statements). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income (Loss) Attributable to Noncontrolling Interests</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to noncontrolling interests was $15 million in 2020 compared with $(66) million in 2019. The loss in 2019 was driven primarily by the portion of goodwill impairment charges related to certain businesses in the Healthcare Services segment that were attributable to noncontrolling interests.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income and Earnings per Common Share</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Merck&#160;&amp; Co., Inc. was $7.1 billion in 2020 and $9.8 billion in 2019. EPS was $2.78 in 2020 and $3.81 in 2019. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Income and Non-GAAP EPS</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are alternative views of the Company&#8217;s performance that Merck is providing because management believes this information enhances investors&#8217; understanding of the Company&#8217;s results as it permits investors to understand how management assesses performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs and certain other items. These excluded items are significant components in understanding and assessing financial performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes non-GAAP&#160;EPS. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management&#8217;s annual compensation is derived in part using non-GAAP pretax income. Since non-GAAP income and non-GAAP&#160;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&#160;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the United States (GAAP). </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:69.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before taxes as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of VelosBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,660</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charges for the formation of collaborations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the discontinuation of COVID-19 vaccine development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of Peloton</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge related to the termination of a collaboration with Samsung</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of Viralytics Limited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes on income as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated tax benefit on excluded items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tax benefit from the settlement of certain federal income tax matters</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax benefit from the reversal of tax reserves related to the divestiture of MCC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tax charge related to the finalization of treasury regulations related to the enactment of the TCJA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP taxes on income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,764</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,097</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,082</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,621&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS assuming dilution as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP EPS assuming dilution</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.34&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Amount in 2020 includes a $1.6 billion intangible asset impairment charge related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Amount in 2019 includes a $612 million intangible asset impairment charge related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. See Note 8 to the consolidated financial statements.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Amount in 2020 includes $826 million related to transactions with Seagen (see Note 3 to the consolidated financial statements). Amount in 2018 represents charge for the formation of a collaboration with Eisai (see Note 4 to the consolidated financial statements).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition and Divestiture-Related Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude the impact of certain amounts recorded in connection with business acquisitions and divestitures. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with business acquisitions and divestitures. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude costs related to restructuring actions (see Note&#160;5 to the consolidated financial statements). These amounts include employee separation costs and accelerated depreciation </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Items</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These items are adjusted for after evaluating them on an individual basis considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2020 are charges for the acquisitions of VelosBio and OncoImmune, charges related to collaborations, including transactions with Seagen (see Note 3 to the consolidated financial statements), a charge for the discontinuation of COVID-19 vaccine development programs, and an adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition. Excluded from non-GAAP income and non-GAAP EPS in 2019 is a charge for the acquisition of Peloton (see Note 3 to the consolidated financial statements), tax charges related to the finalization of U.S. treasury regulations related to the TCJA, a net tax benefit related to the settlement of certain federal income tax matters, and a tax benefit related to the reversal of tax reserves established in connection with the 2014 divestiture of MCC (see Note 15 to the consolidated financial statements). Excluded from non-GAAP income and non-GAAP EPS in 2018 is a charge related to the formation of a collaboration with Eisai (see Note 4 to the consolidated financial statements), a charge related to the termination of a collaboration agreement with Samsung for insulin glargine (see Note 3 to the consolidated financial statements), a charge for the acquisition of Viralytics (see Note 3 to the consolidated financial statements), and measurement-period adjustments related to the provisional amounts recorded for the TCJA (see Note 15 to the consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2021, the Company will be changing the treatment of certain items for the purposes of its non-GAAP reporting. Historically, Merck&#8217;s non-GAAP results excluded the amortization of intangible assets recognized in connection with business acquisitions (reflected as part of acquisition and divestiture-related costs) but did not exclude the amortization of intangibles originating from collaborations, asset acquisitions or licensing arrangements. Beginning in 2021, Merck&#8217;s non-GAAP results will no longer differentiate between the nature of the intangible assets being amortized and will exclude all amortization of intangible assets. Also, beginning in 2021, Merck&#8217;s non-GAAP results will exclude gains and losses on investments in equity securities. Prior period amounts will be recast to conform to the new presentation.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_106"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Pipeline</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the United States and internationally, as well as in late-stage clinical development. A chart reflecting the Company&#8217;s current research pipeline as of February&#160;22, 2021 and related discussion is set forth in Item&#160;1. &#8220;Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and Development&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with business acquisitions, the Company has recorded the fair value of in-process research projects which, at the time of acquisition, had not yet reached technological feasibility. At December&#160;31, 2020, the balance of IPR&amp;D was $3.2 billion (see Note 8 to the consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates. The time periods to receive approvals from the FDA and other regulatory agencies are subject to uncertainty. Significant delays in the approval process, or the Company&#8217;s failure to obtain approval at all, would delay or prevent the Company from realizing revenues from these products. Additionally, if certain of the IPR&amp;D programs fail or are abandoned during development, then the Company will not realize the future cash flows it has estimated and recorded as IPR&amp;D as of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the acquisition date. If such circumstances were to occur, the Company&#8217;s future operating results could be adversely affected and the Company may recognize impairment charges and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019, and 2018 the Company recorded IPR&amp;D impairment charges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $90 million, $172 million and $152 million, respectively (see Note 8 to the consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional research and development will be required before any of the remaining programs reach technological feasibility. The costs to complete the research projects will depend on whether the projects are brought to their final stages of development and are ultimately submitted to the FDA or other regulatory agencies for approval. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, Research Collaborations and License Agreements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck continues to remain focused on pursuing opportunities that have the potential to drive both near- and long-term growth. Certain recent transactions are summarized below; additional details are included in Note 3 to the consolidated financial statements. Merck is actively monitoring the landscape for growth opportunities that meet the Company&#8217;s strategic criteria.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases for $2.7 billion. ArQule&#8217;s lead investigational candidate, MK-1026 (formerly ARQ 531), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as an acquisition of a business. The Company recorded IPR&amp;D of $2.3 billion (related to MK-1026), goodwill of $512 million and other net liabilities of $102 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck and Ridgeback Bio, a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, also known as EIDD-2801), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Molnupiravir is currently being evaluated in Phase 2/3 clinical trials in both the hospital and outpatient settings. The primary completion date for the Phase 2/3 studies is June 2021. The Company anticipates interim efficacy data in the first quarter of 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. Under the terms of the agreement, Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $616&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020 related to this transaction. Seagen is also eligible to receive future contingent milestone payments dependent upon the achievement of certain developmental and sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones and tiered royalties based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million. In addition, OncoImmune shareholders will be eligible to receive future contingent regulatory approval milestone payments and tiered royalties. OncoImmune&#8217;s lead therapeutic candidate MK-7110 (also known as CD24Fc) is being evaluated for the treatment of patients hospitalized with COVID-19. Topline results from a pre-planned interim efficacy analysis from a Phase 3 study of MK-7110 were released in September 2020. Full results from this Phase 3 study, which were consistent with the topline results, were received in February 2021 and will be submitted for publication in the future. The transaction was accounted </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50&#160;million for a 20% ownership interest in the new entity, which was valued at $33&#160;million resulting in a $17&#160;million premium. Merck also recognized other net liabilities of $22&#160;million. The Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $462&#160;million in 2020 related to this transaction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Merck announced it had entered into an agreement with the U.S. Government to support the development, manufacture and initial distribution of MK-7110 upon approval or Emergency Use Authorization (EUA) from the FDA by June 30, 2021. Under the agreement, Merck was to receive up to approximately $356 million for manufacturing and supply of approximately 60,000-100,000 doses of MK-7110 to the U.S. government by June 30, 2021 to help meet the government&#8217;s pandemic response goals. Following the execution of this agreement, Merck received feedback from the FDA that additional data, beyond the study conducted by OncoImmune, would be needed to support a potential EUA application. Based on this FDA feedback, Merck no longer expects to supply the U.S. government with MK-7110 in the first half of 2021. Merck is actively working with FDA to address the agency&#8217;s comments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Merck acquired VelosBio, a privately held clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio&#8217;s lead investigational candidate is MK-2140 (formerly known as VLS-101), an antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180&#160;million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $2.7 billion in 2020 related to the transaction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Merck and Pandion Therapeutics, Inc. (Pandion) entered into a definitive agreement under which Merck will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash representing an approximate total equity value of $1.85 billion. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Under the terms of the acquisition agreement, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Pandion. The closing of the tender offer is subject to certain conditions, including the tender of shares representing at least a majority of the total number of Pandion&#8217;s shares of fully-diluted common stock, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the first half of 2021.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures were $4.7 billion in 2020, $3.5 billion in 2019 and $2.6 billion in 2018. Expenditures in the United States were $2.7 billion in 2020, $1.9 billion in 2019 and $1.5 billion in 2018. The increased capital expenditures in 2020 and 2019 reflect investment in new capital projects focused primarily on increasing manufacturing capacity for Merck&#8217;s key products. The increased capital expenditures in 2020 also reflect the purchase of a manufacturing facility in Dunboyne, Ireland to support upcoming product launches (see Note 3 to the consolidated financial statements). The Company plans to invest more than $20 billion in new capital projects from 2020-2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $1.7 billion in 2020, $1.7 billion in 2019 and $1.4 billion in 2018, of which $1.2 billion in 2020, $1.2 billion in 2019 and $1.0 billion in 2018, related to locations in the United States. Total depreciation expense in 2020 and 2019 included accelerated depreciation of $268 million and $233 million, respectively, associated with restructuring activities (see Note&#160;5 to the consolidated financial statements).</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_112"></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s strong financial profile enables it to fund research and development, focus on external alliances, support in-line products and maximize upcoming launches while providing significant cash returns to shareholders.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Selected Data</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt to total liabilities and equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operations to total debt</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.3:1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5:1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4:1</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decline in working capital in 2020 compared with 2019 is primarily related to increased short-term debt supporting the funding of business development activities and capital expenditures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities was $10.3 billion in 2020 compared with $13.4 billion in 2019, reflecting higher payments related to collaborations which were $2.9 billion in 2020 compared with $805 million in 2019. Cash provided by operating activities continues to be the Company&#8217;s primary source of funds to finance operating needs, capital expenditures, treasury stock purchases and dividends paid to shareholders. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $9.4 billion in 2020 compared with $2.6 billion in 2019. The increase was driven primarily by lower proceeds from the sales of securities and other investments, higher use of cash for acquisitions and higher capital expenditures, partially offset by lower purchases of securities and other investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities was $2.8 billion in 2020 compared with $8.9 billion in 2019. The lower use of cash in financing activities was driven primarily by a net increase in short-term borrowings in 2020 compared with a net decrease in short-term borrowing in 2019, as well as lower purchases of treasury stock, partially offset by higher payments on debt (see below), lower proceeds from the issuance of debt (see below), higher dividends paid to shareholders and lower proceeds from the exercise of stock options.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable (see Note 6 to the consolidated financial statements). The Company factored $2.3 billion and $2.7 billion of accounts receivable in the fourth quarter of 2020 and 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2020 and 2019 the Company had collected $102 million and $256&#160;million, respectively, on behalf of the financial institutions, which was remitted to them in January 2021 and 2020, respectively. The net cash flows from these collections are reported as financing activities in the Consolidated Statement of Cash Flows. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contractual obligations as of December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:32.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payments Due by Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022&#8212;2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024&#8212;2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest related to debt obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transition tax related to the enactment of the TCJA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payments related to collaborations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,007&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Includes future inventory purchases the Company has committed to in connection with certain divestitures. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company&#8217;s Consolidated Balance Sheet reflects liabilities for unrecognized tax benefits, including interest and penalties, of $1.8 billion, including $305 million reflected as a current liability. Due to the high degree of uncertainty regarding the timing of future cash outflows of liabilities for unrecognized tax benefits beyond one year, a reasonable estimate of the period of cash settlement for years beyond 2021 cannot be made.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">In connection with the enactment of the TCJA, the Company is required to pay a one-time transition tax, which the Company has elected to pay over a period of eight years through 2025 as permitted under the TCJA (see Note 15 to the consolidated financial statements).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Reflects payments under collaborative agreements for sales-based milestones that were achieved in 2020 (and therefore deemed to be contractual obligations) but not paid until 2021 (see Note 4 to the consolidated financial statements).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Amounts exclude reasonably certain lease renewals that have not yet been executed (see Note 9 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase obligations are enforceable and legally binding obligations for purchases of goods and services including minimum inventory contracts, research and development and advertising. Amounts do not include contingent milestone payments related to collaborative arrangements or acquisitions as they are not considered contractual obligations until the successful achievement of developmental, regulatory approval or commercial milestones. At December&#160;31, 2020, the Company has recognized liabilities for contingent sales-based milestone payments related to collaborations with AstraZeneca and Eisai where payment remains subject to the achievement of the related sales milestone aggregating $1.0 billion (see Note 4 to the consolidated financial statements). Excluded from research and development obligations are potential future funding commitments of up to approximately $52 million for investments in research venture capital funds. Loans payable and current portion of long-term debt reflects $73 million of long-dated notes that are subject to repayment at the option of the holders. Required funding obligations for 2021 relating to the Company&#8217;s pension and other postretirement benefit plans are not expected to be material. However, the Company currently anticipates contributing approximately $300 million to its U.S. pension plans, $170 million to its international pension plans and $35 million to its other postretirement benefit plans during 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued $4.5&#160;billion principal amount of senior unsecured notes consisting of $1.0&#160;billion of 0.75% notes due 2026, $1.25&#160;billion of 1.45% notes due 2030, $1.0&#160;billion of 2.35% notes due 2040 and $1.25&#160;billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company issued $5.0 billion principal amount of senior unsecured notes consisting of $750 million of 2.90% notes due 2024, $1.75 billion of 3.40% notes due 2029, $1.0 billion of 3.90% notes due 2039, and $1.5 billion of 4.00% notes due 2049. The Company used the net proceeds from the offering for general corporate purposes, including the repayment of outstanding commercial paper borrowings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company filed a securities registration statement with the U.S. Securities and Exchange Commission (SEC) under the automatic shelf registration process available to &#8220;well-known seasoned issuers&#8221; which is effective for three years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to maintain a conservative financial profile. The Company places its cash and investments in instruments that meet high credit quality standards, as specified in its investment policy guidelines. These guidelines also limit the amount of credit exposure to any one issuer. The Company does not participate in any off-balance sheet arrangements involving unconsolidated subsidiaries that provide financing or potentially expose the Company to unrecorded financial obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Merck&#8217;s Board of Directors declared a quarterly dividend of $0.65 per share on the Company&#8217;s outstanding common stock that was paid in January 2021. In January 2021, the Board of Directors declared a quarterly dividend of $0.65 per share on the Company&#8217;s common stock for the second quarter of 2021 payable in April 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Merck&#8217;s Board of Directors authorized purchases of up to $10 billion of Merck&#8217;s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions, on or off an exchange, or in privately negotiated transactions. The Company spent $1.3 billion to purchase 16 million shares of its common stock for its treasury during 2020 under this program. In March 2020, the Company temporarily suspended its share repurchase program. As of&#160;December&#160;31, 2020, the Company&#8217;s remaining share repurchase authorization was $5.9 billion. The Company purchased $4.8 billion and $9.1 billion of its common stock during 2019 and 2018, respectively, under authorized share repurchase programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company&#160;entered into accelerated share repurchase (ASR) agreements with two third-party financial institutions (the Dealers). Under the ASR agreements, Merck agreed to purchase&#160;$5 billion&#160;of Merck&#8217;s common stock, in total, with an initial delivery of 56.7 million&#160;shares of Merck&#8217;s common stock, based on the then-current market price, made by the Dealers to Merck, and payments of&#160;$5 billion&#160;made by Merck to the Dealers in 2018, which were funded with existing cash and investments, as well as short-term borrowings. Upon settlement of the ASR agreements in 2019, Merck received an additional 7.7 million shares as determined by the average daily volume weighted-average price of Merck&#8217;s common stock during the term of the ASR program, less a negotiated discount, bringing the total shares received by Merck under this program to 64.4 million. </span></div><div id="iab6577be4c3840fd8181bdedf457fba5_115"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments Market Risk Disclosures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management, and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (Loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Merck principally sells foreign currency in its revenue hedging program, a uniform weakening of the U.S. dollar would yield the largest overall potential loss in the market value of these hedge instruments. The market value of Merck&#8217;s hedges would have declined by an estimated $593 million and $456 million at December&#160;31, 2020 and 2019, respectively, from a uniform 10% weakening of the U.S.&#160;dollar. The market value was determined using a foreign exchange option pricing model and holding all factors except exchange rates constant. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck&#8217;s major foreign currency exposures relative to the U.S.&#160;dollar. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sensitivity analysis to changes in the value of the U.S.&#160;dollar on foreign currency denominated derivatives, investments and monetary assets and liabilities indicated that if the U.S.&#160;dollar uniformly weakened by 10% against all currency exposures of the Company at December&#160;31, 2020 and 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would have declined by approximately $99 million and $110 million in 2020 and 2019, respectively. Because the Company was in a net short (payable) position relative to its major foreign currencies after consideration of forward contracts, a uniform weakening of the U.S. dollar will yield the largest overall potential net loss in earnings due to exchange. This measurement assumes that a change in one foreign currency relative to the U.S.&#160;dollar would not affect other foreign currencies relative to the U.S.&#160;dollar. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck&#8217;s major foreign currency exposures relative to the U.S.&#160;dollar. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economy of Argentina was determined to be hyperinflationary in 2018; consequently, in accordance with U.S. GAAP, the Company began remeasuring its monetary assets and liabilities for those operations in earnings. The impact to the Company&#8217;s results was immaterial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% notes due 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These interest rate swaps matured in January 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment portfolio includes cash equivalents and short-term investments, the market values of which are not significantly affected by changes in interest rates. The market value of the Company&#8217;s medium- to long-term fixed-rate investments is modestly affected by changes in U.S.&#160;interest rates. Changes in medium- to long-term U.S.&#160;interest rates have a more significant impact on the market value of the Company&#8217;s fixed-rate borrowings, which generally have longer maturities. A sensitivity analysis to measure potential changes in the market value of Merck&#8217;s investments and debt from a change in interest rates indicated that a one percentage point increase in interest rates at December&#160;31, 2020 and 2019 would have positively affected the net aggregate market value of these instruments by $2.6 billion and $2.0 billion, respectively. A one percentage point decrease at December&#160;31, 2020 and 2019 would have negatively affected the net aggregate market value by $3.1 billion and $2.2 billion, respectively. The fair value of Merck&#8217;s debt was determined using pricing models reflecting one percentage point shifts in the appropriate yield curves. The fair values of Merck&#8217;s investments were determined using a combination of pricing and duration models.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_118"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements are prepared in conformity with GAAP and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates. Application of the following accounting policies result in accounting estimates having the potential for the most significant impact on the financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions and Dispositions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses, the Company makes certain judgments, which include assessment of the inputs, processes, and outputs associated with the acquired set of activities. If the Company determines that substantially all of the fair value of gross assets included in a transaction is concentrated in a single asset (or a group of similar assets), the assets would not represent a business. To be considered a business, the assets in a transaction need to include an input and a substantive process that together significantly contribute to the ability to create outputs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. The fair values of intangible assets, including acquired IPR&amp;D, are determined utilizing information available near the acquisition date based on expectations and assumptions that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Amounts allocated to acquired IPR&amp;D are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. Certain of the Company&#8217;s business acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Changes in any of the inputs may result in a significantly different fair value adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company&#8217;s results of operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets related to currently marketed products and product rights are primarily determined by using an income approach through which fair value is estimated based on each asset&#8217;s discounted projected net cash flows. The Company&#8217;s estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry and therapeutic area growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain marketing and regulatory approvals; the ability to manufacture and commercialize </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the products; the extent and timing of potential new product introductions by the Company&#8217;s competitors; and the life of each asset&#8217;s underlying patent, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets related to IPR&amp;D are also determined using an income approach, through which fair value is estimated based on each asset&#8217;s probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using an appropriate discount rate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines the transaction will not be accounted for as an acquisition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired IPR&amp;D with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covers chargebacks and rebates. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its provision for aggregate customer discounts. There were no material adjustments to estimates associated with the aggregate customer discount provision in 2020, 2019 or 2018.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in the aggregate customer discount accrual related to U.S. sales is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for chargebacks are reflected as a direct reduction to accounts receivable and accruals for rebates as current liabilities. The accrued balances relative to these provisions included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $249 million and $2.9 billion, respectively, at December&#160;31, 2020 and were $233 million and $2.2 billion, respectively, at December&#160;31, 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic competition, changes in formularies or launch of over-the-counter products, among others. The product returns provision for U.S. pharmaceutical sales as a percentage of U.S. net pharmaceutical sales was 0.6% in 2020, 1.1% in 2019 and 1.6% in 2018. Outside of the United States, returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the United States, payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through its distribution programs with U.S.&#160;wholesalers, the Company encourages wholesalers to align purchases with underlying demand and maintain inventories below specified levels. The terms of the programs allow the wholesalers to earn fees upon providing visibility into their inventory levels, as well as by achieving certain performance parameters such as inventory management, customer service levels, reducing shortage claims and reducing product returns. Information provided through the wholesaler distribution programs includes items such as sales trends, inventory on-hand, on-order quantity and product returns.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wholesalers generally provide only the above-mentioned data to the Company, as there is no regulatory requirement to report lot level information to manufacturers, which is the level of information needed to determine the remaining shelf life and original sale date of inventory. Given current wholesaler inventory levels, which are generally less than a month, the Company believes that collection of order lot information across all wholesale customers would have limited use in estimating sales discounts and returns.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories Produced in Preparation for Product Launches</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventories produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory does not begin until the related product candidates are in Phase&#160;3 clinical trials and are considered to have a high probability of regulatory approval. The Company monitors the status of each respective product within the regulatory approval process; however, the Company generally does not disclose specific timing for regulatory approval. If the Company is aware of any specific risks or contingencies other than the normal regulatory approval process or if there are any specific issues identified during the research process relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory would generally not be capitalized. Expiry dates of the inventory are affected by the stage of completion. The Company manages the levels of inventory at each stage to optimize the shelf life of the inventory in relation to anticipated market demand in order to avoid product expiry issues. For inventories that are capitalized, anticipated future sales and shelf lives support the realization of the inventory value as the inventory shelf life is sufficient to meet initial product launch requirements. Inventories produced in preparation for product launches capitalized at December&#160;31, 2020 and 2019 were $279 million and $168 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Environmental Liabilities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property and commercial litigation, as well as certain additional matters including governmental and environmental matters (see Note&#160;10 to the consolidated financial statements). The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2020 and 2019 of approximately $250 million and $240 million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. When a legitimate claim for contribution is asserted, a liability is initially accrued based upon the estimated transaction costs to manage the site. Accruals are adjusted as site investigations, feasibility studies and related cost assessments of remedial techniques are completed, and as the extent to which other potentially responsible parties who may be jointly and severally liable can be expected to contribute is determined.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites and takes an active role in identifying and accruing for these costs. In the past, Merck performed a worldwide survey to assess all sites for potential contamination resulting from past industrial activities. Where assessment indicated that physical investigation was warranted, such investigation was performed, providing a better evaluation of the need for remedial action. Where such need was identified, remedial action was then initiated. As definitive information became available during the course of investigations and/or remedial efforts at each site, estimates were refined and accruals were established or adjusted accordingly. These estimates and related accruals continue to be refined annually.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. Expenditures for remediation and environmental liabilities were $11 million in 2020 and are estimated at $46 million in the aggregate for the years 2021 through 2025. In management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $67 million at both December&#160;31, 2020 and 2019. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $65 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, including grants of stock options, over the requisite service period based on the grant date fair value of the awards. The Company determines the fair value of certain share-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. Total pretax share-based compensation expense was $475 million in 2020, $417 million in 2019 and $348 million in 2018. At December&#160;31, 2020, there was $678 million of total pretax unrecognized compensation expense related to nonvested stock option, restricted stock unit and performance share unit awards which will be recognized over a weighted-average period of 1.9&#160;years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pensions and Other Postretirement Benefit Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost for pension plans totaled $454 million in 2020, $137 million in 2019 and $195 million in 2018. Net periodic benefit (credit) for other postretirement benefit plans was $(59) million in 2020, $(49) million in 2019 and $(45) million in 2018. Pension and other postretirement benefit plan information for financial reporting purposes is calculated using actuarial assumptions including a discount rate for plan benefit obligations and an expected rate of return on plan assets. The changes in net periodic benefit cost year over year for pension plans are largely attributable to changes in the discount rate affecting net loss amortization.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The discount rates for the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans ranged from 2.10% to 2.80% at December&#160;31, 2020, compared with a range of 3.20% to 3.50% at December&#160;31, 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, the Company considers long-term compound annualized returns of historical market data, current market conditions and actual returns on the Company&#8217;s plan assets. Using this reference information, the Company develops forward-looking return expectations for each asset category and a weighted-average expected long-term rate of return for a target portfolio allocated across these investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2021, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will range from 6.50% to 6.70%, compared to a range of 7.00% to 7.30% in 2020. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated 30% to 45% in U.S.&#160;equities, 15% to 30% in international equities, 35% to 45% in fixed-income investments, and up to 5% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deviation of returns of the target portfolio, which approximates 11%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For non-U.S.&#160;pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial assumptions are based upon management&#8217;s best estimates and judgment. A reasonably possible change of plus (minus) 25&#160;basis points in the discount rate assumption, with other assumptions held constant, would have had an estimated $80 million favorable (unfavorable) impact on the Company&#8217;s net periodic benefit cost in 2020. A reasonably possible change of plus (minus) 25&#160;basis points in the expected rate of return assumption, with other assumptions held constant, would have had an estimated $40&#160;million favorable (unfavorable) impact on Merck&#8217;s net periodic benefit cost in 2020. Required funding obligations for 2021 relating to the Company&#8217;s pension and other postretirement benefit plans are not expected to be material. The preceding hypothetical changes in the discount rate and expected rate of return assumptions would not impact the Company&#8217;s funding requirements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss amounts, which primarily reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions, are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Expected returns for pension plans are based on a calculated market-related value of assets. Net loss amounts in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs have been recorded in connection with restructuring programs designed to streamline the Company&#8217;s cost structure. As a result, the Company has made estimates and judgments regarding its future plans, including future termination benefits and other exit costs to be incurred when the restructuring actions take place. When accruing termination costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. In connection with these actions, management also assesses the recoverability of long-lived assets employed in the business. In certain instances, asset lives have been shortened based on changes in the expected useful lives of the affected assets. Severance and other related costs are reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Asset-related charges are reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses depending upon the nature of the asset.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairments of Long-Lived Assets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses changes in economic, regulatory and legal conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company&#8217;s property, plant and equipment, goodwill and other intangible assets.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its long-lived assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows approach.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the factors considered in the assessment include general macroeconomic conditions, conditions specific to the industry and market, cost factors which could have a significant effect on earnings or cash flows, the overall financial performance of the reporting unit, and whether there have been sustained declines in the Company&#8217;s share price. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other acquired intangible assets (excluding IPR&amp;D) are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. When events or circumstances warrant a review, the Company will assess recoverability from future operations using pretax undiscounted cash flows derived from the lowest appropriate asset groupings. Impairments are recognized in operating results to the extent that the carrying value of the intangible asset exceeds its fair value, which is determined based on the net present value of estimated future cash flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. For impairment testing purposes, the Company may combine separately recorded IPR&amp;D intangible assets into one unit of account based on the relevant facts and circumstances. Generally, the Company will combine IPR&amp;D intangible assets for testing purposes if they operate as a single asset and are essentially inseparable. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The judgments made in evaluating impairment of long-lived intangibles can materially affect the Company&#8217;s results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairments of Investments</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its investments in marketable debt securities for impairments based on the determination of whether the decline in market value of the investment below the carrying value is other-than-temporary. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the duration and extent to which fair value is less than cost. Changes in fair value that are considered temporary are reported net of tax in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. An other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate is based on pretax income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. An estimated effective tax rate for a year is applied to the Company&#8217;s quarterly operating results. In the event that there is a significant unusual or one-time item recognized, or expected to be recognized, in the Company&#8217;s quarterly operating results, the tax attributable to that item would be separately calculated and recorded at the same time as the unusual or one-time item. The Company considers the resolution of prior year tax matters to be such items. Significant judgment is required in determining the Company&#8217;s tax provision and in evaluating its tax positions. The recognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at the reporting date. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. If the more likely than not threshold is not met in the period for which a tax position is taken, the Company may subsequently recognize the benefit of that tax position if the tax matter is effectively settled, the statute of limitations expires, or if the more likely than not threshold is met in a subsequent period (see Note&#160;15 to the consolidated financial statements).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax regulations require items to be included in the tax return at different times than the items are reflected in the financial statements. Timing differences create deferred tax assets and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in the tax return in future years for which the Company has already recorded the tax benefit in the financial statements. The Company establishes valuation allowances for its deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense recognized in the financial statements for which payment has been deferred or expense for which the Company has already taken a deduction on the tax return, but has not yet recognized as expense in the financial statements. </span></div><div id="iab6577be4c3840fd8181bdedf457fba5_121"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently issued accounting standards, see Note 2 to the consolidated financial statements.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_124"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Factors That May Affect Future Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product approvals, product potential, development programs and include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company&#8217;s filings with the Securities and Exchange Commission, especially on this Form&#160;10-K and Forms 10-Q and 8-K. In Item&#160;1A. &#8220;Risk Factors&#8221; of this annual report on Form&#160;10-K the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_127"></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.8pt">Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the discussion under &#8220;Financial Instruments Market Risk Disclosures&#8221; in Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Financial Statements and Supplementary Data.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_133"></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Financial Statements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheet of Merck&#160;&amp; Co., Inc. and subsidiaries as of December&#160;31, 2020 and 2019, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December&#160;31, 2020, the notes to consolidated financial statements, and the report dated February&#160;25, 2021 of PricewaterhouseCoopers LLP, independent registered public accounting firm, are as follows:</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_136"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEtMS0xLTEtMA_928aba44-74cd-4b40-929a-87e128386ca6">47,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEtMy0xLTEtMA_453d6db4-b273-4178-b295-000b6310fcda">46,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEtNS0xLTEtMA_ca10a547-d651-4d73-a7c5-94b006800944">42,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzMtMS0xLTEtMA_f460424d-0b25-4d7f-9d6e-496f4ecb7c57">15,485</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzMtMy0xLTEtMA_3bf2c42a-2eb2-4603-83e3-bac265c63b52">14,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzMtNS0xLTEtMA_a020aa8d-cafb-4dea-8b04-35dc147651ed">13,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzQtMS0xLTEtMA_370d0294-1036-4c51-9c65-7f9502d92525">10,468</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzQtMy0xLTEtMA_340dd39d-f056-4af3-9851-8935a8bdc1ff">10,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzQtNS0xLTEtMA_5cac05e8-c6c0-4b36-8294-84f59bdce797">10,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzUtMS0xLTEtMA_52e9208f-f78a-4782-91a1-81fb88b8b5bf">13,558</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzUtMy0xLTEtMA_3d76cbc7-1c9a-4c3f-90a1-2dc023460dcb">9,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzUtNS0xLTEtMA_bb109eab-fffb-4c9d-ae32-1b2319660f93">9,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzYtMS0xLTEtMA_e122ef36-398b-4053-8e32-9b1757a9e416">578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzYtMy0xLTEtMA_ce1bc8c8-82e4-4520-aa9c-2a02585e6ed6">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzYtNS0xLTEtMA_ec53ebc6-b2b5-4890-9088-8cc7e9936b43">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzctMS0xLTEtMA_27421474-e1a2-4ac6-9f7b-9ab5642a22c1">886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzctMy0xLTEtMA_9977bc6f-2f54-4c6e-a2d1-d17428fff838">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzctNS0xLTEtMA_66efc25d-24fb-4558-a494-badf15136a95">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:CostsExpensesAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzgtMS0xLTEtMA_2f933681-e6c4-4665-97bc-660d10418da6">39,203</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:CostsExpensesAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzgtMy0xLTEtMA_4fda55a5-eaad-4080-9650-d442dc37c836">35,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:CostsExpensesAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzgtNS0xLTEtMA_6f92c778-8f16-4126-9365-5578e025a904">33,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzktMS0xLTEtMA_c3a17d91-113d-419f-865a-1dc2ed3cf9d1">8,791</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzktMy0xLTEtMA_1390d537-4949-4758-9fe1-775507688d82">11,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzktNS0xLTEtMA_642fc172-5625-4b43-8577-05a37b148653">8,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes on Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEwLTEtMS0xLTA_fe00e8bb-621f-4824-9660-f8721b2d2950">1,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEwLTMtMS0xLTA_461e4065-6807-4b5d-88f4-33f98773816a">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEwLTUtMS0xLTA_79cbb3ef-a760-4c55-b6ad-394f646ba26a">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzExLTEtMS0xLTA_9362e0d3-050d-4011-bd04-942a45f6356c">7,082</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzExLTMtMS0xLTA_443b5a28-fa80-4f5c-bf9c-3944a0e99ad3">9,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzExLTUtMS0xLTA_f508665a-b225-47ee-9e95-aeb254e24cc7">6,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net Income (Loss) Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEyLTEtMS0xLTA_5be5b231-b464-4af8-a8ad-07164a2d34cf">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEyLTMtMS0xLTA_7540186c-dd0b-440c-ad3e-631d1be5554c">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEyLTUtMS0xLTA_f5f53e33-b512-4bcb-934c-99ca1376ef64">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEzLTEtMS0xLTA_42b18cbe-d3b7-4579-9448-3133d5602ff7">7,067</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEzLTMtMS0xLTA_a0c36a54-f62f-4a5b-bf03-7603bf011de0">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEzLTUtMS0xLTA_679d2690-2161-4ab3-be81-de3ddbaefd9e">6,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</span></div></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE0LTEtMS0xLTA_6a4f7073-5adf-4c51-94e0-bfa7741474e8">2.79</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE0LTMtMS0xLTA_e80d022b-9de7-4005-a8a3-5f5f71cf1698">3.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE0LTUtMS0xLTA_c64d7ee4-677a-4bab-9d24-c7c663812013">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE1LTEtMS0xLTA_1976b93b-5a4e-4ae7-920d-36461e252590">2.78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE1LTMtMS0xLTA_7e72aabe-85b2-4d6d-8ee8-dd0e211ac625">3.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE1LTUtMS0xLTA_92bbac15-86be-4e0a-9181-03b12766b4d5">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Comprehensive Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">($ in millions)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzEtMS0xLTEtMA_b02506e4-828c-4a13-8741-095662782990">7,067</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzEtMy0xLTEtMA_f0c681ab-438d-4b71-b6ff-86808e7dcedf">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzEtNS0xLTEtMA_54d5b67d-5e30-45c0-835f-496a62350079">6,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Comprehensive Loss Net of Taxes:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on derivatives, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzMtMS0xLTEtMA_0654dd83-460d-45cb-8f94-6b8bf0a4e957">297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzMtMy0xLTEtMA_51cd718f-fd84-4afe-8f51-b89411e5b2aa">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzMtNS0xLTEtMA_2696b9d6-3ea3-42ec-a8b1-5d5e1c16dd46">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on investments, net of reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzQtMS0xLTEtMA_c8a7db93-c900-4f62-ac54-ea376e662e36">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzQtMy0xLTEtMA_89440ba4-da6d-4673-b809-877258e4832d">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzQtNS0xLTEtMA_e55f4f7b-c574-40eb-9107-552357e7fc07">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzUtMS0xLTEtMA_eba5955a-708e-48db-8f8a-641fec252bd5">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzUtMy0xLTEtMA_a097077a-84d0-491d-b986-70c5acaf024c">705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzUtNS0xLTEtMA_a0585439-c53e-4ac5-a9a9-e06e2a780c87">425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzYtMS0xLTEtMA_cd20c4d8-23b3-4036-8894-ba4f1f0e0dcd">153</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzYtMy0xLTEtMA_5ee6e675-3c1d-42ed-8074-ecb75b9ef122">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzYtNS0xLTEtMA_905108c5-ecdf-42a3-bf3a-e07395828836">223</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzctMS0xLTEtMA_336dae2f-00e0-4cf5-9181-c6db8d8198c5">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzctMy0xLTEtMA_ed84f8e7-60e8-43da-9508-9662c9e2dd6b">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzctNS0xLTEtMA_9f4e4e8d-ff97-47f6-bbc3-50f5d1292579">361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzgtMS0xLTEtMA_3f3f96c4-506c-4301-a1b3-472dcbc6d0b7">6,626</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzgtMy0xLTEtMA_d055abf8-45da-4980-8503-faf7716e7864">9,195</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzgtNS0xLTEtMA_9fb638a3-365d-4cff-849d-4b5dfa891829">5,859</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheet</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMtMS0xLTEtMA_73613d75-49b9-418f-8e15-e9191697a758">8,062</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMtMy0xLTEtMA_89af50ea-67ea-447b-8566-0a5ba1b9624e">9,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQtMS0xLTEtMA_b0f8ebed-6177-4df3-a8e5-db87cf4d408f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQtMy0xLTEtMA_29229680-1c25-4774-baa3-c0896880f058">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjA1Nzc0YmNlMDhmYTRjMWRiMjc4NjkxNTU5NmU0MTdkXzMyOTg1MzQ4ODM1NzU_88432ce1-86cf-48e8-a17a-eb77211ba313">85</ix:nonFraction> in 2020</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjA1Nzc0YmNlMDhmYTRjMWRiMjc4NjkxNTU5NmU0MTdkXzMyOTg1MzQ4ODM1Njg_bbae9f3e-cc47-410b-af74-22028b182727">86</ix:nonFraction> in 2019) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzUtMS0xLTEtMA_89efcd81-788a-400b-a7cf-eb937f42eb76">7,851</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzUtMy0xLTEtMA_98b3572a-cdfb-490c-a4b7-0e24569e3570">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories (excludes inventories of $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmI3NzYxZTdiM2UyMDQ3MjU4ZGY5MTg4N2RiNjYzMzllXzMyOTg1MzQ4ODM1OTI_29710d7a-6392-44cd-931e-f78a178b9626">2,197</ix:nonFraction> in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmI3NzYxZTdiM2UyMDQ3MjU4ZGY5MTg4N2RiNjYzMzllXzMyOTg1MzQ4ODM1ODY_ad121880-6737-4e5a-9043-49447d5fb02d">1,480</ix:nonFraction> in 2019</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">classified in Other assets - see Note&#160;7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzYtMS0xLTEtMA_b746333c-32e4-4c52-b641-001cdfebfdce">6,310</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzYtMy0xLTEtMA_c9a8be2c-d718-47c7-b401-e1bac2133cf3">5,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzctMS0xLTEtMA_9b268f92-d239-46e7-ac72-58b64f48db11">5,541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzctMy0xLTEtMA_979cc2c0-6b40-4080-b1b6-ab190cbfbfa2">4,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzgtMS0xLTEtMA_bc97232b-ca61-4d61-9039-2c637265c134">27,764</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzgtMy0xLTEtMA_3ae10174-7bab-4e2d-8bc2-80bcc3cdc661">27,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzktMS0xLTEtMA_2bf13840-2e38-4c2d-b851-8f2c0a176c9f">785</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzktMy0xLTEtMA_cd0f26f4-7fcd-48a7-956d-ef4c73845dc4">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, Plant and Equipment (at cost)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzExLTEtMS0xLTA_715010e8-0bde-4162-ad74-e1d1af0953e7">350</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzExLTMtMS0xLTA_cacaa655-020b-4386-a1d1-49aa4fa2cbc7">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzEyLTEtMS0xLTA_16cd82ea-ccc8-499f-8d3d-bb81bd46876d">12,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzEyLTMtMS0xLTA_753899b9-400c-4a9e-bd92-66c7b1253c8f">11,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery, equipment and office furnishings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzEzLTEtMS0xLTA_da9b8dd2-e7ba-459c-8f51-bd8760d471a2">16,649</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzEzLTMtMS0xLTA_dacc45d5-7f1d-4302-9642-00dea72571ae">15,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE0LTEtMS0xLTA_f307efe3-5270-4022-bf06-926b575f358b">7,324</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE0LTMtMS0xLTA_2e8d6274-a1ca-4be6-b891-817bb73a8bbe">5,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE1LTEtMS0xLTA_96aa7a90-9607-4933-a2c5-b2f5f11dbba3">36,968</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE1LTMtMS0xLTA_50120178-ddad-4344-8495-c87f44787c04">32,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE2LTEtMS0xLTA_c61308a9-5b7e-468c-ab1a-179e43746c7a">18,982</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE2LTMtMS0xLTA_6934cb7a-3de5-4bad-b3d4-efe1c4b4c505">17,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE3LTEtMS0xLTA_b94329b3-e5b8-49c3-987a-c0c8487db463">17,986</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE3LTMtMS0xLTA_bc484a02-0ece-40de-8ce1-6348deb4fe18">15,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE4LTEtMS0xLTA_0b5975a0-4711-4ed8-ac49-339862483a51">20,238</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE4LTMtMS0xLTA_16af884a-03ed-44e7-b433-4c3f8055e046">19,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Intangibles, Net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE5LTEtMS0xLTA_0447b130-3ed3-4265-9f51-1deafefaa5ba">14,604</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE5LTMtMS0xLTA_f4c86c13-0b2b-4360-936d-b3646a343a35">14,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzIwLTEtMS0xLTA_f3931701-de4b-45f6-b88c-598dab9a49a8">10,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzIwLTMtMS0xLTA_bba6ecae-947d-4a0a-a362-7c8986e6fa36">6,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzIxLTEtMS0xLTA_0d0d3a4a-6998-42a4-a152-473cbb6190d2">91,588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzIxLTMtMS0xLTA_aed5dc00-8e70-4d5f-be1e-c9f38c5aac6a">84,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI0LTEtMS0xLTA_5266c74f-5b99-46a6-91bb-73d9d5ebaf26">6,431</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI0LTMtMS0xLTA_2db4d5f7-7115-4260-80a2-ad3a2d68bcbe">3,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI1LTEtMS0xLTA_6ee3f824-1de8-40ae-88d4-234c0851df3b">4,594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI1LTMtMS0xLTA_a0c3f522-6a27-440c-9791-1bd14e5a9900">3,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI2LTEtMS0xLTA_fa90e4ca-9d0e-4f6c-8fa0-2c29504640f9">13,053</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI2LTMtMS0xLTA_6f909bdc-1e91-4400-a63d-358bb114bbe6">12,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI3LTEtMS0xLTA_4c7676e1-d1d7-4643-b8fd-49988b91ec9e">1,575</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI3LTMtMS0xLTA_b6c34ecb-6ccf-420d-8fc1-9edeed4be4be">736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI4LTEtMS0xLTA_07396bcd-5d9e-4c2b-8677-94b41148f4d9">1,674</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI4LTMtMS0xLTA_a917b291-c16e-44d1-a84b-86498693ff47">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI5LTEtMS0xLTA_70a7726e-0b2c-469e-b693-3ecc6ba0bffe">27,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI5LTMtMS0xLTA_000864e8-6107-42d6-a265-dc3c72a6dc4d">22,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMwLTEtMS0xLTA_f85662a0-bea7-460b-b847-1ab4e2e51d15">25,360</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMwLTMtMS0xLTA_df3556e8-8bf4-437c-89d5-9d0fc8c92bdf">22,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMxLTEtMS0xLTA_57d1bb50-d401-404a-a621-e7ce028ba7b1">1,015</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMxLTMtMS0xLTA_fb0fecce-3550-4967-859f-edfdc43af3b4">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMyLTEtMS0xLTA_4f43ed07-f22b-416f-88d6-4c60ad932ba8">12,482</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMyLTMtMS0xLTA_627c91e2-16e6-4275-8d25-1f31e19688b9">11,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNTcx_6690bbbf-ad57-432e-8f52-9294fb8ebf5a"><ix:nonFraction unitRef="usdPerShare" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNTcx_a87c6853-ecb5-42c3-aa73-5f02bbdf7250">0.50</ix:nonFraction></ix:nonFraction> par value</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Authorized - <ix:nonFraction unitRef="shares" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNjIx_82fed7ed-a110-43e2-aa0e-0282156a5dd4"><ix:nonFraction unitRef="shares" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNjIx_bd85f2d7-ca4a-45ae-b9fd-af9df3ec0970">6,500,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued - <ix:nonFraction unitRef="shares" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNjM3_150a7d12-bbc6-429e-8c4c-58749b272373"><ix:nonFraction unitRef="shares" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNjM3_74da52ef-a0a9-4f7d-8d2b-0e9c7d9bbb9c">3,577,103,522</ix:nonFraction></ix:nonFraction> shares in 2020 and 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTEtMS0xLTA_f30ce4a0-36b2-45f5-b9ad-60c9393c22d6">1,788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTMtMS0xLTA_55031257-58a8-4b83-bf01-9a7e13ca72b5">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM1LTEtMS0xLTA_075f72b7-6808-4611-82c2-1af973d26472">39,588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM1LTMtMS0xLTA_47fc3bc1-6d38-477a-8709-96384d1af2bf">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM2LTEtMS0xLTA_5d82f513-a2b8-409c-a81c-9ca3c9517272">47,362</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM2LTMtMS0xLTA_d576b4a0-9efa-4b22-b4c5-9802abd0caeb">46,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM3LTEtMS0xLTA_9cd62cb5-2e1b-4795-a793-b89014dcac3a">6,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM3LTMtMS0xLTA_b659f645-cd89-48fb-b640-d1d851de15fd">6,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityBeforeTreasuryStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM4LTEtMS0xLTA_3e4b305b-76ca-43ee-8de4-4e7b248fd367">82,104</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityBeforeTreasuryStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM4LTMtMS0xLTA_86a307ec-3acf-4492-a046-5a3e3f93ec8a">81,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less treasury stock, at cost:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjphOTE4MDJkNDVkMDY0NGIyODNmZjZkOGJmMTI1Y2U0OF8zMjk4NTM0ODgzNjI4_8137a30c-6627-4c59-a502-a63f794236d5">1,046,877,695</ix:nonFraction> shares in 2020 and <ix:nonFraction unitRef="shares" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjphOTE4MDJkNDVkMDY0NGIyODNmZjZkOGJmMTI1Y2U0OF8zMjk4NTM0ODgzNjEy_9b8237ef-a2c6-44a8-9a0c-d01b0fb33521">1,038,087,496</ix:nonFraction> shares in 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM5LTEtMS0xLTA_7cf76da7-f2eb-4b88-ac4e-7be028cbc892">56,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM5LTMtMS0xLTA_8fe5e843-c973-43b7-adc2-0bb4a99d8c32">55,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQwLTEtMS0xLTA_4c9ec6e6-b44b-48ba-a28b-2c45b06c6846">25,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQwLTMtMS0xLTA_6bc2ad7b-f61b-4d2d-a7b5-8635bf7eb33b">25,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQxLTEtMS0xLTA_e929ab8f-5158-40fb-9f52-69054a7251dc">87</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQxLTMtMS0xLTA_ff185d60-a315-4b02-9662-d560e7bf2dfd">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQyLTEtMS0xLTA_8d9d354b-f66c-4d55-bc8f-c8da14ed76a6">25,404</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQyLTMtMS0xLTA_6871b343-484b-439e-9ea9-ba5a5bc29030">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQzLTEtMS0xLTA_0ad780ec-9c37-408c-bb8c-ae3df5febacf">91,588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQzLTMtMS0xLTA_6f6ccf28-2fc3-4468-b5b6-5038b210f5f8">84,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Equity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:41.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance January&#160;1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i530838b57a7f40aea997c3c0d8eafce0_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtMS0xLTEtMA_5130b2cd-9543-4c96-ae18-0c33d5871ff9">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d876890752448da45fd177f909c525_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtMy0xLTEtMA_264e2cf5-21c6-499b-bc36-ca639c687fe8">39,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57393189447424cbdff690d6eb86857_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtNS0xLTEtMA_91feae7c-c7c9-4545-9f37-9429a50594f2">41,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a0cf6a00f14978ae5b1e865e6c3e41_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtNy0xLTEtMA_510301ac-5869-428a-bccf-f9de6e373b78">4,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f33a2e859a4576a7e62ef19bff98f0_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtOS0xLTEtMA_4ff55a84-1289-4876-a789-8e6810a474ca">43,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3f97c0c25247749fef8b6deb546624_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtMTEtMS0xLTA_e1b59666-f552-4647-ad9a-d7ec18d5b643">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e100303069b40878e0e19c66282b95b_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtMTMtMS0xLTA_2b83c0ed-57ed-4119-8881-b60fa783e109">34,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057a5c09a76d4467aa5c101819252a07_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzItNS0xLTEtMA_f12d4821-35e6-4f96-b08b-760f61a13188">6,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzItMTMtMS0xLTA_7123e024-921e-4b48-8a8b-c01dfa04fbd5">6,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adoption of new accounting standards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0acb90ffdfa0455fa5f6bad3cc955686_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtNS0xLTEtMTU5_f2036cec-ae6b-4bed-9543-aa94e2792d9f">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3e6a049ad240ddbcd87576b751ad64_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtNy0xLTEtMTU5_836e3ca0-8f65-441f-8b06-9cc52d92e430">274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84af4bb4ea9e41b5a3bb5245f8f322f4_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtMTMtMS0xLTE4ODM1_366ceb93-10d1-4911-9bf9-9617529f3b57">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4872f4e47894212bbb218c64e39c4a7_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtNy0xLTEtMA_2be9f788-c14a-4842-9839-df857d223cf0">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtMTMtMS0xLTA_321f28a9-825e-4bf5-9a3a-27db2d697b00">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzUtMC0xLTEtMTA3My90ZXh0cmVnaW9uOmU3YjI5MDQzYWVjMjRmNDRhZmVhNWIyYzhlNGRlNzk4XzMyOTg1MzQ4ODMzOTQ_49a7383c-3378-4e18-9a30-cffaebcc1cd3">1.99</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i057a5c09a76d4467aa5c101819252a07_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzQtNS0xLTEtMA_dc15f668-c815-4794-b27d-da473f18924a">5,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzQtMTMtMS0xLTA_67cda304-18fd-4114-b40c-b0987ba7000e">5,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2ccd612449647558e0d8cc5f0e5305c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzUtMy0xLTEtMA_db8b4cad-3c67-41d7-9c29-da0b8f66bbc3">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzUtOS0xLTEtMA_fda1cd37-59d5-4b39-956b-5ef9a9a12565">8,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzUtMTMtMS0xLTA_c5ff3453-3a70-4b25-9c5a-f72de064bf89">9,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb0a1d042d5e4a5ebb0664bb2c15ebf6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzctMTEtMS0xLTA_cc65ac8a-d949-4eea-b634-1b7d9664845c">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzctMTMtMS0xLTA_aefdcb4b-31c3-4442-8893-1abba8b3fd6f">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb0a1d042d5e4a5ebb0664bb2c15ebf6_D20180101-20181231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzgtMTEtMS0xLTA_ee319b2e-ce2b-42ae-a835-68026dadd242">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzgtMTMtMS0xLTA_2eae7be5-26d6-4d8a-9a47-264ba8b67011">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2ccd612449647558e0d8cc5f0e5305c_D20180101-20181231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzktMy0xLTEtMA_029792d8-949f-49d2-b839-cc0552805181">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzktOS0xLTEtMA_80fc8c4b-91c3-4fca-96ec-bc7ca4819810">956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzktMTMtMS0xLTA_d5cf4928-3e3f-4fac-ab19-133c41e264d8">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67131e7c55f84174b370dc31e7893725_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTEtMS0xLTA_17ab3f1c-cb07-41ac-a37d-b4440b015bac">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe17ea10ec2d46f9aac4bca5f67dd3f5_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTMtMS0xLTA_0aee4ff8-e432-48c4-a327-5eae76a96b8b">38,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae2e6ec2ed8a4ed5964f5012a0361b21_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTUtMS0xLTA_1162620e-2121-42b3-8fff-05e080410b55">42,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67b4b127a8884ff190bb26aefa784be3_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTctMS0xLTA_dd8d60bc-347e-422a-95e7-5b8e8d006afc">5,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if472f36dd37249baacd8179c8220ecaa_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTktMS0xLTA_30b1c20e-de89-4c39-b0bc-326f8a880759">50,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f70c8d1831f4f1fa906b5a243db58b0_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTExLTEtMS0w_15b5ee34-a8a0-4215-a5bb-24ddf4bd752f">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTEzLTEtMS0w_a5a10403-40c8-4661-9e08-0e7f79290215">26,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763fc5648968415f92f38b504b93bf09_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzExLTUtMS0xLTA_ce84ffac-924b-433b-babe-8c0c8d5b9cae">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzExLTEzLTEtMS0w_1e36d92a-86ee-4dd0-a585-f1898215ca48">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17941d3435994547bd0f648e9860112e_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEzLTctMS0xLTA_9a1be2b6-e6a1-4a33-a3d9-b7036e7a8ba7">648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEzLTEzLTEtMS0w_399a4333-d028-49a4-9b89-d3b8c8ad9092">648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEzLTAtMS0xLTEwNzYvdGV4dHJlZ2lvbjpkZDE5ODFjYjhkMGI0NTYxOTIwNTg3YjZhZDZmOWJiMl8zMjk4NTM0ODgzMzk0_6dffe02e-b43d-4183-ba1a-2c642630ee71">2.26</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i763fc5648968415f92f38b504b93bf09_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE0LTUtMS0xLTA_41f33fd5-3f09-4cf9-aa2a-a524050ec9d8">5,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE0LTEzLTEtMS0w_15a5dc4c-4e67-4607-96ee-cc14fb52e559">5,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009e5e7a34934b2c8895d34fdb93faad_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE1LTMtMS0xLTA_0dfb0180-409e-4709-9cdd-2045be0d9c7c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE1LTktMS0xLTA_e4c6a2d2-d2d0-4b86-bd36-a257986fa34e">5,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE1LTEzLTEtMS0w_8ab32939-b3b7-460b-98e5-93ceb801a1ca">4,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6c92792b11148c6966e23a7b3c4e4e6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE2LTExLTEtMS0w_c7b1c92f-db0b-4318-896d-80d3e063aa9c">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE2LTEzLTEtMS0w_8722f2c7-7146-4e1a-97d4-718ec796c6f1">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6c92792b11148c6966e23a7b3c4e4e6_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE3LTExLTEtMS0w_28d173e7-b180-48b9-9980-379395b010c9">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE3LTEzLTEtMS0w_f3cc8b6c-868d-47d7-bf46-b81ce02d183c">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i009e5e7a34934b2c8895d34fdb93faad_D20190101-20191231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE4LTMtMS0xLTA_d601c1fc-cb7d-4627-9293-d1ca9f2c8999">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE4LTktMS0xLTA_50cf3458-5acd-4dd3-9cfb-0f17736b07ca">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE4LTEzLTEtMS0w_1928e032-dfec-4379-a226-eab0873bbadf">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0896f4b9831541ae8488b94c4eae2335_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTEtMS0xLTA_9843d856-7e2e-46e7-a854-feb05867a9ee">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1000caf1ca924d2e859d474fe4e47375_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTMtMS0xLTA_da8b05f2-503a-4938-9202-c6526918422e">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcf60e98e4e4e8b96733cb145c00b95_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTUtMS0xLTA_8f677a2d-0999-4c91-bcb4-99f032a51be3">46,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090793285fc448169b5f2766fad90f7a_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTctMS0xLTA_719e71af-46c7-4579-bd93-c35050f34ba6">6,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia612eb926af84202b6beec26340d18cc_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTktMS0xLTA_9131d6ef-2669-4e50-9294-559f7fb4a807">55,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b305782607415cb6a709c71a39dc73_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTExLTEtMS0w_ed8907c5-db76-40b4-98aa-f1bb37740cf9">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTEzLTEtMS0w_1c6bb293-1969-48a0-8094-9c9c64c5a06f">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b68c915866b4394b86d1d387ad993a8_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIwLTUtMS0xLTA_09f4008d-29f4-45c1-a9f0-eae086ab695f">7,067</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIwLTEzLTEtMS0w_3ad17d74-35dc-47f9-8571-37dca4fdcf3c">7,067</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07fa82e04dff4428aaae1017c07a4108_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIxLTctMS0xLTA_4cd76156-a1fb-4faa-9982-2b56d188d0a3">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIxLTEzLTEtMS0w_507c178f-8713-4ecf-88f5-e8dba3493893">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIxLTAtMS0xLTEwNzkvdGV4dHJlZ2lvbjo3ZTBlN2E0ZGMwNWY0ZjdlOTJmMDI3YjYwYmFkZDNmNV8zMjk4NTM0ODgzMzk0_853e8a2d-753e-4200-bdd1-7cb7e5fab197">2.48</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b68c915866b4394b86d1d387ad993a8_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIyLTUtMS0xLTA_5b0d0a60-2b52-4469-abaf-4db5590d3dea">6,307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIyLTEzLTEtMS0w_05cbeaac-c3a1-4fc1-a2ba-d78905d87f75">6,307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIzLTktMS0xLTA_2f439789-0627-4dd3-b1aa-6c289ccca996">1,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIzLTEzLTEtMS0w_5229e0b7-a21c-433d-8d83-e1362cc1f83f">1,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96312e064b574ffaa9f1c3392694a627_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI0LTExLTEtMS0w_0e85058d-adcf-420b-8e08-fcb21dcd6147">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI0LTEzLTEtMS0w_e5f39e99-90e2-410c-8f23-e1075ba0fa14">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96312e064b574ffaa9f1c3392694a627_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI1LTExLTEtMS0w_1a333404-24ad-443b-9539-de78ed0b1ecf">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI1LTEzLTEtMS0w_09a923fb-3492-4452-9f0c-487f70bd28c7">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3e65989c80429e8fe99db11d1d76ad_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI2LTMtMS0xLTA_d07fb802-2ecf-48eb-a3d4-fae2bbac1fa1">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI2LTktMS0xLTA_4f8bf4aa-2f56-4fcf-88f5-e09ec34ed65c">444</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI2LTEzLTEtMS0w_0b25b2be-9600-43b9-9a13-5476b2c3a973">372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94362b387b441469ec50222fe704479_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTEtMS0xLTA_9fdf1f2c-3bb2-4eca-bc1c-216180d4df45">1,788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0a54f787d549bab0a21ae47e9740ea_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTMtMS0xLTA_8cee6db3-fe86-4139-8bd1-e069e6449b4f">39,588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433792a99d134359b4473b0754e16132_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTUtMS0xLTA_ca76e640-69cf-4c84-a2dd-941bdf550692">47,362</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie09ace19fb574f50904349a9da836610_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTctMS0xLTA_41ab6fcf-f497-46b9-b4de-009888aec096">6,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice647f7217ff4273a045f1876ac8bbe8_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTktMS0xLTA_bf9c4059-c413-4a20-a3c6-01b0cbfdf561">56,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b572de2338948dd96d08b22dd4171a0_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTExLTEtMS0w_026c67c7-2519-45d8-aa30-36141c170a33">87</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTEzLTEtMS0w_e0466793-cc92-49ec-9cf1-9cb188cf548f">25,404</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">($ in millions)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:69.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzItMS0xLTEtMA_24d8b13e-dc26-4ad5-baa4-ea72ee9559bb">7,082</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzItMy0xLTEtMA_3a4c0944-b182-4371-8e9a-740ab413df69">9,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzItNS0xLTEtMA_77f81ef3-56f3-4679-bfa5-f88609fb8cbe">6,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQtMS0xLTEtMA_8990bfc4-b600-4ed5-8ac7-ebdfaeaa399a">1,899</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQtMy0xLTEtMA_5f722c44-4b62-4fab-ad74-55708c2d1a2f">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQtNS0xLTEtMA_73ab12af-b62a-43cb-b5ef-b5f0f985775d">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtMS0xLTEtMTY1MTY_e21f8541-f8ed-4249-b3d0-1872eee09e4c">1,726</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtMy0xLTEtMTY1MTY_ff4873ba-35d6-40dd-8995-3ff4131448c6">1,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtNS0xLTEtMTY1MTY_c4d420eb-5ce4-4215-97f4-c6f352fbf8f4">1,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtMS0xLTEtMA_c6bb82da-a5ee-4aa2-bf5a-d0ada888bda2">1,718</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtMy0xLTEtMA_af1fcddd-d283-4248-8558-3107bb49917b">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtNS0xLTEtMA_e9ec1382-5887-4713-a94c-b762a898cb69">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Charge for the acquisition of VelosBio Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ChargeForAssetAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtMS0xLTEtMTQ5NzA_3c438599-269c-4c52-91ed-1a7a6bd35a5d">2,660</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="mrk:ChargeForAssetAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtMy0xLTEtMTQ5NzA_c3c6cd91-7d3f-457d-afe4-5a084aa1fa98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="mrk:ChargeForAssetAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtNS0xLTEtMTQ5NzA_62b48806-d87b-4c66-b85a-f5e8c2fd5be1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Charge for the acquisition of Peloton Therapeutics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtMS0xLTEtMA_ac3fd26f-438b-43e8-9e79-e6c801e56577">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtMy0xLTEtMA_b1821928-480f-4138-929a-968af6265705">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtNS0xLTEtMA_7b489d56-af9f-489f-aff2-b75418c63a6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Charge for future payments related to collaboration license options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzctMS0xLTEtMTQzMw_97cb2e48-db52-48be-91bc-45fa4d63baca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzctMy0xLTEtMTQzMw_b758235d-bf80-40aa-827e-572b1786ff3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzctNS0xLTEtMTQzMw_5a3871b5-8792-4b42-85c6-9b16c4cb5074">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzktMS0xLTEtMA_64037c61-f1f7-4686-837c-56a0ae140bb0">668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzktMy0xLTEtMA_3fa3044a-7b26-4d4f-a81d-0d515ea98073">556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzktNS0xLTEtMA_1ff9bb0e-4a12-4272-80b9-07282f5c81a4">509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEwLTEtMS0xLTA_1fbb4860-9c25-4543-96b4-c568e5bd8700">475</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEwLTMtMS0xLTA_c8d6249c-b236-477f-9b2f-a3835f118081">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEwLTUtMS0xLTA_6b81b310-b656-4a15-8480-1ab2cf75a806">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzExLTEtMS0xLTA_3907c2c6-fa88-495d-bc8d-f59cd08828d6">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzExLTMtMS0xLTA_32ea52c3-c765-4972-8bfc-7518c419e4a2">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzExLTUtMS0xLTA_67f71416-58ea-4c8b-9f12-d9e7864b78e1">978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEzLTEtMS0xLTA_96060fc4-212f-478b-938e-3583a726128d">1,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEzLTMtMS0xLTA_90648d26-c306-48a5-afdb-6fce59572741">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEzLTUtMS0xLTA_2d4f094b-f21b-4346-91d3-d3fea189d7fb">418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE0LTEtMS0xLTA_f22ed36a-af05-43f2-b6c6-51bac0d78657">855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE0LTMtMS0xLTA_ef249a97-7c79-4673-9799-935cdefdff13">508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE0LTUtMS0xLTA_3b4fe7cc-b657-4b72-bfab-437e302a5c51">911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE1LTEtMS0xLTA_25a67d1b-9386-4db8-a33c-fe45e54c9b3b">724</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE1LTMtMS0xLTA_91f50c6b-6aaa-4311-b0c2-be317d8f8d4e">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE1LTUtMS0xLTA_df8c8aa3-6e66-4c96-9880-3a7129449f5b">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE2LTEtMS0xLTA_a93083e8-5912-47a4-be20-522e250f975b">1,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE2LTMtMS0xLTA_17871d31-6fe9-4973-8798-432d6eb4d109">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE2LTUtMS0xLTA_7a8e6caa-24c9-4120-9d0c-4e2ed6343e66">341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE3LTEtMS0xLTA_c98c964b-fce1-4f67-bcb4-4eef794f3ce7">560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE3LTMtMS0xLTA_92e1433e-bcc5-4b9e-afd2-dedd8c93c0ea">2,359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE3LTUtMS0xLTA_b6efe0a6-87ee-4f0f-9b67-d5e1b55b626c">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE4LTEtMS0xLTA_4cfaa645-1868-478c-a30d-f43134299533">453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE4LTMtMS0xLTA_3b2661de-6a31-4cd0-996a-35d22db03c71">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE4LTUtMS0xLTA_b5d2855f-61ff-40fe-ade9-fd175c4cacf4">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE5LTEtMS0xLTA_77a0f448-c34b-4626-b1cb-9e66981585f1">2,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE5LTMtMS0xLTA_12b0eca6-017e-41ee-8e7f-b13f045d413f">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE5LTUtMS0xLTA_3820af8d-cdb6-4697-85cb-924663d96b90">674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIwLTEtMS0xLTA_3e6ee809-759d-4de1-acf2-9d4dd779fd10">10,253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIwLTMtMS0xLTA_5bc46de0-93ef-4354-8bbb-7cc44e30d6c4">13,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIwLTUtMS0xLTA_d9d80f55-6f24-4288-a524-df6d90fdb9ca">10,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIyLTEtMS0xLTA_ab9c0e10-2548-4fe6-9784-cc31d67b9486">4,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIyLTMtMS0xLTA_8f976b2a-57b4-4675-bc86-41a6952e7437">3,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIyLTUtMS0xLTA_0ab1a6bb-179b-4dac-8fac-f2e3346e9791">2,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchase of Seagen Inc. common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTEtMS0xLTE2ODc1_88ccbdc3-4e86-4982-86a0-71ac4efe474f">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTMtMS0xLTE2ODc1_da956de4-fc79-44a1-9b4c-41fab0fd9748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTUtMS0xLTE2ODc1_0f6e6477-ea83-4f8f-b180-62270d648fe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of securities and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIzLTEtMS0xLTA_9f2edee2-b6b1-4c22-8cf2-c2677c3ac265">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIzLTMtMS0xLTA_972d89b0-5902-4bb5-b2f5-bd03d2b537f4">3,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIzLTUtMS0xLTA_225053da-118c-4eba-95da-1cc095cf80b5">7,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from sales of securities and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTEtMS0xLTA_19ee71c5-35d0-41d3-9ed4-b4d19317d90a">2,812</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTMtMS0xLTA_bfc3ccd4-9c48-4794-a36d-efa94d7a7d38">8,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTUtMS0xLTA_04e5d3cb-0171-4be1-9a5a-bd484e0f4ef0">15,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Acquisition of VelosBio Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTEtMS0xLTE0OTc5_f8775a24-61d6-473b-adc8-018aaf9087e4">2,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTMtMS0xLTE2ODYx_1938b062-c444-46e2-83ce-4e14a457e9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTUtMS0xLTE2ODY1_3c74428f-136d-434e-8d60-4481edbef4ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Acquisition of ArQule, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTEtMS0xLTE5Mw_20531e26-8723-4e55-8a20-ea4ff067b67d">2,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTMtMS0xLTE5Mw_5cfea7e4-b498-4032-a6fa-340b07291f81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTUtMS0xLTE5Mw_ba700832-1eaa-4ee5-83c9-52b613f66c52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Acquisition of Antelliq Corporation, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTEtMS0xLTA_39c46bbf-c701-432f-845a-2f2e65caf01a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTMtMS0xLTA_77007dd5-6d31-4b13-87f4-a24dc196ada8">3,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTUtMS0xLTA_8d993f23-0f1a-4a99-9a15-a0d835c4195f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI2LTEtMS0xLTA_fe4b28db-511e-4c2c-99a8-52dc03de953c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI2LTMtMS0xLTA_27359339-5313-42b3-ba32-a18ab2495e48">1,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI2LTUtMS0xLTA_cd3091f9-926b-4fdd-a7a2-82bae02377f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTEtMS0xLTA_1e360a38-8eaf-4acb-a9ba-7d6814479bdb">1,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTMtMS0xLTA_a9bc4e86-3fe1-4906-bf69-96b1edb6f7cf">294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTUtMS0xLTA_fbbc6e4e-7c76-4ca8-a3a4-8ff3a49f1d1f">431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI4LTEtMS0xLTA_25c4f02e-d045-481c-866b-785d6d6d15aa">130</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI4LTMtMS0xLTA_45e24a20-145d-4ce1-93da-085f3f2f7c39">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI4LTUtMS0xLTA_0946acb6-b7b6-4fd5-a7c9-b806cbb5deb3">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Cash (Used in) Provided by Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI5LTEtMS0xLTA_dd10c93c-fcf0-48dd-9f55-49d70e5e5ca6">9,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI5LTMtMS0xLTA_d7fb565f-bed0-48a9-a768-b007bb2fac8b">2,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI5LTUtMS0xLTA_4954616a-968a-463e-a28e-8619783a37a5">4,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMxLTEtMS0xLTA_f9fa70b3-b9ad-400c-8c91-a942df6cd550">2,549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMxLTMtMS0xLTA_7b02ba18-40e0-4ccc-a8a2-81ab1f9ac917">3,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMxLTUtMS0xLTA_2b4e56d1-3331-4b13-94de-eeabeae40d4c">5,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Payments on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMyLTEtMS0xLTA_65a4203a-2e7f-4775-a31a-6c8f282c26ac">1,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMyLTMtMS0xLTA_625049c6-d833-4f69-a44e-0416088c3f20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMyLTUtMS0xLTA_89dc9e75-13ea-4026-955e-4a01a9dce1d1">4,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMzLTEtMS0xLTA_a4a468de-9d4a-4868-8b0f-3fe21f728977">4,419</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMzLTMtMS0xLTA_8f2e51c1-1a77-47bf-aaa9-b8f1e52b6a93">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMzLTUtMS0xLTA_a11fc186-92b0-42b2-9792-e8701f72c4e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM0LTEtMS0xLTA_e09d6e6d-ed43-4425-9717-51acedef6e53">1,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM0LTMtMS0xLTA_f95ef4e7-b2f4-4956-a8b3-3dd821312882">4,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM0LTUtMS0xLTA_c66544fc-135b-4f6d-a739-829992a9bfcf">9,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Dividends paid to stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM1LTEtMS0xLTA_05aded61-c0ae-405b-b4fb-5422f75309ca">6,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM1LTMtMS0xLTA_8d64be23-eb2b-4a57-bcfc-837f64ff8828">5,695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM1LTUtMS0xLTA_ffd4c7cb-94d5-4a26-856b-287d67c79cdb">5,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM2LTEtMS0xLTA_0bc2be74-2f48-4eb4-aa47-2133bbb4c6df">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM2LTMtMS0xLTA_b9b4941f-2be6-4179-a345-fba483fea4ab">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM2LTUtMS0xLTA_6748ddab-686e-4967-893d-215d319e28be">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM3LTEtMS0xLTA_341981b5-7efa-4837-972b-691793544d0a">436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM3LTMtMS0xLTA_0bd15d74-3acf-4ef6-914a-cb8fc6511f5e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM3LTUtMS0xLTA_352dc78c-9a5d-4185-a9cb-3450e6badc20">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Cash Used in Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM4LTEtMS0xLTA_ab551a73-fa8c-4b07-af92-ba51077b67c8">2,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM4LTMtMS0xLTA_6e360fae-f346-4f31-b972-192515c0e427">8,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM4LTUtMS0xLTA_75235837-0a0c-4a40-aba4-d4b0d96c7e9f">13,160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM5LTEtMS0xLTA_4a6040da-292d-409f-a979-8ddeb31f649c">253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM5LTMtMS0xLTA_c1fa95ce-bcff-4712-a923-4816d939e5c1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM5LTUtMS0xLTA_ab06957b-490e-45b1-9e32-2298d0762940">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQwLTEtMS0xLTA_40104c90-5936-44dc-b2d8-e9dc7b55ff10">1,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQwLTMtMS0xLTA_ffd8d3df-1d3b-4aa5-b945-d11a5e1ed812">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQwLTUtMS0xLTA_37f739f8-0296-427d-8908-4bd2e33ceb29">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQxLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YWU5ZmMyYTM2OWU0MzM3YjM0YTE4YWMxMmJjNDRlZl8zMjk4NTM0ODgzNjU2_cac3f402-d8ab-4476-990a-840c29be6af4">258</ix:nonFraction> of restricted cash at January 1, 2020 included in Other Assets - see Note 6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQxLTEtMS0xLTA_b52a2be9-c53a-428f-9728-9836a414cb87">9,934</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQxLTMtMS0xLTA_ba1b55d9-2e9f-482d-94a3-3d94039e2a47">7,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e100303069b40878e0e19c66282b95b_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQxLTUtMS0xLTA_16987ebe-0a18-4f47-8d7b-6f4b74e28567">6,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQyLTAtMS0xLTAvdGV4dHJlZ2lvbjo3YmNkMDY2NmUwNmY0N2ZiOGUyYTRjNjhmOGQ5Nzk5NF8zMjk4NTM0ODgzNjc0_2a6dce14-8d22-47b1-bf1c-05a257a883dd">103</ix:nonFraction> of restricted cash at December 31, 2020 included in Other Assets - see Note 6)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQyLTEtMS0xLTA_df0b4d86-1f7f-4911-922a-2590c4a4f647">8,165</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQyLTMtMS0xLTA_dcb6d673-3206-4e54-830f-a0c9f481ff99">9,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQyLTUtMS0xLTA_a0060a8c-f8b2-455b-82ca-9f5ba13897c4">7,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_160"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjAvZnJhZzo3YzczNGMxMzg4YjA0YzRhOGFjZmQ2ZjdiYzhjMmJmOS90ZXh0cmVnaW9uOjdjNzM0YzEzODhiMDRjNGE4YWNmZDZmN2JjOGMyYmY5XzM2NDc_95d49cda-abd7-4646-85e8-caa9c10799be" continuedAt="i9844ccaa88a7497c82a4287a1568c75c" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="i9844ccaa88a7497c82a4287a1568c75c"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#8217;s operations are principally managed on a products basis and include <ix:nonFraction unitRef="segment" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjAvZnJhZzo3YzczNGMxMzg4YjA0YzRhOGFjZmQ2ZjdiYzhjMmJmOS90ZXh0cmVnaW9uOjdjNzM0YzEzODhiMDRjNGE4YWNmZDZmN2JjOGMyYmY5XzMyMQ_6a1a4e35-6174-4871-9700-9c153a159c5c">two</ix:nonFraction> operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had an Alliances segment that primarily included activity from the Company&#8217;s relationship with AstraZeneca LP related to sales of Nexium and Prilosec, which concluded in 2018. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned Spin-Off of Women&#8217;s Health, Biosimilars and Established Brands into a New Company </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, Merck announced its intention to spin-off products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed late in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women&#8217;s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company&#8217;s consolidated financial statements.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_163"></div><div style="margin-bottom:6pt;margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyMzg1_f6323ac6-9420-4b8a-8ae2-f4e3b9f67496" continuedAt="iee9e3ffa63d54c798e07e37fc26a0d75" escape="true">Summary of Accounting Policies</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:continuation id="iee9e3ffa63d54c798e07e37fc26a0d75" continuedAt="i649765a4d5ba42ad9b4d50a532f36b51"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTQ1_d1817024-098b-4444-a956-5f19613dd23d" continuedAt="ic5bc33b4f2d349e4afc0071842886136" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates </span></ix:nonNumeric></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i649765a4d5ba42ad9b4d50a532f36b51" continuedAt="i12b893bf18c7420ab710cc8742195abc"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic5bc33b4f2d349e4afc0071842886136">over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</ix:continuation></span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTM0_7f6fc951-7a4a-48b7-b812-18d2cce299d4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTI3_2e7fede1-9ec8-42e0-8e14-f9683eb3a8b1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTM1_6c8d124f-a0f7-4294-a461-ee12405e61af" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyMzc5_32766664-26c5-4458-9376-ec19fd7cc804" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDE3_a1d574a6-adfb-4f40-b7f0-504762ae4446" continuedAt="i57834a4f74424da789902bb113e87e2f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the duration and extent to which fair value is less than cost. An other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i12b893bf18c7420ab710cc8742195abc" continuedAt="i175e13f5f6e04e689d48d58d5b85fa7c"><ix:continuation id="i57834a4f74424da789902bb113e87e2f"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to other factors is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTMz_2cb71988-a3b2-4d6c-94ae-f11f2386ec15" continuedAt="i97f818c273e34657832593e814792784" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="mrk:SalesDiscounts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEwMDIx_6c8590e1-e252-4d69-abc7-01894233d166">13.1</ix:nonFraction> billion in 2020, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="mrk:SalesDiscounts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEwMDMx_6cc2a6ca-dcda-43cf-b114-4715ea059a95">11.8</ix:nonFraction> billion in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="mrk:SalesDiscounts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEwMDQ0_3e5c2a3d-b296-4048-8132-622179870a41">10.7</ix:nonFraction> billion in 2018. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:AccrualForChargebacks" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzExNzkw_3a9b825a-2741-4f4f-a5e8-773d973a4b70">249</ix:nonFraction> </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i175e13f5f6e04e689d48d58d5b85fa7c" continuedAt="ia573d68b7d8d4249bb54f26964567c01"><ix:continuation id="i97f818c273e34657832593e814792784"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="mrk:AccrualForRebates" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzExNzk3_63f49fef-ddd2-4056-9e3a-5bcc3eeea0d3">2.9</ix:nonFraction> billion, respectively, at December&#160;31, 2020 and were $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:AccrualForChargebacks" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzExODMw_49a2360f-9705-439b-a97e-1c13fe3de778">233</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-8" format="ixt:numdotdecimal" name="mrk:AccrualForRebates" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzExODM3_57ecb268-817f-4f45-a962-d76d7ff3162d">2.2</ix:nonFraction> billion, respectively, at December&#160;31, 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzU2_e83aaddf-6760-4d99-a679-17c8ad2698ac">three</span> to <ix:nonNumeric contextRef="i953fcdd3d90e447480d218ef6e31883b_D20200101-20201231" format="ixt-sec:durwordsen" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzYy_1ca7e9e6-fc53-4a59-97c1-dbdc98e54a24">six months</ix:nonNumeric> before and <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:durmonth" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzc2_7e5a7bb2-55c5-4b1e-b9bb-39bdbbfabc95">12</ix:nonNumeric> months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic competition, changes in formularies or launch of over-the-counter products, among others. Outside of the United States, returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically <ix:nonNumeric contextRef="iee629d83621d4a4cbfa8f64a6cda8b18_D20200101-20201231" format="ixt-sec:durday" name="mrk:RevenuePerformanceObligationPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzMzgy_1e495258-09da-4544-b2a0-50afab93cbb6">36</ix:nonNumeric> days from receipt of invoice and for U.S. animal health customers are typically <ix:nonNumeric contextRef="i0fddbf63ffa94c619baa9b05476b6c33_D20200101-20201231" format="ixt-sec:durday" name="mrk:RevenuePerformanceObligationPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzNDY1_6eddf383-1774-47b4-8dcb-ad11b618052d">30</ix:nonNumeric> days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to <ix:nonNumeric contextRef="i2ffc6813f6914b38827655a976cc9e74_D20200101-20201231" format="ixt-sec:durday" name="mrk:RevenuePerformanceObligationPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzNTc3_73d82771-a332-4dc6-88ae-538291fadf32">90</ix:nonNumeric> days. Outside of the United States, payment terms are typically <ix:nonNumeric contextRef="i7a28618800c243e9a9a56cb43ec76314_D20200101-20201231" format="ixt-sec:durday" name="mrk:RevenuePerformanceObligationPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzNjQ0_cc05f69c-48ee-476d-a0c6-47549802259e">30</ix:nonNumeric> days to <ix:nonNumeric contextRef="ib7ae7baf3bf34777906747207fd9aa2d_D20200101-20201231" format="ixt-sec:durday" name="mrk:RevenuePerformanceObligationPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzNjU1_fa37357a-04a5-4fb1-91f5-295c7e88f4c5">90</ix:nonNumeric> days, although certain markets have longer payment terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for disaggregated revenue disclosures.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTQw_4ba1d63a-a539-4eb4-83d8-effd98195a22" continuedAt="i7bad1bfcb927499aa32fee195ee0dbe8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from <ix:nonNumeric contextRef="i78b12aa625c44405b0d39ee793eaf417_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzOTQ3_d7420739-4e44-4060-b61e-f58f485ef9aa">25</ix:nonNumeric> to <ix:nonNumeric contextRef="ie1033319c2914559931cb908a21c6d0b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzOTUz_2f275722-9527-4503-a723-4ec0bc6747cb">45</ix:nonNumeric>&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and from <ix:nonNumeric contextRef="i58165389de634c2cb2c0d3e8bd443866_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzOTg2_c2ead448-abc9-4f7d-9161-a6f7ee541407">3</ix:nonNumeric> to <ix:nonNumeric contextRef="iff425d31a4c6439287e6017923a0069d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzOTky_d943e045-c3dc-4e82-99f8-a5303c47ad5f">15</ix:nonNumeric>&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7bad1bfcb927499aa32fee195ee0dbe8">.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MDc1_54db4b98-1a67-4bd1-a946-ca4dee9bdb70">1.7</ix:nonFraction> billion in 2020, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MDg1_cd933263-6447-4d3d-ad5d-442f83758481">1.7</ix:nonFraction> billion in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MDk4_4e895b6d-2a77-4445-b0c2-b4b58046436a">1.4</ix:nonFraction> billion in 2018.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDk5_38bb1b91-7910-4c6e-b087-3018ff20339e" continuedAt="i8b6264d53dbc49059a44db4bd6e3d2d5" escape="true">Advertising and Promotion Costs &#8212;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b6264d53dbc49059a44db4bd6e3d2d5"> Advertising and promotion costs are expensed as incurred.</ix:continuation> The Company recorded advertising and promotion expenses of $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MjU5_8827b835-6360-4981-825e-4553626984dd">2.0</ix:nonFraction> billion in 2020, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MjYz_58550bce-e70f-4ddf-88f3-0873df3ee855">2.1</ix:nonFraction> billion in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0Mjcw_1c6b49a7-317e-4405-b050-c4206c166ea5">2.1</ix:nonFraction> billion in 2018.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDgw_87cad53a-cb68-4ba1-814d-ad8d37c8672c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from <ix:nonNumeric contextRef="i35717a97f0d5480bacc494c9ae0ae49a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE1MzMy_89dc11e2-cbaf-467e-8f50-88541d84b495">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i738d85dae80e42aaba01188d809878b2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE1MzM4_437645b1-fd44-42ea-b02f-52d9a2bed7e9">10</ix:nonNumeric>&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDMw_5ee4182d-078b-4549-8742-a0faa5a657f3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDI4_46b28f10-8f02-48b1-b357-dd5363ee9cf0" continuedAt="i57680530fe3140049793efdbac4a58e4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, licenses, trade names and patents, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from <ix:nonNumeric contextRef="i72b8afe3fe844c02ab7183ab38cfe809_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE2NTg0_8fd6a727-e7ca-4cd7-b030-2f9776a741aa">2</ix:nonNumeric> to <ix:nonNumeric contextRef="i953fcdd3d90e447480d218ef6e31883b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE2NTkw_93353762-214d-4d92-8f8b-49e191648f85">24</ix:nonNumeric>&#160;years (see Note&#160;8). The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="ia573d68b7d8d4249bb54f26964567c01" continuedAt="i0fa26b6f67e14b9584c87431721cfd99"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i57680530fe3140049793efdbac4a58e4">future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</ix:continuation></span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyMzg5_e672e63e-e26c-45e0-8736-ecb76a64c738" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="mrk:ContingentConsiderationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDEw_825a28e2-de0a-4647-b2de-6a6a7776d2c6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as an acquisition of a business, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTI5_f9bc8d49-0fb5-4f6a-a427-eb571635d993" continuedAt="ibb2b4a1386c44aac8ce066df98e7bee2" escape="true">Research and Development&#160;&#8212;&#160;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibb2b4a1386c44aac8ce066df98e7bee2">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTYy_3f495169-33ba-46a5-884d-76c723526a61" continuedAt="i3372e6aa8db541f59b1bbe4b2a0f61d9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i0fa26b6f67e14b9584c87431721cfd99" continuedAt="ic4a8f8784c9840db8e570edc155cc161"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:continuation id="i3372e6aa8db541f59b1bbe4b2a0f61d9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></ix:continuation></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTIy_00f77b43-4a7d-4883-97be-1fcb95c47802" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDQ5_8ba50966-4cee-4978-81c1-a58f8c593572" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDA2_25938657-8367-4fd7-a7cf-f23e5d820491" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTE0_0b6f4edc-ad46-43cb-84c3-1cac3dc26a20" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyMzcx_9ea8de62-99d0-46a5-b3a5-b2b9f5a785e8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyOTg1MzQ5MzUxMDM_0a0247a7-05c4-484a-bb00-214285e01cf1" continuedAt="i5c4ce5edbda043f3be8f6dc31f2c2bb3" escape="true">Reclassifications&#160;&#8212;&#160;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c4ce5edbda043f3be8f6dc31f2c2bb3">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="ic4a8f8784c9840db8e570edc155cc161"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTA5_74b48813-5eae-4895-901c-f8f86228bc12" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company retrospectively adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#8217;s collaborative arrangements (see Note 4 and Note 18). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard&#160;Not Yet Adopted &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_169"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="mrk:AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjUzNDI_16c6224b-9765-46ad-bc69-03752bf2716d" continuedAt="i62f7656050114bc1bb231be0803125d2" escape="true">Acquisitions, Divestitures, Research Collaborations and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i62f7656050114bc1bb231be0803125d2" continuedAt="i7761afb1ddd64c7a93758f45b3738cef"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i9ce1d972df3a4822ad7fad1e42f1b354_D20201201-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxNzg_f87cf439-4473-4fbf-8b8f-ef4dacfe8e47">423</ix:nonFraction> million. In addition, OncoImmune shareholders will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ia0d7b698e30044dfb6cffe1fc04d9813_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzEwMjk_dca2b6b5-8b15-4790-b06b-36f022b042bf">255</ix:nonFraction>&#160;million of future contingent regulatory approval milestone payments and tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="ib3fa7c6d136f41a3b40cca31c266c6de_D20201201-20201231" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjU0MDY_4c9e53e7-5175-448d-98e2-92bb666f8b34">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib175c23599ed49f9b1a462f8b563aac4_D20201201-20201231" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjU0MTE_cdce4fc5-01d6-41c0-9b4a-ac5fefc9d8d5">20</ix:nonFraction>%. OncoImmune&#8217;s lead therapeutic candidate MK-7110 (also known as CD24Fc) is being evaluated for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19). The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $<ix:nonFraction unitRef="usd" contextRef="i9ce1d972df3a4822ad7fad1e42f1b354_D20201201-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzg4NjA_0dc9295e-997d-4d06-959f-4fefb14ac4ad">50</ix:nonFraction>&#160;million for a <ix:nonFraction unitRef="number" contextRef="ifb2ee89502b94cd49ce08e1e3c882c21_I20201231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzg4NzM_75ef862f-dcaa-4ac4-8fcf-1d66ba56aafd">20</ix:nonFraction>% ownership interest in the new entity, which was valued at $<ix:nonFraction unitRef="usd" contextRef="ifb2ee89502b94cd49ce08e1e3c882c21_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzcyOTU_c8ef5473-a9cd-45ed-9e72-6bb480ad37b7">33</ix:nonFraction>&#160;million resulting in a $<ix:nonFraction unitRef="usd" contextRef="i9ce1d972df3a4822ad7fad1e42f1b354_D20201201-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:PremiumOnSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2MTY_4031cedd-6158-43ea-b443-4d65b25e9b49">17</ix:nonFraction>&#160;million premium. Merck also </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i7761afb1ddd64c7a93758f45b3738cef" continuedAt="i2f5f4ac6779e45e4abbea5049982712e"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="ifb2ee89502b94cd49ce08e1e3c882c21_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2Mzc_d2fd67c6-2150-4beb-a856-39e7fdd15bef">22</ix:nonFraction>&#160;million. The Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i0fb9fe46e2d94d4ab49c1b03fea4519d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2MzA_0e321388-510e-4ced-a895-72a349024123">462</ix:nonFraction>&#160;million in 2020 related to this transaction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $<ix:nonFraction unitRef="usd" contextRef="ib773c56e9fab416e9e0d022601d5ce4c_D20201201-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY3OTc_c095bcfc-29ab-4e40-bb4e-f64cf8ab2433">2.8</ix:nonFraction> billion. VelosBio&#8217;s lead investigational candidate is MK-2140 (formerly known as VLS-101), an antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $<ix:nonFraction unitRef="usd" contextRef="i98ddf3aa69a84aabaecb0a4d2ed8e2b3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2NDQ_a971b610-fbc7-4bb6-997f-8b42fc8c75d3">180</ix:nonFraction>&#160;million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i528e4f9a522448139a618d9f8e9aa62c_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2NTE_1d0a2f85-0020-44e8-b027-1c217e2f77d4">2.7</ix:nonFraction> billion in 2020 related to the transaction. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxOTU_13b6109a-a211-4b13-ad4a-624c30cbf30f">600</ix:nonFraction>&#160;million and a $<ix:nonFraction unitRef="usd" contextRef="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQyNDU_da197014-a8a1-43bb-b80a-a0ed624eef72">1.0</ix:nonFraction>&#160;billion equity investment in <ix:nonFraction unitRef="shares" contextRef="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQyNjE_a98fc806-63d0-455f-b923-6454216af6bd">5</ix:nonFraction>&#160;million shares of Seagen common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0243fd5dacc84dfa85f4fceec13fbf65_I20200930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQyNjg_59a0b65a-5efd-4d2b-9250-64a8697fcf2e">200</ix:nonFraction> per share. Merck recorded $<ix:nonFraction unitRef="usd" contextRef="i40ca48bff51949d4bf90dd5e362d3f56_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQzMzM_11afe692-b1ca-4119-ae4a-fdb235aedbc5">616</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020 related to this transaction reflecting the upfront payment as well as a $<ix:nonFraction unitRef="usd" contextRef="ia34ed105cdff4df1a7d378c513d91380_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:PremiumOnSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQzNDc_c6c9e700-4960-422c-b19f-79adfdeef6dd">16</ix:nonFraction>&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQyODk_c0fb4647-a0a7-4b3f-9007-d00dead873e7">2.6</ix:nonFraction>&#160;billion, including $<ix:nonFraction unitRef="usd" contextRef="i59fbc25bfc7641aca2fdbe80413efad3_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQzMDk_cec7f77a-480f-4c14-85b0-224761fc6dd8">850</ix:nonFraction>&#160;million in development milestones and $<ix:nonFraction unitRef="usd" contextRef="i02313044742341b49e06fa6a758966bb_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQzMjg_3b0afec4-9aa0-490e-a664-457ef473ab8b">1.75</ix:nonFraction>&#160;billion in sales-based  milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $<ix:nonFraction unitRef="usd" contextRef="i209f5888fc6749a2931c1615385b0e25_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY4MTY_dd5b467f-fa8d-4fd0-82e0-928861d379a1">210</ix:nonFraction>&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i73d37bdc4f354e69b8bcd53b246297ec_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5MDI_f35825b7-fabb-4f57-824a-d99d2d8c0d99">65</ix:nonFraction>&#160;million and will receive tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="ie7690d5c0cc347ed8b222d4300b23e30_D20200901-20200930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5MDg_3e493ea5-4be0-4dab-8399-7768769dcad9">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8b12110871ee41ee9868a579e4bbf80e_D20200901-20200930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5MTM_6253cee5-6c85-46df-b895-012e4f204f40">33</ix:nonFraction>% based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;<ix:nonFraction unitRef="eur" contextRef="idca8cca7b4e4487caad2c748e715f6e0_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5NDg_1dc8534b-0f93-4374-a2af-b9f97b78747f">256</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="idca8cca7b4e4487caad2c748e715f6e0_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5MzA_e46cd3bf-0cd4-45e2-9e73-5c31eaad3979">302</ix:nonFraction>&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="i4224acfa30774326b05925533ba77ee8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5Njc_025514d8-2d97-4c24-95af-d90078b11199">289</ix:nonFraction>&#160;million and other net assets of $<ix:nonFraction unitRef="usd" contextRef="i4224acfa30774326b05925533ba77ee8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5ODQ_6c708558-b3ce-4e8e-abf0-ce8195c7de80">13</ix:nonFraction>&#160;million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $<ix:nonFraction unitRef="usd" contextRef="i610b6867a103424f8f050100dff9795f_D20200701-20200731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwMjA_6b2a4a10-cc78-4bb3-8833-6379ed870371">410</ix:nonFraction>&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i9d1781ced27c45cbbbf893095d8cf6d6_D20200701-20200731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwMDI_3faf6128-c806-48f9-bbfe-c6bf4bdd9913">401</ix:nonFraction>&#160;million related to currently marketed products and inventory of $<ix:nonFraction unitRef="usd" contextRef="i4f3dc7254c8544e48303d0911c527606_I20200731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwMzY_dd0cb276-1a1e-4a72-bb3b-953de8c656cc">9</ix:nonFraction>&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of <ix:nonNumeric contextRef="i03f79093ce234ffb8ea77c30f545b9db_D20200701-20200731" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwNDI_33874ed4-aa7a-4b03-8f79-0916e51e4a0a">15</ix:nonNumeric> years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, also known as EIDD-2801), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i2f5f4ac6779e45e4abbea5049982712e" continuedAt="i41672cdf34cb4033a82481472f5183f9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $<ix:nonFraction unitRef="usd" contextRef="i5d9ba64de11e407f98dad1bd9112b382_D20200601-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwNjk_8a2606b6-9510-40c5-b0bd-16747f13037a">366</ix:nonFraction> million. The acquisition originally provided for Merck to make additional contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwODY_8ec112b7-59b5-4b77-8539-99efb293a5ca">740</ix:nonFraction>&#160;million. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcxNDU_6fe8cc75-4886-4d5c-80ee-161f3b579718">97</ix:nonFraction>&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcxNjM_9cc4b05f-37bd-4f2c-a365-08c442955c1b">136</ix:nonFraction>&#160;million, cash of $<ix:nonFraction unitRef="usd" contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcxODA_0d75ffb8-4737-4d46-a419-f82e9a74f905">59</ix:nonFraction>&#160;million, deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcxOTc_81a9871b-0dfc-4444-a28e-bb3e18a66abb">70</ix:nonFraction>&#160;million and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcyMzY_932c2ea8-c808-4967-a375-9ccd888e5125">32</ix:nonFraction>&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $<ix:nonFraction unitRef="usd" contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcyNTQ_f631d6f9-6ba2-45ae-9f0b-86d92f039fc8">230</ix:nonFraction>&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i6d9b918e005a49c58a372d8e08c8ca72_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDI2NzA_de491d02-5208-4e40-a35a-8c539ef5260e">90</ix:nonFraction>&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. The Company also recorded a reduction in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses resulting from a decrease in the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i6d9b918e005a49c58a372d8e08c8ca72_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDI2ODM_b118e115-d3bc-4608-8780-75c15002253f">45</ix:nonFraction>&#160;million since future contingent milestone payments have been reduced to $<ix:nonFraction unitRef="usd" contextRef="i945ab4055e164145a085c5b93e7c531b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDQ0NjM_b736a21f-2acb-4ec4-ad22-e78a71856163">450</ix:nonFraction>&#160;million in the aggregate, including up to $<ix:nonFraction unitRef="usd" contextRef="i99b9bcefa984431da58d2e033612d715_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDQyMzk_97b384fd-2c51-4d3c-a90e-1dcf91751ac7">60</ix:nonFraction>&#160;million for development milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i4f84cb29fc604ca6b0af582a6e9be121_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDQyNzc_831847fb-2d14-489b-957b-aab2ccc4fa19">196</ix:nonFraction>&#160;million for regulatory approval milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i2dedf39dc8524bb497923e4bea2c9e1e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDQzMjc_e76f8f8d-9fcc-498b-aac4-c4cab7d8e5c7">194</ix:nonFraction>&#160;million for commercial milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $<ix:nonFraction unitRef="usd" contextRef="if1e411be978c47beb7efc4b35966b7a8_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcyNzI_fffd7a1a-457c-4140-9c7f-ae786bce8c10">6.5</ix:nonFraction>&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#8217;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ChargesRelatedToProgramDiscontinuation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjUzNDQ_921fb618-ba8e-4e9b-82e4-c5084032c407">305</ix:nonFraction>&#160;million in 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProductionRelatedImpairmentsOrCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjU0MjQ_2226404b-f6f2-4f38-993f-aa4a9287319b">260</ix:nonFraction>&#160;million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related to fixed-asset and materials write-offs, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining $<ix:nonFraction unitRef="usd" contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjUzNTg_66eb40ef-c54f-4b1c-84b9-b88c04f5089d">45</ix:nonFraction>&#160;million of costs were reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="i36680a86aa854fa98c2457cd53911551_D20200116-20200116" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzEyNDE_30a8f81a-a3cc-439e-aa9a-12125848ba57">2.7</ix:nonFraction> billion included $<ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxMzI_80870371-bd3a-41eb-8f16-a905bc0fb2d5">138</ix:nonFraction>&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxNDY_b6c47116-9426-4d4c-88b4-54b66de6fac9">95</ix:nonFraction>&#160;million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. ArQule&#8217;s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as an acquisition of a business.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i41672cdf34cb4033a82481472f5183f9" continuedAt="i18b899e0c565432aa75a53915864ebec"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2Xzc2OTY1ODE0NzY2NTk_16c7a7c1-71f2-473b-8d73-23ca46df1e8f" continuedAt="i473308abac934cedb76cd9a2c335bcd1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzItMS0xLTEtMzYwNQ_22b259de-0cb1-4a09-9bbb-58a43be31398">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzMtMS0xLTEtMzYwNQ_19d86145-f1f0-49e9-a306-322cbf111f6f">2,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzQtMS0xLTEtMzYwNQ_a81dc66c-5e66-44e2-8f16-35581defea24">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzUtMS0xLTEtMzYwNQ_f460bd57-545b-4ea0-958f-17891b6e576e">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzYtMS0xLTEtMzYwNQ_5eb57953-8060-4331-9492-463418db51bb">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzctMS0xLTEtMzYwNQ_38eeceb1-1f49-4af6-8b1a-dacc1c8b26d8">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzgtMS0xLTEtMzYwNQ_f94ae6d9-7b78-4d19-9bbf-f0c76980748c">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzktMS0xLTEtMzYwNQ_7fc076f5-7c30-405a-9b1f-d9d3ab9f65bb">2,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible asset related to IPR&amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="i0d2cb7efc4324a38981648aa89ddcc18_I20200116" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxNTk_3a5b5bcd-77c8-487e-bc1b-0b66c78384b5">12.5</ix:nonFraction>%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#945; (HIF-2&#945;) for the treatment of patients with cancer and other non-oncology diseases. Peloton&#8217;s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2&#945; inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i07f15f684a9f4e1da581924f2c98bfb6_D20190701-20190731" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzIxODM_f6bada65-56a2-4a66-85fd-64a9b4f5eb77">1.2</ix:nonFraction> billion; additionally, former Peloton shareholders will be eligible to receive $<ix:nonFraction unitRef="usd" contextRef="i347f3eb2160e4032b140b2fdf9799106_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzIyNjU_faee2f8a-89e1-4b50-9b3e-aaeeada93211">50</ix:nonFraction> million upon U.S. regulatory approval, $<ix:nonFraction unitRef="usd" contextRef="i081c04d8d22d4e03a143a335398bd927_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzIyOTk_0b95f2e6-7c0b-4c32-8bd8-a3f57c1a6410">50</ix:nonFraction> million upon first commercial sale in the United States, and up to $<ix:nonFraction unitRef="usd" contextRef="iec9f0c316ec4420c85c71329dbb4ad02_I20190731" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzIzNjE_43ea3d9b-f8d4-4a67-9475-752ba1f2f43c">1.05</ix:nonFraction> billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $<ix:nonFraction unitRef="usd" contextRef="i8341e9d08ff14983a3ef4b4dcd949328_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI0Nzk_3e4e680d-c067-4d15-895a-537d14561059">157</ix:nonFraction> million, deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i8341e9d08ff14983a3ef4b4dcd949328_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI1MTE_2fa3619a-1142-4460-b008-57f5cefc078d">52</ix:nonFraction> million, and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i8341e9d08ff14983a3ef4b4dcd949328_I20190731" decimals="-6" format="ixt:numdotdecimal" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI1NDQ_2b3a6fca-f675-42ef-9e8d-a301eaf3637e">4</ix:nonFraction> million at the acquisition date, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="ib4d11122b7294a4694e482424ef3b691_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI2MTI_911d8289-35ee-4f2c-9a04-042d9c8a2b23">993</ix:nonFraction> million in 2019 related to the transaction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $<ix:nonFraction unitRef="usd" contextRef="ida918a35a96d497a919b2f7b5fbb9713_D20190401-20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI5NTg_1f7d8eeb-6ca8-4822-bbaf-2712cc75c28a">2.3</ix:nonFraction> billion to acquire all outstanding shares of Antelliq and spent $<ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMwMTc_3585c939-e2c2-483c-b580-1b15b8d48633">1.3</ix:nonFraction> billion to repay Antelliq&#8217;s debt. The transaction was accounted for as an acquisition of a business. </span></div><ix:continuation id="i473308abac934cedb76cd9a2c335bcd1"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzEtMS0xLTEtMA_2f021fab-e8c5-4176-a071-6ce09a3a6294">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzItMS0xLTEtMA_9cb023cb-164a-4ac9-a79b-3e59eeafd9c3">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzMtMS0xLTEtMA_1b585282-f901-468c-a50c-2c4e6ce94b78">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzQtMS0xLTEtMA_ed179f7a-0038-4613-b731-b1aa50df87bd">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from <ix:nonNumeric contextRef="i5d04a426e1da4d6ca4a2b650e191b1fc_D20190401-20190401" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzUtMC0xLTEtNDA1Mi90ZXh0cmVnaW9uOmZlZDhiNDU5ZWEwODQ2YzZiMDk4NmY4Zjk1OWFkZThkXzMyOTg1MzQ4ODM0MDk_95669d43-6fb4-4c75-b13b-78adabab8a62">18</ix:nonNumeric>-<ix:nonNumeric contextRef="icdb01ee2305f4539ab9c5f07db7173e7_D20190401-20190401" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzUtMC0xLTEtNDA1Mi90ZXh0cmVnaW9uOmZlZDhiNDU5ZWEwODQ2YzZiMDk4NmY4Zjk1OWFkZThkXzMyOTg1MzQ4ODM0MTU_9900257b-de25-483f-a7e3-0372d5f5aea5">24</ix:nonNumeric> years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzUtMS0xLTEtMA_13757359-08d6-47d3-8ec3-aeac5755a3de">2,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzYtMS0xLTEtMA_fc1ad9b9-323d-4a4f-ab43-c6a089bccb28">589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" sign="-" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzctMS0xLTEtMA_7c56b6a6-5370-4fbc-92e1-841455144c41">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzgtMS0xLTEtMA_f7253914-8c73-4b4f-9585-e7a2d34743f5">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzktMS0xLTEtMA_49864445-9e95-42de-ba7d-cb65c466f22e">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzEwLTEtMS0xLTA_d04f74fa-53c9-4fe1-8c4d-648ce7578227">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="i996ba4f2c0984b8cb870df85ea16273f_I20190401" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzM0NDM_17ba78d6-fb19-48d8-9775-1fd9387471bb">11.5</ix:nonFraction>%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div></ix:continuation></ix:continuation><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i18b899e0c565432aa75a53915864ebec"><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results for 2019 include eight months of activity for Antelliq, while the Company&#8217;s results in 2020 include 13 months of activity. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzM4Mjc_b8a886d4-851c-4970-a197-87ef1a099bd4">47</ix:nonFraction> million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approaches to enable the body&#8217;s immune system to fight disease, for $<ix:nonFraction unitRef="usd" contextRef="i485e704327b34e818bc08bad5c4a5d97_D20190401-20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQyMDE_1266f353-9f8a-453b-ae0c-d9878de32192">301</ix:nonFraction> million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i2da5d31a2da043428a6be3a178933283_I20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQzMjg_d263f459-735b-453a-ac19-ba865c06a58a">156</ix:nonFraction> million, cash of $<ix:nonFraction unitRef="usd" contextRef="i2da5d31a2da043428a6be3a178933283_I20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQzNDA_447ce521-f514-42a8-b0fc-ff837a090531">83</ix:nonFraction> million and other net assets of $<ix:nonFraction unitRef="usd" contextRef="i2da5d31a2da043428a6be3a178933283_I20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQzNjc_b61e614e-9005-4693-b44a-e3a4a3208aef">42</ix:nonFraction> million. The excess of the consideration transferred over the fair value of net assets acquired of $<ix:nonFraction unitRef="usd" contextRef="i2da5d31a2da043428a6be3a178933283_I20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQ0NjE_d6823482-2fa3-486d-89fa-ac6d08640164">20</ix:nonFraction> million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company recorded an aggregate charge of $<ix:nonFraction unitRef="usd" contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQ4Mjg_93d46e0b-e0fb-4aa1-8d0b-4df045079bc3">423</ix:nonFraction> million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conjunction with the termination of a collaboration agreement entered into in 2014 with Samsung Bioepis Co., Ltd. (Samsung) for insulin glargine. The charge reflects a termination payment of $<ix:nonFraction unitRef="usd" contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:Contractterminationfeepayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzUwNDY_cff4301d-9503-4a64-b15b-7343f9285836">155</ix:nonFraction> million, which represents the reimbursement of all fees previously paid by Samsung to Merck under the agreement, plus interest, as well as the release of Merck&#8217;s ongoing obligations under the agreement. The charge also included fixed asset abandonment charges of $<ix:nonFraction unitRef="usd" contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzUzMDQ_7c16ec7e-74ab-44c2-9785-ab45d80a1115">137</ix:nonFraction> million, inventory write-offs of $<ix:nonFraction unitRef="usd" contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProductionRelatedImpairmentsOrCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzUzMzI_30341913-1c43-48f4-82f2-8ed337cfef8c">122</ix:nonFraction> million, as well as other related costs of $<ix:nonFraction unitRef="usd" contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:OtherContractTerminationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzUzNzA_13a8516c-b36e-499f-9fcb-045875cf72bc">9</ix:nonFraction> million. The termination of this agreement had no impact on the Company&#8217;s other collaboration with Samsung.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Merck acquired Viralytics Limited (Viralytics), an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers, for AUD <ix:nonFraction unitRef="aud" contextRef="i1f7489b20f5c48308b9bb04baf6a39d6_D20180601-20180630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzU2NTE_c30d7773-36d9-4cc0-a25c-3a1b9687d46c">502</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i1f7489b20f5c48308b9bb04baf6a39d6_D20180601-20180630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzU2NTU_69976623-5435-4d1f-9c36-a15baef96a53">378</ix:nonFraction> million). The transaction provided Merck with full rights to V937 (formerly known as CVA21), an investigational oncolytic immunotherapy. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $<ix:nonFraction unitRef="usd" contextRef="i26856c5ef4364f19bff668d3dfeed68e_I20180630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzYzNzg_05822a60-1315-42df-b73c-2d8f37cbdfb9">34</ix:nonFraction> million (primarily cash) at the acquisition date and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="iefeacd0e5f5842dbb109b127cdbe7f72_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzY0NjM_f6545763-4e50-4b07-be08-bc62b5f9f6ff">344</ix:nonFraction> million in 2018 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, Merck and Eisai Co., Ltd. (Eisai) entered into a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima, an orally available tyrosine kinase inhibitor discovered by Eisai (see Note 4). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade/Simponi</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1998, a subsidiary of Schering-Plough entered into a licensing agreement with Centocor Ortho Biotech Inc. (Centocor), a Johnson&#160;&amp; Johnson (J&amp;J) company, to market </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is prescribed for the treatment of inflammatory diseases. In 2005, Schering-Plough&#8217;s subsidiary exercised an option under its contract with Centocor for license rights to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fully human monoclonal antibody. The Company has marketing rights to both products throughout Europe, Russia and Turkey. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lost market exclusivity in major European markets in 2015 and the Company no longer has market exclusivity in any of its marketing territories</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to have market exclusivity for </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in all of its marketing territories. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All profits derived from Merck&#8217;s distribution of the two products in these countries are equally divided between Merck and J&amp;J. The Company&#8217;s marketing rights with respect to these products will revert to Janssen Pharmaceuticals, Inc. in the second half of 2024.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_175"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzEwNDIw_72d91640-47e6-4241-925d-c73fabd940f2" continuedAt="ibb9f8d808de64ee080967e35ce874070" escape="true">Collaborative Arrangements</ix:nonNumeric></span></div><ix:continuation id="ibb9f8d808de64ee080967e35ce874070" continuedAt="i736016d551cb4a4f8fc3ef4e9f511dc6"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below.</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor currently approved for certain types of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i736016d551cb4a4f8fc3ef4e9f511dc6" continuedAt="i3e703e3acf164de5b91f019e9b6c2656"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#8217;s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, for multiple indications. In April 2020, Koselugo was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca of $<ix:nonFraction unitRef="usd" contextRef="i22a33fa403504dada396f58875c9157c_D20170701-20170731" decimals="-8" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI0NTQ_23aa28a1-e75c-45de-8c49-16955c5627e8">1.6</ix:nonFraction> billion in 2017 and made payments of $<ix:nonFraction unitRef="usd" contextRef="i22a33fa403504dada396f58875c9157c_D20170701-20170731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI0ODY_b93c8972-917a-4d9c-9951-2d90d73a969f">750</ix:nonFraction> million over a multi-year period for certain license options (of which $<ix:nonFraction unitRef="usd" contextRef="ie2b6640d40ff4e1799c205b35e73ced7_D20171201-20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI1NTI_bbdfd3e6-6a7c-4026-8fda-afaa0d653e0f">250</ix:nonFraction> million was paid in December 2017, $<ix:nonFraction unitRef="usd" contextRef="i45f6bb982b5943a1bbbe16a8ac755b27_D20181201-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI1ODI_5e127fd4-491e-416c-814c-52a5d709f53f">400</ix:nonFraction> million was paid in December 2018 and $<ix:nonFraction unitRef="usd" contextRef="i1d63658c728d4ed98637396020df1f7b_D20191201-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI2MTU_daa58616-a51b-4873-af46-579d700f5cd3">100</ix:nonFraction> million was paid in December 2019). The upfront payment and license option payments were reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2017. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $<ix:nonFraction unitRef="usd" contextRef="i620af11cbb8f4c91a858173de9d019db_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMwNzc_750eeb9b-9f84-47e2-aa6b-213c829fae53">400</ix:nonFraction> million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded $<ix:nonFraction unitRef="usd" contextRef="ia6c051937aae495b8e9e5625eae66971_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMxNzY_13b02b47-a09f-458f-8be7-958dca929242">400</ix:nonFraction> million of liabilities and corresponding increases to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $<ix:nonFraction unitRef="usd" contextRef="i1cd91baf9509462f81a3d9ce3a0cc395_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMzMzU_5a576700-e75b-4a5e-b38e-4b1d8c6984ee">1.0</ix:nonFraction> billion related to Lynparza, of which $<ix:nonFraction unitRef="usd" contextRef="i620af11cbb8f4c91a858173de9d019db_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM4NDgyOTA3MDgyMTE_3867cdd9-3496-4c72-a162-c6405489ed85">550</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i1cd91baf9509462f81a3d9ce3a0cc395_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMzNDg_9799ac5a-fc52-45ad-9b8b-5505f929cbc5">200</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6419d35ddb6b4e628eda2d42348e331a_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMzNTU_88569156-aa52-4006-a39f-201051251300">250</ix:nonFraction> million was paid to AstraZeneca in 2020, 2019 and 2018, respectively. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ic26c0f3b7f0544268df9ca7c0d8af913_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM1MTU_336ae47f-4bb2-4ee3-9a57-4d0b848d5a1e">2.7</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i42a16518bdec4e709a2954f61afd02f6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM4NDgyOTA3MDg3OTc_b4d946b7-d43c-4b4e-93f7-62769dd65f6a">160</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i878da9d0c0714be2bd5756cb5d5e834a_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM5MzU_4b391f78-3ad8-4133-9fe9-745b25f342cf">60</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba602abb2d7549c19eab5306b4002102_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzQwODg_e84d954b-721f-4e4a-a375-de36e2ba463e">140</ix:nonFraction> million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i0e966186f72a4b0ab58ea90de20ec66a_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzQxODU_efc43f24-48e7-4f00-b3df-af6fedb3b114">1.4</ix:nonFraction> billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="i290e0168aaad4d8bbb291ae388c991a3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzQzNDQ_1cd74da4-3f11-456a-96df-a96ce7078a17">1.3</ix:nonFraction> billion at December&#160;31, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i3e703e3acf164de5b91f019e9b6c2656" continuedAt="i2ef28022a9a6446e92e2e494eff6ffa6"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzEwNDEx_1d0d7b11-935b-468f-adae-99f42cf838cc" continuedAt="i531fed8460224900a83f16d447d34333" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7885d0aea044a2285bce8f3e73dfff2_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzEtMS0xLTEtMA_01a7d410-06a9-4dd6-9683-8f9044b1d8e5">725</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32a30c39b1b49b5b51cfcea80332547_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzEtMy0xLTEtMA_ee5fe25d-92b0-447f-a496-6aceff3e7a02">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d315dacfbde4501ba6c19d08de524d2_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzEtNS0xLTEtMA_4fc95b92-08cd-4b53-a620-2607d48ea953">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07de5c0f87bb4cbb837704628b2bd9e8_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzItMS0xLTEtOTg4Mw_21fb1473-54be-4d75-8bd3-b738d94eeaa5">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cccbfd1aaa4196b45c4d6ecaf6cf96_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzItMy0xLTEtOTg4Mw_606b92f4-8d72-413e-87ca-d7bf91e9c05e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a073f8f7b1407aa63ab374b8f4b9a0_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzItNS0xLTEtOTg4Mw_56eb2f9f-0f5c-4e33-959d-49cdae57648a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i330b41f19cde4e878a6b9d06b389bb53_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtMS0xLTEtOTg5NQ_0307c3d1-4b40-4206-bb49-b869214723df">733</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i401735563ecd4f6e8f401746036baa9c_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtMy0xLTEtOTg5Nw_fa2ff207-97bd-47ff-8a84-6cb50ed66dfe">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ece84cc7606444390554357bcf90179_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtNS0xLTEtOTg5OQ_6fae3cc2-7098-49e4-a40c-0a76a08e9c29">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd756807e314175a880dd575077a4e7_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtMS0xLTEtMA_708b3d1d-f661-4ead-9b2a-796e41f7720e">247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697fb80f1e6e4a91ac61fbdcad18f9cc_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtMy0xLTEtMA_02f23dbb-6fc0-48c9-8478-ae7e12b8b38e">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica44f5e5fa844b15a4879fab9631e48e_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtNS0xLTEtMA_954046e6-8a09-4737-b466-f465b6ff156b">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a10731ee0b24e8db15d8038662bb511_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzQtMS0xLTEtMA_8ee428f7-a821-4b37-aaa2-af71cbe98811">160</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de09b10a2384c05b55e43c2f74660f9_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzQtMy0xLTEtMA_edd329a9-17b4-416c-adfa-249d53d7dfae">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5af579547c4a299bf5671d6d56b6c4_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzQtNS0xLTEtMA_34d2110a-185b-4f6e-9f0e-fae9c6b9886f">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b51d3311034c3bac51a0de70567e64_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzUtMS0xLTEtMA_593cb3e7-9ff3-4458-912e-b8f01bc7ae11">133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be4fde20b284f118e551ecaa1276e5b_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzUtMy0xLTEtMA_3270773a-55bb-497e-af58-c5e622cc8008">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc12f18f7224792ae5dcdbaf054352e_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzUtNS0xLTEtMA_a0e4cda9-84bb-4792-a64c-9c67467d94d6">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0326de13695545ddb2210521908c117c_I20201231" decimals="-6" name="mrk:CollaborativeArrangementReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzgtMS0xLTEtMA_2b1bed65-39d0-4e46-b0fd-778ab5cef932">215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4488c2e1f5c64819bf4b59fccdb0e9d3_I20191231" decimals="-6" name="mrk:CollaborativeArrangementReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzgtMy0xLTEtMA_3134b171-d439-40d0-92a9-fa7682a252ad">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0adede01333549d8bc322abf9e22e84f_I20201231" decimals="-6" name="mrk:CollaborativeArrangementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzktMS0xLTEtMA_f86b47ad-105a-46e4-a19c-b6140a66c014">423</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica3ea97cf2554f1d8815cc085464ebc4_I20191231" decimals="-6" name="mrk:CollaborativeArrangementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzktMy0xLTEtMA_570f2697-f59b-4c77-ad46-30b8fe7a8c01">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payments.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai of $<ix:nonFraction unitRef="usd" contextRef="i11173b2b42d64d0cb11c1105fb2ca7d1_D20180301-20180331" decimals="-6" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU3Mzc_3c4b5aef-c743-4a9f-a32e-ccd2cc8da02b">750</ix:nonFraction> million in 2018 and agreed to make payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic2173fc8dee04c56aaeb475acb7c7018_D20180301-20210131" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU3NzI_9030eb84-3705-47a6-80fe-85deb0ec340c">650</ix:nonFraction> million for certain option rights through 2021 (of which $<ix:nonFraction unitRef="usd" contextRef="i199ae1c6ff6e448eb1085cdc50ff93f1_D20190301-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU4MjQ_159c90c0-1152-487d-b0b6-edfac08c445c">325</ix:nonFraction> million was paid in March 2019, $<ix:nonFraction unitRef="usd" contextRef="i9be5634cf9e3423d903fb59b51dfffc9_D20200301-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU4NTE_aba4ed38-d97d-4561-8ad5-121f83620567">200</ix:nonFraction> million was paid in March 2020 and $<ix:nonFraction unitRef="usd" contextRef="i302846733a5e4162a65e06b042b6c625_D20210301-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU4OTU_d9a1e503-4394-409b-9d23-19f7bc5f9d93">125</ix:nonFraction> million is expected to be paid in March 2021). The Company recorded an aggregate charge of $<ix:nonFraction unitRef="usd" contextRef="i884fede8f02b4207af70ce8ef3e7719a_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU5ODE_cdf55e73-4839-4ddd-9114-34977766e42f">1.4</ix:nonFraction> billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2018 related to the upfront payment and future option payments. In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $<ix:nonFraction unitRef="usd" contextRef="iea8401099a9d4f1da0c09f5e4a845f53_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY0MjE_21a5ab6f-518d-4774-9687-f5b6cc6bbd2e">400</ix:nonFraction> million from Merck to Eisai. Accordingly, Merck recorded liabilities of $<ix:nonFraction unitRef="usd" contextRef="ie652d13a7772491b9988fe4ca0cfc66e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY0NjI_6419fb30-72d1-4095-8ae2-86099514333c">400</ix:nonFraction> million and corresponding increases to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $<ix:nonFraction unitRef="usd" contextRef="iad6bc081967747b58d1b8d8f5af214b2_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY2MTg_4c45eb68-4fc8-4563-9564-ac1133c4766a">950</ix:nonFraction> million related to Lenvima, of which $<ix:nonFraction unitRef="usd" contextRef="iea8401099a9d4f1da0c09f5e4a845f53_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM4NDgyOTA3MTA1MDI_a7305f23-5599-412e-9aed-7f116ef42218">500</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iad6bc081967747b58d1b8d8f5af214b2_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM4NDgyOTA3MTA0NzQ_53d1fbed-1f78-4a0c-816c-fdd78712cb54">50</ix:nonFraction> million&#160;was paid to Eisai in 2020 and 2019, respectively. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="iefa940ebb76b40afa60a15a108b7af2f_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY3ODY_a07b26f9-7194-44a2-bd15-9680f914f2d3">2.6</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ic341c5bdad3f434ab0c54a2c5e63395e_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMyOTg1MzQ4OTgwMjA_8885feb5-74c4-4eb1-941e-2c093f5592c7">10</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4f4920692eee4e4d815006aacc7d78b3_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY5NzQ_333e6086-587f-4c87-b909-80964d948c16">250</ix:nonFraction> million, respectively, from Merck to Eisai. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i36f9356746cd4c6aa273dff749ec985b_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzcwNjU_99031731-1260-4a05-85fc-8118b57d2ac2">125</ix:nonFraction> million remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="ic4443e6b872f4ba8905276b85a6342e3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzcyMjM_248c0469-797f-4eb0-a1aa-e6fb9518a4a6">1.1</ix:nonFraction> billion at December&#160;31, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i2ef28022a9a6446e92e2e494eff6ffa6" continuedAt="i6674011d0f984ab8a1cb072e0c0b928b"><ix:continuation id="i531fed8460224900a83f16d447d34333" continuedAt="i396fff53d77740e9893059790f18733c"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491d903bb49f4ed1a82e1b5a703ac09b_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEtMS0xLTEtMA_41758755-890a-4171-ad7e-d56e402e409c">580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0400fa9e2d64e50917ba83f9b0256bc_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEtMy0xLTEtMA_cee17ef1-99c4-4315-bddc-ad5069cb4c78">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia245619b9e664a26b6753a23646c0b18_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEtNS0xLTEtMjk0_44cdf887-0098-4d66-95e9-9c7484a6af01">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f432bff4c4574930a4219c0b5c005_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzMtMS0xLTEtMA_323c919a-310c-46ba-b3f7-779ba4383f2e">271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf4d70ed271480fa94afe6dd9a2000f_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzMtMy0xLTEtMA_bad83be0-a809-4840-937c-d8673f8a6f38">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b505e290fea45b99717b674adac2691_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzMtNS0xLTEtMjk0_a6e51b45-2c96-44aa-afb5-f6fc47ffa544">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9d776541aa4ae082408d286b415f75_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzQtMS0xLTEtMA_58c7c64a-15b9-4b46-a5a3-a937ebdc86c0">73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b435415c6274d44b0dd2ae2de7d186d_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzQtMy0xLTEtMA_b5fb44e2-d489-4946-921b-377ee90df2fa">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7fdf3938156482ab9562725eb331768_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzQtNS0xLTEtMjk0_5dee1e85-a370-4341-a501-e204193a0fe4">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab203463d1344f2b6b7b49ab329c80f_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzUtMS0xLTEtMA_3f33e2a8-df0f-4fc1-8ed6-9cee43ba6ba3">185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570f8d4c86b4b70ae7e83bff83c5ff5_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzUtMy0xLTEtMA_0768a992-bfb6-41a5-ac6c-b45ba1f3f1e0">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440fbf44eff94d33beb60677f2144686_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzUtNS0xLTEtMjk0_710973ec-1275-45e0-8045-87c94318f452">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a84ffaafac460fbd68e4328f87c599_I20201231" decimals="-6" name="mrk:CollaborativeArrangementReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzgtMS0xLTEtMA_c083dadb-2bdb-40ba-b3fd-e8e2d1a366fa">157</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2650552a454bfdac17540247c4ad9a_I20191231" decimals="-6" name="mrk:CollaborativeArrangementReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzgtMy0xLTEtMA_4bbc90aa-9e13-4ad9-ae5c-0dfe6b039baf">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7041cdecd0cc482fb7f6996b7e09667d_I20201231" decimals="-6" name="mrk:CollaborativeArrangementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzktMS0xLTEtMA_40e229c2-0697-45b1-9ad6-956b749380a5">335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7422cf6500bf43efb6beb9930ca4c6c9_I20191231" decimals="-6" name="mrk:CollaborativeArrangementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzktMy0xLTEtMA_8dd44873-c7a7-43aa-8fa8-abfd073a3f29">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4df60e0c1ad4ea8abfda1ae6df07058_I20201231" decimals="-6" name="mrk:CollaborativeArrangementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEwLTEtMS0xLTA_346895d8-3be3-40fd-950e-f2d34469b14e">600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283cb0fd0292451f9077f95aae1b4028_I20191231" decimals="-6" name="mrk:CollaborativeArrangementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEwLTMtMS0xLTA_78c5da85-f21e-4b4a-b3ed-133451b655b9">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount for 2018 includes $<ix:nonFraction unitRef="usd" contextRef="i884fede8f02b4207af70ce8ef3e7719a_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzc2MzE_cdf55e73-4839-4ddd-9114-34977766e42f">1.4</ix:nonFraction> billion related to the upfront payment and option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer&#8217;s Verquvo (vericiguat), which was approved by the FDA in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults. Verquvo is under review by regulatory authorities in other territories including the EU and Japan. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck will commercialize in the United States and Bayer will commercialize in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas (and will record sales of Verquvo) in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, Merck accrued $<ix:nonFraction unitRef="usd" contextRef="i491ff105eeb74cc6979d2752383ad3e7_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzkzNzE_c3c22b82-d66f-45e6-825d-d9d616d19569">725</ix:nonFraction> million of sales-based milestone payments for this collaboration, of which $<ix:nonFraction unitRef="usd" contextRef="i61497bc7d49a49a8b98adf19ffa96211_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMyOTg1MzQ4OTgyMTc_e3b9e10a-dd6c-4ddb-8d18-5b1cd59f33a4">375</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iedff350d0421432989e5b4164f44779f_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzk1Njk_29810825-5457-42d6-b0a6-358206c922c5">350</ix:nonFraction> million was paid to Bayer in 2020 and 2018, respectively. Following the 2021 FDA approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $<ix:nonFraction unitRef="usd" contextRef="if2cc693bd8114433a7e7cebbe0e1a220_D20210101-20210131" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzk2OTk_92f6570e-43f7-4cae-993f-7d0752e40bb1">400</ix:nonFraction> million sales-based milestone payment. Accordingly, Merck will record a liability of $<ix:nonFraction unitRef="usd" contextRef="ic5b17ae627674bfd9c3a3e606fc39a10_I20210131" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMyOTg1MzQ5MDk4MDc_331c802e-6570-4f8a-abd7-e387d6827478">400</ix:nonFraction>&#160;million and a corresponding increase in intangible assets related to this collaboration in the first quarter of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="i50171610356846629bd94e414c848b8f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzEwMDA1_8ba72bfa-0275-4eba-93e1-4ff13ba7db2a">849</ix:nonFraction> million at December&#160;31, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i6674011d0f984ab8a1cb072e0c0b928b"><ix:continuation id="i396fff53d77740e9893059790f18733c"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13429c0926e34225b226ce3b2cdb7e1a_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtMS0xLTEtMTY2NDA_bde43ba8-b849-42a7-8cab-1f5403dae00c">281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897a73e11e48487f9d94d60f05fd9038_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtMy0xLTEtMTY2NDA_dee37828-faa8-40db-ad24-91d7e68ca352">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8080482a8f4179b87efe70700d453f_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtNS0xLTEtMTY2NDA_7405cb37-1dac-4127-b262-806256b2f2d1">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13429c0926e34225b226ce3b2cdb7e1a_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtMS0xLTEtMA_7d33d34e-80a3-405b-b5c9-dae935ec8caa">220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897a73e11e48487f9d94d60f05fd9038_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtMy0xLTEtMA_bb281655-143d-452d-8b48-dd7a1e2ef71c">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8080482a8f4179b87efe70700d453f_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtNS0xLTEtMA_5dc4f80e-530f-4c2b-be05-27bb97c8d984">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13429c0926e34225b226ce3b2cdb7e1a_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzMtMS0xLTEtMA_9d24fe11-5198-4b14-ae77-8665be7c8734">501</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897a73e11e48487f9d94d60f05fd9038_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzMtMy0xLTEtMA_90e21781-0f44-4938-b056-cc63aeedeb71">419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8080482a8f4179b87efe70700d453f_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzMtNS0xLTEtMA_42d831d1-a789-47a1-81dd-1b85b882aef4">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246836ba7661455ea504f59e31b98459_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzUtMS0xLTEtMA_a614a821-604b-4e8c-b4b2-72a16ccbbaa1">115</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1c052cc4f74b61be4c309541e38a86_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzUtMy0xLTEtMA_ba39a64c-dd9d-42fc-93f5-b7cadde99342">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1516d5f6bccc4706bf9051b3e301dca3_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzUtNS0xLTEtMA_a3a62dff-1ce7-41ba-8b39-20fae70339bd">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6830421fe254ed988b3fe026bd6113c_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzYtMS0xLTEtMA_46b86327-bdb9-4a26-b971-1c41bf5fe1c7">61</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805d69de042e4086a978510f436a9822_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzYtMy0xLTEtMA_2fa47621-6090-4fd3-9431-a8950d78b3d0">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6870f468772426088757f8a26d5a6e9_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzYtNS0xLTEtMA_fbbd7055-f813-4b38-b303-5440776a2ced">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593c3840adcb47bfb516fe38bcd2f1dc_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzctMS0xLTEtMA_c78ea155-fc23-4c9e-9888-fbed563c9e12">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78dbe2e542714ef7a4f706598fae075a_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzctMy0xLTEtMA_0b8ea4d0-3487-4f95-9647-ca6500420ba8">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483c42968ecc45ce84311d03c17955f3_D20180101-20181231" decimals="-6" name="mrk:CollaborativeArrangementExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzctNS0xLTEtMA_22996118-3e81-45d1-863f-1a8710698e16">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie47cee1fb9984770a9955c2c750b7a95_I20201231" decimals="-6" name="mrk:CollaborativeArrangementReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEwLTEtMS0xLTA_75980741-8eef-4dc7-a45e-a8a662e11f1e">65</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5318ed6e471f44528573063ca8254b68_I20191231" decimals="-6" name="mrk:CollaborativeArrangementReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEwLTMtMS0xLTA_0a09e9d6-2370-47b7-b2f9-ce4540b345e3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ac791388574e7691237e3081e536f7_I20201231" decimals="-6" format="ixt:zerodash" name="mrk:CollaborativeArrangementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzExLTEtMS0xLTA_4cd1cd25-8142-4b87-8bd7-c9700df662a1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bdad4b05278451caa2c67b1fd87b02e_I20191231" decimals="-6" name="mrk:CollaborativeArrangementPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzExLTMtMS0xLTA_9681877c-9221-4b0b-9f7e-f8699ebf6983">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payment.</span></div></ix:continuation></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_181"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzM0OTc_e4319cb3-e6bd-4f9a-85a4-40a40faee2f7" continuedAt="idcbba54c424745b6a9284a31b3100cae" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="idcbba54c424745b6a9284a31b3100cae" continuedAt="i1eb62b779ae944a8a83b9645d12af690"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, Merck&#160;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program now estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzkzOA_66c43fc7-f2a1-4270-8bfe-86b3f2e32a2c">3.0</ix:nonFraction> billion. The Company estimates that approximately <ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzk4Mw_2b8ce834-fedb-4443-9f33-7f4746edad38">70</ix:nonFraction>% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately <ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzExMzk_ec0d5a1b-9a73-4dd4-9099-a96b0a9a5fda">30</ix:nonFraction>% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i626dcc5c192746988b8441a68e30c032_I20211231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzEzMzc_9c93a809-3626-4e14-8af5-9d3e9feefe89">700</ix:nonFraction> million in 2021 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzE1MTc_928f01c5-1863-405b-bb15-2e70f786fda4">883</ix:nonFraction> million in 2020, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzE1Mjc_dceaf2b7-4066-4cc7-b1a3-110683019f37">927</ix:nonFraction> million in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzE1NDA_c4a78f5a-2c05-46ec-9a99-6ed0f8344472">658</ix:nonFraction> million in 2018 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2020, Merck has recorded total pretax accumulated costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzMyOTg1MzQ4ODczOTU_5da623ce-b9a0-47b3-8e96-6bc4f8a73a32">1.8</ix:nonFraction> billion. For segment reporting, restructuring charges are unallocated expenses.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i1eb62b779ae944a8a83b9645d12af690" continuedAt="idcd223e8d9c8432caa4ad09d22ecca57"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzM1MDY_45379230-f53f-42a6-a70d-45234b0eadfa" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191f68fbe0d14b05907bb1ab69c9f445_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzItMS0xLTEtMA_02e4291e-fa95-42a9-89da-a86cb6c5882b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241eb84e414f48f9aacd4316e70bae28_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzItMy0xLTEtMA_96297eb1-2454-4528-8350-4d477027cd00">143</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406f377346f2457ab0d54b35df3d1600_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzItNS0xLTEtMA_27b55f9f-15e7-4961-a128-90a0dd87d68a">32</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a50fbb06094261ad5ce78fa80bfdca_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzItNy0xLTEtMA_dbf2e172-705f-4ffe-86d3-ed65ce10e6ae">175</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525dc078af8495c9e5d272e8afdb6e3_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzMtMS0xLTEtMA_e130125e-d2c9-4dad-8aec-a4876651db11">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75a71a6eed4446ca55443b556bc6d5d_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzMtMy0xLTEtMA_e9113403-b857-4f6f-a50b-7c4247a474de">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac627a818264bfea847b4e9fcf4bb06_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzMtNS0xLTEtMA_5bb6eebf-d703-4d50-8fe4-880e570abd1b">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i309b4bb1ac054ea4a6873ed465501a43_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzMtNy0xLTEtMA_8e869c8c-0c8a-4ebb-bf9f-54587d8e2b86">47</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f1c852ca6946b889085c1d2eac8943_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzQtMS0xLTEtMA_88bc9192-d9aa-478d-948d-e2acb4e0e3fc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132c0ea6fd274dbcbbfe45e4bfa925ef_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzQtMy0xLTEtMA_567a8d84-a864-48e8-b2e7-b4a1e815f0d9">81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2907e5468544c409931e7a4c508414f_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzQtNS0xLTEtMA_fa2a5a20-019a-434e-8c85-365686c8d2df">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34ed105cdff4df1a7d378c513d91380_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzQtNy0xLTEtMA_3cca3aec-4120-45cd-819d-0089c44d6fba">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie186fc5433844dd6ba21127222d4697e_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzUtMS0xLTEtMA_33e6854e-387a-4367-a6b6-ddeea91db93d">385</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d28d8d5240b476db71452abf822049e_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzUtMy0xLTEtMA_80d7ce28-fba6-460e-976a-bc55879559b3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2d2fb55c0f461397ea5ac456124114_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzUtNS0xLTEtMA_65cdb183-b5cf-4994-a2a5-543db30ed7f9">193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4dd366030a40c8942fc0ce87bb62fb_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzUtNy0xLTEtMA_1c732700-0d0b-419e-be8d-be6a472b4ceb">578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzYtMS0xLTEtMA_288732af-f196-49df-a916-df9b44ebb482">385</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzYtMy0xLTEtMA_96cbf86d-a6a7-48fa-9624-4d77407779c7">268</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzYtNS0xLTEtMA_5355d73c-4a7a-45c4-9671-180fdd3dad46">230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzYtNy0xLTEtMA_46a46f19-4f3f-4a94-9c4a-1754df604ae3">883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fcec778c1341728db868452426a980_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzgtMS0xLTEtMA_7e4c807e-8054-4e29-850e-b8d98432d3a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c2a7a188ae4476beca9dc90f2118fe_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzgtMy0xLTEtMA_9bfeae5d-7a83-41bd-a39d-6ffd315b0300">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c96cd074f44412a6ee38d6cfb5e054_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzgtNS0xLTEtMA_9bbad44a-121c-40cc-9493-8c78133e5037">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88114076b7514409b6d5d5c9d41eec3b_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzgtNy0xLTEtMA_faecf9a7-c1d7-4d6d-b373-4bde0fff7c7f">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e4009b0313c49faafb6d57d35380369_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzktMS0xLTEtMA_07ed1289-a179-43b7-b4fb-035a623e2d26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16991361b0704afcb1a08545a7ef9345_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzktMy0xLTEtMA_ad1f08ae-85a2-4328-b71f-1cc94d2779b0">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0268c06921574bbdaf52522aad280467_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzktNS0xLTEtMA_67fbe6d4-e59d-40cc-8b6a-16a8c80e5c25">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e9a2d3136f48c5b13b1e298ae8df45_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzktNy0xLTEtMA_7bbc394c-ae53-44e0-9c83-0d6315630529">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab50b716a604e0abfd1dc584019060e_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEwLTEtMS0xLTA_a94f743f-d04d-4d34-bdab-f1ce432d4c5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1229966d621a49d0bdc08d199df3b425_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEwLTMtMS0xLTA_21727af3-9ad1-4446-b56f-af5dd929042c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7193bba0f545a0ba937a6de3f640ee_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEwLTUtMS0xLTA_b024b3f7-238d-4418-b75b-8d4c9569a1e2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f5ce19e15f46aeaf70c9fbe7e2be87_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEwLTctMS0xLTA_bc2b7599-a46c-4090-bae0-cc0716ec80e9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41552ef38afe4fba9be6c306a861bda0_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzExLTEtMS0xLTA_22f1d935-07a0-4bea-b024-21e31a69e02c">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e13eba63251417abb5c0ab7664c6e4d_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzExLTMtMS0xLTA_80dbc8b6-9ea5-46a6-8e50-0373b449e5e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83171e10413a49b188f9233c14af2273_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzExLTUtMS0xLTA_f1917633-1af8-4677-9923-cf87472588f6">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab6726b526241b7af9e46ef03b526d1_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzExLTctMS0xLTA_908187c3-ff03-44a2-a1d2-c0e0faa5dbbc">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEyLTEtMS0xLTA_719baddb-6cfb-455a-ab0e-02a27d1f7c05">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEyLTMtMS0xLTA_f79e5b9f-8d58-4e50-91d3-1c57d15608b5">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEyLTUtMS0xLTA_37fcd41b-3c7e-4f3e-be82-08f1c174ea98">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEyLTctMS0xLTA_b952461d-a9aa-4f2b-bbe3-b205b23a762f">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d20764941a4d70a43d94185021fb3e_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE0LTEtMS0xLTA_40fcd9bc-de33-42ed-807c-bdd88ad1e0c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i303d422323e846809130057830f40fa1_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE0LTMtMS0xLTA_06484d8f-c173-4e3d-8a3a-34ae242fece1">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i442a1ac9ec1d4a639edc93d1081da0b7_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE0LTUtMS0xLTA_1bac5ebd-1a33-49d2-ad82-f0582123259e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3185a39a2bf49e2ae8b3d6395304e98_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE0LTctMS0xLTA_88638038-b6c4-4989-a317-bd51155029c1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000067615c4c405d828fc57adc37155d_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE1LTEtMS0xLTA_eb7b8d9c-c3c3-4638-a653-a488734c642e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a6ba62d3268488b96375548230f0997_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE1LTMtMS0xLTA_a0fc66c2-3558-42cd-8181-4cc63b47003d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85c8e6a868e4feba214cf64258745f8_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE1LTUtMS0xLTA_38ae8bc3-3b3a-4696-95a3-9b78d932dc2c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc85f9026150482da03c6e8b08d5382f_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE1LTctMS0xLTA_8b965843-1614-44b9-aef2-c626bee30cd1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bac035ca3547929df24caa6baea983_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE2LTEtMS0xLTA_b15a5f05-e290-4b54-b7c3-01500bb03316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a886b5f1384f9e93e1e2055f773282_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE2LTMtMS0xLTA_2e3e7911-49e4-483a-88dd-d12c548b0ecf">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70612a50b7b04ed0ab9d05830ec20ad5_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE2LTUtMS0xLTA_1f7b18ca-d270-451c-aaf6-d44d4a21247d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5007327f71f42658a82bd6f754e52b1_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE2LTctMS0xLTA_09dc7e40-c554-46c5-aa5f-0a5963fcdb1d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29303b1ae4084cc1a9f349ed8d5206fd_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE3LTEtMS0xLTA_4e09b076-01eb-4351-a6cc-0cccec522a6b">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bb2d3506924e62bdb508461cb588a2_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE3LTMtMS0xLTA_e2c66b86-8255-4cb2-8e0f-cdf91547964c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e3e97d3c08440fbd570966142c7671_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE3LTUtMS0xLTA_debd6840-6bd2-4c60-9758-8476e46f9720">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4dd7b1ee8f549d5afc0e7f66c436a5c_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE3LTctMS0xLTA_6fe56626-84ee-48b6-938f-0a556aab86bb">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ea083b872444e39abc9269525384e0_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE4LTEtMS0xLTA_dc958efd-2b60-425a-bd29-b25196aca5e0">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9671977d7414c988b3c191e1c358988_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE4LTMtMS0xLTA_a75813d0-ca29-4cac-adbe-e6fdba905eb2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66a0f6babbd4e029e67a8693588a68c_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE4LTUtMS0xLTA_6f476c78-773a-416f-80a7-12ac19122bce">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE4LTctMS0xLTA_f934e8dd-1ea9-4357-a537-5ab43472c92c">658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2020, 2019 and 2018 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;13) and share-based compensation. </span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzM0OTM_8cd807e9-467f-43b8-96c8-aebe22abf99c" continuedAt="id1bb465407794f7dbf6b3b863f3b61b6" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:45.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0feec00e0c5476aab00efe202b2d98a_I20181231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzEtMS0xLTEtMA_5e34f7ba-aa6d-4d6f-b13f-ffa520014faa">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbecee173d84b5cbc3262dcf64fb42d_I20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzEtMy0xLTEtMA_9b627fa4-ad43-4be5-a5a8-8305e6573601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de74f34845e4ec4a02ce6ad4c118345_I20181231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzEtNS0xLTEtMA_22524acd-fb86-40ce-b0df-23793b21cc55">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzEtNy0xLTEtMA_9ef8bdc2-ea58-4c08-b58d-0e0ae6347a6c">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzItMS0xLTEtMA_965e1c21-1817-4af6-8eb9-1e85c9ad8509">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzItMy0xLTEtMA_14574e98-5ef3-496c-b2ce-93d06c77620f">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzItNS0xLTEtMA_241b2f20-e353-4cb6-b805-2eeee28787fb">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzItNy0xLTEtMA_432e7393-f870-4afe-9e4b-f7580509c7fb">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzMtMS0xLTEtMA_77580fcd-eb97-4a7c-b199-ba9ffb03f872">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzMtMy0xLTEtMA_0688b51d-0176-4c70-94b1-7eac43f8c073">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzMtNS0xLTEtMA_dd38aa74-8c15-407d-83f1-c0e9a5f459f3">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzMtNy0xLTEtMA_d9d758a9-1bdc-49a8-90bb-ad2a312880e2">461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzQtMS0xLTEtMA_541b8d80-0829-4b26-b10d-6f3edff20c8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231" decimals="-6" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzQtMy0xLTEtMA_68d09820-d83f-459e-bd0b-9aa0dc469331">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231" decimals="-6" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzQtNS0xLTEtMA_5ec4a302-a4d0-4e36-b094-e7bcc9ec238f">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzQtNy0xLTEtMA_1919779a-8b26-41a6-9e8f-58b9bf23ab92">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31627d70cdc54331b46aac1bc8263b56_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzUtMS0xLTEtMA_ae5d6903-f4f0-405e-b1d6-f97a762950f8">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f9cc96dc0b44a9b57239198ed1c72b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzUtMy0xLTEtMA_9e162ad7-9bb4-45e7-89e9-dd30d6906281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a3afbed0fc48ef8a9dcbf1de6c8ca2_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzUtNS0xLTEtMA_df73cfda-f6d3-4193-9acd-4b06fb633029">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzUtNy0xLTEtMA_95fcf649-7db4-4abd-8fd2-5216f33edc11">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzYtMS0xLTEtMA_ca01835d-47bf-483f-b5de-85b591b162e6">385</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzYtMy0xLTEtMA_5846aaeb-8e50-4d97-8f54-8464fe33184e">268</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzYtNS0xLTEtMA_9b0c5c72-3155-4c56-af91-24a64405e062">230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzYtNy0xLTEtMA_73f1e1ac-8fbd-422f-9312-6c714ac5f012">883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzctMS0xLTEtMA_172be874-81aa-45b5-b16e-4e4161f9d0fb">508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzctMy0xLTEtMA_4679f209-86c8-430a-b318-56c8dfc72502">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzctNS0xLTEtMA_c51ce50a-b203-40aa-9f8a-3b68b1cb518b">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzctNy0xLTEtMA_8866fd25-197a-49c1-b0cb-a645705a31f0">809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzgtMS0xLTEtMA_38752600-2021-4d6d-8960-8509855707fb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231" decimals="-6" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzgtMy0xLTEtMA_13b8da88-ffdf-48b8-86da-6e194ff2c004">268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231" decimals="-6" sign="-" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzgtNS0xLTEtMA_2eca5b89-fb93-47ab-a0ee-6689e8cadf0c">38</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzgtNy0xLTEtMA_2495d38d-a535-4af0-8875-1a5a0f92d5eb">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da63b07e7034274b8cf4a20a267d380_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzktMS0xLTEtMA_ddc7223f-64e5-4cc7-91f8-ea25ae05f6f5">567</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee164ec487d47deab4a2cb367a6d6f3_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzktMy0xLTEtMA_774d182f-9726-4db3-9ad8-7a53e1f29074">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a8fa9009f24eeaa07743fda8f3cd94_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzktNS0xLTEtMA_cd553789-743a-4168-9ac0-85a96fbb54b7">36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzktNy0xLTEtMA_e1026ae9-89d1-448c-81d8-9c62b66718c2">603</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="idcd223e8d9c8432caa4ad09d22ecca57" continuedAt="i017f2827345b48e0bc09b69b92831540"><ix:continuation id="id1bb465407794f7dbf6b3b863f3b61b6" continuedAt="i05a2ff1d57704eb28e8e79b87d4ede58">(1)&#160;&#160;&#160;&#160;</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i017f2827345b48e0bc09b69b92831540"><ix:continuation id="i05a2ff1d57704eb28e8e79b87d4ede58">The remaining cash outlays are expected to be substantially completed by the end of 2023.</ix:continuation></ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODE0_d7a8b70c-04f3-479e-9e4b-5f8530e83832" continuedAt="if63bfd6a6c734a209ccbc106cd318df6" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="if63bfd6a6c734a209ccbc106cd318df6" continuedAt="i758d0f9cb24b4bedb1b2e9c93ce0194d"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than <ix:nonNumeric contextRef="i6b4118cf8759442dba9e8fa1ea1b34d5_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:DerivativeAverageRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0ODY_c47fc3ba-8504-4592-aa32-615d64cbb43a">two years</ix:nonNumeric> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than <ix:nonNumeric contextRef="i221ed400ff5c4bea9e2d3cf8e4a80a94_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:DerivativeAverageRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzQ5MTc_0b208c07-a77b-4fd0-8eb0-3a980b44c1d6">one year</ix:nonNumeric>.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i758d0f9cb24b4bedb1b2e9c93ce0194d" continuedAt="i4e7c3ae18d5843749385d7b54623d40c"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODIw_7262aa58-47e8-4442-9696-c268fc2e34c3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:35.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f699b1657a4cecb4b718174538872b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtMS0xLTEtMA_2a2ed16f-37ec-4bf2-b399-4f6681556ac5">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ba11098240e441f8418597d2eaf880d_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtMy0xLTEtMA_6a0ca190-602b-4f46-a459-6ab7418fd8d2">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i430e6b977c1c4ef7a281ebd43d1dc672_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtNS0xLTEtMA_bd65418e-92d7-4920-a9dc-254390d0a9ba">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02369c098d4b43f2a421a2218e9d32f1_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtNy0xLTEtMA_adb29229-60cf-4f1a-b9b4-6727c498f087">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06d5fda89074431f97565335e930712f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtOS0xLTEtMA_bd3119f5-c796-4815-b2c2-3e04f4fdfc49">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0720d84e024817b305c556282b7dcc_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtMTEtMS0xLTA_96341a13-c1d3-42be-9e72-852d6f5d13de">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddec87a959fd4ae7a481edf7b41f776a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtMS0xLTEtMA_c780ed84-f20a-4b9f-82a9-31e284e11797">385</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f7e3451c9c24858a05b98ed5defa565_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtMy0xLTEtMA_8876b082-84d8-4471-9a9d-fd1bbc77b410">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id885d560ad0848c6bb060989b08b75e9_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtNS0xLTEtMA_e02107c7-132f-4066-94eb-f874fc9cfcce">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f64eeff8ec43de9cc630344108c010_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtNy0xLTEtMA_eb5ba7af-4466-4c50-815b-6f2b54c6e78b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae253e40a0d426bbdb3f0cab3da9b51_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtOS0xLTEtMA_08063687-3b57-4280-bf83-772d4cb8be3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b418fc03a0e44ceac8e72b427273960_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtMTEtMS0xLTA_07783ec2-a89b-499e-8aa8-95b1546b9ad0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020,&#160;<ix:nonFraction unitRef="interest_rate_swap" contextRef="i44610560536947e69f16077e7abce690_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDQ4NzM_33328a5f-5caf-46b5-b92c-8c1e194552a5">five</ix:nonFraction> interest rate swaps with notional amounts of&#160;$<ix:nonFraction unitRef="usd" contextRef="i44610560536947e69f16077e7abce690_I20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDQ4MTQ_8def4ae7-5343-4b28-a3c1-d28719947106">250</ix:nonFraction>&#160;million&#160;each matured. These swaps effectively converted the Company&#8217;s&#160;$<ix:nonFraction unitRef="usd" contextRef="i9b47f492e4384e57a7069964eaabf6dd_I20200229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDQ4Mjg_11a2daae-64bd-471c-ad5c-124f749fb707">1.25</ix:nonFraction>&#160;billion,&#160;<ix:nonFraction unitRef="number" contextRef="i9b47f492e4384e57a7069964eaabf6dd_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDQ4NDM_0a41eb94-134f-4423-8298-49a52971618d">1.85</ix:nonFraction>%&#160;fixed-rate notes due 2020 to variable rate debt. <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODA4_9217d411-3e4a-477a-9c22-9aa8b72809e6" continuedAt="i91dd67a3651a493eb607c1adff07b754" escape="true">At December&#160;31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: </ix:nonNumeric></span></div><ix:continuation id="i91dd67a3651a493eb607c1adff07b754"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia88f884909c041e5a8334a8a11ec5b1d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzMtMC0xLTEtMC90ZXh0cmVnaW9uOjA2NzU5N2Y3MTVkZTQ2MWQ5OWQzZjg3ZTA2MTFjMzExXzMyOTg1MzQ4ODMzNTk_b0d3b646-db20-4f90-a22a-7062a0885199">3.875</ix:nonFraction>% notes due 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88f884909c041e5a8334a8a11ec5b1d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzMtMS0xLTEtMA_8c20639c-97d2-48db-9b54-103a0f0dd142">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="interest_rate_swap" contextRef="ia88f884909c041e5a8334a8a11ec5b1d_I20201231" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzMtMy0xLTEtMA_20ebc595-263b-4b37-a1e6-f945482a375a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88f884909c041e5a8334a8a11ec5b1d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzMtNS0xLTEtMA_5a841e58-8720-44ea-9ba8-decfa4682e16">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc6d538660a64a929760160006272b4b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmFkMjZjZDI3MDAwZDQ0YjE4NTI3Nzc4ZDMwZTEyNzMxXzMyOTg1MzQ4ODMzNTc_52fade3b-abe9-4035-adf0-c82008d8a5e5">2.40</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6d538660a64a929760160006272b4b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzQtMS0xLTEtMA_35c7469a-1f8d-4eb6-9455-d52f91432387">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="interest_rate_swap" contextRef="icc6d538660a64a929760160006272b4b_I20201231" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzQtMy0xLTEtMA_495feb94-c78d-4767-9550-2e3bdeae17c3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6d538660a64a929760160006272b4b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzQtNS0xLTEtMA_b69aef2f-dff0-41d5-8a12-05b56a331bfe">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09b41cb38aa34740b1a603947ccefc36_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzUtMC0xLTEtMC90ZXh0cmVnaW9uOmM1YjMwMGZlMjQ4MzQxYjI4N2Q4NmRmNzVhYjVkNjY2XzMyOTg1MzQ4ODMzNTc_5fd77ed7-3e89-4adf-a04e-f0802535ab12">2.35</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b41cb38aa34740b1a603947ccefc36_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzUtMS0xLTEtMA_d3f88c0f-613e-42db-be0c-6147a48db853">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="interest_rate_swap" contextRef="i09b41cb38aa34740b1a603947ccefc36_I20201231" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzUtMy0xLTEtMA_de941509-51b5-42b8-b83d-9652710bd2ba">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b41cb38aa34740b1a603947ccefc36_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzUtNS0xLTEtMA_c3df9637-d03e-4ae8-87ad-2502bd54ecb9">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These interest rate swaps matured in January 2021.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i4e7c3ae18d5843749385d7b54623d40c" continuedAt="i8c500dbdcb294594a2400abf94347746"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODMz_9acca15f-4779-4606-945c-61e07411e2a0" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:43.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425ef8de5ab24cb2ae98743e10aff911_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzMtMS0xLTEtMA_3c03e83b-d997-457d-a019-04b825695249">1,150</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a2e005cb1174aa094650f2d67119a34_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzMtMy0xLTEtMA_d01f1ea0-c966-400a-903d-22d48ac36887">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425ef8de5ab24cb2ae98743e10aff911_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzMtNS0xLTEtMA_44459a0d-e9c1-46e4-85b8-6e6562749d83">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a2e005cb1174aa094650f2d67119a34_I20191231" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzMtNy0xLTEtMA_74abe577-9fc0-43b3-bead-7029c6f337b6">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcba6eceb0784bbe830143aade4b1cb1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzQtMS0xLTEtMA_c0fb0653-4215-470a-a232-2ed705fbc3b6">2,301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9d1e2142f94c22863ddaceb3677823_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzQtMy0xLTEtMA_fd3cde70-d3c4-4c40-a8f1-55dd70eef1d3">3,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcba6eceb0784bbe830143aade4b1cb1_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzQtNS0xLTEtMA_505c8dcf-d281-4067-a225-647125acdc25">53</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9d1e2142f94c22863ddaceb3677823_I20191231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzQtNy0xLTEtMA_033ff2ba-1eb6-4842-aee8-2821ff0e2700">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODEy_837be1e3-7852-40f4-8a25-bb12b4816213" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c598196c7c4f32b1024f98052bb448_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtMy0xLTEtMTAwODk_d148610c-a032-490e-b752-bd68cb9d9e13">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c598196c7c4f32b1024f98052bb448_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtNy0xLTEtMTAwODk_d00851f6-e861-441c-8627-611c759c9f9a">1,150</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94bc6f83a1ef4f3fb5f4a5ba0339bfbc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtOS0xLTEtMTAwODk_f9bdb087-4bed-4bfa-9dc4-d319abfc6c5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94bc6f83a1ef4f3fb5f4a5ba0339bfbc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtMTMtMS0xLTEwMDg5_f7f365b6-f919-444b-af28-2486ad1e0f1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b90c404414f4e0a961177cdf72dce77_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtMy0xLTEtMA_6687dce3-6e45-4894-b5aa-4f2ce5ea4178">54</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b90c404414f4e0a961177cdf72dce77_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtNy0xLTEtMA_bd09097b-5fb9-4584-b720-ccc2bb8121ea">2,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib018b37155eb42059b22223b5da9a50f_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtOS0xLTEtMA_871f9fbf-ac04-4551-8df7-49c94f1d0eac">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib018b37155eb42059b22223b5da9a50f_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtMTMtMS0xLTA_ab78a4e9-dd77-45ac-94ce-ac453a61d69c">3,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf93915f5e8748a5b702271482140b4f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzUtNS0xLTEtMA_77eb3631-4f1b-4cf6-996e-69947423ec40">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf93915f5e8748a5b702271482140b4f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzUtNy0xLTEtMA_b824122d-fbbd-43b1-a734-cf421a99b14f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad3e974650b43728fcd799e35eef6a5_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzUtMTEtMS0xLTA_3344afdf-700a-4aa7-823d-473826d59df3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad3e974650b43728fcd799e35eef6a5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzUtMTMtMS0xLTA_eb9a8d2c-073d-4431-849a-7cdd3203e3a7">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3739cd95e2441d399690968d9f5734d_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzctMy0xLTEtMA_8e0caa9d-fa20-4219-9cf3-2df463265f08">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3739cd95e2441d399690968d9f5734d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzctNy0xLTEtMA_62bdfead-1f55-4366-81de-ab2b433d7bfd">3,183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074470fe2c264f67899fe067fe1d0df8_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzctOS0xLTEtMA_fc95a458-226e-4894-ac6b-69cdd508ea98">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074470fe2c264f67899fe067fe1d0df8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzctMTMtMS0xLTA_3e96a81e-de37-44ef-8f0d-c711c813e8e4">6,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26449e4f0e6e4176aa31d97fbc42b586_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzgtMy0xLTEtMA_637e62a0-6a51-4cc4-88ed-aae56d76559d">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26449e4f0e6e4176aa31d97fbc42b586_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzgtNy0xLTEtMA_a88384a5-2440-4802-9744-c27448c61849">2,030</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f968bae9794c1fb41d0984eda03c04_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzgtOS0xLTEtMA_573d4847-2f61-488c-9f25-335f3853ec30">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f968bae9794c1fb41d0984eda03c04_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzgtMTMtMS0xLTA_bc35d0e2-6cc9-4e4d-bb45-abf4bbba1f06">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98b3a13c41429d91995e92273e4703_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzktNS0xLTEtMA_5367a58d-85c2-4b07-98e6-0b07f0d07ef0">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98b3a13c41429d91995e92273e4703_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzktNy0xLTEtMA_76079954-dec6-4aef-b152-0f3a8b7dec72">5,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibefd44c960cd430e9696cd56751dc0b8_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzktMTEtMS0xLTA_1721da03-56fc-4811-9f28-f5fd10bd7d9c">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibefd44c960cd430e9696cd56751dc0b8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzktMTMtMS0xLTA_d4748b7f-023a-41d5-9d46-08d2711895bc">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189cc2bba23447f08495ab8fd74daf9b_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEwLTUtMS0xLTA_d4776586-4dae-42d9-8070-1dd3452ee360">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189cc2bba23447f08495ab8fd74daf9b_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEwLTctMS0xLTA_013cbe56-9c06-436f-8d2c-d1e973d51908">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b006db8f5ac4d31aa4182239c7ce684_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEwLTExLTEtMS0w_ffc73bb9-12b4-4fbd-916c-710b8179244e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b006db8f5ac4d31aa4182239c7ce684_I20191231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEwLTEzLTEtMS0w_b3c1a6a2-e21a-4cc7-9613-73ec3722bb6e">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c27f7451db44bf808afb15b4e436ff_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTMtMS0xLTA_2f5844ad-8fb6-4452-9d7b-b7a02c0988ef">112</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c27f7451db44bf808afb15b4e436ff_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTUtMS0xLTA_ed56629f-78e8-4641-8623-9a573622e450">218</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c27f7451db44bf808afb15b4e436ff_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTctMS0xLTA_a955c4c4-2ccc-41e7-90da-8cc2db657369">13,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4e1f66a9354462a9d22b56d9240389_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTktMS0xLTA_ef6a8320-4649-4c8b-8555-c28307bdaaf9">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4e1f66a9354462a9d22b56d9240389_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTExLTEtMS0w_5a1fc1b4-b232-4e42-8c5d-f79e7afcb2d4">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4e1f66a9354462a9d22b56d9240389_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTEzLTEtMS0w_8e2cf141-3dbb-46f8-8cbb-f19ec4c4f4a7">14,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7a599f496545fba9341a054b669c26_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEzLTMtMS0xLTA_7e3e54a9-39fb-41ce-97ec-7fa4bde5f238">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7a599f496545fba9341a054b669c26_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEzLTctMS0xLTA_f826d55a-fcaa-4d2c-ab53-41315f121854">7,260</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1a474906bd4f89bf006e7bc9fe12be_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEzLTktMS0xLTA_131bc4cc-8c36-4c57-924f-170cd905765d">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1a474906bd4f89bf006e7bc9fe12be_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEzLTEzLTEtMS0w_6282439e-3a5b-4d65-9cbd-e5bd5c6b1850">7,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c22c5b30fa04d829f43ad58f4fe0781_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE0LTUtMS0xLTA_0d2a26b1-8a35-4a6e-a480-60dbfedea1ca">307</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c22c5b30fa04d829f43ad58f4fe0781_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE0LTctMS0xLTA_eba4d287-7d73-4db8-9136-6539c79f7fe6">11,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3168f8864f4f08853f9c776e12e5e8_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE0LTExLTEtMS0w_f19545da-819e-45ec-8064-2676d4b32ac4">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3168f8864f4f08853f9c776e12e5e8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE0LTEzLTEtMS0w_eb679e85-dead-488b-adec-06821fa8f4c6">8,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b004e801174cc4a3f896b5ed79a5e3_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTMtMS0xLTA_7590204e-f13b-4e5d-bcda-23bbf92822e7">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b004e801174cc4a3f896b5ed79a5e3_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTUtMS0xLTA_f36bb061-27a6-4d29-a72c-ec4b79c1eb76">307</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b004e801174cc4a3f896b5ed79a5e3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTctMS0xLTA_3c549ed3-c75c-45af-a195-7cc237404250">19,070</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686e5291737847fda61bb04fa2bb680a_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTktMS0xLTA_64440255-05fe-4683-8dd5-3d2386f75539">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686e5291737847fda61bb04fa2bb680a_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTExLTEtMS0w_946ca908-afe8-491a-aef2-3dabd21c731e">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686e5291737847fda61bb04fa2bb680a_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTEzLTEtMS0w_6376eb2c-ee7e-4d31-9d32-3db65696398b">15,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTMtMS0xLTA_03627bb9-82be-4187-a0be-d80cc3b72364">182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTUtMS0xLTA_1a6be7ed-1684-495e-a958-01207bb6b911">525</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTctMS0xLTA_0ee319b3-c526-49eb-accf-c80dbf021df7">32,784</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTktMS0xLTA_e3310957-74d1-4e43-87e6-7cf2df81be9a">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTExLTEtMS0w_530cd366-bb12-42bd-bb69-25682d4fe5c2">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTEzLTEtMS0w_3e0e2dc8-b439-4c1d-a847-73010927cda2">30,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODAw_fe3e31dd-ae01-435e-a125-be6a22b57803" continuedAt="i5967c1f8ec3845019908ae8cd8863040" escape="true">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i5967c1f8ec3845019908ae8cd8863040"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:59.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzItMS0xLTEtMA_cacb195a-0232-481f-9c39-645290e36a5b">182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzItMy0xLTEtMA_123fd4bd-f5e7-44d3-ba0b-c4762097a791">525</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzItNS0xLTEtMA_a24627b7-66ca-4715-ae96-4392e09dd570">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzItNy0xLTEtMA_2622188d-1183-48d6-a682-19c95e86bd0c">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzMtMS0xLTEtMA_f201eafd-1062-4038-be3a-d4c07ea30e94">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzMtMy0xLTEtMA_689e3fcc-dcb4-4639-a3ff-ea3cd45754dd">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzMtNS0xLTEtMA_971b08bc-5cb4-418c-9639-feaa25eec079">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzMtNy0xLTEtMA_2cc967be-5fcf-4e17-a539-c9325c2e863e">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collateral posted/received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzQtMS0xLTEtMA_1884d6dc-0c41-4aa8-b484-f80cb659ee31">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzQtMy0xLTEtMA_b279ccd3-4b2b-485e-b514-741ddb61c148">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzQtNS0xLTEtMA_4aa4dd61-fc88-4334-a413-42842b97ac40">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzQtNy0xLTEtMA_968b6c5c-ef8b-45b4-b1b5-d71a21b8c64b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzUtMS0xLTEtMA_ebbcb85a-10dd-412e-8920-b749bfb49de4">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzUtMy0xLTEtMA_39a5c428-03cc-41a7-9d57-be47575e2abb">333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzUtNS0xLTEtMA_ceb50295-a36c-4bdb-bba5-96ab4d207889">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzUtNy0xLTEtMA_069b0dda-f353-407d-a597-8eb13d9af08c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i8c500dbdcb294594a2400abf94347746" continuedAt="iaf13e23ddd8e40c6b6e6e996573a6c26"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODUz_c25603ff-8dfb-4618-931b-3c52127ea6c6" escape="true"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMS0xLTEtMA_928aba44-74cd-4b40-929a-87e128386ca6">47,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMy0xLTEtMA_453d6db4-b273-4178-b295-000b6310fcda">46,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItNS0xLTEtMA_ca10a547-d651-4d73-a7c5-94b006800944">42,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItNy0xLTEtMA_27421474-e1a2-4ac6-9f7b-9ab5642a22c1">886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItOS0xLTEtMA_9977bc6f-2f54-4c6e-a2d1-d17428fff838">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMTEtMS0xLTA_66efc25d-24fb-4558-a494-badf15136a95">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMTMtMS0xLTA_8a5d581e-9619-41d8-b40a-79038b8341f1">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMTUtMS0xLTA_29171df1-950c-4170-b96f-c12396dfa57e">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMTctMS0xLTA_d9e071d4-f60f-41d8-8668-86fe9279350c">361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2bc89ac3e3745259da485c0e123fdb6_D20200101-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzUtNy0xLTEtMA_d8b5268d-f0e2-43b6-b373-26859dd7c2bf">40</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60742cd64004ea490a84445a5be282c_D20190101-20191231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzUtOS0xLTEtMA_70fe74a4-d46c-4230-9288-0c262a414c2e">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ab5c661a48b4562bbbc071a962b540e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzUtMTEtMS0xLTA_4743dc85-e509-4419-ba26-0fe8ef3a2106">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2bc89ac3e3745259da485c0e123fdb6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzYtNy0xLTEtMA_4888a5de-0909-4f84-ae44-0107b813840d">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60742cd64004ea490a84445a5be282c_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzYtOS0xLTEtMA_dbd97c41-201c-4396-967c-d77307dee624">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ab5c661a48b4562bbbc071a962b540e_D20180101-20181231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzYtMTEtMS0xLTA_a09e9029-3176-4801-b228-c044ed0f74fe">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74f699b1657a4cecb4b718174538872b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzktMTMtMS0xLTA_df4023d2-8545-42bc-bbe2-131f97d905ec">383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba11098240e441f8418597d2eaf880d_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzktMTUtMS0xLTA_690edb5b-cd05-4873-884c-467e52367d3f">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i430e6b977c1c4ef7a281ebd43d1dc672_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzktMTctMS0xLTA_b89f7009-a295-443e-ac9b-6fc4e707914e">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab64708b390a456aa95dfe12bee43bbf_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTEtMS0xLTA_9fff6d7d-3ba1-4364-95f9-a881d3b2fa22">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6219e2385d4b37b8a73d0fea710bbf_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTMtMS0xLTA_85042f88-3012-4d6f-b20a-aa8463b3dfee">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f228e2c11eb477aa93be52424102e54_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTUtMS0xLTA_d71abc0c-7188-4997-a83d-848210cde072">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f699b1657a4cecb4b718174538872b_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTEzLTEtMS0w_33cf328d-a55f-4449-ae8e-f30c18f0cdb2">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ba11098240e441f8418597d2eaf880d_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTE1LTEtMS0w_c908e786-f0a7-4900-b554-5415f91ef753">255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i430e6b977c1c4ef7a281ebd43d1dc672_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTE3LTEtMS0w_33b3f797-64c2-416c-a4bb-ccb8aa2b97c6">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2bc89ac3e3745259da485c0e123fdb6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEyLTctMS0xLTA_b1cadb0d-098e-4a13-9f6e-7fdf630dd380">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60742cd64004ea490a84445a5be282c_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEyLTktMS0xLTA_f597edca-96d4-411f-9635-7c5ec7cca5e7">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ab5c661a48b4562bbbc071a962b540e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEyLTExLTEtMS0w_8f938933-af5d-44fc-b876-82d236dd7781">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34a833d327f8451596b0800e5d644c7a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEzLTEzLTEtMS0w_e8aa59af-b9c3-4403-9de1-3463fdd57c42">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17a1659884f848f5aabd436539f2bf47_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEzLTE1LTEtMS0w_995c1dcf-7833-4ca7-956d-65c5dc4cb554">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1c1f1933cbe418ead09d219d10cabe4_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEzLTE3LTEtMS0w_6a3a9f2d-ea53-4197-96e1-d13f57471e4c">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5Nzg4_b3b0ceb0-64bc-4172-8d80-d44308954fb4" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02369c098d4b43f2a421a2218e9d32f1_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzMtMy0xLTEtMA_d547367c-8119-4d42-8dca-0fc3082922b1">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d5fda89074431f97565335e930712f_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzMtNS0xLTEtMA_6b03bebb-6286-4cd8-81e4-5a1b368b666a">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0720d84e024817b305c556282b7dcc_D20180101-20181231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzMtNy0xLTEtMA_964fa3a9-0410-4126-bc1d-f8715e025c46">260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96051c5103e4b92b51fcc3dabaec98d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzQtMy0xLTEtMA_e374c9ec-7971-4e5f-9b4f-d59a08f0c8d1">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9756dfe40bb4a4284b0062e05aefad9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzQtNS0xLTEtMA_227639b2-025a-4819-b97b-c7f724e48255">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98079bd7917c45ce82bcf778574127d0_D20180101-20181231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzQtNy0xLTEtMA_62d7a820-c888-4efc-8b57-936f48af472f">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d9aaa6d14d47c08624bcb65746c4ed_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzUtMy0xLTEtMzU0Mw_c247f3b6-c4c9-40a4-897c-69930123fefb">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ffc89462f2430192ac1ba5cb28f8cc_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzUtNS0xLTEtMzU0Mw_e1f10276-3402-473a-bf01-e160cd453e1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157e712600dd4995a5373a06637c27fa_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzUtNy0xLTEtMzU0Mw_8bd75bf6-9ddb-46e3-b6de-86aeb84b3dd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dedde47b1a347a0971fdd6194fcae67_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzYtMy0xLTEtNTc0Mg_124ecaf6-954f-4695-9cc1-f3401adab201">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af59371761f403683996b2f9e8ed882_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzYtNS0xLTEtNTc0Mg_797219c0-9803-49f0-94fc-66c172662134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248775075bc545c390593609d97824a4_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzYtNy0xLTEtNTc0Mg_71e274e5-7745-4dcd-bdc6-c50fdc7db156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company estimates $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzkzNzc_c52b2f7d-c1c1-4d2e-ab52-236b209ae182">331</ix:nonFraction> million of pretax net unrealized losses on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="iaf13e23ddd8e40c6b6e6e996573a6c26" continuedAt="i7dde90a1e5c74eee9970ce4a7244e904"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5Nzcx_5eadd3d3-0e94-4fd8-8e4e-32f3f89a6751" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:27.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b72497910f4f5b8362034975eafe4d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMS0xLTEtMTAwMjQ_274ec87e-f065-4b8d-b791-44a918960273">84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b72497910f4f5b8362034975eafe4d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMy0xLTEtMTAwMjQ_21b176e8-41a5-4ee4-8189-31a9548fe371">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b72497910f4f5b8362034975eafe4d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtNS0xLTEtMTAwMjQ_eed3e629-0e88-47fa-bec8-e06c3e41893c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b72497910f4f5b8362034975eafe4d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtNy0xLTEtMTAwMjQ_f7fdeebb-bbf2-4e43-9d08-16a2a474150f">84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac680b79731d4242af1965a13712ffcf_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtOS0xLTEtMTAwMjQ_64b84ce2-0fe2-40f7-8cf6-edabbc3a11ee">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac680b79731d4242af1965a13712ffcf_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTEtMS0xLTEwMDI0_3c98f1b4-8de8-4c3e-afcb-c51e6466ce6b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac680b79731d4242af1965a13712ffcf_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTMtMS0xLTEwMDI0_f97f305c-607e-43c9-a5ff-bfc0cd667b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac680b79731d4242af1965a13712ffcf_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTUtMS0xLTEwMDI0_103ca58f-3e37-475f-b45c-687201396143">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMS0xLTEtMTAwMjk_f52b0436-af7e-4b1b-b101-ff4271ac82c1">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMy0xLTEtMTAwMjk_d6a45170-3453-48e0-b206-528ef9b212bc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtNS0xLTEtMTAwMjk_10c54057-b4fd-422e-b260-7b699c0cdfde">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtNy0xLTEtMTAwMjk_e8714e61-6bbc-4f8a-a8a4-d6f237c0273b">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf79a13e56b4dacb00d6c54493be948_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtOS0xLTEtMTAwMjk_05240410-c693-430b-adca-a0072583dfc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf79a13e56b4dacb00d6c54493be948_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTEtMS0xLTEwMDI5_8dd264d7-4945-4073-a138-296fe587fbca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf79a13e56b4dacb00d6c54493be948_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTMtMS0xLTEwMDI5_d5efaa95-4f4f-49c9-9973-c03edcf92a6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf79a13e56b4dacb00d6c54493be948_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTUtMS0xLTEwMDI5_0b503ebb-9dcc-4c8d-84d4-be330b372875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c514e2dbdd434aaf832d950c66924a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMS0xLTEtMA_b8960c46-36e3-4781-9e0b-079e34cd210c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c514e2dbdd434aaf832d950c66924a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMy0xLTEtMA_c9e4c25c-a9e7-4f49-85ee-ace69678de6e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c514e2dbdd434aaf832d950c66924a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtNS0xLTEtMA_c421ca41-55e3-437a-bf3c-3e770b918f44">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c514e2dbdd434aaf832d950c66924a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtNy0xLTEtMA_9af239f6-e090-443c-b9d9-40a97b88ee9b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4120124e4b9b4d7082f37a0ec3592298_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtOS0xLTEtMA_44e05d12-0af6-4aaf-8e4d-fba11d51a82c">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4120124e4b9b4d7082f37a0ec3592298_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTEtMS0xLTA_14f8bc0d-ce0b-47f8-a4a1-feed6906207d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4120124e4b9b4d7082f37a0ec3592298_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTMtMS0xLTA_2411264f-2c57-4c05-8103-c4d19fc7a585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4120124e4b9b4d7082f37a0ec3592298_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTUtMS0xLTA_a5f20660-be75-4e67-9221-a08026f83f3d">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc62c243cd0e4d5686c1f797407cf679_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMS0xLTEtMA_248ee199-eeff-45fd-af7f-720592234cd3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc62c243cd0e4d5686c1f797407cf679_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMy0xLTEtMA_0e424543-b6ef-4c81-afd2-ad8ca4e8ec8e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc62c243cd0e4d5686c1f797407cf679_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtNS0xLTEtMA_0fc0504e-a1ee-4095-9242-a033d91746ea">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc62c243cd0e4d5686c1f797407cf679_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtNy0xLTEtMA_10ac4ed3-f996-40d1-8d97-14c685619c6a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd51a21a4b0451281d898defd8ebb87_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtOS0xLTEtMA_335fe4e6-573b-4a84-86c4-b1213a492f2d">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd51a21a4b0451281d898defd8ebb87_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTEtMS0xLTA_6b2e2930-0b06-45ad-ada8-28a5efcf477a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd51a21a4b0451281d898defd8ebb87_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTMtMS0xLTA_d372f63b-174c-4512-a89f-2460b5d1d7d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd51a21a4b0451281d898defd8ebb87_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTUtMS0xLTA_e4886b98-34a8-4ee1-8b6e-a81b7fdc5910">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a43afc3c18842a8bfb574432eb8396b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMS0xLTEtMA_08543c00-99d6-48ca-831f-459adb5e895e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a43afc3c18842a8bfb574432eb8396b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMy0xLTEtMA_09154273-0393-4bd4-bf0d-2b861f15fe43">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a43afc3c18842a8bfb574432eb8396b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtNS0xLTEtMA_6449c74f-827d-42ce-bd52-9e7f440e6b26">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a43afc3c18842a8bfb574432eb8396b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtNy0xLTEtMA_68c782e3-8b3e-4432-91aa-1d62b144403b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f107554e5944c88d03135cc0d5646e_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtOS0xLTEtMA_d6bf2683-1f2e-48ad-a186-8d055234996b">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f107554e5944c88d03135cc0d5646e_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMTEtMS0xLTA_d39227c2-10e3-4e07-b25a-87f27c2e491c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f107554e5944c88d03135cc0d5646e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMTMtMS0xLTA_8585dfed-b359-4159-8141-551c70ed11f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f107554e5944c88d03135cc0d5646e_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMTUtMS0xLTA_0d3a1b59-503b-42ae-be85-c4ae66a6ee21">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMS0xLTEtMA_7bd1c840-9e85-4af8-b551-dd28b276898d">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMy0xLTEtMA_2fa7aec1-b3a6-4775-9339-0f8fd3e2d023">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktNS0xLTEtMA_f7ad325c-8b7c-4624-9074-b488ed298323">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktNy0xLTEtMA_d449e618-bb7e-4c8a-8253-d05a775fddbc">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktOS0xLTEtMA_1f0acae8-d1d2-40bc-8a7e-2e4592486d7a">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMTEtMS0xLTA_588f3ab5-ab36-4309-867b-cf331dbb98fb">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMTMtMS0xLTA_e301f45d-7568-43e6-935d-3950bb029f03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMTUtMS0xLTA_35d1ce16-95b3-46af-a2f9-fe687142f12c">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzEwLTctMS0xLTA_07b8e89b-032b-47d7-a133-dcf92454173b">1,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzEwLTE1LTEtMS0w_9c12887a-6abe-4fae-bd91-36e002212305">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzExLTctMS0xLTA_fc3c4da7-17fd-4306-a4f7-2f980dbb1671">1,876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzExLTE1LTEtMS0w_df7eba1b-0788-452b-8a7b-768ad3bdfe71">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMDA4_77514532-6640-4563-b6d0-14ee48afdbf1">163</ix:nonFraction> million during 2020. Unrealized net gains recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2019 were $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMTQ2_655556df-de92-48e2-a5e7-ebab9c739ac0">160</ix:nonFraction> million during 2019.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company also had $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMTk3_86efe730-0cd3-423e-a6e4-0c60bab02ab8">586</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMjA0_1645ac46-755c-4172-90f4-f3f3eee3a307">420</ix:nonFraction> million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During 2020 and 2019, the Company recognized unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMzcy_b6435cde-c979-4d2b-83a2-5c82d5a89273">62</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMzc5_3eddec3d-ec51-4a7c-a9d7-01a91ddd58d3">20</ix:nonFraction> million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on certain of these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee. In addition, during 2020 and 2019, the Company recognized unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwNjU3_492a88de-4ce3-4630-b983-2dd6cbdc1941">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwNjY0_2e5fe37b-8779-4116-ad69-4f1c49f18963">13</ix:nonFraction> million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, related to certain of these investments based on unfavorable observable price changes. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values were $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwOTgx_4b91cf54-539a-42b9-a72b-dde1027ea19b">169</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwOTg4_0e52b0e2-3a2b-4320-a15c-79d2b05ff867">24</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i7dde90a1e5c74eee9970ce4a7244e904" continuedAt="i5d8b9dbf323240f79b9729c63d3b571a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5Nzg3_7e0c0709-dc0f-4d3d-bb81-242237cbe75c" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:18.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bd171f0c0d4bf7ba9049b6fe49d4e4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMS0xLTEtOTk5Nw_3227cda7-8e70-4ed8-9d4e-b09a9bb56e51">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51875e63a23141e799f3c721b2e98c35_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMy0xLTEtOTk5Nw_45184f63-0d66-43d0-9919-aecd2e001f19">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97372e9ec431481e8d2ad41c37299b60_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtNS0xLTEtOTk5Nw_9e705590-0c28-4688-9258-af34b0205cec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9818f3ecec9d4b5da3c91600169a5ea9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtNy0xLTEtOTk5Nw_6dbd25b9-6584-4f17-9f04-da51e78220fe">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5099d5a15b8741809c09bd89ce675d38_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtOS0xLTEtOTk5Nw_b116b62a-1f92-4b2e-a079-0682f2fc6eb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449d46bca2a640e3bf828a985bf5b6e7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTEtMS0xLTk5OTc_afefde9f-3653-4285-8bc6-11a55f11318c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f95efcbb854b47837ed0e30678717c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTMtMS0xLTk5OTc_d76f9dbe-8631-4e83-a2f8-4a68e9faf9e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0eb091d5f2d4f76bfd8bf94afcd2d03_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTUtMS0xLTk5OTc_653882e5-4f7f-4331-9fc8-a9053a5c1f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d003a9b64b24e768af4f068b938a189_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMS0xLTEtMA_ce49bfd2-cae1-4e6c-9372-3073d93ff0a2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6bc76e46da449c9f8e5b9c566ed471_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMy0xLTEtMA_79962f5d-6727-4014-8375-fdd53c337eda">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca9ceeab0e241baa78dca85e021d03b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtNS0xLTEtMA_c86d76dc-3c35-4820-b667-4e4e4ff529c6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5979ae1b6734b4482a704ad0292fd9a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtNy0xLTEtMA_91dc8ea0-6efb-4572-af87-c4de583f96bb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4889e793f60e4d05b6ddd2f8025a83f6_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtOS0xLTEtMA_7aa44d88-5fb4-4910-a69b-69faab8f9496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3019315f797d4f6da1bf695e1d0e2adb_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTEtMS0xLTA_b2dcdedc-d54a-4966-97c3-ed18b5d6fbba">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f168f035dcb4b52b45a1f046f60c471_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTMtMS0xLTA_3f9a0635-bb71-466a-b4f9-21cd54a1a734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678944a90428428ab1d1f74e0f90e565_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTUtMS0xLTA_8a22c067-f1fc-4e6b-8a97-ce065139700d">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86760add50e540c9915bc96dfade2cd7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMS0xLTEtMA_7d580b0a-a181-452b-961e-25a235f31400">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic305af5c5eb64be5b8250cc700e82e3b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMy0xLTEtMA_4f455577-c64c-409e-bb11-d95899319fc2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9480f02ab9e4065aeae4c973801cd09_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtNS0xLTEtMA_b213722d-aff0-4333-b0e9-30991bb253ed">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6378f9682e49e986ad883f181e19c4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtNy0xLTEtMA_e8f5bad5-a8a3-4b67-bc35-7d74b59833e7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61514cbea7e4ef19f040db41edfae2e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtOS0xLTEtMA_3fb25c5e-c147-4be6-bce8-a1a5fff1cb01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581be677b2e04a02926271e7f77db17e_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMTEtMS0xLTA_7330f1fa-85eb-46c5-9057-36cb99fc9be7">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe2de3ba6564509844cdb877e313935_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMTMtMS0xLTA_ec599299-8afc-4c98-a194-27cebf87af3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f126cdd894e4acf97878c636bbdca1c_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMTUtMS0xLTA_7ac1d9fa-6d33-4ab9-aa1c-e292f5075e07">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8493f72d249346a0be32eddede66afca_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMS0xLTEtMA_845debda-dcc8-456d-9519-0cc5ed212d5e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ab1f5da5bd49309c4078402b7bc49e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMy0xLTEtMA_a6ef7ac5-34d5-406a-8b95-e22595bd3b30">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40443158b83241babddbc35d611fd36e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctNS0xLTEtMA_7a1fd895-c202-402f-ab87-74d6ab518153">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9e331ce86b43ab95f546a5ce865a32_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctNy0xLTEtMA_4c6ea665-565d-414a-95cc-799e66e390e0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a51ca67bac440cba8e01beb97c8d5f_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctOS0xLTEtMA_9b7cd29f-abea-46c0-94d0-7bdd9e4703f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7788d5f200f54b93a9c93e43368ebea2_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMTEtMS0xLTA_5ca1ae38-281b-4307-828f-2c118e3dcca9">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6c5c42bd2346b1abb083ce9edcfe4d_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMTMtMS0xLTA_b12c7a61-a9f2-4648-a2bb-da0772316242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6b30ab1c0a4434bbad28238f32d3d8_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMTUtMS0xLTA_0e3cf87d-c499-44d5-8253-29fe1843cbff">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf6232f74fa41139923e59a424dc61f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMS0xLTEtMA_35e6bb4f-0c68-42f8-ae06-96759586d133">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12d18ccfca34d6bb8faff8660c8a76a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMy0xLTEtMA_ebfcb9f0-66c4-4db9-95ce-ebc6c78514ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2128132540244319b6739b88b72e0cf6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtNS0xLTEtMA_5acdca0a-f14a-4d3f-9a8d-d913d922d593">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403305af9ece44c9b22ee241dbf53d51_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtNy0xLTEtMA_a51aa884-f621-4f70-a5f0-c43ba85c4331">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec3c8f6c78f649b2b6d8249918906936_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtOS0xLTEtMA_57797c8f-84c1-4073-8d68-71f2c6e2477a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2903ba97df754b6ba63aa316be7a875b_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMTEtMS0xLTA_f63caa42-ead0-4542-9718-9dc5ce5737d4">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b4a3504a044aa29ba5b89de4a75a7b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMTMtMS0xLTA_ff35d89e-7cf1-4130-bbad-5b3bff936a9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02029bf2987943d7b527f9fbbfbaccac_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMTUtMS0xLTA_e6af1eaf-1942-4762-a629-2f03cad222c9">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f02989f1094e35a4db4abadae73636_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTEtMS0xLTA_7483e518-735e-46ac-9443-358f5f962c7a">780</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c58a9e62e44be893953a1c54696515_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTMtMS0xLTA_14633879-114c-4227-8f0c-419068a4afa6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8a59217086413e83da0688d9c2171d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTUtMS0xLTA_54137acd-542a-4f7e-99fa-1755247569df">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a6a626d7d64f7f815bfc2849d97a81_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTctMS0xLTA_0350b4c7-0357-40dc-84b9-53dc19c01def">780</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e33912988a248bc8246486df6397715_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTktMS0xLTA_d62d33ee-49cf-4955-af69-855e1bbb52d8">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabecd6bb38834f98b4af258e1624a7d1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTExLTEtMS0w_38ab85ef-6f83-4f59-8802-12a47d645b3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8acf6daac21d4c88a48854a1221633c2_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTEzLTEtMS0w_8c6d46ba-1afd-4f41-b819-93caecb79c37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517c433fbeac4a0d877922b89aa5b92a_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTE1LTEtMS0w_1822c07a-acc0-49cb-8897-6962375b9feb">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTEtMS0xLTA_e6e4d275-7fae-49bc-880f-b640153f2f25">780</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTMtMS0xLTA_06ae85ce-b08d-4bf9-8f68-b66e48ddaec4">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTUtMS0xLTA_496c8ad3-f6d4-49e1-a43a-4deb3afe552a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTctMS0xLTA_f1f92e7c-660c-4a12-9f24-1471fd92df84">785</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTktMS0xLTA_2d985dd9-5585-41c9-937e-bba3f480632a">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTExLTEtMS0w_fc4c2c17-4edd-488c-a98c-9a00f1ca07a4">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTEzLTEtMS0w_82938805-a24f-493e-a49e-80953167fb1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTE1LTEtMS0w_bbc33780-e279-4126-bcc6-efecacf9ac8f">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf6232f74fa41139923e59a424dc61f_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTEtMS0xLTA_ea2e7f6b-0c61-4925-a2cc-4f60cbf4d23d">84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12d18ccfca34d6bb8faff8660c8a76a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTMtMS0xLTA_da160cda-a636-4edd-b83d-2d885a33042a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2128132540244319b6739b88b72e0cf6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTUtMS0xLTA_d151b931-088a-464f-9e5a-ac93f9a615fb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403305af9ece44c9b22ee241dbf53d51_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTctMS0xLTA_991af96a-4700-4da5-8110-32f690789d7a">84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec3c8f6c78f649b2b6d8249918906936_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTktMS0xLTA_a42d9b81-2866-44e7-8a63-ed3694421c17">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2903ba97df754b6ba63aa316be7a875b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTExLTEtMS0w_7a2c6452-b856-4af8-90fd-665d456a93f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b4a3504a044aa29ba5b89de4a75a7b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTEzLTEtMS0w_b079b169-e55e-4f52-920d-bfdfea1a4462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02029bf2987943d7b527f9fbbfbaccac_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTE1LTEtMS0w_fb6d189d-6116-4a78-b9f8-571dc87d96bb">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f02989f1094e35a4db4abadae73636_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTEtMS0xLTA_a9c37b29-7ebc-482f-9895-dafe8680bb86">1,007</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c58a9e62e44be893953a1c54696515_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTMtMS0xLTA_4254c96f-754a-4c3c-a996-dea82d713bcc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8a59217086413e83da0688d9c2171d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTUtMS0xLTA_abb08e3c-fad6-492b-b553-0a05ae4de20c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a6a626d7d64f7f815bfc2849d97a81_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTctMS0xLTA_1223daaa-5dc1-4071-a272-bfee4009883c">1,007</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e33912988a248bc8246486df6397715_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTktMS0xLTA_bb111b1d-f909-4937-b926-8ad9a3c27957">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabecd6bb38834f98b4af258e1624a7d1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTExLTEtMS0w_d8301f5c-6f71-4cd7-b1ae-1149e7d3eae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8acf6daac21d4c88a48854a1221633c2_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTEzLTEtMS0w_bde54e76-60d9-4972-b06e-7252230bb904">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517c433fbeac4a0d877922b89aa5b92a_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTE1LTEtMS0w_d742f046-9757-45cc-9b41-314fb5b0eef6">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTEtMS0xLTA_de122b42-97a0-4168-8470-e9c77ae2297f">1,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTMtMS0xLTA_720dfe7d-7ea8-42a2-b84e-00fa72cb9752">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTUtMS0xLTA_62c75dbc-6864-4dc0-9005-ed75bee24bc5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTctMS0xLTA_6aaec2da-4d26-44c1-a035-57846b259791">1,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTktMS0xLTA_aa90a0ce-a6d2-4d4b-b7c3-39e5f1427689">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTExLTEtMS0w_292c9ef2-c69e-4bb7-acfd-c4ddb67c19dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTEzLTEtMS0w_697cb569-7a0f-4ffc-8308-f5c5fd65dd90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTE1LTEtMS0w_d2eb0e3c-96b4-4de5-ad09-ea0b78bc6ebb">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9bae92903b40b180b8db555d0dc4af_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTEtMS0xLTA_5a91b610-0790-417c-b41a-1545ac3fa4c5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0d630db304c5fbb6b0d1dd4b0fd96_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTMtMS0xLTA_d8f70295-c2ac-4d0d-acfa-6835967c3aee">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b97df8525e24037aefcb485eb08406f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTUtMS0xLTA_b0c544a3-996f-4970-a62d-c822322616f5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaa816b38bd47f2a17d32d765b2fb2e_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTctMS0xLTA_66152bb4-fe1d-4578-b85f-a9db403f3d8d">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831b4ecbf45d409481738e9647f09306_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTktMS0xLTA_e9ad17b4-39fc-4b73-b3b0-33fb8605f8cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4aa9ea67d9f463dbb092452343a4414_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTExLTEtMS0w_2dab6587-18a5-4f50-83e4-9cadb44e4e8b">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00919146800d4139ac109a85dfb7d711_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTEzLTEtMS0w_d8449ae3-5065-4682-b267-bfb94ae69b1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8999a38e79d4363a379eff3d701a62b_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTE1LTEtMS0w_b0cb63dd-f550-4808-914b-e82ae1953f08">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9295a488115f4c68a8e8c1703fb43b33_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTEtMS0xLTk5NzU_7e88178b-a941-4adb-9e5f-c2c983e7b0a8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240370941e09472fa67b09378158fe7a_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTMtMS0xLTk5NzU_8e2f2e85-2787-4e51-8378-9cb51f591ca1">55</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e355174746e40ccab1d3a022356179f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTUtMS0xLTk5NzU_6fee4ab5-be02-4049-81b3-d49a34790815">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04293f756da241a999ca08cf5205814d_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTctMS0xLTk5NzU_5662b797-db77-4d31-b191-224123c7cb43">55</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5454937046f471eb2aeccd5bdb66a94_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTktMS0xLTk5NzU_a56432d8-ae47-4484-8330-b19cf59f02d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512cc6f095a04b919b00809dc9264562_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTExLTEtMS05OTc1_a5bcc7c2-3891-45b7-b896-f91bbf4347b8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860f8c1284824650bf9be85917582840_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTEzLTEtMS05OTc1_a214d1dc-b591-4b54-9fd4-5d781227f867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3923a650ec254483b01b7e8e723eace4_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTE1LTEtMS05OTc1_b1dec116-e519-48a5-98d2-4f3c174978b7">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00bd05172e849cdb1c49805feb4ff31_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTEtMS0xLTA_3beca5f2-080a-4ab0-b3e4-0cd2862c3b2f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52894ba21b534bdfb980886fec594cbe_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTMtMS0xLTA_47dedbf6-5535-48dd-afd3-811bad30a40c">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388f19daab3349fd94f8e901eebd7ad7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTUtMS0xLTA_4a506b7f-204b-4fd0-b11d-249845180f81">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb53e8019d3444a183fd939d626283cc_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTctMS0xLTA_ab5c3d86-4ceb-4f47-8d77-74daceac331e">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e91fa49f38046778d905adb20038b86_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTktMS0xLTA_5dea8e62-4a92-4c0d-9e0c-00e1eeb9bb95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a9ffaa8ff04b0db0e23fb174f64775_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTExLTEtMS0w_c7401255-b698-45fb-89a4-667b3f5e5151">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6fe4bb91db47469413570dc5792607_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTEzLTEtMS0w_7fb3e54b-1ef7-4e6f-9240-57cdee34214b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf40c6bc57a4a96acd2a20797b47feb_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTE1LTEtMS0w_a16daf78-7946-4107-8ff9-41a7a3674f6d">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTEtMS0xLTA_4225d0c5-9fa2-4e34-8407-d0b0e62f2de6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTMtMS0xLTA_be968bdf-8f80-405f-b30e-9dfddd928e2c">182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTUtMS0xLTA_765ac602-2661-4ef6-9c3d-d09c2b01a778">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTctMS0xLTA_f66a1b48-081e-4c24-b8a4-6d854ec46cda">182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTktMS0xLTA_77d3771a-d6fc-402c-aa3e-5de20db7f1ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTExLTEtMS0w_d832edd1-6046-4347-8c45-9286e1671e7b">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTEzLTEtMS0w_c6acf8b8-71ed-4863-9c2e-bef43e4af32d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTE1LTEtMS0w_c6782358-297e-4933-9b4d-b98139363bec">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTEtMS0xLTA_f5ee9bb7-145e-4e02-b19b-34b12782c90c">1,871</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTMtMS0xLTA_392de990-0425-4025-aa81-4d62dea99468">187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTUtMS0xLTA_acb1f5dc-196d-4d63-b2af-a7ee14819605">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTctMS0xLTA_c830126a-3179-4dbf-9076-e596f62c8cd6">2,058</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTktMS0xLTA_a68a6c91-a797-49eb-a74c-ee9da9d349d9">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTExLTEtMS0w_b460019c-dafa-46f8-a280-17019cdc23d5">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTEzLTEtMS0w_d3aa2480-1b82-4823-a36a-883fff48be36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTE1LTEtMS0w_d92a2955-dc50-44e1-a3b5-a7b59be54803">2,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTEtMS0xLTA_187d45af-f40d-415d-a79a-7cd62d87d688">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTMtMS0xLTA_d0b5877d-5e5a-4ee8-bd26-3a3af5422376">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTUtMS0xLTA_3e4df9ab-8d9d-4b11-bdd1-10b3d5ee3101">841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTctMS0xLTA_8081bdf9-993b-460e-9e5d-c53a57b825b8">841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTktMS0xLTA_9940b7d0-c7d9-4b64-8732-a6210b3fb5f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTExLTEtMS0w_b237fa32-dc35-4156-8958-0654af8ddfa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTEzLTEtMS0w_871c4a52-d7f0-4cf8-9c4a-93e8d1467ccf">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTE1LTEtMS0w_d5282029-f28b-479e-a23e-adbe9ad024b1">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9bae92903b40b180b8db555d0dc4af_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTEtMS0xLTA_6dab3194-3f07-4ad3-a869-d3877007826a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0d630db304c5fbb6b0d1dd4b0fd96_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTMtMS0xLTA_59731262-20ef-4403-9003-e42b421de138">505</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b97df8525e24037aefcb485eb08406f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTUtMS0xLTA_7caeb32b-af04-417c-be70-75c33f7e8386">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaa816b38bd47f2a17d32d765b2fb2e_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTctMS0xLTA_2a1db716-39d9-4b1d-9feb-b7bd6c43a69e">505</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831b4ecbf45d409481738e9647f09306_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTktMS0xLTA_1de6ccf8-a465-4032-8050-2fa8c83adcbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4aa9ea67d9f463dbb092452343a4414_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTExLTEtMS0w_78268534-4de3-4e0e-b43a-bfed19a5b08c">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00919146800d4139ac109a85dfb7d711_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTEzLTEtMS0w_06718f10-e47f-4b97-90f0-37c2dce487e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8999a38e79d4363a379eff3d701a62b_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTE1LTEtMS0w_9e16d4b4-f24b-4bc3-ae03-b002e9ff05be">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00bd05172e849cdb1c49805feb4ff31_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTEtMS0xLTk5ODY_0c43f40c-13f8-4239-abe3-9630f8415ad0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52894ba21b534bdfb980886fec594cbe_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTMtMS0xLTk5ODY_906bee5d-fd58-4aca-8168-22f7c23cef3c">20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388f19daab3349fd94f8e901eebd7ad7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTUtMS0xLTk5ODY_a9da1062-6985-4887-8e7d-3ee3d2548dae">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb53e8019d3444a183fd939d626283cc_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTctMS0xLTk5ODY_3c1bcc0d-84fb-435e-8801-867ddc926ccc">20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e91fa49f38046778d905adb20038b86_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTktMS0xLTk5ODY_3fe16828-f0ab-49b5-aecb-4cbcd48e4017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a9ffaa8ff04b0db0e23fb174f64775_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTExLTEtMS05OTg2_a0666741-f90a-4428-87f1-344d01b24460">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6fe4bb91db47469413570dc5792607_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTEzLTEtMS05OTg2_3046df80-a2dc-41a6-840a-02ccbdb02183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf40c6bc57a4a96acd2a20797b47feb_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTE1LTEtMS05OTg2_78ce3cbf-1d07-4bc1-858d-fddbf4f1122b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9295a488115f4c68a8e8c1703fb43b33_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTEtMS0xLTA_fcf8e5dc-edad-4ca2-b649-e631d4a0a66a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240370941e09472fa67b09378158fe7a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTMtMS0xLTA_e7591c34-ad8b-4e57-9a84-5d69c0fe06f3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e355174746e40ccab1d3a022356179f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTUtMS0xLTA_394e38a3-a4c7-486c-b722-77c9c6d5e188">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04293f756da241a999ca08cf5205814d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTctMS0xLTA_97256372-b817-4388-8220-09d0ae2c5fb8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5454937046f471eb2aeccd5bdb66a94_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTktMS0xLTA_dde403c2-862c-4b1b-a3c6-3e3fd93d325c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512cc6f095a04b919b00809dc9264562_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTExLTEtMS0w_5ad316a6-ea98-4665-af3e-3638c355552f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860f8c1284824650bf9be85917582840_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTEzLTEtMS0w_d6ecc004-2824-4718-b5f8-7283dc78def4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3923a650ec254483b01b7e8e723eace4_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTE1LTEtMS0w_1bf90499-24ed-4ae2-bffb-0542ea816dae">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTEtMS0xLTA_4cdaa356-1149-465c-b97d-5accfd938a4e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTMtMS0xLTA_cc70fdbd-39b6-4bb8-a5cf-750d2eb22d2f">525</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTUtMS0xLTA_9b0582d0-888d-4cc9-aef1-1c9e1859e67f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTctMS0xLTA_85ca3ff1-d721-45ff-9e1a-173aa20adf41">525</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTktMS0xLTA_6526380f-b53e-445b-805f-c5a0551dc159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTExLTEtMS0w_80524ce5-cc20-4c57-884c-e572b092686e">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTEzLTEtMS0w_503fcbbd-ba2a-472a-848f-35c52257b0ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTE1LTEtMS0w_fc56f756-5228-4bf0-88ed-31d08e5c82af">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTEtMS0xLTA_5ac90e0f-d0b1-4f46-8216-1cffefe4635f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTMtMS0xLTA_6133a99c-8192-4938-a59c-b2cd7ec5e2b4">525</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTUtMS0xLTA_98b6db39-f716-43ad-9d10-b8c7c8cab560">841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTctMS0xLTA_1b6b2c8b-ed31-4af8-8322-89637224d239">1,366</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTktMS0xLTA_f2302264-2e6b-482c-b273-a856e7c5df85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTExLTEtMS0w_4dfcd70b-c8cc-413e-8c3c-7f812431e917">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTEzLTEtMS0w_fb2f160e-4488-4800-8b61-31daee3645cb">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTE1LTEtMS0w_8933a792-c151-4da3-9c92-4cfbcabc26bb">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include $<ix:nonFraction unitRef="usd" contextRef="if05886a9b13149dfaff74f75da70ff5d_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEzNjU3_d2501708-b8c3-4998-a723-d7fea36a2a3b">6.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i0a073eb825fe4210b901ff8c5229ca73_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDY0MjM_5f050f59-f5f8-431b-a194-cbd193bd381b">8.9</ix:nonFraction>&#160;billion, respectively, of cash equivalents (which would be considered Level 2 in the fair value hierarchy). </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i5d8b9dbf323240f79b9729c63d3b571a" continuedAt="i071f54d17105428d99709d9c3d0ed5a8"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5Nzk0_224e8502-f470-4747-8b0f-b2fee5b2c691" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzEtMS0xLTEtMA_633585d1-b2e0-4b18-bc86-da82382d9f0d">767</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzEtMy0xLTEtMA_acf64368-a854-47eb-9fe2-ebf043ade945">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzItMS0xLTEtMzQ0Ng_b2177a95-7e15-492d-9e0f-858fc99ab59e">97</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzItMy0xLTEtMzQ0Ng_1880cc96-ecd5-40ff-bcd3-8614b39775cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzItMS0xLTEtMA_0686b2be-49d4-4470-867e-ac3edea06bca">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzItMy0xLTEtMA_e5e51864-dd75-4621-a420-547ab90285cf">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzQtMS0xLTEtMA_7fa430d7-4ed6-4e41-b7fe-1a631e0c3ef9">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzQtMy0xLTEtMA_ab97e326-a67b-442d-9f7a-c021470c57a4">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzUtMS0xLTEtMA_0dea5477-fb1c-45b9-a5c3-dade6791724a">841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzUtMy0xLTEtMA_bfc44b48-a382-4008-8230-ea384fa7c6a3">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Balance at December&#160;31, 2020 includes $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0MDg0_cef0ca80-48b1-4c08-ba18-c1ed80a13f7b">148</ix:nonFraction> million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At December&#160;31, 2020 and 2019, $<ix:nonFraction unitRef="usd" contextRef="i732691c0edd54472919c517d2ba0ba90_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0MTk3_58077d39-0593-4b1f-a925-c415fd67dbfc">711</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7a7a41aa57ca40e6862b37e8bdcf31d5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0MjA0_baf45f0e-7014-49e0-9548-af474e5b95d7">625</ix:nonFraction> million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of <ix:nonFraction unitRef="number" contextRef="i732691c0edd54472919c517d2ba0ba90_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0NDAw_5004c1f1-e1a7-4b62-a1ae-c62554bbfc45">11.5</ix:nonFraction>% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows and a risk-adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="iadc7c95447cb4b7394d986bbf3eb4737_I20201231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0NjYy_90eeb418-97b3-4a92-8c6c-026bfb801c22">8</ix:nonFraction>% to present value the cash flows.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additions to contingent consideration in 2020 relate to the acquisition of Themis. The changes in the estimated fair value of liabilities for contingent consideration in 2020 and 2019 were largely attributable to increases in the liabilities recorded in connection with the termination of the Sanofi Pasteur MSD (SPMSD) joint venture in 2016. In 2020, the increase was partially offset by a decline related to the discontinuation of a COVID-19 vaccine program obtained through the acquisition of Themis. The payments of contingent consideration in both years relate to the SPMSD liabilities described above.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2020, was $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE1ODY3_6714bb04-600a-4842-8ef3-ab1bdf9fa459">36.0</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE1OTA0_5af085e1-db41-466a-a900-d1ab0dd87e61">31.8</ix:nonFraction> billion and at December&#160;31, 2019, was $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE1OTIy_0bed526d-e1f0-4f41-af47-49ab4ce59094">28.8</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE1OTU5_d9638f9b-4b93-4a56-9870-9eb99d138d95">26.3</ix:nonFraction> billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the United&#160;States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented, in aggregate, approximately <ix:nonFraction unitRef="number" contextRef="i66640b35975948b1bb6102116f2f95c0_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE3NDA1_5729cfab-0c88-40e5-b760-6823f4668a39">45</ix:nonFraction>% of total accounts receivable at December&#160;31, 2020. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $<ix:nonFraction unitRef="usd" contextRef="i7c736b947a254ac49c79561ae499a87f_D20201001-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableSale" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE4MDIy_1a47bf86-e773-4f46-abcd-b8ae9296b8cd">2.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iad9160300b5a4225a05fdc2ad5bf9b30_D20191001-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableSale" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE4MDI5_4ea9d98a-6526-49f1-84ab-6761e4bcccfe">2.7</ix:nonFraction> billion of accounts receivable in the fourth quarter of 2020 and 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i071f54d17105428d99709d9c3d0ed5a8" continuedAt="iad5bb4e9e51f47bb8f769be3263b2f9f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2020 and 2019, the Company had collected $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE4NTYw_be7a2015-bc49-4b97-a853-edacb3ac3af2">102</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDY0OTY_cb08eba4-f862-4d0e-b4bf-a5786ead3f49">256</ix:nonFraction>&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in January 2021 and 2020, respectively. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><ix:continuation id="iad5bb4e9e51f47bb8f769be3263b2f9f" continuedAt="i75bc68536fe442b4837c511227358e74"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to counterparties was $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDcxNzY_8a25a654-1f61-43b2-93be-00dd56d17ce0">36</ix:nonFraction> million at December&#160;31, 2020. Cash collateral received by the Company from various counterparties was $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5NTY0_da38cd25-caf4-4611-98f5-a9a04f18b4c2">34</ix:nonFraction> million at December&#160;31, 2019. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i75bc68536fe442b4837c511227358e74">.</ix:continuation> </span></div><div id="iab6577be4c3840fd8181bdedf457fba5_190"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzUzNg_e638698d-89e4-436a-a4a6-e6022f0978d5" continuedAt="ic3b3bd29d1a44f628600ec59d7908bfa" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ic3b3bd29d1a44f628600ec59d7908bfa"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzU0Nw_da6fb426-ae42-4543-8ec9-2686b70445f2" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzEtMS0xLTEtMA_5d0f9838-6381-43b7-b4d4-5a05f46e9f16">1,963</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzEtMy0xLTEtMA_7e04f2ec-323c-4342-8ae6-3410db72255b">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessAndRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzItMS0xLTEtMA_8f1b3bc5-1b8a-4185-80d4-a25366ad5866">6,420</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessAndRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzItMy0xLTEtMA_793d7271-4193-4593-8509-0dc8dce8a9d8">5,650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzMtMS0xLTEtMA_38843ebf-2670-4184-be7a-bdfc72c3b8fe">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzMtMy0xLTEtMA_1cbe30cb-693f-4f15-aebe-6f72b9f529c9">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzQtMS0xLTEtMA_adcc64aa-7a12-4cbc-ae2e-2f17c360fe63">8,589</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzQtMy0xLTEtMA_c6b750f7-67a1-4c95-a4f3-70dd4cb9b319">7,629</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzUtMS0xLTEtMA_af770848-9fbe-49b4-9ac3-7f01ee521809">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzUtMy0xLTEtMA_2ae9e207-7ca0-478a-bfb4-e7923def6f9e">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzYtMS0xLTEtMA_8f060c2d-3808-47bc-9d5e-f1535ab8eb66">8,507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzYtMy0xLTEtMA_c57c6d2d-c349-4ad4-a674-01d042d04e38">7,458</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzgtMS0xLTEtMA_bb5809de-ed60-4368-8831-3c261373b44e">6,310</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzgtMy0xLTEtMA_42a3af75-a3d7-4d1b-8bbb-6f938aa56774">5,978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzktMS0xLTEtMA_5bcb7721-1955-414e-ace3-da8e188fdd89">2,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzktMy0xLTEtMA_c0e67f9d-9f9a-4fa3-b605-47d3a72b1362">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised approximately $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LIFOInventoryAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzEzMQ_652d0d3d-a0ce-4351-b0a2-d31eccd62dd1">2.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LIFOInventoryAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzEzOA_1c6c6e94-53a5-4593-ad4b-00de005572d6">2.6</ix:nonFraction> billion at December&#160;31, 2020 and 2019, respectively. Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2020 and 2019, these amounts included $<ix:nonFraction unitRef="usd" contextRef="id3b3b680e1b34262aaaf5bdb274dafa6_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzMyMQ_a8aa573b-33b9-4cf3-bc17-c583175c6786">1.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i7e5ba2a7e59e4ea0bf92b13e77d6584e_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzMyOA_d0023667-e9f9-47c8-a944-909611e6eafb">1.3</ix:nonFraction> billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $<ix:nonFraction unitRef="usd" contextRef="i0100533904ac46ef9b774bc1b666a843_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzQzOA_0d962da5-567b-4d61-88b2-dc0d7740cc7e">279</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i04309b24f07b4666a134a9d0f656e644_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzQ0NQ_c118d2ea-6f99-42fd-a8cd-0b9b3967ed4d">168</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively, of inventories produced in preparation for product launches.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_193"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0NTg_3fd6a044-f65c-41fc-a721-e54904ef1973" continuedAt="i25e129791afb414388f7833d8920c76a" escape="true">Goodwill and Other Intangibles</ix:nonNumeric></span></div><ix:continuation id="i25e129791afb414388f7833d8920c76a" continuedAt="idd6dc8267f074ca8933ec9d7d7084cbe"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0Nzk_e6cc3810-d4ce-49ee-9935-e74a1fa3154e" continuedAt="i5f7fd674bae449ddaf55ccb757926918" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i532617148a464d439523456b08377125_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzEtMS0xLTEtMA_74dc81e8-e1a2-4e7f-8b25-f8dd90c786e3">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5e6f127527444d84707fb30170819f_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzEtMy0xLTEtMA_3a5dc34e-63e8-415d-9c89-7db7f3a9955a">1,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6e48a8195a4472b5f2937fd2336c6c_I20181231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzEtNS0xLTEtMA_6670ba0f-87f0-49db-b21e-dd6f68dfd5a0">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzEtNy0xLTEtMA_65357e68-1890-4df1-adbe-b41308046c74">18,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b686d23f6794c68a37ebff0a13d5324_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzItMS0xLTEtMA_31b8b1df-a3b5-4706-9135-b37eecc2e7b2">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58799cd60f0b478798fb7372e4698074_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzItMy0xLTEtMA_c9d62c74-3ddb-4d8e-a6c6-5a93b7970e54">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d31fc70051c4a68858b153d5a6e84d4_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzItNS0xLTEtMA_fc7af0c0-aa7a-414e-be01-57e517963f0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzItNy0xLTEtMA_aeae839e-3ad4-4f79-baa9-80398633ca94">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b686d23f6794c68a37ebff0a13d5324_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzMtMS0xLTEtMA_7abd58f9-a79f-43d7-b111-014e8c0fcc73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58799cd60f0b478798fb7372e4698074_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzMtMy0xLTEtMA_bd5de768-8a1a-4e98-b81f-0a89d793f430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d31fc70051c4a68858b153d5a6e84d4_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzMtNS0xLTEtMA_91ce6d7e-65ab-4a41-8fdd-c3e22bb41ebb">162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzMtNy0xLTEtMA_07d8771b-3a49-443d-9525-e056b93490ba">162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b686d23f6794c68a37ebff0a13d5324_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzQtMS0xLTEtMA_ed9c7796-00fc-456f-b9bb-a911c05f6ff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58799cd60f0b478798fb7372e4698074_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzQtMy0xLTEtMA_a9c71e8f-1a5e-47fc-b043-da3496f10818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d31fc70051c4a68858b153d5a6e84d4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzQtNS0xLTEtMA_8dbfe6f5-aa69-4132-8592-896a429debb1">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzQtNy0xLTEtMA_ed7affc3-e00a-4558-9e0a-bc65f7770308">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc97187f000b4d789b7229ce5f27da09_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzUtMS0xLTEtMA_92590502-88dc-4a61-955c-9b3597d37e57">16,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15819e1b053545a9bde3e98453b6f6db_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzUtMy0xLTEtMA_a91d1c60-d50a-4d0d-9973-e4dcac0da226">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a204be8a7764bf2bc2bc61353ea4e61_I20191231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzUtNS0xLTEtMA_c4837d25-f9c0-4380-a9c9-0df27f248246">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzUtNy0xLTEtMA_3ea1f175-1ced-4eb2-9a23-98300b495d25">19,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0372a4dd384371b56eddd9bf14f331_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzYtMS0xLTEtMA_152ed53d-5ffe-4461-9fce-915244270fa7">742</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if73dd2ac8807408f8a19eb712e8ff82e_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzYtMy0xLTEtMA_e3b57e94-383a-4f16-aaaf-78864b7302fb">105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd8d36d804a4f318d753989188298a4_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzYtNS0xLTEtMA_d6431bbb-0427-44e4-b45f-47b024528af0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzYtNy0xLTEtMA_82f882a3-c354-492f-81b4-95d98effb820">847</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0372a4dd384371b56eddd9bf14f331_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzctMS0xLTEtMTg1MjE_ec179aef-f233-43fd-b2d3-223ba6c337c5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if73dd2ac8807408f8a19eb712e8ff82e_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzctMy0xLTEtMTg1MjE_030bd697-7546-4ada-8edc-3b3a7cf9d6f0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cd8d36d804a4f318d753989188298a4_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzctNS0xLTEtMTg1MjE_bc5ff089-d622-45b1-a262-3ad83b26c7c2">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzctNy0xLTEtMTg2NzY_a70c5d84-d348-47ef-b27f-6976c3e376b5">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0372a4dd384371b56eddd9bf14f331_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzgtMS0xLTEtMA_c959bca7-71e5-4d00-a62a-06d58821a1bd">47</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if73dd2ac8807408f8a19eb712e8ff82e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzgtMy0xLTEtMA_155f0827-f664-44c6-962b-235529e846ad">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd8d36d804a4f318d753989188298a4_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzgtNS0xLTEtMA_1b8811d5-01eb-45cb-8b76-a76815ea13ff">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzgtNy0xLTEtMA_ccf18880-ee0f-4a92-9c55-fd8cd304eb53">20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0929727611f46b9a4fabbb67f15cf52_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzktMS0xLTEtMA_c86198df-9e87-4339-85fc-6c2a13022927">16,970</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1150b2b45f4f4e73994ea0b6ecf39132_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzktMy0xLTEtMA_b6a46f65-c4d1-4cef-b161-d1ebcb167287">3,268</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8e2e9cbed5405c909c9467c786afb1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzktNS0xLTEtMA_17a0c30f-1a15-476c-a56c-f801d3e8bc2e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzktNy0xLTEtMA_b42eaa8c-6aa6-4a8e-a4be-cc1acb55f62a">20,238</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other includes cumulative translation adjustments on goodwill balances and certain other adjustments.</span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i5f7fd674bae449ddaf55ccb757926918" continuedAt="ib551a9a918f74411b01ed8ec95354e62">(2)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ib551a9a918f74411b01ed8ec95354e62"> Accumulated goodwill impairment losses were $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTg5NTY_13f3fb21-47e1-4d2d-a849-e437c4db63b7"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTg5NTY_7433238a-25fa-4c28-8348-2395cd6851c7">531</ix:nonFraction></ix:nonFraction> million at both December&#160;31, 2020 and 2019.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="idd6dc8267f074ca8933ec9d7d7084cbe" continuedAt="i07d0a7dae3f0472d9bed54b92a75e056"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The additions to goodwill in the Pharmaceutical segment in 2020 were primarily related to the acquisitions of ArQule and Themis (see Note 3). The additions to goodwill within the Animal Health segment in 2019 primarily relate to the acquisition of Antelliq (see Note 3). The impairments of goodwill within other non-reportable segments in 2019 relate to certain businesses within the Healthcare Services segment. The Healthcare Services segment was fully divested in the first quarter of 2020.</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0NTU_6fc0bb99-bdc7-4a65-83b8-cd42a2cf531a" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:25.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaad2db9e0af480e9820c25f8d39bf48_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItMS0xLTEtMA_a5bb3862-2132-4e15-9c13-504aff093418">45,087</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaad2db9e0af480e9820c25f8d39bf48_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItMy0xLTEtMA_ee57658c-bcf0-4398-9fe2-3692e7c9000b">39,925</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaad2db9e0af480e9820c25f8d39bf48_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItNS0xLTEtMA_46eb88f5-f2b9-436a-aa16-a1d8398ee0cc">5,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9ed711cabf40539749dacb49e1f568_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItNy0xLTEtMA_4ca8c163-71c1-4899-ba09-f7e05d352620">45,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9ed711cabf40539749dacb49e1f568_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItOS0xLTEtMA_7a69d951-124d-4055-97af-570f0850c06d">38,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9ed711cabf40539749dacb49e1f568_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItMTEtMS0xLTA_75b04712-1f46-4e10-9497-c62189b26926">7,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced3a5a3165a403dbf79ac1d619c977c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtMS0xLTEtMA_847b7341-1abe-4875-9b4b-170c13fe1053">4,177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced3a5a3165a403dbf79ac1d619c977c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtMy0xLTEtMA_94e25bfa-190a-46fc-8375-5793f74f1cfa">1,387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced3a5a3165a403dbf79ac1d619c977c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtNS0xLTEtMA_fd8ec70a-a6a5-4b10-953f-9cac1087af53">2,790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ce2a6386134b23bed761ddc429d6f5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtNy0xLTEtMA_2866d8bb-6d21-4c57-8651-9755c193024f">3,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ce2a6386134b23bed761ddc429d6f5_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtOS0xLTEtMA_0a6ad776-6eda-4386-87e6-05e308de6a91">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ce2a6386134b23bed761ddc429d6f5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtMTEtMS0xLTA_834b720c-7766-4ff6-99e7-61a64bb10942">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af2e1d785f64d9b9574fd6067247ae4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzQtMS0xLTEtMA_a5cbf03b-1a91-4e17-977e-2cd676283970">3,228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af2e1d785f64d9b9574fd6067247ae4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzQtNS0xLTEtMA_d0a5ec92-e81c-4fe3-b97a-eba69fc60f1b">3,228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2529a81fe48e2af0847da14387edd_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzQtNy0xLTEtMA_e30c4354-7ebc-40d7-9f6b-d61dedafaea8">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e2529a81fe48e2af0847da14387edd_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzQtMTEtMS0xLTA_edfaf0e6-ceef-4eb0-871d-1866489b05cd">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ece120a22b4a28ae57b244c672e267_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtMS0xLTEtMA_97358fa6-1091-45b2-9c5b-e0719f302202">2,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ece120a22b4a28ae57b244c672e267_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtMy0xLTEtMA_b557306c-f9c1-4e4b-809e-6670e95fa9fc">352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ece120a22b4a28ae57b244c672e267_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtNS0xLTEtMA_647920ce-eefe-4ef2-9d0c-3c8a6925bc74">2,530</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85308ed5ebab473ebc2ea2ac65fa9e3b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtNy0xLTEtMA_a782262c-8af7-4321-8e3c-b612d7dfa548">2,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85308ed5ebab473ebc2ea2ac65fa9e3b_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtOS0xLTEtMA_362f6d52-d522-442c-a2c8-3cccb968811a">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85308ed5ebab473ebc2ea2ac65fa9e3b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtMTEtMS0xLTA_18a62fab-24f8-4dc5-b8ac-4a9e7bac3a12">2,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie066b7e11e1642829a90d72bfad73dbf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtMS0xLTEtMA_5919d007-444f-478a-8246-8d08137e07c6">2,223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie066b7e11e1642829a90d72bfad73dbf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtMy0xLTEtMA_69309f73-cf1b-465c-b487-eb990efbdeef">1,329</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie066b7e11e1642829a90d72bfad73dbf_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtNS0xLTEtMA_19ee5ac8-4901-4022-8c1c-36daabdd8406">894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8737f47e0b428ea8e395b4b91b4140_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtNy0xLTEtMA_22e44b9b-70e6-46c7-8603-1fb12da136a4">2,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8737f47e0b428ea8e395b4b91b4140_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtOS0xLTEtMA_d79ce5f0-92ea-4793-b9ad-2a1f02ce5d2e">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8737f47e0b428ea8e395b4b91b4140_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtMTEtMS0xLTA_139135ab-2ba5-45b8-badf-c4a55b4abafd">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctMS0xLTEtMA_3d45adad-b603-465e-a68d-8e6bc4c898cc">57,597</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctMy0xLTEtMA_bda53b39-2150-4ed3-a5cf-8c41701f3877">42,993</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctNS0xLTEtMA_c95017c1-6693-49c6-bbbd-11036ecc0914">14,604</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctNy0xLTEtMA_feb0073c-cee3-4281-b707-76927967834f">55,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctOS0xLTEtMA_8d0f2696-8249-43d8-9201-ef37b89024d6">41,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctMTEtMS0xLTA_5168d372-335c-427d-86ba-2c668c14e08e">14,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, licenses, trade names and patents, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. Some of the Company&#8217;s more significant acquired intangibles, on a net basis, related to human health marketed products (included in products and product rights above) at December&#160;31, 2020 include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i1173b6885a2f45998fdccfb8d45d893f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzEwNzc_d46b7c21-b36c-45c9-bf0a-111d4be3cd3b">551</ix:nonFraction> million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Implanon/Nexplanon,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i6f8b5fa2afe945b58cc7cc58540a4871_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExMDE_513a7a4a-78da-4a6f-8600-33ca121597d2">354</ix:nonFraction> million; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, $<ix:nonFraction unitRef="usd" contextRef="i45c757b49a734e889c7b8814b17d27c9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExMjY_ccc6d218-3883-442c-8ed3-ba535bfd8719">276</ix:nonFraction> million; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dificid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i9e4557c2c3774ac6bd1f5631a947887f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExMzk_73eb3005-c2fa-4cc0-a5d6-600d136eb200">228</ix:nonFraction> million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i84352a69c7a940baa059487a008d720c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExNTI_b7b66f37-f0ad-4d87-a4aa-b73410d87a39">185</ix:nonFraction> million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i644295df1e6b4e9dbedf44a0e8a544f2_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExNjY_1007a5ef-e27f-4b55-8d1e-887734241c15">154</ix:nonFraction> million; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i63c8541f7de64146a1d1b841885e43cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExODM_454f1887-e7b8-4060-b501-9a63ef836eb4">132</ix:nonFraction> million. Additionally, the Company had $<ix:nonFraction unitRef="usd" contextRef="i44dc8a8199b54644aaa379692dd53d6f_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzEyMTc_4d9d8ee3-ae06-4e6a-b4de-5debde421510">5.4</ix:nonFraction> billion of net acquired intangibles related to animal health marketed products at December&#160;31, 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i5db1bfb9494a4fe2a7e9ed0eaa5d201c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MTEzMzc_d8d1cc0d-2c1f-4632-b4d0-f594962eaf00">2.5</ix:nonFraction>&#160;billion relate primarily to trade names obtained through the 2019 acquisition of Antelliq (see Note 3). Some of the Company&#8217;s more significant net intangible assets included in licenses above at December&#160;31, 2020 include Lynparza, $<ix:nonFraction unitRef="usd" contextRef="i290e0168aaad4d8bbb291ae388c991a3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MDkyOTU_1cd74da4-3f11-456a-96df-a96ce7078a17">1.3</ix:nonFraction> billion and Lenvima, $<ix:nonFraction unitRef="usd" contextRef="ic4443e6b872f4ba8905276b85a6342e3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzE0MDE_248c0469-797f-4eb0-a1aa-e6fb9518a4a6">1.1</ix:nonFraction> billion as a result of collaborations with AstraZeneca and Eisai (see Note 4). At December&#160;31, 2020, IPR&amp;D primarily relates to MK-1026 obtained through the acquisition of ArQule in 2020 (see Note 3) and MK-7264 (gefapixant) obtained through the acquisition of Afferent Pharmaceuticals in 2016. The Company has an intangible asset related to a collaboration with Bayer (see Note 4) that had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i50171610356846629bd94e414c848b8f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzE3NTM_8ba72bfa-0275-4eba-93e1-4ff13ba7db2a">849</ix:nonFraction> million at December&#160;31, 2020 reflected in &#8220;Other&#8221; in the table above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i5f574ea21943431ab05c0b6dbcdce88b_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTc5MTc_f436a620-bb48-46c9-abb8-0001ddf2eaec">1.6</ix:nonFraction>&#160;billion within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset for impairment. The Company revised its cash flow forecasts for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $<ix:nonFraction unitRef="usd" contextRef="i5f574ea21943431ab05c0b6dbcdce88b_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc2OTY1ODE0MjI0OTM_4ea5461b-6ff5-468d-814c-17f93ad1dcc7">120</ix:nonFraction>&#160;million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2020 related to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recall. The remaining intangible asset balance related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="i1173b6885a2f45998fdccfb8d45d893f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MDQwMDE_d46b7c21-b36c-45c9-bf0a-111d4be3cd3b">551</ix:nonFraction> million at December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company recorded impairment charges related to marketed products and other intangibles of $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzE5MDc_5874af55-0485-417b-afa2-cec6ab939aef">705</ix:nonFraction> million. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="i4b02c94bdf4b498b8851fe2c79b417a8_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzE5NDg_e14c0b94-9888-4585-943e-a80ba9f466e0">612</ix:nonFraction> million related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a product for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive organisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i07d0a7dae3f0472d9bed54b92a75e056"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the Company will make a separate determination as to the then useful life of the asset and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MDIyMzA_b17e8e60-6144-406b-ae3f-daeb2cc4d502">90</ix:nonFraction> million IPR&amp;D impairment charge within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#8217;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MDM3MDU_822fe909-e45e-4b4f-b026-1480d67f82cb">45</ix:nonFraction>&#160;million (see Note 6).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTA4NDY_3bd37f7e-deb3-41cd-ace6-9378deed3fea">172</ix:nonFraction> million of IPR&amp;D impairment charges. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="i66d85fef1ef64fa4b7ac0d3e28260cee_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzQ0MTE_00d71c8d-0f29-4253-9241-1b7fd6fe33da">155</ix:nonFraction> million relates to the write-off of the intangible asset balance for programs obtained in connection with the acquisition of IOmet Pharma Ltd following a review of clinical trial results conducted by Merck, along with external clinical trial results for similar compounds. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i66d85fef1ef64fa4b7ac0d3e28260cee_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzQ4MTY_caf8e299-e93b-4a3c-8941-60931929cc62">11</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTA4NTE_0370feae-6ddf-45f9-a86d-f36a31e94555">152</ix:nonFraction> million of IPR&amp;D impairment charges. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="i6db9d51af09c4754abfbb7520bc64c24_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzQ4OTk_8355c493-57e4-4714-a236-9afedc88e1c0">139</ix:nonFraction> million relates to the write-off of the remaining intangible asset balance for a program obtained in connection with the SmartCells acquisition following a decision to terminate the program due to product development issues. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i6db9d51af09c4754abfbb7520bc64c24_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzUyNTY_95fdc811-8f38-4a6f-bd06-b08647347cb8">60</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense primarily recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzcyODg_43c2f732-7758-4c09-b5b9-56618a31a14f">1.9</ix:nonFraction> billion in 2020, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzcyOTg_ab56e3ba-2663-498f-87f6-bd94a786b8b7">2.0</ix:nonFraction> billion in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzczMTE_37b709ef-fc0f-49cb-bbc9-445733f790ac">3.1</ix:nonFraction> billion in 2018. The estimated aggregate amortization expense for each of the next five years is as follows: 2021, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0MTc_ec24d98c-f624-4543-81c9-5c4ab9ecefee">1.5</ix:nonFraction> billion; 2022, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0MjU_b1741e9b-5e15-49ad-9b77-addd6b79d092">1.5</ix:nonFraction> billion; 2023, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0MzM_ea09e984-79dc-4cbf-ba74-64ee0a149881">1.4</ix:nonFraction> billion; 2024, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0NDE_3d6409b1-f528-493c-84f9-6767662ca56c">1.3</ix:nonFraction> billion; 2025, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0NDk_426428c7-4534-4ed3-aff0-ed63a71cc11a">1.2</ix:nonFraction> billion.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_196"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY2ODE_c7921de0-6d9d-4a84-b32a-d9b84b222a09" continuedAt="ic20c7387225642e690c8e6157f9d32a4" escape="true">Loans Payable, Long-Term Debt and Leases</ix:nonNumeric></span></div><ix:continuation id="ic20c7387225642e690c8e6157f9d32a4" continuedAt="i078800752c3b46e9b55c28c3dd6231a6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans payable at December&#160;31, 2020 included $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzExMA_ea8e7fae-1ce5-472b-bd25-6d6ec39147e7">2.3</ix:nonFraction> billion of notes due in 2021, $<ix:nonFraction unitRef="usd" contextRef="i85a6d1399fe54a219de34e4fb8d4af00_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzEzNQ_426b2f55-6505-4f0b-a950-c51d22066498">4.0</ix:nonFraction> billion of commercial paper and $<ix:nonFraction unitRef="usd" contextRef="ib00b85fd4d974a758d1b963871ea7a01_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE2Mg_f066d713-275a-4624-abd6-c8d1f72f5e7c">73</ix:nonFraction> million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2019 included $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTAxMDg_51ce5c36-9b85-47c6-a1a5-b4d7285069bf">1.9</ix:nonFraction> billion of notes due in 2020, $<ix:nonFraction unitRef="usd" contextRef="ie6bb25ba3f5e48d98f224bb95792c81b_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzI4OQ_5b08ee47-ae58-4c2d-939b-33c734dd4f50">1.4</ix:nonFraction> billion of commercial paper and $<ix:nonFraction unitRef="usd" contextRef="ifc988053afe14f7b91f98a61bca385dc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMxNg_3081177d-8d62-4d39-8927-250696804f30">226</ix:nonFraction> million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was <ix:nonFraction unitRef="number" contextRef="i85a6d1399fe54a219de34e4fb8d4af00_I20201231" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzQ2OQ_488901d4-6139-46f5-8bc2-6d2cbdf11869">0.79</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie6bb25ba3f5e48d98f224bb95792c81b_I20191231" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzQ3Ng_e6402788-9fba-45e3-bc05-5f1f36d52b1f">2.23</ix:nonFraction>% for the years ended December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i078800752c3b46e9b55c28c3dd6231a6" continuedAt="i24f22472dd484ee49650a3fb9df1a258"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY2ODc_25303471-9a1c-4e67-a996-060d199c439e" escape="true"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaba347791c48433e925479fecdd16a54_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NzI1YzhhMzA1ZTQzYmRhN2ZkNTU5OGU5MGEzNWQzXzMyOTg1MzQ4ODMzNTc_e614c5f0-0f05-4d74-88c7-29d1000735ee">2.75</ix:nonFraction>% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba347791c48433e925479fecdd16a54_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEtMS0xLTEtMA_df3d6597-d948-4f77-9ec9-5423ea392d5a">2,493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea8732c8c424a298f074a0d05b4f8e4_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEtMy0xLTEtMA_88781731-9324-4c81-a4ac-6576609d6a72">2,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i344abc1ac8df4e5fb7317baa25a573c4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2NmNjODMwMjRiYTQ5ODBhMWE1NGUxNTFjOWM4ZTJlXzMyOTg1MzQ4ODMzNTc_282e711d-ef76-49d3-8a98-a3a3128ee693">3.70</ix:nonFraction>% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344abc1ac8df4e5fb7317baa25a573c4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzItMS0xLTEtMA_e8b02040-d7b8-482a-8c3a-65da151dd64d">1,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6416b36cb32d45d7972ecd5a8eb20bcd_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzItMy0xLTEtMA_8d1a73b7-5c6a-4df2-bfbb-215402182ea8">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i83a3cf0b47ac4f21b67473d021c763ec_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmU0NWVkMGRjYjU2ZTQzNzE4MmQ1NzcxNTQzNzE3ODU0XzMyOTg1MzQ4ODMzNTc_95d1dd1d-4a9b-464a-aa50-98d9a1912e98">2.80</ix:nonFraction>% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a3cf0b47ac4f21b67473d021c763ec_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMtMS0xLTEtMA_fc7a315f-cec3-42c1-b560-fa7708afe08d">1,748</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfc4e4a837d4b3d94e05f841194c53c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMtMy0xLTEtMA_c5a16867-ae8a-4f26-91c3-268b4dbef316">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e9099574c5f4032937d3bc2367b5b64_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmYwZGM0NDJiMTliYTQ3NWY5ZGEwMDEzYWI5ZjQ4Yjk4XzMyOTg1MzQ4ODMzNTc_a9da9b32-ede5-49e9-95d3-5a7ed5fe66af">3.40</ix:nonFraction>% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9099574c5f4032937d3bc2367b5b64_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzQtMS0xLTEtMA_6e172c80-e815-46be-9b4b-a64be65716bf">1,734</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cca79113e2045d5b4e73f3784ef8022_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzQtMy0xLTEtMA_f9376d98-1709-4a19-8b7d-4e587d66921c">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45e429ebe7354c82b1294000a91d6238_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjBiMmU4OGQ3ZjE1NTQ3Y2M4YWU2MmM1ZTAxNWQxZjQyXzMyOTg1MzQ4ODMzNTc_26efc9b5-717b-4bec-8ae6-aff3e984f8ec">4.00</ix:nonFraction>% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e429ebe7354c82b1294000a91d6238_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzUtMS0xLTEtMA_43b5cd74-bbe5-4322-b4aa-473685191c08">1,469</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9960f291154518b7771a8367588623_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzUtMy0xLTEtMA_1e850376-18e4-4c3b-ba6f-48f9c4384377">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd58c6c117ea431ab0dfe66f19331376_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzYtMC0xLTEtNDQ0OC90ZXh0cmVnaW9uOmUwYjcxMzcwODUxNjQxMjliOTI2MThiNzc2ZGZjMDdlXzMyOTg1MzQ4ODMzNTc_80373f98-6515-4b91-8431-bc775af19f64">2.35</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd58c6c117ea431ab0dfe66f19331376_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzYtMS0xLTEtMzc4Ng_6ac2d0d1-3923-4a1e-87e7-cc8ea850ff85">1,269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb84f0d208f541898a079de4407fbc4c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzYtMy0xLTEtMzc4Ng_488c1b76-b4c2-48c7-aa5c-568360344e24">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4ab23cdcdc843a2917bbca28606754f_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzctMC0xLTEtMC90ZXh0cmVnaW9uOmE0ODRiMzYyNWEzMzQyYTE5OTE1ODg5MTMyMDU5NDFlXzMyOTg1MzQ4ODMzNTc_71f978c7-c092-48bf-a3e7-002014e04dd2">4.15</ix:nonFraction>% notes due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ab23cdcdc843a2917bbca28606754f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzctMS0xLTEtMA_ef4b036f-9083-4b7c-9776-f9d0df9cd9bc">1,238</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff98b9634eb4b8abec7f2929324acd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzctMy0xLTEtMA_c6e40b33-0e36-4430-82d3-4c6be33b3845">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78df5306478342eab229fdfa2b5ff46b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzktMC0xLTEtMTA4MzYvdGV4dHJlZ2lvbjphODY2OWIyZWQzMGQ0NTJmOGY5Y2Y3MDgwODQ0NDFkOF8zMjk4NTM0ODgzMzU3_ad725d80-e5bd-46e4-a75f-c2db4a092d67">1.45</ix:nonFraction>% notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78df5306478342eab229fdfa2b5ff46b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzktMS0xLTEtMTA4MzY_55324937-7347-44b3-b849-db78c316005a">1,233</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78222fc09fda4c99ad6c20c30a5771e5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzktMy0xLTEtMTA4MzY_5b05b8b7-78c0-4107-ad42-be05fe2d8c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iceecc1aac1de4bc0a9891ccd1446b5c7_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjo3MTE1ZWYxYzI1N2Q0NzE5OGFhNmZkY2ZmNmY2MTg5Yl8zMjk4NTM0ODgzMzc2_6dc7f57e-c096-40ef-ba93-b69b474d2f89">1.875</ix:nonFraction>% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceecc1aac1de4bc0a9891ccd1446b5c7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEwLTEtMS0xLTA_af4cb041-7e10-4e14-b4b1-546789fe2ffb">1,218</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe272a16def41b5a009731435dffb9b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEwLTMtMS0xLTA_b863cab7-183a-4da4-b3b5-9fecbd40ece4">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i754a95212e81449592b1cdc907c41645_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTAtMS0xLTEwODAzL3RleHRyZWdpb246NDBkNGJjNWRkOTg1NDkzZjk5ZWUxMzRhOTYwN2QxMTlfMzI5ODUzNDg4MzM1OA_9d728011-8c18-47d8-8743-786fbd848721">2.45</ix:nonFraction>% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754a95212e81449592b1cdc907c41645_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTEtMS0xLTEwODAz_9eab2ff8-0c9a-41ae-8896-f8ac33b4b45b">1,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i732723d5fe6a4b868b89375b49d5fd8b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTMtMS0xLTEwODAz_69d1daa9-4744-4805-a274-8fa985de8fa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c412aa3064f462e946f0da6f2d9215d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo4MTc1YmJkYjMyMDI0OWE2OWIzYzM5YzE5NTNkYTk2Ml8zMjk4NTM0ODgzMzU3_96b0ccd0-e9ae-487d-963c-6bd6427a6c8d">2.40</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c412aa3064f462e946f0da6f2d9215d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzExLTEtMS0xLTA_21801a91-d947-4523-af2a-299d3b85d832">1,032</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736b59648d614c0e97f2775844772478_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzExLTMtMS0xLTA_8296aa19-0270-4f20-bd3e-41bfe1e39fff">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1555c8a744114e5db01a64b368754154_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTAtMS0xLTEwODI4L3RleHRyZWdpb246MDk3MjU3NDk4NDU4NDY3MzllOTYxMGM4M2I0NmViNmVfMzI5ODUzNDg4MzM1Nw_13a0bdcf-59a0-4def-a15c-63714ab35934">0.75</ix:nonFraction>% notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1555c8a744114e5db01a64b368754154_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTEtMS0xLTEwODI4_8903d210-9a48-47b7-b9ba-fc3aa9b3d87e">991</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6875a6efe8e744ff842540cb414f8f8a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTMtMS0xLTEwODI4_3c68f4d7-0a0a-4db0-8b44-abfb0f958c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0efc1bff14834532b53dc32625a888ab_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZTI2MGIxYzAxNzM0YzhkODQ2Y2Y4N2IyOGU1YWVlZV8zMjk4NTM0ODgzMzU3_62912551-80ca-4278-8bce-c0c529c7f128">3.90</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efc1bff14834532b53dc32625a888ab_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTEtMS0xLTA_48cceb62-4575-4ea3-95bb-3da426cc3219">983</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294d63d03b95427aab71e6571ccc09c2_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTMtMS0xLTA_ad80cbc1-2697-4758-96cc-94c64b7c2f05">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib13a5c56a92845b8ab48bcaf8bc19e9a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTAtMS0xLTEwODIwL3RleHRyZWdpb246Yzk0ODJjY2NjNzhiNDk0ZjljNDVmZDNlMjg4OThlZTZfMzI5ODUzNDg4MzM1Nw_1442249f-9480-4360-a556-a859ab3efdef">2.35</ix:nonFraction>% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13a5c56a92845b8ab48bcaf8bc19e9a_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTEtMS0xLTEwODIw_6da1ba84-f0f6-4e9e-86a8-b4659b21b8f6">982</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cef927a50d40dd94bf6b3639986635_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTMtMS0xLTEwODIw_ec664f38-f9f1-4ed1-8954-af9665f8d43a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if245f9f1b17449e88cc2103efa045493_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo3YzVkZjU2NmRkNDg0ZjAxYmM2OTlmZjExYzA2YzU0NF8zMjk4NTM0ODgzMzU3_356ac4eb-1eeb-4274-a043-5bd7903e2a54">2.90</ix:nonFraction>% notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if245f9f1b17449e88cc2103efa045493_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTEtMS0xLTA_a6c4703e-375d-4d87-8398-f4cfe8646ce4">746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0cb1fa4d45425fa7783c3a6ef3bc70_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTMtMS0xLTA_fa25e387-9c83-496f-922d-2c0a76190c0c">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80623f99eb964250b8fc54ea685897f5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjozNWMxMzVjZTUyOGY0MTM2OWQ4MWNiZmZhYmRlNjc4OF8zMjk4NTM0ODgzMzU3_6185dd8a-c6cc-4b87-ab3a-abbf7a9983e9">6.50</ix:nonFraction>% notes due 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80623f99eb964250b8fc54ea685897f5_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE0LTEtMS0xLTA_826672a5-cff6-499d-8e48-2726ff72daef">719</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e81d555abbb4c418adeed3f0d9d7565_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE0LTMtMS0xLTA_adca22ec-14a9-4324-998a-bd8ba05a6f98">722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a01f80b4c246a2bf622369fdfa8f18_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTAtMS0xLTAvdGV4dHJlZ2lvbjozZmFlOWRjMzAyYmU0MzBjYTQ0Mzc2YjM5MzQxMDUzOF8zMjk4NTM0ODgzMzc0_9e0e3422-1a2e-47d8-b642-70ba9613b0d8">0.50</ix:nonFraction>% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a01f80b4c246a2bf622369fdfa8f18_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTEtMS0xLTA_231939bb-0991-4e2c-94c0-2a49d16036c6">611</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34867e87009e4b0e99e46b2f6cb4c092_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTMtMS0xLTA_34933bc3-6f70-4817-8974-f4304fb5979c">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49a46592892940408701fcf1a045d8f4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpjY2MzNGZmMmZiMDg0ZTgyOTc2ZTY3M2JiNDcxOGZlOV8zMjk4NTM0ODgzMzc2_83d844a4-e237-4b6d-9f86-031822acf3c1">1.375</ix:nonFraction>% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a46592892940408701fcf1a045d8f4_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE2LTEtMS0xLTA_d9c14474-9e95-4bf8-b496-959c9e0fa891">606</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456e1ba1d4d048b8b9c8e3f642d03c44_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE2LTMtMS0xLTA_0f08affc-7d1b-42f5-9132-9bb2df41b688">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i22ea05d6371640059821d1b96b78bcfb_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjo1OWI4NzQ3NGJkZTk0M2NjYTJkZjU3MjczZDljYzIzYl8zMjk4NTM0ODgzMzc0_aa33c2ff-ba3f-400c-920f-893cc61c9db0">2.50</ix:nonFraction>% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ea05d6371640059821d1b96b78bcfb_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE3LTEtMS0xLTA_737486f6-cba5-423d-9b43-dc0e4cecf628">605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65571cdb0e3545d08e1a78ce87482955_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE3LTMtMS0xLTA_949f0b79-fa34-436d-b455-43bcffa97fbb">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i291cfe0382bb4a1da525a53dd4bd56d2_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMzM3NWYyYTg3MTY0NzlhYmQ1Njc1YTEyZDY5YjM3OF8zMjk4NTM0ODgzMzU3_6790154f-5bd3-4b60-abea-f743d874406b">3.60</ix:nonFraction>% notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291cfe0382bb4a1da525a53dd4bd56d2_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE4LTEtMS0xLTA_cf9b738a-5247-4cac-b53c-4c88da4a98ff">491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e47a06c17e443da59e214105dd3142_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE4LTMtMS0xLTA_5b1d0a52-16df-46cc-98a5-4275634af825">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3fe8e4e022a84cfea391ef6224221b96_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE5LTAtMS0xLTAvdGV4dHJlZ2lvbjphYWM4YjkxOGQ2YjY0NzYyYWQ3YTY3ZjNiMzI2ZjUxNl8zMjk4NTM0ODgzMzU3_ab966a70-5e27-417f-9585-f05dfd8f336a">6.55</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe8e4e022a84cfea391ef6224221b96_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE5LTEtMS0xLTA_05e9ff27-183a-445f-a3ae-143cd0f26132">411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2a2f31269d4bfbbaa9fb0d49f28117_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE5LTMtMS0xLTA_1d9ecd23-546a-40c9-9dfc-ed615839ee06">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a29df5772da4572bbc2b0dc9d2a170b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjowNDc1ZjhiYTdlNTI0NDBiOWVhOTBmN2YyMTc0Y2E1NF8zMjk4NTM0ODgzMzU3_35dcb688-a8b9-4de9-9630-f1f7ef1fcf04">5.75</ix:nonFraction>% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a29df5772da4572bbc2b0dc9d2a170b_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIwLTEtMS0xLTA_5bf66906-c12d-4438-8de8-8535c3ea7112">338</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e537b9b718849abb7a52b86436ee26c_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIwLTMtMS0xLTA_72d9b72e-4c14-49cc-a0f9-3768b8fddfc9">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6be4ea71456d4e0cb0df403c03f0803c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzVkMGY4Y2NjZGI0NzU4OGUzNmRlN2YwMDE5ZTdmNl8zMjk4NTM0ODgzMzYy_04ef7630-d6cd-43cd-8fdb-e2357860a273">5.95</ix:nonFraction>% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be4ea71456d4e0cb0df403c03f0803c_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIxLTEtMS0xLTA_f1956e6e-81bd-4e9a-bc6f-0c28e4e8ed86">306</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f96dfc50594cc98edcf62d8b285b5b_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIxLTMtMS0xLTA_bba5ae77-4306-4fe9-80eb-43b1ec102c51">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b5f170dde14479cad14ff734e5b12f5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjlmYWZmM2VlODU0ZGU2YTQ4MWIxNjMyZWEwYWZiN18zMjk4NTM0ODgzMzU3_e1c2697d-a444-48c6-addf-64050e596287">5.85</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5f170dde14479cad14ff734e5b12f5_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIyLTEtMS0xLTA_fb8e98d2-2c10-490f-aafd-df4b20bd1a2a">271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eeb41177eb24d1d9df2236c98035186_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIyLTMtMS0xLTA_3b5a7c44-420f-48e8-902c-73fec5f49bce">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc08d1a074864992a264a4b6422ccf21_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjplNjMzNzQzZDhmNTc0MmVlYTc1ZjJiODRjMjI4YzNmNV8zMjk4NTM0ODgzMzYz_3cd56e97-344a-4dc8-bb7f-20d2ba0ba10b">6.40</ix:nonFraction>% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc08d1a074864992a264a4b6422ccf21_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIzLTEtMS0xLTA_5dbb5a36-e85c-4bff-9af6-99e7cf98a9c0">250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a54f19f0a746b39d2b9025e8db43c3_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIzLTMtMS0xLTA_17d1ae8a-37d9-4b54-936a-48497847b2be">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9978259f8d4b47488a313e4f6298d224_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpiNTE5NTVkNmM0ZTk0ZmQzYjY3ZGNiZjdjNmE0M2FhOF8zMjk4NTM0ODgzMzYy_55eed09a-9661-46a9-8d31-597d08a631cb">6.30</ix:nonFraction>% debentures due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9978259f8d4b47488a313e4f6298d224_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI0LTEtMS0xLTA_15028c38-42f8-4061-8ce2-42392b0f1cbd">135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22994b5296a4991ac4adf5979eadbd5_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI0LTMtMS0xLTA_cfefbac5-a1e6-4f52-bb56-1d2de2f332de">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icacb65bc336f4dc9bb0c0a000f8b3b2c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI5LTAtMS0xLTM4MDUvdGV4dHJlZ2lvbjplNjYyNTdkODIxZjY0YWZkODBlNmIyOGE1Y2YyZDU3YV8zMjk4NTM0ODgzMzU5_c5c79bf2-6802-4b6e-a42b-1cc4e3c160b3">3.875</ix:nonFraction>% notes due 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacb65bc336f4dc9bb0c0a000f8b3b2c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI5LTEtMS0xLTM4MDU_3781556e-5046-4d81-bdaf-b8eb49d0d23b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a2ef6578e84496b80d826a8bd81fc6_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI5LTMtMS0xLTM4MDU_ab0433b2-f6e2-4334-b1fc-c67cf26c5555">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafd3d72bbfff46e9b1dbe43d5ae389a1_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMwLTAtMS0xLTM4MDUvdGV4dHJlZ2lvbjo2NTcwNDFjMmJkYTI0NWE5YWRjNTIyMzYzNDliYzMyNl8zMjk4NTM0ODgzMzc2_17f7154c-741e-433a-971f-8bba8f97b7a2">1.125</ix:nonFraction>% euro-denominated notes due 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd3d72bbfff46e9b1dbe43d5ae389a1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMwLTEtMS0xLTM4MDU_d4f11004-0b8d-4b04-81bd-8776ab398846">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5065e542a7804f1d9986df718c97d477_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMwLTMtMS0xLTM4MDU_21e211f9-597e-4a1b-a486-d16985453208">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2431c7a6454b38ab36680e0e8d37e3_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI3LTEtMS0xLTA_bfcad97a-4f52-4ded-af44-350dbfb530f0">294</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1148b1b31242e48e86597a3d3f1701_I20191231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI3LTMtMS0xLTA_0e022d84-0fc3-4c02-b8d7-232318779049">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI4LTEtMS0xLTA_4c12d215-bcac-456e-8697-a8124f04a26b">25,360</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI4LTMtMS0xLTA_ff110616-c7e8-4bc5-bf9c-7064c49554e9">22,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes $<ix:nonFraction unitRef="usd" contextRef="i3949abad89e14fd38587a5c5fbfe1511_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzYzNQ_22e0909c-ee90-4c1e-a33f-0007d98cd063">294</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01916148acd5472d9995c901f488ade4_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY0Mg_16895d17-51b2-4287-9375-c4af37feec99">147</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively, of borrowings at variable rates that resulted in effective interest rates of <ix:nonFraction unitRef="number" contextRef="i3949abad89e14fd38587a5c5fbfe1511_I20201231" decimals="4" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3Xzc1MA_69028edf-6751-43c8-8d69-462482165bbb">0.45</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i01916148acd5472d9995c901f488ade4_I20191231" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3Xzc1Nw_9d8d4e10-77e5-49b5-bae1-9c17091d2e12">2.54</ix:nonFraction>% for 2020 and 2019, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the <ix:nonFraction unitRef="number" contextRef="i9978259f8d4b47488a313e4f6298d224_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzgxNg_cac617ca-2b99-4570-acdd-062e7fe84e1e">6.30</ix:nonFraction>% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#8217;s option at any time, at varying redemption prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ia25c4a8026c741e390c5f222dcb409cf_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0MzA_c7a89de4-f7e6-42ed-b94b-cab6003c2531">4.5</ix:nonFraction>&#160;billion principal amount of senior unsecured notes consisting of $<ix:nonFraction unitRef="usd" contextRef="i288d6bcb95724509929f814f722c2cf6_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0NDQ_cc15fa37-f641-4222-8377-98ecd0a9ff99">1.0</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i288d6bcb95724509929f814f722c2cf6_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0NTg_db265a64-cc93-4c09-a955-620775c0cb43">0.75</ix:nonFraction>% notes due 2026, $<ix:nonFraction unitRef="usd" contextRef="i894c10ae01644b8d9f041da769af6d71_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0NjU_7ec500b2-e5c7-468b-8794-9b607907a21c">1.25</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i894c10ae01644b8d9f041da769af6d71_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0ODA_c61f8bfe-8298-4e3c-9da8-f2d8651f27b7">1.45</ix:nonFraction>% notes due 2030, $<ix:nonFraction unitRef="usd" contextRef="i7c1f495cc6884078a83bcc4ce2ed06da_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0ODc_b5c101a7-ec70-41ed-bb03-ad4b161a55f8">1.0</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i7c1f495cc6884078a83bcc4ce2ed06da_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE1MDE_9a7922ea-db5c-464d-b393-dd6b4ef6f931">2.35</ix:nonFraction>% notes due 2040 and $<ix:nonFraction unitRef="usd" contextRef="i2a7670e8fa924f52a3744367cf66477d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE1MDg_8e78fc6b-74ba-4a23-8b3d-667d9a0982ad">1.25</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i2a7670e8fa924f52a3744367cf66477d_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE1MjM_2bfa3948-040f-4574-abb2-9938e56142d7">2.45</ix:nonFraction>% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s borrowings require that Merck comply with covenants and, at December&#160;31, 2020, the Company was in compliance with these covenants.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i24f22472dd484ee49650a3fb9df1a258" continuedAt="i6a609b59328742cc8ba1cf13395a5a27"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2021, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE5NzU_ee2db2b0-43d7-41a7-9d86-c3923d564770">2.3</ix:nonFraction> billion; 2022, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE5ODM_0d9d4c5f-070d-4319-bc31-2036365a8bae">2.3</ix:nonFraction> billion; 2023, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE5OTE_ba858fbc-152a-4abb-891e-24e7c8c1f170">1.7</ix:nonFraction> billion; 2024, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE5OTk_aaf2507e-426e-46ce-a4db-b36770c92951">1.4</ix:nonFraction> billion; 2025, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzIwMDc_96118ce1-fe9f-47fd-870d-2eb159a26b23">2.5</ix:nonFraction> billion. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzIwMzA_25254c2f-0331-4949-b598-acced9a9b0d5">6.0</ix:nonFraction> billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of <ix:nonNumeric contextRef="ibf5a47fd424649b58844b8504c6890af_I20201231" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzM2Nzk_1caef52e-b8ec-44c3-b483-111471a92e68">eight years</ix:nonNumeric>, which include options to extend the leases for up to <ix:nonNumeric contextRef="ibf5a47fd424649b58844b8504c6890af_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzM3MzY_da256b4a-8165-438d-b2a3-098839046c92">four years</ix:nonNumeric> where applicable. Vehicle leases are generally in effect for <ix:nonNumeric contextRef="i6f8e4e7cb13141119d6f1759b7717a08_I20201231" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzM4MDA_7061f492-8380-4232-80d5-4fb3da38b7db">four years</ix:nonNumeric>. The Company does not record short-term leases (leases with an initial term of 12 months or less) on the balance sheet; however, Merck currently has no short-term leases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#8217;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#8217;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost was $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTAxOTk_ec81b617-fe48-47fe-8d31-b419faf93cb0">346</ix:nonFraction>&#160;million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzU4MDk_b66e2b0c-e7e3-4d6e-b25f-6b7852d273d9">339</ix:nonFraction> million in 2019. Rental expense under operating leases, net of sublease income, was $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ5MDQxOTg_90e92387-9426-4727-ae93-258ed7e891c6">322</ix:nonFraction>&#160;million in 2018. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTAyMjA_80252367-3adc-4b3f-abd6-101ea635faeb">340</ix:nonFraction>&#160;million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzU5MDY_dfdc809d-8f5d-4b11-a145-cff039af4cf3">281</ix:nonFraction> million in 2019. Operating lease assets obtained in exchange for lease obligations was $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTAyNDE_11aec7dc-790d-4f22-8d9f-fd9dd23987ed">495</ix:nonFraction>&#160;million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzU5ODg_28466f7f-27d7-4533-a241-1bd5ab081f1c">129</ix:nonFraction> million in 2019. </span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="mrk:AssetsandLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY2OTI_da5285b5-f37e-4a0e-ad51-38ab07a9ecb0" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_50622f13-ac81-4492-afe1-5ad4feaf94c9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_821d9613-2257-47a4-8e9e-6ec850c6c87e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMS0xLTEtMA_0f099356-87bd-4b3e-9050-85b5e601e266">1,725</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMy0xLTEtOTYx_990983ea-432e-466f-9b89-00b92341e572">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_36307b76-5525-434a-87a2-55d497163500"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_ff6866b2-78de-4484-8932-0849a2e904bc">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMS0xLTEtMA_96d7e6da-d0fb-487c-8c86-4cd1690a7758">300</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMy0xLTEtOTYx_12685eae-4c06-41c5-b869-78f256e6a75a">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_8ad1ce04-1366-42d1-95f3-bf2b967b7e47"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_a770729c-7273-4447-83c4-49a31ce0554f">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMS0xLTEtMA_4ed9ad61-212f-4376-9e19-453311aab81c">1,362</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMy0xLTEtOTYx_fa8041f5-1bb8-4731-a9fb-0c682b327ab6">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzYtMS0xLTEtMA_f7e97ac6-2e73-4ffc-9372-55ef59660c70">1,662</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzYtMy0xLTEtMzg5OA_a237ecdc-640d-49e9-936a-c2d5d9c32c02">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzctMS0xLTEtMA_3e28bd8e-179a-4370-82a3-9e995edb9673">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzctMy0xLTEtOTcx_cc586997-6980-4edf-98b8-325638cedee8">7.4</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzgtMS0xLTEtMA_c41a825a-458d-4e49-8436-b3b308b374d3">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzgtMy0xLTEtOTcx_60122a3c-7bb8-484b-9ac6-15c589fee588">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes prepaid leases that have no related lease liability.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i6a609b59328742cc8ba1cf13395a5a27"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY2ODk_3c2cee5f-a085-4549-9b71-fdebc843d0f6" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzAtMS0xLTEtMA_bbb55cd4-10aa-459e-b649-626bba673d70">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzEtMS0xLTEtMA_202c14a4-3266-4a0f-a387-4fe552da6bc9">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzItMS0xLTEtMA_4996648b-75df-49f5-a45f-e6ae8057db8c">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzMtMS0xLTEtMA_7a4c4943-2293-44d1-a99b-754e57a062de">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzQtMS0xLTEtMA_605759b9-579d-4832-81d8-8bce1b8b4451">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzUtMS0xLTEtMA_65fc1d07-2e53-407e-a850-dfeb88002b28">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzYtMS0xLTEtMA_1d4dc43d-eb72-40bf-97dc-4c8fc5115338">1,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzctMS0xLTEtMA_6ef305ac-3f50-43bf-9f8e-1f4a3a33894b">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzgtMS0xLTEtMA_c0b04a0b-6d24-4df3-b7f3-b425ad638eae">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzYzNjk_95f5268b-0efc-46a5-aff3-a60240c3b97d">475</ix:nonFraction> million.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_202"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI2MjA4_a3000f1b-2b1f-40d8-ba89-78f2fa3cfe3f" continuedAt="i70b517a896a74e9e9c24e376422466cc" escape="true">Contingencies and Environmental Liabilities </ix:nonNumeric></span></div><ix:continuation id="i70b517a896a74e9e9c24e376422466cc" continuedAt="i12e5a15ed904496f84b9083de893bf4a"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Litigation). As of December&#160;31, 2020, approximately <ix:nonFraction unitRef="legalmatter" contextRef="if1ad8b2fd3e14ee9bddb13cd515e52a8_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI0NzA_d4c7e81d-6ed0-4fa6-8a62-a420bc26cbde">3,520</ix:nonFraction> cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn v. Merck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the jury returned a verdict in Merck&#8217;s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck&#8217;s motion for judgment as a matter of law in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case and held that the plaintiff&#8217;s failure to warn claim was preempted by federal law.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i12e5a15ed904496f84b9083de893bf4a" continuedAt="icec34460873c44968fa04e3eae0e2eee"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court&#8217;s preemption decision in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately <ix:nonFraction unitRef="legalmatter" contextRef="i93df136354cf4fa38c646e1cf689a82a_D20140301-20140331" decimals="0" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzM2NzA_f2d2e3de-2f72-46dd-aeb6-81756a39d914">650</ix:nonFraction> cases on preemption grounds. Plaintiffs in approximately <ix:nonFraction unitRef="legalmatter" contextRef="i9a481dedbd2d4933a6677cd0e1edf178_D20200101-20201231" decimals="0" name="mrk:LossContingencyClaimsonAppealNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzM3MzA_a5b5cfcb-c4c2-4fb1-91e5-21734c78e6db">515</ix:nonFraction> of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#8217;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#8217;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#8217; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, as of December&#160;31, 2020, approximately <ix:nonFraction unitRef="legalmatter" contextRef="i1eaa63e5d47740128c127b437bacd031_I20201231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzUxNDk_e915e177-f8c5-45fc-9565-cc49227081c4">970</ix:nonFraction> cases were actively pending in the Femur Fracture MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, approximately <ix:nonFraction unitRef="legalmatter" contextRef="ie55841cf14c74bd7b0e16fd09b652e33_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzUyMzE_bb5cae31-4b7f-4319-94b5-05bf3b70775d">2,270</ix:nonFraction> cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, approximately <ix:nonFraction unitRef="legalmatter" contextRef="ia8e56c0040ba4a169fefc5cf5549d74a_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzU1NDc_b223007f-44b6-470a-bdb9-1b5a5b74947d">275</ix:nonFraction> cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are <ix:nonFraction unitRef="legalmatter" contextRef="i431f7512254c41a3ab21b8e40f090091_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzU4MDM_7d131dc1-9cae-466b-b3ab-91abe51ea5c3">four</ix:nonFraction> Femur Fracture cases pending in other state courts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2020, Merck is aware of approximately <ix:nonFraction unitRef="legalmatter" contextRef="ib4047d89366440f5864171ba3e8586b0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzYxOTA_83027fdc-df8c-439a-8e98-62a75770038d">1,480</ix:nonFraction> product users alleging that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the development of pancreatic cancer and other injuries. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the MDL and California State Court, in separate opinions, granted summary judgment to defendants on grounds of federal preemption. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment and expert motions. Briefing of those motions is complete and hearings before both the MDL and California State Court judges took place on October 20 and December 8, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, <ix:nonFraction unitRef="legalmatter" contextRef="i1c91e20a1c71440293d3d8d945468a75_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1Xzc0MjA_5485be5b-ce25-4f4a-956e-c0199d521c5d">six</ix:nonFraction> product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#8217;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(relating to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter discussed above). Merck filed </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="icec34460873c44968fa04e3eae0e2eee" continuedAt="i21121d2cdb574ec1b46567f10a470f71"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that preemption presents a legal question to be resolved by the court. In May 2020, the Illinois Appellate Court issued a mandate to the state trial court, which, as of December 31, 2020, had not scheduled a case management conference.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately <ix:nonFraction unitRef="legalmatter" contextRef="id52db59ac0fa4c2590483162033676b0_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1Xzg1ODc_61b25370-c434-45ad-af64-48b500cf3a87">50</ix:nonFraction> additional claims. The Company intends to continue defending against these lawsuits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck reached a settlement with the Attorney General of Utah to fully resolve the state&#8217;s previously disclosed civil lawsuit alleging that Merck misrepresented the safety of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As part of the resolution, Merck paid the state $<ix:nonFraction unitRef="usd" contextRef="ibbb6a7b18f5c4976971de8a6461cfe40_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzMyOTg1MzQ5MjcwMzA_7209c264-818f-4cd2-85db-76f886532c7a">25</ix:nonFraction>&#160;million. The settlement does not constitute an admission by Merck of any liability or wrongdoing. This agreement marks the final resolution of litigation involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. There is ongoing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation in certain countries outside the United States.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#8217;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#8217;s information request by seeking information relating to Merck&#8217;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#8217;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#8217;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#8217;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#8217;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#8217;s investigation and intends to produce information and/or documents as necessary in response to the CID.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Company&#8217;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i21121d2cdb574ec1b46567f10a470f71" continuedAt="i214b9b1768004ec78b7eef952adc0adc"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#8217; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#8217; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#8217; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint and, in August 2019, retailer opt-out plaintiffs filed an amended complaint. In December 2019, the district court granted the Merck Defendants&#8217; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On August 21, 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of 35 direct purchasers, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted the Merck Defendants&#8217; motion for permission to appeal the district court&#8217;s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2020, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota against Merck and others (the UHC Action). The UHC Action makes similar allegations as those made in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class action. On September 23, 2020, the United States Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation already in progress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, Humana Inc. filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against Merck and others, alleging defendants violated state antitrust laws in multiple states. Also, on December 11, 2020, Centene Corporation and others filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana. Both lawsuits allege similar anticompetitive acts to those alleged in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class action. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rotavirus Vaccines Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, MSD is a defendant in putative class action lawsuits filed in 2018 on behalf of direct purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, alleging violations of federal antitrust laws. The cases were consolidated in the Eastern District of Pennsylvania. In January 2019, the court denied MSD&#8217;s motions to compel arbitration and to dismiss the consolidated complaint. In February 2019, MSD appealed the court&#8217;s order on arbitration to the Third Circuit. In October 2019, the Third Circuit vacated the district court&#8217;s order and remanded for limited discovery on the issue of arbitrability. On July 6, 2020, MSD filed a renewed motion to compel arbitration, and plaintiffs filed a cross motion for summary judgment as to arbitrability. On November 20, 2020, the district court denied MSD&#8217;s motion and granted plaintiffs&#8217; motion. On December 4, 2020, MSD filed a notice of appeal to the Third Circuit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the United States District Court for the District of New Jersey, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fluralaner) products in the United States or its territories between May 1, 2014 and December 27, 2019. The complaint contends </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">causes neurological events and alleges violations of the New Jersey Consumer </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i214b9b1768004ec78b7eef952adc0adc" continuedAt="i39c174fabafe4bec975e3e3fb45fe123"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fraud Act, Breach of Warranty, Product Liability, and related theories. A similar case was filed in Quebec, Canada in May 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by <ix:nonFraction unitRef="legalmatter" contextRef="i7663bc55df4c4c659db0b11ccee9658d_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzE2Mzcz_07be7f53-dbf0-4ec2-aaf9-f6e93e1c0269">two</ix:nonFraction> former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The <ix:nonFraction unitRef="legalmatter" contextRef="i7663bc55df4c4c659db0b11ccee9658d_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzE2ODI1_07be7f53-dbf0-4ec2-aaf9-f6e93e1c0269">two</ix:nonFraction> former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, <ix:nonFraction unitRef="legalmatter" contextRef="idbd659ea6c05471da9fb04c882ed6666_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzE2OTU2_86f4e948-b536-4a68-b46a-33137d04b5d1">two</ix:nonFraction> putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;II vaccine, which charge that the Company misrepresented the efficacy of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#8217;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits have proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the Court. The Company continues to defend against these lawsuits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck KGaA Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2016, to protect its long-established brand rights in the United States, the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the United States, alleging it improperly uses the name &#8220;Merck&#8221; in the United States. KGaA has filed suit against the Company in France, the UK, Germany, Switzerland, Mexico, India, Australia, Singapore, Hong Kong, and China alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In the UK, Australia, Singapore, Hong Kong, and India, KGaA also alleges breach of the parties&#8217; coexistence agreement. The litigation is ongoing in the United States with no trial date set, and also ongoing in numerous jurisdictions outside of the United States; the Company is defending those suits in each jurisdiction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i39c174fabafe4bec975e3e3fb45fe123" continuedAt="ie66246c776bd4662a9d2950a9c151321"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The FDA has granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides a further six months of exclusivity in the United States beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Including this exclusivity, key patent protection extends to January 2023. The Company anticipates that sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States will decline significantly after this loss of market exclusivity. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin, which, if determined to be valid, would preclude generic manufacturers from making sitagliptin phosphate salt and polymorphic forms before that patent, inclusive of pediatric exclusivity, expires in 2027 (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation which, inclusive of pediatric exclusivity, expires in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court has scheduled separate one-day trials on infringement issues in November 2021 through January 2022, to the extent such trials are necessary. In the Company&#8217;s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with <ix:nonFraction unitRef="legalmatter" contextRef="ie6c8d1063fa24db98c2859bbb23cc25a_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzMyOTg1MzQ5MjcwODU_f6f630aa-402f-496d-9cc3-677d6e54415d">nine</ix:nonFraction> generic companies providing that these generic companies can bring their products to the market in May 2027 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent, which other manufacturers joined. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision is expected in May 2021. If the challenges are successful, the unchallenged claims of the 2027 salt/polymorph patent will remain valid, subject to the court proceedings described above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the generic companies are successful, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could lose market exclusivity in Germany as early as July 2022. Challenges to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPC have also occurred in Portugal and Finland, and could occur in other European countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Microspherix LLC (Microspherix) sued the Company in the U.S District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringed several of Microspherix&#8217;s patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until those patents expire in May 2021. The Company brought</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR proceedings in the USPTO and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against the Company. The Company appealed the decisions finding claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO&#8217;s decisions. The matter is no longer stayed in the district court, and the Company is currently litigating the invalidity and non-infringement of the remaining asserted claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="ie66246c776bd4662a9d2950a9c151321"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2020 and 2019 of approximately $<ix:nonFraction unitRef="usd" contextRef="ie6d206d30ad44f5780586176e7331c05_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzIyOTE1_27ac0d7c-d5e3-43ee-9030-048bd6dc7425">250</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i31aeae8af44247eca21b7f933034044c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzIyOTIy_ae0d5666-8683-4d22-ae21-d7a24dd1acef">240</ix:nonFraction> million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#8217;s potential liability varies greatly from site to site. For some sites the potential liability is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccrualForEnvironmentalLossContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI1NDYy_7ca70143-d792-442c-9bf3-34af44f94b63">67</ix:nonFraction> million at both December&#160;31, 2020 and 2019. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:duryear" name="mrk:TermForPayingOffEnvironmentalLiabilities" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI1NzIz_8a335ec7-3817-4501-bf31-e418c9a58c73">15</ix:nonNumeric>&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI1OTk3_26ad0e56-98ec-455e-890f-b5f332cd53d0">65</ix:nonFraction> million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_205"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzE1MDU_977b82a5-1679-44fb-a6f6-10c75e4b1fd5" continuedAt="ib14854d01ad44114ac4e68c32b55084d" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="ib14854d01ad44114ac4e68c32b55084d"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merck certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzcx_26d04162-bf24-4b31-bdd1-b512a1b78fc6">6,500,000,000</ix:nonFraction>&#160;shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzEwMQ_d1e8f31c-d692-4a9a-bbab-e4def4a9f4d2">20,000,000</ix:nonFraction>&#160;shares of preferred stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Stock</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzE1MTE_2728c426-fbcb-46de-9279-b94abe07da15" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0896f4b9831541ae8488b94c4eae2335_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItMS0xLTEtMA_8e743d1a-eee7-4bc7-af8c-a6dcd15add64">3,577</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia612eb926af84202b6beec26340d18cc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItMy0xLTEtMA_f876b673-caef-4364-9534-3eec0865beb8">1,038</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67131e7c55f84174b370dc31e7893725_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItNS0xLTEtMA_eceeba18-b41c-4e54-8af2-42cfcab40537">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if472f36dd37249baacd8179c8220ecaa_I20181231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItNy0xLTEtMA_72f36769-236d-4d72-8e70-8f63d5b4774f">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i530838b57a7f40aea997c3c0d8eafce0_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItOS0xLTEtMA_a9a7a176-6e7c-4361-8ae3-3223001b549f">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93f33a2e859a4576a7e62ef19bff98f0_I20171231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItMTEtMS0xLTA_0ce79c61-c54d-4af2-ab7f-01d5482e39ac">880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19dc4d009aa34aeb9203985671a29f18_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtMS0xLTEtMA_d3395ba2-672b-4696-a130-caa7299e8595">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtMy0xLTEtMA_3b4cd57d-1f25-415a-b3a6-66cff7f3bfde">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66c2178f642f47caab789497db80c0bb_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtNS0xLTEtMA_d09e519d-dcfc-439f-a974-4dce4a8b827a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtNy0xLTEtMA_a514033d-4125-4170-9ef0-a9321c060d25">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0885861e3a0249f99de1e639684e4e6e_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtOS0xLTEtMA_a2db1cb7-c7c3-434a-9df1-b87d42a0783f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtMTEtMS0xLTA_c637916b-5b83-4dfd-9fe7-99b68e86db1b">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19dc4d009aa34aeb9203985671a29f18_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtMS0xLTEtMA_0a68f66f-21b4-4c1e-b2e9-7c485096ff81">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtMy0xLTEtMA_68f7d8dc-199d-459f-8e51-50e7a4782438">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66c2178f642f47caab789497db80c0bb_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtNS0xLTEtMA_48c793b5-a5c1-41dc-82c7-bcd64fb194f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtNy0xLTEtMA_28ee22e3-058c-4949-9c50-8f18f78bb69d">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0885861e3a0249f99de1e639684e4e6e_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtOS0xLTEtMA_a2ac3a1e-2b07-4649-b489-401622303945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtMTEtMS0xLTA_a13b8dd2-99fd-4370-9274-f4bd6da2d8d8">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id94362b387b441469ec50222fe704479_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtMS0xLTEtMA_e3d16060-045a-4656-badb-c00337760e34">3,577</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice647f7217ff4273a045f1876ac8bbe8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtMy0xLTEtMA_29e0ad8b-0711-4658-b720-9bb70fe1b516">1,047</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0896f4b9831541ae8488b94c4eae2335_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtNS0xLTEtMA_786d0271-9a10-46bf-b040-e994b8b374c4">3,577</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia612eb926af84202b6beec26340d18cc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtNy0xLTEtMA_219fbcf7-5ee6-4793-afba-d7100e6bba1c">1,038</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67131e7c55f84174b370dc31e7893725_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtOS0xLTEtMA_232072ca-d5a3-4009-b132-45a42fd3ebb2">3,577</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if472f36dd37249baacd8179c8220ecaa_I20181231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtMTEtMS0xLTA_0e1bfae6-6db2-4275-afc8-3ea4ab2ae1c3">985</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company&#160;entered into accelerated share repurchase (ASR) agreements with two third-party financial institutions (the Dealers). Under the ASR agreements, Merck agreed to purchase&#160;$<ix:nonFraction unitRef="usd" contextRef="i757d42734fe94bb68d3cf7cf12d0c493_I20181231" decimals="-9" sign="-" format="ixt:numdotdecimal" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzUyMQ_f809fa12-7476-45c3-a8d4-20b6fe16d46a">5</ix:nonFraction> billion&#160;of Merck&#8217;s common stock, in total, with an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i78e330e646b54193bfa5012cd95c821c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzU4Nw_6dcb8e2e-9401-4337-9666-59a8be8a0594">56.7</ix:nonFraction> million&#160;shares of Merck&#8217;s common stock, based on the then-current market price, made by the Dealers to Merck, and payments of&#160;$<ix:nonFraction unitRef="usd" contextRef="i757d42734fe94bb68d3cf7cf12d0c493_I20181231" decimals="-9" sign="-" format="ixt:numdotdecimal" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzcwOA_3eeac892-b227-4f2c-8057-0c8c28da124e">5</ix:nonFraction> billion&#160;made by Merck to the Dealers, which were funded with existing cash and investments, as well as short-term borrowings. Upon settlement of the ASR agreements in 2019, Merck received an additional <ix:nonFraction unitRef="shares" contextRef="i1a59deaeb6ac41918736b40c0e87db06_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzEyNzQ_8eddb598-50f2-49c9-ab50-f4ec6040a0a6">7.7</ix:nonFraction> million shares as determined by the average daily volume weighted-average price of Merck&#8217;s common stock during the term of the ASR program, less a negotiated discount, bringing the total shares received by Merck under this program to <ix:nonFraction unitRef="shares" contextRef="i8f31986a93f04797badcd48bd6288494_D20181001-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzE1MDM_e7ff966e-70d0-4a14-925c-ab8294cd2111">64.4</ix:nonFraction> million.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_208"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxNTI_1e5660e6-a3c9-4c36-bc62-81ea53fb7ada" continuedAt="i695448d7c5e74ab6b33720a136f03af0" escape="true">Share-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="i695448d7c5e74ab6b33720a136f03af0" continuedAt="i91d28fa9726348efb23db613ae6b05c8"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#8217;s shareholders.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQ1Mg_e6fd8b7a-6fff-44c5-9afc-d365858876aa">100</ix:nonFraction> million shares collectively were authorized for future grants under the Company&#8217;s share-based compensation plans. These awards are settled with treasury shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzc2OTY1ODEzOTg3OTg_50885ad9-ac7b-4c43-8645-ce817594ddba">three-year</ix:nonNumeric> period, with a contractual term of <ix:nonNumeric contextRef="i72b8afe3fe844c02ab7183ab38cfe809_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzgyNA_d386cafe-23cc-44e2-89be-3fb872f13716">7</ix:nonNumeric>-<ix:nonNumeric contextRef="i953fcdd3d90e447480d218ef6e31883b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzgyNw_816d10f0-055c-4eea-b4ca-ba410a5516a9">10</ix:nonNumeric>&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#8217;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#8217;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#8217;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzc2OTY1ODEzOTg3OTk_7bc94739-d5c7-40a2-bb2c-8ebe391bb207">three years</ix:nonNumeric>. RSU awards generally vest one-third each year over a <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzc2OTY1ODEzOTg4MDA_90a24372-421e-4d89-b44c-c625f579c49e">three-year</ix:nonNumeric> period.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total pretax share-based compensation cost recorded in 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIxNzQ_563a97c4-8f88-427d-9f5d-9bd4f5ba1b4e">475</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIxNzg_fad574d8-1a55-46ca-a3cb-bfe9ec8e5600">417</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIxODU_662c02e6-5fe7-40b4-bddd-11d22808c701">348</ix:nonFraction> million, respectively, with related income tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIyMzk_c078a6ed-a1b5-4c1e-babd-98a8821289d1">65</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIyNDM_025d3ea5-bff8-4ab0-844a-07c224f6148d">57</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIyNTA_9f9d33b6-f082-442a-8bfa-f7320a26662a">55</ix:nonFraction> million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i91d28fa9726348efb23db613ae6b05c8"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#8217;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price of options granted in 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzMzNTg_3eebdc4f-c2f1-4a59-9cb0-6f275480ad4d">77.67</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzMzNjI_b48704bf-f9fb-4d6a-81c0-809a84eca807">80.05</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzMzNjk_0e7f9f11-1c81-4229-a1b3-9b27edfce80e">58.15</ix:nonFraction> per option, respectively. <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxMjc_0a31d06d-26c1-4f49-ac58-2ea9fcaabd3a" continuedAt="iefe0a504754d4b43b9de66e5318e08af" escape="true">The weighted average fair value of options granted in 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzM0NzA_b7374307-4ef9-4eff-900a-a61ef25f384f">9.93</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzM0NzQ_53e89366-2353-4ca4-b6d7-83016684dfa6">10.63</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzM0ODE_36896d95-6a26-4c1b-b3e6-43ff8c790602">8.26</ix:nonFraction> per option, respectively, and were determined using the following assumptions:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="iefe0a504754d4b43b9de66e5318e08af"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzEtMS0xLTEtMA_e5bef7bc-8115-496e-a930-9abc99630db6">3.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzEtMy0xLTEtMA_3ce0ebc4-41d0-4658-afcc-200adbcc9aea">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzEtNS0xLTEtMA_1fa77f4f-1dd8-4a71-8b83-87d1c647cb1a">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzItMS0xLTEtMA_a9a58214-4098-42a5-8e95-70aeaaa45108">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzItMy0xLTEtMA_4316aae0-3323-4b38-b771-06e66952b730">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzItNS0xLTEtMA_0bb38cb4-dcea-4005-bcca-fc81ba520630">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzMtMS0xLTEtMA_8e654f51-b271-4ba1-97ff-6450dcdd6c12">22.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzMtMy0xLTEtMA_4f4a6339-b75d-49dd-bdb3-1c062df0f18b">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzMtNS0xLTEtMA_8656e69c-12ba-4785-b727-e7016f2b78cf">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzQtMS0xLTEtMA_75024c78-65eb-429b-bc1c-20bd4107e896">5.8</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzQtMy0xLTEtMA_d1e78775-8cf6-4df5-a8bb-0047da258224">5.9</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzQtNS0xLTEtMA_1a5794a3-61c2-4342-8f6a-accefe80b064">6.1</ix:nonNumeric></span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxNTQ_f1289687-6d1a-44b3-897e-6b6c40ed5b92" escape="true"><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzEtMS0xLTEtMA_eddc8e5d-1cb3-409f-affc-2bb83af50742">17,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzEtMy0xLTEtMA_043cf7bd-36fe-464c-b22c-dba1a0d88c4c">59.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzItMS0xLTEtMA_f9cd96de-1953-4cf3-b56d-ae8d8cd81141">3,564</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzItMy0xLTEtMA_1f3ffe1f-e11e-4dcc-95ad-9b4e67ac379d">77.67</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzMtMS0xLTEtMA_62309ba3-a8ff-41ad-af96-ace0f2e9f169">1,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzMtMy0xLTEtMA_74b18af8-28a3-43b6-8fd1-d65c17f67ec7">52.73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzQtMS0xLTEtMA_e1c659ff-18a0-46f8-b180-2d125f69f6de">301</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzQtMy0xLTEtMA_0f054c40-01ae-411b-b82c-03a839329fd2">67.73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzUtMS0xLTEtMA_b0ff528a-8c64-42d7-a6b2-62a4793ade71">19,446</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzUtMy0xLTEtMA_40172c70-9fe5-4e02-9b7b-52e208bb7a13">63.64</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzUtNS0xLTEtMA_1038313c-b7a7-4b66-bab2-af117066a9e4">6.27</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzUtNy0xLTEtMA_dcde777a-021c-45ec-8be3-2b724d460c78">353</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable December 31, 2020</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzYtMS0xLTEtMA_948a9757-43ee-4ef5-908c-4ef41c79f9c2">13,141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzYtMy0xLTEtMA_83fc4b19-4a54-4d6a-b871-8624019dd7ea">58.30</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzYtNS0xLTEtMA_afb0dab2-a785-4660-ba9d-7c1dfaf7122e">5.13</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzYtNy0xLTEtMA_d9267f54-c534-4f1a-8ac9-ea492e0b1cca">309</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxNDI_1a531ade-c602-4d2a-814c-73f790642d6c" escape="true"><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzEtMS0xLTEtMA_d767a87e-5c56-4b7b-96ae-7bb50a6c5bbc">51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzEtMy0xLTEtMA_5ce3b278-74cb-4181-8803-519bcf48ca54">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzEtNS0xLTEtMA_874c18dd-0436-4995-bc41-eb8e34743a4d">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzItMS0xLTEtMA_a67f3420-344b-4a6f-9b76-9b2049e1bb1a">25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzItMy0xLTEtMA_7919535e-fc29-48a6-bd44-e47aa00340be">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzItNS0xLTEtMA_766ab603-052b-4b2b-96f1-ad243dbc1d8d">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzMtMS0xLTEtMA_2d05f04e-c38d-4443-8d10-70222103fd49">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzMtMy0xLTEtMA_a8ad012d-dbd5-4a9a-af1f-c9e65ab378e7">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzMtNS0xLTEtMA_deba4eec-5e36-4cad-9dc0-f849bd3b4083">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxMjA_bc0181b5-f343-4188-9b91-e9c292120953" escape="true"><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested January 1, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic34f1f7cd09744c996b65b7244c26c66_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzItMi0xLTEtMA_c66aa706-1508-467a-bc62-e9c05aba9e26">13,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic34f1f7cd09744c996b65b7244c26c66_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzItNC0xLTEtMA_4e79b526-f82c-4694-8fd1-55cb27b918d2">67.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i000733eb4d4149cd92245dbf45a48680_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzItNi0xLTEtMA_c36617a6-90ec-48ad-91c0-3da1308b05f9">1,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i000733eb4d4149cd92245dbf45a48680_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzItOC0xLTEtMA_62b33dc9-4d05-403e-b07c-545c10fb7afa">69.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzMtMi0xLTEtMA_9eeefdc1-751c-4e0a-b270-1f954446e080">6,627</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzMtNC0xLTEtMA_fa643c4d-96b1-4682-a387-5a57a83b32db">77.79</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzMtNi0xLTEtMA_1bacecbb-840d-4709-a1f3-4a22f48d5989">996</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzMtOC0xLTEtMA_5f5f0909-fed8-4864-ade0-1d4d9216933f">77.82</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzQtMi0xLTEtMA_46e5b955-9d76-4cf3-a30f-a6af30013ee1">7,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzQtNC0xLTEtMA_951c79ef-0788-4f21-84f1-072fdc36c4fa">65.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzQtNi0xLTEtMA_ca100ed8-d8ed-4736-923c-0c93f5d9689d">824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzQtOC0xLTEtMA_ef13c10f-01c0-4ce9-aad9-1408135b71aa">64.01</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzUtMi0xLTEtMA_7c0272d1-86ff-4d07-93f5-26296db5db85">728</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzUtNC0xLTEtMA_156f4e39-af6e-46e2-9396-19e20c43c43d">72.06</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzUtNi0xLTEtMA_e09b21bb-333a-41da-b30f-889afaad67fb">44</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzUtOC0xLTEtMA_18ceb38b-407e-49d3-9361-3cad9c089c55">80.06</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e2c8bbf6d144b1590bfc2f06989e5f2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzYtMi0xLTEtMA_827c26f5-f093-4707-94ea-2cddc93faa41">11,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e2c8bbf6d144b1590bfc2f06989e5f2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzYtNC0xLTEtMA_80ed11bc-0169-4e83-9406-9ff7c06ba8db">74.17</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5824e3a83dad4afab742fd2ce8e74b3d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzYtNi0xLTEtMA_d7d795ee-52fb-4977-b68b-f07b08b3c9f8">2,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5824e3a83dad4afab742fd2ce8e74b3d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzYtOC0xLTEtMA_c416f8bf-6226-409b-bb2f-8caf81efc54c">75.08</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzM4NTc_72c09f26-9fc7-43b8-8c7b-c70150e20b51">678</ix:nonFraction> million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQwMjQ_c20260d4-b096-4912-8a14-f1f4ebc740ee">1.9</ix:nonNumeric> years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_214"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MzA_13d867f9-60a9-4816-865c-74d5ea80d358" continuedAt="i441ffbbf27be43079844b8e97b9de573" escape="true">Pension and Other Postretirement Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i441ffbbf27be43079844b8e97b9de573" continuedAt="i4b35205ae2d0459bb8be1bf64c54563d"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic Benefit Cost</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MjA_960e0917-4b23-456e-911f-6e33be676303" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the&#160;following components:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:27.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMS0xLTEtMA_f2c3e83d-afa6-4282-b218-8e6ea90ab3d3">360</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMy0xLTEtMA_f6026b6a-ea2d-4015-b187-9898000065ff">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtNS0xLTEtMA_797b35e8-0231-4699-9133-d2df6fd9031a">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtNy0xLTEtMA_87068c9f-58e4-4561-8ec2-1325dad08a5c">301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtOS0xLTEtMA_1a6bf2b3-ee13-4685-8651-d188137c7e89">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMTEtMS0xLTA_509ed26e-47d3-4388-94d0-1aa134bed19c">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMTMtMS0xLTA_22642f7b-6490-4212-81a3-032b2322f63c">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMTUtMS0xLTA_65dc2862-90a8-4920-85c1-d81dffac7244">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMTctMS0xLTA_8bdc41c0-eaca-4777-9956-1567a80488d5">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMS0xLTEtMA_1c33ad3f-c622-4ad1-9fd6-1bee79d01a3d">431</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMy0xLTEtMA_8ccb79e9-0c4e-4a13-990a-b73de110320c">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtNS0xLTEtMA_b0da443b-67e9-49ae-9ffa-849a191075b1">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtNy0xLTEtMA_c4435b4b-f215-4969-b1a1-1de6474bd56d">137</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtOS0xLTEtMA_3609da06-9a5f-4ee0-be8d-d3882c238110">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMTEtMS0xLTA_f6423783-f626-439d-8842-4af3a009c621">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMTMtMS0xLTA_3209fa06-6cd2-4f50-8ddb-8609650d4f18">57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMTUtMS0xLTA_f92adffc-ef5e-4555-807a-24b61e9a9ed1">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMTctMS0xLTA_f54ad0c9-8e41-4a09-8ac4-526c12f81d3c">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMS0xLTEtMA_9d8f7459-f3e8-4706-a773-c3edc553f446">774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMy0xLTEtMA_59e7a7f0-e88f-4afc-b6ac-8725e61b1ab7">817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtNS0xLTEtMA_d303c5f1-aec3-44a9-a9fa-2c6865343099">851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtNy0xLTEtMA_9a3ecb27-cca2-42aa-998c-55a48b2f5079">415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtOS0xLTEtMA_640ad497-3376-4280-be6a-a8103dfc24d2">426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMTEtMS0xLTA_41df764e-183b-45b1-80f1-0bd7ebfaa25b">431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMTMtMS0xLTA_4dc6f934-3466-435c-9dd9-e223b6ca47f8">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMTUtMS0xLTA_097c7e73-cf3b-4be5-b61d-4742c9923bbc">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMTctMS0xLTA_1ace6e93-417a-4076-bb66-2704df98b2b3">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMS0xLTEtMA_97928554-414b-4eac-8bc3-c452f803970d">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMy0xLTEtMA_aa47afd7-0f26-41e3-920e-347faca952a8">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtNS0xLTEtMA_0d882d79-7eaf-4b34-8333-8596d3205bf8">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtNy0xLTEtMA_1bae8f1c-5dbd-4c8a-9898-81f31bbe4d84">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtOS0xLTEtMA_4bee242a-8bbc-47a3-9b8c-a9b11429eae9">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMTEtMS0xLTA_cc53d62b-c21f-4cde-b6f6-b3282f1b02e3">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMTMtMS0xLTA_619e238f-7939-4e8a-89e0-3e81ba7194d0">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMTUtMS0xLTA_2db09269-53b4-4689-b7c6-a4dd558c4fa3">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMTctMS0xLTA_4219163e-2b8a-480b-be91-9efd242b59b9">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMS0xLTEtMA_974c4955-51b4-468f-b4cb-5c4930dd4763">303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMy0xLTEtMA_c32660e3-1063-4e3d-87a0-c523f55824a3">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctNS0xLTEtMA_71b744b2-fdfa-4c97-be26-42789d2d0744">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctNy0xLTEtMA_87ce0f8b-1859-4bac-8921-b0707fc4c2fc">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctOS0xLTEtMA_7e9d11d2-ba17-4aaf-af19-e8e0cd5c200f">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMTEtMS0xLTA_cccd76cb-ed15-485d-a58c-653dcf053072">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMTMtMS0xLTA_71ce5967-fbf7-4fca-a6af-322df240ff5b">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMTUtMS0xLTA_c6d5490d-f81c-4e35-ac8c-809d1273a2d9">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMTctMS0xLTA_4d46053a-0981-4be6-bc67-0d887f3f1721">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMS0xLTEtMA_75bc72b7-0b77-42f4-b8f3-cb5608bb593c">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMy0xLTEtMA_1802667e-3df0-4a45-917d-4bd738fb07ac">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtNS0xLTEtMA_c18a81e2-169d-4c31-a31c-0666bfecc3b0">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtNy0xLTEtMA_26845ec2-485e-4cc0-a72f-ef9473914fd0">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtOS0xLTEtMA_d1073310-0228-4521-9894-cebddd26e6e4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMTEtMS0xLTA_069c110e-ac5b-4ef8-91b6-bdc985d27184">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMTMtMS0xLTA_d131e25b-b0bb-403c-acb5-92df0c1a8345">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMTUtMS0xLTA_3e4cf93d-7200-4fc3-946f-50f869dbcc96">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMTctMS0xLTA_e73cde02-a541-4ab2-b94c-5b135a5e95db">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMS0xLTEtMA_e4974d01-d486-4ebd-99f8-641c95d0c452">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMy0xLTEtMA_fcac0a5d-6cae-41fb-a2a0-c1242635d34c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktNS0xLTEtMA_f57280d7-a48b-4975-8c98-fb5ee26c3975">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktNy0xLTEtMA_ebd38d7a-9345-45a5-96ba-97697e3c3808">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktOS0xLTEtMA_f2e14ce7-f1de-4223-ba27-3362906e7cc5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMTEtMS0xLTA_5e40c829-15d4-4501-b6a8-110d078deeef">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMTMtMS0xLTA_a433357b-cda2-4439-b9d7-920a6c08eebf">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMTUtMS0xLTA_d43dee40-5c7a-49ee-8fb4-c78d52c6c461">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMTctMS0xLTA_b07e4142-f34d-453c-bc13-6905e0d1ce79">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTEtMS0xLTA_fec07955-1a23-4cf2-b3f6-521fc7f51525">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTMtMS0xLTA_4507513d-6641-41b8-adda-aa550e205bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTUtMS0xLTA_cb23b324-d393-4f4e-9fa5-ca66d26f49a2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTctMS0xLTA_504da084-7ec0-4aa9-8eb2-f072086b3277">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTktMS0xLTA_6b0f58f4-33ed-4b87-9ffa-e4549032e06b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTExLTEtMS0w_66c897b6-bd41-4e68-bd88-d5bb0de689a4">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTEzLTEtMS0w_e81ca972-855c-4436-936c-befd0a7fc96b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTE1LTEtMS0w_077a0f6b-6748-4541-8185-487bd07171bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTE3LTEtMS0w_374435eb-e69e-4ec6-b698-9bf21d476f97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTEtMS0xLTA_1167e9a2-2a5c-40a5-aab7-d2017e17e357">304</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTMtMS0xLTA_b0b9492c-2ded-44b4-861f-3a08b613fce4">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTUtMS0xLTA_cd3af4e7-c73e-4fe3-919d-fca8387445c8">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTctMS0xLTA_20515680-011c-472c-8611-de93c5e30ed1">150</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTktMS0xLTA_5b5d3623-e847-4302-8aa2-2cfb51dd22c6">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTExLTEtMS0w_4caa9e01-4b5f-4d7d-8af9-ae35800a24bd">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTEzLTEtMS0w_ef0bcf82-2e7f-4175-b438-be990e5ea10f">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTE1LTEtMS0w_4f805973-d95b-4928-b873-a83770fb640c">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTE3LTEtMS0w_2ab0db6b-7da1-4374-a947-bba7554daf1c">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in net periodic benefit cost year over year for pension plans are largely attributable to changes in the discount rate affecting net loss amortization. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;5), termination charges were recorded in 2020, 2019 and 2018 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the table above.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 14), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i4b35205ae2d0459bb8be1bf64c54563d" continuedAt="i7ff6f900a559403ba013dfda732c5ee2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obligations and Funded Status</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MTY_146b46ec-0214-4d89-85fe-fe0cc1b0d8ef" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:43.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.453%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtMS0xLTEtMA_0b04ee69-173e-4c39-884b-ab4eb8ce9eb5">11,361</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471a8ae5a9eb4a88ba94d7f35162f55d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtMy0xLTEtMA_fab863d3-aa68-4fb1-b251-34830bea4d3a">9,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtNS0xLTEtMA_dd105075-fb24-4510-95d9-2ec50fb0173a">10,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtNy0xLTEtMA_c81dbd94-3244-444f-ace2-51692718b612">8,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtOS0xLTEtMA_443499e1-737a-4827-8dd9-2f7944471c69">1,102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4874f46f9b2349859720b5a4665c75e5_I20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtMTEtMS0xLTA_72335c94-4702-49d9-8fb1-dfe449e8b98c">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtMS0xLTEtMA_a4071214-2472-454f-b298-4118b4386c16">1,908</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtMy0xLTEtMA_ccf23d15-38bd-48e6-ac8e-d77e9baba3e0">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtNS0xLTEtMA_54c4123b-bd14-4756-82f5-91b111ba7753">1,026</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtNy0xLTEtMA_c7f0ca48-ac3c-454e-ace2-deb5425dca21">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtOS0xLTEtMA_13e91cc4-f210-41d3-b78e-6f9fb437af59">175</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtMTEtMS0xLTA_86412742-3172-4cac-81d4-25354af3aeba">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtMS0xLTEtMA_e43017da-c3e7-4083-89a9-f82aa230948f">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtMy0xLTEtMA_ce060675-2092-4c84-8363-7adac2887c81">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtNS0xLTEtMA_68620d8e-e6a1-4c8d-a5ef-f15fec19027e">387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtNy0xLTEtMA_113bbf69-aed1-496c-9556-5c66980e6e95">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtOS0xLTEtMA_0ad6e8b2-49a4-44db-bd68-b15b6686ac46">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtMTEtMS0xLTA_4fa9c6da-9ab5-47fa-a4c6-8e12902ad1fc">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtMS0xLTEtMA_e37588d9-091c-4671-8efe-a35b1ad57d02">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtMy0xLTEtMA_89ff1552-eca6-40b7-b260-07fc61b1ce40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtNS0xLTEtMA_ed2e65f3-bf4d-4248-9920-5027f4c66e58">746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtNy0xLTEtMA_e790113a-00db-418c-8cf8-1ecebd3fbfb6">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtOS0xLTEtMA_9b9be24c-3627-4fe6-a060-8a655828ed61">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtMTEtMS0xLTA_6f3ee435-cafe-4ae8-99b0-0b15db7a3e45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctMS0xLTEtMA_d2efa7ca-1831-483b-bc2d-3b341ceb2928">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctMy0xLTEtMA_65f54ca9-068c-46b4-a953-24e69c40dcbc">582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctNS0xLTEtMA_8420ba47-f4de-4959-8fee-52ca2cf7b0d2">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctNy0xLTEtMA_718f15ef-a883-476c-bfec-0d018137d6e0">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctOS0xLTEtMA_37153b61-a93d-44dc-8ae5-484940047eb7">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctMTEtMS0xLTA_bd36fabe-9aa1-4517-96a3-6b20fb02b0a0">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtMS0xLTEtMA_37e42de8-f767-4ff3-b26d-0c2f656dea20">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtMy0xLTEtMA_0d6d681f-5a70-43ad-bf6a-868a4e474577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtNS0xLTEtMA_379c2f85-4301-42fc-b3e4-53c0735ab873">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtNy0xLTEtMA_fbd6a8ef-607b-49ca-bff8-a6ecfd9b5997">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtOS0xLTEtMA_293f2b5a-ad0b-4310-b335-adfdd33228fc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtMTEtMS0xLTA_50d1b4d6-3625-4119-b101-3beb37165f1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktMS0xLTEtMA_7af5097d-e16b-4561-ab0c-4a527e9371f9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktMy0xLTEtMA_46672a75-403c-430e-9ab4-0c238faeb49f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktNS0xLTEtMA_5bc43a0a-503e-4b93-8804-5668679b9a76">59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktNy0xLTEtMA_e6e35811-5892-4466-bc52-88b59760b9c4">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktOS0xLTEtMA_9f554730-5137-4675-b301-93ad9047013a">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktMTEtMS0xLTA_79d19840-dfd2-47dd-a05e-f0ce215babe3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTEtMS0xLTA_3ce9007b-cec6-458d-8e6f-14550be85318">12,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTMtMS0xLTA_45fb1afe-0c97-4627-8ec4-0856d406e891">11,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTUtMS0xLTA_d7cedf71-66da-447a-ba11-87ad1cc09211">12,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTctMS0xLTA_5fa1cee9-1399-489c-a5e4-dbd93686a23e">10,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTktMS0xLTA_de76263d-8067-433c-a714-03c5e2fd1fa7">1,221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTExLTEtMS0w_e1bf8c35-196d-4267-a909-f66e97af3c2a">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTEtMS0xLTA_0427ca89-ce4a-47e2-9177-f4eabc440c03">13,003</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471a8ae5a9eb4a88ba94d7f35162f55d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTMtMS0xLTA_6fae7c57-3656-46ab-9401-213596f2eb1a">10,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTUtMS0xLTA_23f58519-bc72-4b84-9e72-0b0fe1ada390">10,612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTctMS0xLTA_53676a59-13e5-4e08-a6ce-9733ae3a6d5b">9,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTktMS0xLTA_d5abaf40-bde0-4ac3-b693-e1747996877f">1,673</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4874f46f9b2349859720b5a4665c75e5_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTExLTEtMS0w_bd9b7ba9-caab-46f8-b3ee-2ee1591a6eb9">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTEtMS0xLTA_f4ca645d-9174-4b0b-9c6e-5e9802b4a823">360</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTMtMS0xLTA_b949ee24-1141-4678-b345-521b575a7d4b">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTUtMS0xLTA_4ecc341e-173c-46c2-9c81-82a4378bb11a">301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTctMS0xLTA_39b1e915-6cd1-4840-9645-cbf6cb44e6fc">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTktMS0xLTA_232a6e6d-89e6-4df9-8e2b-6b484f81824f">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTExLTEtMS0w_8ea4a407-607f-406d-a11c-fa369d744374">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTEtMS0xLTA_16c4a8e7-14f8-43fd-8646-e8fcc02705a8">431</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTMtMS0xLTA_58713cf5-6dc3-45bc-a1ea-195158150047">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTUtMS0xLTA_650a73fc-8135-4474-8d4d-f99df009e8e0">137</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTctMS0xLTA_a8e92349-b79b-4f11-aacc-ad57fc83c589">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTktMS0xLTA_b26b60cb-98ea-4717-93e8-29bae8a32611">57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTExLTEtMS0w_cb7e673d-179d-4bd1-b531-aceb5759b428">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial losses (gains) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTEtMS0xLTA_ab65183e-5efc-4523-8d5f-2ba48d3e9d28">1,594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTMtMS0xLTA_f4d6ecaf-24c9-48de-b32b-d58ef8f44ac1">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTUtMS0xLTA_f17b4435-0ba9-4fcf-ac0b-dff4bb38d0fd">1,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTctMS0xLTA_dda4d3c4-cd7b-44f7-aa92-db866bb1187d">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTktMS0xLTA_9d7df629-93f4-47e0-b237-828bbfbadcae">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTExLTEtMS0w_edb23603-1519-4a95-a3a0-8c9d56a25e22">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTEtMS0xLTA_54aa22b7-b09c-4be9-8afe-5bab69013bae">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTMtMS0xLTA_4f55e2fa-f614-4bf6-b017-790689ebde40">582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTUtMS0xLTA_16fbd6d1-6d21-4d9a-97c5-b07de62ab4ef">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTctMS0xLTA_f7d91582-c43d-41b1-ac1d-6e1fed0402d8">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTktMS0xLTA_88fda7dc-38b9-43aa-a2b6-b947b60358d5">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTExLTEtMS0w_ecea0281-60f1-4298-94b9-ab2ab2c15718">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTEtMS0xLTA_7f585e3a-917a-451d-a7cc-3e3e1bd03cd8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTMtMS0xLTA_b6abe556-9491-41a3-9a65-3d0c24a80060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTUtMS0xLTA_10d14521-f049-4974-89ea-affc68e1fdd1">794</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTctMS0xLTA_ac2fe726-05a2-4f23-82a1-62b8a1153c8e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTktMS0xLTA_dd00074b-fe23-493c-8fe1-d168dd1a314c">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTExLTEtMS0w_0ea0e3c7-d418-4bcc-825a-e63da894cf64">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTEtMS0xLTA_aeffeb80-abd7-44d8-90cd-cb9fe289522c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTMtMS0xLTA_de905bb8-8880-4198-a3b0-bc2f3365a242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTUtMS0xLTA_f0feb021-e56f-4ab7-ba72-13ef96412120">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTctMS0xLTA_e2b2de86-20be-4f68-b6eb-5efee45d55db">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTktMS0xLTA_9d7af221-8c06-4e00-b619-7535a5dbc91f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTExLTEtMS0w_c824e16a-4a84-47f7-9145-6d5a1d316a4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTEtMS0xLTA_34b6e9e3-e39f-4f54-b6df-17cd569d7f78">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTMtMS0xLTA_a85f4fca-b9df-432a-935d-53de6279278f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTUtMS0xLTA_ccf31739-5343-4e1d-ba28-e78bbb1b27e7">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTctMS0xLTA_81762f34-c2d1-419f-b141-163cc91db09e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTktMS0xLTA_8e4ecf94-82ae-4aa9-93ed-1efc675124ee">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTExLTEtMS0w_70b7b9b2-6b72-4ebf-ba76-692f1858a0ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTEtMS0xLTA_7833fdc9-eaf0-4f59-ab7e-ba3dc498585c">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTMtMS0xLTA_e4e99848-0458-4c42-a2fe-b27cbd2324a8">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTUtMS0xLTA_8552d8f0-9a72-4d94-94cd-3684207fbba6">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTctMS0xLTA_84c4cb1b-7739-46e4-82b3-8c74f7ec76b1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTktMS0xLTA_17aad554-e022-4903-a874-f8adb9dd77e2">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTExLTEtMS0w_86900607-0f99-4197-a8da-784e8b9617dc">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTEtMS0xLTA_a0d70b8c-9876-4063-a292-70f46b1b6124">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTMtMS0xLTA_8e4fd1e2-6302-4f08-bfa5-d3cea497d48a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTUtMS0xLTA_a8ae10a8-ae97-4708-a2a1-464175865903">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTctMS0xLTA_a09c2398-68f0-4f0c-b370-63ecc3084a2f">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTktMS0xLTA_38c9ac4c-c215-48ce-ad29-1ea02fc61c2a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTExLTEtMS0w_cc9d6cf7-7f71-4d70-82c2-e30e400f05a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTEtMS0xLTA_ca288b48-27b3-4014-8d05-b2ae2267d44c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTMtMS0xLTA_cc8e71df-2d7e-41ee-9216-27f22bed5b46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTUtMS0xLTA_19c8c10c-597c-4879-9186-e1eb8c02213c">55</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTctMS0xLTA_898deffe-3c5d-4876-85c1-d4befd8113ab">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTktMS0xLTA_0aa93ea9-17c3-4844-8508-6436540ba071">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTExLTEtMS0w_cf2d447b-5a9f-461d-ad7a-b36cd7c798a7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTEtMS0xLTA_df4a23fb-6e04-464b-82a8-f18df8ac50a0">14,613</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTMtMS0xLTA_a8c5f822-d126-4d53-a396-67c07d05034b">13,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTUtMS0xLTA_f883a495-9378-4a24-8176-c49b8de0750a">12,534</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTctMS0xLTA_8052e8d4-ca96-4cd0-9efb-6060141c38e5">10,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTktMS0xLTA_8f4974cd-469d-44cd-993c-79b29846253b">1,607</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTExLTEtMS0w_605ef82f-337a-4e94-9199-b62bf199cf1d">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTEtMS0xLTA_d4622062-c56b-4dff-8e57-594ffadb1594">1,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTMtMS0xLTA_ef055bbc-0c69-42b1-9e54-4c3fbcccff9d">1,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTUtMS0xLTA_c7c54492-bdef-4e03-b2ee-a9d9eb3d515b">485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTctMS0xLTA_a3e89d56-1ae7-471e-a8b7-4e3e096cd76d">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTktMS0xLTA_92977727-c81b-4bc3-bc14-d9b28e018960">386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTExLTEtMS0w_e05ec9ce-a9ad-4e41-848a-69ca40d476a9">571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTEtMS0xLTA_9d33af6c-46c8-4d11-b24d-3d2fb2f6a506">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTMtMS0xLTA_d10ff913-ba4e-42bf-8334-cb11f2cf80ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTUtMS0xLTA_68368f50-89da-423b-b0d2-9890f266d58b">941</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTctMS0xLTA_e7426b4d-049c-4ba4-8d38-4d488ce82b11">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTktMS0xLTA_78000585-aa29-4384-aef4-4a38d3075e90">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTExLTEtMS0w_1d7f1921-a4d5-4446-980f-39bb59c60df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTEtMS0xLTA_2e3f9e9a-e3d6-4176-b0b2-efd42ef7b5dd">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTMtMS0xLTA_3fcb1178-c6b9-4cb9-8439-f8458557d621">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTUtMS0xLTA_0371dcf1-20b6-4573-b312-c4c90d451d2e">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTctMS0xLTA_68529dec-a024-45e6-a7d9-fa1edf069a10">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTktMS0xLTA_b08689f0-f35c-49aa-9509-2ba44de9a11f">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTExLTEtMS0w_3c4f729d-0ae0-4732-baac-67896900a8c6">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTEtMS0xLTA_b97c7148-6b66-4c69-89b0-c3bb7502a5f3">1,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTMtMS0xLTA_995d1278-38b1-4bb6-be78-4f8eaff00e5f">1,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTUtMS0xLTA_264848dd-7d93-4019-8851-6a9051be1246">1,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTctMS0xLTA_4aebb4ae-ddb9-43d1-8e34-75288ba0959d">1,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTktMS0xLTA_d32f3600-321a-40cb-8540-dec279114a84">377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTExLTEtMS0w_0323ab0f-dddb-4543-a1a3-0d07f4783532">561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Actuarial losses (gains) primarily reflect changes in discount rates.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the accumulated benefit obligation was $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzIwMzM_44cdd5de-33d3-46f1-966d-7d3cfea0e116">26.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzIwNDA_9a0f144f-efaa-4cab-b9e6-6ce9a4e1baf4">22.8</ix:nonFraction> billion, respectively, for all pension plans, of which $<ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzIwOTA_a3788beb-eeca-4270-b416-d6304546affa">14.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzIwOTc_7eac651a-1011-441e-8af3-2062d6654b0a">12.8</ix:nonFraction> billion, respectively, related to U.S. pension plans.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i7ff6f900a559403ba013dfda732c5ee2" continuedAt="iee5e42b68a1a48e085635b90c3245b2b"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0Njc_d00cd8af-f3c8-4931-8e6d-526e0cfd984e" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:63.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzMtMS0xLTEtMA_35409ee6-3b8a-42b3-ab24-4cba288032e8">14,613</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzMtMy0xLTEtMA_98a7144f-f77a-486d-ba58-8b25d819fa90">13,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzMtNS0xLTEtMA_5292ebc7-bdd9-40b2-b576-56a640c532b2">8,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzMtNy0xLTEtMA_0166569a-815b-4246-b779-bd00bbf2ec59">7,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzQtMS0xLTEtMA_e4f8a813-4cc3-4396-8e09-9a50f9e65a52">12,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzQtMy0xLTEtMA_e3a5034f-358a-4f9d-bd08-aae42496b4e3">11,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzQtNS0xLTEtMA_d070ef1b-0d74-40ca-89dd-92447abd1c1f">7,526</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzQtNy0xLTEtMA_0e5467b6-897d-46ad-b733-ec7ceb6fcf9f">6,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzYtMS0xLTEtMA_88fabbce-8308-47f7-9e18-47c261ad50db">13,489</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzYtMy0xLTEtMA_696db373-c4e8-4358-932e-1ecbf24198e4">12,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzYtNS0xLTEtMA_df0af0df-aab0-4439-a743-50c4693ad010">4,288</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzYtNy0xLTEtMA_4f9e4f07-8fb0-4fde-9064-44a3294a850f">2,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzctMS0xLTEtMA_4b90f460-6a7b-4ff5-b250-afa0629639c2">11,685</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzctMy0xLTEtMA_2ec556f6-8c25-4e5d-b885-3d4df317f503">10,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzctNS0xLTEtMA_6568fcca-021d-4945-9124-fa6d2249850f">3,033</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzctNy0xLTEtMA_99b8f5f7-2c2a-400c-aabc-ac3c06c7ea77">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan Assets</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160; Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160; Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2020 and 2019, $<ix:nonFraction unitRef="usd" contextRef="i87b8ce0948a842ed9ef92b8f8846b1e7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzMyOTQ_f82cf685-c2f2-4fc8-8647-b7b8405326b7">942</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i89ad1d90c9eb49c08404e53143774bb6_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzMzMDE_44df471d-f865-4fce-bce7-cdbcfd5c8452">860</ix:nonFraction> million, respectively, or approximately <ix:nonFraction unitRef="number" contextRef="i63c8adecec8442f49ba129f60935b000_I20191231" decimals="2" name="mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzMzMzY_3cd83431-97cd-4999-a600-220b036b66a8"><ix:nonFraction unitRef="number" contextRef="ief783e1fed134fbe824b470778e1f671_I20201231" decimals="2" name="mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzMzMzY_ae4ba36b-f940-4e15-b7f8-f050b2e2e28e">4</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s pension investments were categorized as Level&#160;3 assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="iee5e42b68a1a48e085635b90c3245b2b" continuedAt="i084e108f43544f3bb0aa2bc8b915d72b"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MzI_c84dd063-2f89-46da-b5d1-01d0495608bd" continuedAt="i3c2070321b7f4132bcf140965ee21e7d" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:18.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1966c1d9b34614a906164b1b847e14_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMS0xLTEtMA_ec6738fd-9ffd-4d27-a908-8a3852a328df">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079debce911f4d1385c9e937966e9b9a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMy0xLTEtMA_353dedd8-8cdb-4d34-b990-68c401441038">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b5e7d4fb334cc49a3a07e272a89d54_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtNS0xLTEtMA_56e22a75-234c-4f5c-8e97-becf76a7560c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02395d4a531f43ed837de7ae7e2f47bb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtNy0xLTEtMA_c6910772-9bdd-428d-ad65-731d8440fead">303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c8164d243514c2d8cc997890ef95cab_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtOS0xLTEtMA_e82cd062-3cf8-499c-8d74-5fd53f7918b9">308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762afa9f7a1a49199bcaa4c4777b52b7_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTEtMS0xLTA_e166fb2e-9a46-4e45-909c-d0fcdafc4e15">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i896c0ab5f6ee40249192bbeea55f6056_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTMtMS0xLTA_b8c0b27b-eb35-4826-a4b9-3f8871ff527b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb94a8956cd48ecbaecb94d4ffd9314_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTUtMS0xLTA_ab8bd94f-40e4-4279-9b5e-7bfb9c140842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97baa9bccd8e477aa4dbb884bbaca507_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTctMS0xLTA_eceea6a7-0332-43fd-9547-c13b2278e56b">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04401bfc21e40589a67bb73d6d9e7e4_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTktMS0xLTA_7c942d7d-2bf7-4d99-a18b-4b654513c1a9">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dfc8f0a72a24b79a719822430bd3aba_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMS0xLTEtMA_7861b58b-e970-4bc3-bf07-6d965fed2ece">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e067be53a86451abe0e60ecbd4d1b2b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMy0xLTEtMA_500f0581-22e5-4357-9b7a-c676f350a96e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff30bd3bec0342a79f37f6d47d61a152_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctNS0xLTEtMA_7774ee03-f7f5-41a6-a449-00cf7a68319e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66284b3427a4a55b18a3d2307d2311d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctNy0xLTEtMA_61137121-3d7d-4c52-927f-85391971b781">3,884</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492575ea226e4ef79e791f68f775cbcf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctOS0xLTEtMA_a154647b-f923-4ca3-b736-25fc72d074f6">4,090</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa9c1f8e8f14bc88b26db4f04818c63_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTEtMS0xLTA_176b7989-8dd1-475e-9300-d8de1b283ccd">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05de118d42874d8a8b65d9fbbb8cd8c0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTMtMS0xLTA_8c873840-dbd5-4634-a455-88063b79340f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43bae42e68b74c9ea2cef860a864df98_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTUtMS0xLTA_edb1dc11-0a2c-4d6f-b9bd-f77927191082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4839f9e8f263483bb5a57380e0ac49d8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTctMS0xLTA_5714d617-0799-4de1-a82a-fce7fc4e29e8">3,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f92475a0e644fbad104227d35a788c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTktMS0xLTA_8d092611-270b-49c2-9e13-419fb9be7bb3">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b4d58ac72a4b6b9e8a4a3bd3534739_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMS0xLTEtMA_4af4d0c5-7640-4ee8-8076-c6d8e3523bbc">169</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie610ba127e0c486a927aaae038bb4c2a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMy0xLTEtMA_2f88b98c-918c-4b4b-a2af-44c898cb06b3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4f3b3b5ab84f1f88c1687777c06d94_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtNS0xLTEtMA_217ffb35-cf90-437f-8619-34de7216390d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2614fa71de8840c3916410fec8e4c6c2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtNy0xLTEtMA_9265fab3-4f01-4026-bf7c-a283bbb9547c">927</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8493396c311a48c087c4da0df9e9e265_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtOS0xLTEtMA_0f0549c4-2522-4029-8a2d-671e9c43c9ee">1,096</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33c4c3964914ed192b098a7887db425_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTEtMS0xLTA_eed11fe2-030c-4bb5-a5e7-8c5b97fc8ead">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983bc4d845244c9a85c0ce012de520ac_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTMtMS0xLTA_a615b2fd-1f8d-4303-8207-61fe470907e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f904c273db45369ca533911c7fdafd_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTUtMS0xLTA_415bc2c7-d22e-41e1-bf29-587784b90dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07aa6e44c4e64dc09a11f648c3aecf39_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTctMS0xLTA_244d5005-a70b-444a-a050-c44cd84dcae7">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76599c7f104045fa9d3705ce55cae95d_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTktMS0xLTA_c102a8cf-7a2d-4025-a57c-1780e0f490b8">888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a35eceae1749b2afc0e2adfbab500f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMS0xLTEtMTQ3ODc_38825dbb-be55-4849-81f6-31d3236a25c9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf07f551b9e54a50ac5e33ce5e447aaa_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMy0xLTEtMTQ3ODc_6aeffcb0-0f9f-477e-a53d-1a0edbafd003">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafbe4a56619b49ab892a56d15529c893_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtNS0xLTEtMTQ3ODc_0e0003a1-7724-40a0-a799-28d3aab5ebca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb63fb418f534cf9a00bf9ce064c5f01_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtNy0xLTEtMTQ3ODc_4d56c4c2-2cd4-4fd2-aaec-243b0690eb74">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22427a43423b41ee97f6e223da5fc0c1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtOS0xLTEtMTQ3ODc_a9cc851b-83f1-4041-9024-29bca0681812">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fdcc0719b79428ba1c8942ab8420778_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTEtMS0xLTE0Nzg3_b688e07f-f644-4c6a-ac6e-6ef652201ddf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29bf2bf658614113ba17d962e1e99dc1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTMtMS0xLTE0Nzg3_548fcce4-9614-498f-8688-50b6c9f29969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0441dc72fcb54c48aa6e5a54486d62a4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTUtMS0xLTE0Nzg3_79320865-d7c7-4fa0-ae36-826842b9cc7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04061d95b9fb4f6692618bb6b2e163ca_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTctMS0xLTE0Nzg3_16e3149b-27d5-4d05-9554-517043a3e6f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ab217ecf2047ca82f61f394e3b2143_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTktMS0xLTE0Nzg3_44686355-75bf-4b1a-9be2-b020143ddf2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a333a9d32a4a75939aaec5815b2ce7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMS0xLTEtMA_f1a01ba3-90df-4c74-8138-28bf4a7f6551">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a588a2b1824cb39195f5f331917939_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMy0xLTEtMA_96e60b9e-7c2d-4a31-b480-68e0706dedb1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b412ecd46f4665a8377ecba5fa899f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktNS0xLTEtMA_89f60d22-30c5-4147-a122-82be84fb013a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6e39b65bae448395fac9f11f72bd1e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktNy0xLTEtMA_b03a2642-ddfd-4d42-be1e-4e0ddf373695">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd6fe4acd1d43f89863a9719678632f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktOS0xLTEtMA_f4833e63-fa30-491c-8088-1382007d6378">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffdb8aac16a488c88f1530e7c5839e1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTEtMS0xLTA_18dc1ea0-80ee-437e-9840-2c282bc374b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id031685155804a84ac3ff78aa32f7379_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTMtMS0xLTA_61108da0-5a47-4522-a389-db135c69e2d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fda6a6813da45e8b85ab5cc18158c65_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTUtMS0xLTA_6a79fb2f-c13d-4a80-b6c1-3d415e19284e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8e94062e6ca4f1e848b910410e66b4d_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTctMS0xLTA_2ca6d5ad-0c05-4f0b-8ed5-bd1e34e5d949">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7598124a95dd40e180dcd55e241004cf_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTktMS0xLTA_3fc4edda-c411-4bc6-9469-8155f359a57a">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c46ea7c16f04e6f9077e7ada8dc3aee_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTEtMS0xLTA_db05c0fe-95b0-4756-8806-48d4880a2ca3">2,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881d12a48fa145e29b963710be067d8b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTMtMS0xLTA_4071685a-ce32-4a78-acee-dee653b13a8f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963fb897f1a84494b29bbd3cc88a5cde_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTUtMS0xLTA_0134f134-c21b-4d74-9df0-1b81957f0dae">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d998e95188b43bea7ef9db2acaa7908_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTctMS0xLTA_1038f45f-b606-452f-86f9-18a00631b58c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5e8ce709424f55baf4ceb447892b4f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTktMS0xLTA_8daf1abc-ba79-4075-95c6-186205be07db">2,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27f9b2b78804c56a1797bb83137c3b1_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTExLTEtMS0w_b5517870-b583-40ba-93cf-1db3d7084615">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece7c24fe22a4365ac316e8f89696d65_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTEzLTEtMS0w_e6960b71-3e72-42f1-b9f2-d1420c071a1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5510be169a403bb3a2fdf843a3ed07_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTE1LTEtMS0w_fef199d5-ba2f-42ad-81f4-65cd08e95bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1c15bfcb925489c83014b3d69b512e2_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTE3LTEtMS0w_ea8c9d90-6459-4911-92e8-ff4e8b81ad15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607a874a41c14bfc92471a1eb2e4fc73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTE5LTEtMS0w_901d8d1c-d6ea-4ae0-b27f-756d61addf04">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738f3a9fb4864314980f11c6fc424c84_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTEtMS0xLTA_0b57be7f-144a-4735-a464-0cad4577eb4c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb154d7816ba4d54a0aa8908f07daee0_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTMtMS0xLTA_9a843820-0063-4c19-8c9d-03fc8e241533">2,236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i845f426bf5684441b08a4d78f16a13f5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTUtMS0xLTA_d41f665a-5eb3-4708-a5b6-3c3007c4bfeb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0318028fba4d4d2ca13a6790d87c0bac_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTctMS0xLTA_f0f18704-15b5-47c3-b97f-11517f2c515d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18cc995c2f4542db8ad348a6a80f3f7f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTktMS0xLTA_6a700727-4652-4887-bece-9827ece3c6f2">2,236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339d812fd79a4559bef0ec19bfe98349_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTExLTEtMS0w_440f3afd-2412-45b3-b5ed-2c1d5f486734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc88b48898f04f409e0109283ed2987e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTEzLTEtMS0w_917d5bbb-fb16-47f6-9b36-46a8e7b2a14b">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a508f5db8a4cada4798954c65d9223_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTE1LTEtMS0w_bf5e7d2f-69e5-4947-9d6e-45161bbe1e4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29a7f12c8e24256b2319a238659e1a5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTE3LTEtMS0w_4d6ae4ef-5ec9-4bbc-8a65-f73f13a5cde7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia882b52e228c4eabb69646abbee285bb_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTE5LTEtMS0w_206f9f5f-b1e3-4b4a-92f2-1f9197f9a42c">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58a48d4bdd44296a817bc4d6ab8b57d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTEtMS0xLTA_4b8ee976-2eb7-4c14-90d0-b53a4d2e566f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied7dcb9e05394ef4b640628827cf587e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTMtMS0xLTA_28d8af16-cba4-49b3-8170-cfc0fbde8b05">1,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c09a641f9f4bc18e3972169da2930c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTUtMS0xLTA_eb6395ad-83e1-4836-8490-fb832ba7329e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470fbecd1a04428fb6e6a4caff23f1d0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTctMS0xLTA_c8aac7f0-5f03-4892-8696-284145be9ddd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7046796fe24f1c868c09c2c0ec273f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTktMS0xLTA_cf3d6469-fd5f-4e55-a648-ba818d0f324c">1,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9da7337a3242dfbff5100ce601af33_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTExLTEtMS0w_2a0f59d1-e937-4da1-92fa-97dbcd2fee2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3221566626c342a999e23dfe29877216_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTEzLTEtMS0w_e2d14e22-9f22-4180-ac4b-d4b152de129b">1,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c99d58a8ef4f18bbb9b810927e2266_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTE1LTEtMS0w_67b796b8-549f-4e75-9167-1dc9aef0a239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id69b26112f2e43dfb981f625c4a50657_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTE3LTEtMS0w_c91feefb-655b-40a2-bdc2-d17521a6b5df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabd1fedb7e64d168d077d9c93085e62_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTE5LTEtMS0w_6c5ae3b6-a92b-439f-afa3-f477f6ff7017">1,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e1943c724246bb8b80b478f5c0736a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTEtMS0xLTA_3e658d87-5c24-4a3e-974e-fca2c539fefe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39cc1d86c43e45a5bc8a8a5055e74603_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTMtMS0xLTA_8b6d4a3a-4bd4-4461-9e2e-5379bf6ff696">33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663cd110b4a94a17af138ccf8e74215a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTUtMS0xLTA_4b3c39e3-2e0e-4e98-a63a-d27c0ab19b04">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29b60f8e53c4a6ab9ee426df0b5ae37_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTctMS0xLTA_6ad1834f-5a0c-470f-b66c-a925863acc50">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23692025eb79488d8a33a2716b0b4e30_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTktMS0xLTA_d6059994-ae40-46f1-93e0-f966beea984a">33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8b282d6d4b46ffa0cd607de8b36a5f_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTExLTEtMS0w_83eb6162-cc5a-419f-95ae-ef95cfe9ac6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f96273f8de344e0b556346389159cde_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTEzLTEtMS0w_8beb25a3-07b0-45e2-bd09-630a3bd7095a">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2d21f8910346afa7a2eccbd54765f4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTE1LTEtMS0w_d826ae97-5176-450d-90fa-541fd0053674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6df641d6b2e4a7fb6f87a544978da43_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTE3LTEtMS0w_e750aed2-2370-40bc-9478-8c27c3e6e21b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ad2bfb5d1643ac8704a1745e062147_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTE5LTEtMS0w_3a1b0659-775b-4cfc-a0cd-f65d0a343a62">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ec77bd07b245cdaaba698bb230ad64_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTEtMS0xLTA_3ff4a7c3-dc46-4de6-ae30-4faaaa652d96">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbe419490e34f4283f48203f8d00d4f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTMtMS0xLTA_e6f6c510-4907-4153-99f1-5eec6576fdca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59d367709184c039635ea8a9c404195_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTUtMS0xLTA_4b3f9956-dd51-466b-8e85-d164d5e26a3f">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86afa43f33044b8aafbe32dc59a25171_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTctMS0xLTA_8d850a3b-a060-467d-a018-ae1177febef0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i183768f390164f1794cac12bfbf64b84_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTktMS0xLTA_a8391021-1a8f-47f9-8380-12ff4c030731">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db834c97ee14fab88d75f50f80223f6_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTExLTEtMS0w_4d7381f1-7cec-4f2c-969a-4a508540a671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7437b4bf19421b9a91bc99840e0acf_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTEzLTEtMS0w_1a0b491d-c4bf-4200-b1bd-8601a3f463fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74d1efb8d174c4f838e140f7fd23e52_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTE1LTEtMS0w_1555c8bd-22c6-4526-9264-44554099b6f9">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549747388339440e9de44fc9bf5b409d_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTE3LTEtMS0w_fccd6b54-8f23-4eb4-b55a-8609c78e390c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78824aa845834cc8a14b6fb34703097c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTE5LTEtMS0w_24408c29-e8e3-4fd7-b873-569ad272dcae">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73d0fa26e4ae496ea46a709f7fe43c2c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTEtMS0xLTA_03851bbb-142e-4866-b7c4-ebcb3cd3145b">3,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436bb533ef46402880b1b951670aabfc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTMtMS0xLTA_433ce852-8f21-4f49-b5a0-1e1fb20f3834">4,352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec0205bb40a4e4aa25f265fd1063854_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTUtMS0xLTA_e0a1b1bf-f797-4d07-b209-2d2b45571224">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c9b892c37442a186be4817fc66f40f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTctMS0xLTA_318bd749-b13a-4bb0-a4a4-0dd007242403">5,114</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTktMS0xLTA_00cc7dc3-52f6-43a8-a194-b4b03f5e3e7e">12,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5fe2d5dae24dd8abcf648861561996_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTExLTEtMS0w_c897cc18-4d94-4e70-8cb0-2c4a8a95a82b">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2c28218b2834e5ab51167cc6eb02eb6_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTEzLTEtMS0w_6bc4043b-c961-497c-9fd8-a080ed1bffc9">3,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40916875d4914c52a1de3c0cc928e327_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTE1LTEtMS0w_d0a17fac-71c9-40f5-96ba-068448e23a85">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a5827af8cb4a649aac89e78df2a8ca_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTE3LTEtMS0w_9732b632-92c3-4bd4-b00e-309d0ec39fd3">4,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTE5LTEtMS0w_4099d870-63e0-4ffa-9fe7-94b7dc7d0c20">11,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86afe2a27ef042fa97134e39bf3b608b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTEtMS0xLTA_b99ac60d-cf1a-4df2-b317-d5677bc096c9">110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8855de2ab94dbaad3ea5df4e70bf44_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTMtMS0xLTA_4ee4a4ab-4200-42bd-a91a-fb85594af1cf">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i259684d6ca2747128dc9ad3d0b306636_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTUtMS0xLTA_801c64e7-95ab-4372-9a46-7d4ae38f3f3d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2c67f654184b1bae5acf068d5001f0_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTctMS0xLTA_bf9ae47a-d2a5-4fdd-a0d1-6d764e6ded7e">20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcfdabfe8f44d56a22b24a80a126022_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTktMS0xLTA_19c6cdfa-1ca2-4632-b67b-566040e939dc">131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeea9d67616a473aab6b59c7fb911c4b_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTExLTEtMS0w_1e3008a2-7237-4f9b-a536-1e9c2676e547">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e43a005430483da4c326627defc690_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTEzLTEtMS0w_6ba9c987-eee7-42bd-b547-37aa9f5a7df6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64370d94415e4d9cb45ff1cb008bc7f8_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTE1LTEtMS0w_095b1935-a9d1-4f15-ac15-ef44f2b7ee44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e19c56a0f04e119dc0d2f946e31d30_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTE3LTEtMS0w_e97951e3-aefc-40bd-846a-033f59e302ce">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9750dfea550483aa010da7eea306529_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTE5LTEtMS0w_5312a83e-3bc8-4cfa-871d-ca9f38a97ff6">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc4e566933f2436ba71c1f31ac45a19e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTEtMS0xLTA_afb51385-3332-40e7-ab74-b03439e84204">475</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f3cf886e184967b21a73d9c69c8280_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTMtMS0xLTA_3476bb95-a7c0-4786-816a-89f7a323a2d4">4,286</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d72a9e301de4cd0a1a1a7fc0b36c4a4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTUtMS0xLTA_c4929d10-7c23-4203-8207-4c6a4234ad6d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39901cc34fd740158d36857127b01175_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTctMS0xLTA_64a3b58e-09b7-4524-a100-2dc7696e6d00">118</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154bf08968984b7c99f026a36c01c389_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTktMS0xLTA_62b5651a-0da2-4b3f-9a39-503043f1370c">4,879</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040e5118b6d14454b71d08507239b29b_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTExLTEtMS0w_ae05e9da-53dd-457d-a3c8-5d7ee98d2a24">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2938292f70e456cb6f95bd21bc78090_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTEzLTEtMS0w_c1caa90f-646b-43a7-98c3-7328beee38f4">3,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5092f87e8ca34ffdae394fa1e9d5e453_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTE1LTEtMS0w_041b3630-3938-4ecb-ac3b-189ebda4ab92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id457393c18e544d79b6943a75591c9f9_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTE3LTEtMS0w_80d5e2ba-c22c-4c45-b718-55e5a4c79777">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ba248a0903c42bfa04628d1088a7603_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTE5LTEtMS0w_3a5d5a07-dbee-445b-9f43-7ca8912d9018">4,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b23ae04674c46f6be8804520b0a170e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTEtMS0xLTA_a5777381-ddbc-48c1-8b1a-9e9fe20c96f1">1,516</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c07cfb24c14c908e52a77dd7f27872_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTMtMS0xLTA_a492ec24-a0fd-456e-817f-3d6a1718ef93">2,614</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af75dad006d4960bcfe8d7100ff57f1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTUtMS0xLTA_2eef48f7-8f83-4955-99ba-86eeaf2931f3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be20872a4dc4195a2a00b91c7bd9e53_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTctMS0xLTA_ec87e1fa-1b59-4ba7-a852-d0eac9452afe">172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5fca2613e754dacb1d1358910525b05_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTktMS0xLTA_ef092052-dc93-4954-a900-ccd46d630f7d">4,302</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb175a0e182a42959d20bd6d81e8811b_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTExLTEtMS0w_8d817c3e-f351-4539-9629-1b5887f5cb6c">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc802dfc0e4d8b943a8088b309a76c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTEzLTEtMS0w_01977bec-2912-4945-922f-1936b1dd3265">2,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc71c589efe74a8eafc71efb7fc704e4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTE1LTEtMS0w_5c01ef74-9bc6-4258-8c85-f8396fcdf316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if758fbd200de40f9992c9a7b6d18d162_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTE3LTEtMS0w_0c8986ba-b8a4-43a5-8303-8aa5205367fa">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d28cdebd3ef470d805bdfff3c328aba_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTE5LTEtMS0w_484df2b3-ea8a-41a0-9137-28948e61936e">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4529abd8059b44efae78aa81e23a2069_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTEtMS0xLTA_8cba98ad-3338-43a8-84cf-90d59f00e5ee">154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4ade71303f484886aed15962aba524_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTMtMS0xLTA_901cac3d-36a8-49d1-a814-536f29f61e95">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a8ec52ff25456fbf0f605de1c62d83_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTUtMS0xLTA_d2ab064a-a88d-4e54-ab36-26ed1d9a3d72">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7318c9a1044a450c8705fd6d1ea5e7ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTctMS0xLTA_84f7422b-d55d-47a2-bfc7-6486349afd1b">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37caa9d66c6c48c784567a49cd4dfcb5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTktMS0xLTA_a19d4da5-b71d-4004-b5d4-d1c637b203c4">246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf01b81038dd4b0d8ac214954c67671a_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTExLTEtMS0w_08a1f7d6-e525-4138-8326-93ddfc28f247">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd70b64d3e72405ba247566a7383f575_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTEzLTEtMS0w_2032d5b6-461d-4a48-9681-6588e10a37c6">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383c1e83a37649849826069e2ea30e70_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTE1LTEtMS0w_5d4e4e53-8909-4b77-a08f-a55fd2977207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ca88a53b7a422eab11e135ad001f09_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTE3LTEtMS0w_fcc39795-bef0-46af-a74f-266345dcfad4">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0976228eb3844b76813b5ecd4ea518c8_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTE5LTEtMS0w_44a024b7-06e5-4df5-a527-e09c26a81a47">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19223921be5a44f4b5b22d6e5d166870_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTEtMS0xLTA_0ef69cda-867e-47f5-a8e7-a612620a08e8">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d99fc733314c5ba2bf5402ab0d6392_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTMtMS0xLTA_e0826aba-4f59-447a-97a3-debefd388216">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1a97c92462458c929c7092d0e8afef_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTUtMS0xLTA_00b2ce6a-697f-4ac8-8841-4bd8e8f97d68">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84ab6be0c3e403bb9cd82e264108aab_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTctMS0xLTA_45203da6-9cfd-4d57-9f6b-2b1e5596bcd6">172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9acb800bac97417e813ea16d4d5ededf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTktMS0xLTA_b9adbe3a-be0c-4ea0-a0f2-023290e47352">189</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44275a244d0a4892be5505d09958c1a9_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTExLTEtMS0w_5a14dee1-9593-48c9-a594-e08fae1c0743">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51e79c06cea4cdfa2bf6a0d5be0124e_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTEzLTEtMS0w_54fa222b-a04d-460f-94e8-411593ea4c46">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f45e018d1747a68360c2feb30d6b84_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTE1LTEtMS0w_dd77d01b-768e-42be-bed1-d3477755609c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbbda6da3727484e81200d5caf50552f_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTE3LTEtMS0w_579f574e-eea1-4b62-bbff-745c726e1ea4">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd94dd271aa54f69a8baf12100b51778_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTE5LTEtMS0w_8710fc71-4c86-4c4d-8c9c-521d51fbf515">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb967b896a4468fab08e88cae9df856_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTEtMS0xLTA_bbef4428-5dc8-47b3-ad75-69c2fd896ccb">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86344444b47e4721b7a2fc0ea7cc11ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTMtMS0xLTA_05442aca-cfec-498f-83e3-2f0115d31f1c">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22038ea5b4744df99667fec848961056_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTUtMS0xLTA_e63efd56-c6ed-4836-983a-85153afa3489">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia40b98564996403db036113cd733924b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTctMS0xLTA_d483a054-8b5a-4012-81e9-3fd80826dc11">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48c9ebac6d74ee190face5ee60b51f7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTktMS0xLTA_abafb95e-9cbc-4054-b905-5154ce8bf839">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b013c8f53aa4ad0a92b472ab7fc6b81_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTExLTEtMS0w_3cbf46ca-4e9a-48cf-a798-abf4aac4ad8d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib672d0934c6d49c19aca1d0a43b92a58_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTEzLTEtMS0w_c92ad791-e2f8-4418-8df8-1907bd3d2021">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349312ecbb7345d7ae0733d60b92c8e6_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTE1LTEtMS0w_e4f3e05c-e3a3-4ffa-aaa2-f1c3644a2684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i457ae5efb13d44ef94eb093fd86a744c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTE3LTEtMS0w_fd3634db-9909-450b-a140-64477d6134c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780ae83f21484b4f85c3d3e21ba5c7fe_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTE5LTEtMS0w_6932e527-1a37-4454-abaa-571dc163d60f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a46d5d13eec48b0ab6b5862c0d10927_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTEtMS0xLTA_a0087e47-dd1b-43e2-987c-a71d88a81bf9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf91bf6b83d04def977d5ec5adea56d2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTMtMS0xLTA_d28896b3-9673-457a-a357-65a34e5dc3af">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f802b0b6548410683a7feb2a61f6ff9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTUtMS0xLTA_f834d0c5-23b5-4778-9e33-51e14f178a3b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4534e1b0f4594853b0b92171732984b0_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTctMS0xLTA_b72504f8-fc25-41af-a1f9-9b119726433c">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f034b282b3b45ae8315f6d3446c99ee_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTktMS0xLTA_9fc9cd5b-033a-4462-a77a-3b0b7eeacbc6">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic405b218f9744ab780ce9a8a7aab3fde_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTExLTEtMS0w_00f2105e-8165-4d60-a0b2-32d9e416deee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0001ec828bc546a68b1b01be577c9472_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTEzLTEtMS0w_e92303e6-d754-4b52-b18e-eab57d3538a3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if840940eee764ea69eeee426ab4d3762_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTE1LTEtMS0w_81f616d4-851e-41c6-97eb-429e9a7392c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07001dda2e5f4d7ca903f069b0abc178_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTE3LTEtMS0w_9248b7ee-afab-4460-b5ce-4bcb543a56fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f673e87cb9d4be2a8a2fcce749d9a73_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTE5LTEtMS0w_e9447441-1e93-478a-8d57-f9f84d06f1a6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a21cac2295041bd8c7761632655bfe3_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTEtMS0xLTA_6f9ae890-0a31-4978-b187-69e640f96842">505</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie982dbca87ff40549928cb1b655bf842_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTMtMS0xLTA_929479cb-7d86-4ce6-84de-6aa76435ecaa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30d48af822b4482a9b7498a050ddfcc8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTUtMS0xLTA_c2932604-0697-46bd-a586-25280dc182ef">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d0c8c5170b4f6a80534e5ba634dc51_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTctMS0xLTA_81bf5a47-b331-468c-bede-78b0fef1050d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i622fafb065b347f886df4ed478a637b1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTktMS0xLTA_81158311-e83b-448a-afc4-60c4e539ab5e">505</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633bb8841df546c49ab62349cfd6e177_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTExLTEtMS0w_5f98361d-5093-435b-b1e0-9f68270d1d90">565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5993c63f98347de90f6f8e4da9b444b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTEzLTEtMS0w_908e645d-788b-440f-92a3-b38201697782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id334f615428b4033a167d3ecd93c0a56_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTE1LTEtMS0w_c3eb6cdb-23ce-4861-b245-4fed16f8dfa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9f22f4e7c9422aa9d5aec3892f508f_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTE3LTEtMS0w_751afdc8-3159-4fb0-b234-968d0f68a78e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d837922a8c34c35b598417be5b7179e_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTE5LTEtMS0w_5c6cb90f-062a-4828-9db1-c8120bc1f596">565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357033ae6b9242f3a760e4ce6ef092bd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTEtMS0xLTA_ce9c6626-6066-469c-a353-f18c5548e460">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6504027ab63f4de5b4bcaf9260f31835_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTMtMS0xLTA_88277132-1493-40be-9bc6-af122f4d3a76">486</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6fd8f061154a30a819a163c8185ce5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTUtMS0xLTA_abcd2096-3ae5-402a-9bd9-5d3a7f0f0f10">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09db396a1bc405585c8bd00bd42ee90_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTctMS0xLTA_38e4f9fe-9b5e-4e02-977a-29bbfeedec2e">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e9909fc72e4d14ab3b844920200857_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTktMS0xLTA_2a6fd565-16b8-4bb0-b510-8e63419e33a2">492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34620b194a57489abafae0caa71b1e81_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTExLTEtMS0w_c54464e8-7f78-41d0-b9c0-1aed00a96100">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803b0a3f273448c6bd0082f93b43ceef_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTEzLTEtMS0w_539cf032-7343-4f15-ac84-69ff3efaba05">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058faadf9b554518a3b689fa8335bd98_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTE1LTEtMS0w_913169a4-3668-484a-8823-0cd5d2e16784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3677204f7a3e41dfa2f70915e9c33438_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTE3LTEtMS0w_b657b4c4-02fc-4385-944e-9b61077cf0e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c48edd856d446fdaf20a830fb838512_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTE5LTEtMS0w_9685a752-702d-410e-ad3e-774c4cb23edb">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf61bbfdc384cc9be1bc920c1d76754_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTEtMS0xLTA_20b69aa3-77e3-4b1a-a8d3-9fd5ae48a4cb">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied410f99d8eb4af592290310c06476b2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTMtMS0xLTA_74ee5c3e-a527-4a53-a096-517a39ad837b">174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d66850a0b7c440c99a213e0733986ee_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTUtMS0xLTA_322e627f-5790-4ee0-b8fe-b40964e1750a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4d7beef254de9a0eba7eb5cccc084_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTctMS0xLTA_3d0eca62-7099-48ac-b81f-435aabde1ee5">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72fd7651ac6a4a2a94a953d682b650a0_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTktMS0xLTA_c0a37964-08d2-4bef-b92a-e12d22fb2495">177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5161c382e704689bd21397306aea661_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTExLTEtMS0w_e4ccbcb6-114b-4114-af2b-30af8f7a2a59">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6ecdff488f4420ba322ef0fedaaf2b_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTEzLTEtMS0w_7fab2041-9ac8-4c54-9f0a-600f269ab27d">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06a9999d9324811b9a1be2dcab19ac4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTE1LTEtMS0w_7a9fe147-cc8e-4d61-a98a-0b71e0e454eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77d538a77664954990b8a71d696a859_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTE3LTEtMS0w_eef41494-8ebb-4155-903d-55dd042294ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813c30a7a82a437a930c6658dffd6bda_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTE5LTEtMS0w_8fa65a4c-0fc8-4f2a-b4a8-a6356a661191">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21fb50eeb34a4114bc13c96d65cbd097_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTEtMS0xLTA_16229c06-737a-489a-b6d1-14e3d485b46c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8b1f9b69d540cc9ee48b788f947e86_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTMtMS0xLTA_419b5636-7bbe-42db-8701-7a2c312cfe56">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5520bc81f9124c16a0f7c2a4ac6d32d8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTUtMS0xLTA_2cf81c99-5daf-4211-8198-0be85ed89f21">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1ccc0110f849388ab267dc48f11d4c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTctMS0xLTA_70e553e3-a77e-4238-badf-d91822ced81f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8158b6396da446795bd99eab428f39c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTktMS0xLTA_8cc74146-63a2-4298-b549-d5416a69bcf9">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31cd5815632a49b2ba1c177fd6bc40b0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTExLTEtMS0w_e7773ff6-4b79-471b-9fcd-1c394865b800">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab5fd43cc1445d0af3c8df232ceb26c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTEzLTEtMS0w_94da78c0-ddaf-47b5-a595-075d075fa449">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6e35c9626041d98bbf692bd5a64946_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTE1LTEtMS0w_567b2914-ca56-400d-a476-51e45d9f6b1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407cc8de7a564cd591d2cc8905f16ad3_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTE3LTEtMS0w_99b0a1e0-50a0-40c3-8c39-5ea7fd1db1d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402c71bfb56d475d822a8336e13e26c7_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTE5LTEtMS0w_c5c3e59a-9c80-4a24-81c9-0f90156e6890">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a9ec48e8f84f82a1c47ec8330267d6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTEtMS0xLTA_8736921b-96c6-4310-806f-6ab2a3bf88d7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3937995f915a48b5b2629bee83030604_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTMtMS0xLTA_067c0cfc-82eb-4b90-a7a4-e155eb270135">76</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec2179722044d5a5d1eb812df66bc5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTUtMS0xLTA_589c8c8d-8b95-425d-976a-66715cb32eec">935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c42749acb640bf9567f2c696835c1e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTctMS0xLTA_11971780-1113-4e39-8a8b-b3910b72ca9b">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d256b285e747878c834986bfa70aaf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTktMS0xLTA_c1f25c49-d66c-41d9-8711-b75d0e9afe46">1,012</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b83770c83d4ae3892d22a8c95183d3_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTExLTEtMS0w_438c8595-4453-4011-a696-03bcca191dd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54869a5a706b498f8af31af979c71c44_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTEzLTEtMS0w_8e2a2916-d765-4e9b-9a88-9d7fe83fa13a">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7510a56e62d4a91a42048cfc19c7873_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTE1LTEtMS0w_102df34b-f2d8-44a9-ba5a-bde86ac12817">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea763b31b9e48d09c3f501947f1b1b9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTE3LTEtMS0w_c5051f17-206e-4e1f-b8ec-edff355ab1ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04238d138c34d0c9609f710057ea45a_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTE5LTEtMS0w_142c1a63-af61-4a5d-8459-6dc100af68b4">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49eded9c6aae423091e00e60b8b07d6c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTEtMS0xLTA_58592e57-7236-4ea8-b8b9-79e93ff89487">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9fcdadfe1b4674bfcaa0b730e4217d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTMtMS0xLTA_7fd4e60b-1b18-49b7-b1ca-f543f7c666b3">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74504e9a2e54432f8b030a4dbcf9ccec_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTUtMS0xLTA_5595a762-daa1-4659-95c9-3c9452f3b1fc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf9b49410e149e4988f1a1303a8002a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTctMS0xLTA_c12c1016-5068-4cdf-8fac-a8e92dafaf53">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38efeb11d07d46c98df2083b9decac1f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTktMS0xLTA_91f533d5-b437-4895-bde4-ea210f54f6d6">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68339e93b1f64b1dbf950cf628cea274_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTExLTEtMS0w_85cdf1a0-bee9-4b5d-b9f6-120f6171ce81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc97e4e4d57436bb7f739eb609cf62e_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTEzLTEtMS0w_28e10836-0c67-4e30-a759-f0ebdca9779f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2a2c1e08e8478582cb66340b717486_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTE1LTEtMS0w_142338d4-c2b9-405f-b0d0-2d754bceca97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec2478b8f0e417d82d47d2e798bdf92_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTE3LTEtMS0w_27344991-dbca-4ab8-9408-7d13c257a19d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620692e3a36142a99469f7b3c1df10f8_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTE5LTEtMS0w_7008e0a1-073d-4dbe-9e91-534caccf0e2e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fbb0d61bcab437d8de63b52dd292d32_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTEtMS0xLTA_16dfe997-29d8-41e1-8c9b-b4193401106a">2,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7e666cc10345cdb2262b32f0065fe8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTMtMS0xLTA_699a3788-e0ab-48f0-8042-5c5e8ba90183">7,736</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e268cd703d845b29d850a21ed33546e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTUtMS0xLTA_338959bf-2306-463a-afd5-2b80767496f0">935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6d74a08d594448d9548a1eb92cbbf96_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTctMS0xLTA_e5cf2300-bbf6-4c33-8809-87a59c5c666b">599</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTktMS0xLTA_58222e78-006a-4fae-8e7e-355cdaf589ce">12,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dfaa78b8a242ddb57ebc4c9c31d5e2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTExLTEtMS0w_d59f9bbe-4efd-4867-9e63-30b860b61e01">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229c0c3633fc41e78ea30bb9ccd6a28e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTEzLTEtMS0w_41e4c227-0ebb-4349-ba77-aa64f9386f5f">7,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189642b9649f470d84f77e09dac85b67_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTE1LTEtMS0w_d667b497-e8f3-41d5-987f-19fbf1a2228f">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a79dc129ba4160b0dbd0cde3962a9f_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTE3LTEtMS0w_982353bc-46fe-485a-bea5-d39bad02ae85">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTE5LTEtMS0w_c1e8fa59-ef5a-4ba9-9c63-81708634c4c6">10,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i084e108f43544f3bb0aa2bc8b915d72b" continuedAt="ie70bd1e3c1b945a3a50951f14972e3a4"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0NDA_7c4c1318-98d4-4b16-82ff-7a8c72a221ea" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:25.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.629%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adeeac55b484b6f80dd2c5799f04e33_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMS0xLTEtMA_dee0771d-89e4-44fa-97ee-ac1c33dbf899">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5481e593b17d47b1aa1c93ac944e5897_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMy0xLTEtMA_f01c05f5-cd12-417e-afd8-eff2c175afac">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74d1efb8d174c4f838e140f7fd23e52_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtNS0xLTEtMA_a0b597ff-b923-42b2-af03-53b2e3080a96">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40916875d4914c52a1de3c0cc928e327_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtNy0xLTEtMA_278bd5c3-0abd-4107-9196-2ffd536f2041">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a47f45b5b94684b166d8f428a29ac6_I20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtOS0xLTEtMA_a5612099-3e73-4862-a98b-de83dce9d32a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa08043c6f9b4f8ab940e92d8ff823e6_I20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMTEtMS0xLTA_8cc7a529-910d-423b-a788-fb8c161789e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae805d9fc1142e3b9ff8fbb8f056835_I20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMTMtMS0xLTA_7df07e35-7ca7-419b-859d-32d2d3804053">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie76048d496a9406bacee02b8f107dea0_I20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMTUtMS0xLTA_ca3d62c3-68c1-4a89-a0f4-2e9965ce54c1">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d19186cf57479f8c9c9f80797a937c_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMS0xLTEtMA_57e67bf3-cb93-44e2-af17-d2f4b76f70c7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181e86400b884db2a06d3594319d4a0b_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMy0xLTEtMA_bb742850-b5cf-4eae-994c-f8adfdfafaa5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42f4bf6ebef94a2b9c96589c57b30e5d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtNS0xLTEtMA_3e203c22-5e35-4c52-9de2-ef9ec9b0094f">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtNy0xLTEtMA_59d23b36-1fe8-4e49-acff-ea0684ae1388">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b5dfd32194495790f2c8c81a479431_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtOS0xLTEtMA_84ee4c2b-aeb0-48f7-9322-8d8fd4cdfd23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i182aa63f2acb4acc82da9b87c7730e81_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMTEtMS0xLTA_96522ec3-5351-411c-b32b-98da70829a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a92dd071da943828df32be68c3aaeb4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMTMtMS0xLTA_ec2eb071-97ff-42c5-b045-381781e34756">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffa22d9c51f4484bba2b9f4934ac0a1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMTUtMS0xLTA_41e1f161-0578-4c6e-b1b4-b77818177c6d">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d19186cf57479f8c9c9f80797a937c_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMS0xLTEtMA_5d834c59-3463-4223-9ac3-98cfe338578c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181e86400b884db2a06d3594319d4a0b_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMy0xLTEtMA_82d06448-188c-48bf-9206-e2cdc36fe360">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f4bf6ebef94a2b9c96589c57b30e5d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtNS0xLTEtMA_8255caef-ec31-4e8d-bc5e-0fe9886f0b54">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtNy0xLTEtMA_08ece3b9-940f-405c-afe4-aae666f60689">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b5dfd32194495790f2c8c81a479431_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtOS0xLTEtMA_9773a881-f01a-4f49-bfbe-705613ae9340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i182aa63f2acb4acc82da9b87c7730e81_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMTEtMS0xLTA_8aae9a12-9621-42e6-a07e-56ec5e9f2996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a92dd071da943828df32be68c3aaeb4_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMTMtMS0xLTA_7799fd66-5a8a-4c89-8a5f-b54bf64b684f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa22d9c51f4484bba2b9f4934ac0a1a_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMTUtMS0xLTA_fe2802e9-7500-441e-9a14-86f7cc785537">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d19186cf57479f8c9c9f80797a937c_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMS0xLTEtMA_d7c0d917-c2a1-4cec-ab24-de65200c9f89">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181e86400b884db2a06d3594319d4a0b_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMy0xLTEtMA_93b69f40-dd02-431a-9605-787381153e04">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42f4bf6ebef94a2b9c96589c57b30e5d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctNS0xLTEtMA_e4e4957b-5e47-401b-881c-b4ea5b38bea7">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctNy0xLTEtMA_48ccee7a-e963-4cbb-a9a2-aefc12a9316d">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b5dfd32194495790f2c8c81a479431_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctOS0xLTEtMA_357affec-f728-4a81-997b-79212a175140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i182aa63f2acb4acc82da9b87c7730e81_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMTEtMS0xLTA_22815238-b81e-41ce-86dc-da029096c557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a92dd071da943828df32be68c3aaeb4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMTMtMS0xLTA_baee5147-cd87-4db6-806b-b386c90ad349">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffa22d9c51f4484bba2b9f4934ac0a1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMTUtMS0xLTA_f1bbe631-e6ec-4a10-b217-8ada31f30abb">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8face53a5d81405290c2c762e2706f10_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMS0xLTEtMA_109612e9-9b8e-4de2-829d-f10bd1a9d101">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8993b7d37c36436185b4a48db374a7ee_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMy0xLTEtMA_0565ff08-0de6-482e-bb84-f8c068cd8531">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59d367709184c039635ea8a9c404195_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtNS0xLTEtMA_9fae6795-3d9b-454c-a20b-895f40b7a7d3">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec0205bb40a4e4aa25f265fd1063854_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtNy0xLTEtMA_e688a747-66eb-457c-9cd2-8d2adece3bfb">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adeeac55b484b6f80dd2c5799f04e33_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtOS0xLTEtMA_91c4a6ba-522d-42ba-93ca-5700ceaffdea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5481e593b17d47b1aa1c93ac944e5897_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMTEtMS0xLTA_02e5df17-55b1-4381-bf49-5f495902fe4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74d1efb8d174c4f838e140f7fd23e52_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMTMtMS0xLTA_971f7452-7141-4375-a846-0c62f9072ffc">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40916875d4914c52a1de3c0cc928e327_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMTUtMS0xLTA_563a15fe-e686-4a12-bac8-792766d58846">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7510a56e62d4a91a42048cfc19c7873_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTEtMS0xLTA_53636861-93de-40d1-a414-8f33c6d0e505">851</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if840940eee764ea69eeee426ab4d3762_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTMtMS0xLTA_07743c01-9e0c-461d-9c5b-58abc16d0fe1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2a2c1e08e8478582cb66340b717486_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTUtMS0xLTA_5fa6922c-7fa3-49de-9f95-75ef80835a73">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189642b9649f470d84f77e09dac85b67_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTctMS0xLTA_61d2baf6-1f80-4fa4-8c5c-0dd21c15626b">851</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197d5c37737145e4be8b85609364f159_I20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTktMS0xLTA_a0020d32-479e-4ab9-a87c-a535823c4f59">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec259e3fe62049edbdab75f9a4208515_I20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTExLTEtMS0w_88f73c89-6d40-4e9f-b067-f5385fedef25">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ae4a5fc4714d318fd513d240f6ee0c_I20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTEzLTEtMS0w_f1fba4fe-e33f-47e1-b998-cd7c236d24c2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee7f5c6f7f3431b9e2edc9b74fe47c6_I20181231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTE1LTEtMS0w_85be9aaf-17c5-4504-87d7-b4060d0b5882">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d17ed2f94a04fa9aef9f8d5c15caa5f_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTEtMS0xLTA_8776b647-e22e-4ec9-bda5-73e47ddc3b3b">103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd81d119ee0498cbcaa47e8e4e04faa_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTMtMS0xLTA_5d7f9be9-5cdf-4ca3-aa00-d959a410cb57">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6244f9b099ff4947aad981a8256ee577_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTUtMS0xLTA_e1e88c6c-b283-4f34-a534-e751a0ef1c6e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56379a346a34c328d1074093e2a301d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTctMS0xLTA_7b7e132d-58d8-4756-bcf4-c02586bf9365">103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a8d5d4b6784223a646272a4e63a5a7_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTktMS0xLTA_5fcb99ee-c50c-4371-ac1d-552445a4bb92">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f0eeb607674c858416639d103ec85b_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTExLTEtMS0w_910a5607-4e53-4ced-9e71-4e0b8d04a461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4103a039ab6c450b8e3fd2d3aec9b167_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTEzLTEtMS0w_cf41d0fa-2dcc-4ec0-b3bb-cb34e462b7a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248058aeee814ad1b7ccee7a89ac58dc_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTE1LTEtMS0w_209c1de0-a4f4-45b1-b682-e4c48a1e4f14">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d17ed2f94a04fa9aef9f8d5c15caa5f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTEtMS0xLTA_bb3ca6f8-4642-40ca-9478-254726abf82b">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd81d119ee0498cbcaa47e8e4e04faa_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTMtMS0xLTA_5dad1f5b-3a04-4f2a-895e-257349714ebb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6244f9b099ff4947aad981a8256ee577_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTUtMS0xLTA_74da034d-0773-4421-ac6f-9df1bf7d02aa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie56379a346a34c328d1074093e2a301d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTctMS0xLTA_84390335-21aa-4318-96e7-518934d05225">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05a8d5d4b6784223a646272a4e63a5a7_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTktMS0xLTA_b867daed-c10e-46cd-8334-0d2eeaac8c9f">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78f0eeb607674c858416639d103ec85b_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTExLTEtMS0w_392cd287-1926-4894-9d25-0f1c3e785adb">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4103a039ab6c450b8e3fd2d3aec9b167_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTEzLTEtMS0w_fdaf3888-cd46-41e0-aa9f-bab152779ab8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i248058aeee814ad1b7ccee7a89ac58dc_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTE1LTEtMS0w_336a2971-35eb-4fab-bc7a-b01191abf7d0">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d17ed2f94a04fa9aef9f8d5c15caa5f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTEtMS0xLTA_a7c0120f-789f-4f00-835a-e7d813913970">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd81d119ee0498cbcaa47e8e4e04faa_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTMtMS0xLTA_b53cb777-d6b3-4ec3-bf49-dfb53d2ecc4e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6244f9b099ff4947aad981a8256ee577_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTUtMS0xLTA_f5d22593-e954-4476-a975-89de5b67dd4a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie56379a346a34c328d1074093e2a301d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTctMS0xLTA_233bbc9c-e14a-4acf-81f7-517f648c3507">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a8d5d4b6784223a646272a4e63a5a7_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTktMS0xLTA_0cb98d36-3738-49a5-b484-eac5e0adc3da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f0eeb607674c858416639d103ec85b_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTExLTEtMS0w_a3ffc7db-e195-440e-937d-9f1ca6e567ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4103a039ab6c450b8e3fd2d3aec9b167_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTEzLTEtMS0w_2eade3f5-63a1-46a6-b415-eaa26fcdad22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248058aeee814ad1b7ccee7a89ac58dc_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTE1LTEtMS0w_eb63d3d6-2ce9-4b7a-a0b6-81934458a7f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ec2179722044d5a5d1eb812df66bc5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTEtMS0xLTA_0ab654a5-b0cc-458b-aa25-891f6148befb">935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f802b0b6548410683a7feb2a61f6ff9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTMtMS0xLTA_e1319133-cb74-470e-b67b-e8e807a7f751">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74504e9a2e54432f8b030a4dbcf9ccec_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTUtMS0xLTA_10eb371e-3616-40b0-9e0b-c3fcdf435ad2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e268cd703d845b29d850a21ed33546e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTctMS0xLTA_2abbf29b-9fc1-4150-b053-a84b5d470b49">935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7510a56e62d4a91a42048cfc19c7873_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTktMS0xLTA_d2a6a0d3-cd90-407e-b401-cf717324c57f">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if840940eee764ea69eeee426ab4d3762_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTExLTEtMS0w_9bc58a03-1d31-48ca-aa3c-fa4375dd16e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2a2c1e08e8478582cb66340b717486_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTEzLTEtMS0w_707d1a37-ef8b-404d-943b-be5cd54c8b22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189642b9649f470d84f77e09dac85b67_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTE1LTEtMS0w_146ade8b-bbde-4b3a-8c61-52d8d05cd6cf">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i3c2070321b7f4132bcf140965ee21e7d"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:18.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c14cccf97aa4e98bed9ab984d662ca6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMS0xLTEtMA_438bd394-6ef9-4729-985a-18d3be07af1c">31</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c7eb5004e0643efaa0d767fd8811f55_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMy0xLTEtMA_1d923e05-6fd4-49bc-b1bc-ff3443864e7c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1fae753be47e5bd4c21587185b6fa_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtNS0xLTEtMA_9801eda1-fe4f-40c4-9302-a5a95e1b8c62">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df3a94dfc774b0e8194462a843091f5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtNy0xLTEtMA_a416c8f2-8257-4be2-b708-84058eba416b">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15952b0805294332b2734607d6a255b8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtOS0xLTEtMA_56096c80-5f3e-4266-9a93-85e98038fc01">59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f636340dc640479a5f05532e7d057c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTEtMS0xLTA_93f8e63d-90b9-4f84-8ff1-92df134d5c85">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39557d630df942dd86fd2bf4c39cf856_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTMtMS0xLTA_4c5f7912-7442-43cb-9df1-0b6f31a9f6cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699edc2c96984870bd641e2007368c3a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTUtMS0xLTA_9ad3fc8f-9f9c-4bbf-9cdd-aaf6dbafeb5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib791d92b691f48e596977e133b7a160a_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTctMS0xLTA_8cc97339-97f7-4e78-bc5d-7a8e2fbcc057">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef24876a7764b5baf52ca7024d66e6c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTktMS0xLTA_4541c44f-054d-4426-802d-3c530b9706aa">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba9f69f2a94435d9d0a72322f3ae888_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMS0xLTEtMA_0f8043cf-f896-4ff1-9ffe-fe03388418c9">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9da0b7f32d4b4b907aa341ebe4cb77_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMy0xLTEtMA_95036219-576d-4522-8bd3-99af0a03a7cd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43cc1a499218442e95080f98c69c62d5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtNS0xLTEtMA_6fb34c8a-19f2-4cb8-9745-a066cdfc6c44">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bf9bd5acfb401fa74b890b56b423f2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtNy0xLTEtMA_4345026d-2274-42f3-82c2-82c92c1ac108">355</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96f52556ae446d4a890b661e68c63e6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtOS0xLTEtMA_801a2172-4155-40db-b15e-53ca2e7e064f">374</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b79dacdae14f1e977caf0b1f646c03_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTEtMS0xLTA_b0eb3dbf-37f4-41bb-9e0c-c98060854808">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief56854f3aa241a0b9fa4ddfcfe5de10_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTMtMS0xLTA_269c43d5-1d3b-405a-8c81-70ee9762b9d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib62ecf568cb04ff1aacdc2f07c2ffeb2_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTUtMS0xLTA_2ef52579-86bb-434c-b061-4b7226c395bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied08a22fe762423eb0853b09ffc68ba5_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTctMS0xLTA_1358b5d6-8809-457d-a972-71d91160c464">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic57e6fb3e1414f279eb4e83bd905b61c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTktMS0xLTA_1e495565-3f83-4efe-896c-5d88a2469709">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i755cbd5c13c24c81933f62cd6b4eda28_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMS0xLTEtMA_3a3d052c-87c0-4162-9902-c24d50a7c74e">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a189549221f4e24b423fd38671d9d54_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMy0xLTEtMA_d24d911e-934c-4325-b197-062eba5b4b84">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0252b084de946b684173854befd400e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctNS0xLTEtMA_1c1e9ccc-64c8-4512-bd5c-c72b10a12b9d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb1b2bee0774b4aa8d069b01b4b4a15_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctNy0xLTEtMA_a7981e2e-4c49-438e-8fb6-f2b5977a3bc1">85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ef8d12db6e40848a3a69a5aff2a1e9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctOS0xLTEtMA_995eccf8-8970-4bcc-8978-3f4ca3325437">101</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a497acacff4f75ba6294cfa44db5bf_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTEtMS0xLTA_56c3a403-e1b1-44a7-aa25-64bc4d79d368">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15a714c12b94a1ab30adc88613b45ec_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTMtMS0xLTA_600d7b94-bd43-4327-af26-ae5847852429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd632257d3a49bbac09f1ac0c2bfb66_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTUtMS0xLTA_279dc62a-5a0f-49e3-bee5-2218758d4fa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2a774411d90415084d7be23aba71361_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTctMS0xLTA_b16fa882-1acd-49a0-acf0-91bc0aef09a1">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b6ad0ae1984ddb8dff1329153f9b50_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTktMS0xLTA_72f30fab-467d-4734-ad35-4db5c9534cd2">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c7902d5027446ea98179759ec35a86_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMS0xLTEtMA_d3f145e8-1a89-4142-a8d4-846807ea443e">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85e0fb8780a4f668610145bb98e568d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMy0xLTEtMA_e1ba4497-f229-41e4-a833-7f7ec679b989">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23dea03aedd24af7bba7749747e2c448_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtNS0xLTEtMA_aa517dba-b1b7-4247-bfc8-652474f42d6b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbe0c4416b349fb9992bba23dd31615_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtNy0xLTEtMA_c5013427-0acb-4290-af9d-e046091d09b3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6261bbf6434c1fbbb017c083ac826f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtOS0xLTEtMA_df0a3690-a3d8-46af-95c5-21c79dff6654">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099c7987308445478005041a2e2499e4_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTEtMS0xLTA_a1a1e72e-bf4b-4879-befb-083894ec1d16">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7b979b8181471cbb2f4d6499c774b5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTMtMS0xLTA_914d1958-7b40-4864-bd93-036f67d0c6bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9635dab5da6b4d86af14a4b3b3e3d17c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTUtMS0xLTA_7b668a61-0080-40b4-873c-7e6abb8b2a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9accb5aa18f4478b540bfc23200dd1c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTctMS0xLTA_0f661982-47c8-45c1-9f22-aba5d2972131">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d7560a3be3405aa45a2e8965d79a75_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTktMS0xLTA_144041f9-692e-4f98-ad87-a5d0cdef0179">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991d3d8795e7450993baad6ac1542b2e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMS0xLTEtMTQwNzA_ae120829-e175-4a20-8a5f-3ca93ff9a7dd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe94f09fb8b44e858f391b3b456ea158_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMy0xLTEtMTQwODA_a67c66e1-19e9-4e77-80ef-5eb25e47a8cb">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03dcff373b2c4b2e99f9bc879d71f877_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktNS0xLTEtMTQwODQ_87746406-bace-45ea-b573-7f6ad10043bf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4161dc5395848ec97371fb2973a6cf8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktNy0xLTEtMTQwODg_cc0ee1b7-9b75-42d6-847d-57626b2a4a5e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148dc14f164643bc9efe7b919ed342bd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktOS0xLTEtMTQwOTI_2c0aaff3-d398-4695-88b3-f554c03873a2">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd0233a6f6343d6985c502db8bfff5f_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTEtMS0xLTE0MDk1_ba6512d6-e6b3-46d5-beab-95a808ea9f97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79484360495649f0914e71275a2db5f7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTMtMS0xLTE0MDk5_bb45859c-a3dc-45c2-9fe1-dd83276f920e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i952760f0a9e74c05b6d48ac685eb2961_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTUtMS0xLTE0MTAz_2f6c2dff-77af-4559-99e7-940b3cddbbe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e0d1a44c2c42158b392f684f51f780_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTctMS0xLTE0MTA3_f9539dfd-63af-40c8-bbc7-cb9ba02db566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9deec913ce4e429d807dd9d9ffb90a6b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTktMS0xLTE0MTEx_968d8a03-a327-40c9-8a6b-efcb1fc18cc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17183f50f3f84a319239298ca400b998_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTEtMS0xLTA_a4d2af4e-9377-46e2-b6f4-d43cffbc55f8">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd9c6661e1d486f8658b5ab959fdfba_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTMtMS0xLTA_a1d10c7b-d55b-43f8-8113-3328d4c5d675">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib753ab6b2404493bb7bb3e62d12eddca_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTUtMS0xLTA_a2009ff2-75c0-4043-896d-8b723bd12d3a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ffe7e2d5821413da37bc4be396523dc_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTctMS0xLTA_7b1fc4f3-e3b6-4e36-8d8c-0059b10e1c55">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib945d0e7dfa340bf87fc9b367dfeb236_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTktMS0xLTA_d42836ba-ad4d-47e1-8df9-bec8afe60777">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8163064b7e4a40249d86d66b673c237d_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTExLTEtMS0w_6609eab9-115e-447e-a51c-6ede4c62c6de">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ced98f942344b8ab3c48acf6650470_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTEzLTEtMS0w_4a3ecb53-cff9-4ccf-bf42-9d3fffbc82b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9b9a544637409b9b31bfd72192e634_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTE1LTEtMS0w_40efaf77-5f45-4a4e-bdfc-74369ecc4eef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10fba196d5842819ca00cca1ed5d9bd_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTE3LTEtMS0w_594ea1ba-fdef-476a-a2c6-0a5f103f583a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae7bb63a321a4dbca2ff6d7d594a9842_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTE5LTEtMS0w_a55b2b72-d6dd-4208-a5ab-c3623997e8b5">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3515234e4c5489b8a5058fd44abad74_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTEtMS0xLTA_1ec2417e-929d-4c25-bbd6-508e832e7cc9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e22790d03c4f9b8ae9e600bf7d8610_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTMtMS0xLTA_1207f380-f5de-4796-b5ef-4d9e40d3aadb">221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ac062f19214253a973f162cd6b7257_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTUtMS0xLTA_2263026f-ec5c-4ada-af1b-718f3d31629c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d2514b5ecb4f079fe56b573db1a351_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTctMS0xLTA_d478b527-2789-47e5-8964-6af882e61927">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054b0d4c7dcf4dad93d6b261932d1c2a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTktMS0xLTA_cdfc1e78-48f5-4fe0-aaf1-a23feed44833">221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b3ee4288f1434fba7a20a0cc9987ca_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTExLTEtMS0w_b77a7245-3f29-4121-a723-bdf3b2d7cc60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe6a7bef2d8421da8fb84a3f0eb8f61_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTEzLTEtMS0w_138d3805-cbe7-406b-9399-8d6011bb6c57">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9d170f4c6f48cdb4f7d2ceb8f17c94_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTE1LTEtMS0w_4ab29aff-60bb-43c8-b62c-2360e91578a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fb52f964bc44ef98075f84eb2f5ff3_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTE3LTEtMS0w_75dc5246-85d9-48c5-8a7d-fe2f33eb3241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf1c6eec00b45b1895cc6d33e8b5bc4_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTE5LTEtMS0w_bed26139-3ae5-4b27-9c43-30106f0c88e0">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6482ac243747999a0cfa001203778b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTEtMS0xLTA_77c875fb-43c5-4526-95c9-9f5c16c366d9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349bae78403843118305b16989643e38_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTMtMS0xLTA_c52e82c2-146e-4cbc-8672-8f4fc4f2a800">196</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568c8abfe83946f99469ae90bb9eb5ae_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTUtMS0xLTA_983bfc4b-fe63-4aef-a1ef-42079e9c93bb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee961b99d48a42e294600feed306ca7e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTctMS0xLTA_bcbb1de3-e07c-4d60-a016-c459e670e65a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d6adfd31e845609eafb982fa870054_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTktMS0xLTA_6f8b7222-7b19-4581-ad76-7b0558c8d407">196</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a974d49102240d79181f4c266d17f3a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTExLTEtMS0w_74083a57-c131-4070-8256-bedb1836d35e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c1d58045034f7d978522ee23262647_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTEzLTEtMS0w_cc850f5b-eca8-464b-9998-005b10bd842b">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id45dfd155d034c4dac37d090ee18315d_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTE1LTEtMS0w_b8c2553b-2061-4747-9c04-ad4191822261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3707009e777f46e0827af9a448af3671_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTE3LTEtMS0w_e3f018c4-4f22-420d-aa56-ad8f077add0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb206a1757a4824b9d626e0233b0fc0_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTE5LTEtMS0w_e1461a34-c4c5-44e2-83fd-c53ff124ea80">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe1114db0d24d3585c20ee5c36843de_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTEtMS0xLTA_2a4d2313-bf75-45cd-a035-eb4e8ddac40a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd30b86dc69946c795758370be94e534_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTMtMS0xLTA_98879e3e-b84a-4440-aed3-438715c320e8">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if946e67d0b6c4774bc9f3f9e21193f23_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTUtMS0xLTA_f1200031-bbf1-4249-b0bc-3aa0617cc858">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if030402de9be4396ada7e2f22518b79b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTctMS0xLTA_be04ba76-d720-4846-bb2e-cfd805d8dd88">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7862913b018b4ac799b5977d1114dd64_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTktMS0xLTA_35b5c813-f80f-4a69-abef-b14895d45ae8">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3e27f1bf5849a283a049ebe88b1431_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTExLTEtMS0w_a150b788-df42-4497-be02-b88b7855be88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e25808393b84cb8b8588f0b2ba8f09a_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTEzLTEtMS0w_0ae84b2b-ca05-4947-893f-fb06fa07250d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice86e24a0fbd45fdb549c788c2fae42a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTE1LTEtMS0w_90adc3d1-b34d-4364-801e-72c6c4b4f78b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933961f1977a41cab0929eb4211fdd05_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTE3LTEtMS0w_55fb6fb0-f046-4e39-9e1a-755bd1fccaa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2701d8c81625454b892b42c08d22f20d_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTE5LTEtMS0w_8a370cb3-c366-47cc-8c49-c38683e3243f">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cfd92c13d147b1aaef0650037a65e6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTEtMS0xLTA_63814838-0e09-4074-b488-e15e99b64c4e">325</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60637f24b9c34907a65ab4eafa2af829_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTMtMS0xLTA_0fae5e36-75f3-4f54-bdb5-c1b3b0f1e168">428</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6e855b0100414ab5cb98a6a2b9c3f7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTUtMS0xLTA_f2c1a79e-7979-4e80-8c0a-f5a2c0905229">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6988d2c895477a9dda50151b45b1bf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTctMS0xLTA_d2d45b5b-5238-4b2f-a40a-eb51f3e10781">468</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTktMS0xLTA_48555523-6bd1-48ae-b15e-a315a39f3488">1,221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bb985051a0e4022af522f73d07de54c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTExLTEtMS0w_d3fdc731-b95f-4f52-8fc9-65fd43189f68">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if670e72285554034b4161deaea318730_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTEzLTEtMS0w_8a2c4ab0-4503-4b52-a6d0-2c6d985fdfc7">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb83591d5af44b1dbae73ab7ad1e4fba_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTE1LTEtMS0w_2b96dc25-c5b8-420b-9d18-62d61bea879d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c2e264dd3bb4e18b7d7a3a250729f3e_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTE3LTEtMS0w_2d2a6dd8-c8ab-47b0-81da-26ce6aebcb70">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTE5LTEtMS0w_21f9ed1b-873b-4e12-a9e2-807084719a24">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated <ix:nonFraction unitRef="number" contextRef="i90ed9e9d5bef4e08bd9d56bcb3fe7dd1_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0MTY_c31760e8-3dce-41e0-895f-a49e33152324">30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibaf43c3e9e35453580b96b6cc36256f0_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0MjI_372b7d7f-5e60-45e8-a1d2-db3df9367f34">45</ix:nonFraction>% in U.S.&#160;equities, <ix:nonFraction unitRef="number" contextRef="if51206021aaf4c96a2df71f22290016b_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0NDM_30fc84a5-9a1e-45fd-85c8-4ee292fa8d65">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i61232e501c3a45dd9ffc51e1a7b18638_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0NDk_7e94b100-7ed3-48d3-9039-79de6e2a2cc2">30</ix:nonFraction>% in international equities, <ix:nonFraction unitRef="number" contextRef="iaa31db245c334463830834bd6fdfcb7e_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0Nzk_18c96930-8595-44b4-9a53-d47e34bfd863">35</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i43dbdf70f3f84f9bb800dc9b2bc789a1_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0ODU_0aba0d4b-6055-41b3-ac99-7c7d5d9351ef">45</ix:nonFraction>% in fixed-income investments, and up to <ix:nonFraction unitRef="number" contextRef="i1a185822a7fd4092bdcf42d8ed03b009_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU1Mjc_244e976e-1cb5-49a4-9350-836391a93a7f">5</ix:nonFraction>% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates <ix:nonFraction unitRef="number" contextRef="iafec61eba0f44b598174decf94362de9_I20201231" decimals="2" name="mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU3NjM_78eba88e-fcf9-4d90-84e4-5965dda8467d">11</ix:nonFraction>%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="ie70bd1e3c1b945a3a50951f14972e3a4" continuedAt="i1eb1872cad6d4f3ea5c9c30777143ede"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Contributions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected contributions during 2021 are approximately $<ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzYzMjM_47e08632-7702-4e6b-9e0a-237c3898fa52">300</ix:nonFraction> million for U.S. pension plans, approximately $<ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzYzNjQ_b5f63981-1835-4332-b509-b5a1e590bd38">170</ix:nonFraction> million for international pension plans and approximately $<ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzY0MTc_8ee86b69-6a44-401b-8a82-2f722a1b6f51">35</ix:nonFraction> million for other postretirement benefit plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Benefit Payments</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MjI_042bee5c-27b0-4fa1-805d-19a31f3a5d00" escape="true"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzEtMS0xLTEtMA_36a02247-7b58-4061-9b87-5b882f9f22ec">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzEtMy0xLTEtMA_7b0df6ac-f0ae-4580-9e23-1096c25c8dfe">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzEtNS0xLTEtMA_c2c12736-2b40-4383-8617-7fcb6c393e0d">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzItMS0xLTEtMA_a212cdac-6267-4e2a-bc07-153bd9334040">786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzItMy0xLTEtMA_7b9da768-999c-4646-b36d-85c46ce9a644">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzItNS0xLTEtMA_f8a2224f-5043-4985-aece-bc6cb2458f96">86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzMtMS0xLTEtMA_9e3b44cc-8172-41bb-8fb8-5025eb553018">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzMtMy0xLTEtMA_3064d47c-5a7f-4402-ac0a-0b41d915d3b1">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzMtNS0xLTEtMA_438961d1-3b1f-40bd-b521-11fdf6a65a46">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzQtMS0xLTEtMA_16f6c5ef-4d51-4103-97d0-ffa1a83c638b">772</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzQtMy0xLTEtMA_72cd99a3-14e5-4874-b29b-722180fa6a1f">285</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzQtNS0xLTEtMA_2f968fce-0f28-41f0-8f8e-103b720a1757">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzUtMS0xLTEtMA_86e93987-75a2-437e-b780-14dfb13cebab">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzUtMy0xLTEtMA_884fd2f8-fbf4-4515-aa64-902fb4552e48">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzUtNS0xLTEtMA_4cda9f50-0bbc-4a0b-86e0-027fa8541c63">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026&#160;&#8212;&#160;2030</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec46d52043488489055d11d93409d1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzYtMS0xLTEtMA_19aec36c-9c29-4268-9fe7-f69129721da4">4,271</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzYtMy0xLTEtMA_6180607a-13b3-447d-a23d-a357913b37b7">1,688</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzYtNS0xLTEtMA_87323016-ade6-426b-832c-5ee5d00863be">474</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amounts Recognized in Other Comprehensive Income</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. <ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0OTE_d1b979f3-22a2-40d7-b2c8-5c636707c3ed" continuedAt="i016ac6fcef004bf587c3100586cb77aa" escape="true">The following amounts were reflected as components of </ix:nonNumeric></span><ix:continuation id="i016ac6fcef004bf587c3100586cb77aa" continuedAt="i28a1f0afe1644589a74168cc3d28309b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></ix:continuation></div><div style="margin-bottom:6pt"><ix:continuation id="i28a1f0afe1644589a74168cc3d28309b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:28.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) gain arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMS0xLTEtMA_ec67c81f-cf85-4395-a0f2-e229a048dbb8">448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMy0xLTEtMA_64fae807-be88-4e3c-89e9-a46bcf59f60d">816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtNS0xLTEtMA_4560a145-d304-4d9e-87bc-175c36094e6b">397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtNy0xLTEtMA_dd35790c-b9f9-4248-a70f-3e86acacac1c">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtOS0xLTEtMA_49c34d53-2f65-4085-88ad-f9fe52989268">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMTEtMS0xLTA_b287add7-048d-4b21-88d7-b356ce044e9f">505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMTMtMS0xLTA_c8c91550-462c-42ca-88b4-a6d502689c70">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMTUtMS0xLTA_7923fe8f-441e-4f80-97f7-19733ed4946b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMTctMS0xLTA_f50bc14d-4f80-449f-a599-e94d66c8c284">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMS0xLTEtMA_e3487f1b-bc4e-4275-a918-dc19155e4269">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMy0xLTEtMA_340fa8c0-c923-4063-b1a2-ee673ee25c69">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtNS0xLTEtMA_ed7eda09-3822-448d-8d23-245b1451880a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtNy0xLTEtMA_3247dfd3-ad36-4e29-8c61-cddee1843372">62</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtOS0xLTEtMA_34b7053e-9c4e-4f81-b02b-c147eaedc80a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMTEtMS0xLTA_b3892eea-fbfc-42d6-b9df-b377548545c5">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMTMtMS0xLTA_5fa141e0-e0ee-4a4e-904e-0a746f952059">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMTUtMS0xLTA_2d85eb69-1d47-4ea4-9e60-221bffd5d3a4">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMTctMS0xLTA_22ed5b63-1968-42dc-b9ed-07ae2ab48b9a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMS0xLTEtMA_55a77dc0-0220-4907-943e-ec923885412f">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMy0xLTEtMA_79c4a41d-a198-4b4a-a8ff-d3f0fde1afde">820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtNS0xLTEtMA_ee4a2d4b-5fcb-4638-95ce-c2b6c2b24071">401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtNy0xLTEtMA_6139ba2d-2f69-4c70-8806-03e1c27af737">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtOS0xLTEtMA_ba117f34-c510-4d56-9eb8-c5a31237bc6e">228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMTEtMS0xLTA_ff410134-24dd-41bb-b4c4-a33d83dd50ef">515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMTMtMS0xLTA_1e79d254-a56c-4810-8540-de0150c63040">195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMTUtMS0xLTA_786980b6-c30e-463f-b091-aa590467ddde">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMTctMS0xLTA_b3edbc8d-39e4-4f4f-8859-89688b1cb718">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMS0xLTEtMA_a7c6a0ef-9136-43a3-909e-3579a30fb69b">303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMy0xLTEtMA_e37130f3-829c-4933-8071-5b17712bee1f">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtNS0xLTEtMA_3a2ed87e-8e48-4ef1-9484-85c7256b28d7">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtNy0xLTEtMA_63b3e6e8-c926-459f-842c-f14943b428fd">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtOS0xLTEtMA_6a836a46-b617-42a4-a16d-cbd7d186e553">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMTEtMS0xLTA_feae44a2-1c90-4533-8417-056d1c95b25a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMTMtMS0xLTA_e6e3a8be-aec7-4e2a-beb3-7d6e37ee702a">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMTUtMS0xLTA_fd657adc-3142-473c-9e5e-71f32da9bf5b">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMTctMS0xLTA_fd817c52-0d5c-4278-8497-d9ffc0851ca0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMS0xLTEtMA_019cb988-1658-4ab8-89eb-e39c8eefc3fc">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMy0xLTEtMA_e3f9b62f-a2a4-4c3d-96da-867136502523">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctNS0xLTEtMA_b6695a49-e628-462a-b8ad-c298ddcc1140">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctNy0xLTEtMA_150b07d5-3ddc-4662-b146-77c6fee7eceb">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctOS0xLTEtMA_b1030d03-bf4b-4493-9c38-71c15f54e22e">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMTEtMS0xLTA_7a80a4e2-68c4-4249-91be-057da14747ca">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMTMtMS0xLTA_ea6690ec-4b15-4f22-a145-bc816f24b991">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMTUtMS0xLTA_a70b44c7-5a99-4791-91ed-956e0783a910">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMTctMS0xLTA_5e3437eb-02ae-4dac-a861-c46bfa834789">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMS0xLTEtMA_db82eafe-c22a-42b1-83d1-03ff1c39e688">254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMy0xLTEtMA_09cf113b-6378-41ac-8f3a-1a9dc25e3ca0">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtNS0xLTEtMA_1a0890aa-9c77-4a2a-9553-c45a42d56604">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtNy0xLTEtMA_8aae91d5-5191-4dc4-8c23-9eb5e3f44d16">109</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtOS0xLTEtMA_11f3555d-b850-4d02-ba50-aab56df65c43">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMTEtMS0xLTA_357bb804-6b15-41d3-9e59-4440109d4f72">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMTMtMS0xLTA_7e6c3303-8155-409b-a329-371b2c51d8cb">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMTUtMS0xLTA_7df07f20-56f0-42c6-84fd-ec47dfc2bc0f">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMTctMS0xLTA_78db44dd-4836-4a99-8605-b0ce78c4607e">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i1eb1872cad6d4f3ea5c9c30777143ede"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Actuarial Assumptions</span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MDk_187f27ee-ea01-4173-8c54-7dda50f39d37" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:33.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtMS0xLTEtMA_ec037003-f22c-43cb-8bf9-73898063cc6a">3.40</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtMy0xLTEtMA_d20f0f1c-e36e-4c96-b684-626118e72b96">4.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtNS0xLTEtMA_5f80254b-4286-49be-b93b-d3633605c1a3">3.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtNy0xLTEtMA_51f47b97-cf15-4295-bcf2-3f5107800cf3">1.50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtOS0xLTEtMA_dc1133a5-b52d-449a-adc8-5af32fc4d943">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtMTEtMS0xLTA_bfb8c02a-8bac-405f-868a-9beca51d45b5">2.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtMS0xLTEtMA_f7c112fb-de5e-4f3b-827a-bd3355480218">7.30</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtMy0xLTEtMA_86f1e50e-ec8e-41bf-b805-0b28f79e4942">8.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtNS0xLTEtMA_888a9887-6625-43c6-816c-797df0e2eb94">8.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtNy0xLTEtMA_d730ec27-5cce-4008-baf3-5397cebc596d">4.40</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtOS0xLTEtMA_c0b7848a-329a-4178-ac20-568cc52cbfa9">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtMTEtMS0xLTA_5891d2e2-a477-4b69-b85e-c62526d5b2ab">5.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtMS0xLTEtMA_2745e660-9ec7-43a2-bae0-9e16b997430a">4.20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtMy0xLTEtMA_4371490e-78a1-402e-a5b5-9ffa12d30711">4.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtNS0xLTEtMA_3cbf3fce-93c6-4d7b-ae99-dac3d3b7189f">4.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtNy0xLTEtMA_8270af42-5260-4c6b-a0f0-4f8995d57069">2.80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtOS0xLTEtMA_c1fba91b-dfab-4310-808f-56069b217b74">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtMTEtMS0xLTA_9310e618-1479-4f2b-b6d4-9ebf82dab739">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtMS0xLTEtMA_ccf64d8d-71b3-4d88-a9f4-d26a110105ce">4.90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtMy0xLTEtMA_60f52e62-de5d-44e8-9637-a2832e360dbf">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtNS0xLTEtMA_65f12635-eba5-4e67-b5e8-bd3e0ac28cec">3.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtNy0xLTEtMA_e6016f1b-f781-4414-894f-ac8397110c2d">2.80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtOS0xLTEtMA_3204ad1a-d18a-496e-8c46-75c5b6fe66f2">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtMTEtMS0xLTA_4d58e680-5cff-45f9-b4cf-f639ebe6ac72">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafec61eba0f44b598174decf94362de9_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtMS0xLTEtMA_aa55cfd9-afcc-4d3e-ad81-52b8415d7c04">2.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d4c0e028b3f47a5a748c2576dd13eb8_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtMy0xLTEtMA_bec0ee65-9456-4f1b-b069-da53ff19dd6b">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icac8719a9476464ca9bf1d1a240d1510_I20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtNS0xLTEtMA_f0f4e964-dee1-49f2-bbe0-5ed0e55881c4">4.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtNy0xLTEtMA_e608bfd4-5fc6-46a8-b0c2-9e37f37b36e9">1.10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtOS0xLTEtMA_6d49473e-4f27-4b47-ad07-1bf0e2423428">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtMTEtMS0xLTA_a6343f79-c430-43e1-a8d2-6c5d9e844493">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafec61eba0f44b598174decf94362de9_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktMS0xLTEtMA_35cccd83-ab85-4743-86e9-b465adc65716">4.60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d4c0e028b3f47a5a748c2576dd13eb8_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktMy0xLTEtMA_cd56d3d1-5fe6-42ff-83e0-7c777baec175">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icac8719a9476464ca9bf1d1a240d1510_I20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktNS0xLTEtMA_20d5709d-b32d-45b2-960f-d1e1f6f7a404">4.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktNy0xLTEtMA_e4530a67-dc0c-49a3-aab2-9b1c05895577">2.80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktOS0xLTEtMA_84b96717-b177-4429-b402-f4b3cb56d070">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktMTEtMS0xLTA_8e278c49-097b-45ef-bd5d-2e50dd496337">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafec61eba0f44b598174decf94362de9_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTEtMS0xLTA_9578a05d-b871-4135-a3ed-1c3f8277fbe0">4.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d4c0e028b3f47a5a748c2576dd13eb8_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTMtMS0xLTA_807d51da-584c-4ba6-add2-e8c48100515a">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icac8719a9476464ca9bf1d1a240d1510_I20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTUtMS0xLTA_d6d13e20-e6e1-45e7-be5f-e7a45d9c2f50">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTctMS0xLTA_5bd7b8fc-523f-4d1d-b64b-20b59565a8d1">3.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i537a35ed55a14a679dacba9b73800613_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTktMS0xLTA_1073a957-d151-4c78-9193-2ea136979a4b">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTExLTEtMS0w_b67453cb-b9a2-4bf0-b7dd-b2f6ef0394fa">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#8217;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2021, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will range from <ix:nonFraction unitRef="number" contextRef="i7410576a916e42d4bcc349b678e87d26_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzg2MzU_b49d0957-1720-4d4d-9ea2-4b2ef91bf394">6.50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i405bca874530481997ce79928dac111d_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzg2NDE_435210d3-3e15-493f-88d5-b8703775bd53">6.70</ix:nonFraction>%, as compared to a range of <ix:nonFraction unitRef="number" contextRef="i6481cbf5e20244beada5e16fb8e1c7db_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzg2NzE_9f00e878-d5d7-46b5-9371-eab88158153b">7.00</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3b9b18bf3f2b43149e469b0523aeec6f_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzg2Nzc_98326f99-d22d-4113-8b02-82248936d27c">7.30</ix:nonFraction>% in 2020. </span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MzU_2f89987b-dd37-496f-aaa1-035394cbff6d" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTozZmZmMzdmMjBlNTg0NDY4OTU1YmM5NDkzNjE5ZGY1YS90YWJsZXJhbmdlOjNmZmYzN2YyMGU1ODQ0Njg5NTViYzk0OTM2MTlkZjVhXzEtMS0xLTEtMA_51db95d1-52fb-4dc7-9d3f-fef034c30855">6.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTozZmZmMzdmMjBlNTg0NDY4OTU1YmM5NDkzNjE5ZGY1YS90YWJsZXJhbmdlOjNmZmYzN2YyMGU1ODQ0Njg5NTViYzk0OTM2MTlkZjVhXzEtMy0xLTEtMA_457cdde8-0d23-442b-854b-6c66aa1475ce">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTozZmZmMzdmMjBlNTg0NDY4OTU1YmM5NDkzNjE5ZGY1YS90YWJsZXJhbmdlOjNmZmYzN2YyMGU1ODQ0Njg5NTViYzk0OTM2MTlkZjVhXzItMS0xLTEtMA_39b52332-1e1b-49a3-8753-db4acf8393ea">4.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b329e4def234bf9be62b33165383a04_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTozZmZmMzdmMjBlNTg0NDY4OTU1YmM5NDkzNjE5ZGY1YS90YWJsZXJhbmdlOjNmZmYzN2YyMGU1ODQ0Njg5NTViYzk0OTM2MTlkZjVhXzItMy0xLTEtMA_879fb241-af4c-402c-833a-b4e86f72b0e6">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Savings Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains defined contribution savings plans in the United States. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2020, 2019 and 2018 were $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzkzODE_1b8e832b-7259-40b9-a3fd-ba2b686ef2da">166</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzkzODU_d7897dbe-0290-4a5e-9f0b-4acaa5c87e7b">149</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzkzOTI_f09c2b50-71c7-4be8-ba13-27b7ce367373">136</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_217"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEzNDU_18c567f2-d275-4455-9121-58dd3eb00532" continuedAt="i1de48033de8441fcbc9dbcc2055304c9" escape="true">Other (Income) Expense, Net</ix:nonNumeric></span></div><ix:continuation id="i1de48033de8441fcbc9dbcc2055304c9"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEzMzg_2c646aad-053c-4710-9c16-97332096ab77" continuedAt="iebd302be92024045bdd49696ada8cd24" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzEtMS0xLTEtMA_210c4229-089c-48d5-9f68-f23f9090306e">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzEtMy0xLTEtMA_b9690d9d-28cd-4046-9a0e-5c9f2d7b55f4">274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzEtNS0xLTEtMA_c5329a25-0d56-4620-8090-de22ee84faf6">343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzItMS0xLTEtMA_7ac4926a-ff68-4fb9-ab48-37980e6cd5e1">831</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzItMy0xLTEtMA_7a5f5eeb-5ff6-4eb0-a30c-e6dafc8f2fe6">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzItNS0xLTEtMA_ae4ba9ee-9ac9-4ecf-bcca-d5ae62b02d2e">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzMtMS0xLTEtMA_963f3ba2-b3dd-42dd-bff1-472a712a22b2">145</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzMtMy0xLTEtMA_ac0650bc-e32a-4113-8703-eb6f77d33422">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzMtNS0xLTEtMA_47ba3625-960e-4750-8895-32b857e63959">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzQtMS0xLTEtMA_c8aaf291-da29-491b-89e0-4a638937eb11">1,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzQtMy0xLTEtMA_e53229f9-937b-44ae-8699-ee8b5d0eaa90">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzQtNS0xLTEtMA_cba8dcf6-a460-4fac-97ab-324bda2543d8">324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzUtMS0xLTEtMA_c71ba14a-db16-4658-9a5f-629c655a5b5b">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzUtMy0xLTEtMA_5a1074cd-8927-4c9e-b559-36d3cc3dd6ec">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzUtNS0xLTEtMA_d9c74752-5f24-409a-a4d8-5c540ce65a66">512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzYtMS0xLTEtMA_2bc9454c-166e-45d0-9bd2-e80451d04f69">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzYtMy0xLTEtMA_2246ae83-4cff-4abf-98c4-4d10fd83999d">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzYtNS0xLTEtMA_bcc09f75-b65c-4545-b29f-89cdba9057f7">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzctMS0xLTEtMA_d9d0b25f-5e23-4895-aa02-bc550f25d1f1">886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzctMy0xLTEtMA_f88942b8-ccee-44c1-82ea-0b727b3355b9">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzctNS0xLTEtMA_632e4da9-a987-4b93-9afd-8aa4de1d88c1">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="iebd302be92024045bdd49696ada8cd24" continuedAt="ie5e02b23be2948159a36b7257fef5531">(1)  </ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ie5e02b23be2948159a36b7257fef5531">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net (as presented in the table above) in 2019 includes $<ix:nonFraction unitRef="usd" contextRef="ia6314d5000824e4a8abc4c270f634a7a_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzMxOQ_c4caa187-a8eb-4024-8cd7-a9e8d45636fa">162</ix:nonFraction> million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net in 2018 includes a gain of $<ix:nonFraction unitRef="usd" contextRef="i0fdabe48bf6945578d95ee1057e5b49e_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzQ3MA_60761428-5ee0-40e0-9402-5dd1559a8baf">115</ix:nonFraction> million related to the settlement of certain patent litigation, income of $<ix:nonFraction unitRef="usd" contextRef="i553d83c3c5324495837bdbe11f4b2eca_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzUzOQ_21eb6aa6-2bb2-48ae-9575-45160eb8de69">99</ix:nonFraction> million related to AstraZeneca&#8217;s option exercise in 2014 in connection with the termination of the Company&#8217;s relationship with AstraZeneca LP (AZLP), and a gain of $<ix:nonFraction unitRef="usd" contextRef="id83dfd7a1bb849e1b213bae11674e00c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzY5OA_cb48795d-d804-4ad2-9c09-89844dc33b4e">85</ix:nonFraction> million resulting from the receipt of a milestone payment for an out-licensed migraine clinical development program. Other, net in 2018 also includes $<ix:nonFraction unitRef="usd" contextRef="i85b367730bb94d77b0694a73c6126ccb_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzg0Mw_1d393112-e9dc-45b3-8e5f-4a02d74000ec">144</ix:nonFraction> million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8), as well as $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzk2Nw_af4edc2d-4698-4787-87ed-1962d50bc250">41</ix:nonFraction> million of charges related to the write-down of assets held for sale to fair value in anticipation of the dissolution of the Company&#8217;s joint venture with Supera Farma Laboratorios S.A. in Brazil.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid was $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEyOTk_7efbb4e4-dd35-44ef-91a2-83fcaa786257">822</ix:nonFraction> million in 2020, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEzMDk_4bf03b86-a0db-4cb4-93df-a36d60b2f9f2">841</ix:nonFraction> million in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEzMjI_50e1cf97-f953-4355-9bb5-a5aa98aefdc2">777</ix:nonFraction> million in 2018.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_220"></div><div style="margin-top:14pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc4ODE_ccd8962f-4927-49dd-9b74-08b4d0bb70bc" continuedAt="i40cfd1a9a1374566bca38b5f01fac73a" escape="true">Taxes on Income</ix:nonNumeric></span></div><ix:continuation id="i40cfd1a9a1374566bca38b5f01fac73a" continuedAt="i637d83b41dcf424fa8ff9477ef461f5a"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc5MTU_8d17dc6c-e41f-4c77-a3eb-38af342f1491" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:35.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income before taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItMS0xLTEtMA_cea9c812-5a5b-4822-9207-19855c35acec">1,846</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItMy0xLTEtMA_e742ce49-fa81-4d0c-a581-46244932d978">21.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItNS0xLTEtMA_352c14e6-3b87-4dd1-9e7d-e91acbfe4a8d">2,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItNy0xLTEtMA_c95b5ba0-10fc-4274-b00b-6f09883e077a">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItOS0xLTEtMA_9bf52cc4-b110-4eb2-9b45-5cbca25b7d17">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItMTEtMS0xLTA_2cffb381-d38a-45b0-a36c-8a4de41d39b2">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtMS0xLTEtMA_41ec19c0-399a-4522-a7e2-4cf94cd58738">1,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtMy0xLTEtMA_29394117-0feb-4ec8-9ba5-15c048c9d9f0">14.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtNS0xLTEtMA_b158a53d-c60b-4a95-ba55-66f01adfe5bc">1,020</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtNy0xLTEtMA_3e500532-797a-48ab-953c-8eddd7179a2d">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtOS0xLTEtMA_84790aa6-1ab3-47c4-a7f7-b0fa3d2ed97b">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtMTEtMS0xLTA_66a48381-60eb-4c6a-94fc-3f4bf23cdc45">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtMS0xLTEtMA_3543c0ff-c6af-4991-9fe9-a6ba535a5dd3">364</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtMy0xLTEtMA_b82a0d1e-e632-494f-bf53-50089beedc71">4.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtNS0xLTEtMA_24f26c1d-dc10-47cb-9d6a-188ca56d7223">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtNy0xLTEtMA_5b672944-b94f-4545-a01e-eaf2bc79e2e0">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtOS0xLTEtMA_0f59de9e-fff0-4957-8e32-3217beb9a0ff">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtMTEtMS0xLTA_33c55049-8e69-410e-a771-2aaab18cb769">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctMS0xLTEtMA_312e30ff-1ae3-4f2f-84f6-25727d22664a">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctMy0xLTEtMA_b47b6716-5311-44e7-8105-ae0aecb4e334">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctNS0xLTEtMA_10edb35a-5ad4-4fb5-b52b-249a2ed317f8">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctNy0xLTEtMA_8d222bf5-4fa0-4e9b-bf95-636f56c8964b">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctOS0xLTEtMA_a43a8a69-1575-4481-b1ac-18dfb59e5b58">96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctMTEtMS0xLTA_f8c64591-31bc-47f5-9d9b-dcb9bc2a31ea">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMS0xLTEtMTU3NjA_c79b6c89-52bb-42bd-8004-afec6dd3cf48">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMy0xLTEtMTU3NjA_9e10489a-cb9a-4eed-be86-bc695c418a6d">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNS0xLTEtMTU3NjA_46742e4d-282b-43cd-a559-b550212d21d7">403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNy0xLTEtMTU3NjA_49ae0be2-18a7-4e7e-affc-2a7def3dae84">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktOS0xLTEtMTU3NjA_528cd862-1f4b-4124-acc7-1b4dddc73122">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMTEtMS0xLTE1NzYw_4e836606-4eca-43e4-b7e6-cda97b43b69c">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMS0xLTEtMTU3ODg_90d1acbb-6a7e-4cad-a2a8-cd34f9ebb161">559</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMy0xLTEtMTU3ODg_116b0832-038d-4f24-9e5a-c23d4a78944b">6.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNS0xLTEtMTU3ODg_4a25aae2-dc5e-48c2-9bb8-e1462fdca70d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNy0xLTEtMTU3ODg_f0d9bc08-ac17-4410-81f8-b26c643982fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktOS0xLTEtMTU3ODg_74b7f08b-9756-463b-8dc8-3d313147c272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMTEtMS0xLTE1Nzg4_9474c9d4-e21a-4667-b378-472b48dad8d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMS0xLTEtMTU3NzE_ef3b7687-3c8a-4603-9350-c2a84fd7a791">105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMy0xLTEtMTU3NzE_6221e6ef-5bcd-4ec6-ab0d-3a886b6d82b3">1.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNS0xLTEtMTU3NzE_d342570b-18e5-489b-91ed-bab9ffe51944">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNy0xLTEtMTU3NzE_603134ce-edfb-4136-9025-15fa16486322">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktOS0xLTEtMTU3NzE_5635debc-d484-4259-a52b-d43d82fdd5a1">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMTEtMS0xLTE1Nzcx_52107305-585b-4414-ba1f-03fd7b611577">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTEtMS0xLTE1Nzg0_1be8f00c-ad1e-4977-863f-bb1fd57cd03a">97</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTMtMS0xLTE1Nzg0_1cec0988-981a-46f1-a4de-914b9f1e2582">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTUtMS0xLTE1Nzg0_3d11f972-b028-4b92-98ff-37f784d3f2a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTctMS0xLTE1Nzg0_6f0440d6-4a7e-4c6c-b21b-ca32872ad918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTktMS0xLTE1Nzg0_6ec9d58d-258b-4c73-9b23-0753ed143813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTExLTEtMS0xNTc4NA_50d802c2-1182-4d01-b2db-127532cad9bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtMS0xLTEtMA_847909a7-cdaa-4f31-9a33-41c94c7dbce1">67</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtMy0xLTEtMA_8446d44e-9e28-4bd7-9e08-dac0a6424140">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtNS0xLTEtMA_80a96408-19b7-4269-9a5b-6cf63c409bfe">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtNy0xLTEtMA_061f5fce-3b2b-4637-b135-42b4e1ef7bb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtOS0xLTEtMA_7f43fd49-f999-400c-8d01-bc34bc427638">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtMTEtMS0xLTA_7fba8185-eb83-4ab1-9a5c-14cdb151081e">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs, including amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTEtMS0xLTE1Nzky_5d333047-45b5-41c7-a093-26cdbbe1b210">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTMtMS0xLTE1Nzky_ac66bc02-85df-465e-9222-1b7214c28401">0.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTUtMS0xLTE1Nzky_3065a088-52b8-4937-bce3-b6c0e68a6f2b">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTctMS0xLTE1Nzky_37e2d7f5-c45e-43e6-99e3-d92db0a4ebeb">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTktMS0xLTE1Nzky_d6ae4648-30ab-44f3-adf6-99a232e3f2b5">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTExLTEtMS0xNTc5Mg_18aba023-0d77-4deb-8fba-887773ec2f42">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTEtMS0xLTE5MjAw_64826288-2341-48de-ab54-2d44347eeeff">42</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTMtMS0xLTE5MjAw_3416beb9-373a-4c02-ae2c-643e30f57914">0.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTUtMS0xLTE5MjAw_816463c4-41aa-4d3d-8a64-2d12515c3291">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTctMS0xLTE5MjAw_6430e1cd-22bc-4a0b-a68f-f04779131a93">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTktMS0xLTE5MjAw_76ab9adb-74f9-4dba-9078-bc13e538cff5">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTExLTEtMS0xOTIwMA_f077c681-7bc6-41af-b8c4-259afaed3cd7">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Peloton</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMS0xLTEtMA_e18f7da6-072e-40ba-bd10-58d87fe853a4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMy0xLTEtMA_38e4dcdd-34f9-4b31-93de-eb4ad4130e17">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNS0xLTEtMA_55e18536-61dc-4d13-9d62-59af35ea6a61">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNy0xLTEtMA_ee6996d6-a881-4bc2-89a1-9f64b6777630">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktOS0xLTEtMA_5d4b1aa3-35ef-447c-9238-abd55b945ae6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" format="ixt:zerodash" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMTEtMS0xLTA_7192c75c-1d6d-4b5b-9cad-cff13f232183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTEtMS0xLTA_2f5dd804-542c-4f74-90f7-6e6fdabe5c66">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTMtMS0xLTA_52264d42-66dc-45bc-ab11-d203a89b5039">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTUtMS0xLTA_ba850996-6444-48b5-a8ed-b07c17f218d7">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTctMS0xLTA_4fec4c19-058d-45c3-adb4-0649d78c0d08">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTktMS0xLTA_9357aff8-33a6-41ba-a98a-9b44dbed0dc5">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTExLTEtMS0w_2eec5dbd-4081-46f0-bfb5-77b5a5649a92">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTEtMS0xLTA_7e3a7125-7741-4f2a-814f-ffd95e71c059">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTMtMS0xLTA_12938b27-d80f-42e8-b5e7-4fd701163dc8">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTUtMS0xLTA_f4b3e3b5-a3c7-4919-a8fc-300149d01c50">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTctMS0xLTA_df263d2f-df89-41ed-a49c-86f961192215">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTktMS0xLTA_955d126e-b660-4a9b-954b-e30c0a84ba74">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTExLTEtMS0w_199d90cd-d638-4a25-9d36-625de6b3a8eb">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTEtMS0xLTA_55c38b07-3499-481b-b854-48235ebb15ba">1,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTMtMS0xLTA_d6075f97-d32c-4829-881e-240f5f034d40">19.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTUtMS0xLTA_8d4cb446-399b-460c-ac17-075fab13895b">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTctMS0xLTA_aba979b8-1ce4-46cd-9e2e-0768a0c2f169">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTktMS0xLTA_9a415e66-2402-4ce5-9f46-06cbb9ac4436">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTExLTEtMS0w_ebcb5c5b-530c-47f1-908e-9df4611343ad">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i637d83b41dcf424fa8ff9477ef461f5a" continuedAt="i42d68d2fbc1647da823d5c94645d39ed"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017 and the Company reflected the impact of the TCJA in its 2017 financial statements. However, since application of certain provisions of the TCJA remained subject to further interpretation, in certain instances the Company made reasonable estimates of the effects of the TCJA, which were since finalized and resulted in additional income tax expense in 2018 and 2019. The Company&#8217;s remaining transition tax liability under the TCJA, which has been reduced by payments and the utilization of foreign tax credits, was $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzIzMTg_39f5e8d1-2be5-4939-820d-954b7dfe81cd">3.0</ix:nonFraction> billion at December&#160;31, 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i0b58a3ac34da4fe8ae1aff48a5e4e450_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzIzMzc_f4118ac4-d9e2-47c6-be42-a5094f54c6b8">390</ix:nonFraction> million is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the remainder of $<ix:nonFraction unitRef="usd" contextRef="if2ea8b16632d441e9fe3b895f38cce6e_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzIzOTc_39b843e3-b87f-4be9-bd92-7a5a3f5fa5cb">2.6</ix:nonFraction> billion is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the United States, particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2022), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. Towards the end of 2020, a new reduced tax rate arrangement was agreed to in Switzerland for certain newly active legal entities.  </span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc5MDg_6a3f6b3d-f429-4026-98d1-26218ab99868" escape="true"><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before taxes consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzEtMS0xLTEtMA_06104f4b-3e09-42bb-b5a8-2fd259f19b8d">3,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzEtMy0xLTEtMA_fcebafb5-c0b4-4e8e-b68b-8c0d063382c5">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzEtNS0xLTEtMA_59141ce4-07ab-4ef7-9dd4-f3234f78aba8">3,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzItMS0xLTEtMA_a9557721-31b2-4ae8-b90a-1a632ed20bbd">12,283</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzItMy0xLTEtMA_8714cfd0-312c-4a5a-b706-3cdaf83faf12">11,025</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzItNS0xLTEtMA_ea7871e9-8e5f-4eb9-8ff2-5fc7b9fc7c7c">4,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzMtMS0xLTEtMA_d2f1a112-96d0-475f-9c48-366c3364362b">8,791</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzMtMy0xLTEtMA_b95aa049-e553-4920-8f51-1356703e1778">11,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzMtNS0xLTEtMA_1803a6c0-82b4-46bc-b254-83db9a2cbe08">8,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc4NzI_7ab40062-73dc-42a8-aae3-46cfb6c6fcc4" escape="true"><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on income consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzItMS0xLTEtMA_63b56f05-5bf1-4e2a-902e-e8b48ec37c1c">962</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzItMy0xLTEtMA_4f6b5507-b6ca-4808-b381-0d64ca208d84">514</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzItNS0xLTEtMA_9779f524-e963-41ae-aa19-c007f696d9e1">536</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzMtMS0xLTEtMA_8154f4d3-ba78-405a-afde-2ce07dc0a25e">1,362</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzMtMy0xLTEtMA_b7f9f503-e22c-4527-8a55-33a0fe0e1247">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzMtNS0xLTEtMA_1f020630-4105-404d-a0cf-2bd1afd0e1c9">2,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzQtMS0xLTEtMA_168cf810-95b2-4b5c-9a4f-636f9840be62">53</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzQtMy0xLTEtMA_e296d7dd-74a7-4c5d-b699-0a9d94f76fce">77</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzQtNS0xLTEtMA_cf246fb1-3435-4bcb-87ce-436872d81433">200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzUtMS0xLTEtMA_d460bdf0-d091-48ab-b957-778d7cc6b582">2,377</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzUtMy0xLTEtMA_ec27226c-5dd6-46b3-b433-5420638d48e4">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzUtNS0xLTEtMA_52cef32c-0669-4c46-bac5-380b979301bc">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzctMS0xLTEtMA_3abbe200-be61-413b-95a6-d2195cb26506">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzctMy0xLTEtMA_43695ec2-8f30-47ee-951b-302b48b31f3b">330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzctNS0xLTEtMA_ba1cd240-c1da-4590-bfe0-fef9c301326d">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzgtMS0xLTEtMA_cd9aaa31-c1b5-4694-aeae-815a1ed5cf70">40</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzgtMy0xLTEtMA_2a52cd97-b0ba-43af-bbdd-924fc891a8c4">240</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzgtNS0xLTEtMA_16eb9106-a8ea-4038-a63d-160753fcaa31">64</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzktMS0xLTEtMA_bafe57a2-c0f2-44ab-a8c3-a5da62f0c91e">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzktMy0xLTEtMA_d7eca2f6-379d-409a-b2fc-33630028d871">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzktNS0xLTEtMA_b29829d9-f04b-48be-ab20-b886a7b160f0">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzEwLTEtMS0xLTA_0f2f172b-fc71-418c-868d-f1064f4965a5">668</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzEwLTMtMS0xLTA_c9823c55-e6ab-459f-a289-032333322e1c">556</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzEwLTUtMS0xLTA_0318081f-6fe1-43f9-a428-35ece5ffa360">509</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzExLTEtMS0xLTA_f6efbbe7-3fbd-41f0-a056-e7e737fb10ad">1,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzExLTMtMS0xLTA_42c6c8be-6395-428e-a899-65a733e0bec2">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzExLTUtMS0xLTA_1c7cd009-4a89-4afd-9581-87dba1801d9e">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i42d68d2fbc1647da823d5c94645d39ed" continuedAt="i7eb6a7abd5b9441684472db2ad6ede2f"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc4OTY_fc2aa135-ca62-4fd2-ba02-e6a896cd7273" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzItMS0xLTEtMA_633cff31-3305-450e-976e-146383ccef56">141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzItMy0xLTEtMA_21ae9bf8-5bad-468e-ae26-e5134f637fd1">1,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzItNS0xLTEtMA_df5dd61e-7657-4a4f-b169-02b16f279561">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzItNy0xLTEtMA_6832521c-c510-49b9-a466-bdccb1c35380">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzMtMS0xLTEtMA_42da397a-9d3b-4c8f-980c-fa0d42791076">43</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzMtMy0xLTEtMA_14c8f840-9190-4fd8-97ac-b9486b7126ce">335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzMtNS0xLTEtMA_31554b2c-d841-48a9-bd20-7a8e0c0feee5">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzMtNy0xLTEtMA_2d1cf424-1db9-4931-af1b-b132c0ce4e04">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzQtMS0xLTEtMA_89b8855a-3e16-40ea-9463-48ce58761eb4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzQtMy0xLTEtMA_0afa964e-9d13-449c-b140-42c23ca58a6f">588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzQtNS0xLTEtMA_bab80780-846d-41fd-b116-a5e1137e05d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzQtNy0xLTEtMA_b06f18e3-a0a7-4f17-b0b4-f07ca2527d49">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtMS0xLTEtMTY4NDk_b45344ab-8dde-4938-9e90-e3106af7151b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="mrk:DeferredTaxLiabilitiesEquityMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtMy0xLTEtMTY4NDk_9b85169a-1343-4d6f-8f71-bffe1b7392f6">175</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtNS0xLTEtMTY4NDk_d4eb1b00-9bb8-4c91-ace7-b643e0f25bf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:zerodash" name="mrk:DeferredTaxLiabilitiesEquityMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtNy0xLTEtMTY4NDk_258c441f-072c-4615-8e74-f557120eddca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtMS0xLTEtMA_daafbf36-5123-4276-8f8e-4602ad67cf77">834</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtMy0xLTEtMA_a310d20a-b0a5-4e15-9de9-c985698ce6fa">248</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtNS0xLTEtMA_5be590d5-4971-4fee-aab0-5a8bf42964ff">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtNy0xLTEtMA_ece56f11-195e-446c-be5c-0e5685dfc924">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzYtMS0xLTEtMA_91231ea1-636e-469d-80f5-1b43303a4956">252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzYtNS0xLTEtMA_15b38f9d-3a2d-4e74-a703-5c625cfcf44a">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="mrk:DeferredTaxAssetsUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzctMS0xLTEtMA_ed80cfd1-c512-4942-b0a3-5e9344fc0c32">117</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="mrk:DeferredTaxAssetsUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzctNS0xLTEtMA_5981dd89-86ae-49ba-a9fa-fa64d46a71fd">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzgtMS0xLTEtMA_2ec6c227-afef-43e7-ad12-1d6d49f6bcda">794</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzgtNS0xLTEtMA_529ed6fa-9bb7-41fa-8c35-2b34e12319aa">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzktMS0xLTEtMA_5bc4e822-aeae-4c8a-9b02-9060dd85bd57">808</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzktMy0xLTEtMA_892e7c1e-0631-44c6-9e09-fc067debcdaa">81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzktNS0xLTEtMA_8774f422-285b-44fe-9e0f-fa8f56ee6e8c">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzktNy0xLTEtMA_91fbb155-7314-4cbc-8f63-161323108dd7">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEwLTEtMS0xLTA_59dfe0c6-0266-44d1-b852-28a7cd6ab249">2,989</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEwLTMtMS0xLTA_a33735e6-213b-4142-8f36-47c19ea21089">2,677</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEwLTUtMS0xLTA_6c86e6e3-54b3-42dd-8572-1a3d6716a605">3,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEwLTctMS0xLTA_59ae9e4d-1a66-4ad4-ad5e-aca9e94ecade">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzExLTEtMS0xLTA_43e7dac5-8876-49a2-b4fb-7a736c82e1b2">433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzExLTUtMS0xLTA_a0a3274b-d246-493f-ae70-f9de4b64866c">1,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEyLTEtMS0xLTA_bfff0796-dfcb-4feb-ad0e-7532efe3c6d4">2,556</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEyLTMtMS0xLTA_e5692d6b-12eb-47dd-a7dd-bf830768c264">2,677</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEyLTUtMS0xLTA_be83d8ba-1072-49ee-9553-749132f4a63d">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEyLTctMS0xLTA_54346b97-af81-418b-a3e6-d954f111e5b1">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEzLTMtMS0xLTA_8b3c88c7-0340-4f9c-8455-f7b3cbc1a95a">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEzLTctMS0xLTA_7b1e4b31-08ee-4b42-a190-3ae792971f1a">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf552eeb0d424605ab9e87eb7385fe42_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzE1LTEtMS0xLTA_815964a7-ef5e-42d0-8fe8-ffc29dd51311">894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82df9d4f97443e485af19b6f535a820_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzE1LTUtMS0xLTA_cc8ce7bb-21b7-46e5-b399-d5c2766609a5">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzE2LTMtMS0xLTA_5d52fa05-7d61-46fe-b10a-bb4aa36d805f">1,015</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzE2LTctMS0xLTA_e3881e27-67f3-49c1-9c28-277082208e23">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQxMzg_dbd1cbe6-a1c9-48bf-844a-41203a4b64c8">464</ix:nonFraction> million of deferred taxes on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="ibc9efe0064ee4c049327821352c6c0bb_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQyMzc_7269bdcd-d64b-4e1c-82d1-d3f2b76dc37b">433</ix:nonFraction> million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQzNjU_1bf724aa-8bdb-4644-a6ef-aec27cb10a6d">330</ix:nonFraction> million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards, all of which are expected to be fully utilized prior to expiry.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid in 2020, 2019 and 2018 were $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ1Njg_48105fa0-fdfa-4b3e-b41b-3ce9b4e53f87">2.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ1NzI_496ad19a-cfc8-46c5-ad77-546adc3e392b">4.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ1Nzk_cdde5168-2809-405b-a2f5-48c46916447f">1.5</ix:nonFraction> billion, respectively. Tax benefits relating to stock option exercises were $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ2NTA_3e109817-7021-4312-8222-0e928c828b74">55</ix:nonFraction> million in 2020, $<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ2NjA_17d2b5eb-a2e4-46f6-8440-a5e2a6d70e69">65</ix:nonFraction> million in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ2NzM_b16d4676-6899-407e-bf26-6842c64e5ed6">77</ix:nonFraction> million in 2018. </span></div><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc5MDc_d86ca07e-3898-46f8-a46e-56f0775833b8" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzEtMS0xLTEtMA_c2b178e3-f50e-4694-9cf9-145f74d78d46">1,225</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzEtMy0xLTEtMA_13f9ae6e-2c53-4553-9bd9-6f6d6aa5d6be">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e100303069b40878e0e19c66282b95b_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzEtNS0xLTEtMA_c6f64389-bbce-4b1c-9041-21a324d6f133">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzItMS0xLTEtMA_b5e61cc8-c4a9-4a58-bb30-fd2728a2e61a">298</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzItMy0xLTEtMA_96d011b7-ad0f-4b0f-8f20-3045215f61fd">199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzItNS0xLTEtMA_8a7d931f-5c84-493c-bf69-8cc4c46e67ff">221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzMtMS0xLTEtMA_81f1d044-f6cb-44e4-864b-d1cf68b1ee85">110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzMtMy0xLTEtMA_7a6f4865-ca7b-45c2-9c1c-28c9c9fd9e7b">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzMtNS0xLTEtMA_75b65893-8df0-4260-8aa3-01b337837047">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzQtMS0xLTEtMA_33ff9a7f-f48d-4cef-9614-e1bed1f3e1bb">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzQtMy0xLTEtMA_3a20608b-5e26-412d-a93e-adb03c447b96">454</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzQtNS0xLTEtMA_d8ff5986-68c6-4651-8f9e-bc07425d5965">73</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzUtMS0xLTEtMA_0c22d998-884f-4929-9dac-ba79e0d3d9cc">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzUtMy0xLTEtMA_7173a8ec-600e-4545-bb44-1c93179f2c4b">356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzUtNS0xLTEtMA_e309ecaf-99cd-4f3e-b172-84f8fa259b70">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzYtMS0xLTEtMA_68fe6531-abf1-4410-862e-93c00790c92a">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzYtMy0xLTEtMA_11a3f05a-f95c-4eb4-a5db-dcc08c65b8eb">103</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzYtNS0xLTEtMA_a588e310-67c8-4d9d-ab57-4b11fd1a2f05">29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzctMS0xLTEtMA_00da7dcd-9f9f-4823-9c8e-5b3c5bb86a19">1,537</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzctMy0xLTEtMA_a2395059-e766-47a4-ab10-81b10f0e52c7">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzctNS0xLTEtMA_0a06449e-0047-4cd8-97a2-22c7153fdffa">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Amounts in 2019 reflects the settlement with the IRS discussed below. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  Amount in 2019 includes $<ix:nonFraction unitRef="usd" contextRef="iae848d20b3c043e09bea70d1386a41c8_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ4ODA_743d3524-4668-45e0-935f-44397c273622">78</ix:nonFraction> million related to the divestiture of Merck&#8217;s Consumer Care business in 2014.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to recognize the unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzUwMTk_43d19836-0d8c-4f28-b503-62fe8efae06a">1.5</ix:nonFraction> billion at December&#160;31, 2020, the income tax provision would reflect a favorable net impact of $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzUwOTQ_ad5a52ea-cfa5-454a-8139-10e5f1de0e25">1.5</ix:nonFraction> billion.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i7eb6a7abd5b9441684472db2ad6ede2f"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2020 could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzUzNDQ_66fe81c3-4ce9-4c98-ac7e-a15b816805d7">160</ix:nonFraction> million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#8217;s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzU5MzA_d168bd83-7a86-4ef1-8d59-2cc582698e67">27</ix:nonFraction> million in 2020, $(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzU5NDA_f8c8686c-ce92-451a-b032-7ea267c01b0a">101</ix:nonFraction>) million in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzU5NTM_e1001f7a-1864-4308-88c9-b650c4bb0b66">51</ix:nonFraction> million in 2018. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $<ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzYxMjE_295651e7-a5b5-4643-9eac-88af5fffecc6">268</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzYxMjg_aa054c12-691d-4575-b3c4-f0cff775dda1">243</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $<ix:nonFraction unitRef="usd" contextRef="i942f16eff97546a5b0fedc3f590bc635_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzYzNDY_a8a41c4a-dcc3-4153-9945-2baa1a65d315">107</ix:nonFraction> million. The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i942f16eff97546a5b0fedc3f590bc635_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzY1MzM_9beca4f2-ece2-4702-a63f-ed14e9e9552d">364</ix:nonFraction> million net tax benefit in 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS is currently conducting examinations of the Company&#8217;s tax returns for the years 2015 and 2016. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#8217;s income tax returns are open for examination for the period 2003 through 2020.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_223"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzQyMA_ff8f68f5-e7f7-4457-bf2f-5a23874a6615" continuedAt="iaff643e40f994494a5743e87d07faa52" escape="true">Earnings per Share</ix:nonNumeric></span></div><ix:continuation id="iaff643e40f994494a5743e87d07faa52"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzQyMw_ff38d00d-ef37-4a12-9ae3-8d5370e231a9" escape="true"><div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzEtMS0xLTEtMA_682ac9c7-da76-40b2-98d6-5b55b6cb66b2">7,067</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzEtMy0xLTEtMA_b2f3200b-e0d6-4cc5-9850-800b6eff80cc">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzEtNS0xLTEtMA_c3c82e73-db99-4448-a662-b02ddd7ae9f5">6,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzItMS0xLTEtMA_e0f1e745-4985-41da-933a-495b4a5db210">2,530</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzItMy0xLTEtMA_47988912-3a50-49ec-866b-e6ad0f5011ce">2,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzItNS0xLTEtMA_5c172609-3665-4c3b-b936-0852bb9412ff">2,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzMtMS0xLTEtMA_d583d172-a1ea-4e47-b0e1-36dd03c45a8f">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzMtMy0xLTEtMA_f784be6b-7f2c-42bd-affe-1c5d249af9bb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzMtNS0xLTEtMA_2eedb4bd-729e-42e0-a465-0199e8f60bae">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzQtMS0xLTEtMA_e268da52-f639-43ed-b43d-efd5928fbd2e">2,541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzQtMy0xLTEtMA_54b912dd-2b52-497c-94f0-491a7a653ddb">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzQtNS0xLTEtMA_18ae8ca7-2459-497f-af8c-2805a345fead">2,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzUtMS0xLTEtMA_d9291b21-3628-47b1-9804-4424d3bdac8e">2.79</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzUtMy0xLTEtMA_cb7dd3f9-f58e-4ced-91a6-6e409ca9a25c">3.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzUtNS0xLTEtMA_e5a05928-08f0-418b-b446-2bfa2420aad6">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzYtMS0xLTEtMA_28409934-eb52-447a-a673-aff78d9c7be4">2.78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzYtMy0xLTEtMA_8c0eb6e0-2d55-4d62-948a-2a6dd0ec8a6b">3.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzYtNS0xLTEtMA_1b18298e-8b3d-49c2-b9c5-19b67499fc3b">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019 and 2018, <ix:nonFraction unitRef="shares" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzE4OQ_43d73007-f432-4eff-9847-1492c8147a5c">5</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzE5Mw_9074c6ab-8476-4f25-90cb-db15027c5874">2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzIwMA_f6158d3e-376c-4bd2-b116-9100e0cdd920">6</ix:nonFraction> million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</span></div></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_226"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzExMDg_e18f908a-a242-4516-8344-e2751e6f83b2" continuedAt="icfe7a76a10cc43e2b34cb49531831347" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="icfe7a76a10cc43e2b34cb49531831347"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzExMDE_2e7a4bf3-b206-4bde-874c-f511394328c6" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:37.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.903%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1, 2018, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2bfc40d64cf42fb9a74577988a596bf_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtMS0xLTEtMA_eafdd30a-90b9-4571-97f7-60ad7fdbe77a">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i480e76dce93f4111adcabce9984765ce_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtMy0xLTEtMA_82649727-b487-4d6a-b607-f67c503bf2d1">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f8cc640b7474a98b853cd9c382a0cbd_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtNS0xLTEtMA_bcdc3049-abb4-4859-a188-f20860cee23e">2,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1354b93356c743609177591ddcc546e5_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtNy0xLTEtMA_81094f2f-2b15-4115-86ed-8d394b4c882a">1,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a0cf6a00f14978ae5b1e865e6c3e41_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtOS0xLTEtMA_38f9d8b1-4c7c-4537-9d4f-40d8bfe16cb8">4,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItMS0xLTEtMA_2600cd16-4d7b-4a65-93ef-846793e2191b">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItMy0xLTEtMA_d60be137-d4bc-4656-8b12-6b96cd57a945">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItNS0xLTEtMA_1facb57f-c115-42a4-ae75-b9a8c3a0e9ef">728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItNy0xLTEtMA_f897dab6-e505-42c9-bde3-d19f69735f64">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItOS0xLTEtMA_2bc93d6e-8745-439a-8662-6a46e887adf3">692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtMS0xLTEtMA_79160319-a9fe-4791-9824-61eae9e4de5e">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtMy0xLTEtMA_624f57e3-7e26-4aa5-8723-67d0410fa392">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtNS0xLTEtMA_a44c9767-94e5-4bbc-9c70-8655e5fe8562">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtNy0xLTEtMA_f6e9eb53-4359-49c7-89f0-90f28169fc66">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtOS0xLTEtMA_47a49db2-515d-465f-b991-370099af8836">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtMS0xLTEtMA_ca4121a2-5374-4d16-bb47-1395e99cb39f">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtMy0xLTEtMA_884dd1bd-1f50-4515-ae19-c781d9f3f778">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtNS0xLTEtMA_b2da6cec-ef5d-40bb-b7db-3168546665fe">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtNy0xLTEtMA_7311b9cd-f809-438f-83da-93db38771b50">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtOS0xLTEtMA_8cd9f92b-f568-405a-8dfe-8929b28ca3e2">716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtMS0xLTEtMA_dbac5473-d45b-4377-a603-3efe005d9232">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtMy0xLTEtMA_d4326fbb-b16b-4272-b617-a74fb155219f">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtNS0xLTEtMA_caf258db-729b-45da-9635-5f9088c7e6bd">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtNy0xLTEtMA_8d699642-36ed-4ff6-9ed9-a2c8b666b39f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtOS0xLTEtMA_3928be4f-2f4f-4eaf-9a44-0cb811ad4e38">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtMS0xLTEtMA_795d87e1-9a15-4f90-974f-84448b660062">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtMy0xLTEtMA_857e307f-33c5-4b5b-8a66-4ed62b11a4e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtNS0xLTEtMA_539cd838-d3dd-4ed4-8497-a56bedd3ec83">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtNy0xLTEtMA_1d0275ff-a377-4b67-a911-d178cbfad08f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtOS0xLTEtMA_c605a9ff-86b0-49a7-9571-1a8d08145c3d">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctMS0xLTEtMA_477c386a-55ea-4489-a1d5-787c7da432a5">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctMy0xLTEtMA_57474214-2075-49a5-93c2-45f2c0151e87">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctNS0xLTEtMA_46aa1844-6153-4b82-8e70-c7e01e0c516c">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctNy0xLTEtMA_432322e3-a41a-4cc5-a0d1-65429858c888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctOS0xLTEtMA_1365fd6c-83e6-462d-a944-f1369ce0df90">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtMS0xLTEtMA_86225328-c973-4736-a31a-5f04701a0759">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtMy0xLTEtMA_39c61647-9c77-4667-bd4c-12170115bfec">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtNS0xLTEtMA_15fa590a-d2c5-4e7f-a0e7-e6d74af88721">425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtNy0xLTEtMA_a6a19a58-7c3d-4737-91cc-ae1ad8d31484">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtOS0xLTEtMA_82b447a9-7ed8-4fa1-baef-073225d5e029">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption of ASU 2018-02</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTEtMS0xLTM5NDk_58ab0150-39c9-48fd-99da-f614d4275875">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTMtMS0xLTM5NDk_f8f89e97-a1b5-4947-9dc8-933c1b1d8b32">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTUtMS0xLTM5NDk_8808f5fd-554d-4a2d-a431-d9b39bc69b16">344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTctMS0xLTM5NDk_6b13e6f4-e1fb-42c7-84db-5de66af09162">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTktMS0xLTM5NDk_59558335-7030-4ae6-bb20-2b76ed2738dc">266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption of ASU 2016-01</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic550ba60e01a461a85b42e40d108acfb_I20171231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTEtMS0xLTM5NDk_eca51dc7-04de-41d2-a16d-f779258d6b1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2352f0a4d1a4a9c99aae16eca9eb64f_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTMtMS0xLTM5NDk_74ff82fc-0bb6-4578-b534-61f243cabbf6">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice856820a83d4f64ba70affc98cad508_I20171231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTUtMS0xLTM5NDk_acb67c94-83ff-4a0c-9c8d-37a5a66a3337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ff4b660b424b82be57badc5035314b_I20171231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTctMS0xLTM5NDk_a8005466-0ea9-4038-86ca-a58440f910a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d27b6850029421d9b74d51b9b3c2a91_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTktMS0xLTM5NDk_2ca545d8-4ace-452b-8ead-2849ca92891a">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if578ac895a894796b44b038d0fb39402_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktMS0xLTEtMA_cd0f8b23-0ff3-4681-9f44-75667b9c3d65">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fcfb5df86d440c885a97df59dc74f88_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktMy0xLTEtMA_92f72b3e-4756-4099-92c6-f20aae2f6436">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief6f7feea16443b79fb74434abc31baa_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktNS0xLTEtMA_89c4875a-2888-4771-9ea3-e3efabffcb1b">3,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b3e4ef69c5d4f6897a3277c799164dd_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktNy0xLTEtMA_2720d1be-c612-40a7-96f9-5174ac72dd40">2,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67b4b127a8884ff190bb26aefa784be3_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktOS0xLTEtMA_cf482925-bbfb-4399-976a-f143a9c57f48">5,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTEtMS0xLTA_cd144d1e-5a7b-41af-807c-98a75f3c52e0">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTMtMS0xLTA_a3e0d26d-4747-421a-aa31-dda1f308bb25">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTUtMS0xLTA_ee896693-1440-456a-9beb-0bb11121e905">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTctMS0xLTA_f81bbe04-72d0-4179-9b2c-a0184df34a93">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTktMS0xLTA_1ff05527-dd08-4b2f-9bf6-8a8fcb29e0b9">610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTEtMS0xLTA_3630bd38-429f-412f-a7d0-0af4735dcc8e">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTMtMS0xLTA_0caa599b-6d9a-40a3-b4eb-c414d845dffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTUtMS0xLTA_76a8c55c-dbd9-40b6-bb5c-8f0ad14c6e5d">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTctMS0xLTA_0f5691c3-f355-4c95-8238-89e63a8c13a9">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTktMS0xLTA_f587b958-6791-44e5-8c65-9f8d2d6c8b6a">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTEtMS0xLTA_68674468-c238-4f1e-b54d-137e9047afc9">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTMtMS0xLTA_02d7a154-dbc1-4b01-98a7-0b512492f084">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTUtMS0xLTA_37539766-53b6-4d24-821e-4ae9740f5c07">756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTctMS0xLTA_f6b33211-dde3-4aed-bebf-b1a37c892c9a">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTktMS0xLTA_9a0179c1-0369-4461-96b7-cbcf45a7a1e3">449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTEtMS0xLTA_9659fc83-4dfa-4534-b2a3-7e7660f40d8c">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTMtMS0xLTA_0cebf93e-7347-436c-9c3b-7ca7ad4f49c2">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTUtMS0xLTA_b9729ad1-610a-4725-97a1-7929f24aaf51">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTctMS0xLTA_39f61d85-76d9-4ed9-a455-4e1bd2008164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTktMS0xLTA_00d607dd-9a3e-4391-b6bb-5e8990647ff1">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTEtMS0xLTA_1798339a-5593-4246-bddb-2b2ff60b64cf">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTMtMS0xLTA_39472aee-2776-4560-b34f-0452d3e00535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTUtMS0xLTA_d98eb94c-9533-4dab-ace0-625c24bbfcbe">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTctMS0xLTA_e37b2bc4-549d-400f-b403-fe06a0aa6837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTktMS0xLTA_602d5f0d-0edf-427c-92c8-f59d89adb02a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTEtMS0xLTA_cb1ae349-fe42-48f6-beb6-d3ce161063f2">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTMtMS0xLTA_aa41227a-fc6a-40c5-823d-701a66ba0ad1">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTUtMS0xLTA_f46a5ae5-7792-4b3b-a2a7-32185ad0351e">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTctMS0xLTA_9c8412f2-0e56-400f-b094-769f61c45b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTktMS0xLTA_d022e2bc-8647-42a4-bfa7-7594ef051f8d">199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTEtMS0xLTA_8d8e2b5e-7c0e-44ee-9470-52295ffd0c18">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTMtMS0xLTA_9025f6f7-889e-446d-9323-c904336cbe5e">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTUtMS0xLTA_b507abac-111b-4018-8165-c29bf394e5ad">705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTctMS0xLTA_e3d3c09a-3652-49a8-9987-e0f19ea2f62d">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTktMS0xLTA_42b9d434-7608-4c32-b58b-6d7439aa002c">648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4b8ee6455d4a9b89b308842da6473f_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTEtMS0xLTA_4c8cf9cd-b162-48df-8b18-0c534a7402b0">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cce9deabde142dd99183ccb92bf0341_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTMtMS0xLTA_8aee0f47-00cd-477e-8144-278a1fc42ab9">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8c2b49e682e4caeb3bc52179ef40698_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTUtMS0xLTA_c07040fb-9d2e-45ef-b057-94f37f874b53">4,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i924abcecf31e46c1b8d02841a745163b_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTctMS0xLTA_d5a00780-4cb2-404c-8deb-3edbed3dfb4c">1,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090793285fc448169b5f2766fad90f7a_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTktMS0xLTA_e477b01f-8d11-490d-99be-de3f41239df7">6,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTEtMS0xLTA_4fc3d21c-64f0-4f2b-9382-4335cf3aa605">383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTMtMS0xLTA_ac597fef-f35f-45a0-ac1c-d31500c641ec">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTUtMS0xLTA_1cda7d0b-c2f4-436e-8794-af95bb730a6a">599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTctMS0xLTA_0b1ecd15-d788-414d-afad-48dae79d17ef">64</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTktMS0xLTA_6f6faf19-172e-4cfc-8c03-57392be0f5dd">915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTEtMS0xLTA_428210a3-fbdf-441d-a184-4c4b1882d6ef">84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTMtMS0xLTA_297d8710-289e-4a8d-a408-9b7b65cf6337">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTUtMS0xLTA_70467e6a-6ea3-49c5-9325-d7665d3b928d">111</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTctMS0xLTA_f787a220-14c4-4c71-ab43-f28121082186">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTktMS0xLTA_cb54cce9-262f-4789-908f-d703002dd283">284</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTEtMS0xLTA_6e153f7c-7380-4d2d-8aeb-c2a158d05c40">299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTMtMS0xLTA_164158c0-c60f-4591-b75f-8e346fc73fe5">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTUtMS0xLTA_ef421ecf-378d-46eb-97c7-f20749279a40">488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTctMS0xLTA_626e42ab-7305-45c7-9039-fb5aa737fd20">153</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTktMS0xLTA_51e9e210-a184-4de4-bd2a-bc52a9779986">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTEtMS0xLTA_41bbb8a5-bb41-4864-b37e-06f14e728ae7">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTMtMS0xLTA_8892331c-4a02-4ca2-9d5f-7a2519e56f34">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTUtMS0xLTA_b4552cfe-4906-4d65-9e89-7da5acc0cbea">272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTctMS0xLTA_002953d3-bbcf-46a1-bfe1-4686dfbd5739">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTktMS0xLTA_93fcbb9f-10fc-467b-9e8f-78ebcfcc50e3">253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTEtMS0xLTA_4628e25c-5234-4de7-bc4c-bdab8b49617d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTMtMS0xLTA_feebabdb-1f48-4d90-b764-6da368858d47">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTUtMS0xLTA_9b76d26a-458e-4c2e-a34c-829a169a4203">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTctMS0xLTA_200d0fe2-7caf-4021-a72a-f686b1ab2b8a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTktMS0xLTA_96b6bdcc-802f-432a-99b4-777fc3bf1c5a">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTEtMS0xLTA_a70d60b6-393e-4fad-a08a-ab6e86fa98f6">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTMtMS0xLTA_de77fea5-2c2c-4495-809c-926e94fd4d3e">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTUtMS0xLTA_e239bc6d-e615-4df1-982e-c663b836399d">209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTctMS0xLTA_60c09379-2ee9-4b07-8d4a-2f46670ad68c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTktMS0xLTA_42ff64e1-334f-4592-939a-7e417dcad891">190</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTEtMS0xLTA_47f6ddd3-bfb2-4e30-a9ac-72e3ca56eb9d">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTMtMS0xLTA_5212813b-c1c0-438d-b0b1-9440fc8ff6f4">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTUtMS0xLTA_3d062e9c-30e3-4700-bf63-f8d1d88609be">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTctMS0xLTA_3237c4a6-55d8-49a6-a284-e5cea9c7dcec">153</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTktMS0xLTA_7b41043a-4416-4d35-b474-817bc9d489da">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i610c168f90e34562ba8f9dba8f33d1cc_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTEtMS0xLTA_1c10f68b-5194-4907-bf1c-4190149821f1">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife933330c1ac424aa46ca468fd356d4f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTMtMS0xLTA_7b4527b9-aaf3-412c-922d-f53d5956c33a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9afb706ed88c4a9c952412a1568ca05b_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTUtMS0xLTA_ae2d7e03-bf1b-4e98-bdb1-51c22fc3d343">4,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae4b953ffd8449bfa452e08fac76110b_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTctMS0xLTA_2cb37a6c-5109-49ac-9f30-8bbcac50450e">1,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie09ace19fb574f50904349a9da836610_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTktMS0xLTA_7f996a9c-46de-47b4-9ac4-41eb7c61d6e3">6,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized (gains) losses on the sales of available-for-sale investments that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 13).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $<ix:nonFraction unitRef="usd" contextRef="i6f71d04bdcdc440cb39d626bbf39da82_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzczMw_9c706102-9ec4-4b10-87a1-bca57893b56c">5.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i7110e61b679b41dfb55959ead2fa0d94_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzc0MA_6cd12332-3971-470b-9fa6-e4c71c5fd62e">5.1</ix:nonFraction> billion at December 31, 2020 and 2019, respectively, and other postretirement benefit plan net gain of $<ix:nonFraction unitRef="usd" contextRef="i944bd7f6e96e4f45827bcfb3d2cee24b_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzgzNA_aa8baf58-906b-4ecb-a3b6-100087188235">391</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia1028ee01f9f443790787ed899f2bb2a_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzg0MQ_c2b4ac45-1977-48d6-a8f9-e5c2df395d34">247</ix:nonFraction> million at December 31, 2020 and 2019, respectively, as well as pension plan prior service credit of $<ix:nonFraction unitRef="usd" contextRef="ibbfbe344564a46048fb4ab43f38e7fa2_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzkzMw_e8bbe06e-0933-4f24-baf5-02762a67c7a3">255</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6efe006638854a89a541ce4a48c0e6e6_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzk0MA_791c044a-1442-4ec3-8344-abeb18feea53">263</ix:nonFraction> million at December 31, 2020 and 2019, respectively, and other postretirement benefit plan prior service credit of $<ix:nonFraction unitRef="usd" contextRef="i1ddc21fcecc54b61b50c3d29b99a74d7_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzEwNDY_dd50dd47-f93c-4f0e-8719-ff7a8c2c7a1c">244</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i914bdb16078940c8a02194e2230817a8_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzEwNTM_270c6739-0a2f-47ec-a837-aef192ee4285">305</ix:nonFraction> million at December 31, 2020 and 2019, respectively.</span></div></ix:nonNumeric></ix:continuation><div id="iab6577be4c3840fd8181bdedf457fba5_229"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3NDc_5a52b603-b80f-4588-b84f-4e36fdba14a7" continuedAt="ie6c5f25b7aea4adb9e6e79891b3a9347" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="ie6c5f25b7aea4adb9e6e79891b3a9347" continuedAt="i17ab5f9aa45246d9a62c7b99d615fbfd"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a products basis and include <ix:nonFraction unitRef="segment" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzExMg_6a1a4e35-6174-4871-9700-9c153a159c5c">two</ix:nonFraction> operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had an Alliances segment that primarily included activity from the Company&#8217;s relationship with AstraZeneca LP related to sales of Nexium and Prilosec, which concluded in 2018. </span></div></ix:continuation><div style="margin-top:5pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i17ab5f9aa45246d9a62c7b99d615fbfd" continuedAt="i1be6cb106dae4d0f86ac2b50e5a8841c"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3NjQ_7fbfbc70-ee9e-4cb7-864c-39087f5c137c" continuedAt="ic78a9592776f4310a768f63a3c89c818" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:30.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944b92f0135f4cea93c996121cdf4250_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMS0xLTEtMA_8d2c29cc-7d9a-49f9-ba07-d9621d4852b8">8,352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b82cc9ac9bc467aa2d1652a512c75ec_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMy0xLTEtMA_8eabe0d6-7b39-4d53-9f14-d250533324be">6,028</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762e382a2fb74a4f8babd38337173a85_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtNS0xLTEtMA_430818df-7f02-49ac-883f-b39300219972">14,380</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487b197ad43f42b4912ad594d94ebd83_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtNy0xLTEtMA_90d96bb4-fe9e-4cc2-b661-0902cdfa15b0">6,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea50166c87a84aebbe4b0e1f96819e9b_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtOS0xLTEtMA_4dd2158a-4adc-42b7-a5c9-b41cf8d123e2">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06a34e4d2ab44d5bf29fb6afb196f2e_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMTEtMS0xLTA_9ae6f177-2fee-4f88-a9c3-d4400f873d53">11,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33e663e5d3448369da90c6d1a069ec0_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMTMtMS0xLTA_a6b7671f-7290-467e-a256-050a738a10a9">4,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abed73e41814781901f099d40ed7105_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMTUtMS0xLTA_bc600ca1-f922-449d-9ddf-94750041624f">3,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3942b136244804978f116fbd64e6fa_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMTctMS0xLTA_9b78d830-7f9e-496b-a755-3a7aa3012a06">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e466932ee4e460ab0dd0bfb9b1ea289_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMS0xLTEtMA_e7f14b91-2ee2-4c74-ae03-f3ef6d7ee371">417</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913afbc19dee4cb2a26b17a5b2526f58_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMy0xLTEtMA_f8d35718-bee4-48fe-bd51-6fbafede6468">308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86a72289f7a4e82b9b4eb4aa37f655b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtNS0xLTEtMA_ed36df79-3efe-49ee-8680-b711ecd75bf8">725</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic980b87bd8b0418db9d06a8a487b8264_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtNy0xLTEtMA_a8783827-8261-4b15-8790-f843a2483da8">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd394238a2bd4fc599ea677dc8fc9177_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtOS0xLTEtMA_29858791-4d7c-4ed1-a70c-e3a36dd8d618">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i705f2f1b42d3489389778770491f3701_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMTEtMS0xLTA_64252a9d-fbcc-4da3-8942-48cf3f18f271">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e95cee7306454cb048b4b3891df099_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMTMtMS0xLTA_faadcaf4-e523-461f-9b73-fb3e37ebe376">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idacbd259a14a4cc3b723aea685fe8402_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMTUtMS0xLTA_80daaa17-85af-4644-b955-4cdf38143544">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica27ecc79da8419a88633755deac6f27_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMTctMS0xLTA_f708308f-0bd7-48ce-982e-84db21779b21">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b34437d3a04710a586018aad577595_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMS0xLTEtMA_c5245099-3124-4dfe-b493-aa4d06d3ae35">359</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b948ea353cd4ba2a534ccca93683bd7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMy0xLTEtMA_59ff96f2-1dc5-4a9c-b14e-a4098a489097">220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a60cb9fff2c4cc895d8bdf8605a165d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtNS0xLTEtMA_1753740e-76de-423d-860e-4bfe8a1d607b">580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7ae51b0ccc49e49568440c6c4249ba_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtNy0xLTEtMA_8a87901d-3a8d-49d9-89dd-21db9a46d513">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568b7384fa7a46cfaca0984581c67866_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtOS0xLTEtMA_5fc2e1c2-b3a0-4b12-a6e6-3945f096b908">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc913222658499b880f61b227164ce4_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMTEtMS0xLTA_2181fe06-4be5-441a-a926-dcce7963590f">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b7e5ca7b90b402180e94a9e8706abf0_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMTMtMS0xLTA_120c5a61-7fd6-497e-82cf-a2c55f021a02">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01ae12bf7fa44aab5d2eb12ee013b9f_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMTUtMS0xLTA_ed6d783a-7e8f-40e1-8398-ce0c3623d485">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e937a0914304e858eb868231dc9e5c8_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMTctMS0xLTA_04e7b181-0af3-444a-853a-4db6b97a31e9">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fb6e91ba434715b8251869bd7299e0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMS0xLTEtMA_902ba59c-c049-467d-851b-94685b268300">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8b090798424ac8aa3116f12d6083ab_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMy0xLTEtMA_eb5ec18b-5e7e-4ce7-8ba9-03c93db41f58">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd47028645b14cdd8bc6a7f8356b4316_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctNS0xLTEtMA_24c0d392-f4fd-4126-b060-2f13bb1b288d">145</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9dcda80a2b744fdb022181fac4adddd_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctNy0xLTEtMA_039f3c44-2c90-4694-aba9-035f861b8ebd">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie561b863be38430bbd97eb1eb078fef6_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctOS0xLTEtMA_2ac395a1-b270-4c4e-b4bc-c3830b47dd6c">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea786310eb1d478086e32978d875173c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMTEtMS0xLTA_fc3786b5-c122-4999-9aea-7d15a605e1dc">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea00f3442984ed4a0f48e661b09bb6d_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMTMtMS0xLTA_53eb5396-bebc-4b1a-98b6-ddf150b72a8b">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782fc528304543298cebb02d1190ac5b_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMTUtMS0xLTA_22d22b67-1860-40a1-bff9-9c539277df7e">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1145ed6aec9d48c3a25ff2a988aa54d9_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMTctMS0xLTA_f499238e-fb19-464f-b569-7d9962cafaa6">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42905f2114b449e882139c3304e1e067_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMS0xLTEtMA_b1a27963-b499-4301-a27d-769d3c192208">1,755</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b89ba8279e7484d8920197b705b8e22_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMy0xLTEtMA_f7aed74f-fad6-416e-aab6-6cc670e1a673">2,184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f022f4e88e842849c6953bd007071a4_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktNS0xLTEtMA_7c7be340-14d7-40d4-9ab9-d12ae3a01652">3,938</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386b32eac5004086999833832cf45f24_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktNy0xLTEtMA_185235ad-87f4-4c61-8383-737968cb8113">1,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc8ca75e4db4e72a0644865c60bcc0d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktOS0xLTEtMA_14e58f57-31f2-4c1c-bfe9-56eefdb1d131">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930ed6885726482297a6b88617a1004e_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMTEtMS0xLTA_d2e43bdc-4feb-474e-ba22-31d04f60e5ca">3,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a909c96c814060a10e2801793e0e6c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMTMtMS0xLTA_7a55c19d-9ac2-4645-ab8c-53208881dfb7">1,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic440e28e121b44579dee80b8c5d681eb_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMTUtMS0xLTA_9b8ed601-9fd4-43de-af2e-033df60b1925">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de667927bd44a37a2bd00481afd12df_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMTctMS0xLTA_c6460c51-b05a-4309-9fc6-719dac9f8002">3,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id371c43a511c445bb4a2ffeaa7880af4_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTEtMS0xLTA_b3675f8f-b77c-4b80-acdf-a1c2013a1dc2">1,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d2eda461ad492daf3a3842f708bc0f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTMtMS0xLTA_bdbc7a93-3257-446e-80c9-10c325d9fdc1">500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c67db88a3e4613b882d85cae7cf938_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTUtMS0xLTA_ab3750f2-92ca-4bd4-b5a8-b70b0dca3c78">1,878</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b2d959e73643b7b560fc019573878c_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTctMS0xLTA_c5266658-7f13-4ba0-92af-edf971a6dc97">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563016c582e24bb6a9faae151d3fbde3_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTktMS0xLTA_3a0af94f-22c9-4deb-8989-9b344892b85b">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc6b337a3ed481cb8f2d22309e2a645_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTExLTEtMS0w_c7f43b65-8770-426f-8ad6-07df3a66a777">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb152fb64524f35a5ac871ac508cfbd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTEzLTEtMS0w_9aa6dc6c-9915-4266-9d06-97a64dd49fe2">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc8a3df09604d98a7533cea6a7cc1a4_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTE1LTEtMS0w_2a5e8526-6b12-415a-8aa3-55ecf816f28f">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d517618414005bbbe9f82e782a39f_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTE3LTEtMS0w_46edc7a2-e75d-4230-8ab7-25e8fc44e6f1">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie588ee62a35341cd8301ef54adb5166f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTEtMS0xLTA_fa3e846b-af39-46bd-9f1e-ac8f7ee81c38">727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99baf06e598d4cc587b4eea203a0baa5_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTMtMS0xLTA_b7b04333-70b4-4c02-8ddf-7502edd5b1e4">359</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f59b103858d46878eedf45649386455_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTUtMS0xLTA_13e15136-cff6-4005-8c5b-d1c1d3d8fdcd">1,087</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4e6f22b3114161abfe58eb27fdd9b5_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTctMS0xLTA_3c1b08b8-a769-4368-8676-c7bc1fdfaf12">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3244ce2b91904b73b45793012b9deba1_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTktMS0xLTA_99c10081-de56-4c45-afd1-3a8069b118de">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee34845ecb84d00a4446c16e8283f06_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTExLTEtMS0w_90fa889f-076e-4a76-b9f5-0fcb41ea0bbf">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac945c4f8f4d4171981befedd8042eb6_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTEzLTEtMS0w_049e4c0b-ea70-4c85-b74e-55353045a38c">627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13aac18591694ed095c07e398d82a9a4_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTE1LTEtMS0w_c133046f-fb8a-4256-8032-ffbf0c8d7119">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce7fe828cc94d6db92ef54014d5e83d_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTE3LTEtMS0w_80e782a7-e653-4c03-8a3d-7f3923cc29b2">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3082eeb63264d528664dcb84a196ffa_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTEtMS0xLTA_166337e7-6d1c-4c7c-8fa5-368f037d53ad">486</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ddb57daf4449b95d7f5842fbd9cd2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTMtMS0xLTA_624c582a-8ae3-4121-b089-7581cc7a9b95">311</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c04273d563d43ac903ddf81cd8713df_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTUtMS0xLTA_7a8d7fca-29e7-43c8-90fa-782ffd6c2156">797</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7885796f74eb4f47aa093cd5153cdddb_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTctMS0xLTA_60f05127-26a1-44cc-b7a3-c6cb242601e6">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76caa434d4545c2a41daf436667a0c1_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTktMS0xLTA_8706f03d-9799-4543-bc75-92c89ef7ae93">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i698eb8ca231d455e8bd8025f25c5bafb_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTExLTEtMS0w_3fb57beb-c6f1-4575-be1e-b7ae125c8471">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd5c6efee8b467ca3065e20772c0f16_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTEzLTEtMS0w_92753cff-69f3-4150-ac12-27347a1ea058">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c82a481d0e4e5c9cb61cd60076fae7_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTE1LTEtMS0w_5fe34051-d84b-4016-9206-76a632f81db5">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e714cd39394117b1cb6e8777bf32d8_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTE3LTEtMS0w_d26d7936-7639-404a-b2f0-a6112d2c73b3">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eac079c11544e2cbf3daee151f7b5d0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTEtMS0xLTA_3b8164b6-84e4-451d-ac6e-820e46df358f">103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c795d67996d4d41850e0375598399a7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTMtMS0xLTA_523d529d-f40c-4bb8-b2ae-132cae6c01ba">67</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic268fa475d8247a888383acd5008c4c8_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTUtMS0xLTA_4e178677-10b6-4095-b70c-95d235f954f5">170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a79580b224fee9d46fb4cfe23165b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTctMS0xLTA_5e1c8539-2453-4832-a99f-52df148e61e2">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc19564465e4f5a972c56bb809a8f36_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTktMS0xLTA_9cdd39e8-c9aa-4b48-9b7d-d6ec514a748c">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b81e96d6791496eb43340c7203088f8_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTExLTEtMS0w_2021cb8c-ea7d-454f-b001-e5235d97a96d">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9f73dcd0954e21b2a313db04ce7e1c_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTEzLTEtMS0w_a19d5a39-165c-4f99-be32-801b2c649933">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6471730c7cf14bb5a10b893fe2704d8a_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTE1LTEtMS0w_b0e9fe2c-262d-4bef-b0e1-c2fa031d7204">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c40f8fc0d443f0a7972029aa43014a_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTE3LTEtMS0w_9b2a4f1a-26b1-4963-b3eb-5813426a9838">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfced3ea7ba40dc813084356a8e2a71_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTEtMS0xLTA_7baf9427-ff4b-4d63-abca-74a22b23a928">583</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc5c946bf5a44685a08ed2fe940530f4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTMtMS0xLTA_1aa210b8-eea3-46c5-9d08-4ac84d52a848">615</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43a68e5100c460f9ae570bae3642222_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTUtMS0xLTA_daf756fd-ad38-4cda-bbb3-da4d50feee24">1,198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b08c6f8ff94c49933c0e1f8bdf1a79_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTctMS0xLTA_79191ddd-a3a0-4f7c-816d-09375c53210b">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea7542288c045289bbc1900530f6c6e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTktMS0xLTA_8ecc14b1-2f6f-4b3c-95da-f1a531a942ec">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i712dd95c443d44bd97852acba774042c_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTExLTEtMS0w_b032a7e9-4911-4688-90af-7e2d010ab397">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7bd988df8be43ab8a578291ca6766e5_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTEzLTEtMS0w_77caa210-f41a-4238-94e7-af2234ea8f38">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5e6a2873114b8ca3d699b684dfbeed_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTE1LTEtMS0w_56c49454-0fbf-438c-8ee9-03eb2ea71cdd">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a19fa1ef2549e48a8c798ff8cdcca2_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTE3LTEtMS0w_c6fa645b-fcc1-49ec-bbb5-9324ef3b198c">917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia794776b17ba487d81e689c730a89a44_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTEtMS0xLTA_4a6eba07-1184-4aca-a0cd-c0d5107c18d9">42</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if56def4d43604279ae1490a45ca12c8c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTMtMS0xLTA_2133b6aa-648d-4404-8a97-50d61e9e14b7">287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a57852d19f944bd80a118414f3fb03e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTUtMS0xLTA_b43a377a-5b60-4aa5-b2b1-34ccb6d20b9c">329</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb68ee70d874978a87dc2e09bd612fd_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTctMS0xLTA_281bf76b-070d-410d-b674-d724a955d1ff">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837a264760b94cbd823d589b3848eacf_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTktMS0xLTA_2f9d65ae-76cd-4f94-8341-df53e14cf6d7">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981d29244f2a41eeaca918a69762f31d_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTExLTEtMS0w_dd38183e-f71b-4337-a68b-d965597fcf27">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4bf02785f34f25b07ca7068a5d28ca_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTEzLTEtMS0w_806aca20-dc23-457d-9267-5a8143af3429">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i622f7b5d6bd64049b5b32da99600ada9_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTE1LTEtMS0w_2967a39e-26ef-4d51-aafe-da14336704d3">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63db189e7eec4a128a0d35126d4bd81f_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTE3LTEtMS0w_0fc1c063-4f23-4c6a-80ba-be2acca60c90">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fee648ff7994140af926011d3631567_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTEtMS0xLTMwNTE_bed46dc7-d940-4dae-a2ca-b6c944886b3e">119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b60dd13bb14d32b824e1653e259c32_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTMtMS0xLTMwNTE_e110384f-a7df-4158-bac0-695d955af660">162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631ae57e96054ee5afcb44dd7471b663_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTUtMS0xLTMwNTE_43e48297-f7cf-47b3-8c21-63118b3c0023">281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a880330a694ef488f4f7c68d82cd1c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTctMS0xLTMwNTE_50924776-f677-4cd0-9ba3-659e529cbca7">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00da273161ef4edea36fdc16bb3586f6_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTktMS0xLTMwNTE_aa4918ed-3e93-4907-ba4c-33be55bcee0d">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad4b5afd5b04abaa51621d6b0f67e32_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTExLTEtMS0zMDUx_3e9e2c45-d980-4ce0-bfb3-da9db777ffc5">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f990850d9594267a6e1caceafb75e22_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTEzLTEtMS0zMDUx_f57c04a4-69ab-4a08-a5c7-f51ddd2f2c47">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8408528418746d49007de7097987a4a_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTE1LTEtMS0zMDUx_e70a8855-ff66-4f17-a87d-382bae151b28">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcf25c15d3649238957a6c3c1922909_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTE3LTEtMS0zMDUx_33cc96c5-78f6-4fdd-bfb9-750881f0cec1">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a6af99921b4ce385e45e7baf0ceb30_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTEtMS0xLTA_62e43e85-f739-4041-b740-7b998c96768d">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158a181d72de473e981382f4977cf6c9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTMtMS0xLTA_a9020812-ee21-4f08-8647-09cb49e7c924">248</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80beea5c84e343bd885ca3431e912104_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTUtMS0xLTA_af7618ad-66d7-4658-9344-203bcb05ea9e">251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982bda5b96d648869406352d49e6de87_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTctMS0xLTA_908d07ae-9cd9-45aa-804c-4aed50a4c842">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26fced3e231e4bdca37b63bce6e68d8e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTktMS0xLTA_68075b0a-8f6c-49bb-a8aa-65e0239dbedb">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8fc37aa4da24c6fbb3ae07dec2598ed_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTExLTEtMS0w_9ce8d030-5f6c-414f-abfb-1504f378946a">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id86a4dddcb1b448daeff944a4e1e47f5_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTEzLTEtMS0w_c1289d7e-a472-43f3-bc89-9b9d796e2194">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb32068982447049d6b160c7f5328e3_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTE1LTEtMS0w_6c19ac76-bd8b-46a0-9e01-54dc37449abc">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic23472488bb44800886a04efdac600d6_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTE3LTEtMS0w_94e5d3f9-1b1a-4d0b-92a0-40d120e94a95">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00dc40a9ba5740df90cd396ff7e12f29_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTEtMS0xLTg2MTg_7c6dae7e-a189-4e14-a6f6-1714b00e6cc9">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340d2c3e7cd4499c8922b0efb09a24e3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTMtMS0xLTg2MTg_578e489c-5aab-4485-9d89-364f9322ce8d">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86c343bc0a184f35986855d72aef089d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTUtMS0xLTg2MTg_3eabf268-a2db-4104-84be-17b217afbd44">213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80da1dcdb7dd4217893159cf5cfd10ae_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTctMS0xLTg2MTg_def00b4e-35f1-451c-967f-3691bb9a92cc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i244975eafaea4f8981c83f70f314cf09_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTktMS0xLTg2MTg_7cdf98bb-ae6d-4a6b-822a-a46234252f3a">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32db1b78a5840528d295a594b2e7616_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTExLTEtMS04NjE4_96f02b34-48ea-460b-8888-53e2f8bb2296">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743e39e016e44963826fff0f356a69f9_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTEzLTEtMS04NjE4_42aeae8f-42df-466a-9734-838121f701b4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06b3400e18e404eb05b4445a2bc6313_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTE1LTEtMS04NjE4_1dd658be-c243-4500-b857-29096db9d0c8">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6083ea4bda474120b0f548d11216c6a5_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTE3LTEtMS04NjE4_5b6173d2-67d2-4f28-be0f-da823960853c">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af11e6de1ff462890478e6393a18b91_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTEtMS0xLTA_58bdbba5-d86f-4c38-9db8-bee41f5531ce">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c1d7b2f4f44342b7cb4177aafef6ab_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTMtMS0xLTA_d477f17e-c1f9-4b6c-9395-2cc2c748d95a">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52759226e58746448d8a420c332f2381_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTUtMS0xLTA_62dc5093-85ea-419b-bd4f-e4152e6e6ac9">211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8efad0f18a4a45a2614ed77513463a_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTctMS0xLTA_1b2b7f7f-94a3-4565-9477-4bdfdb33063c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ecf2f6aada4757bd26858e97cfcd1c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTktMS0xLTA_a7f916d6-7f11-4e24-b761-b3f8a34d64a6">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf512eb4f541a2b071eb54fdb82c88_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTExLTEtMS0w_1afbec08-838f-48be-bb79-be8997c933ea">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3964e6a61c54a82afe378671d25a543_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTEzLTEtMS0w_b7af8fa9-dcf2-46d4-b312-142d8b4c72ef">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a6bbc3767d4a6ca3952000f13d28c6_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTE1LTEtMS0w_5a1d5e85-e64c-4b49-bdf1-7b1fee72a274">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac4d80bdecb4bab833db37a8d18cb8c_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTE3LTEtMS0w_52a338e7-7eb8-4245-a507-874ad5ac67ae">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb92d1ba39b45128f93a4709dee1c15_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTEtMS0xLTA_18a45aad-904c-4d08-890c-a1831fed6c04">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b2370d6fbc401ab58d1068789e89e6_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTMtMS0xLTA_0bd0641d-d235-498e-8ba6-437577dc13f4">106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593fe290ce72487993a67db241486f76_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTUtMS0xLTA_0c8762a8-721c-466c-9876-891bee5929ed">152</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8cd853b60043e0b70f1bfec080a4d2_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTctMS0xLTA_ea493c55-fef8-431d-a91c-410482c96948">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f99c5231e7c4dc7a81d228fc3415f7b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTktMS0xLTA_3235eda4-41aa-41c8-8c8e-cefb7a7335e8">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfca6579a4ac42e4a4e603af62eb5c01_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTExLTEtMS0w_868efc75-6a40-42ab-a360-b6d1883e7c3d">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c71abcc275f4683af8e0271a80096ab_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTEzLTEtMS0w_5704793b-170c-4a16-9586-7de80f9375d9">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa50d7bd230485abf1e66bfe14032be_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTE1LTEtMS0w_6546d05b-fe10-4549-a4fb-fe92d537c2a9">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42ee491dfce40f7aa8d266a46cf3543_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTE3LTEtMS0w_ccfa7471-94a4-4a51-9f3b-92d74abd3e05">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia213538c877d45ffbeda1c478dce239e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTEtMS0xLTMwNTc_f3474b76-332c-41bf-bae0-99dc0a5943da">74</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021950f39f7d4ff5bdba80113c0e13a6_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTMtMS0xLTMwNTc_2973b5c7-572a-4889-9006-a6a6c08afda8">56</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id025bb2578734377984deb7afd65b7dc_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTUtMS0xLTMwNTc_85bac71a-f447-4340-9949-a4f394068921">130</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce0eede954143acadf9aaa2596ab83e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTctMS0xLTMwNTc_153f3016-cb8b-4535-89b6-cce9dda34741">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5f4f6a1ceb451d81c5435d7c937683_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTktMS0xLTMwNTc_b5102691-8e39-4958-9af0-91a49bcbb619">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8e0ce6e85e94727947ac68e911896ac_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTExLTEtMS0zMDU3_d94aa597-1cb4-45ea-ab68-2d52b5e60154">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab04a7c31974211af284155f6a7dfd4_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTEzLTEtMS0zMDU3_b7455ef6-f50d-4e4e-9972-2f5a0d2b7f6e">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic02b5b66b5be42709792b6f221415e99_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTE1LTEtMS0zMDU3_690be64a-6e5c-40c4-a477-d14397ef4976">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03ebcd3ef9e48ce8bb69abc9273d951_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTE3LTEtMS0zMDU3_6d50245b-108c-4e5d-bd92-6ff955c4b75f">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cbd149a97d401d971e534e429cb2ba_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTEtMS0xLTA_8ee8d3ba-d361-4814-b824-4ea81b3415e6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b8228b2d5564ad0a725a3a7b79ca7b0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTMtMS0xLTA_33859ad2-c9fb-4065-b921-5e35f7271cd0">838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6479fa964a3c49189f62b4bb3b39de1e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTUtMS0xLTA_35344ec2-ea15-4fde-b6db-4e54ad757544">838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdf4f20c8b84ecaa29c0e18c61129ce_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTctMS0xLTA_fc309dca-2470-463c-9580-dc73c53319c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c18fa5bbcf1406fa004601033af85e2_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTktMS0xLTA_736baffa-6de4-4365-ab72-38f16b7179f5">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb282931027048db8b47047f9082a80b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTExLTEtMS0w_77a0d9f4-85ba-44ec-814c-99893534f803">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d6b32b4a6540428d17548fe7806b49_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTEzLTEtMS0w_6ea05f7b-0d61-44c2-b322-3f41e21bca7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id466d72c74484e4c9b0cb94ca903c707_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTE1LTEtMS0w_e0db51f6-a3ab-4093-94de-b9ca280ac416">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02732cb0bc4444dc90c11841a6721a88_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTE3LTEtMS0w_60e50fd6-4561-4e32-8323-4c932af03ece">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204bbdb330e744b0b3ec21cefec837e3_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTEtMS0xLTA_6ef17532-45d6-490a-9ba6-1f6c8eb80e01">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac9ad937795f4b4dae6cdba2cea3e74d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTMtMS0xLTA_afecf580-09be-40dd-a9f9-8f9bffdce528">330</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1b718c831f45e49a8fbf7722d13a2d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTUtMS0xLTA_97069687-3d3d-46d3-a6a9-e1438b9443cb">330</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8aab449a70046f4a0e3b44a0956bc11_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTctMS0xLTA_62acebfb-a79c-4213-81bf-c366b08e5955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296ebee4da8b40bdbe6a589d85f3a4c0_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTktMS0xLTA_3c499c53-8e5b-46ec-82d4-58e0276d8057">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41e158eb1c44c3aaaf6bdce81669ce4_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTExLTEtMS0w_89309277-6e4a-4dea-96de-b429438c609e">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ead8dfa8dc541b28d9320a858a459a7_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTEzLTEtMS0w_2f43c0cb-8b0b-4c47-99aa-12539945f81c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee9488d170c4cfe8fe249373f7a0005_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTE1LTEtMS0w_51828634-c4fd-434d-a4b2-ece9011d46c6">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588e0e2cfde5403d9d0ff73b1f9cb4d0_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTE3LTEtMS0w_5bfce3d5-bbf1-4869-884d-8b7647f069a8">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fdcaf9b54604eb68c5312737d3846b8_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTEtMS0xLTA_90e64948-4fde-4ebc-9e76-15862fef492f">81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031b4271f5cc481aa8b8f2ccc0a1ba58_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTMtMS0xLTA_f9cfa27e-92a8-4e3d-8ab9-c1dea87bc54b">247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfb2239d4d14352bd4a728fd7f880f1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTUtMS0xLTA_264a2ea9-c4fb-49f2-ac68-b6787221f261">327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9231ea96e50a4020a32910e880f0b50c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTctMS0xLTA_c564ffba-27fa-4992-bb74-4d3a12c4d1d6">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5929161d3242ee9a55a4b589697d38_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTktMS0xLTA_9e50645e-e948-4059-b1d0-1fc26a6ec10d">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f37ba6e7a148089b5c5d7be8a75edc_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTExLTEtMS0w_4379697b-b07d-415d-ad56-03125c901496">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cae2150e5694f75822ed5dc50d0ef1e_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTEzLTEtMS0w_484596a6-c7f6-42f4-8c46-dc858d61b674">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33200ae436ee48ecb1d3c2bbc22ec28f_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTE1LTEtMS0w_d1f46c0f-e167-4d78-8075-cf87dac2f71d">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d52e6c1a9c4700a879d6f651d06973_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTE3LTEtMS0w_ad3b81ac-6dd5-4fe7-a9f8-7507cc29612e">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec78dc79b8ce4a3497112535b38ada92_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTEtMS0xLTA_fe0fd8a5-876d-4a98-a548-7a1fb52f54ab">326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a1175a70af145bf8a80dd6f301e589e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTMtMS0xLTA_cb4871f2-c2b2-4a16-96ce-908c512eb02f">531</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28a8fc8006e849fba47a9ef2942dbb3f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTUtMS0xLTA_a8070df3-678a-440f-8eb9-eaeed75aac9d">857</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia340a8ba6ebb4c029daea71176cbe2d0_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTctMS0xLTA_06fa9470-de4e-4f41-b544-fb9eae7f62a2">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0227adf4c24296a707c703a304ac1c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTktMS0xLTA_a991f837-259c-4fce-8dbc-c5e8cb0dcc2d">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78215076410d4611825d515c00ef799a_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTExLTEtMS0w_16afd327-7c2b-4458-a11a-c8b8728776ad">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969a6ffbcd4d46c0940c7138d634f818_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTEzLTEtMS0w_79ec36e1-eed3-4b8b-98c7-e57bfff5c1da">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8e77760bd942eca8efc4de9fe68e8e_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTE1LTEtMS0w_81745ebf-388a-46aa-ac73-ff776b1d53be">627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d2aac33ad54ab59d96297ebc97d425_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTE3LTEtMS0w_8742515b-995d-4422-9142-4f7e2b218e15">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica384a52be1a4278b12ee9bd5f583bf0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTEtMS0xLTA_95559dda-ec26-44ef-b3f9-b2728928962d">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4578066b041421da1aa43b44e975cb9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTMtMS0xLTA_27d5e92f-9aae-4e38-b09d-a1b09fdf1ce2">107</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6940bb247a4473bd0c443d685569d2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTUtMS0xLTA_eb2a3fc8-f3d9-453f-8e33-7f178931bcea">167</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1c976d77fea4c3689cc0098063aad26_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTctMS0xLTA_24aac0b2-26a9-40bb-810d-0a1673aeb3c3">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie370a43016b44af890fcfa0146cbf033_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTktMS0xLTA_f9ccac37-333f-4e15-91f0-5c8deaf53f61">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa036d0f6774475a9fe49fd92e495644_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTExLTEtMS0w_7a034bbf-3220-4e77-96da-a9af2232f8d1">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia37abe5d72534dd093c0b9a1d4a419c0_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTEzLTEtMS0w_03d78953-fb2c-4cf2-943f-24c3ff65717d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492b22beaf094ed68eda935067df1fb5_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTE1LTEtMS0w_627f817e-3bdd-4791-a5c7-e3cadc7b437a">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i389e5536e60c49a5a0ceee0886fca045_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTE3LTEtMS0w_ee866cdd-becb-4cad-81a9-20d1f7e5f0cc">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40c7854b1a4640c3819cb580a9f6f419_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTEtMS0xLTA_ec736f73-90c7-46ac-8c10-607259c735c4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a5487bfd8f452284fbe7d3ff2c5ff9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTMtMS0xLTA_7ef25106-f32b-4c76-a352-5205f3c83c64">483</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65b72cf07aa47b1973dfb9bb3a28323_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTUtMS0xLTA_68274a6f-5811-4a24-85a4-cf42e15d09a3">482</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358a98553f7943209f20f57502c434c9_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTctMS0xLTA_f7555492-0e33-4e41-bc09-34a5ec03a0ec">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0fbc9b5596453f8b88b17db85f5aa9_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTktMS0xLTA_162454ea-b7db-4237-8e6e-712700f655d6">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbddcf663e174f7d911abb1df12ce84f_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTExLTEtMS0w_c9017e6d-7a25-4313-ab3b-be8df65e2fd6">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f563f809894d48ab7c89d2ee8f18f2_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTEzLTEtMS0w_f702df1c-c944-4b4f-8d15-a27cf729ea83">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3769c8c30b424f33a150c2196196a059_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTE1LTEtMS0w_6a25aeea-9bb7-4d72-8ca4-297d0c6000df">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9bf768836345a986b10235dda945a9_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTE3LTEtMS0w_0c2e8f7e-213d-43ee-98c5-4c1e8df8edd3">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic330260f1af24c978c806b2a3416c5e5_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTEtMS0xLTA_a16682f9-e601-4a0b-b4ad-2a5f5634cf55">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ef50a789254301a24d80d4157ed09b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTMtMS0xLTA_5f93f91d-30d1-4ecb-8e5a-f32ffb5409f8">171</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65bb28cfb3444cabded850e87bf4e90_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTUtMS0xLTA_8df6ff31-10d0-484d-8f12-81ebaf3d23ae">182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9aff7abd7c74f4681631afcc4ec4dea_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTctMS0xLTA_18a5cbb6-f9ec-4f14-8510-fdf815288afb">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa6da700c404dd8a7694bfe82d5c830_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTktMS0xLTA_90839c7c-6c92-4bab-8fd4-78a49c751126">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d3bb6b88b54cdd855c97a8e84eaaec_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTExLTEtMS0w_7ff4d22a-cca2-4887-bf0b-94c69e17d3a2">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbfae44be544a3289c07e6254ad7066_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTEzLTEtMS0w_ca5b3a88-b7e4-4d44-a538-d05effb10379">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58961068953643e9a0d7276345f42e0c_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTE1LTEtMS0w_209fe889-5f04-4a5c-8a9e-5604b76bd4bd">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26dff7caf3b24a61bb9d9d43432b1342_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTE3LTEtMS0w_80657d61-f90f-43d7-afe2-5b08e1b5811d">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02da2130a9c547e1b8cfd90b9810c602_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTEtMS0xLTA_bc36f5a0-46cf-450f-999f-6580a7775f60">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9473f3032842009abc88dcbd4241bd_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTMtMS0xLTA_2cd2c7b8-51ea-408e-a18d-63dff8d34efa">453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9850a5dd51c243e993ed526a423fca5f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTUtMS0xLTA_964d7954-dc9e-4aa4-a5bb-9490902df4b6">453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ebce7e3847428bac65d9577590ffba_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTctMS0xLTA_9ceec3ca-5c95-4375-a3e8-81e311c98c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2992f734d65487ea3350732210cf724_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTktMS0xLTA_a1125d16-882b-446a-9d7a-0eb66f3a07ba">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a61b67189614b05922be71c8c421962_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTExLTEtMS0w_6a56538a-9b5e-42ef-8336-def1f9012579">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808dbd3f3e6e43ed9399f61bbb7b4055_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTEzLTEtMS0w_b3eeceb5-7d59-4d17-81da-0cac2f911e63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164de0f742494c9b8cd2d3f94f2923b9_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTE1LTEtMS0w_be2ae58e-d2cf-4398-89c6-941ac9eb9036">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5ffb4bcbf94ae0abcf664e4c6e1872_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTE3LTEtMS0w_bfb518d3-b53a-4ea4-a553-73922edff96f">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765e235347ca4df1873ed1248b331df8_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTEtMS0xLTMwODQ_92fc6fe5-e114-4d62-a784-8b4615c62dca">259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817e3b1fea9f458fac0f6055c49641a9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTMtMS0xLTMwODQ_147b0431-f24f-4bae-82c3-2c5833186029">22</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0433bcc5a7d7432f9bb4a1eb7ce37fd3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTUtMS0xLTMwODQ_67f1e05d-4e0d-4074-b9b1-f307e15276f7">281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50b4573044e4647ac213a16ebc379d6_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTctMS0xLTMwODQ_00d8ce18-ffc3-4beb-9989-2eeb2bcbd520">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6cea25192742dab7d8f55c6193e913_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTktMS0xLTMwODQ_dde3cf4a-9003-4b15-8b8f-12e97af8b7f6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic118b67ceccb466faa220eb7ba62f56e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTExLTEtMS0zMDg0_f28ac939-8a8c-4e16-be03-ce2bc2f61536">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a086b497c64ebbb2509e91e103680e_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTEzLTEtMS0zMDg0_85b2286b-dff1-49eb-99e8-99aca9eb31f9">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db350f249ba416299a4392f33c42f88_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTE1LTEtMS0zMDg0_68c9617c-f6ef-461c-9ed9-e922a641fff5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaaf6f8150b84a25a8315a1b493d2252_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTE3LTEtMS0zMDg0_973f98e6-f9e7-4c1a-b957-e1faaa32e7ea">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ba25329bb24f2ebc68cfb217f3876e_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTEtMS0xLTA_11372927-5b27-45a8-902b-3e2f7d66925a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff1a0642517447883a7677e44f19609_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTMtMS0xLTA_2b7a6919-9844-4288-a5ff-922cd51240d7">220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65dbfd32d29c4a1298cc6b005e57d0b0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTUtMS0xLTA_8d3723de-8b8f-4e4c-afeb-350e20b90e9d">220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5e33fbfd9e47729ed353ad56f6955b_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTctMS0xLTA_48984506-ac64-4df6-a3d7-d92ac37bc698">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428851a5d25042ebb249a9a84028610d_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTktMS0xLTA_2e42fb83-0908-477c-a635-b546278fa5c5">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471a2257c4e044cbb9b7a564c9ac71c3_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTExLTEtMS0w_4d7b423f-d464-4772-8a02-3d6b4ff46fbb">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a09f1a3abd48109fbe59b3fb93d141_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTEzLTEtMS0w_30382672-4735-48f4-9872-dddc9a14c92f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1404f852ad8849619c48eee49eecb017_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTE1LTEtMS0w_44342b35-462f-4900-91be-70495b21646f">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c819bf8048847f3984282adbf7f9562_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTE3LTEtMS0w_a60f0d7b-2290-4e36-8c88-ea0f75a5c867">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib453c2cf19634dcb9f7c38e577527fce_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTEtMS0xLTA_f6f2e973-8a27-4881-9e41-d02de87b0fa4">1,470</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a03414556c84b1f80a00b809a8ce3fc_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTMtMS0xLTA_b9ce3773-bf8a-4688-ba0c-0d3e7cd34232">1,836</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b493f99d5764db3a3587eb876ab87f2_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTUtMS0xLTA_a05a3c65-912d-479a-a7fa-6f5b974dc63d">3,306</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7650b81f2f948028475c26edc5c16eb_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTctMS0xLTA_15647f23-7d01-4878-924d-09dd083a0dd8">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifddd89c3eb0447f3be23aa56aa560afa_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTktMS0xLTA_d8c7a49d-29cc-4f39-a41e-a5cbc65bc3da">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350c3286a7fe4a509add74cc2448733b_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTExLTEtMS0w_c422ad2c-75f5-492f-b5b0-7c4d1e101074">3,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea6a755e6024199aadd27d792902ca8_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTEzLTEtMS0w_ab91640d-97a7-4291-90f5-350faddbbc73">1,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c9e4810f4401bb73a64a044563400_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTE1LTEtMS0w_ab2a737c-7fd1-4b22-8620-317ac6af6625">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdc2a0905fa54560be844a4a5613db12_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTE3LTEtMS0w_78ae010d-3fa1-4c15-bd36-cf9c776be358">3,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08dc5fac7cd845a6bd3b00791e7e5b2f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTEtMS0xLTA_154d9579-33b8-4339-a169-bbf45cf95e3b">477</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2950cbfe843d45e68f856f33961cba31_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTMtMS0xLTA_e8897f7d-c9df-4869-b434-5cd2518dfe05">1,494</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebba189d4a3458198db7346f2a6e713_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTUtMS0xLTA_ccce2c80-fc94-4bb1-804b-db2ae67fe1c9">1,971</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24f803edfbc4167bb3299a898ee2e13_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTctMS0xLTA_aaa56e09-a44e-4033-9f40-8d81540eb9ce">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ddb314823aa47c6954a1f2feca8eebc_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTktMS0xLTA_7c157a59-8c62-456d-acc9-33901bb7d3bf">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ae0bf62de4457894eb884499173f85_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTExLTEtMS0w_7f30def5-10c5-42e9-987a-b8a0044c0e76">2,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb86dc9c584485fb7a5049e10ba046b_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTEzLTEtMS0w_af13dddd-81e4-467e-a95f-1918758da564">811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7f8648b2f44883844130f1d90b85ca_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTE1LTEtMS0w_6592b7fc-a22d-458c-a3d8-36e2852a666d">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e1ba5291ab459dabb27adb7b97387a_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTE3LTEtMS0w_2b7b0532-1a84-4669-8c52-8dfc5566fa64">2,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26737262a3c3462b96de8ebe023d1021_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTEtMS0xLTg2MzQ_a695b61c-6ce6-4515-aaf1-743aff8013d9">488</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3daaadb2da99469f970536fbd9f589ba_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTMtMS0xLTg2MzQ_c0fe8103-ffe2-4475-8710-74f9db4c100d">192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia40a7732f3a44955b312d4698d4c6026_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTUtMS0xLTg2MzQ_80dc2139-fa63-481f-a889-dfaab86bfa4a">680</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83be474e89ab4750bd00aebc5eb6ad68_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTctMS0xLTg2MzQ_d9f44bc9-5bce-490a-8f7e-fcbc0c027a89">568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id315307ab2cb4c808c77a47abdcb132c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTktMS0xLTg2MzQ_0f92bb6f-8e25-46e1-9fb2-debb0b27b1f2">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d95952196a41059a02aa8be7602540_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTExLTEtMS04NjM0_1cbf2331-08db-46f0-8ecc-d813cd988689">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id961d5e81bdf4ce5b89fc5130610e285_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTEzLTEtMS04NjM0_d4f9486d-1337-4f3d-a0e2-70bac49899df">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia103de5e6cbe4fb2a104961a19138f6d_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTE1LTEtMS04NjM0_44a15485-f1eb-42d3-a03e-e1436254291a">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39a5cbe975a499289e9b0481f88571c_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTE3LTEtMS04NjM0_fdaf50a1-83d1-4e78-aa44-e122a386fb73">703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37ee02873134a16a7d2ac745f1f3efb_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTEtMS0xLTA_d2e1d4f8-15fb-4152-9153-14f88b0cf2c0">110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9f2daaae4745d2ae55c4ff7963f472_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTMtMS0xLTA_6d60a926-c58f-4c71-acdb-30def4a59f6b">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2a922a9abe43d5a57491ba600cf3d4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTUtMS0xLTA_e8dd353a-dac9-4992-ba62-112c3ed3b870">236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbaa3f0d655424f8b54cbdd948628ac_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTctMS0xLTA_81bb9f85-9927-463c-a045-6909240e8622">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d42283095d74b78ad5e947157ee6849_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTktMS0xLTA_3f03de13-c205-413b-ae59-2620c8055354">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509aa0b5030e4f4e8b6a1b0424b3b2b5_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTExLTEtMS0w_c1c2b013-dfa3-4c70-9bc4-f45a07256e39">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e10e6c25c3b4557a099fe326409b993_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTEzLTEtMS0w_99716498-c1dc-4683-b292-fe1fb4a47a8f">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7a07462ffa4e17bc9007b49e82bb59_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTE1LTEtMS0w_8d700d3c-1727-4665-b64d-a3a4af5d0b3a">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa9ecb4f9e4493aa7973a44ec374287_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTE3LTEtMS0w_a8b59d4d-6d2e-4eb4-a37d-92b5dd54ffb9">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diversified Brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218d611e83f64fffadaf940a7b0b4fb6_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTEtMS0xLTA_8d63fb8d-93ed-474e-9bc3-2b0b72a9652d">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76b73811b3549068b674f9ad76a7123_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTMtMS0xLTA_58b3bc8d-59c2-4d96-9085-cdd86142dfd8">444</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95423e666a3b4e49b40bfdea87560d09_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTUtMS0xLTA_7e3d7aba-c606-4c5f-b5cc-1c8b5d38d934">462</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f702272ab94a368cb9cf9ce09c4a23_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTctMS0xLTA_6937644a-2dad-411a-8777-de10279448f7">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5266d257b030492988eccda7eea5b5de_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTktMS0xLTA_b9dc5db3-ff60-482e-ae7f-44b145343d71">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdce5f66d1e44a484b2b6697296c809_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTExLTEtMS0w_ff4af05f-a686-4820-921e-9e887691a3d9">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1b7ba9d9fb403ab62cdc18b6eb0b30_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTEzLTEtMS0w_e5c43cdd-93d3-4b7f-a1a4-48b43919002e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9d8e4e0a1e40b5989ef83e9ec5eec8_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTE1LTEtMS0w_eff49f75-866d-4142-95e0-25b84221f0e6">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fc958fd5eb46b88f87a1d5fd077ea1_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTE3LTEtMS0w_92d9a8f4-d767-42e1-adc2-b3b7dc255cc8">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eafdbc1aa0149d59422d69d95d29318_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTEtMS0xLTA_e4d7263c-cace-49b0-bb2f-69945df5932e">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925822b570a24b5ca88a9c40184078f4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTMtMS0xLTA_3a187870-7ffa-4253-b0e5-c8503c121d99">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df1b6b114284f41a95dbc2dad95ed8e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTUtMS0xLTA_65413ce9-b1b3-4253-a4d5-2ff86c3c23de">386</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a056f15d24b6d807f7b9fcf634f8a_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTctMS0xLTA_255acc25-81cf-4d5f-9a0a-96d42b79d767">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c7ec1f79b043b5b18d5e72d1499fdb_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTktMS0xLTA_cee7a834-d6a9-4c99-bbdb-b72ac8ae2c2e">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8352fe1a5ba54b86949f5c412a8f6d84_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTExLTEtMS0w_ae8b45d6-4a14-4367-a2ed-7098a7b79db0">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcf3dfb4b9a4b46a7e562cb5174729e_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTEzLTEtMS0w_d520c61b-6311-47cb-8ad8-2a25d6bd16ba">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3b6478297d44108e0c4b7a552445ed_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTE1LTEtMS0w_6e231732-b512-475b-9132-26981143ff45">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba005e9d4424eb3975bed7e80cec408_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTE3LTEtMS0w_fa421cdd-5145-4b2b-b445-df69679816c8">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id46eaf3fcf0744889088ffbbc1e457c5_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTEtMS0xLTg2NDM_da711246-3868-4f02-8316-9dbd310ffbc5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2213ab4b32ee478b9b62e4101ed98e0d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTMtMS0xLTg2NDM_addfc9c0-e69e-41af-9c0d-492d52d10a79">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3be092e6e874de493898709ec58bcd6_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTUtMS0xLTg2NDM_3a4e276e-e9d6-4e71-9396-da42a0a09b32">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574e546b62164a8a9f5caddcf3c862e0_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTctMS0xLTg2NDM_d9b80d41-ff41-42dd-b45d-c065441dfb1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i976d902516444c31a4ac366db6d832da_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTktMS0xLTg2NDM_eecf5302-c8ae-4278-b6a0-99990ba92bb2">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccebb2ddc10e443c8537cc870f8ba888_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTExLTEtMS04NjQz_f4a9506e-cfa7-486c-bb0d-5a7d27b5a3fc">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2839ccfa8fb44d8fa8ebd57a2d4c45a6_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTEzLTEtMS04NjQz_f1026b36-fc5d-405c-ab3d-3143c59eafe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca98a5ab938484c825c7201cf25965b_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTE1LTEtMS04NjQz_eb19b14f-68a4-4e89-a6c0-ccd333f1d180">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d15a37330f4dd78bdfeef167d3a769_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTE3LTEtMS04NjQz_88b31743-5e77-4f13-af48-84e0d28ffb58">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512a98056064477d978b1b7f932b53ac_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTEtMS0xLTA_02444081-8ef2-47c9-9699-70c9ca256c54">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae8562aa19d49e0880f0646e4267477_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTMtMS0xLTA_f8afa91a-b444-422a-a50d-ebe92f5e21a6">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de3ad1081d5496086b75ba3dfaa828e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTUtMS0xLTA_46c185b2-5493-4a77-8de3-85f8674ee20f">218</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i220331bcd9ca417b9f8990a1d20fde9e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTctMS0xLTA_b40c9280-2575-4e89-94ca-d2741f1b7585">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce7dbd95b264cac956659757d0b8dcb_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTktMS0xLTA_adbf07f4-5c65-4cac-846b-2ab90a46d50b">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c7919a2fdb48038043cef3080be5a6_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTExLTEtMS0w_60663b35-f8df-40d1-bbcf-5a0cc953a6d3">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3e04a9593148d0a9fbc6099bd71fcb_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTEzLTEtMS0w_d187aecd-26dd-43d4-98ac-073ff711f7ce">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63b0377678244a6b0daa177fa91da22_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTE1LTEtMS0w_29956701-d577-4642-a876-e8487e7af230">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51cccff8d27547a1a031e6d2ddfe47e1_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTE3LTEtMS0w_cdcd32cc-070c-496d-b824-96a933411594">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0395da8cb60645ceb3126a26ed0ca226_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTEtMS0xLTA_0239f5a1-c003-46ba-9e5b-4bda6519d448">84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45440e929de74f10b63f714199cbcbe9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTMtMS0xLTA_4520e2da-525f-4130-8629-c1612fd9b817">109</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1082609c81ca485f837033633e3ff2ba_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTUtMS0xLTA_3e13df4b-741a-48e5-82c9-718fdd07da7a">193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bb74f29937f40e19f43e122a3376b3f_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTctMS0xLTA_b4bb1b05-a972-476f-9b9a-21149ed381f4">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3193b9aa442a468b835ac9e65c53542f_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTktMS0xLTA_cfc04558-ef4f-40c2-bc62-b0c5e91db59f">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3ffea7f6f1e4e4983ca7cd6779d45a7_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTExLTEtMS0w_ca2bc995-7b70-4101-9b11-3eb42205166d">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef571096a444eea921f01711727d9bc_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTEzLTEtMS0w_b6198917-d39d-4bed-a016-9a7bb9dc2bac">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14375f6d274a48d9b9b162940b4d25dc_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTE1LTEtMS0w_b8479d15-6661-453e-ade3-a659e69e60a9">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94fd88fa633844479351964383e1f158_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTE3LTEtMS0w_9065bc2a-170e-4741-9000-e8201cad0b8d">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962fd40d3ee6484299bd3c87f64af7d8_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTEtMS0xLTA_f12cdc90-f3be-43e0-8267-688134ade01c">1,555</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic416aba94535424bbb9d655ecaf8bf86_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTMtMS0xLTA_0df4d5c9-ebb1-44c6-a8d3-e6f27845da13">3,152</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462d9a562b7d44599cf894438401f0f2_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTUtMS0xLTA_c92f4539-2da5-4417-9c55-9587d9d828ba">4,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7af0cf69df426784f6ec3b33bf0fc2_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTctMS0xLTA_b6df3080-d7cc-4e28-a6af-ac2645c95464">1,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14dca43e6ead40a69e7edfc8b772ec1c_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTktMS0xLTA_c5556428-1d76-4d74-9685-092614f7032f">3,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4054ed0640d4d4eb44198419c1c1fcb_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTExLTEtMS0w_179a8d27-4da0-424b-b29c-b99a5734925e">4,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e5cfb7bf144a1b85dbe4460106c525_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTEzLTEtMS0w_a1315fc4-86de-458f-8bcb-cd6098838d68">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55dcf9079e34da1816b08c7ce38d62e_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTE1LTEtMS0w_ba359726-9674-4cae-8895-2849fdeedfe7">3,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i576b22bb76944f53a3d4648c3b0410c6_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTE3LTEtMS0w_7c1ae496-e3d1-4d81-88b9-9a558814d7ef">4,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64789569b5264809a363eb25117c7863_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTEtMS0xLTA_a3bacbd4-89cf-4615-8d2b-79769478ce40">19,449</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86793e8a3a894c159132ce9f8e6c1bb8_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTMtMS0xLTA_75bb7018-8493-4e4a-8e18-d273c21595bc">23,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTUtMS0xLTA_427ba0f6-c3f2-4ae6-b741-2866c25bbad0">43,021</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c9e4693f50403c8339af126a90a689_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTctMS0xLTA_320ea6b7-5b1c-47ba-8a6e-e04f182b3d5d">18,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e48594fc2d243a0a8f39b754d4d89c1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTktMS0xLTA_cb353b09-1153-4312-b060-49a02e2b7079">22,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTExLTEtMS0w_6ef67bfd-6f69-4d9a-af4c-5bd1fea1bcab">41,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bc3f554ac349838de0563f48fcffe4_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTEzLTEtMS0w_8f5c20e3-a82a-4ecb-98e0-382bfaeeebe6">16,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ed8c22a5e8422ab95386f092f05a22_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTE1LTEtMS0w_04cc32b8-e5fb-48ca-ba96-049b882edcd0">20,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTE3LTEtMS0w_a19e1fb6-b029-4e04-8cc5-2eb6244099d6">37,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf30c9ce3ea34204891eeb2f7d539507_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTEtMS0xLTA_26501b89-dba3-4bb4-87fc-2036169b2758">612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ec6b2d07874cabb0d1efdbf4e854df_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTMtMS0xLTA_57a0f159-dccc-4997-9289-699c06467f0a">2,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ccff3c21c3473e96622780327f8b12_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTUtMS0xLTA_c1cda7fd-8e93-45ac-b9ef-95485362bc02">2,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9210f70f2d443e5889ab66abde4d50f_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTctMS0xLTA_16df4880-0a9a-48fd-a5d5-7ee43ed71fde">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72cf7144b3a4b4b8c1e9ca00c55b8f4_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTktMS0xLTA_424ecbd7-d796-46d0-9717-5bf676bbecfc">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09dc1fc46d8f403fbb3dee2b1027efac_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTExLTEtMS0w_95cf13da-c4f4-4351-80d2-b08a8b03ef2c">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib820ec90c26a48c1b63f85dba3250264_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTEzLTEtMS0w_f22c68be-6ffc-4265-92dd-ecd8ef45a0cf">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d198392ab6443c6b3cd53afafd9c428_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTE1LTEtMS0w_ae07abf2-cda1-4770-8547-95b5c2f34f26">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacae1b4908084fab9344e4706e647c20_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTE3LTEtMS0w_2b8daa0d-6e5c-43b5-86c6-48ce89c8fb9c">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8aa3dff7c84cbd81161181b2b08825_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTEtMS0xLTA_715b036c-a958-46b3-a77f-7254de8adedb">872</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6859c10e69f430d9106fa8705843e30_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTMtMS0xLTA_d04ffef3-6599-47e5-929c-4ff85ebd9516">892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b389087e5b6434f8d9e6fddb68235bc_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTUtMS0xLTA_db64ad21-f9e7-4d4b-8294-3143b52f5620">1,764</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e7a6ff124a4cdabf9930385a1ebb81_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTctMS0xLTA_0f09d386-add3-49cb-8278-e5f97a8f1a28">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531cef5b6df84d26b7bf2ea92797ba73_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTktMS0xLTA_a130e469-9ddd-405b-8716-4b601db650a0">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa6bd27f83f148fa904f54b109976d82_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTExLTEtMS0w_3965e26d-2146-40cc-b073-75c7a2fba244">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a62c431e03427790bd62d76d11d85a_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTEzLTEtMS0w_7c80d958-8bde-4e51-a7bc-205a048892ae">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f63110b9c74d60afa7701608b4e568_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTE1LTEtMS0w_19291237-2602-49c0-9be6-ab0182c9a31c">872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ae00b7d39b4af0b551da02254dc1fc_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTE3LTEtMS0w_bd800aad-c8ab-4ebf-8bb1-56a664cc38d3">1,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d960b8f6d74e02b74dbdf263f7040a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTEtMS0xLTA_0df90ff9-2b60-4568-85c5-b9980c50c633">1,484</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebadcf45558049f9945a6997f511f459_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTMtMS0xLTA_c027c91b-14bf-4d0f-8b55-4bdde5a0c2ad">3,219</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTUtMS0xLTA_dda9cbb9-160d-4247-9ac2-050acf36ccf8">4,703</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d58d6fc48c42c586a14d29d0057c85_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTctMS0xLTA_ff5f066a-eca9-4906-9369-955b3602e1fa">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383680c7a3bf42a8acc1ed3448266a57_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTktMS0xLTA_14d26005-cc67-49cc-83ae-ff7e3c74ee31">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTExLTEtMS0w_04452d4f-42b2-43cb-8b90-b62081084573">4,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da7dfe4fb3a43148b28617382d7d627_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTEzLTEtMS0w_b0706861-2728-4c8b-bded-f28ec85da9eb">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14adb31336c4a369b484fe90e397510_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTE1LTEtMS0w_4d9e7640-4766-4ace-9e5d-fa361e184a81">2,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTE3LTEtMS0w_2dc07705-676c-4734-bca1-c5cfe3c2c8a3">4,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45187d95cd0942edb66dab8c766886f8_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTEtMS0xLTA_aaa73f3b-a611-4a48-bff4-c4cc89327825">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd2491b77054229931de28963068e3e_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTMtMS0xLTA_952c200a-de9f-4795-b85b-0837634e85f6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33fa4b2aac9444684437df21be88b83_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTUtMS0xLTA_18a579af-21b3-41a7-aa48-142612f7e9bd">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e19eadf02e2447689f31531525302de_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTctMS0xLTA_09ef41de-d951-4571-913e-5e5085697ae2">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a2e88969d1400e802b86560797eb1f_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTktMS0xLTA_f18f4304-548b-40cb-8de2-3ac556476f70">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb55cd05c52044ecac300d08fac63719_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTExLTEtMS0w_e0b43c3b-0e8a-45fe-8d9e-828d12f7bdeb">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b5c015e07a4757829cb06ce4b2aa8b_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTEzLTEtMS0w_973b23f5-a3b6-4f33-ae2c-43839b51f228">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058927efa4b7468ba0ad2de228285af8_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTE1LTEtMS0w_eb16b031-b242-4f90-bdf8-5ca16ee0d392">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTE3LTEtMS0w_decf781e-2a2b-4e5d-a759-aad2e2bdb3d0">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b124f26fbc4ed6bfea843c38aef53c_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTEtMS0xLTA_3327907d-87a8-46a5-827b-306a173ae5a0">20,956</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c11152ee28442a6a313d7ee0d121638_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTMtMS0xLTA_868f47bf-9a5e-42b4-ae83-08c842936502">26,791</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTUtMS0xLTA_dd9210c7-0cc8-4949-aa06-095ff795048d">47,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b8a326cbb045a2adba2e477e561ffb_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTctMS0xLTA_cc349eb7-f357-4ff6-a4a6-236f41fd68f4">20,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic75220e6ebf14568819bd9a9b6188619_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTktMS0xLTA_c31820b1-2364-445a-b0df-7110b72cbb62">25,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTExLTEtMS0w_c522715d-df7f-402c-b369-cb987c9b1372">46,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia318474dcd744baa89624395a2172f09_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTEzLTEtMS0w_ee154d9f-2f73-4fe8-a7ef-4bdc19fb092d">18,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54197fbcf9eb44bfb6b566fc98512a15_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTE1LTEtMS0w_a8c5b300-40ff-43cb-aceb-dc644c7fd563">23,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTE3LTEtMS0w_cfffc731-836c-42f2-95c0-aea4be694d51">42,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a981d56b4f645fe9eeeed274c7cba3f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTEtMS0xLTA_f68ff27b-46fe-4558-83f2-bd2be7758846">71</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d10a58948e44c138c7d0466ca49b76c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTMtMS0xLTA_b87c5792-9abe-4496-a79c-c788326c29b2">176</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed37ac5584840178c946fee09f7a1c0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTUtMS0xLTA_8b9d4b62-395b-4f40-8570-fc8d2c18b767">247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d9ba332d224e66a279d66f036bb8d5_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTctMS0xLTA_17a6a682-7caf-4017-8e94-0c41248cc3a1">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c943b762ec4138807d933021b95604_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTktMS0xLTA_972444a1-ab5e-4715-9883-d30581382e3d">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729d5aea6d6f496f88811f7efeda63ca_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTExLTEtMS0w_b49cc878-a45a-4ac9-acf6-06158ecbcd32">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b0fceaafb44bd1aa406949729a0241_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTEzLTEtMS0w_7c49bdd9-3c95-4d8e-add2-c53d0ec125b2">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d5bac46f7047728d72dfe5c070cbbf_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTE1LTEtMS0w_7cb17a86-711f-4472-ad89-ac3619c17440">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b957d86897d4ded98362051c9b71b26_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTE3LTEtMS0w_70ad4daa-06cf-4e5f-8948-fa3705ad3950">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5949335831d149739ca8f936d4b7a57c_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTEtMS0xLTA_1f38626d-9a62-4882-ae38-4afb05ae7cab">21,027</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaad2b34e87e0423a9ea15f4ae64ee1bf_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTMtMS0xLTA_46700fd2-c625-4827-b27c-fd6fc3127e5f">26,967</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTUtMS0xLTA_c160d4bf-3176-4dba-b1be-9e562bce9529">47,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia16d15f92eef46998d5ead2a1b1771a9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTctMS0xLTA_f50f55eb-1a81-4e53-9a67-b0f6854bae7d">20,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dd811805a64591b10c10d7d8c3a94e_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTktMS0xLTA_51cb2f39-9613-49b7-9cce-c6eb9dcfcd4b">26,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTExLTEtMS0w_adb152c2-6a38-45f3-b7e0-b012ce51a9f2">46,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5401793db14442e29e91d912fc6f3de8_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTEzLTEtMS0w_1b5cb1de-aa04-4655-8a7b-0b27c2fe5e8c">18,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id687c9edba674c009de90ff41d9177bb_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTE1LTEtMS0w_c0276c5d-127e-40cc-9ba2-ce18763f3613">23,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTE3LTEtMS0w_f19ba06d-769b-4774-ac18-69e2469ff5c4">42,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the non-reportable segments of Healthcare Services (fully divested in the first quarter of 2020) and Alliances (which concluded in 2018). </span></div></ix:nonNumeric><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"><ix:continuation id="ic78a9592776f4310a768f63a3c89c818" continuedAt="ib2ea3fc84112470e938fba98e12f1b46">(5)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ib2ea3fc84112470e938fba98e12f1b46">&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i1be6cb106dae4d0f86ac2b50e5a8841c" continuedAt="i4041dfbb0de0425cbbb143785785ba56"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3NDQ_8d448d05-3fc5-475d-affb-56f290b8b45d" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5949335831d149739ca8f936d4b7a57c_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzEtMS0xLTEtMA_9c87ae20-3d33-498c-be0c-48b915b0dfb8">21,027</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia16d15f92eef46998d5ead2a1b1771a9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzEtMy0xLTEtMA_0564f54a-6ba6-4481-8e37-5ad95f0ee3ab">20,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5401793db14442e29e91d912fc6f3de8_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzEtNS0xLTEtMA_5c3dac65-f0ac-4aac-83c5-bcb078db75ad">18,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9717f9d6b3c445492a8c653a191c33e_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzItMS0xLTEtMA_5f47f993-d38e-4371-aa25-eed2666e84aa">13,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83be0173217465a96cf353e15212445_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzItMy0xLTEtMA_9ad3b09b-6a1f-4127-8637-41f68e62da4f">12,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b092f6738974424a865248091f7861b_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzItNS0xLTEtMA_577cdec1-ecf5-4478-ad4e-19faf1412ef5">12,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fa67cf15634c3098a5ad2740b26a0e_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtMS0xLTEtMTMwOTI_b393c0b8-1bed-4ae1-ae6d-20767473055a">3,624</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db75135b55642678e951aa56e432e6d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtMy0xLTEtMTMwOTI_cca62d5d-8f2f-418f-b9b8-c3ef4ed19e49">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36735be07e1646a08e5d2a7ed37255c9_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtNS0xLTEtMTMwOTI_e49f4018-714f-4013-9137-10a1713e3150">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37fd9b761d8b4af6bff239e1d9eb1a83_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtMS0xLTEtMA_080e95b5-d673-4198-985c-8356acc4123f">3,376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e3f46fa37d451a8e35adb77e7ff6bc_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtMy0xLTEtMA_2b67ab42-d43c-4198-8d9b-a2092db07a5f">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba30e2338734c24914a82cefe965a84_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtNS0xLTEtMA_888d1b47-0603-4d97-9bf5-e0ae9d5e6f72">3,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df174afc3444428bb70e46b35047e30_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzUtMS0xLTEtMA_e63e07aa-6665-4f4c-beef-2a7e11f9caa5">2,864</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716b88505d1e48bf95997e445c69d7e8_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzUtMy0xLTEtMA_1d7dde77-53b5-42fe-8f51-3905d66ef62d">2,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbf21a381224062a3ec08810f278afd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzUtNS0xLTEtMA_68e37e48-9c95-4da1-b788-ff36ccd29fa5">2,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e5d06897a04de68392658f8d0f8904_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzYtMS0xLTEtMA_b174ffea-0c78-4252-9404-256cb1c78941">2,274</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3310a35e6b0403a81733f2e2057d4ab_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzYtMy0xLTEtMA_0b3a6d18-55ca-403e-b7c9-02d04f24d131">2,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba4a6cec336e42db876f0c5690a9b6d4_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzYtNS0xLTEtMA_0f6f893b-53b3-49f1-a968-969744acd487">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c03523e781649d89f6ad179f060154a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzctMS0xLTEtMA_e4ed6335-c06e-44ac-b44a-940af0626eb3">1,229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7262343d9a65444c927cc6b62cffc5f0_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzctMy0xLTEtMA_d8c12a8a-9ec6-4eb5-a9e6-29fd431cb53a">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4370b43741f1402a91671b54edbf2db7_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzctNS0xLTEtMA_d6cc6b2f-7e40-4b11-9ca6-c8bac5eb8aab">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzgtMS0xLTEtMA_621b406b-9ed5-479d-b646-5b2ce48dd627">47,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzgtMy0xLTEtMA_704f72e2-ac4b-4c87-b33e-61c0e6abd149">46,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzgtNS0xLTEtMA_7ecfba94-b007-43e4-8444-c903c7d5dee9">42,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3MjU_8a972910-1388-44f0-8f02-89a4f5f14d31" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzItMS0xLTEtMA_631e19ae-fe31-4b7c-b66e-e5bf340c7439">29,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzItMy0xLTEtMA_2428036f-778d-48cc-b982-683104475d49">28,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzItNS0xLTEtMA_8e7906e3-7924-405b-8745-0d095dbcb5f7">24,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzMtMS0xLTEtMA_a19c18cb-64c8-4850-8af9-df01a8ebe377">1,650</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzMtMy0xLTEtMA_535ae1c2-3b5f-4c83-9390-8e774ace842e">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzMtNS0xLTEtMA_c738b0ff-36f8-4720-9a42-1cdf3b3925eb">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33fa4b2aac9444684437df21be88b83_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzQtMS0xLTEtMA_843271b8-dc48-4799-a759-024a2d84a1fa">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb55cd05c52044ecac300d08fac63719_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzQtMy0xLTEtMA_27d53615-0e4c-4443-955f-1cacd0323268">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzQtNS0xLTEtMA_c7491e1e-2e05-48e7-805d-95fcb4b8cd76">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzUtMS0xLTEtMA_af4e48b5-d4fc-4476-92b5-342cc417b07e">31,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzUtMy0xLTEtMA_d4fb8ef2-f708-49f7-a7d4-493eadbe75ae">29,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzUtNS0xLTEtMA_7bda5347-b555-473b-b9e4-8a532e8775b6">26,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed37ac5584840178c946fee09f7a1c0_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzYtMS0xLTEtMA_db1131cd-663b-439e-a90e-9d99c4f17e04">140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729d5aea6d6f496f88811f7efeda63ca_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzYtMy0xLTEtMA_cc41ed7b-b828-4059-893c-5f8fab029835">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b957d86897d4ded98362051c9b71b26_D20180101-20181231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzYtNS0xLTEtMA_ffd091e0-d4e7-4372-ac07-b0998fa3aae8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzgtMS0xLTEtMA_d242569f-2512-4d45-8380-7e5071b343d1">59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzgtMy0xLTEtMA_f67012ec-778c-4861-bf05-6f2ab60cd9c9">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzgtNS0xLTEtMA_29d25a0e-8f6b-4544-a498-0d05ec03c656">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzktMS0xLTEtMA_f4478931-0f91-47a7-9ab6-aa757bc70ac7">831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzktMy0xLTEtMA_6fb27083-21b1-4f58-a6cd-604d04641b25">893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzktNS0xLTEtMA_8895cf79-22ed-4df2-be8b-ba7969bf2b12">772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEwLTEtMS0xLTA_953203e7-016e-4101-aba6-711ea26f66f2">1,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEwLTMtMS0xLTA_9b10636d-ffcd-438f-814e-f164b58578f8">1,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEwLTUtMS0xLTA_aca97e7d-3b38-4be3-9a5f-de7f6e62b5c0">1,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzExLTEtMS0xLTA_2366eb8c-0db1-4599-bba2-31564283cede">13,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzExLTMtMS0xLTA_76f450c7-ec46-48c1-adc5-31b47b8773a9">9,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzExLTUtMS0xLTA_4a8f8b45-a4a8-43e0-af4f-81e80e3c5d12">9,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:AmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEyLTEtMS0xLTA_2e30db45-ba46-48ed-970b-3d800600dd45">1,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:AmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEyLTMtMS0xLTA_43ab7723-54b8-4802-94bb-38cc990013c4">1,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:AmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEyLTUtMS0xLTA_d27ec4c3-b935-4750-805a-02ee77a81a8f">2,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEzLTEtMS0xLTA_21da1bb8-8880-429f-9bb0-8e1466822841">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEzLTMtMS0xLTA_092d7b47-270a-4c97-8892-68e1a747ce21">638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEzLTUtMS0xLTA_0e705dd6-694f-4760-8fc4-451f8a42dbaf">632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge related to the termination of a collaboration with Samsung</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GainLossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE0LTEtMS0xLTA_88ffe264-9704-4fb1-a4c9-b56da7800ae9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:GainLossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE0LTMtMS0xLTA_601713cc-af3f-4a7e-8466-8cec6d08e0f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231" decimals="-6" name="us-gaap:GainLossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE0LTUtMS0xLTA_091ee08d-bb2b-4bd5-b829-4643af9a9f8a">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE2LTEtMS0xLTA_6f5a5836-de4a-4bdb-8074-165f2fc006bf">5,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE2LTMtMS0xLTA_f66b5818-618f-493d-a783-9d31938ba4c2">5,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE2LTUtMS0xLTA_048a3124-8578-4c98-ab0c-d22fb4fa15f6">3,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE3LTEtMS0xLTA_1b2605f8-c067-406c-bcbc-d929ad366c71">8,791</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE3LTMtMS0xLTA_51c9aa61-2e02-4a54-9321-4a39a8b8b25b">11,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE3LTUtMS0xLTA_d0f50a45-30d5-45aa-8571-16f031b5b4f3">8,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><ix:continuation id="i4041dfbb0de0425cbbb143785785ba56"><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3MzY_2655e83a-070b-40e0-bc01-22b47c51b130" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity (income) loss from affiliates and depreciation and amortization included in segment profits is as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:37.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzMtMS0xLTEtMA_ecbb5f03-3b43-430e-b0c8-b0df2412e42e">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzMtMy0xLTEtMA_f8e756f3-f623-4408-9d0e-aca69188bc08">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33fa4b2aac9444684437df21be88b83_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzMtNS0xLTEtMA_e3b5a0f1-a065-485e-8288-74febeea0cfc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzMtNy0xLTEtMA_d60feefc-7a0c-4ee9-9275-d9f6eab5b3e2">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzQtMS0xLTEtMA_1aaa351f-5afb-403e-82eb-68176e98cd50">690</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzQtMy0xLTEtMA_170d930e-4a5b-4ae2-af15-245ade74cf8d">164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33fa4b2aac9444684437df21be88b83_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzQtNS0xLTEtMA_37bac231-3c81-4c74-9da8-6c318696a472">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzQtNy0xLTEtMA_aee54fea-069c-4616-965f-3af0490ced63">855</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzctMS0xLTEtMA_36bdad60-6436-4fd6-80ba-465f6532e589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzctMy0xLTEtMA_165935c2-ac57-49a2-8176-765fad20c2e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb55cd05c52044ecac300d08fac63719_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzctNS0xLTEtMA_bade4662-e980-49bc-9fa1-88a88cac53de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzctNy0xLTEtMA_aa2a7479-9af9-4e70-86ae-d76969c3c25c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzgtMS0xLTEtMA_4c067151-ae50-4a37-a50e-53986bf454a0">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzgtMy0xLTEtMA_fc4d47f8-1e96-4da7-bf2a-09323f6a2ff0">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb55cd05c52044ecac300d08fac63719_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzgtNS0xLTEtMA_0c079a07-c804-477d-83b3-d0f36c5a3f7b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzgtNy0xLTEtMA_fc236d52-f659-4bdf-848b-9e3f8e02b613">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzExLTEtMS0xLTA_db0e1202-0da8-4598-ad14-7e95b9351502">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzExLTMtMS0xLTA_ad912165-1940-41b4-b266-584620e2eccf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzExLTUtMS0xLTA_120de255-4df6-47b1-a361-f44c20ca4873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzExLTctMS0xLTA_e045325b-0294-437a-a83d-00887ecdc506">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzEyLTEtMS0xLTA_a1acc387-ea5d-468a-8157-c4ff537f1bf3">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzEyLTMtMS0xLTA_b352f47d-918e-43d1-85f2-b48ae5bd4fb0">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzEyLTUtMS0xLTA_dc7d1516-97c7-49c1-acaf-8ad4e0656b5d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzEyLTctMS0xLTA_705e77b8-0430-49e3-9b4f-ec20213e7dee">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231" name="us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3NDY_9cc134d0-6b24-466e-9d51-931477ecafbc" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129f29a2040140c08baabf19b38dddd3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzEtMS0xLTEtMA_bc81f7e1-c802-4e86-88d8-e315e1998d66">10,526</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184871e21ba348d1b81fad633a38d169_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzEtMy0xLTEtMA_079e2942-1da8-401d-bd1c-61c44c0429ab">8,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib70ed1d184c44bd8ba1ed708cad91d61_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzEtNS0xLTEtMA_fc1b8648-bc6f-4a24-a949-8829548dc813">8,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e575aafa15847fba6a21907ae53dd63_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzItMS0xLTEtMA_1ac8b3bb-89e2-49b4-b9d7-cc657a6a92a5">6,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08c0043b99c4e2ba8e47c65a339ceb1_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzItMy0xLTEtMA_e0720867-9b9e-45da-8ac9-5a8604d5eeda">4,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c346b2768fb40dd91ac6ebba9fb94d7_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzItNS0xLTEtMA_89360585-8a8f-4a4f-8e3a-abb816dfc006">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f235c0c07d4506bd10df5031278985_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzMtMS0xLTEtMA_a61e88f9-824d-4909-96a0-5363489ba3e8">761</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1c311fbe544e15a962f0cdcb5479e3_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzMtMy0xLTEtMA_17b24c18-ccdd-4979-bc9c-2efd78ec926b">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a7538040e541f19698e90ed9663cbf_I20181231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzMtNS0xLTEtMA_4b7e4c3d-601c-49d9-bb4a-c2659d646ffe">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f4efdd418f74b408cf00135e5d118c4_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzQtMS0xLTEtMA_8ea9af88-4798-407f-bac0-6d951004e777">252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b72e0433646475693a6cb7d2df40022_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzQtMy0xLTEtMA_688b3c43-1f7d-4cbc-bc88-8b5f65282822">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6390040a02294303a155f1923472865c_I20181231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzQtNS0xLTEtMA_3c6d65d3-4ec6-4468-87d0-42212af26aaf">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4add6d698c44de8cd75978f383e97c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzUtMS0xLTEtMA_332eda68-2cd9-4b67-8f55-0b87e6867d1b">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2cad22821de46f29ac5d2e479eed81b_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzUtMy0xLTEtMA_60b87b5c-8f1a-4d89-a2d6-543fe003880f">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52040186e8344d189b9e280fb7fe1b2e_I20181231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzUtNS0xLTEtMA_bc3b9164-b7a9-4480-9474-f92e5d8b2294">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88687f58720d4395a2d6dfdd03bea675_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzYtMS0xLTEtMA_6bf556ae-91b0-4465-8158-6915f0e4c6f2">166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0b0e5a61604c6e866e7abdc8b2f909_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzYtMy0xLTEtMA_2945e94c-dc9a-4421-ad0b-e59ef062c3bd">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dbc20679af844698cd41359e5fd718f_I20181231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzYtNS0xLTEtMA_19ddccab-88b3-4e8e-a264-19b1375e433b">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78313bb854a147e5a42efbba390205fc_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzctMS0xLTEtMA_84c27e02-c503-4e31-8194-149e4df4ae4c">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef9755b84b746e88b21161ca9f7a0f7_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzctMy0xLTEtMA_a8b990ce-be56-4d92-809d-1cb6c830f740">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265675dad9e342e9b47878356a5b781d_I20181231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzctNS0xLTEtMA_c53f21ab-9113-48db-867f-4d54a5dbc49a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzgtMS0xLTEtMA_e95d5e98-fabb-400f-ae67-25193311dee2">17,986</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzgtMy0xLTEtMA_304f8a60-ada5-4b0e-8d98-93005f30e9ca">15,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef6045954534437abb1993aa1937f07_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzgtNS0xLTEtMA_f5a56274-707e-4f3f-a657-90fddfd4290a">13,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_232"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Merck &amp; Co., Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of Merck &amp; Co., Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the COSO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discount Accruals in the U.S. - Medicaid, Managed Care and Medicare Part D Rebates</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, the Company records certain variable consideration including discounts, which are estimated at the time of sale generally using the expected value method. Amounts accrued for aggregate customer discounts as of December 31, 2020 in the U.S. are $3.1 billion and are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. Certain of these discounts take the form of rebates, which are amounts owed based upon definitive contractual agreements or legal requirements with private sector (Managed Care) and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. Management uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision.    </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to customer discount accruals in the U.S. - Medicaid, Managed Care, and Medicare Part D rebates is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing the provisions, as the provisions include assumptions related to changes to price and historical customer segment utilization mix, pertaining to forecasted customer claims that may not be fully paid until a subsequent period.  This in turn led to a high degree of auditor judgment, subjectivity and effort in applying the procedures related to those assumptions and in evaluating the evidence obtained from these procedures.     </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to customer discount accruals in the U.S. - Medicaid, Managed Care, and Medicare Part D rebates, including management&#8217;s controls over the assumptions used to estimate the corresponding rebate accruals.  These procedures also included, among others, (i) developing an independent estimate of the rebate accruals by utilizing third party data on historical customer segment utilization mix in the U.S., changes to price, the terms of the specific rebate programs, and the historical trend of actual rebate claims paid, (ii) comparing the independent estimate to the rebate accruals recorded by management and (iii) testing actual rebate claims paid, including evaluating those claims for consistency with the contractual terms of the Company&#8217;s rebate agreements. </span></div><div style="text-align:justify"><img src="mrk-20201231_g2.jpg" alt="mrk-20201231_g2.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:286px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PricewaterhouseCoopers LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2021</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2002.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_238"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_241"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures. Based on their evaluation, as of the end of the period covered by this Form&#160;10-K, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Act)) are effective. For the fourth quarter of 2020, there have been no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) of the Act. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212;&#160;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December&#160;31, 2020. PricewaterhouseCoopers LLP, an independent registered public accounting firm, has performed its own assessment of the effectiveness of the Company&#8217;s internal control over financial reporting and its attestation report is included in this Form 10-K filing.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_244"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Management&#8217;s Report</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Responsibility for Financial Statements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Responsibility for the integrity and objectivity of the Company&#8217;s financial statements rests with management. The financial statements report on management&#8217;s stewardship of Company assets. These statements are prepared in conformity with generally accepted accounting principles and, accordingly, include amounts that are based on management&#8217;s best estimates and judgments. Nonfinancial information included in the Annual Report on Form&#160;10-K has also been prepared by management and is consistent with the financial statements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To assure that financial information is reliable and assets are safeguarded, management maintains an effective system of internal controls and procedures, important elements of which include: careful selection, training and development of operating and financial managers; an organization that provides appropriate division of responsibility; and communications aimed at assuring that Company policies and procedures are understood throughout the organization. A staff of internal auditors regularly monitors the adequacy and application of internal controls on a worldwide basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To ensure that personnel continue to understand the system of internal controls and procedures, and policies concerning good and prudent business practices, annually all employees of the Company are required to complete Code of Conduct training. This training reinforces the importance and understanding of internal controls by reviewing key corporate policies, procedures and systems. In addition, the Company has compliance programs, including an ethical business practices program to reinforce the Company&#8217;s long-standing commitment to high ethical standards in the conduct of its business.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and other financial information included in the Annual Report on Form&#160;10-K fairly present, in all material respects, the Company&#8217;s financial condition, results of operations and cash flows. Our formal certification to the Securities and Exchange Commission is included in this Form&#160;10-K filing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212;&#160;Integrated </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2020, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="padding:0 1pt"><div><img src="mrk-20201231_g3.jpg" alt="mrk-20201231_g3.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:234px"/></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:69pt"><td colspan="3" style="padding:0 1pt"><div><img src="mrk-20201231_g4.jpg" alt="mrk-20201231_g4.jpg" style="height:78px;margin-bottom:5pt;vertical-align:text-bottom;width:258px"/></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth C. Frazier</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert M. Davis</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chairman, President<br/>and Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Global Services,<br/>and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div id="iab6577be4c3840fd8181bdedf457fba5_247"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_250"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_253"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on directors and nominees is incorporated by reference from the discussion under Proposal&#160;1. Election of Directors of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021. Information on executive officers is set forth in Part&#160;I of this document on page 44.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, if applicable, is incorporated by reference from the discussion under the heading &#8220;Stock Ownership Information&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a Code of Conduct &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Values and Standards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicable to all employees, including the principal executive officer, principal financial officer, principal accounting officer and Controller. The Code of Conduct is available on the Company&#8217;s website at www.merck.com/company-overview/culture-and-values/code-of-conduct/values-and-standards. The Company intends to disclose future amendments to certain provisions of the Code of Conduct, and waivers of the Code of Conduct granted to executive officers and directors, if any, on the website within four business days following the date of any amendment or waiver. Every Merck employee is responsible for adhering to business practices that are in accordance with the law and with ethical principles that reflect the highest standards of corporate and individual behavior.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading &#8220;Board Meetings and Committees&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_256"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Executive Compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required on executive compensation is incorporated by reference from the discussion under the headings &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;All Other Compensation&#8221; table, &#8220;Grants of Plan-Based Awards&#8221; table, &#8220;Outstanding Equity Awards&#8221; table, &#8220;Option Exercises and Stock Vested&#8221; table, &#8220;Pension Benefits&#8221; table, &#8220;Nonqualified Deferred Compensation&#8221; table, &#8220;Potential Payments Upon Termination or a Change in Control&#8221;, including the discussion under the subheadings &#8220;Separation&#8221; and &#8220;Change in Control,&#8221; as well as all footnote information to the various tables, of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on director compensation is incorporated by reference from the discussion under the heading &#8220;Director Compensation&#8221; and related &#8220;2020 Schedule of Director Fees&#8221; table and &#8220;2020 Director Compensation&#8221; table of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information under the headings &#8220;Compensation and Benefits Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation and Benefits Committee Report&#8221; is incorporated by reference from the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_259"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to security ownership of certain beneficial owners and management is incorporated by reference from the discussion under the heading &#8220;Stock Ownership Information&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the options, warrants and rights and other equity compensation under the Company&#8217;s equity compensation plans as of the close of business on December&#160;31, 2020. The table does not include information about tax qualified plans such as the Merck U.S. Savings Plan.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>securities&#160;to&#160;be<br/>issued upon<br/>exercise of<br/>outstanding<br/>options,&#160;warrants<br/>and rights<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price of<br/>outstanding<br/>options, warrants<br/>and rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>securities&#160;remaining<br/>available&#160;for&#160;future<br/>issuance&#160;under&#160;equity<br/>compensation plans<br/>(excluding<br/>securities<br/>reflected&#160;in&#160;column&#160;(a))<br/>(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,446,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,353,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,446,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.64&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,353,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.94pt">Includes options to purchase shares of Company Common Stock and other rights under the following shareholder-approved plans: the Merck &amp; Co., Inc. 2010 and 2019 Incentive Stock Plans, and the Merck&#160;&amp; Co., Inc. 2010 Non-Employee Directors Stock Option Plan.</span></div><div style="margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes approximately 11,914,491&#160;shares of restricted stock units and 2,099,739 performance share units (assuming maximum payouts) under the Merck Sharp&#160;&amp; Dohme 2010 and 2019 Incentive Stock Plans. Also excludes 193,746 shares of phantom stock deferred under the MSD Employee Deferral Program and 564,209 shares of phantom stock deferred under the Merck &amp; Co., Inc. Plan for Deferred Payment of Directors&#8217; Compensation.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_262"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on transactions with related persons is incorporated by reference from the discussion under the heading &#8220;Related Person Transactions&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on director independence is incorporated by reference from the discussion under the heading &#8220;Independence of Directors&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_265"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Principal Accountant Fees and Services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required for this item is incorporated by reference from the discussion under Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm for 2021 beginning with the caption &#8220;Pre-Approval Policy for Services of Independent Registered Public Accounting Firm&#8221; through &#8220;Fees for Services Provided by the Independent Registered Public Accounting Firm&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May 25, 2021.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_268"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_271"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The following documents are filed as part of this Form&#160;10-K</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_274"></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated statement of income for the years ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated statement of comprehensive income for the years ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated balance sheet as of December&#160;31, 2020 and 2019 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated statement of equity for the years ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated statement of cash flows for the years ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to consolidated financial statements</span></div><div style="margin-top:6pt;padding-left:81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report of PricewaterhouseCoopers LLP, independent registered public accounting firm</span></div><div id="iab6577be4c3840fd8181bdedf457fba5_277"></div><div style="margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules are omitted because they are either not required or not applicable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statements of affiliates carried on the equity basis have been omitted because, considered individually or in the aggregate, such affiliates do not constitute a significant subsidiary.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_280"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015815000048/exhibit32-byxlawsxmerckcoi.htm">By-Laws of Merck &amp; Co., Inc. (effective July 22, 2015) &#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed July 28, 2015 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture, dated as of April 1, 1991, between Merck Sharp &amp; Dohme Corp. (f/k/a Schering Corporation) and U.S. Bank Trust National Association (as successor to Morgan Guaranty Trust Company of New York), as Trustee (the 1991 Indenture)&#160;&#8212;&#160;Incorporated by reference to Exhibit&#160;4 to MSD&#8217;s Registration Statement on Form S-3 (No. 33-39349)</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64978/0000950123-97-008101.txt">First Supplemental Indenture to the 1991 Indenture, dated as of October 1, 1997&#160;&#8212;&#160;Incorporated by reference to Exhibit 4(b) to MSD&#8217;s Registration Statement on Form S-3 filed September 25, 1997 (No.&#160;333-36383)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex43.htm">Second Supplemental Indenture to the 1991 Indenture, dated November 3, 2009&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.3 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No.1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312512216683/d318209dex41.htm">Third Supplemental Indenture to the 1991 Indenture, dated May 1, 2012&#160;&#8212; Incorporated by reference to Exhibit 4.1 to Merck &amp; Co., Inc.&#8217;s Form 10-Q Quarterly Report for the period ended March&#160;31, 2012 (No.&#160;1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012303013260/y92128exv4w1.txt">Indenture, dated November 26, 2003, between Merck &amp; Co., Inc. (f/k/a Schering-Plough Corporation) and The Bank of New York as Trustee (the 2003 Indenture)&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Schering-Plough&#8217;s Current Report on Form&#160;8&#8209;K filed November&#160;28, 2003 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012303013260/y92128exv4w3.txt">Second Supplemental Indenture to the 2003 Indenture (including Form of Note), dated November&#160;26, 2003&#160;&#8212; Incorporated by reference to Exhibit 4.3 to Schering-Plough&#8217;s Current Report on Form&#160;8&#8209;K filed November 28, 2003 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012307012711/y39738exv4w1.htm">Third Supplemental Indenture to the 2003 Indenture (including Form of Note), dated September 17, 2007&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Schering-Plough&#8217;s Current Report on Form 8&#8209;K filed September 17, 2007 (No. 1-6571)</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex44.htm">Fifth Supplemental Indenture to the 2003 Indenture, dated November 3, 2009&#160;&#8212;&#160;Incorporated by reference to Exhibit&#160;4.4 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312510278450/dex41.htm">Indenture, dated as of January 6, 2010, between Merck &amp; Co., Inc. and U.S. Bank Trust National Association, as Trustee&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed December 10, 2010 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit410-merckdescriptio.htm">Description</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit410-merckdescriptio.htm"> of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit410-merckdescriptio.htm">Registrant&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit410-merckdescriptio.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit410-merckdescriptio.htm">Common</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit410-merckdescriptio.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit410-merckdescriptio.htm">Stock</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit411-merckdescriptio.htm">Description of the Registrant&#8217;s 1.125% Notes due 2021, 1.875% Notes due 2026, and 2.500% Notes due 2034</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit412-merckdescriptio.htm">Description of the Registrant&#8217;s 0.500% Notes due 2024 and 1.375% Notes due 2036</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000130817915000131/lmrk2015_def14a.htm">Merck &amp; Co., Inc. Executive Incentive Plan (as amended and restated effective June 1, 2015)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 13, 2015 (No.&#160;1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015820000005/ex102deferralprograme.htm">Merck &amp; Co., Inc. Deferral Program Including the Base Salary Deferral Plan (Amended and Restated effective December 1, 2019)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015820000005/ex102deferralprograme.htm"> - Incorporated by reference to Exhibit 10.2 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2019 filed February 26, 2020 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000130817915000131/lmrk2015_def14a.htm">Merck &amp; Co., Inc. 2010 Incentive Stock Plan (as amended and restated June 1, 2015)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 13, 2015 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012311047041/y90523exv10w2.htm">Form of stock option terms for 2011 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.2 to Merck &amp; Co., Inc.&#8217;s Form 10&#8209;Q Quarterly Report for the period ended March 31, 2011 filed May 9, 2011  (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312512084319/d274705dex1020.htm">Form of stock option terms for 2012 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.20 to Merck &amp; Co., Inc.&#8217;s Form 10&#8209;K Annual Report for the fiscal year ended December 31, 2011 filed February&#160;28, 2012 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312513084618/d438975dex1019.htm">Form of stock option terms for 2013 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.19 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2012 filed February&#160;28, 2013 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015815000005/ex1018stockoptiontermsfor2.htm">Form of stock option terms for 2014 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.18 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December&#160;31, 2014 filed February&#160;27, 2015 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015816000063/ex10202015nqsograntsunderm.htm">Form of stock option terms for 2015 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.20 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December&#160;31, 2015 filed February&#160;26, 2016 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000005/ex1012_2018nqsogranttermsu.htm">Form of stock option terms for 2018 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan &#8212; Incorporated by referent to Exhibit 10.12 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2017 filed February 27, 2018 (No. 1-6571)</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015817000010/ex10192016nqsograntsunderm.htm">Form of stock option terms for 2016 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan &#8212;&#160;Incorporated by reference to Exhibit 10.19 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2016 filed February&#160;28, 2017 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000005/ex1017_2018restrictedstock.htm">Form of restricted stock unit terms for 2018 quarterly and annual grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan &#8212; Incorporated by reference to Exhibit 10.17 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2017 filed on February 28, 2018 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000011/exhibit10psuawardtermsunde.htm">2018 Performance Share Unit Award Terms under the Merck &amp; Co., Inc. 2010 Stock Incentive Plan &#8212; Incorporated by reference to Exhibit 10 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 10-Q Quarterly Report for the period ended March 31, 2018 filed May 8, 2018 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000114036119006720/mrk-def14a_052819.htm">Merck &amp; Co., Inc. 2019 Incentive Stock Plan - Incorporated by reference to Appendix C to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 8, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312512485851/d445500dex101.htm">Merck &amp; Co., Inc. Change in Control Separation Benefits Plan (effective as amended and restated, as of January 1, 2013)&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.1 to Merck&#160;&amp; Co., Inc.&#8217;s Current Report on Form&#160;8&#8209;K filed November 29, 2012 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015819000014/ex1019merckusseparationben.htm">Merck &amp; Co., Inc. U.S. Separation Benefits Plan (amended and restated as of January 1, 2019) - Incorporated by reference to Exhibit 10.19 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2018 filed February 27, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012311019286/y87773exv10w17.htm">Merck &amp; Co., Inc. 2010 Non-Employee Directors Stock Option Plan (amended and restated as of December&#160;1, 2010)&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.17 to Merck &amp; Co., Inc.&#8217;s Form 10&#8209;K Annual Report for the fiscal year ended December&#160;31, 2010 filed February 28, 2011 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64978/0000950123-96-004374.txt">Retirement Plan for the Directors of Merck &amp; Co., Inc. (amended and restated June 21, 1996)&#160;&#8212;Incorporated by reference to Exhibit 10.C to MSD&#8217;s Form 10-Q Quarterly Report for the period ended June&#160;30, 1996 filed August 13, 1996 (No. 1-3305)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015820000005/ex1018planforderredpay.htm">Merck &amp; Co., Inc. Plan for Deferred Payment of Directors&#8217; Compensation (Amended and Restated effective as of January 1, 2020)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015820000005/ex1018planforderredpay.htm"> - Incorporated by reference to Exhibit 10.18 to Merck &amp; Co., Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015820000005/ex1018planforderredpay.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015820000005/ex1018planforderredpay.htm">s Form 10-K Annual Report for the fiscal year ended December 31, 2019 filed February 26, 2020 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012304005617/y96428exv10wu.txt">Distribution agreement between Schering-Plough and Centocor, Inc., dated April 3, 1998&#160;&#8212;&#160;Incorporated by reference to Exhibit 10(u) to Schering-Plough&#8217;s Amended 10-K for the year ended December 31, 2003 filed May 3, 2004 (No. 1-6571)&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012307016977/y45185exv10w1.htm">Amendment Agreement to the Distribution Agreement between Centocor, Inc., CAN Development, LLC, and Schering-Plough (Ireland) Company&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.1 to Schering-Plough&#8217;s Current Report on Form 8-K filed December 21, 2007 (No. 1-6571)&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015819000014/a2018form10-k_exhibit1027x.htm">Severance Agreement and General Release between Merck &amp; Co., Inc. and Adam H. Schechter, dated December 1, 2018 - Incorporated by reference to Exhibit 10.27 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2018 filed February 27, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015819000014/a2018form10-k_ex1028xoffer.htm">Offer Letter between Merck &amp; Co., Inc. and Jennifer Zachary, dated March 16, 2018 - Incorporated by reference to Exhibit 10.28 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2018 filed February 27, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">tock </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">ption </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">erms for 2021 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">nnual </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">n</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">on-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">ualified </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">ption </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">g</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">rants </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">u</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex1023-2021annualnqsoterms.htm">nder the Merck &amp; Co., Inc. 2019 Incentive Stock Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">estricted </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">tock </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">u</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">nit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="ex10-24x2021annualrsuterms.htm">erms for 2021 annual grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21-subsidiarylistasof12x.htm">Subsidiaries of Merck &amp; Co., Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23-consentofindependentr.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex241-powerofattorney.htm">Power of Attorney</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex242-certificationofboard.htm">Certified Resolution of Board of Directors</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311-rule13ax14a15dx14ace.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312-rule13ax14a15dx14ace.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321-section1350certifica.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322-section1350certifica.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Certain portions of the exhibit have been omitted pursuant to a request for confidential treatment. The non-public information has been filed separately with the Securities and Exchange Commission pursuant to rule&#160;24b-2 under the Securities Exchange Act of 1934, as amended.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of Merck &amp; Co., Inc.&#8217;s total consolidated assets are not filed as exhibits to this report. Merck &amp; Co., Inc. will furnish a copy of these agreements to the Securities and Exchange Commission on request.</span></td></tr></table></div><div><span><br/></span></div><div id="iab6577be4c3840fd8181bdedf457fba5_283"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><div id="iab6577be4c3840fd8181bdedf457fba5_286"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iab6577be4c3840fd8181bdedf457fba5_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:&#160;&#160;&#160;&#160;February&#160;25, 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:50.801%"><tr><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK&#160;&amp; CO., INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KENNETH C. FRAZIER</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Chairman, President and Chief Executive Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Attorney-in-Fact)</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:28.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KENNETH C. FRAZIER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President and Chief Executive Officer;</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Executive Officer; Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Global Services, and Chief Financial Officer; Principal Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RITA A. KARACHUN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance-Global Controller;</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accounting Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LESLIE A. BRUN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THOMAS R. CECH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MARY ELLEN COE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAMELA J. CRAIG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THOMAS H. GLOCER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISA J. LAVIZZO-MOUREY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAUL B. ROTHMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PATRICIA F. RUSSO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHRISTINE E. SEIDMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INGE G. THULIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KATHY J. WARDEN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PETER C. WENDELL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jennifer Zachary, by signing her name hereto, does hereby sign this document pursuant to powers of attorney duly executed by the persons named, filed with the Securities and Exchange Commission as an exhibit to this document, on behalf of such persons, all in the capacities and on the date stated, such persons including a majority of the directors of the Company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:32.371%"><tr><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Attorney-in-Fact)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>2
<FILENAME>exhibit410-merckdescriptio.htm
<DESCRIPTION>EX-4.10 DESCRIPTION OF MERCK COMMON STOCK
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i10b52c5d54de470283eb9d60d1b25d95_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.10</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Registrant&#8217;s Common Stock</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registered under Section 12 of the Securities Exchange Act of 1934</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth a description of the material terms of the common stock of Merck &#38; Co., Inc. (&#8220;Merck&#8221;).  The description is qualified in its entirety by reference to Merck&#8217;s certificate of incorporation and by-laws, copies of which are included or incorporated by reference as exhibits to Merck&#8217;s most recently filed Annual Report on Form 10-K.  You are encouraged to read Merck&#8217;s certificate of incorporation and by-laws and the applicable provisions of the New Jersey Business Corporation Act for additional information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under its certificate of incorporation, Merck is authorized to issue an aggregate of 6,520,000,000 shares of capital stock, divided into classes as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:60.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">6,500,000,000 shares of common stock, par value $0.50 per share&#59; and</font></div><div style="margin-bottom:12pt;padding-left:60.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">20,000,000 shares of preferred stock, par value $1.00 per share, issuable in one or more series.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the preferences, qualifications, limitations, voting and other rights and restrictions with respect to each class of Merck&#8217;s capital stock having any preference or priority over Merck&#8217;s common stock, the holders of the common stock shall have and possess all rights appertaining to Merck&#8217;s capital stock.  The holders of shares of Merck&#8217;s common stock are entitled to one vote per share for each share held of record on all matters voted on by shareholders, including the election of directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A majority of votes cast by shares of Merck&#8217;s common stock entitled to vote is required for&#58;</font></div><div style="margin-bottom:12pt;padding-left:60.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adoption of a proposed amendment to the certificate of incorporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:60.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of a proposed plan of merger or consolidation&#59;</font></div><div style="margin-bottom:12pt;padding-left:60.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of a sale, lease, exchange or other disposition of all, or substantially all, of Merck&#8217;s assets, not in the usual and regular course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:60.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of a proposed plan of exchange&#59; and</font></div><div style="margin-bottom:12pt;padding-left:60.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of a proposed plan of dissolution.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, unless approved by the affirmative vote of holders of at least two-thirds of the shares of Merck&#8217;s common stock voted thereon by disinterested shareholders, Merck is generally prohibited from purchasing shares of Merck&#8217;s common stock at a price in excess of a fair market price from a person known to Merck to be the beneficial owner of more than 5% of the voting power of the then outstanding shares of Merck&#8217;s common stock, subject to exceptions for certain open market transactions, certain public transactions, purchases pursuant to an offer to purchase made on the same terms and conditions to all holders of Merck&#8217;s common stock and shares held by such a beneficial owner for longer than two years.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Merck&#8217;s common stock are entitled to participate equally in dividends when and as such dividends may be declared by Merck&#8217;s board of directors out of funds legally available therefor.  As a New Jersey corporation, Merck is subject to statutory limitations on the declaration and payment of dividends.  In the event of Merck&#8217;s liquidation, dissolution or winding up, holders of Merck&#8217;s common stock have the right to a ratable portion of assets remaining after satisfaction in full of the prior rights of creditors, including holders of Merck&#8217;s indebtedness, all liabilities and the aggregate liquidation preferences of any outstanding shares of Merck&#8217;s preferred stock.  The holders of Merck&#8217;s common stock have no conversion, redemption, preemptive or cumulative voting rights.  All of the shares of Merck&#8217;s common stock issued by Merck are validly issued, fully paid and non-assessable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for Merck&#8217;s common stock is Equinity Trust Company.</font></div><div style="margin-bottom:12pt;padding-left:28.3pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeover Defense</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of Merck&#8217;s certificate of incorporation and by-laws and of the New Jersey Business Corporation Act (the &#8220;NJBCA&#8221;) may have anti-takeover effects and could delay, defer or prevent a tender offer or takeover attempt that a shareholder might consider to be in such shareholder&#8217;s best interests, including attempts that might result in a premium over the market price for the shares held by shareholders, and may make removal of the incumbent management and directors more difficult.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorized Shares&#59; Undesignated Preferred Stock.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Merck&#8217;s certificate of incorporation authorizes the issuance of up to 6,500,000,000&#160;shares of common stock and 20,000,000&#160;shares of preferred stock.  These additional authorized shares may be used by Merck&#8217;s board of directors, to the extent consistent with its fiduciary duty, to deter future attempts to gain control of Merck, and may discourage attempts by others to attempt to acquire control of Merck without negotiation with Merck&#8217;s board of directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s board of directors has the sole authority, subject to the rights of any outstanding series of Merck&#8217;s preferred stock, to fix the numbers, designations, rights, preferences and limitations of any one or more series of preferred stock, including with respect to voting, dividends, conversion, redemption and liquidation preferences.  As a result of the ability to fix voting rights for a series of preferred stock, Merck&#8217;s board of directors has the power, to the extent consistent with its fiduciary duty, to issue a series of preferred stock to persons friendly to management in order to attempt to block a tender offer, merger or other transaction by which a third party seeks control of Merck, and thereby assist members of management to retain their positions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">No Shareholder Action by Written Consent.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Merck&#8217;s certificate of incorporation provides that shareholders may not act by written consent.  Any shareholder action must be taken at a duly called annual or special meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Special Meetings of Shareholders.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In addition to what is provided by the NJBCA, a special meeting may be called at any time by Merck&#8217;s board of directors and, subject to the rights of the holders of any class or series of preferred stock then outstanding, generally may be called at any time upon the written request, in the form prescribed in Merck&#8217;s by-laws, of the holders of record of at least 15% or more of the capital stock entitled to vote in the election of directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notification of Proposed Business and Nominations for Annual Meetings.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Merck&#8217;s by-laws require that written notice of any shareholder proposal for business at an annual meeting of shareholders, or any shareholder director nomination for an annual meeting of shareholders, be received at least 120&#160;days but no more than 150 days prior to the anniversary date of the preceding year&#8217;s annual meeting&#59; provided, however, in the event that the date of the annual meeting is more than 30 days earlier or later than the anniversary date of the most recent annual meeting of shareholders, the shareholders&#8217; notice must be so delivered not later than the close of business on the later of (i) the 120th day prior to such annual meeting of shareholders or (ii) the 10th day following the day on which a public announcement of the annual meeting date is first made.  Also, Merck&#8217;s by-laws allow a shareholder or a group of no more than 20 shareholders, who or which has maintained continuous qualifying ownership of at least 3% of Merck&#8217;s outstanding common stock for at least three years and has complied with the other requirements set forth in the by-laws, to include director nominees constituting up to 20% of the board of directors in Merck&#8217;s proxy materials for an annual meeting of shareholders.  A request to include such a nominee must be received at least 120 days but no more than 150 days prior to the anniversary of the date Merck commenced mailing of its proxy materials in connection with the most recent annual meeting of shareholders.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">No Cumulative Voting.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Merck&#8217;s certificate of incorporation does not permit cumulative voting in the election of directors. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations with Interested Shareholder.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The NJBCA provides that no corporation organized under the laws of New Jersey (a &#8220;resident domestic corporation&#8221;) may engage in any &#8220;business combination&#8221; (as defined in the NJBCA) with any interested shareholder (generally a 10% or greater shareholder) of such corporation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a period of five years following such interested shareholder&#8217;s stock acquisition, unless either (i) such stock acquisition is approved by the board of directors of such corporation prior to the stock acquisition and any subsequent business combinations with the interested shareholder are approved by (A) members of the board of directors independent of the interested shareholder and (B) the holders of a majority of the voting stock not beneficially owned by the interested shareholder or (ii) such business combination is approved by the board of directors of such corporation prior to the stock acquisition.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, no resident domestic corporation may engage, at any time, in any business combination with any interested shareholder of such corporation other than&#58; (i)&#160;a business combination approved by the board of directors prior to the stock acquisition, (ii)&#160;a business combination approved by the affirmative vote of the holders of two-thirds of the voting stock not beneficially owned by such interested shareholder at a meeting called for such purpose, (iii)&#160;a business combination in which the interested shareholder pays a formula price designed to ensure that all other shareholders receive at least the highest price per share paid by such interested shareholder or (iv) a business combination approved (A) by the board of directors independent of the interested shareholder prior to the consummation of the business combination and (B) the holders of a majority of the voting stock not beneficially owned by the interested shareholder at a meeting called for such purpose if the interested shareholder&#8217;s stock acquisition was approved by the board of directors prior to the consummation of such stock acquisition.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board of Directors.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Merck&#8217;s certificate of incorporation provides that, subject to the rights of the holders of shares of any series of preferred stock then outstanding, the number of directors composing Merck&#8217;s board of directors will not exceed eighteen, and that a director can only be removed by shareholder vote if there is cause for the director&#8217;s removal.  A majority of the directors then constituting Merck&#8217;s board of directors are authorized to fill vacancies on the board of directors, whether created by removal for cause, resignation or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>3
<FILENAME>exhibit411-merckdescriptio.htm
<DESCRIPTION>EX-4.11 DESCRIPTION OF 2021 NOTES, 2026 NOTES, AND 2034 NOTES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5dea5f5c6adc4e599fce897771ea4b04_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.11</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Registrant&#8217;s 1.125% Notes due 2021, 1.875% Notes due 2026 and 2.500% Notes due 2034</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registered under Section 12 of the Securities Exchange Act of 1934</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this description, unless the context requires otherwise&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;2021 notes&#8221; means the 1.125% Notes due 2021 of Merck &#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;2026 notes&#8221; means the 1.875% Notes due 2026 of Merck &#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;2034 notes&#8221; means the 2.500% Notes due 2034 of Merck &#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;holder&#8221; means a direct holder and not a street name or other indirect holder of notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"> &#8220;notes&#8221; means the 2021 notes, 2026 notes and 2034 notes, collectively&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Merck &#38; Co., Inc., but not to any of Merck &#38; Co., Inc.&#8217;s subsidiaries.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth a description of the material terms of the notes.  The description is qualified in its entirety by reference to the indenture, dated as of January 6, 2010, between us and U.S. Bank Trust National Association, as trustee (a copy of which is included as Exhibit 4.1 to our Current Report on Form 8-K filed on December 10, 2010) and, as applicable, the officers&#8217; certificate pursuant to such indenture with respect to the 2021 notes, dated October 15, 2014, including the form of the 2021 notes (a copy of which is included as Exhibit 4.1 to our Current Report on Form 8-K filed on October 15, 2014), the officers&#8217; certificate pursuant to such indenture with respect to the 2026 notes, dated October 15, 2014, including the form of the 2026 notes (a copy of which is included as Exhibit 4.2 to our Current Report on Form 8-K filed on October 15, 2014) or the officers&#8217; certificate pursuant to such indenture with respect to the 2034 notes, dated October 15, 2014, including the form of the 2034 notes (a copy of which is included as Exhibit 4.3 to our Current Report on Form 8-K filed on October 15, 2014).  You are encouraged to read such indenture and officers&#8217; certificates for additional information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 notes, the 2026 notes and the 2034 notes are each a separate series of notes under the indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 notes are initially limited to &#8364;1,000,000,000 aggregate principal amount, which amount remains outstanding as of February 24, 2021, and will mature on October 15, 2021. The 2026 notes are initially limited to &#8364;1,000,000,000 aggregate principal amount, which amount remains outstanding as of February 24, 2021, and will mature on October 15, 2026. The 2034 notes are initially limited to &#8364;500,000,000 aggregate principal amount, which amount remains outstanding as of February 24, 2021, and will mature on October 15, 2034. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are unsecured and rank equally with all our other unsecured and unsubordinated indebtedness from time to time outstanding. The notes are not guaranteed by any of our subsidiaries and are therefore structurally subordinated to all liabilities of our subsidiaries from time to time outstanding, including any guarantees provided by our subsidiaries. The notes also are effectively subordinated to any secured debt we or our subsidiaries incur to the extent of the value of any assets securing such debt.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes were issued in denominations of &#8364;100,000 and integral multiples of &#8364;1,000 in excess thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue as many distinct series of debt securities under the indenture as we wish.  A series of debt securities may be guaranteed by one or more of our subsidiaries.  There is no limit on the amount of debt securities we may issue under the indenture and the provisions of the indenture allow us to issue debt securities with terms different from those previously issued under the indenture.  Also, as discussed below under &#8220;&#8212;Further Issues,&#8221; we may &#8220;reopen&#8221; a previous issue of a series of debt securities and issue additional debt securities of that series.  We also may issue other debt under other indentures or documentation, containing provisions different from those included in the indenture or applicable to the notes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are listed on the New York Stock Exchange. We have no obligation to maintain such listing and we may delist the notes at any time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 notes bear interest at a rate of 1.125% per annum, the 2026 notes bear interest at a rate of 1.875% per annum, and the 2034 notes bear interest at a rate of 2.500% per annum. Interest on the notes is payable annually on October 15 of each year to the person in whose name such notes were registered at the close of business on the&#160;fifteenth calendar day before the next interest payment date. If any payment date for the notes is not a business day, payment is made on the next business day, but we are not liable for any additional interest as a result of the delay in payment. With respect to the notes, by business day, we mean any Monday, Tuesday, Wednesday, Thursday or Friday which is not a day when banking institutions are authorized or obligated by law or executive order to be closed in The City of New York or London and, for any place of payment outside of The City of New York or London, in such place of payment, and on which the Trans-European Automated Real-time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, operates.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to each series of notes, we compute the amount of interest payable on the basis of (i)&#160;the actual number of days in the period for which interest is being calculated and (ii)&#160;the actual number of days from (and including) the last date on which interest was paid on the notes of such series (or October 15, 2014, if no interest has been paid on the notes of such series) to (but excluding) the next scheduled interest payment date. This payment convention is referred to as ACTUAL&#47;ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elavon Financial Services DAC, UK Branch initially acts as principal paying agent and transfer agent for the notes (the &#8220;paying agent&#8221;). Elavon Financial Services DAC initially acts as security registrar (the &#8220;security registrar&#8221;) and U.S. Bank Trust National Association initially acts as trustee (&#8220;trustee&#8221;) for the notes. We have entered into an issuing and paying agency agreement in relation to the notes between us, U.S. Bank Trust National Association, as trustee, Elavon Financial Services Limited, UK Branch, as principal paying agent and transfer agent and Elavon Financial Services Limited as security registrar. Payment of principal of and interest on the notes is made through the office of the principal paying agent in London. The terms &#8220;principal paying agent&#8221; and &#8220;paying agent&#8221; shall include any successors appointed from time to time in accordance with the provisions of the issuing and paying agency agreement, and any reference to an &#8220;agent&#8221; or &#8220;agents&#8221; shall mean any or all (as applicable) of such persons.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payments in Euros</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments of interest and principal, including payments made upon any redemption of the notes, are payable in euros. If, at any time, the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if the euro is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. In such circumstances, the amount payable on any date in euros will be converted into U.S. dollars on the basis of the most recently available market exchange rate for euros. Any payment in respect of the notes so made in U.S. dollars will not constitute an event of default under the notes or the indenture governing the notes. Neither the trustee nor the paying agent shall have any responsibility for any calculation or conversion in connection with the foregoing.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors are subject to foreign exchange risks as to payments of principal and interest that may have important economic and tax consequences to them. </font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Optional Redemption</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of notes is redeemable in whole or in part, at our option at any time or from time to time, at a redemption price equal to the greater of (i)&#160;100% of the principal amount of the notes to be redeemed or (ii)&#160;the sum of the present values of the Remaining Scheduled Payments (as defined below) (not including any portion of such payment of interest accrued as of the date of redemption) discounted to the redemption date on an annual basis </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ACTUAL&#47;ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 15 basis points with respect to the 2021 notes, the Comparable Government Bond Rate plus 15 basis points with respect to the 2026 notes and the Comparable Government Bond Rate plus 15 basis points with respect to the 2034 notes, plus, in each case, accrued and unpaid interest on the principal amount being redeemed to, but excluding, the redemption date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after July 15,&#160;2021 for the 2021 notes, July 15, 2026&#160;for the 2026 notes and July 15, 2034&#160;for the 2034 notes (three months prior to the maturity date of the 2021 notes, the 2026 notes or the 2034 notes, as applicable), we may redeem in whole or in part the 2021 notes, the 2026 notes or the 2034 notes, as applicable, at any time or from time to time, at our option, at a redemption price equal to 100% of the principal amount of the applicable notes being redeemed, plus accrued and unpaid interest on the principal amount being redeemed to, but excluding, the redemption date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to give notice of redemption at least 30&#160;days, but no more than 60&#160;days, prior to the redemption date. The notice will be mailed to the registered address of each holder of that series of notes. The principal amount of a note remaining outstanding after a redemption in part shall be &#8364;100,000 or an integral multiple of &#8364;1,000 in excess thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Government Bond Rate&#8221; means, with respect to any redemption date, the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the notes to be redeemed, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond (as defined below) on the basis of the middle market price of the Comparable Government Bond prevailing at 11&#58;00 a.m. (London time) on such business day as determined by an independent investment bank selected by us.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Government Bond&#8221; means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an independent investment bank selected by us, a German federal government bond whose maturity is closest to the maturity of the notes to be redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such independent investment bank may, with the advice of three brokers of, and&#47;or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;Remaining Scheduled Payments&#8221; means, with respect to each note to be redeemed, the remaining scheduled payments of principal of and interest on the note that would be due after the related redemption date but for the redemption. If that redemption date is not an interest payment date with respect to a note, the amount of the next succeeding scheduled interest payment on the note will be reduced by the amount of interest accrued on the note to the redemption date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If fewer than all of the notes of any series are to be redeemed, the trustee will select the particular notes or portions thereof for redemption from the outstanding notes not previously called, pro rata or by lot, or in such other manner as we direct each in accordance with the depositary&#8217;s procedures.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the notes or portions thereof called for redemption.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are also subject to redemption if certain events occur involving United States taxation. See &#8220;&#8212;Taxation Redemption.&#8221;</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Amounts</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments of principal and interest in respect of the notes are made free and clear of, and without deduction or withholding for or on account of any present or future taxes, duties, assessments or other governmental </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charges of whatsoever nature imposed, levied, collected, withheld or assessed by the United States or any political subdivision or taxing authority of or in the United States (collectively, &#8220;Taxes&#8221;), unless such withholding or deduction is required by law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event such withholding or deduction of Taxes is required by law, subject to the limitations described below, we will pay to the holder of any note that is not a U.S. Holder (as defined below) such additional amounts (&#8220;Additional Amounts&#8221;) as may be necessary in order that every net payment received by such holder of principal of or interest or any other amount payable on the notes (including upon redemption), after deduction or withholding for or on account of such Taxes, will not be less than the amount provided for in such note to be then due and payable before deduction or withholding for or on account of such Taxes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, our obligation to pay Additional Amounts shall not apply to&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;any Taxes which would not have been so imposed but for&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;the existence of any present or former connection between such holder or beneficial owner (or between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity) and the United States, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member, shareholder or other equity owner or person having such a power) being or having been a citizen or resident or treated as a resident of the United States or being or having been engaged in a trade or business in the United States or being or having been present in the United States or having or having had a permanent establishment in the United States&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;the failure of such holder or beneficial owner to comply with any certification, information or other reporting requirement, if compliance is required under United States tax laws and regulations to establish entitlement to a partial or complete exemption from such Taxes (including, but not limited to, the requirement to provide Internal Revenue Service Form&#160;W-8BEN, Form W-8BEN-E, Form&#160;W-8ECI, or any subsequent versions thereof or successor thereto)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;such holder&#8217;s or beneficial owner&#8217;s present or former status as a personal holding company or a foreign personal holding company with respect to the United States, as a controlled foreign corporation with respect to the United States, as a passive foreign investment company with respect to the United States, as a foreign tax exempt organization with respect to the United States or as a corporation which accumulates earnings to avoid United States federal income tax&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;any Taxes imposed by reason of the holder or beneficial owner&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;owning or having owned, directly or indirectly, actually or constructively, 10% or more of the total combined voting power of all classes of our stock, as described in section 871(h)(3) of the Internal Revenue Code of 1986, as amended (the &#8220;Internal Revenue Code&#8221;),</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;being a bank receiving interest described in section&#160;881(c)(3)(A) of the Internal Revenue Code,&#160;or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;being a controlled foreign corporation with respect to the United States that is related to us by stock ownership&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;any Taxes which would not have been so imposed but for the presentation by the holder or beneficial owner of such note for payment on a date more than 30&#160;days after the date on which such payment became due and payable or the date on which payment of the note is duly provided for and notice is given to holders, whichever </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occurs later, except to the extent that the holder or beneficial owner would have been entitled to such Additional Amounts on presenting such note on any date during such 30-day period&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;any estate, inheritance, gift, sales, excise, transfer, personal property, wealth or similar Taxes&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;any Taxes which are payable otherwise than by withholding from a payment on such note&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;any Taxes which are payable by a holder that is not the beneficial owner of the note, or a portion of the note, or that is a fiduciary, partnership, limited liability company or other similar entity, but only to the extent that a beneficial owner, a beneficiary or settlor with respect to such fiduciary or member of such partnership, limited liability company or similar entity would not have been entitled to the payment of an additional amount had such beneficial owner, settlor, beneficiary or member received directly its beneficial or distributive share of the payment&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)&#160;any Taxes required to be withheld by any paying agent from any payment on any note, if such payment can be made without such withholding by at least one other paying agent&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)&#160;any Taxes required to be withheld or deducted where such withholding or deduction is imposed pursuant to European Council Directive 2003&#47;48&#47;EC on the taxation of savings income, or any law implementing or complying with, or introduced in order to conform to, such European Council Directive&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;any Taxes imposed under Sections 1471 through 1474 of the Internal Revenue Code (or any amended or successor provisions), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section&#160;1471(b) of the Code or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement entered into in connection with the implementation of such sections of the Code&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j) any combination of items (a), (b), (c), (d), (e), (f), (g), (h)&#160;and (i).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this section, the acquisition, ownership, enforcement, or holding of or the receipt of any payment with respect to a note will not constitute a connection&#160;(1)&#160;between the holder or beneficial owner and the United States or (2)&#160;between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity and the United States.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in this description, in the indenture or in the notes to principal or interest or other payment on the notes shall be deemed to refer also to Additional Amounts which may be payable under the provisions of this section.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all stamp and other duties, if any, which may be imposed by the United States or any political subdivision thereof or taxing authority therein with respect to the issuance of the notes pursuant to this offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as specifically provided under the heading &#8220;&#8212;Additional Amounts,&#8221; we will not be required to make any payment with respect to any tax, duty, assessment or other governmental charge imposed by any government or any political subdivision or taxing authority of or in the United States.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we undertake that, to the extent permitted by law, we will maintain a paying agent in a Member State of the European Union (if any) that will not require withholding or deduction of tax pursuant to European Council Directive 2003&#47;48&#47;EC on the taxation of savings income or any law implementing or complying with, or introduced in order to conform to, such European Council Directive.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;U.S. Holder&#8221; is a beneficial owner of a note or notes that is for U.S. federal income tax purposes&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an individual who is citizen or resident of the United States&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a corporation (or other entity classified as a corporation for these purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an estate, the income of which is subject to U.S. federal income taxation regardless of the source of that income&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trust, if (1) a U.S. court is able to exercise primary supervision over the trust&#8217;s administration and one or more &#8220;United States persons&#8221; (within the meaning of the Internal Revenue Code) has the authority to control all of the trust&#8217;s substantial decisions, or (2) the trust has a valid election in effect under applicable Treasury regulations to be treated as a &#8220;United States person.&#8221;</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxation Redemption</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes may be redeemed at our option, in whole but not in part, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, together with interest accrued and unpaid to the date fixed for redemption, at any time, on giving not less than 30 nor more than 60&#160;days&#8217; notice in accordance with &#8220;Notices&#8221; below if&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) we have or will become obligated to pay Additional Amounts as a result of (i)&#160;any change in or amendment to the laws, regulations or rulings of the United States or any political subdivision or any taxing authority of or in the United States affecting taxation, or (ii)&#160;any change in or amendment to an official application, interpretation, administration or enforcement of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after October 6, 2014&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;we reasonably determine that such obligation cannot be avoided by our taking reasonable measures available to us without significant difficulty, cost or expense, or</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) any action shall have been taken by a taxing authority, or any action has been brought in a court of competent jurisdiction, in the United States or any political subdivision or taxing authority of or in the United States, including any of those actions specified in (a)&#160;above, whether or not such action was taken or brought with respect to us, or any change, clarification, amendment, application or interpretation of such laws, regulations or rulings shall be officially proposed, in any such case on or after October 6, 2014, which results in a substantial likelihood that we will be required to pay Additional Amounts on the next interest payment date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, no such notice of redemption shall be given earlier than 90&#160;days prior to the earliest date on which we would be, in the case of a redemption for the reasons specified in (a)&#160;above, or there would be a substantial likelihood that we would be, in the case of a redemption for the reasons specified in (b)&#160;above, obligated to pay such Additional Amounts if a payment in respect of the notes were then due and, at the time such notification of redemption is given, such circumstance remains in effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the publication of any notice of redemption pursuant to this section, in the case of a redemption for the reasons specified in (a)&#160;or (b)&#160;above, we will deliver to the trustee&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;a certificate signed by one of our duly authorized officers stating that we are entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to our right so to redeem have occurred,&#160;and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;a written opinion of independent legal counsel of recognized standing to the effect that we have or will become obligated to pay such Additional Amounts as a result of such change or amendment or that there is a substantial likelihood that we will be required to pay such Additional Amounts as a result of such action or proposed change, clarification, amendment, application or interpretation, as the case may be.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such notice, once delivered by us to the trustee, will be irrevocable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modification and Waiver</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three types of changes we can make to the indenture and the notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes Requiring Holder Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  First, there are changes that cannot be made to the notes of any series without specific approval by each holder of the notes of such series affected thereby.  Following is a list of those types of changes&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the payment due date of any installment of the principal or any premium or interest on a note stated in the note&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce any amounts due on a note&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the place or currency of payment on a note&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impair holders&#8217; right to sue for payment&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the percentage of notes of any series, the holders of which must consent to modify or amend the indenture&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the percentage of notes of any series the holders of which must consent to waive compliance with certain provisions of the indenture or to waive certain defaults&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modify any other aspect of the provisions dealing with modification and waiver of the indenture except to increase any such percentage or to provide that certain other provisions of the indenture cannot be modified or waived without the consent of the holder of each outstanding security affected thereby.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes Requiring a Majority Vote</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The second type of change to the indenture and the notes is the kind that requires a vote in favor by holders owning not less than a majority of the principal amount of the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">notes of the particular series affected</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Most changes fall into this category, such as if we wish to obtain a waiver of all or part of the restrictive covenants described below, or a waiver of a past default.  However, we cannot obtain a waiver of a payment default or any other aspect of the indenture or the notes listed in the first category above under &#8220;&#8212;Changes Requiring Holder Approval&#8221; unless we obtain the individual consent of each holder of the notes of such series affected thereby to the waiver.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes Not Requiring Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The third type of change does not require any vote by holders of notes.  This type is limited to the addition or release of a guarantee, corrections and clarifications and other changes that would not adversely affect holders of the notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Further Details Concerning Voting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  When taking a vote, we use the U.S. dollar equivalent to decide how much principal amount to attribute to a note.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes will not be considered outstanding and therefore will not carry voting rights if we have deposited or set aside in trust for the holders thereof money for their payment or redemption.  Notes will also not be eligible to vote if they have been fully defeased as described under &#8220;&#8212;Defeasance&#8212;Full Defeasance.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may set any day as a record date for the purpose of determining the holders of outstanding notes that are entitled to vote or take other action under the indenture.  In some circumstances, the trustee may set a record date for action by holders.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Street name and other indirect holders should consult their banks or brokers for information on how approval may be granted or denied if we seek to change the indenture or the notes or request a waiver.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mergers and Similar Events</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may consolidate or merge with another company or firm.  We may also convey, transfer or lease all of our properties and assets substantially as an entirety to another firm, or buy or lease substantially all of the assets of another firm.  However, we may not take any of these actions unless the following conditions, among others, are met&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are the surviving entity or, when we merge out of existence or convey, transfer or lease all of our properties and assets substantially as an entirety, the other firm must be a corporation, limited liability company, partnership or trust organized under the laws of a U.S. state or the District of Columbia or under federal law and it must agree to be legally responsible for the notes.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The merger, sale of assets or other transaction must not cause a default on the notes, and we must not already be in default unless the merger or other transaction would cure the default.  For purposes of this no-default test, a default would include an event of default, as described under &#8220;&#8212;Default and Remedies&#8212;Events of Default&#8212;What is an Event of Default,&#8221; that has occurred and not been cured.  A default for this purpose would also include the occurrence of any event that would be an event of default if we received the required notice of our default or if under the indenture the default would become an event of default after existing for a specific period of time.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is possible that the merger, sale of assets or other transaction would cause some of our property to become subject to a mortgage or other legal mechanism giving lenders preferential rights in that property over other lenders or over our general creditors if we fail to pay them back.  We have promised to limit these preferential rights, as discussed under &#8220;&#8212;Restrictive Covenants.&#8221;  If a merger or other transaction would create any liens on any of our property, we must comply with those restrictive covenants.  We would do this either by deciding that the liens were permitted, or by following the requirements of the restrictive covenants to grant an equivalent or higher-ranking lien to the holders of the notes on the same property that we own.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the conditions described above are satisfied with respect to any series of notes, we do not need to obtain the approval of the holders of those notes in order to merge or consolidate or to sell our assets.  Also, these conditions apply only if we wish to merge or consolidate with another entity or convey, transfer or lease all of our properties and assets substantially as an entirety.  We do not need to satisfy these conditions if we enter into other types of transactions, including any transaction in which we acquire the stock or assets of another entity, any transaction that involves a change of control but in which we do not merge or consolidate and any transaction in which we convey, transfer or lease less than all of our properties and assets substantially as an entirety.  It is possible that these other types of transactions may result in a reduction in our credit rating, may reduce our operating results or may impair our financial condition.  However, the holders of notes have no approval right with respect to any transaction of this type.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restrictive Covenants</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Secured Debt</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Some of our property may be subject to a mortgage or other legal mechanism that gives our lenders preferential rights in that property over other lenders, including the holders of the notes, or over our general creditors if we fail to pay them back.  These preferential rights are called liens.  Debt which is protected by these preferential rights is called secured debt.  In the indenture, we promise that neither we nor our domestic subsidiaries (as defined below) will incur any new secured debt that is secured by a lien on any of our or our domestic subsidiaries&#8217; principal domestic manufacturing properties (as defined below), or on any shares of stock of any of our domestic subsidiaries that own or lease a principal domestic manufacturing property, unless we grant an equivalent or higher-ranking lien on the same property to the holders of the notes and other outstanding debt securities issued under the indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not need to comply with this restriction if the amount of all debt that would be secured by liens on principal domestic manufacturing properties, including the new debt, the notes and other outstanding debt securities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued under the indenture which we would so secure as described in the previous sentence, and all attributable debt (as defined below) that results from a sale and leaseback transaction involving principal domestic manufacturing properties, is less than 10% of our consolidated net tangible assets (as defined below).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This restriction on secured debt does not apply to debt secured by certain types of liens, and we can disregard this secured debt when we calculate the limits imposed by this restriction.  These types of liens are&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens on the property of any of our domestic subsidiaries, or on their shares of stock, if those liens existed at the time the corporation became our domestic subsidiary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">with respect to any series of notes, any lien existing on the date of issuance of such notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens in favor of us or our domestic subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens in favor of U.S. governmental bodies that we granted in order to assure our payments to such bodies that we owe by law or because of a contract we entered into&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens in favor of any customer arising in respect of payments made by or on behalf of a customer for goods produced for, or services rendered to, customers in the ordinary course of business not exceeding the amount of those payments&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">statutory liens, liens for taxes or assessments or governmental charges or levies not yet due or delinquent or which can be paid without penalty or are being contested in good faith, landlord&#8217;s liens on leased property, easements and other liens of a similar nature&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens on property or shares of stock that existed at the time we acquired them, including property we may acquire through a merger or similar transaction, or that we granted in order to purchase the property, which are sometimes called purchase money mortgages&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">debt secured by liens that extend, renew or replace any of these types of liens.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries may have as much unsecured debt as we may choose.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Sales and Leasebacks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We promise that neither we nor any of our domestic subsidiaries will enter into any sale and leaseback transaction involving a principal domestic manufacturing property, unless we comply with this restrictive covenant.  A sale and leaseback transaction generally is an arrangement between us or a domestic subsidiary and a bank, insurance company or other lender or investor where we or the domestic subsidiary sell a property to a lender or investor more than 120 days after the acquisition of the property or the completion of construction of the property and the beginning of its full operation and we lease the property back from the lender.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can comply with this restrictive covenant in either of two ways&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First, we will be in compliance if we or our domestic subsidiary could grant a lien on the principal domestic manufacturing property in an amount equal to the attributable debt for the sale and leaseback transaction without being required to grant an equivalent or higher-ranking lien to the holders of the notes and other outstanding debt securities issued under the indenture under the restriction on secured debt described above.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Second, we can comply if we retire an amount of our or any domestic subsidiary&#8217;s funded debt which is not subordinated in right of payment to any outstanding notes or other outstanding debt securities issued under the indenture, within 120 days of the transaction, equal to the greater of the net proceeds of the sale of the principal domestic manufacturing property that we lease in the transaction or the fair market value of that property, subject to credits for voluntary retirements of notes and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding debt securities issued under the indenture and funded debt we or the domestic subsidiary may make.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This restriction on sales and leasebacks does not apply to any sale and leaseback transaction that is between us and one of our domestic subsidiaries or between domestic subsidiaries, or that involves a lease for a period of three years or less.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definitions Relating to our Restrictive Covenants</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Following are summaries of the meanings of the terms that are important in understanding the restrictive covenants previously described&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Attributable debt&#8221; means the total net amount of rent, discounted at 1% per annum over the weighted average yield to maturity of the outstanding notes and other outstanding debt securities issued under the indenture compounded semi-annually, that is required to be paid during the remaining term of any lease.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Consolidated net tangible assets&#8221; is the total amount of assets, less reserves and certain other permitted deductible items, after subtracting all current liabilities and all goodwill, trade names, trademarks, patents, unamortized debt discounts and expenses and similar intangible assets, as such amounts appear on our most recent consolidated balance sheet and computed in accordance with generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;domestic subsidiary&#8221; means any of our subsidiaries which transacts substantially all of its business in the United States, has substantially all of its fixed assets located in the United States, or owns or leases principal domestic manufacturing property.  However, a subsidiary whose principal business is financing our operations outside of the United States is not a domestic subsidiary.  A subsidiary is a corporation in which we and&#47;or one or more of our other subsidiaries owns at least 50% of the voting stock (generally defined as stock that ordinarily permits its owners to vote for the election of directors).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Funded debt&#8221; means all debt for borrowed money that either has a maturity of 12 months or more from the date on which the calculation of funded debt is made or has a maturity of less than 12 months from that date but is by its terms renewable or extendible beyond 12 months from that date at the option of the borrower.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;principal domestic manufacturing property&#8221; is any building or other structure or facility, and the land on which it sits and its associated fixtures, that we use primarily for manufacturing, processing or warehousing, that is located in the United States and that has a gross book value in excess of 1% of our consolidated net tangible assets, other than a building, structure or other facility that our board of directors has determined is not of material importance to the total business that we and our subsidiaries conduct or a building or structure which is financed by obligations issued by a state, a territory, or a possession of the United States, or any political subdivision of any of the foregoing, or the District of Columbia, the interest of which is excludable from gross income of the holders under provisions of the tax code.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Further Issues</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, without the consent of holders of any series of the notes, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the notes of that series. Any additional notes of any series, together with the outstanding notes of the applicable series, will constitute a single series of notes under the indenture. No additional notes may be issued if an event of default has occurred and is continuing with respect to the applicable series of notes. Additional notes cannot be issued under the same CUSIP, ISIN or Common Code number unless the additional notes and original notes are fungible for U.S. federal income tax purposes.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defeasance</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Full Defeasance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If there is a change in federal tax law, as described below, we can legally release ourselves from any payment or other obligations on the notes of a series if we put in place other arrangements for the holders of such notes to be repaid.  This is called full defeasance.  In order to achieve full defeasance, we must do the following, among other things&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must deposit in trust for the benefit of all holders of the notes of the series any combination of money (in euros) and Federal Republic of Germany obligations (as defined below) that will generate enough cash to make interest, principal and any other payments on the notes of that series on their various due dates.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There must be a change in current federal tax law or an IRS ruling that lets us make the above deposit without causing holders or beneficial owners of the notes of the series to be taxed on such notes any differently than if we did not make the deposit and just repaid such notes ourselves.  (Under current federal tax law, the deposit and our legal release from such notes would be treated as though we took back beneficial owners&#8217; notes and gave them their share of the cash and notes or bonds deposited in trust.  In that event, beneficial owners could recognize gain or loss on the notes they give back to us.)  </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must deliver to the trustee a legal opinion of our counsel confirming the tax law change described above.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we ever did accomplish full defeasance, as described above, holders of defeased notes would have to rely solely on the trust deposit for repayment on such notes.  Holders of such notes could not look to us for repayment in the unlikely event of any shortfall.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Defeasance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Under current federal tax law, we can make the same type of deposit described above and be released from some of the restrictive covenants in the notes.  This is called covenant defeasance.  In that event, holders of notes would lose the protection of those restrictive covenants but would gain the protection of having money and securities set aside in trust to repay the notes.  In order to achieve covenant defeasance of the notes of a series, we must do the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must deposit in trust for the benefit of all holders of the notes of the series any combination of money (in euros) and Federal Republic of Germany obligations that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must deliver to the trustee a legal opinion of our counsel confirming that under current federal income tax law we may make the above deposit without causing holders or beneficial owners of the notes to be taxed on the notes any differently than if we did not make the deposit and just repaid the notes ourselves.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish covenant defeasance, the following provisions of the indenture and the notes would no longer apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our promises regarding conduct of our business previously described under &#8220;&#8212;Restrictive Covenants.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions regarding mergers or similar transactions, as described under &#8220;&#8212;Mergers and Similar Events.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The events of default relating to mergers or similar transactions and either of the restrictive covenants described under &#8220;&#8212;Restrictive Covenants.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish covenant defeasance, holders of notes can still look to us for repayment of the notes if there were a shortfall in the trust deposit.  In fact, if one of the remaining events of default occurred, such as our bankruptcy, and the notes become immediately due and payable, there may be such a shortfall in the trust deposit.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Federal Republic of Germany obligations&#8221; means (1)&#160;securities that are direct obligations of the Federal Republic of Germany for the payment of which its full faith and credit is pledged or (2)&#160;obligations of a person controlled or supervised by and acting as an agency or instrumentality of the Federal Republic of Germany, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the Federal Republic of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany, which, in either case under clauses (1)&#160;or (2)&#160;are not callable or redeemable at the option of the issuer thereof.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Holders of notes have special rights if an event of default occurs and is not cured, as described later in this subsection.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term event of default with respect to each series of notes means any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not pay the principal or any premium on such series of notes on its due date.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not pay interest on such series of notes within 30 days of its due date.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We remain in breach of either of the restrictive covenants described under &#8220;&#8212;Restrictive Covenants&#8221; or any other covenant or warranty in the indenture for 90 days after we receive a notice of default stating we are in breach.  The notice must be sent by either the trustee or holders of at least 25% of the principal amount of notes of the affected series.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We file for bankruptcy or other specific events of bankruptcy, insolvency or reorganization occur.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not pay Additional Amounts on such series of notes within 30 days after such payment is due.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any payment in respect of the notes made in U.S. dollars due to the unavailability or nonuse of the euro as discussed under &#8220;&#8212;Payments in Euros&#8221; will not constitute an event of default under the notes or the indenture governing the notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default has occurred and has not been cured, the trustee or the holders of at least 25% in principal amount of the outstanding notes of the affected series may declare the entire principal amount of all the notes of that series to be due and immediately payable.  This is called a declaration of acceleration.  The holders of at least a majority in principal amount of the notes of the affected series may cancel a declaration of acceleration of maturity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the indenture at the request of any holders unless such holders offer the trustee reasonable protection, called an indemnity, against expenses and liability.  If reasonable indemnity is provided, the holders of a majority in principal amount of the outstanding notes of the relevant series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee.  These majority holders may also direct the trustee in performing any other action under the indenture with respect to the notes of the applicable series.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a holder of notes of any series bypasses the trustee and brings its own lawsuit or other formal legal action or takes other steps to enforce its rights or protect its interests relating to the notes of such series, the following must occur&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The holder must give the trustee written notice that an event of default has occurred and remains uncured.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The holders of at least 25% in principal amount of all outstanding notes of the relevant series must make a written request that the trustee take action because of the default, and must offer indemnity reasonably satisfactory to the trustee against the cost and other liabilities of taking that action.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trustee must have not received from holders of a majority in principal amount of the outstanding notes of that series a direction inconsistent with the written notice.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trustee must have not taken action for 60 days after receipt of the above notice and offer of indemnity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, a holder of notes is entitled at any time to bring a lawsuit for the payment of money due on its notes on or after their due date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Street name and other indirect holders should consult their banks or brokers for information on how to give notice or direction to or make a request of the trustee and to make or cancel a declaration of acceleration.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We furnish to the trustee every year a written statement of our principal executive, financial or accounting officer certifying that to the best of such signer&#8217;s knowledge we are in compliance with the indenture and the notes, or else specifying any default.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form, Exchange and Registration of Transfer</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued the notes only in fully registered form and without interest coupons.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of notes may have its notes broken into more notes of smaller denominations of not less than &#8364;100,000 or combined into fewer notes of larger denominations, as long as the total principal amount is not changed.  This is called an exchange.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of notes may exchange or register a transfer of notes at the office of the trustee.  The trustee acts as our agent for registering notes in the names of holders and registering transfers of notes.  We may change this appointment to another entity or perform it ourselves.  The entity performing the role of maintaining the list of registered holders is called the security registrar.  It also registers transfers.  A holder of notes may also replace lost, stolen or mutilated notes at that office.  The trustee&#8217;s agent may require an indemnity before replacing any notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of notes is not required to pay a service charge to register a transfer of notes or to exchange notes, but may be required to pay for any tax or other governmental charge associated with the transfer or exchange.  The security registrar makes the registration of transfer or exchange only if it is satisfied with such holder&#8217;s proof of ownership.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may cancel the designation of any trustee.  We may also approve a change in the office through which any trustee acts.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we redeem less than all of the notes of a particular series, we may block the issuance of, registration of transfer or exchange of notes during the period beginning 15 days before the day we mail the notice of redemption and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing.  We may also refuse to register transfers or exchanges of notes selected for redemption, except that we will continue to permit transfers and exchanges of the unredeemed portion of any note being partially redeemed.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules for exchange described above apply to exchange of notes for other notes of the same series and tenor.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment and Paying Agents</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay interest to a holder of notes on each date interest is due if the holder is a direct holder listed in the trustee&#8217;s records at the close of business on the&#160;fifteenth calendar day before the next interest payment date, even if such holder no longer owns the note on the interest due date.  That particular day is called the regular record date.  Holders buying and selling notes must work out between them how to compensate for the fact that we pay all the interest for an interest period to the one who is the registered holder on the regular record date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay interest, principal and any other money due on the notes at the office of the trustee in London, UK.  That office is currently located at125 Old Broad Street, Fifth Floor, London EC2N 1AR United Kingdom.  A holder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of notes must make arrangements to have its payments picked up at or wired from that office.  We may also choose to pay interest by mailing checks.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Street name and other indirect holders should consult their banks or brokers for information on how they may receive payments.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also arrange for additional payment offices, and may cancel or change these offices.  These offices are called paying agents.  We may also choose to act as our own paying agent.  We must notify holders of notes of changes in the paying agents for any particular notes of the series.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notices</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the trustee send notices regarding the notes only to direct holders, using their addresses as listed in the trustee&#8217;s records.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All paying agents must return to us upon our request all money paid by us that remains unclaimed two years after the amount is due to direct holders.  After that&#160;two-year&#160;period, holders of notes may look only to us for payment and not to the trustee, any other paying agent or anyone else.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Book-Entry System</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance, the notes of each series are represented by one or more global notes. Each global note is deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary for the accounts of Clearstream and Euroclear.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors may elect to hold interests in the global notes held by the depository through Clearstream Banking,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Clearstream&#8221;) or Euroclear Bank&#160;S.A.&#47;N.V., as operator of the Euroclear System (&#8220;Euroclear&#8221;) if they are participants of such systems, or indirectly through organizations that are participants in such systems. Clearstream and Euroclear hold interests on behalf of their participants through customers&#8217; securities accounts in Clearstream&#8217;s and Euroclear&#8217;s names on the books of their respective depositories. Book-entry interests in the notes and all transfers relating to the notes are reflected in the book-entry records of Clearstream and Euroclear. Because holders acquire, hold and transfer security entitlements with respect to the notes through Clearstream, Euroclear and their participants, a beneficial holder&#8217;s rights with respect to the notes is subject to the laws (including Article&#160;8 of the Uniform Commercial Code) and contractual provisions governing a holder&#8217;s relationship with its securities intermediary and the relationship between its securities intermediary and each other securities intermediary and between it and us, as the issuer. Except as set forth below, the global notes may be transferred, in whole and not in part, only to another nominee of the depository or to a successor of the depository or its nominee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No global note may be exchanged in whole or in part for notes registered, and no transfer of a global note in whole or in part may be registered, in the name of any person other than the depository or any nominee of the depository unless (i)&#160;the depository has notified us that it is unwilling or unable to continue as depository for such global note or has ceased to be qualified to act as such as required by the indenture, (ii)&#160;there has occurred and is continuing an event of default with respect to the notes or (iii)&#160;we determine in our sole discretion at any time that the global note shall be so exchangeable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any global note that is exchangeable pursuant to the preceding sentence shall be exchangeable in whole for separate notes in registered form of any authorized denomination and of like tenor and aggregate principal amount. These notes shall be registered in the name or names of such person or persons as the depository instructs the trustee. We expect that these instructions would be based upon directions received by the depository from its participants with respect to ownership of beneficial interests in such global note.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in the limited circumstances referred to above, owners of beneficial interests in a global note are not entitled to have such global note registered in their names, will not receive and are not entitled to receive physical </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivery of notes in exchange therefor and are not considered to be the owners or holders of such global note for any purpose under the notes or the indenture. Accordingly, each person owning a beneficial interest in the global note must rely on the procedures of the participant through which such person owns its interest to exercise any rights of a holder under the indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture provides that the depository, as a holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver, or other action which a holder is entitled to give or take under the indenture.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture and the notes are governed by, and construed and enforced in accordance with, the laws of the State of New York applicable to agreements made or instruments entered into and performed in New York State.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relationship with Trustee</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Bank Trust National Association is the trustee under the indenture.  U.S. Bank Trust National Association performs services for us in the ordinary course of business and serves as the trustee with respect to certain of our other outstanding debt securities.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Open Market Purchases</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at any time and from time to time purchase notes in the open market or otherwise.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Paying Agent, Transfer Agent and Security Registrar</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elavon Financial Services DAC is the security registrar with respect to the notes. Elavon Financial Services DAC, UK Branch is the paying agent and transfer agent with respect to the notes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>4
<FILENAME>exhibit412-merckdescriptio.htm
<DESCRIPTION>EX-4.12 DESCRIPTION OF 2024 NOTES AND 2036 NOTES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3a652f9d116546b3bba4e46aa1512f8b_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.12</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Registrant&#8217;s 0.500% Notes due 2024 and 1.375% Notes due 2036</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registered under Section 12 of the Securities Exchange Act of 1934</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this description, unless the context requires otherwise&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;2024 notes&#8221; means the 0.500% Notes due 2024 of Merck &#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;2036 notes&#8221; means the 1.375% Notes due 2036 of Merck &#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;holder&#8221; means a direct holder and not a street name or other indirect holder of notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"> &#8220;notes&#8221; means the 2024 notes and 2036 notes, collectively&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Merck &#38; Co., Inc., but not to any of Merck &#38; Co., Inc.&#8217;s subsidiaries.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth a description of the material terms of the notes.  The description is qualified in its entirety by reference to the indenture, dated as of January 6, 2010, between us and U.S. Bank Trust National Association, as trustee (a copy of which is included as Exhibit 4.1 to our Current Report on Form 8-K filed on December 10, 2010) and, as applicable, the officers&#8217; certificate pursuant to such indenture with respect to the 2024 notes, dated November 2, 2016, including the form of the 2024 notes (a copy of which is included as Exhibit 4.1 to our Current Report on Form 8-K filed on November 2, 2016) or the officers&#8217; certificate pursuant to such indenture with respect to the 2036 notes, dated November 2, 2016, including the form of the 2036 notes (a copy of which is included as Exhibit 4.2 to our Current Report on Form 8-K filed on November 2, 2016).  You are encouraged to read such indenture and officers&#8217; certificates for additional information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 notes and the 2036 notes are each a separate series of notes under the indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 notes are initially limited to &#8364;500,000,000 aggregate principal amount, which amount remains outstanding as of February 24, 2021, and will mature on&#160;November 2, 2024.  The 2036 notes are initially limited to &#8364;500,000,000 aggregate principal amount, which amount remains outstanding as of February 24, 2021, and will mature on&#160;November 2, 2036.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are unsecured and rank equally with all our other unsecured and unsubordinated indebtedness from time to time outstanding.  The notes are not guaranteed by any of our subsidiaries and are therefore structurally subordinated to all liabilities of our subsidiaries from time to time outstanding, including any guarantees provided by our subsidiaries.  The notes also are effectively subordinated to any secured debt we or our subsidiaries incur to the extent of the value of any assets securing such debt.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes were issued in denominations of &#8364;100,000 and integral multiples of &#8364;1,000 in excess thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue as many distinct series of debt securities under the indenture as we wish.  A series of debt securities may be guaranteed by one or more of our subsidiaries.  There is no limit on the amount of debt securities we may issue under the indenture and the provisions of the indenture allow us to issue debt securities with terms different from those previously issued under the indenture.  Also, as discussed below under &#8220;&#8212;Further Issues,&#8221; we may &#8220;reopen&#8221; a previous issue of a series of debt securities and issue additional debt securities of that series.  We also may issue other debt under other indentures or documentation, containing provisions different from those included in the indenture or applicable to the notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are listed on the New York Stock Exchange.  We have no obligation to maintain such listing and we may delist the notes at any time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 notes bear interest at a rate of&#160;0.500% per annum and the 2036 notes bear interest at a rate of&#160;1.375% per annum.  Interest on the notes is payable annually on&#160;November 2 of each year to the person in whose name such notes were registered at the close of business on the&#160;fifteenth calendar day before the next interest payment date.  If any payment date for the notes is not a business day, payment is made on the next business day, but we are not liable for any additional interest as a result of the delay in payment.  With respect to the notes, by business day, we mean any Monday, Tuesday, Wednesday, Thursday or Friday which is not a day when banking institutions are authorized or obligated by law or executive order to be closed in The City of New York or London and, for any place of payment outside of The City of New York or London, in such place of payment, and on which the Trans-European Automated Real-time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, operates.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to each series of notes, we compute the amount of interest payable on the basis of (i)&#160;the actual number of days in the period for which interest is being calculated and (ii)&#160;the actual number of days from (and including) the last date on which interest was paid on the notes of such series (or&#160;November 2, 2016 if no interest has been paid on the notes of such series) to (but excluding) the next scheduled interest payment date.  This payment convention is referred to as ACTUAL&#47;ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elavon Financial Services DAC, UK Branch initially acts as principal paying agent for the notes (the &#8220;paying agent&#8221;).  Elavon Financial Services DAC initially acts as security registrar (the &#8220;security registrar&#8221;) and transfer agent and U.S. Bank Trust National Association initially acts as trustee (&#8220;trustee&#8221;) for the notes.  We have entered into an issuing and paying agency agreement in relation to the notes between us, U.S. Bank Trust National Association, as trustee, Elavon Financial Services DAC, UK Branch, as principal paying agent and Elavon Financial Services Limited as security registrar and transfer agent.  Payment of principal of and interest on the notes is made through the office of the principal paying agent in London.  The terms &#8220;principal paying agent&#8221; and &#8220;paying agent&#8221; shall include any successors appointed from time to time in accordance with the provisions of the issuing and paying agency agreement, and any reference to an &#8220;agent&#8221; or &#8220;agents&#8221; shall mean any or all (as applicable) of such persons.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payments in Euros</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments of interest and principal, including payments made upon any redemption of the notes, are payable in euros.  If, at any time, the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if the euro is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used.  In such circumstances, the amount payable on any date in euros will be converted into U.S. dollars on the basis of the most recently available market exchange rate for euros.  Any payment in respect of the notes so made in U.S. dollars will not constitute an event of default under the notes or the indenture governing the notes.  Neither the trustee nor the paying agent shall have any responsibility for any calculation or conversion in connection with the foregoing.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors are subject to foreign exchange risks as to payments of principal and interest that may have important economic and tax consequences to them.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Optional Redemption</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of notes is redeemable in whole or in part, at our option at any time or from time to time, at a redemption price equal to the greater of (i)&#160;100% of the principal amount of the notes to be redeemed or (ii)&#160;the sum of the present values of the Remaining Scheduled Payments (as defined below) (not including any portion of such payment of interest accrued as of the date of redemption) discounted to the redemption date on an annual basis (ACTUAL&#47;ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 12.5 basis points with respect to the 2024 notes and the Comparable Government Bond Rate plus 15 basis points with respect to the 2036 notes, plus, in each case, accrued and unpaid interest on the principal amount being redeemed to, but excluding, the redemption date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after&#160;August 2,&#160;2024 for the 2024 notes and&#160;August 2, 2036&#160;for the 2036 notes (three months prior to the maturity date of the 2024 notes or the 2036 notes, as applicable), we may redeem in whole or in part the 2024 notes or the 2036 notes, as applicable, at any time or from time to time, at our option, at a redemption price equal to 100% of the principal amount of the applicable notes being redeemed, plus accrued and unpaid interest on the principal amount being redeemed to, but excluding, the redemption date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to give notice of redemption at least 30&#160;days, but no more than 60&#160;days, prior to the redemption date.  The notice will be mailed to the registered address of each holder of that series of notes.  The principal amount of a note remaining outstanding after a redemption in part shall be &#8364;100,000 or an integral multiple of &#8364;1,000 in excess thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Government Bond Rate&#8221; means, with respect to any redemption date, the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the notes to be redeemed, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond (as defined below) on the basis of the middle market price of the Comparable Government Bond prevailing at 11&#58;00 a.m. (London time) on such business day as determined by an independent investment bank selected by us.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Government Bond&#8221; means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an independent investment bank selected by us, a German federal government bond whose maturity is closest to the maturity of the notes to be redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such independent investment bank may, with the advice of three brokers of, and&#47;or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Remaining Scheduled Payments&#8221; means, with respect to each note to be redeemed, the remaining scheduled payments of principal of and interest on the note that would be due after the related redemption date but for the redemption.  If that redemption date is not an interest payment date with respect to a note, the amount of the next succeeding scheduled interest payment on the note will be reduced by the amount of interest accrued on the note to the redemption date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If fewer than all of the notes of any series are to be redeemed, the trustee will select the particular notes or portions thereof for redemption from the outstanding notes not previously called, pro rata or by lot, or in such other manner as we direct each in accordance with the depositary&#8217;s procedures.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the notes or portions thereof called for redemption.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are also subject to redemption if certain events occur involving United States taxation. See &#8220;&#8212;Taxation Redemption.&#8221;</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Amounts</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments of principal and interest in respect of the notes are made free and clear of, and without deduction or withholding for or on account of any present or future taxes, duties, assessments or other governmental charges of whatsoever nature imposed, levied, collected, withheld or assessed by the United States or any political subdivision or taxing authority of or in the United States (collectively, &#8220;Taxes&#8221;), unless such withholding or deduction is required by law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event such withholding or deduction of Taxes is required by law, subject to the limitations described below, we will pay to the holder of any note that is not beneficially owned by a U.S. Holder (as defined below) such additional amounts (&#8220;Additional Amounts&#8221;) as may be necessary in order that every net payment received by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beneficial owner of such note of principal of or interest or any other amount payable on the notes (including upon redemption), after deduction or withholding for or on account of such Taxes, will not be less than the amount provided for in such note to be then due and payable before deduction or withholding for or on account of such Taxes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, our obligation to pay Additional Amounts shall not apply to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;any Taxes which would not have been so imposed but for&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;the existence of any present or former connection between such holder or beneficial owner (or between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity) and the United States, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member, shareholder or other equity owner or person having such a power) being or having been a citizen or resident or treated as a resident of the United States or being or having been engaged in a trade or business in the United States or being or having been present in the United States or having or having had a permanent establishment in the United States&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;the failure of such holder or beneficial owner to comply with any certification, information or other reporting requirement, if compliance is required under United States tax laws and regulations to establish entitlement to a partial or complete exemption from such Taxes (including, but not limited to, the requirement to provide Internal Revenue Service Form&#160;W-8BEN, Form W-8BEN-E, Form&#160;W-8ECI, or any subsequent versions thereof or successor thereto)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;such holder&#8217;s or beneficial owner&#8217;s present or former status as a personal holding company or a foreign personal holding company with respect to the United States, as a controlled foreign corporation with respect to the United States, as a passive foreign investment company with respect to the United States, as a foreign tax exempt organization with respect to the United States or as a corporation which accumulates earnings to avoid United States federal income tax&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any Taxes imposed by reason of the holder or beneficial owner&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;owning or having owned, directly or indirectly, actually or constructively, 10% or more of the total combined voting power of all classes of our stock, as described in section 871(h)(3) of the Internal Revenue Code of 1986, as amended (the &#8220;Internal Revenue Code&#8221;),</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;being a bank receiving interest described in section&#160;881(c)(3)(A) of the Internal Revenue Code,&#160;or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;being a controlled foreign corporation with respect to the United States that is related to us by stock ownership&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any Taxes which would not have been so imposed but for the presentation by the holder or beneficial owner of such note for payment on a date more than 30&#160;days after the date on which such payment became due and payable or the date on which payment of the note is duly provided for and notice is given to holders, whichever occurs later, except to the extent that the holder or beneficial owner would have been entitled to such Additional Amounts on presenting such note on any date during such 30-day period&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any estate, inheritance, gift, sales, excise, transfer, personal property, wealth or similar Taxes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;any Taxes which are payable otherwise than by withholding from a payment on such note&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;any Taxes which are payable by a holder that is not the beneficial owner of the note, or a portion of the note, or that is a fiduciary, partnership, limited liability company or other similar entity, but only to the extent that a beneficial owner, a beneficiary or settlor with respect to such fiduciary or member of such partnership, limited liability company or similar entity would not have been entitled to the payment of an additional amount had such beneficial owner, settlor, beneficiary or member received directly its beneficial or distributive share of the payment&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;any Taxes required to be withheld by any paying agent from any payment on any note, if such payment can be made without such withholding by at least one other paying agent&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;any Taxes imposed under Sections 1471 through 1474 of the Internal Revenue Code (or any amended or successor provisions), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section&#160;1471(b) of the Code or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement entered into in connection with the implementation of such sections of the Code&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any combination of items (a), (b), (c), (d), (e), (f), (g)&#160;and (h).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this section, the acquisition, ownership, enforcement, or holding of or the receipt of any payment with respect to a note will not constitute a connection&#160;(1)&#160;between the holder or beneficial owner and the United States or (2)&#160;between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity and the United States.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in this description, in the indenture or in the notes to principal or interest or other payment on the notes shall be deemed to refer also to Additional Amounts which may be payable under the provisions of this section.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all stamp and other duties, if any, which may be imposed by the United States or any political subdivision thereof or taxing authority therein with respect to the issuance of the notes pursuant to this offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as specifically provided under the heading &#8220;&#8212;Additional Amounts,&#8221; we will not be required to make any payment with respect to any tax, duty, assessment or other governmental charge imposed by any government or any political subdivision or taxing authority of or in the United States.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;U.S. Holder&#8221; is a beneficial owner of a note or notes that is for U.S. federal income tax purposes&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an individual who is a citizen or resident of the United States&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a corporation created or organized in or under the laws of the United States, any state thereof or the District of Columbia&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an estate, the income of which is subject to U.S. federal income taxation regardless of the source of that income&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trust, if (1) a U.S. court is able to exercise primary supervision over the trust&#8217;s administration and one or more &#8220;United States persons&#8221; (within the meaning of the Internal Revenue Code) have the authority </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to control all of the trust&#8217;s substantial decisions, or (2) the trust has a valid election in effect under applicable Treasury regulations to be treated as a &#8220;United States person.&#8221;</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxation Redemption</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes may be redeemed at our option, in whole but not in part, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, together with interest accrued and unpaid to, but excluding, the redemption date, at any time, on giving not less than 30 nor more than 60&#160;days&#8217; notice in accordance with &#8220;Notices&#8221; below if&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;we have or will become obligated to pay Additional Amounts as a result of (i)&#160;any change in or amendment to the laws, regulations or rulings of the United States or any political subdivision or any taxing authority of or in the United States affecting taxation, or (ii)&#160;any change in or amendment to an official application, interpretation, administration or enforcement of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after October 26, 2016&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;we reasonably determine that such obligation cannot be avoided by our taking reasonable measures available to us without significant difficulty, cost or expense, or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any action shall have been taken by a taxing authority, or any action has been brought in a court of competent jurisdiction, in the United States or any political subdivision or taxing authority of or in the United States, including any of those actions specified in (a)&#160;above, whether or not such action was taken or brought with respect to us, or any change, clarification, amendment, application or interpretation of such laws, regulations or rulings shall be officially proposed, in any such case on or after October 26, 2016, which results in a substantial likelihood that we will be required to pay Additional Amounts on the next interest payment date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, no such notice of redemption shall be given earlier than 90&#160;days prior to the earliest date on which we would be, in the case of a redemption for the reasons specified in (a)&#160;above, or there would be a substantial likelihood that we would be, in the case of a redemption for the reasons specified in (b)&#160;above, obligated to pay such Additional Amounts if a payment in respect of the notes were then due and, at the time such notification of redemption is given, such circumstance remains in effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the publication of any notice of redemption pursuant to this section, in the case of a redemption for the reasons specified in (a)&#160;or (b)&#160;above, we will deliver to the trustee&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;a certificate signed by one of our duly authorized officers stating that we are entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to our right so to redeem have occurred,&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;a written opinion of independent legal counsel of recognized standing to the effect that we have or will become obligated to pay such Additional Amounts as a result of such change or amendment or that there is a substantial likelihood that we will be required to pay such Additional Amounts as a result of such action or proposed change, clarification, amendment, application or interpretation, as the case may be.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such notice, once delivered by us to the trustee, will be irrevocable.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modification and Waiver</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three types of changes we can make to the indenture and the notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes Requiring Holder Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  First, there are changes that cannot be made to the notes of any series without specific approval by each holder of the notes of such series affected thereby.  Following is a list of those types of changes&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the payment due date of any installment of the principal or any premium or interest on a note stated in the note&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce any amounts due on a note&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the place or currency of payment on a note&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impair holders&#8217; right to sue for payment&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the percentage of notes of any series, the holders of which must consent to modify or amend the indenture&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the percentage of notes of any series the holders of which must consent to waive compliance with certain provisions of the indenture or to waive certain defaults&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modify any other aspect of the provisions dealing with modification and waiver of the indenture except to increase any such percentage or to provide that certain other provisions of the indenture cannot be modified or waived without the consent of the holder of each outstanding security affected thereby.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes Requiring a Majority Vote</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The second type of change to the indenture and the notes is the kind that requires a vote in favor by holders owning not less than a majority of the principal amount of the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">notes of the particular series affected</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Most changes fall into this category, such as if we wish to obtain a waiver of all or part of the restrictive covenants described below, or a waiver of a past default.  However, we cannot obtain a waiver of a payment default or any other aspect of the indenture or the notes listed in the first category above under &#8220;&#8212;Changes Requiring Holder Approval&#8221; unless we obtain the individual consent of each holder of the notes of such series affected thereby to the waiver.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes Not Requiring Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The third type of change does not require any vote by holders of notes.  This type is limited to the addition or release of a guarantee, corrections and clarifications and other changes that would not adversely affect holders of the notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Further Details Concerning Voting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  When taking a vote, we use the U.S. dollar equivalent to decide how much principal amount to attribute to a note.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes will not be considered outstanding and therefore will not carry voting rights if we have deposited or set aside in trust for the holders thereof money for their payment or redemption.  Notes will also not be eligible to vote if they have been fully defeased as described under &#8220;&#8212;Defeasance&#8212;Full Defeasance.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may set any day as a record date for the purpose of determining the holders of outstanding notes that are entitled to vote or take other action under the indenture.  In some circumstances, the trustee may set a record date for action by holders.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Street name and other indirect holders should consult their banks or brokers for information on how approval may be granted or denied if we seek to change the indenture or the notes or request a waiver.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mergers and Similar Events</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may consolidate or merge with another company or firm.  We may also convey, transfer or lease all of our properties and assets substantially as an entirety to another firm, or buy or lease substantially all of the assets of another firm.  However, we may not take any of these actions unless the following conditions, among others, are met&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are the surviving entity or, when we merge out of existence or convey, transfer or lease all of our properties and assets substantially as an entirety, the other firm must be a corporation, limited liability </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company, partnership or trust organized under the laws of a U.S. state or the District of Columbia or under federal law and it must agree to be legally responsible for the notes.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The merger, sale of assets or other transaction must not cause a default on the notes, and we must not already be in default unless the merger or other transaction would cure the default.  For purposes of this no-default test, a default would include an event of default, as described under &#8220;&#8212;Default and Remedies&#8212;Events of Default&#8212;What is an Event of Default,&#8221; that has occurred and not been cured.  A default for this purpose would also include the occurrence of any event that would be an event of default if we received the required notice of our default or if under the indenture the default would become an event of default after existing for a specific period of time.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is possible that the merger, sale of assets or other transaction would cause some of our property to become subject to a mortgage or other legal mechanism giving lenders preferential rights in that property over other lenders or over our general creditors if we fail to pay them back.  We have promised to limit these preferential rights, as discussed under &#8220;&#8212;Restrictive Covenants.&#8221;  If a merger or other transaction would create any liens on any of our property, we must comply with those restrictive covenants.  We would do this either by deciding that the liens were permitted, or by following the requirements of the restrictive covenants to grant an equivalent or higher-ranking lien to the holders of the notes on the same property that we own.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the conditions described above are satisfied with respect to any series of notes, we do not need to obtain the approval of the holders of those notes in order to merge or consolidate or to sell our assets.  Also, these conditions apply only if we wish to merge or consolidate with another entity or convey, transfer or lease all of our properties and assets substantially as an entirety.  We do not need to satisfy these conditions if we enter into other types of transactions, including any transaction in which we acquire the stock or assets of another entity, any transaction that involves a change of control but in which we do not merge or consolidate and any transaction in which we convey, transfer or lease less than all of our properties and assets substantially as an entirety.  It is possible that these other types of transactions may result in a reduction in our credit rating, may reduce our operating results or may impair our financial condition.  However, the holders of notes have no approval right with respect to any transaction of this type.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restrictive Covenants</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Secured Debt</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Some of our property may be subject to a mortgage or other legal mechanism that gives our lenders preferential rights in that property over other lenders, including the holders of the notes, or over our general creditors if we fail to pay them back.  These preferential rights are called liens.  Debt which is protected by these preferential rights is called secured debt.  In the indenture, we promise that neither we nor our domestic subsidiaries (as defined below) will incur any new secured debt that is secured by a lien on any of our or our domestic subsidiaries&#8217; principal domestic manufacturing properties (as defined below), or on any shares of stock of any of our domestic subsidiaries that own or lease a principal domestic manufacturing property, unless we grant an equivalent or higher-ranking lien on the same property to the holders of the notes and other outstanding debt securities issued under the indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not need to comply with this restriction if the amount of all debt that would be secured by liens on principal domestic manufacturing properties, including the new debt, the notes and other outstanding debt securities issued under the indenture which we would so secure as described in the previous sentence, and all attributable debt (as defined below) that results from a sale and leaseback transaction involving principal domestic manufacturing properties, is less than 10% of our consolidated net tangible assets (as defined below).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This restriction on secured debt does not apply to debt secured by certain types of liens, and we can disregard this secured debt when we calculate the limits imposed by this restriction.  These types of liens are&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens on the property of any of our domestic subsidiaries, or on their shares of stock, if those liens existed at the time the corporation became our domestic subsidiary&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">with respect to any series of notes, any lien existing on the date of issuance of such notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens in favor of us or our domestic subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens in favor of U.S. governmental bodies that we granted in order to assure our payments to such bodies that we owe by law or because of a contract we entered into&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens in favor of any customer arising in respect of payments made by or on behalf of a customer for goods produced for, or services rendered to, customers in the ordinary course of business not exceeding the amount of those payments&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">statutory liens, liens for taxes or assessments or governmental charges or levies not yet due or delinquent or which can be paid without penalty or are being contested in good faith, landlord&#8217;s liens on leased property, easements and other liens of a similar nature&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liens on property or shares of stock that existed at the time we acquired them, including property we may acquire through a merger or similar transaction, or that we granted in order to purchase the property, which are sometimes called purchase money mortgages&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">debt secured by liens that extend, renew or replace any of these types of liens.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries may have as much unsecured debt as we may choose.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Sales and Leasebacks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We promise that neither we nor any of our domestic subsidiaries will enter into any sale and leaseback transaction involving a principal domestic manufacturing property, unless we comply with this restrictive covenant.  A sale and leaseback transaction generally is an arrangement between us or a domestic subsidiary and a bank, insurance company or other lender or investor where we or the domestic subsidiary sell a property to a lender or investor more than 120 days after the acquisition of the property or the completion of construction of the property and the beginning of its full operation and we lease the property back from the lender.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can comply with this restrictive covenant in either of two ways&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First, we will be in compliance if we or our domestic subsidiary could grant a lien on the principal domestic manufacturing property in an amount equal to the attributable debt for the sale and leaseback transaction without being required to grant an equivalent or higher-ranking lien to the holders of the notes and other outstanding debt securities issued under the indenture under the restriction on secured debt described above.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Second, we can comply if we retire an amount of our or any domestic subsidiary&#8217;s funded debt which is not subordinated in right of payment to any outstanding notes or other outstanding debt securities issued under the indenture, within 120 days of the transaction, equal to the greater of the net proceeds of the sale of the principal domestic manufacturing property that we lease in the transaction or the fair market value of that property, subject to credits for voluntary retirements of notes and other outstanding debt securities issued under the indenture and funded debt we or the domestic subsidiary may make.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This restriction on sales and leasebacks does not apply to any sale and leaseback transaction that is between us and one of our domestic subsidiaries or between domestic subsidiaries, or that involves a lease for a period of three years or less.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definitions Relating to our Restrictive Covenants</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Following are summaries of the meanings of the terms that are important in understanding the restrictive covenants previously described&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Attributable debt&#8221; means the total net amount of rent, discounted at 1% per annum over the weighted average yield to maturity of the outstanding notes and other outstanding debt securities issued under the indenture compounded semi-annually, that is required to be paid during the remaining term of any lease.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Consolidated net tangible assets&#8221; is the total amount of assets, less reserves and certain other permitted deductible items, after subtracting all current liabilities and all goodwill, trade names, trademarks, patents, unamortized debt discounts and expenses and similar intangible assets, as such amounts appear on our most recent consolidated balance sheet and computed in accordance with generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;domestic subsidiary&#8221; means any of our subsidiaries which transacts substantially all of its business in the United States, has substantially all of its fixed assets located in the United States, or owns or leases principal domestic manufacturing property.  However, a subsidiary whose principal business is financing our operations outside of the United States is not a domestic subsidiary.  A subsidiary is a corporation in which we and&#47;or one or more of our other subsidiaries owns at least 50% of the voting stock (generally defined as stock that ordinarily permits its owners to vote for the election of directors).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Funded debt&#8221; means all debt for borrowed money that either has a maturity of 12 months or more from the date on which the calculation of funded debt is made or has a maturity of less than 12 months from that date but is by its terms renewable or extendible beyond 12 months from that date at the option of the borrower.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;principal domestic manufacturing property&#8221; is any building or other structure or facility, and the land on which it sits and its associated fixtures, that we use primarily for manufacturing, processing or warehousing, that is located in the United States and that has a gross book value in excess of 1% of our consolidated net tangible assets, other than a building, structure or other facility that our board of directors has determined is not of material importance to the total business that we and our subsidiaries conduct or a building or structure which is financed by obligations issued by a state, a territory, or a possession of the United States, or any political subdivision of any of the foregoing, or the District of Columbia, the interest of which is excludable from gross income of the holders under provisions of the tax code.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Further Issues</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, without the consent of holders of any series of the notes, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the notes of that series.  Any additional notes of any series, together with the outstanding notes of the applicable series, will constitute a single series of notes under the indenture.  No additional notes may be issued if an event of default has occurred and is continuing with respect to the applicable series of notes.  Additional notes cannot be issued under the same CUSIP, ISIN or Common Code number unless the additional notes and original notes are fungible for U.S. federal income tax purposes.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defeasance</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Full Defeasance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If there is a change in federal tax law, as described below, we can legally release ourselves from any payment or other obligations on the notes of a series if we put in place other arrangements for the holders of such notes to be repaid.  This is called full defeasance.  In order to achieve full defeasance, we must do the following, among other things&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must deposit in trust for the benefit of all holders of the notes of the series any combination of money (in euros) and Federal Republic of Germany obligations (as defined below) that will generate enough cash to make interest, principal and any other payments on the notes of that series on their various due dates.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There must be a change in current federal tax law or an IRS ruling that lets us make the above deposit without causing holders or beneficial owners of the notes of the series to be taxed on such notes any differently than if we did not make the deposit and just repaid such notes ourselves.  (Under current federal tax law, the deposit and our legal release from such notes would be treated as though we took </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">back beneficial owners&#8217; notes and gave them their share of the cash and notes or bonds deposited in trust.  In that event, beneficial owners could recognize gain or loss on the notes they give back to us.)</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must deliver to the trustee a legal opinion of our counsel confirming the tax law change described above.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we ever did accomplish full defeasance, as described above, holders of defeased notes would have to rely solely on the trust deposit for repayment on such notes.  Holders of such notes could not look to us for repayment in the unlikely event of any shortfall.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Defeasance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Under current federal tax law, we can make the same type of deposit described above and be released from some of the restrictive covenants in the notes.  This is called covenant defeasance.  In that event, holders of notes would lose the protection of those restrictive covenants but would gain the protection of having money and securities set aside in trust to repay the notes.  In order to achieve covenant defeasance of the notes of a series, we must do the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must deposit in trust for the benefit of all holders of the notes of the series any combination of money (in euros) and Federal Republic of Germany obligations that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must deliver to the trustee a legal opinion of our counsel confirming that under current federal income tax law we may make the above deposit without causing holders or beneficial owners of the notes to be taxed on the notes any differently than if we did not make the deposit and just repaid the notes ourselves.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish covenant defeasance, the following provisions of the indenture and the notes would no longer apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our promises regarding conduct of our business previously described under &#8220;&#8212;Restrictive Covenants.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions regarding mergers or similar transactions, as described under &#8220;&#8212;Mergers and Similar Events.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The events of default relating to mergers or similar transactions and either of the restrictive covenants described under &#8220;&#8212;Restrictive Covenants.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish covenant defeasance, holders of notes can still look to us for repayment of the notes if there were a shortfall in the trust deposit.  In fact, if one of the remaining events of default occurred, such as our bankruptcy, and the notes become immediately due and payable, there may be such a shortfall in the trust deposit.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Federal Republic of Germany obligations&#8221; means (1)&#160;securities that are direct obligations of the Federal Republic of Germany for the payment of which its full faith and credit is pledged or (2)&#160;obligations of a person controlled or supervised by and acting as an agency or instrumentality of the Federal Republic of Germany, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the Federal Republic of Germany, which, in either case under clauses (1)&#160;or (2)&#160;are not callable or redeemable at the option of the issuer thereof.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of notes have special rights if an event of default occurs and is not cured, as described later in this subsection.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term event of default with respect to each series of notes means any of the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not pay the principal or any premium on such series of notes on its due date.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not pay interest on such series of notes within 30 days of its due date.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We remain in breach of either of the restrictive covenants described under &#8220;&#8212;Restrictive Covenants&#8221; or any other covenant or warranty in the indenture for 90 days after we receive a notice of default stating we are in breach.  The notice must be sent by either the trustee or holders of at least 25% of the principal amount of notes of the affected series.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We file for bankruptcy or other specific events of bankruptcy, insolvency or reorganization occur.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not pay Additional Amounts on such series of notes within 30 days after such payment is due.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any payment in respect of the notes made in U.S. dollars due to the unavailability or nonuse of the euro as discussed under &#8220;&#8212;Payments in Euros&#8221; will not constitute an event of default under the notes or the indenture governing the notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default has occurred and has not been cured, the trustee or the holders of at least 25% in principal amount of the outstanding notes of the affected series may declare the entire principal amount of all the notes of that series to be due and immediately payable.  This is called a declaration of acceleration.  The holders of at least a majority in principal amount of the notes of the affected series may cancel a declaration of acceleration of maturity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the indenture at the request of any holders unless such holders offer the trustee reasonable protection, called an indemnity, against expenses and liability.  If reasonable indemnity is provided, the holders of a majority in principal amount of the outstanding notes of the relevant series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee.  These majority holders may also direct the trustee in performing any other action under the indenture with respect to the notes of the applicable series.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a holder of notes of any series bypasses the trustee and brings its own lawsuit or other formal legal action or takes other steps to enforce its rights or protect its interests relating to the notes of such series, the following must occur&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The holder must give the trustee written notice that an event of default has occurred and remains uncured.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The holders of at least 25% in principal amount of all outstanding notes of the relevant series must make a written request that the trustee take action because of the default, and must offer indemnity reasonably satisfactory to the trustee against the cost and other liabilities of taking that action.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trustee must have not received from holders of a majority in principal amount of the outstanding notes of that series a direction inconsistent with the written notice.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trustee must have not taken action for 60 days after receipt of the above notice and offer of indemnity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, a holder of notes is entitled at any time to bring a lawsuit for the payment of money due on its notes on or after their due date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Street name and other indirect holders should consult their banks or brokers for information on how to give notice or direction to or make a request of the trustee and to make or cancel a declaration of acceleration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We furnish to the trustee every year a written statement of our principal executive, financial or accounting officer certifying that to the best of such signer&#8217;s knowledge we are in compliance with the indenture and the notes, or else specifying any default.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form, Exchange and Registration of Transfer</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued the notes only in fully registered form and without interest coupons.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of notes may have its notes broken into more notes of smaller denominations of not less than &#8364;100,000 or combined into fewer notes of larger denominations, as long as the total principal amount is not changed.  This is called an exchange.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of notes may exchange or register a transfer of notes at the office of the trustee.  The trustee acts as our agent for registering notes in the names of holders and registering transfers of notes.  We may change this appointment to another entity or perform it ourselves.  The entity performing the role of maintaining the list of registered holders is called the security registrar.  It also registers transfers.  A holder of notes may also replace lost, stolen or mutilated notes at that office.  The trustee&#8217;s agent may require an indemnity before replacing any notes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of notes is not required to pay a service charge to register a transfer of notes or to exchange notes, but may be required to pay for any tax or other governmental charge associated with the transfer or exchange.  The security registrar makes the registration of transfer or exchange only if it is satisfied with such holder&#8217;s proof of ownership.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may cancel the designation of any trustee.  We may also approve a change in the office through which any trustee acts.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we redeem less than all of the notes of a particular series, we may block the issuance of, registration of transfer or exchange of notes during the period beginning 15 days before the day we mail the notice of redemption and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing.  We may also refuse to register transfers or exchanges of notes selected for redemption, except that we will continue to permit transfers and exchanges of the unredeemed portion of any note being partially redeemed.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules for exchange described above apply to exchange of notes for other notes of the same series and tenor.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment and Paying Agents</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay interest to a holder of notes on each date interest is due if the holder is a direct holder listed in the trustee&#8217;s records at the close of business on the&#160;fifteenth calendar day before the next interest payment date, even if such holder no longer owns the note on the interest due date.  That particular day is called the regular record date.  Holders buying and selling notes must work out between them how to compensate for the fact that we pay all the interest for an interest period to the one who is the registered holder on the regular record date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay interest, principal and any other money due on the notes at the office of the trustee in London, UK.  That office is currently located at125 Old Broad Street, Fifth Floor, London EC2N 1AR United Kingdom.  A holder of notes must make arrangements to have its payments picked up at or wired from that office.  We may also choose to pay interest by mailing checks.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Street name and other indirect holders should consult their banks or brokers for information on how they may receive payments.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also arrange for additional payment offices, and may cancel or change these offices.  These offices are called paying agents.  We may also choose to act as our own paying agent.  We must notify holders of notes of changes in the paying agents for any particular notes of the series.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notices</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the trustee send notices regarding the notes only to direct holders, using their addresses as listed in the trustee&#8217;s records.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All paying agents must return to us upon our request all money paid by us that remains unclaimed two years after the amount is due to direct holders.  After that&#160;two-year&#160;period, holders of notes may look only to us for payment and not to the trustee, any other paying agent or anyone else.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Book-Entry System</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance, the notes of each series are represented by one or more global notes.  Each global note is deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary for the accounts of Clearstream and Euroclear.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors may elect to hold interests in the global notes held by the depository through Clearstream Banking,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Clearstream&#8221;) or Euroclear Bank&#160;S.A.&#47;N.V., as operator of the Euroclear System, (&#8220;Euroclear&#8221;) if they are participants of such systems, or indirectly through organizations that are participants in such systems.  Clearstream and Euroclear hold interests on behalf of their participants through customers&#8217; securities accounts in Clearstream&#8217;s and Euroclear&#8217;s names on the books of their respective depositories.  Book-entry interests in the notes and all transfers relating to the notes are reflected in the book-entry records of Clearstream and Euroclear.  Because holders acquire, hold and transfer security entitlements with respect to the notes through Clearstream, Euroclear and their participants, a beneficial holder&#8217;s rights with respect to the notes is subject to the laws (including Article&#160;8 of the Uniform Commercial Code) and contractual provisions governing a holder&#8217;s relationship with its securities intermediary and the relationship between its securities intermediary and each other securities intermediary and between it and us, as the issuer.  Except as set forth below, the global notes may be transferred, in whole and not in part, only to another nominee of the depository or to a successor of the depository or its nominee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No global note may be exchanged in whole or in part for notes registered, and no transfer of a global note in whole or in part may be registered, in the name of any person other than the depository or any nominee of the depository unless (i)&#160;the depository has notified us that it is unwilling or unable to continue as depository for such global note or has ceased to be qualified to act as such as required by the indenture, (ii)&#160;there has occurred and is continuing an event of default with respect to the notes or (iii)&#160;we determine in our sole discretion at any time that the global note shall be so exchangeable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any global note that is exchangeable pursuant to the preceding sentence shall be exchangeable in whole for separate notes in registered form of any authorized denomination and of like tenor and aggregate principal amount.  These notes shall be registered in the name or names of such person or persons as the depository instructs the trustee.  We expect that these instructions would be based upon directions received by the depository from its participants with respect to ownership of beneficial interests in such global note.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in the limited circumstances referred to above, owners of beneficial interests in a global note are not entitled to have such global note registered in their names, will not receive and are not entitled to receive physical delivery of notes in exchange therefor and are not considered to be the owners or holders of such global note for any purpose under the notes or the indenture.  Accordingly, each person owning a beneficial interest in the global note must rely on the procedures of the participant through which such person owns its interest to exercise any rights of a holder under the indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture provides that the depository, as a holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver, or other action which a holder is entitled to give or take under the indenture.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture and the notes are governed by, and construed and enforced in accordance with, the laws of the State of New York applicable to agreements made or instruments entered into and performed in New York State.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relationship with Trustee</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Bank Trust National Association is the trustee under the indenture.  U.S. Bank Trust National Association performs services for us in the ordinary course of business and serves as the trustee with respect to certain of our other outstanding debt securities.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Open Market Purchases</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at any time and from time to time purchase notes in the open market or otherwise.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Paying Agent, Transfer Agent and Security Registrar</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elavon Financial Services DAC is the security registrar and transfer agent with respect to the notes.  Elavon Financial Services DAC, UK Branch is the paying agent with respect to the notes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>5
<FILENAME>ex10-24x2021annualrsuterms.htm
<DESCRIPTION>EX-10.23 2021 NQSO GRANT TERMS UNDER MERCK CO INC 2019 ISP
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4e410cb1f7b44c21a169c7c43f060893_1"></div><div style="min-height:36pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 10.24</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TERMS FOR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021 RESTRICTED STOCK UNIT GRANTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNDER THE MERCK &#38; CO., 2019 INCENTIVE STOCK PLAN</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document.  </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Different terms may apply to any prior or future RSU Awards.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant Type&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;RSU - Annual</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;May 4, 2021</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Vesting Dates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Portion that Vests</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;First&#58;  33.333%</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Second&#58;  33.333%</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2024&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Third&#58;  Balance</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Eligibility&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Eligibility for grants is determined under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:31.56pt">GENERAL INFORMATION</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  This grant requires you to affirmatively accept it.  You MUST log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.  </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days.  Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.45pt">Restricted Period.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  The Restricted is the period during which this RSU Award is restricted and subject to forfeiture.  The Restricted Period ends with respect to one-third of this RSU Award on each of the First, Second, and Third anniversaries of the Grant Date as shown in the box above, unless ended earlier under Article II below.  No voting rights apply to this RSU Award.  No fractional shares will be awarded&#58;  all calculations are subject to rounding.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.45pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  During the Restricted Period, dividend equivalents will be accrued for the holder (&#8220;you&#8221;) if and to the extent dividends are paid by the Company on Merck Common Stock.  Payment of such dividends will be made, without interest or earnings, at the time of distribution.  If any portion of this RSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion.  Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.01pt">Distribution.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Upon the expiration of the Restricted Period if you are then employed, you will be entitled to receive a number of shares of Merck common stock equal to the number of RSUs that have become unrestricted and the dividend equivalents that accrued on that portion. Prior to distribution, you must deliver to the Company an amount the Company determines to be sufficient to satisfy any amount required to be withheld, including applicable taxes. The Company may, in its sole discretion, withhold from the RSU Award distribution a number of shares to pay applicable withholding (including taxes).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.01pt">409A Compliance.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Internal Revenue Code or any successor thereto. Specifically, distributions made due to a separation from service (as defined in Section 409A) to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will not be made until administratively feasible following the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.45pt">Subject to Recoupment. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For employees in Band 600 and above, this RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If your employment with the Company is terminated during the Restricted Period, your right to the RSU Award will be determined according to the terms in this Section II.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.45pt">General Rule</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.45pt">Sale.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of your RSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date. The remainder will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.01pt">Involuntary Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If the company determines that your employment is involuntarily terminated during the Restricted Period but on or after the First Anniversary, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36&#59; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. An &#8220;involuntary termination&#8221; includes termination of your employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs B, or D through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.01pt">Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> If your employment terminates by retirement during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36&#59; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.45pt">Death.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> If your employment terminates due to your death during the Restricted Period, all of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the remaining, non-forfeited portion of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.9pt">Misconduct.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:9.56pt">Disability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this RSU Award will continue and be distributable in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:10.01pt">Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary after the closing of any change in control, then this RSU Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award. If this RSU does not remain outstanding following the change in control and is not converted into a successor RSU, then you will be entitled to receive cash for this RSU in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck common stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire. Change in control is defined in the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control), but if RSUs are considered &#8220;deferred compensation&#8221; under Section 409A of the Internal Revenue Code, the definition of change in control will be modified to the extent necessary to comply with Section 409A.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.56pt">Joint Venture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Employment with a joint venture or other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-H above apply to this RSU Award while you are employed by the joint venture or other entity.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:27.12pt">TRANSFERABILITY</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This RSU Award is not transferable and may not be assigned or otherwise transferred.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:26.23pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:28.45pt">ADMINISTRATION</font></div><div><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:26.23pt">GRANTS NOT PART OF THE EMPLOYMENT CONTRACT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For further information regarding the Long- Term Incentive Program, please visit the Company intranet Long-Term Incentive homepage. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recoupment of Compensation for Compliance Violations</font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">POLICIES AND PROCEDURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Policy</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment  of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definitions</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Procedures</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Delegation to Management for Certain Recoupment Decisions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Disclosure of Recoupment Decisions</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Miscellaneous</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>6
<FILENAME>ex1023-2021annualnqsoterms.htm
<DESCRIPTION>EX-10.24 2021 RSU GRANT TERMS UNDER MERCK CO INC 2019 ISP
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1ac75a03269a490087468cf0f372b5d0_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:360pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">                                                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 10.23&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">TERMS FOR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">UNDER THE MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:125%">This is a summary of the terms applicable to the stock option specified in this document.  Different terms may apply to any prior or future stock option.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Grant Type&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">NQSO &#8211; Annual</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Option Price&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;$XX.XX</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Grant Date&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">May 4, 2021</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Expiration Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;May 3, 2031</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;text-decoration:underline">Vesting Dates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;text-decoration:underline">Portion that Vests</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">May 4, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;First&#58;  33.333%</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">May 4, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Second&#58;  33.333%</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">May 4, 2024&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Third&#58;  Balance</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:31.56pt">GENERAL INFORMATION</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">IMPORTANT NOTICE&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">This grant requires you to affirmatively accept it.  You </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> log onto the Morgan Stanley website at&#58; </font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days.  Failure to accept the terms and conditions of your stock option within 90 days may result in Forfeiture of the stock option.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the accompanying box. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Eligibility&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> Eligibility for grants is determined under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Subject to Recoupment&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> For employees in Band 600 and above, this Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:29.34pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:10.45pt">General Rule.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">  If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the &#8220;Close of Business&#8221;) on the day before the same day of the third month (&#8220;Within Three Months&#8221;) after the date of the termination (but in no event after the expiration of the Option Period).  Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open.  Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later date (e.g., November 28, 29 and 30 all correspond to February 28 in non-leap years).  If you are rehired by the Company or JV, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier.</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">  </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:10.45pt">Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> If you retire from service with the Company the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately.  Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the day before the fifth anniversary of the termination date or (b) its original Expiration Date.  For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:10.01pt">Involuntary Termination.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">  If your employment is terminated by the Company and the Company determines that such termination was involuntary, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs B or D through H, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire on the day before the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:10.01pt">Sale.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of this stock option award will vest and become exercisable immediately upon such termination&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date. Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire the day before the first anniversary of the date your employment with the Company ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company&#8217;s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a  termination of employment, and may make adjustments, if any, as it deems appropriate, at the time of the distribution of such equity securities, in the kind and&#47;or number of shares subject to this option, and&#47;or in the option price of such option. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:10.45pt">Misconduct.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:10.9pt">Death.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law (e.g., in France, six months from the date of death). If you die while any portion of this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in  paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:9.56pt">Disability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the day before the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:10.01pt">Change in Control.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B through G above or termination prior to a change in control. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A &#34;change in control&#34; has the same meaning that it has under the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:13.56pt">Joint Venture.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a &#8220;JV&#8221;) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through H above apply to this stock option while the option holder is employed by the JV.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:27.12pt">TRANSFERABILITY</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:26.23pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:28.45pt">ADMINISTRATION</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant.  Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%;padding-left:26.23pt">GRANTS NOT PART OF EMPLOYMENT CONTRACT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law.  The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">This stock option is subject to the provisions of the 2019 Incentive Stock Plan.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">For further information regarding the Long- Term Incentive Program, please visit the Company intranet Long-Term Incentive homepage. </font></div><div style="margin-bottom:8pt;padding-left:54pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Recoupment of Compensation for Compliance Violations</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">POLICIES AND PROCEDURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Policy</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee  will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Definitions</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:11.34pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:11.34pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:11.34pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:11.34pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Procedures</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:11.34pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:11.34pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:11.34pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:11.34pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Disclosure of Recoupment Decisions</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Miscellaneous</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law.  Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>7
<FILENAME>ex21-subsidiarylistasof12x.htm
<DESCRIPTION>EX-21 SUBSIDIARY LIST
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic703278e9da94c9285141a2b18b9f47c_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:167%">Exhibit 21</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:167%">MERCK &#38; CO., INC. SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">as of 12&#47;31&#47;2020</font></div><div style="margin-bottom:21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following is a list of subsidiaries of the Company, doing business under the name stated.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Country or State</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Incorporation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7728026 Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abmaxis Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Afferent Pharmaceuticals, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agrident GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agro Verhen B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aleis Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex Argentina S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex Australia Pty. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex Avrasya Hayvan Kimlik Sistemleri Sanayi Ve Ticaret Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex dan-mark ApS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex Europe S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex Group Germany GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex India Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex International do Brasil Ltda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex Maroc S.A.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex New Zealand Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex Polska Spolka z ograniczona odpowiedzialnoscia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex SCR Vostok</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belarus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex Services S.A.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex UK Group Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allflex USA, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alta Plastic Muhendislik Sanayi Ve Ticaret Limited Sirketi</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Animal ID Australia Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antelliq Corporation</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antelliq Finance, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antelliq Holdings France S.A.S</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antelliq Holdings, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antelliq Management, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antimicrobial Stewardship LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ArQule, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AVL Holdings Limited</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beijing Allflex Plastic Products Co. Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beijing Protection Science and Technology Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">People&#8217;s Republic of China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biomark, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Idaho</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BRC Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Burgwedel Biotech GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calporta Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cambridge Resonant Technologies Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canji, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cCam Biotherapeutics Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cherokee Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chevillot S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continuum Professional Services Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Controladora MSD Mexicana Sociedad de Responsabilidad Limitada de Capital Variable</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cooper Veterinary Products (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporation Allflex, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cosmas B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cubist (UK) Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cubist Pharmaceuticals (UK) Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cubist Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dashtag</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Desarrollos Farmaceuticos Y Cosmeticos, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Destron Fearing Corporation</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialstat Trading 91 Pty Ltd T&#47;A Allflex SA</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dieckmann Arzneimittel GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Digital Angel S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Digital Angel S.A.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diosynth France S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diosynth Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diosynth Produtos Farmo-quimicos Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drovers ID Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DSD Holding A&#47;S</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elastec S.R.L</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Essex Pharmaceuticals, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Essexfarm, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ecuador</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Farmacox - Companhia Farmaceutica, Lda </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Farmasix-Produtos Farmaceuticos, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financiere MSD</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fontelabor-Produtos Farmaceuticos, Lda.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Frosst Laboratories, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Frosst Portuguesa - Produtos Farmaceuticos, Lda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fulford (India) Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GlycoFi, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GT Acquisition Sub, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minnesota</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GTS FI B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hangzhou MSD Pharmaceutical Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Harrisvaccines, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iowa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hawk and Falcon L.L.C.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare Services and Solutions, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Heptafarma Companhia Farmaceutica, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hydrochemie GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Idenix GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Idenix SARL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IdentiGEN Canada Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IdentiGEN Czech s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Czech Republic</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IdentiGEN Deutschland GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IdentiGEN Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IdentiGEN North America Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IdentiGEN Switzerland AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immune Design B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immune Design Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insight Acquisition Holdings Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International Indemnity Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet (Ireland) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet (Israel) Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet (M) Sdn. Bhd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet (Thailand) Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thailand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet AB</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Agencies B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Animal Health Taiwan Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Republic of China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Argentina S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Australia Pty Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Canada Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Central America S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Deutschland GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Ecuador S.A.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ecuador</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Egypt for Animal Health SAE</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet GesmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Hellas A.E.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Holdings France SAS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Hungaria &#201;rt&#233;kes&#237;t&#337; Kft</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hungary</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet India Pvt Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet International B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet International GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet International Sarl</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russian Federation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Maroc S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Mexico S.A. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Middle East Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyprus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Nederland B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Philippines, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Productions S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Productions S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Romania SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet SAS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Schering-Plough Animal Health Pty. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet South Africa (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Sp. z.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet UK Production Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Venezolana S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Veterinaria Chile Ltda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet Veteriner Ilaclari Pazarlama ve Ticaret Ltd. Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intervet, s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interveterinaria SA de CV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IOmet Pharma Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratoires Merck Sharp &#38; Dohme-Chibret</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratorios Abello, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratorios Chibret, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratorios Frosst, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratorios Quimico-Farmaceuticos Chibret, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lemifar S. A.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uruguay</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maple Leaf Holdings GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maya Tibbi Urunler Ticaret Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCM Vaccine B.V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Med-Nim (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and Company, Incorporated</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Capital Ventures, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Frosst Canada &#38; Co.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Frosst Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Global Health Innovation Fund, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Global Health Innovation, Private Equity, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck HDAC Research, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Holdings II Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Holdings III Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Holdings IV Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Holdings LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck International Holdings Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Lumira Biosciences Fund L.P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Registry Holdings, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Research Investments LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Research Laboratories Massachusetts, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Argentina) LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Asia) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hong Kong</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Australia) Pty. Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Chile) Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (China) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hong Kong</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Enterprises) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Europe) Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Holdings) Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (I.A.) LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (International) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Israel - 1996) Company Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Malaysia) SDN. BHD.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (New Zealand) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Sweden) A.B.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (Switzerland) GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme (UK) Limited</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Animal Health, S.L.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Asia Pacific Services Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme BH d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bosnia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Bulgaria EOOD</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bulgaria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Colombia S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colombia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Comercializadora, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Cyprus Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyprus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Croatia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme d.o.o. Belgrade</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serbia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme de Espana SAU</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Farmaceutica Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Finance Europe Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Gesellschaft m.b.H.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme IDEA GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme inovativna zdravila d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Slovenia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme International Services B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Latvija</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Latvia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bolivia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Manufacturing Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme OU</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estonia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Peru SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:21pt;padding-right:2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Pharmaceutical Industrial and Commercial Societe Anonyme</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Research GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Romania SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Salud Animal Columbia S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colombia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Saude Animal Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Singapore Trading Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme Tunisie SARL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tunisia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme, Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp &#38; Dohme, s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Slovakia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Sharp Dohme Ilaclari Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck Teknika LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merko Acquisition S.A.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belgium</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merko B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merko Dalton B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merko N.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ML Holdings (Canada) Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MRL San Francisco, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MRL Ventures Fund LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD (I.A.) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD (L-SP) Unterst&#252;tzungskasse GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD (Ningbo) Animal Health Technology Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD (Nippon Holdings) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD (Norge) AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD (Shanghai) Pharmaceuticals Consultancy Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD (Thailand) Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thailand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD AH Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health (Phils.), Inc</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health (Shanghai) Trading Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health A&#47;S</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Danube Biotech GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health FZ-LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Arab Emirates</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Innovation AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Innovation GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Innovation Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Innovation SAS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health K.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Korea Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Korea, Republic of</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Norge AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Oy</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Pension Trustee Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health UK Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health Vietnam Co. Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viet Nam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Animal Health, Lda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Argentina Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Argentina SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Asia Holdings Pte. Ltd.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Belgium BV - SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Biotech B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Brazil Investments B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Central America Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD China (Investments) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD China B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD China Holding Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Cubist Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Czech Republic s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Danmark ApS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Egypt LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD EIC Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Eurofinance</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Farmaceutica C.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD FI BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Finance 2 LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Finance B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Finance Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Finance Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Finland Oy</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD France</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Global Research GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD HH Vietnam Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vietnam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Holdings (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Holdings 2 G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Holdings G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Human Health Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Human Health Holding II B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD IDEA Pharmaceuticals Nigeria Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nigeria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD IDEA Tunisie SARL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tunisia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Idenix Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Innovation &#38; Development GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD International Business GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD International Finance B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD International Finance LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD International GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD International Holdings 2 B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD International Investment Holdings Unlimited Company</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD International Manufacturing GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Investment Holdings (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Investments (Holdings) GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Italia s.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Japan Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Japan Holdings GK</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD K.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Korea Co., Ltd.</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Korea</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Laboratories India LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Latin America Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Latin America Services S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Luxembourg S.a.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Luxembourg</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Merck Sharp &#38; Dohme AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD NL 4 B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Overseas Manufacturing Co (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Panama International Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Participations B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharma (Singapore) Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharma GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharma Hungary Korlatolt Felelossegu Tarsasag</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hungary</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharmaceuticals Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharmaceuticals Investments 1 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharmaceuticals Investments 3 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharmaceuticals Ireland Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russian Federation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Pharmaceuticals Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Polska Dystrybucja Sp. z.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Polska Sp.z.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD R&#38;D (China) Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD R&#38;D Innovation Centre Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD RDC Costa Rica Sociedad de Responsabilidad Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost Rica</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Regional Business Support Center GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Registry Holdings, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Shared Business Services EMEA Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Sharp &#38; Dohme Gesellschaft mit beschr&#228;nkter Haftung</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Switzerland Investments 1 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Switzerland Investments 4 Unlimited Company</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Switzerland Investments 5 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Ukraine Limited Liability Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ukraine</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Unterstutzungskasse GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Vaccines Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Vaccins</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Vaccins Holdings</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Venezuela Holding GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Ventures (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Verwaltungs GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Vietnam Company Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vietnam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Vietnam Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSD Vostok B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSDIG Holdings Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSDRG Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSDRG LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSP Singapore - Sub, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSP Singapore Company, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSP Vaccine Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pennsylvania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multilan AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N.V. Organon</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nihon MSD G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nourifarma - Produtos Quimicos e Farmaceuticos, Sociedade Uniperssoal, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">O.PI.VI S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBS Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBS Human Health Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBS International 9 B.V. </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OBS Mexico Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncoethix GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OncoImmune, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Optimer Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon &#8211; Ecuador S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ecuador</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon &#38; Co.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon (I.A.) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bulgaria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon (India) Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon (Ireland) Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon (Philippines) Incorporated</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon (Shanghai) Pharmaceutical Technology Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peoples Republic of China</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon (Thailand) Ltd.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thailand</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Agencies B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Argentina Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Argentina S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Asia Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Asia Pacific Services Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Austria GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Belgium BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon BH d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bosnia and Herzegovina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon BioSciences International B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon BioSciences Peru S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon BioSciences S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon BioSciences Ventures B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Canada Holdings BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Canada Holdings LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Central East GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Chile SPA</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon China B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Colombia S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colombia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Comercializadora, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Czech Republic s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Denmark ApS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Dominicana S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dominican Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Egypt Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Finance 1 LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Finance Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Finland Oy</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon France</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Global Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Healthcare GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Holding I B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Holdings 9 B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Hong Kong Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hong Kong</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon International GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon International Holdings 9 B.V.  </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon International Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon International Services GmbH</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Ireland Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Italia S.r.l.</font><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Japan Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Japan Holdings G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan </font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon K.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Korea Co. Ltd. </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Korea (the Republic of)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon KSA GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Laboratories Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Latin America S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Latin America Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Limited Liability Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russian Federation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Malaysia Sdn. Bhd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Maroc S.A.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Middle East S.A.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lebanon</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon New Zealand Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Norway AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Participations B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma (Ireland) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma (UK) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma Costa Rica S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costa Rica</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Croatia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma d.o.o. Beograde</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serbia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma FZ-LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Arab Emirates</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma Holdings LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma Israel Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharma S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Pharmaceutical Egypt LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Polska Sp. zo.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Portugal Sociedade Unipessoal Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Puerto Rico LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Puerto Rico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Salud, S.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Singapore Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Slovakia s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Slovakia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon South Africa (Pty) Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Sweden AB</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sweden</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Trade LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Turkey Ilaclari Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon Ukraine Limited Liability Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ukraine</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon USA LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OS ID AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OS ID Hellas M.I.K.E</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">P.T. Merck Sharp &#38; Dohme Indonesia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parlanca Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peloton Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pentair Iceland Holdings ehf.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iceland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pentair Chile SpA</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peocon ehf. </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iceland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pixobot, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Polnet ID Spolka z ograniczona odpowiedzialnoscia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Productos Famaceuticos Organon, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prondil Sociedad An&#243;nima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PT Intervet Indonesia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PT Merck Sharp Dohme Pharma Tbk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> 1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Putexin Investments Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigontec GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigontec, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rosetta Biosoftware UK Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rosetta Inpharmatics LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S.C. Allflex Romania S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S.C.R. (Engineers) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough (India) Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Animal Health Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Bermuda Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Corporation</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Corporation, U.S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough del Peru S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Holdings Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Ind&#250;stria Farmac&#234;utica Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Labo NV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Limited</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paraguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough S.A. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schering-Plough Sante Animale</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCR Allflex Management, Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCR Dairy, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCR Europe S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCR Monitoring Mexico, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sentipharm AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Servicios Organon S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Servicios Veterniarios Servet, Sociedad An&#243;nima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costa Rica</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shanghai MSD Pharmaceutical Trading Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sistemas de Identificacao Animal Ltda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SmartCells, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOL Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-P Ril Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-P Veterinary Holdings Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-P Veterinary Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stallmastaren AB</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SureFlap (NZ) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SureFlap Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SureFlap LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florida</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tag ID Investments, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Theriak B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tilos Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trius Therapeutics LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UAB Merck Sharp &#38; Dohme</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lithuania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undra, S.A. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaki A&#47;S </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaki Aquaculture Systems ehf.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iceland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaki Chile Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaki Scotland Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vall&#233;e S.A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VelosBio Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Venco Farmaceutica S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Venco Holding GmbH</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.540%"><tr><td style="width:1.0%"></td><td style="width:72.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vet Pharma Friesoythe GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veterinaria Premium, Sociedad Anonima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guatemala</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VetInvent, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vetrex B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vetrex Egypt L.L.C.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vilsan Veteriner Ilaclari Ticaret ve Sanayi Anonim Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viralytics Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vocaltag Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vree Health Italia S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vree Health Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Werthenstein Biopharma GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zo&#246;pharm B.V.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:201%">___________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:201%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:201%"> own less than 100%</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">15</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>8
<FILENAME>ex23-consentofindependentr.htm
<DESCRIPTION>EX-23 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i03bd7a67b6474625838185ec25ab5bdf_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form&#160;S-3 (Nos.&#160;333-224016 and 333-224017) and on Form&#160;S-8 (Nos. 333-173025, 333-173024, 333-162883, 333-162884, 333-162885, 333-162886, 333-121089, and 333-233226) of Merck&#160;&#38; Co., Inc. of our report dated February&#160;25, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form&#160;10-K.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>9
<FILENAME>ex241-powerofattorney.htm
<DESCRIPTION>EX-24.1 POWER OF ATTORNEY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iad36bb8675644deda86420ba487b404d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 24.1 </font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;text-decoration:underline">POWER OF ATTORNEY </font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Each of the undersigned does hereby appoint JENNIFER ZACHARY as his&#47;her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck&#160;&#38; Co., Inc. for the fiscal year ended December&#160;31, 2020 under the Securities Exchange Act of 1934, including amendments thereto and all exhibits and other documents in connection therewith. </font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">IN WITNESS WHEREOF, this instrument has been duly executed as of the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:138%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%"> day of February 2021. </font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">MERCK&#160;&#38; CO., Inc. </font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth C. Frazier</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth C. Frazier</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer&#59; Director)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Global Services,<br>  and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert M. Davis</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rita A. Karachun</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance&#8212;Global Controller</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rita A. Karachun</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</font></td></tr></table></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">DIRECTORS </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:42.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Leslie A. Brun</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul B. Rothman</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leslie A. Brun</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul B. Rothman</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas R. Cech</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Patricia F. Russo</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cech</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia F. Russo</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mary Ellen Coe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christine E. Seidman</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mary Ellen Coe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine E. Seidman</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Pamela J. Craig</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Inge G. Thulin</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pamela J. Craig</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inge G. Thulin</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas H. Glocer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathy J. Warden</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas H. Glocer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathy J. Warden</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Risa J. Lavizzo-Mourey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter C. Wendell</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risa J. Lavizzo-Mourey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter C. Wendell</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.2
<SEQUENCE>10
<FILENAME>ex242-certificationofboard.htm
<DESCRIPTION>EX-24.2 CERTIFICATION OF BOARD RESOLUTION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i085873fe650f4152b17185fa2cbfb2f1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 24.2 </font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">I, Kelly Grez, Deputy Corporate Secretary of Merck &#38; Co., Inc. (the &#8220;Company&#8221;), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 25, 2021 in accordance with the provisions of the By-Laws of the Company&#58; </font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;text-decoration:underline">&#8220;Special Resolution No. 13 &#8211; 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%"> </font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">RESOLVED, that the proposed form of the Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2020, attached hereto, is hereby approved with such changes as the proper officers of the Company, with the advice of counsel, deem appropriate&#59; </font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">FURTHER RESOLVED, that each officer and director who may be required to execute the aforesaid Annual Report on Form 10-K or any amendments thereto (whether on behalf of the Company or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) is hereby authorized to execute a power of attorney appointing Jennifer Zachary as his&#47;her true and lawful attorney to execute in his&#47;her name, place and stead (in any such capacity) such Annual Report on Form&#160;10&#8209;K and any and all amendments thereto and any and all exhibits and other documents necessary or incidental in connection therewith and to file the same with the Securities and Exchange Commission, the attorney to have power to act and to have full power and authority to do and perform in the name and on behalf of each of said officers and directors, or both, as the case may be, every act whatsoever necessary or advisable to be done in the premises as fully and to all intents and purposes as any such officer or director might or could do in person&#59; and</font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">FURTHER RESOLVED that an executed copy of the Action by Unanimous Written Consent be filed with the minutes of the meetings of the Board of Directors of the Company.&#34;</font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:138%;position:relative;top:-2.62pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%"> day of February 2021. </font></div><div style="text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:48.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.612%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Corporate Seal&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly Grez</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly Grez<br>Deputy Corporate Secretary</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>ex311-rule13ax14a15dx14ace.htm
<DESCRIPTION>EX-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7d9debf4bda44d1dadc225a81677a510_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth C. Frazier, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div style="margin-top:15pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:45.321%"><tr><td style="width:1.0%"></td><td style="width:9.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth C. Frazier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KENNETH C. FRAZIER<br>Chairman, President and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>ex312-rule13ax14a15dx14ace.htm
<DESCRIPTION>EX-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0afdc07155354291b61d5c1adf70c631_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert M. Davis, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;February&#160;25, 2021 </font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:47.514%"><tr><td style="width:1.0%"></td><td style="width:9.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Executive Vice President, Global Services,<br>and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>ex321-section1350certifica.htm
<DESCRIPTION>EX-32.1 SECTION 1350 CERTIFICATION OF CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib503a881a8da4f2e8d94c452f734c893_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  February 25, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth C. Frazier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;   KENNETH C. FRAZIER</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;     Chairman,&#160;President&#160;and&#160;Chief&#160;Executive&#160;Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>14
<FILENAME>ex322-section1350certifica.htm
<DESCRIPTION>EX-32.2 SECTION 1350 CERTIFICATION OF CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie16fe13895d64e32aa2c25389a530007_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  February 25, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;    ROBERT M. DAVIS</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;      Executive Vice President, Global Services,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and Chief Financial Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>mrk-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3b02abbc-3b84-4f9a-9655-da3777b72964,g:4abc6098-1e3f-4748-b81f-d8be8057e101-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrk="http://www.merck.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merck.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.merck.com/role/CoverPage">
        <link:definition>000010001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofIncome" roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome">
        <link:definition>100010002 - Statement - Consolidated Statement of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofComprehensiveIncome" roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome">
        <link:definition>100020003 - Statement - Consolidated Statement of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheet" roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet">
        <link:definition>100030004 - Statement - Consolidated Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetParenthetical" roleURI="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical">
        <link:definition>100040005 - Statement - Consolidated Balance Sheet (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofEquity" roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity">
        <link:definition>100050006 - Statement - Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofEquityParenthetical" roleURI="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical">
        <link:definition>100060007 - Statement - Consolidated Statement of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlows" roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows">
        <link:definition>100070008 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlowsParenthetical" roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical">
        <link:definition>100080009 - Statement - Consolidated Statement of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://www.merck.com/role/NatureofOperations">
        <link:definition>210011001 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsDetails" roleURI="http://www.merck.com/role/NatureofOperationsDetails">
        <link:definition>240024001 - Disclosure - Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPolicies" roleURI="http://www.merck.com/role/SummaryofAccountingPolicies">
        <link:definition>210031002 - Disclosure - Summary of Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPoliciesPolicies" roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies">
        <link:definition>220042001 - Disclosure - Summary of Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPoliciesDetails" roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails">
        <link:definition>240054002 - Disclosure - Summary of Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements" roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements">
        <link:definition>210061003 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables" roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables">
        <link:definition>230073001 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail" roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail">
        <link:definition>240084003 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Acquisitions Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail" roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail">
        <link:definition>240094004 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Divestitures Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>240104005 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangements" roleURI="http://www.merck.com/role/CollaborativeArrangements">
        <link:definition>210111004 - Disclosure - Collaborative Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsTables" roleURI="http://www.merck.com/role/CollaborativeArrangementsTables">
        <link:definition>230123002 - Disclosure - Collaborative Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsNarrativeDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails">
        <link:definition>240134006 - Disclosure - Collaborative Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails">
        <link:definition>240144007 - Disclosure - Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.merck.com/role/Restructuring">
        <link:definition>210151005 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.merck.com/role/RestructuringTables">
        <link:definition>230163003 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.merck.com/role/RestructuringNarrativeDetails">
        <link:definition>240174008 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails" roleURI="http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails">
        <link:definition>240184009 - Disclosure - Restructuring - Charges Related to Restructuring Program Activities by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails" roleURI="http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails">
        <link:definition>240194010 - Disclosure - Restructuring - Charges and Spending Relating to Restructuring Activities by Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.merck.com/role/FinancialInstruments">
        <link:definition>210201006 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.merck.com/role/FinancialInstrumentsTables">
        <link:definition>230213004 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>240224011 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofNetInvestmentHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
        <link:definition>240234012 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationAboutInterestRateSwapsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails">
        <link:definition>240244013 - Disclosure - Financial Instruments - Information About Interest Rate Swaps (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails">
        <link:definition>240254014 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>240264015 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails">
        <link:definition>240274016 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails">
        <link:definition>240284017 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>240294018 - Disclosure - Financial Instruments - Effects of Derivatives Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails">
        <link:definition>240304019 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>240314020 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
        <link:definition>240324021 - Disclosure - Financial Instruments - Summarized Information About Changes in Liabilities for Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.merck.com/role/Inventories">
        <link:definition>210331007 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.merck.com/role/InventoriesTables">
        <link:definition>230343005 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesInventoriesDetails" roleURI="http://www.merck.com/role/InventoriesInventoriesDetails">
        <link:definition>240354022 - Disclosure - Inventories - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.merck.com/role/InventoriesNarrativeDetails">
        <link:definition>240364023 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibles" roleURI="http://www.merck.com/role/GoodwillandOtherIntangibles">
        <link:definition>210371008 - Disclosure - Goodwill and Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesTables" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesTables">
        <link:definition>230383006 - Disclosure - Goodwill and Other Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesNarrativeDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails">
        <link:definition>240394024 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails">
        <link:definition>240404025 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesOtherIntangiblesDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails">
        <link:definition>240414026 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeases" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeases">
        <link:definition>210421009 - Disclosure - Loans Payable, Long-Term Debt and Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesTables" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables">
        <link:definition>230433007 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesNarrativeDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails">
        <link:definition>240444027 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesLongTermDebtDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails">
        <link:definition>240454028 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails">
        <link:definition>240464029 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails">
        <link:definition>240474030 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1">
        <link:definition>240474030 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandEnvironmentalLiabilities" roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities">
        <link:definition>210481010 - Disclosure - Contingencies and Environmental Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandEnvironmentalLiabilitiesNarrativeDetails" roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails">
        <link:definition>240494031 - Disclosure - Contingencies and Environmental Liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails" roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails">
        <link:definition>240504032 - Disclosure - Contingencies and Environmental Liabilities - Legal Defense Reserves - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails" roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails">
        <link:definition>240514033 - Disclosure - Contingencies and Environmental Liabilities - Environmental Litigation and Matters - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.merck.com/role/Equity">
        <link:definition>210521011 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.merck.com/role/EquityTables">
        <link:definition>230533008 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.merck.com/role/EquityNarrativeDetails">
        <link:definition>240544034 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityShareholdersEquityDetails" roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails">
        <link:definition>240554035 - Disclosure - Equity - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlans" roleURI="http://www.merck.com/role/ShareBasedCompensationPlans">
        <link:definition>210561012 - Disclosure - Share-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansTables" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables">
        <link:definition>230573009 - Disclosure - Share-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansNarrativeDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails">
        <link:definition>240584036 - Disclosure - Share-Based Compensation Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails">
        <link:definition>240594037 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails">
        <link:definition>240604038 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails">
        <link:definition>240614039 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails">
        <link:definition>240624040 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlans" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans">
        <link:definition>210631013 - Disclosure - Pension and Other Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansTables" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables">
        <link:definition>230643010 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansNarrativeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails">
        <link:definition>240654041 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>240664042 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails">
        <link:definition>240674043 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1">
        <link:definition>240674043 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails">
        <link:definition>240684044 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails">
        <link:definition>240694045 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails">
        <link:definition>240704046 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails">
        <link:definition>240714047 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails">
        <link:definition>240724048 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails">
        <link:definition>240734049 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails">
        <link:definition>240744050 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails">
        <link:definition>240754051 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNet" roleURI="http://www.merck.com/role/OtherIncomeExpenseNet">
        <link:definition>210761014 - Disclosure - Other (Income) Expense, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetTables" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables">
        <link:definition>230773011 - Disclosure - Other (Income) Expense, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetNarrativeDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails">
        <link:definition>240784052 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetDetails">
        <link:definition>240794053 - Disclosure - Other (Income) Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncome" roleURI="http://www.merck.com/role/TaxesonIncome">
        <link:definition>210801015 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeTables" roleURI="http://www.merck.com/role/TaxesonIncomeTables">
        <link:definition>230813012 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails">
        <link:definition>240824054 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeNarrativeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails">
        <link:definition>240834055 - Disclosure - Taxes on Income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeIncomeBeforeTaxesDetails" roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails">
        <link:definition>240844056 - Disclosure - Taxes on Income - Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeTaxesonIncomeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails">
        <link:definition>240854057 - Disclosure - Taxes on Income - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeDeferredIncomeTaxesDetails" roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails">
        <link:definition>240864058 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeUnrecognizedTaxBenefitsDetails" roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails">
        <link:definition>240874059 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.merck.com/role/EarningsperShare">
        <link:definition>210881016 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.merck.com/role/EarningsperShareTables">
        <link:definition>230893013 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareCalculationsofEarningsPerShareDetails" roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails">
        <link:definition>240904060 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>240914061 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>210921017 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>230933014 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossDetails" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails">
        <link:definition>240944062 - Disclosure - Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.merck.com/role/SegmentReporting">
        <link:definition>210951018 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.merck.com/role/SegmentReportingTables">
        <link:definition>230963015 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails">
        <link:definition>240974063 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSalesofCompanysProductsDetails" roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails">
        <link:definition>240984064 - Disclosure - Segment Reporting - Sales of Company's Products (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails">
        <link:definition>240994065 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails">
        <link:definition>241004066 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails" roleURI="http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails">
        <link:definition>241014067 - Disclosure - Segment Reporting - Schedule of Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails">
        <link:definition>241024068 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" abstract="true" name="FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" abstract="false" name="ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DificidMember" abstract="true" name="DificidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementsAbstract" abstract="true" name="CollaborativeArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_ThemisMember" abstract="true" name="ThemisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A3.90NotesDue2039Member" abstract="true" name="A3.90NotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" abstract="false" name="OffsettingAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_NuvaringMember" abstract="true" name="NuvaringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherStateCourtMember" abstract="true" name="OtherStateCourtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A1.875EuroNotesDue2026Member" abstract="true" name="A1.875EuroNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AnimalHealthMember" abstract="true" name="AnimalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LossContingencyClaimsonAppealNumber" abstract="false" name="LossContingencyClaimsonAppealNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_Contractterminationfeepayment" abstract="false" name="Contractterminationfeepayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" abstract="true" name="EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_AccrualForChargebacks" abstract="false" name="AccrualForChargebacks" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" abstract="true" name="FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_VioxxMember" abstract="true" name="VioxxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A0.50eurodenominatednotesdue2024Member" abstract="true" name="A0.50eurodenominatednotesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_Pneumovax23Member" abstract="true" name="Pneumovax23Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CorporateObligationsFixedIncomeSecuritiesMember" abstract="true" name="CorporateObligationsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" abstract="true" name="FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_BelsomraMember" abstract="true" name="BelsomraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementProfitSharing" abstract="false" name="CollaborativeArrangementProfitSharing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AcceleratedShareRepurchaseAgreementMember" abstract="true" name="AcceleratedShareRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ProbableContingentPaymentsCollaborativeArrangement" abstract="false" name="ProbableContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" abstract="true" name="DefinedBenefitPlanCashandOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A245NotesDue2050Member" abstract="true" name="A245NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LegalDefenseCostsMember" abstract="true" name="LegalDefenseCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" abstract="true" name="GovernmentAndAgencyObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherPharmaceuticalMember" abstract="true" name="OtherPharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A075NotesDue2026Member" abstract="true" name="A075NotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PensionPlanPriorServiceCostMember" abstract="true" name="PensionPlanPriorServiceCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DevelopedMarketsEquitySecuritiesMember" abstract="true" name="DevelopedMarketsEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_JanuviaMember" abstract="true" name="JanuviaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_NasonexMember" abstract="true" name="NasonexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PrevymisMember" abstract="true" name="PrevymisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" abstract="true" name="SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.5EuroNotesDue2034Member" abstract="true" name="A2.5EuroNotesDue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ZerbaxaMember" abstract="true" name="ZerbaxaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InventoryTable" abstract="true" name="InventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" abstract="false" name="RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_ZepatierMember" abstract="true" name="ZepatierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A415NotesDue2043Member" abstract="true" name="A415NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" abstract="true" name="SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementExpenses" abstract="false" name="CollaborativeArrangementExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AcceleratedShareRepurchaseAgreementOctober292018Member" abstract="true" name="AcceleratedShareRepurchaseAgreementOctober292018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A1.45notesdue2030Member" abstract="true" name="A1.45notesdue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" abstract="false" name="RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_AllianceRevenueAdempasMember" abstract="true" name="AllianceRevenueAdempasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InsuranceContractsOtherInvestmentsMember" abstract="true" name="InsuranceContractsOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FollistimAqMember" abstract="true" name="FollistimAqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" abstract="true" name="GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.35notesdue2040Member" abstract="true" name="A2.35notesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A3.40NotesDue2029Member" abstract="true" name="A3.40NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CorporateObligationsInvestmentFundsMember" abstract="true" name="CorporateObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SeagenMember" abstract="true" name="SeagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillBeNoncash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_CostsExpensesAndOther" abstract="false" name="CostsExpensesAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PensionPlanNetLossMember" abstract="true" name="PensionPlanNetLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DevelopedMarketsEquitiesInvestmentFundsMember" abstract="true" name="DevelopedMarketsEquitiesInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PelotonMember" abstract="true" name="PelotonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AntelliqMember" abstract="true" name="AntelliqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A1.125EuroNotesDue2021Member" abstract="true" name="A1.125EuroNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ArcoxiaMember" abstract="true" name="ArcoxiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ViralyticsMember" abstract="true" name="ViralyticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EurodominatedNotesMember" abstract="true" name="EurodominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" abstract="false" name="IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ScheduleOfOtherIntangiblesTable" abstract="true" name="ScheduleOfOtherIntangiblesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_NoxafilMember" abstract="true" name="NoxafilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract" abstract="true" name="LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsMadetoCollaborativePartner" abstract="false" name="MilestonePaymentsMadetoCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DunboyneMember" abstract="true" name="DunboyneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_IncomeTaxesPayableMember" abstract="true" name="IncomeTaxesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AssetsandLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsandLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member" abstract="true" name="McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SegmentReportingUnallocatedOtherExpensesNet" abstract="false" name="SegmentReportingUnallocatedOtherExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_VelosBioMember" abstract="true" name="VelosBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LenvimaMember" abstract="true" name="LenvimaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SmartCellsProgramMember" abstract="true" name="SmartCellsProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" abstract="true" name="NotesSubjectToRepaymentAtOptionOfHolderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.75NotesDue2025Member" abstract="true" name="A2.75NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" abstract="true" name="CasesCompanyAgreedToTollStatuteOfLimitationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_A145NotesDue2030Member" abstract="true" name="A145NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" abstract="true" name="DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_PatentlitigationMember" abstract="true" name="PatentlitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" abstract="false" name="DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IntangibleAssetsExcludingGoodwillLineItems" abstract="true" name="IntangibleAssetsExcludingGoodwillLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_CommercialandOtherLitigationMember" abstract="true" name="CommercialandOtherLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SivextroMember" abstract="true" name="SivextroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherPostretirementBenefitPlanNetLossMember" abstract="true" name="OtherPostretirementBenefitPlanNetLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_BridionMember" abstract="true" name="BridionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CozaarHyzaarMember" abstract="true" name="CozaarHyzaarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementReceivable" abstract="false" name="CollaborativeArrangementReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AdempasMember" abstract="true" name="AdempasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CGRPreceptorantagonistsMember" abstract="true" name="CGRPreceptorantagonistsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" abstract="true" name="MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ZetiaMember" abstract="true" name="ZetiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_VytorinMember" abstract="true" name="VytorinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DevelopmentMilestonesMember" abstract="true" name="DevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SanofiPasteurMember" abstract="true" name="SanofiPasteurMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SalesDiscounts" abstract="false" name="SalesDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ImplanonNexplanonMember" abstract="true" name="ImplanonNexplanonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" abstract="false" name="EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_CollaborativeArrangementPayable" abstract="false" name="CollaborativeArrangementPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AmortizationOfPurchaseAccountingAdjustments" abstract="false" name="AmortizationOfPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" abstract="false" name="DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A0.500Notesdue2024Member" abstract="true" name="A0.500Notesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" abstract="false" name="DeferredTaxAssetsUnrecognizedTaxBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A2.500Notesdue2034Member" abstract="true" name="A2.500Notesdue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A4.00NotesDue2049Member" abstract="true" name="A4.00NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CommercialmilestoneMember" abstract="true" name="CommercialmilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AcceleratedDepreciationMember" abstract="true" name="AcceleratedDepreciationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" abstract="true" name="SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_NewJerseyStateCourtMember" abstract="true" name="NewJerseyStateCourtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.35NotesDue2022Member" abstract="true" name="A2.35NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SimponiMember" abstract="true" name="SimponiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CubicinMember" abstract="true" name="CubicinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RestructuringReserveNoncashActivity" abstract="false" name="RestructuringReserveNoncashActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrk_CancidasMember" abstract="true" name="CancidasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessFourNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" abstract="true" name="EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" abstract="true" name="ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_MovementinCommonStockandTreasuryStockRollForward" abstract="true" name="MovementinCommonStockandTreasuryStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DeferredTaxLiabilitiesEquityMethodInvestment" abstract="false" name="DeferredTaxLiabilitiesEquityMethodInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ChargesRelatedToProgramDiscontinuation" abstract="false" name="ChargesRelatedToProgramDiscontinuation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A1.375eurodenominatednotesdue2036Member" abstract="true" name="A1.375eurodenominatednotesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A3.70NotesDue2045Member" abstract="true" name="A3.70NotesDue2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SingulairMember" abstract="true" name="SingulairMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_KeytrudaMember" abstract="true" name="KeytrudaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" abstract="false" name="ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_LivestockMember" abstract="true" name="LivestockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A235NotesDue2040Member" abstract="true" name="A235NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.45notesdue2050Member" abstract="true" name="A2.45notesdue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementSalesNet" abstract="false" name="CollaborativeArrangementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PrimaxinMember" abstract="true" name="PrimaxinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LynparzaMember" abstract="true" name="LynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherVariableRateDebtMember" abstract="true" name="OtherVariableRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FixedIncomeObligationsInvestmentFundsMember" abstract="true" name="FixedIncomeObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IsentressIsentressHDMember" abstract="true" name="IsentressIsentressHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AtozetMember" abstract="true" name="AtozetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CompanionAnimalsMember" abstract="true" name="CompanionAnimalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A280NotesDue2023Member" abstract="true" name="A280NotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ArQuleMember" abstract="true" name="ArQuleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember" abstract="true" name="SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A1.375Notesdue2036Member" abstract="true" name="A1.375Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SentinelMember" abstract="true" name="SentinelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SamsungMember" abstract="true" name="SamsungMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AlliancerevenueLynparzaMember" abstract="true" name="AlliancerevenueLynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EmendMember" abstract="true" name="EmendMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.90NotesDue2024Member" abstract="true" name="A2.90NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FosamaxMember" abstract="true" name="FosamaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" abstract="false" name="ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrk_JanumetMember" abstract="true" name="JanumetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FederalMember" abstract="true" name="FederalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PremiumOnSharesAcquired" abstract="false" name="PremiumOnSharesAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A1.85NotesDue2020Member" abstract="true" name="A1.85NotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RevenuePerformanceObligationPaymentTerms" abstract="false" name="RevenuePerformanceObligationPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_ConsumercarebusinessMember" abstract="true" name="ConsumercarebusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" abstract="false" name="CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DebtSecuritiesandEquitySecuritiesFVNI" abstract="false" name="DebtSecuritiesandEquitySecuritiesFVNI" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OtherContractTerminationCosts" abstract="false" name="OtherContractTerminationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OtherNonoperatingIncomeExpenseOther" abstract="false" name="OtherNonoperatingIncomeExpenseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PharmaceuticalsegmentMember" abstract="true" name="PharmaceuticalsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_IAVIMember" abstract="true" name="IAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.40NotesDue2022Member" abstract="true" name="A2.40NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RealEstateInvestmentFundsMember" abstract="true" name="RealEstateInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A1.875Notesdue2026Member" abstract="true" name="A1.875Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InventoriesProducedinPreparationforProductLaunchesMember" abstract="true" name="InventoriesProducedinPreparationforProductLaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DefinedBenefitPlanOtherChangesPlanAssets" abstract="false" name="DefinedBenefitPlanOtherChangesPlanAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotyetCommencedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A0.75notesdue2026Member" abstract="true" name="A0.75notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ImmuneDesignMember" abstract="true" name="ImmuneDesignMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_GardasilGardasil9Member" abstract="true" name="GardasilGardasil9Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ChargeForAssetAcquisition" abstract="false" name="ChargeForAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AnimalHealthsegmentMember" abstract="true" name="AnimalHealthsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AccrualForRebates" abstract="false" name="AccrualForRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AllianceRevenueKoselugoMember" abstract="true" name="AllianceRevenueKoselugoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" abstract="true" name="OtherPostretirementBenefitPlanPriorServiceCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InvanzMember" abstract="true" name="InvanzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" abstract="true" name="MortgageAndAssetBackedSecuritiesInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ProQuadMMRIIVarivaxMember" abstract="true" name="ProQuadMMRIIVarivaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" abstract="true" name="InventoryNotExpectedtobeSoldWithinOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CaliforniaStateCourtMember" abstract="true" name="CaliforniaStateCourtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EmergingMarketsEquitiesInvestmentFundsMember" abstract="true" name="EmergingMarketsEquitiesInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A1.125Notesdue2021Member" abstract="true" name="A1.125Notesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RotateqMember" abstract="true" name="RotateqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" abstract="false" name="AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrk_HealthcareServicesSegmentMember" abstract="true" name="HealthcareServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_IOmetPharmaLtdMember" abstract="true" name="IOmetPharmaLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RoyaltyRatePercentage" abstract="false" name="RoyaltyRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_ContingentPaymentsCollaborativeArrangement" abstract="false" name="ContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IncomeTaxTable" abstract="true" name="IncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_OncoImmuneMember" abstract="true" name="OncoImmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_TermForPayingOffEnvironmentalLiabilities" abstract="false" name="TermForPayingOffEnvironmentalLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_LongTermDebtExcludingCurrentMaturitiesMember" abstract="true" name="LongTermDebtExcludingCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_TukysaMember" abstract="true" name="TukysaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrk_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessFiveNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts" abstract="false" name="CollaborativeArrangementRevenuesNetofCommercializationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A3.875NotesDue2021Member" abstract="true" name="A3.875NotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_VaqtaMember" abstract="true" name="VaqtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RecognizedAsAbstract" abstract="true" name="RecognizedAsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>mrk-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3b02abbc-3b84-4f9a-9655-da3777b72964,g:4abc6098-1e3f-4748-b81f-d8be8057e101-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofIncome"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82060758-1ea3-4109-a617-5ea9c369e7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_92311b73-1098-443b-b9eb-cca554f12aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82060758-1ea3-4109-a617-5ea9c369e7a3" xlink:to="loc_us-gaap_Revenues_92311b73-1098-443b-b9eb-cca554f12aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_cc745909-ab81-4548-adad-f1ef69a96880" xlink:href="mrk-20201231.xsd#mrk_CostsExpensesAndOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82060758-1ea3-4109-a617-5ea9c369e7a3" xlink:to="loc_mrk_CostsExpensesAndOther_cc745909-ab81-4548-adad-f1ef69a96880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_45d7250f-200f-4a92-85ac-3660cca8e53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_87ffac1b-1aaf-433e-9d82-e3e5c4fd6642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_45d7250f-200f-4a92-85ac-3660cca8e53e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_87ffac1b-1aaf-433e-9d82-e3e5c4fd6642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6b356962-d8d9-4aac-980b-ab62597f8f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_45d7250f-200f-4a92-85ac-3660cca8e53e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6b356962-d8d9-4aac-980b-ab62597f8f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_aaa182ba-eaf6-4a6f-8810-221639a68715" xlink:href="mrk-20201231.xsd#mrk_CostsExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_33926577-195f-460a-a2e7-a3d8c6704d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_aaa182ba-eaf6-4a6f-8810-221639a68715" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_33926577-195f-460a-a2e7-a3d8c6704d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cee9e5ca-ad24-48a1-bf48-7f11850335b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_aaa182ba-eaf6-4a6f-8810-221639a68715" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cee9e5ca-ad24-48a1-bf48-7f11850335b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_89f82725-9099-4bd8-b8b1-e86af5953025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_aaa182ba-eaf6-4a6f-8810-221639a68715" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_89f82725-9099-4bd8-b8b1-e86af5953025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_65f1b1ca-6ef0-41ac-bd6e-ea799a97c400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_aaa182ba-eaf6-4a6f-8810-221639a68715" xlink:to="loc_us-gaap_RestructuringCharges_65f1b1ca-6ef0-41ac-bd6e-ea799a97c400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2a60f301-6a3e-4a7e-96f8-b15707b1bc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_aaa182ba-eaf6-4a6f-8810-221639a68715" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2a60f301-6a3e-4a7e-96f8-b15707b1bc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_611bb216-1b63-49e9-8555-fc4da62ff9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_09aea7f8-d4c7-4b2a-923a-4dec35273d67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_611bb216-1b63-49e9-8555-fc4da62ff9cb" xlink:to="loc_us-gaap_ProfitLoss_09aea7f8-d4c7-4b2a-923a-4dec35273d67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_627082a4-e7d7-46a7-90a7-dd672adae29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_611bb216-1b63-49e9-8555-fc4da62ff9cb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_627082a4-e7d7-46a7-90a7-dd672adae29f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7afce731-469d-4f3e-8e6d-b8629f4ffb3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1cad012f-a65a-43af-b2d3-65e18332d1a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7afce731-469d-4f3e-8e6d-b8629f4ffb3e" xlink:to="loc_us-gaap_NetIncomeLoss_1cad012f-a65a-43af-b2d3-65e18332d1a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c0963593-6cc4-4396-89cf-ab99e032e663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7afce731-469d-4f3e-8e6d-b8629f4ffb3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c0963593-6cc4-4396-89cf-ab99e032e663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_feda4519-7969-4e24-bde8-b4dc2867fafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3cc04a43-1eef-41b3-a900-9eb5d48f893d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_feda4519-7969-4e24-bde8-b4dc2867fafb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3cc04a43-1eef-41b3-a900-9eb5d48f893d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8a12ec3e-0db8-407e-bf65-6c4157323e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_feda4519-7969-4e24-bde8-b4dc2867fafb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8a12ec3e-0db8-407e-bf65-6c4157323e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bc978708-2d87-49ea-986a-1ae37bdf24c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_feda4519-7969-4e24-bde8-b4dc2867fafb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bc978708-2d87-49ea-986a-1ae37bdf24c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_09c8646c-85db-412f-9ec2-b2bc2a69c412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_feda4519-7969-4e24-bde8-b4dc2867fafb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_09c8646c-85db-412f-9ec2-b2bc2a69c412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_87da5632-2876-4a81-ba6e-aacf43252817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_feda4519-7969-4e24-bde8-b4dc2867fafb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_87da5632-2876-4a81-ba6e-aacf43252817" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedBalanceSheet"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ef5b5a0b-1055-42af-8062-20b4e8e499cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b853fb31-c040-40c2-a286-7e96fc30b2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef5b5a0b-1055-42af-8062-20b4e8e499cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b853fb31-c040-40c2-a286-7e96fc30b2c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2adfbdc4-69f8-4b64-8c55-6daaaa4b0031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef5b5a0b-1055-42af-8062-20b4e8e499cc" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2adfbdc4-69f8-4b64-8c55-6daaaa4b0031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_068abba4-ff3d-412c-b02a-4eb450b05b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef5b5a0b-1055-42af-8062-20b4e8e499cc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_068abba4-ff3d-412c-b02a-4eb450b05b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_07d6e948-04d3-4e07-8fce-844e24866f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef5b5a0b-1055-42af-8062-20b4e8e499cc" xlink:to="loc_us-gaap_InventoryNet_07d6e948-04d3-4e07-8fce-844e24866f8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_94eb755d-c2ba-4511-8de0-61d23ea307bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef5b5a0b-1055-42af-8062-20b4e8e499cc" xlink:to="loc_us-gaap_OtherAssetsCurrent_94eb755d-c2ba-4511-8de0-61d23ea307bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ceb3e0b-8806-4b7c-8cc2-a64e9d72168c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_51740f68-c620-4c4f-8c29-97ecad6ef8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ceb3e0b-8806-4b7c-8cc2-a64e9d72168c" xlink:to="loc_us-gaap_LiabilitiesCurrent_51740f68-c620-4c4f-8c29-97ecad6ef8b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4c99600e-c028-4d30-8635-dfb26acca609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ceb3e0b-8806-4b7c-8cc2-a64e9d72168c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4c99600e-c028-4d30-8635-dfb26acca609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c9e1b3e-2b80-4e52-9224-8304a52262df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ceb3e0b-8806-4b7c-8cc2-a64e9d72168c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c9e1b3e-2b80-4e52-9224-8304a52262df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fe270828-93d5-4e09-83ae-73b9bb2b277f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ceb3e0b-8806-4b7c-8cc2-a64e9d72168c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fe270828-93d5-4e09-83ae-73b9bb2b277f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_79ac799f-aa0f-460a-80a3-5c3218dcdb82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ceb3e0b-8806-4b7c-8cc2-a64e9d72168c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_79ac799f-aa0f-460a-80a3-5c3218dcdb82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0a2af27c-89a2-4128-9002-0681414d45f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_59a6290f-ef31-46c8-adc8-273228f9cfc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0a2af27c-89a2-4128-9002-0681414d45f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_59a6290f-ef31-46c8-adc8-273228f9cfc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e569cb1c-2a6f-4aaa-9824-7bef16003567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0a2af27c-89a2-4128-9002-0681414d45f7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e569cb1c-2a6f-4aaa-9824-7bef16003567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_cb24cee2-7579-4fd6-970f-c2b31e2b6221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_395abd3c-60b9-41d8-a4e7-1aa54e213913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_cb24cee2-7579-4fd6-970f-c2b31e2b6221" xlink:to="loc_us-gaap_CommonStockValue_395abd3c-60b9-41d8-a4e7-1aa54e213913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_215497af-9f3a-49df-b8f5-5af6fae392f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_cb24cee2-7579-4fd6-970f-c2b31e2b6221" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_215497af-9f3a-49df-b8f5-5af6fae392f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14d44b51-fb6f-4ef9-8b00-1fea6e300c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_cb24cee2-7579-4fd6-970f-c2b31e2b6221" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14d44b51-fb6f-4ef9-8b00-1fea6e300c5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c5033341-16ef-42c1-8db8-17995b5559a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_cb24cee2-7579-4fd6-970f-c2b31e2b6221" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c5033341-16ef-42c1-8db8-17995b5559a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c894024c-165d-4d4d-9798-9fc1b69d4a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_20666bd6-d882-48fc-91f8-3988858606b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c894024c-165d-4d4d-9798-9fc1b69d4a9f" xlink:to="loc_us-gaap_Land_20666bd6-d882-48fc-91f8-3988858606b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_ef4b216f-9535-4bdf-9dae-90f3ef2f0f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c894024c-165d-4d4d-9798-9fc1b69d4a9f" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_ef4b216f-9535-4bdf-9dae-90f3ef2f0f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_bba901a2-920b-4069-ae84-b775895d63a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c894024c-165d-4d4d-9798-9fc1b69d4a9f" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_bba901a2-920b-4069-ae84-b775895d63a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_2b783457-e166-435f-bb93-5a93240e0091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c894024c-165d-4d4d-9798-9fc1b69d4a9f" xlink:to="loc_us-gaap_ConstructionInProgressGross_2b783457-e166-435f-bb93-5a93240e0091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4827576b-4bc0-42de-8bf0-674658ca3a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_8aaf0fdd-6816-4d78-aa76-c5e05eb9d5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4827576b-4bc0-42de-8bf0-674658ca3a69" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_8aaf0fdd-6816-4d78-aa76-c5e05eb9d5bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_53682999-e4ad-4b82-890b-59b2f43fa215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4827576b-4bc0-42de-8bf0-674658ca3a69" xlink:to="loc_us-gaap_TreasuryStockValue_53682999-e4ad-4b82-890b-59b2f43fa215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9e0dcd6b-7bcf-4458-b0f9-e4762c47c712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_29c7ef60-9170-4287-9a97-ae2769e6cbc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e0dcd6b-7bcf-4458-b0f9-e4762c47c712" xlink:to="loc_us-gaap_DebtCurrent_29c7ef60-9170-4287-9a97-ae2769e6cbc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f1870d23-fd38-4f8c-99c3-eb23b823971a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e0dcd6b-7bcf-4458-b0f9-e4762c47c712" xlink:to="loc_us-gaap_AccountsPayableCurrent_f1870d23-fd38-4f8c-99c3-eb23b823971a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f6f6d495-b6d8-47f7-a73b-6dce572bd15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e0dcd6b-7bcf-4458-b0f9-e4762c47c712" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f6f6d495-b6d8-47f7-a73b-6dce572bd15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_8e3b6c28-8a6f-43e5-94c1-1d2d82eb27ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e0dcd6b-7bcf-4458-b0f9-e4762c47c712" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_8e3b6c28-8a6f-43e5-94c1-1d2d82eb27ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_1c74feed-d723-4035-b1f8-1a18ce1ab14e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e0dcd6b-7bcf-4458-b0f9-e4762c47c712" xlink:to="loc_us-gaap_DividendsPayableCurrent_1c74feed-d723-4035-b1f8-1a18ce1ab14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8dfbef19-0dcc-4c0c-99b6-c37128151fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7052efbc-7ff6-4d93-bc87-9e16919c37ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8dfbef19-0dcc-4c0c-99b6-c37128151fe6" xlink:to="loc_us-gaap_AssetsCurrent_7052efbc-7ff6-4d93-bc87-9e16919c37ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_eae7c5ff-0bd1-40d1-8c99-8ae9624a0d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8dfbef19-0dcc-4c0c-99b6-c37128151fe6" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_eae7c5ff-0bd1-40d1-8c99-8ae9624a0d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c7118a51-f665-40c8-af23-65bb52f99f10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8dfbef19-0dcc-4c0c-99b6-c37128151fe6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c7118a51-f665-40c8-af23-65bb52f99f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc207f16-2213-4ef6-9b50-16def8e0798f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8dfbef19-0dcc-4c0c-99b6-c37128151fe6" xlink:to="loc_us-gaap_Goodwill_dc207f16-2213-4ef6-9b50-16def8e0798f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a8b8875-8cf0-4ba0-9e3c-bc363f511efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8dfbef19-0dcc-4c0c-99b6-c37128151fe6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a8b8875-8cf0-4ba0-9e3c-bc363f511efe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_2f10fbbc-2781-4754-8513-8e0475951fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8dfbef19-0dcc-4c0c-99b6-c37128151fe6" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_2f10fbbc-2781-4754-8513-8e0475951fb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07694e73-10d3-43de-a7c8-cfc4f16620e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52bbb7fe-2e93-4dc2-a6ff-12c142b733ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07694e73-10d3-43de-a7c8-cfc4f16620e0" xlink:to="loc_us-gaap_StockholdersEquity_52bbb7fe-2e93-4dc2-a6ff-12c142b733ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_305d7b9f-b583-4988-9b7d-8be44b5adcd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07694e73-10d3-43de-a7c8-cfc4f16620e0" xlink:to="loc_us-gaap_MinorityInterest_305d7b9f-b583-4988-9b7d-8be44b5adcd4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedBalanceSheetParenthetical"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_91166152-c0a3-4597-a9f2-76e91fa13b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_91166152-c0a3-4597-a9f2-76e91fa13b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7cca428b-f237-4cb0-9bd5-56f9a369bf24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7cca428b-f237-4cb0-9bd5-56f9a369bf24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_58b2bd9a-b267-47fe-addb-378b4bc1d357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_ShareBasedCompensation_58b2bd9a-b267-47fe-addb-378b4bc1d357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7bd54584-9f62-436f-8df3-900eec186970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7bd54584-9f62-436f-8df3-900eec186970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_215f542c-4d60-41d1-bb73-5e228ca8eb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_215f542c-4d60-41d1-bb73-5e228ca8eb25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c6b14d0d-9e2b-48ff-b3df-2a4d6268adb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c6b14d0d-9e2b-48ff-b3df-2a4d6268adb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions_58d85b92-939b-4d57-b0b5-b59c2c28173a" xlink:href="mrk-20201231.xsd#mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions_58d85b92-939b-4d57-b0b5-b59c2c28173a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_20fd101d-bd42-48f1-ac5a-fa620770a2e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_ProfitLoss_20fd101d-bd42-48f1-ac5a-fa620770a2e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargeForAssetAcquisition_86970ef6-733d-4645-a657-3a2e0421b4dc" xlink:href="mrk-20201231.xsd#mrk_ChargeForAssetAcquisition"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_mrk_ChargeForAssetAcquisition_86970ef6-733d-4645-a657-3a2e0421b4dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c3bb960b-1489-41a3-9104-717780720867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c3bb960b-1489-41a3-9104-717780720867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_12cc6bed-ad24-447c-a593-7f840e3af668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_12cc6bed-ad24-447c-a593-7f840e3af668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3e6586f6-e9f4-4638-b0f6-96c1fc5a7bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3e6586f6-e9f4-4638-b0f6-96c1fc5a7bee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_fa4aefd9-4f37-40d6-b95a-61ba429097d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_AdjustmentForAmortization_fa4aefd9-4f37-40d6-b95a-61ba429097d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_c8901b68-13df-444e-b3a0-337a017183d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_c8901b68-13df-444e-b3a0-337a017183d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e1cbd989-ddd1-4205-8831-44da871a3a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e1cbd989-ddd1-4205-8831-44da871a3a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_7c694e44-011e-42dd-8b70-12b5b2533a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_7c694e44-011e-42dd-8b70-12b5b2533a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5fdf039a-2bde-4e5f-b1a8-c2d679755366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2a2ea35-8f61-41a7-b8fd-cdd0e2bec114" xlink:to="loc_us-gaap_Depreciation_5fdf039a-2bde-4e5f-b1a8-c2d679755366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_046369a5-3130-4e6a-b66d-ab9bbde83690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_afa33447-8e63-42aa-87dc-b5a7fdc0cb69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_046369a5-3130-4e6a-b66d-ab9bbde83690" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_afa33447-8e63-42aa-87dc-b5a7fdc0cb69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dc907c0-b59d-469c-8b6c-e8cc6b054b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_046369a5-3130-4e6a-b66d-ab9bbde83690" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dc907c0-b59d-469c-8b6c-e8cc6b054b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8fa98fa-b832-4d31-a868-6358bc1d166d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_046369a5-3130-4e6a-b66d-ab9bbde83690" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8fa98fa-b832-4d31-a868-6358bc1d166d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a40923ca-4bb7-4a31-965a-f1a1cf569c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_046369a5-3130-4e6a-b66d-ab9bbde83690" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a40923ca-4bb7-4a31-965a-f1a1cf569c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b22b4916-98f6-480c-8893-5dfbcc8c5b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_f96dfe84-dc73-4278-84c3-7dfddcd15c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b22b4916-98f6-480c-8893-5dfbcc8c5b0f" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_f96dfe84-dc73-4278-84c3-7dfddcd15c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5037bb50-5b7e-4f4f-ae9c-507708c46214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b22b4916-98f6-480c-8893-5dfbcc8c5b0f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5037bb50-5b7e-4f4f-ae9c-507708c46214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3448944f-a700-417c-bf40-15e00a7c9ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b22b4916-98f6-480c-8893-5dfbcc8c5b0f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3448944f-a700-417c-bf40-15e00a7c9ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_30a02afe-17db-4d68-a3a4-4c6f5dfb9d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b22b4916-98f6-480c-8893-5dfbcc8c5b0f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_30a02afe-17db-4d68-a3a4-4c6f5dfb9d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_b7ea343e-8f72-4e94-b7e3-88726c41a817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b22b4916-98f6-480c-8893-5dfbcc8c5b0f" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_b7ea343e-8f72-4e94-b7e3-88726c41a817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_781ebdf4-10ff-4e85-b0fe-cefdcc1115a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b22b4916-98f6-480c-8893-5dfbcc8c5b0f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_781ebdf4-10ff-4e85-b0fe-cefdcc1115a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cf79cffe-2e0b-4bce-8c42-55cbce948aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b22b4916-98f6-480c-8893-5dfbcc8c5b0f" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cf79cffe-2e0b-4bce-8c42-55cbce948aaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_10c13c89-f1bd-4553-b2ac-5649003c7fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_10c13c89-f1bd-4553-b2ac-5649003c7fb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_9bc501ed-c074-4198-8684-29652f4e36e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_9bc501ed-c074-4198-8684-29652f4e36e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_65d4e236-d220-43be-8a37-f4d6c403e153" xlink:href="mrk-20201231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_65d4e236-d220-43be-8a37-f4d6c403e153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_427ff85b-ab86-4ac1-a348-1f8157c89269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_427ff85b-ab86-4ac1-a348-1f8157c89269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_9f24a0d0-8b50-471b-b695-cb8c36138f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_9f24a0d0-8b50-471b-b695-cb8c36138f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_d4df3734-579f-4b94-8750-a04462912cf9" xlink:href="mrk-20201231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_d4df3734-579f-4b94-8750-a04462912cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_edbe75b8-a795-453c-911b-75794c8b2402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_edbe75b8-a795-453c-911b-75794c8b2402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_18cde663-b246-4af6-b539-ab4fcb670866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_18cde663-b246-4af6-b539-ab4fcb670866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_fc7ac898-6079-4044-ab9e-d9764274bacb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_fc7ac898-6079-4044-ab9e-d9764274bacb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_1f44bd8d-f179-4834-8550-6038533b445c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_578a137b-75ca-4514-921b-a23ba4dd8d24" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_1f44bd8d-f179-4834-8550-6038533b445c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofCashFlowsParenthetical"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperations" xlink:type="simple" xlink:href="mrk-20201231.xsd#NatureofOperations"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/NatureofOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#NatureofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a59aee10-e4e5-466b-b988-c18f6ee4886e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb9f5c8a-6ad9-48ee-a8de-705a239e1ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a59aee10-e4e5-466b-b988-c18f6ee4886e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb9f5c8a-6ad9-48ee-a8de-705a239e1ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d4a4085c-21dd-429d-b4a8-758211db8681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a59aee10-e4e5-466b-b988-c18f6ee4886e" xlink:to="loc_us-gaap_Goodwill_d4a4085c-21dd-429d-b4a8-758211db8681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0589935d-e7cd-446f-a6ce-16bc119c4c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_78ce47f2-d320-4b32-952c-b0520a7663c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0589935d-e7cd-446f-a6ce-16bc119c4c1c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_78ce47f2-d320-4b32-952c-b0520a7663c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_decbbef0-db1f-447a-9bbf-73492454cd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0589935d-e7cd-446f-a6ce-16bc119c4c1c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_decbbef0-db1f-447a-9bbf-73492454cd06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2de018ac-6146-4a4c-a6c2-b64f8051fc31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0589935d-e7cd-446f-a6ce-16bc119c4c1c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2de018ac-6146-4a4c-a6c2-b64f8051fc31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dcb88a3c-be74-46a2-9364-9da72e1e1ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0589935d-e7cd-446f-a6ce-16bc119c4c1c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dcb88a3c-be74-46a2-9364-9da72e1e1ae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e78d704a-6d37-439f-8d8b-e28663a08bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0589935d-e7cd-446f-a6ce-16bc119c4c1c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e78d704a-6d37-439f-8d8b-e28663a08bb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ffacc7f7-bc4a-411e-89a7-d7c932968af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0589935d-e7cd-446f-a6ce-16bc119c4c1c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ffacc7f7-bc4a-411e-89a7-d7c932968af9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_564ccec4-69b9-44f2-8a17-806417acdd59" xlink:href="mrk-20201231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0589935d-e7cd-446f-a6ce-16bc119c4c1c" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_564ccec4-69b9-44f2-8a17-806417acdd59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangements"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_1bacc4ee-b2b6-44c1-9197-26c197011792" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_b391f922-5be5-4129-aa6f-8b57e372bc57" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_1bacc4ee-b2b6-44c1-9197-26c197011792" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_b391f922-5be5-4129-aa6f-8b57e372bc57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_7195c7e4-7494-4e02-a096-3f00af03365d" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_1bacc4ee-b2b6-44c1-9197-26c197011792" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_7195c7e4-7494-4e02-a096-3f00af03365d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20201231.xsd#Restructuring"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationAboutInterestRateSwapsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFairValueofHedgesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_997565b2-df21-45bb-a1ad-73a758d37e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4eb360d5-ec63-47b7-b3d6-32c220cd7998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_997565b2-df21-45bb-a1ad-73a758d37e9a" xlink:to="loc_us-gaap_DerivativeAssets_4eb360d5-ec63-47b7-b3d6-32c220cd7998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_74243ee4-4492-4250-b598-60ccb99bdbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_997565b2-df21-45bb-a1ad-73a758d37e9a" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_74243ee4-4492-4250-b598-60ccb99bdbd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7a4b1ad5-2245-4b08-957b-5fb35d331396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_997565b2-df21-45bb-a1ad-73a758d37e9a" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7a4b1ad5-2245-4b08-957b-5fb35d331396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_8a792940-baab-4d1a-8cad-de3a70dd409c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_343cf22b-6806-4a06-a569-af08b8b99fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_8a792940-baab-4d1a-8cad-de3a70dd409c" xlink:to="loc_us-gaap_DerivativeLiabilities_343cf22b-6806-4a06-a569-af08b8b99fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_b54a9ff9-3916-4007-8ee6-d4849cf8ac0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_8a792940-baab-4d1a-8cad-de3a70dd409c" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_b54a9ff9-3916-4007-8ee6-d4849cf8ac0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_ac3c1494-d849-42c2-ae00-a0adae6d4b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_8a792940-baab-4d1a-8cad-de3a70dd409c" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_ac3c1494-d849-42c2-ae00-a0adae6d4b15" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f6ac2897-3727-49ba-b5c4-ceb36d98e050" xlink:href="mrk-20201231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b9f0fa68-27c2-40af-a2f8-4ccf53fc17d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f6ac2897-3727-49ba-b5c4-ceb36d98e050" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b9f0fa68-27c2-40af-a2f8-4ccf53fc17d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_903ea42a-4b13-48fe-8e38-31c8702b875d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f6ac2897-3727-49ba-b5c4-ceb36d98e050" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_903ea42a-4b13-48fe-8e38-31c8702b875d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_b1b03b74-0002-4ad8-ba57-22f1f15674ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cb7a3dc9-9f71-424d-b833-fa50c4645faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_b1b03b74-0002-4ad8-ba57-22f1f15674ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cb7a3dc9-9f71-424d-b833-fa50c4645faf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cff50f02-017f-4154-a6f5-b3ee0ae454ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_b1b03b74-0002-4ad8-ba57-22f1f15674ff" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cff50f02-017f-4154-a6f5-b3ee0ae454ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5c8b6a02-ec71-483f-ae65-38f7ff733150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_18149324-5a69-4025-a381-472d16f6ed9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5c8b6a02-ec71-483f-ae65-38f7ff733150" xlink:to="loc_us-gaap_TradingSecurities_18149324-5a69-4025-a381-472d16f6ed9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_94bb6156-d9a3-461a-8b7b-d01056232102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5c8b6a02-ec71-483f-ae65-38f7ff733150" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_94bb6156-d9a3-461a-8b7b-d01056232102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f4ff2427-ac9e-4040-b70a-1f245a0cd937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5c8b6a02-ec71-483f-ae65-38f7ff733150" xlink:to="loc_us-gaap_DerivativeAssets_f4ff2427-ac9e-4040-b70a-1f245a0cd937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2760be22-bd6e-4cb9-875a-fae1e3efd7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d5955e7c-d070-4538-854e-0e0c4c7d17bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_2760be22-bd6e-4cb9-875a-fae1e3efd7c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d5955e7c-d070-4538-854e-0e0c4c7d17bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_be7a7309-3cd9-46dc-920b-07c8e7bb6702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_2760be22-bd6e-4cb9-875a-fae1e3efd7c7" xlink:to="loc_us-gaap_DerivativeLiabilities_be7a7309-3cd9-46dc-920b-07c8e7bb6702" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20201231.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_3313da22-e61d-451c-b430-14e8515262da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_8f18d32f-cac3-41cf-b068-987fd40d5ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_3313da22-e61d-451c-b430-14e8515262da" xlink:to="loc_us-gaap_InventoryFinishedGoods_8f18d32f-cac3-41cf-b068-987fd40d5ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_304557a3-5bd5-40ef-8751-0c3c4951955e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_3313da22-e61d-451c-b430-14e8515262da" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_304557a3-5bd5-40ef-8751-0c3c4951955e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_acbdf0e9-483b-49cb-adc1-0b9c81324905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_3313da22-e61d-451c-b430-14e8515262da" xlink:to="loc_us-gaap_OtherInventorySupplies_acbdf0e9-483b-49cb-adc1-0b9c81324905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_a3249c6c-5712-4d4d-a287-a9fa16618f91" xlink:href="mrk-20201231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_918cb87f-13f0-4539-a9f7-78d66882ce1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_a3249c6c-5712-4d4d-a287-a9fa16618f91" xlink:to="loc_us-gaap_InventoryLIFOReserve_918cb87f-13f0-4539-a9f7-78d66882ce1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c0a1a21c-4936-4a98-b8c9-766802862caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_a3249c6c-5712-4d4d-a287-a9fa16618f91" xlink:to="loc_us-gaap_InventoryGross_c0a1a21c-4936-4a98-b8c9-766802862caf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangibles"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4ce87219-22ad-4d17-8a1f-9ea196ecf718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1c4de2c6-3dd5-4202-bc42-7af12e57771a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4ce87219-22ad-4d17-8a1f-9ea196ecf718" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1c4de2c6-3dd5-4202-bc42-7af12e57771a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_03a45ef9-f5c8-4ece-ba4b-806bfea527a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4ce87219-22ad-4d17-8a1f-9ea196ecf718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_03a45ef9-f5c8-4ece-ba4b-806bfea527a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeases"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6e4c9ebc-a76d-40f3-a7bf-c55ed464557e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6afe53b5-094d-4d25-9a42-ec0ba168572f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_6e4c9ebc-a76d-40f3-a7bf-c55ed464557e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6afe53b5-094d-4d25-9a42-ec0ba168572f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0fafab3-1450-4c98-97d5-9fdf122cba8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_6e4c9ebc-a76d-40f3-a7bf-c55ed464557e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0fafab3-1450-4c98-97d5-9fdf122cba8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_772ff28b-f4f2-4a53-b8c1-72946f4a69d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b038a768-0942-441a-b5c6-f6283acd494d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_772ff28b-f4f2-4a53-b8c1-72946f4a69d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b038a768-0942-441a-b5c6-f6283acd494d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ce98b8b5-e76a-4094-aa6f-819651735910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_772ff28b-f4f2-4a53-b8c1-72946f4a69d3" xlink:to="loc_us-gaap_OperatingLeaseLiability_ce98b8b5-e76a-4094-aa6f-819651735910" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44fbe06d-8fdb-4fa8-9d86-880b5871d0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a07b6359-59a2-4bb9-9e73-e6bebe133a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44fbe06d-8fdb-4fa8-9d86-880b5871d0db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a07b6359-59a2-4bb9-9e73-e6bebe133a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_83d4f909-6a72-4a50-85a5-4e606910874e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44fbe06d-8fdb-4fa8-9d86-880b5871d0db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_83d4f909-6a72-4a50-85a5-4e606910874e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6a2e3cb4-bf06-45ef-84d3-c07c0e2a0428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44fbe06d-8fdb-4fa8-9d86-880b5871d0db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6a2e3cb4-bf06-45ef-84d3-c07c0e2a0428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1390c64f-016d-4e49-9b13-792177752f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44fbe06d-8fdb-4fa8-9d86-880b5871d0db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1390c64f-016d-4e49-9b13-792177752f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_304fc469-70df-4bca-bee8-b84347fc7449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44fbe06d-8fdb-4fa8-9d86-880b5871d0db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_304fc469-70df-4bca-bee8-b84347fc7449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5f3a238a-531b-48f2-83ba-572985293286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44fbe06d-8fdb-4fa8-9d86-880b5871d0db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5f3a238a-531b-48f2-83ba-572985293286" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilities"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20201231.xsd#Equity"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlans"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_008f52c1-1c48-4d7e-a864-5123869e8e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_008f52c1-1c48-4d7e-a864-5123869e8e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6d230aad-e381-4f97-b5b1-035fae48b9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6d230aad-e381-4f97-b5b1-035fae48b9b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_8448d8f3-7a40-4464-8984-a3105b771742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_8448d8f3-7a40-4464-8984-a3105b771742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d46fd8ce-318f-4048-b98a-fa0cafc1f7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d46fd8ce-318f-4048-b98a-fa0cafc1f7ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_dc1f3e03-54a6-4112-af70-b081c1febcce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_dc1f3e03-54a6-4112-af70-b081c1febcce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_f89a198c-a880-4b54-b140-d1412283727c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_f89a198c-a880-4b54-b140-d1412283727c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_9e0b310b-e92b-400c-a826-fe9372236297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_9e0b310b-e92b-400c-a826-fe9372236297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_774b14a4-86d2-4aef-9c82-a296431e762e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c68ba673-8e96-4142-9a86-b458ff6a833b" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_774b14a4-86d2-4aef-9c82-a296431e762e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_8b88077f-63cd-4677-ad4c-a0d1709745c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_22bc2c7d-8ce3-4084-9a56-e9b15d79b85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_8b88077f-63cd-4677-ad4c-a0d1709745c5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_22bc2c7d-8ce3-4084-9a56-e9b15d79b85c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_1b80a810-e49b-4e0c-b200-87afbd5b9195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_8b88077f-63cd-4677-ad4c-a0d1709745c5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_1b80a810-e49b-4e0c-b200-87afbd5b9195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_fc474433-361c-4355-bff9-5bcee7020a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_8b88077f-63cd-4677-ad4c-a0d1709745c5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_fc474433-361c-4355-bff9-5bcee7020a37" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b606e6b8-a0c5-4afb-ae9b-08ce622d7386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_81226663-93e1-4cd0-a4fb-c20ae6e007ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b606e6b8-a0c5-4afb-ae9b-08ce622d7386" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_81226663-93e1-4cd0-a4fb-c20ae6e007ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ddd6d6c7-aa44-42dd-823b-73a9fea71df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b606e6b8-a0c5-4afb-ae9b-08ce622d7386" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ddd6d6c7-aa44-42dd-823b-73a9fea71df6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_780f5c9d-f2a9-4d2e-b43d-4550a7a1f3f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_671b3fde-6124-460a-acfb-58da785757cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_780f5c9d-f2a9-4d2e-b43d-4550a7a1f3f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_671b3fde-6124-460a-acfb-58da785757cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_c5d46234-3511-4cc4-a1d4-7235b395b30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_780f5c9d-f2a9-4d2e-b43d-4550a7a1f3f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_c5d46234-3511-4cc4-a1d4-7235b395b30a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_aa4d4d99-77b6-48f6-95ad-3793bc4e0024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_830f9479-bc2e-4112-899e-44cccaa0cba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_aa4d4d99-77b6-48f6-95ad-3793bc4e0024" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_830f9479-bc2e-4112-899e-44cccaa0cba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_a397c415-e865-4bb8-9ce5-b090ae17bc95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_aa4d4d99-77b6-48f6-95ad-3793bc4e0024" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_a397c415-e865-4bb8-9ce5-b090ae17bc95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNet"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0196a4d2-62e7-4e37-9978-79480ef223ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3965c521-8268-4e79-88fd-00d0c9a4a317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0196a4d2-62e7-4e37-9978-79480ef223ce" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3965c521-8268-4e79-88fd-00d0c9a4a317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_be6c6e38-245d-4903-8607-be993305768c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0196a4d2-62e7-4e37-9978-79480ef223ce" xlink:to="loc_us-gaap_InterestExpense_be6c6e38-245d-4903-8607-be993305768c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2bb91101-b0a2-44bd-af32-e79ac03bfb78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0196a4d2-62e7-4e37-9978-79480ef223ce" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2bb91101-b0a2-44bd-af32-e79ac03bfb78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7b649b79-01d7-4e5b-80ac-3623dcee6fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0196a4d2-62e7-4e37-9978-79480ef223ce" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7b649b79-01d7-4e5b-80ac-3623dcee6fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_4226cba8-2ed8-4818-abb5-50b4a2ba8fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0196a4d2-62e7-4e37-9978-79480ef223ce" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_4226cba8-2ed8-4818-abb5-50b4a2ba8fc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_2a6847c0-a33e-4212-9e27-b05f2506cc90" xlink:href="mrk-20201231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0196a4d2-62e7-4e37-9978-79480ef223ce" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_2a6847c0-a33e-4212-9e27-b05f2506cc90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncome"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cec2a4a2-f099-4b98-83b5-a1415b1dc2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cec2a4a2-f099-4b98-83b5-a1415b1dc2eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_674eeb6c-7a7c-434a-a6a4-043d4130fcd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_674eeb6c-7a7c-434a-a6a4-043d4130fcd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_3375f602-8619-4ca4-b1da-7aebbd272db9" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_3375f602-8619-4ca4-b1da-7aebbd272db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_bd372302-8563-49c2-a56e-a6617dc94d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_bd372302-8563-49c2-a56e-a6617dc94d41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ad1338b2-22b6-46e8-84ac-bdfcba2427d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ad1338b2-22b6-46e8-84ac-bdfcba2427d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_9be945a3-133c-4bde-a8c5-85e67fea0379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_9be945a3-133c-4bde-a8c5-85e67fea0379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_7e551f4a-7422-4a9f-a94a-f128d7c8e5d1" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_7e551f4a-7422-4a9f-a94a-f128d7c8e5d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_471eeb75-030c-4c39-82ff-d3156e2f0571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_471eeb75-030c-4c39-82ff-d3156e2f0571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a024d0e1-b0c5-4003-bcfd-55e3cd750e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a024d0e1-b0c5-4003-bcfd-55e3cd750e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_4518e075-cfdf-426a-abd3-9f94919cb5fc" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_4518e075-cfdf-426a-abd3-9f94919cb5fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_30ed352c-4b0a-4ce7-90bf-1794761cb1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_30ed352c-4b0a-4ce7-90bf-1794761cb1bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b157aa6c-152f-4f2e-ac7b-d6160241791f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_58f6c313-fac0-4c7b-b6c6-2912d62c2894" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b157aa6c-152f-4f2e-ac7b-d6160241791f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_157a3c78-22d2-4717-a9f5-0d2222b45b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_157a3c78-22d2-4717-a9f5-0d2222b45b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_31a993f5-b907-4da6-b996-b4b82944c74b" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_31a993f5-b907-4da6-b996-b4b82944c74b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4c9bc574-832f-4512-8417-86d415ddfaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4c9bc574-832f-4512-8417-86d415ddfaa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_35374928-0f8f-4cc0-9d89-055343e419ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_35374928-0f8f-4cc0-9d89-055343e419ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_91e0428b-7f46-48d3-b9d7-04a430da1ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_91e0428b-7f46-48d3-b9d7-04a430da1ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2e5186e5-ea00-49c1-8b89-6207151cad2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2e5186e5-ea00-49c1-8b89-6207151cad2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_dbacfd79-4be2-4cd9-93eb-837a0cca878b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_dbacfd79-4be2-4cd9-93eb-837a0cca878b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_7175563a-e465-454f-812c-803de74d7c7e" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_7175563a-e465-454f-812c-803de74d7c7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_67803a7d-229e-41ab-8ab7-9d96fb1e6c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_67803a7d-229e-41ab-8ab7-9d96fb1e6c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_5e3e4ca7-79c7-4777-89c6-84f665bb3393" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_5e3e4ca7-79c7-4777-89c6-84f665bb3393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_3a6ec814-8314-4dfd-a749-7d6db1eb6fb6" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_3a6ec814-8314-4dfd-a749-7d6db1eb6fb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_800bd536-22f3-4cc8-8b8e-b9323b5b86c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_800bd536-22f3-4cc8-8b8e-b9323b5b86c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1ffa4260-ee4f-4545-b0f5-3795ec908f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1ffa4260-ee4f-4545-b0f5-3795ec908f54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_e30da3bc-b812-4db4-b90f-b4e4b7714507" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bdfd5cb0-29e2-455a-8b46-0d01cd4ff4d0" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_e30da3bc-b812-4db4-b90f-b4e4b7714507" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeIncomeBeforeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_414bb0b7-31f9-4b70-87f9-eb301ed4f928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c681b65d-f73b-48b1-8042-5690cc85d9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_414bb0b7-31f9-4b70-87f9-eb301ed4f928" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c681b65d-f73b-48b1-8042-5690cc85d9b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_61ecc2d3-4f34-4b45-8320-8d093e05775f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_414bb0b7-31f9-4b70-87f9-eb301ed4f928" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_61ecc2d3-4f34-4b45-8320-8d093e05775f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeTaxesonIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31d7a0ee-a68f-4d1f-b88d-4389c5f59681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5dacabc3-d8f9-4101-9f5f-1ade4477df9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31d7a0ee-a68f-4d1f-b88d-4389c5f59681" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5dacabc3-d8f9-4101-9f5f-1ade4477df9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_06421afb-8c3c-405c-a501-bf1560bb00ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31d7a0ee-a68f-4d1f-b88d-4389c5f59681" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_06421afb-8c3c-405c-a501-bf1560bb00ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a71c44f1-79a1-4c52-9ec4-4f4a3e3b8666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31d7a0ee-a68f-4d1f-b88d-4389c5f59681" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a71c44f1-79a1-4c52-9ec4-4f4a3e3b8666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_26b60c21-c130-4502-9bd3-5ea4a7d73e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7199c454-28ce-433c-991a-faa946d40ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_26b60c21-c130-4502-9bd3-5ea4a7d73e18" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7199c454-28ce-433c-991a-faa946d40ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_adbc4bce-b9b2-4760-be51-cfb59096b73f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_26b60c21-c130-4502-9bd3-5ea4a7d73e18" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_adbc4bce-b9b2-4760-be51-cfb59096b73f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_09ef056e-561e-4d22-a5c0-6fe1f89249bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b1c6e738-f7e2-42ce-ba88-fcafe68ee7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_09ef056e-561e-4d22-a5c0-6fe1f89249bc" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b1c6e738-f7e2-42ce-ba88-fcafe68ee7e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ca663887-4a65-489f-ae1e-1d2f7aa32a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_09ef056e-561e-4d22-a5c0-6fe1f89249bc" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ca663887-4a65-489f-ae1e-1d2f7aa32a28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d8ad90f8-37c7-4c9c-afd9-a65d58cfbef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_09ef056e-561e-4d22-a5c0-6fe1f89249bc" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d8ad90f8-37c7-4c9c-afd9-a65d58cfbef7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_abb580ce-c856-4b92-9a2e-8596c8160b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f645bc8e-308c-4310-8af1-a2a37e8a7312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_abb580ce-c856-4b92-9a2e-8596c8160b1a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_f645bc8e-308c-4310-8af1-a2a37e8a7312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_27572b34-7e98-4251-89df-6dbdbf30d478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_abb580ce-c856-4b92-9a2e-8596c8160b1a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_27572b34-7e98-4251-89df-6dbdbf30d478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1cfe8c94-1ba6-4e70-b2fb-d82383fa15dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d37f7841-2391-4e84-9e7e-3c0a49a59b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1cfe8c94-1ba6-4e70-b2fb-d82383fa15dd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d37f7841-2391-4e84-9e7e-3c0a49a59b18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_774c3b91-750b-400c-ba85-39fd404fbd3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1cfe8c94-1ba6-4e70-b2fb-d82383fa15dd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_774c3b91-750b-400c-ba85-39fd404fbd3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b364deb5-8ef5-4d68-98a4-90629eeb257e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1cfe8c94-1ba6-4e70-b2fb-d82383fa15dd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b364deb5-8ef5-4d68-98a4-90629eeb257e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_fb9a20f3-a970-4c28-908b-af7fdb3210f8" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1cfe8c94-1ba6-4e70-b2fb-d82383fa15dd" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_fb9a20f3-a970-4c28-908b-af7fdb3210f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_fc3146ca-0ad9-479a-8d4e-ef3ebd34132e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1cfe8c94-1ba6-4e70-b2fb-d82383fa15dd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_fc3146ca-0ad9-479a-8d4e-ef3ebd34132e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_daa53a9a-d643-4b7b-a51a-3c64e5562908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_daa53a9a-d643-4b7b-a51a-3c64e5562908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_2ee4eb18-3ae0-4b1c-a25c-a20ec746373c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_2ee4eb18-3ae0-4b1c-a25c-a20ec746373c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_e1796f96-e060-4de8-933e-5051d6cf21c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_e1796f96-e060-4de8-933e-5051d6cf21c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_80407b09-c6a2-4f9c-bcab-99b37dac54bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_80407b09-c6a2-4f9c-bcab-99b37dac54bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_b1ebb1d0-c517-43c1-a38f-2a9c0c6f3a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_b1ebb1d0-c517-43c1-a38f-2a9c0c6f3a41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_1a86bc6e-5593-436a-b70d-7a7bd025225f" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_1a86bc6e-5593-436a-b70d-7a7bd025225f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_ba182730-64f4-44b1-b540-b5c663b66153" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_ba182730-64f4-44b1-b540-b5c663b66153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f23d964a-477f-43e4-9f3c-bcd58bf8170d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd52a0f5-6ec6-40ef-aaea-839588d30229" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f23d964a-477f-43e4-9f3c-bcd58bf8170d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_275ac2e2-262f-4786-8720-83fc2577ad36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bbab7b45-1669-4f22-8d9b-85f5e16e1b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_275ac2e2-262f-4786-8720-83fc2577ad36" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_bbab7b45-1669-4f22-8d9b-85f5e16e1b1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_256f7dfe-8824-4ad5-9b0b-eb00a2092518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_275ac2e2-262f-4786-8720-83fc2577ad36" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_256f7dfe-8824-4ad5-9b0b-eb00a2092518" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShare" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsperShare"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsperShareTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a28c5c47-9c5d-483a-8818-b22332fd3309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08af0dfa-33e1-41f0-b181-4c83a73a4f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a28c5c47-9c5d-483a-8818-b22332fd3309" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08af0dfa-33e1-41f0-b181-4c83a73a4f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c1334c4e-da48-4d82-a4f6-a918470ac5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a28c5c47-9c5d-483a-8818-b22332fd3309" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c1334c4e-da48-4d82-a4f6-a918470ac5d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsPerShareNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc4d7acf-0d31-4f0d-b30e-dacc1a919ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_574250ea-423b-4558-8c8a-3407cf2e726a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc4d7acf-0d31-4f0d-b30e-dacc1a919ffd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_574250ea-423b-4558-8c8a-3407cf2e726a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2778a13b-bd89-4139-bcb6-c2f3587dde2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc4d7acf-0d31-4f0d-b30e-dacc1a919ffd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2778a13b-bd89-4139-bcb6-c2f3587dde2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bba07558-5973-4084-aff1-f19b5c991f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_985dd882-a032-43ee-9c48-bdfa709e26ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bba07558-5973-4084-aff1-f19b5c991f59" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_985dd882-a032-43ee-9c48-bdfa709e26ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9f120042-1cee-415d-bdf4-be3aabd7a5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bba07558-5973-4084-aff1-f19b5c991f59" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9f120042-1cee-415d-bdf4-be3aabd7a5a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_be170bf6-b38f-4ca4-abe2-98c5f4feb98d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_91708a00-1c94-4b89-ab13-4016a51b8dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_be170bf6-b38f-4ca4-abe2-98c5f4feb98d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_91708a00-1c94-4b89-ab13-4016a51b8dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_014f84d2-bb9d-4ac3-8709-60f397cb3a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_be170bf6-b38f-4ca4-abe2-98c5f4feb98d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_014f84d2-bb9d-4ac3-8709-60f397cb3a6e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReporting"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>mrk-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3b02abbc-3b84-4f9a-9655-da3777b72964,g:4abc6098-1e3f-4748-b81f-d8be8057e101-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended" id="id792817ff80e4b1c882294f21d3e0494_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_db5a5207-dbdb-4ed3-a08b-4a85afcdb144" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentType_db5a5207-dbdb-4ed3-a08b-4a85afcdb144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a9ded0df-248e-4a94-a898-7adec77d380e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentAnnualReport_a9ded0df-248e-4a94-a898-7adec77d380e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a248d204-2812-4d15-8055-ed50a4c236f2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentTransitionReport_a248d204-2812-4d15-8055-ed50a4c236f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_871145b3-4476-432e-8fbd-ff9c49fd9ee8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityFileNumber_871145b3-4476-432e-8fbd-ff9c49fd9ee8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a032524f-c95c-434d-bdf6-d54d8c93358c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityRegistrantName_a032524f-c95c-434d-bdf6-d54d8c93358c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_55859652-c499-4138-ba5c-2efb16cbd3d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_CityAreaCode_55859652-c499-4138-ba5c-2efb16cbd3d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_61bf7a29-11d6-430f-8dc6-2ce01d9d1522" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_LocalPhoneNumber_61bf7a29-11d6-430f-8dc6-2ce01d9d1522" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16c419f5-6481-4bf8-bdf9-0b6f718f6423" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16c419f5-6481-4bf8-bdf9-0b6f718f6423" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1edd52c5-99cd-4eda-b00d-7ccea7a52f91" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityTaxIdentificationNumber_1edd52c5-99cd-4eda-b00d-7ccea7a52f91" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4a74fe97-e81f-4897-9722-b30171e43f99" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityAddressAddressLine1_4a74fe97-e81f-4897-9722-b30171e43f99" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_754b8cfb-5e51-4b17-adcd-4fed90473838" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityAddressCityOrTown_754b8cfb-5e51-4b17-adcd-4fed90473838" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0d6f4530-ec89-4eae-b8f9-d72735dc9800" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityAddressStateOrProvince_0d6f4530-ec89-4eae-b8f9-d72735dc9800" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5d7d6545-128d-4b40-9b3b-6b8f67d49c66" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityAddressPostalZipCode_5d7d6545-128d-4b40-9b3b-6b8f67d49c66" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c23f505d-e9d1-4a8b-bd4a-421df5530c26" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_Security12bTitle_c23f505d-e9d1-4a8b-bd4a-421df5530c26" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6b819f44-8e71-4c39-9ffa-0c485d4f2575" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_TradingSymbol_6b819f44-8e71-4c39-9ffa-0c485d4f2575" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_81df21d5-749d-4d13-b65b-6be8aed5a939" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_SecurityExchangeName_81df21d5-749d-4d13-b65b-6be8aed5a939" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9931a106-14e8-40e5-b978-7d7cc28662e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9931a106-14e8-40e5-b978-7d7cc28662e8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e983276a-eec1-4e83-b0f2-1239add146ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityPublicFloat_e983276a-eec1-4e83-b0f2-1239add146ee" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a025dfcb-ce57-41b9-89a6-d10bfcc874ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a025dfcb-ce57-41b9-89a6-d10bfcc874ae" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_6d10114e-93ce-4115-a692-2f7bbb3512d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityVoluntaryFilers_6d10114e-93ce-4115-a692-2f7bbb3512d8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_89cf6119-d32b-46e4-bf13-e7042dbd478b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityCurrentReportingStatus_89cf6119-d32b-46e4-bf13-e7042dbd478b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d4eef488-2326-4eb1-9e72-930e37abff58" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityInteractiveDataCurrent_d4eef488-2326-4eb1-9e72-930e37abff58" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a4129a7a-d78a-4fd1-9fdf-342db235efc2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityFilerCategory_a4129a7a-d78a-4fd1-9fdf-342db235efc2" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_18040538-d6b5-4add-85f8-1af1abbb0961" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntitySmallBusiness_18040538-d6b5-4add-85f8-1af1abbb0961" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1199725d-15c5-48ac-972f-12377da631af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityEmergingGrowthCompany_1199725d-15c5-48ac-972f-12377da631af" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9de4b04f-d92a-4593-a70d-5af8bcde104a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9de4b04f-d92a-4593-a70d-5af8bcde104a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_57a1344c-b896-43e5-a966-a6d395d028c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityShellCompany_57a1344c-b896-43e5-a966-a6d395d028c5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_71176585-3a69-4a9c-a7cd-e2cc4c8bab2f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_AmendmentFlag_71176585-3a69-4a9c-a7cd-e2cc4c8bab2f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e59b89e0-5274-405b-8131-9b188ef6d591" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentPeriodEndDate_e59b89e0-5274-405b-8131-9b188ef6d591" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_68d4cf79-e29c-47b6-a813-4518bae37fd1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentFiscalYearFocus_68d4cf79-e29c-47b6-a813-4518bae37fd1" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_de8f4cff-13d9-4a59-b79e-2ea81191b378" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentFiscalPeriodFocus_de8f4cff-13d9-4a59-b79e-2ea81191b378" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bdcdcf68-a315-48af-9b3b-ca47228c691c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityCentralIndexKey_bdcdcf68-a315-48af-9b3b-ca47228c691c" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e4106701-6239-4b79-9662-ec3331dc1311" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_CurrentFiscalYearEndDate_e4106701-6239-4b79-9662-ec3331dc1311" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_28252193-6d10-4893-b8fa-bdf5dd8a7bfd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_28252193-6d10-4893-b8fa-bdf5dd8a7bfd" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_a48498f3-bf0d-4037-9f8a-d429a317cb11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentInformationTable_a48498f3-bf0d-4037-9f8a-d429a317cb11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ada8e3fa-706d-4306-9215-c9545636716a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_a48498f3-bf0d-4037-9f8a-d429a317cb11" xlink:to="loc_us-gaap_DebtInstrumentAxis_ada8e3fa-706d-4306-9215-c9545636716a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ada8e3fa-706d-4306-9215-c9545636716a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ada8e3fa-706d-4306-9215-c9545636716a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ada8e3fa-706d-4306-9215-c9545636716a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ada8e3fa-706d-4306-9215-c9545636716a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125Notesdue2021Member_2e4b852f-d5fb-4b8a-8fd3-4708a273052b" xlink:href="mrk-20201231.xsd#mrk_A1.125Notesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A1.125Notesdue2021Member_2e4b852f-d5fb-4b8a-8fd3-4708a273052b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_c7a84f3e-addd-419e-a070-bba33a5f7056" xlink:href="mrk-20201231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A0.500Notesdue2024Member_c7a84f3e-addd-419e-a070-bba33a5f7056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_e9659ecf-fd68-42af-9c3a-73a352bbcc0e" xlink:href="mrk-20201231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A1.875Notesdue2026Member_e9659ecf-fd68-42af-9c3a-73a352bbcc0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_1afa38b8-2a10-4b1b-8938-1fb9be1602ad" xlink:href="mrk-20201231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A2.500Notesdue2034Member_1afa38b8-2a10-4b1b-8938-1fb9be1602ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_cf59f186-82e4-4681-8d6d-e0dd17ae56a8" xlink:href="mrk-20201231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A1.375Notesdue2036Member_cf59f186-82e4-4681-8d6d-e0dd17ae56a8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofIncome"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="extended" id="i3b19bc2c685b49fc8533c2f12fd6bc76_ConsolidatedStatementofIncome"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended" id="i88cfda6be30d4cb98b8dbae90e3e86c7_ConsolidatedStatementofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedBalanceSheet"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="extended" id="i7cb89ec2a08348f1a96ce3d74dfac4ef_ConsolidatedBalanceSheet"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedBalanceSheetParenthetical"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="extended" id="i6b76a444d3c840839b3177c3abb4ec72_ConsolidatedBalanceSheetParenthetical"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="extended" id="id1ad5f79bb09420fbd0636b3c08b9d33_ConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_96ec7a45-576e-4de8-aea7-044ef8f8ccae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_96ec7a45-576e-4de8-aea7-044ef8f8ccae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71a7a5b8-7e03-444e-9272-92a98baf9537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71a7a5b8-7e03-444e-9272-92a98baf9537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b596b4ec-dcc5-496b-ac0b-09a1c76811fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_NetIncomeLoss_b596b4ec-dcc5-496b-ac0b-09a1c76811fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_434b366e-69d6-41a0-9629-08155112adb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_434b366e-69d6-41a0-9629-08155112adb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_f07f3502-bb45-4748-8024-63d2888cafd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_DividendsCommonStockCash_f07f3502-bb45-4748-8024-63d2888cafd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_baf7110a-6955-46cf-a11d-8e26075f277a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_baf7110a-6955-46cf-a11d-8e26075f277a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_07ac46e0-0a6a-4f0d-b7c5-f530d018c0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_07ac46e0-0a6a-4f0d-b7c5-f530d018c0ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_530c8954-5e90-4c3a-b14f-e101fc65dfba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_530c8954-5e90-4c3a-b14f-e101fc65dfba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_fdd07f72-33d9-4cd5-9664-cad42c0d7c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_StockholdersEquityOther_fdd07f72-33d9-4cd5-9664-cad42c0d7c65" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a771a8e6-0e5b-40bb-a0d4-ad4c5de5f0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_96ec7a45-576e-4de8-aea7-044ef8f8ccae" xlink:to="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_29d29938-32c9-4f15-ac40-17114ae6e936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_29d29938-32c9-4f15-ac40-17114ae6e936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_29d29938-32c9-4f15-ac40-17114ae6e936_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29d29938-32c9-4f15-ac40-17114ae6e936" xlink:to="loc_us-gaap_EquityComponentDomain_29d29938-32c9-4f15-ac40-17114ae6e936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29d29938-32c9-4f15-ac40-17114ae6e936" xlink:to="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2788f673-547f-4593-8044-9657df8608d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_CommonStockMember_2788f673-547f-4593-8044-9657df8608d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1301b9d5-814e-4ee5-b5f2-1cf64899a71f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1301b9d5-814e-4ee5-b5f2-1cf64899a71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cf592093-0e12-443f-82b0-8eb2d4b6d835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_RetainedEarningsMember_cf592093-0e12-443f-82b0-8eb2d4b6d835" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f661107d-e009-4330-aa16-451f3a38ad3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f661107d-e009-4330-aa16-451f3a38ad3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_b443261d-0f9f-4ff5-bbfa-288913783fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_TreasuryStockMember_b443261d-0f9f-4ff5-bbfa-288913783fa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d9a8f718-0c72-4330-9e07-0ec8b7f329a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d9a8f718-0c72-4330-9e07-0ec8b7f329a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0bfae21-a7bc-4c4f-908f-3ea2730465ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0bfae21-a7bc-4c4f-908f-3ea2730465ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0bfae21-a7bc-4c4f-908f-3ea2730465ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0bfae21-a7bc-4c4f-908f-3ea2730465ce" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b0bfae21-a7bc-4c4f-908f-3ea2730465ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_58817958-7294-4201-980d-37b661b0db22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0bfae21-a7bc-4c4f-908f-3ea2730465ce" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_58817958-7294-4201-980d-37b661b0db22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_76cfad89-4694-43f5-b2be-7d59aab56205" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_58817958-7294-4201-980d-37b661b0db22" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_76cfad89-4694-43f5-b2be-7d59aab56205" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="extended" id="ic168ac2080c04b86ae0155be60f1530f_ConsolidatedStatementofEquityParenthetical"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended" id="i80ae2d20125849fdb619e5afdf075594_ConsolidatedStatementofCashFlows"/>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="extended" id="i5e87ba06ead749dfb66cf68420ad2f63_ConsolidatedStatementofCashFlowsParenthetical"/>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperations" xlink:type="simple" xlink:href="mrk-20201231.xsd#NatureofOperations"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/NatureofOperations" xlink:type="extended" id="i0eb6c6b51f65475fa5d2f90f556dd906_NatureofOperations"/>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#NatureofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="extended" id="ieab2fa666df34f9cbcd9647ade175a08_NatureofOperationsDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="extended" id="i29cd4112c4ab478abc4fc3925e88d6f5_SummaryofAccountingPolicies"/>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="extended" id="i108515656be247e6baa055999ab18682_SummaryofAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="extended" id="ie3358e474be445af94e0c9aab6ff861d_SummaryofAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:href="mrk-20201231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_41ab16b1-70fa-4e3d-81cc-b1cb9c938da0" xlink:href="mrk-20201231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_41ab16b1-70fa-4e3d-81cc-b1cb9c938da0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_d31345ba-620f-4b9a-b68f-0d5d04242e03" xlink:href="mrk-20201231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_d31345ba-620f-4b9a-b68f-0d5d04242e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_f0d265f2-e85f-4f28-bcd7-de5ecbf3d7a9" xlink:href="mrk-20201231.xsd#mrk_SalesDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_SalesDiscounts_f0d265f2-e85f-4f28-bcd7-de5ecbf3d7a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks_0377c4ee-01dd-48c4-b2ce-aabcae92f123" xlink:href="mrk-20201231.xsd#mrk_AccrualForChargebacks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_AccrualForChargebacks_0377c4ee-01dd-48c4-b2ce-aabcae92f123" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates_0922adb1-6cad-4c18-9185-6366c10278a1" xlink:href="mrk-20201231.xsd#mrk_AccrualForRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_AccrualForRebates_0922adb1-6cad-4c18-9185-6366c10278a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms_48e6e63d-29d2-4a1e-a26a-da8f2d606960" xlink:href="mrk-20201231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_RevenuePerformanceObligationPaymentTerms_48e6e63d-29d2-4a1e-a26a-da8f2d606960" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f4cf92fb-f840-4f28-99ed-4ac672a36e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f4cf92fb-f840-4f28-99ed-4ac672a36e71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_81efb941-4949-46f7-81e5-7bb6b5a4c5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_Depreciation_81efb941-4949-46f7-81e5-7bb6b5a4c5b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_351e2e92-b8ec-493b-b71a-c5164e95b0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_AdvertisingExpense_351e2e92-b8ec-493b-b71a-c5164e95b0c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f9514ae2-b3ac-4e2b-9260-de3fb5c10b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f9514ae2-b3ac-4e2b-9260-de3fb5c10b06" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2c21daed-288c-4794-b725-9d507a5bd695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2c21daed-288c-4794-b725-9d507a5bd695" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b87fdb5c-4e18-433f-b072-ba6ff2a3cc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b87fdb5c-4e18-433f-b072-ba6ff2a3cc7a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_911a4473-d03e-49ca-a694-04204068b1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_911a4473-d03e-49ca-a694-04204068b1d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_srt_ProductOrServiceAxis_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192" xlink:to="loc_srt_ProductsAndServicesDomain_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2bc0ef2f-bf55-4ac2-9b44-57ec977105e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192" xlink:to="loc_srt_ProductsAndServicesDomain_2bc0ef2f-bf55-4ac2-9b44-57ec977105e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_ce0e8874-bfc9-406c-894c-573f022b9c2b" xlink:href="mrk-20201231.xsd#mrk_KeytrudaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2bc0ef2f-bf55-4ac2-9b44-57ec977105e9" xlink:to="loc_mrk_KeytrudaMember_ce0e8874-bfc9-406c-894c-573f022b9c2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7517b5c1-5f2d-46db-8579-3e5af72ff160" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_srt_RangeAxis_7517b5c1-5f2d-46db-8579-3e5af72ff160" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7517b5c1-5f2d-46db-8579-3e5af72ff160_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7517b5c1-5f2d-46db-8579-3e5af72ff160" xlink:to="loc_srt_RangeMember_7517b5c1-5f2d-46db-8579-3e5af72ff160_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3300e551-f994-4559-b9cd-9b9540670db3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7517b5c1-5f2d-46db-8579-3e5af72ff160" xlink:to="loc_srt_RangeMember_3300e551-f994-4559-b9cd-9b9540670db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4ac1c8a-c074-4375-8d49-d24b637c4c37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3300e551-f994-4559-b9cd-9b9540670db3" xlink:to="loc_srt_MinimumMember_a4ac1c8a-c074-4375-8d49-d24b637c4c37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d46e9cf-7767-48ad-a836-9bd40a3b6c28" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3300e551-f994-4559-b9cd-9b9540670db3" xlink:to="loc_srt_MaximumMember_0d46e9cf-7767-48ad-a836-9bd40a3b6c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9f127d35-9e16-40d3-81a3-c47e724532be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_srt_StatementGeographicalAxis_9f127d35-9e16-40d3-81a3-c47e724532be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9f127d35-9e16-40d3-81a3-c47e724532be_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9f127d35-9e16-40d3-81a3-c47e724532be" xlink:to="loc_srt_SegmentGeographicalDomain_9f127d35-9e16-40d3-81a3-c47e724532be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5f2beae2-e23c-4e46-b026-9fc5342bac6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9f127d35-9e16-40d3-81a3-c47e724532be" xlink:to="loc_srt_SegmentGeographicalDomain_5f2beae2-e23c-4e46-b026-9fc5342bac6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_8f378d5a-5d3b-4542-953c-a05f323f51b2" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5f2beae2-e23c-4e46-b026-9fc5342bac6c" xlink:to="loc_country_US_8f378d5a-5d3b-4542-953c-a05f323f51b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_52f0ac3b-09a1-499f-a115-620e9376c937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5f2beae2-e23c-4e46-b026-9fc5342bac6c" xlink:to="loc_us-gaap_NonUsMember_52f0ac3b-09a1-499f-a115-620e9376c937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ef9e4243-0055-4027-984a-53b1fe07fe1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ef9e4243-0055-4027-984a-53b1fe07fe1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ef9e4243-0055-4027-984a-53b1fe07fe1e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef9e4243-0055-4027-984a-53b1fe07fe1e" xlink:to="loc_us-gaap_SegmentDomain_ef9e4243-0055-4027-984a-53b1fe07fe1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cd1878bb-4db6-4474-8cc7-fffe8035dd56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef9e4243-0055-4027-984a-53b1fe07fe1e" xlink:to="loc_us-gaap_SegmentDomain_cd1878bb-4db6-4474-8cc7-fffe8035dd56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_f8b3ba03-696f-4243-922e-f20d7187a699" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cd1878bb-4db6-4474-8cc7-fffe8035dd56" xlink:to="loc_mrk_PharmaceuticalsegmentMember_f8b3ba03-696f-4243-922e-f20d7187a699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_3bbb8087-4b2f-4bb8-8d49-60c49beef821" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cd1878bb-4db6-4474-8cc7-fffe8035dd56" xlink:to="loc_mrk_AnimalHealthsegmentMember_3bbb8087-4b2f-4bb8-8d49-60c49beef821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2cf532aa-4078-4a2e-830e-7a79562fd450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2cf532aa-4078-4a2e-830e-7a79562fd450" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2cf532aa-4078-4a2e-830e-7a79562fd450_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2cf532aa-4078-4a2e-830e-7a79562fd450" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2cf532aa-4078-4a2e-830e-7a79562fd450_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d68834e-9af2-4ba6-a51b-45eace522ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2cf532aa-4078-4a2e-830e-7a79562fd450" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d68834e-9af2-4ba6-a51b-45eace522ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_06d96b16-1128-4463-8089-a01043cd5a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d68834e-9af2-4ba6-a51b-45eace522ddc" xlink:to="loc_us-gaap_BuildingMember_06d96b16-1128-4463-8089-a01043cd5a08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_f2615d7a-0004-4f60-ae69-99b938e0abd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d68834e-9af2-4ba6-a51b-45eace522ddc" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_f2615d7a-0004-4f60-ae69-99b938e0abd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbc58132-d989-40ba-a54b-1e47d86a9e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbc58132-d989-40ba-a54b-1e47d86a9e4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dbc58132-d989-40ba-a54b-1e47d86a9e4f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbc58132-d989-40ba-a54b-1e47d86a9e4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dbc58132-d989-40ba-a54b-1e47d86a9e4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a18dd25b-fc52-4e28-b404-1d85ca45641f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbc58132-d989-40ba-a54b-1e47d86a9e4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a18dd25b-fc52-4e28-b404-1d85ca45641f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a8209a81-0717-4ab3-9ea5-42cf29efa592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a18dd25b-fc52-4e28-b404-1d85ca45641f" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a8209a81-0717-4ab3-9ea5-42cf29efa592" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements" xlink:type="extended" id="ie48a01b916da407f8ce902f56dc7a7aa_AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables" xlink:type="extended" id="idcfe4785061e41308f3d51a8e3480872_AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail" xlink:type="extended" id="idd75ea5986b44ea8b9c5caddbb674427_AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d435e6c0-4420-493d-820d-90c6fffe115c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d435e6c0-4420-493d-820d-90c6fffe115c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9a399419-98a2-493f-a1b1-4b8d50f53147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9a399419-98a2-493f-a1b1-4b8d50f53147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_38e831a5-c383-4ff3-aff7-9ce134000449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_38e831a5-c383-4ff3-aff7-9ce134000449" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4314dbe9-4f64-480d-b6fc-8c9656825bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4314dbe9-4f64-480d-b6fc-8c9656825bf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3b9f2d10-b3e6-405c-9c03-f1cc07545127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3b9f2d10-b3e6-405c-9c03-f1cc07545127" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_837ae31c-0677-4bd0-b8c0-18132fb19e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_837ae31c-0677-4bd0-b8c0-18132fb19e7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1dc932c3-f6de-4bc5-b9f6-5e193e605d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1dc932c3-f6de-4bc5-b9f6-5e193e605d80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_74ca305a-1637-42bf-af92-2000edf1fe92" xlink:href="mrk-20201231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_74ca305a-1637-42bf-af92-2000edf1fe92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8b783d24-28d1-490f-89a4-fc323af1f43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_Goodwill_8b783d24-28d1-490f-89a4-fc323af1f43b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_700193a4-3a6f-4831-8e64-7cebe8c06a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_700193a4-3a6f-4831-8e64-7cebe8c06a37" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_09ac48a5-5c2b-4336-9225-aafed54522a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_09ac48a5-5c2b-4336-9225-aafed54522a3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2c848b1a-55e3-4772-9455-18bb298669b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2c848b1a-55e3-4772-9455-18bb298669b3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d258c1c7-128e-4f39-9805-ed69b6155b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d258c1c7-128e-4f39-9805-ed69b6155b32" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_b7fd706c-2939-44d6-b012-7e626268afb2" xlink:href="mrk-20201231.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_b7fd706c-2939-44d6-b012-7e626268afb2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_a53ae429-bb0c-46a6-a669-8a50789535c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_a53ae429-bb0c-46a6-a669-8a50789535c7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_4ef14c5e-524f-4a5a-bfc0-efec8b6e196d" xlink:href="mrk-20201231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_4ef14c5e-524f-4a5a-bfc0-efec8b6e196d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_fab106fd-43a7-4556-96b7-c41dd469cb34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_fab106fd-43a7-4556-96b7-c41dd469cb34" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_7f650b1e-bca6-4355-b018-8e7abe3ab6b9" xlink:href="mrk-20201231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_RoyaltyRatePercentage_7f650b1e-bca6-4355-b018-8e7abe3ab6b9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_120c9960-c48a-4bcb-9a2c-64f449e6ac9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_120c9960-c48a-4bcb-9a2c-64f449e6ac9e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_fb805323-0262-45d5-9562-f8b0b1df937c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_fb805323-0262-45d5-9562-f8b0b1df937c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_82cced13-877e-486f-bc31-b0edcbc837f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_82cced13-877e-486f-bc31-b0edcbc837f2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_94b9b293-ad9d-4eb8-b8c5-d2de4072190c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_94b9b293-ad9d-4eb8-b8c5-d2de4072190c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_cdca4d77-5c6e-421f-af6d-b17b5997be27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_cdca4d77-5c6e-421f-af6d-b17b5997be27" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9b763866-8666-41d4-8ad6-2aa13ef53f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9b763866-8666-41d4-8ad6-2aa13ef53f71" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c6a2c5fa-f997-4938-ade8-ab4c3ea18052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c6a2c5fa-f997-4938-ade8-ab4c3ea18052" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_7103d82f-ecbe-47c6-9b4b-2d813099365b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_7103d82f-ecbe-47c6-9b4b-2d813099365b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_afe2f9de-c13b-4c94-847e-ee264f8cf306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_SharePrice_afe2f9de-c13b-4c94-847e-ee264f8cf306" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_41249712-4eed-4528-9b09-a83796ef78af" xlink:href="mrk-20201231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_41249712-4eed-4528-9b09-a83796ef78af" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_9597a93d-b67f-4596-ba36-8c5ef0afa77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_9597a93d-b67f-4596-ba36-8c5ef0afa77b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation_a31b287c-d138-4f37-9063-2ae3db1a5e9d" xlink:href="mrk-20201231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_ChargesRelatedToProgramDiscontinuation_a31b287c-d138-4f37-9063-2ae3db1a5e9d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired_cc4709ad-ba39-45cf-85f7-48ea3d779872" xlink:href="mrk-20201231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_PremiumOnSharesAcquired_cc4709ad-ba39-45cf-85f7-48ea3d779872" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_9ee39a0a-343d-4822-93bc-5e689c5cd00a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_Investments_9ee39a0a-343d-4822-93bc-5e689c5cd00a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_61b32f9d-a08d-4a85-b2d6-dc460648a49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_61b32f9d-a08d-4a85-b2d6-dc460648a49e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5b61db8f-3cc0-41f7-8287-0db32fc7190d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5b61db8f-3cc0-41f7-8287-0db32fc7190d" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a9914af8-a5f9-4723-a972-30c15ac0ca90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a9914af8-a5f9-4723-a972-30c15ac0ca90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a9914af8-a5f9-4723-a972-30c15ac0ca90_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9914af8-a5f9-4723-a972-30c15ac0ca90" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a9914af8-a5f9-4723-a972-30c15ac0ca90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e8bd64b7-1b9e-4f8d-a035-498757fcc099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9914af8-a5f9-4723-a972-30c15ac0ca90" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e8bd64b7-1b9e-4f8d-a035-498757fcc099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8f8f2abb-682c-4369-8417-f9236328bef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e8bd64b7-1b9e-4f8d-a035-498757fcc099" xlink:to="loc_us-gaap_SubsequentEventMember_8f8f2abb-682c-4369-8417-f9236328bef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_c3287003-b56c-446e-b5b6-b532609880b0" xlink:href="mrk-20201231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:to="loc_mrk_RegulatoryMilestonesMember_c3287003-b56c-446e-b5b6-b532609880b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialmilestoneMember_13bdf932-102e-4973-a37d-0ca73396be6f" xlink:href="mrk-20201231.xsd#mrk_CommercialmilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:to="loc_mrk_CommercialmilestoneMember_13bdf932-102e-4973-a37d-0ca73396be6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_abed4f33-4a18-4f92-b834-3519cc57fb87" xlink:href="mrk-20201231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:to="loc_mrk_SalesBasedMilestonesMember_abed4f33-4a18-4f92-b834-3519cc57fb87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_9957df60-db6d-4a1f-a81c-ad02b6b1db79" xlink:href="mrk-20201231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:to="loc_mrk_DevelopmentMilestonesMember_9957df60-db6d-4a1f-a81c-ad02b6b1db79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eab11d62-dd00-4643-83b8-b0a500db37a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eab11d62-dd00-4643-83b8-b0a500db37a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eab11d62-dd00-4643-83b8-b0a500db37a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eab11d62-dd00-4643-83b8-b0a500db37a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eab11d62-dd00-4643-83b8-b0a500db37a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eab11d62-dd00-4643-83b8-b0a500db37a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_8d9e9ff6-45e4-496c-9e5c-6037ccbc6446" xlink:href="mrk-20201231.xsd#mrk_OncoImmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_OncoImmuneMember_8d9e9ff6-45e4-496c-9e5c-6037ccbc6446" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_313edcaa-f6a5-4d4d-a57c-6f8820483851" xlink:href="mrk-20201231.xsd#mrk_VelosBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_VelosBioMember_313edcaa-f6a5-4d4d-a57c-6f8820483851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_d71d715c-cf8b-432b-86cb-90ce676535c7" xlink:href="mrk-20201231.xsd#mrk_DunboyneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_DunboyneMember_d71d715c-cf8b-432b-86cb-90ce676535c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember_c25a76d4-18ca-47a2-be58-5ddec03d9d0c" xlink:href="mrk-20201231.xsd#mrk_ThemisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_ThemisMember_c25a76d4-18ca-47a2-be58-5ddec03d9d0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_bc750170-0e7c-4ffe-990b-9debc61df298" xlink:href="mrk-20201231.xsd#mrk_ArQuleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_ArQuleMember_bc750170-0e7c-4ffe-990b-9debc61df298" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember_c61f5dc5-3584-4b0a-a939-9fb340359d8d" xlink:href="mrk-20201231.xsd#mrk_PelotonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_PelotonMember_c61f5dc5-3584-4b0a-a939-9fb340359d8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_89e8f4f3-202e-4d80-a8aa-06826df2608f" xlink:href="mrk-20201231.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_AntelliqMember_89e8f4f3-202e-4d80-a8aa-06826df2608f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember_78e43277-adda-4528-a099-fa099666a0ab" xlink:href="mrk-20201231.xsd#mrk_ImmuneDesignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_ImmuneDesignMember_78e43277-adda-4528-a099-fa099666a0ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ViralyticsMember_b0eee74d-27d0-4b2f-b825-2a90775a5659" xlink:href="mrk-20201231.xsd#mrk_ViralyticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_ViralyticsMember_b0eee74d-27d0-4b2f-b825-2a90775a5659" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c347504-5c3c-428b-96df-ea4f25b78511" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_srt_CounterpartyNameAxis_5c347504-5c3c-428b-96df-ea4f25b78511" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c347504-5c3c-428b-96df-ea4f25b78511_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5c347504-5c3c-428b-96df-ea4f25b78511" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c347504-5c3c-428b-96df-ea4f25b78511_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5c347504-5c3c-428b-96df-ea4f25b78511" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember_8058bc66-ffe6-4b48-8f9d-542e034951c2" xlink:href="mrk-20201231.xsd#mrk_SeagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:to="loc_mrk_SeagenMember_8058bc66-ffe6-4b48-8f9d-542e034951c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_fc9063c0-8cd2-47e7-9d1e-0fac4c8207f1" xlink:href="mrk-20201231.xsd#mrk_SentinelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:to="loc_mrk_SentinelMember_fc9063c0-8cd2-47e7-9d1e-0fac4c8207f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember_061467b2-f686-45b0-94df-873cd679f979" xlink:href="mrk-20201231.xsd#mrk_IAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:to="loc_mrk_IAVIMember_061467b2-f686-45b0-94df-873cd679f979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8f29a4a1-d3ba-4fa0-bb48-79305f15589b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_srt_ProductOrServiceAxis_8f29a4a1-d3ba-4fa0-bb48-79305f15589b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f29a4a1-d3ba-4fa0-bb48-79305f15589b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8f29a4a1-d3ba-4fa0-bb48-79305f15589b" xlink:to="loc_srt_ProductsAndServicesDomain_8f29a4a1-d3ba-4fa0-bb48-79305f15589b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8f29a4a1-d3ba-4fa0-bb48-79305f15589b" xlink:to="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember_f64b1790-0850-4e48-9273-730bc93c5017" xlink:href="mrk-20201231.xsd#mrk_TukysaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:to="loc_mrk_TukysaMember_f64b1790-0850-4e48-9273-730bc93c5017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_3fc872f2-4c43-40c9-8b4e-c6096d9be92c" xlink:href="mrk-20201231.xsd#mrk_SentinelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:to="loc_mrk_SentinelMember_3fc872f2-4c43-40c9-8b4e-c6096d9be92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_4c740deb-5241-472e-b665-07b6744c0057" xlink:href="mrk-20201231.xsd#mrk_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:to="loc_mrk_COVID19Member_4c740deb-5241-472e-b665-07b6744c0057" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_958c6227-2e82-425e-b11a-2c067c0b1673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_958c6227-2e82-425e-b11a-2c067c0b1673" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_958c6227-2e82-425e-b11a-2c067c0b1673_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_958c6227-2e82-425e-b11a-2c067c0b1673" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_958c6227-2e82-425e-b11a-2c067c0b1673_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_254ba74b-8bf5-4b72-9df8-890a055e6eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_958c6227-2e82-425e-b11a-2c067c0b1673" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_254ba74b-8bf5-4b72-9df8-890a055e6eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_da007b23-1a7b-402f-8cec-3607c2e775e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_254ba74b-8bf5-4b72-9df8-890a055e6eb1" xlink:to="loc_us-gaap_ForwardContractsMember_da007b23-1a7b-402f-8cec-3607c2e775e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a79b2188-abad-4d4d-a30a-fcfaf6508dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a79b2188-abad-4d4d-a30a-fcfaf6508dfe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a79b2188-abad-4d4d-a30a-fcfaf6508dfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a79b2188-abad-4d4d-a30a-fcfaf6508dfe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a79b2188-abad-4d4d-a30a-fcfaf6508dfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_023e42bf-245a-4ce1-b742-02542669e224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a79b2188-abad-4d4d-a30a-fcfaf6508dfe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_023e42bf-245a-4ce1-b742-02542669e224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ca7d1b1f-44a3-4304-af49-6accf88621c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_023e42bf-245a-4ce1-b742-02542669e224" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ca7d1b1f-44a3-4304-af49-6accf88621c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8dc1e454-3dcb-45d1-857c-847c44eeca79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_srt_RangeAxis_8dc1e454-3dcb-45d1-857c-847c44eeca79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8dc1e454-3dcb-45d1-857c-847c44eeca79_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8dc1e454-3dcb-45d1-857c-847c44eeca79" xlink:to="loc_srt_RangeMember_8dc1e454-3dcb-45d1-857c-847c44eeca79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7bc9cf8-920b-42d9-ba7e-1781b96f752d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8dc1e454-3dcb-45d1-857c-847c44eeca79" xlink:to="loc_srt_RangeMember_c7bc9cf8-920b-42d9-ba7e-1781b96f752d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9f3321da-2ba4-4b77-a041-17420b57b3cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7bc9cf8-920b-42d9-ba7e-1781b96f752d" xlink:to="loc_srt_MinimumMember_9f3321da-2ba4-4b77-a041-17420b57b3cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6682d590-aef4-4297-88bf-7d8b19cd4246" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7bc9cf8-920b-42d9-ba7e-1781b96f752d" xlink:to="loc_srt_MaximumMember_6682d590-aef4-4297-88bf-7d8b19cd4246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_937747b1-58e0-43ac-b02a-5d7a52fbd225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_937747b1-58e0-43ac-b02a-5d7a52fbd225" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_937747b1-58e0-43ac-b02a-5d7a52fbd225_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_937747b1-58e0-43ac-b02a-5d7a52fbd225" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_937747b1-58e0-43ac-b02a-5d7a52fbd225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_672f11db-2806-4c35-83f9-8c749cb47dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_937747b1-58e0-43ac-b02a-5d7a52fbd225" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_672f11db-2806-4c35-83f9-8c749cb47dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_efa1a939-4ea2-4a15-b781-7be186736298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_672f11db-2806-4c35-83f9-8c749cb47dc5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_efa1a939-4ea2-4a15-b781-7be186736298" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_493036d3-0afc-4a5a-91f2-43d8353d5556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_493036d3-0afc-4a5a-91f2-43d8353d5556" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_493036d3-0afc-4a5a-91f2-43d8353d5556_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_493036d3-0afc-4a5a-91f2-43d8353d5556" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_493036d3-0afc-4a5a-91f2-43d8353d5556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1bc403ae-8d86-4f29-b85c-4ec9ca18446c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_493036d3-0afc-4a5a-91f2-43d8353d5556" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1bc403ae-8d86-4f29-b85c-4ec9ca18446c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1a4e262e-7305-40a7-bf53-04164586fc11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1bc403ae-8d86-4f29-b85c-4ec9ca18446c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1a4e262e-7305-40a7-bf53-04164586fc11" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail" xlink:type="extended" id="ida876f6dd0fc4a9da749ec4f55b15e17_AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_ccd404d9-8b0e-4c40-aa0b-04594914c516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_us-gaap_GainLossOnContractTermination_ccd404d9-8b0e-4c40-aa0b-04594914c516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Contractterminationfeepayment_2b174ebe-bb7c-4218-8d52-2565fe42f70b" xlink:href="mrk-20201231.xsd#mrk_Contractterminationfeepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_mrk_Contractterminationfeepayment_2b174ebe-bb7c-4218-8d52-2565fe42f70b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherContractTerminationCosts_531426cf-8d11-4bc1-bb60-c5384c346a0c" xlink:href="mrk-20201231.xsd#mrk_OtherContractTerminationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_mrk_OtherContractTerminationCosts_531426cf-8d11-4bc1-bb60-c5384c346a0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_23e07dee-55a7-44b2-9282-90f50714bda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_23e07dee-55a7-44b2-9282-90f50714bda9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_3e35e0de-23cd-4094-ba6f-a74d51267234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_3e35e0de-23cd-4094-ba6f-a74d51267234" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1a1d878b-e5cd-465e-a3fd-63a762a03611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1a1d878b-e5cd-465e-a3fd-63a762a03611" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9132f6c-6561-40e4-beac-7c77f3804fb0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1a1d878b-e5cd-465e-a3fd-63a762a03611" xlink:to="loc_srt_CounterpartyNameAxis_a9132f6c-6561-40e4-beac-7c77f3804fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9132f6c-6561-40e4-beac-7c77f3804fb0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a9132f6c-6561-40e4-beac-7c77f3804fb0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9132f6c-6561-40e4-beac-7c77f3804fb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6248086-ab3a-4926-a067-93880e7aa786" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a9132f6c-6561-40e4-beac-7c77f3804fb0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6248086-ab3a-4926-a067-93880e7aa786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SamsungMember_cb39996e-c650-4c8a-a2b4-ed301a1385f9" xlink:href="mrk-20201231.xsd#mrk_SamsungMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6248086-ab3a-4926-a067-93880e7aa786" xlink:to="loc_mrk_SamsungMember_cb39996e-c650-4c8a-a2b4-ed301a1385f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ia8d72676e4e2459e8a3902c139705209_AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0b65b579-9b39-495f-a3a2-122138d5cc25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0b65b579-9b39-495f-a3a2-122138d5cc25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_35093893-9dc2-421d-a847-5082407ff250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_35093893-9dc2-421d-a847-5082407ff250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a50333c7-0879-454b-bf09-091b3ee9244a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a50333c7-0879-454b-bf09-091b3ee9244a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_c38cdbbe-20f7-40a3-9efb-0c0a3dfadd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_c38cdbbe-20f7-40a3-9efb-0c0a3dfadd66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_02a08027-880d-4652-92ec-baef962e1549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_02a08027-880d-4652-92ec-baef962e1549" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_99019409-4500-4c2b-96ec-794337691917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_99019409-4500-4c2b-96ec-794337691917" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bc08c098-77da-4463-b005-20398a628348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bc08c098-77da-4463-b005-20398a628348" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7207010e-af44-4bd3-94f4-7117f31014a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7207010e-af44-4bd3-94f4-7117f31014a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_e0811b85-da79-4480-9fb0-78d9a29d2001" xlink:href="mrk-20201231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_e0811b85-da79-4480-9fb0-78d9a29d2001" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d5d3198d-6924-40b3-9002-746058b7b6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d5d3198d-6924-40b3-9002-746058b7b6aa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a03b34d0-672f-47b0-ae3a-c6dd7175ff9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_Goodwill_a03b34d0-672f-47b0-ae3a-c6dd7175ff9f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c928ed4f-9e06-4541-a80b-268a0a5ca74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c928ed4f-9e06-4541-a80b-268a0a5ca74c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_8b20ce87-12f2-4654-baf0-d9456e86d943" xlink:href="mrk-20201231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_8b20ce87-12f2-4654-baf0-d9456e86d943" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99818658-af55-40eb-8c28-a95c6d85021e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:to="loc_srt_RangeAxis_99818658-af55-40eb-8c28-a95c6d85021e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99818658-af55-40eb-8c28-a95c6d85021e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_99818658-af55-40eb-8c28-a95c6d85021e" xlink:to="loc_srt_RangeMember_99818658-af55-40eb-8c28-a95c6d85021e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba9d15ab-5753-4aca-8ca2-14d54b925e61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_99818658-af55-40eb-8c28-a95c6d85021e" xlink:to="loc_srt_RangeMember_ba9d15ab-5753-4aca-8ca2-14d54b925e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_61d5cd1c-b086-4abb-a3ae-05593d760708" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba9d15ab-5753-4aca-8ca2-14d54b925e61" xlink:to="loc_srt_MinimumMember_61d5cd1c-b086-4abb-a3ae-05593d760708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8055cad6-7656-4b6f-a3ba-09f24127d5cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba9d15ab-5753-4aca-8ca2-14d54b925e61" xlink:to="loc_srt_MaximumMember_8055cad6-7656-4b6f-a3ba-09f24127d5cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c4b28f6f-d591-4024-9879-10bfe55b9547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c4b28f6f-d591-4024-9879-10bfe55b9547" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4b28f6f-d591-4024-9879-10bfe55b9547_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c4b28f6f-d591-4024-9879-10bfe55b9547" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4b28f6f-d591-4024-9879-10bfe55b9547_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df38f7bc-b4cf-4eaf-911a-1306d86ddfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c4b28f6f-d591-4024-9879-10bfe55b9547" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df38f7bc-b4cf-4eaf-911a-1306d86ddfaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_d4d29b7d-a1c0-4e4b-a4a5-b88faa0e5ff4" xlink:href="mrk-20201231.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df38f7bc-b4cf-4eaf-911a-1306d86ddfaa" xlink:to="loc_mrk_AntelliqMember_d4d29b7d-a1c0-4e4b-a4a5-b88faa0e5ff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_752a391d-43ba-4e0d-8fcc-a380c1226874" xlink:href="mrk-20201231.xsd#mrk_ArQuleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df38f7bc-b4cf-4eaf-911a-1306d86ddfaa" xlink:to="loc_mrk_ArQuleMember_752a391d-43ba-4e0d-8fcc-a380c1226874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4c433681-f58e-4cee-80bd-fd92b9f51912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4c433681-f58e-4cee-80bd-fd92b9f51912" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4c433681-f58e-4cee-80bd-fd92b9f51912_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4c433681-f58e-4cee-80bd-fd92b9f51912" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4c433681-f58e-4cee-80bd-fd92b9f51912_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e4691ce5-bab3-4191-b8e7-b18c830d6b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4c433681-f58e-4cee-80bd-fd92b9f51912" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e4691ce5-bab3-4191-b8e7-b18c830d6b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a2d87c1d-d7fc-4c34-80b5-d090dd8dac34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e4691ce5-bab3-4191-b8e7-b18c830d6b6a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a2d87c1d-d7fc-4c34-80b5-d090dd8dac34" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangements"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended" id="i267f8f5c49424d03b343a49b52e204fc_CollaborativeArrangements"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended" id="i7af9ca108a414f57a077889d8c669831_CollaborativeArrangementsTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended" id="i06c35a142def4f0cbc01c2f4ffd65889_CollaborativeArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_48c50481-0e2e-403b-a0b1-0cc7d7b140bb" xlink:href="mrk-20201231.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_48c50481-0e2e-403b-a0b1-0cc7d7b140bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_17709d12-0e8b-443a-9b43-f994287a4f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_17709d12-0e8b-443a-9b43-f994287a4f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7758e1af-9614-403b-b542-2395372eb20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7758e1af-9614-403b-b542-2395372eb20e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_bcdadc3e-b306-49e4-bb07-132fafa8d5a6" xlink:href="mrk-20201231.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_bcdadc3e-b306-49e4-bb07-132fafa8d5a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_657ff9a5-aab7-4eb8-a648-e609442e8601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_Liabilities_657ff9a5-aab7-4eb8-a648-e609442e8601" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_459f1800-1120-4460-96ce-0992c807b3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_459f1800-1120-4460-96ce-0992c807b3e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d531fc2-f4dc-4262-8a1e-cdafaff6985d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d531fc2-f4dc-4262-8a1e-cdafaff6985d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1ccaf23f-0150-49eb-809b-88df37cf5240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1ccaf23f-0150-49eb-809b-88df37cf5240" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_0255b9b5-e206-4045-a1ec-1cc1099a2dce" xlink:href="mrk-20201231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_0255b9b5-e206-4045-a1ec-1cc1099a2dce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_87a9da17-c7cc-49f6-8411-96ac2149161d" xlink:href="mrk-20201231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_87a9da17-c7cc-49f6-8411-96ac2149161d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ea07dc2-3977-44cf-ae85-c37193138a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ea07dc2-3977-44cf-ae85-c37193138a63" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1f4125b2-9a1a-4de3-a353-df191d4e7760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1f4125b2-9a1a-4de3-a353-df191d4e7760" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d578648-30a5-4604-b0f6-072c798cb061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d578648-30a5-4604-b0f6-072c798cb061" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f2ff0a22-c89a-4ced-815a-1a40ef7fd0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f2ff0a22-c89a-4ced-815a-1a40ef7fd0d9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c31d0396-b586-4c2a-9f32-0ea83f5ef9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c31d0396-b586-4c2a-9f32-0ea83f5ef9ca" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6f927367-0264-436c-b100-ce03c01ef14e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6f927367-0264-436c-b100-ce03c01ef14e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a56256f1-6236-4bfe-8ffe-271eb6f126d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a56256f1-6236-4bfe-8ffe-271eb6f126d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a56256f1-6236-4bfe-8ffe-271eb6f126d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a56256f1-6236-4bfe-8ffe-271eb6f126d8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a56256f1-6236-4bfe-8ffe-271eb6f126d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6aeb0e81-b5fb-4e24-bf8b-5a93e43f05fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a56256f1-6236-4bfe-8ffe-271eb6f126d8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6aeb0e81-b5fb-4e24-bf8b-5a93e43f05fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1c4b4b0f-efd0-4f15-a649-aa7dda10ea6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6aeb0e81-b5fb-4e24-bf8b-5a93e43f05fb" xlink:to="loc_us-gaap_SubsequentEventMember_1c4b4b0f-efd0-4f15-a649-aa7dda10ea6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ce040811-b635-4114-a814-8705c942b953" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_srt_CounterpartyNameAxis_ce040811-b635-4114-a814-8705c942b953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce040811-b635-4114-a814-8705c942b953_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ce040811-b635-4114-a814-8705c942b953" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce040811-b635-4114-a814-8705c942b953_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ce040811-b635-4114-a814-8705c942b953" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_3ff12b20-ef73-47b8-93b5-ff12f669acfe" xlink:href="mrk-20201231.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:to="loc_mrk_AstraZenecaMember_3ff12b20-ef73-47b8-93b5-ff12f669acfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_0f6b8fbb-364f-4851-83b3-2a0f7ec5fe47" xlink:href="mrk-20201231.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:to="loc_mrk_EisaiMember_0f6b8fbb-364f-4851-83b3-2a0f7ec5fe47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_3d70cfb7-a4ba-48de-8ace-0ef223ad8475" xlink:href="mrk-20201231.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:to="loc_mrk_BayerAGMember_3d70cfb7-a4ba-48de-8ace-0ef223ad8475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4d521d82-a987-4e54-ad96-cbe9a56f969a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_srt_StatementScenarioAxis_4d521d82-a987-4e54-ad96-cbe9a56f969a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4d521d82-a987-4e54-ad96-cbe9a56f969a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_4d521d82-a987-4e54-ad96-cbe9a56f969a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4d521d82-a987-4e54-ad96-cbe9a56f969a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ebb1ed46-7f34-4ded-93ed-1f08179875b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_4d521d82-a987-4e54-ad96-cbe9a56f969a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ebb1ed46-7f34-4ded-93ed-1f08179875b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_7a7460ec-a4af-4d74-aa9d-0fc3881656bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ebb1ed46-7f34-4ded-93ed-1f08179875b0" xlink:to="loc_srt_ScenarioForecastMember_7a7460ec-a4af-4d74-aa9d-0fc3881656bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed3ec40f-f573-43b3-9925-6c511adcebde" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_srt_ProductOrServiceAxis_ed3ec40f-f573-43b3-9925-6c511adcebde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed3ec40f-f573-43b3-9925-6c511adcebde_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ed3ec40f-f573-43b3-9925-6c511adcebde" xlink:to="loc_srt_ProductsAndServicesDomain_ed3ec40f-f573-43b3-9925-6c511adcebde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ed3ec40f-f573-43b3-9925-6c511adcebde" xlink:to="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_4855890e-577e-40dd-954f-7127f0d6af47" xlink:href="mrk-20201231.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:to="loc_mrk_LynparzaMember_4855890e-577e-40dd-954f-7127f0d6af47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_58566669-f2a6-443e-948a-d3b01707b1ee" xlink:href="mrk-20201231.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:to="loc_mrk_AstraZenecaMember_58566669-f2a6-443e-948a-d3b01707b1ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_87034fd3-5ca2-4f6c-bdf8-51fa86f58b4e" xlink:href="mrk-20201231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:to="loc_mrk_LenvimaMember_87034fd3-5ca2-4f6c-bdf8-51fa86f58b4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_696619b6-4671-45d0-b126-35a81040363a" xlink:href="mrk-20201231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:to="loc_mrk_AdempasMember_696619b6-4671-45d0-b126-35a81040363a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_caad3f15-2a88-42cc-91f7-37480951ee9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_caad3f15-2a88-42cc-91f7-37480951ee9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_e170aeee-e67b-408d-869d-617feb5c8ee6" xlink:href="mrk-20201231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_caad3f15-2a88-42cc-91f7-37480951ee9b" xlink:to="loc_mrk_SalesBasedMilestonesMember_e170aeee-e67b-408d-869d-617feb5c8ee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_5bca32ac-b842-413a-bd8a-ddfe173fa118" xlink:href="mrk-20201231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_caad3f15-2a88-42cc-91f7-37480951ee9b" xlink:to="loc_mrk_RegulatoryMilestonesMember_5bca32ac-b842-413a-bd8a-ddfe173fa118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_36f0d761-37e7-4534-a0dd-6a956bf06e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_36f0d761-37e7-4534-a0dd-6a956bf06e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_0af2e53b-2987-46ac-bbcd-c0206e7c4a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_36f0d761-37e7-4534-a0dd-6a956bf06e3e" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_0af2e53b-2987-46ac-bbcd-c0206e7c4a0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8653446b-77a5-453d-9415-a3c70467cff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8653446b-77a5-453d-9415-a3c70467cff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_5da27c65-6b70-4637-a729-efe6ad83ba50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8653446b-77a5-453d-9415-a3c70467cff2" xlink:to="loc_us-gaap_LicenseMember_5da27c65-6b70-4637-a729-efe6ad83ba50" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails" xlink:type="extended" id="i73e0683ce215456caab447c528f2acaf_CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_92d045c6-6323-4bb3-a9a6-2ff7142dda26" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_92d045c6-6323-4bb3-a9a6-2ff7142dda26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_ef1fae31-dc2e-4983-9155-3b45d6a73ec5" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_ef1fae31-dc2e-4983-9155-3b45d6a73ec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_215b1d60-5d15-47dd-a289-a2c7f6f6b691" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_215b1d60-5d15-47dd-a289-a2c7f6f6b691" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementExpenses_fc594205-e053-4fff-b33f-0638574a2dba" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementExpenses_fc594205-e053-4fff-b33f-0638574a2dba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementReceivable_47ef7258-c901-489b-863d-711963ddd94b" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementReceivable_47ef7258-c901-489b-863d-711963ddd94b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPayable_2097320b-3ad3-4de8-96cd-21f9e9c28225" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementPayable_2097320b-3ad3-4de8-96cd-21f9e9c28225" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9cbe77e9-f047-41ed-8e06-a7bdfa499709" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_srt_CounterpartyNameAxis_9cbe77e9-f047-41ed-8e06-a7bdfa499709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9cbe77e9-f047-41ed-8e06-a7bdfa499709_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9cbe77e9-f047-41ed-8e06-a7bdfa499709" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9cbe77e9-f047-41ed-8e06-a7bdfa499709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9cbe77e9-f047-41ed-8e06-a7bdfa499709" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_ef40dd50-f217-4b19-9e12-dfb6b1e045d0" xlink:href="mrk-20201231.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:to="loc_mrk_AstraZenecaMember_ef40dd50-f217-4b19-9e12-dfb6b1e045d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_9745c3dd-5d9b-4c00-9096-5a9d74a1a801" xlink:href="mrk-20201231.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:to="loc_mrk_EisaiMember_9745c3dd-5d9b-4c00-9096-5a9d74a1a801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_0b7550b3-367b-439f-8235-112037869a32" xlink:href="mrk-20201231.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:to="loc_mrk_BayerAGMember_0b7550b3-367b-439f-8235-112037869a32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b54c4dab-afde-4119-8fa1-c01e7e23e125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b54c4dab-afde-4119-8fa1-c01e7e23e125" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b54c4dab-afde-4119-8fa1-c01e7e23e125_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b54c4dab-afde-4119-8fa1-c01e7e23e125" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b54c4dab-afde-4119-8fa1-c01e7e23e125_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e331ccb3-46ac-401c-8836-23cabcfdb2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b54c4dab-afde-4119-8fa1-c01e7e23e125" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e331ccb3-46ac-401c-8836-23cabcfdb2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_84d16fe4-0504-4902-8558-e5749caeab9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e331ccb3-46ac-401c-8836-23cabcfdb2a5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_84d16fe4-0504-4902-8558-e5749caeab9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_209aa41f-10da-4207-988c-d1f08e04abe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_209aa41f-10da-4207-988c-d1f08e04abe9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_209aa41f-10da-4207-988c-d1f08e04abe9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_209aa41f-10da-4207-988c-d1f08e04abe9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_209aa41f-10da-4207-988c-d1f08e04abe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_209aa41f-10da-4207-988c-d1f08e04abe9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_31d7dbbb-ba62-4490-a304-b2a173e17573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:to="loc_us-gaap_SalesMember_31d7dbbb-ba62-4490-a304-b2a173e17573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_e009dde2-26d1-4432-ac72-a1a6de0f351e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:to="loc_us-gaap_CostOfSalesMember_e009dde2-26d1-4432-ac72-a1a6de0f351e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_03227184-beec-4f24-b95d-09e39801fedf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_03227184-beec-4f24-b95d-09e39801fedf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_804f3f45-b7af-4b0a-82c2-be9f5ede8b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_804f3f45-b7af-4b0a-82c2-be9f5ede8b2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1e700088-f5fc-4a04-b474-97a5b19214a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1e700088-f5fc-4a04-b474-97a5b19214a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1e700088-f5fc-4a04-b474-97a5b19214a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1e700088-f5fc-4a04-b474-97a5b19214a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1e700088-f5fc-4a04-b474-97a5b19214a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1e700088-f5fc-4a04-b474-97a5b19214a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_c5d6967a-968f-4893-8060-31d6eb3b8e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_c5d6967a-968f-4893-8060-31d6eb3b8e75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_9573cb21-7f31-4443-bc61-24eb0c7143f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_9573cb21-7f31-4443-bc61-24eb0c7143f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_eecf8c27-958a-4f0e-a3e4-71f0b02fee68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_eecf8c27-958a-4f0e-a3e4-71f0b02fee68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9de5a396-00f6-43aa-87e8-26b5d431e34c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_srt_ProductOrServiceAxis_9de5a396-00f6-43aa-87e8-26b5d431e34c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9de5a396-00f6-43aa-87e8-26b5d431e34c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9de5a396-00f6-43aa-87e8-26b5d431e34c" xlink:to="loc_srt_ProductsAndServicesDomain_9de5a396-00f6-43aa-87e8-26b5d431e34c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f285266-194a-4339-b14c-d8c469160e02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9de5a396-00f6-43aa-87e8-26b5d431e34c" xlink:to="loc_srt_ProductsAndServicesDomain_0f285266-194a-4339-b14c-d8c469160e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_746c657c-5b60-4629-bc1c-c9b2583b1d4d" xlink:href="mrk-20201231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f285266-194a-4339-b14c-d8c469160e02" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_746c657c-5b60-4629-bc1c-c9b2583b1d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_e8bf2308-163d-47fb-a265-a6194cb40f2b" xlink:href="mrk-20201231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f285266-194a-4339-b14c-d8c469160e02" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_e8bf2308-163d-47fb-a265-a6194cb40f2b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20201231.xsd#Restructuring"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended" id="ie8f5dc0d64e54cb1bd6a14afbf79f5ef_Restructuring"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended" id="id741e0cdfe544ea884ce9b8375cbcae5_RestructuringTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="ib7f023d3e3914f76aed42dd0c4424c22_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e4dd177b-aa50-42b5-81ad-dfbdc2fa193b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e4dd177b-aa50-42b5-81ad-dfbdc2fa193b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_034274ca-f89b-4cb5-8f94-a0dfc6df5302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_034274ca-f89b-4cb5-8f94-a0dfc6df5302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_3df0ac82-9db1-4e1c-b117-e0abd076b5c2" xlink:href="mrk-20201231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_3df0ac82-9db1-4e1c-b117-e0abd076b5c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_30825664-9d36-458f-aee5-686472143d38" xlink:href="mrk-20201231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_30825664-9d36-458f-aee5-686472143d38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_46543f2d-a3c8-47b3-abf7-1f44ec71a694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_46543f2d-a3c8-47b3-abf7-1f44ec71a694" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ce22ab91-6994-430d-a1b1-d3a2c11bbbce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:to="loc_srt_StatementScenarioAxis_ce22ab91-6994-430d-a1b1-d3a2c11bbbce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ce22ab91-6994-430d-a1b1-d3a2c11bbbce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ce22ab91-6994-430d-a1b1-d3a2c11bbbce" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ce22ab91-6994-430d-a1b1-d3a2c11bbbce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_87e01967-bf37-43fa-baae-c45332f09e46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ce22ab91-6994-430d-a1b1-d3a2c11bbbce" xlink:to="loc_srt_ScenarioUnspecifiedDomain_87e01967-bf37-43fa-baae-c45332f09e46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_fee7d0e0-a885-46e6-994e-0edda776ac31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_87e01967-bf37-43fa-baae-c45332f09e46" xlink:to="loc_srt_ScenarioForecastMember_fee7d0e0-a885-46e6-994e-0edda776ac31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5615f98-76b5-4c89-8d72-453051694a31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:to="loc_srt_RangeAxis_d5615f98-76b5-4c89-8d72-453051694a31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5615f98-76b5-4c89-8d72-453051694a31_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d5615f98-76b5-4c89-8d72-453051694a31" xlink:to="loc_srt_RangeMember_d5615f98-76b5-4c89-8d72-453051694a31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_71345202-b5a0-4da8-b4fc-8db8ffbc9198" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d5615f98-76b5-4c89-8d72-453051694a31" xlink:to="loc_srt_RangeMember_71345202-b5a0-4da8-b4fc-8db8ffbc9198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_986093fa-83a6-40ea-bc9a-22b6dc2d3e9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_71345202-b5a0-4da8-b4fc-8db8ffbc9198" xlink:to="loc_srt_MaximumMember_986093fa-83a6-40ea-bc9a-22b6dc2d3e9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7fbe62f-7c9b-4f5d-95ad-e3da879c0fc2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_71345202-b5a0-4da8-b4fc-8db8ffbc9198" xlink:to="loc_srt_MinimumMember_c7fbe62f-7c9b-4f5d-95ad-e3da879c0fc2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails" xlink:type="extended" id="i97654162279d4174a448fbd22e6ae7dc_RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_82a4d574-5f80-4796-ba6a-0dec6457377b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_886b0cdb-27bc-4e19-833b-4653a0e8400f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_82a4d574-5f80-4796-ba6a-0dec6457377b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_886b0cdb-27bc-4e19-833b-4653a0e8400f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_82a4d574-5f80-4796-ba6a-0dec6457377b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_8667a703-fcc3-4845-afb7-f30b4703ee3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_8667a703-fcc3-4845-afb7-f30b4703ee3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_eedcab53-7ec8-49eb-8cbb-6b7be7fb714d" xlink:href="mrk-20201231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:to="loc_mrk_AcceleratedDepreciationMember_eedcab53-7ec8-49eb-8cbb-6b7be7fb714d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_0596dd3e-a346-48d7-8efa-914a60005a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:to="loc_us-gaap_OtherRestructuringMember_0596dd3e-a346-48d7-8efa-914a60005a3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ab5ccd09-305d-484d-903c-389d8f7bb006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ab5ccd09-305d-484d-903c-389d8f7bb006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ab5ccd09-305d-484d-903c-389d8f7bb006_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ab5ccd09-305d-484d-903c-389d8f7bb006" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ab5ccd09-305d-484d-903c-389d8f7bb006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ab5ccd09-305d-484d-903c-389d8f7bb006" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_518df7da-9dac-48f3-991a-18fac1db0f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:to="loc_us-gaap_CostOfSalesMember_518df7da-9dac-48f3-991a-18fac1db0f7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77edd8d4-b355-46ac-be9a-f7fc5702704f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77edd8d4-b355-46ac-be9a-f7fc5702704f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b554f1a-c6f9-47ed-8861-ec8af1cc8fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b554f1a-c6f9-47ed-8861-ec8af1cc8fa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_d9c4ffbb-3303-4e7d-ad63-00979ceadc0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:to="loc_us-gaap_RestructuringChargesMember_d9c4ffbb-3303-4e7d-ad63-00979ceadc0d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails" xlink:type="extended" id="i34e9b9db85c04ff4a16fdad55626195a_RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2f1e9fd4-e150-433d-96d5-ae57568da5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2f1e9fd4-e150-433d-96d5-ae57568da5c8" xlink:to="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_98a58bdb-842c-4340-8096-441d2ed7a25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_us-gaap_RestructuringReserve_98a58bdb-842c-4340-8096-441d2ed7a25c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c8d72029-9c14-4f8c-9461-7f5ad2c02f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c8d72029-9c14-4f8c-9461-7f5ad2c02f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_fcdc1a6f-4be9-4d93-a5ef-5938ba2c3666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_us-gaap_PaymentsForRestructuring_fcdc1a6f-4be9-4d93-a5ef-5938ba2c3666" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveNoncashActivity_966359a1-679a-4a54-94a9-06d69338fe45" xlink:href="mrk-20201231.xsd#mrk_RestructuringReserveNoncashActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_mrk_RestructuringReserveNoncashActivity_966359a1-679a-4a54-94a9-06d69338fe45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b4a24bc6-8f75-4dc5-a743-60fbc34f5918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa41b71-83eb-4d81-9e88-309ba34f482b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2f1e9fd4-e150-433d-96d5-ae57568da5c8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa41b71-83eb-4d81-9e88-309ba34f482b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_568abd5b-c6b8-420c-baec-9516ed6ef8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa41b71-83eb-4d81-9e88-309ba34f482b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_568abd5b-c6b8-420c-baec-9516ed6ef8e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_568abd5b-c6b8-420c-baec-9516ed6ef8e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_568abd5b-c6b8-420c-baec-9516ed6ef8e0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_568abd5b-c6b8-420c-baec-9516ed6ef8e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_568abd5b-c6b8-420c-baec-9516ed6ef8e0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_296c6901-1992-4199-a973-b7d8e12ebc25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_296c6901-1992-4199-a973-b7d8e12ebc25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_78531056-88a4-49a2-9b4a-312de1728224" xlink:href="mrk-20201231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:to="loc_mrk_AcceleratedDepreciationMember_78531056-88a4-49a2-9b4a-312de1728224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_0d9008a6-9081-49ed-88d6-459e512e922a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:to="loc_us-gaap_OtherRestructuringMember_0d9008a6-9081-49ed-88d6-459e512e922a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended" id="i291d4d0c4b0d4c62b344c11fa7d7ebf3_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended" id="ie4e1a5a05ea148ef9463194cc3f1b1d4_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i38441a46e9ff4abda09070b94cb9c153_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_64a7993d-4aef-400d-ae70-c3cb5a9fd01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_64a7993d-4aef-400d-ae70-c3cb5a9fd01c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_ea617f98-10c8-4df0-b649-3e8f33a929ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_ea617f98-10c8-4df0-b649-3e8f33a929ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_18fbf96b-42e2-4d71-85b8-e140a433ed3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_18fbf96b-42e2-4d71-85b8-e140a433ed3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_dfa3ab4d-c038-4e3e-a6f1-fcd5aa55eee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_dfa3ab4d-c038-4e3e-a6f1-fcd5aa55eee6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b55b0bea-ca68-4a54-88ca-b68dca1564a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b55b0bea-ca68-4a54-88ca-b68dca1564a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_beb73564-7bc6-4899-bd9e-6de130b8d8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_beb73564-7bc6-4899-bd9e-6de130b8d8b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_21646151-e608-4819-990d-1d2d50f536e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_21646151-e608-4819-990d-1d2d50f536e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_accc047b-fbc2-490d-a8a9-903ded1403cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_accc047b-fbc2-490d-a8a9-903ded1403cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b7943475-1da0-4bba-b8b6-e15d7109a5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b7943475-1da0-4bba-b8b6-e15d7109a5e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_6766066c-b230-49ab-9883-69f1493f26f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_6766066c-b230-49ab-9883-69f1493f26f0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_f8810b09-604b-42e2-94d2-6dfb03154c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_f8810b09-604b-42e2-94d2-6dfb03154c14" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c9b6a5fc-ca7b-453b-a008-35d669d14b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c9b6a5fc-ca7b-453b-a008-35d669d14b7f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a32a9cf-3141-42c5-a0e9-55a0a50f4838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a32a9cf-3141-42c5-a0e9-55a0a50f4838" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5eeb72f5-dd10-47d9-bf51-3692049b05b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5eeb72f5-dd10-47d9-bf51-3692049b05b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_6851c961-1926-4be6-8585-3abbb4fd5bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_6851c961-1926-4be6-8585-3abbb4fd5bb5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1912ab9e-c24a-43ce-9696-de3db3406c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1912ab9e-c24a-43ce-9696-de3db3406c82" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_7a63d36f-cbc3-4b52-8825-f07c5128827a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_AccountsReceivableSale_7a63d36f-cbc3-4b52-8825-f07c5128827a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_04e55abe-6644-4813-8a9a-6de3f2b3d6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_RestrictedCashCurrent_04e55abe-6644-4813-8a9a-6de3f2b3d6a2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_951edc02-98ca-4a89-8f4d-25c04207efb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_951edc02-98ca-4a89-8f4d-25c04207efb0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_79be56ec-51d8-4553-833f-031e3e8b5966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_79be56ec-51d8-4553-833f-031e3e8b5966" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9521f7cc-b548-47de-b2af-738fbc921a26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_srt_RangeAxis_9521f7cc-b548-47de-b2af-738fbc921a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9521f7cc-b548-47de-b2af-738fbc921a26_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9521f7cc-b548-47de-b2af-738fbc921a26" xlink:to="loc_srt_RangeMember_9521f7cc-b548-47de-b2af-738fbc921a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aba7873f-9a86-45c6-879c-1e6d751e65a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9521f7cc-b548-47de-b2af-738fbc921a26" xlink:to="loc_srt_RangeMember_aba7873f-9a86-45c6-879c-1e6d751e65a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3935de9e-4f21-45db-bfb3-0a70b94a749e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aba7873f-9a86-45c6-879c-1e6d751e65a5" xlink:to="loc_srt_MaximumMember_3935de9e-4f21-45db-bfb3-0a70b94a749e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b1b2404f-1bf0-40ef-b556-99acfc94e79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_HedgingDesignationAxis_b1b2404f-1bf0-40ef-b556-99acfc94e79e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b1b2404f-1bf0-40ef-b556-99acfc94e79e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b1b2404f-1bf0-40ef-b556-99acfc94e79e" xlink:to="loc_us-gaap_HedgingDesignationDomain_b1b2404f-1bf0-40ef-b556-99acfc94e79e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2302b384-be44-4a7a-87a9-31723c11cb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b1b2404f-1bf0-40ef-b556-99acfc94e79e" xlink:to="loc_us-gaap_HedgingDesignationDomain_2302b384-be44-4a7a-87a9-31723c11cb0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6375987e-3203-49a5-ba2e-34215a0d9ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2302b384-be44-4a7a-87a9-31723c11cb0b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6375987e-3203-49a5-ba2e-34215a0d9ae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_237d4f3c-e0ff-47a3-9660-8423f12df209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2302b384-be44-4a7a-87a9-31723c11cb0b" xlink:to="loc_us-gaap_NondesignatedMember_237d4f3c-e0ff-47a3-9660-8423f12df209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5179483a-f15c-42ea-97d1-bd41d9fdc384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5179483a-f15c-42ea-97d1-bd41d9fdc384" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5179483a-f15c-42ea-97d1-bd41d9fdc384_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5179483a-f15c-42ea-97d1-bd41d9fdc384" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5179483a-f15c-42ea-97d1-bd41d9fdc384_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_753a1519-9ec1-4f7e-8e27-f2028f6e99d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5179483a-f15c-42ea-97d1-bd41d9fdc384" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_753a1519-9ec1-4f7e-8e27-f2028f6e99d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f6df42dc-5bf8-4ea9-83ad-a2825a60722a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_753a1519-9ec1-4f7e-8e27-f2028f6e99d1" xlink:to="loc_us-gaap_InterestRateSwapMember_f6df42dc-5bf8-4ea9-83ad-a2825a60722a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fafe008d-abbe-48d1-9955-808b90629705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fafe008d-abbe-48d1-9955-808b90629705" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fafe008d-abbe-48d1-9955-808b90629705_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fafe008d-abbe-48d1-9955-808b90629705" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fafe008d-abbe-48d1-9955-808b90629705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3c70b11-cc9a-445d-9f78-1227d878e7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fafe008d-abbe-48d1-9955-808b90629705" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3c70b11-cc9a-445d-9f78-1227d878e7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b1ae5d2f-107e-4740-8b32-e211ca5c7d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3c70b11-cc9a-445d-9f78-1227d878e7b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b1ae5d2f-107e-4740-8b32-e211ca5c7d45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aa59cf3e-5825-49e8-91ac-b73cfe4804fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aa59cf3e-5825-49e8-91ac-b73cfe4804fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa59cf3e-5825-49e8-91ac-b73cfe4804fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa59cf3e-5825-49e8-91ac-b73cfe4804fa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa59cf3e-5825-49e8-91ac-b73cfe4804fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4a9899-1adf-4b6d-b3ae-40ce8d484054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa59cf3e-5825-49e8-91ac-b73cfe4804fa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4a9899-1adf-4b6d-b3ae-40ce8d484054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cf37b426-929e-4c11-9cb4-f7d4d80b763b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cf37b426-929e-4c11-9cb4-f7d4d80b763b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2b3ca103-6640-4146-bdbe-4a650c8fc1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cf37b426-929e-4c11-9cb4-f7d4d80b763b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2b3ca103-6640-4146-bdbe-4a650c8fc1d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6bdf5d73-382f-47e7-bc11-754b005c42ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6bdf5d73-382f-47e7-bc11-754b005c42ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6bdf5d73-382f-47e7-bc11-754b005c42ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6bdf5d73-382f-47e7-bc11-754b005c42ca" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6bdf5d73-382f-47e7-bc11-754b005c42ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6392a49c-7aaf-41de-bbb6-0486b4254789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6bdf5d73-382f-47e7-bc11-754b005c42ca" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6392a49c-7aaf-41de-bbb6-0486b4254789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ca51e4b5-3f64-44a5-a7e9-8d262988d639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6392a49c-7aaf-41de-bbb6-0486b4254789" xlink:to="loc_us-gaap_AccountsReceivableMember_ca51e4b5-3f64-44a5-a7e9-8d262988d639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_80369c63-d575-4b57-bed3-4662fe3a5163" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_srt_MajorCustomersAxis_80369c63-d575-4b57-bed3-4662fe3a5163" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_80369c63-d575-4b57-bed3-4662fe3a5163_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_80369c63-d575-4b57-bed3-4662fe3a5163" xlink:to="loc_srt_NameOfMajorCustomerDomain_80369c63-d575-4b57-bed3-4662fe3a5163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c0779796-69c4-4b13-87ad-3ffcfb0cc453" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_80369c63-d575-4b57-bed3-4662fe3a5163" xlink:to="loc_srt_NameOfMajorCustomerDomain_c0779796-69c4-4b13-87ad-3ffcfb0cc453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member_b2c77cba-ad69-4aa8-8ab4-14836940a3b4" xlink:href="mrk-20201231.xsd#mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c0779796-69c4-4b13-87ad-3ffcfb0cc453" xlink:to="loc_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member_b2c77cba-ad69-4aa8-8ab4-14836940a3b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4b31acb9-398a-4a09-903c-3a0f83a6f0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_DebtInstrumentAxis_4b31acb9-398a-4a09-903c-3a0f83a6f0f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4b31acb9-398a-4a09-903c-3a0f83a6f0f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4b31acb9-398a-4a09-903c-3a0f83a6f0f4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4b31acb9-398a-4a09-903c-3a0f83a6f0f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ee6a937a-8a9e-451c-b10a-d83c5b43a600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4b31acb9-398a-4a09-903c-3a0f83a6f0f4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ee6a937a-8a9e-451c-b10a-d83c5b43a600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.85NotesDue2020Member_a1dfd171-d6a7-49b8-9d95-97ed0ccf3a90" xlink:href="mrk-20201231.xsd#mrk_A1.85NotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee6a937a-8a9e-451c-b10a-d83c5b43a600" xlink:to="loc_mrk_A1.85NotesDue2020Member_a1dfd171-d6a7-49b8-9d95-97ed0ccf3a90" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="id281e14267bc4b5c84f2c66ff7552b9a_FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b704a2e9-3f03-4762-af9f-03cfbb880aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7b35e0a5-4a0b-416c-b90b-57f1eb82098d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b704a2e9-3f03-4762-af9f-03cfbb880aa0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7b35e0a5-4a0b-416c-b90b-57f1eb82098d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_8a290743-6949-4720-911d-1298e707fd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b704a2e9-3f03-4762-af9f-03cfbb880aa0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_8a290743-6949-4720-911d-1298e707fd66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b704a2e9-3f03-4762-af9f-03cfbb880aa0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_138c6917-f416-4fc9-8342-9ec1d8f3015a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_138c6917-f416-4fc9-8342-9ec1d8f3015a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_138c6917-f416-4fc9-8342-9ec1d8f3015a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_138c6917-f416-4fc9-8342-9ec1d8f3015a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_138c6917-f416-4fc9-8342-9ec1d8f3015a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_62021466-51c6-493f-963d-19123214452d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_138c6917-f416-4fc9-8342-9ec1d8f3015a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_62021466-51c6-493f-963d-19123214452d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6f813ed9-09cb-494f-8f75-e2b3ed55fbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_62021466-51c6-493f-963d-19123214452d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6f813ed9-09cb-494f-8f75-e2b3ed55fbb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_4fa480e9-7548-44af-b7b4-3abb7566671c" xlink:href="mrk-20201231.xsd#mrk_EurodominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_62021466-51c6-493f-963d-19123214452d" xlink:to="loc_mrk_EurodominatedNotesMember_4fa480e9-7548-44af-b7b4-3abb7566671c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_895f3149-11f2-429e-a7da-a6ba1872d72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_895f3149-11f2-429e-a7da-a6ba1872d72b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_895f3149-11f2-429e-a7da-a6ba1872d72b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_895f3149-11f2-429e-a7da-a6ba1872d72b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_895f3149-11f2-429e-a7da-a6ba1872d72b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e1c92e03-77e7-4328-a5fa-f3ee78cb1fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_895f3149-11f2-429e-a7da-a6ba1872d72b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e1c92e03-77e7-4328-a5fa-f3ee78cb1fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_40698ea1-c81c-4551-86d7-31ef797838dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1c92e03-77e7-4328-a5fa-f3ee78cb1fee" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_40698ea1-c81c-4551-86d7-31ef797838dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationAboutInterestRateSwapsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="extended" id="ia807815dfa8b443cb4d81c787a7e4c47_FinancialInstrumentsInformationAboutInterestRateSwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1cea317e-b4a6-44ca-90e6-802bb8e27d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1cea317e-b4a6-44ca-90e6-802bb8e27d35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_8740e764-8710-4ffe-8ca6-8c1afe1cf931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_8740e764-8710-4ffe-8ca6-8c1afe1cf931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_aad91861-1fb1-435c-b62f-438c36d70e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_DerivativeNotionalAmount_aad91861-1fb1-435c-b62f-438c36d70e30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_349da418-5863-4f16-bcb6-747c85a2e257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_349da418-5863-4f16-bcb6-747c85a2e257" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1b8acd37-9373-4ecd-a7fd-1519533195a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1b8acd37-9373-4ecd-a7fd-1519533195a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1b8acd37-9373-4ecd-a7fd-1519533195a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b8acd37-9373-4ecd-a7fd-1519533195a5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1b8acd37-9373-4ecd-a7fd-1519533195a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b8acd37-9373-4ecd-a7fd-1519533195a5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member_fa560d56-f62b-48c2-aa72-f5032e2f1f37" xlink:href="mrk-20201231.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:to="loc_mrk_A3.875NotesDue2021Member_fa560d56-f62b-48c2-aa72-f5032e2f1f37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_90f78588-ef5f-474a-bec8-92d87e5fc9e4" xlink:href="mrk-20201231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:to="loc_mrk_A2.40NotesDue2022Member_90f78588-ef5f-474a-bec8-92d87e5fc9e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_69a18df0-ab18-448f-8223-290ab83e344c" xlink:href="mrk-20201231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:to="loc_mrk_A2.35NotesDue2022Member_69a18df0-ab18-448f-8223-290ab83e344c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_50dc8d22-eab2-438a-b75a-2f59532094b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_50dc8d22-eab2-438a-b75a-2f59532094b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_50dc8d22-eab2-438a-b75a-2f59532094b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_50dc8d22-eab2-438a-b75a-2f59532094b3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_50dc8d22-eab2-438a-b75a-2f59532094b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_01c597ce-79b5-417f-9e5a-884df33e3abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_50dc8d22-eab2-438a-b75a-2f59532094b3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_01c597ce-79b5-417f-9e5a-884df33e3abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b87df624-1249-4025-a67c-029d0232b008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_01c597ce-79b5-417f-9e5a-884df33e3abd" xlink:to="loc_us-gaap_InterestRateSwapMember_b87df624-1249-4025-a67c-029d0232b008" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFairValueofHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="extended" id="i148d4d44e5b04760b4bd29ce1d4f592f_FinancialInstrumentsFairValueofHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_1d296588-6184-4b09-a3fe-16f23958f330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_e727976c-bd59-49e9-b730-c324b9a1173e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d296588-6184-4b09-a3fe-16f23958f330" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_e727976c-bd59-49e9-b730-c324b9a1173e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_b6abab79-26c6-455b-8e91-e73b28b16136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d296588-6184-4b09-a3fe-16f23958f330" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_b6abab79-26c6-455b-8e91-e73b28b16136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_c03f2d0c-df8c-4d7b-a6a7-8d2d2ba7fa5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1d296588-6184-4b09-a3fe-16f23958f330" xlink:to="loc_us-gaap_DerivativeTable_c03f2d0c-df8c-4d7b-a6a7-8d2d2ba7fa5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5977ba5d-b9ff-4f72-a66c-488109153419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c03f2d0c-df8c-4d7b-a6a7-8d2d2ba7fa5b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5977ba5d-b9ff-4f72-a66c-488109153419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5977ba5d-b9ff-4f72-a66c-488109153419_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5977ba5d-b9ff-4f72-a66c-488109153419" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5977ba5d-b9ff-4f72-a66c-488109153419_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_db3c7229-45d7-4048-b199-6b1e8ed363fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5977ba5d-b9ff-4f72-a66c-488109153419" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_db3c7229-45d7-4048-b199-6b1e8ed363fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_f53d785a-e8a4-4229-aafa-5eb11fe8fc1f" xlink:href="mrk-20201231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_db3c7229-45d7-4048-b199-6b1e8ed363fd" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_f53d785a-e8a4-4229-aafa-5eb11fe8fc1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_e4d476f2-eee8-4d36-b2df-81626e935868" xlink:href="mrk-20201231.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_db3c7229-45d7-4048-b199-6b1e8ed363fd" xlink:to="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_e4d476f2-eee8-4d36-b2df-81626e935868" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i396ea46c85884692867c77c1431c92f8_FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a47dd9a5-d23d-4415-b5dd-dc309414e7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:to="loc_us-gaap_DerivativeAssets_a47dd9a5-d23d-4415-b5dd-dc309414e7ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4c6013d8-0b34-4ed2-a48f-4f97d3d04f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:to="loc_us-gaap_DerivativeLiabilities_4c6013d8-0b34-4ed2-a48f-4f97d3d04f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b388a933-67f5-4e12-b613-8c085860056a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b388a933-67f5-4e12-b613-8c085860056a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1ab7c187-120a-40c1-9f55-0cebe816b2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1ab7c187-120a-40c1-9f55-0cebe816b2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1ab7c187-120a-40c1-9f55-0cebe816b2cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1ab7c187-120a-40c1-9f55-0cebe816b2cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1ab7c187-120a-40c1-9f55-0cebe816b2cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1ab7c187-120a-40c1-9f55-0cebe816b2cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_5a078301-8f47-4bc4-8327-ad4ce29cd120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:to="loc_us-gaap_InterestRateContractMember_5a078301-8f47-4bc4-8327-ad4ce29cd120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_95cdf291-c9eb-499e-a7af-82f503a6a466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:to="loc_us-gaap_ForeignExchangeContractMember_95cdf291-c9eb-499e-a7af-82f503a6a466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_323b6afa-8c84-4aea-962a-c6b5fbcfc57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:to="loc_us-gaap_InterestRateSwapMember_323b6afa-8c84-4aea-962a-c6b5fbcfc57d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a242bff2-875b-4dcd-a735-2d62f0575a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:to="loc_us-gaap_HedgingDesignationAxis_a242bff2-875b-4dcd-a735-2d62f0575a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a242bff2-875b-4dcd-a735-2d62f0575a45_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a242bff2-875b-4dcd-a735-2d62f0575a45" xlink:to="loc_us-gaap_HedgingDesignationDomain_a242bff2-875b-4dcd-a735-2d62f0575a45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b083854f-d30b-4bf5-a38c-b79e7e78017b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a242bff2-875b-4dcd-a735-2d62f0575a45" xlink:to="loc_us-gaap_HedgingDesignationDomain_b083854f-d30b-4bf5-a38c-b79e7e78017b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_005014cd-b810-41bf-8f49-4795823356ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b083854f-d30b-4bf5-a38c-b79e7e78017b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_005014cd-b810-41bf-8f49-4795823356ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6e7552de-461e-455b-b9d7-8d62a62785e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b083854f-d30b-4bf5-a38c-b79e7e78017b" xlink:to="loc_us-gaap_NondesignatedMember_6e7552de-461e-455b-b9d7-8d62a62785e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8c0394b7-5ce8-40a0-8492-f24a15b090fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8c0394b7-5ce8-40a0-8492-f24a15b090fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8c0394b7-5ce8-40a0-8492-f24a15b090fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c0394b7-5ce8-40a0-8492-f24a15b090fd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8c0394b7-5ce8-40a0-8492-f24a15b090fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c0394b7-5ce8-40a0-8492-f24a15b090fd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_1bac9c3c-ab7d-4fe6-88a3-34cd3c4789bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:to="loc_us-gaap_OtherAssetsMember_1bac9c3c-ab7d-4fe6-88a3-34cd3c4789bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_bba777a1-3df3-4757-aff1-9c74fee558fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_bba777a1-3df3-4757-aff1-9c74fee558fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_098fed84-6098-4143-9f12-017034a42159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_098fed84-6098-4143-9f12-017034a42159" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9d2497fb-cc81-43fc-8935-4dea7ecdac0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9d2497fb-cc81-43fc-8935-4dea7ecdac0f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended" id="iaf662cb2351c4d4ba7b4f402a9ada1eb_FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="extended" id="i8f3a240ed7f54c8198acb07f4fb01e11_FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e4642e7a-91e6-4584-9d04-409c7ef29e87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_Revenues_e4642e7a-91e6-4584-9d04-409c7ef29e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1129060b-eda0-4131-a935-c09520d24c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1129060b-eda0-4131-a935-c09520d24c04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fcded54b-a5b7-4ce0-81ef-72decf8ac277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fcded54b-a5b7-4ce0-81ef-72decf8ac277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_02da64f3-5555-4a4c-82cc-1294996a4a16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_02da64f3-5555-4a4c-82cc-1294996a4a16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_9a1ecdd6-96a2-48f1-87e9-dd6edfa7b34f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_9a1ecdd6-96a2-48f1-87e9-dd6edfa7b34f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c1271e8e-86e0-4376-877d-d0e2809d3f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c1271e8e-86e0-4376-877d-d0e2809d3f92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_50497c43-9736-46e5-af37-9502844df5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_50497c43-9736-46e5-af37-9502844df5a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_cb34d7c1-c08b-4ab1-b37a-e9e846254c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_cb34d7c1-c08b-4ab1-b37a-e9e846254c98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ceda2480-3e49-48f6-8e23-7d2a7869bbb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ceda2480-3e49-48f6-8e23-7d2a7869bbb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ceda2480-3e49-48f6-8e23-7d2a7869bbb5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ceda2480-3e49-48f6-8e23-7d2a7869bbb5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ceda2480-3e49-48f6-8e23-7d2a7869bbb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a5d8d3a2-8889-4f99-9880-512fc5d45db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ceda2480-3e49-48f6-8e23-7d2a7869bbb5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a5d8d3a2-8889-4f99-9880-512fc5d45db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_0fc77054-d188-414b-81d5-dfe95f0aff57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a5d8d3a2-8889-4f99-9880-512fc5d45db6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_0fc77054-d188-414b-81d5-dfe95f0aff57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_765a1d56-cf2b-4aeb-b578-6fcec12b82f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_765a1d56-cf2b-4aeb-b578-6fcec12b82f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_765a1d56-cf2b-4aeb-b578-6fcec12b82f3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_765a1d56-cf2b-4aeb-b578-6fcec12b82f3" xlink:to="loc_us-gaap_EquityComponentDomain_765a1d56-cf2b-4aeb-b578-6fcec12b82f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b1e9e458-e7a0-4e79-b4a0-27075bb4e121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_765a1d56-cf2b-4aeb-b578-6fcec12b82f3" xlink:to="loc_us-gaap_EquityComponentDomain_b1e9e458-e7a0-4e79-b4a0-27075bb4e121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_9168bc21-57f1-4402-8e77-7e3f5fb7845a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b1e9e458-e7a0-4e79-b4a0-27075bb4e121" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_9168bc21-57f1-4402-8e77-7e3f5fb7845a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a9ac6d01-fbde-41e7-ae14-041a50c487f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a9ac6d01-fbde-41e7-ae14-041a50c487f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9ac6d01-fbde-41e7-ae14-041a50c487f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a9ac6d01-fbde-41e7-ae14-041a50c487f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9ac6d01-fbde-41e7-ae14-041a50c487f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df410c0f-b007-492d-9ec0-beb88d73205c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a9ac6d01-fbde-41e7-ae14-041a50c487f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df410c0f-b007-492d-9ec0-beb88d73205c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a89095d6-1c1e-4130-b280-9ece5351345e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df410c0f-b007-492d-9ec0-beb88d73205c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a89095d6-1c1e-4130-b280-9ece5351345e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ecc66212-1fa1-40b6-a187-03a3a19776ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ecc66212-1fa1-40b6-a187-03a3a19776ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ecc66212-1fa1-40b6-a187-03a3a19776ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ecc66212-1fa1-40b6-a187-03a3a19776ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ecc66212-1fa1-40b6-a187-03a3a19776ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_84e3324c-bc7f-4952-a21b-479d4c1d5fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ecc66212-1fa1-40b6-a187-03a3a19776ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_84e3324c-bc7f-4952-a21b-479d4c1d5fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_dc86346b-d745-4847-b15c-197696799bef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_84e3324c-bc7f-4952-a21b-479d4c1d5fb9" xlink:to="loc_us-gaap_InterestRateSwapMember_dc86346b-d745-4847-b15c-197696799bef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0f39d57f-5eec-4cb9-b621-63412810cf51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_84e3324c-bc7f-4952-a21b-479d4c1d5fb9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0f39d57f-5eec-4cb9-b621-63412810cf51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i0f8d00efc36f49c8809703e373c40619_FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_31287c81-f214-48af-8d67-112cb7c0230a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_49a2aa90-ca9e-43b5-8441-2100158eed0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_31287c81-f214-48af-8d67-112cb7c0230a" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_49a2aa90-ca9e-43b5-8441-2100158eed0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_31287c81-f214-48af-8d67-112cb7c0230a" xlink:to="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2a2af98c-ccb2-47e1-929c-4902300b8c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2a2af98c-ccb2-47e1-929c-4902300b8c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2a2af98c-ccb2-47e1-929c-4902300b8c59_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a2af98c-ccb2-47e1-929c-4902300b8c59" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2a2af98c-ccb2-47e1-929c-4902300b8c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a2af98c-ccb2-47e1-929c-4902300b8c59" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d5916b96-b42b-43c3-a40a-023283e0b121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d5916b96-b42b-43c3-a40a-023283e0b121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f91ad7ab-69ce-4521-8069-cb667d557238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:to="loc_us-gaap_InterestRateSwapMember_f91ad7ab-69ce-4521-8069-cb667d557238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_c794460b-35df-43a8-95ed-ac77d9d3ed9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:to="loc_us-gaap_InterestRateContractMember_c794460b-35df-43a8-95ed-ac77d9d3ed9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_3cccaef9-1b63-4df6-a706-96b8f2e0284b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:to="loc_us-gaap_ForwardContractsMember_3cccaef9-1b63-4df6-a706-96b8f2e0284b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c73f8f4-903b-49e5-911b-b93711d79c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c73f8f4-903b-49e5-911b-b93711d79c59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c73f8f4-903b-49e5-911b-b93711d79c59_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c73f8f4-903b-49e5-911b-b93711d79c59" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c73f8f4-903b-49e5-911b-b93711d79c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c73f8f4-903b-49e5-911b-b93711d79c59" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_aed30781-2cd7-44b3-8bf7-ff2b128bb5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_aed30781-2cd7-44b3-8bf7-ff2b128bb5f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_6f7146b3-0ce6-46a9-b582-ef49d6f913ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:to="loc_us-gaap_SalesMember_6f7146b3-0ce6-46a9-b582-ef49d6f913ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6e757ffe-8b42-434a-b572-e5df821f8c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6e757ffe-8b42-434a-b572-e5df821f8c2b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended" id="i44bf6b6b411f48dda1e6207de3b59e55_FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9a40afc4-1365-4445-ae85-1b330be0f850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9a40afc4-1365-4445-ae85-1b330be0f850" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_684e245d-5631-459c-9600-e1bc70157742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_684e245d-5631-459c-9600-e1bc70157742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0cf2098e-4cee-4851-980c-0a58d6dc5a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0cf2098e-4cee-4851-980c-0a58d6dc5a2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e18a44ba-cdf9-4bc0-b173-d48b3ea56bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e18a44ba-cdf9-4bc0-b173-d48b3ea56bd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_18704eac-8c0a-4817-b562-34f72b3ec300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_18704eac-8c0a-4817-b562-34f72b3ec300" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_8a9af1a2-d142-4471-ae4a-5dbd1965461b" xlink:href="mrk-20201231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_8a9af1a2-d142-4471-ae4a-5dbd1965461b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7af8d824-ffa4-4be5-95fa-9be93945815c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7af8d824-ffa4-4be5-95fa-9be93945815c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7af8d824-ffa4-4be5-95fa-9be93945815c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7af8d824-ffa4-4be5-95fa-9be93945815c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7af8d824-ffa4-4be5-95fa-9be93945815c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c85c0648-e6ca-4a23-8705-6510d5d6f044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7af8d824-ffa4-4be5-95fa-9be93945815c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c85c0648-e6ca-4a23-8705-6510d5d6f044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_133b4409-37a3-4805-b55f-906d31eb8d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c85c0648-e6ca-4a23-8705-6510d5d6f044" xlink:to="loc_us-gaap_InterestRateContractMember_133b4409-37a3-4805-b55f-906d31eb8d7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_933102b2-87ce-449c-b527-6166387511f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_933102b2-87ce-449c-b527-6166387511f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_541ebd0d-1bb7-4b52-9401-83b5d6e2e7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_933102b2-87ce-449c-b527-6166387511f4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_541ebd0d-1bb7-4b52-9401-83b5d6e2e7d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:to="loc_us-gaap_FinancialInstrumentAxis_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a400a2d5-1291-498b-84bc-efa0d1ab2b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_CommercialPaperMember_a400a2d5-1291-498b-84bc-efa0d1ab2b39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_587c80d8-01b6-4cc4-a4a4-22f4a2b202ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_587c80d8-01b6-4cc4-a4a4-22f4a2b202ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_67b23244-2908-43c8-a14e-00595b89f1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_67b23244-2908-43c8-a14e-00595b89f1ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b6b1622f-87c5-497a-ba4b-d317c296c550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b6b1622f-87c5-497a-ba4b-d317c296c550" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_6d6ee694-35cb-4036-8980-3d99fda54fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_6d6ee694-35cb-4036-8980-3d99fda54fec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_2c83c265-923f-4091-9503-165694228ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_EquitySecuritiesMember_2c83c265-923f-4091-9503-165694228ade" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i1aaa6146e2654c71810d6e9da646f1e2_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41efb9f1-ad2c-4cc0-86b2-1e8789c184ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41efb9f1-ad2c-4cc0-86b2-1e8789c184ca" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0cd2f6b7-7e0c-4931-aaab-093b44d3761e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0cd2f6b7-7e0c-4931-aaab-093b44d3761e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_543bf055-d33a-47f1-8366-bb018f4e69fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_543bf055-d33a-47f1-8366-bb018f4e69fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_bad6650a-fb30-43a3-9ead-11828fc6b8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_TradingSecurities_bad6650a-fb30-43a3-9ead-11828fc6b8d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a63d1da1-9719-4e3b-934d-26f45a190f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a63d1da1-9719-4e3b-934d-26f45a190f58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_0d9426dd-ae1a-4b3a-9e88-43df79c2a59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_DerivativeAssets_0d9426dd-ae1a-4b3a-9e88-43df79c2a59d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ff3d4d6a-bdf7-4284-9ced-286a00376f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ff3d4d6a-bdf7-4284-9ced-286a00376f35" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41efb9f1-ad2c-4cc0-86b2-1e8789c184ca" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_de9c7dd1-a338-4cc4-a69a-a683041ce9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_de9c7dd1-a338-4cc4-a69a-a683041ce9cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_12a61f07-e303-43f3-ab77-ef61cea5ccc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:to="loc_us-gaap_DerivativeLiabilities_12a61f07-e303-43f3-ab77-ef61cea5ccc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ba39ceb3-7905-476f-beac-fe2d94836ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ba39ceb3-7905-476f-beac-fe2d94836ddf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41efb9f1-ad2c-4cc0-86b2-1e8789c184ca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ef1264e-1f21-4371-98c5-deac9f0e1205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ef1264e-1f21-4371-98c5-deac9f0e1205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ef1264e-1f21-4371-98c5-deac9f0e1205_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ef1264e-1f21-4371-98c5-deac9f0e1205" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ef1264e-1f21-4371-98c5-deac9f0e1205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_47db0df9-7548-461c-b119-620afa3c7492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ef1264e-1f21-4371-98c5-deac9f0e1205" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_47db0df9-7548-461c-b119-620afa3c7492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5f1dc7e7-a8c4-4843-addb-364769ea4698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_47db0df9-7548-461c-b119-620afa3c7492" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5f1dc7e7-a8c4-4843-addb-364769ea4698" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2e0c936-210f-48fd-9ed3-73bad74d3078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2e0c936-210f-48fd-9ed3-73bad74d3078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d2e0c936-210f-48fd-9ed3-73bad74d3078_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2e0c936-210f-48fd-9ed3-73bad74d3078" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d2e0c936-210f-48fd-9ed3-73bad74d3078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2e0c936-210f-48fd-9ed3-73bad74d3078" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_efe20318-498f-44db-b8d5-e7db87da020b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_efe20318-498f-44db-b8d5-e7db87da020b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9dc263f1-c75f-4699-8bc9-57c7ffd8cdf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9dc263f1-c75f-4699-8bc9-57c7ffd8cdf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ee4044ae-98e8-4181-9d53-ef9643d4c720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ee4044ae-98e8-4181-9d53-ef9643d4c720" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bc63a853-bf5a-43bc-8e30-40ca4e62cced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bc63a853-bf5a-43bc-8e30-40ca4e62cced" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc63a853-bf5a-43bc-8e30-40ca4e62cced_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc63a853-bf5a-43bc-8e30-40ca4e62cced" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc63a853-bf5a-43bc-8e30-40ca4e62cced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc63a853-bf5a-43bc-8e30-40ca4e62cced" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b2b11786-8899-4286-a2a8-6b1fe06f8a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b2b11786-8899-4286-a2a8-6b1fe06f8a93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9462ac19-9cef-4857-9529-0e5764e5bb72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9462ac19-9cef-4857-9529-0e5764e5bb72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d726b1a9-7de6-436b-afdf-27e05926fdcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d726b1a9-7de6-436b-afdf-27e05926fdcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4b810f7b-4b1d-4580-95f9-2907b1c27161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4b810f7b-4b1d-4580-95f9-2907b1c27161" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_5219629c-3c21-41d6-8184-b4f73b25a527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_EquitySecuritiesMember_5219629c-3c21-41d6-8184-b4f73b25a527" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_edb7d9f1-64d0-4446-9b79-6e2597660c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_InvestmentTypeAxis_edb7d9f1-64d0-4446-9b79-6e2597660c16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_edb7d9f1-64d0-4446-9b79-6e2597660c16_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_edb7d9f1-64d0-4446-9b79-6e2597660c16" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_edb7d9f1-64d0-4446-9b79-6e2597660c16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_781d14da-9d90-49e8-b584-a4ce80658b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_edb7d9f1-64d0-4446-9b79-6e2597660c16" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_781d14da-9d90-49e8-b584-a4ce80658b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ef412d8f-71bc-4dd2-9b3a-d83a326c9011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_781d14da-9d90-49e8-b584-a4ce80658b47" xlink:to="loc_us-gaap_CommercialPaperMember_ef412d8f-71bc-4dd2-9b3a-d83a326c9011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_2250b06f-65cd-419f-85c7-42632fcffb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:to="loc_us-gaap_InterestRateContractMember_2250b06f-65cd-419f-85c7-42632fcffb2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_4472611d-ab0d-48d6-9c94-793f06db3876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:to="loc_us-gaap_ForeignExchangeContractMember_4472611d-ab0d-48d6-9c94-793f06db3876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_a2958579-31a1-4586-9e1b-c30fae28a585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_a2958579-31a1-4586-9e1b-c30fae28a585" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended" id="i1d4b1e6a8c2f49468d0392fc039df0b9_FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_fb0462eb-5e94-4d27-a107-630d2bd511a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_fb0462eb-5e94-4d27-a107-630d2bd511a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0a1baf79-4553-4e1c-9f5b-00e749e526f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0a1baf79-4553-4e1c-9f5b-00e749e526f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0a59839a-0c6f-4f9f-b1de-df08f91cab09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0a59839a-0c6f-4f9f-b1de-df08f91cab09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_588683d4-43fe-43c5-8604-63ca3ad18922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_588683d4-43fe-43c5-8604-63ca3ad18922" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_dc4d0471-c4df-46e3-9002-8a93f8ffff03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_dc4d0471-c4df-46e3-9002-8a93f8ffff03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_63b34e48-5fe2-4afd-9e15-4f23403572a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_69766246-7e99-4c29-9c79-e2035fb9befe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_69766246-7e99-4c29-9c79-e2035fb9befe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_dd2f767c-364d-4e17-aa34-0c41c79674a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_dd2f767c-364d-4e17-aa34-0c41c79674a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3d3e8a94-3143-4097-9388-f172d861cab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_dd2f767c-364d-4e17-aa34-0c41c79674a9" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3d3e8a94-3143-4097-9388-f172d861cab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_ef153840-70cf-4cfd-a20c-ff95cc83dabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_ef153840-70cf-4cfd-a20c-ff95cc83dabd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_ef153840-70cf-4cfd-a20c-ff95cc83dabd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_ef153840-70cf-4cfd-a20c-ff95cc83dabd" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_ef153840-70cf-4cfd-a20c-ff95cc83dabd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_076ce106-b8c7-4040-b9e2-26e1272e5395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_ef153840-70cf-4cfd-a20c-ff95cc83dabd" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_076ce106-b8c7-4040-b9e2-26e1272e5395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_22b0e90d-7c32-4af2-bc4c-f1c598983cb0" xlink:href="mrk-20201231.xsd#mrk_SanofiPasteurMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_076ce106-b8c7-4040-b9e2-26e1272e5395" xlink:to="loc_mrk_SanofiPasteurMember_22b0e90d-7c32-4af2-bc4c-f1c598983cb0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20201231.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended" id="ib155054cad11428581b70ab96ce80bbd_Inventories"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended" id="ibab7396efab24f2eb1c00e0c1ee0a280_InventoriesTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended" id="i9bb8ba73758d4b7a89e22a39cc1bce44_InventoriesInventoriesDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="idb476cb2c4854d70b546b347e8664fd9_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_9e566b6c-e728-4a80-957a-df06136f3b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_dfb4155d-2ec2-482f-b0f7-67a1cdcb84a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_9e566b6c-e728-4a80-957a-df06136f3b83" xlink:to="loc_us-gaap_LIFOInventoryAmount_dfb4155d-2ec2-482f-b0f7-67a1cdcb84a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_a51bce15-39ce-40ff-abab-af5f2d6f49b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_9e566b6c-e728-4a80-957a-df06136f3b83" xlink:to="loc_us-gaap_InventoryNoncurrent_a51bce15-39ce-40ff-abab-af5f2d6f49b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_ae006bcc-a5ae-468a-83b4-3b1023c23cf9" xlink:href="mrk-20201231.xsd#mrk_InventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_9e566b6c-e728-4a80-957a-df06136f3b83" xlink:to="loc_mrk_InventoryTable_ae006bcc-a5ae-468a-83b4-3b1023c23cf9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_5437796d-3429-411b-8dfa-99edca83f9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_InventoryTable_ae006bcc-a5ae-468a-83b4-3b1023c23cf9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_5437796d-3429-411b-8dfa-99edca83f9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5437796d-3429-411b-8dfa-99edca83f9bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5437796d-3429-411b-8dfa-99edca83f9bf" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5437796d-3429-411b-8dfa-99edca83f9bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3faaa592-3539-4d10-a64b-0b7c8fc88b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5437796d-3429-411b-8dfa-99edca83f9bf" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3faaa592-3539-4d10-a64b-0b7c8fc88b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_7ce9ad3b-098c-4069-a0da-1979f0006dd5" xlink:href="mrk-20201231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3faaa592-3539-4d10-a64b-0b7c8fc88b77" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_7ce9ad3b-098c-4069-a0da-1979f0006dd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_f2709669-d48e-40a2-af6d-28514931bb81" xlink:href="mrk-20201231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3faaa592-3539-4d10-a64b-0b7c8fc88b77" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_f2709669-d48e-40a2-af6d-28514931bb81" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangibles"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="extended" id="iaf04a7479e474586ba0958cc0e5427dc_GoodwillandOtherIntangibles"/>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended" id="i84401263eb854462a1b78306cc64a745_GoodwillandOtherIntangiblesTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended" id="i753df822c879478592bd8e169c85b5cc_GoodwillandOtherIntangiblesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:href="mrk-20201231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f545b4b4-464e-448c-86b9-945587b6547c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f545b4b4-464e-448c-86b9-945587b6547c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c392974c-640e-4523-9065-638ece0c55ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c392974c-640e-4523-9065-638ece0c55ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12ade775-1c5c-4d3e-8d1d-32df64b87a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12ade775-1c5c-4d3e-8d1d-32df64b87a7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_191f3494-4f0e-4321-ac04-45577297ed9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_InventoryWriteDown_191f3494-4f0e-4321-ac04-45577297ed9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_812d7e2e-0b5d-4374-b96a-5d588e55a877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_812d7e2e-0b5d-4374-b96a-5d588e55a877" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3c4a8c50-dca3-482e-b4be-fcb0474fbd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3c4a8c50-dca3-482e-b4be-fcb0474fbd14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_81d01163-3f4b-48cf-9a99-e8df03a03e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_81d01163-3f4b-48cf-9a99-e8df03a03e61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85121866-b6c4-4b6a-a81b-363072bd0f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85121866-b6c4-4b6a-a81b-363072bd0f51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_baeee253-e595-4cfd-a181-b6b3185669ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_baeee253-e595-4cfd-a181-b6b3185669ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2e238328-49e0-4105-9fa2-6b9859c5e6f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2e238328-49e0-4105-9fa2-6b9859c5e6f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bcbaee67-d0ed-496f-bcbf-f85369ccf77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bcbaee67-d0ed-496f-bcbf-f85369ccf77e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4fbdb80d-b4ad-4d24-948c-c47d387c4af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4fbdb80d-b4ad-4d24-948c-c47d387c4af1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:href="mrk-20201231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a835f716-6d63-4d00-8c97-6b366e728c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a835f716-6d63-4d00-8c97-6b366e728c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a835f716-6d63-4d00-8c97-6b366e728c1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a835f716-6d63-4d00-8c97-6b366e728c1c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a835f716-6d63-4d00-8c97-6b366e728c1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_068ff389-151b-40e2-a6ab-0541792f5b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a835f716-6d63-4d00-8c97-6b366e728c1c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_068ff389-151b-40e2-a6ab-0541792f5b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_936ae2a2-175a-462f-a351-1a0fb74f0096" xlink:href="mrk-20201231.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_068ff389-151b-40e2-a6ab-0541792f5b15" xlink:to="loc_mrk_AntelliqMember_936ae2a2-175a-462f-a351-1a0fb74f0096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_d27bde9b-37af-4ac7-b6f5-4d0294e81d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_d27bde9b-37af-4ac7-b6f5-4d0294e81d0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_32489762-70ec-4209-9ae3-1f96ba299ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:to="loc_us-gaap_TradeNamesMember_32489762-70ec-4209-9ae3-1f96ba299ef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a38404f1-0e89-4fa9-8266-932b3947790b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:to="loc_us-gaap_LicenseMember_a38404f1-0e89-4fa9-8266-932b3947790b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dc07d3d2-1055-49c7-b950-e0fc00933361" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_srt_ProductOrServiceAxis_dc07d3d2-1055-49c7-b950-e0fc00933361" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc07d3d2-1055-49c7-b950-e0fc00933361_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dc07d3d2-1055-49c7-b950-e0fc00933361" xlink:to="loc_srt_ProductsAndServicesDomain_dc07d3d2-1055-49c7-b950-e0fc00933361_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dc07d3d2-1055-49c7-b950-e0fc00933361" xlink:to="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_5ca628b4-1b93-4d4a-b31e-5e15f59b1b03" xlink:href="mrk-20201231.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_ZerbaxaMember_5ca628b4-1b93-4d4a-b31e-5e15f59b1b03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember_4e3693b5-6e63-4d56-8804-1e4a94908b49" xlink:href="mrk-20201231.xsd#mrk_SivextroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_SivextroMember_4e3693b5-6e63-4d56-8804-1e4a94908b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImplanonNexplanonMember_445b4ee7-85e4-41a2-b341-cba431f4a05a" xlink:href="mrk-20201231.xsd#mrk_ImplanonNexplanonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_ImplanonNexplanonMember_445b4ee7-85e4-41a2-b341-cba431f4a05a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_790459bf-0c44-4ec4-a53b-b173b36e9fdb" xlink:href="mrk-20201231.xsd#mrk_DificidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_DificidMember_790459bf-0c44-4ec4-a53b-b173b36e9fdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_ed5932cf-0174-4688-bf02-2dfde942fa94" xlink:href="mrk-20201231.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_GardasilGardasil9Member_ed5932cf-0174-4688-bf02-2dfde942fa94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_55413fbf-b2c8-4def-85b8-02a20039d948" xlink:href="mrk-20201231.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_BridionMember_55413fbf-b2c8-4def-85b8-02a20039d948" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_061e5fe2-28e8-413d-83e7-81ac4e3b5347" xlink:href="mrk-20201231.xsd#mrk_SimponiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_SimponiMember_061e5fe2-28e8-413d-83e7-81ac4e3b5347" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember_ee099a09-c112-499e-80b9-89f66301a525" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_AnimalHealthMember_ee099a09-c112-499e-80b9-89f66301a525" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_b3448f06-b6b1-4bd8-92c9-60ef960687d1" xlink:href="mrk-20201231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_LenvimaMember_b3448f06-b6b1-4bd8-92c9-60ef960687d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_db2ef4f7-3353-4631-bb0a-bd73ce040f2e" xlink:href="mrk-20201231.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_LynparzaMember_db2ef4f7-3353-4631-bb0a-bd73ce040f2e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_730fb118-061f-44e6-bebe-3edf60d1a748" xlink:href="mrk-20201231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_AdempasMember_730fb118-061f-44e6-bebe-3edf60d1a748" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IOmetPharmaLtdMember_2867cb56-f2d0-4efa-a919-767268cff3a9" xlink:href="mrk-20201231.xsd#mrk_IOmetPharmaLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_IOmetPharmaLtdMember_2867cb56-f2d0-4efa-a919-767268cff3a9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SmartCellsProgramMember_109032de-f6b2-4636-99c1-a974b3dcad9d" xlink:href="mrk-20201231.xsd#mrk_SmartCellsProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_SmartCellsProgramMember_109032de-f6b2-4636-99c1-a974b3dcad9d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_3db61096-4c3b-45b0-bb35-0029626e8b58" xlink:href="mrk-20201231.xsd#mrk_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_COVID19Member_3db61096-4c3b-45b0-bb35-0029626e8b58" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c0727ec2-9bb4-4be5-9cb9-6999dc425aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c0727ec2-9bb4-4be5-9cb9-6999dc425aac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c0727ec2-9bb4-4be5-9cb9-6999dc425aac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c0727ec2-9bb4-4be5-9cb9-6999dc425aac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c0727ec2-9bb4-4be5-9cb9-6999dc425aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a2c6b0ee-0176-4d4f-9620-e1b414f21784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c0727ec2-9bb4-4be5-9cb9-6999dc425aac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a2c6b0ee-0176-4d4f-9620-e1b414f21784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ed747ca3-37d1-48d9-a457-02e4804d074e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a2c6b0ee-0176-4d4f-9620-e1b414f21784" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ed747ca3-37d1-48d9-a457-02e4804d074e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="extended" id="i15d279b98dee48c48cf9d99962bf0c28_GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_cbf8ec90-497b-4c98-968b-375c04963ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_cbf8ec90-497b-4c98-968b-375c04963ca2" xlink:to="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bb0d8cd6-c1ef-4f7d-88ca-543b0eda3196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_Goodwill_bb0d8cd6-c1ef-4f7d-88ca-543b0eda3196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fa1715c8-6d2b-4a39-9b5e-67ae259a99c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fa1715c8-6d2b-4a39-9b5e-67ae259a99c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_a192a2e3-ad18-47ad-840f-9357c2798f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_a192a2e3-ad18-47ad-840f-9357c2798f27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e3cd887c-229a-42e1-ac38-26c0ff9bfc0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e3cd887c-229a-42e1-ac38-26c0ff9bfc0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_6d162226-bfec-4a7a-a321-c49e1d988b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_6d162226-bfec-4a7a-a321-c49e1d988b27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a79eeb1-c6cc-4bb2-b8f7-c9dbd851cdf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_cb9407d6-89b0-4c61-be3b-7027504e4abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_cbf8ec90-497b-4c98-968b-375c04963ca2" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_cb9407d6-89b0-4c61-be3b-7027504e4abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_340d1b7c-c845-4da7-821d-1dff233a3c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_cbf8ec90-497b-4c98-968b-375c04963ca2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_340d1b7c-c845-4da7-821d-1dff233a3c37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a819ed7-5c69-4e69-a922-9423f03932fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_340d1b7c-c845-4da7-821d-1dff233a3c37" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a819ed7-5c69-4e69-a922-9423f03932fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a819ed7-5c69-4e69-a922-9423f03932fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a819ed7-5c69-4e69-a922-9423f03932fa" xlink:to="loc_us-gaap_SegmentDomain_8a819ed7-5c69-4e69-a922-9423f03932fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a819ed7-5c69-4e69-a922-9423f03932fa" xlink:to="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_5b32b821-48c0-4dc3-898d-1225ed68e161" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:to="loc_mrk_PharmaceuticalsegmentMember_5b32b821-48c0-4dc3-898d-1225ed68e161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_204aa3da-5f2f-4d63-8289-3339746a9727" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:to="loc_mrk_AnimalHealthsegmentMember_204aa3da-5f2f-4d63-8289-3339746a9727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f72c0b32-b7c9-4eb7-aab9-da200d8227cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f72c0b32-b7c9-4eb7-aab9-da200d8227cc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended" id="i43190066cddc46efada2872cf3f73670_GoodwillandOtherIntangiblesOtherIntangiblesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4b808c3e-9676-4c6c-8ecf-4dfc7d883247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4b808c3e-9676-4c6c-8ecf-4dfc7d883247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_159c8519-14cd-46c2-ab0c-397f434987f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_159c8519-14cd-46c2-ab0c-397f434987f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64aa6b35-bc64-4f30-af6f-5bddc0a71871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64aa6b35-bc64-4f30-af6f-5bddc0a71871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2c300d0f-ace7-40ac-8c7d-8e21471db0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2c300d0f-ace7-40ac-8c7d-8e21471db0c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1592ac48-5d2d-4a48-bdb8-6b95f350f2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:to="loc_us-gaap_LicenseMember_1592ac48-5d2d-4a48-bdb8-6b95f350f2d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_489b0b32-e6a4-462c-b2b1-16f55a4889a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:to="loc_us-gaap_TradeNamesMember_489b0b32-e6a4-462c-b2b1-16f55a4889a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_5398fd8a-fd22-43b5-b254-5b9672266b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_5398fd8a-fd22-43b5-b254-5b9672266b7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c68d3343-0f44-4762-8b94-8d1104ff93b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c68d3343-0f44-4762-8b94-8d1104ff93b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c68d3343-0f44-4762-8b94-8d1104ff93b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c68d3343-0f44-4762-8b94-8d1104ff93b8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c68d3343-0f44-4762-8b94-8d1104ff93b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_07406d87-0526-4b2b-a006-a9b278598a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c68d3343-0f44-4762-8b94-8d1104ff93b8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_07406d87-0526-4b2b-a006-a9b278598a59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c60da35e-e0b1-48c6-96e3-6c554f8d59c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_07406d87-0526-4b2b-a006-a9b278598a59" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c60da35e-e0b1-48c6-96e3-6c554f8d59c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeases"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="extended" id="i6d7778d256704d0998586ab30f6ce07b_LoansPayableLongTermDebtandLeases"/>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="extended" id="i690cbeb72b864313955d278821a9d590_LoansPayableLongTermDebtandLeasesTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="extended" id="ia85b52f982444cd6a9b7bb2b2ffef9b8_LoansPayableLongTermDebtandLeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_bc5f1813-3686-4d45-ae79-5839ce7f1347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtCurrent_bc5f1813-3686-4d45-ae79-5839ce7f1347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_60c9a871-8b6e-4ad6-8ed8-1674eb49b295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_DebtCurrent_60c9a871-8b6e-4ad6-8ed8-1674eb49b295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_34097b9c-f607-4520-8ee1-b757526fb7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_34097b9c-f607-4520-8ee1-b757526fb7b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_47bf0b54-e11d-4dcd-9619-a52376ef646b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_47bf0b54-e11d-4dcd-9619-a52376ef646b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_ef84b2ec-f892-41df-84ba-7ec2d15bc915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_ef84b2ec-f892-41df-84ba-7ec2d15bc915" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3fcd1d85-4b7f-41c2-b43c-127c26d29bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3fcd1d85-4b7f-41c2-b43c-127c26d29bcb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fd1ffe30-6966-4c64-abb7-cc95f99cbabc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fd1ffe30-6966-4c64-abb7-cc95f99cbabc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_56e143fe-6090-4e7f-af6b-ebea15de6524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_56e143fe-6090-4e7f-af6b-ebea15de6524" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f0fc1b77-4a7c-4838-8bd0-bda3d686eaa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f0fc1b77-4a7c-4838-8bd0-bda3d686eaa5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1cb12401-6318-4577-8789-df6797adeee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1cb12401-6318-4577-8789-df6797adeee6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8df46a96-cf66-48b1-91f9-f46969a77ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8df46a96-cf66-48b1-91f9-f46969a77ed5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0d4d7a53-bd4a-42b8-a8e7-b46f4b731d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0d4d7a53-bd4a-42b8-a8e7-b46f4b731d7f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_621a18a9-a05b-4d36-9ca6-a7f555e586cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_621a18a9-a05b-4d36-9ca6-a7f555e586cd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_de57c83e-4e86-4775-a53b-094656f5af70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_de57c83e-4e86-4775-a53b-094656f5af70" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_02657584-535f-4c3f-a6d8-ecedc908b4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_02657584-535f-4c3f-a6d8-ecedc908b4d8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9eb83979-bd1c-4a71-b166-80bcdeacdd9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_OperatingLeaseCost_9eb83979-bd1c-4a71-b166-80bcdeacdd9d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f0d4bbce-c2ca-45ef-8006-815e8a432f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_OperatingLeasePayments_f0d4bbce-c2ca-45ef-8006-815e8a432f37" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_6fe5d5dd-ab1e-4c5f-986e-c4702ecfd0bf" xlink:href="mrk-20201231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_6fe5d5dd-ab1e-4c5f-986e-c4702ecfd0bf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_00ba7f2c-3b91-4690-8ad6-627cc3c2a150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_00ba7f2c-3b91-4690-8ad6-627cc3c2a150" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_64a9a3f3-1a4c-44f6-b69e-877e391a0510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_64a9a3f3-1a4c-44f6-b69e-877e391a0510" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce83232b-96ed-45d2-a1ed-2a64906e1ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce83232b-96ed-45d2-a1ed-2a64906e1ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce83232b-96ed-45d2-a1ed-2a64906e1ba0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce83232b-96ed-45d2-a1ed-2a64906e1ba0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce83232b-96ed-45d2-a1ed-2a64906e1ba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eda1f777-4083-4e44-80f2-9902f33e31d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce83232b-96ed-45d2-a1ed-2a64906e1ba0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eda1f777-4083-4e44-80f2-9902f33e31d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a84d245c-f89f-4e11-84eb-daa718736611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eda1f777-4083-4e44-80f2-9902f33e31d3" xlink:to="loc_us-gaap_BuildingMember_a84d245c-f89f-4e11-84eb-daa718736611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_8ab44e5f-9cbe-4e2c-a49e-2d3fb079b733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eda1f777-4083-4e44-80f2-9902f33e31d3" xlink:to="loc_us-gaap_VehiclesMember_8ab44e5f-9cbe-4e2c-a49e-2d3fb079b733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_862f860b-1563-4278-b253-100aba3f8c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_862f860b-1563-4278-b253-100aba3f8c13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_862f860b-1563-4278-b253-100aba3f8c13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_862f860b-1563-4278-b253-100aba3f8c13" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_862f860b-1563-4278-b253-100aba3f8c13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_5dde7f0e-a037-4a3e-875b-5f7f3893e9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_862f860b-1563-4278-b253-100aba3f8c13" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_5dde7f0e-a037-4a3e-875b-5f7f3893e9e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_671e786e-ff01-4990-acbf-9f3097557653" xlink:href="mrk-20201231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5dde7f0e-a037-4a3e-875b-5f7f3893e9e9" xlink:to="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_671e786e-ff01-4990-acbf-9f3097557653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_585d0a02-d489-4884-8f1c-b917d045f1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5dde7f0e-a037-4a3e-875b-5f7f3893e9e9" xlink:to="loc_us-gaap_CommercialPaperMember_585d0a02-d489-4884-8f1c-b917d045f1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_236cc40a-a1dd-4463-9b8a-fb86f99764ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:to="loc_us-gaap_DebtInstrumentAxis_236cc40a-a1dd-4463-9b8a-fb86f99764ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_236cc40a-a1dd-4463-9b8a-fb86f99764ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_236cc40a-a1dd-4463-9b8a-fb86f99764ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_236cc40a-a1dd-4463-9b8a-fb86f99764ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_236cc40a-a1dd-4463-9b8a-fb86f99764ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember_9f330edf-8bb8-4771-aa07-227b35564a8a" xlink:href="mrk-20201231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_OtherVariableRateDebtMember_9f330edf-8bb8-4771-aa07-227b35564a8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_92e2c337-86a9-44e7-94f0-cf80f24d89f5" xlink:href="mrk-20201231.xsd#mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_92e2c337-86a9-44e7-94f0-cf80f24d89f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.75notesdue2026Member_7f3f36d0-354d-4005-a1cd-488c9f2e70df" xlink:href="mrk-20201231.xsd#mrk_A0.75notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_A0.75notesdue2026Member_7f3f36d0-354d-4005-a1cd-488c9f2e70df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.45notesdue2030Member_8c68fd93-fe8c-48d4-87d1-b80e1c32c192" xlink:href="mrk-20201231.xsd#mrk_A1.45notesdue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_A1.45notesdue2030Member_8c68fd93-fe8c-48d4-87d1-b80e1c32c192" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35notesdue2040Member_dc9edb8f-ba32-49d8-b33a-cb0328ba95c4" xlink:href="mrk-20201231.xsd#mrk_A2.35notesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_A2.35notesdue2040Member_dc9edb8f-ba32-49d8-b33a-cb0328ba95c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.45notesdue2050Member_b53ae726-c155-40c9-9b25-8b8d9457f0b1" xlink:href="mrk-20201231.xsd#mrk_A2.45notesdue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_A2.45notesdue2050Member_b53ae726-c155-40c9-9b25-8b8d9457f0b1" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="extended" id="i1cefd375117448e9bffb95b7577cec06_LoansPayableLongTermDebtandLeasesLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bf5df00e-e886-4319-9926-2f3abb901486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95177e78-6b2f-4401-b41d-b4ec2e6e8287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bf5df00e-e886-4319-9926-2f3abb901486" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95177e78-6b2f-4401-b41d-b4ec2e6e8287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7ced7171-3451-4b47-9aec-9ab55fd4c6ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bf5df00e-e886-4319-9926-2f3abb901486" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7ced7171-3451-4b47-9aec-9ab55fd4c6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5984e201-eb21-49c6-b1f2-2f3c89cdae6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bf5df00e-e886-4319-9926-2f3abb901486" xlink:to="loc_us-gaap_DebtInstrumentTable_5984e201-eb21-49c6-b1f2-2f3c89cdae6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5984e201-eb21-49c6-b1f2-2f3c89cdae6e" xlink:to="loc_us-gaap_DebtInstrumentAxis_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member_058b9eaa-3f30-4364-9c86-101687e61c8b" xlink:href="mrk-20201231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.75NotesDue2025Member_058b9eaa-3f30-4364-9c86-101687e61c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member_e86ea0c6-c1db-4422-acdd-09268b1c9310" xlink:href="mrk-20201231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A3.70NotesDue2045Member_e86ea0c6-c1db-4422-acdd-09268b1c9310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member_4b60586a-494b-414e-9d9d-8026cb6fe244" xlink:href="mrk-20201231.xsd#mrk_A280NotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A280NotesDue2023Member_4b60586a-494b-414e-9d9d-8026cb6fe244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member_46693e1a-c66b-4750-81cc-01eba6dd1286" xlink:href="mrk-20201231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A3.40NotesDue2029Member_46693e1a-c66b-4750-81cc-01eba6dd1286" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member_61fb3cd0-3d50-4140-af3a-42f1139ec838" xlink:href="mrk-20201231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A4.00NotesDue2049Member_61fb3cd0-3d50-4140-af3a-42f1139ec838" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member_e471af3b-a8a3-4f48-a092-370a74f8635e" xlink:href="mrk-20201231.xsd#mrk_A235NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A235NotesDue2040Member_e471af3b-a8a3-4f48-a092-370a74f8635e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member_737130a1-2c50-478e-88c4-e156343e6dd3" xlink:href="mrk-20201231.xsd#mrk_A415NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A415NotesDue2043Member_737130a1-2c50-478e-88c4-e156343e6dd3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member_61cc1f0b-0348-49e4-a560-17d3b8d8dd98" xlink:href="mrk-20201231.xsd#mrk_A145NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A145NotesDue2030Member_61cc1f0b-0348-49e4-a560-17d3b8d8dd98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member_049def19-1255-4567-a553-d2eeaeae7464" xlink:href="mrk-20201231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A1.875EuroNotesDue2026Member_049def19-1255-4567-a553-d2eeaeae7464" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member_c0193644-0cd1-4702-a8fa-100d0ded507b" xlink:href="mrk-20201231.xsd#mrk_A245NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A245NotesDue2050Member_c0193644-0cd1-4702-a8fa-100d0ded507b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_4cb23b51-4416-4d7b-b52e-eb004fba4235" xlink:href="mrk-20201231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.40NotesDue2022Member_4cb23b51-4416-4d7b-b52e-eb004fba4235" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member_f2ed128e-15dd-4fde-99b0-8ab72430c338" xlink:href="mrk-20201231.xsd#mrk_A075NotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A075NotesDue2026Member_f2ed128e-15dd-4fde-99b0-8ab72430c338" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member_317af5a3-a7df-4048-8c6d-1ac0099cf2d1" xlink:href="mrk-20201231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A3.90NotesDue2039Member_317af5a3-a7df-4048-8c6d-1ac0099cf2d1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_51bb65b2-50e8-4052-abf4-2f4155dbc22a" xlink:href="mrk-20201231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.35NotesDue2022Member_51bb65b2-50e8-4052-abf4-2f4155dbc22a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member_4206dcd1-6da3-400d-8e4b-14761ba33609" xlink:href="mrk-20201231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.90NotesDue2024Member_4206dcd1-6da3-400d-8e4b-14761ba33609" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_31c57a13-ff18-490d-a8a7-e7a854f6e540" xlink:href="mrk-20201231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_31c57a13-ff18-490d-a8a7-e7a854f6e540" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member_66bcbe4f-4193-4e99-a63a-909ddb1e07b3" xlink:href="mrk-20201231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A0.50eurodenominatednotesdue2024Member_66bcbe4f-4193-4e99-a63a-909ddb1e07b3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member_5a989489-34a3-41bb-987f-157e9d356bb6" xlink:href="mrk-20201231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A1.375eurodenominatednotesdue2036Member_5a989489-34a3-41bb-987f-157e9d356bb6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member_55a453a4-043f-489b-a42a-df26ea665d8f" xlink:href="mrk-20201231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.5EuroNotesDue2034Member_55a453a4-043f-489b-a42a-df26ea665d8f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_cd2ee7bf-8d23-4316-9eeb-09eab2db2ab2" xlink:href="mrk-20201231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_cd2ee7bf-8d23-4316-9eeb-09eab2db2ab2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_d3a77fb0-677f-4b00-adf2-d5ec2084a224" xlink:href="mrk-20201231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_d3a77fb0-677f-4b00-adf2-d5ec2084a224" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_b00baeec-8253-4fde-bf1e-82cfca5a0692" xlink:href="mrk-20201231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_b00baeec-8253-4fde-bf1e-82cfca5a0692" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_d46bd7e0-b2e8-47f0-be0d-70a795922c1e" xlink:href="mrk-20201231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_d46bd7e0-b2e8-47f0-be0d-70a795922c1e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_da9254a6-d454-4afd-be52-ce289e1eae75" xlink:href="mrk-20201231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_da9254a6-d454-4afd-be52-ce289e1eae75" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_b288087f-1899-42ed-bc43-128ae0b049b3" xlink:href="mrk-20201231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_b288087f-1899-42ed-bc43-128ae0b049b3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_0a8ff515-2325-459d-9211-ae3d7e36cd7c" xlink:href="mrk-20201231.xsd#mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_0a8ff515-2325-459d-9211-ae3d7e36cd7c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member_96795a8f-df60-4fe6-b025-70d0a658bb59" xlink:href="mrk-20201231.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A3.875NotesDue2021Member_96795a8f-df60-4fe6-b025-70d0a658bb59" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125EuroNotesDue2021Member_596da137-2bd8-411d-94b1-7abacc7cd42f" xlink:href="mrk-20201231.xsd#mrk_A1.125EuroNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A1.125EuroNotesDue2021Member_596da137-2bd8-411d-94b1-7abacc7cd42f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember_62a42aee-6eed-454c-b85a-ef1d4ed582c2" xlink:href="mrk-20201231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_OtherLongTermDebtMember_62a42aee-6eed-454c-b85a-ef1d4ed582c2" xlink:type="arc" order="28"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="extended" id="i43e0ff2c45534d1a92b07ed5143ff96e_LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="extended" id="i6733111dc99d4399889714bb8dd91cb0_LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilities"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="extended" id="i9783d51c30294e2fb51913a3eb0d012f_ContingenciesandEnvironmentalLiabilities"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails" xlink:type="extended" id="i00a4d16a9edd4fc594761d20516ad153_ContingenciesandEnvironmentalLiabilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_03a0fece-7f99-4223-9525-755a1433d8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_03a0fece-7f99-4223-9525-755a1433d8ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_535b1f06-84ea-400f-9478-08d8183afc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_535b1f06-84ea-400f-9478-08d8183afc6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber_2d345d89-0cb3-424d-b2f5-b27137e25f93" xlink:href="mrk-20201231.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_mrk_LossContingencyClaimsonAppealNumber_2d345d89-0cb3-424d-b2f5-b27137e25f93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_e87f2d1a-5142-485f-a8bf-18cfb58c1814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_e87f2d1a-5142-485f-a8bf-18cfb58c1814" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_3182dc83-63eb-4d87-80bf-89681ebc0c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_3182dc83-63eb-4d87-80bf-89681ebc0c76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_64444a32-8636-4817-bbf1-329939f9d6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_64444a32-8636-4817-bbf1-329939f9d6fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00d875a0-a20e-4251-a807-d138d7013460" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:to="loc_srt_ProductOrServiceAxis_00d875a0-a20e-4251-a807-d138d7013460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00d875a0-a20e-4251-a807-d138d7013460_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_00d875a0-a20e-4251-a807-d138d7013460" xlink:to="loc_srt_ProductsAndServicesDomain_00d875a0-a20e-4251-a807-d138d7013460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_00d875a0-a20e-4251-a807-d138d7013460" xlink:to="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember_d14828cc-efcc-4093-a994-3ff9e7fa3db0" xlink:href="mrk-20201231.xsd#mrk_FosamaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:to="loc_mrk_FosamaxMember_d14828cc-efcc-4093-a994-3ff9e7fa3db0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_3845d059-2710-4479-8ac5-9273e400bbc0" xlink:href="mrk-20201231.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:to="loc_mrk_JanuviaMember_3845d059-2710-4479-8ac5-9273e400bbc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VioxxMember_15a9b559-5cde-41a9-8c79-1c8879225c9f" xlink:href="mrk-20201231.xsd#mrk_VioxxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:to="loc_mrk_VioxxMember_15a9b559-5cde-41a9-8c79-1c8879225c9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cba545ad-4228-429e-981a-4d88d42216b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:to="loc_srt_LitigationCaseAxis_cba545ad-4228-429e-981a-4d88d42216b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cba545ad-4228-429e-981a-4d88d42216b3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_cba545ad-4228-429e-981a-4d88d42216b3" xlink:to="loc_srt_LitigationCaseTypeDomain_cba545ad-4228-429e-981a-4d88d42216b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_cba545ad-4228-429e-981a-4d88d42216b3" xlink:to="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember_8be117c3-48ca-40cc-b0c5-0b426178a491" xlink:href="mrk-20201231.xsd#mrk_FederalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:to="loc_mrk_FederalMember_8be117c3-48ca-40cc-b0c5-0b426178a491" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NewJerseyStateCourtMember_cab89542-a081-4b3f-9948-dfb15187e05a" xlink:href="mrk-20201231.xsd#mrk_NewJerseyStateCourtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:to="loc_mrk_NewJerseyStateCourtMember_cab89542-a081-4b3f-9948-dfb15187e05a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CaliforniaStateCourtMember_0f70712d-fe3a-4700-b361-3472c98409db" xlink:href="mrk-20201231.xsd#mrk_CaliforniaStateCourtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:to="loc_mrk_CaliforniaStateCourtMember_0f70712d-fe3a-4700-b361-3472c98409db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember_389c29a3-74d7-4236-8b8e-56d4d0ebcc02" xlink:href="mrk-20201231.xsd#mrk_OtherStateCourtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:to="loc_mrk_OtherStateCourtMember_389c29a3-74d7-4236-8b8e-56d4d0ebcc02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a48d6a67-28a1-468b-8c3a-d4ebc0562a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a48d6a67-28a1-468b-8c3a-d4ebc0562a53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_a48d6a67-28a1-468b-8c3a-d4ebc0562a53_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a48d6a67-28a1-468b-8c3a-d4ebc0562a53" xlink:to="loc_us-gaap_LossContingencyNatureDomain_a48d6a67-28a1-468b-8c3a-d4ebc0562a53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a48d6a67-28a1-468b-8c3a-d4ebc0562a53" xlink:to="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_1815dbd8-f7bd-40df-b204-2354d7f9a955" xlink:href="mrk-20201231.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:to="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_1815dbd8-f7bd-40df-b204-2354d7f9a955" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember_8d26b571-d48b-492e-844b-4aa4b70fe242" xlink:href="mrk-20201231.xsd#mrk_PatentlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:to="loc_mrk_PatentlitigationMember_8d26b571-d48b-492e-844b-4aa4b70fe242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember_b927912b-20f4-4921-b9c2-05971df0fe7d" xlink:href="mrk-20201231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:to="loc_mrk_CommercialandOtherLitigationMember_b927912b-20f4-4921-b9c2-05971df0fe7d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails" xlink:type="extended" id="i87fe1cdf01f846aeba919228ab794023_ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2c2df061-71e5-4aac-8750-8ea435710cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_041e8391-189d-4a25-a910-c60fd0669515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2c2df061-71e5-4aac-8750-8ea435710cce" xlink:to="loc_us-gaap_LitigationReserve_041e8391-189d-4a25-a910-c60fd0669515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d015eac2-3e38-4839-b7c0-c703e4c6239c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2c2df061-71e5-4aac-8750-8ea435710cce" xlink:to="loc_us-gaap_LossContingenciesTable_d015eac2-3e38-4839-b7c0-c703e4c6239c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_676cf7bc-7622-4658-ab42-d266c11f98d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d015eac2-3e38-4839-b7c0-c703e4c6239c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_676cf7bc-7622-4658-ab42-d266c11f98d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_676cf7bc-7622-4658-ab42-d266c11f98d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_676cf7bc-7622-4658-ab42-d266c11f98d5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_676cf7bc-7622-4658-ab42-d266c11f98d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d836f7c8-8668-4094-8c08-30dfb24ca554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_676cf7bc-7622-4658-ab42-d266c11f98d5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d836f7c8-8668-4094-8c08-30dfb24ca554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_fdf22bbe-55de-4262-a863-9a3877d5ad4d" xlink:href="mrk-20201231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d836f7c8-8668-4094-8c08-30dfb24ca554" xlink:to="loc_mrk_LegalDefenseCostsMember_fdf22bbe-55de-4262-a863-9a3877d5ad4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails" xlink:type="extended" id="i627b98c9e9b44788a7aa2d1d96e1d13a_ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SiteContingencyLineItems_dc2abe23-7326-45a7-b007-6e06c2552ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SiteContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SiteContingencyTable_678706a8-e10a-421e-83db-1b07b00ce5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SiteContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SiteContingencyLineItems_dc2abe23-7326-45a7-b007-6e06c2552ed2" xlink:to="loc_us-gaap_SiteContingencyTable_678706a8-e10a-421e-83db-1b07b00ce5c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalRemediationSiteAxis_91d69939-8864-4c1c-9386-e025d416949d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalRemediationSiteAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SiteContingencyTable_678706a8-e10a-421e-83db-1b07b00ce5c9" xlink:to="loc_us-gaap_EnvironmentalRemediationSiteAxis_91d69939-8864-4c1c-9386-e025d416949d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalRemediationSiteDomain_91d69939-8864-4c1c-9386-e025d416949d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalRemediationSiteDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EnvironmentalRemediationSiteAxis_91d69939-8864-4c1c-9386-e025d416949d" xlink:to="loc_us-gaap_EnvironmentalRemediationSiteDomain_91d69939-8864-4c1c-9386-e025d416949d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalRemediationSiteDomain_696e2cfd-f88c-43b4-ab4c-169a4bea30c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalRemediationSiteDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EnvironmentalRemediationSiteAxis_91d69939-8864-4c1c-9386-e025d416949d" xlink:to="loc_us-gaap_EnvironmentalRemediationSiteDomain_696e2cfd-f88c-43b4-ab4c-169a4bea30c0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20201231.xsd#Equity"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended" id="i7838aef0119b45cc9b2d23e5e3fe00a9_Equity"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended" id="i4cf45957cd044556b5b5bb22da60702b_EquityTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="extended" id="ic378814625924510b36921e49128f2b6_EquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_1984d07e-aa83-4806-8281-f799cd4e75eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_91aac970-7285-4c9e-8e12-91eae02db568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_1984d07e-aa83-4806-8281-f799cd4e75eb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_91aac970-7285-4c9e-8e12-91eae02db568" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_4b99ed1d-9a42-4234-a6bd-0f977c4f00e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_1984d07e-aa83-4806-8281-f799cd4e75eb" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_4b99ed1d-9a42-4234-a6bd-0f977c4f00e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_1984d07e-aa83-4806-8281-f799cd4e75eb" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_447a635d-f590-4828-a9ba-976f49272971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_447a635d-f590-4828-a9ba-976f49272971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_447a635d-f590-4828-a9ba-976f49272971_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_447a635d-f590-4828-a9ba-976f49272971" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_447a635d-f590-4828-a9ba-976f49272971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5cb837c9-cd9a-419d-a64e-df0757174e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_447a635d-f590-4828-a9ba-976f49272971" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5cb837c9-cd9a-419d-a64e-df0757174e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedShareRepurchaseAgreementMember_a43f66af-0d86-4ed0-8ce2-de4ddbc8ff40" xlink:href="mrk-20201231.xsd#mrk_AcceleratedShareRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5cb837c9-cd9a-419d-a64e-df0757174e65" xlink:to="loc_mrk_AcceleratedShareRepurchaseAgreementMember_a43f66af-0d86-4ed0-8ce2-de4ddbc8ff40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_49857b99-a38f-42eb-a41c-3212b7e47a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_49857b99-a38f-42eb-a41c-3212b7e47a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member_d92e4729-93cb-4f4b-b2a1-1ace2e6ded10" xlink:href="mrk-20201231.xsd#mrk_AcceleratedShareRepurchaseAgreementOctober292018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_49857b99-a38f-42eb-a41c-3212b7e47a6e" xlink:to="loc_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member_d92e4729-93cb-4f4b-b2a1-1ace2e6ded10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="extended" id="i347f7b8eea7e4ec68cface42effa99ad_EquityShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e2320027-6dbb-479a-9d55-2f11b20794fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:href="mrk-20201231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2320027-6dbb-479a-9d55-2f11b20794fd" xlink:to="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_852aeb90-aa34-4263-be81-5e22167f8d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:to="loc_us-gaap_CommonStockSharesIssued_852aeb90-aa34-4263-be81-5e22167f8d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e65ee069-7342-4b97-88ee-cf741473979c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e65ee069-7342-4b97-88ee-cf741473979c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b55e5933-a2d0-43ce-a041-cab773dd084a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b55e5933-a2d0-43ce-a041-cab773dd084a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c00aab7b-ac2f-4ce9-bd2f-dba275940900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_de9cbde1-5ad3-48ba-8caa-401b8f954470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2320027-6dbb-479a-9d55-2f11b20794fd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_de9cbde1-5ad3-48ba-8caa-401b8f954470" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b994f394-2de8-474e-9d30-94f31b3dcf64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9cbde1-5ad3-48ba-8caa-401b8f954470" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b994f394-2de8-474e-9d30-94f31b3dcf64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b994f394-2de8-474e-9d30-94f31b3dcf64_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b994f394-2de8-474e-9d30-94f31b3dcf64" xlink:to="loc_us-gaap_EquityComponentDomain_b994f394-2de8-474e-9d30-94f31b3dcf64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c05a70ca-8288-4ca7-b8a5-5c935819034c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b994f394-2de8-474e-9d30-94f31b3dcf64" xlink:to="loc_us-gaap_EquityComponentDomain_c05a70ca-8288-4ca7-b8a5-5c935819034c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2b1fc626-e19f-46df-9c39-1e8dfb776a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c05a70ca-8288-4ca7-b8a5-5c935819034c" xlink:to="loc_us-gaap_CommonStockMember_2b1fc626-e19f-46df-9c39-1e8dfb776a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_796b4174-4c13-4277-bd04-221fb5259573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c05a70ca-8288-4ca7-b8a5-5c935819034c" xlink:to="loc_us-gaap_TreasuryStockMember_796b4174-4c13-4277-bd04-221fb5259573" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlans"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="extended" id="if102e4ebce3b4659b4f76b7b2f685ad5_ShareBasedCompensationPlans"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="extended" id="i54ecbfce2f2049d68a8f8b1375da0c10_ShareBasedCompensationPlansTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended" id="ib3c82c2dfd884194a86e872fac521cd8_ShareBasedCompensationPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a3c01dc-cac8-4a19-a2c1-a06de4373568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_299e9193-ba8d-4c03-bb20-970d6af4387a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a3c01dc-cac8-4a19-a2c1-a06de4373568" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_299e9193-ba8d-4c03-bb20-970d6af4387a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e1c932-b92e-4026-8474-b6bd1182499a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a3c01dc-cac8-4a19-a2c1-a06de4373568" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e1c932-b92e-4026-8474-b6bd1182499a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_63fe7057-1432-4784-a8c0-6964b4a4e8ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e1c932-b92e-4026-8474-b6bd1182499a" xlink:to="loc_srt_RangeAxis_63fe7057-1432-4784-a8c0-6964b4a4e8ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63fe7057-1432-4784-a8c0-6964b4a4e8ef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_63fe7057-1432-4784-a8c0-6964b4a4e8ef" xlink:to="loc_srt_RangeMember_63fe7057-1432-4784-a8c0-6964b4a4e8ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f76223bf-f444-40ef-803f-71e069270f82" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_63fe7057-1432-4784-a8c0-6964b4a4e8ef" xlink:to="loc_srt_RangeMember_f76223bf-f444-40ef-803f-71e069270f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c388b13-7dd3-4e0d-a56d-300be5620496" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f76223bf-f444-40ef-803f-71e069270f82" xlink:to="loc_srt_MinimumMember_5c388b13-7dd3-4e0d-a56d-300be5620496" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e74a994-38b6-4a75-be91-bccc001354ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f76223bf-f444-40ef-803f-71e069270f82" xlink:to="loc_srt_MaximumMember_9e74a994-38b6-4a75-be91-bccc001354ae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="extended" id="if6e7e1bd83d14fb8b668f1808113bb9b_ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="extended" id="i6cc6b41a5f7a4dc296b0f4baccc861c8_ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="extended" id="i9da7aebb73ae418092390e10c0a812be_ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="extended" id="i48795add97b3452d9fc094ef3342fd14_ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f25966b9-b2e4-4e7b-bd9a-ff8abd532aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f25966b9-b2e4-4e7b-bd9a-ff8abd532aeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_694d700f-a8cf-4462-8719-e518dc47e264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_694d700f-a8cf-4462-8719-e518dc47e264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a2d5df78-f411-495d-b238-0cc384069154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a2d5df78-f411-495d-b238-0cc384069154" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_46121e03-a745-497a-b05e-79d33bf3df46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_46121e03-a745-497a-b05e-79d33bf3df46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dbb56431-9766-45ff-9eba-af41dabec702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dbb56431-9766-45ff-9eba-af41dabec702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_349cc978-23dc-4177-bbf1-da24cc28a42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f25966b9-b2e4-4e7b-bd9a-ff8abd532aeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4de97cac-ed4c-42d9-a107-a4deb63085f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4de97cac-ed4c-42d9-a107-a4deb63085f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba0538b-52a6-4d44-b218-02370d422791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba0538b-52a6-4d44-b218-02370d422791" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_81a751a5-d53f-4bde-8c56-1eb2dc867f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_81a751a5-d53f-4bde-8c56-1eb2dc867f32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f281c7ae-7108-4bf8-ad11-7f613464d38a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f281c7ae-7108-4bf8-ad11-7f613464d38a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ff4525c5-63b6-4d54-96be-ed29f841d872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ad141f-f2cc-4777-9949-949408f58fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f25966b9-b2e4-4e7b-bd9a-ff8abd532aeb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ad141f-f2cc-4777-9949-949408f58fcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7ea79008-9371-4fe7-af97-011ad937d802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ad141f-f2cc-4777-9949-949408f58fcd" xlink:to="loc_us-gaap_AwardTypeAxis_7ea79008-9371-4fe7-af97-011ad937d802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea79008-9371-4fe7-af97-011ad937d802_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7ea79008-9371-4fe7-af97-011ad937d802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea79008-9371-4fe7-af97-011ad937d802_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a09847a9-5140-458a-bb85-c4888b468878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7ea79008-9371-4fe7-af97-011ad937d802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a09847a9-5140-458a-bb85-c4888b468878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3a3dde8b-07da-4404-bad2-4aa54894b7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a09847a9-5140-458a-bb85-c4888b468878" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3a3dde8b-07da-4404-bad2-4aa54894b7a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f93ac84b-d4e7-4c34-b788-9b2b694fde0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a09847a9-5140-458a-bb85-c4888b468878" xlink:to="loc_us-gaap_PerformanceSharesMember_f93ac84b-d4e7-4c34-b788-9b2b694fde0b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended" id="i693b93ff6ada4d61933838eef4509b3a_PensionandOtherPostretirementBenefitPlans"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended" id="ice07cf3bdfc04df9b95547cd4acfc79b_PensionandOtherPostretirementBenefitPlansTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended" id="i1db43c852f7749e192c0f89a08323ae4_PensionandOtherPostretirementBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4ebbf973-2c62-4f74-bad5-b390a4156860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4ebbf973-2c62-4f74-bad5-b390a4156860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fd40346e-c277-44c8-8589-4b180612fac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fd40346e-c277-44c8-8589-4b180612fac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_4b854afc-62a8-4321-863c-1afaed759f93" xlink:href="mrk-20201231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_4b854afc-62a8-4321-863c-1afaed759f93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b683bded-9aa6-4f40-b71c-c37c8319bb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b683bded-9aa6-4f40-b71c-c37c8319bb4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_99bec42f-8d26-4f94-b5dd-7ca3df5dc82d" xlink:href="mrk-20201231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_99bec42f-8d26-4f94-b5dd-7ca3df5dc82d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_9760d2f1-c600-40b2-8b8b-8b80429fa836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_9760d2f1-c600-40b2-8b8b-8b80429fa836" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_9241a1ea-a679-45af-a6f8-10e074b5a61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_9241a1ea-a679-45af-a6f8-10e074b5a61d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_49cc6224-8815-4034-8010-4b03086d0858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_49cc6224-8815-4034-8010-4b03086d0858" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_335dfc51-4c86-4d99-a33d-8e3604bb16c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_335dfc51-4c86-4d99-a33d-8e3604bb16c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_335dfc51-4c86-4d99-a33d-8e3604bb16c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_335dfc51-4c86-4d99-a33d-8e3604bb16c6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_335dfc51-4c86-4d99-a33d-8e3604bb16c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0593043f-508a-4fb2-ab7f-abb4f2e83f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_335dfc51-4c86-4d99-a33d-8e3604bb16c6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0593043f-508a-4fb2-ab7f-abb4f2e83f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2935da64-b7cc-414a-bf58-dfe74365514d" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0593043f-508a-4fb2-ab7f-abb4f2e83f2d" xlink:to="loc_country_US_2935da64-b7cc-414a-bf58-dfe74365514d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8bfc20e8-b0ab-470d-b0c5-0712b3d363f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0593043f-508a-4fb2-ab7f-abb4f2e83f2d" xlink:to="loc_us-gaap_ForeignPlanMember_8bfc20e8-b0ab-470d-b0c5-0712b3d363f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ae76ed14-1d03-465e-89ec-7662785584bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ae76ed14-1d03-465e-89ec-7662785584bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ae76ed14-1d03-465e-89ec-7662785584bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ae76ed14-1d03-465e-89ec-7662785584bb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ae76ed14-1d03-465e-89ec-7662785584bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_054f4e66-4a61-42da-bede-6337f4c5b4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ae76ed14-1d03-465e-89ec-7662785584bb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_054f4e66-4a61-42da-bede-6337f4c5b4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b6d8951a-dbe6-44cc-8436-2936772ecc8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_054f4e66-4a61-42da-bede-6337f4c5b4de" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b6d8951a-dbe6-44cc-8436-2936772ecc8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2e281445-26a4-4709-9cbb-6f23fc6dd1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_054f4e66-4a61-42da-bede-6337f4c5b4de" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2e281445-26a4-4709-9cbb-6f23fc6dd1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_324dbbf6-8bcd-4c53-90a4-f6b8d88d134f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_324dbbf6-8bcd-4c53-90a4-f6b8d88d134f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a62ac7d8-2893-455d-afe7-aa73c57d2faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_324dbbf6-8bcd-4c53-90a4-f6b8d88d134f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a62ac7d8-2893-455d-afe7-aa73c57d2faa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ab544a53-7b6f-4116-a790-b96beff60538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ab544a53-7b6f-4116-a790-b96beff60538" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ab544a53-7b6f-4116-a790-b96beff60538_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ab544a53-7b6f-4116-a790-b96beff60538" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ab544a53-7b6f-4116-a790-b96beff60538_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ab544a53-7b6f-4116-a790-b96beff60538" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_cbb3823f-1470-4ff6-bbf8-2a10089dd29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_cbb3823f-1470-4ff6-bbf8-2a10089dd29b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_900676c6-6bd3-4597-a62a-293f09891523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_900676c6-6bd3-4597-a62a-293f09891523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember_06c19298-b4d1-4872-86f9-90eeb6ea8305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:to="loc_us-gaap_FixedIncomeInvestmentsMember_06c19298-b4d1-4872-86f9-90eeb6ea8305" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_f3db5a36-e2b6-45d7-bd16-0e5f9207342d" xlink:href="mrk-20201231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:to="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_f3db5a36-e2b6-45d7-bd16-0e5f9207342d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45fb81fe-2a10-4938-84c1-3704bb954dcf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_srt_RangeAxis_45fb81fe-2a10-4938-84c1-3704bb954dcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45fb81fe-2a10-4938-84c1-3704bb954dcf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_45fb81fe-2a10-4938-84c1-3704bb954dcf" xlink:to="loc_srt_RangeMember_45fb81fe-2a10-4938-84c1-3704bb954dcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2129a77-2953-4684-bf06-6f3b701a3f1b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_45fb81fe-2a10-4938-84c1-3704bb954dcf" xlink:to="loc_srt_RangeMember_b2129a77-2953-4684-bf06-6f3b701a3f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6b4283ae-12a0-47ab-9dbe-0c216ba35ea7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b2129a77-2953-4684-bf06-6f3b701a3f1b" xlink:to="loc_srt_MinimumMember_6b4283ae-12a0-47ab-9dbe-0c216ba35ea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b792f8de-5732-4168-862c-022ced3e311f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b2129a77-2953-4684-bf06-6f3b701a3f1b" xlink:to="loc_srt_MaximumMember_b792f8de-5732-4168-862c-022ced3e311f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_srt_StatementScenarioAxis_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e7dc6c01-274b-4176-bbe2-55fbeeed3c75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e7dc6c01-274b-4176-bbe2-55fbeeed3c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9d5fd9ba-7b3f-4126-8166-28f5bc025ccd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e7dc6c01-274b-4176-bbe2-55fbeeed3c75" xlink:to="loc_srt_ScenarioForecastMember_9d5fd9ba-7b3f-4126-8166-28f5bc025ccd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i6a8e0b2a839f46caaf0d6804ca54c8e0_PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ad0e99ce-434e-40d0-bf80-05e0bc5b3a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ad0e99ce-434e-40d0-bf80-05e0bc5b3a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_ea08bed5-6fff-4281-bd23-b0895ff43b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_ea08bed5-6fff-4281-bd23-b0895ff43b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_dbd1e68b-957a-4a26-a86e-68120aa757a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_dbd1e68b-957a-4a26-a86e-68120aa757a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1b075333-bc35-4e80-920c-5fa9c70998d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1b075333-bc35-4e80-920c-5fa9c70998d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b3669366-95ff-4248-baf0-859ed7017f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b3669366-95ff-4248-baf0-859ed7017f51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_c6b1062d-caf9-46f4-b106-ea7e0319ca7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_c6b1062d-caf9-46f4-b106-ea7e0319ca7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_76d86bf0-185f-4189-93ff-b5bc45ecd7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_76d86bf0-185f-4189-93ff-b5bc45ecd7b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_2340fd51-444e-4005-819f-2cdee9e493a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_2340fd51-444e-4005-819f-2cdee9e493a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e079cb83-bc89-4b7d-a218-52e4aa56a179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e079cb83-bc89-4b7d-a218-52e4aa56a179" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_3fc436c9-afa9-43c7-aa24-f52400b71cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_3fc436c9-afa9-43c7-aa24-f52400b71cc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3fc436c9-afa9-43c7-aa24-f52400b71cc4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_3fc436c9-afa9-43c7-aa24-f52400b71cc4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3fc436c9-afa9-43c7-aa24-f52400b71cc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c2c2cd40-5d67-4cc2-8e9e-4bbd1af634df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_3fc436c9-afa9-43c7-aa24-f52400b71cc4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c2c2cd40-5d67-4cc2-8e9e-4bbd1af634df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_134ae2aa-4630-4795-965f-38cc32718914" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c2c2cd40-5d67-4cc2-8e9e-4bbd1af634df" xlink:to="loc_country_US_134ae2aa-4630-4795-965f-38cc32718914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_43a99594-44f3-45ea-8699-f39a9145fa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c2c2cd40-5d67-4cc2-8e9e-4bbd1af634df" xlink:to="loc_us-gaap_ForeignPlanMember_43a99594-44f3-45ea-8699-f39a9145fa5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_df7c0219-9af6-45ab-b1bb-8cb4d37213c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_df7c0219-9af6-45ab-b1bb-8cb4d37213c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_df7c0219-9af6-45ab-b1bb-8cb4d37213c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_df7c0219-9af6-45ab-b1bb-8cb4d37213c2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_df7c0219-9af6-45ab-b1bb-8cb4d37213c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0fb8fb68-5920-4163-98ea-a4babe313802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_df7c0219-9af6-45ab-b1bb-8cb4d37213c2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0fb8fb68-5920-4163-98ea-a4babe313802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_a4eda80c-af22-4713-a449-40c5cce6e77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0fb8fb68-5920-4163-98ea-a4babe313802" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_a4eda80c-af22-4713-a449-40c5cce6e77b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_cf2a53ac-738c-430d-970e-a0ae170643f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0fb8fb68-5920-4163-98ea-a4babe313802" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_cf2a53ac-738c-430d-970e-a0ae170643f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended" id="ib0ab334bc5ce4115ab258f377d7ef615_PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2826b94c-f6a4-43c7-8a86-c5fdca92f339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2826b94c-f6a4-43c7-8a86-c5fdca92f339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_d88729f5-9077-48a0-afa3-9bb760eb06e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_d88729f5-9077-48a0-afa3-9bb760eb06e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_911685ec-cb0f-46e4-a360-d23e8847ee67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_911685ec-cb0f-46e4-a360-d23e8847ee67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_a49c89b4-bfab-49ea-8ad1-cb7fc1b0f070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_a49c89b4-bfab-49ea-8ad1-cb7fc1b0f070" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_3e1ec452-bf6f-49a1-a010-ebb314d18b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_3e1ec452-bf6f-49a1-a010-ebb314d18b8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f5096749-674a-4377-8240-9dc073a75738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f5096749-674a-4377-8240-9dc073a75738" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_82fcefff-073d-4dc7-b960-0063c79c1587" xlink:href="mrk-20201231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_82fcefff-073d-4dc7-b960-0063c79c1587" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2210e5ab-1749-45d2-ae89-a30051726282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_2100432e-e927-442b-a64c-b537ab5e9f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_2100432e-e927-442b-a64c-b537ab5e9f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_0c8ad8c7-0c11-436a-9343-d655974252e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_0c8ad8c7-0c11-436a-9343-d655974252e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6c0676ab-0074-4bf3-906b-f57e6092ab87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6c0676ab-0074-4bf3-906b-f57e6092ab87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_0dd6216a-06f9-44db-b57d-bdd2f8822736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_0dd6216a-06f9-44db-b57d-bdd2f8822736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_649e551a-f505-4c88-9d8a-039f21888d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_649e551a-f505-4c88-9d8a-039f21888d5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_d2c08024-0969-4e22-a33f-47e5f72c150c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_d2c08024-0969-4e22-a33f-47e5f72c150c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_332735a8-b134-483b-a38a-67472e036bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_332735a8-b134-483b-a38a-67472e036bf2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_d005a59d-c024-456b-a2c8-8ccab77ad4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_d005a59d-c024-456b-a2c8-8ccab77ad4f6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_70d864f0-92e6-4c06-8dc2-395e88a75eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_70d864f0-92e6-4c06-8dc2-395e88a75eed" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_22cd76dc-5daf-484f-9eec-8e6fe147b088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_22cd76dc-5daf-484f-9eec-8e6fe147b088" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges_8bda7091-8f1a-49df-96b1-d9c089530172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherChanges_8bda7091-8f1a-49df-96b1-d9c089530172" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_02ececf8-9ab2-49f0-9d33-d42521d0fd71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_cf88edf8-fcb9-47ac-8195-0b47692773e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_cf88edf8-fcb9-47ac-8195-0b47692773e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c2ae1bc8-3d0d-4ed0-a928-37e4d7793e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c2ae1bc8-3d0d-4ed0-a928-37e4d7793e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4005003e-6429-46c2-8bd5-ed1f8c6d47de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4005003e-6429-46c2-8bd5-ed1f8c6d47de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e3093f36-1584-41aa-8e16-fc2693a65a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e3093f36-1584-41aa-8e16-fc2693a65a6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_63dfe766-52da-4180-9513-6747ec800db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_63dfe766-52da-4180-9513-6747ec800db9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_63dfe766-52da-4180-9513-6747ec800db9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_63dfe766-52da-4180-9513-6747ec800db9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_63dfe766-52da-4180-9513-6747ec800db9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ea20947-556e-4355-b78b-1435b1cdec08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_63dfe766-52da-4180-9513-6747ec800db9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ea20947-556e-4355-b78b-1435b1cdec08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0dab23d4-bf1e-43f2-a2da-81a10d575605" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ea20947-556e-4355-b78b-1435b1cdec08" xlink:to="loc_country_US_0dab23d4-bf1e-43f2-a2da-81a10d575605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_52ce736a-5345-4def-9021-908330500b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ea20947-556e-4355-b78b-1435b1cdec08" xlink:to="loc_us-gaap_ForeignPlanMember_52ce736a-5345-4def-9021-908330500b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_85700606-19df-4315-914f-dd1ad0d65e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_85700606-19df-4315-914f-dd1ad0d65e67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_85700606-19df-4315-914f-dd1ad0d65e67_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_85700606-19df-4315-914f-dd1ad0d65e67" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_85700606-19df-4315-914f-dd1ad0d65e67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8b3f929d-cf31-4b12-9ebb-f2efa6bcdb7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_85700606-19df-4315-914f-dd1ad0d65e67" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8b3f929d-cf31-4b12-9ebb-f2efa6bcdb7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_779f557a-2f5a-46eb-8208-85ff6978d145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8b3f929d-cf31-4b12-9ebb-f2efa6bcdb7a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_779f557a-2f5a-46eb-8208-85ff6978d145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_b1513e58-9be5-43a6-a4e8-c3595d194892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8b3f929d-cf31-4b12-9ebb-f2efa6bcdb7a" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_b1513e58-9be5-43a6-a4e8-c3595d194892" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="extended" id="i9515330481ed490383d17652266ce415_PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_9c13a6b8-601f-44f9-b954-a21aed9d5d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_9c13a6b8-601f-44f9-b954-a21aed9d5d38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_2b1ec1d8-0f1a-4d16-98c8-0ee64e1b3b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_2b1ec1d8-0f1a-4d16-98c8-0ee64e1b3b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_3fab94b3-2c04-4935-9b03-0183182d2e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_3fab94b3-2c04-4935-9b03-0183182d2e54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_04ffd2d0-2602-4827-ac43-48b638dee45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_04ffd2d0-2602-4827-ac43-48b638dee45b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_de176fb9-e8f3-4cc1-9861-665276099540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_de176fb9-e8f3-4cc1-9861-665276099540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_de176fb9-e8f3-4cc1-9861-665276099540_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_de176fb9-e8f3-4cc1-9861-665276099540" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_de176fb9-e8f3-4cc1-9861-665276099540_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6eb8521-988f-4f93-9d42-b858e9c82bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_de176fb9-e8f3-4cc1-9861-665276099540" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6eb8521-988f-4f93-9d42-b858e9c82bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f81847c9-306d-4b69-bcc7-3aa33aad2f39" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6eb8521-988f-4f93-9d42-b858e9c82bc9" xlink:to="loc_country_US_f81847c9-306d-4b69-bcc7-3aa33aad2f39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9d99a0ff-1fd9-4800-86ff-79200ebb8de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6eb8521-988f-4f93-9d42-b858e9c82bc9" xlink:to="loc_us-gaap_ForeignPlanMember_9d99a0ff-1fd9-4800-86ff-79200ebb8de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_d4c82eff-30e7-4991-b25a-638b5e37b489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_d4c82eff-30e7-4991-b25a-638b5e37b489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d4c82eff-30e7-4991-b25a-638b5e37b489_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d4c82eff-30e7-4991-b25a-638b5e37b489" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d4c82eff-30e7-4991-b25a-638b5e37b489_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a556f377-8d25-4f5c-bb0c-cdaebbbc9076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d4c82eff-30e7-4991-b25a-638b5e37b489" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a556f377-8d25-4f5c-bb0c-cdaebbbc9076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_fa3f8e99-39ec-41fe-a6ec-fbf53212606d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a556f377-8d25-4f5c-bb0c-cdaebbbc9076" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_fa3f8e99-39ec-41fe-a6ec-fbf53212606d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="extended" id="i8755fc8310a54a80be6e17d3584daa28_PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3c97a108-4d4c-4e57-8080-80d4eeccbacf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a071b95e-df90-4b62-b30a-5ead162e09a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3c97a108-4d4c-4e57-8080-80d4eeccbacf" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a071b95e-df90-4b62-b30a-5ead162e09a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3c97a108-4d4c-4e57-8080-80d4eeccbacf" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_da9f5823-8310-4596-8c12-8a3ac73f2e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_da9f5823-8310-4596-8c12-8a3ac73f2e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_da9f5823-8310-4596-8c12-8a3ac73f2e57_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_da9f5823-8310-4596-8c12-8a3ac73f2e57" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_da9f5823-8310-4596-8c12-8a3ac73f2e57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2bd21f6f-616f-4f68-a64e-a4ca27cb5a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_da9f5823-8310-4596-8c12-8a3ac73f2e57" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2bd21f6f-616f-4f68-a64e-a4ca27cb5a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_30243099-bf9f-4749-b8ee-1b7f5f6fc250" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2bd21f6f-616f-4f68-a64e-a4ca27cb5a73" xlink:to="loc_country_US_30243099-bf9f-4749-b8ee-1b7f5f6fc250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_63b86008-26b9-4875-8dc2-6b87957dbba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2bd21f6f-616f-4f68-a64e-a4ca27cb5a73" xlink:to="loc_us-gaap_ForeignPlanMember_63b86008-26b9-4875-8dc2-6b87957dbba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a49349ee-b369-439c-b826-e311bab38e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a49349ee-b369-439c-b826-e311bab38e6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a49349ee-b369-439c-b826-e311bab38e6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a49349ee-b369-439c-b826-e311bab38e6e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a49349ee-b369-439c-b826-e311bab38e6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d69410be-d852-4d9c-ab5d-d43b761356f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a49349ee-b369-439c-b826-e311bab38e6e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d69410be-d852-4d9c-ab5d-d43b761356f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4cee29a1-a423-40aa-8747-0df5ef264edc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d69410be-d852-4d9c-ab5d-d43b761356f6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4cee29a1-a423-40aa-8747-0df5ef264edc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8408269c-6417-43a6-8998-f9cd262e5219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8408269c-6417-43a6-8998-f9cd262e5219" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8408269c-6417-43a6-8998-f9cd262e5219_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8408269c-6417-43a6-8998-f9cd262e5219" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8408269c-6417-43a6-8998-f9cd262e5219_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8408269c-6417-43a6-8998-f9cd262e5219" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ea7c9abc-d59b-4649-b2e1-3143d3940b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ea7c9abc-d59b-4649-b2e1-3143d3940b57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_04eb0c67-12f7-4351-bbbb-df8650aa93d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_04eb0c67-12f7-4351-bbbb-df8650aa93d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4b89e29c-be2e-4fb8-92c8-c0ec935cae48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4b89e29c-be2e-4fb8-92c8-c0ec935cae48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d01833e6-5240-4a65-81b7-b4e84812caba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d01833e6-5240-4a65-81b7-b4e84812caba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f146bb8c-8173-4c13-8105-eef27195bc20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f146bb8c-8173-4c13-8105-eef27195bc20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f146bb8c-8173-4c13-8105-eef27195bc20_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f146bb8c-8173-4c13-8105-eef27195bc20" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f146bb8c-8173-4c13-8105-eef27195bc20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f146bb8c-8173-4c13-8105-eef27195bc20" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_bc8a640e-7dc2-491e-ac9f-f65ff143db0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_bc8a640e-7dc2-491e-ac9f-f65ff143db0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_ea93bece-323b-4e95-ab6e-ecad75d05ac9" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_ea93bece-323b-4e95-ab6e-ecad75d05ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_323673e6-f3e9-42e9-bc45-1c0f52e8a0fb" xlink:href="mrk-20201231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_323673e6-f3e9-42e9-bc45-1c0f52e8a0fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_5f1b2524-9b9a-4778-af2e-2565daf2d766" xlink:href="mrk-20201231.xsd#mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_5f1b2524-9b9a-4778-af2e-2565daf2d766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_ee605152-fa2f-4972-b0c8-adda61034848" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_ee605152-fa2f-4972-b0c8-adda61034848" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember_90175cf4-e476-463c-be66-42dbb55bedc0" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_CorporateObligationsInvestmentFundsMember_90175cf4-e476-463c-be66-42dbb55bedc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_f82da671-78b5-4c8d-8123-9c62c8172731" xlink:href="mrk-20201231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_f82da671-78b5-4c8d-8123-9c62c8172731" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_f0489f8c-a717-4153-8843-ac7d6daa0ff4" xlink:href="mrk-20201231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_f0489f8c-a717-4153-8843-ac7d6daa0ff4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_48070f7d-875f-4eb1-9380-bf3ce87edcfa" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_48070f7d-875f-4eb1-9380-bf3ce87edcfa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_43e8ef1c-7a85-44ef-954f-bf9532f1d80a" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_43e8ef1c-7a85-44ef-954f-bf9532f1d80a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_a9dc6f28-b595-4db0-976e-0639fb600951" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_a9dc6f28-b595-4db0-976e-0639fb600951" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_c0889294-1076-4de2-932c-2aadb0e96d78" xlink:href="mrk-20201231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_c0889294-1076-4de2-932c-2aadb0e96d78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_a2dedd74-a494-4043-87f2-7af3d5929488" xlink:href="mrk-20201231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_a2dedd74-a494-4043-87f2-7af3d5929488" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_0a1f2cf1-a4fe-4c74-9eca-871a1db398e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_us-gaap_OtherInvestmentsMember_0a1f2cf1-a4fe-4c74-9eca-871a1db398e7" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="extended" id="i71dda2edfb204d66aa19be386621bc5c_PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e78186c2-d21d-4f3f-be6d-5c6009458eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e78186c2-d21d-4f3f-be6d-5c6009458eee" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_563dd80b-cce6-4fe2-8f30-d701f9667e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_563dd80b-cce6-4fe2-8f30-d701f9667e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_723c0cb8-e7d0-4f44-bfb9-d3131f4e1934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_723c0cb8-e7d0-4f44-bfb9-d3131f4e1934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_ab7f002b-4fa9-486a-8f8f-72e99b3ca3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_723c0cb8-e7d0-4f44-bfb9-d3131f4e1934" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_ab7f002b-4fa9-486a-8f8f-72e99b3ca3a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_e834749a-f327-4215-a7d9-d8674cf6ddfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_723c0cb8-e7d0-4f44-bfb9-d3131f4e1934" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_e834749a-f327-4215-a7d9-d8674cf6ddfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_4c36bb81-7098-4daf-937b-f1963395d7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_4c36bb81-7098-4daf-937b-f1963395d7f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_85c9d6cf-17ac-4878-9e62-27e87759ad35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_85c9d6cf-17ac-4878-9e62-27e87759ad35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b963f255-503d-4126-85aa-dcc31815e9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e78186c2-d21d-4f3f-be6d-5c6009458eee" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5ec3ee96-dbc8-408d-815a-8af7d9d73637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5ec3ee96-dbc8-408d-815a-8af7d9d73637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ec3ee96-dbc8-408d-815a-8af7d9d73637_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5ec3ee96-dbc8-408d-815a-8af7d9d73637" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ec3ee96-dbc8-408d-815a-8af7d9d73637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_335e0645-db21-4282-a9b7-90822d33d8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5ec3ee96-dbc8-408d-815a-8af7d9d73637" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_335e0645-db21-4282-a9b7-90822d33d8db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b6b36b4c-0fa7-40da-a524-2354108ccad7" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_335e0645-db21-4282-a9b7-90822d33d8db" xlink:to="loc_country_US_b6b36b4c-0fa7-40da-a524-2354108ccad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f8eac300-31ac-469a-9cb5-d053b9e1ba4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_335e0645-db21-4282-a9b7-90822d33d8db" xlink:to="loc_us-gaap_ForeignPlanMember_f8eac300-31ac-469a-9cb5-d053b9e1ba4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_468ffd68-8fba-45c0-bd9b-8e74445902cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_468ffd68-8fba-45c0-bd9b-8e74445902cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_468ffd68-8fba-45c0-bd9b-8e74445902cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_468ffd68-8fba-45c0-bd9b-8e74445902cb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_468ffd68-8fba-45c0-bd9b-8e74445902cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ab3b66cc-31e3-4d90-a469-47cb07c2043a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_468ffd68-8fba-45c0-bd9b-8e74445902cb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ab3b66cc-31e3-4d90-a469-47cb07c2043a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6f5fa8a3-e7b8-4c12-a19c-ebd4fbea2acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ab3b66cc-31e3-4d90-a469-47cb07c2043a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6f5fa8a3-e7b8-4c12-a19c-ebd4fbea2acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_928ef288-bb2b-44c3-bbfe-bb3756c736b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_928ef288-bb2b-44c3-bbfe-bb3756c736b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_928ef288-bb2b-44c3-bbfe-bb3756c736b0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_928ef288-bb2b-44c3-bbfe-bb3756c736b0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_928ef288-bb2b-44c3-bbfe-bb3756c736b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2270d1cb-0f3b-4bf0-9862-f2c04d75d7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_928ef288-bb2b-44c3-bbfe-bb3756c736b0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2270d1cb-0f3b-4bf0-9862-f2c04d75d7c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b694313d-335d-45a8-8cad-ba3a142bb339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2270d1cb-0f3b-4bf0-9862-f2c04d75d7c2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b694313d-335d-45a8-8cad-ba3a142bb339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4d78cda8-5792-4e99-8586-12392f3d25a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4d78cda8-5792-4e99-8586-12392f3d25a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_4d78cda8-5792-4e99-8586-12392f3d25a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4d78cda8-5792-4e99-8586-12392f3d25a1" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_4d78cda8-5792-4e99-8586-12392f3d25a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4d78cda8-5792-4e99-8586-12392f3d25a1" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_3a578946-c4e2-430e-ac0c-600ad4195cc7" xlink:href="mrk-20201231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_3a578946-c4e2-430e-ac0c-600ad4195cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_eb0c6a3a-f3fd-40c9-b69b-164fb1d35322" xlink:href="mrk-20201231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_eb0c6a3a-f3fd-40c9-b69b-164fb1d35322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_fa74a42a-d489-4ca1-a099-ac9488bd81dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:to="loc_us-gaap_OtherInvestmentsMember_fa74a42a-d489-4ca1-a099-ac9488bd81dc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="extended" id="id57cf7b6392c422abb1aefa4c835cc7e_PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86056e5c-e439-4c55-a219-07fee7451cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e7b36e48-9a1f-4669-bcc2-ef8d362effe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86056e5c-e439-4c55-a219-07fee7451cb5" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e7b36e48-9a1f-4669-bcc2-ef8d362effe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86056e5c-e439-4c55-a219-07fee7451cb5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9f7c49c2-d32a-4afe-a1a9-60bcdbe589b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9f7c49c2-d32a-4afe-a1a9-60bcdbe589b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ac1d59ec-ef42-4d02-8ff3-2942efe0af33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9f7c49c2-d32a-4afe-a1a9-60bcdbe589b4" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ac1d59ec-ef42-4d02-8ff3-2942efe0af33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de3cf110-31f1-4b36-bb2f-00f01bb37b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de3cf110-31f1-4b36-bb2f-00f01bb37b15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de3cf110-31f1-4b36-bb2f-00f01bb37b15_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de3cf110-31f1-4b36-bb2f-00f01bb37b15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de3cf110-31f1-4b36-bb2f-00f01bb37b15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de3cf110-31f1-4b36-bb2f-00f01bb37b15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5c612133-2b81-449a-b72a-d7f3ed883631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5c612133-2b81-449a-b72a-d7f3ed883631" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cc8ba3bc-e31c-4dd4-a6b6-52cb884ac33d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cc8ba3bc-e31c-4dd4-a6b6-52cb884ac33d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_17c9a360-f6d0-4fdb-bf76-ac7190ddecd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_17c9a360-f6d0-4fdb-bf76-ac7190ddecd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_901a05a3-46d8-40d4-8e5b-955a2dced48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_901a05a3-46d8-40d4-8e5b-955a2dced48a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a9be7202-b7f8-483b-8d9f-3836d1927cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a9be7202-b7f8-483b-8d9f-3836d1927cdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a9be7202-b7f8-483b-8d9f-3836d1927cdc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a9be7202-b7f8-483b-8d9f-3836d1927cdc" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a9be7202-b7f8-483b-8d9f-3836d1927cdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a9be7202-b7f8-483b-8d9f-3836d1927cdc" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_c7e7e9f5-ee41-46ff-8287-a12274b70ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_c7e7e9f5-ee41-46ff-8287-a12274b70ac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_d7be161e-3d4b-47eb-b1df-59e0baacf6d6" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_d7be161e-3d4b-47eb-b1df-59e0baacf6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_856e7a73-3e44-4d0a-a54f-af05f6b0ceb7" xlink:href="mrk-20201231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_856e7a73-3e44-4d0a-a54f-af05f6b0ceb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_7881747f-12b5-4050-866c-8bee8272954a" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_7881747f-12b5-4050-866c-8bee8272954a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember_d1aad9c2-3630-4a82-a34f-3c7cf841eb31" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_CorporateObligationsInvestmentFundsMember_d1aad9c2-3630-4a82-a34f-3c7cf841eb31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_1fdb070f-1647-4453-8d2f-76e5d202a013" xlink:href="mrk-20201231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_1fdb070f-1647-4453-8d2f-76e5d202a013" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_0bf97ec2-5d80-438f-bd6f-701c570cf4e8" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_0bf97ec2-5d80-438f-bd6f-701c570cf4e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_c3cd5dc4-eae2-4a40-8bd5-c4114c9165d7" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_c3cd5dc4-eae2-4a40-8bd5-c4114c9165d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_85440c5e-d9c6-47a6-a84f-323e31e33764" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_85440c5e-d9c6-47a6-a84f-323e31e33764" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_aaf99596-75d2-42f7-a039-0578cad1d369" xlink:href="mrk-20201231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_aaf99596-75d2-42f7-a039-0578cad1d369" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="extended" id="i661df8861e80478aba9dbb0c1594882f_PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_4775554d-c729-4b74-8059-2adce50e0228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_4775554d-c729-4b74-8059-2adce50e0228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_91fbc3b1-fd00-48f0-8428-b784d5c088f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_91fbc3b1-fd00-48f0-8428-b784d5c088f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_d9a06838-dfa4-4e27-8487-daeb842f04df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_d9a06838-dfa4-4e27-8487-daeb842f04df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_7da547d5-ca99-4b90-a4ff-04e39fd3584d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_7da547d5-ca99-4b90-a4ff-04e39fd3584d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_66d07f1b-bf79-4976-9604-4e3714efbffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_66d07f1b-bf79-4976-9604-4e3714efbffd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d68fa839-aa7a-4515-ba56-c3dfbba2d9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d68fa839-aa7a-4515-ba56-c3dfbba2d9c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b34af640-8ef9-4897-a203-ec9c15cbdfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b34af640-8ef9-4897-a203-ec9c15cbdfa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b34af640-8ef9-4897-a203-ec9c15cbdfa5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b34af640-8ef9-4897-a203-ec9c15cbdfa5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b34af640-8ef9-4897-a203-ec9c15cbdfa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_125bf562-b760-4c9c-9aa3-8041f0498647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b34af640-8ef9-4897-a203-ec9c15cbdfa5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_125bf562-b760-4c9c-9aa3-8041f0498647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_37890c4e-ce97-4f9e-8583-aed1d5b02f6b" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_125bf562-b760-4c9c-9aa3-8041f0498647" xlink:to="loc_country_US_37890c4e-ce97-4f9e-8583-aed1d5b02f6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ecee33d0-87c1-4519-9180-f435ec58e749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_125bf562-b760-4c9c-9aa3-8041f0498647" xlink:to="loc_us-gaap_ForeignPlanMember_ecee33d0-87c1-4519-9180-f435ec58e749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_648524a0-5065-4c7e-9e33-0d76ce3fa22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_648524a0-5065-4c7e-9e33-0d76ce3fa22a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_648524a0-5065-4c7e-9e33-0d76ce3fa22a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_648524a0-5065-4c7e-9e33-0d76ce3fa22a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_648524a0-5065-4c7e-9e33-0d76ce3fa22a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7da56d0b-2cb9-4a25-8f91-f46cd13ec3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_648524a0-5065-4c7e-9e33-0d76ce3fa22a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7da56d0b-2cb9-4a25-8f91-f46cd13ec3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1141dfeb-8c8b-4cb4-872d-460e7ae2244a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7da56d0b-2cb9-4a25-8f91-f46cd13ec3bc" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1141dfeb-8c8b-4cb4-872d-460e7ae2244a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5fbdb01a-7208-4319-ba26-692beb02243b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7da56d0b-2cb9-4a25-8f91-f46cd13ec3bc" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5fbdb01a-7208-4319-ba26-692beb02243b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended" id="if2b4aec497124d6989556108bf570708_PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_174765ec-9c02-46fa-8884-20620cd267ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_174765ec-9c02-46fa-8884-20620cd267ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_506483b0-e77b-4a8f-99a5-489552da3f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_506483b0-e77b-4a8f-99a5-489552da3f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_ad800fd6-d5e6-40b4-985c-3dea577283e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_ad800fd6-d5e6-40b4-985c-3dea577283e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4f8aeecf-cf9e-4eea-9c0a-ee2533655f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4f8aeecf-cf9e-4eea-9c0a-ee2533655f97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_83098cd2-c83b-4c7f-82cb-27cfa6855d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_83098cd2-c83b-4c7f-82cb-27cfa6855d06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_a253b2db-cacf-4ee1-8811-f33178ceb864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_a253b2db-cacf-4ee1-8811-f33178ceb864" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_04a4d1a6-ffea-411e-9a81-b2427cd4ea96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_04a4d1a6-ffea-411e-9a81-b2427cd4ea96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_04a4d1a6-ffea-411e-9a81-b2427cd4ea96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_04a4d1a6-ffea-411e-9a81-b2427cd4ea96" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_04a4d1a6-ffea-411e-9a81-b2427cd4ea96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_59e01fd6-0ffa-4e7d-a1bd-c5e1da09776d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_04a4d1a6-ffea-411e-9a81-b2427cd4ea96" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_59e01fd6-0ffa-4e7d-a1bd-c5e1da09776d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5154e74d-c858-4766-9870-183d6ce81eff" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_59e01fd6-0ffa-4e7d-a1bd-c5e1da09776d" xlink:to="loc_country_US_5154e74d-c858-4766-9870-183d6ce81eff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6956458c-c2e7-4fe5-b3ad-6665e48c0142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_59e01fd6-0ffa-4e7d-a1bd-c5e1da09776d" xlink:to="loc_us-gaap_ForeignPlanMember_6956458c-c2e7-4fe5-b3ad-6665e48c0142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b6c4fb46-a713-454d-b0e9-19786272068d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b6c4fb46-a713-454d-b0e9-19786272068d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b6c4fb46-a713-454d-b0e9-19786272068d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b6c4fb46-a713-454d-b0e9-19786272068d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b6c4fb46-a713-454d-b0e9-19786272068d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d7b0c63a-cccd-493a-baba-e5c512549c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b6c4fb46-a713-454d-b0e9-19786272068d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d7b0c63a-cccd-493a-baba-e5c512549c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_e6fce239-1ed4-48a4-a80a-7d9e7dd79e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d7b0c63a-cccd-493a-baba-e5c512549c14" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_e6fce239-1ed4-48a4-a80a-7d9e7dd79e48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e90941fd-d94e-4c4a-8195-9ddf2f479a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d7b0c63a-cccd-493a-baba-e5c512549c14" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e90941fd-d94e-4c4a-8195-9ddf2f479a9e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="extended" id="i369cce304d974fb99cff5f0ad3076719_PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_948112ad-920d-4f9c-a8bf-5cf508f0da5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_948112ad-920d-4f9c-a8bf-5cf508f0da5e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_78572a9b-a4de-4838-a4f6-635c72b5abe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_78572a9b-a4de-4838-a4f6-635c72b5abe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_7e4ac470-32b8-45f9-b8cf-88f7a3e4cc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_7e4ac470-32b8-45f9-b8cf-88f7a3e4cc77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_4f34401b-b911-47d0-9cd5-bd92b5faca55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_4f34401b-b911-47d0-9cd5-bd92b5faca55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_0848a6b0-6c58-42b6-9150-34e21eed67b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_0848a6b0-6c58-42b6-9150-34e21eed67b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_948112ad-920d-4f9c-a8bf-5cf508f0da5e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_544c5aa7-d8ba-4525-a84a-b5798e049081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_544c5aa7-d8ba-4525-a84a-b5798e049081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_facfeff1-ae5e-4c52-b687-d12bea1319f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_facfeff1-ae5e-4c52-b687-d12bea1319f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_754f6dc8-4ee3-490b-b389-a53f51b30495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_754f6dc8-4ee3-490b-b389-a53f51b30495" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_948112ad-920d-4f9c-a8bf-5cf508f0da5e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_44c2a10b-5ea3-40ae-bc31-4e57a51d8748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_44c2a10b-5ea3-40ae-bc31-4e57a51d8748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_44c2a10b-5ea3-40ae-bc31-4e57a51d8748_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_44c2a10b-5ea3-40ae-bc31-4e57a51d8748" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_44c2a10b-5ea3-40ae-bc31-4e57a51d8748_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_849395c4-1094-45eb-980b-f99e734a1013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_44c2a10b-5ea3-40ae-bc31-4e57a51d8748" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_849395c4-1094-45eb-980b-f99e734a1013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_49421878-0ccb-4466-90ae-65b5fd5ab2bf" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_849395c4-1094-45eb-980b-f99e734a1013" xlink:to="loc_country_US_49421878-0ccb-4466-90ae-65b5fd5ab2bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8d4e1eef-53ee-44c4-9d5d-d2c588f856ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_849395c4-1094-45eb-980b-f99e734a1013" xlink:to="loc_us-gaap_ForeignPlanMember_8d4e1eef-53ee-44c4-9d5d-d2c588f856ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4f9835fa-7088-4631-a873-276ab364ca82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4f9835fa-7088-4631-a873-276ab364ca82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4f9835fa-7088-4631-a873-276ab364ca82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4f9835fa-7088-4631-a873-276ab364ca82" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4f9835fa-7088-4631-a873-276ab364ca82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_667f8d0a-7f8d-4b62-b584-c0253ca2fbb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4f9835fa-7088-4631-a873-276ab364ca82" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_667f8d0a-7f8d-4b62-b584-c0253ca2fbb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b34a3c8a-43c7-44b4-843f-9ac3f941188c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_667f8d0a-7f8d-4b62-b584-c0253ca2fbb6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b34a3c8a-43c7-44b4-843f-9ac3f941188c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="extended" id="ibc149b837bac488c858e3008b0963fdc_PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_50348588-96a5-4968-85b9-bc00247fbd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_304465c4-d137-4f16-976b-6d6d31b72cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_50348588-96a5-4968-85b9-bc00247fbd5b" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_304465c4-d137-4f16-976b-6d6d31b72cb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_e8720e24-15b7-4222-9c0f-a55f1e8b2923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_50348588-96a5-4968-85b9-bc00247fbd5b" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_e8720e24-15b7-4222-9c0f-a55f1e8b2923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2769c786-8137-4de4-9538-136eb25dfe02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_50348588-96a5-4968-85b9-bc00247fbd5b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2769c786-8137-4de4-9538-136eb25dfe02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7fd81aba-d659-4f89-854e-3cb430e6b09d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2769c786-8137-4de4-9538-136eb25dfe02" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7fd81aba-d659-4f89-854e-3cb430e6b09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7fd81aba-d659-4f89-854e-3cb430e6b09d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7fd81aba-d659-4f89-854e-3cb430e6b09d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7fd81aba-d659-4f89-854e-3cb430e6b09d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_82a39ee6-3111-4d93-bde0-30850be81e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7fd81aba-d659-4f89-854e-3cb430e6b09d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_82a39ee6-3111-4d93-bde0-30850be81e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_50f34e1a-1320-436e-9479-aed5ce730ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_82a39ee6-3111-4d93-bde0-30850be81e7e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_50f34e1a-1320-436e-9479-aed5ce730ec0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNet"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended" id="if996656f0c214b9db0fcd755c49d762b_OtherIncomeExpenseNet"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended" id="i8105c702602b4a9bae48359133fa2c2e_OtherIncomeExpenseNetTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended" id="ibb4d0196f8204c67aa49dfc8a6bd9d2e_OtherIncomeExpenseNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:href="mrk-20201231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ffdcc4fb-c2d4-4415-aa3b-40b014a5a58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ffdcc4fb-c2d4-4415-aa3b-40b014a5a58d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncome_d72deecd-3d42-4ef2-9a9d-9210dd2095b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_OtherNoncashIncome_d72deecd-3d42-4ef2-9a9d-9210dd2095b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a7263cf3-d535-422b-9add-b97f7adc0580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a7263cf3-d535-422b-9add-b97f7adc0580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3c50616d-334d-4b48-bd57-615da2c7cf02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3c50616d-334d-4b48-bd57-615da2c7cf02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3ec9fc81-75a8-4087-8047-7c73df72ed4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3ec9fc81-75a8-4087-8047-7c73df72ed4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_5749fd7d-2574-474a-9a85-23fdf97a9e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_InterestPaid_5749fd7d-2574-474a-9a85-23fdf97a9e39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:href="mrk-20201231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e5f770f8-e275-40c2-b68d-0cb735988249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e5f770f8-e275-40c2-b68d-0cb735988249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_e5f770f8-e275-40c2-b68d-0cb735988249_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e5f770f8-e275-40c2-b68d-0cb735988249" xlink:to="loc_us-gaap_LossContingencyNatureDomain_e5f770f8-e275-40c2-b68d-0cb735988249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_053e60e6-93c5-45eb-8573-8fa79d358187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e5f770f8-e275-40c2-b68d-0cb735988249" xlink:to="loc_us-gaap_LossContingencyNatureDomain_053e60e6-93c5-45eb-8573-8fa79d358187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember_29ddaa18-ce5b-40f2-92bf-37976ad93f92" xlink:href="mrk-20201231.xsd#mrk_PatentlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_053e60e6-93c5-45eb-8573-8fa79d358187" xlink:to="loc_mrk_PatentlitigationMember_29ddaa18-ce5b-40f2-92bf-37976ad93f92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0ebdf1a1-da8f-45f2-b3d6-5073331db536" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0ebdf1a1-da8f-45f2-b3d6-5073331db536" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0ebdf1a1-da8f-45f2-b3d6-5073331db536_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0ebdf1a1-da8f-45f2-b3d6-5073331db536" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0ebdf1a1-da8f-45f2-b3d6-5073331db536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fa8064dd-111a-486e-a8f0-5c7c21164e95" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0ebdf1a1-da8f-45f2-b3d6-5073331db536" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fa8064dd-111a-486e-a8f0-5c7c21164e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_7c5b806f-2df3-408e-832a-daa3edbb8721" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_fa8064dd-111a-486e-a8f0-5c7c21164e95" xlink:to="loc_srt_PartnershipInterestMember_7c5b806f-2df3-408e-832a-daa3edbb8721" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1dd943c-f437-49de-8d67-5f164cff2c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1dd943c-f437-49de-8d67-5f164cff2c51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e1dd943c-f437-49de-8d67-5f164cff2c51_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1dd943c-f437-49de-8d67-5f164cff2c51" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e1dd943c-f437-49de-8d67-5f164cff2c51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_708bc8ba-5c4b-489e-a366-12d30afc7644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1dd943c-f437-49de-8d67-5f164cff2c51" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_708bc8ba-5c4b-489e-a366-12d30afc7644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CGRPreceptorantagonistsMember_cf8f0303-377b-402b-8532-da41150e9427" xlink:href="mrk-20201231.xsd#mrk_CGRPreceptorantagonistsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_708bc8ba-5c4b-489e-a366-12d30afc7644" xlink:to="loc_mrk_CGRPreceptorantagonistsMember_cf8f0303-377b-402b-8532-da41150e9427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_62bf5d62-d72b-4e37-80af-33ea43d7cae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_62bf5d62-d72b-4e37-80af-33ea43d7cae8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_62bf5d62-d72b-4e37-80af-33ea43d7cae8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_62bf5d62-d72b-4e37-80af-33ea43d7cae8" xlink:to="loc_us-gaap_SegmentDomain_62bf5d62-d72b-4e37-80af-33ea43d7cae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_15b9f54b-a35f-466f-8ff7-730c0c580254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_62bf5d62-d72b-4e37-80af-33ea43d7cae8" xlink:to="loc_us-gaap_SegmentDomain_15b9f54b-a35f-466f-8ff7-730c0c580254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember_d021a067-c001-46a9-af12-c6c905c3ca21" xlink:href="mrk-20201231.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_15b9f54b-a35f-466f-8ff7-730c0c580254" xlink:to="loc_mrk_HealthcareServicesSegmentMember_d021a067-c001-46a9-af12-c6c905c3ca21" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="extended" id="i400f90d4ca964455aa3d47b03ae1fc05_OtherIncomeExpenseNetDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncome"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended" id="i22b39f3bbe9846a7a3ef74368031410a_TaxesonIncome"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="extended" id="ia64d95dfca4d40c6b3cb8f0993aacc88_TaxesonIncomeTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="extended" id="i224ce5a2131c454da7fc00db1db54bb6_TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="extended" id="i3f4107cf48644c93abcf1e2059bbde7e_TaxesonIncomeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_f097d2c1-882b-46b5-bd53-49f52102c90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_f097d2c1-882b-46b5-bd53-49f52102c90c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_0d1e495a-3cde-4777-9b08-8d45258410e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_0d1e495a-3cde-4777-9b08-8d45258410e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_a001fc69-0849-46d6-b839-7079ee057a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_a001fc69-0849-46d6-b839-7079ee057a2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_cd0a3e5d-a7d1-43d4-9dda-c044ab335779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_cd0a3e5d-a7d1-43d4-9dda-c044ab335779" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_b4ba7383-28c7-41f9-ad99-990556327c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_b4ba7383-28c7-41f9-ad99-990556327c8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_78767d18-dcf5-4b65-b8a1-92b1e6fedbd6" xlink:href="mrk-20201231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_78767d18-dcf5-4b65-b8a1-92b1e6fedbd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_00eb896f-cf3b-47da-86c9-83f8859a639f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_IncomeTaxesPaid_00eb896f-cf3b-47da-86c9-83f8859a639f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3c9e61e7-e45d-47c6-868d-19d886b02240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3c9e61e7-e45d-47c6-868d-19d886b02240" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_06b367ed-0dde-40ad-be04-ecbb8d5c3673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_06b367ed-0dde-40ad-be04-ecbb8d5c3673" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_88331bcb-eb42-4646-b9bb-11b3b3a9fbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_88331bcb-eb42-4646-b9bb-11b3b3a9fbc1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_0a863f9a-d782-4dbf-8840-e34f030825e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_0a863f9a-d782-4dbf-8840-e34f030825e6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_44b1e95f-a0a9-4c91-8e36-546aaeda9d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_44b1e95f-a0a9-4c91-8e36-546aaeda9d58" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_08afaad6-8902-4a28-9591-af8fe9ae8618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_08afaad6-8902-4a28-9591-af8fe9ae8618" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_a0b91c35-ba5f-48ba-b136-d0df269b6533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_a0b91c35-ba5f-48ba-b136-d0df269b6533" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c9c2446f-d903-44d2-814a-74b69238f2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c9c2446f-d903-44d2-814a-74b69238f2b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c9c2446f-d903-44d2-814a-74b69238f2b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9c2446f-d903-44d2-814a-74b69238f2b8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c9c2446f-d903-44d2-814a-74b69238f2b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_27c5d826-2b05-42f4-958f-fe1777469e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9c2446f-d903-44d2-814a-74b69238f2b8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_27c5d826-2b05-42f4-958f-fe1777469e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember_073889e1-0cf7-48aa-b3a4-437a3bd5b418" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_27c5d826-2b05-42f4-958f-fe1777469e24" xlink:to="loc_mrk_IncomeTaxesPayableMember_073889e1-0cf7-48aa-b3a4-437a3bd5b418" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_81e126ce-5d5c-4d9e-9264-9eef557ad379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_27c5d826-2b05-42f4-958f-fe1777469e24" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_81e126ce-5d5c-4d9e-9264-9eef557ad379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6933d82d-b260-42e3-bb52-c5864c6727d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6933d82d-b260-42e3-bb52-c5864c6727d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6933d82d-b260-42e3-bb52-c5864c6727d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6933d82d-b260-42e3-bb52-c5864c6727d3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6933d82d-b260-42e3-bb52-c5864c6727d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8009c1c5-9d13-41d4-bf0c-46942d4a3d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6933d82d-b260-42e3-bb52-c5864c6727d3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8009c1c5-9d13-41d4-bf0c-46942d4a3d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_1a85d811-0b35-4c3e-824e-c6ba38cdbe00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8009c1c5-9d13-41d4-bf0c-46942d4a3d04" xlink:to="loc_us-gaap_ForeignCountryMember_1a85d811-0b35-4c3e-824e-c6ba38cdbe00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ba6c46aa-723c-4d99-aefd-697ee43e13db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8009c1c5-9d13-41d4-bf0c-46942d4a3d04" xlink:to="loc_us-gaap_DomesticCountryMember_ba6c46aa-723c-4d99-aefd-697ee43e13db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_59349caa-15d6-409e-823b-ef2a0a02dd01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_59349caa-15d6-409e-823b-ef2a0a02dd01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_59349caa-15d6-409e-823b-ef2a0a02dd01_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_59349caa-15d6-409e-823b-ef2a0a02dd01" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_59349caa-15d6-409e-823b-ef2a0a02dd01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7ef1f99b-2c20-41ba-a7ff-0bf40028b48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_59349caa-15d6-409e-823b-ef2a0a02dd01" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_7ef1f99b-2c20-41ba-a7ff-0bf40028b48e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_682e8f7b-d53f-4fdf-83ed-b12ed320fefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7ef1f99b-2c20-41ba-a7ff-0bf40028b48e" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_682e8f7b-d53f-4fdf-83ed-b12ed320fefa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeIncomeBeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="extended" id="ifcbf0edeadfa4044885c58e52bd40df3_TaxesonIncomeIncomeBeforeTaxesDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeTaxesonIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="extended" id="i9517d1bf5a98433e8397be95467f643a_TaxesonIncomeTaxesonIncomeDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended" id="iaac3f5a27c594f66b167a5efd0e5b114_TaxesonIncomeDeferredIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_230a83cb-6021-44e1-b165-1af8efc033ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_230a83cb-6021-44e1-b165-1af8efc033ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_e2dbbd79-3bdb-4061-8284-b712a63704a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_e2dbbd79-3bdb-4061-8284-b712a63704a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_78ba0b67-ddf6-4956-881f-c03255860e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_78ba0b67-ddf6-4956-881f-c03255860e91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_f4c634d3-63ea-4f5c-b804-bda4c34feca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_f4c634d3-63ea-4f5c-b804-bda4c34feca3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_8bae0745-ed33-4f3f-bbd4-8228b8f57b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_8bae0745-ed33-4f3f-bbd4-8228b8f57b2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_8193610f-cf93-42fc-88f8-187b9592a5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_8193610f-cf93-42fc-88f8-187b9592a5b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_558acc40-75f6-433c-a31a-e7a0cff2343e" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_558acc40-75f6-433c-a31a-e7a0cff2343e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_369d9bbb-57e4-4d74-b67c-eb2d5e1d2f77" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_369d9bbb-57e4-4d74-b67c-eb2d5e1d2f77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_94285383-5f6b-450f-ab77-f39121a3856b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_94285383-5f6b-450f-ab77-f39121a3856b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b1b31da2-f06c-422f-be75-21a2f7a49850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b1b31da2-f06c-422f-be75-21a2f7a49850" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7b0c3c12-8f52-4b1e-91d4-08728b502503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7b0c3c12-8f52-4b1e-91d4-08728b502503" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_17e83b4f-0896-4fa6-950b-29d062364ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_17e83b4f-0896-4fa6-950b-29d062364ed8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9be7bb10-0050-4179-bd8d-16057cffba29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9be7bb10-0050-4179-bd8d-16057cffba29" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_8163f5f1-392d-4107-855f-8bfd6687d810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_8163f5f1-392d-4107-855f-8bfd6687d810" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2f465e88-7bea-4aab-a791-03635a9ca6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2f465e88-7bea-4aab-a791-03635a9ca6b0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_f0570853-863f-48fa-96c4-4a8506edcb84" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_f0570853-863f-48fa-96c4-4a8506edcb84" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_c0e21063-50a7-4821-873a-b0333f35f579" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_c0e21063-50a7-4821-873a-b0333f35f579" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d19e8038-93a0-4031-8fa5-705af9ccd4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d19e8038-93a0-4031-8fa5-705af9ccd4a0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_4766a8d0-29ad-4e91-9d89-f808fa230315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_4766a8d0-29ad-4e91-9d89-f808fa230315" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_b344da8e-54da-4e54-98ea-40aca94b736c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilities_b344da8e-54da-4e54-98ea-40aca94b736c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_02537401-a48a-4498-8289-be448cad1410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_02537401-a48a-4498-8289-be448cad1410" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_698e0233-2c12-46a8-8319-0adcb3ac8b10" xlink:href="mrk-20201231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_698e0233-2c12-46a8-8319-0adcb3ac8b10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5e4acadf-298b-4c97-9c25-cf7a0501488e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_698e0233-2c12-46a8-8319-0adcb3ac8b10" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5e4acadf-298b-4c97-9c25-cf7a0501488e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5e4acadf-298b-4c97-9c25-cf7a0501488e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e4acadf-298b-4c97-9c25-cf7a0501488e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5e4acadf-298b-4c97-9c25-cf7a0501488e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7968c23b-1a4b-4fcc-8bca-d407b153c23b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e4acadf-298b-4c97-9c25-cf7a0501488e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7968c23b-1a4b-4fcc-8bca-d407b153c23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_cad5eff6-be2c-4ab9-be25-bf62c6047373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7968c23b-1a4b-4fcc-8bca-d407b153c23b" xlink:to="loc_us-gaap_OtherAssetsMember_cad5eff6-be2c-4ab9-be25-bf62c6047373" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i183d577c7ad94f97a3fa9200ad8b6ee0_TaxesonIncomeUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_f8323b7e-672a-42c7-8aa4-23709533019e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_8e171a21-03f7-4896-9207-4c311edde711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_f8323b7e-672a-42c7-8aa4-23709533019e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_8e171a21-03f7-4896-9207-4c311edde711" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_f8323b7e-672a-42c7-8aa4-23709533019e" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f949ac1f-5776-4979-980c-1680f01a64aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f949ac1f-5776-4979-980c-1680f01a64aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f949ac1f-5776-4979-980c-1680f01a64aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f949ac1f-5776-4979-980c-1680f01a64aa" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f949ac1f-5776-4979-980c-1680f01a64aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68301914-d8c6-45ae-b934-fde0c549ba92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f949ac1f-5776-4979-980c-1680f01a64aa" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68301914-d8c6-45ae-b934-fde0c549ba92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ConsumercarebusinessMember_30908d03-6a6d-4149-99fb-0b06005c247b" xlink:href="mrk-20201231.xsd#mrk_ConsumercarebusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68301914-d8c6-45ae-b934-fde0c549ba92" xlink:to="loc_mrk_ConsumercarebusinessMember_30908d03-6a6d-4149-99fb-0b06005c247b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_419aaa25-5446-4354-a566-0f45eb3acb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_419aaa25-5446-4354-a566-0f45eb3acb0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_28942157-e346-467a-a7c6-a2ed8f6b2d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_28942157-e346-467a-a7c6-a2ed8f6b2d6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_28942157-e346-467a-a7c6-a2ed8f6b2d6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_28942157-e346-467a-a7c6-a2ed8f6b2d6e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_28942157-e346-467a-a7c6-a2ed8f6b2d6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_4bd873d9-f415-45d4-9f13-38af0ae62968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_28942157-e346-467a-a7c6-a2ed8f6b2d6e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_4bd873d9-f415-45d4-9f13-38af0ae62968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_5d76407c-4b40-4791-909c-97c53102b856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_TaxPeriodAxis_5d76407c-4b40-4791-909c-97c53102b856" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_5d76407c-4b40-4791-909c-97c53102b856_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_5d76407c-4b40-4791-909c-97c53102b856" xlink:to="loc_us-gaap_TaxPeriodDomain_5d76407c-4b40-4791-909c-97c53102b856_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_bddc78bb-c7bc-4982-94ba-7d8722842666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_5d76407c-4b40-4791-909c-97c53102b856" xlink:to="loc_us-gaap_TaxPeriodDomain_bddc78bb-c7bc-4982-94ba-7d8722842666" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShare" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsperShare"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EarningsperShare" xlink:type="extended" id="i50bb433ee09949089ebed2b84973b307_EarningsperShare"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsperShareTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EarningsperShareTables" xlink:type="extended" id="ia658512516934b8596fd014a4f9a2bf7_EarningsperShareTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended" id="ia5e40c5522b446c0863d004aada0a0ee_EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended" id="i3ac23af3c7744d8183604182a9fea9f0_EarningsPerShareNarrativeDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended" id="i75a99493f3b34495a46c2a4183211612_OtherComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended" id="ibc42eacbbdd947509017e250d12ee28a_OtherComprehensiveIncomeLossTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i719b40852a9e437cad1870f6da3a0395_OtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5dac783c-afed-4111-9ae4-381df15dfc01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5dac783c-afed-4111-9ae4-381df15dfc01" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac7ca81b-0099-435d-9c5d-d507144d3695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac7ca81b-0099-435d-9c5d-d507144d3695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_7ce0dffd-0bdd-4a85-9b16-de66d0e732cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_7ce0dffd-0bdd-4a85-9b16-de66d0e732cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e5da5104-49dc-4fe8-8939-98677014d30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e5da5104-49dc-4fe8-8939-98677014d30d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4fcb4b22-0489-48d9-86bc-b96738fe5547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4fcb4b22-0489-48d9-86bc-b96738fe5547" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_d204d98a-b67f-409e-9bce-55dea84e77e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_d204d98a-b67f-409e-9bce-55dea84e77e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9cbbafe4-38aa-433b-bc2c-707808000b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9cbbafe4-38aa-433b-bc2c-707808000b54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ae7edafc-f515-4d71-91e5-16015225e048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ae7edafc-f515-4d71-91e5-16015225e048" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c2aae2e-f3c9-42f1-964b-a3c68af5cc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c2aae2e-f3c9-42f1-964b-a3c68af5cc2d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_b7f249b0-18ef-4eb8-93be-c0268fd7f255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_b7f249b0-18ef-4eb8-93be-c0268fd7f255" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a14fd01-f79f-4fed-a8c6-5701f283b496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_16c93f2c-fdf1-453f-94a1-870151af81e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5dac783c-afed-4111-9ae4-381df15dfc01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_16c93f2c-fdf1-453f-94a1-870151af81e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5dac783c-afed-4111-9ae4-381df15dfc01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b2de4335-33a8-470d-863d-42f80ac63b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b2de4335-33a8-470d-863d-42f80ac63b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b2de4335-33a8-470d-863d-42f80ac63b02_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2de4335-33a8-470d-863d-42f80ac63b02" xlink:to="loc_us-gaap_EquityComponentDomain_b2de4335-33a8-470d-863d-42f80ac63b02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2de4335-33a8-470d-863d-42f80ac63b02" xlink:to="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_39c25659-ac11-4373-8394-6a5b8148e56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_39c25659-ac11-4373-8394-6a5b8148e56e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_623b14f2-4e63-4f38-a825-91c7bd007fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_623b14f2-4e63-4f38-a825-91c7bd007fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember_f59c0dd7-f24a-4704-a506-45ddf049f1f0" xlink:href="mrk-20201231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:to="loc_mrk_PensionPlanNetLossMember_f59c0dd7-f24a-4704-a506-45ddf049f1f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_9bc67217-ec5f-45ec-af74-94afed17abd8" xlink:href="mrk-20201231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:to="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_9bc67217-ec5f-45ec-af74-94afed17abd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember_884dd4ba-dee7-409d-a514-454cbd2fd414" xlink:href="mrk-20201231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:to="loc_mrk_PensionPlanPriorServiceCostMember_884dd4ba-dee7-409d-a514-454cbd2fd414" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_138554c3-7859-4418-a850-6864a3174ec0" xlink:href="mrk-20201231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:to="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_138554c3-7859-4418-a850-6864a3174ec0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4a169401-0b33-46d1-a701-7f20dcd046bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4a169401-0b33-46d1-a701-7f20dcd046bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5653876-e1c5-4193-99c5-0441cd4b9a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5653876-e1c5-4193-99c5-0441cd4b9a44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91d68435-61ed-4983-8479-3be5d20eeefb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91d68435-61ed-4983-8479-3be5d20eeefb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91d68435-61ed-4983-8479-3be5d20eeefb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91d68435-61ed-4983-8479-3be5d20eeefb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91d68435-61ed-4983-8479-3be5d20eeefb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_efef2335-560b-4d28-b05a-00351be55493" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91d68435-61ed-4983-8479-3be5d20eeefb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_efef2335-560b-4d28-b05a-00351be55493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_55e8a7de-f968-4490-90ad-a22043449850" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_efef2335-560b-4d28-b05a-00351be55493" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_55e8a7de-f968-4490-90ad-a22043449850" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_749bb393-c8b6-40b2-b8df-0f6151a27c01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_749bb393-c8b6-40b2-b8df-0f6151a27c01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_749bb393-c8b6-40b2-b8df-0f6151a27c01_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_749bb393-c8b6-40b2-b8df-0f6151a27c01" xlink:to="loc_us-gaap_TypeOfAdoptionMember_749bb393-c8b6-40b2-b8df-0f6151a27c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_49d8a9d7-ee63-4bdf-8389-c2d25f8ffee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_749bb393-c8b6-40b2-b8df-0f6151a27c01" xlink:to="loc_us-gaap_TypeOfAdoptionMember_49d8a9d7-ee63-4bdf-8389-c2d25f8ffee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_80601968-eb3d-4eda-96d0-659c342c90ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_49d8a9d7-ee63-4bdf-8389-c2d25f8ffee5" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_80601968-eb3d-4eda-96d0-659c342c90ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReporting"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended" id="i6080e4177e0b426daff67f374c1aa9dd_SegmentReporting"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended" id="i2b410511044348968ed1f23fb193b41d_SegmentReportingTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended" id="i51eef8fba7d34d428bbedf4b470eb336_SegmentReportingNarrativeDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended" id="i14278f4e95374fa7a8949e9a21ca6144_SegmentReportingSalesofCompanysProductsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e6e7363b-ac57-48f8-a430-2aee1c236973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3a96d4fb-baf0-4298-820b-938e1bf338c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e6e7363b-ac57-48f8-a430-2aee1c236973" xlink:to="loc_us-gaap_Revenues_3a96d4fb-baf0-4298-820b-938e1bf338c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e6e7363b-ac57-48f8-a430-2aee1c236973" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5f55a4ac-40df-4844-ad45-80b0c3032dc3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_srt_StatementGeographicalAxis_5f55a4ac-40df-4844-ad45-80b0c3032dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5f55a4ac-40df-4844-ad45-80b0c3032dc3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5f55a4ac-40df-4844-ad45-80b0c3032dc3" xlink:to="loc_srt_SegmentGeographicalDomain_5f55a4ac-40df-4844-ad45-80b0c3032dc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d385e44-74da-4e6b-b014-a3b3c81f8d87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5f55a4ac-40df-4844-ad45-80b0c3032dc3" xlink:to="loc_srt_SegmentGeographicalDomain_6d385e44-74da-4e6b-b014-a3b3c81f8d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6b17b97e-e3ba-4ad2-a2a8-b88814c97101" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6d385e44-74da-4e6b-b014-a3b3c81f8d87" xlink:to="loc_country_US_6b17b97e-e3ba-4ad2-a2a8-b88814c97101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_9a104124-a26b-448b-8eab-bdec3de13e4b" xlink:href="mrk-20201231.xsd#mrk_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6d385e44-74da-4e6b-b014-a3b3c81f8d87" xlink:to="loc_mrk_InternationalMember_9a104124-a26b-448b-8eab-bdec3de13e4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1e16520a-8d66-48a9-bd24-39103769476f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_srt_ConsolidationItemsAxis_1e16520a-8d66-48a9-bd24-39103769476f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1e16520a-8d66-48a9-bd24-39103769476f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1e16520a-8d66-48a9-bd24-39103769476f" xlink:to="loc_srt_ConsolidationItemsDomain_1e16520a-8d66-48a9-bd24-39103769476f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e535d32d-5286-4792-ba87-8a6f8d925ae7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1e16520a-8d66-48a9-bd24-39103769476f" xlink:to="loc_srt_ConsolidationItemsDomain_e535d32d-5286-4792-ba87-8a6f8d925ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8d002586-4c65-4f2d-be5a-73f61bdcc4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e535d32d-5286-4792-ba87-8a6f8d925ae7" xlink:to="loc_us-gaap_OperatingSegmentsMember_8d002586-4c65-4f2d-be5a-73f61bdcc4a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_dfa55ad4-51fb-4f4a-9db6-6e57f3b69c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e535d32d-5286-4792-ba87-8a6f8d925ae7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_dfa55ad4-51fb-4f4a-9db6-6e57f3b69c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7ba82e0e-5359-4d39-88d9-c698e3531454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7ba82e0e-5359-4d39-88d9-c698e3531454" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7ba82e0e-5359-4d39-88d9-c698e3531454_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7ba82e0e-5359-4d39-88d9-c698e3531454" xlink:to="loc_us-gaap_SegmentDomain_7ba82e0e-5359-4d39-88d9-c698e3531454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7ba82e0e-5359-4d39-88d9-c698e3531454" xlink:to="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_26d5749e-1693-43c9-83df-02a0fc5dadd5" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:to="loc_mrk_PharmaceuticalsegmentMember_26d5749e-1693-43c9-83df-02a0fc5dadd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_d685147b-1310-4ebf-9efc-fffff6dc79eb" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:to="loc_mrk_AnimalHealthsegmentMember_d685147b-1310-4ebf-9efc-fffff6dc79eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1ababcdd-49e5-4acf-8fbc-4c16e5e9c8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1ababcdd-49e5-4acf-8fbc-4c16e5e9c8a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8d6665fc-e4ad-40e8-9002-147128b7e747" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_srt_ProductOrServiceAxis_8d6665fc-e4ad-40e8-9002-147128b7e747" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8d6665fc-e4ad-40e8-9002-147128b7e747_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8d6665fc-e4ad-40e8-9002-147128b7e747" xlink:to="loc_srt_ProductsAndServicesDomain_8d6665fc-e4ad-40e8-9002-147128b7e747_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8d6665fc-e4ad-40e8-9002-147128b7e747" xlink:to="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_0267fba7-aa62-4693-8b99-8184d776c551" xlink:href="mrk-20201231.xsd#mrk_KeytrudaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_KeytrudaMember_0267fba7-aa62-4693-8b99-8184d776c551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_2e0dc4b8-2ff5-489a-841c-a116aebc54f3" xlink:href="mrk-20201231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_2e0dc4b8-2ff5-489a-841c-a116aebc54f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_30ef797b-9592-4d81-8ed2-2774d44411bd" xlink:href="mrk-20201231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_LenvimaMember_30ef797b-9592-4d81-8ed2-2774d44411bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmendMember_13c6e81e-a3f2-4e89-b6f0-c1ab89b56bf7" xlink:href="mrk-20201231.xsd#mrk_EmendMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_EmendMember_13c6e81e-a3f2-4e89-b6f0-c1ab89b56bf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_a7771845-1279-4468-865f-6fc40a4cf77f" xlink:href="mrk-20201231.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_GardasilGardasil9Member_a7771845-1279-4468-865f-6fc40a4cf77f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_5ec3540f-dce4-49d3-9c99-dee1d984f10e" xlink:href="mrk-20201231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_5ec3540f-dce4-49d3-9c99-dee1d984f10e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_d8b87cef-04c9-4057-abe7-f244784c359e" xlink:href="mrk-20201231.xsd#mrk_Pneumovax23Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_Pneumovax23Member_d8b87cef-04c9-4057-abe7-f244784c359e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_b94c3a83-4813-4ce0-a31a-e8c422a91545" xlink:href="mrk-20201231.xsd#mrk_RotateqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_RotateqMember_b94c3a83-4813-4ce0-a31a-e8c422a91545" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_70f2df99-c36c-46f3-aca7-9c27642a3959" xlink:href="mrk-20201231.xsd#mrk_VaqtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_VaqtaMember_70f2df99-c36c-46f3-aca7-9c27642a3959" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_06e9a35d-84e4-49df-9d4c-8ebd7cbd2589" xlink:href="mrk-20201231.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_BridionMember_06e9a35d-84e4-49df-9d4c-8ebd7cbd2589" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_d34195d0-28af-4f4b-95e6-aef5485d19d9" xlink:href="mrk-20201231.xsd#mrk_NoxafilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_NoxafilMember_d34195d0-28af-4f4b-95e6-aef5485d19d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_e1dc19f7-2ff8-4076-9b03-674274db069e" xlink:href="mrk-20201231.xsd#mrk_PrevymisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_PrevymisMember_e1dc19f7-2ff8-4076-9b03-674274db069e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_774951a6-cca1-457b-afa2-c9d978f2c6bf" xlink:href="mrk-20201231.xsd#mrk_PrimaxinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_PrimaxinMember_774951a6-cca1-457b-afa2-c9d978f2c6bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_0378aa83-f4d8-4e95-984d-21c31c996876" xlink:href="mrk-20201231.xsd#mrk_CancidasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_CancidasMember_0378aa83-f4d8-4e95-984d-21c31c996876" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_df6ae059-4a4a-4bdc-947c-705568ea397a" xlink:href="mrk-20201231.xsd#mrk_InvanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_InvanzMember_df6ae059-4a4a-4bdc-947c-705568ea397a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CubicinMember_326e4e59-833d-4d33-8a15-0098e4cebe4c" xlink:href="mrk-20201231.xsd#mrk_CubicinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_CubicinMember_326e4e59-833d-4d33-8a15-0098e4cebe4c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_57cba671-9f76-486a-a1ac-57457dcfcc8e" xlink:href="mrk-20201231.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ZerbaxaMember_57cba671-9f76-486a-a1ac-57457dcfcc8e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_c4312256-d5b3-49f3-95ad-fd1b9d83c287" xlink:href="mrk-20201231.xsd#mrk_SimponiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_SimponiMember_c4312256-d5b3-49f3-95ad-fd1b9d83c287" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_32e73084-23e2-42d4-ba82-ecd64fd15c88" xlink:href="mrk-20201231.xsd#mrk_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_RemicadeMember_32e73084-23e2-42d4-ba82-ecd64fd15c88" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_2c9fb44d-ef9b-40d1-a557-2c97cd4cbdd3" xlink:href="mrk-20201231.xsd#mrk_BelsomraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_BelsomraMember_2c9fb44d-ef9b-40d1-a557-2c97cd4cbdd3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_4f7d4e97-fc83-41f7-914b-f91743460897" xlink:href="mrk-20201231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_IsentressIsentressHDMember_4f7d4e97-fc83-41f7-914b-f91743460897" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZepatierMember_e4be6c3b-706e-41d7-8607-5405a17b905c" xlink:href="mrk-20201231.xsd#mrk_ZepatierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ZepatierMember_e4be6c3b-706e-41d7-8607-5405a17b905c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaMember_c0515feb-2dc5-4446-b932-0e4900e4b809" xlink:href="mrk-20201231.xsd#mrk_ZetiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ZetiaMember_c0515feb-2dc5-4446-b932-0e4900e4b809" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VytorinMember_d24b73a0-4ed3-4659-8c90-f61ea5379df0" xlink:href="mrk-20201231.xsd#mrk_VytorinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_VytorinMember_d24b73a0-4ed3-4659-8c90-f61ea5379df0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AtozetMember_491fc831-1133-4ccf-bae7-cf8fab044670" xlink:href="mrk-20201231.xsd#mrk_AtozetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_AtozetMember_491fc831-1133-4ccf-bae7-cf8fab044670" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasMember_9817b150-9fe0-403e-b91b-422930ec704e" xlink:href="mrk-20201231.xsd#mrk_AllianceRevenueAdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_AllianceRevenueAdempasMember_9817b150-9fe0-403e-b91b-422930ec704e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_0d8e51f1-663a-47db-895d-c2170af1a214" xlink:href="mrk-20201231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_AdempasMember_0d8e51f1-663a-47db-895d-c2170af1a214" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_10c3ee5b-17d0-429d-9f86-026bd692546e" xlink:href="mrk-20201231.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_JanuviaMember_10c3ee5b-17d0-429d-9f86-026bd692546e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_77cd6e65-5580-422e-9c3c-24976df23d59" xlink:href="mrk-20201231.xsd#mrk_JanumetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_JanumetMember_77cd6e65-5580-422e-9c3c-24976df23d59" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImplanonNexplanonMember_2ed5c244-d987-48d7-ab17-f0e9498bfa5f" xlink:href="mrk-20201231.xsd#mrk_ImplanonNexplanonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ImplanonNexplanonMember_2ed5c244-d987-48d7-ab17-f0e9498bfa5f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NuvaringMember_00701274-0305-4a85-af54-9b801f5ec19f" xlink:href="mrk-20201231.xsd#mrk_NuvaringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_NuvaringMember_00701274-0305-4a85-af54-9b801f5ec19f" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SingulairMember_d48b2e7e-47b0-43af-a334-b4646fd88194" xlink:href="mrk-20201231.xsd#mrk_SingulairMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_SingulairMember_d48b2e7e-47b0-43af-a334-b4646fd88194" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CozaarHyzaarMember_cbecbbe7-89d1-4421-8cc0-13a9d423d86c" xlink:href="mrk-20201231.xsd#mrk_CozaarHyzaarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_CozaarHyzaarMember_cbecbbe7-89d1-4421-8cc0-13a9d423d86c" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArcoxiaMember_3f5e6fb2-aacf-4333-9e84-71763e2c4067" xlink:href="mrk-20201231.xsd#mrk_ArcoxiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ArcoxiaMember_3f5e6fb2-aacf-4333-9e84-71763e2c4067" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NasonexMember_bc6e62f5-0ffc-4325-8d3e-c42774db878a" xlink:href="mrk-20201231.xsd#mrk_NasonexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_NasonexMember_bc6e62f5-0ffc-4325-8d3e-c42774db878a" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FollistimAqMember_2bbc472e-c470-4b36-a996-e8fb01bba22c" xlink:href="mrk-20201231.xsd#mrk_FollistimAqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_FollistimAqMember_2bbc472e-c470-4b36-a996-e8fb01bba22c" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_16e37837-8259-4b05-a160-ece03a66a2a0" xlink:href="mrk-20201231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_OtherPharmaceuticalMember_16e37837-8259-4b05-a160-ece03a66a2a0" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_f8ceb03b-96fe-4f61-9b39-bc43592c02f5" xlink:href="mrk-20201231.xsd#mrk_LivestockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_LivestockMember_f8ceb03b-96fe-4f61-9b39-bc43592c02f5" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_2bdc4b8c-5877-482c-b486-b8f4f171c0aa" xlink:href="mrk-20201231.xsd#mrk_CompanionAnimalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_CompanionAnimalsMember_2bdc4b8c-5877-482c-b486-b8f4f171c0aa" xlink:type="arc" order="38"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="extended" id="ib6b33dbae4ce412c89140a2bac4e54a1_SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0889d63c-74d1-4d63-9d61-1ca06d472a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6cdf21fa-a100-4306-93a4-1e423b8e6fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0889d63c-74d1-4d63-9d61-1ca06d472a94" xlink:to="loc_us-gaap_Revenues_6cdf21fa-a100-4306-93a4-1e423b8e6fc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3cf0e69f-8ee6-4cb5-ae0b-c510dc3a7e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0889d63c-74d1-4d63-9d61-1ca06d472a94" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3cf0e69f-8ee6-4cb5-ae0b-c510dc3a7e79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3cf0e69f-8ee6-4cb5-ae0b-c510dc3a7e79" xlink:to="loc_srt_StatementGeographicalAxis_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b" xlink:to="loc_srt_SegmentGeographicalDomain_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b" xlink:to="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_87b625cb-e481-432e-b5de-7399bd042dfe" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_country_US_87b625cb-e481-432e-b5de-7399bd042dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_78f951d8-4024-4f87-88ce-82d58f6f15be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_us-gaap_EMEAMember_78f951d8-4024-4f87-88ce-82d58f6f15be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_d5542091-2c42-40bc-9cae-e91b738bba54" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_country_CN_d5542091-2c42-40bc-9cae-e91b738bba54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_11380902-5acf-4ccd-bd9f-c0cacf01bd54" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_country_JP_11380902-5acf-4ccd-bd9f-c0cacf01bd54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_84bdc3fc-f14b-44fe-a1a4-78fe5df9f16d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_srt_AsiaPacificMember_84bdc3fc-f14b-44fe-a1a4-78fe5df9f16d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_74bf70dc-9583-4148-9114-d70cdafc2c70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_srt_LatinAmericaMember_74bf70dc-9583-4148-9114-d70cdafc2c70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_bef8fa05-16ca-43c7-8e19-f072e02b0199" xlink:href="mrk-20201231.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_mrk_OtherCountriesMember_bef8fa05-16ca-43c7-8e19-f072e02b0199" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="extended" id="i7993a3ee7ced41c38ba79aa83944b14c_SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_aba29be9-0420-4b2c-b17a-3036503da2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_aba29be9-0420-4b2c-b17a-3036503da2c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_250982fd-04c0-462b-a692-b0e5f36fd3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_InterestExpense_250982fd-04c0-462b-a692-b0e5f36fd3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b778ac67-83b9-465f-b7df-0adc873aebce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b778ac67-83b9-465f-b7df-0adc873aebce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a2f6cf87-7dea-4045-a234-8838222c8aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a2f6cf87-7dea-4045-a234-8838222c8aef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmortizationOfPurchaseAccountingAdjustments_93ca2fbb-0929-4745-9f0a-5227712c7e0e" xlink:href="mrk-20201231.xsd#mrk_AmortizationOfPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_mrk_AmortizationOfPurchaseAccountingAdjustments_93ca2fbb-0929-4745-9f0a-5227712c7e0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_111ab377-3cbc-4df7-84e5-071a0ff103d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_RestructuringCharges_111ab377-3cbc-4df7-84e5-071a0ff103d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_20706724-87ed-453a-becd-422154cb2bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_GainLossOnContractTermination_20706724-87ed-453a-becd-422154cb2bf4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_204b1cdc-ba10-47a3-a749-5a369f69ea5c" xlink:href="mrk-20201231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_204b1cdc-ba10-47a3-a749-5a369f69ea5c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a0ff97e-35e9-4165-975b-0bad49e31621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a0ff97e-35e9-4165-975b-0bad49e31621" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_da9213a2-74c7-472e-9f67-4405c255caeb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:to="loc_srt_ConsolidationItemsAxis_da9213a2-74c7-472e-9f67-4405c255caeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_da9213a2-74c7-472e-9f67-4405c255caeb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_da9213a2-74c7-472e-9f67-4405c255caeb" xlink:to="loc_srt_ConsolidationItemsDomain_da9213a2-74c7-472e-9f67-4405c255caeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_da9213a2-74c7-472e-9f67-4405c255caeb" xlink:to="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4c937c8d-60e8-45c2-bd61-5853e04b879a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:to="loc_us-gaap_OperatingSegmentsMember_4c937c8d-60e8-45c2-bd61-5853e04b879a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_9e7a89ab-3796-4bfa-8467-3dbcb67dd2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:to="loc_us-gaap_CorporateNonSegmentMember_9e7a89ab-3796-4bfa-8467-3dbcb67dd2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_24e8efd4-198a-4262-ae8d-35eb9513c20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_24e8efd4-198a-4262-ae8d-35eb9513c20b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_27147435-a3d9-4630-908e-00f7ecb4b9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_27147435-a3d9-4630-908e-00f7ecb4b9cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_27147435-a3d9-4630-908e-00f7ecb4b9cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_27147435-a3d9-4630-908e-00f7ecb4b9cb" xlink:to="loc_us-gaap_SegmentDomain_27147435-a3d9-4630-908e-00f7ecb4b9cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_27147435-a3d9-4630-908e-00f7ecb4b9cb" xlink:to="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_9f160221-b280-4c43-9d8f-f5e0e503ee13" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:to="loc_mrk_PharmaceuticalsegmentMember_9f160221-b280-4c43-9d8f-f5e0e503ee13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_1b150a56-31cb-4a5c-9ab7-1cb7c9a99567" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:to="loc_mrk_AnimalHealthsegmentMember_1b150a56-31cb-4a5c-9ab7-1cb7c9a99567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_efff61a7-7c31-44cb-90f7-60626c51d891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:to="loc_us-gaap_AllOtherSegmentsMember_efff61a7-7c31-44cb-90f7-60626c51d891" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails" xlink:type="extended" id="i99e8a5adbfc748e69eebbc66f3593352_SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_70d8f87f-1a1f-40ec-9572-e7240197edd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_082f663b-3a21-4e4e-8d76-955bfe87347e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_70d8f87f-1a1f-40ec-9572-e7240197edd9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_082f663b-3a21-4e4e-8d76-955bfe87347e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_727328ab-47c8-4058-a801-4d118090615b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_70d8f87f-1a1f-40ec-9572-e7240197edd9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_727328ab-47c8-4058-a801-4d118090615b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_70d8f87f-1a1f-40ec-9572-e7240197edd9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2db0fb48-fc71-46b2-a30e-b4739041721b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:to="loc_srt_ConsolidationItemsAxis_2db0fb48-fc71-46b2-a30e-b4739041721b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2db0fb48-fc71-46b2-a30e-b4739041721b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2db0fb48-fc71-46b2-a30e-b4739041721b" xlink:to="loc_srt_ConsolidationItemsDomain_2db0fb48-fc71-46b2-a30e-b4739041721b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4b650bb0-3c70-4ded-abc1-ae44992a1d71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2db0fb48-fc71-46b2-a30e-b4739041721b" xlink:to="loc_srt_ConsolidationItemsDomain_4b650bb0-3c70-4ded-abc1-ae44992a1d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a620c951-73b5-4ba8-b210-1ae9cf2d95da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4b650bb0-3c70-4ded-abc1-ae44992a1d71" xlink:to="loc_us-gaap_OperatingSegmentsMember_a620c951-73b5-4ba8-b210-1ae9cf2d95da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b" xlink:to="loc_us-gaap_SegmentDomain_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b" xlink:to="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_e32fc788-0b63-40a5-9c0d-e9b4c32fc980" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:to="loc_mrk_PharmaceuticalsegmentMember_e32fc788-0b63-40a5-9c0d-e9b4c32fc980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_ccaa99c5-3be8-4179-9b37-ae81881ef091" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:to="loc_mrk_AnimalHealthsegmentMember_ccaa99c5-3be8-4179-9b37-ae81881ef091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_851ab612-9c23-4857-8cea-9fd62b8b9611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:to="loc_us-gaap_AllOtherSegmentsMember_851ab612-9c23-4857-8cea-9fd62b8b9611" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="extended" id="ie847f1a330c741ccb3160439c1be2a8a_SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a2b3c60a-7677-4f84-bc0e-ee81f588a9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8778a225-5ca2-492b-982c-d2623d808429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a2b3c60a-7677-4f84-bc0e-ee81f588a9af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8778a225-5ca2-492b-982c-d2623d808429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ff819a2b-566b-4cb2-9d6b-aa5e85e7979b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a2b3c60a-7677-4f84-bc0e-ee81f588a9af" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ff819a2b-566b-4cb2-9d6b-aa5e85e7979b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d35ccd4f-8126-4335-989e-e6fdcae824d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ff819a2b-566b-4cb2-9d6b-aa5e85e7979b" xlink:to="loc_srt_StatementGeographicalAxis_d35ccd4f-8126-4335-989e-e6fdcae824d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d35ccd4f-8126-4335-989e-e6fdcae824d5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d35ccd4f-8126-4335-989e-e6fdcae824d5" xlink:to="loc_srt_SegmentGeographicalDomain_d35ccd4f-8126-4335-989e-e6fdcae824d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d35ccd4f-8126-4335-989e-e6fdcae824d5" xlink:to="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4d9eda23-878d-4bea-b773-799728554fe0" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_country_US_4d9eda23-878d-4bea-b773-799728554fe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_c1716f25-988c-4d8b-8853-e91144d15131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_us-gaap_EMEAMember_c1716f25-988c-4d8b-8853-e91144d15131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_47ee365b-971b-4ad8-baf8-426031b90379" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_srt_AsiaPacificMember_47ee365b-971b-4ad8-baf8-426031b90379" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_ead0b341-b541-4e3d-bcb9-e7e4362c18ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_srt_LatinAmericaMember_ead0b341-b541-4e3d-bcb9-e7e4362c18ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_891e5a77-cc8e-4a99-9fb1-12a1b6dea557" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_country_CN_891e5a77-cc8e-4a99-9fb1-12a1b6dea557" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_d27ab569-a26d-4b1d-8e72-6e27cb56f7f3" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_country_JP_d27ab569-a26d-4b1d-8e72-6e27cb56f7f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_68bc7c64-c160-4943-a8b3-e8089bc605f0" xlink:href="mrk-20201231.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_mrk_OtherCountriesMember_68bc7c64-c160-4943-a8b3-e8089bc605f0" xlink:type="arc" order="6"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>mrk-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3b02abbc-3b84-4f9a-9655-da3777b72964,g:4abc6098-1e3f-4748-b81f-d8be8057e101-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fbc06968-7797-46fe-8bb9-5ce5190dcfe1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_fc33088f-d3a6-4559-8206-87c84fbe199e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product intangibles and licenses, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_610e6ace-528b-492a-bdc3-174c1bcae9a6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target allocation (as percent)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_622e9774-f591-4494-b103-c6eb7e71048b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_b23b86cb-9ad3-4aa8-90ce-21b72a817a9e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_24ff0d29-c62c-4065-9f6e-16df087620b8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1567b302-4504-4042-824a-ec41710afac3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_981cfac6-0cc9-4ccf-b258-fa5ebc55cf2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ac368ce4-e945-4b4a-8aad-a92d263850d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Environmental Liabilities</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b2221db0-2d96-452a-bafd-2e8da499d200_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_36657fef-d00a-41df-a7a1-ed8f12da1ff2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2798bc4a-3bd6-46cb-9cfb-8848d63613fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A235NotesDue2040Member_24968828-d3db-4997-b6cc-a06422464fbd_terseLabel_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040</link:label>
    <link:label id="lab_mrk_A235NotesDue2040Member_label_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2040 [Member]</link:label>
    <link:label id="lab_mrk_A235NotesDue2040Member_documentation_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member" xlink:href="mrk-20201231.xsd#mrk_A235NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A235NotesDue2040Member" xlink:to="lab_mrk_A235NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_d15ec109-0557-4878-881b-b313aa6c845f_terseLabel_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO inventory amount</link:label>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_label_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO Inventory Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LIFOInventoryAmount" xlink:to="lab_us-gaap_LIFOInventoryAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_0a907bd5-b3a7-4391-ad09-2351d41a4193_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b59046ab-c62b-483c-9b3d-621842cf2652_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a69971a-7139-47ea-85ef-16408e263b7a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff237269-9d5a-4bb6-80b9-87a5126c1203_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_af3434c6-c283-4a05-8e35-d03cc0f50d5b_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6064f80a-08aa-43b6-a07d-f9165953d947_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_29984625-cc74-4656-97af-8f815d26d180_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7278068d-e575-40b2-911b-042d3030bbec_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets January&#160;1</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_365a0877-c5da-4dbc-b522-aa6c154d3799_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_508c5a93-4aa1-4227-acc5-8187fa560f1a_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_478b802c-29a6-427e-a131-e0cfe7c44449_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ff718256-a422-4d24-96e9-8800f536fb5b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_936b309a-cc44-4ee0-b81e-e69991c66f13_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SmartCellsProgramMember_ac07ec08-a3e5-4932-aedd-c772af0c29d9_terseLabel_en-US" xlink:label="lab_mrk_SmartCellsProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SmartCells Program</link:label>
    <link:label id="lab_mrk_SmartCellsProgramMember_label_en-US" xlink:label="lab_mrk_SmartCellsProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SmartCells Program [Member]</link:label>
    <link:label id="lab_mrk_SmartCellsProgramMember_documentation_en-US" xlink:label="lab_mrk_SmartCellsProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SmartCells Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SmartCellsProgramMember" xlink:href="mrk-20201231.xsd#mrk_SmartCellsProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SmartCellsProgramMember" xlink:to="lab_mrk_SmartCellsProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_a4de497e-1033-4cea-9d74-8da6aaebdeba_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_fe82bbba-c0de-4846-aafd-c6a05862609b_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_a81a55c8-e6e3-4341-a90c-56d9b2cfda11_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_245fb8c0-04ef-4bb8-a467-cb8fd8be1420_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_47fdee02-d206-4a38-afb8-4ffbf8e9d698_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_2f6298f7-2e39-440e-9b12-fa79e5119899_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_30fdd1d2-dea5-4381-8ae7-de1393267d44_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_aac9c191-13d0-45d8-9bbe-43a1fdc05838_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_30ed55dc-d30a-4d61-9af6-04726d9e4237_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_44610186-c537-4ebf-8064-f08abcbf6bde_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of ArQule, Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1685f549-20d0-4124-80c7-16e43fb79b5c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6a55576c-2cc7-4e5d-aa2c-65c678f2d907_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ffc6cf38-12ea-4553-a0c5-23f5c7a170f8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_41b5cbeb-f94a-494d-ab41-4ee02b101b16_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets, acquired</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ad92b9d8-0b92-442d-92f6-7d4b3d291644_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_076ddd27-8303-4c49-8af4-802644516e39_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28f32747-c779-47a8-961c-66e445ec0d53_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Outstanding, January 1 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7e25bf07-b4c8-475a-ad62-fce40ec4be0e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Outstanding, December 31 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ba95d6ee-35fc-48a7-b3ae-af5d31ec5dd6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dc193d91-b36f-4df8-b2db-3bf64795f908_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4ebe518b-5766-45ef-8d45-0e7d17835e6b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_49ab13f0-99a0-482c-b82e-1ef87c718915_terseLabel_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed To Toll Statute Of Limitations</link:label>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_label_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed ToToll Statute Of Limitations [Member]</link:label>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_documentation_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed To Toll Statute Of Limitations[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:href="mrk-20201231.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:to="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1d75fe06-4a72-4219-a20b-070ecf18fa9a_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1137d56c-c6fa-4482-a1ce-3c2d74fb0080_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_5460012c-4844-44e0-a1ce-f420456e86b9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_eab8bd0c-36cf-4ce3-9830-2712a0c04db3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed asset abandonment costs related to contract termination</link:label>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:to="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_cd8d30ca-4ba0-4803-8dd4-f67092a32a9d_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d308b378-150b-42f3-89e7-45c1419758d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Loss Net of Taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ae26ed63-ee5c-43ef-a35a-6309174bc95e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_9580acad-d691-42f3-8f17-b978a7f2bc70_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_1b3f37d0-a94d-4fe3-96e6-4ea93e69e59d_terseLabel_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets equities, Investment funds</link:label>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets Equities Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets equities investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:href="mrk-20201231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:to="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ff28fb54-5b44-433e-b2ee-996b47f5efa6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_87cb0a0c-7527-4132-a7fa-648dffb701da_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AntelliqMember_9aa7e258-6b6c-44b0-9af4-e2f24f855eb1_terseLabel_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq</link:label>
    <link:label id="lab_mrk_AntelliqMember_label_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq [Member]</link:label>
    <link:label id="lab_mrk_AntelliqMember_documentation_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember" xlink:href="mrk-20201231.xsd#mrk_AntelliqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AntelliqMember" xlink:to="lab_mrk_AntelliqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_58fd9231-c12a-48b3-8945-4161f8ddeb67_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_7a9133e5-5593-4e58-84fa-bcb3ec32ed1c_terseLabel_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Credit</link:label>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_label_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Cost [Member]</link:label>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_documentation_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember" xlink:href="mrk-20201231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PensionPlanPriorServiceCostMember" xlink:to="lab_mrk_PensionPlanPriorServiceCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_df06131c-b85c-4510-b2e2-21af9aa8bf8b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_4ddceca1-89d7-4f58-a053-c6744b5c80d9_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f9b00f2-8883-481e-8727-b83f8d47b255_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_523a688e-8e99-44d5-b9cf-80d4530a52dc_verboseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_aa4ac4cb-1f78-4db3-b5cf-0d285caa4443_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (excludes inventories of $2,197 in 2020 and $1,480 in 2019 classified in Other assets - see Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_49a6db35-fef5-4969-90db-0fc9adeddbfb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_b6cb6866-1c6f-4723-825a-eea647964dc7_terseLabel_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts, Other investments</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_6370eb32-44d0-4101-ad03-36999cf7aa58_verboseLabel_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_label_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts Other Investments [Member]</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_documentation_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember" xlink:href="mrk-20201231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InsuranceContractsOtherInvestmentsMember" xlink:to="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ca3bf241-0bc8-44e4-88a1-3a0025ad3abd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateDomain_9f4f6a7d-3dbd-4315-abc8-4e3f6915808c_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateDomain_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_1498c44b-dafa-4f66-b953-61de3ab8df71_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax liability, current</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6ab5f329-6776-49cc-b1e0-2483bb214674_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of accounts receivable represented by customers with largest balances (as percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2f6e1b4a-39a7-4555-a577-0e321d662738_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_0e1fe705-a254-4450-b400-1711c2cb47a8_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8dc009f5-881a-4905-ab95-673310bd93a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_4a96a56c-f8e0-4da1-ac28-566169ddcaa5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax net unrealized gain (loss) on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_127d189a-a1e2-40e8-9b52-35e03000a7ef_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SiteContingencyLineItems_12beb378-1bf0-4702-8202-cf368bef50d8_terseLabel_en-US" xlink:label="lab_us-gaap_SiteContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_SiteContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_SiteContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SiteContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SiteContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SiteContingencyLineItems" xlink:to="lab_us-gaap_SiteContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f10be6f1-263a-4e77-aa0e-db6c3c9ebbad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_4cf8ab39-aa97-4558-892a-31b4516dee64_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_c74e63c2-d85e-4860-af98-4c150909c6da_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_label_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthsegmentMember" xlink:to="lab_mrk_AnimalHealthsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_c3393881-cfb6-4a70-bcaf-5b83afaa4645_terseLabel_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income obligations, Investment funds</link:label>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:href="mrk-20201231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:to="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c514029e-46a8-47e0-ab4c-927631c93b30_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_09839490-5c8f-420c-b816-1d337dfdf660_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_f0792dab-3f3d-496c-9664-278f901af017_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_eeed0821-6559-4cb5-82cf-eed541444242_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_507d3c60-a97a-4ddd-aec8-68497c620897_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_a8523059-2873-4c19-8d31-4356ebcf37e1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_9d670771-4357-4a53-970e-071fd9d26f2f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3b79dc5e-ad34-4e88-9260-ad4497cde5a9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e4cdf09a-21cf-4b02-a6a6-4fbdf406db24_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_c3f22456-4d16-40e9-a5b9-30e18608cfc5_terseLabel_en-US" xlink:label="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate possible expenditure on environmental matters in excess of amounts accrued</link:label>
    <link:label id="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_label_en-US" xlink:label="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Exit Costs, Reasonably Possible Additional Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:to="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_b7277ce5-48e9-4885-8386-fd6e4b178772_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_daa9d260-6f30-40b3-ae06-448ed1c5592e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_44705a47-c616-4524-8542-4f677f5f8e78_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d7cbdcef-ca4f-4d3e-87b9-5c6726e42a6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Long-Term Debt and Leases</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7dcde4c1-20e5-4e72-9481-7958bfe2e8f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_cde0ddb1-fd65-451a-9669-385863ccc257_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_521d960a-fc30-4230-8862-b64cfe350bc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3d768912-1eb0-438f-a7a8-32a873985a60_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_813640d1-8e2e-4803-86e9-a509153a7a25_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_de11f1e9-f204-4997-9b67-63831d2362f0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities for accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e782eace-3ddb-480b-aaf1-e45a23f1d47f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_23e40629-dae1-45d2-b27c-66e16aefeb48_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_04b30a39-ecd2-4849-aba0-f2326f606013_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other profits</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b70c3b4a-713c-4b77-afa8-f4485a523f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares collectively authorized for future grants under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_1931576c-80b8-4cf6-ab76-e4c40389e9ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in Sales as a result of AOCI reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SanofiPasteurMember_5176ee34-cd01-4fab-a9ec-7eafbdb63a31_terseLabel_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_label_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_documentation_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember" xlink:href="mrk-20201231.xsd#mrk_SanofiPasteurMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SanofiPasteurMember" xlink:to="lab_mrk_SanofiPasteurMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_c5217fb6-bd3f-4553-884f-4d6b520c4e05_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c85f175e-02a0-47ca-91a6-26e48cfe227b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_918e0930-520c-4aff-8b79-81061c18b49f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanuviaMember_8a89eb01-e626-4734-8428-c7fc0a853835_terseLabel_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia</link:label>
    <link:label id="lab_mrk_JanuviaMember_label_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member]</link:label>
    <link:label id="lab_mrk_JanuviaMember_documentation_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember" xlink:href="mrk-20201231.xsd#mrk_JanuviaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanuviaMember" xlink:to="lab_mrk_JanuviaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_eead21ae-b3d1-491b-9ecd-c253a79c013c_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Differential arising from:</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c132f0-ff91-4bf5-8d01-bab5ecdc456f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f9279c1e-6735-436c-a614-634485b961d8_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_3da4af13-fb3f-46cd-9112-66b282fb73df_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain recognized in Other (income) expense, net on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementPayable_c77feb3a-8f2c-476f-b166-fc1bb4a29d86_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables to counterparty</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementPayable_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payable</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementPayable_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPayable" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementPayable" xlink:to="lab_mrk_CollaborativeArrangementPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_a24e9ba3-a331-4cbe-a37a-de4068388568_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_5c2e9f7e-ab70-4851-9b16-5e531d0d3e63_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherStateCourtMember_0e54fc1f-4359-4a72-82cb-75e02e695494_terseLabel_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State Court</link:label>
    <link:label id="lab_mrk_OtherStateCourtMember_label_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State Court [Member]</link:label>
    <link:label id="lab_mrk_OtherStateCourtMember_documentation_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other state court.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember" xlink:href="mrk-20201231.xsd#mrk_OtherStateCourtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherStateCourtMember" xlink:to="lab_mrk_OtherStateCourtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_226b6544-0ade-44ff-adc5-c619b50eebc7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_c67ed992-bd31-4da3-9f11-9ce05298623b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Legal Defense Costs</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_ddd8df8e-fcd0-43fb-91d2-59780c447499_terseLabel_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services</link:label>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_label_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services Segment [Member]</link:label>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_documentation_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember" xlink:href="mrk-20201231.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_HealthcareServicesSegmentMember" xlink:to="lab_mrk_HealthcareServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_be30d3ed-47b4-40e4-ae4e-e73a7588af68_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_03455526-7406-4a42-afc9-ad76bff24d44_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RotateqMember_a4a28553-af1e-4480-a307-d745d2e53978_terseLabel_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq</link:label>
    <link:label id="lab_mrk_RotateqMember_label_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rotateq [Member]</link:label>
    <link:label id="lab_mrk_RotateqMember_documentation_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember" xlink:href="mrk-20201231.xsd#mrk_RotateqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RotateqMember" xlink:to="lab_mrk_RotateqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_11b0ab88-94ba-44b7-b2b0-6816f8efc6e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of Company's Products</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_50a637b5-c060-400d-913f-68ca8755b26c_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f3e5a36d-9c54-4ad2-b114-6e03c754fa57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0fcd510b-2ba4-448c-87f1-d40820e73376_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b2f08f14-3aa2-44c9-95ce-4b74d0d03334_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_0fa53bd2-882d-4076-a9c7-e8c93ae67019_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_708903cd-084d-4df3-8907-711cf7024344_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66c5fa45-15d1-44a4-b8c6-741e6e6038fe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_b276da3f-1304-4976-9018-7cf032df897d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_ac6c00e8-b51b-4798-bdff-5c0ca105966a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_ef3cfb25-2d94-4dd1-83b3-3ad33696542f_terseLabel_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_label_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pharmaceutical [Member]</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_documentation_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember" xlink:href="mrk-20201231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPharmaceuticalMember" xlink:to="lab_mrk_OtherPharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b60c5ebb-8a5c-4917-8db1-86e400520198_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ba195d29-3e36-457a-b2e4-f2613537414a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_bbbf8d86-ed05-48cf-b0b4-28a6c4b69583_terseLabel_en-US" xlink:label="lab_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.30% debentures due 2026</link:label>
    <link:label id="lab_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_label_en-US" xlink:label="lab_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Percentage Debentures Due On Two Thousand And Twenty Six [Member]</link:label>
    <link:label id="lab_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_documentation_en-US" xlink:label="lab_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point three percentage debentures due on two thousand and twenty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember" xlink:href="mrk-20201231.xsd#mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember" xlink:to="lab_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NuvaringMember_4a3dbda8-953b-4c39-96e8-9754ae258b94_terseLabel_en-US" xlink:label="lab_mrk_NuvaringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NuvaRing</link:label>
    <link:label id="lab_mrk_NuvaringMember_label_en-US" xlink:label="lab_mrk_NuvaringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuvaring [Member]</link:label>
    <link:label id="lab_mrk_NuvaringMember_documentation_en-US" xlink:label="lab_mrk_NuvaringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NuvaRing [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NuvaringMember" xlink:href="mrk-20201231.xsd#mrk_NuvaringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NuvaringMember" xlink:to="lab_mrk_NuvaringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_5f7a6a92-85ef-4d71-81ab-a19f52215c81_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_label_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Excluding Current Maturities [Member]</link:label>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Excluding Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:href="mrk-20201231.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:to="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_50827914-f853-4a55-adf1-73fba98e474e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_314e1677-5316-4795-824e-36ad3c6ee25a_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_ddb9394f-2c94-4f94-88ef-b72586a760bd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government bonds</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ad5eed60-6ede-4bd4-bd17-7c20a90fd8b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Nonvested January 1</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5711eb5c-e538-4357-a423-b215a06d4c55_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Nonvested December 31</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_23856e04-f779-4008-a0eb-01daed151b79_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_d6b36fed-dd5d-4734-a7c7-e94c4fe5ab7a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Pneumovax23Member_751e5527-b5be-498e-bf55-baa5dc7e70cd_terseLabel_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_label_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23 [Member]</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_documentation_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23[Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member" xlink:href="mrk-20201231.xsd#mrk_Pneumovax23Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Pneumovax23Member" xlink:to="lab_mrk_Pneumovax23Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e68ef48d-54d6-45d1-9b2d-dc8bfb097666_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of unrecognized prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8aee3816-c3a4-478e-89c4-5831d98a05ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_673a4e2a-bce6-46e6-9b8b-c9e216ab321b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_e77ff427-ceec-4eff-88c8-52a00090a40f_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_2d12a1c9-e6a3-4080-b409-9e7ca217303c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_37c69c90-c70e-4125-91f2-9298bef2fcc3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EnvironmentalRemediationSiteDomain_f51be6a6-595e-439d-a1fc-f7d475c9a594_terseLabel_en-US" xlink:label="lab_us-gaap_EnvironmentalRemediationSiteDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Site [Domain]</link:label>
    <link:label id="lab_us-gaap_EnvironmentalRemediationSiteDomain_label_en-US" xlink:label="lab_us-gaap_EnvironmentalRemediationSiteDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Site [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalRemediationSiteDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalRemediationSiteDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EnvironmentalRemediationSiteDomain" xlink:to="lab_us-gaap_EnvironmentalRemediationSiteDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_032995bf-92fc-4b5b-b205-f38edb95630c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gains</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_f0f1662b-121a-45be-81ba-f6209401e926_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_5c1c4ae0-0c44-4e63-b783-365c83720fcf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4d379874-e52a-40f3-b735-d910c22a65cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CubicinMember_84cacef4-7694-4fdb-9ead-4303fd773116_terseLabel_en-US" xlink:label="lab_mrk_CubicinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cubicin</link:label>
    <link:label id="lab_mrk_CubicinMember_label_en-US" xlink:label="lab_mrk_CubicinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cubicin [Member]</link:label>
    <link:label id="lab_mrk_CubicinMember_documentation_en-US" xlink:label="lab_mrk_CubicinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cubicin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CubicinMember" xlink:href="mrk-20201231.xsd#mrk_CubicinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CubicinMember" xlink:to="lab_mrk_CubicinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f013c546-6e74-4c2d-b51a-debb6c43239f_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_eb6c309e-c534-4c61-8a91-cf8c37ddc756_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_b7f93e24-f1b4-42a2-95e7-1121e369fec0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_b6224db9-685d-433f-83b8-679e861c09d3_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_31c8fd94-b898-4e20-a150-7d5a356b2647_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EmendMember_ab40f533-036d-4b4b-bc09-3d218b68667b_terseLabel_en-US" xlink:label="lab_mrk_EmendMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emend</link:label>
    <link:label id="lab_mrk_EmendMember_label_en-US" xlink:label="lab_mrk_EmendMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emend [Member]</link:label>
    <link:label id="lab_mrk_EmendMember_documentation_en-US" xlink:label="lab_mrk_EmendMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emend [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmendMember" xlink:href="mrk-20201231.xsd#mrk_EmendMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EmendMember" xlink:to="lab_mrk_EmendMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_469d20ec-6986-452e-9a6a-010404c38c60_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11ed6926-467e-4b95-bcf9-0176eeb0899f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4aed201e-b697-433e-acfd-e50d056e7d5b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_de84534a-ebd6-4b2c-acfd-1df7cb5c95ee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_38582967-ac52-48f8-a864-9d10ea5dbdd3_verboseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_fa660fcd-1127-413f-9d7e-08675d6d29cb_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other segments</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_78c324ef-060c-4c55-8d85-f5426a00a7ab_terseLabel_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable future contingent payments collaborative arrangement</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20201231.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2ba71b8d-441d-47a6-9e9a-be91bbe0accb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_252990f7-da7d-4a01-aa11-d206f5c3f998_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties associated with uncertain tax positions, expense (benefit)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1a9d2aeb-47d1-49a7-8725-5a9f0c0b30e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9c8241a2-ff54-4d67-a5ae-2079b0c7d6c3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_f9dfd8c6-7507-4bb8-b55c-afe89be8086c_terseLabel_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_label_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IsentressIsentressHDMember_688d8ad2-bafd-4c65-a7b6-b470ebffa57d_terseLabel_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_label_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member]</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_documentation_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember" xlink:href="mrk-20201231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IsentressIsentressHDMember" xlink:to="lab_mrk_IsentressIsentressHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e3fd8f87-d6b2-47e8-8b86-1c485c4a03e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ee87611e-046d-4125-b221-1f964efa6c69_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7baf069e-0e52-454b-96fc-bd4bd32e44ef_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5a8ba4f1-2e80-4a79-886e-5666c03d4e1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_849a5475-aae4-4a91-a944-4e87afd6f857_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates current cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_9f3722fe-eac8-4a59-a944-de94083c53dc_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI and the foreign-derived intangible income deduction</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7a3234ae-1749-4212-acd8-af28bd6e54df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product intangibles and licenses, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_e7eca7b2-59a2-4f98-992d-3e8ae88c86e8_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_b089898d-7f63-442e-b4bb-3fb49c71c578_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_18ac3ad2-d5db-4f78-ad4b-c185e32ac647_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, equipment and office furnishings</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_03dc8f2f-8923-42be-92c1-678713829fba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_15abca62-5d9d-4374-a842-1d59caf3cdc9_terseLabel_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards</link:label>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_label_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</link:label>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_documentation_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:href="mrk-20201231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:to="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_b591a626-6315-4852-bca1-e273b3da3fae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_c1894d30-a257-40bb-9252-4d422348d4d4_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:href="mrk-20201231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa9d17ce-9291-4642-b027-b3e392e76f76_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4e4ebe9a-ba04-4d9d-bb73-c27b4ed6d101_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_43a0b1b6-ea63-4208-8071-9bf6196a90cf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases and sales, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:to="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_b0724915-ee46-4b56-9608-0bc9e6b36986_negatedTerseLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Antelliq Corporation, net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Four, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Four, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:href="mrk-20201231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e241500d-7fe5-46ca-8e1c-812f955df976_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d86099c2-06fa-4e69-922a-4a49da2ed012_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be66afd1-1c28-43dc-bafd-e1a5e29b22aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_19abef5b-abbc-47fb-8756-5d868b3a0308_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7b19bb4c-e424-479a-af10-0fcfc3864b89_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_389f37b4-0d96-47b5-a1e0-ddaeb8fff0f8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_4717098c-890e-49d5-805e-74fe9d2ecdf7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term and short term debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8fd74511-8115-4a9d-95e2-5466ef6beadf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6f1ab813-78e3-4ec6-a439-3bbfe73b92c8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a6fdaad2-5351-4a88-813c-3eda98c31611_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment (at cost)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_320f2494-1260-47c6-891b-baeeb81589a4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_9e126246-b6d5-4bb9-bb09-085d43a11ddf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_824f243a-a8eb-48cc-a5ff-f6a429f04b90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b0f514d6-c18e-4c13-9bb3-92d752ee4a24_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_767ded61-8ef1-487a-a95f-fef2baee17f1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_337a42cd-5c18-40b4-8df9-5da3d131f9f5_terseLabel_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% notes due 2045</link:label>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_label_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes Due 2045 [Member]</link:label>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_documentation_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes Due 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member" xlink:href="mrk-20201231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.70NotesDue2045Member" xlink:to="lab_mrk_A3.70NotesDue2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8760819b-3285-4722-ad2e-7968f4159f74_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4851753-ecce-49a2-8201-c66252dcfd2c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_46043838-d491-4200-9ed7-45652c4397f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_019812bd-3536-4240-9986-4fb13494abf1_terseLabel_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_label_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember" xlink:href="mrk-20201231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopmentMilestonesMember" xlink:to="lab_mrk_DevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3da5c8ae-0fa4-45bc-a074-2e4bb91ac671_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_53c3d268-9b2b-4699-a4e2-8b87f541bac3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncome_1c303527-168a-466b-9b2d-2e449e23943b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncome_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncome" xlink:to="lab_us-gaap_OtherNoncashIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_e937ed13-9fb5-4dd4-b376-eb433e213219_terseLabel_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_label_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_documentation_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:href="mrk-20201231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:to="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_9d901b41-2aa1-4753-b110-707017bbc1b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax settlements</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ebc80d9-2de7-4223-9c87-5175f01ae630_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_2329eea2-cf31-4aa8-87c3-7bc98c55476d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5d4bd808-e4d3-4ae6-9179-6c511089e222_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b9479421-febc-4743-a4a6-ee898cf8da2e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e21b6b01-267d-41ec-9d4d-dfe14ed8fcae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cb6b4922-434c-4660-94f7-cee5c4ff986f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_10df1732-cfc2-4de4-9633-d56c798e5949_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_046cdfcc-164e-44ae-acdd-62a89e6f7884_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_ec62a774-9da9-4750-9016-21e8fbbbc14b_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_d8be6b4e-ef86-43ef-aca9-2b4154c12338_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_7bcc7b5f-980f-42b8-b355-fca2f2745f2a_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_63c09e7d-5cdb-4c5f-ad0a-b3699d923d11_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SivextroMember_0cef82c3-8d87-4d08-b3f5-39118c330315_terseLabel_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro</link:label>
    <link:label id="lab_mrk_SivextroMember_label_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro [Member]</link:label>
    <link:label id="lab_mrk_SivextroMember_documentation_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember" xlink:href="mrk-20201231.xsd#mrk_SivextroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SivextroMember" xlink:to="lab_mrk_SivextroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_23a15f04-4253-4c10-b10d-c020d94ee5a6_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9fd5bcec-5f7d-40fb-8f55-e14a17508f10_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_9d5cfb2b-3c92-4ac1-b63f-99d404a45875_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_c4806e09-ced6-475c-92fe-8f6d793aa62c_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs, including amortization</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Amortization Of Purchase Accounting Adjustments</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to the amortization of purchase accounting adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4e8914d3-ef26-40c5-beff-7f3089e16245_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a3daefd6-39da-4b77-93e7-fd3d1fd56f3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5b504228-58f7-4a37-af8e-2c4646b2680b_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_433e2a7e-8662-43d2-8591-48c73e759b37_terseLabel_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% notes due 2049</link:label>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_label_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_documentation_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Notes Due 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member" xlink:href="mrk-20201231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A4.00NotesDue2049Member" xlink:to="lab_mrk_A4.00NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6631e5c6-2b62-4c1f-8243-03c8ced0386b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_d1189336-971a-40f1-97e2-3e557bebe212_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage estimate of cumulative pretax costs that will be non-cash (primarily from accelerated depreciation of facilities) (as percent)</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Be Noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:href="mrk-20201231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_025ee5ba-bdd9-42a2-ad8c-7a02027d339b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SimponiMember_2948aa0b-4b69-4222-a06c-2109da2080a9_terseLabel_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi</link:label>
    <link:label id="lab_mrk_SimponiMember_label_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member]</link:label>
    <link:label id="lab_mrk_SimponiMember_documentation_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember" xlink:href="mrk-20201231.xsd#mrk_SimponiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SimponiMember" xlink:to="lab_mrk_SimponiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1956345f-7ead-44f1-a4f9-648afaf1d41b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity (income) loss from affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A415NotesDue2043Member_f61db200-647f-4423-abab-c08668188c41_terseLabel_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% notes due 2043</link:label>
    <link:label id="lab_mrk_A415NotesDue2043Member_label_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2043 [Member]</link:label>
    <link:label id="lab_mrk_A415NotesDue2043Member_documentation_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member" xlink:href="mrk-20201231.xsd#mrk_A415NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A415NotesDue2043Member" xlink:to="lab_mrk_A415NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_d52d38d7-32dc-4a87-af74-4ec25fa3f592_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_811a9bea-9152-4e62-b823-56e4daf10586_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and other postretirement benefits, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_4ae8996a-e769-428a-b260-110e6ec6cc2f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d171c151-7f20-443b-98dc-32338f75f0d7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e651d258-6d8d-4ef2-97da-a816ffdf5b67_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026&#160;&#8212;&#160;2030</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_eefa109b-e5d7-4184-9a5a-461ac7e7bfaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_4e9ba35b-c9b4-4fa5-8ae8-45d37f351d5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_5de510fe-4745-4290-b5b7-04623ed54b75_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_b92d3b87-1dac-40b0-bfd9-a43945e9151c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FosamaxMember_15958226-27f5-4c63-be3d-2ad9cd7704c4_terseLabel_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax</link:label>
    <link:label id="lab_mrk_FosamaxMember_label_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax [Member]</link:label>
    <link:label id="lab_mrk_FosamaxMember_documentation_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember" xlink:href="mrk-20201231.xsd#mrk_FosamaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FosamaxMember" xlink:to="lab_mrk_FosamaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_e4822ddd-a130-4338-883b-8e0da1fd6134_negatedLabel_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_label_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income Expense, Other</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_documentation_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other nonoperating income and expense items not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:href="mrk-20201231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:to="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CGRPreceptorantagonistsMember_d8137f7d-819c-48cc-bac6-524efd020aee_terseLabel_en-US" xlink:label="lab_mrk_CGRPreceptorantagonistsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CGRP receptor antagonists</link:label>
    <link:label id="lab_mrk_CGRPreceptorantagonistsMember_label_en-US" xlink:label="lab_mrk_CGRPreceptorantagonistsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CGRP receptor antagonists [Member]</link:label>
    <link:label id="lab_mrk_CGRPreceptorantagonistsMember_documentation_en-US" xlink:label="lab_mrk_CGRPreceptorantagonistsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CGRP receptor antagonists [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CGRPreceptorantagonistsMember" xlink:href="mrk-20201231.xsd#mrk_CGRPreceptorantagonistsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CGRPreceptorantagonistsMember" xlink:to="lab_mrk_CGRPreceptorantagonistsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b0deab99-9463-48ed-8f2e-2b62c2172734_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_a81fc772-b92d-49bf-b8ac-8d4a7da427b3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_b7602714-f594-4faf-a104-24fa2e3db0f1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_5255f93c-0a23-40ba-bd8a-367e4edbb744_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_db2becef-dbcd-4c94-a2ea-65c8f35fab47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges Related to Restructuring Program Activities by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RestructuringReserveNoncashActivity_231ebbd7-726f-4d91-9510-fd7d0e364004_negatedLabel_en-US" xlink:label="lab_mrk_RestructuringReserveNoncashActivity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveNoncashActivity_label_en-US" xlink:label="lab_mrk_RestructuringReserveNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve Noncash Activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveNoncashActivity_documentation_en-US" xlink:label="lab_mrk_RestructuringReserveNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash activity affecting the restructuring reserve, including accelerated depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveNoncashActivity" xlink:href="mrk-20201231.xsd#mrk_RestructuringReserveNoncashActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RestructuringReserveNoncashActivity" xlink:to="lab_mrk_RestructuringReserveNoncashActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_cf0f844b-a960-48e8-a958-1b762b7ebfb2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative downward price adjustment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_KeytrudaMember_b56b39c2-e370-4af4-a15a-6cb47b83e8c5_terseLabel_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda</link:label>
    <link:label id="lab_mrk_KeytrudaMember_label_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:label id="lab_mrk_KeytrudaMember_documentation_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember" xlink:href="mrk-20201231.xsd#mrk_KeytrudaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_KeytrudaMember" xlink:to="lab_mrk_KeytrudaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_94c4fc28-c51c-48ff-af8e-2970659abbc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_19d3a6de-c1b3-4d61-8c76-8e369b4505b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_8081b3da-d4aa-4df4-98b1-ebadbbd2cafc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_afbba22b-229c-4e2a-88de-c878475dde74_terseLabel_en-US" xlink:label="lab_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Long-Term Debt and Leases - Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_label_en-US" xlink:label="lab_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Long-Term Debt and Leases - Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_documentation_en-US" xlink:label="lab_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Long-Term Debt and Leases - Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract" xlink:href="mrk-20201231.xsd#mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract" xlink:to="lab_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_168dc589-76d9-45df-a127-79db288ae4bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2e701a5f-a424-484c-98cd-9a298968e452_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_db8715c8-188e-432c-86b3-ab9efbabccd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Nonvested RSU and PSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_41956a92-5ea1-4e7c-988c-0b8d90e1ac1c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04e72ee3-1f53-428e-8428-f5b436b7fbfa_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4f5da424-beab-49f3-b5db-60fd3722dd39_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_eace0409-8069-407d-be63-ae6f449089e9_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ca61ac61-ee54-4527-8904-78dc33931d7e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_d045990f-0f69-4709-a82c-5f73109dc094_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_d5363be9-d8cf-4897-bebe-cc63a79d9d96_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average interest rate of commercial paper (as percent)</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_b9a86401-a9f2-453c-97cd-4fa4fb153250_totalLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total sales</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenues, Net of Commercialization Costs</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenues, Net of Commercialization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts" xlink:to="lab_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_6798a314-8dbe-462a-8793-4fa0cf189be8_terseLabel_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets, Equity securities</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_label_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Markets Equity Securities [Member]</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_documentation_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:to="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_8f3f3b1b-d79b-4387-98df-7afbb8673967_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Location and Pretax Gain or Loss Amounts for Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0508ce13-80c3-4293-b49f-7fcc70017399_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1670af72-5571-4d5d-a808-28c137c48e93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Determine Weighted-Average Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_83755f1d-1cb1-4be8-918b-e67838a7f003_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e8d24a51-0801-4172-8f34-65df62a3a33c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ea8ff2a4-e5cd-4588-ba5a-fd2bf30c63ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_b44c29b4-1c4b-4b2a-87ed-239812a58c6d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_93c381f7-d03f-41c0-975a-0b5593af7ac7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_57b22c3c-2370-4718-b463-968e5daa3d82_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_e48c1dd6-bb8f-4561-94aa-35c579136590_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Differential arising from:</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_a7c4195d-c659-484e-9744-e3aadd38cf4e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a94f029c-e4fe-4e4d-8a21-81cffac2029b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_162e56d8-2842-461f-a478-9607ea1ca835_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_749d44c8-cc4f-4838-a61f-3a384f47da7e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_b367f88d-f280-4696-8347-e8cc60dc62ae_terseLabel_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, lease not yet commenced, amount</link:label>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_label_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_documentation_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:href="mrk-20201231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:to="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_98ddcc11-dd64-451d-831c-750998a70992_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_a5318234-b20b-41ac-ac60-7d497e701e62_totalLabel_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current and noncurrent inventories</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of current and noncurrent inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:href="mrk-20201231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:to="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_e2af1157-d1ae-47d6-9fcc-2017c0e9f147_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fe65e364-298d-4f81-a3e6-5d6d244dde1c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_5fb8cd29-c35c-4d37-b15c-7c97da77a048_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_12ad624c-e7db-40b1-99aa-c441304fdfb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b8125e11-f3bc-4a59-8e10-d48fe6b77cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Profits to Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_de42d7a7-966b-4885-b78a-dca9b1b70772_terseLabel_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder</link:label>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_label_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder [Member]</link:label>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_documentation_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:href="mrk-20201231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:to="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f1db1569-f333-4072-9537-ff4566b41292_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A280NotesDue2023Member_c37e7ede-a657-4eea-a067-aa5b99e9a97d_terseLabel_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2023</link:label>
    <link:label id="lab_mrk_A280NotesDue2023Member_label_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Notes Due 2023 [Member]</link:label>
    <link:label id="lab_mrk_A280NotesDue2023Member_documentation_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member" xlink:href="mrk-20201231.xsd#mrk_A280NotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A280NotesDue2023Member" xlink:to="lab_mrk_A280NotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_2fd1c9bc-20e1-4ce9-b178-d58313954ad6_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_36eeed1e-fb62-429f-8256-a93896ccba12_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid to stockholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_d7b58e4f-2930-41ac-a405-38e545aabf7b_terseLabel_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member" xlink:href="mrk-20201231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375Notesdue2036Member" xlink:to="lab_mrk_A1.375Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_713d965c-8900-467f-bf94-e608a0189d05_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upward price adjustment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.85NotesDue2020Member_418e2c5c-9b65-428d-9ee8-6a753bfcc2dc_terseLabel_en-US" xlink:label="lab_mrk_A1.85NotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% Notes Due 2020 [Member]</link:label>
    <link:label id="lab_mrk_A1.85NotesDue2020Member_label_en-US" xlink:label="lab_mrk_A1.85NotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% Notes Due 2020 [Member]</link:label>
    <link:label id="lab_mrk_A1.85NotesDue2020Member_documentation_en-US" xlink:label="lab_mrk_A1.85NotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.85NotesDue2020Member" xlink:href="mrk-20201231.xsd#mrk_A1.85NotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.85NotesDue2020Member" xlink:to="lab_mrk_A1.85NotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_68a942b9-8319-47b8-85c5-9a4e51a5811e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_80b3c06c-fb83-44e7-8a0f-db9de07d06ba_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherChanges_e6ca1026-d546-4b57-badb-cedd3589c5eb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherChanges_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanOtherChanges" xlink:to="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_2c4120d9-49fd-441f-bdcc-82a017985886_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_6e3e5535-a041-498f-9c26-4e3d57592606_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_1215c8a9-a368-428d-af2d-512ac6a72ff4_terseLabel_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs</link:label>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6928aa99-fbd3-4a53-9676-e2f026ab4e53_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CancidasMember_6a01b356-235b-41f0-813e-ffbae4c0981c_terseLabel_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas</link:label>
    <link:label id="lab_mrk_CancidasMember_label_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member]</link:label>
    <link:label id="lab_mrk_CancidasMember_documentation_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember" xlink:href="mrk-20201231.xsd#mrk_CancidasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CancidasMember" xlink:to="lab_mrk_CancidasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9afc460f-007c-4775-8a38-dafc2f51f451_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PelotonMember_22441c73-47fe-4282-8018-1940e0c21f1f_terseLabel_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton</link:label>
    <link:label id="lab_mrk_PelotonMember_label_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton [Member]</link:label>
    <link:label id="lab_mrk_PelotonMember_documentation_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember" xlink:href="mrk-20201231.xsd#mrk_PelotonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PelotonMember" xlink:to="lab_mrk_PelotonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_70fea470-00b0-489d-a595-84590b5079a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_d8939cdc-6673-4ca7-a7c5-241230aab2a6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_926ac19d-4e98-48fe-bf00-482c2263a760_terseLabel_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equities, Investment funds</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Markets Equities Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equities investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:to="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_acd2e7ca-5d78-4f55-9666-8c4ad1cfaa13_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a04905ee-e9f8-4e20-809f-faba07cdb78a_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_2c84e29f-3c79-4d43-868a-e08cd41ce95b_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_513be7f2-0397-49d0-bb11-ea00127880c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2ad5bdf2-aa34-4244-94b2-ecd3f4fce7ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12114fd2-391e-43af-af15-19909bfb1a25_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_10fd70d1-aaf5-4440-ac49-cefdee8d5911_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CostsExpensesAndOther_de3cd0ac-96aa-4daf-9cba-6f0ea7111341_totalLabel_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs, expenses and other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_label_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Expenses And Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_documentation_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of cost of sales, operating expenses and nonoperating income or expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther" xlink:href="mrk-20201231.xsd#mrk_CostsExpensesAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CostsExpensesAndOther" xlink:to="lab_mrk_CostsExpensesAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_df95f893-4716-4e15-bdfd-9f832e01e569_terseLabel_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and Asset-Backed Securities Investment Funds</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and Asset-Backed Securities Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and Asset-Backed Securities Investment Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:href="mrk-20201231.xsd#mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:to="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IOmetPharmaLtdMember_3336229e-b7f2-4395-8a35-4b4b6b82d6ab_terseLabel_en-US" xlink:label="lab_mrk_IOmetPharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOmet Pharma Ltd</link:label>
    <link:label id="lab_mrk_IOmetPharmaLtdMember_label_en-US" xlink:label="lab_mrk_IOmetPharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOmet Pharma Ltd [Member]</link:label>
    <link:label id="lab_mrk_IOmetPharmaLtdMember_documentation_en-US" xlink:label="lab_mrk_IOmetPharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOmet Pharma Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IOmetPharmaLtdMember" xlink:href="mrk-20201231.xsd#mrk_IOmetPharmaLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IOmetPharmaLtdMember" xlink:to="lab_mrk_IOmetPharmaLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74eb0f9d-b97a-4ac2-bec6-d8fd6ba9a11d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_1d03a59c-d879-472f-90c5-095d46299ed6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_4c8ac3d0-5d73-485d-aa90-d06b40951abe_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Information Pertaining to Stock Option Plans</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block]</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional information pertaining to stock option plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:href="mrk-20201231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_e2c8c6a2-521b-41b4-ac18-6e3a7fd0389c_terseLabel_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember" xlink:href="mrk-20201231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RegulatoryMilestonesMember" xlink:to="lab_mrk_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_20fe2e3c-fd6f-48e2-8e59-a4168d1cb301_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_72a74231-98ad-4bf4-bd56-4e928ae2a4b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b4d644b4-01e3-4bf5-add2-31873c1e9704_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_5a329fcb-a80c-4ae2-b64b-a606f287141c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par Value of Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRatePercentage_5c4e709a-da47-4502-b38c-dd68e379e159_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate, percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage" xlink:href="mrk-20201231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRatePercentage" xlink:to="lab_mrk_RoyaltyRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_6523d668-e2cf-4856-bc5f-4f62d0505ede_terseLabel_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate, Investment funds</link:label>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_934d2c84-3368-4899-9487-baf202887a1b_verboseLabel_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate</link:label>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember" xlink:href="mrk-20201231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RealEstateInvestmentFundsMember" xlink:to="lab_mrk_RealEstateInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_aa57d422-9827-4899-9111-178b6f01a815_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d982404b-b14c-453a-aead-7ac91940f403_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DunboyneMember_9aef168a-b7fa-4e2a-bf56-ebdcd1e5447e_terseLabel_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne</link:label>
    <link:label id="lab_mrk_DunboyneMember_label_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne [Member]</link:label>
    <link:label id="lab_mrk_DunboyneMember_documentation_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember" xlink:href="mrk-20201231.xsd#mrk_DunboyneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DunboyneMember" xlink:to="lab_mrk_DunboyneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_12fc7176-b511-48c8-a851-394505c524f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Activity by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_f3d9c7aa-08a9-4f2e-8439-8d1d33fb7105_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b4ed283e-2858-4db9-b8b5-00c51f3250fd_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_91f55fc0-a4f5-48b2-950b-f4ca32fbe2b4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_59dc1c80-498e-4809-bd96-92981725071c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_0ba9f9bf-0c3d-4792-a8af-7ba0bd4e5d97_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.125Notesdue2021Member_df27ff58-2f2d-4f43-8969-9f25e3f46b22_terseLabel_en-US" xlink:label="lab_mrk_A1.125Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2021</link:label>
    <link:label id="lab_mrk_A1.125Notesdue2021Member_label_en-US" xlink:label="lab_mrk_A1.125Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2021 [Member]</link:label>
    <link:label id="lab_mrk_A1.125Notesdue2021Member_documentation_en-US" xlink:label="lab_mrk_A1.125Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125Notesdue2021Member" xlink:href="mrk-20201231.xsd#mrk_A1.125Notesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.125Notesdue2021Member" xlink:to="lab_mrk_A1.125Notesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxLineItems_e71275b6-e76b-4a6e-8dd1-b5ff9e3559fb_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_mrk_IncomeTaxLineItems_label_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_mrk_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxLineItems" xlink:to="lab_mrk_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_1dd0ff57-c4ba-4a53-8d42-ca595d7d1f6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb25d4d4-76aa-4ef4-afba-23db36c8a174_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b73a3331-1887-4617-800f-ee7b4e0319a8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_57df242f-b917-40b1-88f0-208a66702520_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6f12f5c0-1ef1-43a2-93f6-d59ddc3a34ac_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding assuming dilution (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_d02219de-1c76-49af-b8c9-aa5017783745_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_f1af7cdd-c5f8-4f91-adae-3a6818f1fa57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e3f622a4-d022-4bd8-a315-9507eaa35fb0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b94b4ae-5032-4a2d-bde0-c6b08011911a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_77707db0-9272-4076-bc47-4f71c3bfc2c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_5e074801-3fe3-414b-8255-eeb84edeb251_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a71cf498-ef2c-4a5f-a557-815fcfcea7c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_90b48ab7-3b98-48be-8cf1-b9e762f75a8f_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_7f429460-83b8-44ca-b1f8-df1864efe816_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_a017ecfd-a3d7-410e-a4d6-18ddd1d24d7b_terseLabel_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% notes due 2033</link:label>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_label_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Five Zero Percentage Notes Due On Two Thousand And Thirty Three [Member]</link:label>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_documentation_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point five zero percentage notes due on two thousand and thirty three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:href="mrk-20201231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:to="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_53b5fda6-4946-41d8-874e-0241add77ebd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_68e63c51-204c-41a8-94ae-cceefd31bab5_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_120f0b18-11d2-42ca-8c1f-46aacacb731e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7923cfaf-1ce0-4013-8f47-393af6672e1a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_945e92dc-5da4-4d3e-979b-1775ab2dccd8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c95b5fcf-8690-4a34-9e80-a29b9cefc1d2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ae3d1d47-58d5-4030-9eb9-7987f4d4f849_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance January&#160;1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ae7508e8-f667-4ad0-9a7c-66cd59dc9fd1_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance December&#160;31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f3da5c1f-2ad7-4f0b-98f9-d0865cc5b3ff_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_013c2500-46f0-4d60-91e7-5b5871d5e822_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_6bc6c74c-3a4b-4a7d-a7fc-90ea105712b9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_036a2df9-c133-4fc5-ba7e-4d397a768b63_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_29897eb2-bf8e-41a0-98f3-a83a93646e29_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_ea4b8306-20fa-484d-b298-8630a72c02bc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_01a339e8-48fd-42dd-b562-e00336e33caa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_2e55c1dc-0459-49ca-b8e7-e99d649e6fb9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds collected from factoring of receivable, held in restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_50bbaa90-7f62-4ec5-9d75-78ec8af39155_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_878f0a58-0217-450a-8655-42ce4031dc46_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains based on favorable observable price changes</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_34f29344-25ec-49c8-8a4e-3984ba61d6a7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits from adjustments related to examination</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c7c5c1d5-b3e4-4198-a896-c1edc449a8d3_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_befe7398-a9a5-47aa-befb-64e5e00f8a5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation January&#160;1</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_6df0fbc2-722c-42e4-b052-d86e765eec8d_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b3f047e5-59b1-4c2c-a188-dc8bdc0ae917_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AccrualForChargebacks_02a883ac-5187-4261-8078-b75a44884ee7_terseLabel_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for chargebacks reflected as direct reduction to accounts receivable</link:label>
    <link:label id="lab_mrk_AccrualForChargebacks_label_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual For Chargebacks</link:label>
    <link:label id="lab_mrk_AccrualForChargebacks_documentation_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for chargebacks reflected as a direction reduction to accounts receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks" xlink:href="mrk-20201231.xsd#mrk_AccrualForChargebacks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AccrualForChargebacks" xlink:to="lab_mrk_AccrualForChargebacks" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_dce4e952-b2bf-43f3-8fa7-d11353f384d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_c0ed711d-9ae2-4a98-91ef-e67fa62a8968_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrevymisMember_cfd35f03-557e-4fb9-a35e-c12b855ff659_terseLabel_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:label id="lab_mrk_PrevymisMember_label_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:label id="lab_mrk_PrevymisMember_documentation_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember" xlink:href="mrk-20201231.xsd#mrk_PrevymisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrevymisMember" xlink:to="lab_mrk_PrevymisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_9ada0a3c-1e6d-49cd-a03f-db953b4581b2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relating to assets sold during the year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_55ee8938-e76a-4b93-99a3-81ee62893526_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_861ef5c8-5727-4bff-9099-d1bdf5a0b061_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity of stock options that vest per year (as percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_40a9382e-4af3-40fe-a187-d46e6bf0636d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bde761bd-aee4-4b0d-bfa9-52d6690f06cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_134aff2a-a605-4077-9950-38e0f404173e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance January&#160;1 (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e7226d1a-790e-483f-9d47-667539f7660f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance December&#160;31 (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18040f54-7eb3-420d-b99e-e933defc7e3d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FederalMember_c2abe09f-3366-4296-b942-d281a5a9463d_terseLabel_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Court</link:label>
    <link:label id="lab_mrk_FederalMember_label_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_mrk_FederalMember_documentation_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember" xlink:href="mrk-20201231.xsd#mrk_FederalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FederalMember" xlink:to="lab_mrk_FederalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_1b08c13d-5068-4d95-a50a-83931a7d9845_terseLabel_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_label_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member" xlink:href="mrk-20201231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.500Notesdue2034Member" xlink:to="lab_mrk_A2.500Notesdue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_7bac55b0-1aee-4dae-bade-8f8b2ef39263_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of OncoImmune</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Three</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_744abd36-6e60-4bc0-9efa-a497e60de064_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6f0f4c5b-557d-4325-aa7b-b48f63af7fd7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_eb4ef95a-b451-46da-b12d-6b4dc8d69769_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_04a610da-4105-47e9-befe-71fff7eb6548_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_19a39889-8bc3-4cfc-8a5d-9a1fbf1df405_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_7d90b07d-bbdb-4b02-b42a-60e27cf00be1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_e7d29f61-f4bf-4d39-b99e-f9e966252851_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.75notesdue2026Member_ab64843e-7a61-4675-a321-b00f596e1e86_terseLabel_en-US" xlink:label="lab_mrk_A0.75notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026</link:label>
    <link:label id="lab_mrk_A0.75notesdue2026Member_label_en-US" xlink:label="lab_mrk_A0.75notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A0.75notesdue2026Member_documentation_en-US" xlink:label="lab_mrk_A0.75notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.75notesdue2026Member" xlink:href="mrk-20201231.xsd#mrk_A0.75notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.75notesdue2026Member" xlink:to="lab_mrk_A0.75notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_dc249b97-f4d6-46e0-b577-b1e211805e9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_8c07b6ac-b24d-4a21-963e-2abf5c8c3361_terseLabel_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% notes due 2036</link:label>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_label_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percentage Notes Due On Two Thousand And Thirty Six [Member]</link:label>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_documentation_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point seven five percentage notes due on two thousand and thirty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:href="mrk-20201231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:to="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_48dc75c9-1e77-4c61-8369-a386e2bb2b16_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_c4ec6c59-db1b-4db6-ad27-b37a54145082_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_e16ac46a-25c9-4785-9616-b85eac5fb6a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_bf051096-b699-4e71-a9b2-5baf707084d2_terseLabel_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated and Projected Benefit Obligation in Excess of Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:href="mrk-20201231.xsd#mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:to="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_349e4caf-169f-41f8-8b0a-efe7c064ea16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interests issued or issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c875fd08-59ae-45b6-b8e0-085340a18f3c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ea16717-8238-466e-9960-6d94bbb0ea5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_37f39872-f8c5-4c9a-9b05-b707ee9abe4d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_9df42790-1d9e-4b2c-b9c7-8df240ae2063_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI and the foreign-derived intangible income deduction</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_656e7456-ff83-4bb9-96ca-852e2a3e89ec_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_9f0c6d32-2f03-4a10-a538-0229446f10a6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care cost trend rate assumed for next year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_e373bf41-bd26-407b-84bb-a30eef541f65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Rate Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5d235b5d-67a0-463f-9c2f-67fac976c9cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_25961412-709f-4cc1-bb86-3052fce23442_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_86de29ac-92ae-4d12-b67f-5c584c9d4d5d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_be5b611b-4273-48a8-a741-377c3b7820a2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa200be9-163e-4524-bc0d-db8852839370_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CaliforniaStateCourtMember_3bf903b5-5576-4e80-a03c-cc492e732ba5_terseLabel_en-US" xlink:label="lab_mrk_CaliforniaStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California State Court</link:label>
    <link:label id="lab_mrk_CaliforniaStateCourtMember_label_en-US" xlink:label="lab_mrk_CaliforniaStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California State Court [Member]</link:label>
    <link:label id="lab_mrk_CaliforniaStateCourtMember_documentation_en-US" xlink:label="lab_mrk_CaliforniaStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California state court.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CaliforniaStateCourtMember" xlink:href="mrk-20201231.xsd#mrk_CaliforniaStateCourtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CaliforniaStateCourtMember" xlink:to="lab_mrk_CaliforniaStateCourtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b443e87d-570c-45fa-84da-8282fe3f757f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_2817c2af-f2ff-43f5-a06b-7cb611d2a7e4_terseLabel_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product return period and expiration</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_label_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period After to Expiration Date</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_documentation_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period After to Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:href="mrk-20201231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:to="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_01f0677b-780e-4fa7-821c-81afe147c73b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_b07c5e21-fe44-4aa1-98c5-f9c795e7acf9_terseLabel_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_label_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_documentation_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms" xlink:href="mrk-20201231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenuePerformanceObligationPaymentTerms" xlink:to="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_241662ba-057c-424b-8fff-ba50063d97d3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims settled, number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_07854fa4-e0c4-4c3e-930f-3258962ea39b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_3bfb5cc5-f86b-46e9-b873-0ec44e8d1b2f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of exchange rate changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_85a64f19-e001-4fa2-bf1e-53121e89464c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8554411a-6e5b-4a89-b367-e41b594744f0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Contractterminationfeepayment_1f852b62-3080-4054-96a8-71fbe8586c5f_terseLabel_en-US" xlink:label="lab_mrk_Contractterminationfeepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination fee payment</link:label>
    <link:label id="lab_mrk_Contractterminationfeepayment_label_en-US" xlink:label="lab_mrk_Contractterminationfeepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination fee payment</link:label>
    <link:label id="lab_mrk_Contractterminationfeepayment_documentation_en-US" xlink:label="lab_mrk_Contractterminationfeepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination fee payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Contractterminationfeepayment" xlink:href="mrk-20201231.xsd#mrk_Contractterminationfeepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Contractterminationfeepayment" xlink:to="lab_mrk_Contractterminationfeepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_b329b6d6-7149-4e97-b433-ac60cfb46858_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_84938c74-dd25-4923-b7e6-98ffbe86d174_terseLabel_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:href="mrk-20201231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:to="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_26235c6b-8d34-4ff0-8ca9-18ca9b4c08a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_4709eaa6-cb45-411b-9a05-014524849213_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_092b8564-45d3-4fe8-becf-600db2a0579d_terseLabel_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests (as percent)</link:label>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_label_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests</link:label>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_documentation_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:href="mrk-20201231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:to="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ChargeForAssetAcquisition_921bb83d-717a-469f-9c14-05b263778065_terseLabel_en-US" xlink:label="lab_mrk_ChargeForAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of VelosBio Inc.</link:label>
    <link:label id="lab_mrk_ChargeForAssetAcquisition_label_en-US" xlink:label="lab_mrk_ChargeForAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for asset acquisition</link:label>
    <link:label id="lab_mrk_ChargeForAssetAcquisition_documentation_en-US" xlink:label="lab_mrk_ChargeForAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for asset acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargeForAssetAcquisition" xlink:href="mrk-20201231.xsd#mrk_ChargeForAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ChargeForAssetAcquisition" xlink:to="lab_mrk_ChargeForAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_85b95e1f-b264-4def-aa7b-9f4b23e76516_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b1436654-487f-4750-8482-e2bbee5ee675_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_8bc76d84-a8dd-4d2d-a1a7-6b2f1f2c2e6f_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps held</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_9b97e69e-d2eb-49bd-bbd6-c5091421dd9a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Swaps Held</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3248e11d-29b3-4831-8275-d09fae82e31f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_ef6f3995-b517-4a74-b647-e97a9d89275d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_d6972631-09cf-40dd-9723-d9694a55c40f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_29ba1855-eb03-499e-9cfc-e773d0b28856_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_efdbfd2c-5a75-4a19-b022-c9c040d2964c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_219e0869-b2e8-4c77-9954-47198159a41c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service credit amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_05d3f952-2483-4809-ac4a-a88d2782b73a_terseLabel_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Gain</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_label_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Loss [Member]</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_documentation_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:href="mrk-20201231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:to="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_dcf48e20-d31b-4758-b7c8-42b74d455d10_terseLabel_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations, Fixed income securities</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government And Agency Obligations Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:to="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_47a25b4d-14d4-4c1a-8e94-f4d29aa37cbd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_650a1eb1-def2-455e-b755-4a7ee6b841f6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_7333ef78-2fca-42de-a6dd-d261343e69e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_236375c5-8035-4b37-a672-55ded6d40291_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of OncoImmune</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Three, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Three, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_41f4fa88-910f-4cda-b6c6-8fb571611b36_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7a2ff7ab-cc6a-43c0-adf2-6688f60ccad0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6e8db425-9247-4c15-b9b4-3b73f13a548d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fc1cbe85-5c38-4a85-b365-a602a15ba0f0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_4f24d666-24de-4db1-bced-1f5f9b5238a5_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, gain (loss)</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_8367ef4b-a31b-4798-850a-1d74d7a7867b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A145NotesDue2030Member_8a52d88d-2a7c-4fc4-b4e0-8a7a50934340_terseLabel_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030</link:label>
    <link:label id="lab_mrk_A145NotesDue2030Member_label_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% Notes Due 2030 [Member]</link:label>
    <link:label id="lab_mrk_A145NotesDue2030Member_documentation_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member" xlink:href="mrk-20201231.xsd#mrk_A145NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A145NotesDue2030Member" xlink:to="lab_mrk_A145NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_90876025-8df0-47bd-950f-d56ac1652966_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock and Treasury Stock Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_15f69ea5-9f39-4295-8d85-8169a24bc5c2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_11745a14-0847-4879-85fa-667c47581fc6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_54882a01-4bf0-4716-9eed-ce695f5fcb93_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_f45de91e-51e1-4ff6-b3e7-8fec2f52438b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_c7eda525-94b7-4fe8-b46d-035ffd0efdad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_93cdc136-907a-40f3-9329-4d09bf230a99_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_fa456259-532d-4a25-b706-2d8ce4fa69fe_terseLabel_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_label_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_documentation_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:href="mrk-20201231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:to="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ba2480a4-6a8d-4222-ab4f-a1230b177584_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZetiaMember_c07b0ade-18a5-448c-9da2-1d2bbb4f8e21_terseLabel_en-US" xlink:label="lab_mrk_ZetiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia</link:label>
    <link:label id="lab_mrk_ZetiaMember_label_en-US" xlink:label="lab_mrk_ZetiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia [Member]</link:label>
    <link:label id="lab_mrk_ZetiaMember_documentation_en-US" xlink:label="lab_mrk_ZetiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaMember" xlink:href="mrk-20201231.xsd#mrk_ZetiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZetiaMember" xlink:to="lab_mrk_ZetiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2b8039bf-0099-47d0-be98-035714870b6f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory related, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_c0d7be7d-d60d-4be0-91a0-f9c01fadc89d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions to defined contribution savings plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_0d13b169-1ae3-48b8-adc2-7f728a26b51d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss related to unfavorable observable price changes</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_9902bcd7-4a03-4660-9c89-106b9b5b946e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_5ba05d52-0d32-4323-9d75-7a096daf9e9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_f0b62e7b-94f4-4a6f-b0cb-9323bc7193b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_fc4815ea-da09-4ccc-a67a-bbc3184ecb4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed-rate notes, stated interest rate (as percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0132371e-4199-425a-8a57-a78fe07c49a5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_3e726bbb-dd2e-4689-993f-2117a7246fd4_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4768c744-fea5-47dc-b713-001ba15f0851_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d33bd171-78d5-488f-b7b6-d568c8fbbd17_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanumetMember_2c372d4b-13b1-437a-97e7-5bcddde70e5a_terseLabel_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet</link:label>
    <link:label id="lab_mrk_JanumetMember_label_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member]</link:label>
    <link:label id="lab_mrk_JanumetMember_documentation_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember" xlink:href="mrk-20201231.xsd#mrk_JanumetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanumetMember" xlink:to="lab_mrk_JanumetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_b3fe5c0a-85d6-4936-9f64-55b61f767502_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_26e7c21b-61ed-49eb-aadc-a2bc020db97a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_57e9b794-d569-41e4-97f9-92aabfedaf0b_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_83235f0b-691d-494c-a972-857577b66fe5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_34d6304a-e6fa-4ab7-87e2-c090c398bb8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1e4e5427-716a-4cf7-828d-eaf0b3046c4a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5ed58494-af3d-4fc3-acaa-be6e13c8f9c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_4c62e4a5-217b-402d-9542-c91d89d65ae9_terseLabel_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for paying off environmental liabilities</link:label>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_label_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term For Paying Off Environmental Liabilities</link:label>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_documentation_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for paying off environmental liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:href="mrk-20201231.xsd#mrk_TermForPayingOffEnvironmentalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:to="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8dff78b2-4fb6-4678-8e5d-4f62858873da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_372f0cd3-7d59-45be-9958-22719883d9a6_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets (as percent)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3ec90703-403a-430e-a455-780300920f50_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_0a595dd2-1aac-4118-b96b-85019b1e10d3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_9b0ea9ce-6be4-491f-bb42-3c8c75857f44_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of clinical development programs</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_5ef16a69-473d-4e3d-baf6-f28bb6a778ca_terseLabel_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_label_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_documentation_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable" xlink:href="mrk-20201231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable" xlink:to="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AmortizationOfPurchaseAccountingAdjustments_e93ad670-1c1f-4f01-aa33-4d96fd7b446d_negatedLabel_en-US" xlink:label="lab_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of purchase accounting adjustments</link:label>
    <link:label id="lab_mrk_AmortizationOfPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Purchase Accounting Adjustments</link:label>
    <link:label id="lab_mrk_AmortizationOfPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of purchase accounting adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:href="mrk-20201231.xsd#mrk_AmortizationOfPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:to="lab_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_67dc7442-634c-46bf-9212-c661eba03883_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43c06a02-3b66-4e20-8622-c049cb73187f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5bb911b0-7e72-413b-a1e3-4fc9263314f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa064eaa-4e89-4f57-9724-242911d5cbb0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NewJerseyStateCourtMember_8f8dbdd2-e530-4845-92bf-1362ca0591d7_terseLabel_en-US" xlink:label="lab_mrk_NewJerseyStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey State Court</link:label>
    <link:label id="lab_mrk_NewJerseyStateCourtMember_label_en-US" xlink:label="lab_mrk_NewJerseyStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey State Court [Member]</link:label>
    <link:label id="lab_mrk_NewJerseyStateCourtMember_documentation_en-US" xlink:label="lab_mrk_NewJerseyStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey state court member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NewJerseyStateCourtMember" xlink:href="mrk-20201231.xsd#mrk_NewJerseyStateCourtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NewJerseyStateCourtMember" xlink:to="lab_mrk_NewJerseyStateCourtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_75522821-86e7-4298-a51e-55f6043782de_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_340d1394-cf9c-4885-8f80-d0916577b53e_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AdempasMember_9f5c37e8-9a3e-4675-a350-a38349af305c_terseLabel_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:label id="lab_mrk_AdempasMember_label_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas [Member]</link:label>
    <link:label id="lab_mrk_AdempasMember_documentation_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember" xlink:href="mrk-20201231.xsd#mrk_AdempasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AdempasMember" xlink:to="lab_mrk_AdempasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_21570463-3ccf-4e47-8bba-0b23d7f9d695_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c9dc421d-748e-4733-9ec6-c4f383227959_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b104722f-69d5-4f19-95a4-fba80dc35ffc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_878e885c-f4e5-4d2d-9b54-3cfabf1bb9be_terseLabel_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_label_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_documentation_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember" xlink:href="mrk-20201231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AlliancerevenueLynparzaMember" xlink:to="lab_mrk_AlliancerevenueLynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_258d640a-7c11-433b-903c-0780b5d1b462_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c1a4c870-38e3-4709-815b-9cbc6ff910fd_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_cef5bd59-d12b-413e-b8d4-0c436e80e7f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_97345a3f-418a-460d-bb4d-33767449f9b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_611a952a-6d45-4714-bea3-69f37616a1e8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8f5997a5-b410-44ee-9f25-619100937ad5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_2c3ea29d-fb9d-42ed-9b18-e0672c75facd_negatedLabel_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other unallocated, net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_label_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Unallocated Other Expenses Net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_documentation_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net expenses not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:href="mrk-20201231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:to="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4846b62d-d646-44d1-a075-9cddd79337d9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_d2943576-a711-4ca3-80b3-fed9d489e37f_terseLabel_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_label_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_documentation_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:href="mrk-20201231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:to="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_f2712749-5dd4-402f-8a90-2db986ca914c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a2f6d786-d84f-4a38-a06a-4072ee37a2c7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_10c682d6-5208-4934-891d-ce3102d22a68_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down of assets held for sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_543210b0-ac59-4e03-8d8b-dba83dd0969d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_c57e57b4-4f6a-454e-a18f-58c7e60c6e20_terseLabel_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member" xlink:href="mrk-20201231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375eurodenominatednotesdue2036Member" xlink:to="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c8c56b83-9756-43cc-971e-a88668947bcd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_cb9adc31-8d85-4f43-a81a-e0c37b4b31e1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_0d1fe0c4-1388-4833-a8d6-579355bc5725_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_3ac03c3c-4665-45ca-ab04-3e50bc540a4d_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018)</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6cb002d2-4bd7-4e53-83c7-e2cb242950c6_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Tax Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c704322e-b99c-4cae-a6ba-7842414573ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef56c62a-f1e5-4737-a889-98d06ef73519_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_5101e8f9-e338-44bc-9ac1-b6a928fb0402_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_67191878-6780-4640-839f-62eea836ab66_terseLabel_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Company's pension investments categorized as Level 3 assets (as percent)</link:label>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_label_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Pension Investments Which Are Categorized As Level Three Assets Percentage</link:label>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_documentation_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company pension investments which are categorized as level three assets percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:href="mrk-20201231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:to="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8cb66513-31bf-4bcd-8575-0c684a9e2cc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_39a113a9-c078-43ec-8b82-12436dab0642_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_0c265649-dcd1-4550-bdfd-7e737c09a40c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_737b0725-ce2c-41a9-872a-988ee90b0d99_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_311ab4c8-5029-43e5-85c4-d86356b77e34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InvanzMember_24959098-a47b-4f1a-b846-b63dc66a7d31_terseLabel_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz</link:label>
    <link:label id="lab_mrk_InvanzMember_label_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member]</link:label>
    <link:label id="lab_mrk_InvanzMember_documentation_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember" xlink:href="mrk-20201231.xsd#mrk_InvanzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InvanzMember" xlink:to="lab_mrk_InvanzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_32074782-004b-44b0-b1f8-026b0696b0c7_terseLabel_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_label_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_documentation_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation" xlink:href="mrk-20201231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ChargesRelatedToProgramDiscontinuation" xlink:to="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_9d3630e3-42d9-497d-9872-4f1c60c66f3e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right to reclaim cash</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_93058d47-49c6-4a68-98ea-bccf7b02a482_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Right to Reclaim Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_217b6545-dec9-4317-811b-57c23865fa50_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a203b839-6ebe-4424-a50d-8009bda32b8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_40e35d9a-ecba-4b41-927b-d92f672bcbee_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_a1ac3b05-ee62-4440-8f38-3a9fd3699fed_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArcoxiaMember_f810c738-b270-4066-af69-04e592d01b36_terseLabel_en-US" xlink:label="lab_mrk_ArcoxiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcoxia</link:label>
    <link:label id="lab_mrk_ArcoxiaMember_label_en-US" xlink:label="lab_mrk_ArcoxiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcoxia [Member]</link:label>
    <link:label id="lab_mrk_ArcoxiaMember_documentation_en-US" xlink:label="lab_mrk_ArcoxiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcoxia [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArcoxiaMember" xlink:href="mrk-20201231.xsd#mrk_ArcoxiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArcoxiaMember" xlink:to="lab_mrk_ArcoxiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_eeb1193d-bc9e-49a4-8b18-48c582468b9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_74ff2ab6-4273-4f8c-b1ce-18107aec9299_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, Assets</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_label_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Unrecognized Tax Benefits</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_documentation_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets unrecognized tax benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:to="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_cb13e7a4-252d-43cf-a4b3-409c4aa07d3d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_709e4a83-550a-4159-9e43-c05fccf7fe52_terseLabel_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product return period</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_label_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_documentation_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:href="mrk-20201231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:to="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_4c94ca07-5c38-46d2-9eb2-816156e8d792_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_b00b3cad-f11c-49c6-b27e-29d55fb63467_negatedTerseLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Five, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Five, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:href="mrk-20201231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_90a645fd-9c35-4541-9a03-7596b18d950d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_cf63aa59-2a73-4b60-be47-37fbeb1b6f28_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ee73b11e-b3b4-4455-ae9c-d8e3cc52e767_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c45d4012-4aab-4c2b-b6d6-54ef2c2ee844_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member_c171ed6b-71e4-40e1-8b99-bae7458ec574_terseLabel_en-US" xlink:label="lab_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc.</link:label>
    <link:label id="lab_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member_label_en-US" xlink:label="lab_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member_documentation_en-US" xlink:label="lab_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member" xlink:href="mrk-20201231.xsd#mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member" xlink:to="lab_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_948d582e-ef9f-4f54-a462-1ce0156d5f4e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ImplanonNexplanonMember_6d93dfe6-4c7d-4bf5-ac76-7d49e8f2b806_terseLabel_en-US" xlink:label="lab_mrk_ImplanonNexplanonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implanon/Nexplanon</link:label>
    <link:label id="lab_mrk_ImplanonNexplanonMember_label_en-US" xlink:label="lab_mrk_ImplanonNexplanonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implanon/Nexplanon [Member]</link:label>
    <link:label id="lab_mrk_ImplanonNexplanonMember_documentation_en-US" xlink:label="lab_mrk_ImplanonNexplanonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implanon/Nexplanon [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImplanonNexplanonMember" xlink:href="mrk-20201231.xsd#mrk_ImplanonNexplanonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ImplanonNexplanonMember" xlink:to="lab_mrk_ImplanonNexplanonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_cb9b8e90-5359-41f9-b3c9-84631efbf874_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ca50d481-c7be-4084-a8d9-e9c406e48807_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_9f16c0c4-b3fe-4fc2-8c38-3e2be65c29ad_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_f33466df-de93-470f-a310-dc8159dcc1a7_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementsAbstract" xlink:to="lab_mrk_CollaborativeArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_be32c061-5dda-4f23-aa04-b905b444590e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in AOCI by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89a53d04-eb25-4382-a149-f5798d18c7d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_1c72a0e4-e352-4260-bdaf-20129890c0fc_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_f702fa7d-2614-42f9-ae62-71339d9b659a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_bf4ef726-8271-4da3-8c26-ecd8d2c31034_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f12ca6b6-1dc3-4eac-a733-3de1145897c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VioxxMember_ee29918e-e1db-4f34-b563-5f44a1248a56_terseLabel_en-US" xlink:label="lab_mrk_VioxxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vioxx</link:label>
    <link:label id="lab_mrk_VioxxMember_label_en-US" xlink:label="lab_mrk_VioxxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vioxx [Member]</link:label>
    <link:label id="lab_mrk_VioxxMember_documentation_en-US" xlink:label="lab_mrk_VioxxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vioxx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VioxxMember" xlink:href="mrk-20201231.xsd#mrk_VioxxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VioxxMember" xlink:to="lab_mrk_VioxxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_9ea73136-e33c-4e4f-b668-babb8e296eb4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_769b5706-a949-4d3c-a36f-6e80b87f92d8_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_f9856513-dc85-435b-b542-5de4a6ef7919_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_aac4723f-64df-4060-8f13-9d3a2afd3124_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_c5c7a3ec-8bb5-4869-9218-9bb0ae48859a_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_f3158bc8-6d4d-47a3-9d4d-da2df59d08b3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_a0026f48-08d1-483a-816c-2f501f719579_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5562b394-8b0f-4709-aa26-bf98bad7c64e_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_9226fbe8-13bc-43e1-b4ff-ed5afeae518b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_38e75aff-63c4-4bab-8d57-c607f157bb17_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on contract termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_4249d231-3874-4e45-8100-d4df72c4e431_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge related to the termination of a collaboration with Samsung</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnContractTermination" xlink:to="lab_us-gaap_GainLossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_60155222-86a3-461d-a503-20cb8238901b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_194b0cb1-dd1c-4907-8f9e-d79c77e8dec0_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_74452cde-3149-4abf-83f5-208aab37ae42_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_23b7a8fb-8f34-4d5a-9408-b52beef6c4e5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received from counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_a91a108a-7e45-43b8-9b82-c9ec323d79e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_5a98117f-c3bb-4b94-b4e2-ee9608fb0e7d_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs, including amortization</link:label>
    <link:label id="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Amortization Of Purchase Accounting Adjustments</link:label>
    <link:label id="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to amortization of purchase accounting adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:to="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6c7c107-e941-4fc6-bf8f-eb57e3c10648_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_ef089d35-3ab7-48d3-b50f-2b5db452b077_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a6a24ed-3b60-42ad-b381-ee6914b3e89f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_709fb8c9-79bf-4bd0-a2fa-0f16d4fa2b98_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BayerAGMember_7c73b811-7ca9-4b42-ade6-4e171f6e4ddb_terseLabel_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG</link:label>
    <link:label id="lab_mrk_BayerAGMember_label_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:label id="lab_mrk_BayerAGMember_documentation_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember" xlink:href="mrk-20201231.xsd#mrk_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BayerAGMember" xlink:to="lab_mrk_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_22a8306e-534c-4252-86db-ca2cbd610cba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8d64cb08-b7b2-4603-8944-050b83163e6d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_19ad4e92-8cb8-4433-bea5-022c67540831_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate applied to income before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_58715a1a-df6c-488e-9c6e-4d16b60c49a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_9dd87732-8e08-4399-82e9-35758a770a92_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Capitalization</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c2fc7973-09af-42c0-989e-2e2d42e63027_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_feae2006-6dc2-48f1-bdbc-2fe12e46b555_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_d5b4ddfd-45ec-4871-8409-af29ddc8b7ba_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_16537566-c3ef-4f58-a418-2d9f27ce1ddb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArQuleMember_88dc0330-6201-4f31-9280-d14509377c83_terseLabel_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule</link:label>
    <link:label id="lab_mrk_ArQuleMember_label_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule [Member]</link:label>
    <link:label id="lab_mrk_ArQuleMember_documentation_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember" xlink:href="mrk-20201231.xsd#mrk_ArQuleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArQuleMember" xlink:to="lab_mrk_ArQuleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_08962faa-7543-4617-bfe0-20cb5f49a277_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_3c8e440d-8272-4a53-80cf-cb497618dbc2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_812420a5-1827-4384-93b8-a949fc76484a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member_28811cd0-99d5-489c-8304-0edc5b10fc5c_terseLabel_en-US" xlink:label="lab_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement, October 29, 2018</link:label>
    <link:label id="lab_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member_label_en-US" xlink:label="lab_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement, October 29, 2018 [Member]</link:label>
    <link:label id="lab_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member_documentation_en-US" xlink:label="lab_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement, October 29, 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member" xlink:href="mrk-20201231.xsd#mrk_AcceleratedShareRepurchaseAgreementOctober292018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member" xlink:to="lab_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LegalDefenseCostsMember_f8d9dc51-035d-4146-8965-62b0f2dda92c_terseLabel_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_label_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_documentation_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember" xlink:href="mrk-20201231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LegalDefenseCostsMember" xlink:to="lab_mrk_LegalDefenseCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_839ebc80-f2c4-4506-bab8-49a00b391c5a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_44e56a4c-efca-4e07-8624-84f60a871be9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Derivative Pretax (Gain) Loss Recognized in Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_03ba8c98-92d9-4712-aa50-46fbe74fcc1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_853a936b-9990-402c-9ed4-678466d6ebfc_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_4a378bf4-9d57-48fd-9996-4eee81081827_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax for accumulated foreign earnings, liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1b43c17a-66c9-4676-b793-118946e0ebce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_55843a5a-76b2-4540-a98e-180dbbc96d7d_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesDiscounts_db0de56e-a62f-40d7-a5ba-44fd79973f52_terseLabel_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_label_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_documentation_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts" xlink:href="mrk-20201231.xsd#mrk_SalesDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesDiscounts" xlink:to="lab_mrk_SalesDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1177bf1a-5944-4294-921d-f2adebf7b042_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_c547cd11-b4aa-4bd5-b6f5-655bf05b994a_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, equipment and office furnishings</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AstraZenecaMember_37d8ee4f-012d-41b7-bba8-f3cd73ef14a4_terseLabel_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_label_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember" xlink:href="mrk-20201231.xsd#mrk_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AstraZenecaMember" xlink:to="lab_mrk_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_4670c8fe-211f-4983-9630-f48095a213af_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_b1c0436e-8731-4446-a5d3-4f4ccba9fb6a_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and promotion costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_4771d0cc-427d-4727-a08a-3e1dcf96524f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_031f23f7-67ee-414d-a6ea-76fd9f1e1510_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_c364a724-a25d-44c5-8336-3de1aea514c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_cc3d75a8-93fb-4ff6-9098-6f08d485109f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0dd7530e-2191-4588-bcf8-fed8fdbac652_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_174ab4fa-2204-49bd-a8cf-7fe5788b57f4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_8efe4464-10a1-4d6a-b2b7-2a91f5bc1125_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_d86ffd7d-0b3b-43ec-a39a-7a2cb58d4eb6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a7c58334-f249-47a6-87a4-26a19c15a62b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_290053c6-13c2-4ea4-8460-d55c9b508a42_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_f44554a5-28f0-426c-9cac-d469db9ae385_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_599fbe60-ae73-4556-bba2-334e229c84e7_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_29ece7da-4891-4d2c-8d00-1afeeef5eaf3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of loans payable and long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_c014cb64-3ecb-4df9-8cad-ee3590974c93_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember" xlink:href="mrk-20201231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueKoselugoMember" xlink:to="lab_mrk_AllianceRevenueKoselugoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeInvestmentsMember_818c1239-bbb2-4f53-8cfb-5185cb5c7f60_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Investments</link:label>
    <link:label id="lab_us-gaap_FixedIncomeInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeInvestmentsMember" xlink:to="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_9052762f-06b6-4d7b-826c-513db3202a26_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_450dd50e-ea13-4a2f-9648-349d57ccfe07_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_be5d2bae-c912-42ca-b200-11c9a04f939f_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_94aae91c-82fd-4d04-a946-ee1552d42372_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_c796db6b-f600-489c-b4f6-5dd7a8fa20f6_verboseLabel_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset backed-securities, Fixed income securities</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Asset Backed Securities Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset backed securities fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:href="mrk-20201231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:to="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_ab0f9285-4bad-4d10-b5a7-231d0f008752_terseLabel_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% notes due 2029</link:label>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_label_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_documentation_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member" xlink:href="mrk-20201231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.40NotesDue2029Member" xlink:to="lab_mrk_A3.40NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_dbd1f44f-4a04-49ae-ba46-08d471b06936_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_936c621d-caa5-4a10-9cf7-f8a60af52cae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_c359b3f4-de54-418f-8dcb-8cce03fb4ff8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax settlements</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueAdempasMember_de0186a0-025f-4ed4-8c55-6ee6465807df_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas (2)</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasMember" xlink:href="mrk-20201231.xsd#mrk_AllianceRevenueAdempasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueAdempasMember" xlink:to="lab_mrk_AllianceRevenueAdempasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3f1b7f7-139e-4680-ba8a-755a88efc113_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_920a8e4a-bbf8-4b50-92b5-54759e567a4f_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ca94b28b-b3f9-483f-8624-bcb4b47658e8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_b7a5bfec-208a-4c72-8704-886c0935c061_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7d9114c3-848d-4d18-a5cb-d8e8fa580785_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_067ffa61-89b8-45df-ada3-645a656fbe35_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_ac06a039-c2d1-456f-8fd7-1fa738505440_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_db93324a-3e84-4652-9f87-292440ac133a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculations of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_132b3bf0-9402-47c0-a4f5-87c153361d85_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation payments to settle equity awards attributable to precombination service</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_63219f7d-5829-4a82-a9aa-f7e9424bb4f9_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_3bbee3ac-28ab-4ea1-81b3-e03da5a4f986_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_e11313f1-12b4-4df1-b5e7-6c1c8ddd159e_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5cc7dce2-cfc8-4caf-8a10-303f7c1f81ba_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_cf5fe333-7bf2-4c7f-9d8a-b694a02ccfda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_4f76e941-b1dd-465d-b046-e65cdd4c583a_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments made to collaborative partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:href="mrk-20201231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:to="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_bb3d3feb-fe0c-457f-8bc0-736225e695af_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_e19497fc-7074-4556-bbf2-e4d2c76dacd4_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value discount rate</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput" xlink:href="mrk-20201231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetMeasurementInput" xlink:to="lab_mrk_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_cd6f2d13-d42a-43a6-82cd-eed00209a078_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_59f41928-93a7-4a57-94a3-b7f76942a099_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8c9a87db-6f1f-416e-974b-ea107d5868c6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_27d7149f-591b-4761-aa92-a2d6de9e1a6c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b79a04a1-9d03-49b8-bbed-079d6296968c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_647d6633-c365-48e4-96b1-f06d4b290269_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c98343ef-f561-4fe3-872a-87b392b9dda5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SentinelMember_1d1224da-c8ee-458e-9d7b-c4e9c67f49f7_terseLabel_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel</link:label>
    <link:label id="lab_mrk_SentinelMember_label_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel [Member]</link:label>
    <link:label id="lab_mrk_SentinelMember_documentation_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember" xlink:href="mrk-20201231.xsd#mrk_SentinelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SentinelMember" xlink:to="lab_mrk_SentinelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59b9d33b-f967-4620-84ab-b81cb478b8b8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_5f803602-34d8-4f38-8582-c9ad47cd4485_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck&#8217;s profit share of sales in marketing territories</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementProfitSharing" xlink:to="lab_mrk_CollaborativeArrangementProfitSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_be135fc6-f21d-4c08-9ca2-cb3578c091bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_07610b16-3b90-40e8-8f38-4de259a1c175_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d935b628-f564-4d46-bde4-0753305c6fa3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_0caa5bf3-2690-4755-81af-049a3173a477_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7795337a-ae43-4eae-a828-5290fefe91bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_9533cd03-508c-4584-a874-962a9b166a0f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate (as percent)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_155645aa-cf55-4ac5-9706-9ea8c2f452d9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_296f339f-77c0-460b-a870-627290e210a2_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic defined benefit plan (credit) cost other than service cost</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e9fe7180-c247-4222-b12d-7a1621472fab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e9bcfca-aa1f-44f6-b7a8-9c5f1d231acf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0b366698-88c1-42b0-b80c-9909d47d9412_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_e852456d-370d-4d1c-85bb-39897b478e6b_terseLabel_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_8d3afcca-faeb-4f6e-8623-c54fff30b5de_verboseLabel_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member" xlink:href="mrk-20201231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.40NotesDue2022Member" xlink:to="lab_mrk_A2.40NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_012add2f-c668-43ae-8e7d-ee518613cb34_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_fea7dcb4-f7eb-4c45-b579-8c59787b9322_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ea5841df-5c61-40e9-91ac-5d199d8c0974_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a446f630-32e8-4b31-b057-3a19f4d695ee_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_590fd8b5-fb28-4496-8a6f-2f614a9750af_terseLabel_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% euro-denominated notes due 2034</link:label>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_label_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Euro Notes Due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Euro Notes Due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member" xlink:href="mrk-20201231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.5EuroNotesDue2034Member" xlink:to="lab_mrk_A2.5EuroNotesDue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_18ed1630-f75a-49d4-9c1c-afcd23a246de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_32898dfc-2c88-4435-9ad9-12a8672e031d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_717bc988-cec1-46a2-9987-6d69b7b86981_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_5dd88698-ef22-470a-b766-8350079f25b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.&#160;Dollar Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3dbe4a13-f829-411b-b968-08408e67c8c0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_5ae9f7c9-4e13-4461-b694-bbb8a975328b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Revenues by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_e3372f90-0304-4af0-8714-458d1a13de8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service (cost) credit arising during the period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_696a1880-371a-43ae-aebf-92060cf6739c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_0a6b1e1d-4115-4382-8242-1dd7f80838e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Three, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_bfaa925e-8d02-4cd5-ac7d-b2b430c35dfe_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_599117ba-2576-40cf-996a-e14e7f0079ba_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_2f4b1d38-f5e2-49cb-b10b-6c11f2be3057_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_97991c1f-4988-4fcd-a22c-3fc1df6ea716_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of ASU 2018-02</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2a07eafa-0a5d-4e20-91a9-aef4a3ca5c91_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BelsomraMember_85da68fc-32c8-4f07-8ceb-ede967b99592_terseLabel_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra</link:label>
    <link:label id="lab_mrk_BelsomraMember_label_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:label id="lab_mrk_BelsomraMember_documentation_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember" xlink:href="mrk-20201231.xsd#mrk_BelsomraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BelsomraMember" xlink:to="lab_mrk_BelsomraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_2612579a-9a0e-4aa0-b928-6c3899716b56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income on investments in equity securities, net</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_c6498e3d-4a6f-475a-a410-11e4ceba0a22_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_83a27439-262a-4b4a-b2e9-a6f5e0330e00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_4b81bc02-8597-4c74-9055-6ed54dbd6671_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_8e2d40e0-c1f6-4566-8945-25ac009b3e3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_b3a4c3d2-6710-4b47-8399-3b9df4dd53f8_terseLabel_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member" xlink:href="mrk-20201231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.500Notesdue2024Member" xlink:to="lab_mrk_A0.500Notesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LenvimaMember_7ed3d630-e7d5-4ad9-af7e-9a3c307720ae_terseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_189e2c5e-9556-40e0-8694-e3f4697dee7b_verboseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lenvima (1)</link:label>
    <link:label id="lab_mrk_LenvimaMember_label_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:label id="lab_mrk_LenvimaMember_documentation_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember" xlink:href="mrk-20201231.xsd#mrk_LenvimaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LenvimaMember" xlink:to="lab_mrk_LenvimaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_f966a744-df2a-45be-b7ba-13729d44a1eb_terseLabel_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="mrk-20201231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_039c7b2a-c42b-4e8c-94d5-81a0159e4b35_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_0dc0fcbe-19cf-4698-88c4-7680f0f14416_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a9258992-93ee-45dc-a63e-eef2fdb3521f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_014ff839-632c-4424-827c-e1ba5898abdd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plans and other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ffa333f4-ea3e-42da-bed4-a4897d28e382_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e5b75339-2c80-4aea-a5ca-65a36f5f70d6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6435931e-b521-4db0-842d-72791099fbdd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EnvironmentalRemediationSiteAxis_b951cac0-69cb-482f-ac3b-a8bd89b1b045_terseLabel_en-US" xlink:label="lab_us-gaap_EnvironmentalRemediationSiteAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Site [Axis]</link:label>
    <link:label id="lab_us-gaap_EnvironmentalRemediationSiteAxis_label_en-US" xlink:label="lab_us-gaap_EnvironmentalRemediationSiteAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Site [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalRemediationSiteAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalRemediationSiteAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EnvironmentalRemediationSiteAxis" xlink:to="lab_us-gaap_EnvironmentalRemediationSiteAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1ea263cb-72f5-4ceb-ba6f-dfb65db7661d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_07485038-0f9c-4b2d-bab4-e6427800e3d9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_105261c8-987a-4966-a3dc-184e635a13b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock_b0b83082-e6b5-4be3-99a0-dc47ad75c113_terseLabel_en-US" xlink:label="lab_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Divestitures, Research Collaborations and License Agreements</link:label>
    <link:label id="lab_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock_label_en-US" xlink:label="lab_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Divestitures Research Collaborations And License Agreements [Text Block]</link:label>
    <link:label id="lab_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to acquisitions, divestitures, research collaborations and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:href="mrk-20201231.xsd#mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:to="lab_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_9f6f39de-43ea-4542-98ab-1c606573f58c_terseLabel_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_label_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member" xlink:href="mrk-20201231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875Notesdue2026Member" xlink:to="lab_mrk_A1.875Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SingulairMember_ed33b174-ed2d-4e14-afdf-4bd774543fec_terseLabel_en-US" xlink:label="lab_mrk_SingulairMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singulair</link:label>
    <link:label id="lab_mrk_SingulairMember_label_en-US" xlink:label="lab_mrk_SingulairMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singulair [Member]</link:label>
    <link:label id="lab_mrk_SingulairMember_documentation_en-US" xlink:label="lab_mrk_SingulairMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singulair [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SingulairMember" xlink:href="mrk-20201231.xsd#mrk_SingulairMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SingulairMember" xlink:to="lab_mrk_SingulairMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_43b37656-b86e-4549-8c54-601d90169914_terseLabel_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% debentures due 2028</link:label>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_label_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Nine Five Percentage Debentures Due On Two Thousand And Twenty Eight [Member]</link:label>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_documentation_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point nine five percentage debentures due on two thousand and twenty eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:href="mrk-20201231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:to="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0808236e-ba53-4eab-802b-ab08912f5ea2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_550e805d-2a0f-4530-ac24-78d46b8f17bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_14ff4fff-0314-4857-8861-b65c008b85e6_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of the United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZepatierMember_aeb7d7ee-5d6d-4008-82e2-82b1a72b35f1_terseLabel_en-US" xlink:label="lab_mrk_ZepatierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zepatier</link:label>
    <link:label id="lab_mrk_ZepatierMember_label_en-US" xlink:label="lab_mrk_ZepatierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zepatier [Member]</link:label>
    <link:label id="lab_mrk_ZepatierMember_documentation_en-US" xlink:label="lab_mrk_ZepatierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zepatier [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZepatierMember" xlink:href="mrk-20201231.xsd#mrk_ZepatierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZepatierMember" xlink:to="lab_mrk_ZepatierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateAxis_5f753f36-0432-449e-af2f-32417c7ac8bc_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateAxis_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_3eb84c87-7f15-49bc-ac44-bcc3ee4f74c3_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims on appeal, number</link:label>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_label_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims on Appeal, Number</link:label>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_documentation_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims on Appeal, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber" xlink:href="mrk-20201231.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyClaimsonAppealNumber" xlink:to="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bbd50dae-8d69-4d7b-9346-fe836e4746d9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.45notesdue2050Member_dd77591e-40a1-47f2-b2f5-30ca4a0135c8_terseLabel_en-US" xlink:label="lab_mrk_A2.45notesdue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050</link:label>
    <link:label id="lab_mrk_A2.45notesdue2050Member_label_en-US" xlink:label="lab_mrk_A2.45notesdue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050 [Member]</link:label>
    <link:label id="lab_mrk_A2.45notesdue2050Member_documentation_en-US" xlink:label="lab_mrk_A2.45notesdue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.45notesdue2050Member" xlink:href="mrk-20201231.xsd#mrk_A2.45notesdue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.45notesdue2050Member" xlink:to="lab_mrk_A2.45notesdue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0995b9d3-5221-42a0-b5f2-a8bd9690e357_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of (loss) gain recognized in OCI on derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SiteContingencyTable_f4f57e91-9770-4daa-879f-646441b5cf31_terseLabel_en-US" xlink:label="lab_us-gaap_SiteContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_SiteContingencyTable_label_en-US" xlink:label="lab_us-gaap_SiteContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SiteContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SiteContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SiteContingencyTable" xlink:to="lab_us-gaap_SiteContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8fd136b3-c3c8-48dd-a0c0-e97b07ea7432_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_bd2b1255-c680-49c8-82fa-9b6e36e2083b_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ImmuneDesignMember_66f0ae87-a593-408c-9dcd-59c30da76084_terseLabel_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design</link:label>
    <link:label id="lab_mrk_ImmuneDesignMember_label_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design [Member]</link:label>
    <link:label id="lab_mrk_ImmuneDesignMember_documentation_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember" xlink:href="mrk-20201231.xsd#mrk_ImmuneDesignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ImmuneDesignMember" xlink:to="lab_mrk_ImmuneDesignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_COVID19Member_d4a80b98-eb89-40bb-954c-3540958b7a55_terseLabel_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_mrk_COVID19Member_label_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_mrk_COVID19Member_documentation_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member" xlink:href="mrk-20201231.xsd#mrk_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_COVID19Member" xlink:to="lab_mrk_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ae94852e-116b-4808-a226-2bc2d16a5e7d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AtozetMember_f5286f79-514a-4970-b39b-55d79ea2dce2_terseLabel_en-US" xlink:label="lab_mrk_AtozetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atozet</link:label>
    <link:label id="lab_mrk_AtozetMember_label_en-US" xlink:label="lab_mrk_AtozetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atozet [Member]</link:label>
    <link:label id="lab_mrk_AtozetMember_documentation_en-US" xlink:label="lab_mrk_AtozetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atozet [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AtozetMember" xlink:href="mrk-20201231.xsd#mrk_AtozetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AtozetMember" xlink:to="lab_mrk_AtozetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_ff283721-65f6-4342-8284-09c9bad35951_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Peloton</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryTable_72528eb5-3304-4ce1-b27b-13e96a282a13_terseLabel_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_label_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_documentation_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable" xlink:href="mrk-20201231.xsd#mrk_InventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryTable" xlink:to="lab_mrk_InventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_748c448b-6f49-40c8-a7d4-b631ab9632cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_dd487bc9-7e07-4886-aca7-edc1d59f12f8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total segment profits</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_586c7711-4c0e-4515-b5f5-6db18a277c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3f70a92d-abcd-4eb4-811d-6a3012417ca1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_74d86503-a2c5-42bf-b7f8-5de9588d0fa4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_d9489271-ee0d-44f8-8409-00b3da8405b9_terseLabel_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_label_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Other Changes Plan Assets</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_documentation_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in plan assets, not otherwise separately disclosed in the financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:href="mrk-20201231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:to="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2d94c93a-0b6f-41fe-8bcd-3de5b32ecd97_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_3d7da584-5388-4e8d-83ad-4b1fb8dce680_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_7967100b-4429-4bfb-a535-bfb866ee0b6b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_2fc60809-8e51-478d-aa32-1351a088f2ae_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b1963dce-111f-40a7-8f7c-241574d713bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_b5404c3c-a035-4ed0-b9b3-23b6701dd64d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_b6242278-6c79-4492-b443-226065c6c1c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory related, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_7d0e43b6-e821-49ea-b0de-9d6defa317a2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance on foreign NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_32387e5c-4fc4-463c-aa64-3d3b9e3446c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RecognizedAsAbstract_1e3bb711-ade5-4623-bb40-36da47ba106d_terseLabel_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_label_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized As [Abstract]</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_documentation_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract" xlink:href="mrk-20201231.xsd#mrk_RecognizedAsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RecognizedAsAbstract" xlink:to="lab_mrk_RecognizedAsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleratedShareRepurchaseAgreementMember_b9d25b57-4ca8-4c2e-bca2-4e2bfffb4cf0_terseLabel_en-US" xlink:label="lab_mrk_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement</link:label>
    <link:label id="lab_mrk_AcceleratedShareRepurchaseAgreementMember_label_en-US" xlink:label="lab_mrk_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement [Member]</link:label>
    <link:label id="lab_mrk_AcceleratedShareRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_mrk_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedShareRepurchaseAgreementMember" xlink:href="mrk-20201231.xsd#mrk_AcceleratedShareRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleratedShareRepurchaseAgreementMember" xlink:to="lab_mrk_AcceleratedShareRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_75c29ebe-a3d1-484b-8ee4-ae1eb0188d3a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8a8bbbe0-d610-4251-9b61-9a1fc9f04926_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f2b7851f-18bc-4c4e-8006-5ac44850fe41_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrimaxinMember_6d8c392f-7942-4b34-9e35-accf0200bbba_terseLabel_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin</link:label>
    <link:label id="lab_mrk_PrimaxinMember_label_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member]</link:label>
    <link:label id="lab_mrk_PrimaxinMember_documentation_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember" xlink:href="mrk-20201231.xsd#mrk_PrimaxinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrimaxinMember" xlink:to="lab_mrk_PrimaxinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_179cd49e-8693-4f43-849a-afb1ec6aa87e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_a05be6c7-8df5-4651-b368-6fe6d1bf537e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_01a3562f-826f-46b4-9b39-31f4a3ce737d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_0dc119a2-d274-468c-9575-0095647d350d_terseLabel_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to partner as part of collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="mrk-20201231.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_a1570560-5be5-4116-a018-a8052d285cf1_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_1fd0752c-0317-4c01-a74c-b6e81ed60706_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_676ff116-8547-4b37-a16d-ea6571b76850_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_label_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:href="mrk-20201231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:to="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b3e4df83-ed89-490f-ba96-39e5c7cea3a9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_7eceb8af-6d1a-4f8a-88ea-b44f9a1946df_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage estimate of cumulative pretax costs that will result in cash outlays (primarily from employee separation expense) (as percent)</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:href="mrk-20201231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_02e22f70-8f30-4816-9d0a-70f53a6538ac_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Peloton</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VaqtaMember_876e2521-b0fb-4437-9c10-0ae3f2d7b4a4_terseLabel_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta</link:label>
    <link:label id="lab_mrk_VaqtaMember_label_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:label id="lab_mrk_VaqtaMember_documentation_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember" xlink:href="mrk-20201231.xsd#mrk_VaqtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VaqtaMember" xlink:to="lab_mrk_VaqtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6486577a-3c05-4cbe-9f83-f459d9137044_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_ec20021a-55be-4f29-8372-28111e67105a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased currency options</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeOptionMember" xlink:to="lab_us-gaap_ForeignExchangeOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_eeeae3f3-0ed7-44f5-8733-cae777a78f5d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_63086980-8c19-471b-91df-9f72ee0330a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which share-based payment awards vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e3d0fc36-a526-4e97-96a6-ae0bea793987_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NoxafilMember_d7660df3-2fd3-40e6-bb68-f8964b371dd0_terseLabel_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil</link:label>
    <link:label id="lab_mrk_NoxafilMember_label_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member]</link:label>
    <link:label id="lab_mrk_NoxafilMember_documentation_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember" xlink:href="mrk-20201231.xsd#mrk_NoxafilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NoxafilMember" xlink:to="lab_mrk_NoxafilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_11ab995c-0685-41b0-98fa-01a68ac944b6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_0ed4ddbc-0f4c-4705-9221-0620f15946f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_dc2329e3-38cd-407a-adf2-0b1a893f363d_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_d623a276-31e7-4933-ae58-780b67750446_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion, and Amortization [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3cd4cba8-c99d-4299-8f07-5c4ffd243123_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D tax credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9cfdcd2b-e5cb-42a5-b6b5-24843239e77a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_dd48e21f-2708-4f5a-94bb-a1e8c5427953_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_2fa62a07-b9d3-4df0-96e6-6bb90aec66aa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_c5f4b086-1f40-430e-b7d1-d8321a6b077b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_b0f74360-9533-4277-bf5e-f42a69d41fe8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International equities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4a16df35-8b97-43ff-a27e-c0a15c6720a3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_916c0f2e-9885-41d4-b74f-0358efa26e9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_96ab0c70-1fda-4ea2-af0d-790d9a0b3f53_terseLabel_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_label_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad MMR II Varivax [Member]</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_documentation_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:href="mrk-20201231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:to="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2ff3c00a-0617-4eb2-b358-ed1f56021481_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_b8cba7b0-5302-4b17-b0b7-3af52e0b11f9_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d54cb3a3-ec5a-43fc-ac1e-25ba1ed69426_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Between Effective Tax Rate and U.S. Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9e0fc702-7c8a-4ca6-9fc4-becfa80fd256_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_b1a259a5-e6c8-4b87-9ff7-776fa061844d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary growth rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_231a862c-88c8-46b2-af48-8aabf2e20282_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific (other than China and Japan)</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_97a42780-d104-41fc-b37f-7508a43bbe3f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_11f050fd-cc2a-4aca-b24f-d13b43faad49_terseLabel_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Other Investments</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_label_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Other Investments [Member]</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_documentation_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:href="mrk-20201231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:to="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_fd367038-00f7-48fc-b8ec-fa3564ec2bb6_terseLabel_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:href="mrk-20201231.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_f58e7154-73f2-4109-83e4-f2202d452579_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_81b3119e-448c-4c5a-81f2-3df27f7b8198_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_9ab94f72-3c91-4cf7-8c7a-6be079ec070e_totalLabel_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and publicly traded equity securities, fair value</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_label_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_documentation_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:href="mrk-20201231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:to="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_d90f337d-9887-4825-81e2-21cfecd9acc9_terseLabel_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Litigation</link:label>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_label_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Other Litigation [Member]</link:label>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_documentation_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Other Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember" xlink:href="mrk-20201231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CommercialandOtherLitigationMember" xlink:to="lab_mrk_CommercialandOtherLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_7b8cb09b-979f-4c96-a9cf-26e59645ef52_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_618f51c8-930d-4d1b-9207-a58faec6198e_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f4490080-11b0-4f57-930b-b7f1e2bdfe98_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a7605099-7728-49d3-80a6-28e9875be8c3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_81c4fe32-cde4-4cdd-8126-c3048b57594a_terseLabel_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% notes due 2039</link:label>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_label_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% Notes Due 2039 [Member]</link:label>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_documentation_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% Notes Due 2039</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member" xlink:href="mrk-20201231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.90NotesDue2039Member" xlink:to="lab_mrk_A3.90NotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_f2972eb0-2d44-447e-99b9-7850996e9789_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:href="mrk-20201231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_0a16e384-cb13-4050-ba79-4b7e8b5fff9b_totalLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CozaarHyzaarMember_d0c6533b-c2eb-427f-b879-a149f8aac071_terseLabel_en-US" xlink:label="lab_mrk_CozaarHyzaarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cozaar/Hyzaar</link:label>
    <link:label id="lab_mrk_CozaarHyzaarMember_label_en-US" xlink:label="lab_mrk_CozaarHyzaarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cozaar Hyzaar [Member]</link:label>
    <link:label id="lab_mrk_CozaarHyzaarMember_documentation_en-US" xlink:label="lab_mrk_CozaarHyzaarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cozaar/Hyzaar [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CozaarHyzaarMember" xlink:href="mrk-20201231.xsd#mrk_CozaarHyzaarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CozaarHyzaarMember" xlink:to="lab_mrk_CozaarHyzaarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_5a7ac798-1ff2-46a1-96de-9798b4b08967_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_77709df4-de02-4e5c-bb97-53b70b1631cb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4b048c03-d2e7-4d1e-8dfe-a8056e7ba220_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a7331b2c-910c-4f02-9bb6-5d3f151c0c40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax share-based compensation cost</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_33644699-675b-4347-a7ee-4556fcac20be_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_be60dcea-4b20-4fa9-8c92-5103b5f61d33_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_f174c01e-e31a-401e-80b9-4b099ad7029e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire productive assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_74a13d3f-bdac-4a60-a697-b2c79f406b9f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims dismissed number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_5e620778-cfcf-4f74-b40d-f0e5804cfbfe_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_dbfc84b0-db25-4390-bba7-6aaf70c1184a_terseLabel_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.55% notes due 2037</link:label>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_label_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Five Five Percentage Notes Due On Two Thousand And Thirty Seven [Member]</link:label>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_documentation_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point five five percentage notes due on two thousand and thirty seven.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:href="mrk-20201231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:to="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_d49f1153-d7e4-4ed4-90fd-9638d22b7fd6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_277c7b40-b64a-47fe-ada6-e79f4b1249e0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_eb6ff066-8407-4af4-9c3b-59ed9752babe_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_39fcebcf-03cb-4bb2-81a8-c46a7b7fea9c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b82e2af2-2a9e-4939-b754-2ecf457815f8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_23f53ecb-73fd-433e-b103-8cb5bb6719b5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_23ed277a-38b8-49f8-9e99-4ba4880146d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PensionPlanNetLossMember_7ae31f89-5bc0-4c1f-bba0-8fce934368cc_terseLabel_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss</link:label>
    <link:label id="lab_mrk_PensionPlanNetLossMember_label_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss [Member]</link:label>
    <link:label id="lab_mrk_PensionPlanNetLossMember_documentation_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember" xlink:href="mrk-20201231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PensionPlanNetLossMember" xlink:to="lab_mrk_PensionPlanNetLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_1ef05b86-bb64-46b7-ae1c-d43e6af04d68_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum planning cycle of hedges (no more than)</link:label>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Average Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_dd00b450-bc4a-4a47-bb7f-f5f6b66b6990_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_9a2d2465-1671-45b1-88a6-78ce882f2133_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_b9e406f9-91ca-4c1d-ab13-05b63cad3f32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_824d27fe-8e82-4216-ad76-ad81cab4bcf7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4944034d-c542-4e15-81f9-5fe6348d526a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_979e80a7-fc24-458d-a493-a4be250958c0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_76cf9e6e-077c-48af-8d74-7bb93f15dd97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on derivatives, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_cb9be5aa-6a92-45f9-b7cf-95ddec55903a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, pending claims number</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_5294e854-a4a0-477b-9470-59e822fe6a24_terseLabel_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember" xlink:href="mrk-20201231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesBasedMilestonesMember" xlink:to="lab_mrk_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_293d3496-b9b9-453e-b84e-378ed7ae62c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_ca4ef5c2-ebee-4938-884f-723c017a154f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PartnershipInterestMember_51592a2a-14e1-40fb-a82d-f79ecac18108_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca LP</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_label_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember" xlink:to="lab_srt_PartnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1c4f5d03-8126-49be-8532-233c0e7affc6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d33ee930-080f-43ee-adb7-029aa3a78fe6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_5bc72b07-6f1a-48af-a9ea-e0c0c21b0a6a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_25d141e7-aee2-4e9a-941c-bfb3a1ef3b92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PatentlitigationMember_50714578-87df-4d09-8f5b-f2ebb11e47d5_terseLabel_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation</link:label>
    <link:label id="lab_mrk_PatentlitigationMember_label_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation [Member]</link:label>
    <link:label id="lab_mrk_PatentlitigationMember_documentation_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember" xlink:href="mrk-20201231.xsd#mrk_PatentlitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PatentlitigationMember" xlink:to="lab_mrk_PatentlitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_25e545f5-583f-4fcd-92b7-0c829c8b6866_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_f7942b9b-7ef3-4186-875a-11d1f71883bd_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable</link:label>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_label_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_documentation_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxesPayableMember" xlink:to="lab_mrk_IncomeTaxesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ThemisMember_b02c06b2-c8ce-4536-b8fe-de06987f1168_terseLabel_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis</link:label>
    <link:label id="lab_mrk_ThemisMember_label_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis [Member]</link:label>
    <link:label id="lab_mrk_ThemisMember_documentation_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember" xlink:href="mrk-20201231.xsd#mrk_ThemisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ThemisMember" xlink:to="lab_mrk_ThemisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d95259eb-c451-48b5-93ec-fb095bfdc528_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net Income (Loss) Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_efbed077-c2e8-4550-8aaa-738f139aa16e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_d4cf1069-1f2b-4958-b22c-465844914578_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8f5daf97-1b62-4008-b719-1ad68c9aaa34_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_e7aa0f4f-292f-4210-9534-5c348b20ae75_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7c80284e-439e-4dd4-8444-c4367916f4c7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3532d077-df5f-4419-9756-333e324e9b1b_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_80ae0b67-fc43-4249-bdf2-efb76f99f3a9_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_a4a00255-5bf0-4b6f-930f-8eb4365c6802_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_18205ecb-aad3-4d75-8d9c-b3d881d7ba2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9824eb8b-6088-48a6-a698-c2045176c298_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_025a659b-b509-42b4-b625-ed57dc630eeb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b8ccedde-237c-41fd-95d1-736b5143e8fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f5c614ff-3a1f-4c62-9145-5f4dc861370e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information Relative to Stock Option Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_af244f87-2484-485e-9bcb-e6d0f47d8a56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IAVIMember_9bc6fa2d-369e-4850-bc27-dc84f737c446_terseLabel_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI</link:label>
    <link:label id="lab_mrk_IAVIMember_label_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI [Member]</link:label>
    <link:label id="lab_mrk_IAVIMember_documentation_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember" xlink:href="mrk-20201231.xsd#mrk_IAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IAVIMember" xlink:to="lab_mrk_IAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LynparzaMember_f5e7911e-e8bc-40a4-b458-01ac026479f5_terseLabel_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza</link:label>
    <link:label id="lab_mrk_LynparzaMember_label_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:label id="lab_mrk_LynparzaMember_documentation_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember" xlink:href="mrk-20201231.xsd#mrk_LynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LynparzaMember" xlink:to="lab_mrk_LynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_df877e0f-a8b5-4ae4-84c6-5e8933c50907_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_9dc83fd9-dd01-4c1a-acf9-0f15adfad455_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4d2986b0-8e99-4a6e-8f65-650a03a224b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e9ac3266-0aed-45cd-94fe-adc6b6bb4b0e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_3b1b866d-f664-4b47-9840-c4b7bf4cea50_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_61a49b9d-1550-4b4d-8d35-292203fa5823_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Promotion Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CommercialmilestoneMember_3699c123-1dcf-4a3c-a010-56cac6ba58a4_terseLabel_en-US" xlink:label="lab_mrk_CommercialmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone</link:label>
    <link:label id="lab_mrk_CommercialmilestoneMember_label_en-US" xlink:label="lab_mrk_CommercialmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">commercial milestone [Member]</link:label>
    <link:label id="lab_mrk_CommercialmilestoneMember_documentation_en-US" xlink:label="lab_mrk_CommercialmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">commercial milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialmilestoneMember" xlink:href="mrk-20201231.xsd#mrk_CommercialmilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CommercialmilestoneMember" xlink:to="lab_mrk_CommercialmilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_c89d9180-fec6-421b-be79-5547d6aff6ad_terseLabel_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt</link:label>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_label_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt [Member]</link:label>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_documentation_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember" xlink:href="mrk-20201231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherVariableRateDebtMember" xlink:to="lab_mrk_OtherVariableRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8a1ad467-c309-447a-a4a5-d59ac5cd607d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_7ddeb9d3-8573-4588-bfa2-fef4cf81e3e5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementReceivable_384959fd-adce-4088-b998-aad140d929df_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from counterparty</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementReceivable_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Receivable</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementReceivable_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementReceivable" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementReceivable" xlink:to="lab_mrk_CollaborativeArrangementReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ad8ca0ab-2af6-4a0a-a1ec-bef88338794f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f5a289c0-0707-45a3-bdca-281b72449396_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_2f0878e2-6f6f-44b0-9ff2-b1ed74bcf14c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cb1a6546-040e-4f17-a1c7-463d110a2bf3_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_7b3bfbc9-8b1e-4081-b23b-5b3c7235a885_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0e1ed0d8-0137-40cb-bcd5-e60894fef56d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ffcc0988-6f23-4616-b4b0-2726bfb56d23_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_e5879d6d-39b4-446a-b3d7-5d84628d0871_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_40f9c5fb-5d23-4604-b846-2882eb0bed5c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_442b6227-43c2-49ba-a539-3af44a335762_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions_b497ae8e-f63f-4144-ad51-ffa1bcbd11c7_terseLabel_en-US" xlink:label="lab_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for future payments related to collaboration license options</link:label>
    <link:label id="lab_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions_label_en-US" xlink:label="lab_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for future payments related to collaboration license options</link:label>
    <link:label id="lab_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions_documentation_en-US" xlink:label="lab_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for future payments related to collaboration license options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" xlink:href="mrk-20201231.xsd#mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" xlink:to="lab_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b40e321e-0cbc-4894-8a9f-d904633819fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_24c0b854-2047-48d6-9fad-be335c9d7d7f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f395bfc4-494e-46f4-96a9-148702e3d95a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net of allowance for doubtful accounts of $85 in 2020 and $86 in 2019)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_f73ffbc7-b154-4b15-9605-56b291549c02_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_6f8682b7-3774-4b05-abcc-ac195edf8f18_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_186fd7c7-e765-4978-ad45-0510cdc63e45_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementExpenses_b6a24c61-6cd4-4cb9-b90c-96f569a88acb_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementExpenses_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Expenses</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementExpenses_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementExpenses" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementExpenses" xlink:to="lab_mrk_CollaborativeArrangementExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_daf3a6be-08e9-4155-876d-18e21f20d311_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_184cb50f-f90e-40b4-bcba-baaa04b4c33f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_adde819c-707e-429f-8c0a-a0d3bcb4c924_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_f4fabba0-9bb6-4db8-a7e3-7bc7a05d3acb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_7d4fb8ec-cdd9-4782-a6b4-b7e8fbd18fe5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_0520b61b-3032-42db-af83-ce0a884f45c1_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and other postretirement benefits, Liabilities</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_label_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_documentation_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:to="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5f1278ab-39a6-4f31-a26e-2b430cf93692_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventorySupplies_47734f99-f390-4cb4-9f5b-9afd624dc80f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_OtherInventorySupplies_label_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventorySupplies" xlink:to="lab_us-gaap_OtherInventorySupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_a7164ec6-ccb6-4c97-b546-e3ed60d170af_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) receipts, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ee940adb-9d14-41a5-b354-45e11f3e86ee_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6edafc13-28df-4eaa-9ed2-fefa1b60dffa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_9d8cd9a8-b978-4e4e-bb5b-a088c641e47b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits relating to stock option exercises</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_e1191751-317b-4b3e-bb7a-65c1dea389c2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relating to assets still held at December 31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c27665be-a324-48d0-9910-3f1aa9c142f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f003b1b6-f267-4f1b-876e-27887442d2a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_3f1e2cf2-5273-4fa8-bbff-b0ebd7daac4d_terseLabel_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2024</link:label>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_label_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_documentation_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member" xlink:href="mrk-20201231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.90NotesDue2024Member" xlink:to="lab_mrk_A2.90NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_093ae469-579f-45ec-9699-cbdf5ea77640_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_15e9afc8-0bcd-4f2f-8813-c33a21bbd8e5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_174da7d8-23e7-4bef-90cc-c2eb3f915117_terseLabel_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Credit</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_label_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Cost [Member]</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_documentation_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:href="mrk-20201231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:to="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_c6314eb1-9bcf-45e7-b7ef-3ce4ff2b9ac0_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_94c6cfc1-0e42-4426-b0b5-c91916eb7dcb_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f972b90a-86da-4523-a2c4-a8b855462a89_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b4bac3c2-e60c-4ce6-99b8-e1f20fbe5175_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_542ae43a-01d6-4af8-b029-ed32e0436b65_terseLabel_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.40% debentures due 2028</link:label>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_label_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Percentage Debentures Due On Two Thousand And Twenty Eight [Member]</link:label>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_documentation_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point four percentage debentures due on two thousand and twenty eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:href="mrk-20201231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:to="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherCountriesMember_4dd37722-1b6a-4c55-a2e0-cce68c93a7c4_terseLabel_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_label_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_documentation_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember" xlink:href="mrk-20201231.xsd#mrk_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherCountriesMember" xlink:to="lab_mrk_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b6bdd2d4-a826-4e3a-87d2-b23d88febf29_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable net impact to income tax provision if unrecognized tax benefits were recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5faa680b-47f8-4a0d-8123-c8f7ac01596c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_102abed4-fefc-4e94-95f7-9cd40965f287_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_20a0b5f2-6e90-481c-ab91-5c7e0459269f_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_c1b2d843-8091-4327-ac3b-1daa310996ce_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_8aab7def-56b4-402a-a268-47d594d275a0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_640393e1-01a2-4480-93f0-99d68051b44f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary growth rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8cae0c97-b8a9-4b4b-87b0-ede414ff9050_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c9a970a7-d646-447a-85e7-d920e620ef77_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_11af2dd9-8d1f-4a0e-9f7b-f0dcbb55b55d_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_c4f7528f-1b6a-4815-bb69-cb2d436079f4_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_f7d03810-68f1-431a-8dc0-2f4af1786bae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment (at cost)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_a64d1e1a-4e44-4558-9b04-fc9b844521c6_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses and other tax credit carryforwards, Assets</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_label_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets operating loss carryforwards and other tax credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:to="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6407a85a-26db-47dd-a0b7-9b31f9edff8c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_ebbbf3db-eea9-4ce1-b428-45ceaacefc5a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NasonexMember_edc66790-14ed-4c44-aaba-8a75943f1841_terseLabel_en-US" xlink:label="lab_mrk_NasonexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nasonex</link:label>
    <link:label id="lab_mrk_NasonexMember_label_en-US" xlink:label="lab_mrk_NasonexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nasonex [Member]</link:label>
    <link:label id="lab_mrk_NasonexMember_documentation_en-US" xlink:label="lab_mrk_NasonexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nasonex [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NasonexMember" xlink:href="mrk-20201231.xsd#mrk_NasonexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NasonexMember" xlink:to="lab_mrk_NasonexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_945afb15-fe23-4559-b8e2-ae305573b7f2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_46b353a1-452b-4568-9e5c-24ceaecd8c75_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ccb918c6-f36e-49cd-85f2-eb903c2aaba8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ffd01e1f-b6bc-4477-bbb9-557ebe0a63e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c6a9226d-b207-4d69-b8ed-659545a0ccb1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_6f6365f6-74fd-4af6-92de-20d764b2ba2b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charge related to marketed product</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VelosBioMember_a0c14a3a-a179-4904-aee1-859aafdbe1d4_terseLabel_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio</link:label>
    <link:label id="lab_mrk_VelosBioMember_label_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio [Member]</link:label>
    <link:label id="lab_mrk_VelosBioMember_documentation_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember" xlink:href="mrk-20201231.xsd#mrk_VelosBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VelosBioMember" xlink:to="lab_mrk_VelosBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8e8523e9-0299-49df-8e68-539469daefef_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_9754c4bb-37b5-4f50-ae24-37fd4d1b09a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7d831d39-f9fe-4a02-b0b4-0db47cc06765_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_50f73cd0-a6f5-4b8d-b8a1-a1617fce95bd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefits related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_5fc87b51-e902-4c92-81b0-601329db8860_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_78298ed7-93aa-48a8-9fb0-30c21c5fdc71_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity before deduction for treasury stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a18de53b-368c-4229-b548-94d0e4ef831c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5a626085-e45b-4d1b-8d9b-943360dc2a78_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1160db6d-2bc6-474b-8f3a-1da67774eab4_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_72d2686f-31bd-454a-8eb2-d5e874393848_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12a1b3b5-eaff-4963-83d3-f60618f19bfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6290fd9a-5406-4f48-bccb-b7004bb16f43_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherLongTermDebtMember_b31b9379-664f-4b27-a05e-6983982e8a2d_terseLabel_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherLongTermDebtMember_label_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_mrk_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember" xlink:href="mrk-20201231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherLongTermDebtMember" xlink:to="lab_mrk_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_4153fcf9-3474-4097-91d7-ed448e575ed1_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal defense costs reserve</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_abf837ea-e5e0-4be7-bc87-756d834c1f8a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3ef40a01-6751-406c-bafc-cf1b43297aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_14c7eb69-8bab-4037-8611-67f1cc07c8ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Divestitures Research Collaborations and License Agreements Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VytorinMember_355c36fc-b1df-49e7-ad48-17b03f1bd89e_terseLabel_en-US" xlink:label="lab_mrk_VytorinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vytorin</link:label>
    <link:label id="lab_mrk_VytorinMember_label_en-US" xlink:label="lab_mrk_VytorinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vytorin [Member]</link:label>
    <link:label id="lab_mrk_VytorinMember_documentation_en-US" xlink:label="lab_mrk_VytorinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vytorin [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VytorinMember" xlink:href="mrk-20201231.xsd#mrk_VytorinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VytorinMember" xlink:to="lab_mrk_VytorinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SamsungMember_d2335690-37bd-43f8-9227-3466be97891a_terseLabel_en-US" xlink:label="lab_mrk_SamsungMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung</link:label>
    <link:label id="lab_mrk_SamsungMember_label_en-US" xlink:label="lab_mrk_SamsungMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung [Member]</link:label>
    <link:label id="lab_mrk_SamsungMember_documentation_en-US" xlink:label="lab_mrk_SamsungMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SamsungMember" xlink:href="mrk-20201231.xsd#mrk_SamsungMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SamsungMember" xlink:to="lab_mrk_SamsungMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_044bb2a2-d89f-4f26-b0d1-f3357189e5ae_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4caa5cf6-9a30-48b0-937d-38d668cdfb8a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableSale_20b9ba59-2ccc-42ce-acb9-383728bd168d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable factored</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableSale_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableSale" xlink:to="lab_us-gaap_AccountsReceivableSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b3cf7d59-56e4-402a-8c88-90034df55fd8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_938761f7-6456-4e80-9348-1b6e28658029_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_be3a956c-009c-426d-a6d0-af98e8edd9c7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0efe284d-0fd7-4385-b775-af59cfa9a719_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_76eca858-4ddb-4878-88a0-0a1bda590772_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_ecf433fc-f6a4-426a-b837-7566343aa01b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dea3297f-42d0-43c9-a1fb-15bad41df945_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bdd682ba-e6b3-4f0a-b04f-5c7d24f3c97d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ce9cd860-ab8e-4e08-8748-180bc6b1d0d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_a0700720-6f5c-484a-9477-283cd1010748_terseLabel_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations, Investment funds</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government And Agency Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:to="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4b4dd0f1-b474-4e6d-b484-2676d08effab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, reduction resulting from divestiture of Merck's consumer care business</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_86ebc072-d240-47fb-aafa-a0152dbf0741_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_65b18cee-17d5-4cdb-8b6e-f1c6cdc14007_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0cf5310d-1de0-421d-9cb3-273068faffcd_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4a455b95-0bbc-4be3-b57f-570e224d2be4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxTable_00f054db-1037-4c7f-911a-f19faa81da04_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_mrk_IncomeTaxTable_label_en-US" xlink:label="lab_mrk_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_mrk_IncomeTaxTable_documentation_en-US" xlink:label="lab_mrk_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxTable" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxTable" xlink:to="lab_mrk_IncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_03cab869-73e4-4ef8-8be5-70286cdad2bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of securities and other investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_d3a56641-3e19-4cf0-88f7-81d9f56ee50c_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EurodominatedNotesMember_89f3603b-e302-4105-ada7-0bd0382862a9_terseLabel_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-denominated notes</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_label_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_documentation_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember" xlink:href="mrk-20201231.xsd#mrk_EurodominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EurodominatedNotesMember" xlink:to="lab_mrk_EurodominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_363735cb-c0a8-4f49-8357-4fdfcdeccd4f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0ee2f190-9b94-4699-a547-5d88ec955a74_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions related to prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9eb43a64-50c2-4c13-9fc6-200ad5cb1375_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions related to current year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_967c1784-d37b-470f-9b5b-1e16bcf88128_terseLabel_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations, Fixed income securities</link:label>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Obligations Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:to="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_715b7ed7-252a-4e81-b160-609d443b054b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1efb1fb2-8e15-47b1-b0b1-56962db2e685_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_f7ee051d-1fc6-4616-9dff-c605688ba72d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of Peloton Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_277378d5-8072-4d82-bd88-971137c49103_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on investments, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_3ecd01f6-3ce9-48b5-95fc-ef32fa9101bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f0ea8c39-778f-49b5-adb1-609da794b71d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ae04e5e4-664c-40ac-904a-2fead1f4fd30_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_ff90c958-851e-4266-aa87-1df43e8c81b7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and fixed assets write-offs</link:label>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_5ccc2010-767f-4a4e-83ef-790b468469b2_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-off related to contract termination</link:label>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_label_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments or Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_89ad82bc-6fb4-430e-a560-d02c800f76aa_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BridionMember_e8d3b3c0-c33b-4fca-8b3d-8649b6578eb0_terseLabel_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion</link:label>
    <link:label id="lab_mrk_BridionMember_label_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member]</link:label>
    <link:label id="lab_mrk_BridionMember_documentation_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember" xlink:href="mrk-20201231.xsd#mrk_BridionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BridionMember" xlink:to="lab_mrk_BridionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_8ee65962-090e-4b24-b636-0323de539f8e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of exchange rate changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9dfd6a31-6a5f-4da8-97d1-20e56c46d0eb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_9b44072d-433c-4457-9310-e22c4122f628_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b4686573-35a6-4684-a477-b67c63a70246_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e00f43b3-a8f2-4f90-9e0b-1517da3ce7e8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5a24759d-e504-4e7f-8c5d-88dad405e9a6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5c89980-ef31-4ca0-a5ba-e383417b77bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EisaiMember_95b21bd2-3c48-4c63-8f7f-8a4760ffda70_terseLabel_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_mrk_EisaiMember_label_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_mrk_EisaiMember_documentation_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember" xlink:href="mrk-20201231.xsd#mrk_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EisaiMember" xlink:to="lab_mrk_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_daba3bd7-e1a4-4341-9f01-d067dd4aa8bc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_5a0ea84a-2fa5-4d03-aecb-d33292d7a8bc_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SeagenMember_1fb5a6cc-ad26-45ca-be3a-8ebff1d4f0dc_terseLabel_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen</link:label>
    <link:label id="lab_mrk_SeagenMember_label_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen [Member]</link:label>
    <link:label id="lab_mrk_SeagenMember_documentation_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember" xlink:href="mrk-20201231.xsd#mrk_SeagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SeagenMember" xlink:to="lab_mrk_SeagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InternationalMember_f5d397ec-c5ba-440c-b7ad-f02ef143ed9d_terseLabel_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Int&#8217;l</link:label>
    <link:label id="lab_mrk_InternationalMember_label_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_mrk_InternationalMember_documentation_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember" xlink:href="mrk-20201231.xsd#mrk_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InternationalMember" xlink:to="lab_mrk_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_cf6a9a5f-d805-4bef-9f93-1535ae7e2b08_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7c0433d8-29e8-4438-a72d-e8a002913d01_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_55087bdc-5f68-4932-9e3d-48a304393162_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FollistimAqMember_d5dfd4d3-25d3-43ae-8e22-f422d669abab_terseLabel_en-US" xlink:label="lab_mrk_FollistimAqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follistim AQ</link:label>
    <link:label id="lab_mrk_FollistimAqMember_label_en-US" xlink:label="lab_mrk_FollistimAqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follistim Aq [Member]</link:label>
    <link:label id="lab_mrk_FollistimAqMember_documentation_en-US" xlink:label="lab_mrk_FollistimAqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follistim AQ [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FollistimAqMember" xlink:href="mrk-20201231.xsd#mrk_FollistimAqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FollistimAqMember" xlink:to="lab_mrk_FollistimAqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_772cf08f-d00f-476b-a60a-252aa2969072_terseLabel_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_label_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_documentation_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:href="mrk-20201231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:to="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_2b088d52-d938-46e6-bee8-010f6b4cd288_terseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_28686503-419b-4ed9-827a-66b11b91c753_verboseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_label_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment [Member]</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_documentation_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PharmaceuticalsegmentMember" xlink:to="lab_mrk_PharmaceuticalsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e3074d62-eb77-46d7-a790-e4ce51d20886_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets (useful lives ranging from 18-24 years)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d70b6410-d86b-48f0-b5bb-7e18b0cf9a16_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_0e2b7e08-0b34-4185-95bc-29706ba9012a_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and product rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_944ef118-7e06-4587-b435-c6e9cd78dc2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_7bc57463-e6fd-4056-b0e5-3c507395e73e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AccrualForRebates_33ab93f0-fa72-4bd6-8b18-268c725860bf_terseLabel_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for rebates included in accrued and other current liabilities</link:label>
    <link:label id="lab_mrk_AccrualForRebates_label_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual For Rebates</link:label>
    <link:label id="lab_mrk_AccrualForRebates_documentation_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for rebates recorded as current liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates" xlink:href="mrk-20201231.xsd#mrk_AccrualForRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AccrualForRebates" xlink:to="lab_mrk_AccrualForRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a1b2aa53-6927-4a9f-9f6d-c9ed0187ec0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A075NotesDue2026Member_5e7a9787-47a6-4ee2-8e9a-95648fa5706c_terseLabel_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026</link:label>
    <link:label id="lab_mrk_A075NotesDue2026Member_label_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A075NotesDue2026Member_documentation_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Notes due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member" xlink:href="mrk-20201231.xsd#mrk_A075NotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A075NotesDue2026Member" xlink:to="lab_mrk_A075NotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8a16e161-4a45-470b-8690-8c010be3510a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_be27aa65-c8ff-4e17-94a3-8f4caf1b4764_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax&#160;Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_9f0f6fb1-d88d-45a7-a212-2f72977782eb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs, cost incurred to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_1cec778b-07a1-4cf4-975b-03a20cc067aa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.&#160;equities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_948a7898-64b1-4d49-bfbe-339f17154a93_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_79f4f323-ae2c-4b3b-b3ba-325ab68be90c_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthMember_c4adaa5e-8cc1-4a93-8348-ae940f939582_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health</link:label>
    <link:label id="lab_mrk_AnimalHealthMember_label_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthMember" xlink:to="lab_mrk_AnimalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_6149529a-c01e-4f2b-b43c-b3e86d34eabe_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_6f3743c8-f934-442b-8293-e1b66ca4dca7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_03e28cda-ec07-4eee-b29c-936b7d94bcc5_negatedLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment under ASR agreement</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Settlement (Payment) or Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_81115e86-0f12-4ccd-870c-2ccc7466bcbe_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_b4bcf038-20bb-4309-98bb-76ad927cc379_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GardasilGardasil9Member_378b4188-efd3-4143-8262-71d21cd54deb_terseLabel_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_label_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member]</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_documentation_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member" xlink:href="mrk-20201231.xsd#mrk_GardasilGardasil9Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GardasilGardasil9Member" xlink:to="lab_mrk_GardasilGardasil9Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_1590689c-37f1-4e14-80bc-a2a9d3c27010_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, Liabilities</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_label_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Equity Method Investment</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_documentation_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:to="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_f5049f4e-de72-4313-91df-1671c69d33af_terseLabel_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2025</link:label>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_label_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_documentation_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member" xlink:href="mrk-20201231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.75NotesDue2025Member" xlink:to="lab_mrk_A2.75NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_9be36239-d3d8-486d-a063-aae76b5547cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RemicadeMember_a60d759e-d5a7-4c06-b504-7e2777f6aa97_terseLabel_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_mrk_RemicadeMember_label_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_mrk_RemicadeMember_documentation_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember" xlink:href="mrk-20201231.xsd#mrk_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RemicadeMember" xlink:to="lab_mrk_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_62c17efb-fda1-4fed-a350-352d98223c53_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OncoImmuneMember_029f10c5-f655-4501-8e06-e2ec966c7b25_terseLabel_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune</link:label>
    <link:label id="lab_mrk_OncoImmuneMember_label_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune [Member]</link:label>
    <link:label id="lab_mrk_OncoImmuneMember_documentation_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember" xlink:href="mrk-20201231.xsd#mrk_OncoImmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OncoImmuneMember" xlink:to="lab_mrk_OncoImmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9f77bdc2-c16d-4887-9056-a9bce005875e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_2ef6340a-8ef5-42eb-b6c6-63794d48881b_terseLabel_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% notes due 2039</link:label>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_label_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Eight Five Percentage Notes Due On Two Thousand And Thirty Nine [Member]</link:label>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_documentation_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point eight five percentage notes due on two thousand and thirty nine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:href="mrk-20201231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:to="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e7c59404-cb6f-4705-a2c1-f2bacc983ae4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_57f5f64c-1994-4c27-8b33-169c984c78d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_6851b721-4dd5-4b21-b236-ecdefe7db262_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2c96873-807c-4c48-8d9b-1dbef965d5e9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_b034f449-d4c5-40cd-829c-5d3f46e84596_terseLabel_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% euro-denominated notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_label_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Euro Notes Due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Euro Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member" xlink:href="mrk-20201231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875EuroNotesDue2026Member" xlink:to="lab_mrk_A1.875EuroNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f80ba0c-970d-467c-868c-3c85f0a9d38f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_8f89f85b-ff3b-425c-acf3-8d11da59d364_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98b5ed73-e1bc-40f7-a742-67cafd65448d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_56bea829-3d15-41b0-a471-294c964a5198_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_9d1253c7-5a84-45f7-a023-3833ba4a0ab8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.35notesdue2040Member_773bfc1c-fcc5-4cef-995d-b144dffd62b3_terseLabel_en-US" xlink:label="lab_mrk_A2.35notesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040</link:label>
    <link:label id="lab_mrk_A2.35notesdue2040Member_label_en-US" xlink:label="lab_mrk_A2.35notesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040 [Member]</link:label>
    <link:label id="lab_mrk_A2.35notesdue2040Member_documentation_en-US" xlink:label="lab_mrk_A2.35notesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35notesdue2040Member" xlink:href="mrk-20201231.xsd#mrk_A2.35notesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.35notesdue2040Member" xlink:to="lab_mrk_A2.35notesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_b0cdffe6-ba73-43ed-b93a-1ea3fe385543_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZerbaxaMember_cd4a9dc6-11cc-4a44-a9d3-92988a15c140_terseLabel_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_label_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_documentation_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember" xlink:href="mrk-20201231.xsd#mrk_ZerbaxaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZerbaxaMember" xlink:to="lab_mrk_ZerbaxaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_d1cd5dc5-a944-445f-bd1a-008d7ae50fbe_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:href="mrk-20201231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DificidMember_647d8463-c7b7-4670-9127-8fde9cdcea3c_terseLabel_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid</link:label>
    <link:label id="lab_mrk_DificidMember_label_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid [Member]</link:label>
    <link:label id="lab_mrk_DificidMember_documentation_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember" xlink:href="mrk-20201231.xsd#mrk_DificidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DificidMember" xlink:to="lab_mrk_DificidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3f669a46-19e2-4171-bbd0-fa42cf25a71a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_32fe7353-7798-4b1e-9236-989de677e2bf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_2733c3ae-3f50-445e-a40c-2302b4c14538_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_77089c71-6612-4135-bda4-c5b1f08d8436_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets on NOL carryforwards relating to foreign jurisdictions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TukysaMember_90603368-3cd0-45b7-9744-10d4eb989b9d_terseLabel_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa</link:label>
    <link:label id="lab_mrk_TukysaMember_label_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa [Member]</link:label>
    <link:label id="lab_mrk_TukysaMember_documentation_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember" xlink:href="mrk-20201231.xsd#mrk_TukysaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TukysaMember" xlink:to="lab_mrk_TukysaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_8614b8a3-5e62-4054-a60a-2c8646b7dc21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a19a3960-69d4-4ca3-9dbf-e074cb45a055_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_69f9f461-7faf-4eb5-aed0-5bc38fe574c2_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains) losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9d3c48de-4efd-4221-a1e7-e5b8ee9e7559_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04caad4d-a3f3-430e-91de-7050af593b22_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_2d028770-677b-4b16-9a7f-4c876fc33be2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_537998e3-def9-4e83-a37a-a79e1554d475_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_abbafda6-b658-46a1-8e7b-01e8b0d20e61_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_b49940f7-dfa2-4f2c-8149-2305553fb997_terseLabel_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_label_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_documentation_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember" xlink:href="mrk-20201231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleratedDepreciationMember" xlink:to="lab_mrk_AcceleratedDepreciationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb767b07-e7b6-48f1-9b7f-987a8203949f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd11066f-f990-45f5-ae80-ac5d9853178a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_2db31124-2a07-4ddd-8fb4-ccb315eadeae_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_9453ab97-c3f5-4664-b242-152fcff915ee_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of securities and other investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_69f9d437-2ba0-4318-a663-46056ae11fe6_terseLabel_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.60% notes due 2042</link:label>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_label_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]</link:label>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_documentation_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:href="mrk-20201231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:to="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6fab8319-b140-4fc0-b079-a93ca8b01385_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_73f0e57b-e024-4502-8091-5c4589142bec_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_80ce4c2a-42b0-46d9-9f18-54f3c8ad0dea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_ce746d28-a02b-4390-ba9f-2c2bf8c84fd9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition of business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_888af3a0-19bc-4447-a1e1-e8318970e457_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ViralyticsMember_92456607-0ac3-4a1b-81cc-7d15aea6811a_terseLabel_en-US" xlink:label="lab_mrk_ViralyticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viralytics</link:label>
    <link:label id="lab_mrk_ViralyticsMember_label_en-US" xlink:label="lab_mrk_ViralyticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viralytics [Member]</link:label>
    <link:label id="lab_mrk_ViralyticsMember_documentation_en-US" xlink:label="lab_mrk_ViralyticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viralytics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ViralyticsMember" xlink:href="mrk-20201231.xsd#mrk_ViralyticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ViralyticsMember" xlink:to="lab_mrk_ViralyticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LivestockMember_29855799-bc65-4def-8405-9fca55e33366_terseLabel_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock</link:label>
    <link:label id="lab_mrk_LivestockMember_label_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:label id="lab_mrk_LivestockMember_documentation_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember" xlink:href="mrk-20201231.xsd#mrk_LivestockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LivestockMember" xlink:to="lab_mrk_LivestockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_6ee2040a-c1d1-4642-a168-ee67192b0e5f_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A245NotesDue2050Member_d4502c25-613e-4dfe-a9e4-66a62e9d754c_terseLabel_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050</link:label>
    <link:label id="lab_mrk_A245NotesDue2050Member_label_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes Due 2050 [Member]</link:label>
    <link:label id="lab_mrk_A245NotesDue2050Member_documentation_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member" xlink:href="mrk-20201231.xsd#mrk_A245NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A245NotesDue2050Member" xlink:to="lab_mrk_A245NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ee790bdc-6865-49f0-9aed-20185c230c53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_49b8e6b2-53b7-4c9f-ad63-9ef415244978_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_98dca48e-938b-4d97-8d33-ef6585ba6e82_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_fd79aeb6-b0cb-4e0a-818c-a101f9f8e2ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information about the Changes in Liabilities for Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForEnvironmentalLossContingencies_1a6c40fb-e310-477b-9826-d0101ab1775f_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities for environmental matters</link:label>
    <link:label id="lab_us-gaap_AccrualForEnvironmentalLossContingencies_label_en-US" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for Environmental Loss Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccrualForEnvironmentalLossContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:to="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5163ced9-307a-45f5-98b7-2422ecfd31d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_874ba0d3-49f2-4c1e-989b-32e3d62bd553_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ConsumercarebusinessMember_bc18a68c-31e7-46c5-96fc-2a90355cf1dd_terseLabel_en-US" xlink:label="lab_mrk_ConsumercarebusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">consumer care business</link:label>
    <link:label id="lab_mrk_ConsumercarebusinessMember_label_en-US" xlink:label="lab_mrk_ConsumercarebusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">consumer care business [Member]</link:label>
    <link:label id="lab_mrk_ConsumercarebusinessMember_documentation_en-US" xlink:label="lab_mrk_ConsumercarebusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">consumer care business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ConsumercarebusinessMember" xlink:href="mrk-20201231.xsd#mrk_ConsumercarebusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ConsumercarebusinessMember" xlink:to="lab_mrk_ConsumercarebusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_24409a8f-b12b-4355-8bb5-ff6c76a2a71b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments, maximum</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f0ebfa6e-a556-4ad3-9fda-e8fb5d758463_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2f58767d-ce46-49ed-ac31-a2ec467aca9c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available borrowing capacity under credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_29094147-3006-4df8-9d47-26d4614d7d96_terseLabel_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discussion of the accounting policy for contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentConsiderationPolicyTextBlock" xlink:href="mrk-20201231.xsd#mrk_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentConsiderationPolicyTextBlock" xlink:to="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_9873d9b8-8cdf-4049-be9e-de2832813ae3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Seagen Inc. common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_accfd74c-b9d6-4836-a3e7-9ad5dd6bc6f8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire available for sale securities, equity</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_7e48ca1e-1a9a-4eb0-80c9-c0b1e1198eb5_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_86e4b267-e30e-43ab-8b75-5307d8fe3e01_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_da3badba-515c-4e62-87a6-ebd1cc48d046_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43da1069-e5f5-4911-99bb-82c23d9643af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_a67a7e37-30d6-44db-af0f-5799ef6cf04f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherContractTerminationCosts_8792fc41-5190-4884-be3e-92093be027b1_terseLabel_en-US" xlink:label="lab_mrk_OtherContractTerminationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other contract termination costs</link:label>
    <link:label id="lab_mrk_OtherContractTerminationCosts_label_en-US" xlink:label="lab_mrk_OtherContractTerminationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract Termination Costs</link:label>
    <link:label id="lab_mrk_OtherContractTerminationCosts_documentation_en-US" xlink:label="lab_mrk_OtherContractTerminationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract Termination Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherContractTerminationCosts" xlink:href="mrk-20201231.xsd#mrk_OtherContractTerminationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherContractTerminationCosts" xlink:to="lab_mrk_OtherContractTerminationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.125EuroNotesDue2021Member_b0a0cc5f-e8c0-4b29-a90f-ee8b781e9c30_terseLabel_en-US" xlink:label="lab_mrk_A1.125EuroNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% euro-denominated notes due 2021</link:label>
    <link:label id="lab_mrk_A1.125EuroNotesDue2021Member_label_en-US" xlink:label="lab_mrk_A1.125EuroNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Euro Notes Due 2021 [Member]</link:label>
    <link:label id="lab_mrk_A1.125EuroNotesDue2021Member_documentation_en-US" xlink:label="lab_mrk_A1.125EuroNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Euro Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125EuroNotesDue2021Member" xlink:href="mrk-20201231.xsd#mrk_A1.125EuroNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.125EuroNotesDue2021Member" xlink:to="lab_mrk_A1.125EuroNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_6753a0ea-daec-4929-ba9f-30d4ac77dc7a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_fa58af89-1ff9-41c6-b255-d0d335dc78ea_terseLabel_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:href="mrk-20201231.xsd#mrk_AssetsandLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:to="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ca4e7f42-79b9-467f-9bca-01b25c49c429_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_f4ee3281-0ec7-43f0-b4ed-b3fbce809309_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_59d09f96-dd92-41d4-8860-d873f782098c_terseLabel_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_76f3e5fa-caf8-4d1f-8b03-2fa9b6ae03ba_verboseLabel_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member" xlink:href="mrk-20201231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.35NotesDue2022Member" xlink:to="lab_mrk_A2.35NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_ef38128e-4515-44cc-846a-7ec4d46291a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3a2879c3-ccb9-41ce-af63-090cf7d49317_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_c02a623a-3b71-4c1c-a6d6-cae3ba60e48c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_92d95557-68ac-4e5f-ae10-41c03ae3b610_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5bbb271e-0841-4e3e-b22a-80d9f7263f54_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash (Used in) Provided by Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_9273bc34-cc02-4a6a-9487-189509f91a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation and Funded Status</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ee15210-dd98-48f6-b579-3b3a3f54e752_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8cdaaa8-5d2c-43fc-add9-ff4d79c0fde1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_cf79f7fc-a430-4507-aaa2-7d9e66ff029c_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanionAnimalsMember_5b1b66ef-ad0e-4514-8024-ca7e17987a57_terseLabel_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_label_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_documentation_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember" xlink:href="mrk-20201231.xsd#mrk_CompanionAnimalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanionAnimalsMember" xlink:to="lab_mrk_CompanionAnimalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_5836f1d0-6713-4585-85c6-6368c83ff533_terseLabel_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations, Investment funds</link:label>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CorporateObligationsInvestmentFundsMember" xlink:to="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_2204c4da-ea54-4677-84f5-0197ab78487f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_28964b62-fba0-4943-917b-93bd42f3a5e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges and Spending Relating to Restructuring Activities by Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_44f5d673-d80a-46da-b291-f999e651af44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.45notesdue2030Member_573d1c56-3e09-4086-9a8f-f24f297dbeb9_terseLabel_en-US" xlink:label="lab_mrk_A1.45notesdue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030</link:label>
    <link:label id="lab_mrk_A1.45notesdue2030Member_label_en-US" xlink:label="lab_mrk_A1.45notesdue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030 [Member]</link:label>
    <link:label id="lab_mrk_A1.45notesdue2030Member_documentation_en-US" xlink:label="lab_mrk_A1.45notesdue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.45notesdue2030Member" xlink:href="mrk-20201231.xsd#mrk_A1.45notesdue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.45notesdue2030Member" xlink:to="lab_mrk_A1.45notesdue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_18638666-810b-4861-a2b6-40fbb1621382_terseLabel_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024</link:label>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member" xlink:href="mrk-20201231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.50eurodenominatednotesdue2024Member" xlink:to="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_834d9b13-65fc-4932-a89a-d7912d9e4b8c_terseLabel_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments collaborative arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20201231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_3ad7bf0c-e170-4e6a-8fae-ec66b7556e96_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less treasury stock, at cost: 1,046,877,695 shares in 2020 and 1,038,087,496 shares in 2019</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_98a52cc8-7b31-425b-8f4c-daafb5d8cb8a_verboseLabel_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2021</link:label>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_label_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2021 [Member]</link:label>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_documentation_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member" xlink:href="mrk-20201231.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.875NotesDue2021Member" xlink:to="lab_mrk_A3.875NotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c868ed65-5878-412d-83a7-d25a535873fe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_bdf2de25-f14d-43c1-9972-229231136198_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefits</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_772ce2a7-557e-496d-b15c-589f762716ec_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_54f0729e-a27a-4e39-b5dd-5428ca8d023f_terseLabel_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_label_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_documentation_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired" xlink:href="mrk-20201231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PremiumOnSharesAcquired" xlink:to="lab_mrk_PremiumOnSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_ad990a0b-7c07-4598-8be8-21182e8c41ec_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_26fb941e-706c-4907-94e2-665c0181de48_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8513dd30-222d-4d1e-89b3-f04fd9291d00_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate applied to income before taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_0d00babe-1201-4bc1-9377-e2a8c1dd526f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:to="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_d653f597-45ae-44cc-a1ec-b61c0e64e6d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_01eefdd3-29ce-4a26-9894-4b3320f69089_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales of Adempas recorded by Merck</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementSalesNet" xlink:to="lab_mrk_CollaborativeArrangementSalesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eeab160f-e8fc-4171-b1ad-a58ac2bcf8ce_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_a484f128-8f45-4a05-b249-56da24ed2be4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_01ba58a0-ab26-4dba-aad2-ab5208835467_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>mrk-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3b02abbc-3b84-4f9a-9655-da3777b72964,g:4abc6098-1e3f-4748-b81f-d8be8057e101-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_15b0569c-2c30-4b9b-8ed3-ab3b91de2ebe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_a48498f3-bf0d-4037-9f8a-d429a317cb11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_15b0569c-2c30-4b9b-8ed3-ab3b91de2ebe" xlink:to="loc_dei_DocumentInformationTable_a48498f3-bf0d-4037-9f8a-d429a317cb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ada8e3fa-706d-4306-9215-c9545636716a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_a48498f3-bf0d-4037-9f8a-d429a317cb11" xlink:to="loc_us-gaap_DebtInstrumentAxis_ada8e3fa-706d-4306-9215-c9545636716a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ada8e3fa-706d-4306-9215-c9545636716a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125Notesdue2021Member_2e4b852f-d5fb-4b8a-8fd3-4708a273052b" xlink:href="mrk-20201231.xsd#mrk_A1.125Notesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A1.125Notesdue2021Member_2e4b852f-d5fb-4b8a-8fd3-4708a273052b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_c7a84f3e-addd-419e-a070-bba33a5f7056" xlink:href="mrk-20201231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A0.500Notesdue2024Member_c7a84f3e-addd-419e-a070-bba33a5f7056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_e9659ecf-fd68-42af-9c3a-73a352bbcc0e" xlink:href="mrk-20201231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A1.875Notesdue2026Member_e9659ecf-fd68-42af-9c3a-73a352bbcc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_1afa38b8-2a10-4b1b-8938-1fb9be1602ad" xlink:href="mrk-20201231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A2.500Notesdue2034Member_1afa38b8-2a10-4b1b-8938-1fb9be1602ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_cf59f186-82e4-4681-8d6d-e0dd17ae56a8" xlink:href="mrk-20201231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80eb7c5b-0c91-4932-bba8-9ea92ce7b5cd" xlink:to="loc_mrk_A1.375Notesdue2036Member_cf59f186-82e4-4681-8d6d-e0dd17ae56a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_a48498f3-bf0d-4037-9f8a-d429a317cb11" xlink:to="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_db5a5207-dbdb-4ed3-a08b-4a85afcdb144" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentType_db5a5207-dbdb-4ed3-a08b-4a85afcdb144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a9ded0df-248e-4a94-a898-7adec77d380e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentAnnualReport_a9ded0df-248e-4a94-a898-7adec77d380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a248d204-2812-4d15-8055-ed50a4c236f2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentTransitionReport_a248d204-2812-4d15-8055-ed50a4c236f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_871145b3-4476-432e-8fbd-ff9c49fd9ee8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityFileNumber_871145b3-4476-432e-8fbd-ff9c49fd9ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a032524f-c95c-434d-bdf6-d54d8c93358c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityRegistrantName_a032524f-c95c-434d-bdf6-d54d8c93358c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_55859652-c499-4138-ba5c-2efb16cbd3d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_CityAreaCode_55859652-c499-4138-ba5c-2efb16cbd3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_61bf7a29-11d6-430f-8dc6-2ce01d9d1522" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_LocalPhoneNumber_61bf7a29-11d6-430f-8dc6-2ce01d9d1522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16c419f5-6481-4bf8-bdf9-0b6f718f6423" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16c419f5-6481-4bf8-bdf9-0b6f718f6423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1edd52c5-99cd-4eda-b00d-7ccea7a52f91" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityTaxIdentificationNumber_1edd52c5-99cd-4eda-b00d-7ccea7a52f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4a74fe97-e81f-4897-9722-b30171e43f99" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityAddressAddressLine1_4a74fe97-e81f-4897-9722-b30171e43f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_754b8cfb-5e51-4b17-adcd-4fed90473838" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityAddressCityOrTown_754b8cfb-5e51-4b17-adcd-4fed90473838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0d6f4530-ec89-4eae-b8f9-d72735dc9800" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityAddressStateOrProvince_0d6f4530-ec89-4eae-b8f9-d72735dc9800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5d7d6545-128d-4b40-9b3b-6b8f67d49c66" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityAddressPostalZipCode_5d7d6545-128d-4b40-9b3b-6b8f67d49c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c23f505d-e9d1-4a8b-bd4a-421df5530c26" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_Security12bTitle_c23f505d-e9d1-4a8b-bd4a-421df5530c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6b819f44-8e71-4c39-9ffa-0c485d4f2575" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_TradingSymbol_6b819f44-8e71-4c39-9ffa-0c485d4f2575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_81df21d5-749d-4d13-b65b-6be8aed5a939" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_SecurityExchangeName_81df21d5-749d-4d13-b65b-6be8aed5a939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9931a106-14e8-40e5-b978-7d7cc28662e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9931a106-14e8-40e5-b978-7d7cc28662e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e983276a-eec1-4e83-b0f2-1239add146ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityPublicFloat_e983276a-eec1-4e83-b0f2-1239add146ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a025dfcb-ce57-41b9-89a6-d10bfcc874ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a025dfcb-ce57-41b9-89a6-d10bfcc874ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_6d10114e-93ce-4115-a692-2f7bbb3512d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityVoluntaryFilers_6d10114e-93ce-4115-a692-2f7bbb3512d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_89cf6119-d32b-46e4-bf13-e7042dbd478b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityCurrentReportingStatus_89cf6119-d32b-46e4-bf13-e7042dbd478b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d4eef488-2326-4eb1-9e72-930e37abff58" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityInteractiveDataCurrent_d4eef488-2326-4eb1-9e72-930e37abff58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a4129a7a-d78a-4fd1-9fdf-342db235efc2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityFilerCategory_a4129a7a-d78a-4fd1-9fdf-342db235efc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_18040538-d6b5-4add-85f8-1af1abbb0961" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntitySmallBusiness_18040538-d6b5-4add-85f8-1af1abbb0961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1199725d-15c5-48ac-972f-12377da631af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityEmergingGrowthCompany_1199725d-15c5-48ac-972f-12377da631af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9de4b04f-d92a-4593-a70d-5af8bcde104a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9de4b04f-d92a-4593-a70d-5af8bcde104a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_57a1344c-b896-43e5-a966-a6d395d028c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityShellCompany_57a1344c-b896-43e5-a966-a6d395d028c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_71176585-3a69-4a9c-a7cd-e2cc4c8bab2f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_AmendmentFlag_71176585-3a69-4a9c-a7cd-e2cc4c8bab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e59b89e0-5274-405b-8131-9b188ef6d591" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentPeriodEndDate_e59b89e0-5274-405b-8131-9b188ef6d591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_68d4cf79-e29c-47b6-a813-4518bae37fd1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentFiscalYearFocus_68d4cf79-e29c-47b6-a813-4518bae37fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_de8f4cff-13d9-4a59-b79e-2ea81191b378" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentFiscalPeriodFocus_de8f4cff-13d9-4a59-b79e-2ea81191b378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bdcdcf68-a315-48af-9b3b-ca47228c691c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_EntityCentralIndexKey_bdcdcf68-a315-48af-9b3b-ca47228c691c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e4106701-6239-4b79-9662-ec3331dc1311" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_CurrentFiscalYearEndDate_e4106701-6239-4b79-9662-ec3331dc1311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_28252193-6d10-4893-b8fa-bdf5dd8a7bfd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_fa831ce5-99b6-458f-b95a-925436621154" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_28252193-6d10-4893-b8fa-bdf5dd8a7bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_77dd27d2-f376-4584-a27b-2ba0b051972e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_Revenues_77dd27d2-f376-4584-a27b-2ba0b051972e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d59bb31a-ab50-409c-9132-6023ca792b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d59bb31a-ab50-409c-9132-6023ca792b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8559f985-7c5c-41f4-a748-6b623ec6d071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d59bb31a-ab50-409c-9132-6023ca792b0e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8559f985-7c5c-41f4-a748-6b623ec6d071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1e21e127-cde6-439b-a3ac-485dafc75312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d59bb31a-ab50-409c-9132-6023ca792b0e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1e21e127-cde6-439b-a3ac-485dafc75312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c09c6aeb-b396-49cb-a6d4-d1af8fc91959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d59bb31a-ab50-409c-9132-6023ca792b0e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c09c6aeb-b396-49cb-a6d4-d1af8fc91959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e6a94cb7-0c6b-44f9-b9ba-069ec8078804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d59bb31a-ab50-409c-9132-6023ca792b0e" xlink:to="loc_us-gaap_RestructuringCharges_e6a94cb7-0c6b-44f9-b9ba-069ec8078804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f7dcfd16-beac-4fcc-9439-ba9c86e065dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d59bb31a-ab50-409c-9132-6023ca792b0e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f7dcfd16-beac-4fcc-9439-ba9c86e065dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_ff70cc3b-7105-414f-b261-5fc9b3f48cdd" xlink:href="mrk-20201231.xsd#mrk_CostsExpensesAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d59bb31a-ab50-409c-9132-6023ca792b0e" xlink:to="loc_mrk_CostsExpensesAndOther_ff70cc3b-7105-414f-b261-5fc9b3f48cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56bb4b12-012a-4971-a91b-652587444095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56bb4b12-012a-4971-a91b-652587444095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ecd52c3d-624c-44ce-a67e-759681ab89d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ecd52c3d-624c-44ce-a67e-759681ab89d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d2ed14bd-71ac-486b-9bef-fd8abed435c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_ProfitLoss_d2ed14bd-71ac-486b-9bef-fd8abed435c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b5d9a2f2-3299-4bbb-af82-583442fbd699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b5d9a2f2-3299-4bbb-af82-583442fbd699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b351c7e1-1d81-40bb-8468-89e7a136e467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_NetIncomeLoss_b351c7e1-1d81-40bb-8468-89e7a136e467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a180311e-c9ae-4c62-bb2a-0b423a72ef3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_EarningsPerShareBasic_a180311e-c9ae-4c62-bb2a-0b423a72ef3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f1c97aa1-af73-434f-af62-23eee3190aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4a2dd24-d76d-4386-8c02-5208193943a9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f1c97aa1-af73-434f-af62-23eee3190aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07adc25c-7328-48a8-9970-f0d3cae240f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff46a17d-50c2-45d7-943a-1df11e840a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07adc25c-7328-48a8-9970-f0d3cae240f4" xlink:to="loc_us-gaap_NetIncomeLoss_ff46a17d-50c2-45d7-943a-1df11e840a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_891eb62b-fd76-47a5-8593-ca90a2100a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07adc25c-7328-48a8-9970-f0d3cae240f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_891eb62b-fd76-47a5-8593-ca90a2100a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ab86bf9f-c4b0-49f8-9fd1-5c3bb0f01874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_891eb62b-fd76-47a5-8593-ca90a2100a28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ab86bf9f-c4b0-49f8-9fd1-5c3bb0f01874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_765ef162-04b8-4ce0-ae28-91c3ff5ef467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_891eb62b-fd76-47a5-8593-ca90a2100a28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_765ef162-04b8-4ce0-ae28-91c3ff5ef467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c6c13d0d-44e3-47a1-b278-b05162038282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_891eb62b-fd76-47a5-8593-ca90a2100a28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c6c13d0d-44e3-47a1-b278-b05162038282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ddfc34e0-6c9f-40ac-9380-27741386744c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_891eb62b-fd76-47a5-8593-ca90a2100a28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ddfc34e0-6c9f-40ac-9380-27741386744c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7be8bfdb-e868-4211-a0db-a25f7f3a8b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_891eb62b-fd76-47a5-8593-ca90a2100a28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7be8bfdb-e868-4211-a0db-a25f7f3a8b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ad12e989-0bc3-403e-9808-c21f78574e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_07adc25c-7328-48a8-9970-f0d3cae240f4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ad12e989-0bc3-403e-9808-c21f78574e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedBalanceSheet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_35029b72-474a-47cd-8d4e-2646ec9daaef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35029b72-474a-47cd-8d4e-2646ec9daaef" xlink:to="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_086d0533-ca26-47d7-8d3f-22a1b889e304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_086d0533-ca26-47d7-8d3f-22a1b889e304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8968a2d0-c54f-46c9-8141-a972155919f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_086d0533-ca26-47d7-8d3f-22a1b889e304" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8968a2d0-c54f-46c9-8141-a972155919f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_63f9f197-270b-4287-b9f6-d788950da4f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_086d0533-ca26-47d7-8d3f-22a1b889e304" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_63f9f197-270b-4287-b9f6-d788950da4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7e2e2795-236c-4d79-a926-0a9d257d54dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_086d0533-ca26-47d7-8d3f-22a1b889e304" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7e2e2795-236c-4d79-a926-0a9d257d54dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9bbf6f73-f8b0-4744-a517-500519806213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_086d0533-ca26-47d7-8d3f-22a1b889e304" xlink:to="loc_us-gaap_InventoryNet_9bbf6f73-f8b0-4744-a517-500519806213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a8fbb6d1-4385-4bcb-8aa6-148cbe0c6d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_086d0533-ca26-47d7-8d3f-22a1b889e304" xlink:to="loc_us-gaap_OtherAssetsCurrent_a8fbb6d1-4385-4bcb-8aa6-148cbe0c6d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9fd66c6c-8a20-465d-b4f8-a933295e577d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_086d0533-ca26-47d7-8d3f-22a1b889e304" xlink:to="loc_us-gaap_AssetsCurrent_9fd66c6c-8a20-465d-b4f8-a933295e577d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_e3e9326f-ee51-4c81-bc5c-266afeeb68ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_e3e9326f-ee51-4c81-bc5c-266afeeb68ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_5fa7bf3f-d8e1-44cc-bcab-cdb080205cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_5fa7bf3f-d8e1-44cc-bcab-cdb080205cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_2b0f489a-fa6f-4644-99f9-6759e0ffc312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_5fa7bf3f-d8e1-44cc-bcab-cdb080205cbe" xlink:to="loc_us-gaap_Land_2b0f489a-fa6f-4644-99f9-6759e0ffc312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_d925a786-8716-44c1-b45a-ca73d21a133e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_5fa7bf3f-d8e1-44cc-bcab-cdb080205cbe" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_d925a786-8716-44c1-b45a-ca73d21a133e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_7497b5b9-3707-4fac-b618-ea30d429c66c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_5fa7bf3f-d8e1-44cc-bcab-cdb080205cbe" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_7497b5b9-3707-4fac-b618-ea30d429c66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_cad4f7d6-6cfc-43d4-8996-f85362533dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_5fa7bf3f-d8e1-44cc-bcab-cdb080205cbe" xlink:to="loc_us-gaap_ConstructionInProgressGross_cad4f7d6-6cfc-43d4-8996-f85362533dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_403f93c4-c4c6-44c9-94fa-ea5fc9f95769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_5fa7bf3f-d8e1-44cc-bcab-cdb080205cbe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_403f93c4-c4c6-44c9-94fa-ea5fc9f95769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eedad82e-8e39-4a1b-b4ce-1b290a05cef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eedad82e-8e39-4a1b-b4ce-1b290a05cef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0456ca18-fd50-40c0-a0cb-013f59236905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0456ca18-fd50-40c0-a0cb-013f59236905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2ea2b9db-e5a8-45ee-a7c4-9f9ced06708b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_Goodwill_2ea2b9db-e5a8-45ee-a7c4-9f9ced06708b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_aa9d9ea8-b5d2-4830-8b08-a07dbe07c822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_aa9d9ea8-b5d2-4830-8b08-a07dbe07c822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_0132df6c-d7dc-4315-915e-1ecd39f08454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_0132df6c-d7dc-4315-915e-1ecd39f08454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ea504044-adac-46d3-bf21-959ace8c4657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_202b6ad0-1583-4431-a6f2-daeae90da80b" xlink:to="loc_us-gaap_Assets_ea504044-adac-46d3-bf21-959ace8c4657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35029b72-474a-47cd-8d4e-2646ec9daaef" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_36df9985-7ff6-4d95-8aef-c62fb4848954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_36df9985-7ff6-4d95-8aef-c62fb4848954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_ee1dbffc-b5a5-4196-87a0-d5b22be0fabf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36df9985-7ff6-4d95-8aef-c62fb4848954" xlink:to="loc_us-gaap_DebtCurrent_ee1dbffc-b5a5-4196-87a0-d5b22be0fabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0497cafc-adaa-420d-b3c7-198659dcf806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36df9985-7ff6-4d95-8aef-c62fb4848954" xlink:to="loc_us-gaap_AccountsPayableCurrent_0497cafc-adaa-420d-b3c7-198659dcf806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_14dc1571-48a7-4aa2-859e-421b07e29fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36df9985-7ff6-4d95-8aef-c62fb4848954" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_14dc1571-48a7-4aa2-859e-421b07e29fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_cfb9be32-7770-4afc-9904-8e1bca3a87d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36df9985-7ff6-4d95-8aef-c62fb4848954" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_cfb9be32-7770-4afc-9904-8e1bca3a87d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_1be5fd69-547e-4dc9-b06c-e13048348b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36df9985-7ff6-4d95-8aef-c62fb4848954" xlink:to="loc_us-gaap_DividendsPayableCurrent_1be5fd69-547e-4dc9-b06c-e13048348b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c6e6d243-4141-4fe8-9257-14edfc3a02b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36df9985-7ff6-4d95-8aef-c62fb4848954" xlink:to="loc_us-gaap_LiabilitiesCurrent_c6e6d243-4141-4fe8-9257-14edfc3a02b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0aae2e04-9253-46ad-8937-1427d321f247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0aae2e04-9253-46ad-8937-1427d321f247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_748d098e-533d-4b7b-a754-32d1337a5bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_748d098e-533d-4b7b-a754-32d1337a5bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ca62471e-f5ee-4047-bae3-b4d35003901d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ca62471e-f5ee-4047-bae3-b4d35003901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6215f7fb-9a6c-430e-95fd-25d10b254e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:to="loc_us-gaap_CommonStockValue_6215f7fb-9a6c-430e-95fd-25d10b254e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_11245df4-6b21-4b1b-bf56-a963d183b979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_11245df4-6b21-4b1b-bf56-a963d183b979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09fdd87f-a425-4e86-9a7c-567caa1fb721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09fdd87f-a425-4e86-9a7c-567caa1fb721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e8d6fea3-4664-4475-9f67-a69ad8b2fce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e8d6fea3-4664-4475-9f67-a69ad8b2fce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_db4f0262-b16d-4733-95ce-7e071a0495ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_db4f0262-b16d-4733-95ce-7e071a0495ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_ef638853-edcc-477a-af60-3a67de649fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:to="loc_us-gaap_TreasuryStockValue_ef638853-edcc-477a-af60-3a67de649fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_af8d709a-2215-48aa-b13e-4e50c928a4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8cfb659-01bb-4883-85cd-f6821d03e9fa" xlink:to="loc_us-gaap_StockholdersEquity_af8d709a-2215-48aa-b13e-4e50c928a4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e061ef94-01af-492e-be9c-d98b2c6b0881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:to="loc_us-gaap_MinorityInterest_e061ef94-01af-492e-be9c-d98b2c6b0881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f80a76a-6a98-44fe-b88c-3ddcdac8642e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f80a76a-6a98-44fe-b88c-3ddcdac8642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_751e4acc-babc-4148-98c3-7ca7e456258d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ea33e5e-20da-4559-b139-7d9c0b1ceb13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_751e4acc-babc-4148-98c3-7ca7e456258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedBalanceSheetParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4b9ed327-d0d1-4b83-a5c2-fd0474dcd792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a98acf61-d59b-495b-aa5f-607e382868b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b9ed327-d0d1-4b83-a5c2-fd0474dcd792" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a98acf61-d59b-495b-aa5f-607e382868b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f69aa6bc-fb8f-4b1b-bb61-7be1a1117dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b9ed327-d0d1-4b83-a5c2-fd0474dcd792" xlink:to="loc_us-gaap_InventoryNoncurrent_f69aa6bc-fb8f-4b1b-bb61-7be1a1117dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_36bfe624-c745-4fb1-a640-06bbd950387d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b9ed327-d0d1-4b83-a5c2-fd0474dcd792" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_36bfe624-c745-4fb1-a640-06bbd950387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f70e8357-9ef3-4382-87b6-a0d8ecea7762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b9ed327-d0d1-4b83-a5c2-fd0474dcd792" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f70e8357-9ef3-4382-87b6-a0d8ecea7762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_17b8e374-2c03-433f-9206-4e2bf9b96db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b9ed327-d0d1-4b83-a5c2-fd0474dcd792" xlink:to="loc_us-gaap_CommonStockSharesIssued_17b8e374-2c03-433f-9206-4e2bf9b96db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_47cd3d1e-bd41-472a-9179-c0d9f57ba4d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b9ed327-d0d1-4b83-a5c2-fd0474dcd792" xlink:to="loc_us-gaap_TreasuryStockShares_47cd3d1e-bd41-472a-9179-c0d9f57ba4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_abc3a240-666f-4485-aa31-934ea7ff2e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_abc3a240-666f-4485-aa31-934ea7ff2e74" xlink:to="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_29d29938-32c9-4f15-ac40-17114ae6e936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_29d29938-32c9-4f15-ac40-17114ae6e936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29d29938-32c9-4f15-ac40-17114ae6e936" xlink:to="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2788f673-547f-4593-8044-9657df8608d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_CommonStockMember_2788f673-547f-4593-8044-9657df8608d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1301b9d5-814e-4ee5-b5f2-1cf64899a71f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1301b9d5-814e-4ee5-b5f2-1cf64899a71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cf592093-0e12-443f-82b0-8eb2d4b6d835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_RetainedEarningsMember_cf592093-0e12-443f-82b0-8eb2d4b6d835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f661107d-e009-4330-aa16-451f3a38ad3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f661107d-e009-4330-aa16-451f3a38ad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_b443261d-0f9f-4ff5-bbfa-288913783fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_TreasuryStockMember_b443261d-0f9f-4ff5-bbfa-288913783fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d9a8f718-0c72-4330-9e07-0ec8b7f329a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b09f9f3-8f1b-4880-90b8-9eac5a53df44" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d9a8f718-0c72-4330-9e07-0ec8b7f329a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0bfae21-a7bc-4c4f-908f-3ea2730465ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0bfae21-a7bc-4c4f-908f-3ea2730465ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_58817958-7294-4201-980d-37b661b0db22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b0bfae21-a7bc-4c4f-908f-3ea2730465ce" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_58817958-7294-4201-980d-37b661b0db22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_76cfad89-4694-43f5-b2be-7d59aab56205" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_58817958-7294-4201-980d-37b661b0db22" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_76cfad89-4694-43f5-b2be-7d59aab56205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_96ec7a45-576e-4de8-aea7-044ef8f8ccae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66dd8e68-4447-4e35-beb7-ca6e47cb5540" xlink:to="loc_us-gaap_StatementLineItems_96ec7a45-576e-4de8-aea7-044ef8f8ccae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_96ec7a45-576e-4de8-aea7-044ef8f8ccae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71a7a5b8-7e03-444e-9272-92a98baf9537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71a7a5b8-7e03-444e-9272-92a98baf9537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b596b4ec-dcc5-496b-ac0b-09a1c76811fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_NetIncomeLoss_b596b4ec-dcc5-496b-ac0b-09a1c76811fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_434b366e-69d6-41a0-9629-08155112adb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_434b366e-69d6-41a0-9629-08155112adb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_f07f3502-bb45-4748-8024-63d2888cafd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_DividendsCommonStockCash_f07f3502-bb45-4748-8024-63d2888cafd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_baf7110a-6955-46cf-a11d-8e26075f277a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_baf7110a-6955-46cf-a11d-8e26075f277a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_07ac46e0-0a6a-4f0d-b7c5-f530d018c0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_07ac46e0-0a6a-4f0d-b7c5-f530d018c0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_530c8954-5e90-4c3a-b14f-e101fc65dfba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_530c8954-5e90-4c3a-b14f-e101fc65dfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_fdd07f72-33d9-4cd5-9664-cad42c0d7c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_StockholdersEquityOther_fdd07f72-33d9-4cd5-9664-cad42c0d7c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a771a8e6-0e5b-40bb-a0d4-ad4c5de5f0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58ba018c-7045-413d-85eb-1ef724acd824" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a771a8e6-0e5b-40bb-a0d4-ad4c5de5f0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d2f1b0c1-4940-46df-acce-a0ac18ad9635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_ea43edca-45c8-4ad7-a2a6-30c275a761f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d2f1b0c1-4940-46df-acce-a0ac18ad9635" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_ea43edca-45c8-4ad7-a2a6-30c275a761f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7203e092-c538-42b7-817b-90523042202d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e9dafabd-fafc-4a74-99af-df758c1a7cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7203e092-c538-42b7-817b-90523042202d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e9dafabd-fafc-4a74-99af-df758c1a7cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_679829b0-e5ca-4de2-92e7-0a718c444c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e9dafabd-fafc-4a74-99af-df758c1a7cdb" xlink:to="loc_us-gaap_ProfitLoss_679829b0-e5ca-4de2-92e7-0a718c444c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e9dafabd-fafc-4a74-99af-df758c1a7cdb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_913069d3-1c70-4ef9-9b3b-b251a7f94797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_us-gaap_AdjustmentForAmortization_913069d3-1c70-4ef9-9b3b-b251a7f94797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_288066da-4486-4d94-acae-b8def955f17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_us-gaap_Depreciation_288066da-4486-4d94-acae-b8def955f17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_52b9b8ea-3c79-45c2-b2f9-49af4a20b32e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_52b9b8ea-3c79-45c2-b2f9-49af4a20b32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargeForAssetAcquisition_f0753c01-90e4-457b-a206-da7b5e7fe6f5" xlink:href="mrk-20201231.xsd#mrk_ChargeForAssetAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_mrk_ChargeForAssetAcquisition_f0753c01-90e4-457b-a206-da7b5e7fe6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f4cf5507-2006-4816-b348-4f68d7b165f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f4cf5507-2006-4816-b348-4f68d7b165f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions_9e51428f-dbb5-4584-8741-4ea862ada0e9" xlink:href="mrk-20201231.xsd#mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions_9e51428f-dbb5-4584-8741-4ea862ada0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cc20bc18-2da8-466e-a33f-390935d705ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cc20bc18-2da8-466e-a33f-390935d705ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cf4d5312-af6f-440b-8839-771e9aad0530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_us-gaap_ShareBasedCompensation_cf4d5312-af6f-440b-8839-771e9aad0530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_dab3e315-592b-46ce-bb2a-05c799b95759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_dab3e315-592b-46ce-bb2a-05c799b95759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfd51f3a-2ef8-42f7-8e15-7dce24812747" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_35419a02-5753-4a76-8b94-8946e1c16fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_35419a02-5753-4a76-8b94-8946e1c16fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_59db2d3f-7083-46ac-b1e6-f0e1e24b4037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_59db2d3f-7083-46ac-b1e6-f0e1e24b4037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ff5cb95b-fab4-4b60-8e20-977c6745a6c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ff5cb95b-fab4-4b60-8e20-977c6745a6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d67c5bd5-872a-47eb-80fd-cf69d4839403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d67c5bd5-872a-47eb-80fd-cf69d4839403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2d4ede9c-177a-427b-a24c-31d45e4c9add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2d4ede9c-177a-427b-a24c-31d45e4c9add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e574233a-2a84-4b78-bf20-1163a55385bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e574233a-2a84-4b78-bf20-1163a55385bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c7c57acf-40f5-48ae-a9a9-dd0981e71d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0778ab3e-b17d-44c6-8920-51b06144cee1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c7c57acf-40f5-48ae-a9a9-dd0981e71d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb4fb511-1d48-41c5-ab05-886f3921699b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e9dafabd-fafc-4a74-99af-df758c1a7cdb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb4fb511-1d48-41c5-ab05-886f3921699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7203e092-c538-42b7-817b-90523042202d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_e6be9ef8-ca21-4e80-bbaa-99d9c44e0176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_e6be9ef8-ca21-4e80-bbaa-99d9c44e0176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_296eb1f6-c678-405c-af5b-fcfeffeff529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_296eb1f6-c678-405c-af5b-fcfeffeff529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_14530af3-7537-4c25-b081-2ff6dafce37d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_14530af3-7537-4c25-b081-2ff6dafce37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_56452df8-3f3d-4529-a9ea-87f502495a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_56452df8-3f3d-4529-a9ea-87f502495a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_f3a34605-4505-4e3e-ba80-dd7090128264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_f3a34605-4505-4e3e-ba80-dd7090128264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_40041494-6ea0-4718-889b-91dcd66003de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_40041494-6ea0-4718-889b-91dcd66003de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_c50361eb-4ba3-4369-afd9-cfe6ed6a239c" xlink:href="mrk-20201231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_c50361eb-4ba3-4369-afd9-cfe6ed6a239c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_54787c25-7656-4993-8335-c33ec2867985" xlink:href="mrk-20201231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_54787c25-7656-4993-8335-c33ec2867985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_519d6876-299b-4c67-995a-98d7e7620df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_519d6876-299b-4c67-995a-98d7e7620df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ecbe1b8c-ba1f-4d6d-8b26-242ed58162ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ecbe1b8c-ba1f-4d6d-8b26-242ed58162ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_deee1044-ad1a-4822-8eec-afcb57ee77c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1770230a-077c-4272-b359-f46b83ada38a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_deee1044-ad1a-4822-8eec-afcb57ee77c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7203e092-c538-42b7-817b-90523042202d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_589b438d-4abb-48e4-91ba-3721a8512561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_589b438d-4abb-48e4-91ba-3721a8512561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3acd1997-ea5a-421c-8f64-94e1e97edd99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3acd1997-ea5a-421c-8f64-94e1e97edd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8a2ba9a8-30ce-4576-8685-02bd6f705bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8a2ba9a8-30ce-4576-8685-02bd6f705bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ac173a4c-6ac9-41a9-b5e3-27cbaefd2249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ac173a4c-6ac9-41a9-b5e3-27cbaefd2249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_e6a4ae1c-f59c-4443-b06b-6a664e5f857e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_e6a4ae1c-f59c-4443-b06b-6a664e5f857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_af49ffea-7edb-4b35-9ea2-d83d43d524aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_af49ffea-7edb-4b35-9ea2-d83d43d524aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b4da3508-b183-4dcf-9fa5-9bd14a75923d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b4da3508-b183-4dcf-9fa5-9bd14a75923d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1548a626-93bc-4ee3-afb8-8a1c5d26ff44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ba5b9b13-89b2-4ffd-b25e-01e4c0c815e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1548a626-93bc-4ee3-afb8-8a1c5d26ff44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a45c4596-8c05-4c75-85a6-85326a62d122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7203e092-c538-42b7-817b-90523042202d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a45c4596-8c05-4c75-85a6-85326a62d122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_71ba41c5-4057-431e-a56e-202a382cd689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7203e092-c538-42b7-817b-90523042202d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_71ba41c5-4057-431e-a56e-202a382cd689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c0d6d4a-9c08-4c23-b1b0-45b09b585943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7203e092-c538-42b7-817b-90523042202d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c0d6d4a-9c08-4c23-b1b0-45b09b585943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e64dca70-eebe-4da0-a0ce-1792feda3987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7203e092-c538-42b7-817b-90523042202d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e64dca70-eebe-4da0-a0ce-1792feda3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="simple" xlink:href="mrk-20201231.xsd#ConsolidatedStatementofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b38353ef-a183-49a5-aba1-0ddfb7a52c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9b19adc5-9914-417f-bc5a-e94b834ec039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b38353ef-a183-49a5-aba1-0ddfb7a52c52" xlink:to="loc_us-gaap_RestrictedCash_9b19adc5-9914-417f-bc5a-e94b834ec039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperations" xlink:type="simple" xlink:href="mrk-20201231.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ae57803-a074-4789-9ece-ecca0820d945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_4b3a71ee-239e-4d8b-b267-18d1f94dafd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ae57803-a074-4789-9ece-ecca0820d945" xlink:to="loc_us-gaap_NatureOfOperations_4b3a71ee-239e-4d8b-b267-18d1f94dafd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#NatureofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0e3a7f3-6b8e-415f-b6ca-179f8ccd71b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7f85d53c-5fb1-41e3-8504-2d187f3c3eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0e3a7f3-6b8e-415f-b6ca-179f8ccd71b8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7f85d53c-5fb1-41e3-8504-2d187f3c3eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_98795771-1eb9-4e9b-b229-5ee8c78c49c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_30dc7884-0706-4b05-af5a-2ec7fb393ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98795771-1eb9-4e9b-b229-5ee8c78c49c9" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_30dc7884-0706-4b05-af5a-2ec7fb393ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0cd5f6d9-d855-45ea-9c7c-494bcaca86e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0cd5f6d9-d855-45ea-9c7c-494bcaca86e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_9913957f-44c4-484e-a135-e3f7e85406d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_9913957f-44c4-484e-a135-e3f7e85406d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_47108888-74d4-413b-9b63-73895b6ab168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_47108888-74d4-413b-9b63-73895b6ab168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c0ccae67-38a4-4134-ab2f-deb286150448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c0ccae67-38a4-4134-ab2f-deb286150448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_033bceed-aa1f-4927-987f-1507070513aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_033bceed-aa1f-4927-987f-1507070513aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_3afe4b57-04c1-4ddf-803c-1f56662eb786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_3afe4b57-04c1-4ddf-803c-1f56662eb786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_aa3c1f95-9be9-4528-a751-93c066fd29bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_aa3c1f95-9be9-4528-a751-93c066fd29bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_89328453-1642-44e1-87ae-ffa34f880ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_89328453-1642-44e1-87ae-ffa34f880ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_fdf84055-17ba-43a7-92ab-f209e435f976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_fdf84055-17ba-43a7-92ab-f209e435f976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_da0a24a5-7243-4874-a654-a423693fe467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_da0a24a5-7243-4874-a654-a423693fe467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4d0133e7-fedc-4fd4-8912-6ea0323c3202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4d0133e7-fedc-4fd4-8912-6ea0323c3202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_a76eb0eb-31ed-4cc6-b032-2214d708f7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_a76eb0eb-31ed-4cc6-b032-2214d708f7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1279eb8c-0a74-42d9-be42-10bbb03ad919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1279eb8c-0a74-42d9-be42-10bbb03ad919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentConsiderationPolicyTextBlock_d05160d7-29f0-42d0-8bd2-b1aad7f50656" xlink:href="mrk-20201231.xsd#mrk_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_mrk_ContingentConsiderationPolicyTextBlock_d05160d7-29f0-42d0-8bd2-b1aad7f50656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a30affa2-ee57-4644-86e5-be96856efea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a30affa2-ee57-4644-86e5-be96856efea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_88375bd4-c734-4f2c-9dd4-e9464084b6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_88375bd4-c734-4f2c-9dd4-e9464084b6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_84731c63-3843-4c83-8bcc-bc36bf2622ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_84731c63-3843-4c83-8bcc-bc36bf2622ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_194cf084-d126-4e5d-b3f5-fdb26039a9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_194cf084-d126-4e5d-b3f5-fdb26039a9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_457984bf-c362-4cea-be50-ded154af5326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_457984bf-c362-4cea-be50-ded154af5326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_fd9daa59-ff05-45d1-a8f9-3a687a6bcdc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_fd9daa59-ff05-45d1-a8f9-3a687a6bcdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d4753059-24ad-47dc-8a61-9a4d55ab965c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_UseOfEstimates_d4753059-24ad-47dc-8a61-9a4d55ab965c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b248954a-805b-4da4-8955-6a835251dc1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b248954a-805b-4da4-8955-6a835251dc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_80f6bd38-7eed-44da-8f04-db62ce7486fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a91c22e9-83eb-4d49-b237-577245f87fa1" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_80f6bd38-7eed-44da-8f04-db62ce7486fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SummaryofAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5f1d1810-61a0-42fa-84b2-fb2145942e97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f1d1810-61a0-42fa-84b2-fb2145942e97" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_srt_ProductOrServiceAxis_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2bc0ef2f-bf55-4ac2-9b44-57ec977105e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cd75c17f-f07c-4bbf-ba5f-4d83edbdd192" xlink:to="loc_srt_ProductsAndServicesDomain_2bc0ef2f-bf55-4ac2-9b44-57ec977105e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_ce0e8874-bfc9-406c-894c-573f022b9c2b" xlink:href="mrk-20201231.xsd#mrk_KeytrudaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2bc0ef2f-bf55-4ac2-9b44-57ec977105e9" xlink:to="loc_mrk_KeytrudaMember_ce0e8874-bfc9-406c-894c-573f022b9c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7517b5c1-5f2d-46db-8579-3e5af72ff160" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_srt_RangeAxis_7517b5c1-5f2d-46db-8579-3e5af72ff160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3300e551-f994-4559-b9cd-9b9540670db3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7517b5c1-5f2d-46db-8579-3e5af72ff160" xlink:to="loc_srt_RangeMember_3300e551-f994-4559-b9cd-9b9540670db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4ac1c8a-c074-4375-8d49-d24b637c4c37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3300e551-f994-4559-b9cd-9b9540670db3" xlink:to="loc_srt_MinimumMember_a4ac1c8a-c074-4375-8d49-d24b637c4c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d46e9cf-7767-48ad-a836-9bd40a3b6c28" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3300e551-f994-4559-b9cd-9b9540670db3" xlink:to="loc_srt_MaximumMember_0d46e9cf-7767-48ad-a836-9bd40a3b6c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9f127d35-9e16-40d3-81a3-c47e724532be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_srt_StatementGeographicalAxis_9f127d35-9e16-40d3-81a3-c47e724532be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5f2beae2-e23c-4e46-b026-9fc5342bac6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9f127d35-9e16-40d3-81a3-c47e724532be" xlink:to="loc_srt_SegmentGeographicalDomain_5f2beae2-e23c-4e46-b026-9fc5342bac6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_8f378d5a-5d3b-4542-953c-a05f323f51b2" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5f2beae2-e23c-4e46-b026-9fc5342bac6c" xlink:to="loc_country_US_8f378d5a-5d3b-4542-953c-a05f323f51b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_52f0ac3b-09a1-499f-a115-620e9376c937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5f2beae2-e23c-4e46-b026-9fc5342bac6c" xlink:to="loc_us-gaap_NonUsMember_52f0ac3b-09a1-499f-a115-620e9376c937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ef9e4243-0055-4027-984a-53b1fe07fe1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ef9e4243-0055-4027-984a-53b1fe07fe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cd1878bb-4db6-4474-8cc7-fffe8035dd56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef9e4243-0055-4027-984a-53b1fe07fe1e" xlink:to="loc_us-gaap_SegmentDomain_cd1878bb-4db6-4474-8cc7-fffe8035dd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_f8b3ba03-696f-4243-922e-f20d7187a699" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cd1878bb-4db6-4474-8cc7-fffe8035dd56" xlink:to="loc_mrk_PharmaceuticalsegmentMember_f8b3ba03-696f-4243-922e-f20d7187a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_3bbb8087-4b2f-4bb8-8d49-60c49beef821" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cd1878bb-4db6-4474-8cc7-fffe8035dd56" xlink:to="loc_mrk_AnimalHealthsegmentMember_3bbb8087-4b2f-4bb8-8d49-60c49beef821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2cf532aa-4078-4a2e-830e-7a79562fd450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2cf532aa-4078-4a2e-830e-7a79562fd450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d68834e-9af2-4ba6-a51b-45eace522ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2cf532aa-4078-4a2e-830e-7a79562fd450" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d68834e-9af2-4ba6-a51b-45eace522ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_06d96b16-1128-4463-8089-a01043cd5a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d68834e-9af2-4ba6-a51b-45eace522ddc" xlink:to="loc_us-gaap_BuildingMember_06d96b16-1128-4463-8089-a01043cd5a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_f2615d7a-0004-4f60-ae69-99b938e0abd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d68834e-9af2-4ba6-a51b-45eace522ddc" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_f2615d7a-0004-4f60-ae69-99b938e0abd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbc58132-d989-40ba-a54b-1e47d86a9e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbc58132-d989-40ba-a54b-1e47d86a9e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a18dd25b-fc52-4e28-b404-1d85ca45641f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbc58132-d989-40ba-a54b-1e47d86a9e4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a18dd25b-fc52-4e28-b404-1d85ca45641f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a8209a81-0717-4ab3-9ea5-42cf29efa592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a18dd25b-fc52-4e28-b404-1d85ca45641f" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a8209a81-0717-4ab3-9ea5-42cf29efa592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:href="mrk-20201231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef4df99-0c93-4f76-b9db-1d5878a99f85" xlink:to="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_41ab16b1-70fa-4e3d-81cc-b1cb9c938da0" xlink:href="mrk-20201231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_41ab16b1-70fa-4e3d-81cc-b1cb9c938da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_d31345ba-620f-4b9a-b68f-0d5d04242e03" xlink:href="mrk-20201231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_d31345ba-620f-4b9a-b68f-0d5d04242e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_f0d265f2-e85f-4f28-bcd7-de5ecbf3d7a9" xlink:href="mrk-20201231.xsd#mrk_SalesDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_SalesDiscounts_f0d265f2-e85f-4f28-bcd7-de5ecbf3d7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks_0377c4ee-01dd-48c4-b2ce-aabcae92f123" xlink:href="mrk-20201231.xsd#mrk_AccrualForChargebacks"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_AccrualForChargebacks_0377c4ee-01dd-48c4-b2ce-aabcae92f123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates_0922adb1-6cad-4c18-9185-6366c10278a1" xlink:href="mrk-20201231.xsd#mrk_AccrualForRebates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_AccrualForRebates_0922adb1-6cad-4c18-9185-6366c10278a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms_48e6e63d-29d2-4a1e-a26a-da8f2d606960" xlink:href="mrk-20201231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_mrk_RevenuePerformanceObligationPaymentTerms_48e6e63d-29d2-4a1e-a26a-da8f2d606960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f4cf92fb-f840-4f28-99ed-4ac672a36e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f4cf92fb-f840-4f28-99ed-4ac672a36e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_81efb941-4949-46f7-81e5-7bb6b5a4c5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_Depreciation_81efb941-4949-46f7-81e5-7bb6b5a4c5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_351e2e92-b8ec-493b-b71a-c5164e95b0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_AdvertisingExpense_351e2e92-b8ec-493b-b71a-c5164e95b0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f9514ae2-b3ac-4e2b-9260-de3fb5c10b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f9514ae2-b3ac-4e2b-9260-de3fb5c10b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2c21daed-288c-4794-b725-9d507a5bd695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2c21daed-288c-4794-b725-9d507a5bd695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b87fdb5c-4e18-433f-b072-ba6ff2a3cc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b87fdb5c-4e18-433f-b072-ba6ff2a3cc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_911a4473-d03e-49ca-a694-04204068b1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_70b5a0f8-9829-4b8a-abbd-d711e70963d1" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_911a4473-d03e-49ca-a694-04204068b1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_861e3034-c176-4437-8fcb-f71984b2b622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock_5052bde7-86e0-44d3-ac56-f698ea932f11" xlink:href="mrk-20201231.xsd#mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_861e3034-c176-4437-8fcb-f71984b2b622" xlink:to="loc_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock_5052bde7-86e0-44d3-ac56-f698ea932f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a5c2fbb4-42e3-4f35-9345-a245b9df89f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e97a08c4-faa0-4e1b-b6d1-647eda45f4d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a5c2fbb4-42e3-4f35-9345-a245b9df89f6" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e97a08c4-faa0-4e1b-b6d1-647eda45f4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f3262670-242b-4382-8680-0116c3c45583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f3262670-242b-4382-8680-0116c3c45583" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a9914af8-a5f9-4723-a972-30c15ac0ca90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a9914af8-a5f9-4723-a972-30c15ac0ca90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e8bd64b7-1b9e-4f8d-a035-498757fcc099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9914af8-a5f9-4723-a972-30c15ac0ca90" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e8bd64b7-1b9e-4f8d-a035-498757fcc099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8f8f2abb-682c-4369-8417-f9236328bef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e8bd64b7-1b9e-4f8d-a035-498757fcc099" xlink:to="loc_us-gaap_SubsequentEventMember_8f8f2abb-682c-4369-8417-f9236328bef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_0565e91a-8fc3-4bd4-ac8c-1ad1ebd537a6" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_c3287003-b56c-446e-b5b6-b532609880b0" xlink:href="mrk-20201231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:to="loc_mrk_RegulatoryMilestonesMember_c3287003-b56c-446e-b5b6-b532609880b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialmilestoneMember_13bdf932-102e-4973-a37d-0ca73396be6f" xlink:href="mrk-20201231.xsd#mrk_CommercialmilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:to="loc_mrk_CommercialmilestoneMember_13bdf932-102e-4973-a37d-0ca73396be6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_abed4f33-4a18-4f92-b834-3519cc57fb87" xlink:href="mrk-20201231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:to="loc_mrk_SalesBasedMilestonesMember_abed4f33-4a18-4f92-b834-3519cc57fb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_9957df60-db6d-4a1f-a81c-ad02b6b1db79" xlink:href="mrk-20201231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_093e9851-6209-4c39-a183-26bef7d4594a" xlink:to="loc_mrk_DevelopmentMilestonesMember_9957df60-db6d-4a1f-a81c-ad02b6b1db79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eab11d62-dd00-4643-83b8-b0a500db37a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eab11d62-dd00-4643-83b8-b0a500db37a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eab11d62-dd00-4643-83b8-b0a500db37a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_8d9e9ff6-45e4-496c-9e5c-6037ccbc6446" xlink:href="mrk-20201231.xsd#mrk_OncoImmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_OncoImmuneMember_8d9e9ff6-45e4-496c-9e5c-6037ccbc6446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_313edcaa-f6a5-4d4d-a57c-6f8820483851" xlink:href="mrk-20201231.xsd#mrk_VelosBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_VelosBioMember_313edcaa-f6a5-4d4d-a57c-6f8820483851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_d71d715c-cf8b-432b-86cb-90ce676535c7" xlink:href="mrk-20201231.xsd#mrk_DunboyneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_DunboyneMember_d71d715c-cf8b-432b-86cb-90ce676535c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember_c25a76d4-18ca-47a2-be58-5ddec03d9d0c" xlink:href="mrk-20201231.xsd#mrk_ThemisMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_ThemisMember_c25a76d4-18ca-47a2-be58-5ddec03d9d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_bc750170-0e7c-4ffe-990b-9debc61df298" xlink:href="mrk-20201231.xsd#mrk_ArQuleMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_ArQuleMember_bc750170-0e7c-4ffe-990b-9debc61df298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember_c61f5dc5-3584-4b0a-a939-9fb340359d8d" xlink:href="mrk-20201231.xsd#mrk_PelotonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_PelotonMember_c61f5dc5-3584-4b0a-a939-9fb340359d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_89e8f4f3-202e-4d80-a8aa-06826df2608f" xlink:href="mrk-20201231.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_AntelliqMember_89e8f4f3-202e-4d80-a8aa-06826df2608f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember_78e43277-adda-4528-a099-fa099666a0ab" xlink:href="mrk-20201231.xsd#mrk_ImmuneDesignMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_ImmuneDesignMember_78e43277-adda-4528-a099-fa099666a0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ViralyticsMember_b0eee74d-27d0-4b2f-b825-2a90775a5659" xlink:href="mrk-20201231.xsd#mrk_ViralyticsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dea6a801-39e0-4e08-8212-3ea6187c3118" xlink:to="loc_mrk_ViralyticsMember_b0eee74d-27d0-4b2f-b825-2a90775a5659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c347504-5c3c-428b-96df-ea4f25b78511" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_srt_CounterpartyNameAxis_5c347504-5c3c-428b-96df-ea4f25b78511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5c347504-5c3c-428b-96df-ea4f25b78511" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember_8058bc66-ffe6-4b48-8f9d-542e034951c2" xlink:href="mrk-20201231.xsd#mrk_SeagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:to="loc_mrk_SeagenMember_8058bc66-ffe6-4b48-8f9d-542e034951c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_fc9063c0-8cd2-47e7-9d1e-0fac4c8207f1" xlink:href="mrk-20201231.xsd#mrk_SentinelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:to="loc_mrk_SentinelMember_fc9063c0-8cd2-47e7-9d1e-0fac4c8207f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember_061467b2-f686-45b0-94df-873cd679f979" xlink:href="mrk-20201231.xsd#mrk_IAVIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41e31199-0ccc-4f96-85d9-f000eaabe791" xlink:to="loc_mrk_IAVIMember_061467b2-f686-45b0-94df-873cd679f979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8f29a4a1-d3ba-4fa0-bb48-79305f15589b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_srt_ProductOrServiceAxis_8f29a4a1-d3ba-4fa0-bb48-79305f15589b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8f29a4a1-d3ba-4fa0-bb48-79305f15589b" xlink:to="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember_f64b1790-0850-4e48-9273-730bc93c5017" xlink:href="mrk-20201231.xsd#mrk_TukysaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:to="loc_mrk_TukysaMember_f64b1790-0850-4e48-9273-730bc93c5017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_3fc872f2-4c43-40c9-8b4e-c6096d9be92c" xlink:href="mrk-20201231.xsd#mrk_SentinelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:to="loc_mrk_SentinelMember_3fc872f2-4c43-40c9-8b4e-c6096d9be92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_4c740deb-5241-472e-b665-07b6744c0057" xlink:href="mrk-20201231.xsd#mrk_COVID19Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb6d78a0-f4c0-4b60-a4c8-699cd4722daf" xlink:to="loc_mrk_COVID19Member_4c740deb-5241-472e-b665-07b6744c0057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_958c6227-2e82-425e-b11a-2c067c0b1673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_958c6227-2e82-425e-b11a-2c067c0b1673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_254ba74b-8bf5-4b72-9df8-890a055e6eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_958c6227-2e82-425e-b11a-2c067c0b1673" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_254ba74b-8bf5-4b72-9df8-890a055e6eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_da007b23-1a7b-402f-8cec-3607c2e775e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_254ba74b-8bf5-4b72-9df8-890a055e6eb1" xlink:to="loc_us-gaap_ForwardContractsMember_da007b23-1a7b-402f-8cec-3607c2e775e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a79b2188-abad-4d4d-a30a-fcfaf6508dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a79b2188-abad-4d4d-a30a-fcfaf6508dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_023e42bf-245a-4ce1-b742-02542669e224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a79b2188-abad-4d4d-a30a-fcfaf6508dfe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_023e42bf-245a-4ce1-b742-02542669e224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ca7d1b1f-44a3-4304-af49-6accf88621c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_023e42bf-245a-4ce1-b742-02542669e224" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ca7d1b1f-44a3-4304-af49-6accf88621c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8dc1e454-3dcb-45d1-857c-847c44eeca79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_srt_RangeAxis_8dc1e454-3dcb-45d1-857c-847c44eeca79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7bc9cf8-920b-42d9-ba7e-1781b96f752d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8dc1e454-3dcb-45d1-857c-847c44eeca79" xlink:to="loc_srt_RangeMember_c7bc9cf8-920b-42d9-ba7e-1781b96f752d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9f3321da-2ba4-4b77-a041-17420b57b3cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7bc9cf8-920b-42d9-ba7e-1781b96f752d" xlink:to="loc_srt_MinimumMember_9f3321da-2ba4-4b77-a041-17420b57b3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6682d590-aef4-4297-88bf-7d8b19cd4246" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7bc9cf8-920b-42d9-ba7e-1781b96f752d" xlink:to="loc_srt_MaximumMember_6682d590-aef4-4297-88bf-7d8b19cd4246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_937747b1-58e0-43ac-b02a-5d7a52fbd225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_937747b1-58e0-43ac-b02a-5d7a52fbd225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_672f11db-2806-4c35-83f9-8c749cb47dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_937747b1-58e0-43ac-b02a-5d7a52fbd225" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_672f11db-2806-4c35-83f9-8c749cb47dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_efa1a939-4ea2-4a15-b781-7be186736298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_672f11db-2806-4c35-83f9-8c749cb47dc5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_efa1a939-4ea2-4a15-b781-7be186736298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_493036d3-0afc-4a5a-91f2-43d8353d5556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_493036d3-0afc-4a5a-91f2-43d8353d5556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1bc403ae-8d86-4f29-b85c-4ec9ca18446c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_493036d3-0afc-4a5a-91f2-43d8353d5556" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1bc403ae-8d86-4f29-b85c-4ec9ca18446c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1a4e262e-7305-40a7-bf53-04164586fc11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1bc403ae-8d86-4f29-b85c-4ec9ca18446c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1a4e262e-7305-40a7-bf53-04164586fc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff9fd3f5-05d9-4d02-a5ef-6bd6dafebe9c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d435e6c0-4420-493d-820d-90c6fffe115c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d435e6c0-4420-493d-820d-90c6fffe115c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9a399419-98a2-493f-a1b1-4b8d50f53147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9a399419-98a2-493f-a1b1-4b8d50f53147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_38e831a5-c383-4ff3-aff7-9ce134000449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_38e831a5-c383-4ff3-aff7-9ce134000449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4314dbe9-4f64-480d-b6fc-8c9656825bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4314dbe9-4f64-480d-b6fc-8c9656825bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3b9f2d10-b3e6-405c-9c03-f1cc07545127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3b9f2d10-b3e6-405c-9c03-f1cc07545127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_837ae31c-0677-4bd0-b8c0-18132fb19e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_837ae31c-0677-4bd0-b8c0-18132fb19e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1dc932c3-f6de-4bc5-b9f6-5e193e605d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1dc932c3-f6de-4bc5-b9f6-5e193e605d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_74ca305a-1637-42bf-af92-2000edf1fe92" xlink:href="mrk-20201231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_74ca305a-1637-42bf-af92-2000edf1fe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8b783d24-28d1-490f-89a4-fc323af1f43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_Goodwill_8b783d24-28d1-490f-89a4-fc323af1f43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_700193a4-3a6f-4831-8e64-7cebe8c06a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_700193a4-3a6f-4831-8e64-7cebe8c06a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_09ac48a5-5c2b-4336-9225-aafed54522a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_09ac48a5-5c2b-4336-9225-aafed54522a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2c848b1a-55e3-4772-9455-18bb298669b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2c848b1a-55e3-4772-9455-18bb298669b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d258c1c7-128e-4f39-9805-ed69b6155b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d258c1c7-128e-4f39-9805-ed69b6155b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_b7fd706c-2939-44d6-b012-7e626268afb2" xlink:href="mrk-20201231.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_b7fd706c-2939-44d6-b012-7e626268afb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_a53ae429-bb0c-46a6-a669-8a50789535c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity_a53ae429-bb0c-46a6-a669-8a50789535c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_4ef14c5e-524f-4a5a-bfc0-efec8b6e196d" xlink:href="mrk-20201231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_4ef14c5e-524f-4a5a-bfc0-efec8b6e196d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_fab106fd-43a7-4556-96b7-c41dd469cb34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_fab106fd-43a7-4556-96b7-c41dd469cb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_7f650b1e-bca6-4355-b018-8e7abe3ab6b9" xlink:href="mrk-20201231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_RoyaltyRatePercentage_7f650b1e-bca6-4355-b018-8e7abe3ab6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_120c9960-c48a-4bcb-9a2c-64f449e6ac9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_120c9960-c48a-4bcb-9a2c-64f449e6ac9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_fb805323-0262-45d5-9562-f8b0b1df937c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_fb805323-0262-45d5-9562-f8b0b1df937c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_82cced13-877e-486f-bc31-b0edcbc837f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_82cced13-877e-486f-bc31-b0edcbc837f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_94b9b293-ad9d-4eb8-b8c5-d2de4072190c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_94b9b293-ad9d-4eb8-b8c5-d2de4072190c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_cdca4d77-5c6e-421f-af6d-b17b5997be27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_cdca4d77-5c6e-421f-af6d-b17b5997be27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9b763866-8666-41d4-8ad6-2aa13ef53f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9b763866-8666-41d4-8ad6-2aa13ef53f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c6a2c5fa-f997-4938-ade8-ab4c3ea18052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c6a2c5fa-f997-4938-ade8-ab4c3ea18052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_7103d82f-ecbe-47c6-9b4b-2d813099365b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_7103d82f-ecbe-47c6-9b4b-2d813099365b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_afe2f9de-c13b-4c94-847e-ee264f8cf306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_SharePrice_afe2f9de-c13b-4c94-847e-ee264f8cf306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_41249712-4eed-4528-9b09-a83796ef78af" xlink:href="mrk-20201231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_41249712-4eed-4528-9b09-a83796ef78af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_9597a93d-b67f-4596-ba36-8c5ef0afa77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_9597a93d-b67f-4596-ba36-8c5ef0afa77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation_a31b287c-d138-4f37-9063-2ae3db1a5e9d" xlink:href="mrk-20201231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_ChargesRelatedToProgramDiscontinuation_a31b287c-d138-4f37-9063-2ae3db1a5e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired_cc4709ad-ba39-45cf-85f7-48ea3d779872" xlink:href="mrk-20201231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_mrk_PremiumOnSharesAcquired_cc4709ad-ba39-45cf-85f7-48ea3d779872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_9ee39a0a-343d-4822-93bc-5e689c5cd00a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_Investments_9ee39a0a-343d-4822-93bc-5e689c5cd00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_61b32f9d-a08d-4a85-b2d6-dc460648a49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_61b32f9d-a08d-4a85-b2d6-dc460648a49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5b61db8f-3cc0-41f7-8287-0db32fc7190d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c56f05f6-9a9b-43b7-a8f9-4a0fff4c2adb" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5b61db8f-3cc0-41f7-8287-0db32fc7190d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8b0495d7-e60b-483c-aa02-6a74edbba9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1a1d878b-e5cd-465e-a3fd-63a762a03611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8b0495d7-e60b-483c-aa02-6a74edbba9f9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1a1d878b-e5cd-465e-a3fd-63a762a03611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9132f6c-6561-40e4-beac-7c77f3804fb0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1a1d878b-e5cd-465e-a3fd-63a762a03611" xlink:to="loc_srt_CounterpartyNameAxis_a9132f6c-6561-40e4-beac-7c77f3804fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6248086-ab3a-4926-a067-93880e7aa786" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a9132f6c-6561-40e4-beac-7c77f3804fb0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6248086-ab3a-4926-a067-93880e7aa786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SamsungMember_cb39996e-c650-4c8a-a2b4-ed301a1385f9" xlink:href="mrk-20201231.xsd#mrk_SamsungMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6248086-ab3a-4926-a067-93880e7aa786" xlink:to="loc_mrk_SamsungMember_cb39996e-c650-4c8a-a2b4-ed301a1385f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1a1d878b-e5cd-465e-a3fd-63a762a03611" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_ccd404d9-8b0e-4c40-aa0b-04594914c516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_us-gaap_GainLossOnContractTermination_ccd404d9-8b0e-4c40-aa0b-04594914c516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Contractterminationfeepayment_2b174ebe-bb7c-4218-8d52-2565fe42f70b" xlink:href="mrk-20201231.xsd#mrk_Contractterminationfeepayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_mrk_Contractterminationfeepayment_2b174ebe-bb7c-4218-8d52-2565fe42f70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherContractTerminationCosts_531426cf-8d11-4bc1-bb60-c5384c346a0c" xlink:href="mrk-20201231.xsd#mrk_OtherContractTerminationCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_mrk_OtherContractTerminationCosts_531426cf-8d11-4bc1-bb60-c5384c346a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_23e07dee-55a7-44b2-9282-90f50714bda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss_23e07dee-55a7-44b2-9282-90f50714bda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_3e35e0de-23cd-4094-ba6f-a74d51267234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64daa4b5-2946-4e80-ac90-e330592f66fd" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_3e35e0de-23cd-4094-ba6f-a74d51267234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_974098ea-a829-4a06-8212-6616e73c1f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_974098ea-a829-4a06-8212-6616e73c1f0f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99818658-af55-40eb-8c28-a95c6d85021e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:to="loc_srt_RangeAxis_99818658-af55-40eb-8c28-a95c6d85021e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba9d15ab-5753-4aca-8ca2-14d54b925e61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_99818658-af55-40eb-8c28-a95c6d85021e" xlink:to="loc_srt_RangeMember_ba9d15ab-5753-4aca-8ca2-14d54b925e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_61d5cd1c-b086-4abb-a3ae-05593d760708" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba9d15ab-5753-4aca-8ca2-14d54b925e61" xlink:to="loc_srt_MinimumMember_61d5cd1c-b086-4abb-a3ae-05593d760708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8055cad6-7656-4b6f-a3ba-09f24127d5cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba9d15ab-5753-4aca-8ca2-14d54b925e61" xlink:to="loc_srt_MaximumMember_8055cad6-7656-4b6f-a3ba-09f24127d5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c4b28f6f-d591-4024-9879-10bfe55b9547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c4b28f6f-d591-4024-9879-10bfe55b9547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df38f7bc-b4cf-4eaf-911a-1306d86ddfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c4b28f6f-d591-4024-9879-10bfe55b9547" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df38f7bc-b4cf-4eaf-911a-1306d86ddfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_d4d29b7d-a1c0-4e4b-a4a5-b88faa0e5ff4" xlink:href="mrk-20201231.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df38f7bc-b4cf-4eaf-911a-1306d86ddfaa" xlink:to="loc_mrk_AntelliqMember_d4d29b7d-a1c0-4e4b-a4a5-b88faa0e5ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_752a391d-43ba-4e0d-8fcc-a380c1226874" xlink:href="mrk-20201231.xsd#mrk_ArQuleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df38f7bc-b4cf-4eaf-911a-1306d86ddfaa" xlink:to="loc_mrk_ArQuleMember_752a391d-43ba-4e0d-8fcc-a380c1226874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4c433681-f58e-4cee-80bd-fd92b9f51912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4c433681-f58e-4cee-80bd-fd92b9f51912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e4691ce5-bab3-4191-b8e7-b18c830d6b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4c433681-f58e-4cee-80bd-fd92b9f51912" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e4691ce5-bab3-4191-b8e7-b18c830d6b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a2d87c1d-d7fc-4c34-80b5-d090dd8dac34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e4691ce5-bab3-4191-b8e7-b18c830d6b6a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a2d87c1d-d7fc-4c34-80b5-d090dd8dac34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92cd0675-cd9f-4169-9534-8c1c31c5fb17" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0b65b579-9b39-495f-a3a2-122138d5cc25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0b65b579-9b39-495f-a3a2-122138d5cc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_35093893-9dc2-421d-a847-5082407ff250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_35093893-9dc2-421d-a847-5082407ff250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a50333c7-0879-454b-bf09-091b3ee9244a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a50333c7-0879-454b-bf09-091b3ee9244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_c38cdbbe-20f7-40a3-9efb-0c0a3dfadd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_c38cdbbe-20f7-40a3-9efb-0c0a3dfadd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_02a08027-880d-4652-92ec-baef962e1549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_02a08027-880d-4652-92ec-baef962e1549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_99019409-4500-4c2b-96ec-794337691917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_99019409-4500-4c2b-96ec-794337691917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bc08c098-77da-4463-b005-20398a628348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bc08c098-77da-4463-b005-20398a628348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7207010e-af44-4bd3-94f4-7117f31014a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7207010e-af44-4bd3-94f4-7117f31014a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_e0811b85-da79-4480-9fb0-78d9a29d2001" xlink:href="mrk-20201231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_e0811b85-da79-4480-9fb0-78d9a29d2001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d5d3198d-6924-40b3-9002-746058b7b6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d5d3198d-6924-40b3-9002-746058b7b6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a03b34d0-672f-47b0-ae3a-c6dd7175ff9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_Goodwill_a03b34d0-672f-47b0-ae3a-c6dd7175ff9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c928ed4f-9e06-4541-a80b-268a0a5ca74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c928ed4f-9e06-4541-a80b-268a0a5ca74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_8b20ce87-12f2-4654-baf0-d9456e86d943" xlink:href="mrk-20201231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bd5d2209-e201-4e0c-8956-116367b05e6a" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_8b20ce87-12f2-4654-baf0-d9456e86d943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_27083030-5116-47d8-a91d-7c81a84278a9" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c576d848-de54-4e1e-8ce8-94fd92c4ffc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_27083030-5116-47d8-a91d-7c81a84278a9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c576d848-de54-4e1e-8ce8-94fd92c4ffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_46bfa157-a00f-4654-995b-0d4873573e31" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_068d1da0-6748-4822-93c9-366dc3cdf33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_46bfa157-a00f-4654-995b-0d4873573e31" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_068d1da0-6748-4822-93c9-366dc3cdf33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_ca977e0b-a0ec-4db0-8353-72e54a6732fc" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_ca977e0b-a0ec-4db0-8353-72e54a6732fc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a56256f1-6236-4bfe-8ffe-271eb6f126d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a56256f1-6236-4bfe-8ffe-271eb6f126d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6aeb0e81-b5fb-4e24-bf8b-5a93e43f05fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a56256f1-6236-4bfe-8ffe-271eb6f126d8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6aeb0e81-b5fb-4e24-bf8b-5a93e43f05fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1c4b4b0f-efd0-4f15-a649-aa7dda10ea6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6aeb0e81-b5fb-4e24-bf8b-5a93e43f05fb" xlink:to="loc_us-gaap_SubsequentEventMember_1c4b4b0f-efd0-4f15-a649-aa7dda10ea6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ce040811-b635-4114-a814-8705c942b953" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_srt_CounterpartyNameAxis_ce040811-b635-4114-a814-8705c942b953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ce040811-b635-4114-a814-8705c942b953" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_3ff12b20-ef73-47b8-93b5-ff12f669acfe" xlink:href="mrk-20201231.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:to="loc_mrk_AstraZenecaMember_3ff12b20-ef73-47b8-93b5-ff12f669acfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_0f6b8fbb-364f-4851-83b3-2a0f7ec5fe47" xlink:href="mrk-20201231.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:to="loc_mrk_EisaiMember_0f6b8fbb-364f-4851-83b3-2a0f7ec5fe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_3d70cfb7-a4ba-48de-8ace-0ef223ad8475" xlink:href="mrk-20201231.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a27d31a4-0e9d-4534-a45c-474e1e2cc8ea" xlink:to="loc_mrk_BayerAGMember_3d70cfb7-a4ba-48de-8ace-0ef223ad8475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4d521d82-a987-4e54-ad96-cbe9a56f969a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_srt_StatementScenarioAxis_4d521d82-a987-4e54-ad96-cbe9a56f969a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ebb1ed46-7f34-4ded-93ed-1f08179875b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_4d521d82-a987-4e54-ad96-cbe9a56f969a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ebb1ed46-7f34-4ded-93ed-1f08179875b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_7a7460ec-a4af-4d74-aa9d-0fc3881656bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ebb1ed46-7f34-4ded-93ed-1f08179875b0" xlink:to="loc_srt_ScenarioForecastMember_7a7460ec-a4af-4d74-aa9d-0fc3881656bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed3ec40f-f573-43b3-9925-6c511adcebde" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_srt_ProductOrServiceAxis_ed3ec40f-f573-43b3-9925-6c511adcebde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ed3ec40f-f573-43b3-9925-6c511adcebde" xlink:to="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_4855890e-577e-40dd-954f-7127f0d6af47" xlink:href="mrk-20201231.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:to="loc_mrk_LynparzaMember_4855890e-577e-40dd-954f-7127f0d6af47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_58566669-f2a6-443e-948a-d3b01707b1ee" xlink:href="mrk-20201231.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:to="loc_mrk_AstraZenecaMember_58566669-f2a6-443e-948a-d3b01707b1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_87034fd3-5ca2-4f6c-bdf8-51fa86f58b4e" xlink:href="mrk-20201231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:to="loc_mrk_LenvimaMember_87034fd3-5ca2-4f6c-bdf8-51fa86f58b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_696619b6-4671-45d0-b126-35a81040363a" xlink:href="mrk-20201231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ab609c0-aeac-414c-85a2-f39a16dd895a" xlink:to="loc_mrk_AdempasMember_696619b6-4671-45d0-b126-35a81040363a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_caad3f15-2a88-42cc-91f7-37480951ee9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f35f2f2a-075a-4e7f-8e44-b60cfd216a1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_caad3f15-2a88-42cc-91f7-37480951ee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_e170aeee-e67b-408d-869d-617feb5c8ee6" xlink:href="mrk-20201231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_caad3f15-2a88-42cc-91f7-37480951ee9b" xlink:to="loc_mrk_SalesBasedMilestonesMember_e170aeee-e67b-408d-869d-617feb5c8ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_5bca32ac-b842-413a-bd8a-ddfe173fa118" xlink:href="mrk-20201231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_caad3f15-2a88-42cc-91f7-37480951ee9b" xlink:to="loc_mrk_RegulatoryMilestonesMember_5bca32ac-b842-413a-bd8a-ddfe173fa118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_36f0d761-37e7-4534-a0dd-6a956bf06e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96377ac7-8032-4a42-9c6d-0c4c5a0cf5a2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_36f0d761-37e7-4534-a0dd-6a956bf06e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_0af2e53b-2987-46ac-bbcd-c0206e7c4a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_36f0d761-37e7-4534-a0dd-6a956bf06e3e" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_0af2e53b-2987-46ac-bbcd-c0206e7c4a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8653446b-77a5-453d-9415-a3c70467cff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7d440a8-8b3f-43d7-b9d6-128c9ebd36aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8653446b-77a5-453d-9415-a3c70467cff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_5da27c65-6b70-4637-a729-efe6ad83ba50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8653446b-77a5-453d-9415-a3c70467cff2" xlink:to="loc_us-gaap_LicenseMember_5da27c65-6b70-4637-a729-efe6ad83ba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ebdc03-2396-4498-ba63-2dbdb37b818b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_48c50481-0e2e-403b-a0b1-0cc7d7b140bb" xlink:href="mrk-20201231.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_48c50481-0e2e-403b-a0b1-0cc7d7b140bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_17709d12-0e8b-443a-9b43-f994287a4f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_17709d12-0e8b-443a-9b43-f994287a4f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7758e1af-9614-403b-b542-2395372eb20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7758e1af-9614-403b-b542-2395372eb20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_bcdadc3e-b306-49e4-bb07-132fafa8d5a6" xlink:href="mrk-20201231.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_bcdadc3e-b306-49e4-bb07-132fafa8d5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_657ff9a5-aab7-4eb8-a648-e609442e8601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_Liabilities_657ff9a5-aab7-4eb8-a648-e609442e8601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_459f1800-1120-4460-96ce-0992c807b3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_459f1800-1120-4460-96ce-0992c807b3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d531fc2-f4dc-4262-8a1e-cdafaff6985d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8d531fc2-f4dc-4262-8a1e-cdafaff6985d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1ccaf23f-0150-49eb-809b-88df37cf5240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1ccaf23f-0150-49eb-809b-88df37cf5240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_0255b9b5-e206-4045-a1ec-1cc1099a2dce" xlink:href="mrk-20201231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_0255b9b5-e206-4045-a1ec-1cc1099a2dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_87a9da17-c7cc-49f6-8411-96ac2149161d" xlink:href="mrk-20201231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_87a9da17-c7cc-49f6-8411-96ac2149161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ea07dc2-3977-44cf-ae85-c37193138a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ea07dc2-3977-44cf-ae85-c37193138a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1f4125b2-9a1a-4de3-a353-df191d4e7760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1f4125b2-9a1a-4de3-a353-df191d4e7760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d578648-30a5-4604-b0f6-072c798cb061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d578648-30a5-4604-b0f6-072c798cb061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f2ff0a22-c89a-4ced-815a-1a40ef7fd0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f2ff0a22-c89a-4ced-815a-1a40ef7fd0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c31d0396-b586-4c2a-9f32-0ea83f5ef9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c31d0396-b586-4c2a-9f32-0ea83f5ef9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6f927367-0264-436c-b100-ce03c01ef14e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_101ab1d6-5742-46e1-a1ed-3c7a600b9a3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6f927367-0264-436c-b100-ce03c01ef14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_a6be7742-bd40-42e5-af8d-d4451232d247" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_a6be7742-bd40-42e5-af8d-d4451232d247" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9cbe77e9-f047-41ed-8e06-a7bdfa499709" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_srt_CounterpartyNameAxis_9cbe77e9-f047-41ed-8e06-a7bdfa499709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9cbe77e9-f047-41ed-8e06-a7bdfa499709" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_ef40dd50-f217-4b19-9e12-dfb6b1e045d0" xlink:href="mrk-20201231.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:to="loc_mrk_AstraZenecaMember_ef40dd50-f217-4b19-9e12-dfb6b1e045d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_9745c3dd-5d9b-4c00-9096-5a9d74a1a801" xlink:href="mrk-20201231.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:to="loc_mrk_EisaiMember_9745c3dd-5d9b-4c00-9096-5a9d74a1a801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_0b7550b3-367b-439f-8235-112037869a32" xlink:href="mrk-20201231.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ad5db35-78dd-441d-b930-bfa997d2233a" xlink:to="loc_mrk_BayerAGMember_0b7550b3-367b-439f-8235-112037869a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b54c4dab-afde-4119-8fa1-c01e7e23e125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b54c4dab-afde-4119-8fa1-c01e7e23e125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e331ccb3-46ac-401c-8836-23cabcfdb2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b54c4dab-afde-4119-8fa1-c01e7e23e125" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e331ccb3-46ac-401c-8836-23cabcfdb2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_84d16fe4-0504-4902-8558-e5749caeab9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e331ccb3-46ac-401c-8836-23cabcfdb2a5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_84d16fe4-0504-4902-8558-e5749caeab9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_209aa41f-10da-4207-988c-d1f08e04abe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_209aa41f-10da-4207-988c-d1f08e04abe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_209aa41f-10da-4207-988c-d1f08e04abe9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_31d7dbbb-ba62-4490-a304-b2a173e17573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:to="loc_us-gaap_SalesMember_31d7dbbb-ba62-4490-a304-b2a173e17573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_e009dde2-26d1-4432-ac72-a1a6de0f351e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:to="loc_us-gaap_CostOfSalesMember_e009dde2-26d1-4432-ac72-a1a6de0f351e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_03227184-beec-4f24-b95d-09e39801fedf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_03227184-beec-4f24-b95d-09e39801fedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_804f3f45-b7af-4b0a-82c2-be9f5ede8b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b988f9ae-35a8-4bae-8398-b724d2b2ffb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_804f3f45-b7af-4b0a-82c2-be9f5ede8b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1e700088-f5fc-4a04-b474-97a5b19214a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1e700088-f5fc-4a04-b474-97a5b19214a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1e700088-f5fc-4a04-b474-97a5b19214a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_c5d6967a-968f-4893-8060-31d6eb3b8e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_c5d6967a-968f-4893-8060-31d6eb3b8e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_9573cb21-7f31-4443-bc61-24eb0c7143f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_9573cb21-7f31-4443-bc61-24eb0c7143f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_eecf8c27-958a-4f0e-a3e4-71f0b02fee68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00d3dff4-d82e-4b06-85aa-29a9f991b09a" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_eecf8c27-958a-4f0e-a3e4-71f0b02fee68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9de5a396-00f6-43aa-87e8-26b5d431e34c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_srt_ProductOrServiceAxis_9de5a396-00f6-43aa-87e8-26b5d431e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f285266-194a-4339-b14c-d8c469160e02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9de5a396-00f6-43aa-87e8-26b5d431e34c" xlink:to="loc_srt_ProductsAndServicesDomain_0f285266-194a-4339-b14c-d8c469160e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_746c657c-5b60-4629-bc1c-c9b2583b1d4d" xlink:href="mrk-20201231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f285266-194a-4339-b14c-d8c469160e02" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_746c657c-5b60-4629-bc1c-c9b2583b1d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_e8bf2308-163d-47fb-a265-a6194cb40f2b" xlink:href="mrk-20201231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f285266-194a-4339-b14c-d8c469160e02" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_e8bf2308-163d-47fb-a265-a6194cb40f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_314a627a-ab46-4729-94f9-2d294dc2f898" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_92d045c6-6323-4bb3-a9a6-2ff7142dda26" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_92d045c6-6323-4bb3-a9a6-2ff7142dda26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_ef1fae31-dc2e-4983-9155-3b45d6a73ec5" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_ef1fae31-dc2e-4983-9155-3b45d6a73ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_215b1d60-5d15-47dd-a289-a2c7f6f6b691" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts_215b1d60-5d15-47dd-a289-a2c7f6f6b691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementExpenses_fc594205-e053-4fff-b33f-0638574a2dba" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementExpenses_fc594205-e053-4fff-b33f-0638574a2dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementReceivable_47ef7258-c901-489b-863d-711963ddd94b" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementReceivable_47ef7258-c901-489b-863d-711963ddd94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPayable_2097320b-3ad3-4de8-96cd-21f9e9c28225" xlink:href="mrk-20201231.xsd#mrk_CollaborativeArrangementPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff30faf-c775-40f5-a720-3c20f4f12cd6" xlink:to="loc_mrk_CollaborativeArrangementPayable_2097320b-3ad3-4de8-96cd-21f9e9c28225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20201231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1a7a25e5-bef4-4d9b-b192-78f9f27cb588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bcacea71-a658-40d1-93fc-894eba552ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1a7a25e5-bef4-4d9b-b192-78f9f27cb588" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bcacea71-a658-40d1-93fc-894eba552ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b2f507c3-bdd0-4516-8290-c45a8327c842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_99cf6861-5c04-4336-94c8-c8f5c4898138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b2f507c3-bdd0-4516-8290-c45a8327c842" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_99cf6861-5c04-4336-94c8-c8f5c4898138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e589873c-cdc5-4b17-984d-a48a50572da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b2f507c3-bdd0-4516-8290-c45a8327c842" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e589873c-cdc5-4b17-984d-a48a50572da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4998e203-61a2-4f42-b159-c2bdaea59c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4998e203-61a2-4f42-b159-c2bdaea59c85" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ce22ab91-6994-430d-a1b1-d3a2c11bbbce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:to="loc_srt_StatementScenarioAxis_ce22ab91-6994-430d-a1b1-d3a2c11bbbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_87e01967-bf37-43fa-baae-c45332f09e46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ce22ab91-6994-430d-a1b1-d3a2c11bbbce" xlink:to="loc_srt_ScenarioUnspecifiedDomain_87e01967-bf37-43fa-baae-c45332f09e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_fee7d0e0-a885-46e6-994e-0edda776ac31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_87e01967-bf37-43fa-baae-c45332f09e46" xlink:to="loc_srt_ScenarioForecastMember_fee7d0e0-a885-46e6-994e-0edda776ac31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5615f98-76b5-4c89-8d72-453051694a31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:to="loc_srt_RangeAxis_d5615f98-76b5-4c89-8d72-453051694a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_71345202-b5a0-4da8-b4fc-8db8ffbc9198" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d5615f98-76b5-4c89-8d72-453051694a31" xlink:to="loc_srt_RangeMember_71345202-b5a0-4da8-b4fc-8db8ffbc9198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_986093fa-83a6-40ea-bc9a-22b6dc2d3e9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_71345202-b5a0-4da8-b4fc-8db8ffbc9198" xlink:to="loc_srt_MaximumMember_986093fa-83a6-40ea-bc9a-22b6dc2d3e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7fbe62f-7c9b-4f5d-95ad-e3da879c0fc2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_71345202-b5a0-4da8-b4fc-8db8ffbc9198" xlink:to="loc_srt_MinimumMember_c7fbe62f-7c9b-4f5d-95ad-e3da879c0fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e26b7beb-82bc-4de0-a9d5-2fcef62c3282" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e4dd177b-aa50-42b5-81ad-dfbdc2fa193b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e4dd177b-aa50-42b5-81ad-dfbdc2fa193b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_034274ca-f89b-4cb5-8f94-a0dfc6df5302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_034274ca-f89b-4cb5-8f94-a0dfc6df5302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_3df0ac82-9db1-4e1c-b117-e0abd076b5c2" xlink:href="mrk-20201231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_3df0ac82-9db1-4e1c-b117-e0abd076b5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_30825664-9d36-458f-aee5-686472143d38" xlink:href="mrk-20201231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_30825664-9d36-458f-aee5-686472143d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_46543f2d-a3c8-47b3-abf7-1f44ec71a694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_10658777-7851-4f02-b714-7b61c2db52cc" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_46543f2d-a3c8-47b3-abf7-1f44ec71a694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_26ecdf1b-f7a7-49c8-a66b-4fb6b4367f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_26ecdf1b-f7a7-49c8-a66b-4fb6b4367f66" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f9e4c1ba-7fe2-45ca-b891-2cb07c7e0efd" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_8667a703-fcc3-4845-afb7-f30b4703ee3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_8667a703-fcc3-4845-afb7-f30b4703ee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_eedcab53-7ec8-49eb-8cbb-6b7be7fb714d" xlink:href="mrk-20201231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:to="loc_mrk_AcceleratedDepreciationMember_eedcab53-7ec8-49eb-8cbb-6b7be7fb714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_0596dd3e-a346-48d7-8efa-914a60005a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6c2a9b21-ea0b-411d-838b-7bb14620623b" xlink:to="loc_us-gaap_OtherRestructuringMember_0596dd3e-a346-48d7-8efa-914a60005a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ab5ccd09-305d-484d-903c-389d8f7bb006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ab5ccd09-305d-484d-903c-389d8f7bb006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ab5ccd09-305d-484d-903c-389d8f7bb006" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_518df7da-9dac-48f3-991a-18fac1db0f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:to="loc_us-gaap_CostOfSalesMember_518df7da-9dac-48f3-991a-18fac1db0f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77edd8d4-b355-46ac-be9a-f7fc5702704f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77edd8d4-b355-46ac-be9a-f7fc5702704f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b554f1a-c6f9-47ed-8861-ec8af1cc8fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b554f1a-c6f9-47ed-8861-ec8af1cc8fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_d9c4ffbb-3303-4e7d-ad63-00979ceadc0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8472ca14-ec0c-49b1-880f-590ab7b87156" xlink:to="loc_us-gaap_RestructuringChargesMember_d9c4ffbb-3303-4e7d-ad63-00979ceadc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_82a4d574-5f80-4796-ba6a-0dec6457377b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0536585-8eee-46a8-aaa1-da8c5c8bc395" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_82a4d574-5f80-4796-ba6a-0dec6457377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_886b0cdb-27bc-4e19-833b-4653a0e8400f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_82a4d574-5f80-4796-ba6a-0dec6457377b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_886b0cdb-27bc-4e19-833b-4653a0e8400f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_95dcd324-133a-4373-b8b8-ab353da1d070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa41b71-83eb-4d81-9e88-309ba34f482b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_95dcd324-133a-4373-b8b8-ab353da1d070" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa41b71-83eb-4d81-9e88-309ba34f482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_568abd5b-c6b8-420c-baec-9516ed6ef8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa41b71-83eb-4d81-9e88-309ba34f482b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_568abd5b-c6b8-420c-baec-9516ed6ef8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_568abd5b-c6b8-420c-baec-9516ed6ef8e0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_296c6901-1992-4199-a973-b7d8e12ebc25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_296c6901-1992-4199-a973-b7d8e12ebc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_78531056-88a4-49a2-9b4a-312de1728224" xlink:href="mrk-20201231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:to="loc_mrk_AcceleratedDepreciationMember_78531056-88a4-49a2-9b4a-312de1728224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_0d9008a6-9081-49ed-88d6-459e512e922a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3f86ea6d-d467-45c4-b59b-3d75badf6e19" xlink:to="loc_us-gaap_OtherRestructuringMember_0d9008a6-9081-49ed-88d6-459e512e922a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2f1e9fd4-e150-433d-96d5-ae57568da5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fa41b71-83eb-4d81-9e88-309ba34f482b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2f1e9fd4-e150-433d-96d5-ae57568da5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2f1e9fd4-e150-433d-96d5-ae57568da5c8" xlink:to="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_98a58bdb-842c-4340-8096-441d2ed7a25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_us-gaap_RestructuringReserve_98a58bdb-842c-4340-8096-441d2ed7a25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c8d72029-9c14-4f8c-9461-7f5ad2c02f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c8d72029-9c14-4f8c-9461-7f5ad2c02f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_fcdc1a6f-4be9-4d93-a5ef-5938ba2c3666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_us-gaap_PaymentsForRestructuring_fcdc1a6f-4be9-4d93-a5ef-5938ba2c3666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveNoncashActivity_966359a1-679a-4a54-94a9-06d69338fe45" xlink:href="mrk-20201231.xsd#mrk_RestructuringReserveNoncashActivity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_mrk_RestructuringReserveNoncashActivity_966359a1-679a-4a54-94a9-06d69338fe45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b4a24bc6-8f75-4dc5-a743-60fbc34f5918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b76bb75d-e836-49a6-a8d8-d60180562cd2" xlink:to="loc_us-gaap_RestructuringReserve_b4a24bc6-8f75-4dc5-a743-60fbc34f5918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5b02d82-f68d-425f-8b76-a2e42468636d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_b8c63515-cdf7-4458-bce4-78e3f5441612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5b02d82-f68d-425f-8b76-a2e42468636d" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_b8c63515-cdf7-4458-bce4-78e3f5441612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_cbe4e56c-aba3-4781-a798-36ff559600ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_cbe4e56c-aba3-4781-a798-36ff559600ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_1d1e7a76-fecc-45bd-bcdd-6c9690623a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_1d1e7a76-fecc-45bd-bcdd-6c9690623a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_65db2ef0-0f9c-4a9d-b5d3-4710210b4847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_65db2ef0-0f9c-4a9d-b5d3-4710210b4847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_c8c239d7-a231-44b8-a498-1e7719f0c7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_c8c239d7-a231-44b8-a498-1e7719f0c7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_5f42aeb0-281f-4733-93a3-590f6d285fa7" xlink:href="mrk-20201231.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_5f42aeb0-281f-4733-93a3-590f6d285fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7f14c6eb-c2b5-40da-b1ae-f58c7b7b3cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7f14c6eb-c2b5-40da-b1ae-f58c7b7b3cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1c68a549-09ad-4963-93e3-da56b4669be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1c68a549-09ad-4963-93e3-da56b4669be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_abe71cb4-b137-4c12-9672-eff54bf25f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_abe71cb4-b137-4c12-9672-eff54bf25f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2e0f1809-22ce-47e4-afe9-bd3fef8d3af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2e0f1809-22ce-47e4-afe9-bd3fef8d3af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_978c87eb-40a5-461f-8695-1cc5e4ed1297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05026bda-ab93-4a0c-b362-f7ad7a40623c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_978c87eb-40a5-461f-8695-1cc5e4ed1297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d074c1d8-4a1c-40f2-8905-7ec8a44b1a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d074c1d8-4a1c-40f2-8905-7ec8a44b1a46" xlink:to="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9521f7cc-b548-47de-b2af-738fbc921a26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_srt_RangeAxis_9521f7cc-b548-47de-b2af-738fbc921a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aba7873f-9a86-45c6-879c-1e6d751e65a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9521f7cc-b548-47de-b2af-738fbc921a26" xlink:to="loc_srt_RangeMember_aba7873f-9a86-45c6-879c-1e6d751e65a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3935de9e-4f21-45db-bfb3-0a70b94a749e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aba7873f-9a86-45c6-879c-1e6d751e65a5" xlink:to="loc_srt_MaximumMember_3935de9e-4f21-45db-bfb3-0a70b94a749e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b1b2404f-1bf0-40ef-b556-99acfc94e79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_HedgingDesignationAxis_b1b2404f-1bf0-40ef-b556-99acfc94e79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2302b384-be44-4a7a-87a9-31723c11cb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b1b2404f-1bf0-40ef-b556-99acfc94e79e" xlink:to="loc_us-gaap_HedgingDesignationDomain_2302b384-be44-4a7a-87a9-31723c11cb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6375987e-3203-49a5-ba2e-34215a0d9ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2302b384-be44-4a7a-87a9-31723c11cb0b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6375987e-3203-49a5-ba2e-34215a0d9ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_237d4f3c-e0ff-47a3-9660-8423f12df209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2302b384-be44-4a7a-87a9-31723c11cb0b" xlink:to="loc_us-gaap_NondesignatedMember_237d4f3c-e0ff-47a3-9660-8423f12df209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5179483a-f15c-42ea-97d1-bd41d9fdc384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5179483a-f15c-42ea-97d1-bd41d9fdc384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_753a1519-9ec1-4f7e-8e27-f2028f6e99d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5179483a-f15c-42ea-97d1-bd41d9fdc384" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_753a1519-9ec1-4f7e-8e27-f2028f6e99d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f6df42dc-5bf8-4ea9-83ad-a2825a60722a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_753a1519-9ec1-4f7e-8e27-f2028f6e99d1" xlink:to="loc_us-gaap_InterestRateSwapMember_f6df42dc-5bf8-4ea9-83ad-a2825a60722a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fafe008d-abbe-48d1-9955-808b90629705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fafe008d-abbe-48d1-9955-808b90629705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3c70b11-cc9a-445d-9f78-1227d878e7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fafe008d-abbe-48d1-9955-808b90629705" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3c70b11-cc9a-445d-9f78-1227d878e7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b1ae5d2f-107e-4740-8b32-e211ca5c7d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3c70b11-cc9a-445d-9f78-1227d878e7b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b1ae5d2f-107e-4740-8b32-e211ca5c7d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aa59cf3e-5825-49e8-91ac-b73cfe4804fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aa59cf3e-5825-49e8-91ac-b73cfe4804fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4a9899-1adf-4b6d-b3ae-40ce8d484054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa59cf3e-5825-49e8-91ac-b73cfe4804fa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4a9899-1adf-4b6d-b3ae-40ce8d484054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cf37b426-929e-4c11-9cb4-f7d4d80b763b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5034b56f-d5b8-4d8b-a054-b0ff55e6bc51" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cf37b426-929e-4c11-9cb4-f7d4d80b763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2b3ca103-6640-4146-bdbe-4a650c8fc1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cf37b426-929e-4c11-9cb4-f7d4d80b763b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2b3ca103-6640-4146-bdbe-4a650c8fc1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6bdf5d73-382f-47e7-bc11-754b005c42ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6bdf5d73-382f-47e7-bc11-754b005c42ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6392a49c-7aaf-41de-bbb6-0486b4254789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6bdf5d73-382f-47e7-bc11-754b005c42ca" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6392a49c-7aaf-41de-bbb6-0486b4254789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ca51e4b5-3f64-44a5-a7e9-8d262988d639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6392a49c-7aaf-41de-bbb6-0486b4254789" xlink:to="loc_us-gaap_AccountsReceivableMember_ca51e4b5-3f64-44a5-a7e9-8d262988d639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_80369c63-d575-4b57-bed3-4662fe3a5163" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_srt_MajorCustomersAxis_80369c63-d575-4b57-bed3-4662fe3a5163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c0779796-69c4-4b13-87ad-3ffcfb0cc453" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_80369c63-d575-4b57-bed3-4662fe3a5163" xlink:to="loc_srt_NameOfMajorCustomerDomain_c0779796-69c4-4b13-87ad-3ffcfb0cc453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member_b2c77cba-ad69-4aa8-8ab4-14836940a3b4" xlink:href="mrk-20201231.xsd#mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c0779796-69c4-4b13-87ad-3ffcfb0cc453" xlink:to="loc_mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member_b2c77cba-ad69-4aa8-8ab4-14836940a3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4b31acb9-398a-4a09-903c-3a0f83a6f0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_DebtInstrumentAxis_4b31acb9-398a-4a09-903c-3a0f83a6f0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ee6a937a-8a9e-451c-b10a-d83c5b43a600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4b31acb9-398a-4a09-903c-3a0f83a6f0f4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ee6a937a-8a9e-451c-b10a-d83c5b43a600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.85NotesDue2020Member_a1dfd171-d6a7-49b8-9d95-97ed0ccf3a90" xlink:href="mrk-20201231.xsd#mrk_A1.85NotesDue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ee6a937a-8a9e-451c-b10a-d83c5b43a600" xlink:to="loc_mrk_A1.85NotesDue2020Member_a1dfd171-d6a7-49b8-9d95-97ed0ccf3a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_79735c85-4a7e-4ce8-926b-393c934dbae2" xlink:to="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_64a7993d-4aef-400d-ae70-c3cb5a9fd01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_64a7993d-4aef-400d-ae70-c3cb5a9fd01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_ea617f98-10c8-4df0-b649-3e8f33a929ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_ea617f98-10c8-4df0-b649-3e8f33a929ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_18fbf96b-42e2-4d71-85b8-e140a433ed3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_18fbf96b-42e2-4d71-85b8-e140a433ed3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_dfa3ab4d-c038-4e3e-a6f1-fcd5aa55eee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_dfa3ab4d-c038-4e3e-a6f1-fcd5aa55eee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b55b0bea-ca68-4a54-88ca-b68dca1564a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b55b0bea-ca68-4a54-88ca-b68dca1564a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_beb73564-7bc6-4899-bd9e-6de130b8d8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_beb73564-7bc6-4899-bd9e-6de130b8d8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_21646151-e608-4819-990d-1d2d50f536e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_21646151-e608-4819-990d-1d2d50f536e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_accc047b-fbc2-490d-a8a9-903ded1403cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_accc047b-fbc2-490d-a8a9-903ded1403cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b7943475-1da0-4bba-b8b6-e15d7109a5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b7943475-1da0-4bba-b8b6-e15d7109a5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_6766066c-b230-49ab-9883-69f1493f26f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_6766066c-b230-49ab-9883-69f1493f26f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_f8810b09-604b-42e2-94d2-6dfb03154c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_f8810b09-604b-42e2-94d2-6dfb03154c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c9b6a5fc-ca7b-453b-a008-35d669d14b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c9b6a5fc-ca7b-453b-a008-35d669d14b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a32a9cf-3141-42c5-a0e9-55a0a50f4838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a32a9cf-3141-42c5-a0e9-55a0a50f4838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5eeb72f5-dd10-47d9-bf51-3692049b05b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5eeb72f5-dd10-47d9-bf51-3692049b05b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_6851c961-1926-4be6-8585-3abbb4fd5bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_6851c961-1926-4be6-8585-3abbb4fd5bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1912ab9e-c24a-43ce-9696-de3db3406c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1912ab9e-c24a-43ce-9696-de3db3406c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_7a63d36f-cbc3-4b52-8825-f07c5128827a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_AccountsReceivableSale_7a63d36f-cbc3-4b52-8825-f07c5128827a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_04e55abe-6644-4813-8a9a-6de3f2b3d6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_RestrictedCashCurrent_04e55abe-6644-4813-8a9a-6de3f2b3d6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_951edc02-98ca-4a89-8f4d-25c04207efb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_951edc02-98ca-4a89-8f4d-25c04207efb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_79be56ec-51d8-4553-833f-031e3e8b5966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2cde8e9a-d9da-445e-9df5-f77a29b1836a" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_79be56ec-51d8-4553-833f-031e3e8b5966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2e4548e9-e211-49cb-9059-2803bb6ff210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2e4548e9-e211-49cb-9059-2803bb6ff210" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_138c6917-f416-4fc9-8342-9ec1d8f3015a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_138c6917-f416-4fc9-8342-9ec1d8f3015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_62021466-51c6-493f-963d-19123214452d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_138c6917-f416-4fc9-8342-9ec1d8f3015a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_62021466-51c6-493f-963d-19123214452d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6f813ed9-09cb-494f-8f75-e2b3ed55fbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_62021466-51c6-493f-963d-19123214452d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6f813ed9-09cb-494f-8f75-e2b3ed55fbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_4fa480e9-7548-44af-b7b4-3abb7566671c" xlink:href="mrk-20201231.xsd#mrk_EurodominatedNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_62021466-51c6-493f-963d-19123214452d" xlink:to="loc_mrk_EurodominatedNotesMember_4fa480e9-7548-44af-b7b4-3abb7566671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_895f3149-11f2-429e-a7da-a6ba1872d72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_895f3149-11f2-429e-a7da-a6ba1872d72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e1c92e03-77e7-4328-a5fa-f3ee78cb1fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_895f3149-11f2-429e-a7da-a6ba1872d72b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e1c92e03-77e7-4328-a5fa-f3ee78cb1fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_40698ea1-c81c-4551-86d7-31ef797838dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1c92e03-77e7-4328-a5fa-f3ee78cb1fee" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_40698ea1-c81c-4551-86d7-31ef797838dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b704a2e9-3f03-4762-af9f-03cfbb880aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_5dc15777-9b0a-4394-bcea-20435392bc7c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b704a2e9-3f03-4762-af9f-03cfbb880aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7b35e0a5-4a0b-416c-b90b-57f1eb82098d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b704a2e9-3f03-4762-af9f-03cfbb880aa0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_7b35e0a5-4a0b-416c-b90b-57f1eb82098d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_8a290743-6949-4720-911d-1298e707fd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b704a2e9-3f03-4762-af9f-03cfbb880aa0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_8a290743-6949-4720-911d-1298e707fd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationAboutInterestRateSwapsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ab5479bc-05c7-43eb-a067-a89704989ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ab5479bc-05c7-43eb-a067-a89704989ad0" xlink:to="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1b8acd37-9373-4ecd-a7fd-1519533195a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1b8acd37-9373-4ecd-a7fd-1519533195a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b8acd37-9373-4ecd-a7fd-1519533195a5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member_fa560d56-f62b-48c2-aa72-f5032e2f1f37" xlink:href="mrk-20201231.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:to="loc_mrk_A3.875NotesDue2021Member_fa560d56-f62b-48c2-aa72-f5032e2f1f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_90f78588-ef5f-474a-bec8-92d87e5fc9e4" xlink:href="mrk-20201231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:to="loc_mrk_A2.40NotesDue2022Member_90f78588-ef5f-474a-bec8-92d87e5fc9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_69a18df0-ab18-448f-8223-290ab83e344c" xlink:href="mrk-20201231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a5a3db-ac66-4b42-b1d7-a6331c0a4119" xlink:to="loc_mrk_A2.35NotesDue2022Member_69a18df0-ab18-448f-8223-290ab83e344c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_50dc8d22-eab2-438a-b75a-2f59532094b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_50dc8d22-eab2-438a-b75a-2f59532094b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_01c597ce-79b5-417f-9e5a-884df33e3abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_50dc8d22-eab2-438a-b75a-2f59532094b3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_01c597ce-79b5-417f-9e5a-884df33e3abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b87df624-1249-4025-a67c-029d0232b008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_01c597ce-79b5-417f-9e5a-884df33e3abd" xlink:to="loc_us-gaap_InterestRateSwapMember_b87df624-1249-4025-a67c-029d0232b008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_66bca241-98b9-499b-9804-53d1c4c02e4d" xlink:to="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1cea317e-b4a6-44ca-90e6-802bb8e27d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1cea317e-b4a6-44ca-90e6-802bb8e27d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_8740e764-8710-4ffe-8ca6-8c1afe1cf931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_8740e764-8710-4ffe-8ca6-8c1afe1cf931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_aad91861-1fb1-435c-b62f-438c36d70e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_DerivativeNotionalAmount_aad91861-1fb1-435c-b62f-438c36d70e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_349da418-5863-4f16-bcb6-747c85a2e257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_855f8752-fa6f-48df-ba14-d7a4cad5a507" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_349da418-5863-4f16-bcb6-747c85a2e257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFairValueofHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_775954a6-9f3e-40a9-930e-d5885ac83b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_c03f2d0c-df8c-4d7b-a6a7-8d2d2ba7fa5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_775954a6-9f3e-40a9-930e-d5885ac83b3b" xlink:to="loc_us-gaap_DerivativeTable_c03f2d0c-df8c-4d7b-a6a7-8d2d2ba7fa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5977ba5d-b9ff-4f72-a66c-488109153419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c03f2d0c-df8c-4d7b-a6a7-8d2d2ba7fa5b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5977ba5d-b9ff-4f72-a66c-488109153419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_db3c7229-45d7-4048-b199-6b1e8ed363fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5977ba5d-b9ff-4f72-a66c-488109153419" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_db3c7229-45d7-4048-b199-6b1e8ed363fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_f53d785a-e8a4-4229-aafa-5eb11fe8fc1f" xlink:href="mrk-20201231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_db3c7229-45d7-4048-b199-6b1e8ed363fd" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_f53d785a-e8a4-4229-aafa-5eb11fe8fc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_e4d476f2-eee8-4d36-b2df-81626e935868" xlink:href="mrk-20201231.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_db3c7229-45d7-4048-b199-6b1e8ed363fd" xlink:to="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_e4d476f2-eee8-4d36-b2df-81626e935868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_1d296588-6184-4b09-a3fe-16f23958f330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c03f2d0c-df8c-4d7b-a6a7-8d2d2ba7fa5b" xlink:to="loc_us-gaap_DerivativeLineItems_1d296588-6184-4b09-a3fe-16f23958f330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_e727976c-bd59-49e9-b730-c324b9a1173e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d296588-6184-4b09-a3fe-16f23958f330" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_e727976c-bd59-49e9-b730-c324b9a1173e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_b6abab79-26c6-455b-8e91-e73b28b16136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d296588-6184-4b09-a3fe-16f23958f330" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_b6abab79-26c6-455b-8e91-e73b28b16136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a0865352-862e-484b-af25-cb3b2445e805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a0865352-862e-484b-af25-cb3b2445e805" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1ab7c187-120a-40c1-9f55-0cebe816b2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1ab7c187-120a-40c1-9f55-0cebe816b2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1ab7c187-120a-40c1-9f55-0cebe816b2cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_5a078301-8f47-4bc4-8327-ad4ce29cd120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:to="loc_us-gaap_InterestRateContractMember_5a078301-8f47-4bc4-8327-ad4ce29cd120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_95cdf291-c9eb-499e-a7af-82f503a6a466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:to="loc_us-gaap_ForeignExchangeContractMember_95cdf291-c9eb-499e-a7af-82f503a6a466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_323b6afa-8c84-4aea-962a-c6b5fbcfc57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_20757f1f-7c7b-4f64-996c-1e992c898028" xlink:to="loc_us-gaap_InterestRateSwapMember_323b6afa-8c84-4aea-962a-c6b5fbcfc57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a242bff2-875b-4dcd-a735-2d62f0575a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:to="loc_us-gaap_HedgingDesignationAxis_a242bff2-875b-4dcd-a735-2d62f0575a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b083854f-d30b-4bf5-a38c-b79e7e78017b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a242bff2-875b-4dcd-a735-2d62f0575a45" xlink:to="loc_us-gaap_HedgingDesignationDomain_b083854f-d30b-4bf5-a38c-b79e7e78017b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_005014cd-b810-41bf-8f49-4795823356ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b083854f-d30b-4bf5-a38c-b79e7e78017b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_005014cd-b810-41bf-8f49-4795823356ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6e7552de-461e-455b-b9d7-8d62a62785e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b083854f-d30b-4bf5-a38c-b79e7e78017b" xlink:to="loc_us-gaap_NondesignatedMember_6e7552de-461e-455b-b9d7-8d62a62785e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8c0394b7-5ce8-40a0-8492-f24a15b090fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8c0394b7-5ce8-40a0-8492-f24a15b090fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c0394b7-5ce8-40a0-8492-f24a15b090fd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_1bac9c3c-ab7d-4fe6-88a3-34cd3c4789bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:to="loc_us-gaap_OtherAssetsMember_1bac9c3c-ab7d-4fe6-88a3-34cd3c4789bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_bba777a1-3df3-4757-aff1-9c74fee558fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_bba777a1-3df3-4757-aff1-9c74fee558fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_098fed84-6098-4143-9f12-017034a42159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_098fed84-6098-4143-9f12-017034a42159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9d2497fb-cc81-43fc-8935-4dea7ecdac0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ec6af7bb-35a2-4022-a7ef-89d31fc08242" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9d2497fb-cc81-43fc-8935-4dea7ecdac0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3716755d-22df-44fd-b0f0-a4f2fa9a71e2" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a47dd9a5-d23d-4415-b5dd-dc309414e7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:to="loc_us-gaap_DerivativeAssets_a47dd9a5-d23d-4415-b5dd-dc309414e7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4c6013d8-0b34-4ed2-a48f-4f97d3d04f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:to="loc_us-gaap_DerivativeLiabilities_4c6013d8-0b34-4ed2-a48f-4f97d3d04f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b388a933-67f5-4e12-b613-8c085860056a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f40a1481-c769-44d8-9cfe-7925e314fbd5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b388a933-67f5-4e12-b613-8c085860056a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_7978ac8a-bc22-411d-9565-124f168508a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:to="loc_us-gaap_DerivativeAssets_7978ac8a-bc22-411d-9565-124f168508a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_412a646f-3c53-4dbd-8aa9-de1fc8df062b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_412a646f-3c53-4dbd-8aa9-de1fc8df062b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_12efb79d-20a1-44a1-9ef0-3c436d99fd25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_12efb79d-20a1-44a1-9ef0-3c436d99fd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3f6eaafa-2f01-43a2-b702-b15d9dce46ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3f6eaafa-2f01-43a2-b702-b15d9dce46ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bd8f3679-5a6a-42a8-88be-da62e70104f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:to="loc_us-gaap_DerivativeLiabilities_bd8f3679-5a6a-42a8-88be-da62e70104f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_be8a0e92-7642-4522-9903-99cc4b3dcd86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_be8a0e92-7642-4522-9903-99cc4b3dcd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_4724f0c0-90b8-4154-af90-f01ec405a3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_4724f0c0-90b8-4154-af90-f01ec405a3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_459b73aa-2aff-4d92-8933-96683fd92401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6abc80b1-44ee-482f-bd6c-3927f740bbf5" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_459b73aa-2aff-4d92-8933-96683fd92401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_16f6d77a-25b9-4ef2-9b35-fb7ea678ee3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_16f6d77a-25b9-4ef2-9b35-fb7ea678ee3e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ceda2480-3e49-48f6-8e23-7d2a7869bbb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ceda2480-3e49-48f6-8e23-7d2a7869bbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a5d8d3a2-8889-4f99-9880-512fc5d45db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ceda2480-3e49-48f6-8e23-7d2a7869bbb5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a5d8d3a2-8889-4f99-9880-512fc5d45db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_0fc77054-d188-414b-81d5-dfe95f0aff57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a5d8d3a2-8889-4f99-9880-512fc5d45db6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_0fc77054-d188-414b-81d5-dfe95f0aff57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_765a1d56-cf2b-4aeb-b578-6fcec12b82f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_765a1d56-cf2b-4aeb-b578-6fcec12b82f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b1e9e458-e7a0-4e79-b4a0-27075bb4e121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_765a1d56-cf2b-4aeb-b578-6fcec12b82f3" xlink:to="loc_us-gaap_EquityComponentDomain_b1e9e458-e7a0-4e79-b4a0-27075bb4e121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_9168bc21-57f1-4402-8e77-7e3f5fb7845a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b1e9e458-e7a0-4e79-b4a0-27075bb4e121" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_9168bc21-57f1-4402-8e77-7e3f5fb7845a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a9ac6d01-fbde-41e7-ae14-041a50c487f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a9ac6d01-fbde-41e7-ae14-041a50c487f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df410c0f-b007-492d-9ec0-beb88d73205c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a9ac6d01-fbde-41e7-ae14-041a50c487f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df410c0f-b007-492d-9ec0-beb88d73205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a89095d6-1c1e-4130-b280-9ece5351345e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df410c0f-b007-492d-9ec0-beb88d73205c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a89095d6-1c1e-4130-b280-9ece5351345e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ecc66212-1fa1-40b6-a187-03a3a19776ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ecc66212-1fa1-40b6-a187-03a3a19776ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_84e3324c-bc7f-4952-a21b-479d4c1d5fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ecc66212-1fa1-40b6-a187-03a3a19776ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_84e3324c-bc7f-4952-a21b-479d4c1d5fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_dc86346b-d745-4847-b15c-197696799bef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_84e3324c-bc7f-4952-a21b-479d4c1d5fb9" xlink:to="loc_us-gaap_InterestRateSwapMember_dc86346b-d745-4847-b15c-197696799bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0f39d57f-5eec-4cb9-b621-63412810cf51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_84e3324c-bc7f-4952-a21b-479d4c1d5fb9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0f39d57f-5eec-4cb9-b621-63412810cf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bc871fe6-55c2-4955-9694-e891554a0dfb" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e4642e7a-91e6-4584-9d04-409c7ef29e87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_Revenues_e4642e7a-91e6-4584-9d04-409c7ef29e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1129060b-eda0-4131-a935-c09520d24c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1129060b-eda0-4131-a935-c09520d24c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fcded54b-a5b7-4ce0-81ef-72decf8ac277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fcded54b-a5b7-4ce0-81ef-72decf8ac277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_02da64f3-5555-4a4c-82cc-1294996a4a16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_02da64f3-5555-4a4c-82cc-1294996a4a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_9a1ecdd6-96a2-48f1-87e9-dd6edfa7b34f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_9a1ecdd6-96a2-48f1-87e9-dd6edfa7b34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c1271e8e-86e0-4376-877d-d0e2809d3f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c1271e8e-86e0-4376-877d-d0e2809d3f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_50497c43-9736-46e5-af37-9502844df5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_50497c43-9736-46e5-af37-9502844df5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_cb34d7c1-c08b-4ab1-b37a-e9e846254c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_760c6600-5f26-4eaa-a143-2d02a8dce0a3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_cb34d7c1-c08b-4ab1-b37a-e9e846254c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2bd21262-8b5f-4535-8df1-752d4bf2e422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2bd21262-8b5f-4535-8df1-752d4bf2e422" xlink:to="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2a2af98c-ccb2-47e1-929c-4902300b8c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2a2af98c-ccb2-47e1-929c-4902300b8c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a2af98c-ccb2-47e1-929c-4902300b8c59" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d5916b96-b42b-43c3-a40a-023283e0b121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d5916b96-b42b-43c3-a40a-023283e0b121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f91ad7ab-69ce-4521-8069-cb667d557238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:to="loc_us-gaap_InterestRateSwapMember_f91ad7ab-69ce-4521-8069-cb667d557238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_c794460b-35df-43a8-95ed-ac77d9d3ed9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:to="loc_us-gaap_InterestRateContractMember_c794460b-35df-43a8-95ed-ac77d9d3ed9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_3cccaef9-1b63-4df6-a706-96b8f2e0284b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbfb6969-7e1e-4b29-889d-94b375874580" xlink:to="loc_us-gaap_ForwardContractsMember_3cccaef9-1b63-4df6-a706-96b8f2e0284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c73f8f4-903b-49e5-911b-b93711d79c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c73f8f4-903b-49e5-911b-b93711d79c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c73f8f4-903b-49e5-911b-b93711d79c59" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_aed30781-2cd7-44b3-8bf7-ff2b128bb5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_aed30781-2cd7-44b3-8bf7-ff2b128bb5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_6f7146b3-0ce6-46a9-b582-ef49d6f913ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:to="loc_us-gaap_SalesMember_6f7146b3-0ce6-46a9-b582-ef49d6f913ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6e757ffe-8b42-434a-b572-e5df821f8c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f876c7c-9916-44e0-95d5-50774e0b4fc4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6e757ffe-8b42-434a-b572-e5df821f8c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_31287c81-f214-48af-8d67-112cb7c0230a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_624a53b5-118d-4f15-989d-681e9dea11a5" xlink:to="loc_us-gaap_DerivativeLineItems_31287c81-f214-48af-8d67-112cb7c0230a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_49a2aa90-ca9e-43b5-8441-2100158eed0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_31287c81-f214-48af-8d67-112cb7c0230a" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_49a2aa90-ca9e-43b5-8441-2100158eed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5247581c-7d77-43db-927e-f1487648efd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5247581c-7d77-43db-927e-f1487648efd3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7af8d824-ffa4-4be5-95fa-9be93945815c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7af8d824-ffa4-4be5-95fa-9be93945815c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c85c0648-e6ca-4a23-8705-6510d5d6f044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7af8d824-ffa4-4be5-95fa-9be93945815c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c85c0648-e6ca-4a23-8705-6510d5d6f044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_133b4409-37a3-4805-b55f-906d31eb8d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c85c0648-e6ca-4a23-8705-6510d5d6f044" xlink:to="loc_us-gaap_InterestRateContractMember_133b4409-37a3-4805-b55f-906d31eb8d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_933102b2-87ce-449c-b527-6166387511f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfe27b6f-666f-4b03-9f7d-30e37b23d5e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_933102b2-87ce-449c-b527-6166387511f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_541ebd0d-1bb7-4b52-9401-83b5d6e2e7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_933102b2-87ce-449c-b527-6166387511f4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_541ebd0d-1bb7-4b52-9401-83b5d6e2e7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:to="loc_us-gaap_FinancialInstrumentAxis_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_768e54ed-2db5-4e4b-a1d4-8b1fd9e73a0f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a400a2d5-1291-498b-84bc-efa0d1ab2b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_CommercialPaperMember_a400a2d5-1291-498b-84bc-efa0d1ab2b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_587c80d8-01b6-4cc4-a4a4-22f4a2b202ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_587c80d8-01b6-4cc4-a4a4-22f4a2b202ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_67b23244-2908-43c8-a14e-00595b89f1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_67b23244-2908-43c8-a14e-00595b89f1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b6b1622f-87c5-497a-ba4b-d317c296c550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b6b1622f-87c5-497a-ba4b-d317c296c550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_6d6ee694-35cb-4036-8980-3d99fda54fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_6d6ee694-35cb-4036-8980-3d99fda54fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_2c83c265-923f-4091-9503-165694228ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19025100-3e56-4231-a6c8-604e0502aee2" xlink:to="loc_us-gaap_EquitySecuritiesMember_2c83c265-923f-4091-9503-165694228ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b7f9c853-5144-4ae5-aef0-a929554e3e07" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9a40afc4-1365-4445-ae85-1b330be0f850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9a40afc4-1365-4445-ae85-1b330be0f850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_684e245d-5631-459c-9600-e1bc70157742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_684e245d-5631-459c-9600-e1bc70157742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0cf2098e-4cee-4851-980c-0a58d6dc5a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0cf2098e-4cee-4851-980c-0a58d6dc5a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e18a44ba-cdf9-4bc0-b173-d48b3ea56bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e18a44ba-cdf9-4bc0-b173-d48b3ea56bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_18704eac-8c0a-4817-b562-34f72b3ec300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_18704eac-8c0a-4817-b562-34f72b3ec300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_8a9af1a2-d142-4471-ae4a-5dbd1965461b" xlink:href="mrk-20201231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0a14f7d-538f-4d33-a633-802d1a5ae2ca" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_8a9af1a2-d142-4471-ae4a-5dbd1965461b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5ff959f4-1698-4b0b-9d33-82ecf50c1cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5247581c-7d77-43db-927e-f1487648efd3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5ff959f4-1698-4b0b-9d33-82ecf50c1cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_85433566-e2ce-4967-a75b-e90d5d2b2ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_85433566-e2ce-4967-a75b-e90d5d2b2ded" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ef1264e-1f21-4371-98c5-deac9f0e1205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ef1264e-1f21-4371-98c5-deac9f0e1205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_47db0df9-7548-461c-b119-620afa3c7492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ef1264e-1f21-4371-98c5-deac9f0e1205" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_47db0df9-7548-461c-b119-620afa3c7492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5f1dc7e7-a8c4-4843-addb-364769ea4698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_47db0df9-7548-461c-b119-620afa3c7492" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5f1dc7e7-a8c4-4843-addb-364769ea4698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2e0c936-210f-48fd-9ed3-73bad74d3078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2e0c936-210f-48fd-9ed3-73bad74d3078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2e0c936-210f-48fd-9ed3-73bad74d3078" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_efe20318-498f-44db-b8d5-e7db87da020b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_efe20318-498f-44db-b8d5-e7db87da020b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9dc263f1-c75f-4699-8bc9-57c7ffd8cdf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9dc263f1-c75f-4699-8bc9-57c7ffd8cdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ee4044ae-98e8-4181-9d53-ef9643d4c720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93d554a7-eae9-41d5-b6b3-94e1c29ede87" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ee4044ae-98e8-4181-9d53-ef9643d4c720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bc63a853-bf5a-43bc-8e30-40ca4e62cced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bc63a853-bf5a-43bc-8e30-40ca4e62cced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc63a853-bf5a-43bc-8e30-40ca4e62cced" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b2b11786-8899-4286-a2a8-6b1fe06f8a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b2b11786-8899-4286-a2a8-6b1fe06f8a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9462ac19-9cef-4857-9529-0e5764e5bb72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9462ac19-9cef-4857-9529-0e5764e5bb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d726b1a9-7de6-436b-afdf-27e05926fdcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d726b1a9-7de6-436b-afdf-27e05926fdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4b810f7b-4b1d-4580-95f9-2907b1c27161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4b810f7b-4b1d-4580-95f9-2907b1c27161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_5219629c-3c21-41d6-8184-b4f73b25a527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc324fea-f687-42c0-bea9-3fbd884a6eb4" xlink:to="loc_us-gaap_EquitySecuritiesMember_5219629c-3c21-41d6-8184-b4f73b25a527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_edb7d9f1-64d0-4446-9b79-6e2597660c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_InvestmentTypeAxis_edb7d9f1-64d0-4446-9b79-6e2597660c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_781d14da-9d90-49e8-b584-a4ce80658b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_edb7d9f1-64d0-4446-9b79-6e2597660c16" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_781d14da-9d90-49e8-b584-a4ce80658b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ef412d8f-71bc-4dd2-9b3a-d83a326c9011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_781d14da-9d90-49e8-b584-a4ce80658b47" xlink:to="loc_us-gaap_CommercialPaperMember_ef412d8f-71bc-4dd2-9b3a-d83a326c9011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c470c0e5-9f15-4a3f-bb6d-44f9d9c3ec9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_2250b06f-65cd-419f-85c7-42632fcffb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:to="loc_us-gaap_InterestRateContractMember_2250b06f-65cd-419f-85c7-42632fcffb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_4472611d-ab0d-48d6-9c94-793f06db3876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:to="loc_us-gaap_ForeignExchangeContractMember_4472611d-ab0d-48d6-9c94-793f06db3876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_a2958579-31a1-4586-9e1b-c30fae28a585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5c87b6c4-1877-4121-a4fe-3b8b7ce7ebc8" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_a2958579-31a1-4586-9e1b-c30fae28a585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41efb9f1-ad2c-4cc0-86b2-1e8789c184ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_685c377e-bfd1-49f4-9297-eece1aca719a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41efb9f1-ad2c-4cc0-86b2-1e8789c184ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41efb9f1-ad2c-4cc0-86b2-1e8789c184ca" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0cd2f6b7-7e0c-4931-aaab-093b44d3761e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0cd2f6b7-7e0c-4931-aaab-093b44d3761e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_543bf055-d33a-47f1-8366-bb018f4e69fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_543bf055-d33a-47f1-8366-bb018f4e69fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_bad6650a-fb30-43a3-9ead-11828fc6b8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_TradingSecurities_bad6650a-fb30-43a3-9ead-11828fc6b8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a63d1da1-9719-4e3b-934d-26f45a190f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a63d1da1-9719-4e3b-934d-26f45a190f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_0d9426dd-ae1a-4b3a-9e88-43df79c2a59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_DerivativeAssets_0d9426dd-ae1a-4b3a-9e88-43df79c2a59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ff3d4d6a-bdf7-4284-9ced-286a00376f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a1d01671-93e4-46d9-9775-a8890237bb1a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ff3d4d6a-bdf7-4284-9ced-286a00376f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41efb9f1-ad2c-4cc0-86b2-1e8789c184ca" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_de9c7dd1-a338-4cc4-a69a-a683041ce9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_de9c7dd1-a338-4cc4-a69a-a683041ce9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_12a61f07-e303-43f3-ab77-ef61cea5ccc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:to="loc_us-gaap_DerivativeLiabilities_12a61f07-e303-43f3-ab77-ef61cea5ccc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ba39ceb3-7905-476f-beac-fe2d94836ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3bc1143d-8296-439a-80bc-6bf9eecb9864" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ba39ceb3-7905-476f-beac-fe2d94836ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4ad414ae-6f0d-4f14-adfa-08383c529eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4ad414ae-6f0d-4f14-adfa-08383c529eb6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_dd2f767c-364d-4e17-aa34-0c41c79674a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d749f9de-0fc7-4c75-8457-3a58bbbdb6a6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_dd2f767c-364d-4e17-aa34-0c41c79674a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3d3e8a94-3143-4097-9388-f172d861cab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_dd2f767c-364d-4e17-aa34-0c41c79674a9" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3d3e8a94-3143-4097-9388-f172d861cab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_ef153840-70cf-4cfd-a20c-ff95cc83dabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_ef153840-70cf-4cfd-a20c-ff95cc83dabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_076ce106-b8c7-4040-b9e2-26e1272e5395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_ef153840-70cf-4cfd-a20c-ff95cc83dabd" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_076ce106-b8c7-4040-b9e2-26e1272e5395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_22b0e90d-7c32-4af2-bc4c-f1c598983cb0" xlink:href="mrk-20201231.xsd#mrk_SanofiPasteurMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_076ce106-b8c7-4040-b9e2-26e1272e5395" xlink:to="loc_mrk_SanofiPasteurMember_22b0e90d-7c32-4af2-bc4c-f1c598983cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6c4f37ea-787d-4774-9d64-825a23e3eab1" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_fb0462eb-5e94-4d27-a107-630d2bd511a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_fb0462eb-5e94-4d27-a107-630d2bd511a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0a1baf79-4553-4e1c-9f5b-00e749e526f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0a1baf79-4553-4e1c-9f5b-00e749e526f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0a59839a-0c6f-4f9f-b1de-df08f91cab09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0a59839a-0c6f-4f9f-b1de-df08f91cab09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_588683d4-43fe-43c5-8604-63ca3ad18922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_588683d4-43fe-43c5-8604-63ca3ad18922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_dc4d0471-c4df-46e3-9002-8a93f8ffff03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_dc4d0471-c4df-46e3-9002-8a93f8ffff03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_63b34e48-5fe2-4afd-9e15-4f23403572a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b0dc749-b3e5-4eee-8bc5-dd6a2d62b11f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_63b34e48-5fe2-4afd-9e15-4f23403572a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_69766246-7e99-4c29-9c79-e2035fb9befe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2f26175a-6113-4e8e-8acb-e53f29e2daf9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_69766246-7e99-4c29-9c79-e2035fb9befe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20201231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ed8c0391-3662-4bcd-a130-9fde6e272ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_d2bce120-3665-4407-87e8-89c5d2942097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ed8c0391-3662-4bcd-a130-9fde6e272ded" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_d2bce120-3665-4407-87e8-89c5d2942097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7710e548-fe95-4c69-83b1-884b01e66faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e2f68f54-0456-4f47-8e8f-de58a1099c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7710e548-fe95-4c69-83b1-884b01e66faa" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e2f68f54-0456-4f47-8e8f-de58a1099c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_03e00490-4c7a-4cac-85f8-fa4aeec66697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_241f96fe-955c-4e27-9bd4-083398c45c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e00490-4c7a-4cac-85f8-fa4aeec66697" xlink:to="loc_us-gaap_InventoryFinishedGoods_241f96fe-955c-4e27-9bd4-083398c45c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_488de5cd-1595-4a4a-9709-18322e554c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e00490-4c7a-4cac-85f8-fa4aeec66697" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_488de5cd-1595-4a4a-9709-18322e554c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_5254bf14-e314-4cc8-b2e1-4262e05b20c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e00490-4c7a-4cac-85f8-fa4aeec66697" xlink:to="loc_us-gaap_OtherInventorySupplies_5254bf14-e314-4cc8-b2e1-4262e05b20c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d9db0152-805e-4eb0-b523-eafa38c91c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e00490-4c7a-4cac-85f8-fa4aeec66697" xlink:to="loc_us-gaap_InventoryGross_d9db0152-805e-4eb0-b523-eafa38c91c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_8cf52dc5-69db-42d2-b6fd-b1b853c91def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e00490-4c7a-4cac-85f8-fa4aeec66697" xlink:to="loc_us-gaap_InventoryLIFOReserve_8cf52dc5-69db-42d2-b6fd-b1b853c91def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_94e1b859-ffa0-4a18-975b-c45461a747c3" xlink:href="mrk-20201231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e00490-4c7a-4cac-85f8-fa4aeec66697" xlink:to="loc_mrk_InventoryNetAndInventoryNoncurrent_94e1b859-ffa0-4a18-975b-c45461a747c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract_701f6891-b79c-4541-8b15-43ebab0e67c9" xlink:href="mrk-20201231.xsd#mrk_RecognizedAsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03e00490-4c7a-4cac-85f8-fa4aeec66697" xlink:to="loc_mrk_RecognizedAsAbstract_701f6891-b79c-4541-8b15-43ebab0e67c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_83362f40-077b-49da-afe2-b09fb2fcb1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_701f6891-b79c-4541-8b15-43ebab0e67c9" xlink:to="loc_us-gaap_InventoryNet_83362f40-077b-49da-afe2-b09fb2fcb1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_edaf5cdb-14cf-4599-8b42-e87941654a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_701f6891-b79c-4541-8b15-43ebab0e67c9" xlink:to="loc_us-gaap_InventoryNoncurrent_edaf5cdb-14cf-4599-8b42-e87941654a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0e6f9cd6-73d5-457f-88ba-3b8cb57004a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_ae006bcc-a5ae-468a-83b4-3b1023c23cf9" xlink:href="mrk-20201231.xsd#mrk_InventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0e6f9cd6-73d5-457f-88ba-3b8cb57004a0" xlink:to="loc_mrk_InventoryTable_ae006bcc-a5ae-468a-83b4-3b1023c23cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_5437796d-3429-411b-8dfa-99edca83f9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_ae006bcc-a5ae-468a-83b4-3b1023c23cf9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_5437796d-3429-411b-8dfa-99edca83f9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3faaa592-3539-4d10-a64b-0b7c8fc88b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5437796d-3429-411b-8dfa-99edca83f9bf" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3faaa592-3539-4d10-a64b-0b7c8fc88b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_7ce9ad3b-098c-4069-a0da-1979f0006dd5" xlink:href="mrk-20201231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3faaa592-3539-4d10-a64b-0b7c8fc88b77" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_7ce9ad3b-098c-4069-a0da-1979f0006dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_f2709669-d48e-40a2-af6d-28514931bb81" xlink:href="mrk-20201231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3faaa592-3539-4d10-a64b-0b7c8fc88b77" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_f2709669-d48e-40a2-af6d-28514931bb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_9e566b6c-e728-4a80-957a-df06136f3b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_ae006bcc-a5ae-468a-83b4-3b1023c23cf9" xlink:to="loc_us-gaap_InventoryLineItems_9e566b6c-e728-4a80-957a-df06136f3b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_dfb4155d-2ec2-482f-b0f7-67a1cdcb84a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_9e566b6c-e728-4a80-957a-df06136f3b83" xlink:to="loc_us-gaap_LIFOInventoryAmount_dfb4155d-2ec2-482f-b0f7-67a1cdcb84a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_a51bce15-39ce-40ff-abab-af5f2d6f49b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_9e566b6c-e728-4a80-957a-df06136f3b83" xlink:to="loc_us-gaap_InventoryNoncurrent_a51bce15-39ce-40ff-abab-af5f2d6f49b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daab112d-e55b-4d19-a9fe-caa572869c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0be98932-6048-4e66-8ba1-64c8d925d30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daab112d-e55b-4d19-a9fe-caa572869c41" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0be98932-6048-4e66-8ba1-64c8d925d30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0b889c7b-d7af-4c82-8663-4e40a004ccf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e9ccd14d-53c6-45fa-8f48-44af1acee0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0b889c7b-d7af-4c82-8663-4e40a004ccf6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e9ccd14d-53c6-45fa-8f48-44af1acee0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_3f957463-52f7-48cf-a089-1e2919e5e352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0b889c7b-d7af-4c82-8663-4e40a004ccf6" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_3f957463-52f7-48cf-a089-1e2919e5e352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_237c5ca8-c382-477d-847a-82db1ba78adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:href="mrk-20201231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_237c5ca8-c382-477d-847a-82db1ba78adb" xlink:to="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a835f716-6d63-4d00-8c97-6b366e728c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a835f716-6d63-4d00-8c97-6b366e728c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_068ff389-151b-40e2-a6ab-0541792f5b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a835f716-6d63-4d00-8c97-6b366e728c1c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_068ff389-151b-40e2-a6ab-0541792f5b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_936ae2a2-175a-462f-a351-1a0fb74f0096" xlink:href="mrk-20201231.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_068ff389-151b-40e2-a6ab-0541792f5b15" xlink:to="loc_mrk_AntelliqMember_936ae2a2-175a-462f-a351-1a0fb74f0096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b3b9cd1-fcf2-4564-8dd8-dc15aeb3f3ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_d27bde9b-37af-4ac7-b6f5-4d0294e81d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_d27bde9b-37af-4ac7-b6f5-4d0294e81d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_32489762-70ec-4209-9ae3-1f96ba299ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:to="loc_us-gaap_TradeNamesMember_32489762-70ec-4209-9ae3-1f96ba299ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a38404f1-0e89-4fa9-8266-932b3947790b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8041809e-58bd-4e1c-917c-58e254b8c1d5" xlink:to="loc_us-gaap_LicenseMember_a38404f1-0e89-4fa9-8266-932b3947790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dc07d3d2-1055-49c7-b950-e0fc00933361" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_srt_ProductOrServiceAxis_dc07d3d2-1055-49c7-b950-e0fc00933361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dc07d3d2-1055-49c7-b950-e0fc00933361" xlink:to="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_5ca628b4-1b93-4d4a-b31e-5e15f59b1b03" xlink:href="mrk-20201231.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_ZerbaxaMember_5ca628b4-1b93-4d4a-b31e-5e15f59b1b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember_4e3693b5-6e63-4d56-8804-1e4a94908b49" xlink:href="mrk-20201231.xsd#mrk_SivextroMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_SivextroMember_4e3693b5-6e63-4d56-8804-1e4a94908b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImplanonNexplanonMember_445b4ee7-85e4-41a2-b341-cba431f4a05a" xlink:href="mrk-20201231.xsd#mrk_ImplanonNexplanonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_ImplanonNexplanonMember_445b4ee7-85e4-41a2-b341-cba431f4a05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_790459bf-0c44-4ec4-a53b-b173b36e9fdb" xlink:href="mrk-20201231.xsd#mrk_DificidMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_DificidMember_790459bf-0c44-4ec4-a53b-b173b36e9fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_ed5932cf-0174-4688-bf02-2dfde942fa94" xlink:href="mrk-20201231.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_GardasilGardasil9Member_ed5932cf-0174-4688-bf02-2dfde942fa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_55413fbf-b2c8-4def-85b8-02a20039d948" xlink:href="mrk-20201231.xsd#mrk_BridionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_BridionMember_55413fbf-b2c8-4def-85b8-02a20039d948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_061e5fe2-28e8-413d-83e7-81ac4e3b5347" xlink:href="mrk-20201231.xsd#mrk_SimponiMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_SimponiMember_061e5fe2-28e8-413d-83e7-81ac4e3b5347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember_ee099a09-c112-499e-80b9-89f66301a525" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_AnimalHealthMember_ee099a09-c112-499e-80b9-89f66301a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_b3448f06-b6b1-4bd8-92c9-60ef960687d1" xlink:href="mrk-20201231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_LenvimaMember_b3448f06-b6b1-4bd8-92c9-60ef960687d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_db2ef4f7-3353-4631-bb0a-bd73ce040f2e" xlink:href="mrk-20201231.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_LynparzaMember_db2ef4f7-3353-4631-bb0a-bd73ce040f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_730fb118-061f-44e6-bebe-3edf60d1a748" xlink:href="mrk-20201231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_AdempasMember_730fb118-061f-44e6-bebe-3edf60d1a748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IOmetPharmaLtdMember_2867cb56-f2d0-4efa-a919-767268cff3a9" xlink:href="mrk-20201231.xsd#mrk_IOmetPharmaLtdMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_IOmetPharmaLtdMember_2867cb56-f2d0-4efa-a919-767268cff3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SmartCellsProgramMember_109032de-f6b2-4636-99c1-a974b3dcad9d" xlink:href="mrk-20201231.xsd#mrk_SmartCellsProgramMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_SmartCellsProgramMember_109032de-f6b2-4636-99c1-a974b3dcad9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_3db61096-4c3b-45b0-bb35-0029626e8b58" xlink:href="mrk-20201231.xsd#mrk_COVID19Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3a864948-5202-416d-8da7-36ceb60c2d87" xlink:to="loc_mrk_COVID19Member_3db61096-4c3b-45b0-bb35-0029626e8b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c0727ec2-9bb4-4be5-9cb9-6999dc425aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c0727ec2-9bb4-4be5-9cb9-6999dc425aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a2c6b0ee-0176-4d4f-9620-e1b414f21784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c0727ec2-9bb4-4be5-9cb9-6999dc425aac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a2c6b0ee-0176-4d4f-9620-e1b414f21784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ed747ca3-37d1-48d9-a457-02e4804d074e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a2c6b0ee-0176-4d4f-9620-e1b414f21784" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ed747ca3-37d1-48d9-a457-02e4804d074e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:href="mrk-20201231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_7c1e827e-35a7-4d97-a265-f6099f80a195" xlink:to="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f545b4b4-464e-448c-86b9-945587b6547c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f545b4b4-464e-448c-86b9-945587b6547c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c392974c-640e-4523-9065-638ece0c55ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c392974c-640e-4523-9065-638ece0c55ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12ade775-1c5c-4d3e-8d1d-32df64b87a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12ade775-1c5c-4d3e-8d1d-32df64b87a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_191f3494-4f0e-4321-ac04-45577297ed9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_InventoryWriteDown_191f3494-4f0e-4321-ac04-45577297ed9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_812d7e2e-0b5d-4374-b96a-5d588e55a877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_812d7e2e-0b5d-4374-b96a-5d588e55a877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3c4a8c50-dca3-482e-b4be-fcb0474fbd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3c4a8c50-dca3-482e-b4be-fcb0474fbd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_81d01163-3f4b-48cf-9a99-e8df03a03e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_81d01163-3f4b-48cf-9a99-e8df03a03e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85121866-b6c4-4b6a-a81b-363072bd0f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85121866-b6c4-4b6a-a81b-363072bd0f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_baeee253-e595-4cfd-a181-b6b3185669ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_baeee253-e595-4cfd-a181-b6b3185669ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2e238328-49e0-4105-9fa2-6b9859c5e6f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2e238328-49e0-4105-9fa2-6b9859c5e6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bcbaee67-d0ed-496f-bcbf-f85369ccf77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bcbaee67-d0ed-496f-bcbf-f85369ccf77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4fbdb80d-b4ad-4d24-948c-c47d387c4af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_eff589a7-1231-4e5a-8b1a-85844c3ad739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4fbdb80d-b4ad-4d24-948c-c47d387c4af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_986146e6-2170-40d3-93bc-d15ab414a36d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_340d1b7c-c845-4da7-821d-1dff233a3c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_986146e6-2170-40d3-93bc-d15ab414a36d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_340d1b7c-c845-4da7-821d-1dff233a3c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a819ed7-5c69-4e69-a922-9423f03932fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_340d1b7c-c845-4da7-821d-1dff233a3c37" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a819ed7-5c69-4e69-a922-9423f03932fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a819ed7-5c69-4e69-a922-9423f03932fa" xlink:to="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_5b32b821-48c0-4dc3-898d-1225ed68e161" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:to="loc_mrk_PharmaceuticalsegmentMember_5b32b821-48c0-4dc3-898d-1225ed68e161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_204aa3da-5f2f-4d63-8289-3339746a9727" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:to="loc_mrk_AnimalHealthsegmentMember_204aa3da-5f2f-4d63-8289-3339746a9727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f72c0b32-b7c9-4eb7-aab9-da200d8227cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5f5d2715-81ee-4872-aa01-d0d67b6e4c50" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f72c0b32-b7c9-4eb7-aab9-da200d8227cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_cbf8ec90-497b-4c98-968b-375c04963ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_340d1b7c-c845-4da7-821d-1dff233a3c37" xlink:to="loc_us-gaap_GoodwillLineItems_cbf8ec90-497b-4c98-968b-375c04963ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_cbf8ec90-497b-4c98-968b-375c04963ca2" xlink:to="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bb0d8cd6-c1ef-4f7d-88ca-543b0eda3196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_Goodwill_bb0d8cd6-c1ef-4f7d-88ca-543b0eda3196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fa1715c8-6d2b-4a39-9b5e-67ae259a99c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fa1715c8-6d2b-4a39-9b5e-67ae259a99c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_a192a2e3-ad18-47ad-840f-9357c2798f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_a192a2e3-ad18-47ad-840f-9357c2798f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e3cd887c-229a-42e1-ac38-26c0ff9bfc0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e3cd887c-229a-42e1-ac38-26c0ff9bfc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_6d162226-bfec-4a7a-a321-c49e1d988b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_6d162226-bfec-4a7a-a321-c49e1d988b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a79eeb1-c6cc-4bb2-b8f7-c9dbd851cdf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_43716009-bd8a-4284-93bb-54eaa1db12bf" xlink:to="loc_us-gaap_Goodwill_3a79eeb1-c6cc-4bb2-b8f7-c9dbd851cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_cb9407d6-89b0-4c61-be3b-7027504e4abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_cbf8ec90-497b-4c98-968b-375c04963ca2" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_cb9407d6-89b0-4c61-be3b-7027504e4abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e08f470a-d69a-4b78-940c-af1464b18ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e08f470a-d69a-4b78-940c-af1464b18ebf" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bc7fd97-ec27-49bf-8e44-0c0b3d479b7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2c300d0f-ace7-40ac-8c7d-8e21471db0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2c300d0f-ace7-40ac-8c7d-8e21471db0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1592ac48-5d2d-4a48-bdb8-6b95f350f2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:to="loc_us-gaap_LicenseMember_1592ac48-5d2d-4a48-bdb8-6b95f350f2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_489b0b32-e6a4-462c-b2b1-16f55a4889a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:to="loc_us-gaap_TradeNamesMember_489b0b32-e6a4-462c-b2b1-16f55a4889a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_5398fd8a-fd22-43b5-b254-5b9672266b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a71d9304-4610-43c0-bceb-f9f5e042180b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_5398fd8a-fd22-43b5-b254-5b9672266b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c68d3343-0f44-4762-8b94-8d1104ff93b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c68d3343-0f44-4762-8b94-8d1104ff93b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_07406d87-0526-4b2b-a006-a9b278598a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c68d3343-0f44-4762-8b94-8d1104ff93b8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_07406d87-0526-4b2b-a006-a9b278598a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c60da35e-e0b1-48c6-96e3-6c554f8d59c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_07406d87-0526-4b2b-a006-a9b278598a59" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c60da35e-e0b1-48c6-96e3-6c554f8d59c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2fb19561-f8f3-4e01-8606-28f7a9e48771" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4b808c3e-9676-4c6c-8ecf-4dfc7d883247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4b808c3e-9676-4c6c-8ecf-4dfc7d883247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_159c8519-14cd-46c2-ab0c-397f434987f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_159c8519-14cd-46c2-ab0c-397f434987f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64aa6b35-bc64-4f30-af6f-5bddc0a71871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e87915aa-7aa4-43f6-a788-8753d6a2f2de" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64aa6b35-bc64-4f30-af6f-5bddc0a71871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeases"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_46666a53-d59b-443d-9cd1-762619574da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_01c3b6ae-ae90-4d4d-9c08-fd33168e9e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_46666a53-d59b-443d-9cd1-762619574da5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_01c3b6ae-ae90-4d4d-9c08-fd33168e9e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1b8674d5-912e-4642-a570-3f50c00e0b70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e4d88096-dc3d-4653-9479-2c07f4fe354c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1b8674d5-912e-4642-a570-3f50c00e0b70" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e4d88096-dc3d-4653-9479-2c07f4fe354c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock_3227e705-545c-432a-ab20-f6ce8349e2ec" xlink:href="mrk-20201231.xsd#mrk_AssetsandLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1b8674d5-912e-4642-a570-3f50c00e0b70" xlink:to="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock_3227e705-545c-432a-ab20-f6ce8349e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ed4872c0-bc88-4fd9-a24a-14607cb92181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1b8674d5-912e-4642-a570-3f50c00e0b70" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ed4872c0-bc88-4fd9-a24a-14607cb92181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_71af03f5-f060-411e-bcff-8fb7334f83ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_71af03f5-f060-411e-bcff-8fb7334f83ad" xlink:to="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce83232b-96ed-45d2-a1ed-2a64906e1ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce83232b-96ed-45d2-a1ed-2a64906e1ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eda1f777-4083-4e44-80f2-9902f33e31d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce83232b-96ed-45d2-a1ed-2a64906e1ba0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eda1f777-4083-4e44-80f2-9902f33e31d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a84d245c-f89f-4e11-84eb-daa718736611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eda1f777-4083-4e44-80f2-9902f33e31d3" xlink:to="loc_us-gaap_BuildingMember_a84d245c-f89f-4e11-84eb-daa718736611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_8ab44e5f-9cbe-4e2c-a49e-2d3fb079b733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eda1f777-4083-4e44-80f2-9902f33e31d3" xlink:to="loc_us-gaap_VehiclesMember_8ab44e5f-9cbe-4e2c-a49e-2d3fb079b733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_862f860b-1563-4278-b253-100aba3f8c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_862f860b-1563-4278-b253-100aba3f8c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_5dde7f0e-a037-4a3e-875b-5f7f3893e9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_862f860b-1563-4278-b253-100aba3f8c13" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_5dde7f0e-a037-4a3e-875b-5f7f3893e9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_671e786e-ff01-4990-acbf-9f3097557653" xlink:href="mrk-20201231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5dde7f0e-a037-4a3e-875b-5f7f3893e9e9" xlink:to="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_671e786e-ff01-4990-acbf-9f3097557653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_585d0a02-d489-4884-8f1c-b917d045f1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5dde7f0e-a037-4a3e-875b-5f7f3893e9e9" xlink:to="loc_us-gaap_CommercialPaperMember_585d0a02-d489-4884-8f1c-b917d045f1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_236cc40a-a1dd-4463-9b8a-fb86f99764ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:to="loc_us-gaap_DebtInstrumentAxis_236cc40a-a1dd-4463-9b8a-fb86f99764ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_236cc40a-a1dd-4463-9b8a-fb86f99764ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember_9f330edf-8bb8-4771-aa07-227b35564a8a" xlink:href="mrk-20201231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_OtherVariableRateDebtMember_9f330edf-8bb8-4771-aa07-227b35564a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_92e2c337-86a9-44e7-94f0-cf80f24d89f5" xlink:href="mrk-20201231.xsd#mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_92e2c337-86a9-44e7-94f0-cf80f24d89f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.75notesdue2026Member_7f3f36d0-354d-4005-a1cd-488c9f2e70df" xlink:href="mrk-20201231.xsd#mrk_A0.75notesdue2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_A0.75notesdue2026Member_7f3f36d0-354d-4005-a1cd-488c9f2e70df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.45notesdue2030Member_8c68fd93-fe8c-48d4-87d1-b80e1c32c192" xlink:href="mrk-20201231.xsd#mrk_A1.45notesdue2030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_A1.45notesdue2030Member_8c68fd93-fe8c-48d4-87d1-b80e1c32c192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35notesdue2040Member_dc9edb8f-ba32-49d8-b33a-cb0328ba95c4" xlink:href="mrk-20201231.xsd#mrk_A2.35notesdue2040Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_A2.35notesdue2040Member_dc9edb8f-ba32-49d8-b33a-cb0328ba95c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.45notesdue2050Member_b53ae726-c155-40c9-9b25-8b8d9457f0b1" xlink:href="mrk-20201231.xsd#mrk_A2.45notesdue2050Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_479b3369-f58b-4e7c-8fcc-e66575cea1cb" xlink:to="loc_mrk_A2.45notesdue2050Member_b53ae726-c155-40c9-9b25-8b8d9457f0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5b18a81f-b9de-4847-a541-0a48318aad05" xlink:to="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_bc5f1813-3686-4d45-ae79-5839ce7f1347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtCurrent_bc5f1813-3686-4d45-ae79-5839ce7f1347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_60c9a871-8b6e-4ad6-8ed8-1674eb49b295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_DebtCurrent_60c9a871-8b6e-4ad6-8ed8-1674eb49b295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_34097b9c-f607-4520-8ee1-b757526fb7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_34097b9c-f607-4520-8ee1-b757526fb7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_47bf0b54-e11d-4dcd-9619-a52376ef646b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_47bf0b54-e11d-4dcd-9619-a52376ef646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_ef84b2ec-f892-41df-84ba-7ec2d15bc915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_ef84b2ec-f892-41df-84ba-7ec2d15bc915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3fcd1d85-4b7f-41c2-b43c-127c26d29bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3fcd1d85-4b7f-41c2-b43c-127c26d29bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fd1ffe30-6966-4c64-abb7-cc95f99cbabc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fd1ffe30-6966-4c64-abb7-cc95f99cbabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_56e143fe-6090-4e7f-af6b-ebea15de6524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_56e143fe-6090-4e7f-af6b-ebea15de6524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f0fc1b77-4a7c-4838-8bd0-bda3d686eaa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f0fc1b77-4a7c-4838-8bd0-bda3d686eaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1cb12401-6318-4577-8789-df6797adeee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1cb12401-6318-4577-8789-df6797adeee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8df46a96-cf66-48b1-91f9-f46969a77ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8df46a96-cf66-48b1-91f9-f46969a77ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0d4d7a53-bd4a-42b8-a8e7-b46f4b731d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0d4d7a53-bd4a-42b8-a8e7-b46f4b731d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_621a18a9-a05b-4d36-9ca6-a7f555e586cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_621a18a9-a05b-4d36-9ca6-a7f555e586cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_de57c83e-4e86-4775-a53b-094656f5af70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_de57c83e-4e86-4775-a53b-094656f5af70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_02657584-535f-4c3f-a6d8-ecedc908b4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_02657584-535f-4c3f-a6d8-ecedc908b4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9eb83979-bd1c-4a71-b166-80bcdeacdd9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_OperatingLeaseCost_9eb83979-bd1c-4a71-b166-80bcdeacdd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f0d4bbce-c2ca-45ef-8006-815e8a432f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_OperatingLeasePayments_f0d4bbce-c2ca-45ef-8006-815e8a432f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_6fe5d5dd-ab1e-4c5f-986e-c4702ecfd0bf" xlink:href="mrk-20201231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_6fe5d5dd-ab1e-4c5f-986e-c4702ecfd0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_00ba7f2c-3b91-4690-8ad6-627cc3c2a150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_00ba7f2c-3b91-4690-8ad6-627cc3c2a150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_64a9a3f3-1a4c-44f6-b69e-877e391a0510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_444d3008-edd5-44c2-a114-69bad5a8a8a8" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_64a9a3f3-1a4c-44f6-b69e-877e391a0510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_31ba7c3e-7ebe-43cb-9702-86eb426ac1ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5984e201-eb21-49c6-b1f2-2f3c89cdae6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_31ba7c3e-7ebe-43cb-9702-86eb426ac1ed" xlink:to="loc_us-gaap_DebtInstrumentTable_5984e201-eb21-49c6-b1f2-2f3c89cdae6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5984e201-eb21-49c6-b1f2-2f3c89cdae6e" xlink:to="loc_us-gaap_DebtInstrumentAxis_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd0d3e5c-5f8e-464b-a536-f89bdd222bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member_058b9eaa-3f30-4364-9c86-101687e61c8b" xlink:href="mrk-20201231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.75NotesDue2025Member_058b9eaa-3f30-4364-9c86-101687e61c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member_e86ea0c6-c1db-4422-acdd-09268b1c9310" xlink:href="mrk-20201231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A3.70NotesDue2045Member_e86ea0c6-c1db-4422-acdd-09268b1c9310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member_4b60586a-494b-414e-9d9d-8026cb6fe244" xlink:href="mrk-20201231.xsd#mrk_A280NotesDue2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A280NotesDue2023Member_4b60586a-494b-414e-9d9d-8026cb6fe244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member_46693e1a-c66b-4750-81cc-01eba6dd1286" xlink:href="mrk-20201231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A3.40NotesDue2029Member_46693e1a-c66b-4750-81cc-01eba6dd1286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member_61fb3cd0-3d50-4140-af3a-42f1139ec838" xlink:href="mrk-20201231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A4.00NotesDue2049Member_61fb3cd0-3d50-4140-af3a-42f1139ec838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member_e471af3b-a8a3-4f48-a092-370a74f8635e" xlink:href="mrk-20201231.xsd#mrk_A235NotesDue2040Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A235NotesDue2040Member_e471af3b-a8a3-4f48-a092-370a74f8635e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member_737130a1-2c50-478e-88c4-e156343e6dd3" xlink:href="mrk-20201231.xsd#mrk_A415NotesDue2043Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A415NotesDue2043Member_737130a1-2c50-478e-88c4-e156343e6dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member_61cc1f0b-0348-49e4-a560-17d3b8d8dd98" xlink:href="mrk-20201231.xsd#mrk_A145NotesDue2030Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A145NotesDue2030Member_61cc1f0b-0348-49e4-a560-17d3b8d8dd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member_049def19-1255-4567-a553-d2eeaeae7464" xlink:href="mrk-20201231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A1.875EuroNotesDue2026Member_049def19-1255-4567-a553-d2eeaeae7464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member_c0193644-0cd1-4702-a8fa-100d0ded507b" xlink:href="mrk-20201231.xsd#mrk_A245NotesDue2050Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A245NotesDue2050Member_c0193644-0cd1-4702-a8fa-100d0ded507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_4cb23b51-4416-4d7b-b52e-eb004fba4235" xlink:href="mrk-20201231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.40NotesDue2022Member_4cb23b51-4416-4d7b-b52e-eb004fba4235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member_f2ed128e-15dd-4fde-99b0-8ab72430c338" xlink:href="mrk-20201231.xsd#mrk_A075NotesDue2026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A075NotesDue2026Member_f2ed128e-15dd-4fde-99b0-8ab72430c338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member_317af5a3-a7df-4048-8c6d-1ac0099cf2d1" xlink:href="mrk-20201231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A3.90NotesDue2039Member_317af5a3-a7df-4048-8c6d-1ac0099cf2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_51bb65b2-50e8-4052-abf4-2f4155dbc22a" xlink:href="mrk-20201231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.35NotesDue2022Member_51bb65b2-50e8-4052-abf4-2f4155dbc22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member_4206dcd1-6da3-400d-8e4b-14761ba33609" xlink:href="mrk-20201231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.90NotesDue2024Member_4206dcd1-6da3-400d-8e4b-14761ba33609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_31c57a13-ff18-490d-a8a7-e7a854f6e540" xlink:href="mrk-20201231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_31c57a13-ff18-490d-a8a7-e7a854f6e540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member_66bcbe4f-4193-4e99-a63a-909ddb1e07b3" xlink:href="mrk-20201231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A0.50eurodenominatednotesdue2024Member_66bcbe4f-4193-4e99-a63a-909ddb1e07b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member_5a989489-34a3-41bb-987f-157e9d356bb6" xlink:href="mrk-20201231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A1.375eurodenominatednotesdue2036Member_5a989489-34a3-41bb-987f-157e9d356bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member_55a453a4-043f-489b-a42a-df26ea665d8f" xlink:href="mrk-20201231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A2.5EuroNotesDue2034Member_55a453a4-043f-489b-a42a-df26ea665d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_cd2ee7bf-8d23-4316-9eeb-09eab2db2ab2" xlink:href="mrk-20201231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_cd2ee7bf-8d23-4316-9eeb-09eab2db2ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_d3a77fb0-677f-4b00-adf2-d5ec2084a224" xlink:href="mrk-20201231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_d3a77fb0-677f-4b00-adf2-d5ec2084a224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_b00baeec-8253-4fde-bf1e-82cfca5a0692" xlink:href="mrk-20201231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_b00baeec-8253-4fde-bf1e-82cfca5a0692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_d46bd7e0-b2e8-47f0-be0d-70a795922c1e" xlink:href="mrk-20201231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_d46bd7e0-b2e8-47f0-be0d-70a795922c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_da9254a6-d454-4afd-be52-ce289e1eae75" xlink:href="mrk-20201231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_da9254a6-d454-4afd-be52-ce289e1eae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_b288087f-1899-42ed-bc43-128ae0b049b3" xlink:href="mrk-20201231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_b288087f-1899-42ed-bc43-128ae0b049b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_0a8ff515-2325-459d-9211-ae3d7e36cd7c" xlink:href="mrk-20201231.xsd#mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember_0a8ff515-2325-459d-9211-ae3d7e36cd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member_96795a8f-df60-4fe6-b025-70d0a658bb59" xlink:href="mrk-20201231.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A3.875NotesDue2021Member_96795a8f-df60-4fe6-b025-70d0a658bb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125EuroNotesDue2021Member_596da137-2bd8-411d-94b1-7abacc7cd42f" xlink:href="mrk-20201231.xsd#mrk_A1.125EuroNotesDue2021Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_A1.125EuroNotesDue2021Member_596da137-2bd8-411d-94b1-7abacc7cd42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember_62a42aee-6eed-454c-b85a-ef1d4ed582c2" xlink:href="mrk-20201231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a2c85f6-71f7-4596-bc83-4415fc1cf5e3" xlink:to="loc_mrk_OtherLongTermDebtMember_62a42aee-6eed-454c-b85a-ef1d4ed582c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bf5df00e-e886-4319-9926-2f3abb901486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5984e201-eb21-49c6-b1f2-2f3c89cdae6e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bf5df00e-e886-4319-9926-2f3abb901486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95177e78-6b2f-4401-b41d-b4ec2e6e8287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bf5df00e-e886-4319-9926-2f3abb901486" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95177e78-6b2f-4401-b41d-b4ec2e6e8287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7ced7171-3451-4b47-9aec-9ab55fd4c6ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bf5df00e-e886-4319-9926-2f3abb901486" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7ced7171-3451-4b47-9aec-9ab55fd4c6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:href="mrk-20201231.xsd#mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c3c88c2-473d-4311-94a9-09d7d456650d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c3c88c2-473d-4311-94a9-09d7d456650d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_de2b9d36-ab96-4e6f-a2d7-3777e4acb10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_de2b9d36-ab96-4e6f-a2d7-3777e4acb10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9076595-be1d-4325-a4ab-a2535afd88d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9076595-be1d-4325-a4ab-a2535afd88d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_97e1bf90-91dd-44f7-8d1d-ee0e82e92dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseLiability_97e1bf90-91dd-44f7-8d1d-ee0e82e92dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a7da9320-a7fc-4741-b12e-2a6d66172267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a7da9320-a7fc-4741-b12e-2a6d66172267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_14787884-ca2c-4f2a-8962-9cc66a3674e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_14787884-ca2c-4f2a-8962-9cc66a3674e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e3a8f41f-e553-4bea-acca-8a0df57982ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e3a8f41f-e553-4bea-acca-8a0df57982ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_626a5031-1833-419d-8688-4cce8b7d894a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_626a5031-1833-419d-8688-4cce8b7d894a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ca683f91-cf76-4338-97db-2438ef4a03a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract_b6f82c34-2321-405c-9e89-0a1399a39109" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ca683f91-cf76-4338-97db-2438ef4a03a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e00ace68-91c7-47c9-bc3a-960ac94defcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e00ace68-91c7-47c9-bc3a-960ac94defcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_05b01a52-d8b9-4f72-9135-3ae260a415a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_05b01a52-d8b9-4f72-9135-3ae260a415a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bc098484-ee52-4724-ba8d-052724e345b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bc098484-ee52-4724-ba8d-052724e345b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ae4a8fd-8bc6-45a1-9a9c-4965c127d773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ae4a8fd-8bc6-45a1-9a9c-4965c127d773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_814746e6-55ea-4625-a2fe-1419e5c9f72c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_814746e6-55ea-4625-a2fe-1419e5c9f72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_515ea9f3-a400-4eae-ae33-1574328c22da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_515ea9f3-a400-4eae-ae33-1574328c22da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6dee455-0d97-42ff-8a76-da3aaafcf276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6dee455-0d97-42ff-8a76-da3aaafcf276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bf0c2a83-0727-45d6-ad32-a66e596269af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bf0c2a83-0727-45d6-ad32-a66e596269af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2f2b0888-3093-46d3-aab3-6cbefe4ea2fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7e5da41-9c9a-49ed-b147-8963f976b8ed" xlink:to="loc_us-gaap_OperatingLeaseLiability_2f2b0888-3093-46d3-aab3-6cbefe4ea2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="simple" xlink:href="mrk-20201231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilities"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_349928fc-aad7-4612-a998-39e681ec180e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65f28710-8398-4cd6-9c3f-e43b59658c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_349928fc-aad7-4612-a998-39e681ec180e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65f28710-8398-4cd6-9c3f-e43b59658c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22e9ecf9-42b2-4680-97a2-8a89d1581a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22e9ecf9-42b2-4680-97a2-8a89d1581a6b" xlink:to="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00d875a0-a20e-4251-a807-d138d7013460" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:to="loc_srt_ProductOrServiceAxis_00d875a0-a20e-4251-a807-d138d7013460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_00d875a0-a20e-4251-a807-d138d7013460" xlink:to="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember_d14828cc-efcc-4093-a994-3ff9e7fa3db0" xlink:href="mrk-20201231.xsd#mrk_FosamaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:to="loc_mrk_FosamaxMember_d14828cc-efcc-4093-a994-3ff9e7fa3db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_3845d059-2710-4479-8ac5-9273e400bbc0" xlink:href="mrk-20201231.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:to="loc_mrk_JanuviaMember_3845d059-2710-4479-8ac5-9273e400bbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VioxxMember_15a9b559-5cde-41a9-8c79-1c8879225c9f" xlink:href="mrk-20201231.xsd#mrk_VioxxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa6f2860-468a-44ae-a8a9-8e9cd8750b80" xlink:to="loc_mrk_VioxxMember_15a9b559-5cde-41a9-8c79-1c8879225c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cba545ad-4228-429e-981a-4d88d42216b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:to="loc_srt_LitigationCaseAxis_cba545ad-4228-429e-981a-4d88d42216b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_cba545ad-4228-429e-981a-4d88d42216b3" xlink:to="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember_8be117c3-48ca-40cc-b0c5-0b426178a491" xlink:href="mrk-20201231.xsd#mrk_FederalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:to="loc_mrk_FederalMember_8be117c3-48ca-40cc-b0c5-0b426178a491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NewJerseyStateCourtMember_cab89542-a081-4b3f-9948-dfb15187e05a" xlink:href="mrk-20201231.xsd#mrk_NewJerseyStateCourtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:to="loc_mrk_NewJerseyStateCourtMember_cab89542-a081-4b3f-9948-dfb15187e05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CaliforniaStateCourtMember_0f70712d-fe3a-4700-b361-3472c98409db" xlink:href="mrk-20201231.xsd#mrk_CaliforniaStateCourtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:to="loc_mrk_CaliforniaStateCourtMember_0f70712d-fe3a-4700-b361-3472c98409db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember_389c29a3-74d7-4236-8b8e-56d4d0ebcc02" xlink:href="mrk-20201231.xsd#mrk_OtherStateCourtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5283f0be-c48d-4afc-bc2d-344ad605e1d4" xlink:to="loc_mrk_OtherStateCourtMember_389c29a3-74d7-4236-8b8e-56d4d0ebcc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a48d6a67-28a1-468b-8c3a-d4ebc0562a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a48d6a67-28a1-468b-8c3a-d4ebc0562a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a48d6a67-28a1-468b-8c3a-d4ebc0562a53" xlink:to="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_1815dbd8-f7bd-40df-b204-2354d7f9a955" xlink:href="mrk-20201231.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:to="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_1815dbd8-f7bd-40df-b204-2354d7f9a955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember_8d26b571-d48b-492e-844b-4aa4b70fe242" xlink:href="mrk-20201231.xsd#mrk_PatentlitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:to="loc_mrk_PatentlitigationMember_8d26b571-d48b-492e-844b-4aa4b70fe242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember_b927912b-20f4-4921-b9c2-05971df0fe7d" xlink:href="mrk-20201231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cc7590f7-5519-4f4c-acb3-a72312a7624f" xlink:to="loc_mrk_CommercialandOtherLitigationMember_b927912b-20f4-4921-b9c2-05971df0fe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_00b61ea4-0b12-457a-ad23-ae85e5b62f66" xlink:to="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_03a0fece-7f99-4223-9525-755a1433d8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_03a0fece-7f99-4223-9525-755a1433d8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_535b1f06-84ea-400f-9478-08d8183afc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_535b1f06-84ea-400f-9478-08d8183afc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber_2d345d89-0cb3-424d-b2f5-b27137e25f93" xlink:href="mrk-20201231.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_mrk_LossContingencyClaimsonAppealNumber_2d345d89-0cb3-424d-b2f5-b27137e25f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_e87f2d1a-5142-485f-a8bf-18cfb58c1814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_e87f2d1a-5142-485f-a8bf-18cfb58c1814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_3182dc83-63eb-4d87-80bf-89681ebc0c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_3182dc83-63eb-4d87-80bf-89681ebc0c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_64444a32-8636-4817-bbf1-329939f9d6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e957cb0-8695-496f-86ba-053ac2f9a0f5" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_64444a32-8636-4817-bbf1-329939f9d6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0b63e4f1-b96c-4427-a4e9-1192d2e776fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d015eac2-3e38-4839-b7c0-c703e4c6239c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0b63e4f1-b96c-4427-a4e9-1192d2e776fb" xlink:to="loc_us-gaap_LossContingenciesTable_d015eac2-3e38-4839-b7c0-c703e4c6239c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_676cf7bc-7622-4658-ab42-d266c11f98d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d015eac2-3e38-4839-b7c0-c703e4c6239c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_676cf7bc-7622-4658-ab42-d266c11f98d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d836f7c8-8668-4094-8c08-30dfb24ca554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_676cf7bc-7622-4658-ab42-d266c11f98d5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d836f7c8-8668-4094-8c08-30dfb24ca554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_fdf22bbe-55de-4262-a863-9a3877d5ad4d" xlink:href="mrk-20201231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d836f7c8-8668-4094-8c08-30dfb24ca554" xlink:to="loc_mrk_LegalDefenseCostsMember_fdf22bbe-55de-4262-a863-9a3877d5ad4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2c2df061-71e5-4aac-8750-8ea435710cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d015eac2-3e38-4839-b7c0-c703e4c6239c" xlink:to="loc_us-gaap_LossContingenciesLineItems_2c2df061-71e5-4aac-8750-8ea435710cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_041e8391-189d-4a25-a910-c60fd0669515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2c2df061-71e5-4aac-8750-8ea435710cce" xlink:to="loc_us-gaap_LitigationReserve_041e8391-189d-4a25-a910-c60fd0669515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80316ca1-70b6-4d40-b702-0be1d91dadce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SiteContingencyTable_678706a8-e10a-421e-83db-1b07b00ce5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SiteContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80316ca1-70b6-4d40-b702-0be1d91dadce" xlink:to="loc_us-gaap_SiteContingencyTable_678706a8-e10a-421e-83db-1b07b00ce5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalRemediationSiteAxis_91d69939-8864-4c1c-9386-e025d416949d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalRemediationSiteAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SiteContingencyTable_678706a8-e10a-421e-83db-1b07b00ce5c9" xlink:to="loc_us-gaap_EnvironmentalRemediationSiteAxis_91d69939-8864-4c1c-9386-e025d416949d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalRemediationSiteDomain_696e2cfd-f88c-43b4-ab4c-169a4bea30c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalRemediationSiteDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EnvironmentalRemediationSiteAxis_91d69939-8864-4c1c-9386-e025d416949d" xlink:to="loc_us-gaap_EnvironmentalRemediationSiteDomain_696e2cfd-f88c-43b4-ab4c-169a4bea30c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SiteContingencyLineItems_dc2abe23-7326-45a7-b007-6e06c2552ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SiteContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SiteContingencyTable_678706a8-e10a-421e-83db-1b07b00ce5c9" xlink:to="loc_us-gaap_SiteContingencyLineItems_dc2abe23-7326-45a7-b007-6e06c2552ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_c0b5f9e8-80ad-4b1a-a74f-dccb188d0026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccrualForEnvironmentalLossContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80316ca1-70b6-4d40-b702-0be1d91dadce" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_c0b5f9e8-80ad-4b1a-a74f-dccb188d0026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TermForPayingOffEnvironmentalLiabilities_8f9ecee1-b124-4a20-b0c9-1bcd8da71614" xlink:href="mrk-20201231.xsd#mrk_TermForPayingOffEnvironmentalLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80316ca1-70b6-4d40-b702-0be1d91dadce" xlink:to="loc_mrk_TermForPayingOffEnvironmentalLiabilities_8f9ecee1-b124-4a20-b0c9-1bcd8da71614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_36c91323-2b3d-4da9-b4b2-2130632a3ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80316ca1-70b6-4d40-b702-0be1d91dadce" xlink:to="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_36c91323-2b3d-4da9-b4b2-2130632a3ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20201231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d22e6508-b323-49ea-af9e-cad9af1e4ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7faeaf55-2b67-4a7d-9fc6-fe0d7bd235c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d22e6508-b323-49ea-af9e-cad9af1e4ba1" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7faeaf55-2b67-4a7d-9fc6-fe0d7bd235c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_40c972da-8f9b-40d6-b564-56bc7d32b4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_c8059da2-5ed9-4a08-a59a-d6167f070fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40c972da-8f9b-40d6-b564-56bc7d32b4b4" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_c8059da2-5ed9-4a08-a59a-d6167f070fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6c99328a-cad4-4002-a58b-673555ad8c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a832e153-17b7-4a0e-bdf1-0b2a0d5c4963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6c99328a-cad4-4002-a58b-673555ad8c63" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a832e153-17b7-4a0e-bdf1-0b2a0d5c4963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_88bd4c8b-b0e7-433d-b021-13d415777354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6c99328a-cad4-4002-a58b-673555ad8c63" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_88bd4c8b-b0e7-433d-b021-13d415777354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6c99328a-cad4-4002-a58b-673555ad8c63" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_447a635d-f590-4828-a9ba-976f49272971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_447a635d-f590-4828-a9ba-976f49272971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5cb837c9-cd9a-419d-a64e-df0757174e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_447a635d-f590-4828-a9ba-976f49272971" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5cb837c9-cd9a-419d-a64e-df0757174e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedShareRepurchaseAgreementMember_a43f66af-0d86-4ed0-8ce2-de4ddbc8ff40" xlink:href="mrk-20201231.xsd#mrk_AcceleratedShareRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5cb837c9-cd9a-419d-a64e-df0757174e65" xlink:to="loc_mrk_AcceleratedShareRepurchaseAgreementMember_a43f66af-0d86-4ed0-8ce2-de4ddbc8ff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_49857b99-a38f-42eb-a41c-3212b7e47a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_f7d7cdbf-1cbd-4f9d-8be3-33ccdd767460" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_49857b99-a38f-42eb-a41c-3212b7e47a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member_d92e4729-93cb-4f4b-b2a1-1ace2e6ded10" xlink:href="mrk-20201231.xsd#mrk_AcceleratedShareRepurchaseAgreementOctober292018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_49857b99-a38f-42eb-a41c-3212b7e47a6e" xlink:to="loc_mrk_AcceleratedShareRepurchaseAgreementOctober292018Member_d92e4729-93cb-4f4b-b2a1-1ace2e6ded10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_1984d07e-aa83-4806-8281-f799cd4e75eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_0f2ad8fb-27ae-4c29-a099-1b5d1e0fc9d2" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesLineItems_1984d07e-aa83-4806-8281-f799cd4e75eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_91aac970-7285-4c9e-8e12-91eae02db568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_1984d07e-aa83-4806-8281-f799cd4e75eb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_91aac970-7285-4c9e-8e12-91eae02db568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_4b99ed1d-9a42-4234-a6bd-0f977c4f00e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_1984d07e-aa83-4806-8281-f799cd4e75eb" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_4b99ed1d-9a42-4234-a6bd-0f977c4f00e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EquityShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6e2a627d-d332-4f35-bfdc-3bbaba6c8a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_de9cbde1-5ad3-48ba-8caa-401b8f954470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6e2a627d-d332-4f35-bfdc-3bbaba6c8a98" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_de9cbde1-5ad3-48ba-8caa-401b8f954470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b994f394-2de8-474e-9d30-94f31b3dcf64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9cbde1-5ad3-48ba-8caa-401b8f954470" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b994f394-2de8-474e-9d30-94f31b3dcf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c05a70ca-8288-4ca7-b8a5-5c935819034c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b994f394-2de8-474e-9d30-94f31b3dcf64" xlink:to="loc_us-gaap_EquityComponentDomain_c05a70ca-8288-4ca7-b8a5-5c935819034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2b1fc626-e19f-46df-9c39-1e8dfb776a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c05a70ca-8288-4ca7-b8a5-5c935819034c" xlink:to="loc_us-gaap_CommonStockMember_2b1fc626-e19f-46df-9c39-1e8dfb776a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_796b4174-4c13-4277-bd04-221fb5259573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c05a70ca-8288-4ca7-b8a5-5c935819034c" xlink:to="loc_us-gaap_TreasuryStockMember_796b4174-4c13-4277-bd04-221fb5259573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e2320027-6dbb-479a-9d55-2f11b20794fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9cbde1-5ad3-48ba-8caa-401b8f954470" xlink:to="loc_us-gaap_ClassOfStockLineItems_e2320027-6dbb-479a-9d55-2f11b20794fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:href="mrk-20201231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e2320027-6dbb-479a-9d55-2f11b20794fd" xlink:to="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_852aeb90-aa34-4263-be81-5e22167f8d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:to="loc_us-gaap_CommonStockSharesIssued_852aeb90-aa34-4263-be81-5e22167f8d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e65ee069-7342-4b97-88ee-cf741473979c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e65ee069-7342-4b97-88ee-cf741473979c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b55e5933-a2d0-43ce-a041-cab773dd084a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b55e5933-a2d0-43ce-a041-cab773dd084a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c00aab7b-ac2f-4ce9-bd2f-dba275940900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_142e5cc4-d0d4-4adf-868e-273605f7ff2f" xlink:to="loc_us-gaap_CommonStockSharesIssued_c00aab7b-ac2f-4ce9-bd2f-dba275940900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ada0d77a-5cf9-4ca1-9aa9-6527366e3979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b9fa6926-9671-47aa-bafa-9c0167d2d494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ada0d77a-5cf9-4ca1-9aa9-6527366e3979" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b9fa6926-9671-47aa-bafa-9c0167d2d494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf7ba558-f6f6-4be4-93bd-a7923a85d6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c4f4f248-de49-42ad-9aa7-6464f51e46e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf7ba558-f6f6-4be4-93bd-a7923a85d6a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c4f4f248-de49-42ad-9aa7-6464f51e46e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fd765d1a-fce4-4707-b931-56532aac4b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf7ba558-f6f6-4be4-93bd-a7923a85d6a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fd765d1a-fce4-4707-b931-56532aac4b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_ed2e3b9a-cef0-4f2d-a8cc-8dd7a875c7b3" xlink:href="mrk-20201231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf7ba558-f6f6-4be4-93bd-a7923a85d6a8" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_ed2e3b9a-cef0-4f2d-a8cc-8dd7a875c7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9e7113cf-7700-4d5c-8f49-d678f14b7b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf7ba558-f6f6-4be4-93bd-a7923a85d6a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9e7113cf-7700-4d5c-8f49-d678f14b7b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e50647c7-dba0-46f1-9df6-fe206cec32d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e50647c7-dba0-46f1-9df6-fe206cec32d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0dfd6b31-a44f-41a8-bf64-8d89a6cf7c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0dfd6b31-a44f-41a8-bf64-8d89a6cf7c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_502eec90-f23b-456e-8a16-7aee436e8015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_502eec90-f23b-456e-8a16-7aee436e8015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e1c932-b92e-4026-8474-b6bd1182499a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e1c932-b92e-4026-8474-b6bd1182499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_63fe7057-1432-4784-a8c0-6964b4a4e8ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e1c932-b92e-4026-8474-b6bd1182499a" xlink:to="loc_srt_RangeAxis_63fe7057-1432-4784-a8c0-6964b4a4e8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f76223bf-f444-40ef-803f-71e069270f82" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_63fe7057-1432-4784-a8c0-6964b4a4e8ef" xlink:to="loc_srt_RangeMember_f76223bf-f444-40ef-803f-71e069270f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c388b13-7dd3-4e0d-a56d-300be5620496" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f76223bf-f444-40ef-803f-71e069270f82" xlink:to="loc_srt_MinimumMember_5c388b13-7dd3-4e0d-a56d-300be5620496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e74a994-38b6-4a75-be91-bccc001354ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f76223bf-f444-40ef-803f-71e069270f82" xlink:to="loc_srt_MaximumMember_9e74a994-38b6-4a75-be91-bccc001354ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a3c01dc-cac8-4a19-a2c1-a06de4373568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0e1c932-b92e-4026-8474-b6bd1182499a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a3c01dc-cac8-4a19-a2c1-a06de4373568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_299e9193-ba8d-4c03-bb20-970d6af4387a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a3c01dc-cac8-4a19-a2c1-a06de4373568" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_299e9193-ba8d-4c03-bb20-970d6af4387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fb321b09-f99c-4a34-a7bc-9c8a3894e71b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_ShareBasedCompensation_fb321b09-f99c-4a34-a7bc-9c8a3894e71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_96713fa0-cd50-4c95-8824-c2fd82cd6a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_96713fa0-cd50-4c95-8824-c2fd82cd6a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b1d7c107-f137-41ee-8098-0374e751aeb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b1d7c107-f137-41ee-8098-0374e751aeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ecaba02-32d0-444a-84ec-8c9b474ac2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ecaba02-32d0-444a-84ec-8c9b474ac2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7fe4bbe8-f558-4ab6-af8c-7b2ed1071bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7fe4bbe8-f558-4ab6-af8c-7b2ed1071bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b16b6835-3ec6-49b6-9566-e41aeba048d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68322a97-e0b5-4f80-8dcb-db972a91ee1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b16b6835-3ec6-49b6-9566-e41aeba048d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_369b973d-fdf4-4563-b3ae-add6bd964741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d4739da4-0289-4185-9970-eca549ed4666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_369b973d-fdf4-4563-b3ae-add6bd964741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d4739da4-0289-4185-9970-eca549ed4666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_369f7f64-a017-49fd-bdb0-bb7b0fbc276b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_369b973d-fdf4-4563-b3ae-add6bd964741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_369f7f64-a017-49fd-bdb0-bb7b0fbc276b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f0615e24-e70f-48a9-9481-2d6c4caa40a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_369b973d-fdf4-4563-b3ae-add6bd964741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f0615e24-e70f-48a9-9481-2d6c4caa40a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80f7477d-0d59-44a8-b4bd-ebe890477414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_369b973d-fdf4-4563-b3ae-add6bd964741" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80f7477d-0d59-44a8-b4bd-ebe890477414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65954f72-60f5-43c6-ae75-16b3c79c0a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65954f72-60f5-43c6-ae75-16b3c79c0a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2bd2c3f2-d638-4685-a24f-f19952abb398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65954f72-60f5-43c6-ae75-16b3c79c0a10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2bd2c3f2-d638-4685-a24f-f19952abb398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_381580de-8700-4c6b-817b-87e2f58e3d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65954f72-60f5-43c6-ae75-16b3c79c0a10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_381580de-8700-4c6b-817b-87e2f58e3d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2df8257c-4fd8-4849-a5fe-6f23e2bdfccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65954f72-60f5-43c6-ae75-16b3c79c0a10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2df8257c-4fd8-4849-a5fe-6f23e2bdfccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_760b1563-ca5d-4fb9-a1a3-4ec70273c7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65954f72-60f5-43c6-ae75-16b3c79c0a10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_760b1563-ca5d-4fb9-a1a3-4ec70273c7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_74b7a1e9-6cd8-4769-8a20-d4319d74c110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65954f72-60f5-43c6-ae75-16b3c79c0a10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_74b7a1e9-6cd8-4769-8a20-d4319d74c110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b274a1ec-2338-4fe9-a3fe-600a48230a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b274a1ec-2338-4fe9-a3fe-600a48230a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3af84678-c063-4506-8fa7-6783f15328e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3af84678-c063-4506-8fa7-6783f15328e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff3d323c-bc4f-40f5-a688-d5da233bb2b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3af84678-c063-4506-8fa7-6783f15328e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff3d323c-bc4f-40f5-a688-d5da233bb2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_85ebf5ed-1653-48d9-86f9-778240e0cbeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3af84678-c063-4506-8fa7-6783f15328e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_85ebf5ed-1653-48d9-86f9-778240e0cbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c572bdf6-64c5-42a9-97ee-f6f23b08f530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3af84678-c063-4506-8fa7-6783f15328e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c572bdf6-64c5-42a9-97ee-f6f23b08f530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ae154f3e-e4b3-415f-a85f-c316f0205adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3af84678-c063-4506-8fa7-6783f15328e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ae154f3e-e4b3-415f-a85f-c316f0205adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5a6e585-8dea-4a30-8c44-7789a9d710bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3af84678-c063-4506-8fa7-6783f15328e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5a6e585-8dea-4a30-8c44-7789a9d710bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1091b710-1d18-47c6-8d00-ddaa7890397b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1091b710-1d18-47c6-8d00-ddaa7890397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3b8b43e2-7494-40c5-ba69-386bb178ac92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3b8b43e2-7494-40c5-ba69-386bb178ac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74997e9d-080c-468e-9a82-a63ec2f94b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74997e9d-080c-468e-9a82-a63ec2f94b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f6a6221-560e-4131-9466-b2e9eeada111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f6a6221-560e-4131-9466-b2e9eeada111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bd3eca3d-52d3-4844-8fbc-29de54af31ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd00ab3e-0cd4-4378-91a7-041e71e872da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bd3eca3d-52d3-4844-8fbc-29de54af31ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8605e80d-829c-4437-988b-bdc195e452c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_647ae5f3-4cac-4897-b5c0-d1f66365d58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8605e80d-829c-4437-988b-bdc195e452c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_647ae5f3-4cac-4897-b5c0-d1f66365d58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_89c0e955-d21c-4977-a8f2-494086bb7b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8605e80d-829c-4437-988b-bdc195e452c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_89c0e955-d21c-4977-a8f2-494086bb7b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_39ad82e8-23bf-47ad-b6e3-6e360ba1bfa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8605e80d-829c-4437-988b-bdc195e452c6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_39ad82e8-23bf-47ad-b6e3-6e360ba1bfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4e4e6ec9-8225-471e-9762-a5f550999f68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ad141f-f2cc-4777-9949-949408f58fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4e4e6ec9-8225-471e-9762-a5f550999f68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ad141f-f2cc-4777-9949-949408f58fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7ea79008-9371-4fe7-af97-011ad937d802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ad141f-f2cc-4777-9949-949408f58fcd" xlink:to="loc_us-gaap_AwardTypeAxis_7ea79008-9371-4fe7-af97-011ad937d802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a09847a9-5140-458a-bb85-c4888b468878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7ea79008-9371-4fe7-af97-011ad937d802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a09847a9-5140-458a-bb85-c4888b468878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3a3dde8b-07da-4404-bad2-4aa54894b7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a09847a9-5140-458a-bb85-c4888b468878" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3a3dde8b-07da-4404-bad2-4aa54894b7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f93ac84b-d4e7-4c34-b788-9b2b694fde0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a09847a9-5140-458a-bb85-c4888b468878" xlink:to="loc_us-gaap_PerformanceSharesMember_f93ac84b-d4e7-4c34-b788-9b2b694fde0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f25966b9-b2e4-4e7b-bd9a-ff8abd532aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ad141f-f2cc-4777-9949-949408f58fcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f25966b9-b2e4-4e7b-bd9a-ff8abd532aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f25966b9-b2e4-4e7b-bd9a-ff8abd532aeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_694d700f-a8cf-4462-8719-e518dc47e264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_694d700f-a8cf-4462-8719-e518dc47e264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a2d5df78-f411-495d-b238-0cc384069154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a2d5df78-f411-495d-b238-0cc384069154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_46121e03-a745-497a-b05e-79d33bf3df46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_46121e03-a745-497a-b05e-79d33bf3df46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dbb56431-9766-45ff-9eba-af41dabec702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dbb56431-9766-45ff-9eba-af41dabec702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_349cc978-23dc-4177-bbf1-da24cc28a42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddc24f3c-6afe-4e28-8a4e-2ace6f3409b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_349cc978-23dc-4177-bbf1-da24cc28a42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f25966b9-b2e4-4e7b-bd9a-ff8abd532aeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4de97cac-ed4c-42d9-a107-a4deb63085f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4de97cac-ed4c-42d9-a107-a4deb63085f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba0538b-52a6-4d44-b218-02370d422791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba0538b-52a6-4d44-b218-02370d422791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_81a751a5-d53f-4bde-8c56-1eb2dc867f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_81a751a5-d53f-4bde-8c56-1eb2dc867f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f281c7ae-7108-4bf8-ad11-7f613464d38a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f281c7ae-7108-4bf8-ad11-7f613464d38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ff4525c5-63b6-4d54-96be-ed29f841d872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_467bae37-a7a0-43c4-b6b0-aec8c59ec29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ff4525c5-63b6-4d54-96be-ed29f841d872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dc4bcbd9-cc91-498d-83f7-6c94b60f952a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7f13da95-1f77-4c96-a656-5262b4473cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dc4bcbd9-cc91-498d-83f7-6c94b60f952a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7f13da95-1f77-4c96-a656-5262b4473cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_bb59bd7b-927e-4d1e-b1b4-f567cc1a1f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_bb59bd7b-927e-4d1e-b1b4-f567cc1a1f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_783acb3b-fc4d-4c0c-80ed-8d44a58d6f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_783acb3b-fc4d-4c0c-80ed-8d44a58d6f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_67943c23-2b45-4d5b-b78e-330ede81a8f1" xlink:href="mrk-20201231.xsd#mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_67943c23-2b45-4d5b-b78e-330ede81a8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_46039df9-9da2-453c-a444-9d5c3ae121a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_46039df9-9da2-453c-a444-9d5c3ae121a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_a1090303-03ab-4452-a5b5-a06077366cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_a1090303-03ab-4452-a5b5-a06077366cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_ef1854a0-4d65-43e7-8ba2-f09ad2da4a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_ef1854a0-4d65-43e7-8ba2-f09ad2da4a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_0ca60a56-eae2-4ac2-ae68-9f511ce82ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_0ca60a56-eae2-4ac2-ae68-9f511ce82ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_d7f4c61d-0cde-4efc-bffc-23c793f0a540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_d7f4c61d-0cde-4efc-bffc-23c793f0a540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_117de833-7722-41a8-8075-1600a6db7467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1b6386e-6960-4f57-8be0-5bb9bbfd2bdd" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_117de833-7722-41a8-8075-1600a6db7467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_29b6e786-f542-461e-9f69-a974ff4dfba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_29b6e786-f542-461e-9f69-a974ff4dfba2" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_335dfc51-4c86-4d99-a33d-8e3604bb16c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_335dfc51-4c86-4d99-a33d-8e3604bb16c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0593043f-508a-4fb2-ab7f-abb4f2e83f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_335dfc51-4c86-4d99-a33d-8e3604bb16c6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0593043f-508a-4fb2-ab7f-abb4f2e83f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2935da64-b7cc-414a-bf58-dfe74365514d" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0593043f-508a-4fb2-ab7f-abb4f2e83f2d" xlink:to="loc_country_US_2935da64-b7cc-414a-bf58-dfe74365514d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8bfc20e8-b0ab-470d-b0c5-0712b3d363f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0593043f-508a-4fb2-ab7f-abb4f2e83f2d" xlink:to="loc_us-gaap_ForeignPlanMember_8bfc20e8-b0ab-470d-b0c5-0712b3d363f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ae76ed14-1d03-465e-89ec-7662785584bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ae76ed14-1d03-465e-89ec-7662785584bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_054f4e66-4a61-42da-bede-6337f4c5b4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ae76ed14-1d03-465e-89ec-7662785584bb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_054f4e66-4a61-42da-bede-6337f4c5b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b6d8951a-dbe6-44cc-8436-2936772ecc8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_054f4e66-4a61-42da-bede-6337f4c5b4de" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b6d8951a-dbe6-44cc-8436-2936772ecc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2e281445-26a4-4709-9cbb-6f23fc6dd1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_054f4e66-4a61-42da-bede-6337f4c5b4de" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2e281445-26a4-4709-9cbb-6f23fc6dd1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_324dbbf6-8bcd-4c53-90a4-f6b8d88d134f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6881daf2-8dff-4a76-94e3-2fe8f5bf25a3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_324dbbf6-8bcd-4c53-90a4-f6b8d88d134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a62ac7d8-2893-455d-afe7-aa73c57d2faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_324dbbf6-8bcd-4c53-90a4-f6b8d88d134f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a62ac7d8-2893-455d-afe7-aa73c57d2faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ab544a53-7b6f-4116-a790-b96beff60538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ab544a53-7b6f-4116-a790-b96beff60538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ab544a53-7b6f-4116-a790-b96beff60538" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_cbb3823f-1470-4ff6-bbf8-2a10089dd29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_cbb3823f-1470-4ff6-bbf8-2a10089dd29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_900676c6-6bd3-4597-a62a-293f09891523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_900676c6-6bd3-4597-a62a-293f09891523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember_06c19298-b4d1-4872-86f9-90eeb6ea8305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:to="loc_us-gaap_FixedIncomeInvestmentsMember_06c19298-b4d1-4872-86f9-90eeb6ea8305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_f3db5a36-e2b6-45d7-bd16-0e5f9207342d" xlink:href="mrk-20201231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5fcdf17f-1989-414c-8e27-759793ecc3bd" xlink:to="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_f3db5a36-e2b6-45d7-bd16-0e5f9207342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45fb81fe-2a10-4938-84c1-3704bb954dcf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_srt_RangeAxis_45fb81fe-2a10-4938-84c1-3704bb954dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2129a77-2953-4684-bf06-6f3b701a3f1b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_45fb81fe-2a10-4938-84c1-3704bb954dcf" xlink:to="loc_srt_RangeMember_b2129a77-2953-4684-bf06-6f3b701a3f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6b4283ae-12a0-47ab-9dbe-0c216ba35ea7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b2129a77-2953-4684-bf06-6f3b701a3f1b" xlink:to="loc_srt_MinimumMember_6b4283ae-12a0-47ab-9dbe-0c216ba35ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b792f8de-5732-4168-862c-022ced3e311f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b2129a77-2953-4684-bf06-6f3b701a3f1b" xlink:to="loc_srt_MaximumMember_b792f8de-5732-4168-862c-022ced3e311f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_srt_StatementScenarioAxis_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e7dc6c01-274b-4176-bbe2-55fbeeed3c75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_bb4fd40f-27ec-47e2-ad37-8b4645ebdb06" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e7dc6c01-274b-4176-bbe2-55fbeeed3c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9d5fd9ba-7b3f-4126-8166-28f5bc025ccd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e7dc6c01-274b-4176-bbe2-55fbeeed3c75" xlink:to="loc_srt_ScenarioForecastMember_9d5fd9ba-7b3f-4126-8166-28f5bc025ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_679c19c0-dda6-47a2-ac7a-33d3a62c6919" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4ebbf973-2c62-4f74-bad5-b390a4156860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4ebbf973-2c62-4f74-bad5-b390a4156860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fd40346e-c277-44c8-8589-4b180612fac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fd40346e-c277-44c8-8589-4b180612fac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_4b854afc-62a8-4321-863c-1afaed759f93" xlink:href="mrk-20201231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_4b854afc-62a8-4321-863c-1afaed759f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b683bded-9aa6-4f40-b71c-c37c8319bb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b683bded-9aa6-4f40-b71c-c37c8319bb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_99bec42f-8d26-4f94-b5dd-7ca3df5dc82d" xlink:href="mrk-20201231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_99bec42f-8d26-4f94-b5dd-7ca3df5dc82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_9760d2f1-c600-40b2-8b8b-8b80429fa836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_9760d2f1-c600-40b2-8b8b-8b80429fa836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_9241a1ea-a679-45af-a6f8-10e074b5a61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_9241a1ea-a679-45af-a6f8-10e074b5a61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_49cc6224-8815-4034-8010-4b03086d0858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_241d9d33-1b19-4ffd-a817-5c7e4e2a4d1c" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_49cc6224-8815-4034-8010-4b03086d0858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f01b149-80da-4ff6-8351-5aa6098b705f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f01b149-80da-4ff6-8351-5aa6098b705f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_3fc436c9-afa9-43c7-aa24-f52400b71cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_3fc436c9-afa9-43c7-aa24-f52400b71cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c2c2cd40-5d67-4cc2-8e9e-4bbd1af634df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_3fc436c9-afa9-43c7-aa24-f52400b71cc4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c2c2cd40-5d67-4cc2-8e9e-4bbd1af634df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_134ae2aa-4630-4795-965f-38cc32718914" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c2c2cd40-5d67-4cc2-8e9e-4bbd1af634df" xlink:to="loc_country_US_134ae2aa-4630-4795-965f-38cc32718914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_43a99594-44f3-45ea-8699-f39a9145fa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c2c2cd40-5d67-4cc2-8e9e-4bbd1af634df" xlink:to="loc_us-gaap_ForeignPlanMember_43a99594-44f3-45ea-8699-f39a9145fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_df7c0219-9af6-45ab-b1bb-8cb4d37213c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_df7c0219-9af6-45ab-b1bb-8cb4d37213c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0fb8fb68-5920-4163-98ea-a4babe313802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_df7c0219-9af6-45ab-b1bb-8cb4d37213c2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0fb8fb68-5920-4163-98ea-a4babe313802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_a4eda80c-af22-4713-a449-40c5cce6e77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0fb8fb68-5920-4163-98ea-a4babe313802" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_a4eda80c-af22-4713-a449-40c5cce6e77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_cf2a53ac-738c-430d-970e-a0ae170643f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0fb8fb68-5920-4163-98ea-a4babe313802" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_cf2a53ac-738c-430d-970e-a0ae170643f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_cecc8f67-fe5d-4778-92f0-073d3d8da006" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ad0e99ce-434e-40d0-bf80-05e0bc5b3a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ad0e99ce-434e-40d0-bf80-05e0bc5b3a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_ea08bed5-6fff-4281-bd23-b0895ff43b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_ea08bed5-6fff-4281-bd23-b0895ff43b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_dbd1e68b-957a-4a26-a86e-68120aa757a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_dbd1e68b-957a-4a26-a86e-68120aa757a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1b075333-bc35-4e80-920c-5fa9c70998d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1b075333-bc35-4e80-920c-5fa9c70998d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b3669366-95ff-4248-baf0-859ed7017f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b3669366-95ff-4248-baf0-859ed7017f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_c6b1062d-caf9-46f4-b106-ea7e0319ca7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_c6b1062d-caf9-46f4-b106-ea7e0319ca7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_76d86bf0-185f-4189-93ff-b5bc45ecd7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_76d86bf0-185f-4189-93ff-b5bc45ecd7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_2340fd51-444e-4005-819f-2cdee9e493a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_2340fd51-444e-4005-819f-2cdee9e493a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e079cb83-bc89-4b7d-a218-52e4aa56a179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_82ed466e-55bb-4a54-8e67-4aeafdac45b0" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e079cb83-bc89-4b7d-a218-52e4aa56a179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_af672524-13e3-4daa-936b-d24bb795b3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_af672524-13e3-4daa-936b-d24bb795b3d6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_63dfe766-52da-4180-9513-6747ec800db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_63dfe766-52da-4180-9513-6747ec800db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ea20947-556e-4355-b78b-1435b1cdec08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_63dfe766-52da-4180-9513-6747ec800db9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ea20947-556e-4355-b78b-1435b1cdec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0dab23d4-bf1e-43f2-a2da-81a10d575605" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ea20947-556e-4355-b78b-1435b1cdec08" xlink:to="loc_country_US_0dab23d4-bf1e-43f2-a2da-81a10d575605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_52ce736a-5345-4def-9021-908330500b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5ea20947-556e-4355-b78b-1435b1cdec08" xlink:to="loc_us-gaap_ForeignPlanMember_52ce736a-5345-4def-9021-908330500b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_85700606-19df-4315-914f-dd1ad0d65e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_85700606-19df-4315-914f-dd1ad0d65e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8b3f929d-cf31-4b12-9ebb-f2efa6bcdb7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_85700606-19df-4315-914f-dd1ad0d65e67" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8b3f929d-cf31-4b12-9ebb-f2efa6bcdb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_779f557a-2f5a-46eb-8208-85ff6978d145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8b3f929d-cf31-4b12-9ebb-f2efa6bcdb7a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_779f557a-2f5a-46eb-8208-85ff6978d145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_b1513e58-9be5-43a6-a4e8-c3595d194892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8b3f929d-cf31-4b12-9ebb-f2efa6bcdb7a" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_b1513e58-9be5-43a6-a4e8-c3595d194892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f8ef7da1-6908-4ab2-bd37-d1e9b2cbb011" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2826b94c-f6a4-43c7-8a86-c5fdca92f339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2826b94c-f6a4-43c7-8a86-c5fdca92f339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_d88729f5-9077-48a0-afa3-9bb760eb06e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_d88729f5-9077-48a0-afa3-9bb760eb06e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_911685ec-cb0f-46e4-a360-d23e8847ee67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_911685ec-cb0f-46e4-a360-d23e8847ee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_a49c89b4-bfab-49ea-8ad1-cb7fc1b0f070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_a49c89b4-bfab-49ea-8ad1-cb7fc1b0f070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_3e1ec452-bf6f-49a1-a010-ebb314d18b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_3e1ec452-bf6f-49a1-a010-ebb314d18b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f5096749-674a-4377-8240-9dc073a75738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f5096749-674a-4377-8240-9dc073a75738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_82fcefff-073d-4dc7-b960-0063c79c1587" xlink:href="mrk-20201231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_82fcefff-073d-4dc7-b960-0063c79c1587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2210e5ab-1749-45d2-ae89-a30051726282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e68f9717-5be3-4658-a973-48faa77fb52a" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2210e5ab-1749-45d2-ae89-a30051726282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_2100432e-e927-442b-a64c-b537ab5e9f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_2100432e-e927-442b-a64c-b537ab5e9f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_0c8ad8c7-0c11-436a-9343-d655974252e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_0c8ad8c7-0c11-436a-9343-d655974252e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6c0676ab-0074-4bf3-906b-f57e6092ab87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6c0676ab-0074-4bf3-906b-f57e6092ab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_0dd6216a-06f9-44db-b57d-bdd2f8822736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_0dd6216a-06f9-44db-b57d-bdd2f8822736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_649e551a-f505-4c88-9d8a-039f21888d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_649e551a-f505-4c88-9d8a-039f21888d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_d2c08024-0969-4e22-a33f-47e5f72c150c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_d2c08024-0969-4e22-a33f-47e5f72c150c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_332735a8-b134-483b-a38a-67472e036bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_332735a8-b134-483b-a38a-67472e036bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_d005a59d-c024-456b-a2c8-8ccab77ad4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_d005a59d-c024-456b-a2c8-8ccab77ad4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_70d864f0-92e6-4c06-8dc2-395e88a75eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_70d864f0-92e6-4c06-8dc2-395e88a75eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_22cd76dc-5daf-484f-9eec-8e6fe147b088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_22cd76dc-5daf-484f-9eec-8e6fe147b088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges_8bda7091-8f1a-49df-96b1-d9c089530172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherChanges_8bda7091-8f1a-49df-96b1-d9c089530172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_02ececf8-9ab2-49f0-9d33-d42521d0fd71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_88e4f097-606b-4f05-8570-48506a997c93" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_02ececf8-9ab2-49f0-9d33-d42521d0fd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_cf88edf8-fcb9-47ac-8195-0b47692773e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_cf88edf8-fcb9-47ac-8195-0b47692773e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef465f57-5ea7-416e-bc22-44eb764e5906" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c2ae1bc8-3d0d-4ed0-a928-37e4d7793e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c2ae1bc8-3d0d-4ed0-a928-37e4d7793e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4005003e-6429-46c2-8bd5-ed1f8c6d47de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4005003e-6429-46c2-8bd5-ed1f8c6d47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e3093f36-1584-41aa-8e16-fc2693a65a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f4ede36d-0311-407c-9efe-5535e3ff2d46" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e3093f36-1584-41aa-8e16-fc2693a65a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1988ffd7-73fe-4a43-a910-99f2ad6ee63b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1988ffd7-73fe-4a43-a910-99f2ad6ee63b" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_de176fb9-e8f3-4cc1-9861-665276099540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_de176fb9-e8f3-4cc1-9861-665276099540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6eb8521-988f-4f93-9d42-b858e9c82bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_de176fb9-e8f3-4cc1-9861-665276099540" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6eb8521-988f-4f93-9d42-b858e9c82bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f81847c9-306d-4b69-bcc7-3aa33aad2f39" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6eb8521-988f-4f93-9d42-b858e9c82bc9" xlink:to="loc_country_US_f81847c9-306d-4b69-bcc7-3aa33aad2f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9d99a0ff-1fd9-4800-86ff-79200ebb8de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6eb8521-988f-4f93-9d42-b858e9c82bc9" xlink:to="loc_us-gaap_ForeignPlanMember_9d99a0ff-1fd9-4800-86ff-79200ebb8de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_d4c82eff-30e7-4991-b25a-638b5e37b489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_d4c82eff-30e7-4991-b25a-638b5e37b489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a556f377-8d25-4f5c-bb0c-cdaebbbc9076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d4c82eff-30e7-4991-b25a-638b5e37b489" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a556f377-8d25-4f5c-bb0c-cdaebbbc9076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_fa3f8e99-39ec-41fe-a6ec-fbf53212606d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a556f377-8d25-4f5c-bb0c-cdaebbbc9076" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_fa3f8e99-39ec-41fe-a6ec-fbf53212606d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_56158226-c90b-4e43-874c-286ed9c74a05" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_9c13a6b8-601f-44f9-b954-a21aed9d5d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_9c13a6b8-601f-44f9-b954-a21aed9d5d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_2b1ec1d8-0f1a-4d16-98c8-0ee64e1b3b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_2b1ec1d8-0f1a-4d16-98c8-0ee64e1b3b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_3fab94b3-2c04-4935-9b03-0183182d2e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_3fab94b3-2c04-4935-9b03-0183182d2e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_04ffd2d0-2602-4827-ac43-48b638dee45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9dd60ec-6276-49d8-a244-c0b159010516" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_04ffd2d0-2602-4827-ac43-48b638dee45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b9c55631-5796-4551-aca1-b526736caa21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b9c55631-5796-4551-aca1-b526736caa21" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_da9f5823-8310-4596-8c12-8a3ac73f2e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_da9f5823-8310-4596-8c12-8a3ac73f2e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2bd21f6f-616f-4f68-a64e-a4ca27cb5a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_da9f5823-8310-4596-8c12-8a3ac73f2e57" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2bd21f6f-616f-4f68-a64e-a4ca27cb5a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_30243099-bf9f-4749-b8ee-1b7f5f6fc250" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2bd21f6f-616f-4f68-a64e-a4ca27cb5a73" xlink:to="loc_country_US_30243099-bf9f-4749-b8ee-1b7f5f6fc250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_63b86008-26b9-4875-8dc2-6b87957dbba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2bd21f6f-616f-4f68-a64e-a4ca27cb5a73" xlink:to="loc_us-gaap_ForeignPlanMember_63b86008-26b9-4875-8dc2-6b87957dbba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a49349ee-b369-439c-b826-e311bab38e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a49349ee-b369-439c-b826-e311bab38e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d69410be-d852-4d9c-ab5d-d43b761356f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a49349ee-b369-439c-b826-e311bab38e6e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d69410be-d852-4d9c-ab5d-d43b761356f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4cee29a1-a423-40aa-8747-0df5ef264edc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d69410be-d852-4d9c-ab5d-d43b761356f6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4cee29a1-a423-40aa-8747-0df5ef264edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8408269c-6417-43a6-8998-f9cd262e5219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8408269c-6417-43a6-8998-f9cd262e5219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8408269c-6417-43a6-8998-f9cd262e5219" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ea7c9abc-d59b-4649-b2e1-3143d3940b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ea7c9abc-d59b-4649-b2e1-3143d3940b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_04eb0c67-12f7-4351-bbbb-df8650aa93d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_04eb0c67-12f7-4351-bbbb-df8650aa93d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4b89e29c-be2e-4fb8-92c8-c0ec935cae48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4b89e29c-be2e-4fb8-92c8-c0ec935cae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d01833e6-5240-4a65-81b7-b4e84812caba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19f461c7-d1f4-4ec8-a49a-9c9b7d8611ea" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d01833e6-5240-4a65-81b7-b4e84812caba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f146bb8c-8173-4c13-8105-eef27195bc20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f146bb8c-8173-4c13-8105-eef27195bc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f146bb8c-8173-4c13-8105-eef27195bc20" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_bc8a640e-7dc2-491e-ac9f-f65ff143db0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_bc8a640e-7dc2-491e-ac9f-f65ff143db0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_ea93bece-323b-4e95-ab6e-ecad75d05ac9" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_ea93bece-323b-4e95-ab6e-ecad75d05ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_323673e6-f3e9-42e9-bc45-1c0f52e8a0fb" xlink:href="mrk-20201231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_323673e6-f3e9-42e9-bc45-1c0f52e8a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_5f1b2524-9b9a-4778-af2e-2565daf2d766" xlink:href="mrk-20201231.xsd#mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_5f1b2524-9b9a-4778-af2e-2565daf2d766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_ee605152-fa2f-4972-b0c8-adda61034848" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_ee605152-fa2f-4972-b0c8-adda61034848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember_90175cf4-e476-463c-be66-42dbb55bedc0" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_CorporateObligationsInvestmentFundsMember_90175cf4-e476-463c-be66-42dbb55bedc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_f82da671-78b5-4c8d-8123-9c62c8172731" xlink:href="mrk-20201231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_f82da671-78b5-4c8d-8123-9c62c8172731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_f0489f8c-a717-4153-8843-ac7d6daa0ff4" xlink:href="mrk-20201231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_f0489f8c-a717-4153-8843-ac7d6daa0ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_48070f7d-875f-4eb1-9380-bf3ce87edcfa" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_48070f7d-875f-4eb1-9380-bf3ce87edcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_43e8ef1c-7a85-44ef-954f-bf9532f1d80a" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_43e8ef1c-7a85-44ef-954f-bf9532f1d80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_a9dc6f28-b595-4db0-976e-0639fb600951" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_a9dc6f28-b595-4db0-976e-0639fb600951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_c0889294-1076-4de2-932c-2aadb0e96d78" xlink:href="mrk-20201231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_c0889294-1076-4de2-932c-2aadb0e96d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_a2dedd74-a494-4043-87f2-7af3d5929488" xlink:href="mrk-20201231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_a2dedd74-a494-4043-87f2-7af3d5929488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_0a1f2cf1-a4fe-4c74-9eca-871a1db398e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8e6542c9-510d-4664-bba8-31992ae33f82" xlink:to="loc_us-gaap_OtherInvestmentsMember_0a1f2cf1-a4fe-4c74-9eca-871a1db398e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3c97a108-4d4c-4e57-8080-80d4eeccbacf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8948e988-54c5-47b0-9174-2ead0a7df908" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3c97a108-4d4c-4e57-8080-80d4eeccbacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a071b95e-df90-4b62-b30a-5ead162e09a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3c97a108-4d4c-4e57-8080-80d4eeccbacf" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a071b95e-df90-4b62-b30a-5ead162e09a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7b981959-12a5-4a4f-b8ed-23ea5142a1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7b981959-12a5-4a4f-b8ed-23ea5142a1d1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5ec3ee96-dbc8-408d-815a-8af7d9d73637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5ec3ee96-dbc8-408d-815a-8af7d9d73637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_335e0645-db21-4282-a9b7-90822d33d8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5ec3ee96-dbc8-408d-815a-8af7d9d73637" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_335e0645-db21-4282-a9b7-90822d33d8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b6b36b4c-0fa7-40da-a524-2354108ccad7" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_335e0645-db21-4282-a9b7-90822d33d8db" xlink:to="loc_country_US_b6b36b4c-0fa7-40da-a524-2354108ccad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f8eac300-31ac-469a-9cb5-d053b9e1ba4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_335e0645-db21-4282-a9b7-90822d33d8db" xlink:to="loc_us-gaap_ForeignPlanMember_f8eac300-31ac-469a-9cb5-d053b9e1ba4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_468ffd68-8fba-45c0-bd9b-8e74445902cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_468ffd68-8fba-45c0-bd9b-8e74445902cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ab3b66cc-31e3-4d90-a469-47cb07c2043a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_468ffd68-8fba-45c0-bd9b-8e74445902cb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ab3b66cc-31e3-4d90-a469-47cb07c2043a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6f5fa8a3-e7b8-4c12-a19c-ebd4fbea2acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ab3b66cc-31e3-4d90-a469-47cb07c2043a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6f5fa8a3-e7b8-4c12-a19c-ebd4fbea2acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_928ef288-bb2b-44c3-bbfe-bb3756c736b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_928ef288-bb2b-44c3-bbfe-bb3756c736b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2270d1cb-0f3b-4bf0-9862-f2c04d75d7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_928ef288-bb2b-44c3-bbfe-bb3756c736b0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2270d1cb-0f3b-4bf0-9862-f2c04d75d7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b694313d-335d-45a8-8cad-ba3a142bb339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2270d1cb-0f3b-4bf0-9862-f2c04d75d7c2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b694313d-335d-45a8-8cad-ba3a142bb339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4d78cda8-5792-4e99-8586-12392f3d25a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4d78cda8-5792-4e99-8586-12392f3d25a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4d78cda8-5792-4e99-8586-12392f3d25a1" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_3a578946-c4e2-430e-ac0c-600ad4195cc7" xlink:href="mrk-20201231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_3a578946-c4e2-430e-ac0c-600ad4195cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_eb0c6a3a-f3fd-40c9-b69b-164fb1d35322" xlink:href="mrk-20201231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_eb0c6a3a-f3fd-40c9-b69b-164fb1d35322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_fa74a42a-d489-4ca1-a099-ac9488bd81dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_010557bf-a017-4d3b-8e42-188a4cf10ee2" xlink:to="loc_us-gaap_OtherInvestmentsMember_fa74a42a-d489-4ca1-a099-ac9488bd81dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e78186c2-d21d-4f3f-be6d-5c6009458eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_77be8f96-da06-4479-8d14-86a0e03cc6f5" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e78186c2-d21d-4f3f-be6d-5c6009458eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e78186c2-d21d-4f3f-be6d-5c6009458eee" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_563dd80b-cce6-4fe2-8f30-d701f9667e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_563dd80b-cce6-4fe2-8f30-d701f9667e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_723c0cb8-e7d0-4f44-bfb9-d3131f4e1934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_723c0cb8-e7d0-4f44-bfb9-d3131f4e1934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_ab7f002b-4fa9-486a-8f8f-72e99b3ca3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_723c0cb8-e7d0-4f44-bfb9-d3131f4e1934" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_ab7f002b-4fa9-486a-8f8f-72e99b3ca3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_e834749a-f327-4215-a7d9-d8674cf6ddfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_723c0cb8-e7d0-4f44-bfb9-d3131f4e1934" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_e834749a-f327-4215-a7d9-d8674cf6ddfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_4c36bb81-7098-4daf-937b-f1963395d7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_4c36bb81-7098-4daf-937b-f1963395d7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_85c9d6cf-17ac-4878-9e62-27e87759ad35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_85c9d6cf-17ac-4878-9e62-27e87759ad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b963f255-503d-4126-85aa-dcc31815e9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b92e0aad-2441-4312-aed4-7d573fc8a9e8" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b963f255-503d-4126-85aa-dcc31815e9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6d891572-fe75-4640-b189-1ff0e7aafd10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6d891572-fe75-4640-b189-1ff0e7aafd10" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9f7c49c2-d32a-4afe-a1a9-60bcdbe589b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ef41bc38-f9a6-4f16-b1b3-c6022c0d6df6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9f7c49c2-d32a-4afe-a1a9-60bcdbe589b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ac1d59ec-ef42-4d02-8ff3-2942efe0af33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9f7c49c2-d32a-4afe-a1a9-60bcdbe589b4" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ac1d59ec-ef42-4d02-8ff3-2942efe0af33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de3cf110-31f1-4b36-bb2f-00f01bb37b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de3cf110-31f1-4b36-bb2f-00f01bb37b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de3cf110-31f1-4b36-bb2f-00f01bb37b15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5c612133-2b81-449a-b72a-d7f3ed883631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5c612133-2b81-449a-b72a-d7f3ed883631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cc8ba3bc-e31c-4dd4-a6b6-52cb884ac33d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cc8ba3bc-e31c-4dd4-a6b6-52cb884ac33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_17c9a360-f6d0-4fdb-bf76-ac7190ddecd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_17c9a360-f6d0-4fdb-bf76-ac7190ddecd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_901a05a3-46d8-40d4-8e5b-955a2dced48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_501b897f-5c72-42d9-b5e5-d5d0847caa0c" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_901a05a3-46d8-40d4-8e5b-955a2dced48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a9be7202-b7f8-483b-8d9f-3836d1927cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a9be7202-b7f8-483b-8d9f-3836d1927cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a9be7202-b7f8-483b-8d9f-3836d1927cdc" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_c7e7e9f5-ee41-46ff-8287-a12274b70ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_c7e7e9f5-ee41-46ff-8287-a12274b70ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_d7be161e-3d4b-47eb-b1df-59e0baacf6d6" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_d7be161e-3d4b-47eb-b1df-59e0baacf6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_856e7a73-3e44-4d0a-a54f-af05f6b0ceb7" xlink:href="mrk-20201231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_856e7a73-3e44-4d0a-a54f-af05f6b0ceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_7881747f-12b5-4050-866c-8bee8272954a" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_7881747f-12b5-4050-866c-8bee8272954a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember_d1aad9c2-3630-4a82-a34f-3c7cf841eb31" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_CorporateObligationsInvestmentFundsMember_d1aad9c2-3630-4a82-a34f-3c7cf841eb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_1fdb070f-1647-4453-8d2f-76e5d202a013" xlink:href="mrk-20201231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_1fdb070f-1647-4453-8d2f-76e5d202a013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_0bf97ec2-5d80-438f-bd6f-701c570cf4e8" xlink:href="mrk-20201231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_0bf97ec2-5d80-438f-bd6f-701c570cf4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_c3cd5dc4-eae2-4a40-8bd5-c4114c9165d7" xlink:href="mrk-20201231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_c3cd5dc4-eae2-4a40-8bd5-c4114c9165d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_85440c5e-d9c6-47a6-a84f-323e31e33764" xlink:href="mrk-20201231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_85440c5e-d9c6-47a6-a84f-323e31e33764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_aaf99596-75d2-42f7-a039-0578cad1d369" xlink:href="mrk-20201231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f6e6a41b-29b4-4e57-947f-cf0b378d7457" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_aaf99596-75d2-42f7-a039-0578cad1d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86056e5c-e439-4c55-a219-07fee7451cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_65426a1b-135c-4028-b2d2-f62bcd13c868" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86056e5c-e439-4c55-a219-07fee7451cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e7b36e48-9a1f-4669-bcc2-ef8d362effe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_86056e5c-e439-4c55-a219-07fee7451cb5" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e7b36e48-9a1f-4669-bcc2-ef8d362effe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d5308729-82ce-4a2e-a217-23359ded53a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d5308729-82ce-4a2e-a217-23359ded53a4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b34af640-8ef9-4897-a203-ec9c15cbdfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b34af640-8ef9-4897-a203-ec9c15cbdfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_125bf562-b760-4c9c-9aa3-8041f0498647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b34af640-8ef9-4897-a203-ec9c15cbdfa5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_125bf562-b760-4c9c-9aa3-8041f0498647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_37890c4e-ce97-4f9e-8583-aed1d5b02f6b" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_125bf562-b760-4c9c-9aa3-8041f0498647" xlink:to="loc_country_US_37890c4e-ce97-4f9e-8583-aed1d5b02f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ecee33d0-87c1-4519-9180-f435ec58e749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_125bf562-b760-4c9c-9aa3-8041f0498647" xlink:to="loc_us-gaap_ForeignPlanMember_ecee33d0-87c1-4519-9180-f435ec58e749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_648524a0-5065-4c7e-9e33-0d76ce3fa22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_648524a0-5065-4c7e-9e33-0d76ce3fa22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7da56d0b-2cb9-4a25-8f91-f46cd13ec3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_648524a0-5065-4c7e-9e33-0d76ce3fa22a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7da56d0b-2cb9-4a25-8f91-f46cd13ec3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1141dfeb-8c8b-4cb4-872d-460e7ae2244a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7da56d0b-2cb9-4a25-8f91-f46cd13ec3bc" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1141dfeb-8c8b-4cb4-872d-460e7ae2244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5fbdb01a-7208-4319-ba26-692beb02243b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7da56d0b-2cb9-4a25-8f91-f46cd13ec3bc" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5fbdb01a-7208-4319-ba26-692beb02243b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50aa717c-bd8b-471a-b5fc-06d9fc96f36e" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_4775554d-c729-4b74-8059-2adce50e0228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_4775554d-c729-4b74-8059-2adce50e0228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_91fbc3b1-fd00-48f0-8428-b784d5c088f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_91fbc3b1-fd00-48f0-8428-b784d5c088f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_d9a06838-dfa4-4e27-8487-daeb842f04df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_d9a06838-dfa4-4e27-8487-daeb842f04df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_7da547d5-ca99-4b90-a4ff-04e39fd3584d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_7da547d5-ca99-4b90-a4ff-04e39fd3584d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_66d07f1b-bf79-4976-9604-4e3714efbffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_66d07f1b-bf79-4976-9604-4e3714efbffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d68fa839-aa7a-4515-ba56-c3dfbba2d9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1abf2c8c-92e4-47aa-94c7-91b4710dd8f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d68fa839-aa7a-4515-ba56-c3dfbba2d9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9243f1db-087e-4fd9-8ecd-8e65ce39e8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9243f1db-087e-4fd9-8ecd-8e65ce39e8fe" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_04a4d1a6-ffea-411e-9a81-b2427cd4ea96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_04a4d1a6-ffea-411e-9a81-b2427cd4ea96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_59e01fd6-0ffa-4e7d-a1bd-c5e1da09776d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_04a4d1a6-ffea-411e-9a81-b2427cd4ea96" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_59e01fd6-0ffa-4e7d-a1bd-c5e1da09776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5154e74d-c858-4766-9870-183d6ce81eff" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_59e01fd6-0ffa-4e7d-a1bd-c5e1da09776d" xlink:to="loc_country_US_5154e74d-c858-4766-9870-183d6ce81eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6956458c-c2e7-4fe5-b3ad-6665e48c0142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_59e01fd6-0ffa-4e7d-a1bd-c5e1da09776d" xlink:to="loc_us-gaap_ForeignPlanMember_6956458c-c2e7-4fe5-b3ad-6665e48c0142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b6c4fb46-a713-454d-b0e9-19786272068d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b6c4fb46-a713-454d-b0e9-19786272068d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d7b0c63a-cccd-493a-baba-e5c512549c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b6c4fb46-a713-454d-b0e9-19786272068d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d7b0c63a-cccd-493a-baba-e5c512549c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_e6fce239-1ed4-48a4-a80a-7d9e7dd79e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d7b0c63a-cccd-493a-baba-e5c512549c14" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_e6fce239-1ed4-48a4-a80a-7d9e7dd79e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e90941fd-d94e-4c4a-8195-9ddf2f479a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d7b0c63a-cccd-493a-baba-e5c512549c14" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e90941fd-d94e-4c4a-8195-9ddf2f479a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c72a47fa-245c-4bc0-8ba3-aac2ec362bcf" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_174765ec-9c02-46fa-8884-20620cd267ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_174765ec-9c02-46fa-8884-20620cd267ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_506483b0-e77b-4a8f-99a5-489552da3f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_506483b0-e77b-4a8f-99a5-489552da3f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_ad800fd6-d5e6-40b4-985c-3dea577283e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_ad800fd6-d5e6-40b4-985c-3dea577283e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4f8aeecf-cf9e-4eea-9c0a-ee2533655f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4f8aeecf-cf9e-4eea-9c0a-ee2533655f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_83098cd2-c83b-4c7f-82cb-27cfa6855d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_83098cd2-c83b-4c7f-82cb-27cfa6855d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_a253b2db-cacf-4ee1-8811-f33178ceb864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_502d86c2-d707-4e78-9735-a53269626c23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_a253b2db-cacf-4ee1-8811-f33178ceb864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dc743aa6-bbb9-47da-8e41-9c683df966fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dc743aa6-bbb9-47da-8e41-9c683df966fb" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_44c2a10b-5ea3-40ae-bc31-4e57a51d8748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_44c2a10b-5ea3-40ae-bc31-4e57a51d8748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_849395c4-1094-45eb-980b-f99e734a1013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_44c2a10b-5ea3-40ae-bc31-4e57a51d8748" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_849395c4-1094-45eb-980b-f99e734a1013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_49421878-0ccb-4466-90ae-65b5fd5ab2bf" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_849395c4-1094-45eb-980b-f99e734a1013" xlink:to="loc_country_US_49421878-0ccb-4466-90ae-65b5fd5ab2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8d4e1eef-53ee-44c4-9d5d-d2c588f856ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_849395c4-1094-45eb-980b-f99e734a1013" xlink:to="loc_us-gaap_ForeignPlanMember_8d4e1eef-53ee-44c4-9d5d-d2c588f856ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4f9835fa-7088-4631-a873-276ab364ca82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4f9835fa-7088-4631-a873-276ab364ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_667f8d0a-7f8d-4b62-b584-c0253ca2fbb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4f9835fa-7088-4631-a873-276ab364ca82" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_667f8d0a-7f8d-4b62-b584-c0253ca2fbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b34a3c8a-43c7-44b4-843f-9ac3f941188c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_667f8d0a-7f8d-4b62-b584-c0253ca2fbb6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b34a3c8a-43c7-44b4-843f-9ac3f941188c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_948112ad-920d-4f9c-a8bf-5cf508f0da5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e58ddf33-8fe4-42d3-bb0a-72f2c7f4f279" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_948112ad-920d-4f9c-a8bf-5cf508f0da5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_948112ad-920d-4f9c-a8bf-5cf508f0da5e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_78572a9b-a4de-4838-a4f6-635c72b5abe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_78572a9b-a4de-4838-a4f6-635c72b5abe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_7e4ac470-32b8-45f9-b8cf-88f7a3e4cc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_7e4ac470-32b8-45f9-b8cf-88f7a3e4cc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_4f34401b-b911-47d0-9cd5-bd92b5faca55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_4f34401b-b911-47d0-9cd5-bd92b5faca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_0848a6b0-6c58-42b6-9150-34e21eed67b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_f3ad9450-0824-4779-bed9-7c78d85ca383" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_0848a6b0-6c58-42b6-9150-34e21eed67b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_948112ad-920d-4f9c-a8bf-5cf508f0da5e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_544c5aa7-d8ba-4525-a84a-b5798e049081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_544c5aa7-d8ba-4525-a84a-b5798e049081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_facfeff1-ae5e-4c52-b687-d12bea1319f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_facfeff1-ae5e-4c52-b687-d12bea1319f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_754f6dc8-4ee3-490b-b389-a53f51b30495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_76f69bda-6475-43aa-b360-5ac2627cfb25" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_754f6dc8-4ee3-490b-b389-a53f51b30495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9cd2a425-0c6e-4d6b-996b-dcf7a936ac42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2769c786-8137-4de4-9538-136eb25dfe02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9cd2a425-0c6e-4d6b-996b-dcf7a936ac42" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2769c786-8137-4de4-9538-136eb25dfe02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7fd81aba-d659-4f89-854e-3cb430e6b09d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2769c786-8137-4de4-9538-136eb25dfe02" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7fd81aba-d659-4f89-854e-3cb430e6b09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_82a39ee6-3111-4d93-bde0-30850be81e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7fd81aba-d659-4f89-854e-3cb430e6b09d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_82a39ee6-3111-4d93-bde0-30850be81e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_50f34e1a-1320-436e-9479-aed5ce730ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_82a39ee6-3111-4d93-bde0-30850be81e7e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_50f34e1a-1320-436e-9479-aed5ce730ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_50348588-96a5-4968-85b9-bc00247fbd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2769c786-8137-4de4-9538-136eb25dfe02" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_50348588-96a5-4968-85b9-bc00247fbd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_304465c4-d137-4f16-976b-6d6d31b72cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_50348588-96a5-4968-85b9-bc00247fbd5b" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_304465c4-d137-4f16-976b-6d6d31b72cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_e8720e24-15b7-4222-9c0f-a55f1e8b2923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_50348588-96a5-4968-85b9-bc00247fbd5b" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_e8720e24-15b7-4222-9c0f-a55f1e8b2923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_508c9edc-9b2b-451e-b58b-c08f42df6e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_133a51d6-77ff-489c-9b26-b613840efad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_508c9edc-9b2b-451e-b58b-c08f42df6e76" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_133a51d6-77ff-489c-9b26-b613840efad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_c2043ac2-4866-497d-a1c1-8291222dffca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_b5df577d-2982-4bbf-a33e-9e4f0a1dfaca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c2043ac2-4866-497d-a1c1-8291222dffca" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_b5df577d-2982-4bbf-a33e-9e4f0a1dfaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_6a6dedbd-dd70-4a6c-9e53-391c3add265b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:href="mrk-20201231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6a6dedbd-dd70-4a6c-9e53-391c3add265b" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e5f770f8-e275-40c2-b68d-0cb735988249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e5f770f8-e275-40c2-b68d-0cb735988249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_053e60e6-93c5-45eb-8573-8fa79d358187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e5f770f8-e275-40c2-b68d-0cb735988249" xlink:to="loc_us-gaap_LossContingencyNatureDomain_053e60e6-93c5-45eb-8573-8fa79d358187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember_29ddaa18-ce5b-40f2-92bf-37976ad93f92" xlink:href="mrk-20201231.xsd#mrk_PatentlitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_053e60e6-93c5-45eb-8573-8fa79d358187" xlink:to="loc_mrk_PatentlitigationMember_29ddaa18-ce5b-40f2-92bf-37976ad93f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0ebdf1a1-da8f-45f2-b3d6-5073331db536" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0ebdf1a1-da8f-45f2-b3d6-5073331db536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fa8064dd-111a-486e-a8f0-5c7c21164e95" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0ebdf1a1-da8f-45f2-b3d6-5073331db536" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fa8064dd-111a-486e-a8f0-5c7c21164e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_7c5b806f-2df3-408e-832a-daa3edbb8721" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_fa8064dd-111a-486e-a8f0-5c7c21164e95" xlink:to="loc_srt_PartnershipInterestMember_7c5b806f-2df3-408e-832a-daa3edbb8721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1dd943c-f437-49de-8d67-5f164cff2c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1dd943c-f437-49de-8d67-5f164cff2c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_708bc8ba-5c4b-489e-a366-12d30afc7644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1dd943c-f437-49de-8d67-5f164cff2c51" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_708bc8ba-5c4b-489e-a366-12d30afc7644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CGRPreceptorantagonistsMember_cf8f0303-377b-402b-8532-da41150e9427" xlink:href="mrk-20201231.xsd#mrk_CGRPreceptorantagonistsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_708bc8ba-5c4b-489e-a366-12d30afc7644" xlink:to="loc_mrk_CGRPreceptorantagonistsMember_cf8f0303-377b-402b-8532-da41150e9427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_62bf5d62-d72b-4e37-80af-33ea43d7cae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_62bf5d62-d72b-4e37-80af-33ea43d7cae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_15b9f54b-a35f-466f-8ff7-730c0c580254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_62bf5d62-d72b-4e37-80af-33ea43d7cae8" xlink:to="loc_us-gaap_SegmentDomain_15b9f54b-a35f-466f-8ff7-730c0c580254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember_d021a067-c001-46a9-af12-c6c905c3ca21" xlink:href="mrk-20201231.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_15b9f54b-a35f-466f-8ff7-730c0c580254" xlink:to="loc_mrk_HealthcareServicesSegmentMember_d021a067-c001-46a9-af12-c6c905c3ca21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:href="mrk-20201231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_bb69810a-69de-471f-9765-a6dc14e44c64" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ffdcc4fb-c2d4-4415-aa3b-40b014a5a58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ffdcc4fb-c2d4-4415-aa3b-40b014a5a58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncome_d72deecd-3d42-4ef2-9a9d-9210dd2095b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_OtherNoncashIncome_d72deecd-3d42-4ef2-9a9d-9210dd2095b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a7263cf3-d535-422b-9add-b97f7adc0580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a7263cf3-d535-422b-9add-b97f7adc0580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3c50616d-334d-4b48-bd57-615da2c7cf02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3c50616d-334d-4b48-bd57-615da2c7cf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3ec9fc81-75a8-4087-8047-7c73df72ed4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3ec9fc81-75a8-4087-8047-7c73df72ed4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_5749fd7d-2574-474a-9a85-23fdf97a9e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_cb5de57b-4e8e-4ef2-ae09-98dbc0d89345" xlink:to="loc_us-gaap_InterestPaid_5749fd7d-2574-474a-9a85-23fdf97a9e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1ad2a34a-8a32-4906-90fd-f1bbc4d57f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f70df1a9-473e-4b36-bbdf-e29dc8838ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1ad2a34a-8a32-4906-90fd-f1bbc4d57f1d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f70df1a9-473e-4b36-bbdf-e29dc8838ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e15b0622-2c20-490b-9d2f-ea7a0a6bb9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1ad2a34a-8a32-4906-90fd-f1bbc4d57f1d" xlink:to="loc_us-gaap_InterestExpense_e15b0622-2c20-490b-9d2f-ea7a0a6bb9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0b384c63-3cb0-431d-96ba-1e1a7a04f2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1ad2a34a-8a32-4906-90fd-f1bbc4d57f1d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0b384c63-3cb0-431d-96ba-1e1a7a04f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4ed6f132-54e5-410a-9998-4fa57697fc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1ad2a34a-8a32-4906-90fd-f1bbc4d57f1d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4ed6f132-54e5-410a-9998-4fa57697fc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_c8b8c5f4-37fa-46f4-a362-04684fcad7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1ad2a34a-8a32-4906-90fd-f1bbc4d57f1d" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_c8b8c5f4-37fa-46f4-a362-04684fcad7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_085db0f2-8b0d-46b2-97d4-cc8a04d60920" xlink:href="mrk-20201231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1ad2a34a-8a32-4906-90fd-f1bbc4d57f1d" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_085db0f2-8b0d-46b2-97d4-cc8a04d60920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d1331da7-ccde-437d-a12d-39ac8995b6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1ad2a34a-8a32-4906-90fd-f1bbc4d57f1d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d1331da7-ccde-437d-a12d-39ac8995b6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_18312d79-5cd9-46c6-82da-70a6543e709f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_931f4f2b-3835-4e8a-9cc3-f5ec0d7c43b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18312d79-5cd9-46c6-82da-70a6543e709f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_931f4f2b-3835-4e8a-9cc3-f5ec0d7c43b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5858f3af-bd6e-45f5-9a33-bb6fa561cabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_26bcd6c0-7940-4b04-85c0-fad91ed4a786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5858f3af-bd6e-45f5-9a33-bb6fa561cabd" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_26bcd6c0-7940-4b04-85c0-fad91ed4a786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d54d3059-aa85-4c2f-a593-39503e1536f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5858f3af-bd6e-45f5-9a33-bb6fa561cabd" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d54d3059-aa85-4c2f-a593-39503e1536f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4951fcc8-c825-44e4-a71e-d6c4e0c5e0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5858f3af-bd6e-45f5-9a33-bb6fa561cabd" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4951fcc8-c825-44e4-a71e-d6c4e0c5e0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c4095a81-3cea-4a39-8d50-b55985b67a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5858f3af-bd6e-45f5-9a33-bb6fa561cabd" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c4095a81-3cea-4a39-8d50-b55985b67a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6dbc39e3-bfa8-4dd9-85eb-3cdb4429e635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5858f3af-bd6e-45f5-9a33-bb6fa561cabd" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6dbc39e3-bfa8-4dd9-85eb-3cdb4429e635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8edca6-4191-4d60-ae8a-3938f866e2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_eac3ab28-7410-455c-a72c-05ecf355e91f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8edca6-4191-4d60-ae8a-3938f866e2fa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_eac3ab28-7410-455c-a72c-05ecf355e91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a707fea7-a008-48dd-822a-6d3f14f29ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_eac3ab28-7410-455c-a72c-05ecf355e91f" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a707fea7-a008-48dd-822a-6d3f14f29ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_eac3ab28-7410-455c-a72c-05ecf355e91f" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_63bb2a2c-1013-4e35-b1cf-ec5a4eb4323d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_63bb2a2c-1013-4e35-b1cf-ec5a4eb4323d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_6f123175-32dc-4263-b2e0-cda0b4b4ca08" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_6f123175-32dc-4263-b2e0-cda0b4b4ca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_41471340-cfb9-414f-b236-618687727046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_41471340-cfb9-414f-b236-618687727046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_123a161a-14ed-4409-a3d1-e40567c224d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_123a161a-14ed-4409-a3d1-e40567c224d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_7f09aadf-831e-4815-9098-843074f6d87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_7f09aadf-831e-4815-9098-843074f6d87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_fc402d13-f117-4fb4-94c7-60b6def5ea9a" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_fc402d13-f117-4fb4-94c7-60b6def5ea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_28e6b201-a790-40dd-a2ae-aa0221a55b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_28e6b201-a790-40dd-a2ae-aa0221a55b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_3b401e24-61a7-4ef5-ac6e-99031c2e0f92" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_3b401e24-61a7-4ef5-ac6e-99031c2e0f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0930fe7d-b526-483f-b304-c8c2deec6c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0930fe7d-b526-483f-b304-c8c2deec6c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_520c11c4-11f2-4bda-abaf-3fe5a27ea487" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_520c11c4-11f2-4bda-abaf-3fe5a27ea487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_eb68d348-4e48-4408-be75-05dfa326f3cf" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_eb68d348-4e48-4408-be75-05dfa326f3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_09ffd752-bc0b-4e42-9d63-289909268499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_09ffd752-bc0b-4e42-9d63-289909268499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_64cac5d9-76b0-4cb1-ac00-ef8e680f9aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_09909db6-bc6c-473c-8a5c-a425f6d8e19f" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_64cac5d9-76b0-4cb1-ac00-ef8e680f9aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3c541cbd-ac2e-40fb-baee-b2e8e5da462f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_eac3ab28-7410-455c-a72c-05ecf355e91f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3c541cbd-ac2e-40fb-baee-b2e8e5da462f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c6b09751-157a-407a-b1d0-2fa025f970d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8edca6-4191-4d60-ae8a-3938f866e2fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c6b09751-157a-407a-b1d0-2fa025f970d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c5369a7c-07f8-4168-8b40-35b5f0c04fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c6b09751-157a-407a-b1d0-2fa025f970d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c5369a7c-07f8-4168-8b40-35b5f0c04fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c6b09751-157a-407a-b1d0-2fa025f970d8" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cc21d736-efaa-4aca-b8ed-3de497ebaad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cc21d736-efaa-4aca-b8ed-3de497ebaad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_f0376bae-2345-4f43-b8eb-982fc84b5090" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_f0376bae-2345-4f43-b8eb-982fc84b5090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_bcd103f6-5bb0-45bc-bd6a-03a815140964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_bcd103f6-5bb0-45bc-bd6a-03a815140964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8997a0dc-9697-4841-962d-1a4b142a235d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8997a0dc-9697-4841-962d-1a4b142a235d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_0b352fd0-0819-44ec-b1a8-b16fd37e6e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_0b352fd0-0819-44ec-b1a8-b16fd37e6e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_e7d03b6b-6b30-4086-86c0-7caa0bcbef68" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_e7d03b6b-6b30-4086-86c0-7caa0bcbef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_cbcbd904-15ac-4ae9-9287-b7578a7a884a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_cbcbd904-15ac-4ae9-9287-b7578a7a884a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_21ecde0a-4220-419b-8c1e-5216c9a88f46" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_21ecde0a-4220-419b-8c1e-5216c9a88f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9342a5e7-3f61-4020-b004-dff165a6accb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9342a5e7-3f61-4020-b004-dff165a6accb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_8a6a31fc-979e-4a51-9660-561ee6882c8e" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_8a6a31fc-979e-4a51-9660-561ee6882c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_26dca3b2-cf1a-4310-aba4-8071eb3192f9" xlink:href="mrk-20201231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_26dca3b2-cf1a-4310-aba4-8071eb3192f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_084505eb-cb1b-40e2-943e-35674c5aa567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_084505eb-cb1b-40e2-943e-35674c5aa567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b7420a37-79a1-4e2a-aa31-f7e10445eef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_4a7f552a-1340-4318-808c-e97da0e738bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b7420a37-79a1-4e2a-aa31-f7e10445eef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8f503f5c-03e2-4fef-88f8-030d0e772b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c6b09751-157a-407a-b1d0-2fa025f970d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8f503f5c-03e2-4fef-88f8-030d0e772b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_70a00aa5-8d39-4f14-8f0d-3f656d497ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_70a00aa5-8d39-4f14-8f0d-3f656d497ec8" xlink:to="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c9c2446f-d903-44d2-814a-74b69238f2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c9c2446f-d903-44d2-814a-74b69238f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_27c5d826-2b05-42f4-958f-fe1777469e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9c2446f-d903-44d2-814a-74b69238f2b8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_27c5d826-2b05-42f4-958f-fe1777469e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember_073889e1-0cf7-48aa-b3a4-437a3bd5b418" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_27c5d826-2b05-42f4-958f-fe1777469e24" xlink:to="loc_mrk_IncomeTaxesPayableMember_073889e1-0cf7-48aa-b3a4-437a3bd5b418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_81e126ce-5d5c-4d9e-9264-9eef557ad379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_27c5d826-2b05-42f4-958f-fe1777469e24" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_81e126ce-5d5c-4d9e-9264-9eef557ad379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6933d82d-b260-42e3-bb52-c5864c6727d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6933d82d-b260-42e3-bb52-c5864c6727d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8009c1c5-9d13-41d4-bf0c-46942d4a3d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6933d82d-b260-42e3-bb52-c5864c6727d3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8009c1c5-9d13-41d4-bf0c-46942d4a3d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_1a85d811-0b35-4c3e-824e-c6ba38cdbe00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8009c1c5-9d13-41d4-bf0c-46942d4a3d04" xlink:to="loc_us-gaap_ForeignCountryMember_1a85d811-0b35-4c3e-824e-c6ba38cdbe00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ba6c46aa-723c-4d99-aefd-697ee43e13db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8009c1c5-9d13-41d4-bf0c-46942d4a3d04" xlink:to="loc_us-gaap_DomesticCountryMember_ba6c46aa-723c-4d99-aefd-697ee43e13db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_59349caa-15d6-409e-823b-ef2a0a02dd01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_59349caa-15d6-409e-823b-ef2a0a02dd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7ef1f99b-2c20-41ba-a7ff-0bf40028b48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_59349caa-15d6-409e-823b-ef2a0a02dd01" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_7ef1f99b-2c20-41ba-a7ff-0bf40028b48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_682e8f7b-d53f-4fdf-83ed-b12ed320fefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_7ef1f99b-2c20-41ba-a7ff-0bf40028b48e" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_682e8f7b-d53f-4fdf-83ed-b12ed320fefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_8bfc6ed3-b738-42a9-8d3b-ae4a6c65fe68" xlink:to="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_f097d2c1-882b-46b5-bd53-49f52102c90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_f097d2c1-882b-46b5-bd53-49f52102c90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_0d1e495a-3cde-4777-9b08-8d45258410e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_0d1e495a-3cde-4777-9b08-8d45258410e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_a001fc69-0849-46d6-b839-7079ee057a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_a001fc69-0849-46d6-b839-7079ee057a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_cd0a3e5d-a7d1-43d4-9dda-c044ab335779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_cd0a3e5d-a7d1-43d4-9dda-c044ab335779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_b4ba7383-28c7-41f9-ad99-990556327c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_b4ba7383-28c7-41f9-ad99-990556327c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_78767d18-dcf5-4b65-b8a1-92b1e6fedbd6" xlink:href="mrk-20201231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_78767d18-dcf5-4b65-b8a1-92b1e6fedbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_00eb896f-cf3b-47da-86c9-83f8859a639f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_IncomeTaxesPaid_00eb896f-cf3b-47da-86c9-83f8859a639f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3c9e61e7-e45d-47c6-868d-19d886b02240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3c9e61e7-e45d-47c6-868d-19d886b02240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_06b367ed-0dde-40ad-be04-ecbb8d5c3673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_06b367ed-0dde-40ad-be04-ecbb8d5c3673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_88331bcb-eb42-4646-b9bb-11b3b3a9fbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_88331bcb-eb42-4646-b9bb-11b3b3a9fbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_0a863f9a-d782-4dbf-8840-e34f030825e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_0a863f9a-d782-4dbf-8840-e34f030825e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_44b1e95f-a0a9-4c91-8e36-546aaeda9d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_44b1e95f-a0a9-4c91-8e36-546aaeda9d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_08afaad6-8902-4a28-9591-af8fe9ae8618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_08afaad6-8902-4a28-9591-af8fe9ae8618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_a0b91c35-ba5f-48ba-b136-d0df269b6533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_b838d71d-7960-41b8-a8d6-fb0f1da1eec3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_a0b91c35-ba5f-48ba-b136-d0df269b6533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e9eedd4c-064f-48ef-ab27-472a75443e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b344ff95-9b93-4ec4-901c-2badff011826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9eedd4c-064f-48ef-ab27-472a75443e54" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b344ff95-9b93-4ec4-901c-2badff011826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ed639e92-a10c-4000-b184-0e49d986037d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9eedd4c-064f-48ef-ab27-472a75443e54" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ed639e92-a10c-4000-b184-0e49d986037d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_128b2e45-9fa6-4825-8416-c1d13697ec09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9eedd4c-064f-48ef-ab27-472a75443e54" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_128b2e45-9fa6-4825-8416-c1d13697ec09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeTaxesonIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_47e16bca-eceb-4a25-9f97-80511ddc7116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_27353281-6382-4fb8-9d92-c461ff821d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47e16bca-eceb-4a25-9f97-80511ddc7116" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_27353281-6382-4fb8-9d92-c461ff821d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_339e359d-7e61-4f33-8ac1-cefeb72621ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_27353281-6382-4fb8-9d92-c461ff821d68" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_339e359d-7e61-4f33-8ac1-cefeb72621ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9e60cbcd-30a0-4300-9a44-f03537ff8bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_27353281-6382-4fb8-9d92-c461ff821d68" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9e60cbcd-30a0-4300-9a44-f03537ff8bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_47010145-9fc9-4bff-9023-d51310feefb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_27353281-6382-4fb8-9d92-c461ff821d68" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_47010145-9fc9-4bff-9023-d51310feefb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8ac9fa3c-cf4d-44a0-b1c6-08884d5d0bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_27353281-6382-4fb8-9d92-c461ff821d68" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8ac9fa3c-cf4d-44a0-b1c6-08884d5d0bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_44bc9439-2a75-4837-8a30-b41b704360bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47e16bca-eceb-4a25-9f97-80511ddc7116" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_44bc9439-2a75-4837-8a30-b41b704360bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_053367e6-9361-4ba6-8243-845f1d61b816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_44bc9439-2a75-4837-8a30-b41b704360bc" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_053367e6-9361-4ba6-8243-845f1d61b816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8c2064ad-a360-4a57-b0d3-bc94065f9567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_44bc9439-2a75-4837-8a30-b41b704360bc" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8c2064ad-a360-4a57-b0d3-bc94065f9567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_73fe0cd9-0d6f-4288-aad5-fa694cb16b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_44bc9439-2a75-4837-8a30-b41b704360bc" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_73fe0cd9-0d6f-4288-aad5-fa694cb16b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d4bbf972-1bd4-447c-ac5d-d4bfc70bbf28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_44bc9439-2a75-4837-8a30-b41b704360bc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d4bbf972-1bd4-447c-ac5d-d4bfc70bbf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_756acf7b-5ffb-43da-a841-ef692f1ab260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47e16bca-eceb-4a25-9f97-80511ddc7116" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_756acf7b-5ffb-43da-a841-ef692f1ab260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_54b44c30-c590-4680-9158-4b1afab5c896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_698e0233-2c12-46a8-8319-0adcb3ac8b10" xlink:href="mrk-20201231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_54b44c30-c590-4680-9158-4b1afab5c896" xlink:to="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_698e0233-2c12-46a8-8319-0adcb3ac8b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5e4acadf-298b-4c97-9c25-cf7a0501488e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_698e0233-2c12-46a8-8319-0adcb3ac8b10" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5e4acadf-298b-4c97-9c25-cf7a0501488e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7968c23b-1a4b-4fcc-8bca-d407b153c23b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e4acadf-298b-4c97-9c25-cf7a0501488e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7968c23b-1a4b-4fcc-8bca-d407b153c23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_cad5eff6-be2c-4ab9-be25-bf62c6047373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7968c23b-1a4b-4fcc-8bca-d407b153c23b" xlink:to="loc_us-gaap_OtherAssetsMember_cad5eff6-be2c-4ab9-be25-bf62c6047373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:href="mrk-20201231.xsd#mrk_IncomeTaxLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_698e0233-2c12-46a8-8319-0adcb3ac8b10" xlink:to="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_230a83cb-6021-44e1-b165-1af8efc033ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_230a83cb-6021-44e1-b165-1af8efc033ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_e2dbbd79-3bdb-4061-8284-b712a63704a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_e2dbbd79-3bdb-4061-8284-b712a63704a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_78ba0b67-ddf6-4956-881f-c03255860e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_78ba0b67-ddf6-4956-881f-c03255860e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_f4c634d3-63ea-4f5c-b804-bda4c34feca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_f4c634d3-63ea-4f5c-b804-bda4c34feca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_8bae0745-ed33-4f3f-bbd4-8228b8f57b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_8bae0745-ed33-4f3f-bbd4-8228b8f57b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_8193610f-cf93-42fc-88f8-187b9592a5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_8193610f-cf93-42fc-88f8-187b9592a5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_558acc40-75f6-433c-a31a-e7a0cff2343e" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_558acc40-75f6-433c-a31a-e7a0cff2343e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_369d9bbb-57e4-4d74-b67c-eb2d5e1d2f77" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_369d9bbb-57e4-4d74-b67c-eb2d5e1d2f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_94285383-5f6b-450f-ab77-f39121a3856b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_94285383-5f6b-450f-ab77-f39121a3856b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b1b31da2-f06c-422f-be75-21a2f7a49850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b1b31da2-f06c-422f-be75-21a2f7a49850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7b0c3c12-8f52-4b1e-91d4-08728b502503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7b0c3c12-8f52-4b1e-91d4-08728b502503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_17e83b4f-0896-4fa6-950b-29d062364ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_17e83b4f-0896-4fa6-950b-29d062364ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9be7bb10-0050-4179-bd8d-16057cffba29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9be7bb10-0050-4179-bd8d-16057cffba29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_8163f5f1-392d-4107-855f-8bfd6687d810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_8163f5f1-392d-4107-855f-8bfd6687d810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2f465e88-7bea-4aab-a791-03635a9ca6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2f465e88-7bea-4aab-a791-03635a9ca6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_f0570853-863f-48fa-96c4-4a8506edcb84" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_f0570853-863f-48fa-96c4-4a8506edcb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_c0e21063-50a7-4821-873a-b0333f35f579" xlink:href="mrk-20201231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_c0e21063-50a7-4821-873a-b0333f35f579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d19e8038-93a0-4031-8fa5-705af9ccd4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d19e8038-93a0-4031-8fa5-705af9ccd4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_4766a8d0-29ad-4e91-9d89-f808fa230315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_4766a8d0-29ad-4e91-9d89-f808fa230315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_b344da8e-54da-4e54-98ea-40aca94b736c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredTaxLiabilities_b344da8e-54da-4e54-98ea-40aca94b736c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_02537401-a48a-4498-8289-be448cad1410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_a5f40f65-83bb-494d-814f-033893b6d1c1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_02537401-a48a-4498-8289-be448cad1410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#TaxesonIncomeUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_52eeb1ce-1d51-43d0-8095-c66d79a2cb85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52eeb1ce-1d51-43d0-8095-c66d79a2cb85" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f949ac1f-5776-4979-980c-1680f01a64aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f949ac1f-5776-4979-980c-1680f01a64aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68301914-d8c6-45ae-b934-fde0c549ba92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f949ac1f-5776-4979-980c-1680f01a64aa" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68301914-d8c6-45ae-b934-fde0c549ba92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ConsumercarebusinessMember_30908d03-6a6d-4149-99fb-0b06005c247b" xlink:href="mrk-20201231.xsd#mrk_ConsumercarebusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_68301914-d8c6-45ae-b934-fde0c549ba92" xlink:to="loc_mrk_ConsumercarebusinessMember_30908d03-6a6d-4149-99fb-0b06005c247b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_419aaa25-5446-4354-a566-0f45eb3acb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b78b0ce1-d3d9-4b20-a662-407ac7c7c12d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_419aaa25-5446-4354-a566-0f45eb3acb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_28942157-e346-467a-a7c6-a2ed8f6b2d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_28942157-e346-467a-a7c6-a2ed8f6b2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_4bd873d9-f415-45d4-9f13-38af0ae62968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_28942157-e346-467a-a7c6-a2ed8f6b2d6e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_4bd873d9-f415-45d4-9f13-38af0ae62968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_5d76407c-4b40-4791-909c-97c53102b856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_TaxPeriodAxis_5d76407c-4b40-4791-909c-97c53102b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_bddc78bb-c7bc-4982-94ba-7d8722842666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_5d76407c-4b40-4791-909c-97c53102b856" xlink:to="loc_us-gaap_TaxPeriodDomain_bddc78bb-c7bc-4982-94ba-7d8722842666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_f8323b7e-672a-42c7-8aa4-23709533019e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_672ddda9-c98d-4d2a-b645-b9361f516c34" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_f8323b7e-672a-42c7-8aa4-23709533019e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_8e171a21-03f7-4896-9207-4c311edde711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_f8323b7e-672a-42c7-8aa4-23709533019e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_8e171a21-03f7-4896-9207-4c311edde711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52eeb1ce-1d51-43d0-8095-c66d79a2cb85" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_89da661e-ba77-4791-988c-097d493b15bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_89da661e-ba77-4791-988c-097d493b15bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f0e7db6c-8e03-4f90-aaf7-ba685ed3a20f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f0e7db6c-8e03-4f90-aaf7-ba685ed3a20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4761fea7-aa5f-43ab-89cd-44ce8c30d782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4761fea7-aa5f-43ab-89cd-44ce8c30d782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_96b39286-a807-4d05-bb73-d9605613c015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_96b39286-a807-4d05-bb73-d9605613c015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0cbf4fe8-0349-45bb-85be-d870b33ed853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_0cbf4fe8-0349-45bb-85be-d870b33ed853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_92efc8fc-db95-42c4-9360-4b11082a522e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_92efc8fc-db95-42c4-9360-4b11082a522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_06a60c7d-6a57-4096-8064-5f56815f7de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e417056d-fd82-4885-be22-05c1a34af218" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_06a60c7d-6a57-4096-8064-5f56815f7de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShare" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7bee4c82-edd0-490f-b44e-a2e972f5a56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f9fee575-5f48-48d5-b2b6-100e0058ddc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7bee4c82-edd0-490f-b44e-a2e972f5a56d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f9fee575-5f48-48d5-b2b6-100e0058ddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3401228f-c2f5-4af2-bb5c-1c543d8d7244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7a85986a-76ae-4096-b04c-8927c158fcde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3401228f-c2f5-4af2-bb5c-1c543d8d7244" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7a85986a-76ae-4096-b04c-8927c158fcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_af5a0771-8f27-4466-998a-812bd927cef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e6dcc0e-518a-4961-9cc1-a12f466e663e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af5a0771-8f27-4466-998a-812bd927cef0" xlink:to="loc_us-gaap_NetIncomeLoss_1e6dcc0e-518a-4961-9cc1-a12f466e663e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0dd8ee26-5dec-499a-8092-2e7b47aa96d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af5a0771-8f27-4466-998a-812bd927cef0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0dd8ee26-5dec-499a-8092-2e7b47aa96d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_737d5977-067b-4a1e-a65f-8da87408c549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af5a0771-8f27-4466-998a-812bd927cef0" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_737d5977-067b-4a1e-a65f-8da87408c549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4bca398-ff27-45cf-8781-de68d9795b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af5a0771-8f27-4466-998a-812bd927cef0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4bca398-ff27-45cf-8781-de68d9795b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_08f77b25-22dc-4565-a0bd-d4ff7b251437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af5a0771-8f27-4466-998a-812bd927cef0" xlink:to="loc_us-gaap_EarningsPerShareBasic_08f77b25-22dc-4565-a0bd-d4ff7b251437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7dec5264-7fec-4f64-86ea-d752c5c27072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af5a0771-8f27-4466-998a-812bd927cef0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7dec5264-7fec-4f64-86ea-d752c5c27072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4e8059a1-2674-4e27-a47f-79ab9858dbf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bdbd0ef6-5a15-4063-9d9f-305ef06627b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e8059a1-2674-4e27-a47f-79ab9858dbf0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bdbd0ef6-5a15-4063-9d9f-305ef06627b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_799a950a-ddd8-4e4f-9a25-1041a56860f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_bc22e299-5229-43e3-9d44-cd7088116e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_799a950a-ddd8-4e4f-9a25-1041a56860f3" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_bc22e299-5229-43e3-9d44-cd7088116e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1472ec6e-4dea-4393-a773-14f7fdd3adb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b116a8fa-c286-4f1c-8a9a-bfed4c8acee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1472ec6e-4dea-4393-a773-14f7fdd3adb9" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b116a8fa-c286-4f1c-8a9a-bfed4c8acee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_24f7c010-3d1a-4de7-89d2-94e59b4e2895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24f7c010-3d1a-4de7-89d2-94e59b4e2895" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b2de4335-33a8-470d-863d-42f80ac63b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b2de4335-33a8-470d-863d-42f80ac63b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2de4335-33a8-470d-863d-42f80ac63b02" xlink:to="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_39c25659-ac11-4373-8394-6a5b8148e56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_39c25659-ac11-4373-8394-6a5b8148e56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_623b14f2-4e63-4f38-a825-91c7bd007fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_623b14f2-4e63-4f38-a825-91c7bd007fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember_f59c0dd7-f24a-4704-a506-45ddf049f1f0" xlink:href="mrk-20201231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:to="loc_mrk_PensionPlanNetLossMember_f59c0dd7-f24a-4704-a506-45ddf049f1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_9bc67217-ec5f-45ec-af74-94afed17abd8" xlink:href="mrk-20201231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:to="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_9bc67217-ec5f-45ec-af74-94afed17abd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember_884dd4ba-dee7-409d-a514-454cbd2fd414" xlink:href="mrk-20201231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:to="loc_mrk_PensionPlanPriorServiceCostMember_884dd4ba-dee7-409d-a514-454cbd2fd414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_138554c3-7859-4418-a850-6864a3174ec0" xlink:href="mrk-20201231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b242eda9-c706-462c-b04e-0e12c03fa102" xlink:to="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_138554c3-7859-4418-a850-6864a3174ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4a169401-0b33-46d1-a701-7f20dcd046bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4a169401-0b33-46d1-a701-7f20dcd046bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5653876-e1c5-4193-99c5-0441cd4b9a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_243f5a8a-d965-4fdc-b8db-923c05fe9c81" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5653876-e1c5-4193-99c5-0441cd4b9a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91d68435-61ed-4983-8479-3be5d20eeefb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91d68435-61ed-4983-8479-3be5d20eeefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_efef2335-560b-4d28-b05a-00351be55493" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91d68435-61ed-4983-8479-3be5d20eeefb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_efef2335-560b-4d28-b05a-00351be55493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_55e8a7de-f968-4490-90ad-a22043449850" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_efef2335-560b-4d28-b05a-00351be55493" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_55e8a7de-f968-4490-90ad-a22043449850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_749bb393-c8b6-40b2-b8df-0f6151a27c01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_749bb393-c8b6-40b2-b8df-0f6151a27c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_49d8a9d7-ee63-4bdf-8389-c2d25f8ffee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_749bb393-c8b6-40b2-b8df-0f6151a27c01" xlink:to="loc_us-gaap_TypeOfAdoptionMember_49d8a9d7-ee63-4bdf-8389-c2d25f8ffee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_80601968-eb3d-4eda-96d0-659c342c90ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_49d8a9d7-ee63-4bdf-8389-c2d25f8ffee5" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_80601968-eb3d-4eda-96d0-659c342c90ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5dac783c-afed-4111-9ae4-381df15dfc01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_afae6538-78fb-4520-9e25-57f5d9412203" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5dac783c-afed-4111-9ae4-381df15dfc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5dac783c-afed-4111-9ae4-381df15dfc01" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac7ca81b-0099-435d-9c5d-d507144d3695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac7ca81b-0099-435d-9c5d-d507144d3695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_7ce0dffd-0bdd-4a85-9b16-de66d0e732cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_7ce0dffd-0bdd-4a85-9b16-de66d0e732cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e5da5104-49dc-4fe8-8939-98677014d30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e5da5104-49dc-4fe8-8939-98677014d30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4fcb4b22-0489-48d9-86bc-b96738fe5547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4fcb4b22-0489-48d9-86bc-b96738fe5547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_d204d98a-b67f-409e-9bce-55dea84e77e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_d204d98a-b67f-409e-9bce-55dea84e77e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9cbbafe4-38aa-433b-bc2c-707808000b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9cbbafe4-38aa-433b-bc2c-707808000b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ae7edafc-f515-4d71-91e5-16015225e048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ae7edafc-f515-4d71-91e5-16015225e048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c2aae2e-f3c9-42f1-964b-a3c68af5cc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c2aae2e-f3c9-42f1-964b-a3c68af5cc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_b7f249b0-18ef-4eb8-93be-c0268fd7f255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_b7f249b0-18ef-4eb8-93be-c0268fd7f255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a14fd01-f79f-4fed-a8c6-5701f283b496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52a562a4-5d41-4f10-9223-02373c4930be" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a14fd01-f79f-4fed-a8c6-5701f283b496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_16c93f2c-fdf1-453f-94a1-870151af81e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5dac783c-afed-4111-9ae4-381df15dfc01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_16c93f2c-fdf1-453f-94a1-870151af81e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e95458f7-5f6a-4d71-901a-72a7e11a974c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_013e6001-4ee9-4463-8231-478600e62d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e95458f7-5f6a-4d71-901a-72a7e11a974c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_013e6001-4ee9-4463-8231-478600e62d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4abb32b0-7170-4245-9097-9b288414f355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6f43fc98-5ad4-43f3-9e7f-7fcbfbeca981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4abb32b0-7170-4245-9097-9b288414f355" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6f43fc98-5ad4-43f3-9e7f-7fcbfbeca981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_d6e2ac9b-5ffc-494b-b25e-4bade95ca0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4abb32b0-7170-4245-9097-9b288414f355" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_d6e2ac9b-5ffc-494b-b25e-4bade95ca0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_48706f95-75e2-4928-9a6b-a7d9266bafae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4abb32b0-7170-4245-9097-9b288414f355" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_48706f95-75e2-4928-9a6b-a7d9266bafae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_4f3b6a5f-df45-4712-ae27-e0663f426778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4abb32b0-7170-4245-9097-9b288414f355" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_4f3b6a5f-df45-4712-ae27-e0663f426778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_fa4010a2-e895-4907-bc22-be63643262a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4abb32b0-7170-4245-9097-9b288414f355" xlink:to="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_fa4010a2-e895-4907-bc22-be63643262a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bdb2bc0f-dc48-439a-a322-c983d9d8edba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0690df47-5205-40ec-8a83-7e43934fb846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bdb2bc0f-dc48-439a-a322-c983d9d8edba" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0690df47-5205-40ec-8a83-7e43934fb846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3d452142-bd64-4b5f-836e-c6f9a288c671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3d452142-bd64-4b5f-836e-c6f9a288c671" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5f55a4ac-40df-4844-ad45-80b0c3032dc3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_srt_StatementGeographicalAxis_5f55a4ac-40df-4844-ad45-80b0c3032dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d385e44-74da-4e6b-b014-a3b3c81f8d87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5f55a4ac-40df-4844-ad45-80b0c3032dc3" xlink:to="loc_srt_SegmentGeographicalDomain_6d385e44-74da-4e6b-b014-a3b3c81f8d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6b17b97e-e3ba-4ad2-a2a8-b88814c97101" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6d385e44-74da-4e6b-b014-a3b3c81f8d87" xlink:to="loc_country_US_6b17b97e-e3ba-4ad2-a2a8-b88814c97101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_9a104124-a26b-448b-8eab-bdec3de13e4b" xlink:href="mrk-20201231.xsd#mrk_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6d385e44-74da-4e6b-b014-a3b3c81f8d87" xlink:to="loc_mrk_InternationalMember_9a104124-a26b-448b-8eab-bdec3de13e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1e16520a-8d66-48a9-bd24-39103769476f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_srt_ConsolidationItemsAxis_1e16520a-8d66-48a9-bd24-39103769476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e535d32d-5286-4792-ba87-8a6f8d925ae7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1e16520a-8d66-48a9-bd24-39103769476f" xlink:to="loc_srt_ConsolidationItemsDomain_e535d32d-5286-4792-ba87-8a6f8d925ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8d002586-4c65-4f2d-be5a-73f61bdcc4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e535d32d-5286-4792-ba87-8a6f8d925ae7" xlink:to="loc_us-gaap_OperatingSegmentsMember_8d002586-4c65-4f2d-be5a-73f61bdcc4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_dfa55ad4-51fb-4f4a-9db6-6e57f3b69c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e535d32d-5286-4792-ba87-8a6f8d925ae7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_dfa55ad4-51fb-4f4a-9db6-6e57f3b69c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7ba82e0e-5359-4d39-88d9-c698e3531454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7ba82e0e-5359-4d39-88d9-c698e3531454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7ba82e0e-5359-4d39-88d9-c698e3531454" xlink:to="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_26d5749e-1693-43c9-83df-02a0fc5dadd5" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:to="loc_mrk_PharmaceuticalsegmentMember_26d5749e-1693-43c9-83df-02a0fc5dadd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_d685147b-1310-4ebf-9efc-fffff6dc79eb" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:to="loc_mrk_AnimalHealthsegmentMember_d685147b-1310-4ebf-9efc-fffff6dc79eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1ababcdd-49e5-4acf-8fbc-4c16e5e9c8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2038b853-5fa6-4778-a377-3a818bb5ad64" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1ababcdd-49e5-4acf-8fbc-4c16e5e9c8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8d6665fc-e4ad-40e8-9002-147128b7e747" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_srt_ProductOrServiceAxis_8d6665fc-e4ad-40e8-9002-147128b7e747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8d6665fc-e4ad-40e8-9002-147128b7e747" xlink:to="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_0267fba7-aa62-4693-8b99-8184d776c551" xlink:href="mrk-20201231.xsd#mrk_KeytrudaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_KeytrudaMember_0267fba7-aa62-4693-8b99-8184d776c551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_2e0dc4b8-2ff5-489a-841c-a116aebc54f3" xlink:href="mrk-20201231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_2e0dc4b8-2ff5-489a-841c-a116aebc54f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_30ef797b-9592-4d81-8ed2-2774d44411bd" xlink:href="mrk-20201231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_LenvimaMember_30ef797b-9592-4d81-8ed2-2774d44411bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmendMember_13c6e81e-a3f2-4e89-b6f0-c1ab89b56bf7" xlink:href="mrk-20201231.xsd#mrk_EmendMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_EmendMember_13c6e81e-a3f2-4e89-b6f0-c1ab89b56bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_a7771845-1279-4468-865f-6fc40a4cf77f" xlink:href="mrk-20201231.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_GardasilGardasil9Member_a7771845-1279-4468-865f-6fc40a4cf77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_5ec3540f-dce4-49d3-9c99-dee1d984f10e" xlink:href="mrk-20201231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_5ec3540f-dce4-49d3-9c99-dee1d984f10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_d8b87cef-04c9-4057-abe7-f244784c359e" xlink:href="mrk-20201231.xsd#mrk_Pneumovax23Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_Pneumovax23Member_d8b87cef-04c9-4057-abe7-f244784c359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_b94c3a83-4813-4ce0-a31a-e8c422a91545" xlink:href="mrk-20201231.xsd#mrk_RotateqMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_RotateqMember_b94c3a83-4813-4ce0-a31a-e8c422a91545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_70f2df99-c36c-46f3-aca7-9c27642a3959" xlink:href="mrk-20201231.xsd#mrk_VaqtaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_VaqtaMember_70f2df99-c36c-46f3-aca7-9c27642a3959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_06e9a35d-84e4-49df-9d4c-8ebd7cbd2589" xlink:href="mrk-20201231.xsd#mrk_BridionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_BridionMember_06e9a35d-84e4-49df-9d4c-8ebd7cbd2589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_d34195d0-28af-4f4b-95e6-aef5485d19d9" xlink:href="mrk-20201231.xsd#mrk_NoxafilMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_NoxafilMember_d34195d0-28af-4f4b-95e6-aef5485d19d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_e1dc19f7-2ff8-4076-9b03-674274db069e" xlink:href="mrk-20201231.xsd#mrk_PrevymisMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_PrevymisMember_e1dc19f7-2ff8-4076-9b03-674274db069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_774951a6-cca1-457b-afa2-c9d978f2c6bf" xlink:href="mrk-20201231.xsd#mrk_PrimaxinMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_PrimaxinMember_774951a6-cca1-457b-afa2-c9d978f2c6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_0378aa83-f4d8-4e95-984d-21c31c996876" xlink:href="mrk-20201231.xsd#mrk_CancidasMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_CancidasMember_0378aa83-f4d8-4e95-984d-21c31c996876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_df6ae059-4a4a-4bdc-947c-705568ea397a" xlink:href="mrk-20201231.xsd#mrk_InvanzMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_InvanzMember_df6ae059-4a4a-4bdc-947c-705568ea397a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CubicinMember_326e4e59-833d-4d33-8a15-0098e4cebe4c" xlink:href="mrk-20201231.xsd#mrk_CubicinMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_CubicinMember_326e4e59-833d-4d33-8a15-0098e4cebe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_57cba671-9f76-486a-a1ac-57457dcfcc8e" xlink:href="mrk-20201231.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ZerbaxaMember_57cba671-9f76-486a-a1ac-57457dcfcc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_c4312256-d5b3-49f3-95ad-fd1b9d83c287" xlink:href="mrk-20201231.xsd#mrk_SimponiMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_SimponiMember_c4312256-d5b3-49f3-95ad-fd1b9d83c287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_32e73084-23e2-42d4-ba82-ecd64fd15c88" xlink:href="mrk-20201231.xsd#mrk_RemicadeMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_RemicadeMember_32e73084-23e2-42d4-ba82-ecd64fd15c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_2c9fb44d-ef9b-40d1-a557-2c97cd4cbdd3" xlink:href="mrk-20201231.xsd#mrk_BelsomraMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_BelsomraMember_2c9fb44d-ef9b-40d1-a557-2c97cd4cbdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_4f7d4e97-fc83-41f7-914b-f91743460897" xlink:href="mrk-20201231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_IsentressIsentressHDMember_4f7d4e97-fc83-41f7-914b-f91743460897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZepatierMember_e4be6c3b-706e-41d7-8607-5405a17b905c" xlink:href="mrk-20201231.xsd#mrk_ZepatierMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ZepatierMember_e4be6c3b-706e-41d7-8607-5405a17b905c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaMember_c0515feb-2dc5-4446-b932-0e4900e4b809" xlink:href="mrk-20201231.xsd#mrk_ZetiaMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ZetiaMember_c0515feb-2dc5-4446-b932-0e4900e4b809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VytorinMember_d24b73a0-4ed3-4659-8c90-f61ea5379df0" xlink:href="mrk-20201231.xsd#mrk_VytorinMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_VytorinMember_d24b73a0-4ed3-4659-8c90-f61ea5379df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AtozetMember_491fc831-1133-4ccf-bae7-cf8fab044670" xlink:href="mrk-20201231.xsd#mrk_AtozetMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_AtozetMember_491fc831-1133-4ccf-bae7-cf8fab044670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasMember_9817b150-9fe0-403e-b91b-422930ec704e" xlink:href="mrk-20201231.xsd#mrk_AllianceRevenueAdempasMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_AllianceRevenueAdempasMember_9817b150-9fe0-403e-b91b-422930ec704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_0d8e51f1-663a-47db-895d-c2170af1a214" xlink:href="mrk-20201231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_AdempasMember_0d8e51f1-663a-47db-895d-c2170af1a214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_10c3ee5b-17d0-429d-9f86-026bd692546e" xlink:href="mrk-20201231.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_JanuviaMember_10c3ee5b-17d0-429d-9f86-026bd692546e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_77cd6e65-5580-422e-9c3c-24976df23d59" xlink:href="mrk-20201231.xsd#mrk_JanumetMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_JanumetMember_77cd6e65-5580-422e-9c3c-24976df23d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImplanonNexplanonMember_2ed5c244-d987-48d7-ab17-f0e9498bfa5f" xlink:href="mrk-20201231.xsd#mrk_ImplanonNexplanonMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ImplanonNexplanonMember_2ed5c244-d987-48d7-ab17-f0e9498bfa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NuvaringMember_00701274-0305-4a85-af54-9b801f5ec19f" xlink:href="mrk-20201231.xsd#mrk_NuvaringMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_NuvaringMember_00701274-0305-4a85-af54-9b801f5ec19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SingulairMember_d48b2e7e-47b0-43af-a334-b4646fd88194" xlink:href="mrk-20201231.xsd#mrk_SingulairMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_SingulairMember_d48b2e7e-47b0-43af-a334-b4646fd88194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CozaarHyzaarMember_cbecbbe7-89d1-4421-8cc0-13a9d423d86c" xlink:href="mrk-20201231.xsd#mrk_CozaarHyzaarMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_CozaarHyzaarMember_cbecbbe7-89d1-4421-8cc0-13a9d423d86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArcoxiaMember_3f5e6fb2-aacf-4333-9e84-71763e2c4067" xlink:href="mrk-20201231.xsd#mrk_ArcoxiaMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_ArcoxiaMember_3f5e6fb2-aacf-4333-9e84-71763e2c4067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NasonexMember_bc6e62f5-0ffc-4325-8d3e-c42774db878a" xlink:href="mrk-20201231.xsd#mrk_NasonexMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_NasonexMember_bc6e62f5-0ffc-4325-8d3e-c42774db878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FollistimAqMember_2bbc472e-c470-4b36-a996-e8fb01bba22c" xlink:href="mrk-20201231.xsd#mrk_FollistimAqMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_FollistimAqMember_2bbc472e-c470-4b36-a996-e8fb01bba22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_16e37837-8259-4b05-a160-ece03a66a2a0" xlink:href="mrk-20201231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_OtherPharmaceuticalMember_16e37837-8259-4b05-a160-ece03a66a2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_f8ceb03b-96fe-4f61-9b39-bc43592c02f5" xlink:href="mrk-20201231.xsd#mrk_LivestockMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_LivestockMember_f8ceb03b-96fe-4f61-9b39-bc43592c02f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_2bdc4b8c-5877-482c-b486-b8f4f171c0aa" xlink:href="mrk-20201231.xsd#mrk_CompanionAnimalsMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c00d14-fd0a-48cf-870c-553007d6c061" xlink:to="loc_mrk_CompanionAnimalsMember_2bdc4b8c-5877-482c-b486-b8f4f171c0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e6e7363b-ac57-48f8-a430-2aee1c236973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52968df1-2836-4c3f-8ce3-e97b6be35bf9" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e6e7363b-ac57-48f8-a430-2aee1c236973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3a96d4fb-baf0-4298-820b-938e1bf338c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e6e7363b-ac57-48f8-a430-2aee1c236973" xlink:to="loc_us-gaap_Revenues_3a96d4fb-baf0-4298-820b-938e1bf338c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f001eb8b-eb9e-4b33-b737-b93cbc28ccbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3cf0e69f-8ee6-4cb5-ae0b-c510dc3a7e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f001eb8b-eb9e-4b33-b737-b93cbc28ccbe" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3cf0e69f-8ee6-4cb5-ae0b-c510dc3a7e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3cf0e69f-8ee6-4cb5-ae0b-c510dc3a7e79" xlink:to="loc_srt_StatementGeographicalAxis_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2e9e6d04-90c9-4e40-a1d7-d7fb8254b60b" xlink:to="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_87b625cb-e481-432e-b5de-7399bd042dfe" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_country_US_87b625cb-e481-432e-b5de-7399bd042dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_78f951d8-4024-4f87-88ce-82d58f6f15be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_us-gaap_EMEAMember_78f951d8-4024-4f87-88ce-82d58f6f15be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_d5542091-2c42-40bc-9cae-e91b738bba54" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_country_CN_d5542091-2c42-40bc-9cae-e91b738bba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_11380902-5acf-4ccd-bd9f-c0cacf01bd54" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_country_JP_11380902-5acf-4ccd-bd9f-c0cacf01bd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_84bdc3fc-f14b-44fe-a1a4-78fe5df9f16d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_srt_AsiaPacificMember_84bdc3fc-f14b-44fe-a1a4-78fe5df9f16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_74bf70dc-9583-4148-9114-d70cdafc2c70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_srt_LatinAmericaMember_74bf70dc-9583-4148-9114-d70cdafc2c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_bef8fa05-16ca-43c7-8e19-f072e02b0199" xlink:href="mrk-20201231.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0a7b9888-355d-4717-be47-e47c7a525474" xlink:to="loc_mrk_OtherCountriesMember_bef8fa05-16ca-43c7-8e19-f072e02b0199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0889d63c-74d1-4d63-9d61-1ca06d472a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3cf0e69f-8ee6-4cb5-ae0b-c510dc3a7e79" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0889d63c-74d1-4d63-9d61-1ca06d472a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6cdf21fa-a100-4306-93a4-1e423b8e6fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0889d63c-74d1-4d63-9d61-1ca06d472a94" xlink:to="loc_us-gaap_Revenues_6cdf21fa-a100-4306-93a4-1e423b8e6fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2bf83ad3-8433-46ac-99a4-b13bb47e14fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2bf83ad3-8433-46ac-99a4-b13bb47e14fe" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_da9213a2-74c7-472e-9f67-4405c255caeb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:to="loc_srt_ConsolidationItemsAxis_da9213a2-74c7-472e-9f67-4405c255caeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_da9213a2-74c7-472e-9f67-4405c255caeb" xlink:to="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4c937c8d-60e8-45c2-bd61-5853e04b879a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:to="loc_us-gaap_OperatingSegmentsMember_4c937c8d-60e8-45c2-bd61-5853e04b879a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_9e7a89ab-3796-4bfa-8467-3dbcb67dd2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:to="loc_us-gaap_CorporateNonSegmentMember_9e7a89ab-3796-4bfa-8467-3dbcb67dd2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_24e8efd4-198a-4262-ae8d-35eb9513c20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c051a3be-60fb-4356-a7b9-338a5a36c3e5" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_24e8efd4-198a-4262-ae8d-35eb9513c20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_27147435-a3d9-4630-908e-00f7ecb4b9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_27147435-a3d9-4630-908e-00f7ecb4b9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_27147435-a3d9-4630-908e-00f7ecb4b9cb" xlink:to="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_9f160221-b280-4c43-9d8f-f5e0e503ee13" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:to="loc_mrk_PharmaceuticalsegmentMember_9f160221-b280-4c43-9d8f-f5e0e503ee13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_1b150a56-31cb-4a5c-9ab7-1cb7c9a99567" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:to="loc_mrk_AnimalHealthsegmentMember_1b150a56-31cb-4a5c-9ab7-1cb7c9a99567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_efff61a7-7c31-44cb-90f7-60626c51d891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_08a1544d-199f-4b50-abbd-98da52654372" xlink:to="loc_us-gaap_AllOtherSegmentsMember_efff61a7-7c31-44cb-90f7-60626c51d891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1feafced-d849-4749-b86d-9a2063d8d105" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_aba29be9-0420-4b2c-b17a-3036503da2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_aba29be9-0420-4b2c-b17a-3036503da2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_250982fd-04c0-462b-a692-b0e5f36fd3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_InterestExpense_250982fd-04c0-462b-a692-b0e5f36fd3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b778ac67-83b9-465f-b7df-0adc873aebce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b778ac67-83b9-465f-b7df-0adc873aebce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a2f6cf87-7dea-4045-a234-8838222c8aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a2f6cf87-7dea-4045-a234-8838222c8aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmortizationOfPurchaseAccountingAdjustments_93ca2fbb-0929-4745-9f0a-5227712c7e0e" xlink:href="mrk-20201231.xsd#mrk_AmortizationOfPurchaseAccountingAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_mrk_AmortizationOfPurchaseAccountingAdjustments_93ca2fbb-0929-4745-9f0a-5227712c7e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_111ab377-3cbc-4df7-84e5-071a0ff103d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_RestructuringCharges_111ab377-3cbc-4df7-84e5-071a0ff103d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_20706724-87ed-453a-becd-422154cb2bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_GainLossOnContractTermination_20706724-87ed-453a-becd-422154cb2bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_204b1cdc-ba10-47a3-a749-5a369f69ea5c" xlink:href="mrk-20201231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_204b1cdc-ba10-47a3-a749-5a369f69ea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a0ff97e-35e9-4165-975b-0bad49e31621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7ae31f0e-2503-4e09-8890-d0965e0752e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a0ff97e-35e9-4165-975b-0bad49e31621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_190eac9d-9900-4d17-bad2-ab3da80a6f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_190eac9d-9900-4d17-bad2-ab3da80a6f8b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2db0fb48-fc71-46b2-a30e-b4739041721b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:to="loc_srt_ConsolidationItemsAxis_2db0fb48-fc71-46b2-a30e-b4739041721b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4b650bb0-3c70-4ded-abc1-ae44992a1d71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2db0fb48-fc71-46b2-a30e-b4739041721b" xlink:to="loc_srt_ConsolidationItemsDomain_4b650bb0-3c70-4ded-abc1-ae44992a1d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a620c951-73b5-4ba8-b210-1ae9cf2d95da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4b650bb0-3c70-4ded-abc1-ae44992a1d71" xlink:to="loc_us-gaap_OperatingSegmentsMember_a620c951-73b5-4ba8-b210-1ae9cf2d95da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fb09ff66-0bec-4e56-b83d-d65fd58f6a6b" xlink:to="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_e32fc788-0b63-40a5-9c0d-e9b4c32fc980" xlink:href="mrk-20201231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:to="loc_mrk_PharmaceuticalsegmentMember_e32fc788-0b63-40a5-9c0d-e9b4c32fc980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_ccaa99c5-3be8-4179-9b37-ae81881ef091" xlink:href="mrk-20201231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:to="loc_mrk_AnimalHealthsegmentMember_ccaa99c5-3be8-4179-9b37-ae81881ef091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_851ab612-9c23-4857-8cea-9fd62b8b9611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f7cbba57-31f8-4a04-8f11-ec5d2929139c" xlink:to="loc_us-gaap_AllOtherSegmentsMember_851ab612-9c23-4857-8cea-9fd62b8b9611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_70d8f87f-1a1f-40ec-9572-e7240197edd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04515dae-3bd1-481e-bf11-d53cff61c9ac" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_70d8f87f-1a1f-40ec-9572-e7240197edd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_082f663b-3a21-4e4e-8d76-955bfe87347e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_70d8f87f-1a1f-40ec-9572-e7240197edd9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_082f663b-3a21-4e4e-8d76-955bfe87347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_727328ab-47c8-4058-a801-4d118090615b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_70d8f87f-1a1f-40ec-9572-e7240197edd9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_727328ab-47c8-4058-a801-4d118090615b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20201231.xsd#SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bf218918-51f7-4ec6-95b2-40285073c1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ff819a2b-566b-4cb2-9d6b-aa5e85e7979b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bf218918-51f7-4ec6-95b2-40285073c1d0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ff819a2b-566b-4cb2-9d6b-aa5e85e7979b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d35ccd4f-8126-4335-989e-e6fdcae824d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ff819a2b-566b-4cb2-9d6b-aa5e85e7979b" xlink:to="loc_srt_StatementGeographicalAxis_d35ccd4f-8126-4335-989e-e6fdcae824d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d35ccd4f-8126-4335-989e-e6fdcae824d5" xlink:to="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4d9eda23-878d-4bea-b773-799728554fe0" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_country_US_4d9eda23-878d-4bea-b773-799728554fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_c1716f25-988c-4d8b-8853-e91144d15131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_us-gaap_EMEAMember_c1716f25-988c-4d8b-8853-e91144d15131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_47ee365b-971b-4ad8-baf8-426031b90379" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_srt_AsiaPacificMember_47ee365b-971b-4ad8-baf8-426031b90379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_ead0b341-b541-4e3d-bcb9-e7e4362c18ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_srt_LatinAmericaMember_ead0b341-b541-4e3d-bcb9-e7e4362c18ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_891e5a77-cc8e-4a99-9fb1-12a1b6dea557" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_country_CN_891e5a77-cc8e-4a99-9fb1-12a1b6dea557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_d27ab569-a26d-4b1d-8e72-6e27cb56f7f3" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_country_JP_d27ab569-a26d-4b1d-8e72-6e27cb56f7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_68bc7c64-c160-4943-a8b3-e8089bc605f0" xlink:href="mrk-20201231.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0070fd4d-fe78-45cd-97a5-230d5318ed0b" xlink:to="loc_mrk_OtherCountriesMember_68bc7c64-c160-4943-a8b3-e8089bc605f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a2b3c60a-7677-4f84-bc0e-ee81f588a9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ff819a2b-566b-4cb2-9d6b-aa5e85e7979b" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a2b3c60a-7677-4f84-bc0e-ee81f588a9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8778a225-5ca2-492b-982c-d2623d808429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a2b3c60a-7677-4f84-bc0e-ee81f588a9af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8778a225-5ca2-492b-982c-d2623d808429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mrk-20201231_g1.jpg
<TEXT>
begin 644 mrk-20201231_g1.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
M'_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_X
MA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;
M_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*
MF?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_
M $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)
M=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_
M ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*
MAKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y
M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ!_X/>?^
M36?@?_V4#4?_ $A%?M]7X@_\'O/_ ":S\#_^R@:C_P"D(H \_P#^#3;_ )2F
M?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&33IR37DS]3CC,'))JI%I^:.JHKE?^%Z_!'_ *+'X5_\*&V_^+H_X7K\$?\
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M*].^G-3TC?7K?5_XDNAYF!S.&+JU(/2ST\U_7YGJM%<[_P +>^$W_14/#O\
MX.X/_BZ/^%O?";_HJ'AW_P '<'_Q=?H/UO"_\_(_>CT^>'='145SO_"WOA-_
MT5#P[_X.X/\ XNK^@^-?!OBF:2W\,>+=,U&2)0TJ6%_',4!XR0C' JHXG#SE
MRQFF_5#4X-V3-.H9=1T^"\BTZ:^A2XG5C# TH#R!>I5>IQWQTJ:OQF_X)V_'
M7_@GSX_^+?Q(_8H_X+%?"?P[I7[5-Y\1=6?5O$7Q7TM%D\16TMY*VFG1M4F
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K\0?\ @]Y_Y-9^!_\ V4#4?_2$5^WU?B#_ ,'O
M/_)K/P/_ .R@:C_Z0B@#S_\ X--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F
M?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PC5O\
M@F/^P+KNJW.MZO\ LM>%[B[O+AY[J>2W?=)([%F8_/U))/XU!_PZR_X)Z_\
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MCO\ !/P+^WS^S/X+\:?%OPWI.K3:WXFD33M1UJ&&;8=!G4,5=@5!9T SC<6
M&37U717E-MN[/6225D?D=\"OV-?CY\$O^"G'Q1_X)9^'_"3G]F;Q[XNT[XXK
M?DL(+"Q2=C=>'HP!MVW&K06*F'<,6=K-E6\\D=/^QM\=_@EJO_!R]^U1'IGQ
M=\-7']J?"KPI;:8\&MP.MY/!;VHFBB8-B1T+J&522"<$<''ZE44AGY*?L=_M
M4?L>^%_^#A']N7Q#\2OVB/AQIVF:UHO@*+0=1UWQ780VU]):Z)!#=)!++($D
M>*3".JDE6!! (-?9_P"SS^UI^P'_ ,+T\:?"7]DSXA^"-8MYH)?&_P 4->\(
M^(+271M!NI%L["!9Y8"84N+H6[/Y>X-_HTTCX,B;_IRB@#\'?^"97[#?[-?_
M  4__86_:+\)> /'?A;1_C3HG[5WB?Q7\*OB!I<L!U?1[B'['-IUUYB9F>PD
MD+J?O1G>S*/,12/M[]EO]M'P=_P5I_8F^)?_  3X_:>U_3?AW^T.?"FM> /B
MIX"O;F.&\M]0>SEMGU.R@+ W%JX87"F/<J\KDJ%=_P!!** /S0_X(B?MI?#C
M]E+]ES1O^"8W[>_B[1_A)\9?@R;K1[C1?&^IQ:;;^(=-%U+)::EID]P4CO8&
MB<)F-F;,3,0%9:^Y/!/[5GPD^)FHZCJOP[\5:9J_@S1+)WUCXAVVJ1_V-'=;
MU5;6&Z_U5RP'F&5HW*PLJ(QWOM7MO%/@7P3XYMXK3QMX.TK6(H'+P1:KI\5P
ML;$8)42*0#CN*TK:VMK*VCL[.W2*&) D442!510,!0!P !QB@#\#_P#@F7^P
M9\"?^"D_[,/QH\8_ KX\Z5X(_:(^'W[5GC#Q+\(_B1X?U./[?802"R>#[0D9
M+SZ9.VX9(902Y3=F2.3[D_X),?\ !=SX1_M:MJ?[*7[8'C;PAX&_:%\":O-H
M/B72$UVW&F>)KFWE,#7>E3[S%/O=23 C,RG)7<F&'Z'T4 %%%% !1110 5XC
MJO\ P3=_87UO4[G6=6_9F\-3W5W.\US/) ^Z21V+,Q^;J22:]NHK&MAL/B$O
M:P4K=TG^9Z679QF^42D\!B*E%RM?DG*%[;7Y6KVZ7/"O^'9/[!'_ $:YX7_\
M!W_^+H_X=D_L$?\ 1KGA?_P'?_XNO=:*P_LW+O\ GS#_ ,!7^1ZG^NG&/_0R
MQ'_@ZI_\D>%?\.R?V"/^C7/"_P#X#O\ _%U^</[:O[%R_';]ON]_9O\ V&/@
M;9:;8>%])L[7Q!=V2-%86US(#/)/<3-D)A)43:,L3$P56.17[)UG>'?"'A;P
MBMZOACP_:6']HZA-?:@;6 (;FYE;=)-(1R[L>YR< #H *\[,N'\%F%*-)1C!
M7NW&*3:71.VEWU/L.#/%KB7A/'5L=4KU,34=-QIQJ59RIQE)KWY1<O>Y4FE'
M35WNK6?X_P#[$/[&$/P/_;YMOV:OVZ?@98ZA9^*-'O+?P[<WZM+8W-S$!.D]
MO,I"N#'%(FTX8&10RJW%?HY_P[)_8(_Z-<\+_P#@._\ \77LGB+PAX7\7"R_
MX2;0+2^.FZA%?:>US"&:VN8VW)+&3RC@]QC@D'@D'1HRWA_!9?2E2E&,U>Z<
MHIM)]&[:V?47&?BUQ+Q9CJ6.I5ZF&J>S4:D:=6<:<I1;]^,5+W>9-)QUU5[N
M^GA7_#LG]@C_ *-<\+_^ [__ !='_#LG]@C_ *-<\+_^ [__ !=>ZT5Z/]FY
M=_SYA_X"O\CY#_73C'_H98C_ ,'5/_DCPK_AV3^P1_T:YX7_ / =_P#XNO;M
M+TRPT33+;1M*M5@M;2!(;:!/NQQHH55'L  *GHK:CA<-AVW2@HW[)+\CS<QS
MS.LWC%8_$U*RC>W/.4[7WMS-VOUL?EC_ ,'%GQ!^!*?M ?L2^ OBGXO\+-;1
M?M0Z+=^)=&UR\MVCCTO*)--=12G"VV)%#-(-F&Y.*_1#X*_L_P#[+GP3L;KQ
M+^SK\$_ /A&VUN);B]U#P5X;L;!+],;ED>2UC42C!R&)(YS7?45N>6?DK^RM
M^U3^Q[H'_!Q)^V5XE^(G[1'PYL-*U#P9X*M=)U+7/%5C#;7=Q;Z9;I<1P2S2
M!)7C8A7"$E&!#8(('VA^SW^UM^P/)\=O&/PA_9,^(7@K6XI[:;QO\3]>\(:]
M:2Z-H,[)9Z?"L\T!,*7%R+<OY>X-BUGE?!=/,^FJ* /R(_X-]_VK_P!ASPM\
M,_VH;'XO?M'?"S2Y=7_:_P#&>K:=!XG\6Z=;M>:7<0V ANHUN) 9+>0QRA7&
M4;8^#P:^E_%O[7W[$U__ ,$^_P!H'PO^SAX\\+K\*_ASX%UC0;#Q?IVMVYT6
MXU:?3;RZFTJQD4B.;[/'+:X\IF4FX\I>8FK[@HH _"_]B_\ 8GB^*_\ P1P_
M9P_X* _\$WX_#"?M-? /2[G5$MM&6 R>*K<W=TE[H.IK"0[R30*ZQ&3YPV44
MH)"Z_JG_ ,$]O^"D'[,__!2'X'Z3\6O@9XVL1JLU@K^)_!%Q?Q_VMX<NUPLU
MK=0<2)LDRHD*A)!M920PKWVB@#\W/^"XG[,WQT\-_M'?L[?\%:?V=/AQJ?C:
M]_9\\1SKX^\%Z%;F?4=0\-W91;F:SB',LL,9N 4&21.'QMC:OHCXI?M^?L$?
M&W]B/QG\2]"_:F^'E[X5UCP1J4$TFH^)K6WVF6TD0VMQ#.ZO#-EMC02*L@8[
M2H/%?3=8=Q\,?AK=^)!XRNOAYH<NL+('759-)A:Y# 8#>:5W9 [YH _'7X6C
M3/@7_P &;5SX0^+"0^#]6U7X5>)4M-+\0*-/N;R>YUF]>$)%-M:1Y4EB9< E
MUD0C(8&KNF_LW6OPP_88_9F_X+0?\$M_#GAS5?B1\(?@QH-M\6/!_A,0JOCK
MP\VF6[:K8W"P _\ $Q@822AF'F[T8,'>.)*_9FB@#\XO^"EG_!1C]C#]L7_@
MA%\9?C)\$/V@O#%]8^)OA=<QVNF7&M6\6H6UY,JJ+&>V9_,CN0YV>61DGE=R
MD,?5?^"0GP'_ &&O$G[#WP&^/OPI^"?PKN_%MM\)/#D5_P",M"\,::VIP7PT
MNW%PDMU''YR3"3>'5F#AMP;G-?9%% 'F.N_MB?L\>&_VL]#_ &'M9\>F'XF^
M(_",_B;2/#O]F7+";3(I7B>;SQ&85.^.3"%PQ$;''3/IU5WTG2I-437)-,MV
MO8H&ACO#"IE2)B&9 ^,A254D9P2H]*L4 %%%% !7)?%GX$_"'X[:=::3\7O
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MU6QAN;:XC,<]O<1!XY$(P593P01V-+8V-CI=E%INF6<5O;P1K'!;P1A$C0#
M55'  '  H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\0?^#WG_ )-9
M^!__ &4#4?\ TA%?M]7X@_\ ![S_ ,FL_ __ +*!J/\ Z0B@#S__ (--O^4I
MG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OQ!_X/>?\ DUGX'_\ 90-1_P#2$5^W
MU?B#_P 'O/\ R:S\#_\ LH&H_P#I"* //_\ @TV_Y2F?M=_]O'_I\GK]_J_
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M"OU2I\"\1QXFX=I8F3_>1]V?^)=?^WE:7SMT'EV*^MX53>ZT?K_P=PHHHK[
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M &/<O_I,U>Z5X7^UA_R6SX'_ /8]R_\ I,U>Z4 %%%% !1110 4444 %%%%
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MQN68]S7J_5\ERS7$3^L5/Y8.U-?XJF\O2"2[5#ROK&=YIIAX?5Z?\\U>H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7$FA_L/? R\\3P[S&WCSQ6DFG:%"0<%DW8ENL'JB!6'7D5J^!?\ @GU\.?\
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M7$U%".VO5]DMVWT2NWT/>Z\ ^/\ _P %'?@%\%_%7_"IO" U+XB_$.9C':^
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MM;R?]Z;E+S.S!9)@L%6]N[U*O6I-\T_1/:*_NP48^04445Y)ZX4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLEHE)6EIWMT/M<LQ$<3@XM:-:/U7]7"BBBOM3T HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[C]R_P CP#1/^"7/["_AO6;3Q#H7P2DM;ZPNH[FSNH?%>JAX948,CJ?M7!#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW>7_ -+<1_ZFNC_OF886E_W&57_U'C6_ [#]M7XY?M._L^>"A\1O@5\ ]/\
M'VF6<1?6[1=3EBOK51G,B0I&WG1@8W;3N7KM*Y9?RR_;?_X*Y_$_]M+X0Q_!
MB_\ AEIGAG36U6&]OI;'4))Y+KR@^V)MRJ FYE?IG=&O-?H[_P .^OC'XMY^
M+_\ P4:^,&I!O];%X6O;?0HY/8K"C_*?3-?E5^T+^S;/\0_VZ?%?[/7[(WA3
M7O$QT_66L$>[O3=W,]Q$%2[N;B=L*J^?YF9&VJ!C)SR?CN*:V<*FN1RC"I[O
M)[K;].6[]=6?T=X%9=X<RQ<_K$:5;$81>V6)2K4X02:7O^U<(MIN\7[..B;>
MJN=[^Q+_ ,%>OBC^QK\'%^"5E\+M,\3:=!J<]UI\U[J,L$ELLNUFA&U6!7>'
M?IG,C5^IO[&'QJ_:;^/G@?\ X6)\>?@-I_@&QO(P^B6!U.66^N$./WDL+QKY
M"8Z!CO;KM48+?E%_P3_\#:G^S#_P4K\&_#?]I_X4K97LFI/IZ6>O6:N+>[F1
MEM+F$G*2?OQ&$E4D?,64Y -?N-77P?\ 7ZU!NM6?+3?*H62M9=7:_HO+Y'SW
MTB?]5,NS6G'+<OI^TQ<57>*4Y24^:33Y(J7)=VO*33NI*R3?,%%%%?<'\P!1
M110 4444 %%%% !1110 5^(/_![S_P FL_ __LH&H_\ I"*_;ZOQ!_X/>?\
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MD4/](5^<G_!?&36D^-O["B^$#C6C^V-X;\C8#N^R_.+K..?+\L_/C^&OT;H
M***\O^*WA3]K/5_%SWGP?^*_A?2-%,"!++5M">XF$@'SL7!'!/04 <W^UA_R
M6SX'_P#8]R_^DS5[I7R%\7?#'[46D_'+X/-\7?B?X:U>.3QH1IRZ5HC6YAD$
M)+E\D[@5R /6OJ7[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7
MC?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#
M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M&6:#.<QV<1)2SB&2 J#(4E=VW"CWK[%XW_Z#=E_X#'_&O3^OX#)_=R_WZO\
MS]DMO^O<'MY3E[W5*#/+_L_'YS[V8^Y2_P"?,7O_ -?9KXO.$?=Z-S15^%?P
ME^&GP0\$6?PW^$G@G3_#^AV"XMM.TV (@/=V[NYQEG8EF/))-=%6/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-?/U*E2M4<ZC;D]6WJV^[9]%3ITZ--0II*
M*T26B2[)&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-06;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L4DDD<4;2RN%502S,<
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M#^T/XU3P#\*_&^IW]\T9EF=_"-S'!;1 @&6:5ALA09'S.0,D 9) /?\ C/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !11576]<T7PSH]SXA\1ZO:Z?864#37E]>W"Q0P1J,L[N
MQ"JH')).!32<G9;B;45=[%JO)?VH_P!M3X'?LFZ9:Q>/]7N-0\1:L1'X=\%:
M!;F[U?5Y2<*D-NO."W&]MJ9XSD@'QWQ'^VK\=OVP->N_A?\ \$W?#,0T>"<V
MVN?&_P 363+I%B0<.NGPN,WTR]CC8"!D%6#UZ;^RY^P=\)?V:M3N?B->W]_X
MT^(NK MKWQ&\5R?:-1NG(PRQ%B1;1=A&G\(4,S[0:^ACE>%RM*IFC?-NJ47[
M[_QO54UY-.;_ )4GS'SDLUQ>:R=/*DN7K6DO<7^!:.H_--07\S:Y3RFT_9G_
M &I?V_;N+Q5^W+J4_@/X<-*LVF_!/PSJ3+/?1YRIU>\3:SGH?)CP!Q_JV4Y^
MK_ W@/P5\,?"EEX%^'?A6PT31M.A$5CIFF6JPPPJ.RJH ]R>I))/)K6HK@Q^
M:XG'QC3:4*4?AA'2,?.V[?>4FY/JST,ORC"Y?*55-SJR^*I+6<O*^R7:,4HK
MH@HHHKS#U HHHH **** "BBB@ HHHH **AU'4=/TBPFU75KZ&UM;>)I+BYN)
M0D<2 9+,S8"@#DDU\Z^)?VU/&GQHUVZ^&W["/@./Q;=P2&#4O'VK;X?#^EMW
M(DQNNW'7;'P>&&\9%>;F&;8++%%5I>]+X8Q3E.3[1BM7YO9;MI&56M3HVYMW
MLNK]$>T_%OXT?"WX%>$I?''Q:\;6.B:;%D":[D^:9L9V1H,O*_\ LH"?:O"!
M\1OVN/VS?]&^"VDW?PF^'L_#>,]=M0=;U2(][.VSBW1ATE<YP0RMD%:Z?X2_
ML->&M(\71?&3]HOQ==?$WQZ"'CU;78Q]BTTYSLLK3_5PJ#R#@D$979DBO=Z\
MSZKF^<ZXN3H4?^?<'^\DO[]1?#_AIN__ $\:T,>2O7^/W8]EO\WT]%]YYO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ\T^V_X)D:/\2KN/6OVR_P!HOQQ\6KD.)&TB]U Z7HJN#G*6-HP"G/\ MX(
MR*^HJ*/[+HU-<1)U/\3T_P# 5:/WIOS$^.,RPGNY12IX-=Z4?WG_ (.FYUEY
M\LXKR1S/PQ^#'PD^"VB#P[\)/AMHGANRP-\&C:;';B0CNY0 NW^TQ)/K7344
M5Z$(0IQ48JR78^1Q&(Q&+K2K5YN<Y:MR;;;\V]6%%%%48A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7X@_\ ![S_ ,FL_ __ +*!J/\ Z0BOV^K\0?\
M@]Y_Y-9^!_\ V4#4?_2$4 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\
M*4S]KO\ [>/_ $^3U^_U !3+F9K>VDG2W>9D0L(HL;G(&=HR0,GIR0/>GT4
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M7$U(PBNLFDOO9$ZD*<>:;LO,]+H) &2:^;O^&HOVMOC:?(_9C_92GT;3I?\
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MS*L8S_#N93W%?3U%"RNA/7$-U'_>>G_@*M'\!2XYS7"KDRFG3P4?^G,;5/\
MP=)SK>J]HEY&#\//A9\-/A)H2^&/A=X T;P[IZX_T/1=-BMHR1W(C4;C[G)-
M;U%%>A&,8148JR1\C6KUL35=6M)RD]6VVVWYMZL****HR"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OQ!_X/>?\ DUGX'_\ 90-1
M_P#2$5^WU?B#_P 'O/\ R:S\#_\ LH&H_P#I"* //_\ @TV_Y2F?M=_]O'_I
M\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH POA=\2/"7QB^&OA_XM>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU#R?#GBW9I.M[VPD3,W^CW![#9(<$GHDDE?)7_"R?^H+_P"3/_V-?4O[$?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXQ9_QUP]6RS/*<)OVBJTIQ7(Z;5TX6UYH<DI)7]Y.S<I=+=%%%?0GY"%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&Q/A35O!MG!:ZT);:1/L,T@NAY<<V?*9L_*KDG.,4 ?JC1110 4444 %%%%
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M_P#@!\,K#3M5CC&I>)M4-U-<W*AP1!;^9,[LNX;I& QP8NQ-?K)7P?\ %O\
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M^W?JFDV4O^N\-?"+3$TF-!W47L@,[J>F&7I]:Y/[2]K_ +O2E/SMRK[Y6O\
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MFNO_  -GU"BBBN ] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?K>DZJ[1Z=?QS,@RP0]!0!:K\0?^#WG_ )-9^!__ &4#4?\ TA%?M]7X@_\
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M_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\
MY\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
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M?_SXP_\ ?H4?V=I__/C#_P!^A4U%48$/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ!_X
M/>?^36?@?_V4#4?_ $A%?M]7X@_\'O/_ ":S\#_^R@:C_P"D(H \_P#^#3;_
M )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@
MHHHH **** "BBB@ HHHH **** /"_P!K#_DMGP/_ .Q[E_\ 29J]TKPO]K#_
M )+9\#_^Q[E_])FKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OQ!_X/>?^36?@?_V4#4?_ $A%?M]7X@_\'O/_
M ":S\#_^R@:C_P"D(H \_P#^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG
M[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** /"_P!K
M#_DMGP/_ .Q[E_\ 29J]TKPO]K#_ )+9\#_^Q[E_])FKW2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ!_X/>?^
M36?@?_V4#4?_ $A%?M]7X@_\'O/_ ":S\#_^R@:C_P"D(H \_P#^#3;_ )2F
M?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@ HHHH
M **** "BBB@ HHHH **** /"_P!K#_DMGP/_ .Q[E_\ 29J]TKPO]K#_ )+9
M\#_^Q[E_])FKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGP/_ .Q[E_\ 29J]TKPO]K#_ )+9\#_^Q[E_])FKW2@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M \%_X=U? _\ Z&[QW_X5\]'_  [J^!__ $-WCO\ \*^>O>J* /!?^'=7P/\
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MT?\ #NKX'_\ 0W>._P#PKYZ]ZHH \%_X=U? _P#Z&[QW_P"%?/1_P[J^!_\
MT-WCO_PKYZ]ZHH \%_X=U? __H;O'?\ X5\]'_#NKX'_ /0W>.__  KYZ]ZH
MH \%_P"'=7P/_P"AN\=_^%?/1_P[J^!__0W>._\ PKYZ]ZHH \%_X=U? _\
MZ&[QW_X5\]'_  [J^!__ $-WCO\ \*^>O>J* /!?^'=7P/\ ^AN\=_\ A7SU
MY9\??V./AGX$^)GPP\-Z'XJ\7FV\3>*I++4C<^)IG<1" N/+)^XV1U%?9M>?
M?&/X,ZG\3?'O@#Q?8ZU!:Q^#O$+ZC<PS1L6N%,138I'0Y.>: .&_X=U? _\
MZ&[QW_X5\]'_  [J^!__ $-WCO\ \*^>O>J* /!?^'=7P/\ ^AN\=_\ A7ST
M?\.ZO@?_ -#=X[_\*^>O>J* /!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO
M_P *^>O>J* /!?\ AW5\#_\ H;O'?_A7ST?\.ZO@?_T-WCO_ ,*^>O>J* /!
M?^'=7P/_ .AN\=_^%?/1_P .ZO@?_P!#=X[_ /"OGKWJB@#P7_AW5\#_ /H;
MO'?_ (5\]'_#NKX'_P#0W>.__"OGKWJB@#P7_AW5\#_^AN\=_P#A7ST?\.ZO
M@?\ ]#=X[_\ "OGKWJB@#P7_ (=U? __ *&[QW_X5\]'_#NKX'_]#=X[_P#"
MOGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\ 0W>._P#PKYZ]ZHH \%_X
M=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ]ZHH \%_X=U? __H;O'?\
MX5\]'_#NKX'_ /0W>.__  KYZ]ZHH ^,O"?[''PSU7]KCQ;\*+KQ5XO_ ++T
MKPK87MJR>)IA,9978-N?JR\<#M7J?_#NKX'_ /0W>.__  KYZ[GPY\&=3T3]
MI+Q)\<9=:@>TUSP]9Z=%8K&PDB:%B2Y/0@YKT&@#P7_AW5\#_P#H;O'?_A7S
MT?\ #NKX'_\ 0W>._P#PKYZ]ZHH \%_X=U? _P#Z&[QW_P"%?/1_P[J^!_\
MT-WCO_PKYZ]ZHH \%_X=U? __H;O'?\ X5\]'_#NKX'_ /0W>.__  KYZ]ZH
MH \%_P"'=7P/_P"AN\=_^%?/1_P[J^!__0W>._\ PKYZ]ZHH \%_X=U? _\
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M4 >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\
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M K\0?^#WG_DUGX'_ /90-1_](17[?5^(/_![S_R:S\#_ /LH&H_^D(H \_\
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M+7BGPC^SSXI\22_:IYM&34K;1].G+MQ<10W\T^W^$B$HH$:H!U7[=?PRT_\
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M^K\2WEF=4M86.GABRQ0V6;:&/"J/O,0#[2HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "HTN[22X>TCN8VEB ,D2N"R ],CJ,UC_ !-T'Q9XJ^'6
MN^&/ GBX^']:U+2;BUTO7EMQ,VFSR1LB7*HW#M&2'"G@E0#QFORL_P""HO\
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M#D?7O OP^_X(B_&'P?J/B/3]-:\T#3+#0K*\O4CDNV34['$42L096"C)"@D
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M\$_LZ_!/PC\ ?AM9O!X?\%>&K'0]%BE8,XM;6!((RY &YRJ LW<DGO75T44
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M3RJEAH.A:5>W>I:7HMI;7%_()+ZXM[94>Y<# :1@,N0. 3GB@#X(_P""A_\
MP69_X)_?#[XP:A^P1\0_VSM*\!S+:[?BEXBLA=RW6FV<@(;2K.2TBD,5_,OR
MO+E3:Q,S B=HMO$?MQ1_LZ?\%F/^"+'Q8^ W_!+ G7=(\ 6VF6_@>71M"FL-
M/GO]+:VO?[)L4G2-WD6U5(@0@C#W,0#L5<+^G-% 'YA_\%0/B3X)_P""N/[(
MWP)_90_9S\1V>MZ]\8OB)X<U?Q;H^FSB2Y\*Z#9%KK5KJ_C!W69MI46V*2['
M-PPA WY _3RJEAH.A:5>W>I:7HMI;7%_()+ZXM[94>Y<# :1@,N0. 3GBK=
M!1110 4444 %%%% !1110 5^(/\ P>\_\FL_ _\ [*!J/_I"*_;ZOQ!_X/>?
M^36?@?\ ]E U'_TA% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7\GO\ P2[_ ."P
MOPV_X(]_\% _VBOB1\2/@[KGC&#QCKE_IMM;:'?PP/;O%JT\I=C*,$$'&!7Z
M"?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S
M^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS
M_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$
M#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"B
ML?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH
M _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;
MZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-
MY_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_9
M9_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ
M[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_
MX45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X
M4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S
M^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS
M_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$
M#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"B
ML?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH
M _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;
MZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-
MY_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_9
M9_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ
M[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_
MX45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X
M4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S
M^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS
M_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$
M#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"B
ML?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH
M _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;
MZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-
MY_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_9
M9_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ
M[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_
MX45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X
M4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S
M^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS
M_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$
M#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"B
ML?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH
M _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;
MZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-
MY_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_9
M9_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ
M[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_
MX45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X
M4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S
M^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS
M_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$
M#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"B
ML?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH
M _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;
MZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-
MY_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_9
M9_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ
M[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_
MX45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X
M4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S
M^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS
M_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$
M#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"B
ML?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH
M _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;
MZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-
MY_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_9
M9_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ
M[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_
MX45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X
M4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S
M^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS
M_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$
M#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"B
ML?\ "@#]OJ_$'_@]Y_Y-9^!__90-1_\ 2$4?\1O/[+/_ $8]\0/_  HK'_"O
M@/\ X+Z?\%]/A%_P6$^$7@#X;_#?X ^)/!T_@[Q)=:E<W.N:G;SI<)+;B((H
)B&001G)H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mrk-20201231_g2.jpg
<TEXT>
begin 644 mrk-20201231_g2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0C:17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S #(P,#@Z,3(Z
M,3@@,38Z-#DZ,#$      Z !  ,    !__\  * "  0    !   "S: #  0
M   !    D0         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   >D
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ ( "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M@   .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M  D           $ .$))300*       !   X0DE-)Q        H  0
M   ".$))30/T       2 #4    ! "T    &       !.$))30/W       <
M  #_____________________________ ^@  #A"24T$         @  .$))
M300"       "   X0DE-!#        $! #A"24T$+0      !@ !     CA"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -)    !@              D0   LT    * %4 ;@!T &D = !L
M &4 9  M #$    !                          $              LT
M  "1                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  "1     %)G:'1L;VYG   "S0    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    !/_         X0DE-!!0       0    ".$))300,
M  ?      0   *     @   !X   /     >D !@  ?_8_^  $$I&248  0(
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M6M24_P#_V3A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
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M4%!,     &YO;F4                    !  #VU@ !     -,M041"10
M
M!6-P<G0   #     ,F1E<V,   #T    9W=T<'0   %<    %&)K<'0   %P
M    %&M44D,   &$   "#'1E>'0     0V]P>7)I9VAT(#$Y.3D@061O8F4@
M4WES=&5M<R!);F-O<G!O<F%T960   !D97-C          U$;W0@1V%I;B R
M,"4
M                                                 %A96B
M  #VU@ !     -,M6%E:(                     !C=7)V         0
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M# P,# P,# P,# S_P  +" "1 LT! 1$ _]T ! !:_\0 T@    <! 0$! 0
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M\_F+^5BIY<_YR9_+&\MM:M"B7&MZ9 UHTB%Z-*;:2JM04-%*Y[^_*_\ /O\
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M)=ZA>RFBQQ1*68GZ!L.^?$_\O?-?GO\ YS9_YRFN]4M]6FTK\L?*CO-!%$A
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M&42Y,#!R>8H"UPR@ ;T'B%KGV8M[>"TMX+6UA2WMK:-8K>",!41$'%54#8
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MC4_)GF&S\PV5I,UO=2VK\O2E1BI5U-"NZFE1ODPS9L^9][J,WF/_ )^#V=C
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M75_,MQ:+_A[3M/N8KN<O,0!(T<9?CP4D_&!N*82_\X*_FS^8/YT?E!JGG/\
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M >IQ]F!#4[5IVSLLU_8V\\-K<7L$%S<@FWMY)%5Y " >*D@FA(Z8+S9NFYV
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MX*A(V\?'/=WEC\LO)/ESRA9Z#^A;2>QDM(GN[F>-:7!D0.7Y$;5+5%,^*O\
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M9Z>_YQ^_Y^-?EKYWM=#\I?F]<KY!_,J7_1K^5X9$TJ:930$2M4PLW=7%!UY
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MZ4.^?.3\G/SS_-W_ )]\^?/-_P"7/YB^2[G6/R[N;XF/1HJ1R"2O$7EE<O\
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M7/D3\QK!--\]>4M+\U6<53!'J-NDS1DD$F-R.25H*\2,(_*GY*?E-Y'NUO\
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0;-FS9LV;-FS9LV;-FS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>mrk-20201231_g3.jpg
<TEXT>
begin 644 mrk-20201231_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0G64&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              )P   +     & &< ,P R
M &@ .0 Y     0                         !              "P
M)P                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     !SH    !    <    !D
M  %0   @T   !QX &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  9 ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MB5MJR+,5^[(RG-&VRVNYK:_L%&39NN?8WU,^SU/^T5J+F=!'3_JYU;!Z5O\
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MJ_\ /[UU"2E))))*4HV5UVL=7:T/K>"US' $$'EKFE2224__V3A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  V "X ,     $
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M 0$!                     !   00#  (! P($!04     !@,$!0<! @@
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MPZ&SB:[;=/>+2;_8<+A%;TT,T%O5%P6]=2.A&Y-N8ZZL G?KH;?$B4VE#_W
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M@5>RC];1&#!*[K\-@&JKUZX^PV3C8$>@XQJGOOG&FJ26F/X8_7P*^$>2%_\
MR#["* YZ&6)4?INHJS)49/FQ8F4U;;WL,NVL"!9LL#.X'&T25@7+U=$C)-Q+
MMW6&,W*3C1%JIJV>-7B$.%B4/K>O:]$!FOP0'$@X%"VD:Q$ \:'HJ%&AEI#)
MZ)1*$%"Q[5"/B](Y-/7"/V4],I_'SCXSX&:?3KG;&^==?KUUVUUV^,?5C7;.
MN=M<;?QQKMG3'SC^?QC_ *>!]\ \ \#KNVC5^U<L7S9N]8O6ZS1XS=HIN6KM
MJY3V1<-G+=;7=%=NNCOG3?3?&==M<YQG&<9\"+-R\*\:]!QR,=<7,=*FRC+.
MBD-//  ?CC47<I9WRE(!A_",XPW"95+"JFNKN)D&3G713?7"F-=]\;!__].U
M=S8&>G$9Z8,9;EAYP8YZW*WAG)DB56GM.EMY-5,$\ZM8:<-"QA%-%X9%_P!7
MO7V)II%(,6>7VNVKI/[B6N- :5X!X%?K@WIXQY)YE >/XOESI/J'-5,BP6XZ
MNGF8.B+/YGZFYF;34](\SG;7IY@5.*,JB0>UHO%1,XW+")@JWDF:SMMEXT70
M4W!C')X'/CYJ;GO2II64]W%;0M!EAJ!!\]%RO]B*#T(2-&L*6K_1=K#E<Y5P
M60+2R;HK=1S'^KBO>1>[)-T]6L>P"=O@'@'@'@'@'@'@'@5C+_([2[MZBL07
MZ70*N,N,Z!OIQ3E<DG3HA_9RM"HJ@YUJ.C=\5-(W T&!_HWI"\RC]R95+EK^
M]!5<C;+!.JC(%LC#Q[4+#%"Q%+C]-5M <ZJA;BCX03BXBLEZ\G&1,'+"L:C^
J$Q5A21A(2R! FIE';*S[9TY6=N,J*K*J+;[[Y#;?@'@'@'@'@'@'@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>mrk-20201231_g4.jpg
<TEXT>
begin 644 mrk-20201231_g4.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X19,17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    F    <@$R  (    4    F(=I  0    !    K    -@ +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$P+C @5VEN9&]W
M<P R,#$T.C W.C(U(#$Q.C$Q.C0Y   #H $  P    '__P  H ( !     $
M  + H , !     $   #9          8! P #     0 &   !&@ %     0
M 28!&P %     0   2X!*  #     0 "   " 0 $     0   38" @ $
M 0  %0X         2     $   !(     ?_8_^  $$I&248  0(  $@ 2
M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(                  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
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MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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M_2G]NOY+_MS_;?___^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _0      !( -0    $ +0    8       $X0DE-
M _<      !P  /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M X<    &              #9   "P    "D 4@ @ $0 80!V &D <P @ &4
M; !E &, = !R &\ ;@!I &, ( !S &D 9P!N &$ = !U '( 90 @ "T ( !W
M &@ ;P!L &4 ( !N &$ ;0!E     0                         !
M          +     V0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    V0    !29VAT;&]N9P   L     &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -D
M    4F=H=&QO;F<   +      W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3004       $
M 3A"24T$#      5*@    $   "@    ,0   >   %O@   5#@ 8  '_V/_@
M !!*1DE&  $"  !( $@  /_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M                  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 !_^X
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M^K?3NN.QCFFT#&?NVUOVMM8XL?;B9+2'>KB7/HH=;5_P2U4DDE+ !H#6B -
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MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0      >P
M  $!    & !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $4 ; !E
M &T 90!N '0 <P   !T 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !% &P 90!M &4 ;@!T ', (  Q #  +@ P     0 X0DE-! 8       <
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M4D%96%E:( ?/  8  P       &%C<W!-4T94     &YO;F4
M       !  #VU@ !     -,M041"10
M                                !6-P<G0   #     3&1E<V,   $,
M    :7=T<'0   %X    %&)K<'0   &,    %&M44D,   &@    #G1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DY($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A
M=&5D+B!!;&P@4FEG:'1S(%)E<V5R=F5D+@!D97-C          ]'<F%Y($=A
M;6UA(#(N,@
M                                                          !8
M65H@        \U0  0    $6SUA96B                      8W5R=@
M       ! C,  /_N  Y!9&]B90!D      #_VP!#  8$! 0%! 8%!08)!@4&
M"0L(!@8("PP*"@L*"@P0# P,# P,$ P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  +" #9 L ! 1$ _]T ! !8_\0 T@    <! 0$! 0
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MD=U;A\/+[/J+]K.+_P#.%'E@1:5YA\S.M#=31:?;$BA"P*)I:5)^%FEB_P"
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MR" "C*'D+GCRWV"?\,V3BS_(3R/%IT5C<12W*0@A"7*E>7@PH1]!PSB_)?\
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MGVO'U& Y.SN0JHB=6=F;M@#R!^9WDSSY:75SY:OOK:63K'=1NCQ2(9 2A9'
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M;GB?4FM>%S 7%*\02DB@_*3##5/^<S?RRMN2V.GZI?OQJKB*&)">M"S2\_\
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M4\E>5Y+O3[*QN/JL5OIBL+VYEC6C.9(.4O%ZMPCC9/W7#U5Y9RS6/RN_-O\
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MB_)S2KM+I=$:\FC*M$;RXFF52N]2A<1-O_,C9U*"WA@C2*!!%"@ 2- %4 ;
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M%[JRW_ERV?U19/&1,Y'V8W/V"JO1N?'XOY,])P6\-O$L4$:Q0H J1HO%0H%
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MFZ</'IMS:@#^[BO+@C;_ (S/*<C.K?\ .&'D:17;2=:U2QE;F4]8PW$25^R
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MG'_.O_.&VN1ZM$/)]\DVFR@!_P!(O22)_=HDHZ#_ %.7^MGHK\J_RXTO\O\
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>;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>mrk-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrk="http://www.merck.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mrk-20201231.xsd" xlink:type="simple"/>
    <context id="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a69ae5ef81348d4b09b8c83b9741937_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.125Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib21d7c48408a40228dbaaa754ce181ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id93e99ad3baf40e8aa1621b924a2b8b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if42c8fd57f9e4140bb466d7b0aec1493_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ce73055eb814c269b6620f3c2a24a2e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i525fed88e739475e9bdd2c20f8225d78_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ia25c4a8026c741e390c5f222dcb409cf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i16ad2dca7dc9466c926cfba76668c892_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if65645d9ce3443819f0f193e3bf67acc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i530838b57a7f40aea997c3c0d8eafce0_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i65d876890752448da45fd177f909c525_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id57393189447424cbdff690d6eb86857_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id7a0cf6a00f14978ae5b1e865e6c3e41_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i93f33a2e859a4576a7e62ef19bff98f0_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5c3f97c0c25247749fef8b6deb546624_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2e100303069b40878e0e19c66282b95b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i057a5c09a76d4467aa5c101819252a07_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0acb90ffdfa0455fa5f6bad3cc955686_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="icb3e6a049ad240ddbcd87576b751ad64_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i84af4bb4ea9e41b5a3bb5245f8f322f4_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id4872f4e47894212bbb218c64e39c4a7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie2ccd612449647558e0d8cc5f0e5305c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifb0a1d042d5e4a5ebb0664bb2c15ebf6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i67131e7c55f84174b370dc31e7893725_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibe17ea10ec2d46f9aac4bca5f67dd3f5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iae2e6ec2ed8a4ed5964f5012a0361b21_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i67b4b127a8884ff190bb26aefa784be3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if472f36dd37249baacd8179c8220ecaa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3f70c8d1831f4f1fa906b5a243db58b0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0ef6045954534437abb1993aa1937f07_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i763fc5648968415f92f38b504b93bf09_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i17941d3435994547bd0f648e9860112e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i009e5e7a34934b2c8895d34fdb93faad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6c92792b11148c6966e23a7b3c4e4e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0896f4b9831541ae8488b94c4eae2335_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1000caf1ca924d2e859d474fe4e47375_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8fcf60e98e4e4e8b96733cb145c00b95_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i090793285fc448169b5f2766fad90f7a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia612eb926af84202b6beec26340d18cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6b305782607415cb6a709c71a39dc73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b68c915866b4394b86d1d387ad993a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07fa82e04dff4428aaae1017c07a4108_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96312e064b574ffaa9f1c3392694a627_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb3e65989c80429e8fe99db11d1d76ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id94362b387b441469ec50222fe704479_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f0a54f787d549bab0a21ae47e9740ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i433792a99d134359b4473b0754e16132_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie09ace19fb574f50904349a9da836610_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice647f7217ff4273a045f1876ac8bbe8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b572de2338948dd96d08b22dd4171a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72b8afe3fe844c02ab7183ab38cfe809_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i953fcdd3d90e447480d218ef6e31883b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee629d83621d4a4cbfa8f64a6cda8b18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0fddbf63ffa94c619baa9b05476b6c33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2ffc6813f6914b38827655a976cc9e74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a28618800c243e9a9a56cb43ec76314_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib7ae7baf3bf34777906747207fd9aa2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78b12aa625c44405b0d39ee793eaf417_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1033319c2914559931cb908a21c6d0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58165389de634c2cb2c0d3e8bd443866_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff425d31a4c6439287e6017923a0069d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35717a97f0d5480bacc494c9ae0ae49a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i738d85dae80e42aaba01188d809878b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ce1d972df3a4822ad7fad1e42f1b354_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0d7b698e30044dfb6cffe1fc04d9813_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3fa7c6d136f41a3b40cca31c266c6de_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib175c23599ed49f9b1a462f8b563aac4_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb2ee89502b94cd49ce08e1e3c882c21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fb9fe46e2d94d4ab49c1b03fea4519d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib773c56e9fab416e9e0d022601d5ce4c_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98ddf3aa69a84aabaecb0a4d2ed8e2b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i528e4f9a522448139a618d9f8e9aa62c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0243fd5dacc84dfa85f4fceec13fbf65_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i40ca48bff51949d4bf90dd5e362d3f56_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia34ed105cdff4df1a7d378c513d91380_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59fbc25bfc7641aca2fdbe80413efad3_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02313044742341b49e06fa6a758966bb_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i209f5888fc6749a2931c1615385b0e25_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i73d37bdc4f354e69b8bcd53b246297ec_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie7690d5c0cc347ed8b222d4300b23e30_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b12110871ee41ee9868a579e4bbf80e_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idca8cca7b4e4487caad2c748e715f6e0_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4224acfa30774326b05925533ba77ee8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i610b6867a103424f8f050100dff9795f_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i9d1781ced27c45cbbbf893095d8cf6d6_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i4f3dc7254c8544e48303d0911c527606_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i03f79093ce234ffb8ea77c30f545b9db_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i5d9ba64de11e407f98dad1bd9112b382_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i54d078ec4ada42c9ad9804ab857bdb70_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6d9b918e005a49c58a372d8e08c8ca72_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i945ab4055e164145a085c5b93e7c531b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99b9bcefa984431da58d2e033612d715_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f84cb29fc604ca6b0af582a6e9be121_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2dedf39dc8524bb497923e4bea2c9e1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1e411be978c47beb7efc4b35966b7a8_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:IAVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36680a86aa854fa98c2457cd53911551_D20200116-20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-16</startDate>
            <endDate>2020-01-16</endDate>
        </period>
    </context>
    <context id="i8908727197fb4c19a64ffa96d563a2bc_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="i0d2cb7efc4324a38981648aa89ddcc18_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="i07f15f684a9f4e1da581924f2c98bfb6_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i347f3eb2160e4032b140b2fdf9799106_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i081c04d8d22d4e03a143a335398bd927_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:CommercialmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="iec9f0c316ec4420c85c71329dbb4ad02_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i8341e9d08ff14983a3ef4b4dcd949328_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="ib4d11122b7294a4694e482424ef3b691_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida918a35a96d497a919b2f7b5fbb9713_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i29f6fdbabce3486cb4cfe03f8f281390_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="i5d04a426e1da4d6ca4a2b650e191b1fc_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="icdb01ee2305f4539ab9c5f07db7173e7_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i996ba4f2c0984b8cb870df85ea16273f_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="i485e704327b34e818bc08bad5c4a5d97_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i2da5d31a2da043428a6be3a178933283_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SamsungMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1f7489b20f5c48308b9bb04baf6a39d6_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ViralyticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i26856c5ef4364f19bff668d3dfeed68e_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ViralyticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="iefeacd0e5f5842dbb109b127cdbe7f72_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ViralyticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i22a33fa403504dada396f58875c9157c_D20170701-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="ie2b6640d40ff4e1799c205b35e73ced7_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i45f6bb982b5943a1bbbe16a8ac755b27_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1d63658c728d4ed98637396020df1f7b_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i620af11cbb8f4c91a858173de9d019db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6c051937aae495b8e9e5625eae66971_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1cd91baf9509462f81a3d9ce3a0cc395_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6419d35ddb6b4e628eda2d42348e331a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic26c0f3b7f0544268df9ca7c0d8af913_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42a16518bdec4e709a2954f61afd02f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i878da9d0c0714be2bd5756cb5d5e834a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba602abb2d7549c19eab5306b4002102_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0e966186f72a4b0ab58ea90de20ec66a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i290e0168aaad4d8bbb291ae388c991a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7885d0aea044a2285bce8f3e73dfff2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia32a30c39b1b49b5b51cfcea80332547_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d315dacfbde4501ba6c19d08de524d2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i07de5c0f87bb4cbb837704628b2bd9e8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i44cccbfd1aaa4196b45c4d6ecaf6cf96_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99a073f8f7b1407aa63ab374b8f4b9a0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i330b41f19cde4e878a6b9d06b389bb53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i401735563ecd4f6e8f401746036baa9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ece84cc7606444390554357bcf90179_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4fd756807e314175a880dd575077a4e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i697fb80f1e6e4a91ac61fbdcad18f9cc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica44f5e5fa844b15a4879fab9631e48e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6a10731ee0b24e8db15d8038662bb511_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4de09b10a2384c05b55e43c2f74660f9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b5af579547c4a299bf5671d6d56b6c4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i70b51d3311034c3bac51a0de70567e64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9be4fde20b284f118e551ecaa1276e5b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4fc12f18f7224792ae5dcdbaf054352e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0326de13695545ddb2210521908c117c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4488c2e1f5c64819bf4b59fccdb0e9d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0adede01333549d8bc322abf9e22e84f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica3ea97cf2554f1d8815cc085464ebc4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11173b2b42d64d0cb11c1105fb2ca7d1_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ic2173fc8dee04c56aaeb475acb7c7018_D20180301-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i199ae1c6ff6e448eb1085cdc50ff93f1_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9be5634cf9e3423d903fb59b51dfffc9_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i302846733a5e4162a65e06b042b6c625_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i884fede8f02b4207af70ce8ef3e7719a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iea8401099a9d4f1da0c09f5e4a845f53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie652d13a7772491b9988fe4ca0cfc66e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad6bc081967747b58d1b8d8f5af214b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iefa940ebb76b40afa60a15a108b7af2f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic341c5bdad3f434ab0c54a2c5e63395e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f4920692eee4e4d815006aacc7d78b3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i36f9356746cd4c6aa273dff749ec985b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4443e6b872f4ba8905276b85a6342e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i491d903bb49f4ed1a82e1b5a703ac09b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0400fa9e2d64e50917ba83f9b0256bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia245619b9e664a26b6753a23646c0b18_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i454f432bff4c4574930a4219c0b5c005_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icaf4d70ed271480fa94afe6dd9a2000f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b505e290fea45b99717b674adac2691_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifd9d776541aa4ae082408d286b415f75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b435415c6274d44b0dd2ae2de7d186d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic7fdf3938156482ab9562725eb331768_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaab203463d1344f2b6b7b49ab329c80f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7570f8d4c86b4b70ae7e83bff83c5ff5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i440fbf44eff94d33beb60677f2144686_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i96a84ffaafac460fbd68e4328f87c599_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d2650552a454bfdac17540247c4ad9a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7041cdecd0cc482fb7f6996b7e09667d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7422cf6500bf43efb6beb9930ca4c6c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id4df60e0c1ad4ea8abfda1ae6df07058_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i283cb0fd0292451f9077f95aae1b4028_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i491ff105eeb74cc6979d2752383ad3e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61497bc7d49a49a8b98adf19ffa96211_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedff350d0421432989e5b4164f44779f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if2cc693bd8114433a7e7cebbe0e1a220_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ic5b17ae627674bfd9c3a3e606fc39a10_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i50171610356846629bd94e414c848b8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13429c0926e34225b226ce3b2cdb7e1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i897a73e11e48487f9d94d60f05fd9038_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2b8080482a8f4179b87efe70700d453f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i246836ba7661455ea504f59e31b98459_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d1c052cc4f74b61be4c309541e38a86_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1516d5f6bccc4706bf9051b3e301dca3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic6830421fe254ed988b3fe026bd6113c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i805d69de042e4086a978510f436a9822_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic6870f468772426088757f8a26d5a6e9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i593c3840adcb47bfb516fe38bcd2f1dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78dbe2e542714ef7a4f706598fae075a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i483c42968ecc45ce84311d03c17955f3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie47cee1fb9984770a9955c2c750b7a95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5318ed6e471f44528573063ca8254b68_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69ac791388574e7691237e3081e536f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bdad4b05278451caa2c67b1fd87b02e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i626dcc5c192746988b8441a68e30c032_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i191f68fbe0d14b05907bb1ab69c9f445_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i241eb84e414f48f9aacd4316e70bae28_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i406f377346f2457ab0d54b35df3d1600_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5a50fbb06094261ad5ce78fa80bfdca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id525dc078af8495c9e5d272e8afdb6e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id75a71a6eed4446ca55443b556bc6d5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ac627a818264bfea847b4e9fcf4bb06_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i309b4bb1ac054ea4a6873ed465501a43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91f1c852ca6946b889085c1d2eac8943_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i132c0ea6fd274dbcbbfe45e4bfa925ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2907e5468544c409931e7a4c508414f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie186fc5433844dd6ba21127222d4697e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d28d8d5240b476db71452abf822049e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f2d2fb55c0f461397ea5ac456124114_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a4dd366030a40c8942fc0ce87bb62fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5fcec778c1341728db868452426a980_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i44c2a7a188ae4476beca9dc90f2118fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id3c96cd074f44412a6ee38d6cfb5e054_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88114076b7514409b6d5d5c9d41eec3b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e4009b0313c49faafb6d57d35380369_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16991361b0704afcb1a08545a7ef9345_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0268c06921574bbdaf52522aad280467_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48e9a2d3136f48c5b13b1e298ae8df45_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibab50b716a604e0abfd1dc584019060e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1229966d621a49d0bdc08d199df3b425_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a7193bba0f545a0ba937a6de3f640ee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4f5ce19e15f46aeaf70c9fbe7e2be87_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i41552ef38afe4fba9be6c306a861bda0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e13eba63251417abb5c0ab7664c6e4d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83171e10413a49b188f9233c14af2273_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ab6726b526241b7af9e46ef03b526d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8d20764941a4d70a43d94185021fb3e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i303d422323e846809130057830f40fa1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i442a1ac9ec1d4a639edc93d1081da0b7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib3185a39a2bf49e2ae8b3d6395304e98_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i000067615c4c405d828fc57adc37155d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3a6ba62d3268488b96375548230f0997_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if85c8e6a868e4feba214cf64258745f8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icc85f9026150482da03c6e8b08d5382f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i56bac035ca3547929df24caa6baea983_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id7a886b5f1384f9e93e1e2055f773282_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i70612a50b7b04ed0ab9d05830ec20ad5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if5007327f71f42658a82bd6f754e52b1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i29303b1ae4084cc1a9f349ed8d5206fd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if8bb2d3506924e62bdb508461cb588a2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib7e3e97d3c08440fbd570966142c7671_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib4dd7b1ee8f549d5afc0e7f66c436a5c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia7ea083b872444e39abc9269525384e0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id9671977d7414c988b3c191e1c358988_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic66a0f6babbd4e029e67a8693588a68c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id0feec00e0c5476aab00efe202b2d98a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7bbecee173d84b5cbc3262dcf64fb42d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2de74f34845e4ec4a02ce6ad4c118345_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i31627d70cdc54331b46aac1bc8263b56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61f9cc96dc0b44a9b57239198ed1c72b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5a3afbed0fc48ef8a9dcbf1de6c8ca2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3da63b07e7034274b8cf4a20a267d380_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ee164ec487d47deab4a2cb367a6d6f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7a8fa9009f24eeaa07743fda8f3cd94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b4118cf8759442dba9e8fa1ea1b34d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i221ed400ff5c4bea9e2d3cf8e4a80a94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74f699b1657a4cecb4b718174538872b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ba11098240e441f8418597d2eaf880d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i430e6b977c1c4ef7a281ebd43d1dc672_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i02369c098d4b43f2a421a2218e9d32f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i06d5fda89074431f97565335e930712f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica0720d84e024817b305c556282b7dcc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iddec87a959fd4ae7a481edf7b41f776a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f7e3451c9c24858a05b98ed5defa565_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id885d560ad0848c6bb060989b08b75e9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i17f64eeff8ec43de9cc630344108c010_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibae253e40a0d426bbdb3f0cab3da9b51_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6b418fc03a0e44ceac8e72b427273960_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i44610560536947e69f16077e7abce690_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i9b47f492e4384e57a7069964eaabf6dd_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.85NotesDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ia88f884909c041e5a8334a8a11ec5b1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc6d538660a64a929760160006272b4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09b41cb38aa34740b1a603947ccefc36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i425ef8de5ab24cb2ae98743e10aff911_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a2e005cb1174aa094650f2d67119a34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifcba6eceb0784bbe830143aade4b1cb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb9d1e2142f94c22863ddaceb3677823_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5c598196c7c4f32b1024f98052bb448_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94bc6f83a1ef4f3fb5f4a5ba0339bfbc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b90c404414f4e0a961177cdf72dce77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib018b37155eb42059b22223b5da9a50f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf93915f5e8748a5b702271482140b4f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ad3e974650b43728fcd799e35eef6a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3739cd95e2441d399690968d9f5734d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i074470fe2c264f67899fe067fe1d0df8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i26449e4f0e6e4176aa31d97fbc42b586_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1f968bae9794c1fb41d0984eda03c04_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f98b3a13c41429d91995e92273e4703_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibefd44c960cd430e9696cd56751dc0b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i189cc2bba23447f08495ab8fd74daf9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b006db8f5ac4d31aa4182239c7ce684_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3c27f7451db44bf808afb15b4e436ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f4e1f66a9354462a9d22b56d9240389_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea7a599f496545fba9341a054b669c26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d1a474906bd4f89bf006e7bc9fe12be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c22c5b30fa04d829f43ad58f4fe0781_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a3168f8864f4f08853f9c776e12e5e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i47b004e801174cc4a3f896b5ed79a5e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i686e5291737847fda61bb04fa2bb680a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2bc89ac3e3745259da485c0e123fdb6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia60742cd64004ea490a84445a5be282c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ab5c661a48b4562bbbc071a962b540e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iab64708b390a456aa95dfe12bee43bbf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf6219e2385d4b37b8a73d0fea710bbf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f228e2c11eb477aa93be52424102e54_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i34a833d327f8451596b0800e5d644c7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17a1659884f848f5aabd436539f2bf47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if1c1f1933cbe418ead09d219d10cabe4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib96051c5103e4b92b51fcc3dabaec98d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9756dfe40bb4a4284b0062e05aefad9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98079bd7917c45ce82bcf778574127d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic8d9aaa6d14d47c08624bcb65746c4ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92ffc89462f2430192ac1ba5cb28f8cc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i157e712600dd4995a5373a06637c27fa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0dedde47b1a347a0971fdd6194fcae67_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8af59371761f403683996b2f9e8ed882_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i248775075bc545c390593609d97824a4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if2b72497910f4f5b8362034975eafe4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac680b79731d4242af1965a13712ffcf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaf79a13e56b4dacb00d6c54493be948_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0c514e2dbdd434aaf832d950c66924a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4120124e4b9b4d7082f37a0ec3592298_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc62c243cd0e4d5686c1f797407cf679_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1cd51a21a4b0451281d898defd8ebb87_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a43afc3c18842a8bfb574432eb8396b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99f107554e5944c88d03135cc0d5646e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9bd171f0c0d4bf7ba9049b6fe49d4e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51875e63a23141e799f3c721b2e98c35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97372e9ec431481e8d2ad41c37299b60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9818f3ecec9d4b5da3c91600169a5ea9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5099d5a15b8741809c09bd89ce675d38_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i449d46bca2a640e3bf828a985bf5b6e7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74f95efcbb854b47837ed0e30678717c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib0eb091d5f2d4f76bfd8bf94afcd2d03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1d003a9b64b24e768af4f068b938a189_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d6bc76e46da449c9f8e5b9c566ed471_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifca9ceeab0e241baa78dca85e021d03b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5979ae1b6734b4482a704ad0292fd9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4889e793f60e4d05b6ddd2f8025a83f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3019315f797d4f6da1bf695e1d0e2adb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f168f035dcb4b52b45a1f046f60c471_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i678944a90428428ab1d1f74e0f90e565_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86760add50e540c9915bc96dfade2cd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic305af5c5eb64be5b8250cc700e82e3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9480f02ab9e4065aeae4c973801cd09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e6378f9682e49e986ad883f181e19c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id61514cbea7e4ef19f040db41edfae2e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i581be677b2e04a02926271e7f77db17e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibbe2de3ba6564509844cdb877e313935_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f126cdd894e4acf97878c636bbdca1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8493f72d249346a0be32eddede66afca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01ab1f5da5bd49309c4078402b7bc49e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40443158b83241babddbc35d611fd36e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a9e331ce86b43ab95f546a5ce865a32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77a51ca67bac440cba8e01beb97c8d5f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7788d5f200f54b93a9c93e43368ebea2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f6c5c42bd2346b1abb083ce9edcfe4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd6b30ab1c0a4434bbad28238f32d3d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibaf6232f74fa41139923e59a424dc61f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id12d18ccfca34d6bb8faff8660c8a76a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2128132540244319b6739b88b72e0cf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i403305af9ece44c9b22ee241dbf53d51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec3c8f6c78f649b2b6d8249918906936_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2903ba97df754b6ba63aa316be7a875b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i49b4a3504a044aa29ba5b89de4a75a7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i02029bf2987943d7b527f9fbbfbaccac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7f02989f1094e35a4db4abadae73636_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83c58a9e62e44be893953a1c54696515_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e8a59217086413e83da0688d9c2171d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81a6a626d7d64f7f815bfc2849d97a81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e33912988a248bc8246486df6397715_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iabecd6bb38834f98b4af258e1624a7d1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8acf6daac21d4c88a48854a1221633c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i517c433fbeac4a0d877922b89aa5b92a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6584b76ba97e4e2d92b394330f179c16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0c5289be2704fd3939c74e58673fcb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a7496836c554c4c8e7d708f7cc69249_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b3758cf682b409f8450b04bc57aa0b7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd74ed33e96944c3a04c8497e2aceddb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia72079f482c740f3946c8e6aa0108539_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba9bae92903b40b180b8db555d0dc4af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieac0d630db304c5fbb6b0d1dd4b0fd96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b97df8525e24037aefcb485eb08406f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8aaa816b38bd47f2a17d32d765b2fb2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i831b4ecbf45d409481738e9647f09306_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4aa9ea67d9f463dbb092452343a4414_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i00919146800d4139ac109a85dfb7d711_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib8999a38e79d4363a379eff3d701a62b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9295a488115f4c68a8e8c1703fb43b33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i240370941e09472fa67b09378158fe7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e355174746e40ccab1d3a022356179f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04293f756da241a999ca08cf5205814d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5454937046f471eb2aeccd5bdb66a94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i512cc6f095a04b919b00809dc9264562_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i860f8c1284824650bf9be85917582840_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3923a650ec254483b01b7e8e723eace4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic00bd05172e849cdb1c49805feb4ff31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52894ba21b534bdfb980886fec594cbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i388f19daab3349fd94f8e901eebd7ad7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb53e8019d3444a183fd939d626283cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e91fa49f38046778d905adb20038b86_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77a9ffaa8ff04b0db0e23fb174f64775_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec6fe4bb91db47469413570dc5792607_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecf40c6bc57a4a96acd2a20797b47feb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if05886a9b13149dfaff74f75da70ff5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a073eb825fe4210b901ff8c5229ca73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i732691c0edd54472919c517d2ba0ba90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a7a41aa57ca40e6862b37e8bdcf31d5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadc7c95447cb4b7394d986bbf3eb4737_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66640b35975948b1bb6102116f2f95c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c736b947a254ac49c79561ae499a87f_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad9160300b5a4225a05fdc2ad5bf9b30_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id3b3b680e1b34262aaaf5bdb274dafa6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e5ba2a7e59e4ea0bf92b13e77d6584e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0100533904ac46ef9b774bc1b666a843_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04309b24f07b4666a134a9d0f656e644_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i532617148a464d439523456b08377125_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3e5e6f127527444d84707fb30170819f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3b6e48a8195a4472b5f2937fd2336c6c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4b686d23f6794c68a37ebff0a13d5324_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i58799cd60f0b478798fb7372e4698074_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d31fc70051c4a68858b153d5a6e84d4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc97187f000b4d789b7229ce5f27da09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15819e1b053545a9bde3e98453b6f6db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a204be8a7764bf2bc2bc61353ea4e61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d0372a4dd384371b56eddd9bf14f331_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if73dd2ac8807408f8a19eb712e8ff82e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cd8d36d804a4f318d753989188298a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0929727611f46b9a4fabbb67f15cf52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1150b2b45f4f4e73994ea0b6ecf39132_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a8e2e9cbed5405c909c9467c786afb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifaad2db9e0af480e9820c25f8d39bf48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c9ed711cabf40539749dacb49e1f568_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iced3a5a3165a403dbf79ac1d619c977c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3ce2a6386134b23bed761ddc429d6f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5af2e1d785f64d9b9574fd6067247ae4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4e2529a81fe48e2af0847da14387edd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46ece120a22b4a28ae57b244c672e267_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85308ed5ebab473ebc2ea2ac65fa9e3b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie066b7e11e1642829a90d72bfad73dbf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c8737f47e0b428ea8e395b4b91b4140_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1173b6885a2f45998fdccfb8d45d893f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f8b5fa2afe945b58cc7cc58540a4871_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45c757b49a734e889c7b8814b17d27c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e4557c2c3774ac6bd1f5631a947887f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84352a69c7a940baa059487a008d720c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i644295df1e6b4e9dbedf44a0e8a544f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63c8541f7de64146a1d1b841885e43cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44dc8a8199b54644aaa379692dd53d6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5db1bfb9494a4fe2a7e9ed0eaa5d201c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f574ea21943431ab05c0b6dbcdce88b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b02c94bdf4b498b8851fe2c79b417a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66d85fef1ef64fa4b7ac0d3e28260cee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IOmetPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6db9d51af09c4754abfbb7520bc64c24_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SmartCellsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i85a6d1399fe54a219de34e4fb8d4af00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib00b85fd4d974a758d1b963871ea7a01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6bb25ba3f5e48d98f224bb95792c81b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc988053afe14f7b91f98a61bca385dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaba347791c48433e925479fecdd16a54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieea8732c8c424a298f074a0d05b4f8e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i344abc1ac8df4e5fb7317baa25a573c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6416b36cb32d45d7972ecd5a8eb20bcd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83a3cf0b47ac4f21b67473d021c763ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8dfc4e4a837d4b3d94e05f841194c53c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e9099574c5f4032937d3bc2367b5b64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9cca79113e2045d5b4e73f3784ef8022_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45e429ebe7354c82b1294000a91d6238_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc9960f291154518b7771a8367588623_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd58c6c117ea431ab0dfe66f19331376_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb84f0d208f541898a079de4407fbc4c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia4ab23cdcdc843a2917bbca28606754f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ff98b9634eb4b8abec7f2929324acd8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78df5306478342eab229fdfa2b5ff46b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78222fc09fda4c99ad6c20c30a5771e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iceecc1aac1de4bc0a9891ccd1446b5c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfe272a16def41b5a009731435dffb9b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i754a95212e81449592b1cdc907c41645_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i732723d5fe6a4b868b89375b49d5fd8b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c412aa3064f462e946f0da6f2d9215d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i736b59648d614c0e97f2775844772478_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1555c8a744114e5db01a64b368754154_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6875a6efe8e744ff842540cb414f8f8a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0efc1bff14834532b53dc32625a888ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i294d63d03b95427aab71e6571ccc09c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib13a5c56a92845b8ab48bcaf8bc19e9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41cef927a50d40dd94bf6b3639986635_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if245f9f1b17449e88cc2103efa045493_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb0cb1fa4d45425fa7783c3a6ef3bc70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80623f99eb964250b8fc54ea685897f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e81d555abbb4c418adeed3f0d9d7565_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20a01f80b4c246a2bf622369fdfa8f18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34867e87009e4b0e99e46b2f6cb4c092_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i49a46592892940408701fcf1a045d8f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i456e1ba1d4d048b8b9c8e3f642d03c44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22ea05d6371640059821d1b96b78bcfb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65571cdb0e3545d08e1a78ce87482955_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i291cfe0382bb4a1da525a53dd4bd56d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7e47a06c17e443da59e214105dd3142_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fe8e4e022a84cfea391ef6224221b96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b2a2f31269d4bfbbaa9fb0d49f28117_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a29df5772da4572bbc2b0dc9d2a170b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e537b9b718849abb7a52b86436ee26c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6be4ea71456d4e0cb0df403c03f0803c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7f96dfc50594cc98edcf62d8b285b5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b5f170dde14479cad14ff734e5b12f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8eeb41177eb24d1d9df2236c98035186_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc08d1a074864992a264a4b6422ccf21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04a54f19f0a746b39d2b9025e8db43c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9978259f8d4b47488a313e4f6298d224_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id22994b5296a4991ac4adf5979eadbd5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icacb65bc336f4dc9bb0c0a000f8b3b2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73a2ef6578e84496b80d826a8bd81fc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafd3d72bbfff46e9b1dbe43d5ae389a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.125EuroNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5065e542a7804f1d9986df718c97d477_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.125EuroNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee2431c7a6454b38ab36680e0e8d37e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a1148b1b31242e48e86597a3d3f1701_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3949abad89e14fd38587a5c5fbfe1511_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01916148acd5472d9995c901f488ade4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i288d6bcb95724509929f814f722c2cf6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.75notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i894c10ae01644b8d9f041da769af6d71_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.45notesdue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7c1f495cc6884078a83bcc4ce2ed06da_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35notesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2a7670e8fa924f52a3744367cf66477d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.45notesdue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibf5a47fd424649b58844b8504c6890af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f8e4e7cb13141119d6f1759b7717a08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1ad8b2fd3e14ee9bddb13cd515e52a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93df136354cf4fa38c646e1cf689a82a_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="i9a481dedbd2d4933a6677cd0e1edf178_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1eaa63e5d47740128c127b437bacd031_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie55841cf14c74bd7b0e16fd09b652e33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:NewJerseyStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8e56c0040ba4a169fefc5cf5549d74a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:CaliforniaStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i431f7512254c41a3ab21b8e40f090091_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4047d89366440f5864171ba3e8586b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c91e20a1c71440293d3d8d945468a75_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id52db59ac0fa4c2590483162033676b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbb6a7b18f5c4976971de8a6461cfe40_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VioxxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7663bc55df4c4c659db0b11ccee9658d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbd659ea6c05471da9fb04c882ed6666_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6c8d1063fa24db98c2859bbb23cc25a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:PatentlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6d206d30ad44f5780586176e7331c05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31aeae8af44247eca21b7f933034044c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i19dc4d009aa34aeb9203985671a29f18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66c2178f642f47caab789497db80c0bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0885861e3a0249f99de1e639684e4e6e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i757d42734fe94bb68d3cf7cf12d0c493_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrk:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i78e330e646b54193bfa5012cd95c821c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">mrk:AcceleratedShareRepurchaseAgreementOctober292018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1a59deaeb6ac41918736b40c0e87db06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrk:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8f31986a93f04797badcd48bd6288494_D20181001-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrk:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ic34f1f7cd09744c996b65b7244c26c66_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i000733eb4d4149cd92245dbf45a48680_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e2c8bbf6d144b1590bfc2f06989e5f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5824e3a83dad4afab742fd2ce8e74b3d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id3904142e5a54c00990a8925a4162afb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idfc972870d3e469faf7b5829c17b665c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i471a8ae5a9eb4a88ba94d7f35162f55d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i537a35ed55a14a679dacba9b73800613_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7b329e4def234bf9be62b33165383a04_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4874f46f9b2349859720b5a4665c75e5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i04ec46d52043488489055d11d93409d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8290bb9fd604f50bbd5b1c20107b822_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87b8ce0948a842ed9ef92b8f8846b1e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89ad1d90c9eb49c08404e53143774bb6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i63c8adecec8442f49ba129f60935b000_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief783e1fed134fbe824b470778e1f671_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b1966c1d9b34614a906164b1b847e14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i079debce911f4d1385c9e937966e9b9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0b5e7d4fb334cc49a3a07e272a89d54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02395d4a531f43ed837de7ae7e2f47bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c8164d243514c2d8cc997890ef95cab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i762afa9f7a1a49199bcaa4c4777b52b7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i896c0ab5f6ee40249192bbeea55f6056_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2fb94a8956cd48ecbaecb94d4ffd9314_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97baa9bccd8e477aa4dbb884bbaca507_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id04401bfc21e40589a67bb73d6d9e7e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5dfc8f0a72a24b79a719822430bd3aba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e067be53a86451abe0e60ecbd4d1b2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff30bd3bec0342a79f37f6d47d61a152_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia66284b3427a4a55b18a3d2307d2311d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i492575ea226e4ef79e791f68f775cbcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifaa9c1f8e8f14bc88b26db4f04818c63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i05de118d42874d8a8b65d9fbbb8cd8c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43bae42e68b74c9ea2cef860a864df98_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4839f9e8f263483bb5a57380e0ac49d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87f92475a0e644fbad104227d35a788c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i09b4d58ac72a4b6b9e8a4a3bd3534739_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie610ba127e0c486a927aaae038bb4c2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b4f3b3b5ab84f1f88c1687777c06d94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2614fa71de8840c3916410fec8e4c6c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8493396c311a48c087c4da0df9e9e265_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia33c4c3964914ed192b098a7887db425_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i983bc4d845244c9a85c0ce012de520ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i55f904c273db45369ca533911c7fdafd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07aa6e44c4e64dc09a11f648c3aecf39_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76599c7f104045fa9d3705ce55cae95d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i09a35eceae1749b2afc0e2adfbab500f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf07f551b9e54a50ac5e33ce5e447aaa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafbe4a56619b49ab892a56d15529c893_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb63fb418f534cf9a00bf9ce064c5f01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22427a43423b41ee97f6e223da5fc0c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fdcc0719b79428ba1c8942ab8420778_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i29bf2bf658614113ba17d962e1e99dc1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0441dc72fcb54c48aa6e5a54486d62a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i04061d95b9fb4f6692618bb6b2e163ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24ab217ecf2047ca82f61f394e3b2143_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65a333a9d32a4a75939aaec5815b2ce7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3a588a2b1824cb39195f5f331917939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89b412ecd46f4665a8377ecba5fa899f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b6e39b65bae448395fac9f11f72bd1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifdd6fe4acd1d43f89863a9719678632f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifffdb8aac16a488c88f1530e7c5839e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id031685155804a84ac3ff78aa32f7379_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4fda6a6813da45e8b85ab5cc18158c65_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8e94062e6ca4f1e848b910410e66b4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7598124a95dd40e180dcd55e241004cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c46ea7c16f04e6f9077e7ada8dc3aee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i881d12a48fa145e29b963710be067d8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i963fb897f1a84494b29bbd3cc88a5cde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d998e95188b43bea7ef9db2acaa7908_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc5e8ce709424f55baf4ceb447892b4f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if27f9b2b78804c56a1797bb83137c3b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iece7c24fe22a4365ac316e8f89696d65_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a5510be169a403bb3a2fdf843a3ed07_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib1c15bfcb925489c83014b3d69b512e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i607a874a41c14bfc92471a1eb2e4fc73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i738f3a9fb4864314980f11c6fc424c84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb154d7816ba4d54a0aa8908f07daee0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i845f426bf5684441b08a4d78f16a13f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0318028fba4d4d2ca13a6790d87c0bac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18cc995c2f4542db8ad348a6a80f3f7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i339d812fd79a4559bef0ec19bfe98349_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc88b48898f04f409e0109283ed2987e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31a508f5db8a4cada4798954c65d9223_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id29a7f12c8e24256b2319a238659e1a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia882b52e228c4eabb69646abbee285bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if58a48d4bdd44296a817bc4d6ab8b57d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied7dcb9e05394ef4b640628827cf587e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11c09a641f9f4bc18e3972169da2930c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i470fbecd1a04428fb6e6a4caff23f1d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f7046796fe24f1c868c09c2c0ec273f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb9da7337a3242dfbff5100ce601af33_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3221566626c342a999e23dfe29877216_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i27c99d58a8ef4f18bbb9b810927e2266_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id69b26112f2e43dfb981f625c4a50657_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idabd1fedb7e64d168d077d9c93085e62_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60e1943c724246bb8b80b478f5c0736a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39cc1d86c43e45a5bc8a8a5055e74603_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i663cd110b4a94a17af138ccf8e74215a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id29b60f8e53c4a6ab9ee426df0b5ae37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23692025eb79488d8a33a2716b0b4e30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b8b282d6d4b46ffa0cd607de8b36a5f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f96273f8de344e0b556346389159cde_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d2d21f8910346afa7a2eccbd54765f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6df641d6b2e4a7fb6f87a544978da43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51ad2bfb5d1643ac8704a1745e062147_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3ec77bd07b245cdaaba698bb230ad64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3dbe419490e34f4283f48203f8d00d4f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia59d367709184c039635ea8a9c404195_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86afa43f33044b8aafbe32dc59a25171_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i183768f390164f1794cac12bfbf64b84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3db834c97ee14fab88d75f50f80223f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec7437b4bf19421b9a91bc99840e0acf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if74d1efb8d174c4f838e140f7fd23e52_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i549747388339440e9de44fc9bf5b409d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78824aa845834cc8a14b6fb34703097c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73d0fa26e4ae496ea46a709f7fe43c2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i436bb533ef46402880b1b951670aabfc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ec0205bb40a4e4aa25f265fd1063854_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44c9b892c37442a186be4817fc66f40f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b5fe2d5dae24dd8abcf648861561996_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2c28218b2834e5ab51167cc6eb02eb6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40916875d4914c52a1de3c0cc928e327_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51a5827af8cb4a649aac89e78df2a8ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86afe2a27ef042fa97134e39bf3b608b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d8855de2ab94dbaad3ea5df4e70bf44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i259684d6ca2747128dc9ad3d0b306636_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa2c67f654184b1bae5acf068d5001f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedcfdabfe8f44d56a22b24a80a126022_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibeea9d67616a473aab6b59c7fb911c4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7e43a005430483da4c326627defc690_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64370d94415e4d9cb45ff1cb008bc7f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97e19c56a0f04e119dc0d2f946e31d30_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9750dfea550483aa010da7eea306529_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc4e566933f2436ba71c1f31ac45a19e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16f3cf886e184967b21a73d9c69c8280_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d72a9e301de4cd0a1a1a7fc0b36c4a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39901cc34fd740158d36857127b01175_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i154bf08968984b7c99f026a36c01c389_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i040e5118b6d14454b71d08507239b29b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2938292f70e456cb6f95bd21bc78090_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5092f87e8ca34ffdae394fa1e9d5e453_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id457393c18e544d79b6943a75591c9f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ba248a0903c42bfa04628d1088a7603_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b23ae04674c46f6be8804520b0a170e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6c07cfb24c14c908e52a77dd7f27872_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4af75dad006d4960bcfe8d7100ff57f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6be20872a4dc4195a2a00b91c7bd9e53_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5fca2613e754dacb1d1358910525b05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb175a0e182a42959d20bd6d81e8811b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1dc802dfc0e4d8b943a8088b309a76c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc71c589efe74a8eafc71efb7fc704e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if758fbd200de40f9992c9a7b6d18d162_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d28cdebd3ef470d805bdfff3c328aba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4529abd8059b44efae78aa81e23a2069_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b4ade71303f484886aed15962aba524_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13a8ec52ff25456fbf0f605de1c62d83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7318c9a1044a450c8705fd6d1ea5e7ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37caa9d66c6c48c784567a49cd4dfcb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf01b81038dd4b0d8ac214954c67671a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd70b64d3e72405ba247566a7383f575_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i383c1e83a37649849826069e2ea30e70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia5ca88a53b7a422eab11e135ad001f09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0976228eb3844b76813b5ecd4ea518c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i19223921be5a44f4b5b22d6e5d166870_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08d99fc733314c5ba2bf5402ab0d6392_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd1a97c92462458c929c7092d0e8afef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if84ab6be0c3e403bb9cd82e264108aab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9acb800bac97417e813ea16d4d5ededf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44275a244d0a4892be5505d09958c1a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie51e79c06cea4cdfa2bf6a0d5be0124e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69f45e018d1747a68360c2feb30d6b84_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibbbda6da3727484e81200d5caf50552f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd94dd271aa54f69a8baf12100b51778_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffb967b896a4468fab08e88cae9df856_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86344444b47e4721b7a2fc0ea7cc11ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22038ea5b4744df99667fec848961056_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia40b98564996403db036113cd733924b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie48c9ebac6d74ee190face5ee60b51f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b013c8f53aa4ad0a92b472ab7fc6b81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib672d0934c6d49c19aca1d0a43b92a58_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i349312ecbb7345d7ae0733d60b92c8e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i457ae5efb13d44ef94eb093fd86a744c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i780ae83f21484b4f85c3d3e21ba5c7fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a46d5d13eec48b0ab6b5862c0d10927_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf91bf6b83d04def977d5ec5adea56d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f802b0b6548410683a7feb2a61f6ff9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4534e1b0f4594853b0b92171732984b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f034b282b3b45ae8315f6d3446c99ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic405b218f9744ab780ce9a8a7aab3fde_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0001ec828bc546a68b1b01be577c9472_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if840940eee764ea69eeee426ab4d3762_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07001dda2e5f4d7ca903f069b0abc178_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f673e87cb9d4be2a8a2fcce749d9a73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a21cac2295041bd8c7761632655bfe3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie982dbca87ff40549928cb1b655bf842_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30d48af822b4482a9b7498a050ddfcc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38d0c8c5170b4f6a80534e5ba634dc51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i622fafb065b347f886df4ed478a637b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i633bb8841df546c49ab62349cfd6e177_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia5993c63f98347de90f6f8e4da9b444b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id334f615428b4033a167d3ecd93c0a56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee9f22f4e7c9422aa9d5aec3892f508f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8d837922a8c34c35b598417be5b7179e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i357033ae6b9242f3a760e4ce6ef092bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6504027ab63f4de5b4bcaf9260f31835_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e6fd8f061154a30a819a163c8185ce5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id09db396a1bc405585c8bd00bd42ee90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4e9909fc72e4d14ab3b844920200857_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34620b194a57489abafae0caa71b1e81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i803b0a3f273448c6bd0082f93b43ceef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i058faadf9b554518a3b689fa8335bd98_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3677204f7a3e41dfa2f70915e9c33438_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c48edd856d446fdaf20a830fb838512_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cf61bbfdc384cc9be1bc920c1d76754_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied410f99d8eb4af592290310c06476b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d66850a0b7c440c99a213e0733986ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0dc4d7beef254de9a0eba7eb5cccc084_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72fd7651ac6a4a2a94a953d682b650a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5161c382e704689bd21397306aea661_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c6ecdff488f4420ba322ef0fedaaf2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic06a9999d9324811b9a1be2dcab19ac4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie77d538a77664954990b8a71d696a859_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i813c30a7a82a437a930c6658dffd6bda_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i21fb50eeb34a4114bc13c96d65cbd097_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb8b1f9b69d540cc9ee48b788f947e86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5520bc81f9124c16a0f7c2a4ac6d32d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf1ccc0110f849388ab267dc48f11d4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8158b6396da446795bd99eab428f39c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31cd5815632a49b2ba1c177fd6bc40b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ab5fd43cc1445d0af3c8df232ceb26c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae6e35c9626041d98bbf692bd5a64946_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i407cc8de7a564cd591d2cc8905f16ad3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i402c71bfb56d475d822a8336e13e26c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16a9ec48e8f84f82a1c47ec8330267d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3937995f915a48b5b2629bee83030604_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91ec2179722044d5a5d1eb812df66bc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0c42749acb640bf9567f2c696835c1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4d256b285e747878c834986bfa70aaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28b83770c83d4ae3892d22a8c95183d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i54869a5a706b498f8af31af979c71c44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7510a56e62d4a91a42048cfc19c7873_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ea763b31b9e48d09c3f501947f1b1b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id04238d138c34d0c9609f710057ea45a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i49eded9c6aae423091e00e60b8b07d6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied9fcdadfe1b4674bfcaa0b730e4217d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74504e9a2e54432f8b030a4dbcf9ccec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bf9b49410e149e4988f1a1303a8002a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38efeb11d07d46c98df2083b9decac1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68339e93b1f64b1dbf950cf628cea274_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4fc97e4e4d57436bb7f739eb609cf62e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf2a2c1e08e8478582cb66340b717486_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ec2478b8f0e417d82d47d2e798bdf92_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i620692e3a36142a99469f7b3c1df10f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1fbb0d61bcab437d8de63b52dd292d32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d7e666cc10345cdb2262b32f0065fe8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e268cd703d845b29d850a21ed33546e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6d74a08d594448d9548a1eb92cbbf96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8dfaa78b8a242ddb57ebc4c9c31d5e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i229c0c3633fc41e78ea30bb9ccd6a28e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i189642b9649f470d84f77e09dac85b67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87a79dc129ba4160b0dbd0cde3962a9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5adeeac55b484b6f80dd2c5799f04e33_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5481e593b17d47b1aa1c93ac944e5897_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71a47f45b5b94684b166d8f428a29ac6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifa08043c6f9b4f8ab940e92d8ff823e6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3ae805d9fc1142e3b9ff8fbb8f056835_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie76048d496a9406bacee02b8f107dea0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic4d19186cf57479f8c9c9f80797a937c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i181e86400b884db2a06d3594319d4a0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42f4bf6ebef94a2b9c96589c57b30e5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56b5dfd32194495790f2c8c81a479431_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i182aa63f2acb4acc82da9b87c7730e81_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2a92dd071da943828df32be68c3aaeb4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iffa22d9c51f4484bba2b9f4934ac0a1a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8face53a5d81405290c2c762e2706f10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8993b7d37c36436185b4a48db374a7ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i197d5c37737145e4be8b85609364f159_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iec259e3fe62049edbdab75f9a4208515_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie5ae4a5fc4714d318fd513d240f6ee0c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieee7f5c6f7f3431b9e2edc9b74fe47c6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0d17ed2f94a04fa9aef9f8d5c15caa5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfd81d119ee0498cbcaa47e8e4e04faa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6244f9b099ff4947aad981a8256ee577_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie56379a346a34c328d1074093e2a301d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05a8d5d4b6784223a646272a4e63a5a7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i78f0eeb607674c858416639d103ec85b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4103a039ab6c450b8e3fd2d3aec9b167_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i248058aeee814ad1b7ccee7a89ac58dc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c14cccf97aa4e98bed9ab984d662ca6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c7eb5004e0643efaa0d767fd8811f55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4bc1fae753be47e5bd4c21587185b6fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4df3a94dfc774b0e8194462a843091f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15952b0805294332b2734607d6a255b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37f636340dc640479a5f05532e7d057c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i39557d630df942dd86fd2bf4c39cf856_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i699edc2c96984870bd641e2007368c3a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib791d92b691f48e596977e133b7a160a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icef24876a7764b5baf52ca7024d66e6c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ba9f69f2a94435d9d0a72322f3ae888_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e9da0b7f32d4b4b907aa341ebe4cb77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43cc1a499218442e95080f98c69c62d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60bf9bd5acfb401fa74b890b56b423f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie96f52556ae446d4a890b661e68c63e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0b79dacdae14f1e977caf0b1f646c03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief56854f3aa241a0b9fa4ddfcfe5de10_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib62ecf568cb04ff1aacdc2f07c2ffeb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ied08a22fe762423eb0853b09ffc68ba5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic57e6fb3e1414f279eb4e83bd905b61c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i755cbd5c13c24c81933f62cd6b4eda28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a189549221f4e24b423fd38671d9d54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0252b084de946b684173854befd400e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdb1b2bee0774b4aa8d069b01b4b4a15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6ef8d12db6e40848a3a69a5aff2a1e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43a497acacff4f75ba6294cfa44db5bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie15a714c12b94a1ab30adc88613b45ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dd632257d3a49bbac09f1ac0c2bfb66_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie2a774411d90415084d7be23aba71361_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78b6ad0ae1984ddb8dff1329153f9b50_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75c7902d5027446ea98179759ec35a86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id85e0fb8780a4f668610145bb98e568d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23dea03aedd24af7bba7749747e2c448_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4cbe0c4416b349fb9992bba23dd31615_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a6261bbf6434c1fbbb017c083ac826f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i099c7987308445478005041a2e2499e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a7b979b8181471cbb2f4d6499c774b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9635dab5da6b4d86af14a4b3b3e3d17c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9accb5aa18f4478b540bfc23200dd1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i10d7560a3be3405aa45a2e8965d79a75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i991d3d8795e7450993baad6ac1542b2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe94f09fb8b44e858f391b3b456ea158_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03dcff373b2c4b2e99f9bc879d71f877_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4161dc5395848ec97371fb2973a6cf8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i148dc14f164643bc9efe7b919ed342bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bd0233a6f6343d6985c502db8bfff5f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i79484360495649f0914e71275a2db5f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i952760f0a9e74c05b6d48ac685eb2961_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86e0d1a44c2c42158b392f684f51f780_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9deec913ce4e429d807dd9d9ffb90a6b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17183f50f3f84a319239298ca400b998_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bd9c6661e1d486f8658b5ab959fdfba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib753ab6b2404493bb7bb3e62d12eddca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ffe7e2d5821413da37bc4be396523dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib945d0e7dfa340bf87fc9b367dfeb236_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8163064b7e4a40249d86d66b673c237d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80ced98f942344b8ab3c48acf6650470_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a9b9a544637409b9b31bfd72192e634_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia10fba196d5842819ca00cca1ed5d9bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae7bb63a321a4dbca2ff6d7d594a9842_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id3515234e4c5489b8a5058fd44abad74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1e22790d03c4f9b8ae9e600bf7d8610_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37ac062f19214253a973f162cd6b7257_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26d2514b5ecb4f079fe56b573db1a351_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i054b0d4c7dcf4dad93d6b261932d1c2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8b3ee4288f1434fba7a20a0cc9987ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibbe6a7bef2d8421da8fb84a3f0eb8f61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a9d170f4c6f48cdb4f7d2ceb8f17c94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93fb52f964bc44ef98075f84eb2f5ff3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3bf1c6eec00b45b1895cc6d33e8b5bc4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc6482ac243747999a0cfa001203778b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i349bae78403843118305b16989643e38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i568c8abfe83946f99469ae90bb9eb5ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee961b99d48a42e294600feed306ca7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5d6adfd31e845609eafb982fa870054_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a974d49102240d79181f4c266d17f3a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3c1d58045034f7d978522ee23262647_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id45dfd155d034c4dac37d090ee18315d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3707009e777f46e0827af9a448af3671_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafb206a1757a4824b9d626e0233b0fc0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idfe1114db0d24d3585c20ee5c36843de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd30b86dc69946c795758370be94e534_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if946e67d0b6c4774bc9f3f9e21193f23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if030402de9be4396ada7e2f22518b79b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7862913b018b4ac799b5977d1114dd64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a3e27f1bf5849a283a049ebe88b1431_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e25808393b84cb8b8588f0b2ba8f09a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice86e24a0fbd45fdb549c788c2fae42a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i933961f1977a41cab0929eb4211fdd05_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2701d8c81625454b892b42c08d22f20d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42cfd92c13d147b1aaef0650037a65e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60637f24b9c34907a65ab4eafa2af829_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d6e855b0100414ab5cb98a6a2b9c3f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d6988d2c895477a9dda50151b45b1bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bb985051a0e4022af522f73d07de54c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if670e72285554034b4161deaea318730_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb83591d5af44b1dbae73ab7ad1e4fba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c2e264dd3bb4e18b7d7a3a250729f3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i90ed9e9d5bef4e08bd9d56bcb3fe7dd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibaf43c3e9e35453580b96b6cc36256f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if51206021aaf4c96a2df71f22290016b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61232e501c3a45dd9ffc51e1a7b18638_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa31db245c334463830834bd6fdfcb7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43dbdf70f3f84f9bb800dc9b2bc789a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a185822a7fd4092bdcf42d8ed03b009_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DefinedBenefitPlanCashandOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafec61eba0f44b598174decf94362de9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2d4c0e028b3f47a5a748c2576dd13eb8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icac8719a9476464ca9bf1d1a240d1510_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7410576a916e42d4bcc349b678e87d26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i405bca874530481997ce79928dac111d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6481cbf5e20244beada5e16fb8e1c7db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b9b18bf3f2b43149e469b0523aeec6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6314d5000824e4a8abc4c270f634a7a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0fdabe48bf6945578d95ee1057e5b49e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:PatentlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i553d83c3c5324495837bdbe11f4b2eca_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id83dfd7a1bb849e1b213bae11674e00c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mrk:CGRPreceptorantagonistsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i85b367730bb94d77b0694a73c6126ccb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0b58a3ac34da4fe8ae1aff48a5e4e450_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:IncomeTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2ea8b16632d441e9fe3b895f38cce6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf552eeb0d424605ab9e87eb7385fe42_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic82df9d4f97443e485af19b6f535a820_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc9efe0064ee4c049327821352c6c0bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae848d20b3c043e09bea70d1386a41c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mrk:ConsumercarebusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i942f16eff97546a5b0fedc3f590bc635_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2bfc40d64cf42fb9a74577988a596bf_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i480e76dce93f4111adcabce9984765ce_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7f8cc640b7474a98b853cd9c382a0cbd_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1354b93356c743609177591ddcc546e5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic550ba60e01a461a85b42e40d108acfb_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia2352f0a4d1a4a9c99aae16eca9eb64f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ice856820a83d4f64ba70affc98cad508_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i34ff4b660b424b82be57badc5035314b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6d27b6850029421d9b74d51b9b3c2a91_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if578ac895a894796b44b038d0fb39402_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0fcfb5df86d440c885a97df59dc74f88_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ief6f7feea16443b79fb74434abc31baa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6b3e4ef69c5d4f6897a3277c799164dd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf4b8ee6455d4a9b89b308842da6473f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2cce9deabde142dd99183ccb92bf0341_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8c2b49e682e4caeb3bc52179ef40698_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i924abcecf31e46c1b8d02841a745163b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i610c168f90e34562ba8f9dba8f33d1cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife933330c1ac424aa46ca468fd356d4f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9afb706ed88c4a9c952412a1568ca05b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae4b953ffd8449bfa452e08fac76110b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f71d04bdcdc440cb39d626bbf39da82_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7110e61b679b41dfb55959ead2fa0d94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i944bd7f6e96e4f45827bcfb3d2cee24b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1028ee01f9f443790787ed899f2bb2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibbfbe344564a46048fb4ab43f38e7fa2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6efe006638854a89a541ce4a48c0e6e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ddc21fcecc54b61b50c3d29b99a74d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i914bdb16078940c8a02194e2230817a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i944b92f0135f4cea93c996121cdf4250_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b82cc9ac9bc467aa2d1652a512c75ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i762e382a2fb74a4f8babd38337173a85_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i487b197ad43f42b4912ad594d94ebd83_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea50166c87a84aebbe4b0e1f96819e9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib06a34e4d2ab44d5bf29fb6afb196f2e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id33e663e5d3448369da90c6d1a069ec0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2abed73e41814781901f099d40ed7105_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idd3942b136244804978f116fbd64e6fa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6e466932ee4e460ab0dd0bfb9b1ea289_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i913afbc19dee4cb2a26b17a5b2526f58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if86a72289f7a4e82b9b4eb4aa37f655b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic980b87bd8b0418db9d06a8a487b8264_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd394238a2bd4fc599ea677dc8fc9177_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i705f2f1b42d3489389778770491f3701_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie3e95cee7306454cb048b4b3891df099_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idacbd259a14a4cc3b723aea685fe8402_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ica27ecc79da8419a88633755deac6f27_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i81b34437d3a04710a586018aad577595_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b948ea353cd4ba2a534ccca93683bd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a60cb9fff2c4cc895d8bdf8605a165d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd7ae51b0ccc49e49568440c6c4249ba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i568b7384fa7a46cfaca0984581c67866_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifdc913222658499b880f61b227164ce4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6b7e5ca7b90b402180e94a9e8706abf0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib01ae12bf7fa44aab5d2eb12ee013b9f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9e937a0914304e858eb868231dc9e5c8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i62fb6e91ba434715b8251869bd7299e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea8b090798424ac8aa3116f12d6083ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd47028645b14cdd8bc6a7f8356b4316_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9dcda80a2b744fdb022181fac4adddd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie561b863be38430bbd97eb1eb078fef6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea786310eb1d478086e32978d875173c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifea00f3442984ed4a0f48e661b09bb6d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i782fc528304543298cebb02d1190ac5b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1145ed6aec9d48c3a25ff2a988aa54d9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i42905f2114b449e882139c3304e1e067_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b89ba8279e7484d8920197b705b8e22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f022f4e88e842849c6953bd007071a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i386b32eac5004086999833832cf45f24_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5bc8ca75e4db4e72a0644865c60bcc0d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i930ed6885726482297a6b88617a1004e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48a909c96c814060a10e2801793e0e6c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic440e28e121b44579dee80b8c5d681eb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6de667927bd44a37a2bd00481afd12df_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id371c43a511c445bb4a2ffeaa7880af4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0d2eda461ad492daf3a3842f708bc0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i06c67db88a3e4613b882d85cae7cf938_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03b2d959e73643b7b560fc019573878c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i563016c582e24bb6a9faae151d3fbde3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iffc6b337a3ed481cb8f2d22309e2a645_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icfb152fb64524f35a5ac871ac508cfbd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5cc8a3df09604d98a7533cea6a7cc1a4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iea8d517618414005bbbe9f82e782a39f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie588ee62a35341cd8301ef54adb5166f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99baf06e598d4cc587b4eea203a0baa5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f59b103858d46878eedf45649386455_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa4e6f22b3114161abfe58eb27fdd9b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3244ce2b91904b73b45793012b9deba1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ee34845ecb84d00a4446c16e8283f06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iac945c4f8f4d4171981befedd8042eb6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i13aac18591694ed095c07e398d82a9a4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1ce7fe828cc94d6db92ef54014d5e83d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia3082eeb63264d528664dcb84a196ffa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b8ddb57daf4449b95d7f5842fbd9cd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c04273d563d43ac903ddf81cd8713df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7885796f74eb4f47aa093cd5153cdddb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic76caa434d4545c2a41daf436667a0c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i698eb8ca231d455e8bd8025f25c5bafb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1cd5c6efee8b467ca3065e20772c0f16_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i61c82a481d0e4e5c9cb61cd60076fae7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i51e714cd39394117b1cb6e8777bf32d8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3eac079c11544e2cbf3daee151f7b5d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c795d67996d4d41850e0375598399a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic268fa475d8247a888383acd5008c4c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i792a79580b224fee9d46fb4cfe23165b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5bc19564465e4f5a972c56bb809a8f36_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b81e96d6791496eb43340c7203088f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b9f73dcd0954e21b2a313db04ce7e1c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6471730c7cf14bb5a10b893fe2704d8a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i96c40f8fc0d443f0a7972029aa43014a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2cfced3ea7ba40dc813084356a8e2a71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc5c946bf5a44685a08ed2fe940530f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie43a68e5100c460f9ae570bae3642222_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03b08c6f8ff94c49933c0e1f8bdf1a79_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieea7542288c045289bbc1900530f6c6e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i712dd95c443d44bd97852acba774042c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id7bd988df8be43ab8a578291ca6766e5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3a5e6a2873114b8ca3d699b684dfbeed_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia6a19fa1ef2549e48a8c798ff8cdcca2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia794776b17ba487d81e689c730a89a44_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if56def4d43604279ae1490a45ca12c8c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a57852d19f944bd80a118414f3fb03e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedb68ee70d874978a87dc2e09bd612fd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i837a264760b94cbd823d589b3848eacf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i981d29244f2a41eeaca918a69762f31d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5d4bf02785f34f25b07ca7068a5d28ca_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i622f7b5d6bd64049b5b32da99600ada9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i63db189e7eec4a128a0d35126d4bd81f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4fee648ff7994140af926011d3631567_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i44b60dd13bb14d32b824e1653e259c32_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i631ae57e96054ee5afcb44dd7471b663_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7a880330a694ef488f4f7c68d82cd1c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i00da273161ef4edea36fdc16bb3586f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9ad4b5afd5b04abaa51621d6b0f67e32_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f990850d9594267a6e1caceafb75e22_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id8408528418746d49007de7097987a4a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7dcf25c15d3649238957a6c3c1922909_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i95a6af99921b4ce385e45e7baf0ceb30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i158a181d72de473e981382f4977cf6c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i80beea5c84e343bd885ca3431e912104_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i982bda5b96d648869406352d49e6de87_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i26fced3e231e4bdca37b63bce6e68d8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie8fc37aa4da24c6fbb3ae07dec2598ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id86a4dddcb1b448daeff944a4e1e47f5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifdb32068982447049d6b160c7f5328e3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic23472488bb44800886a04efdac600d6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i00dc40a9ba5740df90cd396ff7e12f29_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i340d2c3e7cd4499c8922b0efb09a24e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86c343bc0a184f35986855d72aef089d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i80da1dcdb7dd4217893159cf5cfd10ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i244975eafaea4f8981c83f70f314cf09_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia32db1b78a5840528d295a594b2e7616_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i743e39e016e44963826fff0f356a69f9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if06b3400e18e404eb05b4445a2bc6313_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6083ea4bda474120b0f548d11216c6a5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2af11e6de1ff462890478e6393a18b91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65c1d7b2f4f44342b7cb4177aafef6ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52759226e58746448d8a420c332f2381_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f8efad0f18a4a45a2614ed77513463a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i96ecf2f6aada4757bd26858e97cfcd1c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i34bf512eb4f541a2b071eb54fdb82c88_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3964e6a61c54a82afe378671d25a543_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i75a6bbc3767d4a6ca3952000f13d28c6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0ac4d80bdecb4bab833db37a8d18cb8c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idbb92d1ba39b45128f93a4709dee1c15_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56b2370d6fbc401ab58d1068789e89e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i593fe290ce72487993a67db241486f76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc8cd853b60043e0b70f1bfec080a4d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f99c5231e7c4dc7a81d228fc3415f7b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idfca6579a4ac42e4a4e603af62eb5c01_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c71abcc275f4683af8e0271a80096ab_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0fa50d7bd230485abf1e66bfe14032be_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic42ee491dfce40f7aa8d266a46cf3543_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia213538c877d45ffbeda1c478dce239e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i021950f39f7d4ff5bdba80113c0e13a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id025bb2578734377984deb7afd65b7dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ce0eede954143acadf9aaa2596ab83e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea5f4f6a1ceb451d81c5435d7c937683_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic8e0ce6e85e94727947ac68e911896ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1ab04a7c31974211af284155f6a7dfd4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic02b5b66b5be42709792b6f221415e99_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib03ebcd3ef9e48ce8bb69abc9273d951_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia3cbd149a97d401d971e534e429cb2ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b8228b2d5564ad0a725a3a7b79ca7b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6479fa964a3c49189f62b4bb3b39de1e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccdf4f20c8b84ecaa29c0e18c61129ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c18fa5bbcf1406fa004601033af85e2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibb282931027048db8b47047f9082a80b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67d6b32b4a6540428d17548fe7806b49_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id466d72c74484e4c9b0cb94ca903c707_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i02732cb0bc4444dc90c11841a6721a88_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i204bbdb330e744b0b3ec21cefec837e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac9ad937795f4b4dae6cdba2cea3e74d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e1b718c831f45e49a8fbf7722d13a2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8aab449a70046f4a0e3b44a0956bc11_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i296ebee4da8b40bdbe6a589d85f3a4c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if41e158eb1c44c3aaaf6bdce81669ce4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ead8dfa8dc541b28d9320a858a459a7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ieee9488d170c4cfe8fe249373f7a0005_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i588e0e2cfde5403d9d0ff73b1f9cb4d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2fdcaf9b54604eb68c5312737d3846b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i031b4271f5cc481aa8b8f2ccc0a1ba58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3dfb2239d4d14352bd4a728fd7f880f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9231ea96e50a4020a32910e880f0b50c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7a5929161d3242ee9a55a4b589697d38_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia5f37ba6e7a148089b5c5d7be8a75edc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4cae2150e5694f75822ed5dc50d0ef1e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i33200ae436ee48ecb1d3c2bbc22ec28f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib8d52e6c1a9c4700a879d6f651d06973_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec78dc79b8ce4a3497112535b38ada92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a1175a70af145bf8a80dd6f301e589e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28a8fc8006e849fba47a9ef2942dbb3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia340a8ba6ebb4c029daea71176cbe2d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f0227adf4c24296a707c703a304ac1c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i78215076410d4611825d515c00ef799a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i969a6ffbcd4d46c0940c7138d634f818_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifb8e77760bd942eca8efc4de9fe68e8e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib6d2aac33ad54ab59d96297ebc97d425_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ica384a52be1a4278b12ee9bd5f583bf0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4578066b041421da1aa43b44e975cb9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b6940bb247a4473bd0c443d685569d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1c976d77fea4c3689cc0098063aad26_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie370a43016b44af890fcfa0146cbf033_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifa036d0f6774475a9fe49fd92e495644_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia37abe5d72534dd093c0b9a1d4a419c0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i492b22beaf094ed68eda935067df1fb5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i389e5536e60c49a5a0ceee0886fca045_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i40c7854b1a4640c3819cb580a9f6f419_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66a5487bfd8f452284fbe7d3ff2c5ff9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id65b72cf07aa47b1973dfb9bb3a28323_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i358a98553f7943209f20f57502c434c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b0fbc9b5596453f8b88b17db85f5aa9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifbddcf663e174f7d911abb1df12ce84f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3f563f809894d48ab7c89d2ee8f18f2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3769c8c30b424f33a150c2196196a059_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3a9bf768836345a986b10235dda945a9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic330260f1af24c978c806b2a3416c5e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0ef50a789254301a24d80d4157ed09b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie65bb28cfb3444cabded850e87bf4e90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9aff7abd7c74f4681631afcc4ec4dea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5aa6da700c404dd8a7694bfe82d5c830_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i60d3bb6b88b54cdd855c97a8e84eaaec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3bbfae44be544a3289c07e6254ad7066_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i58961068953643e9a0d7276345f42e0c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i26dff7caf3b24a61bb9d9d43432b1342_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i02da2130a9c547e1b8cfd90b9810c602_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e9473f3032842009abc88dcbd4241bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9850a5dd51c243e993ed526a423fca5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95ebce7e3847428bac65d9577590ffba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2992f734d65487ea3350732210cf724_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9a61b67189614b05922be71c8c421962_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i808dbd3f3e6e43ed9399f61bbb7b4055_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i164de0f742494c9b8cd2d3f94f2923b9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1e5ffb4bcbf94ae0abcf664e4c6e1872_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i765e235347ca4df1873ed1248b331df8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i817e3b1fea9f458fac0f6055c49641a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0433bcc5a7d7432f9bb4a1eb7ce37fd3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic50b4573044e4647ac213a16ebc379d6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iec6cea25192742dab7d8f55c6193e913_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic118b67ceccb466faa220eb7ba62f56e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i93a086b497c64ebbb2509e91e103680e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8db350f249ba416299a4392f33c42f88_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifaaf6f8150b84a25a8315a1b493d2252_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i74ba25329bb24f2ebc68cfb217f3876e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieff1a0642517447883a7677e44f19609_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65dbfd32d29c4a1298cc6b005e57d0b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe5e33fbfd9e47729ed353ad56f6955b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i428851a5d25042ebb249a9a84028610d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i471a2257c4e044cbb9b7a564c9ac71c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09a09f1a3abd48109fbe59b3fb93d141_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1404f852ad8849619c48eee49eecb017_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3c819bf8048847f3984282adbf7f9562_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib453c2cf19634dcb9f7c38e577527fce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a03414556c84b1f80a00b809a8ce3fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b493f99d5764db3a3587eb876ab87f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7650b81f2f948028475c26edc5c16eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifddd89c3eb0447f3be23aa56aa560afa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i350c3286a7fe4a509add74cc2448733b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifea6a755e6024199aadd27d792902ca8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0d8c9e4810f4401bb73a64a044563400_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icdc2a0905fa54560be844a4a5613db12_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i08dc5fac7cd845a6bd3b00791e7e5b2f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2950cbfe843d45e68f856f33961cba31_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icebba189d4a3458198db7346f2a6e713_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id24f803edfbc4167bb3299a898ee2e13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ddb314823aa47c6954a1f2feca8eebc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id8ae0bf62de4457894eb884499173f85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9cb86dc9c584485fb7a5049e10ba046b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3b7f8648b2f44883844130f1d90b85ca_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib5e1ba5291ab459dabb27adb7b97387a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i26737262a3c3462b96de8ebe023d1021_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3daaadb2da99469f970536fbd9f589ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia40a7732f3a44955b312d4698d4c6026_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83be474e89ab4750bd00aebc5eb6ad68_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id315307ab2cb4c808c77a47abdcb132c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2d95952196a41059a02aa8be7602540_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id961d5e81bdf4ce5b89fc5130610e285_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia103de5e6cbe4fb2a104961a19138f6d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie39a5cbe975a499289e9b0481f88571c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id37ee02873134a16a7d2ac745f1f3efb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e9f2daaae4745d2ae55c4ff7963f472_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f2a922a9abe43d5a57491ba600cf3d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7bbaa3f0d655424f8b54cbdd948628ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d42283095d74b78ad5e947157ee6849_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i509aa0b5030e4f4e8b6a1b0424b3b2b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e10e6c25c3b4557a099fe326409b993_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibd7a07462ffa4e17bc9007b49e82bb59_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2aa9ecb4f9e4493aa7973a44ec374287_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i218d611e83f64fffadaf940a7b0b4fb6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id76b73811b3549068b674f9ad76a7123_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95423e666a3b4e49b40bfdea87560d09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7f702272ab94a368cb9cf9ce09c4a23_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5266d257b030492988eccda7eea5b5de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9cdce5f66d1e44a484b2b6697296c809_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief1b7ba9d9fb403ab62cdc18b6eb0b30_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3e9d8e4e0a1e40b5989ef83e9ec5eec8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i11fc958fd5eb46b88f87a1d5fd077ea1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7eafdbc1aa0149d59422d69d95d29318_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i925822b570a24b5ca88a9c40184078f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1df1b6b114284f41a95dbc2dad95ed8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i966a056f15d24b6d807f7b9fcf634f8a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83c7ec1f79b043b5b18d5e72d1499fdb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8352fe1a5ba54b86949f5c412a8f6d84_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3fcf3dfb4b9a4b46a7e562cb5174729e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9b3b6478297d44108e0c4b7a552445ed_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0ba005e9d4424eb3975bed7e80cec408_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id46eaf3fcf0744889088ffbbc1e457c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2213ab4b32ee478b9b62e4101ed98e0d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3be092e6e874de493898709ec58bcd6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i574e546b62164a8a9f5caddcf3c862e0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i976d902516444c31a4ac366db6d832da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iccebb2ddc10e443c8537cc870f8ba888_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2839ccfa8fb44d8fa8ebd57a2d4c45a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1ca98a5ab938484c825c7201cf25965b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib8d15a37330f4dd78bdfeef167d3a769_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i512a98056064477d978b1b7f932b53ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifae8562aa19d49e0880f0646e4267477_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6de3ad1081d5496086b75ba3dfaa828e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i220331bcd9ca417b9f8990a1d20fde9e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibce7dbd95b264cac956659757d0b8dcb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie8c7919a2fdb48038043cef3080be5a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc3e04a9593148d0a9fbc6099bd71fcb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic63b0377678244a6b0daa177fa91da22_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i51cccff8d27547a1a031e6d2ddfe47e1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0395da8cb60645ceb3126a26ed0ca226_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45440e929de74f10b63f714199cbcbe9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1082609c81ca485f837033633e3ff2ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bb74f29937f40e19f43e122a3376b3f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3193b9aa442a468b835ac9e65c53542f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id3ffea7f6f1e4e4983ca7cd6779d45a7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ef571096a444eea921f01711727d9bc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i14375f6d274a48d9b9b162940b4d25dc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i94fd88fa633844479351964383e1f158_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i962fd40d3ee6484299bd3c87f64af7d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic416aba94535424bbb9d655ecaf8bf86_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i462d9a562b7d44599cf894438401f0f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab7af0cf69df426784f6ec3b33bf0fc2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i14dca43e6ead40a69e7edfc8b772ec1c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic4054ed0640d4d4eb44198419c1c1fcb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i80e5cfb7bf144a1b85dbe4460106c525_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib55dcf9079e34da1816b08c7ce38d62e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i576b22bb76944f53a3d4648c3b0410c6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i64789569b5264809a363eb25117c7863_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86793e8a3a894c159132ce9f8e6c1bb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4c9e4693f50403c8339af126a90a689_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e48594fc2d243a0a8f39b754d4d89c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i49bc3f554ac349838de0563f48fcffe4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if2ed8c22a5e8422ab95386f092f05a22_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaf30c9ce3ea34204891eeb2f7d539507_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72ec6b2d07874cabb0d1efdbf4e854df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0ccff3c21c3473e96622780327f8b12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9210f70f2d443e5889ab66abde4d50f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia72cf7144b3a4b4b8c1e9ca00c55b8f4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09dc1fc46d8f403fbb3dee2b1027efac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib820ec90c26a48c1b63f85dba3250264_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1d198392ab6443c6b3cd53afafd9c428_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iacae1b4908084fab9344e4706e647c20_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2f8aa3dff7c84cbd81161181b2b08825_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6859c10e69f430d9106fa8705843e30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b389087e5b6434f8d9e6fddb68235bc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13e7a6ff124a4cdabf9930385a1ebb81_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i531cef5b6df84d26b7bf2ea92797ba73_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa6bd27f83f148fa904f54b109976d82_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i37a62c431e03427790bd62d76d11d85a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie5f63110b9c74d60afa7701608b4e568_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i99ae00b7d39b4af0b551da02254dc1fc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if3d960b8f6d74e02b74dbdf263f7040a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebadcf45558049f9945a6997f511f459_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72d58d6fc48c42c586a14d29d0057c85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i383680c7a3bf42a8acc1ed3448266a57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6da7dfe4fb3a43148b28617382d7d627_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic14adb31336c4a369b484fe90e397510_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i45187d95cd0942edb66dab8c766886f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0bd2491b77054229931de28963068e3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id33fa4b2aac9444684437df21be88b83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e19eadf02e2447689f31531525302de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i90a2e88969d1400e802b86560797eb1f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idb55cd05c52044ecac300d08fac63719_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i19b5c015e07a4757829cb06ce4b2aa8b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i058927efa4b7468ba0ad2de228285af8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i78b124f26fbc4ed6bfea843c38aef53c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c11152ee28442a6a313d7ee0d121638_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8b8a326cbb045a2adba2e477e561ffb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic75220e6ebf14568819bd9a9b6188619_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia318474dcd744baa89624395a2172f09_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i54197fbcf9eb44bfb6b566fc98512a15_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5a981d56b4f645fe9eeeed274c7cba3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d10a58948e44c138c7d0466ca49b76c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ed37ac5584840178c946fee09f7a1c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9d9ba332d224e66a279d66f036bb8d5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i30c943b762ec4138807d933021b95604_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i729d5aea6d6f496f88811f7efeda63ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if9b0fceaafb44bd1aa406949729a0241_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i62d5bac46f7047728d72dfe5c070cbbf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3b957d86897d4ded98362051c9b71b26_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5949335831d149739ca8f936d4b7a57c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaad2b34e87e0423a9ea15f4ae64ee1bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia16d15f92eef46998d5ead2a1b1771a9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia0dd811805a64591b10c10d7d8c3a94e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5401793db14442e29e91d912fc6f3de8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id687c9edba674c009de90ff41d9177bb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id9717f9d6b3c445492a8c653a191c33e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if83be0173217465a96cf353e15212445_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b092f6738974424a865248091f7861b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id0fa67cf15634c3098a5ad2740b26a0e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8db75135b55642678e951aa56e432e6d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36735be07e1646a08e5d2a7ed37255c9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i37fd9b761d8b4af6bff239e1d9eb1a83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8e3f46fa37d451a8e35adb77e7ff6bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7ba30e2338734c24914a82cefe965a84_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8df174afc3444428bb70e46b35047e30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i716b88505d1e48bf95997e445c69d7e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2bbf21a381224062a3ec08810f278afd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib1e5d06897a04de68392658f8d0f8904_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3310a35e6b0403a81733f2e2057d4ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba4a6cec336e42db876f0c5690a9b6d4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3c03523e781649d89f6ad179f060154a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7262343d9a65444c927cc6b62cffc5f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4370b43741f1402a91671b54edbf2db7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i129f29a2040140c08baabf19b38dddd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i184871e21ba348d1b81fad633a38d169_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib70ed1d184c44bd8ba1ed708cad91d61_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3e575aafa15847fba6a21907ae53dd63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie08c0043b99c4e2ba8e47c65a339ceb1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c346b2768fb40dd91ac6ebba9fb94d7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if2f235c0c07d4506bd10df5031278985_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d1c311fbe544e15a962f0cdcb5479e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6a7538040e541f19698e90ed9663cbf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2f4efdd418f74b408cf00135e5d118c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b72e0433646475693a6cb7d2df40022_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6390040a02294303a155f1923472865c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iee4add6d698c44de8cd75978f383e97c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2cad22821de46f29ac5d2e479eed81b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i52040186e8344d189b9e280fb7fe1b2e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i88687f58720d4395a2d6dfdd03bea675_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d0b0e5a61604c6e866e7abdc8b2f909_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dbc20679af844698cd41359e5fd718f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i78313bb854a147e5a42efbba390205fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ef9755b84b746e88b21161ca9f7a0f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i265675dad9e342e9b47878356a5b781d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mrk:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="aud">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="interest_rate_swap">
        <measure>mrk:interest_rate_swap</measure>
    </unit>
    <unit id="legalmatter">
        <measure>mrk:legalmatter</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV80L2ZyYWc6MDFiMGI4MmNkNmU0NGIxYjlhMjdkMmMxYmMwYWNmMTcvdGFibGU6YjBkYjA0MWM1NjQwNDBkNDg0MDc3NjJhMThhMTQzYmYvdGFibGVyYW5nZTpiMGRiMDQxYzU2NDA0MGQ0ODQwNzc2MmExOGExNDNiZl80LTEtMS0xLTA_ceea1a96-b757-4abb-95a6-48689749c7f2">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV80L2ZyYWc6MDFiMGI4MmNkNmU0NGIxYjlhMjdkMmMxYmMwYWNmMTcvdGFibGU6YjBkYjA0MWM1NjQwNDBkNDg0MDc3NjJhMThhMTQzYmYvdGFibGVyYW5nZTpiMGRiMDQxYzU2NDA0MGQ0ODQwNzc2MmExOGExNDNiZl81LTEtMS0xLTA_39d56554-d2af-4c87-9aca-277655209051">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV80L2ZyYWc6MDFiMGI4MmNkNmU0NGIxYjlhMjdkMmMxYmMwYWNmMTcvdGFibGU6YjBkYjA0MWM1NjQwNDBkNDg0MDc3NjJhMThhMTQzYmYvdGFibGVyYW5nZTpiMGRiMDQxYzU2NDA0MGQ0ODQwNzc2MmExOGExNDNiZl82LTEtMS0xLTA_fd1b9e0e-616d-44eb-9194-a6d2d644344c">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV80L2ZyYWc6MDFiMGI4MmNkNmU0NGIxYjlhMjdkMmMxYmMwYWNmMTcvdGFibGU6YjBkYjA0MWM1NjQwNDBkNDg0MDc3NjJhMThhMTQzYmYvdGFibGVyYW5nZTpiMGRiMDQxYzU2NDA0MGQ0ODQwNzc2MmExOGExNDNiZl85LTEtMS0xLTA_10ee7f6f-07c8-49c6-b175-a3c2fe2acee6">0000310158</dei:EntityCentralIndexKey>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate
      contextRef="i72b8afe3fe844c02ab7183ab38cfe809_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzU2_e83aaddf-6760-4d99-a679-17c8ad2698ac">P3M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_50622f13-ac81-4492-afe1-5ad4feaf94c9">us-gaap:OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_821d9613-2257-47a4-8e9e-6ec850c6c87e">us-gaap:OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_36307b76-5525-434a-87a2-55d497163500">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_ff6866b2-78de-4484-8932-0849a2e904bc">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_8ad1ce04-1366-42d1-95f3-bf2b967b7e47">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_a770729c-7273-4447-83c4-49a31ce0554f">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTEvZnJhZzowZjg4NGRlMDhjNDY0Zjg3YmJhNjBlZjIxNmMwZGM5NS90YWJsZToyMDk1NDljMzg0MGE0NTc4OWUwMTQzYzk5ZDNkYjFkNi90YWJsZXJhbmdlOjIwOTU0OWMzODQwYTQ1Nzg5ZTAxNDNjOTlkM2RiMWQ2XzEtMS0xLTEtMA_d8d9a076-4f04-4d2f-bce3-9ba225e75d4f"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE2_6f1590ec-6703-44d9-911f-b42a0c28643e">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6ZDZjMjI5ZTkwOTRlNDA2YWFmZmZlYjRlODc3ZmUxODUvdGFibGVyYW5nZTpkNmMyMjllOTA5NGU0MDZhYWZmZmViNGU4NzdmZTE4NV8wLTEtMS0xLTA_9959f17a-dc3f-4252-ada8-5e5d0b88db43">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMjQ_35011d6a-2638-4b00-9b4d-eb8ca3ec95db">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMjQ_4fa96099-fef4-4dcd-af60-0671d2a9dc64">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NGY5ZjhlNmM4Y2MyNDM3Y2IxYWZiNzA2MWRlMjBmYTgvdGFibGVyYW5nZTo0ZjlmOGU2YzhjYzI0MzdjYjFhZmI3MDYxZGUyMGZhOF8wLTEtMS0xLTA_0f75622b-f66d-4b8c-839a-86cc5cde5bc6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE3_bc73f54d-addf-40f5-a135-79dc7e3a5866">1-6571</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzIx_c6d1016f-9d88-4266-8876-ffce639db101">Merck&#160;&amp; Co., Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YjE0ZGVlZTc3N2I5NGMxZjkwM2FmZGNiMGNmOTQ2MTgvdGFibGVyYW5nZTpiMTRkZWVlNzc3Yjk0YzFmOTAzYWZkY2IwY2Y5NDYxOF8wLTAtMS0xLTA_70adda38-a311-4bd4-87b9-cadd3dfa3777">2000 Galloping Hill Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YjE0ZGVlZTc3N2I5NGMxZjkwM2FmZGNiMGNmOTQ2MTgvdGFibGVyYW5nZTpiMTRkZWVlNzc3Yjk0YzFmOTAzYWZkY2IwY2Y5NDYxOF8xLTAtMS0xLTA_315af606-c25b-45c5-8380-43cf21febd92">Kenilworth</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YjE0ZGVlZTc3N2I5NGMxZjkwM2FmZGNiMGNmOTQ2MTgvdGFibGVyYW5nZTpiMTRkZWVlNzc3Yjk0YzFmOTAzYWZkY2IwY2Y5NDYxOF8xLTItMS0xLTA_b85972e4-3268-46d5-a19a-c4a9f7529f82">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YjE0ZGVlZTc3N2I5NGMxZjkwM2FmZGNiMGNmOTQ2MTgvdGFibGVyYW5nZTpiMTRkZWVlNzc3Yjk0YzFmOTAzYWZkY2IwY2Y5NDYxOF8xLTMtMS0xLTA_d5f8f715-1b99-4116-a3d7-40be5913fd1b">07033</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzIy_dd8497c3-2078-4125-bb42-4d8fe0791316">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE4_974f7ff2-be69-4859-98a1-043192399eae">740-4000</dei:LocalPhoneNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NGZjNDk5MTVjY2ZiNGMyMGIzZjQ1MDlhNzU5NTNiOTgvdGFibGVyYW5nZTo0ZmM0OTkxNWNjZmI0YzIwYjNmNDUwOWE3NTk1M2I5OF8wLTAtMS0xLTA_1a32ba1b-3b37-462e-94b0-f65188952ce3">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NGZjNDk5MTVjY2ZiNGMyMGIzZjQ1MDlhNzU5NTNiOTgvdGFibGVyYW5nZTo0ZmM0OTkxNWNjZmI0YzIwYjNmNDUwOWE3NTk1M2I5OF8wLTEtMS0xLTA_7978163a-135e-42c3-96d6-8fa52b2be135">22-1918501</dei:EntityTaxIdentificationNumber>
    <dei:Security12bTitle
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8yLTAtMS0xLTA_84348ad5-12e0-4a63-8716-df13b8de6cd6">Common Stock ($0.50&#160;par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8yLTEtMS0xLTA_a38b0bfd-ba56-432f-b67f-b508224bb97c">MRK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8yLTItMS0xLTA_d6a59bd7-e021-47d9-933c-736354d4836d">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i0a69ae5ef81348d4b09b8c83b9741937_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8zLTAtMS0xLTA_cfa6cdac-af2f-4f0a-8359-ae9187b7542b">1.125% Notes due 2021</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0a69ae5ef81348d4b09b8c83b9741937_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8zLTEtMS0xLTA_d71a2f90-9e64-457f-bf8e-7d362c91af82">MRK/21</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0a69ae5ef81348d4b09b8c83b9741937_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl8zLTItMS0xLTA_ce875610-35fa-46df-8073-4172b76e9f89">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib21d7c48408a40228dbaaa754ce181ab_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl80LTAtMS0xLTA_8d0a44f2-4df6-4699-8b65-712b8abf9515">0.500% Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib21d7c48408a40228dbaaa754ce181ab_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl80LTEtMS0xLTA_bb63b8db-92db-440f-b7f7-7910dd9164af">MRK 24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib21d7c48408a40228dbaaa754ce181ab_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl80LTItMS0xLTA_d987e9ec-d20e-4ad9-aee1-4ef4b76d9f09">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id93e99ad3baf40e8aa1621b924a2b8b8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl81LTAtMS0xLTA_0d883439-bfbf-423b-a1f9-74b7b165783a">1.875% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id93e99ad3baf40e8aa1621b924a2b8b8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl81LTEtMS0xLTA_351bbfde-5de5-45fe-8691-a0c30865f112">MRK/26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id93e99ad3baf40e8aa1621b924a2b8b8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl81LTItMS0xLTA_6266efd8-cbc6-4e43-802c-e90000841863">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if42c8fd57f9e4140bb466d7b0aec1493_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl82LTAtMS0xLTA_64d610fe-2acc-47a6-9467-a2504abd0392">2.500% Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if42c8fd57f9e4140bb466d7b0aec1493_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl82LTEtMS0xLTA_0dd00c93-3743-440f-88b2-ca94878f4f86">MRK/34</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if42c8fd57f9e4140bb466d7b0aec1493_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl82LTItMS0xLTA_b0c4cd65-4ef6-4f52-9e14-40a9bd3dd909">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6ce73055eb814c269b6620f3c2a24a2e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl83LTAtMS0xLTA_914b3e1b-51ca-4a13-a59c-e9cb35d7aebe">1.375% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6ce73055eb814c269b6620f3c2a24a2e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl83LTEtMS0xLTA_2ce21fe4-2cd5-4698-b086-c2dd543194f1">MRK 36A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6ce73055eb814c269b6620f3c2a24a2e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6MDU4Y2EwNjE3YTE5NDRkNjhlN2NhZjY5MmZiMmZiODYvdGFibGVyYW5nZTowNThjYTA2MTdhMTk0NGQ2OGU3Y2FmNjkyZmIyZmI4Nl83LTItMS0xLTA_5f9b897d-ef38-466e-a8bf-95c7be8e0260">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i525fed88e739475e9bdd2c20f8225d78_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8zMjk4NTM0ODg2ODIz_42f7e0fa-b8e4-42da-9374-5e4f731b777f"
      unitRef="shares">2530315668</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat
      contextRef="ia25c4a8026c741e390c5f222dcb409cf_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8zMjk4NTM0ODg2ODg2_3e431ff6-47eb-4101-91f7-c49fb990e0f7"
      unitRef="usd">195461000000</dei:EntityPublicFloat>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzIz_667b1d0e-be1f-47ea-b604-bc4197fbf3fa">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE5_836afa71-d6ed-4c8e-9bb9-755b96b85158">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzIw_053dd703-2a3c-4c59-bc20-9e1539abe22d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzI0_10295048-b5c9-4fbb-be58-b7313c59ea8b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NWIwYmJkMGU0MjNlNDk0OGE0ZDY4YmMxZWE5ZGZlZTYvdGFibGVyYW5nZTo1YjBiYmQwZTQyM2U0OTQ4YTRkNjhiYzFlYTlkZmVlNl8wLTAtMS0xLTA_4cd8332f-fdb2-449f-8f6b-0d8294724ced">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NWIwYmJkMGU0MjNlNDk0OGE0ZDY4YmMxZWE5ZGZlZTYvdGFibGVyYW5nZTo1YjBiYmQwZTQyM2U0OTQ4YTRkNjhiYzFlYTlkZmVlNl8xLTMtMS0xLTA_e8cecc6c-2da4-4da2-adfc-13198135a8b0">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6NWIwYmJkMGU0MjNlNDk0OGE0ZDY4YmMxZWE5ZGZlZTYvdGFibGVyYW5nZTo1YjBiYmQwZTQyM2U0OTQ4YTRkNjhiYzFlYTlkZmVlNl8yLTMtMS0xLTA_2773aee7-c757-41ae-8703-06c909256d97">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV83Njk2NTgxMzk3NDk5_66944dc2-7c0c-4e7a-ade0-a41bad38acbc">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGV4dHJlZ2lvbjo3MDczZDg5MmM1YWM0NTFlYmJhOTc3ZTE4YWU3ZjQ1YV8yMzE0_694729f7-29fd-47e1-baa0-d2d8e1e2e8b6">false</dei:EntityShellCompany>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xL2ZyYWc6NzA3M2Q4OTJjNWFjNDUxZWJiYTk3N2UxOGFlN2Y0NWEvdGFibGU6YTJkYjM1NmI3MmNiNDAzMzk4ZTNlNjEzNzE3NzgyZjEvdGFibGVyYW5nZTphMmRiMzU2YjcyY2I0MDMzOThlM2U2MTM3MTc3ODJmMV8yLTAtMS0xLTA_a9a11893-f099-41de-9945-7a143c0dc1f8">Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;25, 2021, to be filed with the &lt;br/&gt;Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:Revenues
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEtMS0xLTEtMA_928aba44-74cd-4b40-929a-87e128386ca6"
      unitRef="usd">47994000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEtMy0xLTEtMA_453d6db4-b273-4178-b295-000b6310fcda"
      unitRef="usd">46840000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEtNS0xLTEtMA_ca10a547-d651-4d73-a7c5-94b006800944"
      unitRef="usd">42294000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzMtMS0xLTEtMA_f460424d-0b25-4d7f-9d6e-496f4ecb7c57"
      unitRef="usd">15485000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzMtMy0xLTEtMA_3bf2c42a-2eb2-4603-83e3-bac265c63b52"
      unitRef="usd">14112000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzMtNS0xLTEtMA_a020aa8d-cafb-4dea-8b04-35dc147651ed"
      unitRef="usd">13509000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzQtMS0xLTEtMA_370d0294-1036-4c51-9c65-7f9502d92525"
      unitRef="usd">10468000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzQtMy0xLTEtMA_340dd39d-f056-4af3-9851-8935a8bdc1ff"
      unitRef="usd">10615000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzQtNS0xLTEtMA_5cac05e8-c6c0-4b36-8294-84f59bdce797"
      unitRef="usd">10102000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzUtMS0xLTEtMA_52e9208f-f78a-4782-91a1-81fb88b8b5bf"
      unitRef="usd">13558000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzUtMy0xLTEtMA_3d76cbc7-1c9a-4c3f-90a1-2dc023460dcb"
      unitRef="usd">9872000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzUtNS0xLTEtMA_bb109eab-fffb-4c9d-ae32-1b2319660f93"
      unitRef="usd">9752000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzYtMS0xLTEtMA_e122ef36-398b-4053-8e32-9b1757a9e416"
      unitRef="usd">578000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzYtMy0xLTEtMA_ce1bc8c8-82e4-4520-aa9c-2a02585e6ed6"
      unitRef="usd">638000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzYtNS0xLTEtMA_ec53ebc6-b2b5-4890-9088-8cc7e9936b43"
      unitRef="usd">632000000</us-gaap:RestructuringCharges>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzctMS0xLTEtMA_27421474-e1a2-4ac6-9f7b-9ab5642a22c1"
      unitRef="usd">886000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzctMy0xLTEtMA_9977bc6f-2f54-4c6e-a2d1-d17428fff838"
      unitRef="usd">-139000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzctNS0xLTEtMA_66efc25d-24fb-4558-a494-badf15136a95"
      unitRef="usd">402000000</us-gaap:OtherNonoperatingIncomeExpense>
    <mrk:CostsExpensesAndOther
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzgtMS0xLTEtMA_2f933681-e6c4-4665-97bc-660d10418da6"
      unitRef="usd">39203000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzgtMy0xLTEtMA_4fda55a5-eaad-4080-9650-d442dc37c836"
      unitRef="usd">35376000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzgtNS0xLTEtMA_6f92c778-8f16-4126-9365-5578e025a904"
      unitRef="usd">33593000000</mrk:CostsExpensesAndOther>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzktMS0xLTEtMA_c3a17d91-113d-419f-865a-1dc2ed3cf9d1"
      unitRef="usd">8791000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzktMy0xLTEtMA_1390d537-4949-4758-9fe1-775507688d82"
      unitRef="usd">11464000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzktNS0xLTEtMA_642fc172-5625-4b43-8577-05a37b148653"
      unitRef="usd">8701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEwLTEtMS0xLTA_fe00e8bb-621f-4824-9660-f8721b2d2950"
      unitRef="usd">1709000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEwLTMtMS0xLTA_461e4065-6807-4b5d-88f4-33f98773816a"
      unitRef="usd">1687000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEwLTUtMS0xLTA_79cbb3ef-a760-4c55-b6ad-394f646ba26a"
      unitRef="usd">2508000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzExLTEtMS0xLTA_9362e0d3-050d-4011-bd04-942a45f6356c"
      unitRef="usd">7082000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzExLTMtMS0xLTA_443b5a28-fa80-4f5c-bf9c-3944a0e99ad3"
      unitRef="usd">9777000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzExLTUtMS0xLTA_f508665a-b225-47ee-9e95-aeb254e24cc7"
      unitRef="usd">6193000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEyLTEtMS0xLTA_5be5b231-b464-4af8-a8ad-07164a2d34cf"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEyLTMtMS0xLTA_7540186c-dd0b-440c-ad3e-631d1be5554c"
      unitRef="usd">-66000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEyLTUtMS0xLTA_f5f53e33-b512-4bcb-934c-99ca1376ef64"
      unitRef="usd">-27000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEzLTEtMS0xLTA_42b18cbe-d3b7-4579-9448-3133d5602ff7"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEzLTMtMS0xLTA_a0c36a54-f62f-4a5b-bf03-7603bf011de0"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzEzLTUtMS0xLTA_679d2690-2161-4ab3-be81-de3ddbaefd9e"
      unitRef="usd">6220000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE0LTEtMS0xLTA_6a4f7073-5adf-4c51-94e0-bfa7741474e8"
      unitRef="usdPerShare">2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE0LTMtMS0xLTA_e80d022b-9de7-4005-a8a3-5f5f71cf1698"
      unitRef="usdPerShare">3.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE0LTUtMS0xLTA_c64d7ee4-677a-4bab-9d24-c7c663812013"
      unitRef="usdPerShare">2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE1LTEtMS0xLTA_1976b93b-5a4e-4ae7-920d-36461e252590"
      unitRef="usdPerShare">2.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE1LTMtMS0xLTA_7e72aabe-85b2-4d6d-8ee8-dd0e211ac625"
      unitRef="usdPerShare">3.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTpjMTQ1ZDA4YzIwMWQ0YTU5OGZhNDI0OWVlOTc2NjVhOC90YWJsZXJhbmdlOmMxNDVkMDhjMjAxZDRhNTk4ZmE0MjQ5ZWU5NzY2NWE4XzE1LTUtMS0xLTA_92bbac15-86be-4e0a-9181-03b12766b4d5"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzEtMS0xLTEtMA_b02506e4-828c-4a13-8741-095662782990"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzEtMy0xLTEtMA_f0c681ab-438d-4b71-b6ff-86808e7dcedf"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzEtNS0xLTEtMA_54d5b67d-5e30-45c0-835f-496a62350079"
      unitRef="usd">6220000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzMtMS0xLTEtMA_0654dd83-460d-45cb-8f94-6b8bf0a4e957"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzMtMy0xLTEtMA_51cd718f-fd84-4afe-8f51-b89411e5b2aa"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzMtNS0xLTEtMA_2696b9d6-3ea3-42ec-a8b1-5d5e1c16dd46"
      unitRef="usd">297000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzQtMS0xLTEtMA_c8a7db93-c900-4f62-ac54-ea376e662e36"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzQtMy0xLTEtMA_89440ba4-da6d-4673-b809-877258e4832d"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzQtNS0xLTEtMA_e55f4f7b-c574-40eb-9107-552357e7fc07"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzUtMS0xLTEtMA_eba5955a-708e-48db-8f8a-641fec252bd5"
      unitRef="usd">279000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzUtMy0xLTEtMA_a097077a-84d0-491d-b986-70c5acaf024c"
      unitRef="usd">705000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzUtNS0xLTEtMA_a0585439-c53e-4ac5-a9a9-e06e2a780c87"
      unitRef="usd">425000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzYtMS0xLTEtMA_cd20c4d8-23b3-4036-8894-ba4f1f0e0dcd"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzYtMy0xLTEtMA_5ee6e675-3c1d-42ed-8074-ecb75b9ef122"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzYtNS0xLTEtMA_905108c5-ecdf-42a3-bf3a-e07395828836"
      unitRef="usd">-223000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzctMS0xLTEtMA_336dae2f-00e0-4cf5-9181-c6db8d8198c5"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzctMy0xLTEtMA_ed84f8e7-60e8-43da-9508-9662c9e2dd6b"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzctNS0xLTEtMA_9f4e4e8d-ff97-47f6-bbc3-50f5d1292579"
      unitRef="usd">-361000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzgtMS0xLTEtMA_3f3f96c4-506c-4301-a1b3-472dcbc6d0b7"
      unitRef="usd">6626000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzgtMy0xLTEtMA_d055abf8-45da-4980-8503-faf7716e7864"
      unitRef="usd">9195000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzYvZnJhZzo0ZjZkYWEwMDc3NzI0MThiODhhMmY5ZjVkYTBkMGMzMC90YWJsZTozNzM4ZDY2N2ZjM2Q0YmEzODgwZWM3NzAxMTkwYzkzMS90YWJsZXJhbmdlOjM3MzhkNjY3ZmMzZDRiYTM4ODBlYzc3MDExOTBjOTMxXzgtNS0xLTEtMA_9fb638a3-365d-4cff-849d-4b5dfa891829"
      unitRef="usd">5859000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMtMS0xLTEtMA_73613d75-49b9-418f-8e15-e9191697a758"
      unitRef="usd">8062000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMtMy0xLTEtMA_89af50ea-67ea-447b-8566-0a5ba1b9624e"
      unitRef="usd">9676000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQtMS0xLTEtMA_b0f8ebed-6177-4df3-a8e5-db87cf4d408f"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQtMy0xLTEtMA_29229680-1c25-4774-baa3-c0896880f058"
      unitRef="usd">774000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjA1Nzc0YmNlMDhmYTRjMWRiMjc4NjkxNTU5NmU0MTdkXzMyOTg1MzQ4ODM1NzU_88432ce1-86cf-48e8-a17a-eb77211ba313"
      unitRef="usd">85000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjA1Nzc0YmNlMDhmYTRjMWRiMjc4NjkxNTU5NmU0MTdkXzMyOTg1MzQ4ODM1Njg_bbae9f3e-cc47-410b-af74-22028b182727"
      unitRef="usd">86000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzUtMS0xLTEtMA_89efcd81-788a-400b-a7cf-eb937f42eb76"
      unitRef="usd">7851000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzUtMy0xLTEtMA_98b3572a-cdfb-490c-a4b7-0e24569e3570"
      unitRef="usd">6778000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmI3NzYxZTdiM2UyMDQ3MjU4ZGY5MTg4N2RiNjYzMzllXzMyOTg1MzQ4ODM1OTI_29710d7a-6392-44cd-931e-f78a178b9626"
      unitRef="usd">2197000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmI3NzYxZTdiM2UyMDQ3MjU4ZGY5MTg4N2RiNjYzMzllXzMyOTg1MzQ4ODM1ODY_ad121880-6737-4e5a-9043-49447d5fb02d"
      unitRef="usd">1480000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzYtMS0xLTEtMA_b746333c-32e4-4c52-b641-001cdfebfdce"
      unitRef="usd">6310000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzYtMy0xLTEtMA_c9a8be2c-d718-47c7-b401-e1bac2133cf3"
      unitRef="usd">5978000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzctMS0xLTEtMA_9b268f92-d239-46e7-ac72-58b64f48db11"
      unitRef="usd">5541000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzctMy0xLTEtMA_979cc2c0-6b40-4080-b1b6-ab190cbfbfa2"
      unitRef="usd">4277000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzgtMS0xLTEtMA_bc97232b-ca61-4d61-9039-2c637265c134"
      unitRef="usd">27764000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzgtMy0xLTEtMA_3ae10174-7bab-4e2d-8bc2-80bcc3cdc661"
      unitRef="usd">27483000000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzktMS0xLTEtMA_2bf13840-2e38-4c2d-b851-8f2c0a176c9f"
      unitRef="usd">785000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzktMy0xLTEtMA_cd0f26f4-7fcd-48a7-956d-ef4c73845dc4"
      unitRef="usd">1469000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:Land
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzExLTEtMS0xLTA_715010e8-0bde-4162-ad74-e1d1af0953e7"
      unitRef="usd">350000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzExLTMtMS0xLTA_cacaa655-020b-4386-a1d1-49aa4fa2cbc7"
      unitRef="usd">343000000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzEyLTEtMS0xLTA_16cd82ea-ccc8-499f-8d3d-bb81bd46876d"
      unitRef="usd">12645000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzEyLTMtMS0xLTA_753899b9-400c-4a9e-bd92-66c7b1253c8f"
      unitRef="usd">11989000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzEzLTEtMS0xLTA_da9b8dd2-e7ba-459c-8f51-bd8760d471a2"
      unitRef="usd">16649000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzEzLTMtMS0xLTA_dacc45d5-7f1d-4302-9642-00dea72571ae"
      unitRef="usd">15394000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE0LTEtMS0xLTA_f307efe3-5270-4022-bf06-926b575f358b"
      unitRef="usd">7324000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE0LTMtMS0xLTA_2e8d6274-a1ca-4be6-b891-817bb73a8bbe"
      unitRef="usd">5013000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE1LTEtMS0xLTA_96aa7a90-9607-4933-a2c5-b2f5f11dbba3"
      unitRef="usd">36968000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE1LTMtMS0xLTA_50120178-ddad-4344-8495-c87f44787c04"
      unitRef="usd">32739000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE2LTEtMS0xLTA_c61308a9-5b7e-468c-ab1a-179e43746c7a"
      unitRef="usd">18982000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE2LTMtMS0xLTA_6934cb7a-3de5-4bad-b3d4-efe1c4b4c505"
      unitRef="usd">17686000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE3LTEtMS0xLTA_b94329b3-e5b8-49c3-987a-c0c8487db463"
      unitRef="usd">17986000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE3LTMtMS0xLTA_bc484a02-0ece-40de-8ce1-6348deb4fe18"
      unitRef="usd">15053000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE4LTEtMS0xLTA_0b5975a0-4711-4ed8-ac49-339862483a51"
      unitRef="usd">20238000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE4LTMtMS0xLTA_16af884a-03ed-44e7-b433-4c3f8055e046"
      unitRef="usd">19425000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE5LTEtMS0xLTA_0447b130-3ed3-4265-9f51-1deafefaa5ba"
      unitRef="usd">14604000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzE5LTMtMS0xLTA_f4c86c13-0b2b-4360-936d-b3646a343a35"
      unitRef="usd">14196000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzIwLTEtMS0xLTA_f3931701-de4b-45f6-b88c-598dab9a49a8"
      unitRef="usd">10211000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzIwLTMtMS0xLTA_bba6ecae-947d-4a0a-a362-7c8986e6fa36"
      unitRef="usd">6771000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzIxLTEtMS0xLTA_0d0d3a4a-6998-42a4-a152-473cbb6190d2"
      unitRef="usd">91588000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzIxLTMtMS0xLTA_aed5dc00-8e70-4d5f-be1e-c9f38c5aac6a"
      unitRef="usd">84397000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI0LTEtMS0xLTA_5266c74f-5b99-46a6-91bb-73d9d5ebaf26"
      unitRef="usd">6431000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI0LTMtMS0xLTA_2db4d5f7-7115-4260-80a2-ad3a2d68bcbe"
      unitRef="usd">3610000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI1LTEtMS0xLTA_6ee3f824-1de8-40ae-88d4-234c0851df3b"
      unitRef="usd">4594000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI1LTMtMS0xLTA_a0c3f522-6a27-440c-9791-1bd14e5a9900"
      unitRef="usd">3738000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI2LTEtMS0xLTA_fa90e4ca-9d0e-4f6c-8fa0-2c29504640f9"
      unitRef="usd">13053000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI2LTMtMS0xLTA_6f909bdc-1e91-4400-a63d-358bb114bbe6"
      unitRef="usd">12549000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI3LTEtMS0xLTA_4c7676e1-d1d7-4643-b8fd-49988b91ec9e"
      unitRef="usd">1575000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI3LTMtMS0xLTA_b6c34ecb-6ccf-420d-8fc1-9edeed4be4be"
      unitRef="usd">736000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI4LTEtMS0xLTA_07396bcd-5d9e-4c2b-8677-94b41148f4d9"
      unitRef="usd">1674000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI4LTMtMS0xLTA_a917b291-c16e-44d1-a84b-86498693ff47"
      unitRef="usd">1587000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI5LTEtMS0xLTA_70a7726e-0b2c-469e-b693-3ecc6ba0bffe"
      unitRef="usd">27327000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzI5LTMtMS0xLTA_000864e8-6107-42d6-a265-dc3c72a6dc4d"
      unitRef="usd">22220000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMwLTEtMS0xLTA_f85662a0-bea7-460b-b847-1ab4e2e51d15"
      unitRef="usd">25360000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMwLTMtMS0xLTA_df3556e8-8bf4-437c-89d5-9d0fc8c92bdf"
      unitRef="usd">22736000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMxLTEtMS0xLTA_57d1bb50-d401-404a-a621-e7ce028ba7b1"
      unitRef="usd">1015000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMxLTMtMS0xLTA_fb0fecce-3550-4967-859f-edfdc43af3b4"
      unitRef="usd">1470000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMyLTEtMS0xLTA_4f43ed07-f22b-416f-88d6-4c60ad932ba8"
      unitRef="usd">12482000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzMyLTMtMS0xLTA_627c91e2-16e6-4275-8d25-1f31e19688b9"
      unitRef="usd">11970000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNTcx_6690bbbf-ad57-432e-8f52-9294fb8ebf5a"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNTcx_a87c6853-ecb5-42c3-aa73-5f02bbdf7250"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNjIx_82fed7ed-a110-43e2-aa0e-0282156a5dd4"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNjIx_bd85f2d7-ca4a-45ae-b9fd-af9df3ec0970"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNjM3_150a7d12-bbc6-429e-8c4c-58749b272373"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzQxNzVkNDhhNDE0NWI1OGZiZGQxNmViZTNjNjM0Nl8zMjk4NTM0ODgzNjM3_74da52ef-a0a9-4f7d-8d2b-0e9c7d9bbb9c"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTEtMS0xLTA_f30ce4a0-36b2-45f5-b9ad-60c9393c22d6"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM0LTMtMS0xLTA_55031257-58a8-4b83-bf01-9a7e13ca72b5"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM1LTEtMS0xLTA_075f72b7-6808-4611-82c2-1af973d26472"
      unitRef="usd">39588000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM1LTMtMS0xLTA_47fc3bc1-6d38-477a-8709-96384d1af2bf"
      unitRef="usd">39660000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM2LTEtMS0xLTA_5d82f513-a2b8-409c-a81c-9ca3c9517272"
      unitRef="usd">47362000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM2LTMtMS0xLTA_d576b4a0-9efa-4b22-b4c5-9802abd0caeb"
      unitRef="usd">46602000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM3LTEtMS0xLTA_9cd62cb5-2e1b-4795-a793-b89014dcac3a"
      unitRef="usd">-6634000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM3LTMtMS0xLTA_b659f645-cd89-48fb-b640-d1d851de15fd"
      unitRef="usd">-6193000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM4LTEtMS0xLTA_3e4b305b-76ca-43ee-8de4-4e7b248fd367"
      unitRef="usd">82104000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM4LTMtMS0xLTA_86a307ec-3acf-4492-a046-5a3e3f93ec8a"
      unitRef="usd">81857000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockShares
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjphOTE4MDJkNDVkMDY0NGIyODNmZjZkOGJmMTI1Y2U0OF8zMjk4NTM0ODgzNjI4_8137a30c-6627-4c59-a502-a63f794236d5"
      unitRef="shares">1046877695</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjphOTE4MDJkNDVkMDY0NGIyODNmZjZkOGJmMTI1Y2U0OF8zMjk4NTM0ODgzNjEy_9b8237ef-a2c6-44a8-9a0c-d01b0fb33521"
      unitRef="shares">1038087496</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM5LTEtMS0xLTA_7cf76da7-f2eb-4b88-ac4e-7be028cbc892"
      unitRef="usd">56787000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzM5LTMtMS0xLTA_8fe5e843-c973-43b7-adc2-0bb4a99d8c32"
      unitRef="usd">55950000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQwLTEtMS0xLTA_4c9ec6e6-b44b-48ba-a28b-2c45b06c6846"
      unitRef="usd">25317000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQwLTMtMS0xLTA_6bc2ad7b-f61b-4d2d-a7b5-8635bf7eb33b"
      unitRef="usd">25907000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQxLTEtMS0xLTA_e929ab8f-5158-40fb-9f52-69054a7251dc"
      unitRef="usd">87000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQxLTMtMS0xLTA_ff185d60-a315-4b02-9662-d560e7bf2dfd"
      unitRef="usd">94000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQyLTEtMS0xLTA_8d9d354b-f66c-4d55-bc8f-c8da14ed76a6"
      unitRef="usd">25404000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQyLTMtMS0xLTA_6871b343-484b-439e-9ea9-ba5a5bc29030"
      unitRef="usd">26001000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQzLTEtMS0xLTA_0ad780ec-9c37-408c-bb8c-ae3df5febacf"
      unitRef="usd">91588000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xMzkvZnJhZzo5ODY4MGMxZWIxMmQ0MTJlOThlYzM3YTRhZWNkYjg2ZC90YWJsZTo3Zjk0YTdkZWY2ZGM0Y2FlODNlZmMxMGNhZDgxYTZmYi90YWJsZXJhbmdlOjdmOTRhN2RlZjZkYzRjYWU4M2VmYzEwY2FkODFhNmZiXzQzLTMtMS0xLTA_6f6ccf28-2fc3-4468-b5b6-5038b210f5f8"
      unitRef="usd">84397000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i530838b57a7f40aea997c3c0d8eafce0_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtMS0xLTEtMA_5130b2cd-9543-4c96-ae18-0c33d5871ff9"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65d876890752448da45fd177f909c525_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtMy0xLTEtMA_264e2cf5-21c6-499b-bc36-ca639c687fe8"
      unitRef="usd">39902000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id57393189447424cbdff690d6eb86857_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtNS0xLTEtMA_91feae7c-c7c9-4545-9f37-9429a50594f2"
      unitRef="usd">41350000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7a0cf6a00f14978ae5b1e865e6c3e41_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtNy0xLTEtMA_510301ac-5869-428a-bccf-f9de6e373b78"
      unitRef="usd">-4910000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93f33a2e859a4576a7e62ef19bff98f0_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtOS0xLTEtMA_4ff55a84-1289-4876-a789-8e6810a474ca"
      unitRef="usd">-43794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c3f97c0c25247749fef8b6deb546624_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtMTEtMS0xLTA_e1b59666-f552-4647-ad9a-d7ec18d5b643"
      unitRef="usd">233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e100303069b40878e0e19c66282b95b_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEtMTMtMS0xLTA_2b83c0ed-57ed-4119-8881-b60fa783e109"
      unitRef="usd">34569000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i057a5c09a76d4467aa5c101819252a07_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzItNS0xLTEtMA_f12d4821-35e6-4f96-b08b-760f61a13188"
      unitRef="usd">6220000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzItMTMtMS0xLTA_7123e024-921e-4b48-8a8b-c01dfa04fbd5"
      unitRef="usd">6220000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0acb90ffdfa0455fa5f6bad3cc955686_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtNS0xLTEtMTU5_f2036cec-ae6b-4bed-9543-aa94e2792d9f"
      unitRef="usd">322000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb3e6a049ad240ddbcd87576b751ad64_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtNy0xLTEtMTU5_836e3ca0-8f65-441f-8b06-9cc52d92e430"
      unitRef="usd">-274000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84af4bb4ea9e41b5a3bb5245f8f322f4_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtMTMtMS0xLTE4ODM1_366ceb93-10d1-4911-9bf9-9617529f3b57"
      unitRef="usd">48000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id4872f4e47894212bbb218c64e39c4a7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtNy0xLTEtMA_2be9f788-c14a-4842-9839-df857d223cf0"
      unitRef="usd">-361000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzMtMTMtMS0xLTA_321f28a9-825e-4bf5-9a3a-27db2d697b00"
      unitRef="usd">-361000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzUtMC0xLTEtMTA3My90ZXh0cmVnaW9uOmU3YjI5MDQzYWVjMjRmNDRhZmVhNWIyYzhlNGRlNzk4XzMyOTg1MzQ4ODMzOTQ_49a7383c-3378-4e18-9a30-cffaebcc1cd3"
      unitRef="usdPerShare">1.99</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i057a5c09a76d4467aa5c101819252a07_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzQtNS0xLTEtMA_dc15f668-c815-4794-b27d-da473f18924a"
      unitRef="usd">5313000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzQtMTMtMS0xLTA_67cda304-18fd-4114-b40c-b0987ba7000e"
      unitRef="usd">5313000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie2ccd612449647558e0d8cc5f0e5305c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzUtMy0xLTEtMA_db8b4cad-3c67-41d7-9c29-da0b8f66bbc3"
      unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzUtOS0xLTEtMA_fda1cd37-59d5-4b39-956b-5ef9a9a12565"
      unitRef="usd">8091000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzUtMTMtMS0xLTA_c5ff3453-3a70-4b25-9c5a-f72de064bf89"
      unitRef="usd">9091000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifb0a1d042d5e4a5ebb0664bb2c15ebf6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzctMTEtMS0xLTA_cc65ac8a-d949-4eea-b634-1b7d9664845c"
      unitRef="usd">-27000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzctMTMtMS0xLTA_aefdcb4b-31c3-4442-8893-1abba8b3fd6f"
      unitRef="usd">-27000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ifb0a1d042d5e4a5ebb0664bb2c15ebf6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzgtMTEtMS0xLTA_ee319b2e-ce2b-42ae-a835-68026dadd242"
      unitRef="usd">25000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzgtMTMtMS0xLTA_2eae7be5-26d6-4d8a-9a47-264ba8b67011"
      unitRef="usd">25000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="ie2ccd612449647558e0d8cc5f0e5305c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzktMy0xLTEtMA_029792d8-949f-49d2-b839-cc0552805181"
      unitRef="usd">94000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzktOS0xLTEtMA_80fc8c4b-91c3-4fca-96ec-bc7ca4819810"
      unitRef="usd">-956000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzktMTMtMS0xLTA_d5cf4928-3e3f-4fac-ab19-133c41e264d8"
      unitRef="usd">-862000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67131e7c55f84174b370dc31e7893725_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTEtMS0xLTA_17ab3f1c-cb07-41ac-a37d-b4440b015bac"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe17ea10ec2d46f9aac4bca5f67dd3f5_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTMtMS0xLTA_0aee4ff8-e432-48c4-a327-5eae76a96b8b"
      unitRef="usd">38808000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae2e6ec2ed8a4ed5964f5012a0361b21_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTUtMS0xLTA_1162620e-2121-42b3-8fff-05e080410b55"
      unitRef="usd">42579000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67b4b127a8884ff190bb26aefa784be3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTctMS0xLTA_dd8d60bc-347e-422a-95e7-5b8e8d006afc"
      unitRef="usd">-5545000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if472f36dd37249baacd8179c8220ecaa_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTktMS0xLTA_30b1c20e-de89-4c39-b0bc-326f8a880759"
      unitRef="usd">-50929000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3f70c8d1831f4f1fa906b5a243db58b0_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTExLTEtMS0w_15b5ee34-a8a0-4215-a5bb-24ddf4bd752f"
      unitRef="usd">181000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEwLTEzLTEtMS0w_a5a10403-40c8-4661-9e08-0e7f79290215"
      unitRef="usd">26882000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i763fc5648968415f92f38b504b93bf09_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzExLTUtMS0xLTA_ce84ffac-924b-433b-babe-8c0c8d5b9cae"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzExLTEzLTEtMS0w_1e36d92a-86ee-4dd0-a585-f1898215ca48"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i17941d3435994547bd0f648e9860112e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEzLTctMS0xLTA_9a1be2b6-e6a1-4a33-a3d9-b7036e7a8ba7"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEzLTEzLTEtMS0w_399a4333-d028-49a4-9b89-d3b8c8ad9092"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzEzLTAtMS0xLTEwNzYvdGV4dHJlZ2lvbjpkZDE5ODFjYjhkMGI0NTYxOTIwNTg3YjZhZDZmOWJiMl8zMjk4NTM0ODgzMzk0_6dffe02e-b43d-4183-ba1a-2c642630ee71"
      unitRef="usdPerShare">2.26</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i763fc5648968415f92f38b504b93bf09_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE0LTUtMS0xLTA_41f33fd5-3f09-4cf9-aa2a-a524050ec9d8"
      unitRef="usd">5820000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE0LTEzLTEtMS0w_15a5dc4c-4e67-4607-96ee-cc14fb52e559"
      unitRef="usd">5820000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i009e5e7a34934b2c8895d34fdb93faad_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE1LTMtMS0xLTA_0dfb0180-409e-4709-9cdd-2045be0d9c7c"
      unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE1LTktMS0xLTA_e4c6a2d2-d2d0-4b86-bd36-a257986fa34e"
      unitRef="usd">5780000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE1LTEzLTEtMS0w_8ab32939-b3b7-460b-98e5-93ceb801a1ca"
      unitRef="usd">4780000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib6c92792b11148c6966e23a7b3c4e4e6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE2LTExLTEtMS0w_c7b1c92f-db0b-4318-896d-80d3e063aa9c"
      unitRef="usd">-66000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE2LTEzLTEtMS0w_8722f2c7-7146-4e1a-97d4-718ec796c6f1"
      unitRef="usd">-66000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib6c92792b11148c6966e23a7b3c4e4e6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE3LTExLTEtMS0w_28d173e7-b180-48b9-9980-379395b010c9"
      unitRef="usd">21000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE3LTEzLTEtMS0w_f3cc8b6c-868d-47d7-bf46-b81ce02d183c"
      unitRef="usd">21000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i009e5e7a34934b2c8895d34fdb93faad_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE4LTMtMS0xLTA_d601c1fc-cb7d-4627-9293-d1ca9f2c8999"
      unitRef="usd">148000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE4LTktMS0xLTA_50cf3458-5acd-4dd3-9cfb-0f17736b07ca"
      unitRef="usd">-759000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE4LTEzLTEtMS0w_1928e032-dfec-4379-a226-eab0873bbadf"
      unitRef="usd">-611000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0896f4b9831541ae8488b94c4eae2335_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTEtMS0xLTA_9843d856-7e2e-46e7-a854-feb05867a9ee"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1000caf1ca924d2e859d474fe4e47375_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTMtMS0xLTA_da8b05f2-503a-4938-9202-c6526918422e"
      unitRef="usd">39660000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fcf60e98e4e4e8b96733cb145c00b95_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTUtMS0xLTA_8f677a2d-0999-4c91-bcb4-99f032a51be3"
      unitRef="usd">46602000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i090793285fc448169b5f2766fad90f7a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTctMS0xLTA_719e71af-46c7-4579-bd93-c35050f34ba6"
      unitRef="usd">-6193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia612eb926af84202b6beec26340d18cc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTktMS0xLTA_9131d6ef-2669-4e50-9294-559f7fb4a807"
      unitRef="usd">-55950000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6b305782607415cb6a709c71a39dc73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTExLTEtMS0w_ed8907c5-db76-40b4-98aa-f1bb37740cf9"
      unitRef="usd">94000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzE5LTEzLTEtMS0w_1c6bb293-1969-48a0-8094-9c9c64c5a06f"
      unitRef="usd">26001000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i6b68c915866b4394b86d1d387ad993a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIwLTUtMS0xLTA_09f4008d-29f4-45c1-a9f0-eae086ab695f"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIwLTEzLTEtMS0w_3ad17d74-35dc-47f9-8571-37dca4fdcf3c"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i07fa82e04dff4428aaae1017c07a4108_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIxLTctMS0xLTA_4cd76156-a1fb-4faa-9982-2b56d188d0a3"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIxLTEzLTEtMS0w_507c178f-8713-4ecf-88f5-e8dba3493893"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIxLTAtMS0xLTEwNzkvdGV4dHJlZ2lvbjo3ZTBlN2E0ZGMwNWY0ZjdlOTJmMDI3YjYwYmFkZDNmNV8zMjk4NTM0ODgzMzk0_853e8a2d-753e-4200-bdd1-7cb7e5fab197"
      unitRef="usdPerShare">2.48</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6b68c915866b4394b86d1d387ad993a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIyLTUtMS0xLTA_5b0d0a60-2b52-4469-abaf-4db5590d3dea"
      unitRef="usd">6307000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIyLTEzLTEtMS0w_05cbeaac-c3a1-4fc1-a2ba-d78905d87f75"
      unitRef="usd">6307000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIzLTktMS0xLTA_2f439789-0627-4dd3-b1aa-6c289ccca996"
      unitRef="usd">1281000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzIzLTEzLTEtMS0w_5229e0b7-a21c-433d-8d83-e1362cc1f83f"
      unitRef="usd">1281000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i96312e064b574ffaa9f1c3392694a627_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI0LTExLTEtMS0w_0e85058d-adcf-420b-8e08-fcb21dcd6147"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI0LTEzLTEtMS0w_e5f39e99-90e2-410c-8f23-e1075ba0fa14"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i96312e064b574ffaa9f1c3392694a627_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI1LTExLTEtMS0w_1a333404-24ad-443b-9539-de78ed0b1ecf"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI1LTEzLTEtMS0w_09a923fb-3492-4452-9f0c-487f70bd28c7"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="icb3e65989c80429e8fe99db11d1d76ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI2LTMtMS0xLTA_d07fb802-2ecf-48eb-a3d4-fae2bbac1fa1"
      unitRef="usd">72000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI2LTktMS0xLTA_4f8bf4aa-2f56-4fcf-88f5-e09ec34ed65c"
      unitRef="usd">-444000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI2LTEzLTEtMS0w_0b25b2be-9600-43b9-9a13-5476b2c3a973"
      unitRef="usd">-372000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id94362b387b441469ec50222fe704479_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTEtMS0xLTA_9fdf1f2c-3bb2-4eca-bc1c-216180d4df45"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f0a54f787d549bab0a21ae47e9740ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTMtMS0xLTA_8cee6db3-fe86-4139-8bd1-e069e6449b4f"
      unitRef="usd">39588000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i433792a99d134359b4473b0754e16132_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTUtMS0xLTA_ca76e640-69cf-4c84-a2dd-941bdf550692"
      unitRef="usd">47362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie09ace19fb574f50904349a9da836610_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTctMS0xLTA_41ab6fcf-f497-46b9-b4de-009888aec096"
      unitRef="usd">-6634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice647f7217ff4273a045f1876ac8bbe8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTktMS0xLTA_bf9c4059-c413-4a20-a3c6-01b0cbfdf561"
      unitRef="usd">-56787000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b572de2338948dd96d08b22dd4171a0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTExLTEtMS0w_026c67c7-2519-45d8-aa30-36141c170a33"
      unitRef="usd">87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNDUvZnJhZzo3NWFhMGY1NDFmYzQ0NmRmYmNmYTk3ZjBjNDg5Y2M2Ny90YWJsZTo3ZDBjMzdlMmY0YTg0YmJjYjY5OWViNDE4YTQ0YTkyNi90YWJsZXJhbmdlOjdkMGMzN2UyZjRhODRiYmNiNjk5ZWI0MThhNDRhOTI2XzI3LTEzLTEtMS0w_e0466793-cc92-49ec-9cf1-9cb188cf548f"
      unitRef="usd">25404000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzItMS0xLTEtMA_24d8b13e-dc26-4ad5-baa4-ea72ee9559bb"
      unitRef="usd">7082000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzItMy0xLTEtMA_3a4c0944-b182-4371-8e9a-740ab413df69"
      unitRef="usd">9777000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzItNS0xLTEtMA_77f81ef3-56f3-4679-bfa5-f88609fb8cbe"
      unitRef="usd">6193000000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQtMS0xLTEtMA_8990bfc4-b600-4ed5-8ac7-ebdfaeaa399a"
      unitRef="usd">1899000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQtMy0xLTEtMA_5f722c44-4b62-4fab-ad74-55708c2d1a2f"
      unitRef="usd">1973000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQtNS0xLTEtMA_73ab12af-b62a-43cb-b5ef-b5f0f985775d"
      unitRef="usd">3103000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtMS0xLTEtMTY1MTY_e21f8541-f8ed-4249-b3d0-1872eee09e4c"
      unitRef="usd">1726000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtMy0xLTEtMTY1MTY_ff4873ba-35d6-40dd-8995-3ff4131448c6"
      unitRef="usd">1679000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtNS0xLTEtMTY1MTY_c4d420eb-5ce4-4215-97f4-c6f352fbf8f4"
      unitRef="usd">1416000000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtMS0xLTEtMA_c6bb82da-a5ee-4aa2-bf5a-d0ada888bda2"
      unitRef="usd">1718000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtMy0xLTEtMA_af1fcddd-d283-4248-8558-3107bb49917b"
      unitRef="usd">1040000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzUtNS0xLTEtMA_e9ec1382-5887-4713-a94c-b762a898cb69"
      unitRef="usd">296000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <mrk:ChargeForAssetAcquisition
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtMS0xLTEtMTQ5NzA_3c438599-269c-4c52-91ed-1a7a6bd35a5d"
      unitRef="usd">2660000000</mrk:ChargeForAssetAcquisition>
    <mrk:ChargeForAssetAcquisition
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtMy0xLTEtMTQ5NzA_c3c6cd91-7d3f-457d-afe4-5a084aa1fa98"
      unitRef="usd">0</mrk:ChargeForAssetAcquisition>
    <mrk:ChargeForAssetAcquisition
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtNS0xLTEtMTQ5NzA_62b48806-d87b-4c66-b85a-f5e8c2fd5be1"
      unitRef="usd">0</mrk:ChargeForAssetAcquisition>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtMS0xLTEtMA_ac3fd26f-438b-43e8-9e79-e6c801e56577"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtMy0xLTEtMA_b1821928-480f-4138-929a-968af6265705"
      unitRef="usd">993000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzYtNS0xLTEtMA_7b489d56-af9f-489f-aff2-b75418c63a6e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzctMS0xLTEtMTQzMw_97cb2e48-db52-48be-91bc-45fa4d63baca"
      unitRef="usd">0</mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions>
    <mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzctMy0xLTEtMTQzMw_b758235d-bf80-40aa-827e-572b1786ff3e"
      unitRef="usd">0</mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions>
    <mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzctNS0xLTEtMTQzMw_5a3871b5-8792-4b42-85c6-9b16c4cb5074"
      unitRef="usd">650000000</mrk:ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzktMS0xLTEtMA_64037c61-f1f7-4686-837c-56a0ae140bb0"
      unitRef="usd">-668000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzktMy0xLTEtMA_3fa3044a-7b26-4d4f-a81d-0d515ea98073"
      unitRef="usd">-556000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzktNS0xLTEtMA_1ff9bb0e-4a12-4272-80b9-07282f5c81a4"
      unitRef="usd">-509000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEwLTEtMS0xLTA_1fbb4860-9c25-4543-96b4-c568e5bd8700"
      unitRef="usd">475000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEwLTMtMS0xLTA_c8d6249c-b236-477f-9b2f-a3835f118081"
      unitRef="usd">417000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEwLTUtMS0xLTA_6b81b310-b656-4a15-8480-1ab2cf75a806"
      unitRef="usd">348000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzExLTEtMS0xLTA_3907c2c6-fa88-495d-bc8d-f59cd08828d6"
      unitRef="usd">49000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzExLTMtMS0xLTA_32ea52c3-c765-4972-8bfc-7518c419e4a2"
      unitRef="usd">-184000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzExLTUtMS0xLTA_67f71416-58ea-4c8b-9f12-d9e7864b78e1"
      unitRef="usd">-978000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEzLTEtMS0xLTA_96060fc4-212f-478b-938e-3583a726128d"
      unitRef="usd">1002000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEzLTMtMS0xLTA_90648d26-c306-48a5-afdb-6fce59572741"
      unitRef="usd">-294000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzEzLTUtMS0xLTA_2d4f094b-f21b-4346-91d3-d3fea189d7fb"
      unitRef="usd">418000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE0LTEtMS0xLTA_f22ed36a-af05-43f2-b6c6-51bac0d78657"
      unitRef="usd">855000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE0LTMtMS0xLTA_ef249a97-7c79-4673-9799-935cdefdff13"
      unitRef="usd">508000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE0LTUtMS0xLTA_3b4fe7cc-b657-4b72-bfab-437e302a5c51"
      unitRef="usd">911000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE1LTEtMS0xLTA_25a67d1b-9386-4db8-a33c-fe45e54c9b3b"
      unitRef="usd">724000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE1LTMtMS0xLTA_91f50c6b-6aaa-4311-b0c2-be317d8f8d4e"
      unitRef="usd">399000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE1LTUtMS0xLTA_df8c8aa3-6e66-4c96-9880-3a7129449f5b"
      unitRef="usd">230000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE2LTEtMS0xLTA_a93083e8-5912-47a4-be20-522e250f975b"
      unitRef="usd">-1138000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE2LTMtMS0xLTA_17871d31-6fe9-4973-8798-432d6eb4d109"
      unitRef="usd">376000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE2LTUtMS0xLTA_7a8e6caa-24c9-4120-9d0c-4e2ed6343e66"
      unitRef="usd">-341000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE3LTEtMS0xLTA_c98c964b-fce1-4f67-bcb4-4eef794f3ce7"
      unitRef="usd">560000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE3LTMtMS0xLTA_92e1433e-bcc5-4b9e-afd2-dedd8c93c0ea"
      unitRef="usd">-2359000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE3LTUtMS0xLTA_b6efe0a6-87ee-4f0f-9b67-d5e1b55b626c"
      unitRef="usd">827000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE4LTEtMS0xLTA_4cfaa645-1868-478c-a30d-f43134299533"
      unitRef="usd">-453000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE4LTMtMS0xLTA_3b2661de-6a31-4cd0-996a-35d22db03c71"
      unitRef="usd">-237000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE4LTUtMS0xLTA_b5d2855f-61ff-40fe-ade9-fd175c4cacf4"
      unitRef="usd">-266000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE5LTEtMS0xLTA_77a0f448-c34b-4626-b1cb-9e66981585f1"
      unitRef="usd">2426000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE5LTMtMS0xLTA_12b0eca6-017e-41ee-8e7f-b13f045d413f"
      unitRef="usd">32000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzE5LTUtMS0xLTA_3820af8d-cdb6-4697-85cb-924663d96b90"
      unitRef="usd">674000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIwLTEtMS0xLTA_3e6ee809-759d-4de1-acf2-9d4dd779fd10"
      unitRef="usd">10253000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIwLTMtMS0xLTA_5bc46de0-93ef-4354-8bbb-7cc44e30d6c4"
      unitRef="usd">13440000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIwLTUtMS0xLTA_d9d80f55-6f24-4288-a524-df6d90fdb9ca"
      unitRef="usd">10922000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIyLTEtMS0xLTA_ab9c0e10-2548-4fe6-9784-cc31d67b9486"
      unitRef="usd">4684000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIyLTMtMS0xLTA_8f976b2a-57b4-4675-bc86-41a6952e7437"
      unitRef="usd">3473000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIyLTUtMS0xLTA_0ab1a6bb-179b-4dac-8fac-f2e3346e9791"
      unitRef="usd">2615000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTEtMS0xLTE2ODc1_88ccbdc3-4e86-4982-86a0-71ac4efe474f"
      unitRef="usd">1000000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTMtMS0xLTE2ODc1_da956de4-fc79-44a1-9b4c-41fab0fd9748"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTUtMS0xLTE2ODc1_0f6e6477-ea83-4f8f-b180-62270d648fe7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIzLTEtMS0xLTA_9f2edee2-b6b1-4c22-8cf2-c2677c3ac265"
      unitRef="usd">95000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIzLTMtMS0xLTA_972d89b0-5902-4bb5-b2f5-bd03d2b537f4"
      unitRef="usd">3202000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzIzLTUtMS0xLTA_225053da-118c-4eba-95da-1cc095cf80b5"
      unitRef="usd">7994000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTEtMS0xLTA_19ee71c5-35d0-41d3-9ed4-b4d19317d90a"
      unitRef="usd">2812000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTMtMS0xLTA_bfc3ccd4-9c48-4794-a36d-efa94d7a7d38"
      unitRef="usd">8622000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI0LTUtMS0xLTA_04e5d3cb-0171-4be1-9a5a-bd484e0f4ef0"
      unitRef="usd">15252000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTEtMS0xLTE0OTc5_f8775a24-61d6-473b-adc8-018aaf9087e4"
      unitRef="usd">2696000000</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTMtMS0xLTE2ODYx_1938b062-c444-46e2-83ce-4e14a457e9da"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTUtMS0xLTE2ODY1_3c74428f-136d-434e-8d60-4481edbef4ae"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTEtMS0xLTE5Mw_20531e26-8723-4e55-8a20-ea4ff067b67d"
      unitRef="usd">2545000000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTMtMS0xLTE5Mw_5cfea7e4-b498-4032-a6fa-340b07291f81"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTUtMS0xLTE5Mw_ba700832-1eaa-4ee5-83c9-52b613f66c52"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTEtMS0xLTA_39c46bbf-c701-432f-845a-2f2e65caf01a"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTMtMS0xLTA_77007dd5-6d31-4b13-87f4-a24dc196ada8"
      unitRef="usd">3620000000</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI1LTUtMS0xLTA_8d993f23-0f1a-4a99-9a15-a0d835c4195f"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI2LTEtMS0xLTA_fe4b28db-511e-4c2c-99a8-52dc03de953c"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI2LTMtMS0xLTA_27359339-5313-42b3-ba32-a18ab2495e48"
      unitRef="usd">1040000000</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI2LTUtMS0xLTA_cd3091f9-926b-4fdd-a7a2-82bae02377f8"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTEtMS0xLTA_1e360a38-8eaf-4acb-a9ba-7d6814479bdb"
      unitRef="usd">1365000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTMtMS0xLTA_a9bc4e86-3fe1-4906-bf69-96b1edb6f7cf"
      unitRef="usd">294000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI3LTUtMS0xLTA_fbbc6e4e-7c76-4ca8-a3a4-8ff3a49f1d1f"
      unitRef="usd">431000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI4LTEtMS0xLTA_25c4f02e-d045-481c-866b-785d6d6d15aa"
      unitRef="usd">-130000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI4LTMtMS0xLTA_45e24a20-145d-4ce1-93da-085f3f2f7c39"
      unitRef="usd">-378000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI4LTUtMS0xLTA_0946acb6-b7b6-4fd5-a7c9-b806cbb5deb3"
      unitRef="usd">-102000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI5LTEtMS0xLTA_dd10c93c-fcf0-48dd-9f55-49d70e5e5ca6"
      unitRef="usd">-9443000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI5LTMtMS0xLTA_d7fb565f-bed0-48a9-a768-b007bb2fac8b"
      unitRef="usd">-2629000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzI5LTUtMS0xLTA_4954616a-968a-463e-a28e-8619783a37a5"
      unitRef="usd">4314000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMxLTEtMS0xLTA_f9fa70b3-b9ad-400c-8c91-a942df6cd550"
      unitRef="usd">2549000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMxLTMtMS0xLTA_7b02ba18-40e0-4ccc-a8a2-81ab1f9ac917"
      unitRef="usd">-3710000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMxLTUtMS0xLTA_2b4e56d1-3331-4b13-94de-eeabeae40d4c"
      unitRef="usd">5124000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMyLTEtMS0xLTA_65a4203a-2e7f-4775-a31a-6c8f282c26ac"
      unitRef="usd">1957000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMyLTMtMS0xLTA_625049c6-d833-4f69-a44e-0416088c3f20"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMyLTUtMS0xLTA_89dc9e75-13ea-4026-955e-4a01a9dce1d1"
      unitRef="usd">4287000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMzLTEtMS0xLTA_a4a468de-9d4a-4868-8b0f-3fe21f728977"
      unitRef="usd">4419000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMzLTMtMS0xLTA_8f2e51c1-1a77-47bf-aaa9-b8f1e52b6a93"
      unitRef="usd">4958000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzMzLTUtMS0xLTA_a11fc186-92b0-42b2-9792-e8701f72c4e9"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM0LTEtMS0xLTA_e09d6e6d-ed43-4425-9717-51acedef6e53"
      unitRef="usd">1281000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM0LTMtMS0xLTA_f95ef4e7-b2f4-4956-a8b3-3dd821312882"
      unitRef="usd">4780000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM0LTUtMS0xLTA_c66544fc-135b-4f6d-a739-829992a9bfcf"
      unitRef="usd">9091000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM1LTEtMS0xLTA_05aded61-c0ae-405b-b4fb-5422f75309ca"
      unitRef="usd">6215000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM1LTMtMS0xLTA_8d64be23-eb2b-4a57-bcfc-837f64ff8828"
      unitRef="usd">5695000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM1LTUtMS0xLTA_ffd4c7cb-94d5-4a26-856b-287d67c79cdb"
      unitRef="usd">5172000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM2LTEtMS0xLTA_0bc2be74-2f48-4eb4-aa47-2133bbb4c6df"
      unitRef="usd">89000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM2LTMtMS0xLTA_b9b4941f-2be6-4179-a345-fba483fea4ab"
      unitRef="usd">361000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM2LTUtMS0xLTA_6748ddab-686e-4967-893d-215d319e28be"
      unitRef="usd">591000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM3LTEtMS0xLTA_341981b5-7efa-4837-972b-691793544d0a"
      unitRef="usd">-436000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM3LTMtMS0xLTA_0bd15d74-3acf-4ef6-914a-cb8fc6511f5e"
      unitRef="usd">5000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM3LTUtMS0xLTA_352dc78c-9a5d-4185-a9cb-3450e6badc20"
      unitRef="usd">-325000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM4LTEtMS0xLTA_ab551a73-fa8c-4b07-af92-ba51077b67c8"
      unitRef="usd">-2832000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM4LTMtMS0xLTA_6e360fae-f346-4f31-b972-192515c0e427"
      unitRef="usd">-8861000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM4LTUtMS0xLTA_75235837-0a0c-4a40-aba4-d4b0d96c7e9f"
      unitRef="usd">-13160000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM5LTEtMS0xLTA_4a6040da-292d-409f-a979-8ddeb31f649c"
      unitRef="usd">253000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM5LTMtMS0xLTA_c1fa95ce-bcff-4712-a923-4816d939e5c1"
      unitRef="usd">17000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzM5LTUtMS0xLTA_ab06957b-490e-45b1-9e32-2298d0762940"
      unitRef="usd">-205000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQwLTEtMS0xLTA_40104c90-5936-44dc-b2d8-e9dc7b55ff10"
      unitRef="usd">-1769000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQwLTMtMS0xLTA_ffd8d3df-1d3b-4aa5-b945-d11a5e1ed812"
      unitRef="usd">1967000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQwLTUtMS0xLTA_37f739f8-0296-427d-8908-4bd2e33ceb29"
      unitRef="usd">1871000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:RestrictedCash
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQxLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YWU5ZmMyYTM2OWU0MzM3YjM0YTE4YWMxMmJjNDRlZl8zMjk4NTM0ODgzNjU2_cac3f402-d8ab-4476-990a-840c29be6af4"
      unitRef="usd">258000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQxLTEtMS0xLTA_b52a2be9-c53a-428f-9728-9836a414cb87"
      unitRef="usd">9934000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQxLTMtMS0xLTA_ba1b55d9-2e9f-482d-94a3-3d94039e2a47"
      unitRef="usd">7967000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e100303069b40878e0e19c66282b95b_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQxLTUtMS0xLTA_16987ebe-0a18-4f47-8d7b-6f4b74e28567"
      unitRef="usd">6096000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQyLTAtMS0xLTAvdGV4dHJlZ2lvbjo3YmNkMDY2NmUwNmY0N2ZiOGUyYTRjNjhmOGQ5Nzk5NF8zMjk4NTM0ODgzNjc0_2a6dce14-8d22-47b1-bf1c-05a257a883dd"
      unitRef="usd">103000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQyLTEtMS0xLTA_df0b4d86-1f7f-4911-922a-2590c4a4f647"
      unitRef="usd">8165000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQyLTMtMS0xLTA_dcb6d673-3206-4e54-830f-a0c9f481ff99"
      unitRef="usd">9934000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNTEvZnJhZzphYWFlYjQ1ZTViOGI0ZDQ1YjNjOTg5MmI1NDk1NDc2Ny90YWJsZTo3ZmNjNjVkNjI5ODY0MTkwYTZiNGVjZmJhMTBjYWQ2Yi90YWJsZXJhbmdlOjdmY2M2NWQ2Mjk4NjQxOTBhNmI0ZWNmYmExMGNhZDZiXzQyLTUtMS0xLTA_a0060a8c-f8b2-455b-82ca-9f5ba13897c4"
      unitRef="usd">7967000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjAvZnJhZzo3YzczNGMxMzg4YjA0YzRhOGFjZmQ2ZjdiYzhjMmJmOS90ZXh0cmVnaW9uOjdjNzM0YzEzODhiMDRjNGE4YWNmZDZmN2JjOGMyYmY5XzM2NDc_95d49cda-abd7-4646-85e8-caa9c10799be">Nature of Operations&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#x2019;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously had an Alliances segment that primarily included activity from the Company&#x2019;s relationship with AstraZeneca LP related to sales of Nexium and Prilosec, which concluded in 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Planned Spin-Off of Women&#x2019;s Health, Biosimilars and Established Brands into a New Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, Merck announced its intention to spin-off products from its women&#x2019;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp;amp; Co. (Organon) through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vytorin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as well as the rest of Merck&#x2019;s diversified brands franchise. Merck&#x2019;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed late in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women&#x2019;s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjAvZnJhZzo3YzczNGMxMzg4YjA0YzRhOGFjZmQ2ZjdiYzhjMmJmOS90ZXh0cmVnaW9uOjdjNzM0YzEzODhiMDRjNGE4YWNmZDZmN2JjOGMyYmY5XzMyMQ_6a1a4e35-6174-4871-9700-9c153a159c5c"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyMzg1_f6323ac6-9420-4b8a-8ae2-f4e3b9f67496">Summary of Accounting Policies&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#x2019; interests are shown as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in equity. Investments in affiliates &lt;/span&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#x2019;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#x2019;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Equivalents&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#x2019;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the duration and extent to which fair value is less than cost. An other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to other factors is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for debt securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for equity securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#x2019;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The nature of the Company&#x2019;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.1 billion in 2020, $11.8 billion in 2019 and $10.7 billion in 2018. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#x2019;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were $249 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million and $2.9 billion, respectively, at December&#160;31, 2020 and were $233 million and $2.2 billion, respectively, at December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside of the United States, variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#x2019;s total unbudgeted spending and the Company&#x2019;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzU2_e83aaddf-6760-4d99-a679-17c8ad2698ac"&gt;three&lt;/span&gt; to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic competition, changes in formularies or launch of over-the-counter products, among others. Outside of the United States, returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck&#x2019;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, have longer payment terms, some of which are up to 90 days. Outside of the United States, payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 18 for disaggregated revenue disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Depreciation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Buildings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and from 3 to 15&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Machinery, equipment and office furnishings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Depreciation expense was $1.7 billion in 2020, $1.7 billion in 2019 and $1.4 billion in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advertising and Promotion Costs &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.0 billion in 2020, $2.1 billion in 2019 and $2.1 billion in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Capitalization&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired Intangibles&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangibles include products and product rights, licenses, trade names and patents, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years (see Note&#160;8). The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired In-Process Research and Development&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&#160;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as an acquisition of a business, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; over its remaining useful life, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Compensation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Costs&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Legal Defense Costs&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (GAAP) and, accordingly, include certain amounts that are based on management&#x2019;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company retrospectively adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#x2019;s collaborative arrangements (see Note 4 and Note 18). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standard&#160;Not Yet Adopted &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTQ1_d1817024-098b-4444-a956-5f19613dd23d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#x2019; interests are shown as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in equity. Investments in affiliates &lt;/span&gt;over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTM0_7f6fc951-7a4a-48b7-b812-18d2cce299d4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#x2019;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#x2019;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.&lt;/span&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTI3_2e7fede1-9ec8-42e0-8e14-f9683eb3a8b1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTM1_6c8d124f-a0f7-4294-a461-ee12405e61af">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Equivalents&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyMzc5_32766664-26c5-4458-9376-ec19fd7cc804">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.&lt;/span&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDE3_a1d574a6-adfb-4f40-b7f0-504762ae4446">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#x2019;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the duration and extent to which fair value is less than cost. An other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related &lt;/span&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to other factors is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for debt securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for equity securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTMz_2cb71988-a3b2-4d6c-94ae-f11f2386ec15">&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#x2019;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The nature of the Company&#x2019;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.1 billion in 2020, $11.8 billion in 2019 and $10.7 billion in 2018. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#x2019;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were $249 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million and $2.9 billion, respectively, at December&#160;31, 2020 and were $233 million and $2.2 billion, respectively, at December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside of the United States, variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#x2019;s total unbudgeted spending and the Company&#x2019;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzU2_e83aaddf-6760-4d99-a679-17c8ad2698ac"&gt;three&lt;/span&gt; to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic competition, changes in formularies or launch of over-the-counter products, among others. Outside of the United States, returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck&#x2019;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, have longer payment terms, some of which are up to 90 days. Outside of the United States, payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 18 for disaggregated revenue disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <mrk:SalesDiscounts
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEwMDIx_6c8590e1-e252-4d69-abc7-01894233d166"
      unitRef="usd">13100000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEwMDMx_6cc2a6ca-dcda-43cf-b114-4715ea059a95"
      unitRef="usd">11800000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEwMDQ0_3e5c2a3d-b296-4048-8132-622179870a41"
      unitRef="usd">10700000000</mrk:SalesDiscounts>
    <mrk:AccrualForChargebacks
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzExNzkw_3a9b825a-2741-4f4f-a5e8-773d973a4b70"
      unitRef="usd">249000000</mrk:AccrualForChargebacks>
    <mrk:AccrualForRebates
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzExNzk3_63f49fef-ddd2-4056-9e3a-5bcc3eeea0d3"
      unitRef="usd">2900000000</mrk:AccrualForRebates>
    <mrk:AccrualForChargebacks
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzExODMw_49a2360f-9705-439b-a97e-1c13fe3de778"
      unitRef="usd">233000000</mrk:AccrualForChargebacks>
    <mrk:AccrualForRebates
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzExODM3_57ecb268-817f-4f45-a962-d76d7ff3162d"
      unitRef="usd">2200000000</mrk:AccrualForRebates>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate
      contextRef="i953fcdd3d90e447480d218ef6e31883b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzYy_1ca7e9e6-fc53-4a59-97c1-dbdc98e54a24">P6M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzc2_7e5a7bb2-55c5-4b1e-b9bb-39bdbbfabc95">P12M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="iee629d83621d4a4cbfa8f64a6cda8b18_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzMzgy_1e495258-09da-4544-b2a0-50afab93cbb6">P36D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i0fddbf63ffa94c619baa9b05476b6c33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzNDY1_6eddf383-1774-47b4-8dcb-ad11b618052d">P30D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i2ffc6813f6914b38827655a976cc9e74_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzNTc3_73d82771-a332-4dc6-88ae-538291fadf32">P90D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i7a28618800c243e9a9a56cb43ec76314_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzNjQ0_cc05f69c-48ee-476d-a0c6-47549802259e">P30D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="ib7ae7baf3bf34777906747207fd9aa2d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzNjU1_fa37357a-04a5-4fb1-91f5-295c7e88f4c5">P90D</mrk:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTQw_4ba1d63a-a539-4eb4-83d8-effd98195a22">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Depreciation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Buildings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and from 3 to 15&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Machinery, equipment and office furnishings&lt;/span&gt;.</us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i78b12aa625c44405b0d39ee793eaf417_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzOTQ3_d7420739-4e44-4060-b61e-f58f485ef9aa">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie1033319c2914559931cb908a21c6d0b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzOTUz_2f275722-9527-4503-a723-4ec0bc6747cb">P45Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i58165389de634c2cb2c0d3e8bd443866_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzOTg2_c2ead448-abc9-4f7d-9161-a6f7ee541407">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iff425d31a4c6439287e6017923a0069d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEzOTky_d943e045-c3dc-4e82-99f8-a5303c47ad5f">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MDc1_54db4b98-1a67-4bd1-a946-ca4dee9bdb70"
      unitRef="usd">1700000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MDg1_cd933263-6447-4d3d-ad5d-442f83758481"
      unitRef="usd">1700000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MDk4_4e895b6d-2a77-4445-b0c2-b4b58046436a"
      unitRef="usd">1400000000</us-gaap:Depreciation>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDk5_38bb1b91-7910-4c6e-b087-3018ff20339e">Advertising and Promotion Costs &#x2014; Advertising and promotion costs are expensed as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MjU5_8827b835-6360-4981-825e-4553626984dd"
      unitRef="usd">2000000000.0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0MjYz_58550bce-e70f-4ddf-88f3-0873df3ee855"
      unitRef="usd">2100000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE0Mjcw_1c6b49a7-317e-4405-b050-c4206c166ea5"
      unitRef="usd">2100000000</us-gaap:AdvertisingExpense>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDgw_87cad53a-cb68-4ba1-814d-ad8d37c8672c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Capitalization&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i35717a97f0d5480bacc494c9ae0ae49a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE1MzMy_89dc11e2-cbaf-467e-8f50-88541d84b495">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i738d85dae80e42aaba01188d809878b2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE1MzM4_437645b1-fd44-42ea-b02f-52d9a2bed7e9">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDMw_5ee4182d-078b-4549-8742-a0faa5a657f3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).&lt;/span&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDI4_46b28f10-8f02-48b1-b357-dd5363ee9cf0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired Intangibles&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangibles include products and product rights, licenses, trade names and patents, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years (see Note&#160;8). The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted &lt;/span&gt;future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i72b8afe3fe844c02ab7183ab38cfe809_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE2NTg0_8fd6a727-e7ca-4cd7-b030-2f9776a741aa">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i953fcdd3d90e447480d218ef6e31883b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzE2NTkw_93353762-214d-4d92-8f8b-49e191648f85">P24Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyMzg5_e672e63e-e26c-45e0-8736-ecb76a64c738">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired In-Process Research and Development&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <mrk:ContingentConsiderationPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDEw_825a28e2-de0a-4647-b2de-6a6a7776d2c6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&#160;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as an acquisition of a business, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.&lt;/span&gt;</mrk:ContingentConsiderationPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTI5_f9bc8d49-0fb5-4f6a-a427-eb571635d993">Research and Development&#160;&#x2014;&#160;Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTYy_3f495169-33ba-46a5-884d-76c723526a61">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; over its remaining useful life, subject to impairment testing.&lt;/span&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTIy_00f77b43-4a7d-4883-97be-1fcb95c47802">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Compensation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDQ5_8ba50966-4cee-4978-81c1-a58f8c593572">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Costs&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.&lt;/span&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNDA2_25938657-8367-4fd7-a7cf-f23e5d820491">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Legal Defense Costs&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTE0_0b6f4edc-ad46-43cb-84c3-1cac3dc26a20">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyMzcx_9ea8de62-99d0-46a5-b3a5-b2b9f5a785e8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (GAAP) and, accordingly, include certain amounts that are based on management&#x2019;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyOTg1MzQ5MzUxMDM_0a0247a7-05c4-484a-bb00-214285e01cf1">Reclassifications&#160;&#x2014;&#160;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzMyNTA5_74b48813-5eae-4895-901c-f8f86228bc12">&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company retrospectively adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#x2019;s collaborative arrangements (see Note 4 and Note 18). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standard&#160;Not Yet Adopted &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <mrk:AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjUzNDI_16c6224b-9765-46ad-bc69-03752bf2716d">Acquisitions, Divestitures, Research Collaborations and License Agreements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#x2019;s financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million. In addition, OncoImmune shareholders will be eligible to receive up to $255&#160;million of future contingent regulatory approval milestone payments and tiered royalties ranging from 10% to 20%. OncoImmune&#x2019;s lead therapeutic candidate MK-7110 (also known as CD24Fc) is being evaluated for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19). The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50&#160;million for a 20% ownership interest in the new entity, which was valued at $33&#160;million resulting in a $17&#160;million premium. Merck also &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized other net liabilities of $22&#160;million. The Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $462&#160;million in 2020 related to this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio&#x2019;s lead investigational candidate is MK-2140 (formerly known as VLS-101), an antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180&#160;million (primarily cash) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $2.7 billion in 2020 related to the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen&#x2019;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $616&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6&#160;billion, including $850&#160;million in development milestones and $1.75&#160;billion in sales-based  milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65&#160;million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck&#x2019;s territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#x20ac;256&#160;million ($302&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289&#160;million and other net assets of $13&#160;million. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401&#160;million related to currently marketed products and inventory of $9&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, also known as EIDD-2801), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments of up to $740&#160;million. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $97&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;amp;D of $136&#160;million, cash of $59&#160;million, deferred tax assets of $70&#160;million and other net liabilities of $32&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $230&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;amp;D impairment charge of $90&#160;million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. The Company also recorded a reduction in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expenses resulting from a decrease in the related liability for contingent consideration of $45&#160;million since future contingent milestone payments have been reduced to $450&#160;million in the aggregate, including up to $60&#160;million for development milestones, up to $196&#160;million for regulatory approval milestones, and up to $194&#160;million for commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#x2019;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305&#160;million in 2020, of which $260&#160;million was reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and related to fixed-asset and materials write-offs, as well as the recognition of liabilities for purchase commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The remaining $45&#160;million of costs were reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95&#160;million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2020. ArQule&#x2019;s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton&#x2019;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as an acquisition of a business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D MK-1026 (formerly ARQ 531) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangement for ARQ 087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of the identifiable intangible asset related to IPR&amp;amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#x3b1; (HIF-2&#x3b1;) for the treatment of patients with cancer and other non-oncology diseases. Peloton&#x2019;s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2&#x3b1; inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $1.2 billion; additionally, former Peloton shareholders will be eligible to receive $50 million upon U.S. regulatory approval, $50 million upon first commercial sale in the United States, and up to $1.05 billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $52 million, and other net liabilities of $4 million at the acquisition date, as well as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $993 million in 2019 related to the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq&#x2019;s debt. The transaction was accounted for as an acquisition of a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets (useful lives ranging from 18-24 years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results for 2019 include eight months of activity for Antelliq, while the Company&#x2019;s results in 2020 include 13 months of activity. The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; approaches to enable the body&#x2019;s immune system to fight disease, for $301 million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company recorded an aggregate charge of $423 million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in conjunction with the termination of a collaboration agreement entered into in 2014 with Samsung Bioepis Co., Ltd. (Samsung) for insulin glargine. The charge reflects a termination payment of $155 million, which represents the reimbursement of all fees previously paid by Samsung to Merck under the agreement, plus interest, as well as the release of Merck&#x2019;s ongoing obligations under the agreement. The charge also included fixed asset abandonment charges of $137 million, inventory write-offs of $122 million, as well as other related costs of $9 million. The termination of this agreement had no impact on the Company&#x2019;s other collaboration with Samsung.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, Merck acquired Viralytics Limited (Viralytics), an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers, for AUD 502 million ($378 million). The transaction provided Merck with full rights to V937 (formerly known as CVA21), an investigational oncolytic immunotherapy. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $34 million (primarily cash) at the acquisition date and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $344 million in 2018 related to the transaction. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, Merck and Eisai Co., Ltd. (Eisai) entered into a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima, an orally available tyrosine kinase inhibitor discovered by Eisai (see Note 4). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remicade/Simponi&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 1998, a subsidiary of Schering-Plough entered into a licensing agreement with Centocor Ortho Biotech Inc. (Centocor), a Johnson&#160;&amp;amp; Johnson (J&amp;amp;J) company, to market &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remicade,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which is prescribed for the treatment of inflammatory diseases. In 2005, Schering-Plough&#x2019;s subsidiary exercised an option under its contract with Centocor for license rights to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simponi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a fully human monoclonal antibody. The Company has marketing rights to both products throughout Europe, Russia and Turkey. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remicade&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lost market exclusivity in major European markets in 2015 and the Company no longer has market exclusivity in any of its marketing territories&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company continues to have market exclusivity for &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simponi&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in all of its marketing territories. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All profits derived from Merck&#x2019;s distribution of the two products in these countries are equally divided between Merck and J&amp;amp;J. The Company&#x2019;s marketing rights with respect to these products will revert to Janssen Pharmaceuticals, Inc. in the second half of 2024.&lt;/span&gt;&lt;/div&gt;</mrk:AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9ce1d972df3a4822ad7fad1e42f1b354_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxNzg_f87cf439-4473-4fbf-8b8f-ef4dacfe8e47"
      unitRef="usd">423000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ia0d7b698e30044dfb6cffe1fc04d9813_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzEwMjk_dca2b6b5-8b15-4790-b06b-36f022b042bf"
      unitRef="usd">255000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <mrk:RoyaltyRatePercentage
      contextRef="ib3fa7c6d136f41a3b40cca31c266c6de_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjU0MDY_4c9e53e7-5175-448d-98e2-92bb666f8b34"
      unitRef="number">0.10</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="ib175c23599ed49f9b1a462f8b563aac4_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjU0MTE_cdce4fc5-01d6-41c0-9b4a-ac5fefc9d8d5"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9ce1d972df3a4822ad7fad1e42f1b354_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzg4NjA_0dc9295e-997d-4d06-959f-4fefb14ac4ad"
      unitRef="usd">50000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifb2ee89502b94cd49ce08e1e3c882c21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzg4NzM_75ef862f-dcaa-4ac4-8fcf-1d66ba56aafd"
      unitRef="number">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:Investments
      contextRef="ifb2ee89502b94cd49ce08e1e3c882c21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzcyOTU_c8ef5473-a9cd-45ed-9e72-6bb480ad37b7"
      unitRef="usd">33000000</us-gaap:Investments>
    <mrk:PremiumOnSharesAcquired
      contextRef="i9ce1d972df3a4822ad7fad1e42f1b354_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2MTY_4031cedd-6158-43ea-b443-4d65b25e9b49"
      unitRef="usd">17000000</mrk:PremiumOnSharesAcquired>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="ifb2ee89502b94cd49ce08e1e3c882c21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2Mzc_d2fd67c6-2150-4beb-a856-39e7fdd15bef"
      unitRef="usd">-22000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0fb9fe46e2d94d4ab49c1b03fea4519d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2MzA_0e321388-510e-4ced-a895-72a349024123"
      unitRef="usd">462000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib773c56e9fab416e9e0d022601d5ce4c_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY3OTc_c095bcfc-29ab-4e40-bb4e-f64cf8ab2433"
      unitRef="usd">2800000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i98ddf3aa69a84aabaecb0a4d2ed8e2b3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2NDQ_a971b610-fbc7-4bb6-997f-8b42fc8c75d3"
      unitRef="usd">180000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i528e4f9a522448139a618d9f8e9aa62c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5Mzk2NTE_1d0a2f85-0020-44e8-b027-1c217e2f77d4"
      unitRef="usd">2700000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxOTU_13b6109a-a211-4b13-ad4a-624c30cbf30f"
      unitRef="usd">600000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity
      contextRef="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQyNDU_da197014-a8a1-43bb-b80a-a0ed624eef72"
      unitRef="usd">1000000000.0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQyNjE_a98fc806-63d0-455f-b923-6454216af6bd"
      unitRef="shares">5000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SharePrice
      contextRef="i0243fd5dacc84dfa85f4fceec13fbf65_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQyNjg_59a0b65a-5efd-4d2b-9250-64a8697fcf2e"
      unitRef="usdPerShare">200</us-gaap:SharePrice>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i40ca48bff51949d4bf90dd5e362d3f56_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQzMzM_11afe692-b1ca-4119-ae4a-fdb235aedbc5"
      unitRef="usd">616000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:PremiumOnSharesAcquired
      contextRef="ia34ed105cdff4df1a7d378c513d91380_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQzNDc_c6c9e700-4960-422c-b19f-79adfdeef6dd"
      unitRef="usd">16000000</mrk:PremiumOnSharesAcquired>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i90ded19f18484eb59f4e48a83d33fa50_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQyODk_c0fb4647-a0a7-4b3f-9007-d00dead873e7"
      unitRef="usd">2600000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i59fbc25bfc7641aca2fdbe80413efad3_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQzMDk_cec7f77a-480f-4c14-85b0-224761fc6dd8"
      unitRef="usd">850000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i02313044742341b49e06fa6a758966bb_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQzMjg_3b0afec4-9aa0-490e-a664-457ef473ab8b"
      unitRef="usd">1750000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i209f5888fc6749a2931c1615385b0e25_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY4MTY_dd5b467f-fa8d-4fd0-82e0-928861d379a1"
      unitRef="usd">210000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i73d37bdc4f354e69b8bcd53b246297ec_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5MDI_f35825b7-fabb-4f57-824a-d99d2d8c0d99"
      unitRef="usd">65000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:RoyaltyRatePercentage
      contextRef="ie7690d5c0cc347ed8b222d4300b23e30_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5MDg_3e493ea5-4be0-4dab-8399-7768769dcad9"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i8b12110871ee41ee9868a579e4bbf80e_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5MTM_6253cee5-6c85-46df-b895-012e4f204f40"
      unitRef="number">0.33</mrk:RoyaltyRatePercentage>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="idca8cca7b4e4487caad2c748e715f6e0_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5NDg_1dc8534b-0f93-4374-a2af-b9f97b78747f"
      unitRef="eur">256000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="idca8cca7b4e4487caad2c748e715f6e0_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5MzA_e46cd3bf-0cd4-45e2-9e73-5c31eaad3979"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i4224acfa30774326b05925533ba77ee8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5Njc_025514d8-2d97-4c24-95af-d90078b11199"
      unitRef="usd">289000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i4224acfa30774326b05925533ba77ee8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjY5ODQ_6c708558-b3ce-4e8e-abf0-ce8195c7de80"
      unitRef="usd">13000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i610b6867a103424f8f050100dff9795f_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwMjA_6b2a4a10-cc78-4bb3-8833-6379ed870371"
      unitRef="usd">410000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i9d1781ced27c45cbbbf893095d8cf6d6_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwMDI_3faf6128-c806-48f9-bbfe-c6bf4bdd9913"
      unitRef="usd">401000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i4f3dc7254c8544e48303d0911c527606_I20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwMzY_dd0cb276-1a1e-4a72-bb3b-953de8c656cc"
      unitRef="usd">9000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i03f79093ce234ffb8ea77c30f545b9db_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwNDI_33874ed4-aa7a-4b03-8f79-0916e51e4a0a">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5d9ba64de11e407f98dad1bd9112b382_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwNjk_8a2606b6-9510-40c5-b0bd-16747f13037a"
      unitRef="usd">366000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcwODY_8ec112b7-59b5-4b77-8539-99efb293a5ca"
      unitRef="usd">740000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcxNDU_6fe8cc75-4886-4d5c-80ee-161f3b579718"
      unitRef="usd">97000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcxNjM_9cc4b05f-37bd-4f2c-a365-08c442955c1b"
      unitRef="usd">136000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcxODA_0d75ffb8-4737-4d46-a419-f82e9a74f905"
      unitRef="usd">59000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcxOTc_81a9871b-0dfc-4444-a28e-bb3e18a66abb"
      unitRef="usd">70000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcyMzY_932c2ea8-c808-4967-a375-9ccd888e5125"
      unitRef="usd">-32000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:Goodwill
      contextRef="i54d078ec4ada42c9ad9804ab857bdb70_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcyNTQ_f631d6f9-6ba2-45ae-9f0b-86d92f039fc8"
      unitRef="usd">230000000</us-gaap:Goodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6d9b918e005a49c58a372d8e08c8ca72_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDI2NzA_de491d02-5208-4e40-a35a-8c539ef5260e"
      unitRef="usd">90000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6d9b918e005a49c58a372d8e08c8ca72_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDI2ODM_b118e115-d3bc-4608-8780-75c15002253f"
      unitRef="usd">-45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i945ab4055e164145a085c5b93e7c531b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDQ0NjM_b736a21f-2acb-4ec4-ad22-e78a71856163"
      unitRef="usd">450000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i99b9bcefa984431da58d2e033612d715_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDQyMzk_97b384fd-2c51-4d3c-a90e-1dcf91751ac7"
      unitRef="usd">60000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i4f84cb29fc604ca6b0af582a6e9be121_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDQyNzc_831847fb-2d14-489b-957b-aab2ccc4fa19"
      unitRef="usd">196000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i2dedf39dc8524bb497923e4bea2c9e1e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NDQzMjc_e76f8f8d-9fcc-498b-aac4-c4cab7d8e5c7"
      unitRef="usd">194000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="if1e411be978c47beb7efc4b35966b7a8_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MjcyNzI_fffd7a1a-457c-4140-9c7f-ae786bce8c10"
      unitRef="usd">6500000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:ChargesRelatedToProgramDiscontinuation
      contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjUzNDQ_921fb618-ba8e-4e9b-82e4-c5084032c407"
      unitRef="usd">305000000</mrk:ChargesRelatedToProgramDiscontinuation>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjU0MjQ_2226404b-f6f2-4f38-993f-aa4a9287319b"
      unitRef="usd">260000000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5NjUzNTg_66eb40ef-c54f-4b1c-84b9-b88c04f5089d"
      unitRef="usd">45000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i36680a86aa854fa98c2457cd53911551_D20200116-20200116"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzEyNDE_30a8f81a-a3cc-439e-aa9a-12125848ba57"
      unitRef="usd">2700000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxMzI_80870371-bd3a-41eb-8f16-a905bc0fb2d5"
      unitRef="usd">138000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxNDY_b6c47116-9426-4d4c-88b4-54b66de6fac9"
      unitRef="usd">95000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2Xzc2OTY1ODE0NzY2NTk_16c7a7c1-71f2-473b-8d73-23ca46df1e8f">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D MK-1026 (formerly ARQ 531) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangement for ARQ 087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of the identifiable intangible asset related to IPR&amp;amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets (useful lives ranging from 18-24 years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzItMS0xLTEtMzYwNQ_22b259de-0cb1-4a09-9bbb-58a43be31398"
      unitRef="usd">145000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzMtMS0xLTEtMzYwNQ_19d86145-f1f0-49e9-a306-322cbf111f6f"
      unitRef="usd">2280000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzQtMS0xLTEtMzYwNQ_a81dc66c-5e66-44e2-8f16-35581defea24"
      unitRef="usd">80000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzUtMS0xLTEtMzYwNQ_f460bd57-545b-4ea0-958f-17891b6e576e"
      unitRef="usd">361000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzYtMS0xLTEtMzYwNQ_5eb57953-8060-4331-9492-463418db51bb"
      unitRef="usd">34000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzctMS0xLTEtMzYwNQ_38eeceb1-1f49-4af6-8b1a-dacc1c8b26d8"
      unitRef="usd">2178000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzgtMS0xLTEtMzYwNQ_f94ae6d9-7b78-4d19-9bbf-f0c76980748c"
      unitRef="usd">512000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i8908727197fb4c19a64ffa96d563a2bc_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjZmRiZDI1ZWZhZjY0MTdkOGI2NGZjMWM3OWU2YTFjZi90YWJsZXJhbmdlOmNmZGJkMjVlZmFmNjQxN2Q4YjY0ZmMxYzc5ZTZhMWNmXzktMS0xLTEtMzYwNQ_7fc076f5-7c30-405a-9b1f-d9d3ab9f65bb"
      unitRef="usd">2690000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="i0d2cb7efc4324a38981648aa89ddcc18_I20200116"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMyOTg1MzQ5MzQxNTk_3a5b5bcd-77c8-487e-bc1b-0b66c78384b5"
      unitRef="number">0.125</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i07f15f684a9f4e1da581924f2c98bfb6_D20190701-20190731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzIxODM_f6bada65-56a2-4a66-85fd-64a9b4f5eb77"
      unitRef="usd">1200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i347f3eb2160e4032b140b2fdf9799106_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzIyNjU_faee2f8a-89e1-4b50-9b3e-aaeeada93211"
      unitRef="usd">50000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i081c04d8d22d4e03a143a335398bd927_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzIyOTk_0b95f2e6-7c0b-4c32-8bd8-a3f57c1a6410"
      unitRef="usd">50000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="iec9f0c316ec4420c85c71329dbb4ad02_I20190731"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzIzNjE_43ea3d9b-f8d4-4a67-9475-752ba1f2f43c"
      unitRef="usd">1050000000.00</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i8341e9d08ff14983a3ef4b4dcd949328_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI0Nzk_3e4e680d-c067-4d15-895a-537d14561059"
      unitRef="usd">157000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i8341e9d08ff14983a3ef4b4dcd949328_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI1MTE_2fa3619a-1142-4460-b008-57f5cefc078d"
      unitRef="usd">52000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i8341e9d08ff14983a3ef4b4dcd949328_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI1NDQ_2b3a6fca-f675-42ef-9e8d-a301eaf3637e"
      unitRef="usd">4000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib4d11122b7294a4694e482424ef3b691_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI2MTI_911d8289-35ee-4f2c-9a04-042d9c8a2b23"
      unitRef="usd">993000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ida918a35a96d497a919b2f7b5fbb9713_D20190401-20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzI5NTg_1f7d8eeb-6ca8-4822-bbaf-2712cc75c28a"
      unitRef="usd">2300000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzMwMTc_3585c939-e2c2-483c-b580-1b15b8d48633"
      unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzEtMS0xLTEtMA_2f021fab-e8c5-4176-a071-6ce09a3a6294"
      unitRef="usd">31000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzItMS0xLTEtMA_9cb023cb-164a-4ac9-a79b-3e59eeafd9c3"
      unitRef="usd">73000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzMtMS0xLTEtMA_1b585282-f901-468c-a50c-2c4e6ce94b78"
      unitRef="usd">93000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzQtMS0xLTEtMA_ed179f7a-0038-4613-b731-b1aa50df87bd"
      unitRef="usd">60000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5d04a426e1da4d6ca4a2b650e191b1fc_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzUtMC0xLTEtNDA1Mi90ZXh0cmVnaW9uOmZlZDhiNDU5ZWEwODQ2YzZiMDk4NmY4Zjk1OWFkZThkXzMyOTg1MzQ4ODM0MDk_95669d43-6fb4-4c75-b13b-78adabab8a62">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icdb01ee2305f4539ab9c5f07db7173e7_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzUtMC0xLTEtNDA1Mi90ZXh0cmVnaW9uOmZlZDhiNDU5ZWEwODQ2YzZiMDk4NmY4Zjk1OWFkZThkXzMyOTg1MzQ4ODM0MTU_9900257b-de25-483f-a7e3-0372d5f5aea5">P24Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzUtMS0xLTEtMA_13757359-08d6-47d3-8ec3-aeac5755a3de"
      unitRef="usd">2689000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzYtMS0xLTEtMA_fc1ad9b9-323d-4a4f-ab43-c6a089bccb28"
      unitRef="usd">589000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzctMS0xLTEtMA_7c56b6a6-5370-4fbc-92e1-841455144c41"
      unitRef="usd">-82000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzgtMS0xLTEtMA_f7253914-8c73-4b4f-9585-e7a2d34743f5"
      unitRef="usd">2275000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzktMS0xLTEtMA_49864445-9e95-42de-ba7d-cb65c466f22e"
      unitRef="usd">1376000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90YWJsZTpjM2ViOTE2ZDk0NDI0ZjZhYTA4NWZiNjY1MTM0YTJhNi90YWJsZXJhbmdlOmMzZWI5MTZkOTQ0MjRmNmFhMDg1ZmI2NjUxMzRhMmE2XzEwLTEtMS0xLTA_d04f74fa-53c9-4fe1-8c4d-648ce7578227"
      unitRef="usd">3651000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="i996ba4f2c0984b8cb870df85ea16273f_I20190401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzM0NDM_17ba78d6-fb19-48d8-9775-1fd9387471bb"
      unitRef="number">0.115</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="i29f6fdbabce3486cb4cfe03f8f281390_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzM4Mjc_b8a886d4-851c-4970-a197-87ef1a099bd4"
      unitRef="usd">47000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i485e704327b34e818bc08bad5c4a5d97_D20190401-20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQyMDE_1266f353-9f8a-453b-ae0c-d9878de32192"
      unitRef="usd">301000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i2da5d31a2da043428a6be3a178933283_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQzMjg_d263f459-735b-453a-ac19-ba865c06a58a"
      unitRef="usd">156000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i2da5d31a2da043428a6be3a178933283_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQzNDA_447ce521-f514-42a8-b0fc-ff837a090531"
      unitRef="usd">83000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i2da5d31a2da043428a6be3a178933283_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQzNjc_b61e614e-9005-4693-b44a-e3a4a3208aef"
      unitRef="usd">42000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:Goodwill
      contextRef="i2da5d31a2da043428a6be3a178933283_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQ0NjE_d6823482-2fa3-486d-89fa-ac6d08640164"
      unitRef="usd">20000000</us-gaap:Goodwill>
    <us-gaap:GainLossOnContractTermination
      contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzQ4Mjg_93d46e0b-e0fb-4aa1-8d0b-4df045079bc3"
      unitRef="usd">-423000000</us-gaap:GainLossOnContractTermination>
    <mrk:Contractterminationfeepayment
      contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzUwNDY_cff4301d-9503-4a64-b15b-7343f9285836"
      unitRef="usd">155000000</mrk:Contractterminationfeepayment>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss
      contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzUzMDQ_7c16ec7e-74ab-44c2-9785-ab45d80a1115"
      unitRef="usd">137000000</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzUzMzI_30341913-1c43-48f4-82f2-8ed337cfef8c"
      unitRef="usd">122000000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <mrk:OtherContractTerminationCosts
      contextRef="i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzUzNzA_13a8516c-b36e-499f-9fcb-045875cf72bc"
      unitRef="usd">9000000</mrk:OtherContractTerminationCosts>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1f7489b20f5c48308b9bb04baf6a39d6_D20180601-20180630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzU2NTE_c30d7773-36d9-4cc0-a25c-3a1b9687d46c"
      unitRef="aud">502000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1f7489b20f5c48308b9bb04baf6a39d6_D20180601-20180630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzU2NTU_69976623-5435-4d1f-9c36-a15baef96a53"
      unitRef="usd">378000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i26856c5ef4364f19bff668d3dfeed68e_I20180630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzYzNzg_05822a60-1315-42df-b73c-2d8f37cbdfb9"
      unitRef="usd">34000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iefeacd0e5f5842dbb109b127cdbe7f72_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjkvZnJhZzoyODk1NDc0NzJjODY0YmQxYjBhOTAzYjBmOGU3MzlmNi90ZXh0cmVnaW9uOjI4OTU0NzQ3MmM4NjRiZDFiMGE5MDNiMGY4ZTczOWY2XzY0NjM_f6545763-4e50-4b07-be08-bc62b5f9f6ff"
      unitRef="usd">344000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzEwNDIw_72d91640-47e6-4241-925d-c73fabd940f2">Collaborative Arrangements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#x2019;s more significant collaborative arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#x2019;s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor currently approved for certain types of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#x2019;s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, for multiple indications. In April 2020, Koselugo was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options (of which $250 million was paid in December 2017, $400 million was paid in December 2018 and $100 million was paid in December 2019). The upfront payment and license option payments were reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2017. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $400 million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded $400 million of liabilities and corresponding increases to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $550 million, $200 million and $250 million was paid to AstraZeneca in 2020, 2019 and 2018, respectively. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $160&#160;million, $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.3 billion at December&#160;31, 2020 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Eisai&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and Lenvima.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, Merck made an upfront payment to Eisai of $750 million in 2018 and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). The Company recorded an aggregate charge of $1.4 billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2018 related to the upfront payment and future option payments. In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $400 million from Merck to Eisai. Accordingly, Merck recorded liabilities of $400 million and corresponding increases to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million related to Lenvima, of which $500 million and $50 million&#160;was paid to Eisai in 2020 and 2019, respectively. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020 and 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $10&#160;million and $250 million, respectively, from Merck to Eisai. Potential future regulatory milestone payments of $125 million remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at December&#160;31, 2020 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount for 2018 includes $1.4 billion related to the upfront payment and option payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone and future option payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bayer AG&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#x2019;s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer&#x2019;s Verquvo (vericiguat), which was approved by the FDA in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults. Verquvo is under review by regulatory authorities in other territories including the EU and Japan. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck will commercialize in the United States and Bayer will commercialize in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas (and will record sales of Verquvo) in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2020, Merck accrued $725 million of sales-based milestone payments for this collaboration, of which $375&#160;million and $350 million was paid to Bayer in 2020 and 2018, respectively. Following the 2021 FDA approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone payment. Accordingly, Merck will record a liability of $400&#160;million and a corresponding increase in intangible assets related to this collaboration in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $849 million at December&#160;31, 2020 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; Other Noncurrent Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents accrued milestone payment.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i22a33fa403504dada396f58875c9157c_D20170701-20170731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI0NTQ_23aa28a1-e75c-45de-8c49-16955c5627e8"
      unitRef="usd">1600000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i22a33fa403504dada396f58875c9157c_D20170701-20170731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI0ODY_b93c8972-917a-4d9c-9951-2d90d73a969f"
      unitRef="usd">750000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie2b6640d40ff4e1799c205b35e73ced7_D20171201-20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI1NTI_bbdfd3e6-6a7c-4026-8fda-afaa0d653e0f"
      unitRef="usd">250000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i45f6bb982b5943a1bbbe16a8ac755b27_D20181201-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI1ODI_5e127fd4-491e-416c-814c-52a5d709f53f"
      unitRef="usd">400000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1d63658c728d4ed98637396020df1f7b_D20191201-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzI2MTU_daa58616-a51b-4873-af46-579d700f5cd3"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="i620af11cbb8f4c91a858173de9d019db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMwNzc_750eeb9b-9f84-47e2-aa6b-213c829fae53"
      unitRef="usd">400000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="ia6c051937aae495b8e9e5625eae66971_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMxNzY_13b02b47-a09f-458f-8be7-958dca929242"
      unitRef="usd">400000000</us-gaap:Liabilities>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="i1cd91baf9509462f81a3d9ce3a0cc395_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMzMzU_5a576700-e75b-4a5e-b38e-4b1d8c6984ee"
      unitRef="usd">1000000000.0</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i620af11cbb8f4c91a858173de9d019db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM4NDgyOTA3MDgyMTE_3867cdd9-3496-4c72-a162-c6405489ed85"
      unitRef="usd">550000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i1cd91baf9509462f81a3d9ce3a0cc395_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMzNDg_9799ac5a-fc52-45ad-9b8b-5505f929cbc5"
      unitRef="usd">200000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i6419d35ddb6b4e628eda2d42348e331a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMzNTU_88569156-aa52-4006-a39f-201051251300"
      unitRef="usd">250000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic26c0f3b7f0544268df9ca7c0d8af913_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM1MTU_336ae47f-4bb2-4ee3-9a57-4d0b848d5a1e"
      unitRef="usd">2700000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i42a16518bdec4e709a2954f61afd02f6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM4NDgyOTA3MDg3OTc_b4d946b7-d43c-4b4e-93f7-62769dd65f6a"
      unitRef="usd">160000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i878da9d0c0714be2bd5756cb5d5e834a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM5MzU_4b391f78-3ad8-4133-9fe9-745b25f342cf"
      unitRef="usd">60000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="iba602abb2d7549c19eab5306b4002102_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzQwODg_e84d954b-721f-4e4a-a375-de36e2ba463e"
      unitRef="usd">140000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i0e966186f72a4b0ab58ea90de20ec66a_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzQxODU_efc43f24-48e7-4f00-b3df-af6fedb3b114"
      unitRef="usd">1400000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i290e0168aaad4d8bbb291ae388c991a3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzQzNDQ_1cd74da4-3f11-456a-96df-a96ce7078a17"
      unitRef="usd">1300000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzEwNDEx_1d0d7b11-935b-468f-adae-99f42cf838cc">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount for 2018 includes $1.4 billion related to the upfront payment and option payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone and future option payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; Other Noncurrent Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents accrued milestone payment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="if7885d0aea044a2285bce8f3e73dfff2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzEtMS0xLTEtMA_01a7d410-06a9-4dd6-9683-8f9044b1d8e5"
      unitRef="usd">725000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="ia32a30c39b1b49b5b51cfcea80332547_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzEtMy0xLTEtMA_ee5fe25d-92b0-447f-a496-6aceff3e7a02"
      unitRef="usd">444000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i3d315dacfbde4501ba6c19d08de524d2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzEtNS0xLTEtMA_4fc95b92-08cd-4b53-a620-2607d48ea953"
      unitRef="usd">187000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i07de5c0f87bb4cbb837704628b2bd9e8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzItMS0xLTEtOTg4Mw_21fb1473-54be-4d75-8bd3-b738d94eeaa5"
      unitRef="usd">8000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i44cccbfd1aaa4196b45c4d6ecaf6cf96_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzItMy0xLTEtOTg4Mw_606b92f4-8d72-413e-87ca-d7bf91e9c05e"
      unitRef="usd">0</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i99a073f8f7b1407aa63ab374b8f4b9a0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzItNS0xLTEtOTg4Mw_56eb2f9f-0f5c-4e33-959d-49cdae57648a"
      unitRef="usd">0</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i330b41f19cde4e878a6b9d06b389bb53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtMS0xLTEtOTg5NQ_0307c3d1-4b40-4206-bb49-b869214723df"
      unitRef="usd">733000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i401735563ecd4f6e8f401746036baa9c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtMy0xLTEtOTg5Nw_fa2ff207-97bd-47ff-8a84-6cb50ed66dfe"
      unitRef="usd">444000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i8ece84cc7606444390554357bcf90179_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtNS0xLTEtOTg5OQ_6fae3cc2-7098-49e4-a40c-0a76a08e9c29"
      unitRef="usd">187000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i4fd756807e314175a880dd575077a4e7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtMS0xLTEtMA_708b3d1d-f661-4ead-9b2a-796e41f7720e"
      unitRef="usd">247000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i697fb80f1e6e4a91ac61fbdcad18f9cc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtMy0xLTEtMA_02f23dbb-6fc0-48c9-8478-ae7e12b8b38e"
      unitRef="usd">148000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="ica44f5e5fa844b15a4879fab9631e48e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzMtNS0xLTEtMA_954046e6-8a09-4737-b466-f465b6ff156b"
      unitRef="usd">93000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i6a10731ee0b24e8db15d8038662bb511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzQtMS0xLTEtMA_8ee428f7-a821-4b37-aaa2-af71cbe98811"
      unitRef="usd">160000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i4de09b10a2384c05b55e43c2f74660f9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzQtMy0xLTEtMA_edd329a9-17b4-416c-adfa-249d53d7dfae"
      unitRef="usd">138000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i9b5af579547c4a299bf5671d6d56b6c4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzQtNS0xLTEtMA_34d2110a-185b-4f6e-9f0e-fae9c6b9886f"
      unitRef="usd">48000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i70b51d3311034c3bac51a0de70567e64_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzUtMS0xLTEtMA_593cb3e7-9ff3-4458-912e-b8f01bc7ae11"
      unitRef="usd">133000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i9be4fde20b284f118e551ecaa1276e5b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzUtMy0xLTEtMA_3270773a-55bb-497e-af58-c5e622cc8008"
      unitRef="usd">168000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i4fc12f18f7224792ae5dcdbaf054352e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzUtNS0xLTEtMA_a0e4cda9-84bb-4792-a64c-9c67467d94d6"
      unitRef="usd">152000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementReceivable
      contextRef="i0326de13695545ddb2210521908c117c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzgtMS0xLTEtMA_2b1bed65-39d0-4e46-b0fd-778ab5cef932"
      unitRef="usd">215000000</mrk:CollaborativeArrangementReceivable>
    <mrk:CollaborativeArrangementReceivable
      contextRef="i4488c2e1f5c64819bf4b59fccdb0e9d3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzgtMy0xLTEtMA_3134b171-d439-40d0-92a9-fa7682a252ad"
      unitRef="usd">128000000</mrk:CollaborativeArrangementReceivable>
    <mrk:CollaborativeArrangementPayable
      contextRef="i0adede01333549d8bc322abf9e22e84f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzktMS0xLTEtMA_f86b47ad-105a-46e4-a19c-b6140a66c014"
      unitRef="usd">423000000</mrk:CollaborativeArrangementPayable>
    <mrk:CollaborativeArrangementPayable
      contextRef="ica3ea97cf2554f1d8815cc085464ebc4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZToyYTViYWU1OTk0YzI0ZTc0YjJjNjY2MDAxZGIzOGYyYy90YWJsZXJhbmdlOjJhNWJhZTU5OTRjMjRlNzRiMmM2NjYwMDFkYjM4ZjJjXzktMy0xLTEtMA_570f2697-f59b-4c77-ad46-30b8fe7a8c01"
      unitRef="usd">577000000</mrk:CollaborativeArrangementPayable>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i11173b2b42d64d0cb11c1105fb2ca7d1_D20180301-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU3Mzc_3c4b5aef-c743-4a9f-a32e-ccd2cc8da02b"
      unitRef="usd">750000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic2173fc8dee04c56aaeb475acb7c7018_D20180301-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU3NzI_9030eb84-3705-47a6-80fe-85deb0ec340c"
      unitRef="usd">650000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i199ae1c6ff6e448eb1085cdc50ff93f1_D20190301-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU4MjQ_159c90c0-1152-487d-b0b6-edfac08c445c"
      unitRef="usd">325000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9be5634cf9e3423d903fb59b51dfffc9_D20200301-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU4NTE_aba4ed38-d97d-4561-8ad5-121f83620567"
      unitRef="usd">200000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i302846733a5e4162a65e06b042b6c625_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU4OTU_d9a1e503-4394-409b-9d23-19f7bc5f9d93"
      unitRef="usd">125000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i884fede8f02b4207af70ce8ef3e7719a_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzU5ODE_cdf55e73-4839-4ddd-9114-34977766e42f"
      unitRef="usd">1400000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="iea8401099a9d4f1da0c09f5e4a845f53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY0MjE_21a5ab6f-518d-4774-9687-f5b6cc6bbd2e"
      unitRef="usd">400000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="ie652d13a7772491b9988fe4ca0cfc66e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY0NjI_6419fb30-72d1-4095-8ae2-86099514333c"
      unitRef="usd">400000000</us-gaap:Liabilities>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="iad6bc081967747b58d1b8d8f5af214b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY2MTg_4c45eb68-4fc8-4563-9564-ac1133c4766a"
      unitRef="usd">950000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="iea8401099a9d4f1da0c09f5e4a845f53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM4NDgyOTA3MTA1MDI_a7305f23-5599-412e-9aed-7f116ef42218"
      unitRef="usd">500000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="iad6bc081967747b58d1b8d8f5af214b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzM4NDgyOTA3MTA0NzQ_53d1fbed-1f78-4a0c-816c-fdd78712cb54"
      unitRef="usd">50000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="iefa940ebb76b40afa60a15a108b7af2f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY3ODY_a07b26f9-7194-44a2-bd15-9680f914f2d3"
      unitRef="usd">2600000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="ic341c5bdad3f434ab0c54a2c5e63395e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMyOTg1MzQ4OTgwMjA_8885feb5-74c4-4eb1-941e-2c093f5592c7"
      unitRef="usd">10000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i4f4920692eee4e4d815006aacc7d78b3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzY5NzQ_333e6086-587f-4c87-b909-80964d948c16"
      unitRef="usd">250000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i36f9356746cd4c6aa273dff749ec985b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzcwNjU_99031731-1260-4a05-85fc-8118b57d2ac2"
      unitRef="usd">125000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic4443e6b872f4ba8905276b85a6342e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzcyMjM_248c0469-797f-4eb0-a1aa-e6fb9518a4a6"
      unitRef="usd">1100000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i491d903bb49f4ed1a82e1b5a703ac09b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEtMS0xLTEtMA_41758755-890a-4171-ad7e-d56e402e409c"
      unitRef="usd">580000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="ie0400fa9e2d64e50917ba83f9b0256bc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEtMy0xLTEtMA_cee17ef1-99c4-4315-bddc-ad5069cb4c78"
      unitRef="usd">404000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="ia245619b9e664a26b6753a23646c0b18_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEtNS0xLTEtMjk0_44cdf887-0098-4d66-95e9-9c7484a6af01"
      unitRef="usd">149000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i454f432bff4c4574930a4219c0b5c005_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzMtMS0xLTEtMA_323c919a-310c-46ba-b3f7-779ba4383f2e"
      unitRef="usd">271000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="icaf4d70ed271480fa94afe6dd9a2000f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzMtMy0xLTEtMA_bad83be0-a809-4840-937c-d8673f8a6f38"
      unitRef="usd">206000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i9b505e290fea45b99717b674adac2691_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzMtNS0xLTEtMjk0_a6e51b45-2c96-44aa-afb5-f6fc47ffa544"
      unitRef="usd">39000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="ifd9d776541aa4ae082408d286b415f75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzQtMS0xLTEtMA_58c7c64a-15b9-4b46-a5a3-a937ebdc86c0"
      unitRef="usd">73000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i8b435415c6274d44b0dd2ae2de7d186d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzQtMy0xLTEtMA_b5fb44e2-d489-4946-921b-377ee90df2fa"
      unitRef="usd">80000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="ic7fdf3938156482ab9562725eb331768_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzQtNS0xLTEtMjk0_5dee1e85-a370-4341-a501-e204193a0fe4"
      unitRef="usd">13000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="iaab203463d1344f2b6b7b49ab329c80f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzUtMS0xLTEtMA_3f33e2a8-df0f-4fc1-8ed6-9cee43ba6ba3"
      unitRef="usd">185000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i7570f8d4c86b4b70ae7e83bff83c5ff5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzUtMy0xLTEtMA_0768a992-bfb6-41a5-ac6c-b45ba1f3f1e0"
      unitRef="usd">189000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i440fbf44eff94d33beb60677f2144686_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzUtNS0xLTEtMjk0_710973ec-1275-45e0-8045-87c94318f452"
      unitRef="usd">1489000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementReceivable
      contextRef="i96a84ffaafac460fbd68e4328f87c599_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzgtMS0xLTEtMA_c083dadb-2bdb-40ba-b3fd-e8e2d1a366fa"
      unitRef="usd">157000000</mrk:CollaborativeArrangementReceivable>
    <mrk:CollaborativeArrangementReceivable
      contextRef="i3d2650552a454bfdac17540247c4ad9a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzgtMy0xLTEtMA_4bbc90aa-9e13-4ad9-ae5c-0dfe6b039baf"
      unitRef="usd">150000000</mrk:CollaborativeArrangementReceivable>
    <mrk:CollaborativeArrangementPayable
      contextRef="i7041cdecd0cc482fb7f6996b7e09667d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzktMS0xLTEtMA_40e229c2-0697-45b1-9ad6-956b749380a5"
      unitRef="usd">335000000</mrk:CollaborativeArrangementPayable>
    <mrk:CollaborativeArrangementPayable
      contextRef="i7422cf6500bf43efb6beb9930ca4c6c9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzktMy0xLTEtMA_8dd44873-c7a7-43aa-8fa8-abfd073a3f29"
      unitRef="usd">700000000</mrk:CollaborativeArrangementPayable>
    <mrk:CollaborativeArrangementPayable
      contextRef="id4df60e0c1ad4ea8abfda1ae6df07058_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEwLTEtMS0xLTA_346895d8-3be3-40fd-950e-f2d34469b14e"
      unitRef="usd">600000000</mrk:CollaborativeArrangementPayable>
    <mrk:CollaborativeArrangementPayable
      contextRef="i283cb0fd0292451f9077f95aae1b4028_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTpjY2YxYzNkMzVjNGY0N2FiYjQ2NzgzMTAzNmRjOWM5Mi90YWJsZXJhbmdlOmNjZjFjM2QzNWM0ZjQ3YWJiNDY3ODMxMDM2ZGM5YzkyXzEwLTMtMS0xLTA_78c5da85-f21e-4b4a-b3ed-133451b655b9"
      unitRef="usd">525000000</mrk:CollaborativeArrangementPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i884fede8f02b4207af70ce8ef3e7719a_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzc2MzE_cdf55e73-4839-4ddd-9114-34977766e42f"
      unitRef="usd">1400000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="i491ff105eeb74cc6979d2752383ad3e7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzkzNzE_c3c22b82-d66f-45e6-825d-d9d616d19569"
      unitRef="usd">725000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i61497bc7d49a49a8b98adf19ffa96211_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMyOTg1MzQ4OTgyMTc_e3b9e10a-dd6c-4ddb-8d18-5b1cd59f33a4"
      unitRef="usd">375000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="iedff350d0421432989e5b4164f44779f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzk1Njk_29810825-5457-42d6-b0a6-358206c922c5"
      unitRef="usd">350000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="if2cc693bd8114433a7e7cebbe0e1a220_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzk2OTk_92f6570e-43f7-4cae-993f-7d0752e40bb1"
      unitRef="usd">400000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="ic5b17ae627674bfd9c3a3e606fc39a10_I20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzMyOTg1MzQ5MDk4MDc_331c802e-6570-4f8a-abd7-e387d6827478"
      unitRef="usd">400000000</us-gaap:Liabilities>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i50171610356846629bd94e414c848b8f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90ZXh0cmVnaW9uOjYyMDQwZDcyYTYyYjRhM2JhZGRhMTQ5ZGVhMzE4ZTFmXzEwMDA1_8ba72bfa-0275-4eba-93e1-4ff13ba7db2a"
      unitRef="usd">849000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i13429c0926e34225b226ce3b2cdb7e1a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtMS0xLTEtMTY2NDA_bde43ba8-b849-42a7-8cab-1f5403dae00c"
      unitRef="usd">281000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i897a73e11e48487f9d94d60f05fd9038_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtMy0xLTEtMTY2NDA_dee37828-faa8-40db-ad24-91d7e68ca352"
      unitRef="usd">204000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i2b8080482a8f4179b87efe70700d453f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtNS0xLTEtMTY2NDA_7405cb37-1dac-4127-b262-806256b2f2d1"
      unitRef="usd">139000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i13429c0926e34225b226ce3b2cdb7e1a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtMS0xLTEtMA_7d33d34e-80a3-405b-b5c9-dae935ec8caa"
      unitRef="usd">220000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i897a73e11e48487f9d94d60f05fd9038_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtMy0xLTEtMA_bb281655-143d-452d-8b48-dd7a1e2ef71c"
      unitRef="usd">215000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i2b8080482a8f4179b87efe70700d453f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEtNS0xLTEtMA_5dc4f80e-530f-4c2b-be05-27bb97c8d984"
      unitRef="usd">190000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i13429c0926e34225b226ce3b2cdb7e1a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzMtMS0xLTEtMA_9d24fe11-5198-4b14-ae77-8665be7c8734"
      unitRef="usd">501000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i897a73e11e48487f9d94d60f05fd9038_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzMtMy0xLTEtMA_90e21781-0f44-4938-b056-cc63aeedeb71"
      unitRef="usd">419000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts
      contextRef="i2b8080482a8f4179b87efe70700d453f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzMtNS0xLTEtMA_42d831d1-a789-47a1-81dd-1b85b882aef4"
      unitRef="usd">329000000</mrk:CollaborativeArrangementRevenuesNetofCommercializationCosts>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i246836ba7661455ea504f59e31b98459_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzUtMS0xLTEtMA_a614a821-604b-4e8c-b4b2-72a16ccbbaa1"
      unitRef="usd">115000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i1d1c052cc4f74b61be4c309541e38a86_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzUtMy0xLTEtMA_ba39a64c-dd9d-42fc-93f5-b7cadde99342"
      unitRef="usd">113000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i1516d5f6bccc4706bf9051b3e301dca3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzUtNS0xLTEtMA_a3a62dff-1ce7-41ba-8b39-20fae70339bd"
      unitRef="usd">216000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="ic6830421fe254ed988b3fe026bd6113c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzYtMS0xLTEtMA_46b86327-bdb9-4a26-b971-1c41bf5fe1c7"
      unitRef="usd">61000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i805d69de042e4086a978510f436a9822_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzYtMy0xLTEtMA_2fa47621-6090-4fd3-9431-a8950d78b3d0"
      unitRef="usd">41000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="ic6870f468772426088757f8a26d5a6e9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzYtNS0xLTEtMA_fbbd7055-f813-4b38-b303-5440776a2ced"
      unitRef="usd">35000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i593c3840adcb47bfb516fe38bcd2f1dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzctMS0xLTEtMA_c78ea155-fc23-4c9e-9888-fbed563c9e12"
      unitRef="usd">63000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i78dbe2e542714ef7a4f706598fae075a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzctMy0xLTEtMA_0b8ea4d0-3487-4f95-9647-ca6500420ba8"
      unitRef="usd">126000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementExpenses
      contextRef="i483c42968ecc45ce84311d03c17955f3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzctNS0xLTEtMA_22996118-3e81-45d1-863f-1a8710698e16"
      unitRef="usd">127000000</mrk:CollaborativeArrangementExpenses>
    <mrk:CollaborativeArrangementReceivable
      contextRef="ie47cee1fb9984770a9955c2c750b7a95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEwLTEtMS0xLTA_75980741-8eef-4dc7-a45e-a8a662e11f1e"
      unitRef="usd">65000000</mrk:CollaborativeArrangementReceivable>
    <mrk:CollaborativeArrangementReceivable
      contextRef="i5318ed6e471f44528573063ca8254b68_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzEwLTMtMS0xLTA_0a09e9d6-2370-47b7-b2f9-ce4540b345e3"
      unitRef="usd">49000000</mrk:CollaborativeArrangementReceivable>
    <mrk:CollaborativeArrangementPayable
      contextRef="i69ac791388574e7691237e3081e536f7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzExLTEtMS0xLTA_4cd1cd25-8142-4b87-8bd7-c9700df662a1"
      unitRef="usd">0</mrk:CollaborativeArrangementPayable>
    <mrk:CollaborativeArrangementPayable
      contextRef="i1bdad4b05278451caa2c67b1fd87b02e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNzUvZnJhZzo2MjA0MGQ3MmE2MmI0YTNiYWRkYTE0OWRlYTMxOGUxZi90YWJsZTo5NWRmZGQ1MDUzNDQ0NThmODhlZDU0NWEwMGE5ZjAzYi90YWJsZXJhbmdlOjk1ZGZkZDUwNTM0NDQ1OGY4OGVkNTQ1YTAwYTlmMDNiXzExLTMtMS0xLTA_9681877c-9221-4b0b-9f7e-f8699ebf6983"
      unitRef="usd">375000000</mrk:CollaborativeArrangementPayable>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzM0OTc_e4319cb3-e6bd-4f9a-85a4-40a40faee2f7">Restructuring&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In early 2019, Merck&#160;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#x2019;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#x2019;s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program now estimated to be approximately $3.0 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $700 million in 2021 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded total pretax costs of $883 million in 2020, $927 million in 2019 and $658 million in 2018 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2020, Merck has recorded total pretax accumulated costs of approximately $1.8 billion. For segment reporting, restructuring charges are unallocated expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;578&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other activity in 2020, 2019 and 2018 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;13) and share-based compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring reserves December&#160;31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be substantially completed by the end of 2023.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzkzOA_66c43fc7-f2a1-4270-8bfe-86b3f2e32a2c"
      unitRef="usd">3000000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzk4Mw_2b8ce834-fedb-4443-9f33-7f4746edad38"
      unitRef="number">0.70</mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzExMzk_ec0d5a1b-9a73-4dd4-9099-a96b0a9a5fda"
      unitRef="number">0.30</mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i626dcc5c192746988b8441a68e30c032_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzEzMzc_9c93a809-3626-4e14-8af5-9d3e9feefe89"
      unitRef="usd">700000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzE1MTc_928f01c5-1863-405b-bb15-2e70f786fda4"
      unitRef="usd">883000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzE1Mjc_dceaf2b7-4066-4cc7-b1a3-110683019f37"
      unitRef="usd">927000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzE1NDA_c4a78f5a-2c05-46ec-9a99-6ed0f8344472"
      unitRef="usd">658000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzMyOTg1MzQ4ODczOTU_5da623ce-b9a0-47b3-8e96-6bc4f8a73a32"
      unitRef="usd">1800000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzM1MDY_45379230-f53f-42a6-a70d-45234b0eadfa">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;578&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i191f68fbe0d14b05907bb1ab69c9f445_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzItMS0xLTEtMA_02e4291e-fa95-42a9-89da-a86cb6c5882b"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i241eb84e414f48f9aacd4316e70bae28_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzItMy0xLTEtMA_96297eb1-2454-4528-8350-4d477027cd00"
      unitRef="usd">143000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i406f377346f2457ab0d54b35df3d1600_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzItNS0xLTEtMA_27b55f9f-15e7-4961-a128-90a0dd87d68a"
      unitRef="usd">32000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id5a50fbb06094261ad5ce78fa80bfdca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzItNy0xLTEtMA_dbf2e172-705f-4ffe-86d3-ed65ce10e6ae"
      unitRef="usd">175000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id525dc078af8495c9e5d272e8afdb6e3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzMtMS0xLTEtMA_e130125e-d2c9-4dad-8aec-a4876651db11"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id75a71a6eed4446ca55443b556bc6d5d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzMtMy0xLTEtMA_e9113403-b857-4f6f-a50b-7c4247a474de"
      unitRef="usd">44000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0ac627a818264bfea847b4e9fcf4bb06_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzMtNS0xLTEtMA_5bb6eebf-d703-4d50-8fe4-880e570abd1b"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i309b4bb1ac054ea4a6873ed465501a43_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzMtNy0xLTEtMA_8e869c8c-0c8a-4ebb-bf9f-54587d8e2b86"
      unitRef="usd">47000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i91f1c852ca6946b889085c1d2eac8943_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzQtMS0xLTEtMA_88bc9192-d9aa-478d-948d-e2acb4e0e3fc"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i132c0ea6fd274dbcbbfe45e4bfa925ef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzQtMy0xLTEtMA_567a8d84-a864-48e8-b2e7-b4a1e815f0d9"
      unitRef="usd">81000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie2907e5468544c409931e7a4c508414f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzQtNS0xLTEtMA_fa2a5a20-019a-434e-8c85-365686c8d2df"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia34ed105cdff4df1a7d378c513d91380_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzQtNy0xLTEtMA_3cca3aec-4120-45cd-819d-0089c44d6fba"
      unitRef="usd">83000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie186fc5433844dd6ba21127222d4697e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzUtMS0xLTEtMA_33e6854e-387a-4367-a6b6-ddeea91db93d"
      unitRef="usd">385000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9d28d8d5240b476db71452abf822049e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzUtMy0xLTEtMA_80d7ce28-fba6-460e-976a-bc55879559b3"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0f2d2fb55c0f461397ea5ac456124114_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzUtNS0xLTEtMA_65cdb183-b5cf-4994-a2a5-543db30ed7f9"
      unitRef="usd">193000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1a4dd366030a40c8942fc0ce87bb62fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzUtNy0xLTEtMA_1c732700-0d0b-419e-be8d-be6a472b4ceb"
      unitRef="usd">578000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzYtMS0xLTEtMA_288732af-f196-49df-a916-df9b44ebb482"
      unitRef="usd">385000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzYtMy0xLTEtMA_96cbf86d-a6a7-48fa-9624-4d77407779c7"
      unitRef="usd">268000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzYtNS0xLTEtMA_5355d73c-4a7a-45c4-9671-180fdd3dad46"
      unitRef="usd">230000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzYtNy0xLTEtMA_46a46f19-4f3f-4a94-9c4a-1754df604ae3"
      unitRef="usd">883000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id5fcec778c1341728db868452426a980_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzgtMS0xLTEtMA_7e4c807e-8054-4e29-850e-b8d98432d3a5"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i44c2a7a188ae4476beca9dc90f2118fe_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzgtMy0xLTEtMA_9bfeae5d-7a83-41bd-a39d-6ffd315b0300"
      unitRef="usd">198000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id3c96cd074f44412a6ee38d6cfb5e054_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzgtNS0xLTEtMA_9bbad44a-121c-40cc-9493-8c78133e5037"
      unitRef="usd">53000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i88114076b7514409b6d5d5c9d41eec3b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzgtNy0xLTEtMA_faecf9a7-c1d7-4d6d-b373-4bde0fff7c7f"
      unitRef="usd">251000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0e4009b0313c49faafb6d57d35380369_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzktMS0xLTEtMA_07ed1289-a179-43b7-b4fb-035a623e2d26"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i16991361b0704afcb1a08545a7ef9345_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzktMy0xLTEtMA_ad1f08ae-85a2-4328-b71f-1cc94d2779b0"
      unitRef="usd">33000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0268c06921574bbdaf52522aad280467_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzktNS0xLTEtMA_67fbe6d4-e59d-40cc-8b6a-16a8c80e5c25"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i48e9a2d3136f48c5b13b1e298ae8df45_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzktNy0xLTEtMA_7bbc394c-ae53-44e0-9c83-0d6315630529"
      unitRef="usd">34000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibab50b716a604e0abfd1dc584019060e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEwLTEtMS0xLTA_a94f743f-d04d-4d34-bdab-f1ce432d4c5a"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1229966d621a49d0bdc08d199df3b425_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEwLTMtMS0xLTA_21727af3-9ad1-4446-b56f-af5dd929042c"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4a7193bba0f545a0ba937a6de3f640ee_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEwLTUtMS0xLTA_b024b3f7-238d-4418-b75b-8d4c9569a1e2"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if4f5ce19e15f46aeaf70c9fbe7e2be87_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEwLTctMS0xLTA_bc2b7599-a46c-4090-bae0-cc0716ec80e9"
      unitRef="usd">4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i41552ef38afe4fba9be6c306a861bda0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzExLTEtMS0xLTA_22f1d935-07a0-4bea-b024-21e31a69e02c"
      unitRef="usd">572000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4e13eba63251417abb5c0ab7664c6e4d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzExLTMtMS0xLTA_80dbc8b6-9ea5-46a6-8e50-0373b449e5e2"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i83171e10413a49b188f9233c14af2273_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzExLTUtMS0xLTA_f1917633-1af8-4677-9923-cf87472588f6"
      unitRef="usd">66000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4ab6726b526241b7af9e46ef03b526d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzExLTctMS0xLTA_908187c3-ff03-44a2-a1d2-c0e0faa5dbbc"
      unitRef="usd">638000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEyLTEtMS0xLTA_719baddb-6cfb-455a-ab0e-02a27d1f7c05"
      unitRef="usd">572000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEyLTMtMS0xLTA_f79e5b9f-8d58-4e50-91d3-1c57d15608b5"
      unitRef="usd">233000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEyLTUtMS0xLTA_37fcd41b-3c7e-4f3e-be82-08f1c174ea98"
      unitRef="usd">122000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzEyLTctMS0xLTA_b952461d-a9aa-4f2b-bbe3-b205b23a762f"
      unitRef="usd">927000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if8d20764941a4d70a43d94185021fb3e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE0LTEtMS0xLTA_40fcd9bc-de33-42ed-807c-bdd88ad1e0c9"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i303d422323e846809130057830f40fa1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE0LTMtMS0xLTA_06484d8f-c173-4e3d-8a3a-34ae242fece1"
      unitRef="usd">10000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i442a1ac9ec1d4a639edc93d1081da0b7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE0LTUtMS0xLTA_1bac5ebd-1a33-49d2-ad82-f0582123259e"
      unitRef="usd">11000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib3185a39a2bf49e2ae8b3d6395304e98_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE0LTctMS0xLTA_88638038-b6c4-4989-a317-bd51155029c1"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i000067615c4c405d828fc57adc37155d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE1LTEtMS0xLTA_eb7b8d9c-c3c3-4638-a653-a488734c642e"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3a6ba62d3268488b96375548230f0997_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE1LTMtMS0xLTA_a0fc66c2-3558-42cd-8181-4cc63b47003d"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if85c8e6a868e4feba214cf64258745f8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE1LTUtMS0xLTA_38ae8bc3-3b3a-4696-95a3-9b78d932dc2c"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="icc85f9026150482da03c6e8b08d5382f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE1LTctMS0xLTA_8b965843-1614-44b9-aef2-c626bee30cd1"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i56bac035ca3547929df24caa6baea983_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE2LTEtMS0xLTA_b15a5f05-e290-4b54-b7c3-01500bb03316"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id7a886b5f1384f9e93e1e2055f773282_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE2LTMtMS0xLTA_2e3e7911-49e4-483a-88dd-d12c548b0ecf"
      unitRef="usd">-13000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i70612a50b7b04ed0ab9d05830ec20ad5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE2LTUtMS0xLTA_1f7b18ca-d270-451c-aaf6-d44d4a21247d"
      unitRef="usd">15000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if5007327f71f42658a82bd6f754e52b1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE2LTctMS0xLTA_09dc7e40-c554-46c5-aa5f-0a5963fcdb1d"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i29303b1ae4084cc1a9f349ed8d5206fd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE3LTEtMS0xLTA_4e09b076-01eb-4351-a6cc-0cccec522a6b"
      unitRef="usd">473000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if8bb2d3506924e62bdb508461cb588a2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE3LTMtMS0xLTA_e2c66b86-8255-4cb2-8e0f-cdf91547964c"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib7e3e97d3c08440fbd570966142c7671_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE3LTUtMS0xLTA_debd6840-6bd2-4c60-9758-8476e46f9720"
      unitRef="usd">159000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib4dd7b1ee8f549d5afc0e7f66c436a5c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE3LTctMS0xLTA_6fe56626-84ee-48b6-938f-0a556aab86bb"
      unitRef="usd">632000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia7ea083b872444e39abc9269525384e0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE4LTEtMS0xLTA_dc958efd-2b60-425a-bd29-b25196aca5e0"
      unitRef="usd">473000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id9671977d7414c988b3c191e1c358988_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE4LTMtMS0xLTA_a75813d0-ca29-4cac-adbe-e6fdba905eb2"
      unitRef="usd">-1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic66a0f6babbd4e029e67a8693588a68c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE4LTUtMS0xLTA_6f476c78-773a-416f-80a7-12ac19122bce"
      unitRef="usd">186000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowOGE2YWY0ZjY2ZTg0ODNmYWI1YmMzZTE0YzRhMmNlMi90YWJsZXJhbmdlOjA4YTZhZjRmNjZlODQ4M2ZhYjViYzNlMTRjNGEyY2UyXzE4LTctMS0xLTA_f934e8dd-1ea9-4357-a537-5ab43472c92c"
      unitRef="usd">658000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90ZXh0cmVnaW9uOmIwYTE0OGI2OTNlOTQ3NmM5MzIzODEwMDNjZjcxNWMyXzM0OTM_8cd807e9-467f-43b8-96c8-aebe22abf99c">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring reserves December&#160;31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be substantially completed by the end of 2023.</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="id0feec00e0c5476aab00efe202b2d98a_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzEtMS0xLTEtMA_5e34f7ba-aa6d-4d6f-b13f-ffa520014faa"
      unitRef="usd">443000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7bbecee173d84b5cbc3262dcf64fb42d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzEtMy0xLTEtMA_9b627fa4-ad43-4be5-a5a8-8305e6573601"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2de74f34845e4ec4a02ce6ad4c118345_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzEtNS0xLTEtMA_22524acd-fb86-40ce-b0df-23793b21cc55"
      unitRef="usd">91000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzEtNy0xLTEtMA_9ef8bdc2-ea58-4c08-b58d-0e0ae6347a6c"
      unitRef="usd">534000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzItMS0xLTEtMA_965e1c21-1817-4af6-8eb9-1e85c9ad8509"
      unitRef="usd">572000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzItMy0xLTEtMA_14574e98-5ef3-496c-b2ce-93d06c77620f"
      unitRef="usd">233000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzItNS0xLTEtMA_241b2f20-e353-4cb6-b805-2eeee28787fb"
      unitRef="usd">122000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzItNy0xLTEtMA_432e7393-f870-4afe-9e4b-f7580509c7fb"
      unitRef="usd">927000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzMtMS0xLTEtMA_77580fcd-eb97-4a7c-b199-ba9ffb03f872"
      unitRef="usd">325000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzMtMy0xLTEtMA_0688b51d-0176-4c70-94b1-7eac43f8c073"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzMtNS0xLTEtMA_dd38aa74-8c15-407d-83f1-c0e9a5f459f3"
      unitRef="usd">136000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzMtNy0xLTEtMA_d9d758a9-1bdc-49a8-90bb-ad2a312880e2"
      unitRef="usd">461000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="ibe8d08f3421b4f699a7be4a21af0316d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzQtMS0xLTEtMA_541b8d80-0829-4b26-b10d-6f3edff20c8c"
      unitRef="usd">0</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i3ffc76f2903a4586802ac2f99017d0cb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzQtMy0xLTEtMA_68d09820-d83f-459e-bd0b-9aa0dc469331"
      unitRef="usd">233000000</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i9ac5f404ea5b4c36a99cd701251b5c30_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzQtNS0xLTEtMA_5ec4a302-a4d0-4e36-b094-e7bcc9ec238f"
      unitRef="usd">8000000</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzQtNy0xLTEtMA_1919779a-8b26-41a6-9e8f-58b9bf23ab92"
      unitRef="usd">241000000</mrk:RestructuringReserveNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="i31627d70cdc54331b46aac1bc8263b56_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzUtMS0xLTEtMA_ae5d6903-f4f0-405e-b1d6-f97a762950f8"
      unitRef="usd">690000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i61f9cc96dc0b44a9b57239198ed1c72b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzUtMy0xLTEtMA_9e162ad7-9bb4-45e7-89e9-dd30d6906281"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie5a3afbed0fc48ef8a9dcbf1de6c8ca2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzUtNS0xLTEtMA_df73cfda-f6d3-4193-9acd-4b06fb633029"
      unitRef="usd">69000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzUtNy0xLTEtMA_95fcf649-7db4-4abd-8fd2-5216f33edc11"
      unitRef="usd">759000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzYtMS0xLTEtMA_ca01835d-47bf-483f-b5de-85b591b162e6"
      unitRef="usd">385000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzYtMy0xLTEtMA_5846aaeb-8e50-4d97-8f54-8464fe33184e"
      unitRef="usd">268000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzYtNS0xLTEtMA_9b0c5c72-3155-4c56-af91-24a64405e062"
      unitRef="usd">230000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzYtNy0xLTEtMA_73f1e1ac-8fbd-422f-9312-6c714ac5f012"
      unitRef="usd">883000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzctMS0xLTEtMA_172be874-81aa-45b5-b16e-4e4161f9d0fb"
      unitRef="usd">508000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzctMy0xLTEtMA_4679f209-86c8-430a-b318-56c8dfc72502"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzctNS0xLTEtMA_c51ce50a-b203-40aa-9f8a-3b68b1cb518b"
      unitRef="usd">301000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzctNy0xLTEtMA_8866fd25-197a-49c1-b0cb-a645705a31f0"
      unitRef="usd">809000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i1d9140a931174e6e9137a85b288f1b66_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzgtMS0xLTEtMA_38752600-2021-4d6d-8960-8509855707fb"
      unitRef="usd">0</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="id04b3ed2c0324d97862553fce89424ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzgtMy0xLTEtMA_13b8da88-ffdf-48b8-86da-6e194ff2c004"
      unitRef="usd">268000000</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i6e0cb3328b1746e3970c1beed243fc44_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzgtNS0xLTEtMA_2eca5b89-fb93-47ab-a0ee-6689e8cadf0c"
      unitRef="usd">-38000000</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzgtNy0xLTEtMA_2495d38d-a535-4af0-8875-1a5a0f92d5eb"
      unitRef="usd">230000000</mrk:RestructuringReserveNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="i3da63b07e7034274b8cf4a20a267d380_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzktMS0xLTEtMA_ddc7223f-64e5-4cc7-91f8-ea25ae05f6f5"
      unitRef="usd">567000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i1ee164ec487d47deab4a2cb367a6d6f3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzktMy0xLTEtMA_774d182f-9726-4db3-9ad8-7a53e1f29074"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if7a8fa9009f24eeaa07743fda8f3cd94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzktNS0xLTEtMA_cd553789-743a-4168-9ac0-85a96fbb54b7"
      unitRef="usd">36000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODEvZnJhZzpiMGExNDhiNjkzZTk0NzZjOTMyMzgxMDAzY2Y3MTVjMi90YWJsZTowODg5YTU1ZTIyZWM0ZjRkODdiODE1OTU5NDI4YzlhNy90YWJsZXJhbmdlOjA4ODlhNTVlMjJlYzRmNGQ4N2I4MTU5NTk0MjhjOWE3XzktNy0xLTEtMA_e1026ae9-89d1-448c-81d8-9c62b66718c2"
      unitRef="usd">603000000</us-gaap:RestructuringReserve>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODE0_d7a8b70c-04f3-479e-9e4b-5f8530e83832">Financial Instruments&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of the Company&#x2019;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company&#x2019;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and reclassified into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#x2019;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The forward contracts are not designated as hedges and are marked to market through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and remain in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#x2019;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; No amounts were reclassified from AOCI into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020,&#160;five interest rate swaps with notional amounts of&#160;$250&#160;million&#160;each matured. These swaps effectively converted the Company&#x2019;s&#160;$1.25&#160;billion,&#160;1.85%&#160;fixed-rate notes due 2020 to variable rate debt. At December&#160;31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par Value of Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of Interest Rate Swaps Held&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Swap Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.875% notes due 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These interest rate swaps matured in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-Term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32,784&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below). The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash collateral posted/received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of (loss) gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivatives serve as economic hedges against rising treasury rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company estimates $331 million of pretax net unrealized losses on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount ultimately reclassified to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments in Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net gains recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at December&#160;31, 2020 were $163 million during 2020. Unrealized net gains recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at December&#160;31, 2019 were $160 million during 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the Company also had $586 million and $420 million, respectively, of equity investments without readily determinable fair values included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During 2020 and 2019, the Company recognized unrealized gains of $62 million and $20 million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on certain of these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee. In addition, during 2020 and 2019, the Company recognized unrealized losses of $3 million and $13 million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, related to certain of these investments based on unfavorable observable price changes. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values were $169 million and $24 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;785&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,871&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,058&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; include $6.8 billion and $8.9&#160;billion, respectively, of cash equivalents (which would be considered Level 2 in the fair value hierarchy). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Balance at December&#160;31, 2020 includes $148 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; At December&#160;31, 2020 and 2019, $711 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows and a risk-adjusted discount rate of 8% to present value the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additions to contingent consideration in 2020 relate to the acquisition of Themis. The changes in the estimated fair value of liabilities for contingent consideration in 2020 and 2019 were largely attributable to increases in the liabilities recorded in connection with the termination of the Sanofi Pasteur MSD (SPMSD) joint venture in 2016. In 2020, the increase was partially offset by a decline related to the discontinuation of a COVID-19 vaccine program obtained through the acquisition of Themis. The payments of contingent consideration in both years relate to the SPMSD liabilities described above.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2020, was $36.0 billion compared with a carrying value of $31.8 billion and at December&#160;31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#x2019;s investment policy guidelines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s accounts receivable arise from product sales in the United&#160;States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented, in aggregate, approximately 45% of total accounts receivable at December&#160;31, 2020. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.7 billion of accounts receivable in the fourth quarter of 2020 and 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2020 and 2019, the Company had collected $102 million and $256&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the related obligation to remit the cash within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company remitted the cash to the financial institutions in January 2021 and 2020, respectively. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#x2019;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#x2019;s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to counterparties was $36 million at December&#160;31, 2020. Cash collateral received by the Company from various counterparties was $34 million at December&#160;31, 2019. The obligation to return such collateral is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i6b4118cf8759442dba9e8fa1ea1b34d5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0ODY_c47fc3ba-8504-4592-aa32-615d64cbb43a">P2Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i221ed400ff5c4bea9e2d3cf8e4a80a94_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzQ5MTc_0b208c07-a77b-4fd0-8eb0-3a980b44c1d6">P1Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODIw_7262aa58-47e8-4442-9696-c268fc2e34c3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; No amounts were reclassified from AOCI into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i74f699b1657a4cecb4b718174538872b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtMS0xLTEtMA_2a2ed16f-37ec-4bf2-b399-4f6681556ac5"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3ba11098240e441f8418597d2eaf880d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtMy0xLTEtMA_6a0ca190-602b-4f46-a459-6ab7418fd8d2"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i430e6b977c1c4ef7a281ebd43d1dc672_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtNS0xLTEtMA_bd65418e-92d7-4920-a9dc-254390d0a9ba"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i02369c098d4b43f2a421a2218e9d32f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtNy0xLTEtMA_adb29229-60cf-4f1a-b9b4-6727c498f087"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i06d5fda89074431f97565335e930712f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtOS0xLTEtMA_bd3119f5-c796-4815-b2c2-3e04f4fdfc49"
      unitRef="usd">31000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ica0720d84e024817b305c556282b7dcc_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzMtMTEtMS0xLTA_96341a13-c1d3-42be-9e72-852d6f5d13de"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="iddec87a959fd4ae7a481edf7b41f776a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtMS0xLTEtMA_c780ed84-f20a-4b9f-82a9-31e284e11797"
      unitRef="usd">-385000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i4f7e3451c9c24858a05b98ed5defa565_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtMy0xLTEtMA_8876b082-84d8-4471-9a9d-fd1bbc77b410"
      unitRef="usd">75000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="id885d560ad0848c6bb060989b08b75e9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtNS0xLTEtMA_e02107c7-132f-4066-94eb-f874fc9cfcce"
      unitRef="usd">183000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i17f64eeff8ec43de9cc630344108c010_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtNy0xLTEtMA_eb5ba7af-4466-4c50-815b-6f2b54c6e78b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ibae253e40a0d426bbdb3f0cab3da9b51_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtOS0xLTEtMA_08063687-3b57-4280-bf83-772d4cb8be3b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i6b418fc03a0e44ceac8e72b427273960_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowNzZmYjUzN2FlYzE0NTkxYWRmZDVlMzZiNGM0NjY1Ny90YWJsZXJhbmdlOjA3NmZiNTM3YWVjMTQ1OTFhZGZkNWUzNmI0YzQ2NjU3XzQtMTEtMS0xLTA_07783ec2-a89b-499e-8aa8-95b1546b9ad0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i44610560536947e69f16077e7abce690_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDQ4NzM_33328a5f-5caf-46b5-b92c-8c1e194552a5"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i44610560536947e69f16077e7abce690_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDQ4MTQ_8def4ae7-5343-4b28-a3c1-d28719947106"
      unitRef="usd">250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9b47f492e4384e57a7069964eaabf6dd_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDQ4Mjg_11a2daae-64bd-471c-ad5c-124f749fb707"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9b47f492e4384e57a7069964eaabf6dd_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDQ4NDM_0a41eb94-134f-4423-8298-49a52971618d"
      unitRef="number">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODA4_9217d411-3e4a-477a-9c22-9aa8b72809e6">At December&#160;31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: &lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par Value of Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of Interest Rate Swaps Held&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Swap Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.875% notes due 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These interest rate swaps matured in January 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia88f884909c041e5a8334a8a11ec5b1d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzMtMC0xLTEtMC90ZXh0cmVnaW9uOjA2NzU5N2Y3MTVkZTQ2MWQ5OWQzZjg3ZTA2MTFjMzExXzMyOTg1MzQ4ODMzNTk_b0d3b646-db20-4f90-a22a-7062a0885199"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia88f884909c041e5a8334a8a11ec5b1d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzMtMS0xLTEtMA_8c20639c-97d2-48db-9b54-103a0f0dd142"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="ia88f884909c041e5a8334a8a11ec5b1d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzMtMy0xLTEtMA_20ebc595-263b-4b37-a1e6-f945482a375a"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia88f884909c041e5a8334a8a11ec5b1d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzMtNS0xLTEtMA_5a841e58-8720-44ea-9ba8-decfa4682e16"
      unitRef="usd">1150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icc6d538660a64a929760160006272b4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmFkMjZjZDI3MDAwZDQ0YjE4NTI3Nzc4ZDMwZTEyNzMxXzMyOTg1MzQ4ODMzNTc_52fade3b-abe9-4035-adf0-c82008d8a5e5"
      unitRef="number">0.0240</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icc6d538660a64a929760160006272b4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzQtMS0xLTEtMA_35c7469a-1f8d-4eb6-9455-d52f91432387"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="icc6d538660a64a929760160006272b4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzQtMy0xLTEtMA_495feb94-c78d-4767-9550-2e3bdeae17c3"
      unitRef="interest_rate_swap">4</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icc6d538660a64a929760160006272b4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzQtNS0xLTEtMA_b69aef2f-dff0-41d5-8a12-05b56a331bfe"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i09b41cb38aa34740b1a603947ccefc36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzUtMC0xLTEtMC90ZXh0cmVnaW9uOmM1YjMwMGZlMjQ4MzQxYjI4N2Q4NmRmNzVhYjVkNjY2XzMyOTg1MzQ4ODMzNTc_5fd77ed7-3e89-4adf-a04e-f0802535ab12"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i09b41cb38aa34740b1a603947ccefc36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzUtMS0xLTEtMA_d3f88c0f-613e-42db-be0c-6147a48db853"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i09b41cb38aa34740b1a603947ccefc36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzUtMy0xLTEtMA_de941509-51b5-42b8-b83d-9652710bd2ba"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i09b41cb38aa34740b1a603947ccefc36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpjYzhhYTg1YzUxN2I0ODI5ODM3MDk3M2ViNmU5ODE2MS90YWJsZXJhbmdlOmNjOGFhODVjNTE3YjQ4Mjk4MzcwOTczZWI2ZTk4MTYxXzUtNS0xLTEtMA_c3df9637-d03e-4ae8-87ad-2502bd54ecb9"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODMz_9acca15f-4779-4606-945c-61e07411e2a0">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-Term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i425ef8de5ab24cb2ae98743e10aff911_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzMtMS0xLTEtMA_3c03e83b-d997-457d-a019-04b825695249"
      unitRef="usd">1150000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i6a2e005cb1174aa094650f2d67119a34_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzMtMy0xLTEtMA_d01f1ea0-c966-400a-903d-22d48ac36887"
      unitRef="usd">1249000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i425ef8de5ab24cb2ae98743e10aff911_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzMtNS0xLTEtMA_44459a0d-e9c1-46e4-85b8-6e6562749d83"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i6a2e005cb1174aa094650f2d67119a34_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzMtNy0xLTEtMA_74abe577-9fc0-43b3-bead-7029c6f337b6"
      unitRef="usd">-1000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ifcba6eceb0784bbe830143aade4b1cb1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzQtMS0xLTEtMA_c0fb0653-4215-470a-a232-2ed705fbc3b6"
      unitRef="usd">2301000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ifb9d1e2142f94c22863ddaceb3677823_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzQtMy0xLTEtMA_fd3cde70-d3c4-4c40-a8f1-55dd70eef1d3"
      unitRef="usd">3409000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ifcba6eceb0784bbe830143aade4b1cb1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzQtNS0xLTEtMA_505c8dcf-d281-4067-a225-647125acdc25"
      unitRef="usd">53000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ifb9d1e2142f94c22863ddaceb3677823_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo0NTcwNGMyZjQwZTg0ZThjYWRjYTJjZjQxMDgzYjQyYS90YWJsZXJhbmdlOjQ1NzA0YzJmNDBlODRlOGNhZGNhMmNmNDEwODNiNDJhXzQtNy0xLTEtMA_033ff2ba-1eb6-4842-aee8-2821ff0e2700"
      unitRef="usd">14000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODEy_837be1e3-7852-40f4-8a25-bb12b4816213">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32,784&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="id5c598196c7c4f32b1024f98052bb448_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtMy0xLTEtMTAwODk_d148610c-a032-490e-b752-bd68cb9d9e13"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id5c598196c7c4f32b1024f98052bb448_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtNy0xLTEtMTAwODk_d00851f6-e861-441c-8627-611c759c9f9a"
      unitRef="usd">1150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i94bc6f83a1ef4f3fb5f4a5ba0339bfbc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtOS0xLTEtMTAwODk_f9bdb087-4bed-4bfa-9dc4-d319abfc6c5c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i94bc6f83a1ef4f3fb5f4a5ba0339bfbc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtMTMtMS0xLTEwMDg5_f7f365b6-f919-444b-af28-2486ad1e0f1f"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i3b90c404414f4e0a961177cdf72dce77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtMy0xLTEtMA_6687dce3-6e45-4894-b5aa-4f2ce5ea4178"
      unitRef="usd">54000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3b90c404414f4e0a961177cdf72dce77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtNy0xLTEtMA_bd09097b-5fb9-4584-b720-ccc2bb8121ea"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ib018b37155eb42059b22223b5da9a50f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtOS0xLTEtMA_871f9fbf-ac04-4551-8df7-49c94f1d0eac"
      unitRef="usd">15000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib018b37155eb42059b22223b5da9a50f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzQtMTMtMS0xLTA_ab78a4e9-dd77-45ac-94ce-ac453a61d69c"
      unitRef="usd">3400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="icf93915f5e8748a5b702271482140b4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzUtNS0xLTEtMA_77eb3631-4f1b-4cf6-996e-69947423ec40"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icf93915f5e8748a5b702271482140b4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzUtNy0xLTEtMA_b824122d-fbbd-43b1-a734-cf421a99b14f"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i8ad3e974650b43728fcd799e35eef6a5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzUtMTEtMS0xLTA_3344afdf-700a-4aa7-823d-473826d59df3"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8ad3e974650b43728fcd799e35eef6a5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzUtMTMtMS0xLTA_eb9a8d2c-073d-4431-849a-7cdd3203e3a7"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ia3739cd95e2441d399690968d9f5734d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzctMy0xLTEtMA_8e0caa9d-fa20-4219-9cf3-2df463265f08"
      unitRef="usd">12000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia3739cd95e2441d399690968d9f5734d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzctNy0xLTEtMA_62bdfead-1f55-4366-81de-ab2b433d7bfd"
      unitRef="usd">3183000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i074470fe2c264f67899fe067fe1d0df8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzctOS0xLTEtMA_fc95a458-226e-4894-ac6b-69cdd508ea98"
      unitRef="usd">152000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i074470fe2c264f67899fe067fe1d0df8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzctMTMtMS0xLTA_3e96a81e-de37-44ef-8f0d-c711c813e8e4"
      unitRef="usd">6117000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i26449e4f0e6e4176aa31d97fbc42b586_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzgtMy0xLTEtMA_637e62a0-6a51-4cc4-88ed-aae56d76559d"
      unitRef="usd">45000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i26449e4f0e6e4176aa31d97fbc42b586_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzgtNy0xLTEtMA_a88384a5-2440-4802-9744-c27448c61849"
      unitRef="usd">2030000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ic1f968bae9794c1fb41d0984eda03c04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzgtOS0xLTEtMA_573d4847-2f61-488c-9f25-335f3853ec30"
      unitRef="usd">55000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic1f968bae9794c1fb41d0984eda03c04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzgtMTMtMS0xLTA_bc35d0e2-6cc9-4e4d-bb45-abf4bbba1f06"
      unitRef="usd">2160000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i6f98b3a13c41429d91995e92273e4703_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzktNS0xLTEtMA_5367a58d-85c2-4b07-98e6-0b07f0d07ef0"
      unitRef="usd">217000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6f98b3a13c41429d91995e92273e4703_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzktNy0xLTEtMA_76079954-dec6-4aef-b152-0f3a8b7dec72"
      unitRef="usd">5049000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ibefd44c960cd430e9696cd56751dc0b8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzktMTEtMS0xLTA_1721da03-56fc-4811-9f28-f5fd10bd7d9c"
      unitRef="usd">22000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibefd44c960cd430e9696cd56751dc0b8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzktMTMtMS0xLTA_d4748b7f-023a-41d5-9d46-08d2711895bc"
      unitRef="usd">1748000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i189cc2bba23447f08495ab8fd74daf9b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEwLTUtMS0xLTA_d4776586-4dae-42d9-8070-1dd3452ee360"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i189cc2bba23447f08495ab8fd74daf9b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEwLTctMS0xLTA_013cbe56-9c06-436f-8d2c-d1e973d51908"
      unitRef="usd">52000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i8b006db8f5ac4d31aa4182239c7ce684_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEwLTExLTEtMS0w_ffc73bb9-12b4-4fbd-916c-710b8179244e"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8b006db8f5ac4d31aa4182239c7ce684_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEwLTEzLTEtMS0w_b3c1a6a2-e21a-4cc7-9613-73ec3722bb6e"
      unitRef="usd">53000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ie3c27f7451db44bf808afb15b4e436ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTMtMS0xLTA_2f5844ad-8fb6-4452-9d7b-b7a02c0988ef"
      unitRef="usd">112000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ie3c27f7451db44bf808afb15b4e436ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTUtMS0xLTA_ed56629f-78e8-4641-8623-9a573622e450"
      unitRef="usd">218000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie3c27f7451db44bf808afb15b4e436ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTctMS0xLTA_a955c4c4-2ccc-41e7-90da-8cc2db657369"
      unitRef="usd">13714000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i5f4e1f66a9354462a9d22b56d9240389_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTktMS0xLTA_ef6a8320-4649-4c8b-8555-c28307bdaaf9"
      unitRef="usd">222000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5f4e1f66a9354462a9d22b56d9240389_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTExLTEtMS0w_5a1fc1b4-b232-4e42-8c5d-f79e7afcb2d4"
      unitRef="usd">24000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5f4e1f66a9354462a9d22b56d9240389_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzExLTEzLTEtMS0w_8e2cf141-3dbb-46f8-8cbb-f19ec4c4f4a7"
      unitRef="usd">14728000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="iea7a599f496545fba9341a054b669c26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEzLTMtMS0xLTA_7e3e54a9-39fb-41ce-97ec-7fa4bde5f238"
      unitRef="usd">70000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iea7a599f496545fba9341a054b669c26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEzLTctMS0xLTA_f826d55a-fcaa-4d2c-ab53-41315f121854"
      unitRef="usd">7260000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i3d1a474906bd4f89bf006e7bc9fe12be_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEzLTktMS0xLTA_131bc4cc-8c36-4c57-924f-170cd905765d"
      unitRef="usd">66000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3d1a474906bd4f89bf006e7bc9fe12be_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzEzLTEzLTEtMS0w_6282439e-3a5b-4d65-9cbd-e5bd5c6b1850"
      unitRef="usd">7245000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i4c22c5b30fa04d829f43ad58f4fe0781_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE0LTUtMS0xLTA_0d2a26b1-8a35-4a6e-a480-60dbfedea1ca"
      unitRef="usd">307000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i4c22c5b30fa04d829f43ad58f4fe0781_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE0LTctMS0xLTA_eba4d287-7d73-4db8-9136-6539c79f7fe6"
      unitRef="usd">11810000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i0a3168f8864f4f08853f9c776e12e5e8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE0LTExLTEtMS0w_f19545da-819e-45ec-8064-2676d4b32ac4"
      unitRef="usd">73000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0a3168f8864f4f08853f9c776e12e5e8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE0LTEzLTEtMS0w_eb679e85-dead-488b-adec-06821fa8f4c6"
      unitRef="usd">8693000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i47b004e801174cc4a3f896b5ed79a5e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTMtMS0xLTA_7590204e-f13b-4e5d-bcda-23bbf92822e7"
      unitRef="usd">70000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i47b004e801174cc4a3f896b5ed79a5e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTUtMS0xLTA_f36bb061-27a6-4d29-a72c-ec4b79c1eb76"
      unitRef="usd">307000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i47b004e801174cc4a3f896b5ed79a5e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTctMS0xLTA_3c549ed3-c75c-45af-a195-7cc237404250"
      unitRef="usd">19070000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i686e5291737847fda61bb04fa2bb680a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTktMS0xLTA_64440255-05fe-4683-8dd5-3d2386f75539"
      unitRef="usd">66000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i686e5291737847fda61bb04fa2bb680a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTExLTEtMS0w_946ca908-afe8-491a-aef2-3dabd21c731e"
      unitRef="usd">73000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i686e5291737847fda61bb04fa2bb680a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE1LTEzLTEtMS0w_6376eb2c-ee7e-4d31-9d32-3db65696398b"
      unitRef="usd">15938000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTMtMS0xLTA_03627bb9-82be-4187-a0be-d80cc3b72364"
      unitRef="usd">182000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTUtMS0xLTA_1a6be7ed-1684-495e-a958-01207bb6b911"
      unitRef="usd">525000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTctMS0xLTA_0ee319b3-c526-49eb-accf-c80dbf021df7"
      unitRef="usd">32784000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTktMS0xLTA_e3310957-74d1-4e43-87e6-7cf2df81be9a"
      unitRef="usd">288000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTExLTEtMS0w_530cd366-bb12-42bd-bb69-25682d4fe5c2"
      unitRef="usd">97000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTowYmE1Y2JiMWRhMzY0YjRiYTY0ZWQ1ZTgyZDU2NTk3Zi90YWJsZXJhbmdlOjBiYTVjYmIxZGEzNjRiNGJhNjRlZDVlODJkNTY1OTdmXzE2LTEzLTEtMS0w_3e0e2dc8-b439-4c1d-a847-73010927cda2"
      unitRef="usd">30666000000</us-gaap:DerivativeNotionalAmount>
    <mrk:OffsettingAssetsAndLiabilitiesTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODAw_fe3e31dd-ae01-435e-a125-be6a22b57803">The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash collateral posted/received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mrk:OffsettingAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzItMS0xLTEtMA_cacb195a-0232-481f-9c39-645290e36a5b"
      unitRef="usd">182000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzItMy0xLTEtMA_123fd4bd-f5e7-44d3-ba0b-c4762097a791"
      unitRef="usd">525000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzItNS0xLTEtMA_a24627b7-66ca-4715-ae96-4392e09dd570"
      unitRef="usd">288000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzItNy0xLTEtMA_2622188d-1183-48d6-a682-19c95e86bd0c"
      unitRef="usd">97000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzMtMS0xLTEtMA_f201eafd-1062-4038-be3a-d4c07ea30e94"
      unitRef="usd">156000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzMtMy0xLTEtMA_689e3fcc-dcb4-4639-a3ff-ea3cd45754dd"
      unitRef="usd">156000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzMtNS0xLTEtMA_971b08bc-5cb4-418c-9639-feaa25eec079"
      unitRef="usd">84000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzMtNy0xLTEtMA_2cc967be-5fcf-4e17-a539-c9325c2e863e"
      unitRef="usd">84000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzQtMS0xLTEtMA_1884d6dc-0c41-4aa8-b484-f80cb659ee31"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzQtMy0xLTEtMA_b279ccd3-4b2b-485e-b514-741ddb61c148"
      unitRef="usd">36000000</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzQtNS0xLTEtMA_4aa4dd61-fc88-4334-a413-42842b97ac40"
      unitRef="usd">34000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzQtNy0xLTEtMA_968b6c5c-ef8b-45b4-b1b5-d71a21b8c64b"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzUtMS0xLTEtMA_ebbcb85a-10dd-412e-8920-b749bfb49de4"
      unitRef="usd">26000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzUtMy0xLTEtMA_39a5c428-03cc-41a7-9d57-be47575e2abb"
      unitRef="usd">333000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzUtNS0xLTEtMA_ceb50295-a36c-4bdb-bba5-96ab4d207889"
      unitRef="usd">170000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTo4OGFjMTRhYjk5MjE0NDI0YjlmYjg3NzI2M2IxNGE0YS90YWJsZXJhbmdlOjg4YWMxNGFiOTkyMTQ0MjRiOWZiODc3MjYzYjE0YTRhXzUtNy0xLTEtMA_069b0dda-f353-407d-a597-8eb13d9af08c"
      unitRef="usd">13000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5ODUz_c25603ff-8dfb-4618-931b-3c52127ea6c6">&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of (loss) gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:Revenues
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMS0xLTEtMA_928aba44-74cd-4b40-929a-87e128386ca6"
      unitRef="usd">47994000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMy0xLTEtMA_453d6db4-b273-4178-b295-000b6310fcda"
      unitRef="usd">46840000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItNS0xLTEtMA_ca10a547-d651-4d73-a7c5-94b006800944"
      unitRef="usd">42294000000</us-gaap:Revenues>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItNy0xLTEtMA_27421474-e1a2-4ac6-9f7b-9ab5642a22c1"
      unitRef="usd">886000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItOS0xLTEtMA_9977bc6f-2f54-4c6e-a2d1-d17428fff838"
      unitRef="usd">-139000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMTEtMS0xLTA_66efc25d-24fb-4558-a494-badf15136a95"
      unitRef="usd">402000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMTMtMS0xLTA_8a5d581e-9619-41d8-b40a-79038b8341f1"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMTUtMS0xLTA_29171df1-950c-4170-b96f-c12396dfa57e"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzItMTctMS0xLTA_d9e071d4-f60f-41d8-8668-86fe9279350c"
      unitRef="usd">-361000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="if2bc89ac3e3745259da485c0e123fdb6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzUtNy0xLTEtMA_d8b5268d-f0e2-43b6-b373-26859dd7c2bf"
      unitRef="usd">40000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ia60742cd64004ea490a84445a5be282c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzUtOS0xLTEtMA_70fe74a4-d46c-4230-9288-0c262a414c2e"
      unitRef="usd">95000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i2ab5c661a48b4562bbbc071a962b540e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzUtMTEtMS0xLTA_4743dc85-e509-4419-ba26-0fe8ef3a2106"
      unitRef="usd">-27000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="if2bc89ac3e3745259da485c0e123fdb6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzYtNy0xLTEtMA_4888a5de-0909-4f84-ae44-0107b813840d"
      unitRef="usd">-76000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ia60742cd64004ea490a84445a5be282c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzYtOS0xLTEtMA_dbd97c41-201c-4396-967c-d77307dee624"
      unitRef="usd">-65000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i2ab5c661a48b4562bbbc071a962b540e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzYtMTEtMS0xLTA_a09e9029-3176-4801-b228-c044ed0f74fe"
      unitRef="usd">50000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i74f699b1657a4cecb4b718174538872b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzktMTMtMS0xLTA_df4023d2-8545-42bc-bbe2-131f97d905ec"
      unitRef="usd">-383000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3ba11098240e441f8418597d2eaf880d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzktMTUtMS0xLTA_690edb5b-cd05-4873-884c-467e52367d3f"
      unitRef="usd">87000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i430e6b977c1c4ef7a281ebd43d1dc672_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzktMTctMS0xLTA_b89f7009-a295-443e-ac9b-6fc4e707914e"
      unitRef="usd">228000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:Revenues
      contextRef="iab64708b390a456aa95dfe12bee43bbf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTEtMS0xLTA_9fff6d7d-3ba1-4364-95f9-a881d3b2fa22"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf6219e2385d4b37b8a73d0fea710bbf_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTMtMS0xLTA_85042f88-3012-4d6f-b20a-aa8463b3dfee"
      unitRef="usd">255000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f228e2c11eb477aa93be52424102e54_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTUtMS0xLTA_d71abc0c-7188-4997-a83d-848210cde072"
      unitRef="usd">-160000000</us-gaap:Revenues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i74f699b1657a4cecb4b718174538872b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTEzLTEtMS0w_33cf328d-a55f-4449-ae8e-f30c18f0cdb2"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i3ba11098240e441f8418597d2eaf880d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTE1LTEtMS0w_c908e786-f0a7-4900-b554-5415f91ef753"
      unitRef="usd">-255000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i430e6b977c1c4ef7a281ebd43d1dc672_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEwLTE3LTEtMS0w_33b3f797-64c2-416c-a4bb-ccb8aa2b97c6"
      unitRef="usd">160000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if2bc89ac3e3745259da485c0e123fdb6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEyLTctMS0xLTA_b1cadb0d-098e-4a13-9f6e-7fdf630dd380"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia60742cd64004ea490a84445a5be282c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEyLTktMS0xLTA_f597edca-96d4-411f-9635-7c5ec7cca5e7"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2ab5c661a48b4562bbbc071a962b540e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEyLTExLTEtMS0w_8f938933-af5d-44fc-b876-82d236dd7781"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i34a833d327f8451596b0800e5d644c7a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEzLTEzLTEtMS0w_e8aa59af-b9c3-4403-9de1-3463fdd57c42"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i17a1659884f848f5aabd436539f2bf47_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEzLTE1LTEtMS0w_995c1dcf-7833-4ca7-956d-65c5dc4cb554"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="if1c1f1933cbe418ead09d219d10cabe4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTozYTJjNjNkMDNhYzM0NmQ5YjU1NjlmNDA3YmY3MWUwYS90YWJsZXJhbmdlOjNhMmM2M2QwM2FjMzQ2ZDliNTU2OWY0MDdiZjcxZTBhXzEzLTE3LTEtMS0w_6a3a9f2d-ea53-4197-96e1-d13f57471e4c"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5Nzg4_b3b0ceb0-64bc-4172-8d80-d44308954fb4">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivatives serve as economic hedges against rising treasury rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i02369c098d4b43f2a421a2218e9d32f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzMtMy0xLTEtMA_d547367c-8119-4d42-8dca-0fc3082922b1"
      unitRef="usd">12000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i06d5fda89074431f97565335e930712f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzMtNS0xLTEtMA_6b03bebb-6286-4cd8-81e4-5a1b368b666a"
      unitRef="usd">-174000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ica0720d84e024817b305c556282b7dcc_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzMtNy0xLTEtMA_964fa3a9-0410-4126-bc1d-f8715e025c46"
      unitRef="usd">260000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ib96051c5103e4b92b51fcc3dabaec98d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzQtMy0xLTEtMA_e374c9ec-7971-4e5f-9b4f-d59a08f0c8d1"
      unitRef="usd">-13000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ia9756dfe40bb4a4284b0062e05aefad9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzQtNS0xLTEtMA_227639b2-025a-4819-b97b-c7f724e48255"
      unitRef="usd">-1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i98079bd7917c45ce82bcf778574127d0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzQtNy0xLTEtMA_62d7a820-c888-4efc-8b57-936f48af472f"
      unitRef="usd">8000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic8d9aaa6d14d47c08624bcb65746c4ed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzUtMy0xLTEtMzU0Mw_c247f3b6-c4c9-40a4-897c-69930123fefb"
      unitRef="usd">-9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i92ffc89462f2430192ac1ba5cb28f8cc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzUtNS0xLTEtMzU0Mw_e1f10276-3402-473a-bf01-e160cd453e1f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i157e712600dd4995a5373a06637c27fa_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzUtNy0xLTEtMzU0Mw_8bd75bf6-9ddb-46e3-b6de-86aeb84b3dd9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0dedde47b1a347a0971fdd6194fcae67_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzYtMy0xLTEtNTc0Mg_124ecaf6-954f-4695-9cc1-f3401adab201"
      unitRef="usd">-15000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8af59371761f403683996b2f9e8ed882_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzYtNS0xLTEtNTc0Mg_797219c0-9803-49f0-94fc-66c172662134"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i248775075bc545c390593609d97824a4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpkOTgxNjMwZjA4YTQ0ZWU3YWFhYzZjYTYwNzk4NWE2Ni90YWJsZXJhbmdlOmQ5ODE2MzBmMDhhNDRlZTdhYWFjNmNhNjA3OTg1YTY2XzYtNy0xLTEtNTc0Mg_71e274e5-7745-4dcd-bdc6-c50fdc7db156"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzkzNzc_c52b2f7d-c1c1-4d2e-ab52-236b209ae182"
      unitRef="usd">-331000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5Nzcx_5eadd3d3-0e94-4fd8-8e4e-32f3f89a6751">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net gains recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at December&#160;31, 2020 were $163 million during 2020. Unrealized net gains recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at December&#160;31, 2019 were $160 million during 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if2b72497910f4f5b8362034975eafe4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMS0xLTEtMTAwMjQ_274ec87e-f065-4b8d-b791-44a918960273"
      unitRef="usd">84000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if2b72497910f4f5b8362034975eafe4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMy0xLTEtMTAwMjQ_21b176e8-41a5-4ee4-8189-31a9548fe371"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if2b72497910f4f5b8362034975eafe4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtNS0xLTEtMTAwMjQ_eed3e629-0e88-47fa-bec8-e06c3e41893c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2b72497910f4f5b8362034975eafe4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtNy0xLTEtMTAwMjQ_f7fdeebb-bbf2-4e43-9d08-16a2a474150f"
      unitRef="usd">84000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iac680b79731d4242af1965a13712ffcf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtOS0xLTEtMTAwMjQ_64b84ce2-0fe2-40f7-8cf6-edabbc3a11ee"
      unitRef="usd">266000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iac680b79731d4242af1965a13712ffcf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTEtMS0xLTEwMDI0_3c98f1b4-8de8-4c3e-afcb-c51e6466ce6b"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iac680b79731d4242af1965a13712ffcf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTMtMS0xLTEwMDI0_f97f305c-607e-43c9-a5ff-bfc0cd667b04"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac680b79731d4242af1965a13712ffcf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTUtMS0xLTEwMDI0_103ca58f-3e37-475f-b45c-687201396143"
      unitRef="usd">269000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMS0xLTEtMTAwMjk_f52b0436-af7e-4b1b-b101-ff4271ac82c1"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMy0xLTEtMTAwMjk_d6a45170-3453-48e0-b206-528ef9b212bc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtNS0xLTEtMTAwMjk_10c54057-b4fd-422e-b260-7b699c0cdfde"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b352f2dc20b4f3fa9c0a4901ccade0e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtNy0xLTEtMTAwMjk_e8714e61-6bbc-4f8a-a8a4-d6f237c0273b"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idaf79a13e56b4dacb00d6c54493be948_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtOS0xLTEtMTAwMjk_05240410-c693-430b-adca-a0072583dfc5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idaf79a13e56b4dacb00d6c54493be948_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTEtMS0xLTEwMDI5_8dd264d7-4945-4073-a138-296fe587fbca"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idaf79a13e56b4dacb00d6c54493be948_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTMtMS0xLTEwMDI5_d5efaa95-4f4f-49c9-9973-c03edcf92a6c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idaf79a13e56b4dacb00d6c54493be948_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTUtMS0xLTEwMDI5_0b503ebb-9dcc-4c8d-84d4-be330b372875"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie0c514e2dbdd434aaf832d950c66924a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMS0xLTEtMA_b8960c46-36e3-4781-9e0b-079e34cd210c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie0c514e2dbdd434aaf832d950c66924a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMy0xLTEtMA_c9e4c25c-a9e7-4f49-85ee-ace69678de6e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie0c514e2dbdd434aaf832d950c66924a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtNS0xLTEtMA_c421ca41-55e3-437a-bf3c-3e770b918f44"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0c514e2dbdd434aaf832d950c66924a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtNy0xLTEtMA_9af239f6-e090-443c-b9d9-40a97b88ee9b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4120124e4b9b4d7082f37a0ec3592298_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtOS0xLTEtMA_44e05d12-0af6-4aaf-8e4d-fba11d51a82c"
      unitRef="usd">668000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4120124e4b9b4d7082f37a0ec3592298_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTEtMS0xLTA_14f8bc0d-ce0b-47f8-a4a1-feed6906207d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4120124e4b9b4d7082f37a0ec3592298_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTMtMS0xLTA_2411264f-2c57-4c05-8103-c4d19fc7a585"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4120124e4b9b4d7082f37a0ec3592298_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzMtMTUtMS0xLTA_a5f20660-be75-4e67-9221-a08026f83f3d"
      unitRef="usd">668000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifc62c243cd0e4d5686c1f797407cf679_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMS0xLTEtMA_248ee199-eeff-45fd-af7f-720592234cd3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifc62c243cd0e4d5686c1f797407cf679_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMy0xLTEtMA_0e424543-b6ef-4c81-afd2-ad8ca4e8ec8e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifc62c243cd0e4d5686c1f797407cf679_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtNS0xLTEtMA_0fc0504e-a1ee-4095-9242-a033d91746ea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc62c243cd0e4d5686c1f797407cf679_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtNy0xLTEtMA_10ac4ed3-f996-40d1-8d97-14c685619c6a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1cd51a21a4b0451281d898defd8ebb87_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtOS0xLTEtMA_335fe4e6-573b-4a84-86c4-b1213a492f2d"
      unitRef="usd">608000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1cd51a21a4b0451281d898defd8ebb87_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTEtMS0xLTA_6b2e2930-0b06-45ad-ada8-28a5efcf477a"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1cd51a21a4b0451281d898defd8ebb87_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTMtMS0xLTA_d372f63b-174c-4512-a89f-2460b5d1d7d3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1cd51a21a4b0451281d898defd8ebb87_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzQtMTUtMS0xLTA_e4886b98-34a8-4ee1-8b6e-a81b7fdc5910"
      unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4a43afc3c18842a8bfb574432eb8396b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMS0xLTEtMA_08543c00-99d6-48ca-831f-459adb5e895e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4a43afc3c18842a8bfb574432eb8396b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMy0xLTEtMA_09154273-0393-4bd4-bf0d-2b861f15fe43"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4a43afc3c18842a8bfb574432eb8396b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtNS0xLTEtMA_6449c74f-827d-42ce-bd52-9e7f440e6b26"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a43afc3c18842a8bfb574432eb8396b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtNy0xLTEtMA_68c782e3-8b3e-4432-91aa-1d62b144403b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i99f107554e5944c88d03135cc0d5646e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtOS0xLTEtMA_d6bf2683-1f2e-48ad-a186-8d055234996b"
      unitRef="usd">226000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i99f107554e5944c88d03135cc0d5646e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMTEtMS0xLTA_d39227c2-10e3-4e07-b25a-87f27c2e491c"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i99f107554e5944c88d03135cc0d5646e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMTMtMS0xLTA_8585dfed-b359-4159-8141-551c70ed11f9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99f107554e5944c88d03135cc0d5646e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzYtMTUtMS0xLTA_0d3a1b59-503b-42ae-be85-c4ae66a6ee21"
      unitRef="usd">227000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMS0xLTEtMA_7bd1c840-9e85-4af8-b551-dd28b276898d"
      unitRef="usd">89000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMy0xLTEtMA_2fa7aec1-b3a6-4775-9339-0f8fd3e2d023"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktNS0xLTEtMA_f7ad325c-8b7c-4624-9074-b488ed298323"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktNy0xLTEtMA_d449e618-bb7e-4c8a-8253-d05a775fddbc"
      unitRef="usd">89000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktOS0xLTEtMA_1f0acae8-d1d2-40bc-8a7e-2e4592486d7a"
      unitRef="usd">1768000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMTEtMS0xLTA_588f3ab5-ab36-4309-867b-cf331dbb98fb"
      unitRef="usd">17000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMTMtMS0xLTA_e301f45d-7568-43e6-935d-3950bb029f03"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzktMTUtMS0xLTA_35d1ce16-95b3-46af-a2f9-fe687142f12c"
      unitRef="usd">1785000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzEwLTctMS0xLTA_07b8e89b-032b-47d7-a133-dcf92454173b"
      unitRef="usd">1787000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzEwLTE1LTEtMS0w_9c12887a-6abe-4fae-bd91-36e002212305"
      unitRef="usd">838000000</us-gaap:EquitySecuritiesFvNi>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzExLTctMS0xLTA_fc3c4da7-17fd-4306-a4f7-2f980dbb1671"
      unitRef="usd">1876000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTplMmIzZjY3MjlhZDE0ZWUxYmUzZjA4MjNmZTE0NGI0My90YWJsZXJhbmdlOmUyYjNmNjcyOWFkMTRlZTFiZTNmMDgyM2ZlMTQ0YjQzXzExLTE1LTEtMS0w_df7eba1b-0788-452b-8a7b-768ad3bdfe71"
      unitRef="usd">2623000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMDA4_77514532-6640-4563-b6d0-14ee48afdbf1"
      unitRef="usd">163000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMTQ2_655556df-de92-48e2-a5e7-ebab9c739ac0"
      unitRef="usd">160000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMTk3_86efe730-0cd3-423e-a6e4-0c60bab02ab8"
      unitRef="usd">586000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMjA0_1645ac46-755c-4172-90f4-f3f3eee3a307"
      unitRef="usd">420000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMzcy_b6435cde-c979-4d2b-83a2-5c82d5a89273"
      unitRef="usd">62000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwMzc5_3eddec3d-ec51-4a7c-a9d7-01a91ddd58d3"
      unitRef="usd">20000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwNjU3_492a88de-4ce3-4630-b983-2dd6cbdc1941"
      unitRef="usd">3000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwNjY0_2e5fe37b-8779-4116-ad69-4f1c49f18963"
      unitRef="usd">13000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwOTgx_4b91cf54-539a-42b9-a72b-dde1027ea19b"
      unitRef="usd">169000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEwOTg4_0e52b0e2-3a2b-4320-a15c-79d2b05ff867"
      unitRef="usd">24000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5Nzg3_7e0c0709-dc0f-4d3d-bb81-242237cbe75c">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;785&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,871&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,058&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9bd171f0c0d4bf7ba9049b6fe49d4e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMS0xLTEtOTk5Nw_3227cda7-8e70-4ed8-9d4e-b09a9bb56e51"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51875e63a23141e799f3c721b2e98c35_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMy0xLTEtOTk5Nw_45184f63-0d66-43d0-9919-aecd2e001f19"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97372e9ec431481e8d2ad41c37299b60_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtNS0xLTEtOTk5Nw_9e705590-0c28-4688-9258-af34b0205cec"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9818f3ecec9d4b5da3c91600169a5ea9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtNy0xLTEtOTk5Nw_6dbd25b9-6584-4f17-9f04-da51e78220fe"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5099d5a15b8741809c09bd89ce675d38_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtOS0xLTEtOTk5Nw_b116b62a-1f92-4b2e-a079-0682f2fc6eb9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i449d46bca2a640e3bf828a985bf5b6e7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTEtMS0xLTk5OTc_afefde9f-3653-4285-8bc6-11a55f11318c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74f95efcbb854b47837ed0e30678717c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTMtMS0xLTk5OTc_d76f9dbe-8631-4e83-a2f8-4a68e9faf9e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0eb091d5f2d4f76bfd8bf94afcd2d03_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTUtMS0xLTk5OTc_653882e5-4f7f-4331-9fc8-a9053a5c1f90"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d003a9b64b24e768af4f068b938a189_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMS0xLTEtMA_ce49bfd2-cae1-4e6c-9372-3073d93ff0a2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d6bc76e46da449c9f8e5b9c566ed471_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMy0xLTEtMA_79962f5d-6727-4014-8375-fdd53c337eda"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifca9ceeab0e241baa78dca85e021d03b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtNS0xLTEtMA_c86d76dc-3c35-4820-b667-4e4e4ff529c6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5979ae1b6734b4482a704ad0292fd9a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtNy0xLTEtMA_91dc8ea0-6efb-4572-af87-c4de583f96bb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4889e793f60e4d05b6ddd2f8025a83f6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtOS0xLTEtMA_7aa44d88-5fb4-4910-a69b-69faab8f9496"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3019315f797d4f6da1bf695e1d0e2adb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTEtMS0xLTA_b2dcdedc-d54a-4966-97c3-ed18b5d6fbba"
      unitRef="usd">668000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f168f035dcb4b52b45a1f046f60c471_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTMtMS0xLTA_3f9a0635-bb71-466a-b4f9-21cd54a1a734"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i678944a90428428ab1d1f74e0f90e565_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzUtMTUtMS0xLTA_8a22c067-f1fc-4e6b-8a97-ce065139700d"
      unitRef="usd">668000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86760add50e540c9915bc96dfade2cd7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMS0xLTEtMA_7d580b0a-a181-452b-961e-25a235f31400"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic305af5c5eb64be5b8250cc700e82e3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMy0xLTEtMA_4f455577-c64c-409e-bb11-d95899319fc2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9480f02ab9e4065aeae4c973801cd09_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtNS0xLTEtMA_b213722d-aff0-4333-b0e9-30991bb253ed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e6378f9682e49e986ad883f181e19c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtNy0xLTEtMA_e8f5bad5-a8a3-4b67-bc35-7d74b59833e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id61514cbea7e4ef19f040db41edfae2e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtOS0xLTEtMA_3fb25c5e-c147-4be6-bce8-a1a5fff1cb01"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i581be677b2e04a02926271e7f77db17e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMTEtMS0xLTA_7330f1fa-85eb-46c5-9057-36cb99fc9be7"
      unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbe2de3ba6564509844cdb877e313935_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMTMtMS0xLTA_ec599299-8afc-4c98-a194-27cebf87af3b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f126cdd894e4acf97878c636bbdca1c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzYtMTUtMS0xLTA_7ac1d9fa-6d33-4ab9-aa1c-e292f5075e07"
      unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8493f72d249346a0be32eddede66afca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMS0xLTEtMA_845debda-dcc8-456d-9519-0cc5ed212d5e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01ab1f5da5bd49309c4078402b7bc49e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMy0xLTEtMA_a6ef7ac5-34d5-406a-8b95-e22595bd3b30"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40443158b83241babddbc35d611fd36e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctNS0xLTEtMA_7a1fd895-c202-402f-ab87-74d6ab518153"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a9e331ce86b43ab95f546a5ce865a32_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctNy0xLTEtMA_4c6ea665-565d-414a-95cc-799e66e390e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i77a51ca67bac440cba8e01beb97c8d5f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctOS0xLTEtMA_9b7cd29f-abea-46c0-94d0-7bdd9e4703f1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7788d5f200f54b93a9c93e43368ebea2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMTEtMS0xLTA_5ca1ae38-281b-4307-828f-2c118e3dcca9"
      unitRef="usd">227000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f6c5c42bd2346b1abb083ce9edcfe4d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMTMtMS0xLTA_b12c7a61-a9f2-4648-a2bb-da0772316242"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd6b30ab1c0a4434bbad28238f32d3d8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzctMTUtMS0xLTA_0e3cf87d-c499-44d5-8253-29fe1843cbff"
      unitRef="usd">227000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibaf6232f74fa41139923e59a424dc61f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMS0xLTEtMA_35e6bb4f-0c68-42f8-ae06-96759586d133"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id12d18ccfca34d6bb8faff8660c8a76a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMy0xLTEtMA_ebfcb9f0-66c4-4db9-95ce-ebc6c78514ec"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2128132540244319b6739b88b72e0cf6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtNS0xLTEtMA_5acdca0a-f14a-4d3f-9a8d-d913d922d593"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i403305af9ece44c9b22ee241dbf53d51_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtNy0xLTEtMA_a51aa884-f621-4f70-a5f0-c43ba85c4331"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec3c8f6c78f649b2b6d8249918906936_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtOS0xLTEtMA_57797c8f-84c1-4073-8d68-71f2c6e2477a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2903ba97df754b6ba63aa316be7a875b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMTEtMS0xLTA_f63caa42-ead0-4542-9718-9dc5ce5737d4"
      unitRef="usd">209000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49b4a3504a044aa29ba5b89de4a75a7b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMTMtMS0xLTA_ff35d89e-7cf1-4130-bbad-5b3bff936a9b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02029bf2987943d7b527f9fbbfbaccac_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzgtMTUtMS0xLTA_e6af1eaf-1942-4762-a629-2f03cad222c9"
      unitRef="usd">209000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id7f02989f1094e35a4db4abadae73636_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTEtMS0xLTA_7483e518-735e-46ac-9443-358f5f962c7a"
      unitRef="usd">780000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i83c58a9e62e44be893953a1c54696515_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTMtMS0xLTA_14633879-114c-4227-8f0c-419068a4afa6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0e8a59217086413e83da0688d9c2171d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTUtMS0xLTA_54137acd-542a-4f7e-99fa-1755247569df"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i81a6a626d7d64f7f815bfc2849d97a81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTctMS0xLTA_0350b4c7-0357-40dc-84b9-53dc19c01def"
      unitRef="usd">780000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9e33912988a248bc8246486df6397715_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTktMS0xLTA_d62d33ee-49cf-4955-af69-855e1bbb52d8"
      unitRef="usd">518000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iabecd6bb38834f98b4af258e1624a7d1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTExLTEtMS0w_38ab85ef-6f83-4f59-8802-12a47d645b3d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8acf6daac21d4c88a48854a1221633c2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTEzLTEtMS0w_8c6d46ba-1afd-4f41-b819-93caecb79c37"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i517c433fbeac4a0d877922b89aa5b92a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEwLTE1LTEtMS0w_1822c07a-acc0-49cb-8897-6962375b9feb"
      unitRef="usd">518000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:TradingSecurities
      contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTEtMS0xLTA_e6e4d275-7fae-49bc-880f-b640153f2f25"
      unitRef="usd">780000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTMtMS0xLTA_06ae85ce-b08d-4bf9-8f68-b66e48ddaec4"
      unitRef="usd">5000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTUtMS0xLTA_496c8ad3-f6d4-49e1-a43a-4deb3afe552a"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTctMS0xLTA_f1f92e7c-660c-4a12-9f24-1471fd92df84"
      unitRef="usd">785000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTktMS0xLTA_2d985dd9-5585-41c9-937e-bba3f480632a"
      unitRef="usd">518000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTExLTEtMS0w_fc4c2c17-4edd-488c-a98c-9a00f1ca07a4"
      unitRef="usd">1725000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTEzLTEtMS0w_82938805-a24f-493e-a49e-80953167fb1d"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzExLTE1LTEtMS0w_bbc33780-e279-4126-bcc6-efecacf9ac8f"
      unitRef="usd">2243000000</us-gaap:TradingSecurities>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibaf6232f74fa41139923e59a424dc61f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTEtMS0xLTA_ea2e7f6b-0c61-4925-a2cc-4f60cbf4d23d"
      unitRef="usd">84000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id12d18ccfca34d6bb8faff8660c8a76a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTMtMS0xLTA_da160cda-a636-4edd-b83d-2d885a33042a"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2128132540244319b6739b88b72e0cf6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTUtMS0xLTA_d151b931-088a-464f-9e5a-ac93f9a615fb"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i403305af9ece44c9b22ee241dbf53d51_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTctMS0xLTA_991af96a-4700-4da5-8110-32f690789d7a"
      unitRef="usd">84000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iec3c8f6c78f649b2b6d8249918906936_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTktMS0xLTA_a42d9b81-2866-44e7-8a63-ed3694421c17"
      unitRef="usd">60000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2903ba97df754b6ba63aa316be7a875b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTExLTEtMS0w_7a2c6452-b856-4af8-90fd-665d456a93f6"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i49b4a3504a044aa29ba5b89de4a75a7b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTEzLTEtMS0w_b079b169-e55e-4f52-920d-bfdfea1a4462"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i02029bf2987943d7b527f9fbbfbaccac_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzEzLTE1LTEtMS0w_fb6d189d-6116-4a78-b9f8-571dc87d96bb"
      unitRef="usd">60000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id7f02989f1094e35a4db4abadae73636_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTEtMS0xLTA_a9c37b29-7ebc-482f-9895-dafe8680bb86"
      unitRef="usd">1007000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i83c58a9e62e44be893953a1c54696515_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTMtMS0xLTA_4254c96f-754a-4c3c-a996-dea82d713bcc"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0e8a59217086413e83da0688d9c2171d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTUtMS0xLTA_abb08e3c-fad6-492b-b553-0a05ae4de20c"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i81a6a626d7d64f7f815bfc2849d97a81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTctMS0xLTA_1223daaa-5dc1-4071-a272-bfee4009883c"
      unitRef="usd">1007000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9e33912988a248bc8246486df6397715_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTktMS0xLTA_bb111b1d-f909-4937-b926-8ad9a3c27957"
      unitRef="usd">320000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iabecd6bb38834f98b4af258e1624a7d1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTExLTEtMS0w_d8301f5c-6f71-4cd7-b1ae-1149e7d3eae5"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8acf6daac21d4c88a48854a1221633c2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTEzLTEtMS0w_bde54e76-60d9-4972-b06e-7252230bb904"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i517c433fbeac4a0d877922b89aa5b92a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE3LTE1LTEtMS0w_d742f046-9757-45cc-9b41-314fb5b0eef6"
      unitRef="usd">320000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTEtMS0xLTA_de122b42-97a0-4168-8470-e9c77ae2297f"
      unitRef="usd">1091000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTMtMS0xLTA_720dfe7d-7ea8-42a2-b84e-00fa72cb9752"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTUtMS0xLTA_62c75dbc-6864-4dc0-9005-ed75bee24bc5"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTctMS0xLTA_6aaec2da-4d26-44c1-a035-57846b259791"
      unitRef="usd">1091000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTktMS0xLTA_aa90a0ce-a6d2-4d4b-b7c3-39e5f1427689"
      unitRef="usd">380000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTExLTEtMS0w_292c9ef2-c69e-4bb7-acfd-c4ddb67c19dd"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTEzLTEtMS0w_697cb569-7a0f-4ffc-8308-f5c5fd65dd90"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTE1LTEtMS0w_d2eb0e3c-96b4-4de5-ad09-ea0b78bc6ebb"
      unitRef="usd">380000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DerivativeAssets
      contextRef="iba9bae92903b40b180b8db555d0dc4af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTEtMS0xLTA_5a91b610-0790-417c-b41a-1545ac3fa4c5"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ieac0d630db304c5fbb6b0d1dd4b0fd96_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTMtMS0xLTA_d8f70295-c2ac-4d0d-acfa-6835967c3aee"
      unitRef="usd">90000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4b97df8525e24037aefcb485eb08406f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTUtMS0xLTA_b0c544a3-996f-4970-a62d-c822322616f5"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8aaa816b38bd47f2a17d32d765b2fb2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTctMS0xLTA_66152bb4-fe1d-4578-b85f-a9db403f3d8d"
      unitRef="usd">90000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i831b4ecbf45d409481738e9647f09306_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTktMS0xLTA_e9ad17b4-39fc-4b73-b3b0-33fb8605f8cf"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib4aa9ea67d9f463dbb092452343a4414_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTExLTEtMS0w_2dab6587-18a5-4f50-83e4-9cadb44e4e8b"
      unitRef="usd">169000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i00919146800d4139ac109a85dfb7d711_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTEzLTEtMS0w_d8449ae3-5065-4682-b267-bfb94ae69b1c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib8999a38e79d4363a379eff3d701a62b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIwLTE1LTEtMS0w_b0cb63dd-f550-4808-914b-e82ae1953f08"
      unitRef="usd">169000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9295a488115f4c68a8e8c1703fb43b33_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTEtMS0xLTk5NzU_7e88178b-a941-4adb-9e5f-c2c983e7b0a8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i240370941e09472fa67b09378158fe7a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTMtMS0xLTk5NzU_8e2f2e85-2787-4e51-8378-9cb51f591ca1"
      unitRef="usd">55000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6e355174746e40ccab1d3a022356179f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTUtMS0xLTk5NzU_6fee4ab5-be02-4049-81b3-d49a34790815"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i04293f756da241a999ca08cf5205814d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTctMS0xLTk5NzU_5662b797-db77-4d31-b191-224123c7cb43"
      unitRef="usd">55000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id5454937046f471eb2aeccd5bdb66a94_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTktMS0xLTk5NzU_a56432d8-ae47-4484-8330-b19cf59f02d6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i512cc6f095a04b919b00809dc9264562_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTExLTEtMS05OTc1_a5bcc7c2-3891-45b7-b896-f91bbf4347b8"
      unitRef="usd">15000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i860f8c1284824650bf9be85917582840_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTEzLTEtMS05OTc1_a214d1dc-b591-4b54-9fd4-5d781227f867"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3923a650ec254483b01b7e8e723eace4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzE4LTE1LTEtMS05OTc1_b1dec116-e519-48a5-98d2-4f3c174978b7"
      unitRef="usd">15000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic00bd05172e849cdb1c49805feb4ff31_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTEtMS0xLTA_3beca5f2-080a-4ab0-b3e4-0cd2862c3b2f"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i52894ba21b534bdfb980886fec594cbe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTMtMS0xLTA_47dedbf6-5535-48dd-afd3-811bad30a40c"
      unitRef="usd">37000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i388f19daab3349fd94f8e901eebd7ad7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTUtMS0xLTA_4a506b7f-204b-4fd0-b11d-249845180f81"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="icb53e8019d3444a183fd939d626283cc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTctMS0xLTA_ab5c3d86-4ceb-4f47-8d77-74daceac331e"
      unitRef="usd">37000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6e91fa49f38046778d905adb20038b86_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTktMS0xLTA_5dea8e62-4a92-4c0d-9e0c-00e1eeb9bb95"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i77a9ffaa8ff04b0db0e23fb174f64775_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTExLTEtMS0w_c7401255-b698-45fb-89a4-667b3f5e5151"
      unitRef="usd">104000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iec6fe4bb91db47469413570dc5792607_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTEzLTEtMS0w_7fb3e54b-1ef7-4e6f-9240-57cdee34214b"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iecf40c6bc57a4a96acd2a20797b47feb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIxLTE1LTEtMS0w_a16daf78-7946-4107-8ff9-41a7a3674f6d"
      unitRef="usd">104000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTEtMS0xLTA_4225d0c5-9fa2-4e34-8407-d0b0e62f2de6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTMtMS0xLTA_be968bdf-8f80-405f-b30e-9dfddd928e2c"
      unitRef="usd">182000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTUtMS0xLTA_765ac602-2661-4ef6-9c3d-d09c2b01a778"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTctMS0xLTA_f66a1b48-081e-4c24-b8a4-6d854ec46cda"
      unitRef="usd">182000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTktMS0xLTA_77d3771a-d6fc-402c-aa3e-5de20db7f1ae"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTExLTEtMS0w_d832edd1-6046-4347-8c45-9286e1671e7b"
      unitRef="usd">288000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTEzLTEtMS0w_c6acf8b8-71ed-4863-9c2e-bef43e4af32d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzIzLTE1LTEtMS0w_c6782358-297e-4933-9b4d-b98139363bec"
      unitRef="usd">288000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTEtMS0xLTA_f5ee9bb7-145e-4e02-b19b-34b12782c90c"
      unitRef="usd">1871000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTMtMS0xLTA_392de990-0425-4025-aa81-4d62dea99468"
      unitRef="usd">187000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTUtMS0xLTA_acb1f5dc-196d-4d63-b2af-a7ee14819605"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTctMS0xLTA_c830126a-3179-4dbf-9076-e596f62c8cd6"
      unitRef="usd">2058000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTktMS0xLTA_a68a6c91-a797-49eb-a74c-ee9da9d349d9"
      unitRef="usd">898000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTExLTEtMS0w_b460019c-dafa-46f8-a280-17019cdc23d5"
      unitRef="usd">2013000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTEzLTEtMS0w_d3aa2480-1b82-4823-a36a-883fff48be36"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI0LTE1LTEtMS0w_d92a2955-dc50-44e1-a3b5-a7b59be54803"
      unitRef="usd">2911000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTEtMS0xLTA_187d45af-f40d-415d-a79a-7cd62d87d688"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTMtMS0xLTA_d0b5877d-5e5a-4ee8-bd26-3a3af5422376"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTUtMS0xLTA_3e4df9ab-8d9d-4b11-bdd1-10b3d5ee3101"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTctMS0xLTA_8081bdf9-993b-460e-9e5d-c53a57b825b8"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTktMS0xLTA_9940b7d0-c7d9-4b64-8732-a6210b3fb5f9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTExLTEtMS0w_b237fa32-dc35-4156-8958-0654af8ddfa6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTEzLTEtMS0w_871c4a52-d7f0-4cf8-9c4a-93e8d1467ccf"
      unitRef="usd">767000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTE1LTEtMS0w_d5282029-f28b-479e-a23e-adbe9ad024b1"
      unitRef="usd">767000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="iba9bae92903b40b180b8db555d0dc4af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTEtMS0xLTA_6dab3194-3f07-4ad3-a869-d3877007826a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ieac0d630db304c5fbb6b0d1dd4b0fd96_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTMtMS0xLTA_59731262-20ef-4403-9003-e42b421de138"
      unitRef="usd">505000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4b97df8525e24037aefcb485eb08406f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTUtMS0xLTA_7caeb32b-af04-417c-be70-75c33f7e8386"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8aaa816b38bd47f2a17d32d765b2fb2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTctMS0xLTA_2a1db716-39d9-4b1d-9feb-b7bd6c43a69e"
      unitRef="usd">505000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i831b4ecbf45d409481738e9647f09306_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTktMS0xLTA_1de6ccf8-a465-4032-8050-2fa8c83adcbc"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib4aa9ea67d9f463dbb092452343a4414_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTExLTEtMS0w_78268534-4de3-4e0e-b43a-bfed19a5b08c"
      unitRef="usd">95000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i00919146800d4139ac109a85dfb7d711_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTEzLTEtMS0w_06718f10-e47f-4b97-90f0-37c2dce487e8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib8999a38e79d4363a379eff3d701a62b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI5LTE1LTEtMS0w_9e16d4b4-f24b-4bc3-ae03-b002e9ff05be"
      unitRef="usd">95000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic00bd05172e849cdb1c49805feb4ff31_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTEtMS0xLTk5ODY_0c43f40c-13f8-4239-abe3-9630f8415ad0"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i52894ba21b534bdfb980886fec594cbe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTMtMS0xLTk5ODY_906bee5d-fd58-4aca-8168-22f7c23cef3c"
      unitRef="usd">20000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i388f19daab3349fd94f8e901eebd7ad7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTUtMS0xLTk5ODY_a9da1062-6985-4887-8e7d-3ee3d2548dae"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icb53e8019d3444a183fd939d626283cc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTctMS0xLTk5ODY_3c1bcc0d-84fb-435e-8801-867ddc926ccc"
      unitRef="usd">20000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6e91fa49f38046778d905adb20038b86_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTktMS0xLTk5ODY_3fe16828-f0ab-49b5-aecb-4cbcd48e4017"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i77a9ffaa8ff04b0db0e23fb174f64775_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTExLTEtMS05OTg2_a0666741-f90a-4428-87f1-344d01b24460"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iec6fe4bb91db47469413570dc5792607_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTEzLTEtMS05OTg2_3046df80-a2dc-41a6-840a-02ccbdb02183"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iecf40c6bc57a4a96acd2a20797b47feb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzI3LTE1LTEtMS05OTg2_78ce3cbf-1d07-4bc1-858d-fddbf4f1122b"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9295a488115f4c68a8e8c1703fb43b33_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTEtMS0xLTA_fcf8e5dc-edad-4ca2-b649-e631d4a0a66a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i240370941e09472fa67b09378158fe7a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTMtMS0xLTA_e7591c34-ad8b-4e57-9a84-5d69c0fe06f3"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6e355174746e40ccab1d3a022356179f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTUtMS0xLTA_394e38a3-a4c7-486c-b722-77c9c6d5e188"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i04293f756da241a999ca08cf5205814d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTctMS0xLTA_97256372-b817-4388-8220-09d0ae2c5fb8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id5454937046f471eb2aeccd5bdb66a94_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTktMS0xLTA_dde403c2-862c-4b1b-a3c6-3e3fd93d325c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i512cc6f095a04b919b00809dc9264562_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTExLTEtMS0w_5ad316a6-ea98-4665-af3e-3638c355552f"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i860f8c1284824650bf9be85917582840_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTEzLTEtMS0w_d6ecc004-2824-4718-b5f8-7283dc78def4"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3923a650ec254483b01b7e8e723eace4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMwLTE1LTEtMS0w_1bf90499-24ed-4ae2-bffb-0542ea816dae"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTEtMS0xLTA_4cdaa356-1149-465c-b97d-5accfd938a4e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTMtMS0xLTA_cc70fdbd-39b6-4bb8-a5cf-750d2eb22d2f"
      unitRef="usd">525000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTUtMS0xLTA_9b0582d0-888d-4cc9-aef1-1c9e1859e67f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTctMS0xLTA_85ca3ff1-d721-45ff-9e1a-173aa20adf41"
      unitRef="usd">525000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTktMS0xLTA_6526380f-b53e-445b-805f-c5a0551dc159"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTExLTEtMS0w_80524ce5-cc20-4c57-884c-e572b092686e"
      unitRef="usd">97000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTEzLTEtMS0w_503fcbbd-ba2a-472a-848f-35c52257b0ed"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMyLTE1LTEtMS0w_fc56f756-5228-4bf0-88ed-31d08e5c82af"
      unitRef="usd">97000000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6584b76ba97e4e2d92b394330f179c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTEtMS0xLTA_5ac90e0f-d0b1-4f46-8216-1cffefe4635f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i002af26c3a1842fc97e91b66a3a0e0e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTMtMS0xLTA_6133a99c-8192-4938-a59c-b2cd7ec5e2b4"
      unitRef="usd">525000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id0c5289be2704fd3939c74e58673fcb0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTUtMS0xLTA_98b6db39-f716-43ad-9d10-b8c7c8cab560"
      unitRef="usd">841000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9a7496836c554c4c8e7d708f7cc69249_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTctMS0xLTA_1b6b2c8b-ed31-4af8-8322-89637224d239"
      unitRef="usd">1366000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1b3758cf682b409f8450b04bc57aa0b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTktMS0xLTA_f2302264-2e6b-482c-b273-a856e7c5df85"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i31caf9dfe249401192c22d3a5ec9c8f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTExLTEtMS0w_4dfcd70b-c8cc-413e-8c3c-7f812431e917"
      unitRef="usd">97000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icd74ed33e96944c3a04c8497e2aceddb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTEzLTEtMS0w_fb2f160e-4488-4800-8b61-31daee3645cb"
      unitRef="usd">767000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia72079f482c740f3946c8e6aa0108539_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZTpiMWViODUzOThlMGI0ODhiOWFkMDczZjRjYjYwM2YyYS90YWJsZXJhbmdlOmIxZWI4NTM5OGUwYjQ4OGI5YWQwNzNmNGNiNjAzZjJhXzMzLTE1LTEtMS0w_8933a792-c151-4da3-9c92-4cfbcabc26bb"
      unitRef="usd">864000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="if05886a9b13149dfaff74f75da70ff5d_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzEzNjU3_d2501708-b8c3-4998-a723-d7fea36a2a3b"
      unitRef="usd">6800000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i0a073eb825fe4210b901ff8c5229ca73_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDY0MjM_5f050f59-f5f8-431b-a194-cbd193bd381b"
      unitRef="usd">8900000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5Nzk0_224e8502-f470-4747-8b0f-b2fee5b2c691">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Balance at December&#160;31, 2020 includes $148 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; At December&#160;31, 2020 and 2019, $711 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows and a risk-adjusted discount rate of 8% to present value the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzEtMS0xLTEtMA_633585d1-b2e0-4b18-bc86-da82382d9f0d"
      unitRef="usd">767000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzEtMy0xLTEtMA_acf64368-a854-47eb-9fe2-ebf043ade945"
      unitRef="usd">788000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzItMS0xLTEtMzQ0Ng_b2177a95-7e15-492d-9e0f-858fc99ab59e"
      unitRef="usd">97000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzItMy0xLTEtMzQ0Ng_1880cc96-ecd5-40ff-bcd3-8614b39775cb"
      unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzItMS0xLTEtMA_0686b2be-49d4-4470-867e-ac3edea06bca"
      unitRef="usd">83000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzItMy0xLTEtMA_e5e51864-dd75-4621-a420-547ab90285cf"
      unitRef="usd">64000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzQtMS0xLTEtMA_7fa430d7-4ed6-4e41-b7fe-1a631e0c3ef9"
      unitRef="usd">106000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzQtMy0xLTEtMA_ab97e326-a67b-442d-9f7a-c021470c57a4"
      unitRef="usd">85000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzUtMS0xLTEtMA_0dea5477-fb1c-45b9-a5c3-dade6791724a"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90YWJsZToxNWQ0ZWJkOGYxODQ0MTgwYWIyNjI5ZTVlY2NiOWIxMy90YWJsZXJhbmdlOjE1ZDRlYmQ4ZjE4NDQxODBhYjI2MjllNWVjY2I5YjEzXzUtMy0xLTEtMA_bfc44b48-a382-4008-8230-ea384fa7c6a3"
      unitRef="usd">767000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0MDg0_cef0ca80-48b1-4c08-ba18-c1ed80a13f7b"
      unitRef="usd">148000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i732691c0edd54472919c517d2ba0ba90_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0MTk3_58077d39-0593-4b1f-a925-c415fd67dbfc"
      unitRef="usd">711000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7a7a41aa57ca40e6862b37e8bdcf31d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0MjA0_baf45f0e-7014-49e0-9548-af474e5b95d7"
      unitRef="usd">625000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i732691c0edd54472919c517d2ba0ba90_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0NDAw_5004c1f1-e1a7-4b62-a1ae-c62554bbfc45"
      unitRef="number">0.115</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iadc7c95447cb4b7394d986bbf3eb4737_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE0NjYy_90eeb418-97b3-4a92-8c6c-026bfb801c22"
      unitRef="number">0.08</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE1ODY3_6714bb04-600a-4842-8ef3-ab1bdf9fa459"
      unitRef="usd">36000000000.0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE1OTA0_5af085e1-db41-466a-a900-d1ab0dd87e61"
      unitRef="usd">31800000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE1OTIy_0bed526d-e1f0-4f41-af47-49ab4ce59094"
      unitRef="usd">28800000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE1OTU5_d9638f9b-4b93-4a56-9870-9eb99d138d95"
      unitRef="usd">26300000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i66640b35975948b1bb6102116f2f95c0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE3NDA1_5729cfab-0c88-40e5-b760-6823f4668a39"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableSale
      contextRef="i7c736b947a254ac49c79561ae499a87f_D20201001-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE4MDIy_1a47bf86-e773-4f46-abcd-b8ae9296b8cd"
      unitRef="usd">2300000000</us-gaap:AccountsReceivableSale>
    <us-gaap:AccountsReceivableSale
      contextRef="iad9160300b5a4225a05fdc2ad5bf9b30_D20191001-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE4MDI5_4ea9d98a-6526-49f1-84ab-6761e4bcccfe"
      unitRef="usd">2700000000</us-gaap:AccountsReceivableSale>
    <us-gaap:RestrictedCashCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE4NTYw_be7a2015-bc49-4b97-a853-edacb3ac3af2"
      unitRef="usd">102000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDY0OTY_cb08eba4-f862-4d0e-b4bf-a5786ead3f49"
      unitRef="usd">256000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzMyOTg1MzQ5MDcxNzY_8a25a654-1f61-43b2-93be-00dd56d17ce0"
      unitRef="usd">36000000</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xODQvZnJhZzozZTQwODc2ZTcyYmU0OGRkYTc3NzU1MTdmZWQ2Zjk3ZS90ZXh0cmVnaW9uOjNlNDA4NzZlNzJiZTQ4ZGRhNzc3NTUxN2ZlZDZmOTdlXzE5NTY0_da38cd25-caf4-4611-98f5-a9a04f18b4c2"
      unitRef="usd">34000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzUzNg_e638698d-89e4-436a-a4a6-e6022f0978d5">Inventories&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories valued under the LIFO method comprised approximately $2.9 billion and $2.6 billion at December&#160;31, 2020 and 2019, respectively. Amounts recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2020 and 2019, these amounts included $1.9 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $279 million and $168 million at December&#160;31, 2020 and 2019, respectively, of inventories produced in preparation for product launches.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzU0Nw_da6fb426-ae42-4543-8ec9-2686b70445f2">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzEtMS0xLTEtMA_5d0f9838-6381-43b7-b4d4-5a05f46e9f16"
      unitRef="usd">1963000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzEtMy0xLTEtMA_7e04f2ec-323c-4342-8ae6-3410db72255b"
      unitRef="usd">1772000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzItMS0xLTEtMA_8f1b3bc5-1b8a-4185-80d4-a25366ad5866"
      unitRef="usd">6420000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzItMy0xLTEtMA_793d7271-4193-4593-8509-0dc8dce8a9d8"
      unitRef="usd">5650000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:OtherInventorySupplies
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzMtMS0xLTEtMA_38843ebf-2670-4184-be7a-bdfc72c3b8fe"
      unitRef="usd">206000000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzMtMy0xLTEtMA_1cbe30cb-693f-4f15-aebe-6f72b9f529c9"
      unitRef="usd">207000000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryGross
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzQtMS0xLTEtMA_adcc64aa-7a12-4cbc-ae2e-2f17c360fe63"
      unitRef="usd">8589000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzQtMy0xLTEtMA_c6b750f7-67a1-4c95-a4f3-70dd4cb9b319"
      unitRef="usd">7629000000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzUtMS0xLTEtMA_af770848-9fbe-49b4-9ac3-7f01ee521809"
      unitRef="usd">82000000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzUtMy0xLTEtMA_2ae9e207-7ca0-478a-bfb4-e7923def6f9e"
      unitRef="usd">171000000</us-gaap:InventoryLIFOReserve>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzYtMS0xLTEtMA_8f060c2d-3808-47bc-9d5e-f1535ab8eb66"
      unitRef="usd">8507000000</mrk:InventoryNetAndInventoryNoncurrent>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzYtMy0xLTEtMA_c57c6d2d-c349-4ad4-a674-01d042d04e38"
      unitRef="usd">7458000000</mrk:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzgtMS0xLTEtMA_bb5809de-ed60-4368-8831-3c261373b44e"
      unitRef="usd">6310000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzgtMy0xLTEtMA_42a3af75-a3d7-4d1b-8bbb-6f938aa56774"
      unitRef="usd">5978000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzktMS0xLTEtMA_5bcb7721-1955-414e-ace3-da8e188fdd89"
      unitRef="usd">2197000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90YWJsZTo5N2U1ZTMxNzJmYTI0YjczYTU2NDIzOTkzZDgxYTU2MS90YWJsZXJhbmdlOjk3ZTVlMzE3MmZhMjRiNzNhNTY0MjM5OTNkODFhNTYxXzktMy0xLTEtMA_c0e67f9d-9f9a-4fa3-b605-47d3a72b1362"
      unitRef="usd">1480000000</us-gaap:InventoryNoncurrent>
    <us-gaap:LIFOInventoryAmount
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzEzMQ_652d0d3d-a0ce-4351-b0a2-d31eccd62dd1"
      unitRef="usd">2900000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:LIFOInventoryAmount
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzEzOA_1c6c6e94-53a5-4593-ad4b-00de005572d6"
      unitRef="usd">2600000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:InventoryNoncurrent
      contextRef="id3b3b680e1b34262aaaf5bdb274dafa6_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzMyMQ_a8aa573b-33b9-4cf3-bc17-c583175c6786"
      unitRef="usd">1900000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i7e5ba2a7e59e4ea0bf92b13e77d6584e_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzMyOA_d0023667-e9f9-47c8-a944-909611e6eafb"
      unitRef="usd">1300000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i0100533904ac46ef9b774bc1b666a843_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzQzOA_0d962da5-567b-4d61-88b2-dc0d7740cc7e"
      unitRef="usd">279000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i04309b24f07b4666a134a9d0f656e644_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTAvZnJhZzoyNzBlZjdiYjQzODk0MmFmYmMxOWFjYjZlZmIzZDY5MC90ZXh0cmVnaW9uOjI3MGVmN2JiNDM4OTQyYWZiYzE5YWNiNmVmYjNkNjkwXzQ0NQ_c118d2ea-6f99-42fd-a8cd-0b9b3967ed4d"
      unitRef="usd">168000000</us-gaap:InventoryNoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0NTg_3fd6a044-f65c-41fc-a721-e54904ef1973">Goodwill and Other Intangibles&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes goodwill activity by segment:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31, 2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other includes cumulative translation adjustments on goodwill balances and certain other adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The additions to goodwill in the Pharmaceutical segment in 2020 were primarily related to the acquisitions of ArQule and Themis (see Note 3). The additions to goodwill within the Animal Health segment in 2019 primarily relate to the acquisition of Antelliq (see Note 3). The impairments of goodwill within other non-reportable segments in 2019 relate to certain businesses within the Healthcare Services segment. The Healthcare Services segment was fully divested in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangibles at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products and product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45,087&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,162&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57,597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,604&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangibles include products and product rights, licenses, trade names and patents, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. Some of the Company&#x2019;s more significant acquired intangibles, on a net basis, related to human health marketed products (included in products and product rights above) at December&#160;31, 2020 include &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $551 million;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Implanon/Nexplanon,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $354 million; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil/Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 9, $276 million; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dificid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $228 million;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $185 million;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $154 million; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simponi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $132 million. Additionally, the Company had $5.4 billion of net acquired intangibles related to animal health marketed products at December&#160;31, 2020, of which $2.5&#160;billion relate primarily to trade names obtained through the 2019 acquisition of Antelliq (see Note 3). Some of the Company&#x2019;s more significant net intangible assets included in licenses above at December&#160;31, 2020 include Lynparza, $1.3 billion and Lenvima, $1.1 billion as a result of collaborations with AstraZeneca and Eisai (see Note 4). At December&#160;31, 2020, IPR&amp;amp;D primarily relates to MK-1026 obtained through the acquisition of ArQule in 2020 (see Note 3) and MK-7264 (gefapixant) obtained through the acquisition of Afferent Pharmaceuticals in 2016. The Company has an intangible asset related to a collaboration with Bayer (see Note 4) that had a carrying value of $849 million at December&#160;31, 2020 reflected in &#x201c;Other&#x201d; in the table above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company recorded an impairment charge of $1.6&#160;billion within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible asset for impairment. The Company revised its cash flow forecasts for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120&#160;million to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in 2020 related to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recall. The remaining intangible asset balance related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $551 million at December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company recorded impairment charges related to marketed products and other intangibles of $705 million. Of this amount, $612 million related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a product for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive organisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which indicated that the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; that, when compared with its related carrying value, resulted in the impairment charge noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the Company will make a separate determination as to the then useful life of the asset and begin amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company recorded a $90 million IPR&amp;amp;D impairment charge within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#x2019;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45&#160;million (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company recorded $172 million of IPR&amp;amp;D impairment charges. Of this amount, $155 million relates to the write-off of the intangible asset balance for programs obtained in connection with the acquisition of IOmet Pharma Ltd following a review of clinical trial results conducted by Merck, along with external clinical trial results for similar compounds. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $11 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company recorded $152 million of IPR&amp;amp;D impairment charges. Of this amount, $139 million relates to the write-off of the remaining intangible asset balance for a program obtained in connection with the SmartCells acquisition following a decision to terminate the program due to product development issues. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $60 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IPR&amp;amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;amp;D programs and profitably commercialize the underlying product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense primarily recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $1.9 billion in 2020, $2.0 billion in 2019 and $3.1 billion in 2018. The estimated aggregate amortization expense for each of the next five years is as follows: 2021, $1.5 billion; 2022, $1.5 billion; 2023, $1.4 billion; 2024, $1.3 billion; 2025, $1.2 billion.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0Nzk_e6cc3810-d4ce-49ee-9935-e74a1fa3154e">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes goodwill activity by segment:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31, 2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other includes cumulative translation adjustments on goodwill balances and certain other adjustments.&lt;/span&gt;&lt;/div&gt;(2) Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2020 and 2019.</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i532617148a464d439523456b08377125_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzEtMS0xLTEtMA_74dc81e8-e1a2-4e7f-8b25-f8dd90c786e3"
      unitRef="usd">16162000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3e5e6f127527444d84707fb30170819f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzEtMy0xLTEtMA_3a5dc34e-63e8-415d-9c89-7db7f3a9955a"
      unitRef="usd">1870000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3b6e48a8195a4472b5f2937fd2336c6c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzEtNS0xLTEtMA_6670ba0f-87f0-49db-b21e-dd6f68dfd5a0"
      unitRef="usd">221000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzEtNy0xLTEtMA_65357e68-1890-4df1-adbe-b41308046c74"
      unitRef="usd">18253000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i4b686d23f6794c68a37ebff0a13d5324_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzItMS0xLTEtMA_31b8b1df-a3b5-4706-9135-b37eecc2e7b2"
      unitRef="usd">19000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i58799cd60f0b478798fb7372e4698074_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzItMy0xLTEtMA_c9d62c74-3ddb-4d8e-a6c6-5a93b7970e54"
      unitRef="usd">1322000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3d31fc70051c4a68858b153d5a6e84d4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzItNS0xLTEtMA_fc7af0c0-aa7a-414e-be01-57e517963f0e"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzItNy0xLTEtMA_aeae839e-3ad4-4f79-baa9-80398633ca94"
      unitRef="usd">1341000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4b686d23f6794c68a37ebff0a13d5324_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzMtMS0xLTEtMA_7abd58f9-a79f-43d7-b111-014e8c0fcc73"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i58799cd60f0b478798fb7372e4698074_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzMtMy0xLTEtMA_bd5de768-8a1a-4e98-b81f-0a89d793f430"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3d31fc70051c4a68858b153d5a6e84d4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzMtNS0xLTEtMA_91ce6d7e-65ab-4a41-8fdd-c3e22bb41ebb"
      unitRef="usd">162000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzMtNy0xLTEtMA_07d8771b-3a49-443d-9525-e056b93490ba"
      unitRef="usd">162000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4b686d23f6794c68a37ebff0a13d5324_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzQtMS0xLTEtMA_ed9c7796-00fc-456f-b9bb-a911c05f6ff0"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i58799cd60f0b478798fb7372e4698074_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzQtMy0xLTEtMA_a9c71e8f-1a5e-47fc-b043-da3496f10818"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i3d31fc70051c4a68858b153d5a6e84d4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzQtNS0xLTEtMA_8dbfe6f5-aa69-4132-8592-896a429debb1"
      unitRef="usd">-7000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzQtNy0xLTEtMA_ed7affc3-e00a-4558-9e0a-bc65f7770308"
      unitRef="usd">-7000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="ifc97187f000b4d789b7229ce5f27da09_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzUtMS0xLTEtMA_92590502-88dc-4a61-955c-9b3597d37e57"
      unitRef="usd">16181000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i15819e1b053545a9bde3e98453b6f6db_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzUtMy0xLTEtMA_a91d1c60-d50a-4d0d-9973-e4dcac0da226"
      unitRef="usd">3192000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9a204be8a7764bf2bc2bc61353ea4e61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzUtNS0xLTEtMA_c4837d25-f9c0-4380-a9c9-0df27f248246"
      unitRef="usd">52000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzUtNy0xLTEtMA_3ea1f175-1ced-4eb2-9a23-98300b495d25"
      unitRef="usd">19425000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i5d0372a4dd384371b56eddd9bf14f331_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzYtMS0xLTEtMA_152ed53d-5ffe-4461-9fce-915244270fa7"
      unitRef="usd">742000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if73dd2ac8807408f8a19eb712e8ff82e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzYtMy0xLTEtMA_e3b57e94-383a-4f16-aaaf-78864b7302fb"
      unitRef="usd">105000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1cd8d36d804a4f318d753989188298a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzYtNS0xLTEtMA_d6431bbb-0427-44e4-b45f-47b024528af0"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzYtNy0xLTEtMA_82f882a3-c354-492f-81b4-95d98effb820"
      unitRef="usd">847000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i5d0372a4dd384371b56eddd9bf14f331_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzctMS0xLTEtMTg1MjE_ec179aef-f233-43fd-b2d3-223ba6c337c5"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="if73dd2ac8807408f8a19eb712e8ff82e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzctMy0xLTEtMTg1MjE_030bd697-7546-4ada-8edc-3b3a7cf9d6f0"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i1cd8d36d804a4f318d753989188298a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzctNS0xLTEtMTg1MjE_bc5ff089-d622-45b1-a262-3ad83b26c7c2"
      unitRef="usd">54000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzctNy0xLTEtMTg2NzY_a70c5d84-d348-47ef-b27f-6976c3e376b5"
      unitRef="usd">54000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i5d0372a4dd384371b56eddd9bf14f331_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzgtMS0xLTEtMA_c959bca7-71e5-4d00-a62a-06d58821a1bd"
      unitRef="usd">47000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="if73dd2ac8807408f8a19eb712e8ff82e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzgtMy0xLTEtMA_155f0827-f664-44c6-962b-235529e846ad"
      unitRef="usd">-29000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i1cd8d36d804a4f318d753989188298a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzgtNS0xLTEtMA_1b8811d5-01eb-45cb-8b76-a76815ea13ff"
      unitRef="usd">2000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzgtNy0xLTEtMA_ccf18880-ee0f-4a92-9c55-fd8cd304eb53"
      unitRef="usd">20000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="ib0929727611f46b9a4fabbb67f15cf52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzktMS0xLTEtMA_c86198df-9e87-4339-85fc-6c2a13022927"
      unitRef="usd">16970000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1150b2b45f4f4e73994ea0b6ecf39132_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzktMy0xLTEtMA_b6a46f65-c4d1-4cef-b161-d1ebcb167287"
      unitRef="usd">3268000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3a8e2e9cbed5405c909c9467c786afb1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzktNS0xLTEtMA_17a0c30f-1a15-476c-a56c-f801d3e8bc2e"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZTo1OGNmNmEzY2RhMTc0NzRiODUzYjNhNzE0ODU4M2I2NC90YWJsZXJhbmdlOjU4Y2Y2YTNjZGExNzQ3NGI4NTNiM2E3MTQ4NTgzYjY0XzktNy0xLTEtMA_b42eaa8c-6aa6-4a8e-a4be-cc1acb55f62a"
      unitRef="usd">20238000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTg5NTY_13f3fb21-47e1-4d2d-a849-e437c4db63b7"
      unitRef="usd">531000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTg5NTY_7433238a-25fa-4c28-8348-2395cd6851c7"
      unitRef="usd">531000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0NTU_6fc0bb99-bdc7-4a65-83b8-cd42a2cf531a">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangibles at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products and product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45,087&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,162&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57,597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,604&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ifaad2db9e0af480e9820c25f8d39bf48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItMS0xLTEtMA_a5bb3862-2132-4e15-9c13-504aff093418"
      unitRef="usd">45087000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifaad2db9e0af480e9820c25f8d39bf48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItMy0xLTEtMA_ee57658c-bcf0-4398-9fe2-3692e7c9000b"
      unitRef="usd">39925000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifaad2db9e0af480e9820c25f8d39bf48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItNS0xLTEtMA_46eb88f5-f2b9-436a-aa16-a1d8398ee0cc"
      unitRef="usd">5162000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2c9ed711cabf40539749dacb49e1f568_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItNy0xLTEtMA_4ca8c163-71c1-4899-ba09-f7e05d352620"
      unitRef="usd">45947000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2c9ed711cabf40539749dacb49e1f568_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItOS0xLTEtMA_7a69d951-124d-4055-97af-570f0850c06d"
      unitRef="usd">38852000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2c9ed711cabf40539749dacb49e1f568_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzItMTEtMS0xLTA_75b04712-1f46-4e10-9497-c62189b26926"
      unitRef="usd">7095000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iced3a5a3165a403dbf79ac1d619c977c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtMS0xLTEtMA_847b7341-1abe-4875-9b4b-170c13fe1053"
      unitRef="usd">4177000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iced3a5a3165a403dbf79ac1d619c977c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtMy0xLTEtMA_94e25bfa-190a-46fc-8375-5793f74f1cfa"
      unitRef="usd">1387000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iced3a5a3165a403dbf79ac1d619c977c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtNS0xLTEtMA_fd8ec70a-a6a5-4b10-953f-9cac1087af53"
      unitRef="usd">2790000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ib3ce2a6386134b23bed761ddc429d6f5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtNy0xLTEtMA_2866d8bb-6d21-4c57-8651-9755c193024f"
      unitRef="usd">3185000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib3ce2a6386134b23bed761ddc429d6f5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtOS0xLTEtMA_0a6ad776-6eda-4386-87e6-05e308de6a91"
      unitRef="usd">824000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib3ce2a6386134b23bed761ddc429d6f5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzMtMTEtMS0xLTA_834b720c-7766-4ff6-99e7-61a64bb10942"
      unitRef="usd">2361000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5af2e1d785f64d9b9574fd6067247ae4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzQtMS0xLTEtMA_a5cbf03b-1a91-4e17-977e-2cd676283970"
      unitRef="usd">3228000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5af2e1d785f64d9b9574fd6067247ae4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzQtNS0xLTEtMA_d0a5ec92-e81c-4fe3-b97a-eba69fc60f1b"
      unitRef="usd">3228000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="if4e2529a81fe48e2af0847da14387edd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzQtNy0xLTEtMA_e30c4354-7ebc-40d7-9f6b-d61dedafaea8"
      unitRef="usd">1032000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if4e2529a81fe48e2af0847da14387edd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzQtMTEtMS0xLTA_edfaf0e6-ceef-4eb0-871d-1866489b05cd"
      unitRef="usd">1032000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i46ece120a22b4a28ae57b244c672e267_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtMS0xLTEtMA_97358fa6-1091-45b2-9c5b-e0719f302202"
      unitRef="usd">2882000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i46ece120a22b4a28ae57b244c672e267_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtMy0xLTEtMA_b557306c-f9c1-4e4b-809e-6670e95fa9fc"
      unitRef="usd">352000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i46ece120a22b4a28ae57b244c672e267_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtNS0xLTEtMA_647920ce-eefe-4ef2-9d0c-3c8a6925bc74"
      unitRef="usd">2530000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i85308ed5ebab473ebc2ea2ac65fa9e3b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtNy0xLTEtMA_a782262c-8af7-4321-8e3c-b612d7dfa548"
      unitRef="usd">2899000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i85308ed5ebab473ebc2ea2ac65fa9e3b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtOS0xLTEtMA_362f6d52-d522-442c-a2c8-3cccb968811a"
      unitRef="usd">217000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i85308ed5ebab473ebc2ea2ac65fa9e3b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzUtMTEtMS0xLTA_18a62fab-24f8-4dc5-b8ac-4a9e7bac3a12"
      unitRef="usd">2682000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ie066b7e11e1642829a90d72bfad73dbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtMS0xLTEtMA_5919d007-444f-478a-8246-8d08137e07c6"
      unitRef="usd">2223000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie066b7e11e1642829a90d72bfad73dbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtMy0xLTEtMA_69309f73-cf1b-465c-b487-eb990efbdeef"
      unitRef="usd">1329000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie066b7e11e1642829a90d72bfad73dbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtNS0xLTEtMA_19ee5ac8-4901-4022-8c1c-36daabdd8406"
      unitRef="usd">894000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i1c8737f47e0b428ea8e395b4b91b4140_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtNy0xLTEtMA_22e44b9b-70e6-46c7-8603-1fb12da136a4"
      unitRef="usd">2261000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1c8737f47e0b428ea8e395b4b91b4140_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtOS0xLTEtMA_d79ce5f0-92ea-4793-b9ad-2a1f02ce5d2e"
      unitRef="usd">1235000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1c8737f47e0b428ea8e395b4b91b4140_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzYtMTEtMS0xLTA_139135ab-2ba5-45b8-badf-c4a55b4abafd"
      unitRef="usd">1026000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctMS0xLTEtMA_3d45adad-b603-465e-a68d-8e6bc4c898cc"
      unitRef="usd">57597000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctMy0xLTEtMA_bda53b39-2150-4ed3-a5cf-8c41701f3877"
      unitRef="usd">42993000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctNS0xLTEtMA_c95017c1-6693-49c6-bbbd-11036ecc0914"
      unitRef="usd">14604000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctNy0xLTEtMA_feb0073c-cee3-4281-b707-76927967834f"
      unitRef="usd">55324000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctOS0xLTEtMA_8d0f2696-8249-43d8-9201-ef37b89024d6"
      unitRef="usd">41128000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90YWJsZToxM2Q0ZmM3OTI1MTE0ZTI4YjU4NTZhOWU1MzFiN2U1Yy90YWJsZXJhbmdlOjEzZDRmYzc5MjUxMTRlMjhiNTg1NmE5ZTUzMWI3ZTVjXzctMTEtMS0xLTA_5168d372-335c-427d-86ba-2c668c14e08e"
      unitRef="usd">14196000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1173b6885a2f45998fdccfb8d45d893f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzEwNzc_d46b7c21-b36c-45c9-bf0a-111d4be3cd3b"
      unitRef="usd">551000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6f8b5fa2afe945b58cc7cc58540a4871_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExMDE_513a7a4a-78da-4a6f-8600-33ca121597d2"
      unitRef="usd">354000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i45c757b49a734e889c7b8814b17d27c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExMjY_ccc6d218-3883-442c-8ed3-ba535bfd8719"
      unitRef="usd">276000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9e4557c2c3774ac6bd1f5631a947887f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExMzk_73eb3005-c2fa-4cc0-a5d6-600d136eb200"
      unitRef="usd">228000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i84352a69c7a940baa059487a008d720c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExNTI_b7b66f37-f0ad-4d87-a4aa-b73410d87a39"
      unitRef="usd">185000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i644295df1e6b4e9dbedf44a0e8a544f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExNjY_1007a5ef-e27f-4b55-8d1e-887734241c15"
      unitRef="usd">154000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i63c8541f7de64146a1d1b841885e43cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzExODM_454f1887-e7b8-4060-b501-9a63ef836eb4"
      unitRef="usd">132000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i44dc8a8199b54644aaa379692dd53d6f_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzEyMTc_4d9d8ee3-ae06-4e6a-b4de-5debde421510"
      unitRef="usd">5400000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5db1bfb9494a4fe2a7e9ed0eaa5d201c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MTEzMzc_d8d1cc0d-2c1f-4632-b4d0-f594962eaf00"
      unitRef="usd">2500000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i290e0168aaad4d8bbb291ae388c991a3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MDkyOTU_1cd74da4-3f11-456a-96df-a96ce7078a17"
      unitRef="usd">1300000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic4443e6b872f4ba8905276b85a6342e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzE0MDE_248c0469-797f-4eb0-a1aa-e6fb9518a4a6"
      unitRef="usd">1100000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i50171610356846629bd94e414c848b8f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzE3NTM_8ba72bfa-0275-4eba-93e1-4ff13ba7db2a"
      unitRef="usd">849000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i5f574ea21943431ab05c0b6dbcdce88b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTc5MTc_f436a620-bb48-46c9-abb8-0001ddf2eaec"
      unitRef="usd">1600000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:InventoryWriteDown
      contextRef="i5f574ea21943431ab05c0b6dbcdce88b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc2OTY1ODE0MjI0OTM_4ea5461b-6ff5-468d-814c-17f93ad1dcc7"
      unitRef="usd">120000000</us-gaap:InventoryWriteDown>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1173b6885a2f45998fdccfb8d45d893f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MDQwMDE_d46b7c21-b36c-45c9-bf0a-111d4be3cd3b"
      unitRef="usd">551000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzE5MDc_5874af55-0485-417b-afa2-cec6ab939aef"
      unitRef="usd">705000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i4b02c94bdf4b498b8851fe2c79b417a8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzE5NDg_e14c0b94-9888-4585-943e-a80ba9f466e0"
      unitRef="usd">612000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MDIyMzA_b17e8e60-6144-406b-ae3f-daeb2cc4d502"
      unitRef="usd">90000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i3c3d5452a51a4fc291cdd234223f7733_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ5MDM3MDU_822fe909-e45e-4b4f-b026-1480d67f82cb"
      unitRef="usd">-45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTA4NDY_3bd37f7e-deb3-41cd-ace6-9378deed3fea"
      unitRef="usd">172000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i66d85fef1ef64fa4b7ac0d3e28260cee_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzQ0MTE_00d71c8d-0f29-4253-9241-1b7fd6fe33da"
      unitRef="usd">155000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i66d85fef1ef64fa4b7ac0d3e28260cee_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzQ4MTY_caf8e299-e93b-4a3c-8941-60931929cc62"
      unitRef="usd">-11000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzMyOTg1MzQ4OTA4NTE_0370feae-6ddf-45f9-a86d-f36a31e94555"
      unitRef="usd">152000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6db9d51af09c4754abfbb7520bc64c24_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzQ4OTk_8355c493-57e4-4714-a236-9afedc88e1c0"
      unitRef="usd">139000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6db9d51af09c4754abfbb7520bc64c24_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzUyNTY_95fdc811-8f38-4a6f-bd06-b08647347cb8"
      unitRef="usd">-60000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzcyODg_43c2f732-7758-4c09-b5b9-56618a31a14f"
      unitRef="usd">1900000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzcyOTg_ab56e3ba-2663-498f-87f6-bd94a786b8b7"
      unitRef="usd">2000000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzczMTE_37b709ef-fc0f-49cb-bbc9-445733f790ac"
      unitRef="usd">3100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0MTc_ec24d98c-f624-4543-81c9-5c4ab9ecefee"
      unitRef="usd">1500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0MjU_b1741e9b-5e15-49ad-9b77-addd6b79d092"
      unitRef="usd">1500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0MzM_ea09e984-79dc-4cbf-ba74-64ee0a149881"
      unitRef="usd">1400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0NDE_3d6409b1-f528-493c-84f9-6767662ca56c"
      unitRef="usd">1300000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTMvZnJhZzpjNzM3YzFhMmE1MWM0ZTI0OGYwMzE1NjhjZjhkMjE0Zi90ZXh0cmVnaW9uOmM3MzdjMWEyYTUxYzRlMjQ4ZjAzMTU2OGNmOGQyMTRmXzc0NDk_426428c7-4534-4ed3-aff0-ed63a71cc11a"
      unitRef="usd">1200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY2ODE_c7921de0-6d9d-4a84-b32a-d9b84b222a09">Loans Payable, Long-Term Debt and Leases&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loans Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loans payable at December&#160;31, 2020 included $2.3 billion of notes due in 2021, $4.0 billion of commercial paper and $73 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2019 included $1.9 billion of notes due in 2020, $1.4 billion of commercial paper and $226 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.79% and 2.23% for the years ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,748&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,734&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15% notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45% notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.875% euro-denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75% notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;991&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;982&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50% notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;719&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50% euro-denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375% euro-denominated notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50% euro-denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60% notes due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.30% debentures due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875% notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.125% euro-denominated notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (as presented in the table above) includes $294 million and $147 million at December&#160;31, 2020 and 2019, respectively, of borrowings at variable rates that resulted in effective interest rates of 0.45% and 2.54% for 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#x2019;s option at any time, at varying redemption prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company issued $4.5&#160;billion principal amount of senior unsecured notes consisting of $1.0&#160;billion of 0.75% notes due 2026, $1.25&#160;billion of 1.45% notes due 2030, $1.0&#160;billion of 2.35% notes due 2040 and $1.25&#160;billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp;amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s borrowings require that Merck comply with covenants and, at December&#160;31, 2020, the Company was in compliance with these covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate maturities of long-term debt for each of the next five years are as follows: 2021, $2.3 billion; 2022, $2.3 billion; 2023, $1.7 billion; 2024, $1.4 billion; 2025, $2.5 billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a $6.0 billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company&#x2019;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of eight years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company does not record short-term leases (leases with an initial term of 12 months or less) on the balance sheet; however, Merck currently has no short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#x2019;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#x2019;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost was $346&#160;million in 2020 and $339 million in 2019. Rental expense under operating leases, net of sublease income, was $322&#160;million in 2018. Cash paid for amounts included in the measurement of operating lease liabilities was $340&#160;million in 2020 and $281 million in 2019. Operating lease assets obtained in exchange for lease obligations was $495&#160;million in 2020 and $129 million in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_50622f13-ac81-4492-afe1-5ad4feaf94c9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_821d9613-2257-47a4-8e9e-6ec850c6c87e"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_36307b76-5525-434a-87a2-55d497163500"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_ff6866b2-78de-4484-8932-0849a2e904bc"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_8ad1ce04-1366-42d1-95f3-bf2b967b7e47"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_a770729c-7273-4447-83c4-49a31ce0554f"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Includes prepaid leases that have no related lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating leases liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $475 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzExMA_ea8e7fae-1ce5-472b-bd25-6d6ec39147e7"
      unitRef="usd">2300000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i85a6d1399fe54a219de34e4fb8d4af00_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzEzNQ_426b2f55-6505-4f0b-a950-c51d22066498"
      unitRef="usd">4000000000.0</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ib00b85fd4d974a758d1b963871ea7a01_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE2Mg_f066d713-275a-4624-abd6-c8d1f72f5e7c"
      unitRef="usd">73000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTAxMDg_51ce5c36-9b85-47c6-a1a5-b4d7285069bf"
      unitRef="usd">1900000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ie6bb25ba3f5e48d98f224bb95792c81b_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzI4OQ_5b08ee47-ae58-4c2d-939b-33c734dd4f50"
      unitRef="usd">1400000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ifc988053afe14f7b91f98a61bca385dc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMxNg_3081177d-8d62-4d39-8927-250696804f30"
      unitRef="usd">226000000</us-gaap:DebtCurrent>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="i85a6d1399fe54a219de34e4fb8d4af00_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzQ2OQ_488901d4-6139-46f5-8bc2-6d2cbdf11869"
      unitRef="number">0.0079</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="ie6bb25ba3f5e48d98f224bb95792c81b_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzQ3Ng_e6402788-9fba-45e3-bc05-5f1f36d52b1f"
      unitRef="number">0.0223</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY2ODc_25303471-9a1c-4e67-a996-060d199c439e">&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,748&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,734&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15% notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45% notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.875% euro-denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75% notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;991&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;982&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50% notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;719&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50% euro-denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375% euro-denominated notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50% euro-denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60% notes due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.30% debentures due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875% notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.125% euro-denominated notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaba347791c48433e925479fecdd16a54_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NzI1YzhhMzA1ZTQzYmRhN2ZkNTU5OGU5MGEzNWQzXzMyOTg1MzQ4ODMzNTc_e614c5f0-0f05-4d74-88c7-29d1000735ee"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaba347791c48433e925479fecdd16a54_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEtMS0xLTEtMA_df3d6597-d948-4f77-9ec9-5423ea392d5a"
      unitRef="usd">2493000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieea8732c8c424a298f074a0d05b4f8e4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEtMy0xLTEtMA_88781731-9324-4c81-a4ac-6576609d6a72"
      unitRef="usd">2492000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i344abc1ac8df4e5fb7317baa25a573c4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzItMC0xLTEtMC90ZXh0cmVnaW9uOjY2NmNjODMwMjRiYTQ5ODBhMWE1NGUxNTFjOWM4ZTJlXzMyOTg1MzQ4ODMzNTc_282e711d-ef76-49d3-8a98-a3a3128ee693"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i344abc1ac8df4e5fb7317baa25a573c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzItMS0xLTEtMA_e8b02040-d7b8-482a-8c3a-65da151dd64d"
      unitRef="usd">1976000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6416b36cb32d45d7972ecd5a8eb20bcd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzItMy0xLTEtMA_8d1a73b7-5c6a-4df2-bfbb-215402182ea8"
      unitRef="usd">1975000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i83a3cf0b47ac4f21b67473d021c763ec_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmU0NWVkMGRjYjU2ZTQzNzE4MmQ1NzcxNTQzNzE3ODU0XzMyOTg1MzQ4ODMzNTc_95d1dd1d-4a9b-464a-aa50-98d9a1912e98"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i83a3cf0b47ac4f21b67473d021c763ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMtMS0xLTEtMA_fc7a315f-cec3-42c1-b560-fa7708afe08d"
      unitRef="usd">1748000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8dfc4e4a837d4b3d94e05f841194c53c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMtMy0xLTEtMA_c5a16867-ae8a-4f26-91c3-268b4dbef316"
      unitRef="usd">1747000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4e9099574c5f4032937d3bc2367b5b64_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmYwZGM0NDJiMTliYTQ3NWY5ZGEwMDEzYWI5ZjQ4Yjk4XzMyOTg1MzQ4ODMzNTc_a9da9b32-ede5-49e9-95d3-5a7ed5fe66af"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4e9099574c5f4032937d3bc2367b5b64_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzQtMS0xLTEtMA_6e172c80-e815-46be-9b4b-a64be65716bf"
      unitRef="usd">1734000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9cca79113e2045d5b4e73f3784ef8022_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzQtMy0xLTEtMA_f9376d98-1709-4a19-8b7d-4e587d66921c"
      unitRef="usd">1732000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i45e429ebe7354c82b1294000a91d6238_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjBiMmU4OGQ3ZjE1NTQ3Y2M4YWU2MmM1ZTAxNWQxZjQyXzMyOTg1MzQ4ODMzNTc_26efc9b5-717b-4bec-8ae6-aff3e984f8ec"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i45e429ebe7354c82b1294000a91d6238_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzUtMS0xLTEtMA_43b5cd74-bbe5-4322-b4aa-473685191c08"
      unitRef="usd">1469000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibc9960f291154518b7771a8367588623_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzUtMy0xLTEtMA_1e850376-18e4-4c3b-ba6f-48f9c4384377"
      unitRef="usd">1468000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibd58c6c117ea431ab0dfe66f19331376_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzYtMC0xLTEtNDQ0OC90ZXh0cmVnaW9uOmUwYjcxMzcwODUxNjQxMjliOTI2MThiNzc2ZGZjMDdlXzMyOTg1MzQ4ODMzNTc_80373f98-6515-4b91-8431-bc775af19f64"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibd58c6c117ea431ab0dfe66f19331376_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzYtMS0xLTEtMzc4Ng_6ac2d0d1-3923-4a1e-87e7-cc8ea850ff85"
      unitRef="usd">1269000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieb84f0d208f541898a079de4407fbc4c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzYtMy0xLTEtMzc4Ng_488c1b76-b4c2-48c7-aa5c-568360344e24"
      unitRef="usd">1248000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4ab23cdcdc843a2917bbca28606754f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzctMC0xLTEtMC90ZXh0cmVnaW9uOmE0ODRiMzYyNWEzMzQyYTE5OTE1ODg5MTMyMDU5NDFlXzMyOTg1MzQ4ODMzNTc_71f978c7-c092-48bf-a3e7-002014e04dd2"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia4ab23cdcdc843a2917bbca28606754f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzctMS0xLTEtMA_ef4b036f-9083-4b7c-9776-f9d0df9cd9bc"
      unitRef="usd">1238000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2ff98b9634eb4b8abec7f2929324acd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzctMy0xLTEtMA_c6e40b33-0e36-4430-82d3-4c6be33b3845"
      unitRef="usd">1238000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i78df5306478342eab229fdfa2b5ff46b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzktMC0xLTEtMTA4MzYvdGV4dHJlZ2lvbjphODY2OWIyZWQzMGQ0NTJmOGY5Y2Y3MDgwODQ0NDFkOF8zMjk4NTM0ODgzMzU3_ad725d80-e5bd-46e4-a75f-c2db4a092d67"
      unitRef="number">0.0145</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i78df5306478342eab229fdfa2b5ff46b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzktMS0xLTEtMTA4MzY_55324937-7347-44b3-b849-db78c316005a"
      unitRef="usd">1233000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i78222fc09fda4c99ad6c20c30a5771e5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzktMy0xLTEtMTA4MzY_5b05b8b7-78c0-4107-ad42-be05fe2d8c5d"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iceecc1aac1de4bc0a9891ccd1446b5c7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjo3MTE1ZWYxYzI1N2Q0NzE5OGFhNmZkY2ZmNmY2MTg5Yl8zMjk4NTM0ODgzMzc2_6dc7f57e-c096-40ef-ba93-b69b474d2f89"
      unitRef="number">0.01875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iceecc1aac1de4bc0a9891ccd1446b5c7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEwLTEtMS0xLTA_af4cb041-7e10-4e14-b4b1-546789fe2ffb"
      unitRef="usd">1218000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icfe272a16def41b5a009731435dffb9b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEwLTMtMS0xLTA_b863cab7-183a-4da4-b3b5-9fecbd40ece4"
      unitRef="usd">1107000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i754a95212e81449592b1cdc907c41645_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTAtMS0xLTEwODAzL3RleHRyZWdpb246NDBkNGJjNWRkOTg1NDkzZjk5ZWUxMzRhOTYwN2QxMTlfMzI5ODUzNDg4MzM1OA_9d728011-8c18-47d8-8743-786fbd848721"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i754a95212e81449592b1cdc907c41645_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTEtMS0xLTEwODAz_9eab2ff8-0c9a-41ae-8896-f8ac33b4b45b"
      unitRef="usd">1211000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i732723d5fe6a4b868b89375b49d5fd8b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTMtMS0xLTEwODAz_69d1daa9-4744-4805-a274-8fa985de8fa9"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1c412aa3064f462e946f0da6f2d9215d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo4MTc1YmJkYjMyMDI0OWE2OWIzYzM5YzE5NTNkYTk2Ml8zMjk4NTM0ODgzMzU3_96b0ccd0-e9ae-487d-963c-6bd6427a6c8d"
      unitRef="number">0.0240</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1c412aa3064f462e946f0da6f2d9215d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzExLTEtMS0xLTA_21801a91-d947-4523-af2a-299d3b85d832"
      unitRef="usd">1032000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i736b59648d614c0e97f2775844772478_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzExLTMtMS0xLTA_8296aa19-0270-4f20-bd3e-41bfe1e39fff"
      unitRef="usd">1010000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1555c8a744114e5db01a64b368754154_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTAtMS0xLTEwODI4L3RleHRyZWdpb246MDk3MjU3NDk4NDU4NDY3MzllOTYxMGM4M2I0NmViNmVfMzI5ODUzNDg4MzM1Nw_13a0bdcf-59a0-4def-a15c-63714ab35934"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1555c8a744114e5db01a64b368754154_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTEtMS0xLTEwODI4_8903d210-9a48-47b7-b9ba-fc3aa9b3d87e"
      unitRef="usd">991000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6875a6efe8e744ff842540cb414f8f8a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTMtMS0xLTEwODI4_3c68f4d7-0a0a-4db0-8b44-abfb0f958c32"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0efc1bff14834532b53dc32625a888ab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZTI2MGIxYzAxNzM0YzhkODQ2Y2Y4N2IyOGU1YWVlZV8zMjk4NTM0ODgzMzU3_62912551-80ca-4278-8bce-c0c529c7f128"
      unitRef="number">0.0390</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0efc1bff14834532b53dc32625a888ab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTEtMS0xLTA_48cceb62-4575-4ea3-95bb-3da426cc3219"
      unitRef="usd">983000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i294d63d03b95427aab71e6571ccc09c2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEyLTMtMS0xLTA_ad80cbc1-2697-4758-96cc-94c64b7c2f05"
      unitRef="usd">982000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib13a5c56a92845b8ab48bcaf8bc19e9a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTAtMS0xLTEwODIwL3RleHRyZWdpb246Yzk0ODJjY2NjNzhiNDk0ZjljNDVmZDNlMjg4OThlZTZfMzI5ODUzNDg4MzM1Nw_1442249f-9480-4360-a556-a859ab3efdef"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib13a5c56a92845b8ab48bcaf8bc19e9a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTEtMS0xLTEwODIw_6da1ba84-f0f6-4e9e-86a8-b4659b21b8f6"
      unitRef="usd">982000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i41cef927a50d40dd94bf6b3639986635_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTMtMS0xLTEwODIw_ec664f38-f9f1-4ed1-8954-af9665f8d43a"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if245f9f1b17449e88cc2103efa045493_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo3YzVkZjU2NmRkNDg0ZjAxYmM2OTlmZjExYzA2YzU0NF8zMjk4NTM0ODgzMzU3_356ac4eb-1eeb-4274-a043-5bd7903e2a54"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if245f9f1b17449e88cc2103efa045493_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTEtMS0xLTA_a6c4703e-375d-4d87-8398-f4cfe8646ce4"
      unitRef="usd">746000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieb0cb1fa4d45425fa7783c3a6ef3bc70_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzEzLTMtMS0xLTA_fa25e387-9c83-496f-922d-2c0a76190c0c"
      unitRef="usd">745000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i80623f99eb964250b8fc54ea685897f5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjozNWMxMzVjZTUyOGY0MTM2OWQ4MWNiZmZhYmRlNjc4OF8zMjk4NTM0ODgzMzU3_6185dd8a-c6cc-4b87-ab3a-abbf7a9983e9"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i80623f99eb964250b8fc54ea685897f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE0LTEtMS0xLTA_826672a5-cff6-499d-8e48-2726ff72daef"
      unitRef="usd">719000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3e81d555abbb4c418adeed3f0d9d7565_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE0LTMtMS0xLTA_adca22ec-14a9-4324-998a-bd8ba05a6f98"
      unitRef="usd">722000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i20a01f80b4c246a2bf622369fdfa8f18_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTAtMS0xLTAvdGV4dHJlZ2lvbjozZmFlOWRjMzAyYmU0MzBjYTQ0Mzc2YjM5MzQxMDUzOF8zMjk4NTM0ODgzMzc0_9e0e3422-1a2e-47d8-b642-70ba9613b0d8"
      unitRef="number">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i20a01f80b4c246a2bf622369fdfa8f18_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTEtMS0xLTA_231939bb-0991-4e2c-94c0-2a49d16036c6"
      unitRef="usd">611000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i34867e87009e4b0e99e46b2f6cb4c092_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE1LTMtMS0xLTA_34933bc3-6f70-4817-8974-f4304fb5979c"
      unitRef="usd">555000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i49a46592892940408701fcf1a045d8f4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpjY2MzNGZmMmZiMDg0ZTgyOTc2ZTY3M2JiNDcxOGZlOV8zMjk4NTM0ODgzMzc2_83d844a4-e237-4b6d-9f86-031822acf3c1"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i49a46592892940408701fcf1a045d8f4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE2LTEtMS0xLTA_d9c14474-9e95-4bf8-b496-959c9e0fa891"
      unitRef="usd">606000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i456e1ba1d4d048b8b9c8e3f642d03c44_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE2LTMtMS0xLTA_0f08affc-7d1b-42f5-9132-9bb2df41b688"
      unitRef="usd">551000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i22ea05d6371640059821d1b96b78bcfb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjo1OWI4NzQ3NGJkZTk0M2NjYTJkZjU3MjczZDljYzIzYl8zMjk4NTM0ODgzMzc0_aa33c2ff-ba3f-400c-920f-893cc61c9db0"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i22ea05d6371640059821d1b96b78bcfb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE3LTEtMS0xLTA_737486f6-cba5-423d-9b43-dc0e4cecf628"
      unitRef="usd">605000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i65571cdb0e3545d08e1a78ce87482955_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE3LTMtMS0xLTA_949f0b79-fa34-436d-b455-43bcffa97fbb"
      unitRef="usd">550000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i291cfe0382bb4a1da525a53dd4bd56d2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMzM3NWYyYTg3MTY0NzlhYmQ1Njc1YTEyZDY5YjM3OF8zMjk4NTM0ODgzMzU3_6790154f-5bd3-4b60-abea-f743d874406b"
      unitRef="number">0.0360</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i291cfe0382bb4a1da525a53dd4bd56d2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE4LTEtMS0xLTA_cf9b738a-5247-4cac-b53c-4c88da4a98ff"
      unitRef="usd">491000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if7e47a06c17e443da59e214105dd3142_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE4LTMtMS0xLTA_5b1d0a52-16df-46cc-98a5-4275634af825"
      unitRef="usd">490000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3fe8e4e022a84cfea391ef6224221b96_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE5LTAtMS0xLTAvdGV4dHJlZ2lvbjphYWM4YjkxOGQ2YjY0NzYyYWQ3YTY3ZjNiMzI2ZjUxNl8zMjk4NTM0ODgzMzU3_ab966a70-5e27-417f-9585-f05dfd8f336a"
      unitRef="number">0.0655</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3fe8e4e022a84cfea391ef6224221b96_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE5LTEtMS0xLTA_05e9ff27-183a-445f-a3ae-143cd0f26132"
      unitRef="usd">411000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4b2a2f31269d4bfbbaa9fb0d49f28117_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzE5LTMtMS0xLTA_1d9ecd23-546a-40c9-9dfc-ed615839ee06"
      unitRef="usd">412000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8a29df5772da4572bbc2b0dc9d2a170b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjowNDc1ZjhiYTdlNTI0NDBiOWVhOTBmN2YyMTc0Y2E1NF8zMjk4NTM0ODgzMzU3_35dcb688-a8b9-4de9-9630-f1f7ef1fcf04"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8a29df5772da4572bbc2b0dc9d2a170b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIwLTEtMS0xLTA_5bf66906-c12d-4438-8de8-8535c3ea7112"
      unitRef="usd">338000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3e537b9b718849abb7a52b86436ee26c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIwLTMtMS0xLTA_72d9b72e-4c14-49cc-a0f9-3768b8fddfc9"
      unitRef="usd">338000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6be4ea71456d4e0cb0df403c03f0803c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzVkMGY4Y2NjZGI0NzU4OGUzNmRlN2YwMDE5ZTdmNl8zMjk4NTM0ODgzMzYy_04ef7630-d6cd-43cd-8fdb-e2357860a273"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6be4ea71456d4e0cb0df403c03f0803c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIxLTEtMS0xLTA_f1956e6e-81bd-4e9a-bc6f-0c28e4e8ed86"
      unitRef="usd">306000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib7f96dfc50594cc98edcf62d8b285b5b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIxLTMtMS0xLTA_bba5ae77-4306-4fe9-80eb-43b1ec102c51"
      unitRef="usd">306000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3b5f170dde14479cad14ff734e5b12f5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjlmYWZmM2VlODU0ZGU2YTQ4MWIxNjMyZWEwYWZiN18zMjk4NTM0ODgzMzU3_e1c2697d-a444-48c6-addf-64050e596287"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3b5f170dde14479cad14ff734e5b12f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIyLTEtMS0xLTA_fb8e98d2-2c10-490f-aafd-df4b20bd1a2a"
      unitRef="usd">271000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8eeb41177eb24d1d9df2236c98035186_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIyLTMtMS0xLTA_3b5a7c44-420f-48e8-902c-73fec5f49bce"
      unitRef="usd">271000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifc08d1a074864992a264a4b6422ccf21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjplNjMzNzQzZDhmNTc0MmVlYTc1ZjJiODRjMjI4YzNmNV8zMjk4NTM0ODgzMzYz_3cd56e97-344a-4dc8-bb7f-20d2ba0ba10b"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifc08d1a074864992a264a4b6422ccf21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIzLTEtMS0xLTA_5dbb5a36-e85c-4bff-9af6-99e7cf98a9c0"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i04a54f19f0a746b39d2b9025e8db43c3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzIzLTMtMS0xLTA_17d1ae8a-37d9-4b54-936a-48497847b2be"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9978259f8d4b47488a313e4f6298d224_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpiNTE5NTVkNmM0ZTk0ZmQzYjY3ZGNiZjdjNmE0M2FhOF8zMjk4NTM0ODgzMzYy_55eed09a-9661-46a9-8d31-597d08a631cb"
      unitRef="number">0.0630</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9978259f8d4b47488a313e4f6298d224_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI0LTEtMS0xLTA_15028c38-42f8-4061-8ce2-42392b0f1cbd"
      unitRef="usd">135000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id22994b5296a4991ac4adf5979eadbd5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI0LTMtMS0xLTA_cfefbac5-a1e6-4f52-bb56-1d2de2f332de"
      unitRef="usd">135000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icacb65bc336f4dc9bb0c0a000f8b3b2c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI5LTAtMS0xLTM4MDUvdGV4dHJlZ2lvbjplNjYyNTdkODIxZjY0YWZkODBlNmIyOGE1Y2YyZDU3YV8zMjk4NTM0ODgzMzU5_c5c79bf2-6802-4b6e-a42b-1cc4e3c160b3"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icacb65bc336f4dc9bb0c0a000f8b3b2c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI5LTEtMS0xLTM4MDU_3781556e-5046-4d81-bdaf-b8eb49d0d23b"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i73a2ef6578e84496b80d826a8bd81fc6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI5LTMtMS0xLTM4MDU_ab0433b2-f6e2-4334-b1fc-c67cf26c5555"
      unitRef="usd">1151000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iafd3d72bbfff46e9b1dbe43d5ae389a1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMwLTAtMS0xLTM4MDUvdGV4dHJlZ2lvbjo2NTcwNDFjMmJkYTI0NWE5YWRjNTIyMzYzNDliYzMyNl8zMjk4NTM0ODgzMzc2_17f7154c-741e-433a-971f-8bba8f97b7a2"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iafd3d72bbfff46e9b1dbe43d5ae389a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMwLTEtMS0xLTM4MDU_d4f11004-0b8d-4b04-81bd-8776ab398846"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5065e542a7804f1d9986df718c97d477_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzMwLTMtMS0xLTM4MDU_21e211f9-597e-4a1b-a486-d16985453208"
      unitRef="usd">1113000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iee2431c7a6454b38ab36680e0e8d37e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI3LTEtMS0xLTA_bfcad97a-4f52-4ded-af44-350dbfb530f0"
      unitRef="usd">294000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4a1148b1b31242e48e86597a3d3f1701_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI3LTMtMS0xLTA_0e022d84-0fc3-4c02-b8d7-232318779049"
      unitRef="usd">148000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI4LTEtMS0xLTA_4c12d215-bcac-456e-8697-a8124f04a26b"
      unitRef="usd">25360000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmZjhkODRmMDU4NmU0ZmRkODBkYTlkZTNlMzE1MmM4MS90YWJsZXJhbmdlOmZmOGQ4NGYwNTg2ZTRmZGQ4MGRhOWRlM2UzMTUyYzgxXzI4LTMtMS0xLTA_ff110616-c7e8-4bc5-bf9c-7064c49554e9"
      unitRef="usd">22736000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3949abad89e14fd38587a5c5fbfe1511_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzYzNQ_22e0909c-ee90-4c1e-a33f-0007d98cd063"
      unitRef="usd">294000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i01916148acd5472d9995c901f488ade4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY0Mg_16895d17-51b2-4287-9375-c4af37feec99"
      unitRef="usd">147000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i3949abad89e14fd38587a5c5fbfe1511_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3Xzc1MA_69028edf-6751-43c8-8d69-462482165bbb"
      unitRef="number">0.0045</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i01916148acd5472d9995c901f488ade4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3Xzc1Nw_9d8d4e10-77e5-49b5-bae1-9c17091d2e12"
      unitRef="number">0.0254</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9978259f8d4b47488a313e4f6298d224_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzgxNg_cac617ca-2b99-4570-acdd-062e7fe84e1e"
      unitRef="number">0.0630</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia25c4a8026c741e390c5f222dcb409cf_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0MzA_c7a89de4-f7e6-42ed-b94b-cab6003c2531"
      unitRef="usd">4500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i288d6bcb95724509929f814f722c2cf6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0NDQ_cc15fa37-f641-4222-8377-98ecd0a9ff99"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i288d6bcb95724509929f814f722c2cf6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0NTg_db265a64-cc93-4c09-a955-620775c0cb43"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i894c10ae01644b8d9f041da769af6d71_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0NjU_7ec500b2-e5c7-468b-8794-9b607907a21c"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i894c10ae01644b8d9f041da769af6d71_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0ODA_c61f8bfe-8298-4e3c-9da8-f2d8651f27b7"
      unitRef="number">0.0145</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7c1f495cc6884078a83bcc4ce2ed06da_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE0ODc_b5c101a7-ec70-41ed-bb03-ad4b161a55f8"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7c1f495cc6884078a83bcc4ce2ed06da_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE1MDE_9a7922ea-db5c-464d-b393-dd6b4ef6f931"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2a7670e8fa924f52a3744367cf66477d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE1MDg_8e78fc6b-74ba-4a23-8b3d-667d9a0982ad"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2a7670e8fa924f52a3744367cf66477d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTE1MjM_2bfa3948-040f-4574-abb2-9938e56142d7"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE5NzU_ee2db2b0-43d7-41a7-9d86-c3923d564770"
      unitRef="usd">2300000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE5ODM_0d9d4c5f-070d-4319-bc31-2036365a8bae"
      unitRef="usd">2300000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE5OTE_ba858fbc-152a-4abb-891e-24e7c8c1f170"
      unitRef="usd">1700000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzE5OTk_aaf2507e-426e-46ce-a4db-b36770c92951"
      unitRef="usd">1400000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzIwMDc_96118ce1-fe9f-47fd-870d-2eb159a26b23"
      unitRef="usd">2500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzIwMzA_25254c2f-0331-4949-b598-acced9a9b0d5"
      unitRef="usd">6000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibf5a47fd424649b58844b8504c6890af_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzM2Nzk_1caef52e-b8ec-44c3-b483-111471a92e68">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ibf5a47fd424649b58844b8504c6890af_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzM3MzY_da256b4a-8165-438d-b2a3-098839046c92">P4Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6f8e4e7cb13141119d6f1759b7717a08_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzM4MDA_7061f492-8380-4232-80d5-4fb3da38b7db">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseCost
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTAxOTk_ec81b617-fe48-47fe-8d31-b419faf93cb0"
      unitRef="usd">346000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzU4MDk_b66e2b0c-e7e3-4d6e-b25f-6b7852d273d9"
      unitRef="usd">339000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ5MDQxOTg_90e92387-9426-4727-ae93-258ed7e891c6"
      unitRef="usd">322000000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasePayments
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTAyMjA_80252367-3adc-4b3f-abd6-101ea635faeb"
      unitRef="usd">340000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzU5MDY_dfdc809d-8f5d-4b11-a145-cff039af4cf3"
      unitRef="usd">281000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzMyOTg1MzQ4OTAyNDE_11aec7dc-790d-4f22-8d9f-fd9dd23987ed"
      unitRef="usd">495000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzU5ODg_28466f7f-27d7-4533-a241-1bd5ab081f1c"
      unitRef="usd">129000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mrk:AssetsandLiabilitiesLesseeTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY2OTI_da5285b5-f37e-4a0e-ad51-38ab07a9ecb0">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_50622f13-ac81-4492-afe1-5ad4feaf94c9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_821d9613-2257-47a4-8e9e-6ec850c6c87e"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_36307b76-5525-434a-87a2-55d497163500"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_ff6866b2-78de-4484-8932-0849a2e904bc"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_8ad1ce04-1366-42d1-95f3-bf2b967b7e47"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_a770729c-7273-4447-83c4-49a31ce0554f"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Includes prepaid leases that have no related lease liability.&lt;/span&gt;&lt;/div&gt;</mrk:AssetsandLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMS0xLTEtMA_0f099356-87bd-4b3e-9050-85b5e601e266"
      unitRef="usd">1725000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMy0xLTEtOTYx_990983ea-432e-466f-9b89-00b92341e572"
      unitRef="usd">1073000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMS0xLTEtMA_96d7e6da-d0fb-487c-8c86-4cd1690a7758"
      unitRef="usd">300000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMy0xLTEtOTYx_12685eae-4c06-41c5-b869-78f256e6a75a"
      unitRef="usd">236000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMS0xLTEtMA_4ed9ad61-212f-4376-9e19-453311aab81c"
      unitRef="usd">1362000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMy0xLTEtOTYx_fa8041f5-1bb8-4731-a9fb-0c682b327ab6"
      unitRef="usd">768000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzYtMS0xLTEtMA_f7e97ac6-2e73-4ffc-9372-55ef59660c70"
      unitRef="usd">1662000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzYtMy0xLTEtMzg5OA_a237ecdc-640d-49e9-936a-c2d5d9c32c02"
      unitRef="usd">1004000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzctMS0xLTEtMA_3e28bd8e-179a-4370-82a3-9e995edb9673">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzctMy0xLTEtOTcx_cc586997-6980-4edf-98b8-325638cedee8">P7Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzgtMS0xLTEtMA_c41a825a-458d-4e49-8436-b3b308b374d3"
      unitRef="number">0.028</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzgtMy0xLTEtOTcx_60122a3c-7bb8-484b-9ac6-15c589fee588"
      unitRef="number">0.032</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzY2ODk_3c2cee5f-a085-4549-9b71-fdebc843d0f6">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating leases liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzAtMS0xLTEtMA_bbb55cd4-10aa-459e-b649-626bba673d70"
      unitRef="usd">336000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzEtMS0xLTEtMA_202c14a4-3266-4a0f-a387-4fe552da6bc9"
      unitRef="usd">277000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzItMS0xLTEtMA_4996648b-75df-49f5-a45f-e6ae8057db8c"
      unitRef="usd">252000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzMtMS0xLTEtMA_7a4c4943-2293-44d1-a99b-754e57a062de"
      unitRef="usd">187000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzQtMS0xLTEtMA_605759b9-579d-4832-81d8-8bce1b8b4451"
      unitRef="usd">162000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzUtMS0xLTEtMA_65fc1d07-2e53-407e-a850-dfeb88002b28"
      unitRef="usd">665000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzYtMS0xLTEtMA_1d4dc43d-eb72-40bf-97dc-4c8fc5115338"
      unitRef="usd">1879000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzctMS0xLTEtMA_6ef305ac-3f50-43bf-9f8e-1f4a3a33894b"
      unitRef="usd">217000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTpmNTUxMjMzMWEwNmE0YWQ2OGJiOTYzYmRjZmU5YjBhMy90YWJsZXJhbmdlOmY1NTEyMzMxYTA2YTRhZDY4YmI5NjNiZGNmZTliMGEzXzgtMS0xLTEtMA_c0b04a0b-6d24-4df3-b7f3-b425ad638eae"
      unitRef="usd">1662000000</us-gaap:OperatingLeaseLiability>
    <mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90ZXh0cmVnaW9uOjc1NTVmOWJkYmIzMDRhYzg5ODViMTc4Y2YwOTU4YmE3XzYzNjk_95f5268b-0efc-46a5-aff3-a60240c3b97d"
      unitRef="usd">475000000</mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI2MjA4_a3000f1b-2b1f-40d8-ba89-78f2fa3cfe3f">Contingencies and Environmental Liabilities &lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#x2019;s financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Litigation). As of December&#160;31, 2020, approximately 3,520 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glynn v. Merck&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the jury returned a verdict in Merck&#x2019;s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck&#x2019;s motion for judgment as a matter of law in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glynn&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; case and held that the plaintiff&#x2019;s failure to warn claim was preempted by federal law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court&#x2019;s preemption decision in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glynn&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#x2019;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#x2019;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#x2019; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, as of December&#160;31, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, approximately 2,270 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, there are four Femur Fracture cases pending in other state courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia/Janumet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December&#160;31, 2020, Merck is aware of approximately 1,480 product users alleging that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the development of pancreatic cancer and other injuries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2015, the MDL and California State Court, in separate opinions, granted summary judgment to defendants on grounds of federal preemption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment and expert motions. Briefing of those motions is complete and hearings before both the MDL and California State Court judges took place on October 20 and December 8, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#x2019;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merck Sharp &amp;amp; Dohme Corp. v. Albrecht &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(relating to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; matter discussed above). Merck filed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the opinion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Albrecht&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Albrecht&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, that preemption presents a legal question to be resolved by the court. In May 2020, the Illinois Appellate Court issued a mandate to the state trial court, which, as of December 31, 2020, had not scheduled a case management conference.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vioxx&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck reached a settlement with the Attorney General of Utah to fully resolve the state&#x2019;s previously disclosed civil lawsuit alleging that Merck misrepresented the safety of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vioxx&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As part of the resolution, Merck paid the state $25&#160;million. The settlement does not constitute an admission by Merck of any liability or wrongdoing. This agreement marks the final resolution of litigation involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vioxx&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States. There is ongoing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vioxx&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; litigation in certain countries outside the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#x2019;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#x2019;s information request by seeking information relating to Merck&#x2019;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#x2019;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#x2019;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#x2019;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#x2019;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#x2019;s investigation and intends to produce information and/or documents as necessary in response to the CID.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, the Company&#x2019;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#x2019;s policy is to cooperate with these authorities and to provide responses as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial and Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#x2019; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#x2019; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#x2019; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint and, in August 2019, retailer opt-out plaintiffs filed an amended complaint. In December 2019, the district court granted the Merck Defendants&#x2019; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On August 21, 2020, the district court granted in part the direct purchasers&#x2019; motion for class certification and certified a class of 35 direct purchasers, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted the Merck Defendants&#x2019; motion for permission to appeal the district court&#x2019;s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 4, 2020, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota against Merck and others (the UHC Action). The UHC Action makes similar allegations as those made in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;class action. On September 23, 2020, the United States Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; litigation already in progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 11, 2020, Humana Inc. filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against Merck and others, alleging defendants violated state antitrust laws in multiple states. Also, on December 11, 2020, Centene Corporation and others filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana. Both lawsuits allege similar anticompetitive acts to those alleged in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;class action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rotavirus Vaccines Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, MSD is a defendant in putative class action lawsuits filed in 2018 on behalf of direct purchasers of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RotaTeq&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, alleging violations of federal antitrust laws. The cases were consolidated in the Eastern District of Pennsylvania. In January 2019, the court denied MSD&#x2019;s motions to compel arbitration and to dismiss the consolidated complaint. In February 2019, MSD appealed the court&#x2019;s order on arbitration to the Third Circuit. In October 2019, the Third Circuit vacated the district court&#x2019;s order and remanded for limited discovery on the issue of arbitrability. On July 6, 2020, MSD filed a renewed motion to compel arbitration, and plaintiffs filed a cross motion for summary judgment as to arbitrability. On November 20, 2020, the district court denied MSD&#x2019;s motion and granted plaintiffs&#x2019; motion. On December 4, 2020, MSD filed a notice of appeal to the Third Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in January 2020, the Company was served with a complaint in the United States District Court for the District of New Jersey, seeking to certify a nationwide class action of purchasers or users of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(fluralaner) products in the United States or its territories between May 1, 2014 and December 27, 2019. The complaint contends &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;causes neurological events and alleges violations of the New Jersey Consumer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fraud Act, Breach of Warranty, Product Liability, and related theories. A similar case was filed in Quebec, Canada in May 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;M-M-R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;M&#x2011;M&#x2011;R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;II vaccine, which charge that the Company misrepresented the efficacy of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;M-M-R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#x2019;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits have proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the Court. The Company continues to defend against these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merck KGaA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in January 2016, to protect its long-established brand rights in the United States, the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the United States, alleging it improperly uses the name &#x201c;Merck&#x201d; in the United States. KGaA has filed suit against the Company in France, the UK, Germany, Switzerland, Mexico, India, Australia, Singapore, Hong Kong, and China alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In the UK, Australia, Singapore, Hong Kong, and India, KGaA also alleges breach of the parties&#x2019; coexistence agreement. The litigation is ongoing in the United States with no trial date set, and also ongoing in numerous jurisdictions outside of the United States; the Company is defending those suits in each jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#x2019;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#x2019;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia, Janumet, Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The FDA has granted pediatric exclusivity with respect to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which provides a further six months of exclusivity in the United States beyond the expiration of all patents listed in the FDA&#x2019;s Orange Book. Including this exclusivity, key patent protection extends to January 2023. The Company anticipates that sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States will decline significantly after this loss of market exclusivity. However, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin, which, if determined to be valid, would preclude generic manufacturers from making sitagliptin phosphate salt and polymorphic forms before that patent, inclusive of pediatric exclusivity, expires in 2027 (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; formulation which, inclusive of pediatric exclusivity, expires in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company&#x2019;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court has scheduled separate one-day trials on infringement issues in November 2021 through January 2022, to the extent such trials are necessary. In the Company&#x2019;s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has settled with nine generic companies providing that these generic companies can bring their products to the market in May 2027 or earlier under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in 2019, Mylan filed a petition for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inter Partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent, which other manufacturers joined. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision is expected in May 2021. If the challenges are successful, the unchallenged claims of the 2027 salt/polymorph patent will remain valid, subject to the court proceedings described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. If the generic companies are successful, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; could lose market exclusivity in Germany as early as July 2022. Challenges to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SPC have also occurred in Portugal and Finland, and could occur in other European countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nexplanon &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, Microspherix LLC (Microspherix) sued the Company in the U.S District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nexplanon &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;infringed several of Microspherix&#x2019;s patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until those patents expire in May 2021. The Company brought&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR proceedings in the USPTO and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against the Company. The Company appealed the decisions finding claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO&#x2019;s decisions. The matter is no longer stayed in the district court, and the Company is currently litigating the invalidity and non-infringement of the remaining asserted claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#x2019;s financial condition, results of operations or cash flows either individually or in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Defense Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#x2019;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2020 and 2019 of approximately $250 million and $240 million, respectively, represents the Company&#x2019;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#x2019;s potential liability varies greatly from site to site. For some sites the potential liability is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In management&#x2019;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $67 million at both December&#160;31, 2020 and 2019. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $65 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#x2019;s financial condition, results of operations or liquidity for any year.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if1ad8b2fd3e14ee9bddb13cd515e52a8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI0NzA_d4c7e81d-6ed0-4fa6-8a62-a420bc26cbde"
      unitRef="legalmatter">3520</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i93df136354cf4fa38c646e1cf689a82a_D20140301-20140331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzM2NzA_f2d2e3de-2f72-46dd-aeb6-81756a39d914"
      unitRef="legalmatter">650</us-gaap:LossContingencyClaimsDismissedNumber>
    <mrk:LossContingencyClaimsonAppealNumber
      contextRef="i9a481dedbd2d4933a6677cd0e1edf178_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzM3MzA_a5b5cfcb-c4c2-4fb1-91e5-21734c78e6db"
      unitRef="legalmatter">515</mrk:LossContingencyClaimsonAppealNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i1eaa63e5d47740128c127b437bacd031_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzUxNDk_e915e177-f8c5-45fc-9565-cc49227081c4"
      unitRef="legalmatter">970</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie55841cf14c74bd7b0e16fd09b652e33_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzUyMzE_bb5cae31-4b7f-4319-94b5-05bf3b70775d"
      unitRef="legalmatter">2270</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ia8e56c0040ba4a169fefc5cf5549d74a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzU1NDc_b223007f-44b6-470a-bdb9-1b5a5b74947d"
      unitRef="legalmatter">275</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i431f7512254c41a3ab21b8e40f090091_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzU4MDM_7d131dc1-9cae-466b-b3ab-91abe51ea5c3"
      unitRef="legalmatter">4</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib4047d89366440f5864171ba3e8586b0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzYxOTA_83027fdc-df8c-439a-8e98-62a75770038d"
      unitRef="legalmatter">1480</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i1c91e20a1c71440293d3d8d945468a75_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1Xzc0MjA_5485be5b-ce25-4f4a-956e-c0199d521c5d"
      unitRef="legalmatter">6</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id52db59ac0fa4c2590483162033676b0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1Xzg1ODc_61b25370-c434-45ad-af64-48b500cf3a87"
      unitRef="legalmatter">50</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ibbb6a7b18f5c4976971de8a6461cfe40_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzMyOTg1MzQ5MjcwMzA_7209c264-818f-4cd2-85db-76f886532c7a"
      unitRef="usd">-25000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i7663bc55df4c4c659db0b11ccee9658d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzE2Mzcz_07be7f53-dbf0-4ec2-aaf9-f6e93e1c0269"
      unitRef="legalmatter">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i7663bc55df4c4c659db0b11ccee9658d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzE2ODI1_07be7f53-dbf0-4ec2-aaf9-f6e93e1c0269"
      unitRef="legalmatter">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="idbd659ea6c05471da9fb04c882ed6666_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzE2OTU2_86f4e948-b536-4a68-b46a-33137d04b5d1"
      unitRef="legalmatter">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="ie6c8d1063fa24db98c2859bbb23cc25a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzMyOTg1MzQ5MjcwODU_f6f630aa-402f-496d-9cc3-677d6e54415d"
      unitRef="legalmatter">9</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LitigationReserve
      contextRef="ie6d206d30ad44f5780586176e7331c05_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzIyOTE1_27ac0d7c-d5e3-43ee-9030-048bd6dc7425"
      unitRef="usd">250000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="i31aeae8af44247eca21b7f933034044c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzIyOTIy_ae0d5666-8683-4d22-ae21-d7a24dd1acef"
      unitRef="usd">240000000</us-gaap:LitigationReserve>
    <us-gaap:AccrualForEnvironmentalLossContingencies
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI1NDYy_7ca70143-d792-442c-9bf3-34af44f94b63"
      unitRef="usd">67000000</us-gaap:AccrualForEnvironmentalLossContingencies>
    <mrk:TermForPayingOffEnvironmentalLiabilities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI1NzIz_8a335ec7-3817-4501-bf31-e418c9a58c73">P15Y</mrk:TermForPayingOffEnvironmentalLiabilities>
    <us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDIvZnJhZzozY2VjNTc4MjBlMGU0YTE2YmMxNTE5ZDZhNDE4YjkyNS90ZXh0cmVnaW9uOjNjZWM1NzgyMGUwZTRhMTZiYzE1MTlkNmE0MThiOTI1XzI1OTk3_26ad0e56-98ec-455e-890f-b5f332cd53d0"
      unitRef="usd">65000000</us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzE1MDU_977b82a5-1679-44fb-a6f6-10c75e4b1fd5">Equity&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merck certificate of incorporation authorizes 6,500,000,000&#160;shares of common stock and 20,000,000&#160;shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock and treasury stock transactions (shares in millions) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,047&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances primarily reflect activity under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company&#160;entered into accelerated share repurchase (ASR) agreements with two third-party financial institutions (the Dealers). Under the ASR agreements, Merck agreed to purchase&#160;$5 billion&#160;of Merck&#x2019;s common stock, in total, with an initial delivery of 56.7 million&#160;shares of Merck&#x2019;s common stock, based on the then-current market price, made by the Dealers to Merck, and payments of&#160;$5 billion&#160;made by Merck to the Dealers, which were funded with existing cash and investments, as well as short-term borrowings. Upon settlement of the ASR agreements in 2019, Merck received an additional 7.7 million shares as determined by the average daily volume weighted-average price of Merck&#x2019;s common stock during the term of the ASR program, less a negotiated discount, bringing the total shares received by Merck under this program to 64.4 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzcx_26d04162-bf24-4b31-bdd1-b512a1b78fc6"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzEwMQ_d1e8f31c-d692-4a9a-bbab-e4def4a9f4d2"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzE1MTE_2728c426-fbcb-46de-9279-b94abe07da15">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock and treasury stock transactions (shares in millions) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,047&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances primarily reflect activity under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0896f4b9831541ae8488b94c4eae2335_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItMS0xLTEtMA_8e743d1a-eee7-4bc7-af8c-a6dcd15add64"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia612eb926af84202b6beec26340d18cc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItMy0xLTEtMA_f876b673-caef-4364-9534-3eec0865beb8"
      unitRef="shares">1038000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i67131e7c55f84174b370dc31e7893725_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItNS0xLTEtMA_eceeba18-b41c-4e54-8af2-42cfcab40537"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if472f36dd37249baacd8179c8220ecaa_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItNy0xLTEtMA_72f36769-236d-4d72-8e70-8f63d5b4774f"
      unitRef="shares">985000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i530838b57a7f40aea997c3c0d8eafce0_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItOS0xLTEtMA_a9a7a176-6e7c-4361-8ae3-3223001b549f"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i93f33a2e859a4576a7e62ef19bff98f0_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzItMTEtMS0xLTA_0ce79c61-c54d-4af2-ab7f-01d5482e39ac"
      unitRef="shares">880000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i19dc4d009aa34aeb9203985671a29f18_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtMS0xLTEtMA_d3395ba2-672b-4696-a130-caa7299e8595"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtMy0xLTEtMA_3b4cd57d-1f25-415a-b3a6-66cff7f3bfde"
      unitRef="shares">16000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i66c2178f642f47caab789497db80c0bb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtNS0xLTEtMA_d09e519d-dcfc-439f-a974-4dce4a8b827a"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtNy0xLTEtMA_a514033d-4125-4170-9ef0-a9321c060d25"
      unitRef="shares">66000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0885861e3a0249f99de1e639684e4e6e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtOS0xLTEtMA_a2db1cb7-c7c3-434a-9df1-b87d42a0783f"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzMtMTEtMS0xLTA_c637916b-5b83-4dfd-9fe7-99b68e86db1b"
      unitRef="shares">122000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i19dc4d009aa34aeb9203985671a29f18_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtMS0xLTEtMA_0a68f66f-21b4-4c1e-b2e9-7c485096ff81"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9f7b9dc833b447539bd5634113f1344a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtMy0xLTEtMA_68f7d8dc-199d-459f-8e51-50e7a4782438"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i66c2178f642f47caab789497db80c0bb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtNS0xLTEtMA_48c793b5-a5c1-41dc-82c7-bcd64fb194f1"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9e9f94a1c0784e80a2cf4c830f427648_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtNy0xLTEtMA_28ee22e3-058c-4949-9c50-8f18f78bb69d"
      unitRef="shares">13000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0885861e3a0249f99de1e639684e4e6e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtOS0xLTEtMA_a2ac3a1e-2b07-4649-b489-401622303945"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia98977fe998e4f1caec12fcf96fbd183_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzQtMTEtMS0xLTA_a13b8dd2-99fd-4370-9274-f4bd6da2d8d8"
      unitRef="shares">17000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:CommonStockSharesIssued
      contextRef="id94362b387b441469ec50222fe704479_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtMS0xLTEtMA_e3d16060-045a-4656-badb-c00337760e34"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ice647f7217ff4273a045f1876ac8bbe8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtMy0xLTEtMA_29e0ad8b-0711-4658-b720-9bb70fe1b516"
      unitRef="shares">1047000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0896f4b9831541ae8488b94c4eae2335_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtNS0xLTEtMA_786d0271-9a10-46bf-b040-e994b8b374c4"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia612eb926af84202b6beec26340d18cc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtNy0xLTEtMA_219fbcf7-5ee6-4793-afba-d7100e6bba1c"
      unitRef="shares">1038000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i67131e7c55f84174b370dc31e7893725_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtOS0xLTEtMA_232072ca-d5a3-4009-b132-45a42fd3ebb2"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if472f36dd37249baacd8179c8220ecaa_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90YWJsZTozMWM2MDljZjY3ODc0MzM2ODA1NzNjZmVmMjE0NmM4OS90YWJsZXJhbmdlOjMxYzYwOWNmNjc4NzQzMzY4MDU3M2NmZWYyMTQ2Yzg5XzUtMTEtMS0xLTA_0e1bfae6-6db2-4275-afc8-3ea4ab2ae1c3"
      unitRef="shares">985000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="i757d42734fe94bb68d3cf7cf12d0c493_I20181231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzUyMQ_f809fa12-7476-45c3-a8d4-20b6fe16d46a"
      unitRef="usd">-5000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i78e330e646b54193bfa5012cd95c821c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzU4Nw_6dcb8e2e-9401-4337-9666-59a8be8a0594"
      unitRef="shares">56700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="i757d42734fe94bb68d3cf7cf12d0c493_I20181231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzcwOA_3eeac892-b227-4f2c-8057-0c8c28da124e"
      unitRef="usd">-5000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1a59deaeb6ac41918736b40c0e87db06_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzEyNzQ_8eddb598-50f2-49c9-ab50-f4ec6040a0a6"
      unitRef="shares">7700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i8f31986a93f04797badcd48bd6288494_D20181001-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDUvZnJhZzphOTc4YzRkMjFlNTA0ZjUwOWJjYmZmYTZlMzhhZTNhMS90ZXh0cmVnaW9uOmE5NzhjNGQyMWU1MDRmNTA5YmNiZmZhNmUzOGFlM2ExXzE1MDM_e7ff966e-70d0-4a14-925c-ab8294cd2111"
      unitRef="shares">64400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxNTI_1e5660e6-a3c9-4c36-bc62-81ea53fb7ada">Share-Based Compensation Plans&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#x2019;s shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, 100 million shares collectively were authorized for future grants under the Company&#x2019;s share-based compensation plans. These awards are settled with treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#x2019;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#x2019;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#x2019;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total pretax share-based compensation cost recorded in 2020, 2019 and 2018 was $475 million, $417 million and $348 million, respectively, with related income tax benefits of $65 million, $57 million and $55 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#x2019;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price of options granted in 2020, 2019 and 2018 was $77.67, $80.05 and $58.15 per option, respectively. The weighted average fair value of options granted in 2020, 2019 and 2018 was $9.93, $10.63 and $8.26 per option, respectively, and were determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information relative to stock option plan activity (options in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;58.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information pertaining to stock option plans is provided in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested January 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,627&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(728)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.06&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80.06&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74.17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75.08&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, there was $678 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQ1Mg_e6fd8b7a-6fff-44c5-9afc-d365858876aa"
      unitRef="shares">100000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzc2OTY1ODEzOTg3OTg_50885ad9-ac7b-4c43-8645-ce817594ddba">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i72b8afe3fe844c02ab7183ab38cfe809_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzgyNA_d386cafe-23cc-44e2-89be-3fb872f13716">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i953fcdd3d90e447480d218ef6e31883b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzgyNw_816d10f0-055c-4eea-b4ca-ba410a5516a9">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzc2OTY1ODEzOTg3OTk_7bc94739-d5c7-40a2-bb2c-8ebe391bb207">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzc2OTY1ODEzOTg4MDA_90a24372-421e-4d89-b44c-c625f579c49e">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensation
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIxNzQ_563a97c4-8f88-427d-9f5d-9bd4f5ba1b4e"
      unitRef="usd">475000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIxNzg_fad574d8-1a55-46ca-a3cb-bfe9ec8e5600"
      unitRef="usd">417000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIxODU_662c02e6-5fe7-40b4-bddd-11d22808c701"
      unitRef="usd">348000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIyMzk_c078a6ed-a1b5-4c1e-babd-98a8821289d1"
      unitRef="usd">65000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIyNDM_025d3ea5-bff8-4ab0-844a-07c224f6148d"
      unitRef="usd">57000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzIyNTA_9f9d33b6-f082-442a-8bfa-f7320a26662a"
      unitRef="usd">55000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzMzNTg_3eebdc4f-c2f1-4a59-9cb0-6f275480ad4d"
      unitRef="usdPerShare">77.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzMzNjI_b48704bf-f9fb-4d6a-81c0-809a84eca807"
      unitRef="usdPerShare">80.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzMzNjk_0e7f9f11-1c81-4229-a1b3-9b27edfce80e"
      unitRef="usdPerShare">58.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxMjc_0a31d06d-26c1-4f49-ac58-2ea9fcaabd3a">The weighted average fair value of options granted in 2020, 2019 and 2018 was $9.93, $10.63 and $8.26 per option, respectively, and were determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzM0NzA_b7374307-4ef9-4eff-900a-a61ef25f384f"
      unitRef="usdPerShare">9.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzM0NzQ_53e89366-2353-4ca4-b6d7-83016684dfa6"
      unitRef="usdPerShare">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzM0ODE_36896d95-6a26-4c1b-b3e6-43ff8c790602"
      unitRef="usdPerShare">8.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzEtMS0xLTEtMA_e5bef7bc-8115-496e-a930-9abc99630db6"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzEtMy0xLTEtMA_3ce0ebc4-41d0-4658-afcc-200adbcc9aea"
      unitRef="number">0.032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzEtNS0xLTEtMA_1fa77f4f-1dd8-4a71-8b83-87d1c647cb1a"
      unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzItMS0xLTEtMA_a9a58214-4098-42a5-8e95-70aeaaa45108"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzItMy0xLTEtMA_4316aae0-3323-4b38-b771-06e66952b730"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzItNS0xLTEtMA_0bb38cb4-dcea-4005-bcca-fc81ba520630"
      unitRef="number">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzMtMS0xLTEtMA_8e654f51-b271-4ba1-97ff-6450dcdd6c12"
      unitRef="number">0.221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzMtMy0xLTEtMA_4f4a6339-b75d-49dd-bdb3-1c062df0f18b"
      unitRef="number">0.187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzMtNS0xLTEtMA_8656e69c-12ba-4785-b727-e7016f2b78cf"
      unitRef="number">0.191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzQtMS0xLTEtMA_75024c78-65eb-429b-bc1c-20bd4107e896">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzQtMy0xLTEtMA_d1e78775-8cf6-4df5-a8bb-0047da258224">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTpkYjliZjZiMTVmOTE0NWMzODAxM2RhMDQ1MzNhMzJiYi90YWJsZXJhbmdlOmRiOWJmNmIxNWY5MTQ1YzM4MDEzZGEwNDUzM2EzMmJiXzQtNS0xLTEtMA_1a5794a3-61c2-4342-8f6a-accefe80b064">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxNTQ_f1289687-6d1a-44b3-897e-6b6c40ed5b92">&lt;div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information relative to stock option plan activity (options in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;58.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzEtMS0xLTEtMA_eddc8e5d-1cb3-409f-affc-2bb83af50742"
      unitRef="shares">17868000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzEtMy0xLTEtMA_043cf7bd-36fe-464c-b22c-dba1a0d88c4c"
      unitRef="usdPerShare">59.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzItMS0xLTEtMA_f9cd96de-1953-4cf3-b56d-ae8d8cd81141"
      unitRef="shares">3564000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzItMy0xLTEtMA_1f3ffe1f-e11e-4dcc-95ad-9b4e67ac379d"
      unitRef="usdPerShare">77.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzMtMS0xLTEtMA_62309ba3-a8ff-41ad-af96-ace0f2e9f169"
      unitRef="shares">1685000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzMtMy0xLTEtMA_74b18af8-28a3-43b6-8fd1-d65c17f67ec7"
      unitRef="usdPerShare">52.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzQtMS0xLTEtMA_e1c659ff-18a0-46f8-b180-2d125f69f6de"
      unitRef="shares">301000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzQtMy0xLTEtMA_0f054c40-01ae-411b-b82c-03a839329fd2"
      unitRef="usdPerShare">67.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzUtMS0xLTEtMA_b0ff528a-8c64-42d7-a6b2-62a4793ade71"
      unitRef="shares">19446000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzUtMy0xLTEtMA_40172c70-9fe5-4e02-9b7b-52e208bb7a13"
      unitRef="usdPerShare">63.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzUtNS0xLTEtMA_1038313c-b7a7-4b66-bab2-af117066a9e4">P6Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzUtNy0xLTEtMA_dcde777a-021c-45ec-8be3-2b724d460c78"
      unitRef="usd">353000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzYtMS0xLTEtMA_948a9757-43ee-4ef5-908c-4ef41c79f9c2"
      unitRef="shares">13141000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzYtMy0xLTEtMA_83fc4b19-4a54-4d6a-b871-8624019dd7ea"
      unitRef="usdPerShare">58.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzYtNS0xLTEtMA_afb0dab2-a785-4660-ba9d-7c1dfaf7122e">P5Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo4ZDBmOTgyNDZmYTg0MDBhOTRlNmNhNjBhYmVmNDJiYy90YWJsZXJhbmdlOjhkMGY5ODI0NmZhODQwMGE5NGU2Y2E2MGFiZWY0MmJjXzYtNy0xLTEtMA_d9267f54-c534-4f1a-8ac9-ea492e0b1cca"
      unitRef="usd">309000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxNDI_1a531ade-c602-4d2a-814c-73f790642d6c">&lt;div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information pertaining to stock option plans is provided in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzEtMS0xLTEtMA_d767a87e-5c56-4b7b-96ae-7bb50a6c5bbc"
      unitRef="usd">51000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzEtMy0xLTEtMA_5ce3b278-74cb-4181-8803-519bcf48ca54"
      unitRef="usd">295000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzEtNS0xLTEtMA_874c18dd-0436-4995-bc41-eb8e34743a4d"
      unitRef="usd">348000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzItMS0xLTEtMA_a67f3420-344b-4a6f-9b76-9b2049e1bb1a"
      unitRef="usd">25000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzItMy0xLTEtMA_7919535e-fc29-48a6-bd44-e47aa00340be"
      unitRef="usd">27000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzItNS0xLTEtMA_766ab603-052b-4b2b-96f1-ad243dbc1d8d"
      unitRef="usd">29000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzMtMS0xLTEtMA_2d05f04e-c38d-4443-8d10-70222103fd49"
      unitRef="usd">89000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzMtMy0xLTEtMA_a8ad012d-dbd5-4a9a-af1f-c9e65ab378e7"
      unitRef="usd">361000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTplYzZmN2E4NzM2ZmE0ZGFjODFmMWE4NzJmYjFmNzdhNy90YWJsZXJhbmdlOmVjNmY3YTg3MzZmYTRkYWM4MWYxYTg3MmZiMWY3N2E3XzMtNS0xLTEtMA_deba4eec-5e36-4cad-9dc0-f849bd3b4083"
      unitRef="usd">591000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQxMjA_bc0181b5-f343-4188-9b91-e9c292120953">&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested January 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,627&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(728)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.06&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80.06&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74.17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75.08&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic34f1f7cd09744c996b65b7244c26c66_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzItMi0xLTEtMA_c66aa706-1508-467a-bc62-e9c05aba9e26"
      unitRef="shares">13527000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic34f1f7cd09744c996b65b7244c26c66_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzItNC0xLTEtMA_4e79b526-f82c-4694-8fd1-55cb27b918d2"
      unitRef="usdPerShare">67.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i000733eb4d4149cd92245dbf45a48680_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzItNi0xLTEtMA_c36617a6-90ec-48ad-91c0-3da1308b05f9"
      unitRef="shares">1972000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i000733eb4d4149cd92245dbf45a48680_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzItOC0xLTEtMA_62b33dc9-4d05-403e-b07c-545c10fb7afa"
      unitRef="usdPerShare">69.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzMtMi0xLTEtMA_9eeefdc1-751c-4e0a-b270-1f954446e080"
      unitRef="shares">6627000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzMtNC0xLTEtMA_fa643c4d-96b1-4682-a387-5a57a83b32db"
      unitRef="usdPerShare">77.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzMtNi0xLTEtMA_1bacecbb-840d-4709-a1f3-4a22f48d5989"
      unitRef="shares">996000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzMtOC0xLTEtMA_5f5f0909-fed8-4864-ade0-1d4d9216933f"
      unitRef="usdPerShare">77.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzQtMi0xLTEtMA_46e5b955-9d76-4cf3-a30f-a6af30013ee1"
      unitRef="shares">7511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzQtNC0xLTEtMA_951c79ef-0788-4f21-84f1-072fdc36c4fa"
      unitRef="usdPerShare">65.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzQtNi0xLTEtMA_ca100ed8-d8ed-4736-923c-0c93f5d9689d"
      unitRef="shares">824000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzQtOC0xLTEtMA_ef13c10f-01c0-4ce9-aad9-1408135b71aa"
      unitRef="usdPerShare">64.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzUtMi0xLTEtMA_7c0272d1-86ff-4d07-93f5-26296db5db85"
      unitRef="shares">728000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iff2f2477e6a9444283892ae43ba5d53d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzUtNC0xLTEtMA_156f4e39-af6e-46e2-9396-19e20c43c43d"
      unitRef="usdPerShare">72.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzUtNi0xLTEtMA_e09b21bb-333a-41da-b30f-889afaad67fb"
      unitRef="shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idaf443ab4cd74abd8a493082e24a1489_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzUtOC0xLTEtMA_18ceb38b-407e-49d3-9361-3cad9c089c55"
      unitRef="usdPerShare">80.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1e2c8bbf6d144b1590bfc2f06989e5f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzYtMi0xLTEtMA_827c26f5-f093-4707-94ea-2cddc93faa41"
      unitRef="shares">11915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1e2c8bbf6d144b1590bfc2f06989e5f2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzYtNC0xLTEtMA_80ed11bc-0169-4e83-9406-9ff7c06ba8db"
      unitRef="usdPerShare">74.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5824e3a83dad4afab742fd2ce8e74b3d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzYtNi0xLTEtMA_d7d795ee-52fb-4977-b68b-f07b08b3c9f8"
      unitRef="shares">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5824e3a83dad4afab742fd2ce8e74b3d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90YWJsZTo5NWNmMzNhOTE5NmY0NjRmODVhOGFmZDcwY2IzYjgyMS90YWJsZXJhbmdlOjk1Y2YzM2E5MTk2ZjQ2NGY4NWE4YWZkNzBjYjNiODIxXzYtOC0xLTEtMA_c416f8bf-6226-409b-bb2f-8caf81efc54c"
      unitRef="usdPerShare">75.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzM4NTc_72c09f26-9fc7-43b8-8c7b-c70150e20b51"
      unitRef="usd">678000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMDgvZnJhZzoyNDM5YWFiNzQ5NmM0N2EwOGM2ZmY4MGIzNTJjOTE1Mi90ZXh0cmVnaW9uOjI0MzlhYWI3NDk2YzQ3YTA4YzZmZjgwYjM1MmM5MTUyXzQwMjQ_c20260d4-b096-4912-8a14-f1f4ebc740ee">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MzA_13d867f9-60a9-4816-865c-74d5ea80d358">Pension and Other Postretirement Benefit Plans&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the&#160;following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&#160;Postretirement&#160;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in net periodic benefit cost year over year for pension plans are largely attributable to changes in the discount rate affecting net loss amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with restructuring actions (see Note&#160;5), termination charges were recorded in 2020, 2019 and 2018 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost (credit) other than the service cost component are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (see Note 14), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Obligations and Funded Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11,361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,908&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit obligation January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,003&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial losses (gains) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit obligation December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,534&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funded status December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;941&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Actuarial losses (gains) primarily reflect changes in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the accumulated benefit obligation was $26.4 billion and $22.8 billion, respectively, for all pension plans, of which $14.4 billion and $12.8 billion, respectively, related to U.S. pension plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to the funded status of selected pension plans at December 31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension plans with a projected benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension plans with an accumulated benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160; Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160; Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2020 and 2019, $942 million and $860 million, respectively, or approximately 4% of the Company&#x2019;s pension investments were categorized as Level&#160;3 assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s pension plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,884&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,090&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,096&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,819&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,819&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;475&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;172&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;172&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other fixed income obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,012&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,736&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;599&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The plans&#x2019; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#x2019;s pension plan assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets sold during the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;374&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;428&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#x2019;s U.S.&#160;pension and other postretirement benefit plans is allocated 30% to 45% in U.S.&#160;equities, 15% to 30% in international equities, 35% to 45% in fixed-income investments, and up to 5% in cash and other investments. The portfolio&#x2019;s equity weighting is consistent with the long-term nature of the plans&#x2019; benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 11%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Contributions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected contributions during 2021 are approximately $300 million for U.S. pension plans, approximately $170 million for international pension plans and approximately $35 million for other postretirement benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Benefit Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&#160;&#x2014;&#160;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amounts Recognized in Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Postretirement&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (loss) gain arising during the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (cost) credit arising during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization included in benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service credit amortization included in benefit cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;109&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Actuarial Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Pension&#160;and&#160;Other&lt;br/&gt;Postretirement&#160;Benefit&#160;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#x2019;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2021, the expected rate of return for the Company&#x2019;s U.S. pension and other postretirement benefit plans will range from 6.50% to 6.70%, as compared to a range of 7.00% to 7.30% in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The health care cost trend rate assumptions for other postretirement benefit plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year that the trend rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Savings Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also maintains defined contribution savings plans in the United States. The Company matches a percentage of each employee&#x2019;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2020, 2019 and 2018 were $166 million, $149 million and $136 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MjA_960e0917-4b23-456e-911f-6e33be676303">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the&#160;following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&#160;Postretirement&#160;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMS0xLTEtMA_f2c3e83d-afa6-4282-b218-8e6ea90ab3d3"
      unitRef="usd">360000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMy0xLTEtMA_f6026b6a-ea2d-4015-b187-9898000065ff"
      unitRef="usd">293000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtNS0xLTEtMA_797b35e8-0231-4699-9133-d2df6fd9031a"
      unitRef="usd">326000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtNy0xLTEtMA_87068c9f-58e4-4561-8ec2-1325dad08a5c"
      unitRef="usd">301000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtOS0xLTEtMA_1a6bf2b3-ee13-4685-8651-d188137c7e89"
      unitRef="usd">238000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMTEtMS0xLTA_509ed26e-47d3-4388-94d0-1aa134bed19c"
      unitRef="usd">238000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMTMtMS0xLTA_22642f7b-6490-4212-81a3-032b2322f63c"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMTUtMS0xLTA_65dc2862-90a8-4920-85c1-d81dffac7244"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzMtMTctMS0xLTA_8bdc41c0-eaca-4777-9956-1567a80488d5"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMS0xLTEtMA_1c33ad3f-c622-4ad1-9fd6-1bee79d01a3d"
      unitRef="usd">431000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMy0xLTEtMA_8ccb79e9-0c4e-4a13-990a-b73de110320c"
      unitRef="usd">458000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtNS0xLTEtMA_b0da443b-67e9-49ae-9ffa-849a191075b1"
      unitRef="usd">432000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtNy0xLTEtMA_c4435b4b-f215-4969-b1a1-1de6474bd56d"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtOS0xLTEtMA_3609da06-9a5f-4ee0-be8d-d3882c238110"
      unitRef="usd">177000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMTEtMS0xLTA_f6423783-f626-439d-8842-4af3a009c621"
      unitRef="usd">178000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMTMtMS0xLTA_3209fa06-6cd2-4f50-8ddb-8609650d4f18"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMTUtMS0xLTA_f92adffc-ef5e-4555-807a-24b61e9a9ed1"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzQtMTctMS0xLTA_f54ad0c9-8e41-4a09-8ac4-526c12f81d3c"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMS0xLTEtMA_9d8f7459-f3e8-4706-a773-c3edc553f446"
      unitRef="usd">774000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMy0xLTEtMA_59e7a7f0-e88f-4afc-b6ac-8725e61b1ab7"
      unitRef="usd">817000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtNS0xLTEtMA_d303c5f1-aec3-44a9-a9fa-2c6865343099"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtNy0xLTEtMA_9a3ecb27-cca2-42aa-998c-55a48b2f5079"
      unitRef="usd">415000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtOS0xLTEtMA_640ad497-3376-4280-be6a-a8103dfc24d2"
      unitRef="usd">426000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMTEtMS0xLTA_41df764e-183b-45b1-80f1-0bd7ebfaa25b"
      unitRef="usd">431000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMTMtMS0xLTA_4dc6f934-3466-435c-9dd9-e223b6ca47f8"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMTUtMS0xLTA_097c7e73-cf3b-4be5-b61d-4742c9923bbc"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzUtMTctMS0xLTA_1ace6e93-417a-4076-bb66-2704df98b2b3"
      unitRef="usd">83000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMS0xLTEtMA_97928554-414b-4eac-8bc3-c452f803970d"
      unitRef="usd">-49000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMy0xLTEtMA_aa47afd7-0f26-41e3-920e-347faca952a8"
      unitRef="usd">-49000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtNS0xLTEtMA_0d882d79-7eaf-4b34-8333-8596d3205bf8"
      unitRef="usd">-50000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtNy0xLTEtMA_1bae8f1c-5dbd-4c8a-9898-81f31bbe4d84"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtOS0xLTEtMA_4bee242a-8bbc-47a3-9b8c-a9b11429eae9"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMTEtMS0xLTA_cc53d62b-c21f-4cde-b6f6-b3282f1b02e3"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMTMtMS0xLTA_619e238f-7939-4e8a-89e0-3e81ba7194d0"
      unitRef="usd">-73000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMTUtMS0xLTA_2db09269-53b4-4689-b7c6-a4dd558c4fa3"
      unitRef="usd">-78000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzYtMTctMS0xLTA_4219163e-2b8a-480b-be91-9efd242b59b9"
      unitRef="usd">-84000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMS0xLTEtMA_974c4955-51b4-468f-b4cb-5c4930dd4763"
      unitRef="usd">-303000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMy0xLTEtMA_c32660e3-1063-4e3d-87a0-c523f55824a3"
      unitRef="usd">-151000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctNS0xLTEtMA_71b744b2-fdfa-4c97-be26-42789d2d0744"
      unitRef="usd">-232000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctNy0xLTEtMA_87ce0f8b-1859-4bac-8921-b0707fc4c2fc"
      unitRef="usd">-127000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctOS0xLTEtMA_7e9d11d2-ba17-4aaf-af19-e8e0cd5c200f"
      unitRef="usd">-64000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMTEtMS0xLTA_cccd76cb-ed15-485d-a58c-653dcf053072"
      unitRef="usd">-84000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMTMtMS0xLTA_71ce5967-fbf7-4fca-a6af-322df240ff5b"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMTUtMS0xLTA_c6d5490d-f81c-4e35-ac8c-809d1273a2d9"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzctMTctMS0xLTA_4d46053a-0981-4be6-bc67-0d887f3f1721"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMS0xLTEtMA_75bc72b7-0b77-42f4-b8f3-cb5608bb593c"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMy0xLTEtMA_1802667e-3df0-4a45-917d-4bd738fb07ac"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtNS0xLTEtMA_c18a81e2-169d-4c31-a31c-0666bfecc3b0"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtNy0xLTEtMA_26845ec2-485e-4cc0-a72f-ef9473914fd0"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtOS0xLTEtMA_d1073310-0228-4521-9894-cebddd26e6e4"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMTEtMS0xLTA_069c110e-ac5b-4ef8-91b6-bdc985d27184"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMTMtMS0xLTA_d131e25b-b0bb-403c-acb5-92df0c1a8345"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMTUtMS0xLTA_3e4cf93d-7200-4fc3-946f-50f869dbcc96"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzgtMTctMS0xLTA_e73cde02-a541-4ab2-b94c-5b135a5e95db"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMS0xLTEtMA_e4974d01-d486-4ebd-99f8-641c95d0c452"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMy0xLTEtMA_fcac0a5d-6cae-41fb-a2a0-c1242635d34c"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktNS0xLTEtMA_f57280d7-a48b-4975-8c98-fb5ee26c3975"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktNy0xLTEtMA_ebd38d7a-9345-45a5-96ba-97697e3c3808"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktOS0xLTEtMA_f2e14ce7-f1de-4223-ba27-3362906e7cc5"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMTEtMS0xLTA_5e40c829-15d4-4501-b6a8-110d078deeef"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMTMtMS0xLTA_a433357b-cda2-4439-b9d7-920a6c08eebf"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMTUtMS0xLTA_d43dee40-5c7a-49ee-8fb4-c78d52c6c461"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzktMTctMS0xLTA_b07e4142-f34d-453c-bc13-6905e0d1ce79"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTEtMS0xLTA_fec07955-1a23-4cf2-b3f6-521fc7f51525"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTMtMS0xLTA_4507513d-6641-41b8-adda-aa550e205bf2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTUtMS0xLTA_cb23b324-d393-4f4e-9fa5-ca66d26f49a2"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTctMS0xLTA_504da084-7ec0-4aa9-8eb2-f072086b3277"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTktMS0xLTA_6b0f58f4-33ed-4b87-9ffa-e4549032e06b"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTExLTEtMS0w_66c897b6-bd41-4e68-bd88-d5bb0de689a4"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTEzLTEtMS0w_e81ca972-855c-4436-936c-befd0a7fc96b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTE1LTEtMS0w_077a0f6b-6748-4541-8185-487bd07171bc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzEwLTE3LTEtMS0w_374435eb-e69e-4ec6-b698-9bf21d476f97"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTEtMS0xLTA_1167e9a2-2a5c-40a5-aab7-d2017e17e357"
      unitRef="usd">304000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTMtMS0xLTA_b0b9492c-2ded-44b4-861f-3a08b613fce4"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTUtMS0xLTA_cd3af4e7-c73e-4fe3-919d-fca8387445c8"
      unitRef="usd">123000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTctMS0xLTA_20515680-011c-472c-8611-de93c5e30ed1"
      unitRef="usd">150000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTktMS0xLTA_5b5d3623-e847-4302-8aa2-2cfb51dd22c6"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTExLTEtMS0w_4caa9e01-4b5f-4d7d-8af9-ae35800a24bd"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTEzLTEtMS0w_ef0bcf82-2e7f-4175-b438-be990e5ea10f"
      unitRef="usd">-59000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTE1LTEtMS0w_4f805973-d95b-4928-b873-a83770fb640c"
      unitRef="usd">-49000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTowMWJjYTBjODFlMDg0YTc3YWEyMzYwMDM2Y2Y1MDhmNC90YWJsZXJhbmdlOjAxYmNhMGM4MWUwODRhNzdhYTIzNjAwMzZjZjUwOGY0XzExLTE3LTEtMS0w_2ab0db6b-7da1-4374-a947-bba7554daf1c"
      unitRef="usd">-45000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MTY_146b46ec-0214-4d89-85fe-fe0cc1b0d8ef">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11,361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,908&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit obligation January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,003&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial losses (gains) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit obligation December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,534&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funded status December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;941&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Actuarial losses (gains) primarily reflect changes in discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtMS0xLTEtMA_0b04ee69-173e-4c39-884b-ab4eb8ce9eb5"
      unitRef="usd">11361000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i471a8ae5a9eb4a88ba94d7f35162f55d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtMy0xLTEtMA_fab863d3-aa68-4fb1-b251-34830bea4d3a"
      unitRef="usd">9648000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtNS0xLTEtMA_dd105075-fb24-4510-95d9-2ec50fb0173a"
      unitRef="usd">10163000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtNy0xLTEtMA_c81dbd94-3244-444f-ace2-51692718b612"
      unitRef="usd">8580000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtOS0xLTEtMA_443499e1-737a-4827-8dd9-2f7944471c69"
      unitRef="usd">1102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4874f46f9b2349859720b5a4665c75e5_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzMtMTEtMS0xLTA_72335c94-4702-49d9-8fb1-dfe449e8b98c"
      unitRef="usd">968000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtMS0xLTEtMA_a4071214-2472-454f-b298-4118b4386c16"
      unitRef="usd">1908000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtMy0xLTEtMA_ccf23d15-38bd-48e6-ac8e-d77e9baba3e0"
      unitRef="usd">2165000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtNS0xLTEtMA_54c4123b-bd14-4756-82f5-91b111ba7753"
      unitRef="usd">1026000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtNy0xLTEtMA_c7f0ca48-ac3c-454e-ace2-deb5425dca21"
      unitRef="usd">1505000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtOS0xLTEtMA_13e91cc4-f210-41d3-b78e-6f9fb437af59"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzQtMTEtMS0xLTA_86412742-3172-4cac-81d4-25354af3aeba"
      unitRef="usd">203000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtMS0xLTEtMA_e43017da-c3e7-4083-89a9-f82aa230948f"
      unitRef="usd">199000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtMy0xLTEtMA_ce060675-2092-4c84-8363-7adac2887c81"
      unitRef="usd">130000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtNS0xLTEtMA_68620d8e-e6a1-4c8d-a5ef-f15fec19027e"
      unitRef="usd">387000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtNy0xLTEtMA_113bbf69-aed1-496c-9556-5c66980e6e95"
      unitRef="usd">262000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtOS0xLTEtMA_0ad6e8b2-49a4-44db-bd68-b15b6686ac46"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzUtMTEtMS0xLTA_4fa9c6da-9ab5-47fa-a4c6-8e12902ad1fc"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtMS0xLTEtMA_e37588d9-091c-4671-8efe-a35b1ad57d02"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtMy0xLTEtMA_89ff1552-eca6-40b7-b260-07fc61b1ce40"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtNS0xLTEtMA_ed2e65f3-bf4d-4248-9920-5027f4c66e58"
      unitRef="usd">746000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtNy0xLTEtMA_e790113a-00db-418c-8cf8-1ecebd3fbfb6"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtOS0xLTEtMA_9b9be24c-3627-4fe6-a060-8a655828ed61"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzYtMTEtMS0xLTA_6f3ee435-cafe-4ae8-99b0-0b15db7a3e45"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctMS0xLTEtMA_d2efa7ca-1831-483b-bc2d-3b341ceb2928"
      unitRef="usd">751000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctMy0xLTEtMA_65f54ca9-068c-46b4-a953-24e69c40dcbc"
      unitRef="usd">582000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctNS0xLTEtMA_8420ba47-f4de-4959-8fee-52ca2cf7b0d2"
      unitRef="usd">215000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctNy0xLTEtMA_718f15ef-a883-476c-bfec-0d018137d6e0"
      unitRef="usd">230000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctOS0xLTEtMA_37153b61-a93d-44dc-8ae5-484940047eb7"
      unitRef="usd">93000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzctMTEtMS0xLTA_bd36fabe-9aa1-4517-96a3-6b20fb02b0a0"
      unitRef="usd">104000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtMS0xLTEtMA_37e42de8-f767-4ff3-b26d-0c2f656dea20"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtMy0xLTEtMA_0d6d681f-5a70-43ad-bf6a-868a4e474577"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtNS0xLTEtMA_379c2f85-4301-42fc-b3e4-53c0735ab873"
      unitRef="usd">117000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtNy0xLTEtMA_fbd6a8ef-607b-49ca-bff8-a6ecfd9b5997"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtOS0xLTEtMA_293f2b5a-ad0b-4310-b335-adfdd33228fc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzgtMTEtMS0xLTA_50d1b4d6-3625-4119-b101-3beb37165f1b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktMS0xLTEtMA_7af5097d-e16b-4561-ab0c-4a527e9371f9"
      unitRef="usd">0</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktMy0xLTEtMA_46672a75-403c-430e-9ab4-0c238faeb49f"
      unitRef="usd">0</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktNS0xLTEtMA_5bc43a0a-503e-4b93-8804-5668679b9a76"
      unitRef="usd">59000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktNy0xLTEtMA_e6e35811-5892-4466-bc52-88b59760b9c4"
      unitRef="usd">27000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktOS0xLTEtMA_9f554730-5137-4675-b301-93ad9047013a"
      unitRef="usd">18000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzktMTEtMS0xLTA_79d19840-dfd2-47dd-a05e-f0ce215babe3"
      unitRef="usd">21000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTEtMS0xLTA_3ce9007b-cec6-458d-8e6f-14550be85318"
      unitRef="usd">12672000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTMtMS0xLTA_45fb1afe-0c97-4627-8ec4-0856d406e891"
      unitRef="usd">11361000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTUtMS0xLTA_d7cedf71-66da-447a-ba11-87ad1cc09211"
      unitRef="usd">12049000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTctMS0xLTA_5fa1cee9-1399-489c-a5e4-dbd93686a23e"
      unitRef="usd">10163000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTktMS0xLTA_de76263d-8067-433c-a714-03c5e2fd1fa7"
      unitRef="usd">1221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEwLTExLTEtMS0w_e1bf8c35-196d-4267-a909-f66e97af3c2a"
      unitRef="usd">1102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTEtMS0xLTA_0427ca89-ce4a-47e2-9177-f4eabc440c03"
      unitRef="usd">13003000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i471a8ae5a9eb4a88ba94d7f35162f55d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTMtMS0xLTA_6fae7c57-3656-46ab-9401-213596f2eb1a"
      unitRef="usd">10620000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTUtMS0xLTA_23f58519-bc72-4b84-9e72-0b0fe1ada390"
      unitRef="usd">10612000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTctMS0xLTA_53676a59-13e5-4e08-a6ce-9733ae3a6d5b"
      unitRef="usd">9083000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTktMS0xLTA_d5abaf40-bde0-4ac3-b693-e1747996877f"
      unitRef="usd">1673000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4874f46f9b2349859720b5a4665c75e5_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzExLTExLTEtMS0w_bd9b7ba9-caab-46f8-b3ee-2ee1591a6eb9"
      unitRef="usd">1615000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTEtMS0xLTA_f4ca645d-9174-4b0b-9c6e-5e9802b4a823"
      unitRef="usd">360000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTMtMS0xLTA_b949ee24-1141-4678-b345-521b575a7d4b"
      unitRef="usd">293000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTUtMS0xLTA_4ecc341e-173c-46c2-9c81-82a4378bb11a"
      unitRef="usd">301000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTctMS0xLTA_39b1e915-6cd1-4840-9645-cbf6cb44e6fc"
      unitRef="usd">238000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTktMS0xLTA_232a6e6d-89e6-4df9-8e2b-6b484f81824f"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEyLTExLTEtMS0w_8ea4a407-607f-406d-a11c-fa369d744374"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTEtMS0xLTA_16c4a8e7-14f8-43fd-8646-e8fcc02705a8"
      unitRef="usd">431000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTMtMS0xLTA_58713cf5-6dc3-45bc-a1ea-195158150047"
      unitRef="usd">458000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTUtMS0xLTA_650a73fc-8135-4474-8d4d-f99df009e8e0"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTctMS0xLTA_a8e92349-b79b-4f11-aacc-ad57fc83c589"
      unitRef="usd">177000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTktMS0xLTA_b26b60cb-98ea-4717-93e8-29bae8a32611"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzEzLTExLTEtMS0w_cb7e673d-179d-4bd1-b531-aceb5759b428"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTEtMS0xLTA_ab65183e-5efc-4523-8d5f-2ba48d3e9d28"
      unitRef="usd">-1594000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTMtMS0xLTA_f4d6ecaf-24c9-48de-b32b-d58ef8f44ac1"
      unitRef="usd">-2165000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTUtMS0xLTA_f17b4435-0ba9-4fcf-ac0b-dff4bb38d0fd"
      unitRef="usd">-1036000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTctMS0xLTA_dda4d3c4-cd7b-44f7-aa92-db866bb1187d"
      unitRef="usd">-1313000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTktMS0xLTA_9d7df629-93f4-47e0-b237-828bbfbadcae"
      unitRef="usd">98000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE0LTExLTEtMS0w_edb23603-1519-4a95-a3a0-8c9d56a25e22"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTEtMS0xLTA_54aa22b7-b09c-4be9-8afe-5bab69013bae"
      unitRef="usd">751000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTMtMS0xLTA_4f55e2fa-f614-4bf6-b017-790689ebde40"
      unitRef="usd">582000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTUtMS0xLTA_16fbd6d1-6d21-4d9a-97c5-b07de62ab4ef"
      unitRef="usd">215000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTctMS0xLTA_f7d91582-c43d-41b1-ac1d-6e1fed0402d8"
      unitRef="usd">230000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTktMS0xLTA_88fda7dc-38b9-43aa-a2b6-b947b60358d5"
      unitRef="usd">93000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE1LTExLTEtMS0w_ecea0281-60f1-4298-94b9-ab2ab2c15718"
      unitRef="usd">104000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTEtMS0xLTA_7f585e3a-917a-451d-a7cc-3e3e1bd03cd8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTMtMS0xLTA_b6abe556-9491-41a3-9a65-3d0c24a80060"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTUtMS0xLTA_10d14521-f049-4974-89ea-affc68e1fdd1"
      unitRef="usd">794000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTctMS0xLTA_ac2fe726-05a2-4f23-82a1-62b8a1153c8e"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTktMS0xLTA_dd00074b-fe23-493c-8fe1-d168dd1a314c"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE2LTExLTEtMS0w_0ea0e3c7-d418-4bcc-825a-e63da894cf64"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTEtMS0xLTA_aeffeb80-abd7-44d8-90cd-cb9fe289522c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTMtMS0xLTA_de905bb8-8880-4198-a3b0-bc2f3365a242"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTUtMS0xLTA_f0feb021-e56f-4ab7-ba72-13ef96412120"
      unitRef="usd">-64000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTctMS0xLTA_e2b2de86-20be-4f68-b6eb-5efee45d55db"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTktMS0xLTA_9d7af221-8c06-4e00-b619-7535a5dbc91f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE3LTExLTEtMS0w_c824e16a-4a84-47f7-9145-6d5a1d316a4d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTEtMS0xLTA_34b6e9e3-e39f-4f54-b6df-17cd569d7f78"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTMtMS0xLTA_a85f4fca-b9df-432a-935d-53de6279278f"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTUtMS0xLTA_ccf31739-5343-4e1d-ba28-e78bbb1b27e7"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTctMS0xLTA_81762f34-c2d1-419f-b141-163cc91db09e"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTktMS0xLTA_8e4ecf94-82ae-4aa9-93ed-1efc675124ee"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE4LTExLTEtMS0w_70b7b9b2-6b72-4ebf-ba76-692f1858a0ba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTEtMS0xLTA_7833fdc9-eaf0-4f59-ab7e-ba3dc498585c"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTMtMS0xLTA_e4e99848-0458-4c42-a2fe-b27cbd2324a8"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTUtMS0xLTA_8552d8f0-9a72-4d94-94cd-3684207fbba6"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTctMS0xLTA_84c4cb1b-7739-46e4-82b3-8c74f7ec76b1"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTktMS0xLTA_17aad554-e022-4903-a874-f8adb9dd77e2"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzE5LTExLTEtMS0w_86900607-0f99-4197-a8da-784e8b9617dc"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTEtMS0xLTA_a0d70b8c-9876-4063-a292-70f46b1b6124"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTMtMS0xLTA_8e4fd1e2-6302-4f08-bfa5-d3cea497d48a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTUtMS0xLTA_a8ae10a8-ae97-4708-a2a1-464175865903"
      unitRef="usd">117000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTctMS0xLTA_a09c2398-68f0-4f0c-b370-63ecc3084a2f"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTktMS0xLTA_38c9ac4c-c215-48ce-ad29-1ea02fc61c2a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIwLTExLTEtMS0w_cc9d6cf7-7f71-4d70-82c2-e30e400f05a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTEtMS0xLTA_ca288b48-27b3-4014-8d05-b2ae2267d44c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTMtMS0xLTA_cc8e71df-2d7e-41ee-9216-27f22bed5b46"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTUtMS0xLTA_19c8c10c-597c-4879-9186-e1eb8c02213c"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTctMS0xLTA_898deffe-3c5d-4876-85c1-d4befd8113ab"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTktMS0xLTA_0aa93ea9-17c3-4844-8508-6436540ba071"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIxLTExLTEtMS0w_cf2d447b-5a9f-461d-ad7a-b36cd7c798a7"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTEtMS0xLTA_df4a23fb-6e04-464b-82a8-f18df8ac50a0"
      unitRef="usd">14613000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTMtMS0xLTA_a8c5f822-d126-4d53-a396-67c07d05034b"
      unitRef="usd">13003000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTUtMS0xLTA_f883a495-9378-4a24-8176-c49b8de0750a"
      unitRef="usd">12534000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTctMS0xLTA_8052e8d4-ca96-4cd0-9efb-6060141c38e5"
      unitRef="usd">10612000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTktMS0xLTA_8f4974cd-469d-44cd-993c-79b29846253b"
      unitRef="usd">1607000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIyLTExLTEtMS0w_605ef82f-337a-4e94-9199-b62bf199cf1d"
      unitRef="usd">1673000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTEtMS0xLTA_d4622062-c56b-4dff-8e57-594ffadb1594"
      unitRef="usd">-1941000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTMtMS0xLTA_ef055bbc-0c69-42b1-9e54-4c3fbcccff9d"
      unitRef="usd">-1642000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTUtMS0xLTA_c7c54492-bdef-4e03-b2ee-a9d9eb3d515b"
      unitRef="usd">-485000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTctMS0xLTA_a3e89d56-1ae7-471e-a8b7-4e3e096cd76d"
      unitRef="usd">-449000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTktMS0xLTA_92977727-c81b-4bc3-bc14-d9b28e018960"
      unitRef="usd">-386000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzIzLTExLTEtMS0w_e05ec9ce-a9ad-4e41-848a-69ca40d476a9"
      unitRef="usd">-571000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTEtMS0xLTA_9d33af6c-46c8-4d11-b24d-3d2fb2f6a506"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTMtMS0xLTA_d10ff913-ba4e-42bf-8334-cb11f2cf80ea"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTUtMS0xLTA_68368f50-89da-423b-b0d2-9890f266d58b"
      unitRef="usd">941000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTctMS0xLTA_e7426b4d-049c-4ba4-8d38-4d488ce82b11"
      unitRef="usd">837000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTktMS0xLTA_78000585-aa29-4384-aef4-4a38d3075e90"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI1LTExLTEtMS0w_1d7f1921-a4d5-4446-980f-39bb59c60df3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTEtMS0xLTA_2e3f9e9a-e3d6-4176-b0b2-efd42ef7b5dd"
      unitRef="usd">82000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTMtMS0xLTA_3fcb1178-c6b9-4cb9-8439-f8458557d621"
      unitRef="usd">92000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTUtMS0xLTA_0371dcf1-20b6-4573-b312-c4c90d451d2e"
      unitRef="usd">13000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTctMS0xLTA_68529dec-a024-45e6-a7d9-fa1edf069a10"
      unitRef="usd">18000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTktMS0xLTA_b08689f0-f35c-49aa-9509-2ba44de9a11f"
      unitRef="usd">9000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI2LTExLTEtMS0w_3c4f729d-0ae0-4732-baac-67896900a8c6"
      unitRef="usd">10000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTEtMS0xLTA_b97c7148-6b66-4c69-89b0-c3bb7502a5f3"
      unitRef="usd">1859000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTMtMS0xLTA_995d1278-38b1-4bb6-be78-4f8eaff00e5f"
      unitRef="usd">1550000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTUtMS0xLTA_264848dd-7d93-4019-8851-6a9051be1246"
      unitRef="usd">1413000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTctMS0xLTA_4aebb4ae-ddb9-43d1-8e34-75288ba0959d"
      unitRef="usd">1268000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTktMS0xLTA_d32f3600-321a-40cb-8540-dec279114a84"
      unitRef="usd">377000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4ZGMxODg0OGRmZmM0ZTI5OWVjYWY2Y2FhNWM0YThlZi90YWJsZXJhbmdlOjhkYzE4ODQ4ZGZmYzRlMjk5ZWNhZjZjYWE1YzRhOGVmXzI3LTExLTEtMS0w_0323ab0f-dddb-4543-a1a3-0d07f4783532"
      unitRef="usd">561000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzIwMzM_44cdd5de-33d3-46f1-966d-7d3cfea0e116"
      unitRef="usd">26400000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzIwNDA_9a0f144f-efaa-4cab-b9e6-6ce9a4e1baf4"
      unitRef="usd">22800000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzIwOTA_a3788beb-eeca-4270-b416-d6304546affa"
      unitRef="usd">14400000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzIwOTc_7eac651a-1011-441e-8af3-2062d6654b0a"
      unitRef="usd">12800000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0Njc_d00cd8af-f3c8-4931-8e6d-526e0cfd984e">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to the funded status of selected pension plans at December 31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension plans with a projected benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension plans with an accumulated benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzMtMS0xLTEtMA_35409ee6-3b8a-42b3-ab24-4cba288032e8"
      unitRef="usd">14613000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzMtMy0xLTEtMA_98a7144f-f77a-486d-ba58-8b25d819fa90"
      unitRef="usd">13003000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzMtNS0xLTEtMA_5292ebc7-bdd9-40b2-b576-56a640c532b2"
      unitRef="usd">8951000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzMtNy0xLTEtMA_0166569a-815b-4246-b779-bd00bbf2ec59"
      unitRef="usd">7421000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzQtMS0xLTEtMA_e4f8a813-4cc3-4396-8e09-9a50f9e65a52"
      unitRef="usd">12672000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzQtMy0xLTEtMA_e3a5034f-358a-4f9d-bd08-aae42496b4e3"
      unitRef="usd">11361000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzQtNS0xLTEtMA_d070ef1b-0d74-40ca-89dd-92447abd1c1f"
      unitRef="usd">7526000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzQtNy0xLTEtMA_0e5467b6-897d-46ad-b733-ec7ceb6fcf9f"
      unitRef="usd">6135000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzYtMS0xLTEtMA_88fabbce-8308-47f7-9e18-47c261ad50db"
      unitRef="usd">13489000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzYtMy0xLTEtMA_696db373-c4e8-4358-932e-1ecbf24198e4"
      unitRef="usd">12009000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzYtNS0xLTEtMA_df0af0df-aab0-4439-a743-50c4693ad010"
      unitRef="usd">4288000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzYtNy0xLTEtMA_4f9e4f07-8fb0-4fde-9064-44a3294a850f"
      unitRef="usd">2476000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzctMS0xLTEtMA_4b90f460-6a7b-4ff5-b250-afa0629639c2"
      unitRef="usd">11685000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzctMy0xLTEtMA_2ec556f6-8c25-4e5d-b885-3d4df317f503"
      unitRef="usd">10484000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzctNS0xLTEtMA_6568fcca-021d-4945-9124-fa6d2249850f"
      unitRef="usd">3033000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpmOTZkYzQ5ZDA5M2E0NmFkOGIzNTIwNGMyZTU1M2IwZC90YWJsZXJhbmdlOmY5NmRjNDlkMDkzYTQ2YWQ4YjM1MjA0YzJlNTUzYjBkXzctNy0xLTEtMA_99b8f5f7-2c2a-400c-aabc-ac3c06c7ea77"
      unitRef="usd">1501000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87b8ce0948a842ed9ef92b8f8846b1e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzMyOTQ_f82cf685-c2f2-4fc8-8647-b7b8405326b7"
      unitRef="usd">942000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89ad1d90c9eb49c08404e53143774bb6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzMzMDE_44df471d-f865-4fce-bce7-cdbcfd5c8452"
      unitRef="usd">860000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage
      contextRef="i63c8adecec8442f49ba129f60935b000_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzMzMzY_3cd83431-97cd-4999-a600-220b036b66a8"
      unitRef="number">0.04</mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage>
    <mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage
      contextRef="ief783e1fed134fbe824b470778e1f671_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzMzMzY_ae4ba36b-f940-4e15-b7f8-f050b2e2e28e"
      unitRef="number">0.04</mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MzI_c84dd063-2f89-46da-b5d1-01d0495608bd">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s pension plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,884&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,090&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,096&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,819&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,819&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;475&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;172&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;172&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other fixed income obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,012&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,736&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;599&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The plans&#x2019; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;374&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;428&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b1966c1d9b34614a906164b1b847e14_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMS0xLTEtMA_ec6738fd-9ffd-4d27-a908-8a3852a328df"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i079debce911f4d1385c9e937966e9b9a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMy0xLTEtMA_353dedd8-8cdb-4d34-b990-68c401441038"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic0b5e7d4fb334cc49a3a07e272a89d54_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtNS0xLTEtMA_56e22a75-234c-4f5c-8e97-becf76a7560c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02395d4a531f43ed837de7ae7e2f47bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtNy0xLTEtMA_c6910772-9bdd-428d-ad65-731d8440fead"
      unitRef="usd">303000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3c8164d243514c2d8cc997890ef95cab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtOS0xLTEtMA_e82cd062-3cf8-499c-8d74-5fd53f7918b9"
      unitRef="usd">308000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i762afa9f7a1a49199bcaa4c4777b52b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTEtMS0xLTA_e166fb2e-9a46-4e45-909c-d0fcdafc4e15"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i896c0ab5f6ee40249192bbeea55f6056_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTMtMS0xLTA_b8c0b27b-eb35-4826-a4b9-3f8871ff527b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2fb94a8956cd48ecbaecb94d4ffd9314_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTUtMS0xLTA_ab8bd94f-40e4-4279-9b5e-7bfb9c140842"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97baa9bccd8e477aa4dbb884bbaca507_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTctMS0xLTA_eceea6a7-0332-43fd-9547-c13b2278e56b"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id04401bfc21e40589a67bb73d6d9e7e4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzUtMTktMS0xLTA_7c942d7d-2bf7-4d99-a18b-4b654513c1a9"
      unitRef="usd">239000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5dfc8f0a72a24b79a719822430bd3aba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMS0xLTEtMA_7861b58b-e970-4bc3-bf07-6d965fed2ece"
      unitRef="usd">206000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2e067be53a86451abe0e60ecbd4d1b2b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMy0xLTEtMA_500f0581-22e5-4357-9b7a-c676f350a96e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iff30bd3bec0342a79f37f6d47d61a152_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctNS0xLTEtMA_7774ee03-f7f5-41a6-a449-00cf7a68319e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia66284b3427a4a55b18a3d2307d2311d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctNy0xLTEtMA_61137121-3d7d-4c52-927f-85391971b781"
      unitRef="usd">3884000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i492575ea226e4ef79e791f68f775cbcf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctOS0xLTEtMA_a154647b-f923-4ca3-b736-25fc72d074f6"
      unitRef="usd">4090000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifaa9c1f8e8f14bc88b26db4f04818c63_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTEtMS0xLTA_176b7989-8dd1-475e-9300-d8de1b283ccd"
      unitRef="usd">205000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i05de118d42874d8a8b65d9fbbb8cd8c0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTMtMS0xLTA_8c873840-dbd5-4634-a455-88063b79340f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i43bae42e68b74c9ea2cef860a864df98_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTUtMS0xLTA_edb1dc11-0a2c-4d6f-b9bd-f77927191082"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4839f9e8f263483bb5a57380e0ac49d8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTctMS0xLTA_5714d617-0799-4de1-a82a-fce7fc4e29e8"
      unitRef="usd">3542000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87f92475a0e644fbad104227d35a788c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzctMTktMS0xLTA_8d092611-270b-49c2-9e13-419fb9be7bb3"
      unitRef="usd">3747000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i09b4d58ac72a4b6b9e8a4a3bd3534739_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMS0xLTEtMA_4af4d0c5-7640-4ee8-8076-c6d8e3523bbc"
      unitRef="usd">169000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie610ba127e0c486a927aaae038bb4c2a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMy0xLTEtMA_2f88b98c-918c-4b4b-a2af-44c898cb06b3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2b4f3b3b5ab84f1f88c1687777c06d94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtNS0xLTEtMA_217ffb35-cf90-437f-8619-34de7216390d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2614fa71de8840c3916410fec8e4c6c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtNy0xLTEtMA_9265fab3-4f01-4026-bf7c-a283bbb9547c"
      unitRef="usd">927000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8493396c311a48c087c4da0df9e9e265_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtOS0xLTEtMA_0f0549c4-2522-4029-8a2d-671e9c43c9ee"
      unitRef="usd">1096000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia33c4c3964914ed192b098a7887db425_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTEtMS0xLTA_eed11fe2-030c-4bb5-a5e7-8c5b97fc8ead"
      unitRef="usd">165000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i983bc4d845244c9a85c0ce012de520ac_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTMtMS0xLTA_a615b2fd-1f8d-4303-8207-61fe470907e3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i55f904c273db45369ca533911c7fdafd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTUtMS0xLTA_415bc2c7-d22e-41e1-bf29-587784b90dde"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i07aa6e44c4e64dc09a11f648c3aecf39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTctMS0xLTA_244d5005-a70b-444a-a050-c44cd84dcae7"
      unitRef="usd">723000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i76599c7f104045fa9d3705ce55cae95d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTktMS0xLTA_c102a8cf-7a2d-4025-a57c-1780e0f490b8"
      unitRef="usd">888000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i09a35eceae1749b2afc0e2adfbab500f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMS0xLTEtMTQ3ODc_38825dbb-be55-4849-81f6-31d3236a25c9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaf07f551b9e54a50ac5e33ce5e447aaa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMy0xLTEtMTQ3ODc_6aeffcb0-0f9f-477e-a53d-1a0edbafd003"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iafbe4a56619b49ab892a56d15529c893_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtNS0xLTEtMTQ3ODc_0e0003a1-7724-40a0-a799-28d3aab5ebca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb63fb418f534cf9a00bf9ce064c5f01_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtNy0xLTEtMTQ3ODc_4d56c4c2-2cd4-4fd2-aaec-243b0690eb74"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22427a43423b41ee97f6e223da5fc0c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtOS0xLTEtMTQ3ODc_a9cc851b-83f1-4041-9024-29bca0681812"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1fdcc0719b79428ba1c8942ab8420778_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTEtMS0xLTE0Nzg3_b688e07f-f644-4c6a-ac6e-6ef652201ddf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29bf2bf658614113ba17d962e1e99dc1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTMtMS0xLTE0Nzg3_548fcce4-9614-498f-8688-50b6c9f29969"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0441dc72fcb54c48aa6e5a54486d62a4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTUtMS0xLTE0Nzg3_79320865-d7c7-4fa0-ae36-826842b9cc7e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i04061d95b9fb4f6692618bb6b2e163ca_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTctMS0xLTE0Nzg3_16e3149b-27d5-4d05-9554-517043a3e6f8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i24ab217ecf2047ca82f61f394e3b2143_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzgtMTktMS0xLTE0Nzg3_44686355-75bf-4b1a-9be2-b020143ddf2d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i65a333a9d32a4a75939aaec5815b2ce7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMS0xLTEtMA_f1a01ba3-90df-4c74-8138-28bf4a7f6551"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia3a588a2b1824cb39195f5f331917939_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMy0xLTEtMA_96e60b9e-7c2d-4a31-b480-68e0706dedb1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89b412ecd46f4665a8377ecba5fa899f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktNS0xLTEtMA_89f60d22-30c5-4147-a122-82be84fb013a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9b6e39b65bae448395fac9f11f72bd1e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktNy0xLTEtMA_b03a2642-ddfd-4d42-be1e-4e0ddf373695"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifdd6fe4acd1d43f89863a9719678632f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktOS0xLTEtMA_f4833e63-fa30-491c-8088-1382007d6378"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifffdb8aac16a488c88f1530e7c5839e1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTEtMS0xLTA_18dc1ea0-80ee-437e-9840-2c282bc374b6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id031685155804a84ac3ff78aa32f7379_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTMtMS0xLTA_61108da0-5a47-4522-a389-db135c69e2d0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4fda6a6813da45e8b85ab5cc18158c65_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTUtMS0xLTA_6a79fb2f-c13d-4a80-b6c1-3d415e19284e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic8e94062e6ca4f1e848b910410e66b4d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTctMS0xLTA_2ca6d5ad-0c05-4f0b-8ed5-bd1e34e5d949"
      unitRef="usd">173000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7598124a95dd40e180dcd55e241004cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzktMTktMS0xLTA_3fc4edda-c411-4bc6-9469-8155f359a57a"
      unitRef="usd">173000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1c46ea7c16f04e6f9077e7ada8dc3aee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTEtMS0xLTA_db05c0fe-95b0-4756-8806-48d4880a2ca3"
      unitRef="usd">2819000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i881d12a48fa145e29b963710be067d8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTMtMS0xLTA_4071685a-ce32-4a78-acee-dee653b13a8f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i963fb897f1a84494b29bbd3cc88a5cde_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTUtMS0xLTA_0134f134-c21b-4d74-9df0-1b81957f0dae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9d998e95188b43bea7ef9db2acaa7908_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTctMS0xLTA_1038f45f-b606-452f-86f9-18a00631b58c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idc5e8ce709424f55baf4ceb447892b4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTktMS0xLTA_8daf1abc-ba79-4075-95c6-186205be07db"
      unitRef="usd">2819000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if27f9b2b78804c56a1797bb83137c3b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTExLTEtMS0w_b5517870-b583-40ba-93cf-1db3d7084615"
      unitRef="usd">2451000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iece7c24fe22a4365ac316e8f89696d65_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTEzLTEtMS0w_e6960b71-3e72-42f1-b9f2-d1420c071a1b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a5510be169a403bb3a2fdf843a3ed07_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTE1LTEtMS0w_fef199d5-ba2f-42ad-81f4-65cd08e95bf4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib1c15bfcb925489c83014b3d69b512e2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTE3LTEtMS0w_ea8c9d90-6459-4911-92e8-ff4e8b81ad15"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i607a874a41c14bfc92471a1eb2e4fc73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzEyLTE5LTEtMS0w_901d8d1c-d6ea-4ae0-b27f-756d61addf04"
      unitRef="usd">2451000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i738f3a9fb4864314980f11c6fc424c84_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTEtMS0xLTA_0b57be7f-144a-4735-a464-0cad4577eb4c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifb154d7816ba4d54a0aa8908f07daee0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTMtMS0xLTA_9a843820-0063-4c19-8c9d-03fc8e241533"
      unitRef="usd">2236000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i845f426bf5684441b08a4d78f16a13f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTUtMS0xLTA_d41f665a-5eb3-4708-a5b6-3c3007c4bfeb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0318028fba4d4d2ca13a6790d87c0bac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTctMS0xLTA_f0f18704-15b5-47c3-b97f-11517f2c515d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i18cc995c2f4542db8ad348a6a80f3f7f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTktMS0xLTA_6a700727-4652-4887-bece-9827ece3c6f2"
      unitRef="usd">2236000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i339d812fd79a4559bef0ec19bfe98349_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTExLTEtMS0w_440f3afd-2412-45b3-b5ed-2c1d5f486734"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibc88b48898f04f409e0109283ed2987e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTEzLTEtMS0w_917d5bbb-fb16-47f6-9b36-46a8e7b2a14b"
      unitRef="usd">2094000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i31a508f5db8a4cada4798954c65d9223_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTE1LTEtMS0w_bf5e7d2f-69e5-4947-9d6e-45161bbe1e4e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id29a7f12c8e24256b2319a238659e1a5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTE3LTEtMS0w_4d6ae4ef-5ec9-4bbc-8a65-f73f13a5cde7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia882b52e228c4eabb69646abbee285bb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE0LTE5LTEtMS0w_206f9f5f-b1e3-4b4a-92f2-1f9197f9a42c"
      unitRef="usd">2094000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if58a48d4bdd44296a817bc4d6ab8b57d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTEtMS0xLTA_4b8ee976-2eb7-4c14-90d0-b53a4d2e566f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied7dcb9e05394ef4b640628827cf587e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTMtMS0xLTA_28d8af16-cba4-49b3-8170-cfc0fbde8b05"
      unitRef="usd">1994000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i11c09a641f9f4bc18e3972169da2930c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTUtMS0xLTA_eb6395ad-83e1-4836-8490-fb832ba7329e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i470fbecd1a04428fb6e6a4caff23f1d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTctMS0xLTA_c8aac7f0-5f03-4892-8696-284145be9ddd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4f7046796fe24f1c868c09c2c0ec273f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTktMS0xLTA_cf3d6469-fd5f-4e55-a648-ba818d0f324c"
      unitRef="usd">1994000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icb9da7337a3242dfbff5100ce601af33_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTExLTEtMS0w_2a0f59d1-e937-4da1-92fa-97dbcd2fee2f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3221566626c342a999e23dfe29877216_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTEzLTEtMS0w_e2d14e22-9f22-4180-ac4b-d4b152de129b"
      unitRef="usd">1582000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27c99d58a8ef4f18bbb9b810927e2266_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTE1LTEtMS0w_67b796b8-549f-4e75-9167-1dc9aef0a239"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id69b26112f2e43dfb981f625c4a50657_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTE3LTEtMS0w_c91feefb-655b-40a2-bdc2-d17521a6b5df"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idabd1fedb7e64d168d077d9c93085e62_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE1LTE5LTEtMS0w_6c5ae3b6-a92b-439f-afa3-f477f6ff7017"
      unitRef="usd">1582000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60e1943c724246bb8b80b478f5c0736a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTEtMS0xLTA_3e658d87-5c24-4a3e-974e-fca2c539fefe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i39cc1d86c43e45a5bc8a8a5055e74603_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTMtMS0xLTA_8b6d4a3a-4bd4-4461-9e2e-5379bf6ff696"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i663cd110b4a94a17af138ccf8e74215a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTUtMS0xLTA_4b3c39e3-2e0e-4e98-a63a-d27c0ab19b04"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id29b60f8e53c4a6ab9ee426df0b5ae37_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTctMS0xLTA_6ad1834f-5a0c-470f-b66c-a925863acc50"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i23692025eb79488d8a33a2716b0b4e30_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTktMS0xLTA_d6059994-ae40-46f1-93e0-f966beea984a"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2b8b282d6d4b46ffa0cd607de8b36a5f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTExLTEtMS0w_83eb6162-cc5a-419f-95ae-ef95cfe9ac6e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f96273f8de344e0b556346389159cde_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTEzLTEtMS0w_8beb25a3-07b0-45e2-bd09-630a3bd7095a"
      unitRef="usd">178000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d2d21f8910346afa7a2eccbd54765f4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTE1LTEtMS0w_d826ae97-5176-450d-90fa-541fd0053674"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id6df641d6b2e4a7fb6f87a544978da43_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTE3LTEtMS0w_e750aed2-2370-40bc-9478-8c27c3e6e21b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i51ad2bfb5d1643ac8704a1745e062147_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE2LTE5LTEtMS0w_3a1b0659-775b-4cfc-a0cd-f65d0a343a62"
      unitRef="usd">178000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic3ec77bd07b245cdaaba698bb230ad64_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTEtMS0xLTA_3ff4a7c3-dc46-4de6-ae30-4faaaa652d96"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3dbe419490e34f4283f48203f8d00d4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTMtMS0xLTA_e6f6c510-4907-4153-99f1-5eec6576fdca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia59d367709184c039635ea8a9c404195_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTUtMS0xLTA_4b3f9956-dd51-466b-8e85-d164d5e26a3f"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i86afa43f33044b8aafbe32dc59a25171_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTctMS0xLTA_8d850a3b-a060-467d-a018-ae1177febef0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i183768f390164f1794cac12bfbf64b84_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTktMS0xLTA_a8391021-1a8f-47f9-8380-12ff4c030731"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3db834c97ee14fab88d75f50f80223f6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTExLTEtMS0w_4d7381f1-7cec-4f2c-969a-4a508540a671"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iec7437b4bf19421b9a91bc99840e0acf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTEzLTEtMS0w_1a0b491d-c4bf-4200-b1bd-8601a3f463fe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if74d1efb8d174c4f838e140f7fd23e52_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTE1LTEtMS0w_1555c8bd-22c6-4526-9264-44554099b6f9"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i549747388339440e9de44fc9bf5b409d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTE3LTEtMS0w_fccd6b54-8f23-4eb4-b55a-8609c78e390c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i78824aa845834cc8a14b6fb34703097c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE3LTE5LTEtMS0w_24408c29-e8e3-4fd7-b873-569ad272dcae"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i73d0fa26e4ae496ea46a709f7fe43c2c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTEtMS0xLTA_03851bbb-142e-4866-b7c4-ebcb3cd3145b"
      unitRef="usd">3199000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i436bb533ef46402880b1b951670aabfc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTMtMS0xLTA_433ce852-8f21-4f49-b5a0-1e1fb20f3834"
      unitRef="usd">4352000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0ec0205bb40a4e4aa25f265fd1063854_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTUtMS0xLTA_e0a1b1bf-f797-4d07-b209-2d2b45571224"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i44c9b892c37442a186be4817fc66f40f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTctMS0xLTA_318bd749-b13a-4bb0-a4a4-0dd007242403"
      unitRef="usd">5114000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTktMS0xLTA_00cc7dc3-52f6-43a8-a194-b4b03f5e3e7e"
      unitRef="usd">12672000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3b5fe2d5dae24dd8abcf648861561996_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTExLTEtMS0w_c897cc18-4d94-4e70-8cb0-2c4a8a95a82b"
      unitRef="usd">2824000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic2c28218b2834e5ab51167cc6eb02eb6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTEzLTEtMS0w_6bc4043b-c961-497c-9fd8-a080ed1bffc9"
      unitRef="usd">3854000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i40916875d4914c52a1de3c0cc928e327_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTE1LTEtMS0w_d0a17fac-71c9-40f5-96ba-068448e23a85"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i51a5827af8cb4a649aac89e78df2a8ca_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTE3LTEtMS0w_9732b632-92c3-4bd4-b00e-309d0ec39fd3"
      unitRef="usd">4674000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idfc972870d3e469faf7b5829c17b665c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzE4LTE5LTEtMS0w_4099d870-63e0-4ffa-9fe7-94b7dc7d0c20"
      unitRef="usd">11361000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i86afe2a27ef042fa97134e39bf3b608b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTEtMS0xLTA_b99ac60d-cf1a-4df2-b317-d5677bc096c9"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d8855de2ab94dbaad3ea5df4e70bf44_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTMtMS0xLTA_4ee4a4ab-4200-42bd-a91a-fb85594af1cf"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i259684d6ca2747128dc9ad3d0b306636_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTUtMS0xLTA_801c64e7-95ab-4372-9a46-7d4ae38f3f3d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaa2c67f654184b1bae5acf068d5001f0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTctMS0xLTA_bf9ae47a-d2a5-4fdd-a0d1-6d764e6ded7e"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iedcfdabfe8f44d56a22b24a80a126022_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTktMS0xLTA_19c6cdfa-1ca2-4632-b67b-566040e939dc"
      unitRef="usd">131000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibeea9d67616a473aab6b59c7fb911c4b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTExLTEtMS0w_1e3008a2-7237-4f9b-a536-1e9c2676e547"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7e43a005430483da4c326627defc690_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTEzLTEtMS0w_6ba9c987-eee7-42bd-b547-37aa9f5a7df6"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i64370d94415e4d9cb45ff1cb008bc7f8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTE1LTEtMS0w_095b1935-a9d1-4f15-ac15-ef44f2b7ee44"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97e19c56a0f04e119dc0d2f946e31d30_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTE3LTEtMS0w_e97951e3-aefc-40bd-846a-033f59e302ce"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie9750dfea550483aa010da7eea306529_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIxLTE5LTEtMS0w_5312a83e-3bc8-4cfa-871d-ca9f38a97ff6"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc4e566933f2436ba71c1f31ac45a19e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTEtMS0xLTA_afb51385-3332-40e7-ab74-b03439e84204"
      unitRef="usd">475000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i16f3cf886e184967b21a73d9c69c8280_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTMtMS0xLTA_3476bb95-a7c0-4786-816a-89f7a323a2d4"
      unitRef="usd">4286000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6d72a9e301de4cd0a1a1a7fc0b36c4a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTUtMS0xLTA_c4929d10-7c23-4203-8207-4c6a4234ad6d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i39901cc34fd740158d36857127b01175_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTctMS0xLTA_64a3b58e-09b7-4524-a100-2dc7696e6d00"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i154bf08968984b7c99f026a36c01c389_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTktMS0xLTA_62b5651a-0da2-4b3f-9a39-503043f1370c"
      unitRef="usd">4879000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i040e5118b6d14454b71d08507239b29b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTExLTEtMS0w_ae05e9da-53dd-457d-a3c8-5d7ee98d2a24"
      unitRef="usd">546000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic2938292f70e456cb6f95bd21bc78090_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTEzLTEtMS0w_c1caa90f-646b-43a7-98c3-7328beee38f4"
      unitRef="usd">3761000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5092f87e8ca34ffdae394fa1e9d5e453_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTE1LTEtMS0w_041b3630-3938-4ecb-ac3b-189ebda4ab92"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id457393c18e544d79b6943a75591c9f9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTE3LTEtMS0w_80d5e2ba-c22c-4c45-b718-55e5a4c79777"
      unitRef="usd">96000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4ba248a0903c42bfa04628d1088a7603_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzIzLTE5LTEtMS0w_3a5d5a07-dbee-445b-9f43-7ca8912d9018"
      unitRef="usd">4403000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b23ae04674c46f6be8804520b0a170e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTEtMS0xLTA_a5777381-ddbc-48c1-8b1a-9e9fe20c96f1"
      unitRef="usd">1516000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie6c07cfb24c14c908e52a77dd7f27872_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTMtMS0xLTA_a492ec24-a0fd-456e-817f-3d6a1718ef93"
      unitRef="usd">2614000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4af75dad006d4960bcfe8d7100ff57f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTUtMS0xLTA_2eef48f7-8f83-4955-99ba-86eeaf2931f3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6be20872a4dc4195a2a00b91c7bd9e53_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTctMS0xLTA_ec87e1fa-1b59-4ba7-a852-d0eac9452afe"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic5fca2613e754dacb1d1358910525b05_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTktMS0xLTA_ef092052-dc93-4954-a900-ccd46d630f7d"
      unitRef="usd">4302000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icb175a0e182a42959d20bd6d81e8811b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTExLTEtMS0w_8d817c3e-f351-4539-9629-1b5887f5cb6c"
      unitRef="usd">462000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia1dc802dfc0e4d8b943a8088b309a76c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTEzLTEtMS0w_01977bec-2912-4945-922f-1936b1dd3265"
      unitRef="usd">2534000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idc71c589efe74a8eafc71efb7fc704e4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTE1LTEtMS0w_5c01ef74-9bc6-4258-8c85-f8396fcdf316"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if758fbd200de40f9992c9a7b6d18d162_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTE3LTEtMS0w_0c8986ba-b8a4-43a5-8303-8aa5205367fa"
      unitRef="usd">207000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7d28cdebd3ef470d805bdfff3c328aba_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI0LTE5LTEtMS0w_484df2b3-ea8a-41a0-9137-28948e61936e"
      unitRef="usd">3203000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4529abd8059b44efae78aa81e23a2069_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTEtMS0xLTA_8cba98ad-3338-43a8-84cf-90d59f00e5ee"
      unitRef="usd">154000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b4ade71303f484886aed15962aba524_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTMtMS0xLTA_901cac3d-36a8-49d1-a814-536f29f61e95"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i13a8ec52ff25456fbf0f605de1c62d83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTUtMS0xLTA_d2ab064a-a88d-4e54-ab36-26ed1d9a3d72"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7318c9a1044a450c8705fd6d1ea5e7ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTctMS0xLTA_84f7422b-d55d-47a2-bfc7-6486349afd1b"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37caa9d66c6c48c784567a49cd4dfcb5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTktMS0xLTA_a19d4da5-b71d-4004-b5d4-d1c637b203c4"
      unitRef="usd">246000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idf01b81038dd4b0d8ac214954c67671a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTExLTEtMS0w_08a1f7d6-e525-4138-8326-93ddfc28f247"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd70b64d3e72405ba247566a7383f575_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTEzLTEtMS0w_2032d5b6-461d-4a48-9681-6588e10a37c6"
      unitRef="usd">96000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i383c1e83a37649849826069e2ea30e70_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTE1LTEtMS0w_5d4e4e53-8909-4b77-a08f-a55fd2977207"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5ca88a53b7a422eab11e135ad001f09_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTE3LTEtMS0w_fcc39795-bef0-46af-a74f-266345dcfad4"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0976228eb3844b76813b5ecd4ea518c8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI1LTE5LTEtMS0w_44a024b7-06e5-4df5-a527-e09c26a81a47"
      unitRef="usd">252000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i19223921be5a44f4b5b22d6e5d166870_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTEtMS0xLTA_0ef69cda-867e-47f5-a8e7-a612620a08e8"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08d99fc733314c5ba2bf5402ab0d6392_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTMtMS0xLTA_e0826aba-4f59-447a-97a3-debefd388216"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd1a97c92462458c929c7092d0e8afef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTUtMS0xLTA_00b2ce6a-697f-4ac8-8841-4bd8e8f97d68"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if84ab6be0c3e403bb9cd82e264108aab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTctMS0xLTA_45203da6-9cfd-4d57-9f6b-2b1e5596bcd6"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9acb800bac97417e813ea16d4d5ededf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTktMS0xLTA_b9adbe3a-be0c-4ea0-a0f2-023290e47352"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i44275a244d0a4892be5505d09958c1a9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTExLTEtMS0w_5a14dee1-9593-48c9-a594-e08fae1c0743"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie51e79c06cea4cdfa2bf6a0d5be0124e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTEzLTEtMS0w_54fa222b-a04d-460f-94e8-411593ea4c46"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i69f45e018d1747a68360c2feb30d6b84_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTE1LTEtMS0w_dd77d01b-768e-42be-bed1-d3477755609c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibbbda6da3727484e81200d5caf50552f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTE3LTEtMS0w_579f574e-eea1-4b62-bbff-745c726e1ea4"
      unitRef="usd">109000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd94dd271aa54f69a8baf12100b51778_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI2LTE5LTEtMS0w_8710fc71-4c86-4c4d-8c9c-521d51fbf515"
      unitRef="usd">125000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iffb967b896a4468fab08e88cae9df856_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTEtMS0xLTA_bbef4428-5dc8-47b3-ad75-69c2fd896ccb"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i86344444b47e4721b7a2fc0ea7cc11ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTMtMS0xLTA_05442aca-cfec-498f-83e3-2f0115d31f1c"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22038ea5b4744df99667fec848961056_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTUtMS0xLTA_e63efd56-c6ed-4836-983a-85153afa3489"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia40b98564996403db036113cd733924b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTctMS0xLTA_d483a054-8b5a-4012-81e9-3fd80826dc11"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie48c9ebac6d74ee190face5ee60b51f7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTktMS0xLTA_abafb95e-9cbc-4054-b905-5154ce8bf839"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3b013c8f53aa4ad0a92b472ab7fc6b81_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTExLTEtMS0w_3cbf46ca-4e9a-48cf-a798-abf4aac4ad8d"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib672d0934c6d49c19aca1d0a43b92a58_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTEzLTEtMS0w_c92ad791-e2f8-4418-8df8-1907bd3d2021"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i349312ecbb7345d7ae0733d60b92c8e6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTE1LTEtMS0w_e4f3e05c-e3a3-4ffa-aaa2-f1c3644a2684"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i457ae5efb13d44ef94eb093fd86a744c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTE3LTEtMS0w_fd3634db-9909-450b-a140-64477d6134c4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i780ae83f21484b4f85c3d3e21ba5c7fe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI3LTE5LTEtMS0w_6932e527-1a37-4454-abaa-571dc163d60f"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a46d5d13eec48b0ab6b5862c0d10927_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTEtMS0xLTA_a0087e47-dd1b-43e2-987c-a71d88a81bf9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaf91bf6b83d04def977d5ec5adea56d2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTMtMS0xLTA_d28896b3-9673-457a-a357-65a34e5dc3af"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f802b0b6548410683a7feb2a61f6ff9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTUtMS0xLTA_f834d0c5-23b5-4778-9e33-51e14f178a3b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4534e1b0f4594853b0b92171732984b0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTctMS0xLTA_b72504f8-fc25-41af-a1f9-9b119726433c"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3f034b282b3b45ae8315f6d3446c99ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTktMS0xLTA_9fc9cd5b-033a-4462-a77a-3b0b7eeacbc6"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic405b218f9744ab780ce9a8a7aab3fde_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTExLTEtMS0w_00f2105e-8165-4d60-a0b2-32d9e416deee"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0001ec828bc546a68b1b01be577c9472_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTEzLTEtMS0w_e92303e6-d754-4b52-b18e-eab57d3538a3"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if840940eee764ea69eeee426ab4d3762_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTE1LTEtMS0w_81f616d4-851e-41c6-97eb-429e9a7392c4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i07001dda2e5f4d7ca903f069b0abc178_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTE3LTEtMS0w_9248b7ee-afab-4460-b5ce-4bcb543a56fe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3f673e87cb9d4be2a8a2fcce749d9a73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzI4LTE5LTEtMS0w_e9447441-1e93-478a-8d57-f9f84d06f1a6"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4a21cac2295041bd8c7761632655bfe3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTEtMS0xLTA_6f9ae890-0a31-4978-b187-69e640f96842"
      unitRef="usd">505000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie982dbca87ff40549928cb1b655bf842_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTMtMS0xLTA_929479cb-7d86-4ce6-84de-6aa76435ecaa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i30d48af822b4482a9b7498a050ddfcc8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTUtMS0xLTA_c2932604-0697-46bd-a586-25280dc182ef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38d0c8c5170b4f6a80534e5ba634dc51_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTctMS0xLTA_81bf5a47-b331-468c-bede-78b0fef1050d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i622fafb065b347f886df4ed478a637b1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTktMS0xLTA_81158311-e83b-448a-afc4-60c4e539ab5e"
      unitRef="usd">505000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i633bb8841df546c49ab62349cfd6e177_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTExLTEtMS0w_5f98361d-5093-435b-b1e0-9f68270d1d90"
      unitRef="usd">565000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5993c63f98347de90f6f8e4da9b444b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTEzLTEtMS0w_908e645d-788b-440f-92a3-b38201697782"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id334f615428b4033a167d3ecd93c0a56_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTE1LTEtMS0w_c3eb6cdb-23ce-4861-b245-4fed16f8dfa0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee9f22f4e7c9422aa9d5aec3892f508f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTE3LTEtMS0w_751afdc8-3159-4fb0-b234-968d0f68a78e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d837922a8c34c35b598417be5b7179e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMwLTE5LTEtMS0w_5c6cb90f-062a-4828-9db1-c8120bc1f596"
      unitRef="usd">565000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i357033ae6b9242f3a760e4ce6ef092bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTEtMS0xLTA_ce9c6626-6066-469c-a353-f18c5548e460"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6504027ab63f4de5b4bcaf9260f31835_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTMtMS0xLTA_88277132-1493-40be-9bc6-af122f4d3a76"
      unitRef="usd">486000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9e6fd8f061154a30a819a163c8185ce5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTUtMS0xLTA_abcd2096-3ae5-402a-9bd9-5d3a7f0f0f10"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id09db396a1bc405585c8bd00bd42ee90_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTctMS0xLTA_38e4f9fe-9b5e-4e02-977a-29bbfeedec2e"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic4e9909fc72e4d14ab3b844920200857_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTktMS0xLTA_2a6fd565-16b8-4bb0-b510-8e63419e33a2"
      unitRef="usd">492000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i34620b194a57489abafae0caa71b1e81_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTExLTEtMS0w_c54464e8-7f78-41d0-b9c0-1aed00a96100"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i803b0a3f273448c6bd0082f93b43ceef_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTEzLTEtMS0w_539cf032-7343-4f15-ac84-69ff3efaba05"
      unitRef="usd">376000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i058faadf9b554518a3b689fa8335bd98_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTE1LTEtMS0w_913169a4-3668-484a-8823-0cd5d2e16784"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3677204f7a3e41dfa2f70915e9c33438_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTE3LTEtMS0w_b657b4c4-02fc-4385-944e-9b61077cf0e5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c48edd856d446fdaf20a830fb838512_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMyLTE5LTEtMS0w_9685a752-702d-410e-ad3e-774c4cb23edb"
      unitRef="usd">379000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4cf61bbfdc384cc9be1bc920c1d76754_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTEtMS0xLTA_20b69aa3-77e3-4b1a-a8d3-9fd5ae48a4cb"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied410f99d8eb4af592290310c06476b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTMtMS0xLTA_74ee5c3e-a527-4a53-a096-517a39ad837b"
      unitRef="usd">174000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3d66850a0b7c440c99a213e0733986ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTUtMS0xLTA_322e627f-5790-4ee0-b8fe-b40964e1750a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0dc4d7beef254de9a0eba7eb5cccc084_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTctMS0xLTA_3d0eca62-7099-48ac-b81f-435aabde1ee5"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i72fd7651ac6a4a2a94a953d682b650a0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTktMS0xLTA_c0a37964-08d2-4bef-b92a-e12d22fb2495"
      unitRef="usd">177000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id5161c382e704689bd21397306aea661_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTExLTEtMS0w_e4ccbcb6-114b-4114-af2b-30af8f7a2a59"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c6ecdff488f4420ba322ef0fedaaf2b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTEzLTEtMS0w_7fab2041-9ac8-4c54-9f0a-600f269ab27d"
      unitRef="usd">135000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic06a9999d9324811b9a1be2dcab19ac4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTE1LTEtMS0w_7a9fe147-cc8e-4d61-a98a-0b71e0e454eb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie77d538a77664954990b8a71d696a859_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTE3LTEtMS0w_eef41494-8ebb-4155-903d-55dd042294ee"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i813c30a7a82a437a930c6658dffd6bda_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzMzLTE5LTEtMS0w_8fa65a4c-0fc8-4f2a-b4a8-a6356a661191"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i21fb50eeb34a4114bc13c96d65cbd097_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTEtMS0xLTA_16229c06-737a-489a-b6d1-14e3d485b46c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifb8b1f9b69d540cc9ee48b788f947e86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTMtMS0xLTA_419b5636-7bbe-42db-8701-7a2c312cfe56"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5520bc81f9124c16a0f7c2a4ac6d32d8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTUtMS0xLTA_2cf81c99-5daf-4211-8198-0be85ed89f21"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaf1ccc0110f849388ab267dc48f11d4c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTctMS0xLTA_70e553e3-a77e-4238-badf-d91822ced81f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if8158b6396da446795bd99eab428f39c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTktMS0xLTA_8cc74146-63a2-4298-b549-d5416a69bcf9"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i31cd5815632a49b2ba1c177fd6bc40b0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTExLTEtMS0w_e7773ff6-4b79-471b-9fcd-1c394865b800"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5ab5fd43cc1445d0af3c8df232ceb26c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTEzLTEtMS0w_94da78c0-ddaf-47b5-a595-075d075fa449"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iae6e35c9626041d98bbf692bd5a64946_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTE1LTEtMS0w_567b2914-ca56-400d-a476-51e45d9f6b1b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i407cc8de7a564cd591d2cc8905f16ad3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTE3LTEtMS0w_99b0a1e0-50a0-40c3-8c39-5ea7fd1db1d8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i402c71bfb56d475d822a8336e13e26c7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM0LTE5LTEtMS0w_c5c3e59a-9c80-4a24-81c9-0f90156e6890"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i16a9ec48e8f84f82a1c47ec8330267d6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTEtMS0xLTA_8736921b-96c6-4310-806f-6ab2a3bf88d7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3937995f915a48b5b2629bee83030604_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTMtMS0xLTA_067c0cfc-82eb-4b90-a7a4-e155eb270135"
      unitRef="usd">76000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i91ec2179722044d5a5d1eb812df66bc5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTUtMS0xLTA_589c8c8d-8b95-425d-976a-66715cb32eec"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic0c42749acb640bf9567f2c696835c1e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTctMS0xLTA_11971780-1113-4e39-8a8b-b3910b72ca9b"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic4d256b285e747878c834986bfa70aaf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTktMS0xLTA_c1f25c49-d66c-41d9-8711-b75d0e9afe46"
      unitRef="usd">1012000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i28b83770c83d4ae3892d22a8c95183d3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTExLTEtMS0w_438c8595-4453-4011-a696-03bcca191dd0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54869a5a706b498f8af31af979c71c44_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTEzLTEtMS0w_8e2a2916-d765-4e9b-9a88-9d7fe83fa13a"
      unitRef="usd">65000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7510a56e62d4a91a42048cfc19c7873_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTE1LTEtMS0w_102df34b-f2d8-44a9-ba5a-bde86ac12817"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0ea763b31b9e48d09c3f501947f1b1b9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTE3LTEtMS0w_c5051f17-206e-4e1f-b8ec-edff355ab1ff"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id04238d138c34d0c9609f710057ea45a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM2LTE5LTEtMS0w_142c1a63-af61-4a5d-8459-6dc100af68b4"
      unitRef="usd">916000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i49eded9c6aae423091e00e60b8b07d6c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTEtMS0xLTA_58592e57-7236-4ea8-b8b9-79e93ff89487"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied9fcdadfe1b4674bfcaa0b730e4217d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTMtMS0xLTA_7fd4e60b-1b18-49b7-b1ca-f543f7c666b3"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74504e9a2e54432f8b030a4dbcf9ccec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTUtMS0xLTA_5595a762-daa1-4659-95c9-3c9452f3b1fc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5bf9b49410e149e4988f1a1303a8002a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTctMS0xLTA_c12c1016-5068-4cdf-8fac-a8e92dafaf53"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38efeb11d07d46c98df2083b9decac1f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTktMS0xLTA_91f533d5-b437-4895-bde4-ea210f54f6d6"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i68339e93b1f64b1dbf950cf628cea274_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTExLTEtMS0w_85cdf1a0-bee9-4b5d-b9f6-120f6171ce81"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4fc97e4e4d57436bb7f739eb609cf62e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTEzLTEtMS0w_28e10836-0c67-4e30-a759-f0ebdca9779f"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf2a2c1e08e8478582cb66340b717486_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTE1LTEtMS0w_142338d4-c2b9-405f-b0d0-2d754bceca97"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3ec2478b8f0e417d82d47d2e798bdf92_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTE3LTEtMS0w_27344991-dbca-4ab8-9408-7d13c257a19d"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i620692e3a36142a99469f7b3c1df10f8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM3LTE5LTEtMS0w_7008e0a1-073d-4dbe-9e91-534caccf0e2e"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1fbb0d61bcab437d8de63b52dd292d32_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTEtMS0xLTA_16dfe997-29d8-41e1-8c9b-b4193401106a"
      unitRef="usd">2779000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d7e666cc10345cdb2262b32f0065fe8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTMtMS0xLTA_699a3788-e0ab-48f0-8042-5c5e8ba90183"
      unitRef="usd">7736000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9e268cd703d845b29d850a21ed33546e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTUtMS0xLTA_338959bf-2306-463a-afd5-2b80767496f0"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia6d74a08d594448d9548a1eb92cbbf96_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTctMS0xLTA_e5cf2300-bbf6-4c33-8809-87a59c5c666b"
      unitRef="usd">599000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTktMS0xLTA_58222e78-006a-4fae-8e7e-355cdaf589ce"
      unitRef="usd">12049000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if8dfaa78b8a242ddb57ebc4c9c31d5e2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTExLTEtMS0w_d59f9bbe-4efd-4867-9e63-30b860b61e01"
      unitRef="usd">1727000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i229c0c3633fc41e78ea30bb9ccd6a28e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTEzLTEtMS0w_41e4c227-0ebb-4349-ba77-aa64f9386f5f"
      unitRef="usd">7052000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i189642b9649f470d84f77e09dac85b67_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTE1LTEtMS0w_d667b497-e8f3-41d5-987f-19fbf1a2228f"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87a79dc129ba4160b0dbd0cde3962a9f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTE3LTEtMS0w_982353bc-46fe-485a-bea5-d39bad02ae85"
      unitRef="usd">533000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5OTc1NDg0ZjgzNDE0NzUyYTIzNjJiYjY4NzYzNjc3Mi90YWJsZXJhbmdlOjk5NzU0ODRmODM0MTQ3NTJhMjM2MmJiNjg3NjM2NzcyXzM4LTE5LTEtMS0w_c1e8fa59-ef5a-4ba9-9c63-81708634c4c6"
      unitRef="usd">10163000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0NDA_7c4c1318-98d4-4b16-82ff-7a8c72a221ea">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#x2019;s pension plan assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets sold during the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5adeeac55b484b6f80dd2c5799f04e33_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMS0xLTEtMA_dee0771d-89e4-44fa-97ee-ac1c33dbf899"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5481e593b17d47b1aa1c93ac944e5897_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMy0xLTEtMA_f01c05f5-cd12-417e-afd8-eff2c175afac"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if74d1efb8d174c4f838e140f7fd23e52_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtNS0xLTEtMA_a0b597ff-b923-42b2-af03-53b2e3080a96"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i40916875d4914c52a1de3c0cc928e327_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtNy0xLTEtMA_278bd5c3-0abd-4107-9196-2ffd536f2041"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i71a47f45b5b94684b166d8f428a29ac6_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtOS0xLTEtMA_a5612099-3e73-4862-a98b-de83dce9d32a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifa08043c6f9b4f8ab940e92d8ff823e6_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMTEtMS0xLTA_8cc7a529-910d-423b-a788-fb8c161789e8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3ae805d9fc1142e3b9ff8fbb8f056835_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMTMtMS0xLTA_7df07e35-7ca7-419b-859d-32d2d3804053"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie76048d496a9406bacee02b8f107dea0_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzMtMTUtMS0xLTA_ca3d62c3-68c1-4a89-a0f4-2e9965ce54c1"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ic4d19186cf57479f8c9c9f80797a937c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMS0xLTEtMA_57e67bf3-cb93-44e2-af17-d2f4b76f70c7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i181e86400b884db2a06d3594319d4a0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMy0xLTEtMA_bb742850-b5cf-4eae-994c-f8adfdfafaa5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i42f4bf6ebef94a2b9c96589c57b30e5d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtNS0xLTEtMA_3e203c22-5e35-4c52-9de2-ef9ec9b0094f"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtNy0xLTEtMA_59d23b36-1fe8-4e49-acff-ea0684ae1388"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i56b5dfd32194495790f2c8c81a479431_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtOS0xLTEtMA_84ee4c2b-aeb0-48f7-9322-8d8fd4cdfd23"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i182aa63f2acb4acc82da9b87c7730e81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMTEtMS0xLTA_96522ec3-5351-411c-b32b-98da70829a48"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i2a92dd071da943828df32be68c3aaeb4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMTMtMS0xLTA_ec2eb071-97ff-42c5-b045-381781e34756"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="iffa22d9c51f4484bba2b9f4934ac0a1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzUtMTUtMS0xLTA_41e1f161-0578-4c6e-b1b4-b77818177c6d"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="ic4d19186cf57479f8c9c9f80797a937c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMS0xLTEtMA_5d834c59-3463-4223-9ac3-98cfe338578c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i181e86400b884db2a06d3594319d4a0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMy0xLTEtMA_82d06448-188c-48bf-9206-e2cdc36fe360"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i42f4bf6ebef94a2b9c96589c57b30e5d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtNS0xLTEtMA_8255caef-ec31-4e8d-bc5e-0fe9886f0b54"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtNy0xLTEtMA_08ece3b9-940f-405c-afe4-aae666f60689"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i56b5dfd32194495790f2c8c81a479431_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtOS0xLTEtMA_9773a881-f01a-4f49-bfbe-705613ae9340"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i182aa63f2acb4acc82da9b87c7730e81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMTEtMS0xLTA_8aae9a12-9621-42e6-a07e-56ec5e9f2996"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i2a92dd071da943828df32be68c3aaeb4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMTMtMS0xLTA_7799fd66-5a8a-4c89-8a5f-b54bf64b684f"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="iffa22d9c51f4484bba2b9f4934ac0a1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzYtMTUtMS0xLTA_fe2802e9-7500-441e-9a14-86f7cc785537"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ic4d19186cf57479f8c9c9f80797a937c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMS0xLTEtMA_d7c0d917-c2a1-4cec-ab24-de65200c9f89"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i181e86400b884db2a06d3594319d4a0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMy0xLTEtMA_93b69f40-dd02-431a-9605-787381153e04"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i42f4bf6ebef94a2b9c96589c57b30e5d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctNS0xLTEtMA_e4e4957b-5e47-401b-881c-b4ea5b38bea7"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctNy0xLTEtMA_48ccee7a-e963-4cbb-a9a2-aefc12a9316d"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i56b5dfd32194495790f2c8c81a479431_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctOS0xLTEtMA_357affec-f728-4a81-997b-79212a175140"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i182aa63f2acb4acc82da9b87c7730e81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMTEtMS0xLTA_22815238-b81e-41ce-86dc-da029096c557"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i2a92dd071da943828df32be68c3aaeb4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMTMtMS0xLTA_baee5147-cd87-4db6-806b-b386c90ad349"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="iffa22d9c51f4484bba2b9f4934ac0a1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzctMTUtMS0xLTA_f1bbe631-e6ec-4a10-b217-8ada31f30abb"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8face53a5d81405290c2c762e2706f10_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMS0xLTEtMA_109612e9-9b8e-4de2-829d-f10bd1a9d101"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8993b7d37c36436185b4a48db374a7ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMy0xLTEtMA_0565ff08-0de6-482e-bb84-f8c068cd8531"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia59d367709184c039635ea8a9c404195_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtNS0xLTEtMA_9fae6795-3d9b-454c-a20b-895f40b7a7d3"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0ec0205bb40a4e4aa25f265fd1063854_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtNy0xLTEtMA_e688a747-66eb-457c-9cd2-8d2adece3bfb"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5adeeac55b484b6f80dd2c5799f04e33_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtOS0xLTEtMA_91c4a6ba-522d-42ba-93ca-5700ceaffdea"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5481e593b17d47b1aa1c93ac944e5897_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMTEtMS0xLTA_02e5df17-55b1-4381-bf49-5f495902fe4d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if74d1efb8d174c4f838e140f7fd23e52_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMTMtMS0xLTA_971f7452-7141-4375-a846-0c62f9072ffc"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i40916875d4914c52a1de3c0cc928e327_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzgtMTUtMS0xLTA_563a15fe-e686-4a12-bac8-792766d58846"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7510a56e62d4a91a42048cfc19c7873_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTEtMS0xLTA_53636861-93de-40d1-a414-8f33c6d0e505"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if840940eee764ea69eeee426ab4d3762_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTMtMS0xLTA_07743c01-9e0c-461d-9c5b-58abc16d0fe1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf2a2c1e08e8478582cb66340b717486_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTUtMS0xLTA_5fa6922c-7fa3-49de-9f95-75ef80835a73"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i189642b9649f470d84f77e09dac85b67_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTctMS0xLTA_61d2baf6-1f80-4fa4-8c5c-0dd21c15626b"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i197d5c37737145e4be8b85609364f159_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTktMS0xLTA_a0020d32-479e-4ab9-a87c-a535823c4f59"
      unitRef="usd">811000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iec259e3fe62049edbdab75f9a4208515_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTExLTEtMS0w_88f73c89-6d40-4e9f-b067-f5385fedef25"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie5ae4a5fc4714d318fd513d240f6ee0c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTEzLTEtMS0w_f1fba4fe-e33f-47e1-b998-cd7c236d24c2"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieee7f5c6f7f3431b9e2edc9b74fe47c6_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEwLTE1LTEtMS0w_85be9aaf-17c5-4504-87d7-b4060d0b5882"
      unitRef="usd">813000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i0d17ed2f94a04fa9aef9f8d5c15caa5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTEtMS0xLTA_8776b647-e22e-4ec9-bda5-73e47ddc3b3b"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="idfd81d119ee0498cbcaa47e8e4e04faa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTMtMS0xLTA_5d7f9be9-5cdf-4ca3-aa00-d959a410cb57"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i6244f9b099ff4947aad981a8256ee577_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTUtMS0xLTA_e1e88c6c-b283-4f34-a534-e751a0ef1c6e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ie56379a346a34c328d1074093e2a301d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTctMS0xLTA_7b7e132d-58d8-4756-bcf4-c02586bf9365"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i05a8d5d4b6784223a646272a4e63a5a7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTktMS0xLTA_5fcb99ee-c50c-4371-ac1d-552445a4bb92"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i78f0eeb607674c858416639d103ec85b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTExLTEtMS0w_910a5607-4e53-4ced-9e71-4e0b8d04a461"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i4103a039ab6c450b8e3fd2d3aec9b167_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTEzLTEtMS0w_cf41d0fa-2dcc-4ec0-b3bb-cb34e462b7a3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i248058aeee814ad1b7ccee7a89ac58dc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEyLTE1LTEtMS0w_209c1de0-a4f4-45b1-b682-e4c48a1e4f14"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i0d17ed2f94a04fa9aef9f8d5c15caa5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTEtMS0xLTA_bb3ca6f8-4642-40ca-9478-254726abf82b"
      unitRef="usd">-17000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="idfd81d119ee0498cbcaa47e8e4e04faa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTMtMS0xLTA_5dad1f5b-3a04-4f2a-895e-257349714ebb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i6244f9b099ff4947aad981a8256ee577_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTUtMS0xLTA_74da034d-0773-4421-ac6f-9df1bf7d02aa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ie56379a346a34c328d1074093e2a301d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTctMS0xLTA_84390335-21aa-4318-96e7-518934d05225"
      unitRef="usd">-17000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i05a8d5d4b6784223a646272a4e63a5a7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTktMS0xLTA_b867daed-c10e-46cd-8334-0d2eeaac8c9f"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i78f0eeb607674c858416639d103ec85b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTExLTEtMS0w_392cd287-1926-4894-9d25-0f1c3e785adb"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i4103a039ab6c450b8e3fd2d3aec9b167_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTEzLTEtMS0w_fdaf3888-cd46-41e0-aa9f-bab152779ab8"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i248058aeee814ad1b7ccee7a89ac58dc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzEzLTE1LTEtMS0w_336a2971-35eb-4fab-bc7a-b01191abf7d0"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i0d17ed2f94a04fa9aef9f8d5c15caa5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTEtMS0xLTA_a7c0120f-789f-4f00-835a-e7d813913970"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="idfd81d119ee0498cbcaa47e8e4e04faa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTMtMS0xLTA_b53cb777-d6b3-4ec3-bf49-dfb53d2ecc4e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i6244f9b099ff4947aad981a8256ee577_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTUtMS0xLTA_f5d22593-e954-4476-a975-89de5b67dd4a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="ie56379a346a34c328d1074093e2a301d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTctMS0xLTA_233bbc9c-e14a-4acf-81f7-517f648c3507"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i05a8d5d4b6784223a646272a4e63a5a7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTktMS0xLTA_0cb98d36-3738-49a5-b484-eac5e0adc3da"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i78f0eeb607674c858416639d103ec85b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTExLTEtMS0w_a3ffc7db-e195-440e-937d-9f1ca6e567ac"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i4103a039ab6c450b8e3fd2d3aec9b167_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTEzLTEtMS0w_2eade3f5-63a1-46a6-b415-eaa26fcdad22"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i248058aeee814ad1b7ccee7a89ac58dc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE0LTE1LTEtMS0w_eb63d3d6-2ce9-4b7a-a0b6-81934458a7f4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i91ec2179722044d5a5d1eb812df66bc5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTEtMS0xLTA_0ab654a5-b0cc-458b-aa25-891f6148befb"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f802b0b6548410683a7feb2a61f6ff9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTMtMS0xLTA_e1319133-cb74-470e-b67b-e8e807a7f751"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74504e9a2e54432f8b030a4dbcf9ccec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTUtMS0xLTA_10eb371e-3616-40b0-9e0b-c3fcdf435ad2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9e268cd703d845b29d850a21ed33546e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTctMS0xLTA_2abbf29b-9fc1-4150-b053-a84b5d470b49"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7510a56e62d4a91a42048cfc19c7873_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTktMS0xLTA_d2a6a0d3-cd90-407e-b401-cf717324c57f"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if840940eee764ea69eeee426ab4d3762_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTExLTEtMS0w_9bc58a03-1d31-48ca-aa3c-fa4375dd16e5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf2a2c1e08e8478582cb66340b717486_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTEzLTEtMS0w_707d1a37-ef8b-404d-943b-be5cd54c8b22"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i189642b9649f470d84f77e09dac85b67_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZToxOTRmODljYzYyMGI0MDJiODc2NmYxMjZhMDVkNGZkMS90YWJsZXJhbmdlOjE5NGY4OWNjNjIwYjQwMmI4NzY2ZjEyNmEwNWQ0ZmQxXzE1LTE1LTEtMS0w_146ade8b-bbde-4b3a-8c61-52d8d05cd6cf"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6c14cccf97aa4e98bed9ab984d662ca6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMS0xLTEtMA_438bd394-6ef9-4729-985a-18d3be07af1c"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5c7eb5004e0643efaa0d767fd8811f55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMy0xLTEtMA_1d923e05-6fd4-49bc-b1bc-ff3443864e7c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4bc1fae753be47e5bd4c21587185b6fa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtNS0xLTEtMA_9801eda1-fe4f-40c4-9302-a5a95e1b8c62"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4df3a94dfc774b0e8194462a843091f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtNy0xLTEtMA_a416c8f2-8257-4be2-b708-84058eba416b"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i15952b0805294332b2734607d6a255b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtOS0xLTEtMA_56096c80-5f3e-4266-9a93-85e98038fc01"
      unitRef="usd">59000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37f636340dc640479a5f05532e7d057c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTEtMS0xLTA_93f8e63d-90b9-4f84-8ff1-92df134d5c85"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i39557d630df942dd86fd2bf4c39cf856_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTMtMS0xLTA_4c5f7912-7442-43cb-9df1-0b6f31a9f6cd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i699edc2c96984870bd641e2007368c3a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTUtMS0xLTA_9ad3fc8f-9f9c-4bbf-9cdd-aaf6dbafeb5a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib791d92b691f48e596977e133b7a160a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTctMS0xLTA_8cc97339-97f7-4e78-bc5d-7a8e2fbcc057"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icef24876a7764b5baf52ca7024d66e6c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzQtMTktMS0xLTA_4541c44f-054d-4426-802d-3c530b9706aa"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8ba9f69f2a94435d9d0a72322f3ae888_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMS0xLTEtMA_0f8043cf-f896-4ff1-9ffe-fe03388418c9"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0e9da0b7f32d4b4b907aa341ebe4cb77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMy0xLTEtMA_95036219-576d-4522-8bd3-99af0a03a7cd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i43cc1a499218442e95080f98c69c62d5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtNS0xLTEtMA_6fb34c8a-19f2-4cb8-9745-a066cdfc6c44"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60bf9bd5acfb401fa74b890b56b423f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtNy0xLTEtMA_4345026d-2274-42f3-82c2-82c92c1ac108"
      unitRef="usd">355000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie96f52556ae446d4a890b661e68c63e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtOS0xLTEtMA_801a2172-4155-40db-b15e-53ca2e7e064f"
      unitRef="usd">374000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie0b79dacdae14f1e977caf0b1f646c03_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTEtMS0xLTA_b0eb3dbf-37f4-41bb-9e0c-c98060854808"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ief56854f3aa241a0b9fa4ddfcfe5de10_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTMtMS0xLTA_269c43d5-1d3b-405a-8c81-70ee9762b9d9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib62ecf568cb04ff1aacdc2f07c2ffeb2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTUtMS0xLTA_2ef52579-86bb-434c-b061-4b7226c395bd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied08a22fe762423eb0853b09ffc68ba5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTctMS0xLTA_1358b5d6-8809-457d-a972-71d91160c464"
      unitRef="usd">324000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic57e6fb3e1414f279eb4e83bd905b61c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzYtMTktMS0xLTA_1e495565-3f83-4efe-896c-5d88a2469709"
      unitRef="usd">343000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i755cbd5c13c24c81933f62cd6b4eda28_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMS0xLTEtMA_3a3d052c-87c0-4162-9902-c24d50a7c74e"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a189549221f4e24b423fd38671d9d54_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMy0xLTEtMA_d24d911e-934c-4325-b197-062eba5b4b84"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0252b084de946b684173854befd400e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctNS0xLTEtMA_1c1e9ccc-64c8-4512-bd5c-c72b10a12b9d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibdb1b2bee0774b4aa8d069b01b4b4a15_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctNy0xLTEtMA_a7981e2e-4c49-438e-8fb6-f2b5977a3bc1"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie6ef8d12db6e40848a3a69a5aff2a1e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctOS0xLTEtMA_995eccf8-8970-4bcc-8978-3f4ca3325437"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i43a497acacff4f75ba6294cfa44db5bf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTEtMS0xLTA_56c3a403-e1b1-44a7-aa25-64bc4d79d368"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie15a714c12b94a1ab30adc88613b45ec_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTMtMS0xLTA_600d7b94-bd43-4327-af26-ae5847852429"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4dd632257d3a49bbac09f1ac0c2bfb66_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTUtMS0xLTA_279dc62a-5a0f-49e3-bee5-2218758d4fa9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2a774411d90415084d7be23aba71361_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTctMS0xLTA_b16fa882-1acd-49a0-acf0-91bc0aef09a1"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i78b6ad0ae1984ddb8dff1329153f9b50_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzctMTktMS0xLTA_72f30fab-467d-4734-ad35-4db5c9534cd2"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75c7902d5027446ea98179759ec35a86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMS0xLTEtMA_d3f145e8-1a89-4142-a8d4-846807ea443e"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id85e0fb8780a4f668610145bb98e568d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMy0xLTEtMA_e1ba4497-f229-41e4-a833-7f7ec679b989"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i23dea03aedd24af7bba7749747e2c448_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtNS0xLTEtMA_aa517dba-b1b7-4247-bfc8-652474f42d6b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4cbe0c4416b349fb9992bba23dd31615_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtNy0xLTEtMA_c5013427-0acb-4290-af9d-e046091d09b3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a6261bbf6434c1fbbb017c083ac826f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtOS0xLTEtMA_df0a3690-a3d8-46af-95c5-21c79dff6654"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i099c7987308445478005041a2e2499e4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTEtMS0xLTA_a1a1e72e-bf4b-4879-befb-083894ec1d16"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9a7b979b8181471cbb2f4d6499c774b5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTMtMS0xLTA_914d1958-7b40-4864-bd93-036f67d0c6bb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9635dab5da6b4d86af14a4b3b3e3d17c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTUtMS0xLTA_7b668a61-0080-40b4-873c-7e6abb8b2a65"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic9accb5aa18f4478b540bfc23200dd1c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTctMS0xLTA_0f661982-47c8-45c1-9f22-aba5d2972131"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i10d7560a3be3405aa45a2e8965d79a75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzgtMTktMS0xLTA_144041f9-692e-4f98-ad87-a5d0cdef0179"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i991d3d8795e7450993baad6ac1542b2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMS0xLTEtMTQwNzA_ae120829-e175-4a20-8a5f-3ca93ff9a7dd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe94f09fb8b44e858f391b3b456ea158_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMy0xLTEtMTQwODA_a67c66e1-19e9-4e77-80ef-5eb25e47a8cb"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i03dcff373b2c4b2e99f9bc879d71f877_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktNS0xLTEtMTQwODQ_87746406-bace-45ea-b573-7f6ad10043bf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia4161dc5395848ec97371fb2973a6cf8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktNy0xLTEtMTQwODg_cc0ee1b7-9b75-42d6-847d-57626b2a4a5e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i148dc14f164643bc9efe7b919ed342bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktOS0xLTEtMTQwOTI_2c0aaff3-d398-4695-88b3-f554c03873a2"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0bd0233a6f6343d6985c502db8bfff5f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTEtMS0xLTE0MDk1_ba6512d6-e6b3-46d5-beab-95a808ea9f97"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i79484360495649f0914e71275a2db5f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTMtMS0xLTE0MDk5_bb45859c-a3dc-45c2-9fe1-dd83276f920e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i952760f0a9e74c05b6d48ac685eb2961_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTUtMS0xLTE0MTAz_2f6c2dff-77af-4559-99e7-940b3cddbbe7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i86e0d1a44c2c42158b392f684f51f780_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTctMS0xLTE0MTA3_f9539dfd-63af-40c8-bbc7-cb9ba02db566"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9deec913ce4e429d807dd9d9ffb90a6b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzktMTktMS0xLTE0MTEx_968d8a03-a327-40c9-8a6b-efcb1fc18cc2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17183f50f3f84a319239298ca400b998_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTEtMS0xLTA_a4d2af4e-9377-46e2-b6f4-d43cffbc55f8"
      unitRef="usd">258000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8bd9c6661e1d486f8658b5ab959fdfba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTMtMS0xLTA_a1d10c7b-d55b-43f8-8113-3328d4c5d675"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib753ab6b2404493bb7bb3e62d12eddca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTUtMS0xLTA_a2009ff2-75c0-4043-896d-8b723bd12d3a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ffe7e2d5821413da37bc4be396523dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTctMS0xLTA_7b1fc4f3-e3b6-4e36-8d8c-0059b10e1c55"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib945d0e7dfa340bf87fc9b367dfeb236_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTktMS0xLTA_d42836ba-ad4d-47e1-8df9-bec8afe60777"
      unitRef="usd">258000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8163064b7e4a40249d86d66b673c237d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTExLTEtMS0w_6609eab9-115e-447e-a51c-6ede4c62c6de"
      unitRef="usd">225000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80ced98f942344b8ab3c48acf6650470_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTEzLTEtMS0w_4a3ecb53-cff9-4ccf-bf42-9d3fffbc82b6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a9b9a544637409b9b31bfd72192e634_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTE1LTEtMS0w_40efaf77-5f45-4a4e-bdfc-74369ecc4eef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia10fba196d5842819ca00cca1ed5d9bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTE3LTEtMS0w_594ea1ba-fdef-476a-a2c6-0a5f103f583a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iae7bb63a321a4dbca2ff6d7d594a9842_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzExLTE5LTEtMS0w_a55b2b72-d6dd-4208-a5ab-c3623997e8b5"
      unitRef="usd">225000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id3515234e4c5489b8a5058fd44abad74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTEtMS0xLTA_1ec2417e-929d-4c25-bbd6-508e832e7cc9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic1e22790d03c4f9b8ae9e600bf7d8610_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTMtMS0xLTA_1207f380-f5de-4796-b5ef-4d9e40d3aadb"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37ac062f19214253a973f162cd6b7257_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTUtMS0xLTA_2263026f-ec5c-4ada-af1b-718f3d31629c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i26d2514b5ecb4f079fe56b573db1a351_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTctMS0xLTA_d478b527-2789-47e5-8964-6af882e61927"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i054b0d4c7dcf4dad93d6b261932d1c2a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTktMS0xLTA_cdfc1e78-48f5-4fe0-aaf1-a23feed44833"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if8b3ee4288f1434fba7a20a0cc9987ca_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTExLTEtMS0w_b77a7245-3f29-4121-a723-bdf3b2d7cc60"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibbe6a7bef2d8421da8fb84a3f0eb8f61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTEzLTEtMS0w_138d3805-cbe7-406b-9399-8d6011bb6c57"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9a9d170f4c6f48cdb4f7d2ceb8f17c94_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTE1LTEtMS0w_4ab29aff-60bb-43c8-b62c-2360e91578a8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i93fb52f964bc44ef98075f84eb2f5ff3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTE3LTEtMS0w_75dc5246-85d9-48c5-8a7d-fe2f33eb3241"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3bf1c6eec00b45b1895cc6d33e8b5bc4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzEzLTE5LTEtMS0w_bed26139-3ae5-4b27-9c43-30106f0c88e0"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc6482ac243747999a0cfa001203778b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTEtMS0xLTA_77c875fb-43c5-4526-95c9-9f5c16c366d9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i349bae78403843118305b16989643e38_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTMtMS0xLTA_c52e82c2-146e-4cbc-8672-8f4fc4f2a800"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i568c8abfe83946f99469ae90bb9eb5ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTUtMS0xLTA_983bfc4b-fe63-4aef-a1ef-42079e9c93bb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee961b99d48a42e294600feed306ca7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTctMS0xLTA_bcbb1de3-e07c-4d60-a016-c459e670e65a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic5d6adfd31e845609eafb982fa870054_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTktMS0xLTA_6f8b7222-7b19-4581-ad76-7b0558c8d407"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8a974d49102240d79181f4c266d17f3a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTExLTEtMS0w_74083a57-c131-4070-8256-bedb1836d35e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia3c1d58045034f7d978522ee23262647_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTEzLTEtMS0w_cc850f5b-eca8-464b-9998-005b10bd842b"
      unitRef="usd">149000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id45dfd155d034c4dac37d090ee18315d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTE1LTEtMS0w_b8c2553b-2061-4747-9c04-ad4191822261"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3707009e777f46e0827af9a448af3671_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTE3LTEtMS0w_e3f018c4-4f22-420d-aa56-ad8f077add0f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iafb206a1757a4824b9d626e0233b0fc0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE0LTE5LTEtMS0w_e1461a34-c4c5-44e2-83fd-c53ff124ea80"
      unitRef="usd">149000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idfe1114db0d24d3585c20ee5c36843de_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTEtMS0xLTA_2a4d2313-bf75-45cd-a035-eb4e8ddac40a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idd30b86dc69946c795758370be94e534_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTMtMS0xLTA_98879e3e-b84a-4440-aed3-438715c320e8"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if946e67d0b6c4774bc9f3f9e21193f23_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTUtMS0xLTA_f1200031-bbf1-4249-b0bc-3aa0617cc858"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if030402de9be4396ada7e2f22518b79b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTctMS0xLTA_be04ba76-d720-4846-bb2e-cfd805d8dd88"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7862913b018b4ac799b5977d1114dd64_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTktMS0xLTA_35b5c813-f80f-4a69-abef-b14895d45ae8"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1a3e27f1bf5849a283a049ebe88b1431_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTExLTEtMS0w_a150b788-df42-4497-be02-b88b7855be88"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3e25808393b84cb8b8588f0b2ba8f09a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTEzLTEtMS0w_0ae84b2b-ca05-4947-893f-fb06fa07250d"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice86e24a0fbd45fdb549c788c2fae42a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTE1LTEtMS0w_90adc3d1-b34d-4364-801e-72c6c4b4f78b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i933961f1977a41cab0929eb4211fdd05_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTE3LTEtMS0w_55fb6fb0-f046-4e39-9e1a-755bd1fccaa8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2701d8c81625454b892b42c08d22f20d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE1LTE5LTEtMS0w_8a370cb3-c366-47cc-8c49-c38683e3243f"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i42cfd92c13d147b1aaef0650037a65e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTEtMS0xLTA_63814838-0e09-4074-b488-e15e99b64c4e"
      unitRef="usd">325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60637f24b9c34907a65ab4eafa2af829_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTMtMS0xLTA_0fae5e36-75f3-4f54-bdb5-c1b3b0f1e168"
      unitRef="usd">428000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d6e855b0100414ab5cb98a6a2b9c3f7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTUtMS0xLTA_f2c1a79e-7979-4e80-8c0a-f5a2c0905229"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d6988d2c895477a9dda50151b45b1bf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTctMS0xLTA_d2d45b5b-5238-4b2f-a40a-eb51f3e10781"
      unitRef="usd">468000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTktMS0xLTA_48555523-6bd1-48ae-b15e-a315a39f3488"
      unitRef="usd">1221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0bb985051a0e4022af522f73d07de54c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTExLTEtMS0w_d3fdc731-b95f-4f52-8fc9-65fd43189f68"
      unitRef="usd">312000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if670e72285554034b4161deaea318730_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTEzLTEtMS0w_8a2c4ab0-4503-4b52-a6d0-2c6d985fdfc7"
      unitRef="usd">362000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idb83591d5af44b1dbae73ab7ad1e4fba_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTE1LTEtMS0w_2b96dc25-c5b8-420b-9d18-62d61bea879d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1c2e264dd3bb4e18b7d7a3a250729f3e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTE3LTEtMS0w_2d2a6dd8-c8ab-47b0-81da-26ce6aebcb70"
      unitRef="usd">428000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTphNGZlNDA2OGQ5ODU0M2FlOTdlZmYwMTNkNzE0NDgwZC90YWJsZXJhbmdlOmE0ZmU0MDY4ZDk4NTQzYWU5N2VmZjAxM2Q3MTQ0ODBkXzE2LTE5LTEtMS0w_21f9ed1b-873b-4e12-a9e2-807084719a24"
      unitRef="usd">1102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i90ed9e9d5bef4e08bd9d56bcb3fe7dd1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0MTY_c31760e8-3dce-41e0-895f-a49e33152324"
      unitRef="number">0.30</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ibaf43c3e9e35453580b96b6cc36256f0_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0MjI_372b7d7f-5e60-45e8-a1d2-db3df9367f34"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="if51206021aaf4c96a2df71f22290016b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0NDM_30fc84a5-9a1e-45fd-85c8-4ee292fa8d65"
      unitRef="number">0.15</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i61232e501c3a45dd9ffc51e1a7b18638_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0NDk_7e94b100-7ed3-48d3-9039-79de6e2a2cc2"
      unitRef="number">0.30</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iaa31db245c334463830834bd6fdfcb7e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0Nzk_18c96930-8595-44b4-9a53-d47e34bfd863"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i43dbdf70f3f84f9bb800dc9b2bc789a1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU0ODU_0aba0d4b-6055-41b3-ac99-7c7d5d9351ef"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i1a185822a7fd4092bdcf42d8ed03b009_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU1Mjc_244e976e-1cb5-49a4-9350-836391a93a7f"
      unitRef="number">0.05</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests
      contextRef="iafec61eba0f44b598174decf94362de9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzU3NjM_78eba88e-fcf9-4d90-84e4-5965dda8467d"
      unitRef="number">0.11</mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzYzMjM_47e08632-7702-4e6b-9e0a-237c3898fa52"
      unitRef="usd">300000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzYzNjQ_b5f63981-1835-4332-b509-b5a1e590bd38"
      unitRef="usd">170000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzY0MTc_8ee86b69-6a44-401b-8a82-2f722a1b6f51"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MjI_042bee5c-27b0-4fa1-805d-19a31f3a5d00">&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&#160;&#x2014;&#160;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzEtMS0xLTEtMA_36a02247-7b58-4061-9b87-5b882f9f22ec"
      unitRef="usd">816000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzEtMy0xLTEtMA_7b0df6ac-f0ae-4580-9e23-1096c25c8dfe"
      unitRef="usd">274000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzEtNS0xLTEtMA_c2c12736-2b40-4383-8617-7fcb6c393e0d"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzItMS0xLTEtMA_a212cdac-6267-4e2a-bc07-153bd9334040"
      unitRef="usd">786000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzItMy0xLTEtMA_7b9da768-999c-4646-b36d-85c46ce9a644"
      unitRef="usd">277000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzItNS0xLTEtMA_f8a2224f-5043-4985-aece-bc6cb2458f96"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzMtMS0xLTEtMA_9e3b44cc-8172-41bb-8fb8-5025eb553018"
      unitRef="usd">781000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzMtMy0xLTEtMA_3064d47c-5a7f-4402-ac0a-0b41d915d3b1"
      unitRef="usd">284000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzMtNS0xLTEtMA_438961d1-3b1f-40bd-b521-11fdf6a65a46"
      unitRef="usd">87000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzQtMS0xLTEtMA_16f6c5ef-4d51-4103-97d0-ffa1a83c638b"
      unitRef="usd">772000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzQtMy0xLTEtMA_72cd99a3-14e5-4874-b29b-722180fa6a1f"
      unitRef="usd">285000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzQtNS0xLTEtMA_2f968fce-0f28-41f0-8f8e-103b720a1757"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzUtMS0xLTEtMA_86e93987-75a2-437e-b780-14dfb13cebab"
      unitRef="usd">782000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzUtMy0xLTEtMA_884fd2f8-fbf4-4515-aa64-902fb4552e48"
      unitRef="usd">287000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzUtNS0xLTEtMA_4cda9f50-0bbc-4a0b-86e0-027fa8541c63"
      unitRef="usd">91000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i04ec46d52043488489055d11d93409d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzYtMS0xLTEtMA_19aec36c-9c29-4268-9fe7-f69129721da4"
      unitRef="usd">4271000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzYtMy0xLTEtMA_6180607a-13b3-447d-a23d-a357913b37b7"
      unitRef="usd">1688000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTpkMjNiYTA5NjEzOGU0MDQ0YjA3MTgwYTNjNzUyZGI5NC90YWJsZXJhbmdlOmQyM2JhMDk2MTM4ZTQwNDRiMDcxODBhM2M3NTJkYjk0XzYtNS0xLTEtMA_87323016-ade6-426b-832c-5ee5d00863be"
      unitRef="usd">474000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0OTE_d1b979f3-22a2-40d7-b2c8-5c636707c3ed">The following amounts were reflected as components of &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Postretirement&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (loss) gain arising during the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (cost) credit arising during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization included in benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service credit amortization included in benefit cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;109&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMS0xLTEtMA_ec67c81f-cf85-4395-a0f2-e229a048dbb8"
      unitRef="usd">-448000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMy0xLTEtMA_64fae807-be88-4e3c-89e9-a46bcf59f60d"
      unitRef="usd">-816000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtNS0xLTEtMA_4560a145-d304-4d9e-87bc-175c36094e6b"
      unitRef="usd">-397000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtNy0xLTEtMA_dd35790c-b9f9-4248-a70f-3e86acacac1c"
      unitRef="usd">-407000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtOS0xLTEtMA_49c34d53-2f65-4085-88ad-f9fe52989268"
      unitRef="usd">-227000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMTEtMS0xLTA_b287add7-048d-4b21-88d7-b356ce044e9f"
      unitRef="usd">-505000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMTMtMS0xLTA_c8c91550-462c-42ca-88b4-a6d502689c70"
      unitRef="usd">198000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMTUtMS0xLTA_7923fe8f-441e-4f80-97f7-19733ed4946b"
      unitRef="usd">112000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzMtMTctMS0xLTA_f50bc14d-4f80-449f-a599-e94d66c8c284"
      unitRef="usd">186000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMS0xLTEtMA_e3487f1b-bc4e-4275-a918-dc19155e4269"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMy0xLTEtMA_340fa8c0-c923-4063-b1a2-ee673ee25c69"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtNS0xLTEtMA_ed7eda09-3822-448d-8d23-245b1451880a"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtNy0xLTEtMA_3247dfd3-ad36-4e29-8c61-cddee1843372"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtOS0xLTEtMA_34b7053e-9c4e-4f81-b02b-c147eaedc80a"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMTEtMS0xLTA_b3892eea-fbfc-42d6-b9df-b377548545c5"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMTMtMS0xLTA_5fa141e0-e0ee-4a4e-904e-0a746f952059"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMTUtMS0xLTA_2d85eb69-1d47-4ea4-9e60-221bffd5d3a4"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzQtMTctMS0xLTA_22ed5b63-1968-42dc-b9ed-07ae2ab48b9a"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMS0xLTEtMA_55a77dc0-0220-4907-943e-ec923885412f"
      unitRef="usd">449000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMy0xLTEtMA_79c4a41d-a198-4b4a-a8ff-d3f0fde1afde"
      unitRef="usd">820000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtNS0xLTEtMA_ee4a2d4b-5fcb-4638-95ce-c2b6c2b24071"
      unitRef="usd">401000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtNy0xLTEtMA_6139ba2d-2f69-4c70-8806-03e1c27af737"
      unitRef="usd">345000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtOS0xLTEtMA_ba117f34-c510-4d56-9eb8-c5a31237bc6e"
      unitRef="usd">228000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMTEtMS0xLTA_ff410134-24dd-41bb-b4c4-a33d83dd50ef"
      unitRef="usd">515000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMTMtMS0xLTA_1e79d254-a56c-4810-8540-de0150c63040"
      unitRef="usd">-195000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMTUtMS0xLTA_786980b6-c30e-463f-b091-aa590467ddde"
      unitRef="usd">-101000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzUtMTctMS0xLTA_b3edbc8d-39e4-4f4f-8859-89688b1cb718"
      unitRef="usd">-188000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMS0xLTEtMA_a7c6a0ef-9136-43a3-909e-3579a30fb69b"
      unitRef="usd">-303000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMy0xLTEtMA_e37130f3-829c-4933-8071-5b17712bee1f"
      unitRef="usd">-151000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtNS0xLTEtMA_3a2ed87e-8e48-4ef1-9484-85c7256b28d7"
      unitRef="usd">-232000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtNy0xLTEtMA_63b3e6e8-c926-459f-842c-f14943b428fd"
      unitRef="usd">-127000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtOS0xLTEtMA_6a836a46-b617-42a4-a16d-cbd7d186e553"
      unitRef="usd">-64000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMTEtMS0xLTA_feae44a2-1c90-4533-8417-056d1c95b25a"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMTMtMS0xLTA_e6e3a8be-aec7-4e2a-beb3-7d6e37ee702a"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMTUtMS0xLTA_fd657adc-3142-473c-9e5e-71f32da9bf5b"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzYtMTctMS0xLTA_fd817c52-0d5c-4278-8497-d9ffc0851ca0"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMS0xLTEtMA_019cb988-1658-4ab8-89eb-e39c8eefc3fc"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMy0xLTEtMA_e3f9b62f-a2a4-4c3d-96da-867136502523"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctNS0xLTEtMA_b6695a49-e628-462a-b8ad-c298ddcc1140"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctNy0xLTEtMA_150b07d5-3ddc-4662-b146-77c6fee7eceb"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctOS0xLTEtMA_b1030d03-bf4b-4493-9c38-71c15f54e22e"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMTEtMS0xLTA_7a80a4e2-68c4-4249-91be-057da14747ca"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMTMtMS0xLTA_ea6690ec-4b15-4f22-a145-bc816f24b991"
      unitRef="usd">-73000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMTUtMS0xLTA_a70b44c7-5a99-4791-91ed-956e0783a910"
      unitRef="usd">-78000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzctMTctMS0xLTA_5e3437eb-02ae-4dac-a861-c46bfa834789"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i70d26d3aaefa420f9dc535a69eb81a25_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMS0xLTEtMA_db82eafe-c22a-42b1-83d1-03ff1c39e688"
      unitRef="usd">254000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="if421236fa4a541d68ad4ca4e59f6c971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMy0xLTEtMA_09cf113b-6378-41ac-8f3a-1a9dc25e3ca0"
      unitRef="usd">102000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="ib2b57e32c3154201b0b774c2ca4d582a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtNS0xLTEtMA_1a0890aa-9c77-4a2a-9553-c45a42d56604"
      unitRef="usd">182000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtNy0xLTEtMA_8aae91d5-5191-4dc4-8c23-9eb5e3f44d16"
      unitRef="usd">109000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtOS0xLTEtMA_11f3555d-b850-4d02-ba50-aab56df65c43"
      unitRef="usd">52000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMTEtMS0xLTA_357bb804-6b15-41d3-9e59-4440109d4f72"
      unitRef="usd">71000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMTMtMS0xLTA_7e6c3303-8155-409b-a329-371b2c51d8cb"
      unitRef="usd">-91000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i4af508ebd720423d8aa53a468a7d94de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMTUtMS0xLTA_7df07f20-56f0-42c6-84fd-ec47dfc2bc0f"
      unitRef="usd">-88000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="ia25221b92b814bf59e9e1fec08d727bd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo4OTY3NDAyNTQ2Mzg0MzkwYmQ4ZWZhMzM0ZjMwZTk4YS90YWJsZXJhbmdlOjg5Njc0MDI1NDYzODQzOTBiZDhlZmEzMzRmMzBlOThhXzgtMTctMS0xLTA_78db44dd-4836-4a99-8605-b0ce78c4607e"
      unitRef="usd">-83000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MDk_187f27ee-ea01-4173-8c54-7dda50f39d37">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Pension&#160;and&#160;Other&lt;br/&gt;Postretirement&#160;Benefit&#160;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtMS0xLTEtMA_ec037003-f22c-43cb-8bf9-73898063cc6a"
      unitRef="number">0.0340</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtMy0xLTEtMA_d20f0f1c-e36e-4c96-b684-626118e72b96"
      unitRef="number">0.0440</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtNS0xLTEtMA_5f80254b-4286-49be-b93b-d3633605c1a3"
      unitRef="number">0.0370</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtNy0xLTEtMA_51f47b97-cf15-4295-bcf2-3f5107800cf3"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtOS0xLTEtMA_dc1133a5-b52d-449a-adc8-5af32fc4d943"
      unitRef="number">0.0220</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzMtMTEtMS0xLTA_bfb8c02a-8bac-405f-868a-9beca51d45b5"
      unitRef="number">0.0210</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtMS0xLTEtMA_f7c112fb-de5e-4f3b-827a-bd3355480218"
      unitRef="number">0.0730</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtMy0xLTEtMA_86f1e50e-ec8e-41bf-b805-0b28f79e4942"
      unitRef="number">0.0810</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtNS0xLTEtMA_888a9887-6625-43c6-816c-797df0e2eb94"
      unitRef="number">0.0820</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtNy0xLTEtMA_d730ec27-5cce-4008-baf3-5397cebc596d"
      unitRef="number">0.0440</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtOS0xLTEtMA_c0b7848a-329a-4178-ac20-568cc52cbfa9"
      unitRef="number">0.0490</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzQtMTEtMS0xLTA_5891d2e2-a477-4b69-b85e-c62526d5b2ab"
      unitRef="number">0.0510</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtMS0xLTEtMA_2745e660-9ec7-43a2-bae0-9e16b997430a"
      unitRef="number">0.0420</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtMy0xLTEtMA_4371490e-78a1-402e-a5b5-9ffa12d30711"
      unitRef="number">0.0430</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtNS0xLTEtMA_3cbf3fce-93c6-4d7b-ae99-dac3d3b7189f"
      unitRef="number">0.0430</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtNy0xLTEtMA_8270af42-5260-4c6b-a0f0-4f8995d57069"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtOS0xLTEtMA_c1fba91b-dfab-4310-808f-56069b217b74"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzUtMTEtMS0xLTA_9310e618-1479-4f2b-b6d4-9ebf82dab739"
      unitRef="number">0.0290</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtMS0xLTEtMA_ccf64d8d-71b3-4d88-a9f4-d26a110105ce"
      unitRef="number">0.0490</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i37dccf7b51864ce6ac1f90918ae004ce_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtMy0xLTEtMA_60f52e62-de5d-44e8-9637-a2832e360dbf"
      unitRef="number">0.0340</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i88d3da4478fa4714bf4a5845265058cc_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtNS0xLTEtMA_65f12635-eba5-4e67-b5e8-bd3e0ac28cec"
      unitRef="number">0.0330</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="id3904142e5a54c00990a8925a4162afb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtNy0xLTEtMA_e6016f1b-f781-4414-894f-ac8397110c2d"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="ie4ecaa04cb534d8cb7aa51dbd73385af_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtOS0xLTEtMA_3204ad1a-d18a-496e-8c46-75c5b6fe66f2"
      unitRef="number">0.0290</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i89ca92cb30d34368ba8bef89d28ca07e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzYtMTEtMS0xLTA_4d58e680-5cff-45f9-b4cf-f639ebe6ac72"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="iafec61eba0f44b598174decf94362de9_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtMS0xLTEtMA_aa55cfd9-afcc-4d3e-ad81-52b8415d7c04"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i2d4c0e028b3f47a5a748c2576dd13eb8_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtMy0xLTEtMA_bec0ee65-9456-4f1b-b069-da53ff19dd6b"
      unitRef="number">0.0340</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="icac8719a9476464ca9bf1d1a240d1510_I20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtNS0xLTEtMA_f0f4e964-dee1-49f2-bbe0-5ed0e55881c4"
      unitRef="number">0.0440</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtNy0xLTEtMA_e608bfd4-5fc6-46a8-b0c2-9e37f37b36e9"
      unitRef="number">0.0110</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtOS0xLTEtMA_6d49473e-4f27-4b47-ad07-1bf0e2423428"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzgtMTEtMS0xLTA_a6343f79-c430-43e1-a8d2-6c5d9e844493"
      unitRef="number">0.0220</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="iafec61eba0f44b598174decf94362de9_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktMS0xLTEtMA_35cccd83-ab85-4743-86e9-b465adc65716"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i2d4c0e028b3f47a5a748c2576dd13eb8_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktMy0xLTEtMA_cd56d3d1-5fe6-42ff-83e0-7c777baec175"
      unitRef="number">0.0420</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="icac8719a9476464ca9bf1d1a240d1510_I20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktNS0xLTEtMA_20d5709d-b32d-45b2-960f-d1e1f6f7a404"
      unitRef="number">0.0430</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktNy0xLTEtMA_e4530a67-dc0c-49a3-aab2-9b1c05895577"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktOS0xLTEtMA_84b96717-b177-4429-b402-f4b3cb56d070"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzktMTEtMS0xLTA_8e278c49-097b-45ef-bd5d-2e50dd496337"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="iafec61eba0f44b598174decf94362de9_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTEtMS0xLTA_9578a05d-b871-4135-a3ed-1c3f8277fbe0"
      unitRef="number">0.0470</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i2d4c0e028b3f47a5a748c2576dd13eb8_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTMtMS0xLTA_807d51da-584c-4ba6-add2-e8c48100515a"
      unitRef="number">0.0490</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="icac8719a9476464ca9bf1d1a240d1510_I20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTUtMS0xLTA_d6d13e20-e6e1-45e7-be5f-e7a45d9c2f50"
      unitRef="number">0.0340</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i2c1e48b9c0aa43d4a297be83318ec9e1_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTctMS0xLTA_5bd7b8fc-523f-4d1d-b64b-20b59565a8d1"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i537a35ed55a14a679dacba9b73800613_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTktMS0xLTA_1073a957-d151-4c78-9193-2ea136979a4b"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="iebb5f2e4d88a4bd59f3acc17dffb019c_I20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTo5NzRiMmVkNTU1Njc0ZWY0YTQ4ODExZWZkNzNiZDJlMy90YWJsZXJhbmdlOjk3NGIyZWQ1NTU2NzRlZjRhNDg4MTFlZmQ3M2JkMmUzXzEwLTExLTEtMS0w_b67453cb-b9a2-4bf0-b7dd-b2f6ef0394fa"
      unitRef="number">0.0290</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i7410576a916e42d4bcc349b678e87d26_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzg2MzU_b49d0957-1720-4d4d-9ea2-4b2ef91bf394"
      unitRef="number">0.0650</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i405bca874530481997ce79928dac111d_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzg2NDE_435210d3-3e15-493f-88d5-b8703775bd53"
      unitRef="number">0.0670</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i6481cbf5e20244beada5e16fb8e1c7db_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzg2NzE_9f00e878-d5d7-46b5-9371-eab88158153b"
      unitRef="number">0.0700</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i3b9b18bf3f2b43149e469b0523aeec6f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzg2Nzc_98326f99-d22d-4113-8b02-82248936d27c"
      unitRef="number">0.0730</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzk0MzU_2f89987b-dd37-496f-aaa1-035394cbff6d">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The health care cost trend rate assumptions for other postretirement benefit plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year that the trend rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTozZmZmMzdmMjBlNTg0NDY4OTU1YmM5NDkzNjE5ZGY1YS90YWJsZXJhbmdlOjNmZmYzN2YyMGU1ODQ0Njg5NTViYzk0OTM2MTlkZjVhXzEtMS0xLTEtMA_51db95d1-52fb-4dc7-9d3f-fef034c30855"
      unitRef="number">0.066</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTozZmZmMzdmMjBlNTg0NDY4OTU1YmM5NDkzNjE5ZGY1YS90YWJsZXJhbmdlOjNmZmYzN2YyMGU1ODQ0Njg5NTViYzk0OTM2MTlkZjVhXzEtMy0xLTEtMA_457cdde8-0d23-442b-854b-6c66aa1475ce"
      unitRef="number">0.068</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="id8290bb9fd604f50bbd5b1c20107b822_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTozZmZmMzdmMjBlNTg0NDY4OTU1YmM5NDkzNjE5ZGY1YS90YWJsZXJhbmdlOjNmZmYzN2YyMGU1ODQ0Njg5NTViYzk0OTM2MTlkZjVhXzItMS0xLTEtMA_39b52332-1e1b-49a3-8753-db4acf8393ea"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i7b329e4def234bf9be62b33165383a04_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90YWJsZTozZmZmMzdmMjBlNTg0NDY4OTU1YmM5NDkzNjE5ZGY1YS90YWJsZXJhbmdlOjNmZmYzN2YyMGU1ODQ0Njg5NTViYzk0OTM2MTlkZjVhXzItMy0xLTEtMA_879fb241-af4c-402c-833a-b4e86f72b0e6"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzkzODE_1b8e832b-7259-40b9-a3fd-ba2b686ef2da"
      unitRef="usd">166000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzkzODU_d7897dbe-0290-4a5e-9f0b-4acaa5c87e7b"
      unitRef="usd">149000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTQvZnJhZzowMzc0ZGQ3NjUxMjc0YTYwYjg0YjA4M2NmNGM4MjUwZC90ZXh0cmVnaW9uOjAzNzRkZDc2NTEyNzRhNjBiODRiMDgzY2Y0YzgyNTBkXzkzOTI_f09c2b50-71c7-4be8-ba13-27b7ce367373"
      unitRef="usd">136000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEzNDU_18c567f2-d275-4455-9121-58dd3eb00532">Other (Income) Expense, Net&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;831&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from investments in equity securities, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net (as presented in the table above) in 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net in 2018 includes a gain of $115 million related to the settlement of certain patent litigation, income of $99 million related to AstraZeneca&#x2019;s option exercise in 2014 in connection with the termination of the Company&#x2019;s relationship with AstraZeneca LP (AZLP), and a gain of $85 million resulting from the receipt of a milestone payment for an out-licensed migraine clinical development program. Other, net in 2018 also includes $144 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8), as well as $41 million of charges related to the write-down of assets held for sale to fair value in anticipation of the dissolution of the Company&#x2019;s joint venture with Supera Farma Laboratorios S.A. in Brazil.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest paid was $822 million in 2020, $841 million in 2019 and $777 million in 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEzMzg_2c646aad-053c-4710-9c16-97332096ab77">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;831&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from investments in equity securities, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzEtMS0xLTEtMA_210c4229-089c-48d5-9f68-f23f9090306e"
      unitRef="usd">59000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzEtMy0xLTEtMA_b9690d9d-28cd-4046-9a0e-5c9f2d7b55f4"
      unitRef="usd">274000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzEtNS0xLTEtMA_c5329a25-0d56-4620-8090-de22ee84faf6"
      unitRef="usd">343000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzItMS0xLTEtMA_7ac4926a-ff68-4fb9-ab48-37980e6cd5e1"
      unitRef="usd">831000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzItMy0xLTEtMA_7a5f5eeb-5ff6-4eb0-a30c-e6dafc8f2fe6"
      unitRef="usd">893000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzItNS0xLTEtMA_ae4ba9ee-9ac9-4ecf-bcca-d5ae62b02d2e"
      unitRef="usd">772000000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzMtMS0xLTEtMA_963f3ba2-b3dd-42dd-bff1-472a712a22b2"
      unitRef="usd">-145000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzMtMy0xLTEtMA_ac0650bc-e32a-4113-8703-eb6f77d33422"
      unitRef="usd">-187000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzMtNS0xLTEtMA_47ba3625-960e-4750-8895-32b857e63959"
      unitRef="usd">-145000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzQtMS0xLTEtMA_c8aaf291-da29-491b-89e0-4a638937eb11"
      unitRef="usd">1338000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzQtMy0xLTEtMA_e53229f9-937b-44ae-8699-ee8b5d0eaa90"
      unitRef="usd">170000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzQtNS0xLTEtMA_cba8dcf6-a460-4fac-97ab-324bda2543d8"
      unitRef="usd">324000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzUtMS0xLTEtMA_c71ba14a-db16-4658-9a5f-629c655a5b5b"
      unitRef="usd">-339000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzUtMy0xLTEtMA_5a1074cd-8927-4c9e-b559-36d3cc3dd6ec"
      unitRef="usd">-545000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzUtNS0xLTEtMA_d9c74752-5f24-409a-a4d8-5c540ce65a66"
      unitRef="usd">-512000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzYtMS0xLTEtMA_2bc9454c-166e-45d0-9bd2-e80451d04f69"
      unitRef="usd">126000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzYtMy0xLTEtMA_2246ae83-4cff-4abf-98c4-4d10fd83999d"
      unitRef="usd">-48000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzYtNS0xLTEtMA_bcc09f75-b65c-4545-b29f-89cdba9057f7"
      unitRef="usd">140000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzctMS0xLTEtMA_d9d0b25f-5e23-4895-aa02-bc550f25d1f1"
      unitRef="usd">886000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzctMy0xLTEtMA_f88942b8-ccee-44c1-82ea-0b727b3355b9"
      unitRef="usd">-139000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90YWJsZTphYTg3ZTJjYjQyYjQ0MmNlOWMyNzNkMDJhODM4NDk0Yi90YWJsZXJhbmdlOmFhODdlMmNiNDJiNDQyY2U5YzI3M2QwMmE4Mzg0OTRiXzctNS0xLTEtMA_632e4da9-a987-4b93-9afd-8aa4de1d88c1"
      unitRef="usd">402000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia6314d5000824e4a8abc4c270f634a7a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzMxOQ_c4caa187-a8eb-4024-8cd7-a9e8d45636fa"
      unitRef="usd">162000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i0fdabe48bf6945578d95ee1057e5b49e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzQ3MA_60761428-5ee0-40e0-9402-5dd1559a8baf"
      unitRef="usd">115000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OtherNoncashIncome
      contextRef="i553d83c3c5324495837bdbe11f4b2eca_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzUzOQ_21eb6aa6-2bb2-48ae-9575-45160eb8de69"
      unitRef="usd">99000000</us-gaap:OtherNoncashIncome>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="id83dfd7a1bb849e1b213bae11674e00c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzY5OA_cb48795d-d804-4ad2-9c09-89844dc33b4e"
      unitRef="usd">85000000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i85b367730bb94d77b0694a73c6126ccb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzg0Mw_1d393112-e9dc-45b3-8e5f-4a02d74000ec"
      unitRef="usd">144000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzk2Nw_af4edc2d-4698-4787-87ed-1962d50bc250"
      unitRef="usd">41000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:InterestPaid
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEyOTk_7efbb4e4-dd35-44ef-91a2-83fcaa786257"
      unitRef="usd">822000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEzMDk_4bf03b86-a0db-4cb4-93df-a36d60b2f9f2"
      unitRef="usd">841000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMTcvZnJhZzo2Njc1ZjNiN2Q1ZjM0YTY4OGNhYTQ2ZTM4NjdlNGJjYS90ZXh0cmVnaW9uOjY2NzVmM2I3ZDVmMzRhNjg4Y2FhNDZlMzg2N2U0YmNhXzEzMjI_50e1cf97-f953-4355-9bb5-a5aa98aefdc2"
      unitRef="usd">777000000</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc4ODE_ccd8962f-4927-49dd-9b74-08b4d0bb70bc">Taxes on Income&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate applied to income before taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Differential arising from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;GILTI and the foreign-derived intangible income deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;364&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of VelosBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of OncoImmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related costs, including amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Peloton&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Cuts and Jobs Act of 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017 and the Company reflected the impact of the TCJA in its 2017 financial statements. However, since application of certain provisions of the TCJA remained subject to further interpretation, in certain instances the Company made reasonable estimates of the effects of the TCJA, which were since finalized and resulted in additional income tax expense in 2018 and 2019. The Company&#x2019;s remaining transition tax liability under the TCJA, which has been reduced by payments and the utilization of foreign tax credits, was $3.0 billion at December&#160;31, 2020, of which $390 million is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the remainder of $2.6 billion is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the United States, particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2022), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. Towards the end of 2020, a new reduced tax rate arrangement was agreed to in Switzerland for certain newly active legal entities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before taxes consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,791&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taxes on income consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(668)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product intangibles and licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pensions and other postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;834&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses and other tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,677&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,556&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,677&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2020, $464 million of deferred taxes on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $433 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $330 million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards, all of which are expected to be fully utilized prior to expiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes paid in 2020, 2019 and 2018 were $2.7 billion, $4.5 billion and $1.5 billion, respectively. Tax benefits relating to stock option exercises were $55 million in 2020, $65 million in 2019 and $77 million in 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,537&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amounts in 2019 reflects the settlement with the IRS discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Amount in 2019 includes $78 million related to the divestiture of Merck&#x2019;s Consumer Care business in 2014.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company were to recognize the unrecognized tax benefits of $1.5 billion at December&#160;31, 2020, the income tax provision would reflect a favorable net impact of $1.5 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2020 could decrease by up to approximately $160 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#x2019;s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $27 million in 2020, $(101) million in 2019 and $51 million in 2018. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $268 million and $243 million as of December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck&#x2019;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company&#x2019;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $364 million net tax benefit in 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IRS is currently conducting examinations of the Company&#x2019;s tax returns for the years 2015 and 2016. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#x2019;s income tax returns are open for examination for the period 2003 through 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc5MTU_8d17dc6c-e41f-4c77-a3eb-38af342f1491">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate applied to income before taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Differential arising from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;GILTI and the foreign-derived intangible income deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;364&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of VelosBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of OncoImmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related costs, including amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Peloton&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Cuts and Jobs Act of 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItMS0xLTEtMA_cea9c812-5a5b-4822-9207-19855c35acec"
      unitRef="usd">1846000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItMy0xLTEtMA_e742ce49-fa81-4d0c-a581-46244932d978"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItNS0xLTEtMA_352c14e6-3b87-4dd1-9e7d-e91acbfe4a8d"
      unitRef="usd">2408000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItNy0xLTEtMA_c95b5ba0-10fc-4274-b00b-6f09883e077a"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItOS0xLTEtMA_9bf52cc4-b110-4eb2-9b45-5cbca25b7d17"
      unitRef="usd">1827000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzItMTEtMS0xLTA_2cffb381-d38a-45b0-a36c-8a4de41d39b2"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtMS0xLTEtMA_41ec19c0-399a-4522-a7e2-4cf94cd58738"
      unitRef="usd">-1242000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtMy0xLTEtMA_29394117-0feb-4ec8-9ba5-15c048c9d9f0"
      unitRef="number">-0.141</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtNS0xLTEtMA_b158a53d-c60b-4a95-ba55-66f01adfe5bc"
      unitRef="usd">-1020000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtNy0xLTEtMA_3e500532-797a-48ab-953c-8eddd7179a2d"
      unitRef="number">-0.089</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtOS0xLTEtMA_84790aa6-1ab3-47c4-a7f7-b0fa3d2ed97b"
      unitRef="usd">-245000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzQtMTEtMS0xLTA_66a48381-60eb-4c6a-94fc-3f4bf23cdc45"
      unitRef="number">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtMS0xLTEtMA_3543c0ff-c6af-4991-9fe9-a6ba535a5dd3"
      unitRef="usd">364000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtMy0xLTEtMA_b82a0d1e-e632-494f-bf53-50089beedc71"
      unitRef="number">0.041</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtNS0xLTEtMA_24f26c1d-dc10-47cb-9d6a-188ca56d7223"
      unitRef="usd">336000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtNy0xLTEtMA_5b672944-b94f-4545-a01e-eaf2bc79e2e0"
      unitRef="number">0.029</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtOS0xLTEtMA_0f59de9e-fff0-4957-8e32-3217beb9a0ff"
      unitRef="usd">-25000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzUtMTEtMS0xLTA_33c55049-8e69-410e-a771-2aaab18cb769"
      unitRef="number">-0.003</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctMS0xLTEtMA_312e30ff-1ae3-4f2f-84f6-25727d22664a"
      unitRef="usd">110000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctMy0xLTEtMA_b47b6716-5311-44e7-8105-ae0aecb4e334"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctNS0xLTEtMA_10edb35a-5ad4-4fb5-b52b-249a2ed317f8"
      unitRef="usd">118000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctNy0xLTEtMA_8d222bf5-4fa0-4e9b-bf95-636f56c8964b"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctOS0xLTEtMA_a43a8a69-1575-4481-b1ac-18dfb59e5b58"
      unitRef="usd">96000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzctMTEtMS0xLTA_f8c64591-31bc-47f5-9d9b-dcb9bc2a31ea"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMS0xLTEtMTU3NjA_c79b6c89-52bb-42bd-8004-afec6dd3cf48"
      unitRef="usd">-13000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMy0xLTEtMTU3NjA_9e10489a-cb9a-4eed-be86-bc695c418a6d"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNS0xLTEtMTU3NjA_46742e4d-282b-43cd-a559-b550212d21d7"
      unitRef="usd">-403000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNy0xLTEtMTU3NjA_49ae0be2-18a7-4e7e-affc-2a7def3dae84"
      unitRef="number">-0.035</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktOS0xLTEtMTU3NjA_528cd862-1f4b-4124-acc7-1b4dddc73122"
      unitRef="usd">-22000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMTEtMS0xLTE1NzYw_4e836606-4eca-43e4-b7e6-cda97b43b69c"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMS0xLTEtMTU3ODg_90d1acbb-6a7e-4cad-a2a8-cd34f9ebb161"
      unitRef="usd">559000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMy0xLTEtMTU3ODg_116b0832-038d-4f24-9e5a-c23d4a78944b"
      unitRef="number">0.063</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNS0xLTEtMTU3ODg_4a25aae2-dc5e-48c2-9bb8-e1462fdca70d"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNy0xLTEtMTU3ODg_f0d9bc08-ac17-4410-81f8-b26c643982fc"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktOS0xLTEtMTU3ODg_74b7f08b-9756-463b-8dc8-3d313147c272"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMTEtMS0xLTE1Nzg4_9474c9d4-e21a-4667-b378-472b48dad8d0"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMS0xLTEtMTU3NzE_ef3b7687-3c8a-4603-9350-c2a84fd7a791"
      unitRef="usd">105000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMy0xLTEtMTU3NzE_6221e6ef-5bcd-4ec6-ab0d-3a886b6d82b3"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNS0xLTEtMTU3NzE_d342570b-18e5-489b-91ed-bab9ffe51944"
      unitRef="usd">39000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNy0xLTEtMTU3NzE_603134ce-edfb-4136-9025-15fa16486322"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktOS0xLTEtMTU3NzE_5635debc-d484-4259-a52b-d43d82fdd5a1"
      unitRef="usd">56000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMTEtMS0xLTE1Nzcx_52107305-585b-4414-ba1f-03fd7b611577"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTEtMS0xLTE1Nzg0_1be8f00c-ad1e-4977-863f-bb1fd57cd03a"
      unitRef="usd">97000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTMtMS0xLTE1Nzg0_1cec0988-981a-46f1-a4de-914b9f1e2582"
      unitRef="number">0.011</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTUtMS0xLTE1Nzg0_3d11f972-b028-4b92-98ff-37f784d3f2a7"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTctMS0xLTE1Nzg0_6f0440d6-4a7e-4c6c-b21b-ca32872ad918"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTktMS0xLTE1Nzg0_6ec9d58d-258b-4c73-9b23-0753ed143813"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzExLTExLTEtMS0xNTc4NA_50d802c2-1182-4d01-b2db-127532cad9bc"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtMS0xLTEtMA_847909a7-cdaa-4f31-9a33-41c94c7dbce1"
      unitRef="usd">67000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtMy0xLTEtMA_8446d44e-9e28-4bd7-9e08-dac0a6424140"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtNS0xLTEtMA_80a96408-19b7-4269-9a5b-6cf63c409bfe"
      unitRef="usd">-2000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtNy0xLTEtMA_061f5fce-3b2b-4637-b135-42b4e1ef7bb9"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtOS0xLTEtMA_7f43fd49-f999-400c-8d01-bc34bc427638"
      unitRef="usd">201000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzgtMTEtMS0xLTA_7fba8185-eb83-4ab1-9a5c-14cdb151081e"
      unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTEtMS0xLTE1Nzky_5d333047-45b5-41c7-a093-26cdbbe1b210"
      unitRef="usd">46000000</mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTMtMS0xLTE1Nzky_ac66bc02-85df-465e-9222-1b7214c28401"
      unitRef="number">0.005</mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTUtMS0xLTE1Nzky_3065a088-52b8-4937-bce3-b6c0e68a6f2b"
      unitRef="usd">95000000</mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTctMS0xLTE1Nzky_37e2d7f5-c45e-43e6-99e3-d92db0a4ebeb"
      unitRef="number">0.008</mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTktMS0xLTE1Nzky_d6ae4648-30ab-44f3-adf6-99a232e3f2b5"
      unitRef="usd">267000000</mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEzLTExLTEtMS0xNTc5Mg_18aba023-0d77-4deb-8fba-887773ec2f42"
      unitRef="number">0.031</mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTEtMS0xLTE5MjAw_64826288-2341-48de-ab54-2d44347eeeff"
      unitRef="usd">42000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTMtMS0xLTE5MjAw_3416beb9-373a-4c02-ae2c-643e30f57914"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTUtMS0xLTE5MjAw_816463c4-41aa-4d3d-8a64-2d12515c3291"
      unitRef="usd">113000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTctMS0xLTE5MjAw_6430e1cd-22bc-4a0b-a68f-f04779131a93"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTktMS0xLTE5MjAw_76ab9adb-74f9-4dba-9078-bc13e538cff5"
      unitRef="usd">269000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTExLTEtMS0xOTIwMA_f077c681-7bc6-41af-b8c4-259afaed3cd7"
      unitRef="number">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMS0xLTEtMA_e18f7da6-072e-40ba-bd10-58d87fe853a4"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMy0xLTEtMA_38e4dcdd-34f9-4b31-93de-eb4ad4130e17"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNS0xLTEtMA_55e18536-61dc-4d13-9d62-59af35ea6a61"
      unitRef="usd">209000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktNy0xLTEtMA_ee6996d6-a881-4bc2-89a1-9f64b6777630"
      unitRef="number">0.018</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktOS0xLTEtMA_5d4b1aa3-35ef-447c-9238-abd55b945ae6"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzktMTEtMS0xLTA_7192c75c-1d6d-4b5b-9cad-cff13f232183"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTEtMS0xLTA_2f5dd804-542c-4f74-90f7-6e6fdabe5c66"
      unitRef="usd">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTMtMS0xLTA_52264d42-66dc-45bc-ab11-d203a89b5039"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTUtMS0xLTA_ba850996-6444-48b5-a8ed-b07c17f218d7"
      unitRef="usd">117000000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTctMS0xLTA_4fec4c19-058d-45c3-adb4-0649d78c0d08"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTktMS0xLTA_9357aff8-33a6-41ba-a98a-9b44dbed0dc5"
      unitRef="usd">289000000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzEwLTExLTEtMS0w_2eec5dbd-4081-46f0-bfb5-77b5a5649a92"
      unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTEtMS0xLTA_7e3a7125-7741-4f2a-814f-ffd95e71c059"
      unitRef="usd">-52000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTMtMS0xLTA_12938b27-d80f-42e8-b5e7-4fd701163dc8"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTUtMS0xLTA_f4b3e3b5-a3c7-4919-a8fc-300149d01c50"
      unitRef="usd">-87000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTctMS0xLTA_df263d2f-df89-41ed-a49c-86f961192215"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTktMS0xLTA_955d126e-b660-4a9b-954b-e30c0a84ba74"
      unitRef="usd">-13000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE0LTExLTEtMS0w_199d90cd-d638-4a25-9d36-625de6b3a8eb"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTEtMS0xLTA_55c38b07-3499-481b-b854-48235ebb15ba"
      unitRef="usd">1709000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTMtMS0xLTA_d6075f97-d32c-4829-881e-240f5f034d40"
      unitRef="number">0.194</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTUtMS0xLTA_8d4cb446-399b-460c-ac17-075fab13895b"
      unitRef="usd">1687000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTctMS0xLTA_aba979b8-1ce4-46cd-9e2e-0768a0c2f169"
      unitRef="number">0.147</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTktMS0xLTA_9a415e66-2402-4ce5-9f46-06cbb9ac4436"
      unitRef="usd">2508000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTpiZTE4NjBkNmMwMTA0N2FmOTE4ZTZiYjlhOThlMDNhNS90YWJsZXJhbmdlOmJlMTg2MGQ2YzAxMDQ3YWY5MThlNmJiOWE5OGUwM2E1XzE1LTExLTEtMS0w_ebcb5c5b-530c-47f1-908e-9df4611343ad"
      unitRef="number">0.288</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzIzMTg_39f5e8d1-2be5-4939-820d-954b7dfe81cd"
      unitRef="usd">3000000000.0</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent
      contextRef="i0b58a3ac34da4fe8ae1aff48a5e4e450_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzIzMzc_f4118ac4-d9e2-47c6-be42-a5094f54c6b8"
      unitRef="usd">390000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent
      contextRef="if2ea8b16632d441e9fe3b895f38cce6e_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzIzOTc_39b843e3-b87f-4be9-bd92-7a5a3f5fa5cb"
      unitRef="usd">2600000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc5MDg_6a3f6b3d-f429-4026-98d1-26218ab99868">&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before taxes consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,791&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzEtMS0xLTEtMA_06104f4b-3e09-42bb-b5a8-2fd259f19b8d"
      unitRef="usd">-3492000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzEtMy0xLTEtMA_fcebafb5-c0b4-4e8e-b68b-8c0d063382c5"
      unitRef="usd">439000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzEtNS0xLTEtMA_59141ce4-07ab-4ef7-9dd4-f3234f78aba8"
      unitRef="usd">3717000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzItMS0xLTEtMA_a9557721-31b2-4ae8-b90a-1a632ed20bbd"
      unitRef="usd">12283000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzItMy0xLTEtMA_8714cfd0-312c-4a5a-b706-3cdaf83faf12"
      unitRef="usd">11025000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzItNS0xLTEtMA_ea7871e9-8e5f-4eb9-8ff2-5fc7b9fc7c7c"
      unitRef="usd">4984000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzMtMS0xLTEtMA_d2f1a112-96d0-475f-9c48-366c3364362b"
      unitRef="usd">8791000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzMtMy0xLTEtMA_b95aa049-e553-4920-8f51-1356703e1778"
      unitRef="usd">11464000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo1YzNjY2JhMGFkYTg0NDRiODY5NDRiZmRkMjFmNmYxNC90YWJsZXJhbmdlOjVjM2NjYmEwYWRhODQ0NGI4Njk0NGJmZGQyMWY2ZjE0XzMtNS0xLTEtMA_1803a6c0-82b4-46bc-b254-83db9a2cbe08"
      unitRef="usd">8701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc4NzI_7ab40062-73dc-42a8-aae3-46cfb6c6fcc4">&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taxes on income consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(668)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzItMS0xLTEtMA_63b56f05-5bf1-4e2a-902e-e8b48ec37c1c"
      unitRef="usd">962000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzItMy0xLTEtMA_4f6b5507-b6ca-4808-b381-0d64ca208d84"
      unitRef="usd">514000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzItNS0xLTEtMA_9779f524-e963-41ae-aa19-c007f696d9e1"
      unitRef="usd">536000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzMtMS0xLTEtMA_8154f4d3-ba78-405a-afde-2ce07dc0a25e"
      unitRef="usd">1362000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzMtMy0xLTEtMA_b7f9f503-e22c-4527-8a55-33a0fe0e1247"
      unitRef="usd">1806000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzMtNS0xLTEtMA_1f020630-4105-404d-a0cf-2bd1afd0e1c9"
      unitRef="usd">2281000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzQtMS0xLTEtMA_168cf810-95b2-4b5c-9a4f-636f9840be62"
      unitRef="usd">53000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzQtMy0xLTEtMA_e296d7dd-74a7-4c5d-b699-0a9d94f76fce"
      unitRef="usd">-77000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzQtNS0xLTEtMA_cf246fb1-3435-4bcb-87ce-436872d81433"
      unitRef="usd">200000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzUtMS0xLTEtMA_d460bdf0-d091-48ab-b957-778d7cc6b582"
      unitRef="usd">2377000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzUtMy0xLTEtMA_ec27226c-5dd6-46b3-b433-5420638d48e4"
      unitRef="usd">2243000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzUtNS0xLTEtMA_52cef32c-0669-4c46-bac5-380b979301bc"
      unitRef="usd">3017000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzctMS0xLTEtMA_3abbe200-be61-413b-95a6-d2195cb26506"
      unitRef="usd">-605000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzctMy0xLTEtMA_43695ec2-8f30-47ee-951b-302b48b31f3b"
      unitRef="usd">-330000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzctNS0xLTEtMA_ba1cd240-c1da-4590-bfe0-fef9c301326d"
      unitRef="usd">-402000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzgtMS0xLTEtMA_cd9aaa31-c1b5-4694-aeae-815a1ed5cf70"
      unitRef="usd">-40000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzgtMy0xLTEtMA_2a52cd97-b0ba-43af-bbdd-924fc891a8c4"
      unitRef="usd">-240000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzgtNS0xLTEtMA_16eb9106-a8ea-4038-a63d-160753fcaa31"
      unitRef="usd">-64000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzktMS0xLTEtMA_bafe57a2-c0f2-44ab-a8c3-a5da62f0c91e"
      unitRef="usd">-23000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzktMy0xLTEtMA_d7eca2f6-379d-409a-b2fc-33630028d871"
      unitRef="usd">14000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzktNS0xLTEtMA_b29829d9-f04b-48be-ab20-b886a7b160f0"
      unitRef="usd">-43000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzEwLTEtMS0xLTA_0f2f172b-fc71-418c-868d-f1064f4965a5"
      unitRef="usd">-668000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzEwLTMtMS0xLTA_c9823c55-e6ab-459f-a289-032333322e1c"
      unitRef="usd">-556000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzEwLTUtMS0xLTA_0318081f-6fe1-43f9-a428-35ece5ffa360"
      unitRef="usd">-509000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzExLTEtMS0xLTA_f6efbbe7-3fbd-41f0-a056-e7e737fb10ad"
      unitRef="usd">1709000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzExLTMtMS0xLTA_42c6c8be-6395-428e-a899-65a733e0bec2"
      unitRef="usd">1687000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowMGQ2YWI3ZTdmOTA0YWVlODE3MjQ0Y2I4YTRkNzY4OC90YWJsZXJhbmdlOjAwZDZhYjdlN2Y5MDRhZWU4MTcyNDRjYjhhNGQ3Njg4XzExLTUtMS0xLTA_1c7cd009-4a89-4afd-9581-87dba1801d9e"
      unitRef="usd">2508000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc4OTY_fc2aa135-ca62-4fd2-ba02-e6a896cd7273">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product intangibles and licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pensions and other postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;834&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses and other tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,677&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,556&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,677&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzItMS0xLTEtMA_633cff31-3305-450e-976e-146383ccef56"
      unitRef="usd">141000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzItMy0xLTEtMA_21ae9bf8-5bad-468e-ae26-e5134f637fd1"
      unitRef="usd">1250000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzItNS0xLTEtMA_df5dd61e-7657-4a4f-b169-02b16f279561"
      unitRef="usd">442000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzItNy0xLTEtMA_6832521c-c510-49b9-a466-bdccb1c35380"
      unitRef="usd">1778000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzMtMS0xLTEtMA_42da397a-9d3b-4c8f-980c-fa0d42791076"
      unitRef="usd">43000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzMtMy0xLTEtMA_14c8f840-9190-4fd8-97ac-b9486b7126ce"
      unitRef="usd">335000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzMtNS0xLTEtMA_31554b2c-d841-48a9-bd20-7a8e0c0feee5"
      unitRef="usd">32000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzMtNy0xLTEtMA_2d1cf424-1db9-4931-af1b-b132c0ce4e04"
      unitRef="usd">354000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzQtMS0xLTEtMA_89b8855a-3e16-40ea-9463-48ce58761eb4"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzQtMy0xLTEtMA_0afa964e-9d13-449c-b140-42c23ca58a6f"
      unitRef="usd">588000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzQtNS0xLTEtMA_bab80780-846d-41fd-b116-a5e1137e05d4"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzQtNy0xLTEtMA_b06f18e3-a0a7-4f17-b0b4-f07ca2527d49"
      unitRef="usd">594000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtMS0xLTEtMTY4NDk_b45344ab-8dde-4938-9e90-e3106af7151b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <mrk:DeferredTaxLiabilitiesEquityMethodInvestment
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtMy0xLTEtMTY4NDk_9b85169a-1343-4d6f-8f71-bffe1b7392f6"
      unitRef="usd">175000000</mrk:DeferredTaxLiabilitiesEquityMethodInvestment>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtNS0xLTEtMTY4NDk_d4eb1b00-9bb8-4c91-ace7-b643e0f25bf8"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <mrk:DeferredTaxLiabilitiesEquityMethodInvestment
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtNy0xLTEtMTY4NDk_258c441f-072c-4615-8e74-f557120eddca"
      unitRef="usd">0</mrk:DeferredTaxLiabilitiesEquityMethodInvestment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtMS0xLTEtMA_daafbf36-5123-4276-8f8e-4602ad67cf77"
      unitRef="usd">834000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtMy0xLTEtMA_a310d20a-b0a5-4e15-9de9-c985698ce6fa"
      unitRef="usd">248000000</mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtNS0xLTEtMA_5be590d5-4971-4fee-aab0-5a8bf42964ff"
      unitRef="usd">785000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzUtNy0xLTEtMA_ece56f11-195e-446c-be5c-0e5685dfc924"
      unitRef="usd">191000000</mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzYtMS0xLTEtMA_91231ea1-636e-469d-80f5-1b43303a4956"
      unitRef="usd">252000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzYtNS0xLTEtMA_15b38f9d-3a2d-4e74-a703-5c625cfcf44a"
      unitRef="usd">322000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <mrk:DeferredTaxAssetsUnrecognizedTaxBenefits
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzctMS0xLTEtMA_ed80cfd1-c512-4942-b0a3-5e9344fc0c32"
      unitRef="usd">117000000</mrk:DeferredTaxAssetsUnrecognizedTaxBenefits>
    <mrk:DeferredTaxAssetsUnrecognizedTaxBenefits
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzctNS0xLTEtMA_5981dd89-86ae-49ba-a9fa-fa64d46a71fd"
      unitRef="usd">109000000</mrk:DeferredTaxAssetsUnrecognizedTaxBenefits>
    <mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzgtMS0xLTEtMA_2ec6c227-afef-43e7-ad12-1d6d49f6bcda"
      unitRef="usd">794000000</mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards>
    <mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzgtNS0xLTEtMA_529ed6fa-9bb7-41fa-8c35-2b34e12319aa"
      unitRef="usd">897000000</mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzktMS0xLTEtMA_5bc4e822-aeae-4c8a-9b02-9060dd85bd57"
      unitRef="usd">808000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzktMy0xLTEtMA_892e7c1e-0631-44c6-9e09-fc067debcdaa"
      unitRef="usd">81000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzktNS0xLTEtMA_8774f422-285b-44fe-9e0f-fa8f56ee6e8c"
      unitRef="usd">764000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzktNy0xLTEtMA_91fbb155-7314-4cbc-8f63-161323108dd7"
      unitRef="usd">84000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEwLTEtMS0xLTA_59dfe0c6-0266-44d1-b852-28a7cd6ab249"
      unitRef="usd">2989000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEwLTMtMS0xLTA_a33735e6-213b-4142-8f36-47c19ea21089"
      unitRef="usd">2677000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEwLTUtMS0xLTA_6c86e6e3-54b3-42dd-8572-1a3d6716a605"
      unitRef="usd">3351000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEwLTctMS0xLTA_59ae9e4d-1a66-4ad4-ad5e-aca9e94ecade"
      unitRef="usd">3001000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzExLTEtMS0xLTA_43e7dac5-8876-49a2-b4fb-7a736c82e1b2"
      unitRef="usd">433000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzExLTUtMS0xLTA_a0a3274b-d246-493f-ae70-f9de4b64866c"
      unitRef="usd">1100000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEyLTEtMS0xLTA_bfff0796-dfcb-4feb-ad0e-7532efe3c6d4"
      unitRef="usd">2556000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEyLTMtMS0xLTA_e5692d6b-12eb-47dd-a7dd-bf830768c264"
      unitRef="usd">2677000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEyLTUtMS0xLTA_be83d8ba-1072-49ee-9553-749132f4a63d"
      unitRef="usd">2251000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEyLTctMS0xLTA_54346b97-af81-418b-a3e6-d954f111e5b1"
      unitRef="usd">3001000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEzLTMtMS0xLTA_8b3c88c7-0340-4f9c-8455-f7b3cbc1a95a"
      unitRef="usd">121000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzEzLTctMS0xLTA_7b1e4b31-08ee-4b42-a190-3ae792971f1a"
      unitRef="usd">750000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="idf552eeb0d424605ab9e87eb7385fe42_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzE1LTEtMS0xLTA_815964a7-ef5e-42d0-8fe8-ffc29dd51311"
      unitRef="usd">894000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ic82df9d4f97443e485af19b6f535a820_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzE1LTUtMS0xLTA_cc8ce7bb-21b7-46e5-b399-d5c2766609a5"
      unitRef="usd">719000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzE2LTMtMS0xLTA_5d52fa05-7d61-46fe-b10a-bb4aa36d805f"
      unitRef="usd">1015000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTowYmYwYWEyZDVkOGE0MjE3YTc0NjE2YTc2MDA3YzEwMi90YWJsZXJhbmdlOjBiZjBhYTJkNWQ4YTQyMTdhNzQ2MTZhNzYwMDdjMTAyXzE2LTctMS0xLTA_e3881e27-67f3-49c1-9c28-277082208e23"
      unitRef="usd">1470000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQxMzg_dbd1cbe6-a1c9-48bf-844a-41203a4b64c8"
      unitRef="usd">464000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="ibc9efe0064ee4c049327821352c6c0bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQyMzc_7269bdcd-d64b-4e1c-82d1-d3f2b76dc37b"
      unitRef="usd">433000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQzNjU_1bf724aa-8bdb-4644-a6ef-aec27cb10a6d"
      unitRef="usd">330000000</mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic>
    <us-gaap:IncomeTaxesPaid
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ1Njg_48105fa0-fdfa-4b3e-b41b-3ce9b4e53f87"
      unitRef="usd">2700000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ1NzI_496ad19a-cfc8-46c5-ad77-546adc3e392b"
      unitRef="usd">4500000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ1Nzk_cdde5168-2809-405b-a2f5-48c46916447f"
      unitRef="usd">1500000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ2NTA_3e109817-7021-4312-8222-0e928c828b74"
      unitRef="usd">55000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ2NjA_17d2b5eb-a2e4-46f6-8440-a5e2a6d70e69"
      unitRef="usd">65000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ2NzM_b16d4676-6899-407e-bf26-6842c64e5ed6"
      unitRef="usd">77000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzc5MDc_d86ca07e-3898-46f8-a46e-56f0775833b8">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,537&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amounts in 2019 reflects the settlement with the IRS discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Amount in 2019 includes $78 million related to the divestiture of Merck&#x2019;s Consumer Care business in 2014.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzEtMS0xLTEtMA_c2b178e3-f50e-4694-9cf9-145f74d78d46"
      unitRef="usd">1225000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzEtMy0xLTEtMA_13f9ae6e-2c53-4553-9bd9-6f6d6aa5d6be"
      unitRef="usd">1893000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2e100303069b40878e0e19c66282b95b_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzEtNS0xLTEtMA_c6f64389-bbce-4b1c-9041-21a324d6f133"
      unitRef="usd">1723000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzItMS0xLTEtMA_b5e61cc8-c4a9-4a58-bb30-fd2728a2e61a"
      unitRef="usd">298000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzItMy0xLTEtMA_96d011b7-ad0f-4b0f-8f20-3045215f61fd"
      unitRef="usd">199000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzItNS0xLTEtMA_8a7d931f-5c84-493c-bf69-8cc4c46e67ff"
      unitRef="usd">221000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzMtMS0xLTEtMA_81f1d044-f6cb-44e4-864b-d1cf68b1ee85"
      unitRef="usd">110000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzMtMy0xLTEtMA_7a6f4865-ca7b-45c2-9c1c-28c9c9fd9e7b"
      unitRef="usd">46000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzMtNS0xLTEtMA_75b65893-8df0-4260-8aa3-01b337837047"
      unitRef="usd">142000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzQtMS0xLTEtMA_33ff9a7f-f48d-4cef-9614-e1bed1f3e1bb"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzQtMy0xLTEtMA_3a20608b-5e26-412d-a93e-adb03c447b96"
      unitRef="usd">454000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzQtNS0xLTEtMA_d8ff5986-68c6-4651-8f9e-bc07425d5965"
      unitRef="usd">73000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzUtMS0xLTEtMA_0c22d998-884f-4929-9dac-ba79e0d3d9cc"
      unitRef="usd">70000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzUtMy0xLTEtMA_7173a8ec-600e-4545-bb44-1c93179f2c4b"
      unitRef="usd">356000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzUtNS0xLTEtMA_e309ecaf-99cd-4f3e-b172-84f8fa259b70"
      unitRef="usd">91000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzYtMS0xLTEtMA_68fe6531-abf1-4410-862e-93c00790c92a"
      unitRef="usd">22000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzYtMy0xLTEtMA_11a3f05a-f95c-4eb4-a5db-dcc08c65b8eb"
      unitRef="usd">103000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzYtNS0xLTEtMA_a588e310-67c8-4d9d-ab57-4b11fd1a2f05"
      unitRef="usd">29000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzctMS0xLTEtMA_00da7dcd-9f9f-4823-9c8e-5b3c5bb86a19"
      unitRef="usd">1537000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzctMy0xLTEtMA_a2395059-e766-47a4-ab10-81b10f0e52c7"
      unitRef="usd">1225000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90YWJsZTo0ZTY3YzFkMWRhOGI0NWQzOGQxYTQwOTkwYzkwMjIwNC90YWJsZXJhbmdlOjRlNjdjMWQxZGE4YjQ1ZDM4ZDFhNDA5OTBjOTAyMjA0XzctNS0xLTEtMA_0a06449e-0047-4cd8-97a2-22c7153fdffa"
      unitRef="usd">1893000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="iae848d20b3c043e09bea70d1386a41c8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzQ4ODA_743d3524-4668-45e0-935f-44397c273622"
      unitRef="usd">78000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzUwMTk_43d19836-0d8c-4f28-b503-62fe8efae06a"
      unitRef="usd">1500000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzUwOTQ_ad5a52ea-cfa5-454a-8139-10e5f1de0e25"
      unitRef="usd">1500000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzUzNDQ_66fe81c3-4ce9-4c98-ac7e-a15b816805d7"
      unitRef="usd">160000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzU5MzA_d168bd83-7a86-4ef1-8d59-2cc582698e67"
      unitRef="usd">27000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzU5NDA_f8c8686c-ce92-451a-b032-7ea267c01b0a"
      unitRef="usd">-101000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzU5NTM_e1001f7a-1864-4308-88c9-b650c4bb0b66"
      unitRef="usd">51000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzYxMjE_295651e7-a5b5-4643-9eac-88af5fffecc6"
      unitRef="usd">268000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzYxMjg_aa054c12-691d-4575-b3c4-f0cff775dda1"
      unitRef="usd">243000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxesPaid
      contextRef="i942f16eff97546a5b0fedc3f590bc635_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzYzNDY_a8a41c4a-dcc3-4153-9945-2baa1a65d315"
      unitRef="usd">107000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i942f16eff97546a5b0fedc3f590bc635_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjAvZnJhZzo5YmI0MDk1NzdjYzg0MzUxYWIwZGM5ZTE2NzhiZWU3Zi90ZXh0cmVnaW9uOjliYjQwOTU3N2NjODQzNTFhYjBkYzllMTY3OGJlZTdmXzY1MzM_9beca4f2-ece2-4702-a63f-ed14e9e9552d"
      unitRef="usd">364000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzQyMA_ff8f68f5-e7f7-4457-bf2f-5a23874a6615">Earnings per Share&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share (shares in millions) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per common share attributable to Merck &amp;amp; Co., Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per common share assuming dilution attributable to Merck &amp;amp; Co., Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, 2019 and 2018, 5 million, 2 million and 6 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzQyMw_ff38d00d-ef37-4a12-9ae3-8d5370e231a9">&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share (shares in millions) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per common share attributable to Merck &amp;amp; Co., Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per common share assuming dilution attributable to Merck &amp;amp; Co., Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzEtMS0xLTEtMA_682ac9c7-da76-40b2-98d6-5b55b6cb66b2"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzEtMy0xLTEtMA_b2f3200b-e0d6-4cc5-9850-800b6eff80cc"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzEtNS0xLTEtMA_c3c82e73-db99-4448-a662-b02ddd7ae9f5"
      unitRef="usd">6220000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzItMS0xLTEtMA_e0f1e745-4985-41da-933a-495b4a5db210"
      unitRef="shares">2530000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzItMy0xLTEtMA_47988912-3a50-49ec-866b-e6ad0f5011ce"
      unitRef="shares">2565000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzItNS0xLTEtMA_5c172609-3665-4c3b-b936-0852bb9412ff"
      unitRef="shares">2664000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzMtMS0xLTEtMA_d583d172-a1ea-4e47-b0e1-36dd03c45a8f"
      unitRef="shares">11000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzMtMy0xLTEtMA_f784be6b-7f2c-42bd-affe-1c5d249af9bb"
      unitRef="shares">15000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzMtNS0xLTEtMA_2eedb4bd-729e-42e0-a465-0199e8f60bae"
      unitRef="shares">15000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzQtMS0xLTEtMA_e268da52-f639-43ed-b43d-efd5928fbd2e"
      unitRef="shares">2541000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzQtMy0xLTEtMA_54b912dd-2b52-497c-94f0-491a7a653ddb"
      unitRef="shares">2580000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzQtNS0xLTEtMA_18ae8ca7-2459-497f-af8c-2805a345fead"
      unitRef="shares">2679000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzUtMS0xLTEtMA_d9291b21-3628-47b1-9804-4424d3bdac8e"
      unitRef="usdPerShare">2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzUtMy0xLTEtMA_cb7dd3f9-f58e-4ced-91a6-6e409ca9a25c"
      unitRef="usdPerShare">3.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzUtNS0xLTEtMA_e5a05928-08f0-418b-b446-2bfa2420aad6"
      unitRef="usdPerShare">2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzYtMS0xLTEtMA_28409934-eb52-447a-a673-aff78d9c7be4"
      unitRef="usdPerShare">2.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzYtMy0xLTEtMA_8c0eb6e0-2d55-4d62-948a-2a6dd0ec8a6b"
      unitRef="usdPerShare">3.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90YWJsZTpiYTM0M2FhMjJjOGI0MTQxOGY0OTY0YjI5YTQ0ZWJkNy90YWJsZXJhbmdlOmJhMzQzYWEyMmM4YjQxNDE4ZjQ5NjRiMjlhNDRlYmQ3XzYtNS0xLTEtMA_1b18298e-8b3d-49c2-b9c5-19b67499fc3b"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzE4OQ_43d73007-f432-4eff-9847-1492c8147a5c"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzE5Mw_9074c6ab-8476-4f25-90cb-db15027c5874"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjMvZnJhZzpkY2Q4ODQwYjU2MWM0YjBhYThmMjFmYThjOTMyYzQ0ZS90ZXh0cmVnaW9uOmRjZDg4NDBiNTYxYzRiMGFhOGYyMWZhOGM5MzJjNDRlXzIwMA_f6158d3e-376c-4bd2-b116-9100e0cdd920"
      unitRef="shares">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzExMDg_e18f908a-a242-4516-8344-e2751e6f83b2">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by component are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2018, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption of ASU 2018-02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption of ASU 2016-01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Relates to foreign currency cash flow hedges that were reclassified from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents net realized (gains) losses on the sales of available-for-sale investments that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 13).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes pension plan net loss of $5.4 billion and $5.1 billion at December 31, 2020 and 2019, respectively, and other postretirement benefit plan net gain of $391 million and $247 million at December 31, 2020 and 2019, respectively, as well as pension plan prior service credit of $255 million and $263 million at December 31, 2020 and 2019, respectively, and other postretirement benefit plan prior service credit of $244 million and $305 million at December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzExMDE_2e7a4bf3-b206-4bde-874c-f511394328c6">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by component are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2018, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption of ASU 2018-02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption of ASU 2016-01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Relates to foreign currency cash flow hedges that were reclassified from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents net realized (gains) losses on the sales of available-for-sale investments that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 13).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes pension plan net loss of $5.4 billion and $5.1 billion at December 31, 2020 and 2019, respectively, and other postretirement benefit plan net gain of $391 million and $247 million at December 31, 2020 and 2019, respectively, as well as pension plan prior service credit of $255 million and $263 million at December 31, 2020 and 2019, respectively, and other postretirement benefit plan prior service credit of $244 million and $305 million at December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2bfc40d64cf42fb9a74577988a596bf_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtMS0xLTEtMA_eafdd30a-90b9-4571-97f7-60ad7fdbe77a"
      unitRef="usd">-108000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i480e76dce93f4111adcabce9984765ce_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtMy0xLTEtMA_82649727-b487-4d6a-b607-f67c503bf2d1"
      unitRef="usd">-61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f8cc640b7474a98b853cd9c382a0cbd_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtNS0xLTEtMA_bcdc3049-abb4-4859-a188-f20860cee23e"
      unitRef="usd">-2787000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1354b93356c743609177591ddcc546e5_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtNy0xLTEtMA_81094f2f-2b15-4115-86ed-8d394b4c882a"
      unitRef="usd">-1954000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7a0cf6a00f14978ae5b1e865e6c3e41_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEtOS0xLTEtMA_38f9d8b1-4c7c-4537-9d4f-40d8bfe16cb8"
      unitRef="usd">-4910000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItMS0xLTEtMA_2600cd16-4d7b-4a65-93ef-846793e2191b"
      unitRef="usd">228000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItMy0xLTEtMA_d60be137-d4bc-4656-8b12-6b96cd57a945"
      unitRef="usd">-108000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItNS0xLTEtMA_1facb57f-c115-42a4-ae75-b9a8c3a0e9ef"
      unitRef="usd">-728000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItNy0xLTEtMA_f897dab6-e505-42c9-bde3-d19f69735f64"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzItOS0xLTEtMA_2bc93d6e-8745-439a-8662-6a46e887adf3"
      unitRef="usd">-692000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtMS0xLTEtMA_79160319-a9fe-4791-9824-61eae9e4de5e"
      unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtMy0xLTEtMA_624f57e3-7e26-4aa5-8723-67d0410fa392"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtNS0xLTEtMA_a44c9767-94e5-4bbc-9c70-8655e5fe8562"
      unitRef="usd">-169000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtNy0xLTEtMA_f6e9eb53-4359-49c7-89f0-90f28169fc66"
      unitRef="usd">139000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzMtOS0xLTEtMA_47a49db2-515d-465f-b991-370099af8836"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtMS0xLTEtMA_ca4121a2-5374-4d16-bb47-1395e99cb39f"
      unitRef="usd">173000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtMy0xLTEtMA_884dd1bd-1f50-4515-ae19-c781d9f3f778"
      unitRef="usd">-107000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtNS0xLTEtMA_b2da6cec-ef5d-40bb-b7db-3168546665fe"
      unitRef="usd">-559000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtNy0xLTEtMA_7311b9cd-f809-438f-83da-93db38771b50"
      unitRef="usd">-223000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzQtOS0xLTEtMA_8cd9f92b-f568-405a-8dfe-8929b28ca3e2"
      unitRef="usd">-716000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtMS0xLTEtMA_dbac5473-d45b-4377-a603-3efe005d9232"
      unitRef="usd">-157000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtMy0xLTEtMA_d4326fbb-b16b-4272-b617-a74fb155219f"
      unitRef="usd">-97000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtNS0xLTEtMA_caf258db-729b-45da-9635-5f9088c7e6bd"
      unitRef="usd">-170000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtNy0xLTEtMA_8d699642-36ed-4ff6-9ed9-a2c8b666b39f"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzUtOS0xLTEtMA_3928be4f-2f4f-4eaf-9a44-0cb811ad4e38"
      unitRef="usd">-424000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtMS0xLTEtMA_795d87e1-9a15-4f90-974f-84448b660062"
      unitRef="usd">-33000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtMy0xLTEtMA_857e307f-33c5-4b5b-8a66-4ed62b11a4e1"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtNS0xLTEtMA_539cd838-d3dd-4ed4-8497-a56bedd3ec83"
      unitRef="usd">-36000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtNy0xLTEtMA_1d0275ff-a377-4b67-a911-d178cbfad08f"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzYtOS0xLTEtMA_c605a9ff-86b0-49a7-9571-1a8d08145c3d"
      unitRef="usd">-69000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctMS0xLTEtMA_477c386a-55ea-4489-a1d5-787c7da432a5"
      unitRef="usd">-124000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctMy0xLTEtMA_57474214-2075-49a5-93c2-45f2c0151e87"
      unitRef="usd">-97000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctNS0xLTEtMA_46aa1844-6153-4b82-8e70-c7e01e0c516c"
      unitRef="usd">-134000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctNy0xLTEtMA_432322e3-a41a-4cc5-a0d1-65429858c888"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzctOS0xLTEtMA_1365fd6c-83e6-462d-a944-f1369ce0df90"
      unitRef="usd">-355000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtMS0xLTEtMA_86225328-c973-4736-a31a-5f04701a0759"
      unitRef="usd">297000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtMy0xLTEtMA_39c61647-9c77-4667-bd4c-12170115bfec"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtNS0xLTEtMA_15fa590a-d2c5-4e7f-a0e7-e6d74af88721"
      unitRef="usd">-425000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtNy0xLTEtMA_a6a19a58-7c3d-4737-91cc-ae1ad8d31484"
      unitRef="usd">-223000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzgtOS0xLTEtMA_82b447a9-7ed8-4fa1-baef-073225d5e029"
      unitRef="usd">-361000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="ie392eeda6d7342ba99a2b5d50dcd9ad6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTEtMS0xLTM5NDk_58ab0150-39c9-48fd-99da-f614d4275875"
      unitRef="usd">-23000000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="i838fc15955db4a4d9d463da8b122b50c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTMtMS0xLTM5NDk_f8f89e97-a1b5-4947-9dc8-933c1b1d8b32"
      unitRef="usd">1000000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="ic2b285d78fbd4c388aacdbe87f0ddba8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTUtMS0xLTM5NDk_8808f5fd-554d-4a2d-a431-d9b39bc69b16"
      unitRef="usd">-344000000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="i5554cfa2d29a466aac9505bf633bc19f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTctMS0xLTM5NDk_6b13e6f4-e1fb-42c7-84db-5de66af09162"
      unitRef="usd">100000000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTktMS0xLTM5NDk_59558335-7030-4ae6-bb20-2b76ed2738dc"
      unitRef="usd">-266000000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic550ba60e01a461a85b42e40d108acfb_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTEtMS0xLTM5NDk_eca51dc7-04de-41d2-a16d-f779258d6b1b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2352f0a4d1a4a9c99aae16eca9eb64f_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTMtMS0xLTM5NDk_74ff82fc-0bb6-4578-b534-61f243cabbf6"
      unitRef="usd">-8000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice856820a83d4f64ba70affc98cad508_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTUtMS0xLTM5NDk_acb67c94-83ff-4a0c-9c8d-37a5a66a3337"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34ff4b660b424b82be57badc5035314b_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTctMS0xLTM5NDk_a8005466-0ea9-4038-86ca-a58440f910a2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d27b6850029421d9b74d51b9b3c2a91_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTktMS0xLTM5NDk_2ca545d8-4ace-452b-8ead-2849ca92891a"
      unitRef="usd">-8000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if578ac895a894796b44b038d0fb39402_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktMS0xLTEtMA_cd0f8b23-0ff3-4681-9f44-75667b9c3d65"
      unitRef="usd">166000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fcfb5df86d440c885a97df59dc74f88_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktMy0xLTEtMA_92f72b3e-4756-4099-92c6-f20aae2f6436"
      unitRef="usd">-78000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief6f7feea16443b79fb74434abc31baa_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktNS0xLTEtMA_89c4875a-2888-4771-9ea3-e3efabffcb1b"
      unitRef="usd">-3556000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b3e4ef69c5d4f6897a3277c799164dd_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktNy0xLTEtMA_2720d1be-c612-40a7-96f9-5174ac72dd40"
      unitRef="usd">-2077000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67b4b127a8884ff190bb26aefa784be3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzktOS0xLTEtMA_cf482925-bbfb-4399-976a-f143a9c57f48"
      unitRef="usd">-5545000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTEtMS0xLTA_cd144d1e-5a7b-41af-807c-98a75f3c52e0"
      unitRef="usd">86000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTMtMS0xLTA_a3e0d26d-4747-421a-aa31-dda1f308bb25"
      unitRef="usd">140000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTUtMS0xLTA_ee896693-1440-456a-9beb-0bb11121e905"
      unitRef="usd">-948000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTctMS0xLTA_f81bbe04-72d0-4179-9b2c-a0184df34a93"
      unitRef="usd">112000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEwLTktMS0xLTA_1ff05527-dd08-4b2f-9bf6-8a8fcb29e0b9"
      unitRef="usd">-610000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTEtMS0xLTA_3630bd38-429f-412f-a7d0-0af4735dcc8e"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTMtMS0xLTA_0caa599b-6d9a-40a3-b4eb-c414d845dffb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTUtMS0xLTA_76a8c55c-dbd9-40b6-bb5c-8f0ad14c6e5d"
      unitRef="usd">-192000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTctMS0xLTA_0f5691c3-f355-4c95-8238-89e63a8c13a9"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzExLTktMS0xLTA_f587b958-6791-44e5-8c65-9f8d2d6c8b6a"
      unitRef="usd">-161000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTEtMS0xLTA_68674468-c238-4f1e-b54d-137e9047afc9"
      unitRef="usd">71000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTMtMS0xLTA_02d7a154-dbc1-4b01-98a7-0b512492f084"
      unitRef="usd">140000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTUtMS0xLTA_37539766-53b6-4d24-821e-4ae9740f5c07"
      unitRef="usd">-756000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTctMS0xLTA_f6b33211-dde3-4aed-bebf-b1a37c892c9a"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEyLTktMS0xLTA_9a0179c1-0369-4461-96b7-cbcf45a7a1e3"
      unitRef="usd">-449000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTEtMS0xLTA_9659fc83-4dfa-4534-b2a3-7e7660f40d8c"
      unitRef="usd">261000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTMtMS0xLTA_0cebf93e-7347-436c-9c3b-7ca7ad4f49c2"
      unitRef="usd">44000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTUtMS0xLTA_b9729ad1-610a-4725-97a1-7929f24aaf51"
      unitRef="usd">-66000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTctMS0xLTA_39f61d85-76d9-4ed9-a455-4e1bd2008164"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzEzLTktMS0xLTA_00d607dd-9a3e-4391-b6bb-5e8990647ff1"
      unitRef="usd">239000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTEtMS0xLTA_1798339a-5593-4246-bddb-2b2ff60b64cf"
      unitRef="usd">55000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTMtMS0xLTA_39472aee-2776-4560-b34f-0452d3e00535"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTUtMS0xLTA_d98eb94c-9533-4dab-ace0-625c24bbfcbe"
      unitRef="usd">-15000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTctMS0xLTA_e37b2bc4-549d-400f-b403-fe06a0aa6837"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE0LTktMS0xLTA_602d5f0d-0edf-427c-92c8-f59d89adb02a"
      unitRef="usd">40000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTEtMS0xLTA_cb1ae349-fe42-48f6-beb6-d3ce161063f2"
      unitRef="usd">206000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTMtMS0xLTA_aa41227a-fc6a-40c5-823d-701a66ba0ad1"
      unitRef="usd">44000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTUtMS0xLTA_f46a5ae5-7792-4b3b-a2a7-32185ad0351e"
      unitRef="usd">-51000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTctMS0xLTA_9c8412f2-0e56-400f-b094-769f61c45b04"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE1LTktMS0xLTA_d022e2bc-8647-42a4-bfa7-7594ef051f8d"
      unitRef="usd">199000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i15d47b75757c4d728b08f1bb1805d752_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTEtMS0xLTA_8d8e2b5e-7c0e-44ee-9470-52295ffd0c18"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic78cf7ef5a1746aea4d38272d6f3b347_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTMtMS0xLTA_9025f6f7-889e-446d-9323-c904336cbe5e"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibb2390f133644d4e99d0d6f47a30af53_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTUtMS0xLTA_b507abac-111b-4018-8165-c29bf394e5ad"
      unitRef="usd">-705000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia83b168c80e9469e9f828d7f7a3e922a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTctMS0xLTA_e3d3c09a-3652-49a8-9987-e0f19ea2f62d"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzE2LTktMS0xLTA_42b9d434-7608-4c32-b58b-6d7439aa002c"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf4b8ee6455d4a9b89b308842da6473f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTEtMS0xLTA_4c8cf9cd-b162-48df-8b18-0c534a7402b0"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2cce9deabde142dd99183ccb92bf0341_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTMtMS0xLTA_8aee0f47-00cd-477e-8144-278a1fc42ab9"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8c2b49e682e4caeb3bc52179ef40698_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTUtMS0xLTA_c07040fb-9d2e-45ef-b057-94f37f874b53"
      unitRef="usd">-4261000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i924abcecf31e46c1b8d02841a745163b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTctMS0xLTA_d5a00780-4cb2-404c-8deb-3edbed3dfb4c"
      unitRef="usd">-1981000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i090793285fc448169b5f2766fad90f7a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIxLTktMS0xLTA_e477b01f-8d11-490d-99be-de3f41239df7"
      unitRef="usd">-6193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTEtMS0xLTA_4fc3d21c-64f0-4f2b-9382-4335cf3aa605"
      unitRef="usd">-383000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTMtMS0xLTA_ac597fef-f35f-45a0-ac1c-d31500c641ec"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTUtMS0xLTA_1cda7d0b-c2f4-436e-8794-af95bb730a6a"
      unitRef="usd">-599000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTctMS0xLTA_0b1ecd15-d788-414d-afad-48dae79d17ef"
      unitRef="usd">64000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIyLTktMS0xLTA_6f6faf19-172e-4cfc-8c03-57392be0f5dd"
      unitRef="usd">-915000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTEtMS0xLTA_428210a3-fbdf-441d-a184-4c4b1882d6ef"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTMtMS0xLTA_297d8710-289e-4a8d-a408-9b7b65cf6337"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTUtMS0xLTA_70467e6a-6ea3-49c5-9325-d7665d3b928d"
      unitRef="usd">-111000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTctMS0xLTA_f787a220-14c4-4c71-ab43-f28121082186"
      unitRef="usd">-89000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzIzLTktMS0xLTA_cb54cce9-262f-4789-908f-d703002dd283"
      unitRef="usd">-284000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTEtMS0xLTA_6e153f7c-7380-4d2d-8aeb-c2a158d05c40"
      unitRef="usd">-299000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTMtMS0xLTA_164158c0-c60f-4591-b75f-8e346fc73fe5"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTUtMS0xLTA_ef421ecf-378d-46eb-97c7-f20749279a40"
      unitRef="usd">-488000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTctMS0xLTA_626e42ab-7305-45c7-9039-fb5aa737fd20"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI0LTktMS0xLTA_51e9e210-a184-4de4-bd2a-bc52a9779986"
      unitRef="usd">-631000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTEtMS0xLTA_41bbb8a5-bb41-4864-b37e-06f14e728ae7"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTMtMS0xLTA_8892331c-4a02-4ca2-9d5f-7a2519e56f34"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTUtMS0xLTA_b4552cfe-4906-4d65-9e89-7da5acc0cbea"
      unitRef="usd">-272000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTctMS0xLTA_002953d3-bbcf-46a1-bfe1-4686dfbd5739"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI1LTktMS0xLTA_93fcbb9f-10fc-467b-9e8f-78ebcfcc50e3"
      unitRef="usd">-253000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTEtMS0xLTA_4628e25c-5234-4de7-bc4c-bdab8b49617d"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTMtMS0xLTA_feebabdb-1f48-4d90-b764-6da368858d47"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTUtMS0xLTA_9b76d26a-458e-4c2e-a34c-829a169a4203"
      unitRef="usd">-63000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTctMS0xLTA_200d0fe2-7caf-4021-a72a-f686b1ab2b8a"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI2LTktMS0xLTA_96b6bdcc-802f-432a-99b4-777fc3bf1c5a"
      unitRef="usd">-63000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTEtMS0xLTA_a70d60b6-393e-4fad-a08a-ab6e86fa98f6"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTMtMS0xLTA_de77fea5-2c2c-4495-809c-926e94fd4d3e"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTUtMS0xLTA_e239bc6d-e615-4df1-982e-c663b836399d"
      unitRef="usd">-209000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTctMS0xLTA_60c09379-2ee9-4b07-8d4a-2f46670ad68c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI3LTktMS0xLTA_42ff64e1-334f-4592-939a-7e417dcad891"
      unitRef="usd">-190000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifbb7352165254abc85bdc12afecc1f46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTEtMS0xLTA_47f6ddd3-bfb2-4e30-a9ac-72e3ca56eb9d"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia54cef201b36433da0709d5cd68223fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTMtMS0xLTA_5212813b-c1c0-438d-b0b1-9440fc8ff6f4"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if7bc60184796412db0b520303bfe2f0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTUtMS0xLTA_3d062e9c-30e3-4700-bf63-f8d1d88609be"
      unitRef="usd">-279000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8266cda993ca48c4b693d39ab53729f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTctMS0xLTA_3237c4a6-55d8-49a6-a284-e5cea9c7dcec"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI4LTktMS0xLTA_7b41043a-4416-4d35-b474-817bc9d489da"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i610c168f90e34562ba8f9dba8f33d1cc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTEtMS0xLTA_1c10f68b-5194-4907-bf1c-4190149821f1"
      unitRef="usd">-266000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife933330c1ac424aa46ca468fd356d4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTMtMS0xLTA_7b4527b9-aaf3-412c-922d-f53d5956c33a"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9afb706ed88c4a9c952412a1568ca05b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTUtMS0xLTA_ae2d7e03-bf1b-4e98-bdb1-51c22fc3d343"
      unitRef="usd">-4540000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae4b953ffd8449bfa452e08fac76110b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTctMS0xLTA_2cb37a6c-5109-49ac-9f30-8bbcac50450e"
      unitRef="usd">-1828000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie09ace19fb574f50904349a9da836610_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90YWJsZTo5Yzg5MDRmYjdiNjQ0NWI3YjZiNjE4MmM4MWNlMzlmYy90YWJsZXJhbmdlOjljODkwNGZiN2I2NDQ1YjdiNmI2MTgyYzgxY2UzOWZjXzI5LTktMS0xLTA_7f996a9c-46de-47b4-9ac4-41eb7c61d6e3"
      unitRef="usd">-6634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i6f71d04bdcdc440cb39d626bbf39da82_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzczMw_9c706102-9ec4-4b10-87a1-bca57893b56c"
      unitRef="usd">5400000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i7110e61b679b41dfb55959ead2fa0d94_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzc0MA_6cd12332-3971-470b-9fa6-e4c71c5fd62e"
      unitRef="usd">5100000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i944bd7f6e96e4f45827bcfb3d2cee24b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzgzNA_aa8baf58-906b-4ecb-a3b6-100087188235"
      unitRef="usd">-391000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ia1028ee01f9f443790787ed899f2bb2a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzg0MQ_c2b4ac45-1977-48d6-a8f9-e5c2df395d34"
      unitRef="usd">-247000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ibbfbe344564a46048fb4ab43f38e7fa2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzkzMw_e8bbe06e-0933-4f24-baf5-02762a67c7a3"
      unitRef="usd">-255000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i6efe006638854a89a541ce4a48c0e6e6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzk0MA_791c044a-1442-4ec3-8344-abeb18feea53"
      unitRef="usd">-263000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i1ddc21fcecc54b61b50c3d29b99a74d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzEwNDY_dd50dd47-f93c-4f0e-8719-ff7a8c2c7a1c"
      unitRef="usd">-244000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i914bdb16078940c8a02194e2230817a8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjYvZnJhZzo5NTQ1YWU4OTIyNGE0MTVhOGM0YmViZTIyYzU3ZDRlYy90ZXh0cmVnaW9uOjk1NDVhZTg5MjI0YTQxNWE4YzRiZWJlMjJjNTdkNGVjXzEwNTM_270c6739-0a2f-47ec-a837-aef192ee4285"
      unitRef="usd">-305000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3NDc_5a52b603-b80f-4588-b84f-4e36fdba14a7">Segment Reporting&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously had an Alliances segment that primarily included activity from the Company&#x2019;s relationship with AstraZeneca LP related to sales of Nexium and Prilosec, which concluded in 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;8,352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;6,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;14,380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;11,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;417&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R II/Varivax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,878&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,087&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;583&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;162&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cubicin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress HD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;857&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zepatier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zetia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vytorin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Atozet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,971&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Women&#x2019;s Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Implanon/Nexplanon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;488&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;NuvaRing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Diversified Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Singulair&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cozaar/Hyzaar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;386&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Arcoxia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Nasonex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Follistim AQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;109&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;19,449&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;23,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;43,021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;18,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;22,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;41,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;16,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;20,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;37,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;872&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,764&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Other segment sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;20,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;26,791&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;47,747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;20,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;46,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;18,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;23,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;42,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;176&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,967&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;47,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents sales for the non-reportable segments of Healthcare Services (fully divested in the first quarter of 2020) and Alliances (which concluded in 2018). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,624&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,376&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,864&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,274&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income before taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,722&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge related to the termination of a collaboration with Samsung&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income Before Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,791&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#x2019;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other unallocated, net includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value of liabilities for contingent consideration, and other miscellaneous income or expense items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity (income) loss from affiliates and depreciation and amortization included in segment profits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity (income) loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;690&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity (income) loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity (income) loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, by geographic area where located is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzExMg_6a1a4e35-6174-4871-9700-9c153a159c5c"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3NjQ_7fbfbc70-ee9e-4cb7-864c-39087f5c137c">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;8,352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;6,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;14,380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;11,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;417&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R II/Varivax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,878&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,087&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;583&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;162&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cubicin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress HD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;857&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zepatier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zetia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vytorin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Atozet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,971&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Women&#x2019;s Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Implanon/Nexplanon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;488&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;NuvaRing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Diversified Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Singulair&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cozaar/Hyzaar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;386&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Arcoxia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Nasonex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Follistim AQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;109&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;19,449&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;23,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;43,021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;18,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;22,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;41,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;16,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;20,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;37,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;872&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,764&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Other segment sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;20,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;26,791&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;47,747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;20,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;46,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;18,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;23,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;42,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;176&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,967&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;47,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents sales for the non-reportable segments of Healthcare Services (fully divested in the first quarter of 2020) and Alliances (which concluded in 2018). &lt;/span&gt;&lt;/div&gt;(5)&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="i944b92f0135f4cea93c996121cdf4250_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMS0xLTEtMA_8d2c29cc-7d9a-49f9-ba07-d9621d4852b8"
      unitRef="usd">8352000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b82cc9ac9bc467aa2d1652a512c75ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMy0xLTEtMA_8eabe0d6-7b39-4d53-9f14-d250533324be"
      unitRef="usd">6028000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i762e382a2fb74a4f8babd38337173a85_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtNS0xLTEtMA_430818df-7f02-49ac-883f-b39300219972"
      unitRef="usd">14380000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i487b197ad43f42b4912ad594d94ebd83_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtNy0xLTEtMA_90d96bb4-fe9e-4cc2-b661-0902cdfa15b0"
      unitRef="usd">6305000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea50166c87a84aebbe4b0e1f96819e9b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtOS0xLTEtMA_4dd2158a-4adc-42b7-a5c9-b41cf8d123e2"
      unitRef="usd">4779000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib06a34e4d2ab44d5bf29fb6afb196f2e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMTEtMS0xLTA_9ae6f177-2fee-4f88-a9c3-d4400f873d53"
      unitRef="usd">11084000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id33e663e5d3448369da90c6d1a069ec0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMTMtMS0xLTA_a6b7671f-7290-467e-a256-050a738a10a9"
      unitRef="usd">4150000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2abed73e41814781901f099d40ed7105_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMTUtMS0xLTA_bc600ca1-f922-449d-9ddf-94750041624f"
      unitRef="usd">3021000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd3942b136244804978f116fbd64e6fa_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQtMTctMS0xLTA_9b78d830-7f9e-496b-a755-3a7aa3012a06"
      unitRef="usd">7171000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e466932ee4e460ab0dd0bfb9b1ea289_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMS0xLTEtMA_e7f14b91-2ee2-4c74-ae03-f3ef6d7ee371"
      unitRef="usd">417000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i913afbc19dee4cb2a26b17a5b2526f58_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMy0xLTEtMA_f8d35718-bee4-48fe-bd51-6fbafede6468"
      unitRef="usd">308000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if86a72289f7a4e82b9b4eb4aa37f655b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtNS0xLTEtMA_ed36df79-3efe-49ee-8680-b711ecd75bf8"
      unitRef="usd">725000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic980b87bd8b0418db9d06a8a487b8264_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtNy0xLTEtMA_a8783827-8261-4b15-8790-f843a2483da8"
      unitRef="usd">269000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd394238a2bd4fc599ea677dc8fc9177_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtOS0xLTEtMA_29858791-4d7c-4ed1-a70c-e3a36dd8d618"
      unitRef="usd">176000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i705f2f1b42d3489389778770491f3701_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMTEtMS0xLTA_64252a9d-fbcc-4da3-8942-48cf3f18f271"
      unitRef="usd">444000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3e95cee7306454cb048b4b3891df099_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMTMtMS0xLTA_faadcaf4-e523-461f-9b73-fb3e37ebe376"
      unitRef="usd">127000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idacbd259a14a4cc3b723aea685fe8402_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMTUtMS0xLTA_80daaa17-85af-4644-b955-4cdf38143544"
      unitRef="usd">61000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica27ecc79da8419a88633755deac6f27_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUtMTctMS0xLTA_f708308f-0bd7-48ce-982e-84db21779b21"
      unitRef="usd">187000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81b34437d3a04710a586018aad577595_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMS0xLTEtMA_c5245099-3124-4dfe-b493-aa4d06d3ae35"
      unitRef="usd">359000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b948ea353cd4ba2a534ccca93683bd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMy0xLTEtMA_59ff96f2-1dc5-4a9c-b14e-a4098a489097"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a60cb9fff2c4cc895d8bdf8605a165d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtNS0xLTEtMA_1753740e-76de-423d-860e-4bfe8a1d607b"
      unitRef="usd">580000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd7ae51b0ccc49e49568440c6c4249ba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtNy0xLTEtMA_8a87901d-3a8d-49d9-89dd-21db9a46d513"
      unitRef="usd">239000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i568b7384fa7a46cfaca0984581c67866_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtOS0xLTEtMA_5fc2e1c2-b3a0-4b12-a6e6-3945f096b908"
      unitRef="usd">165000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdc913222658499b880f61b227164ce4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMTEtMS0xLTA_2181fe06-4be5-441a-a926-dcce7963590f"
      unitRef="usd">404000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b7e5ca7b90b402180e94a9e8706abf0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMTMtMS0xLTA_120c5a61-7fd6-497e-82cf-a2c55f021a02"
      unitRef="usd">95000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib01ae12bf7fa44aab5d2eb12ee013b9f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMTUtMS0xLTA_ed6d783a-7e8f-40e1-8398-ce0c3623d485"
      unitRef="usd">54000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e937a0914304e858eb868231dc9e5c8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzYtMTctMS0xLTA_04e7b181-0af3-444a-853a-4db6b97a31e9"
      unitRef="usd">149000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62fb6e91ba434715b8251869bd7299e0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMS0xLTEtMA_902ba59c-c049-467d-851b-94685b268300"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea8b090798424ac8aa3116f12d6083ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMy0xLTEtMA_eb5ec18b-5e7e-4ce7-8ba9-03c93db41f58"
      unitRef="usd">127000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd47028645b14cdd8bc6a7f8356b4316_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctNS0xLTEtMA_24c0d392-f4fd-4126-b060-2f13bb1b288d"
      unitRef="usd">145000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9dcda80a2b744fdb022181fac4adddd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctNy0xLTEtMA_039f3c44-2c90-4694-aba9-035f861b8ebd"
      unitRef="usd">183000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie561b863be38430bbd97eb1eb078fef6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctOS0xLTEtMA_2ac395a1-b270-4c4e-b4bc-c3830b47dd6c"
      unitRef="usd">205000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea786310eb1d478086e32978d875173c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMTEtMS0xLTA_fc3786b5-c122-4999-9aea-7d15a605e1dc"
      unitRef="usd">388000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifea00f3442984ed4a0f48e661b09bb6d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMTMtMS0xLTA_53eb5396-bebc-4b1a-98b6-ddf150b72a8b"
      unitRef="usd">312000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i782fc528304543298cebb02d1190ac5b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMTUtMS0xLTA_22d22b67-1860-40a1-bff9-9c539277df7e"
      unitRef="usd">210000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1145ed6aec9d48c3a25ff2a988aa54d9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzctMTctMS0xLTA_f499238e-fb19-464f-b569-7d9962cafaa6"
      unitRef="usd">522000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42905f2114b449e882139c3304e1e067_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMS0xLTEtMA_b1a27963-b499-4301-a27d-769d3c192208"
      unitRef="usd">1755000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b89ba8279e7484d8920197b705b8e22_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMy0xLTEtMA_f7aed74f-fad6-416e-aab6-6cc670e1a673"
      unitRef="usd">2184000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f022f4e88e842849c6953bd007071a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktNS0xLTEtMA_7c7be340-14d7-40d4-9ab9-d12ae3a01652"
      unitRef="usd">3938000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i386b32eac5004086999833832cf45f24_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktNy0xLTEtMA_185235ad-87f4-4c61-8383-737968cb8113"
      unitRef="usd">1831000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bc8ca75e4db4e72a0644865c60bcc0d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktOS0xLTEtMA_14e58f57-31f2-4c1c-bfe9-56eefdb1d131"
      unitRef="usd">1905000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i930ed6885726482297a6b88617a1004e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMTEtMS0xLTA_d2e43bdc-4feb-474e-ba22-31d04f60e5ca"
      unitRef="usd">3737000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48a909c96c814060a10e2801793e0e6c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMTMtMS0xLTA_7a55c19d-9ac2-4645-ab8c-53208881dfb7"
      unitRef="usd">1873000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic440e28e121b44579dee80b8c5d681eb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMTUtMS0xLTA_9b8ed601-9fd4-43de-af2e-033df60b1925"
      unitRef="usd">1279000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6de667927bd44a37a2bd00481afd12df_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzktMTctMS0xLTA_c6460c51-b05a-4309-9fc6-719dac9f8002"
      unitRef="usd">3151000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id371c43a511c445bb4a2ffeaa7880af4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTEtMS0xLTA_b3675f8f-b77c-4b80-acdf-a1c2013a1dc2"
      unitRef="usd">1378000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0d2eda461ad492daf3a3842f708bc0f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTMtMS0xLTA_bdbc7a93-3257-446e-80c9-10c325d9fdc1"
      unitRef="usd">500000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06c67db88a3e4613b882d85cae7cf938_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTUtMS0xLTA_ab3750f2-92ca-4bd4-b5a8-b70b0dca3c78"
      unitRef="usd">1878000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03b2d959e73643b7b560fc019573878c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTctMS0xLTA_c5266658-7f13-4ba0-92af-edf971a6dc97"
      unitRef="usd">1683000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i563016c582e24bb6a9faae151d3fbde3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTktMS0xLTA_3a0af94f-22c9-4deb-8989-9b344892b85b"
      unitRef="usd">592000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iffc6b337a3ed481cb8f2d22309e2a645_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTExLTEtMS0w_c7f43b65-8770-426f-8ad6-07df3a66a777"
      unitRef="usd">2275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfb152fb64524f35a5ac871ac508cfbd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTEzLTEtMS0w_9aa6dc6c-9915-4266-9d06-97a64dd49fe2"
      unitRef="usd">1430000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5cc8a3df09604d98a7533cea6a7cc1a4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTE1LTEtMS0w_2a5e8526-6b12-415a-8aa3-55ecf816f28f"
      unitRef="usd">368000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea8d517618414005bbbe9f82e782a39f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEwLTE3LTEtMS0w_46edc7a2-e75d-4230-8ab7-25e8fc44e6f1"
      unitRef="usd">1798000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie588ee62a35341cd8301ef54adb5166f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTEtMS0xLTA_fa3e846b-af39-46bd-9f1e-ac8f7ee81c38"
      unitRef="usd">727000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99baf06e598d4cc587b4eea203a0baa5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTMtMS0xLTA_b7b04333-70b4-4c02-8ddf-7502edd5b1e4"
      unitRef="usd">359000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f59b103858d46878eedf45649386455_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTUtMS0xLTA_13e15136-cff6-4005-8c5b-d1c1d3d8fdcd"
      unitRef="usd">1087000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa4e6f22b3114161abfe58eb27fdd9b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTctMS0xLTA_3c1b08b8-a769-4368-8676-c7bc1fdfaf12"
      unitRef="usd">679000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3244ce2b91904b73b45793012b9deba1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTktMS0xLTA_99c10081-de56-4c45-afd1-3a8069b118de"
      unitRef="usd">247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ee34845ecb84d00a4446c16e8283f06_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTExLTEtMS0w_90fa889f-076e-4a76-b9f5-0fcb41ea0bbf"
      unitRef="usd">926000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac945c4f8f4d4171981befedd8042eb6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTEzLTEtMS0w_049e4c0b-ea70-4c85-b74e-55353045a38c"
      unitRef="usd">627000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13aac18591694ed095c07e398d82a9a4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTE1LTEtMS0w_c133046f-fb8a-4256-8032-ffbf0c8d7119"
      unitRef="usd">281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ce7fe828cc94d6db92ef54014d5e83d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzExLTE3LTEtMS0w_80e782a7-e653-4c03-8a3d-7f3923cc29b2"
      unitRef="usd">907000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3082eeb63264d528664dcb84a196ffa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTEtMS0xLTA_166337e7-6d1c-4c7c-8fa5-368f037d53ad"
      unitRef="usd">486000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b8ddb57daf4449b95d7f5842fbd9cd2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTMtMS0xLTA_624c582a-8ae3-4121-b089-7581cc7a9b95"
      unitRef="usd">311000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c04273d563d43ac903ddf81cd8713df_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTUtMS0xLTA_7a8d7fca-29e7-43c8-90fa-782ffd6c2156"
      unitRef="usd">797000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7885796f74eb4f47aa093cd5153cdddb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTctMS0xLTA_60f05127-26a1-44cc-b7a3-c6cb242601e6"
      unitRef="usd">506000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic76caa434d4545c2a41daf436667a0c1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTktMS0xLTA_8706f03d-9799-4543-bc75-92c89ef7ae93"
      unitRef="usd">284000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i698eb8ca231d455e8bd8025f25c5bafb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTExLTEtMS0w_3fb57beb-c6f1-4575-be1e-b7ae125c8471"
      unitRef="usd">791000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1cd5c6efee8b467ca3065e20772c0f16_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTEzLTEtMS0w_92753cff-69f3-4150-ac12-27347a1ea058"
      unitRef="usd">496000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61c82a481d0e4e5c9cb61cd60076fae7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTE1LTEtMS0w_5fe34051-d84b-4016-9206-76a632f81db5"
      unitRef="usd">232000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51e714cd39394117b1cb6e8777bf32d8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEyLTE3LTEtMS0w_d26d7936-7639-404a-b2f0-a6112d2c73b3"
      unitRef="usd">728000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3eac079c11544e2cbf3daee151f7b5d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTEtMS0xLTA_3b8164b6-84e4-451d-ac6e-820e46df358f"
      unitRef="usd">103000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c795d67996d4d41850e0375598399a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTMtMS0xLTA_523d529d-f40c-4bb8-b2ae-132cae6c01ba"
      unitRef="usd">67000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic268fa475d8247a888383acd5008c4c8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTUtMS0xLTA_4e178677-10b6-4095-b70c-95d235f954f5"
      unitRef="usd">170000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i792a79580b224fee9d46fb4cfe23165b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTctMS0xLTA_5e1c8539-2453-4832-a99f-52df148e61e2"
      unitRef="usd">130000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bc19564465e4f5a972c56bb809a8f36_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTktMS0xLTA_9cdd39e8-c9aa-4b48-9b7d-d6ec514a748c"
      unitRef="usd">108000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b81e96d6791496eb43340c7203088f8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTExLTEtMS0w_2021cb8c-ea7d-454f-b001-e5235d97a96d"
      unitRef="usd">238000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b9f73dcd0954e21b2a313db04ce7e1c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTEzLTEtMS0w_a19d5a39-165c-4f99-be32-801b2c649933"
      unitRef="usd">127000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6471730c7cf14bb5a10b893fe2704d8a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTE1LTEtMS0w_b0e9fe2c-262d-4bef-b0e1-c2fa031d7204"
      unitRef="usd">112000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96c40f8fc0d443f0a7972029aa43014a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzEzLTE3LTEtMS0w_9b2a4f1a-26b1-4963-b3eb-5813426a9838"
      unitRef="usd">239000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cfced3ea7ba40dc813084356a8e2a71_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTEtMS0xLTA_7baf9427-ff4b-4d63-abca-74a22b23a928"
      unitRef="usd">583000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc5c946bf5a44685a08ed2fe940530f4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTMtMS0xLTA_1aa210b8-eea3-46c5-9d08-4ac84d52a848"
      unitRef="usd">615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie43a68e5100c460f9ae570bae3642222_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTUtMS0xLTA_daf756fd-ad38-4cda-bbb3-da4d50feee24"
      unitRef="usd">1198000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03b08c6f8ff94c49933c0e1f8bdf1a79_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTctMS0xLTA_79191ddd-a3a0-4f7c-816d-09375c53210b"
      unitRef="usd">533000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieea7542288c045289bbc1900530f6c6e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTktMS0xLTA_8ecc14b1-2f6f-4b3c-95da-f1a531a942ec"
      unitRef="usd">598000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i712dd95c443d44bd97852acba774042c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTExLTEtMS0w_b032a7e9-4911-4688-90af-7e2d010ab397"
      unitRef="usd">1131000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7bd988df8be43ab8a578291ca6766e5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTEzLTEtMS0w_77caa210-f41a-4238-94e7-af2234ea8f38"
      unitRef="usd">386000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a5e6a2873114b8ca3d699b684dfbeed_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTE1LTEtMS0w_56c49454-0fbf-438c-8ee9-03eb2ea71cdd"
      unitRef="usd">531000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6a19fa1ef2549e48a8c798ff8cdcca2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE1LTE3LTEtMS0w_c6fa645b-fcc1-49ec-bbb5-9324ef3b198c"
      unitRef="usd">917000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia794776b17ba487d81e689c730a89a44_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTEtMS0xLTA_4a6eba07-1184-4aca-a0cd-c0d5107c18d9"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if56def4d43604279ae1490a45ca12c8c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTMtMS0xLTA_2133b6aa-648d-4404-8a97-50d61e9e14b7"
      unitRef="usd">287000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a57852d19f944bd80a118414f3fb03e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTUtMS0xLTA_b43a377a-5b60-4aa5-b2b1-34ccb6d20b9c"
      unitRef="usd">329000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iedb68ee70d874978a87dc2e09bd612fd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTctMS0xLTA_281bf76b-070d-410d-b674-d724a955d1ff"
      unitRef="usd">282000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i837a264760b94cbd823d589b3848eacf_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTktMS0xLTA_2f9d65ae-76cd-4f94-8341-df53e14cf6d7"
      unitRef="usd">380000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i981d29244f2a41eeaca918a69762f31d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTExLTEtMS0w_dd38183e-f71b-4337-a68b-d965597fcf27"
      unitRef="usd">662000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d4bf02785f34f25b07ca7068a5d28ca_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTEzLTEtMS0w_806aca20-dc23-457d-9267-5a8143af3429"
      unitRef="usd">353000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i622f7b5d6bd64049b5b32da99600ada9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTE1LTEtMS0w_2967a39e-26ef-4d51-aafe-da14336704d3"
      unitRef="usd">389000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63db189e7eec4a128a0d35126d4bd81f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE2LTE3LTEtMS0w_0fc1c063-4f23-4c6a-80ba-be2acca60c90"
      unitRef="usd">742000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fee648ff7994140af926011d3631567_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTEtMS0xLTMwNTE_bed46dc7-d940-4dae-a2ca-b6c944886b3e"
      unitRef="usd">119000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44b60dd13bb14d32b824e1653e259c32_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTMtMS0xLTMwNTE_e110384f-a7df-4158-bac0-695d955af660"
      unitRef="usd">162000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i631ae57e96054ee5afcb44dd7471b663_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTUtMS0xLTMwNTE_43e48297-f7cf-47b3-8c21-63118b3c0023"
      unitRef="usd">281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7a880330a694ef488f4f7c68d82cd1c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTctMS0xLTMwNTE_50924776-f677-4cd0-9ba3-659e529cbca7"
      unitRef="usd">84000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00da273161ef4edea36fdc16bb3586f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTktMS0xLTMwNTE_aa4918ed-3e93-4907-ba4c-33be55bcee0d"
      unitRef="usd">81000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ad4b5afd5b04abaa51621d6b0f67e32_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTExLTEtMS0zMDUx_3e9e2c45-d980-4ce0-bfb3-da9db777ffc5"
      unitRef="usd">165000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f990850d9594267a6e1caceafb75e22_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTEzLTEtMS0zMDUx_f57c04a4-69ab-4a08-a5c7-f51ddd2f2c47"
      unitRef="usd">46000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8408528418746d49007de7097987a4a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTE1LTEtMS0zMDUx_e70a8855-ff66-4f17-a87d-382bae151b28"
      unitRef="usd">27000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7dcf25c15d3649238957a6c3c1922909_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTE3LTEtMS0zMDUx_33cc96c5-78f6-4fdd-bfb9-750881f0cec1"
      unitRef="usd">72000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95a6af99921b4ce385e45e7baf0ceb30_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTEtMS0xLTA_62e43e85-f739-4041-b740-7b998c96768d"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i158a181d72de473e981382f4977cf6c9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTMtMS0xLTA_a9020812-ee21-4f08-8647-09cb49e7c924"
      unitRef="usd">248000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80beea5c84e343bd885ca3431e912104_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTUtMS0xLTA_af7618ad-66d7-4658-9344-203bcb05ea9e"
      unitRef="usd">251000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i982bda5b96d648869406352d49e6de87_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTctMS0xLTA_908d07ae-9cd9-45aa-804c-4aed50a4c842"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26fced3e231e4bdca37b63bce6e68d8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTktMS0xLTA_68075b0a-8f6c-49bb-a8aa-65e0239dbedb"
      unitRef="usd">271000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8fc37aa4da24c6fbb3ae07dec2598ed_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTExLTEtMS0w_9ce8d030-5f6c-414f-abfb-1504f378946a"
      unitRef="usd">273000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id86a4dddcb1b448daeff944a4e1e47f5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTEzLTEtMS0w_c1289d7e-a472-43f3-bc89-9b9d796e2194"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdb32068982447049d6b160c7f5328e3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTE1LTEtMS0w_6c19ac76-bd8b-46a0-9e01-54dc37449abc"
      unitRef="usd">258000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic23472488bb44800886a04efdac600d6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE3LTE3LTEtMS0w_94e5d3f9-1b1a-4d0b-92a0-40d120e94a95"
      unitRef="usd">265000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00dc40a9ba5740df90cd396ff7e12f29_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTEtMS0xLTg2MTg_7c6dae7e-a189-4e14-a6f6-1714b00e6cc9"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i340d2c3e7cd4499c8922b0efb09a24e3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTMtMS0xLTg2MTg_578e489c-5aab-4485-9d89-364f9322ce8d"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86c343bc0a184f35986855d72aef089d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTUtMS0xLTg2MTg_3eabf268-a2db-4104-84be-17b217afbd44"
      unitRef="usd">213000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80da1dcdb7dd4217893159cf5cfd10ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTctMS0xLTg2MTg_def00b4e-35f1-451c-967f-3691bb9a92cc"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i244975eafaea4f8981c83f70f314cf09_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTktMS0xLTg2MTg_7cdf98bb-ae6d-4a6b-822a-a46234252f3a"
      unitRef="usd">242000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia32db1b78a5840528d295a594b2e7616_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTExLTEtMS04NjE4_96f02b34-48ea-460b-8888-53e2f8bb2296"
      unitRef="usd">249000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i743e39e016e44963826fff0f356a69f9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTEzLTEtMS04NjE4_42aeae8f-42df-466a-9734-838121f701b4"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if06b3400e18e404eb05b4445a2bc6313_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTE1LTEtMS04NjE4_1dd658be-c243-4500-b857-29096db9d0c8"
      unitRef="usd">314000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6083ea4bda474120b0f548d11216c6a5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTE3LTEtMS04NjE4_5b6173d2-67d2-4f28-be0f-da823960853c"
      unitRef="usd">326000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2af11e6de1ff462890478e6393a18b91_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTEtMS0xLTA_58bdbba5-d86f-4c38-9db8-bee41f5531ce"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65c1d7b2f4f44342b7cb4177aafef6ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTMtMS0xLTA_d477f17e-c1f9-4b6c-9395-2cc2c748d95a"
      unitRef="usd">202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i52759226e58746448d8a420c332f2381_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTUtMS0xLTA_62dc5093-85ea-419b-bd4f-e4152e6e6ac9"
      unitRef="usd">211000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f8efad0f18a4a45a2614ed77513463a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTctMS0xLTA_1b2b7f7f-94a3-4565-9477-4bdfdb33063c"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96ecf2f6aada4757bd26858e97cfcd1c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTktMS0xLTA_a7f916d6-7f11-4e24-b761-b3f8a34d64a6"
      unitRef="usd">233000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34bf512eb4f541a2b071eb54fdb82c88_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTExLTEtMS0w_1afbec08-838f-48be-bb79-be8997c933ea"
      unitRef="usd">263000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3964e6a61c54a82afe378671d25a543_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTEzLTEtMS0w_b7af8fa9-dcf2-46d4-b312-142d8b4c72ef"
      unitRef="usd">253000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75a6bbc3767d4a6ca3952000f13d28c6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTE1LTEtMS0w_5a1d5e85-e64c-4b49-bdf1-7b1fee72a274"
      unitRef="usd">243000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ac4d80bdecb4bab833db37a8d18cb8c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE4LTE3LTEtMS0w_52a338e7-7eb8-4245-a507-874ad5ac67ae"
      unitRef="usd">496000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbb92d1ba39b45128f93a4709dee1c15_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTEtMS0xLTA_18a45aad-904c-4d08-890c-a1831fed6c04"
      unitRef="usd">46000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56b2370d6fbc401ab58d1068789e89e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTMtMS0xLTA_0bd0641d-d235-498e-8ba6-437577dc13f4"
      unitRef="usd">106000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i593fe290ce72487993a67db241486f76_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTUtMS0xLTA_0c8762a8-721c-466c-9876-891bee5929ed"
      unitRef="usd">152000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc8cd853b60043e0b70f1bfec080a4d2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTctMS0xLTA_ea493c55-fef8-431d-a91c-410482c96948"
      unitRef="usd">92000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f99c5231e7c4dc7a81d228fc3415f7b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTktMS0xLTA_3235eda4-41aa-41c8-8c8e-cefb7a7335e8"
      unitRef="usd">165000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfca6579a4ac42e4a4e603af62eb5c01_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTExLTEtMS0w_868efc75-6a40-42ab-a360-b6d1883e7c3d"
      unitRef="usd">257000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c71abcc275f4683af8e0271a80096ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTEzLTEtMS0w_5704793b-170c-4a16-9586-7de80f9375d9"
      unitRef="usd">191000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0fa50d7bd230485abf1e66bfe14032be_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTE1LTEtMS0w_6546d05b-fe10-4549-a4fb-fe92d537c2a9"
      unitRef="usd">176000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic42ee491dfce40f7aa8d266a46cf3543_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzE5LTE3LTEtMS0w_ccfa7471-94a4-4a51-9f3b-92d74abd3e05"
      unitRef="usd">367000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia213538c877d45ffbeda1c478dce239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTEtMS0xLTMwNTc_f3474b76-332c-41bf-bae0-99dc0a5943da"
      unitRef="usd">74000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i021950f39f7d4ff5bdba80113c0e13a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTMtMS0xLTMwNTc_2973b5c7-572a-4889-9006-a6a6c08afda8"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id025bb2578734377984deb7afd65b7dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTUtMS0xLTMwNTc_85bac71a-f447-4340-9949-a4f394068921"
      unitRef="usd">130000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ce0eede954143acadf9aaa2596ab83e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTctMS0xLTMwNTc_153f3016-cb8b-4535-89b6-cce9dda34741"
      unitRef="usd">63000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea5f4f6a1ceb451d81c5435d7c937683_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTktMS0xLTMwNTc_b5102691-8e39-4958-9af0-91a49bcbb619"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8e0ce6e85e94727947ac68e911896ac_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTExLTEtMS0zMDU3_d94aa597-1cb4-45ea-ab68-2d52b5e60154"
      unitRef="usd">121000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ab04a7c31974211af284155f6a7dfd4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTEzLTEtMS0zMDU3_b7455ef6-f50d-4e4e-9972-2f5a0d2b7f6e"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic02b5b66b5be42709792b6f221415e99_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTE1LTEtMS0zMDU3_690be64a-6e5c-40c4-a477-d14397ef4976"
      unitRef="usd">45000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib03ebcd3ef9e48ce8bb69abc9273d951_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTE3LTEtMS0zMDU3_6d50245b-108c-4e5d-bd92-6ff955c4b75f"
      unitRef="usd">87000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3cbd149a97d401d971e534e429cb2ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTEtMS0xLTA_8ee8d3ba-d361-4814-b824-4ea81b3415e6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b8228b2d5564ad0a725a3a7b79ca7b0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTMtMS0xLTA_33859ad2-c9fb-4065-b921-5e35f7271cd0"
      unitRef="usd">838000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6479fa964a3c49189f62b4bb3b39de1e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTUtMS0xLTA_35344ec2-ea15-4fde-b6db-4e54ad757544"
      unitRef="usd">838000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccdf4f20c8b84ecaa29c0e18c61129ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTctMS0xLTA_fc309dca-2470-463c-9580-dc73c53319c0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c18fa5bbcf1406fa004601033af85e2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTktMS0xLTA_736baffa-6de4-4365-ab72-38f16b7179f5"
      unitRef="usd">830000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb282931027048db8b47047f9082a80b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTExLTEtMS0w_77a0d9f4-85ba-44ec-814c-99893534f803"
      unitRef="usd">830000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67d6b32b4a6540428d17548fe7806b49_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTEzLTEtMS0w_6ea05f7b-0d61-44c2-b322-3f41e21bca7c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id466d72c74484e4c9b0cb94ca903c707_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTE1LTEtMS0w_e0db51f6-a3ab-4093-94de-b9ca280ac416"
      unitRef="usd">893000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02732cb0bc4444dc90c11841a6721a88_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIyLTE3LTEtMS0w_60e50fd6-4561-4e32-8323-4c932af03ece"
      unitRef="usd">893000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i204bbdb330e744b0b3ec21cefec837e3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTEtMS0xLTA_6ef17532-45d6-490a-9ba6-1f6c8eb80e01"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac9ad937795f4b4dae6cdba2cea3e74d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTMtMS0xLTA_afecf580-09be-40dd-a9f9-8f9bffdce528"
      unitRef="usd">330000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e1b718c831f45e49a8fbf7722d13a2d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTUtMS0xLTA_97069687-3d3d-46d3-a6a9-e1438b9443cb"
      unitRef="usd">330000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8aab449a70046f4a0e3b44a0956bc11_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTctMS0xLTA_62acebfb-a79c-4213-81bf-c366b08e5955"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i296ebee4da8b40bdbe6a589d85f3a4c0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTktMS0xLTA_3c499c53-8e5b-46ec-82d4-58e0276d8057"
      unitRef="usd">411000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if41e158eb1c44c3aaaf6bdce81669ce4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTExLTEtMS0w_89309277-6e4a-4dea-96de-b429438c609e"
      unitRef="usd">411000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ead8dfa8dc541b28d9320a858a459a7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTEzLTEtMS0w_2f43c0cb-8b0b-4c47-99aa-12539945f81c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieee9488d170c4cfe8fe249373f7a0005_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTE1LTEtMS0w_51828634-c4fd-434d-a4b2-ece9011d46c6"
      unitRef="usd">582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i588e0e2cfde5403d9d0ff73b1f9cb4d0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzIzLTE3LTEtMS0w_5bfce3d5-bbf1-4869-884d-8b7647f069a8"
      unitRef="usd">582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2fdcaf9b54604eb68c5312737d3846b8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTEtMS0xLTA_90e64948-4fde-4ebc-9e76-15862fef492f"
      unitRef="usd">81000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i031b4271f5cc481aa8b8f2ccc0a1ba58_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTMtMS0xLTA_f9cfa27e-92a8-4e3d-8ab9-c1dea87bc54b"
      unitRef="usd">247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3dfb2239d4d14352bd4a728fd7f880f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTUtMS0xLTA_264a2ea9-c4fb-49f2-ac68-b6787221f261"
      unitRef="usd">327000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9231ea96e50a4020a32910e880f0b50c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTctMS0xLTA_c564ffba-27fa-4992-bb74-4d3a12c4d1d6"
      unitRef="usd">92000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a5929161d3242ee9a55a4b589697d38_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTktMS0xLTA_9e50645e-e948-4059-b1d0-1fc26a6ec10d"
      unitRef="usd">214000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5f37ba6e7a148089b5c5d7be8a75edc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTExLTEtMS0w_4379697b-b07d-415d-ad56-03125c901496"
      unitRef="usd">306000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cae2150e5694f75822ed5dc50d0ef1e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTEzLTEtMS0w_484596a6-c7f6-42f4-8c46-dc858d61b674"
      unitRef="usd">96000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33200ae436ee48ecb1d3c2bbc22ec28f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTE1LTEtMS0w_d1f46c0f-e167-4d78-8075-cf87dac2f71d"
      unitRef="usd">164000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8d52e6c1a9c4700a879d6f651d06973_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI1LTE3LTEtMS0w_ad3b81ac-6dd5-4fe7-a9f8-7507cc29612e"
      unitRef="usd">260000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec78dc79b8ce4a3497112535b38ada92_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTEtMS0xLTA_fe0fd8a5-876d-4a98-a548-7a1fb52f54ab"
      unitRef="usd">326000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a1175a70af145bf8a80dd6f301e589e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTMtMS0xLTA_cb4871f2-c2b2-4a16-96ce-908c512eb02f"
      unitRef="usd">531000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28a8fc8006e849fba47a9ef2942dbb3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTUtMS0xLTA_a8070df3-678a-440f-8eb9-eaeed75aac9d"
      unitRef="usd">857000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia340a8ba6ebb4c029daea71176cbe2d0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTctMS0xLTA_06fa9470-de4e-4f41-b544-fb9eae7f62a2"
      unitRef="usd">398000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f0227adf4c24296a707c703a304ac1c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTktMS0xLTA_a991f837-259c-4fce-8dbc-c5e8cb0dcc2d"
      unitRef="usd">576000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78215076410d4611825d515c00ef799a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTExLTEtMS0w_16afd327-7c2b-4458-a11a-c8b8728776ad"
      unitRef="usd">975000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i969a6ffbcd4d46c0940c7138d634f818_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTEzLTEtMS0w_79ec36e1-eed3-4b8b-98c7-e57bfff5c1da"
      unitRef="usd">513000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb8e77760bd942eca8efc4de9fe68e8e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTE1LTEtMS0w_81745ebf-388a-46aa-ac73-ff776b1d53be"
      unitRef="usd">627000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6d2aac33ad54ab59d96297ebc97d425_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI3LTE3LTEtMS0w_8742515b-995d-4422-9142-4f7e2b218e15"
      unitRef="usd">1140000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica384a52be1a4278b12ee9bd5f583bf0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTEtMS0xLTA_95559dda-ec26-44ef-b3f9-b2728928962d"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4578066b041421da1aa43b44e975cb9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTMtMS0xLTA_27d5e92f-9aae-4e38-b09d-a1b09fdf1ce2"
      unitRef="usd">107000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b6940bb247a4473bd0c443d685569d2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTUtMS0xLTA_eb2a3fc8-f3d9-453f-8e33-7f178931bcea"
      unitRef="usd">167000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1c976d77fea4c3689cc0098063aad26_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTctMS0xLTA_24aac0b2-26a9-40bb-810d-0a1673aeb3c3"
      unitRef="usd">118000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie370a43016b44af890fcfa0146cbf033_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTktMS0xLTA_f9ccac37-333f-4e15-91f0-5c8deaf53f61"
      unitRef="usd">252000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa036d0f6774475a9fe49fd92e495644_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTExLTEtMS0w_7a034bbf-3220-4e77-96da-a9af2232f8d1"
      unitRef="usd">370000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia37abe5d72534dd093c0b9a1d4a419c0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTEzLTEtMS0w_03d78953-fb2c-4cf2-943f-24c3ff65717d"
      unitRef="usd">8000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i492b22beaf094ed68eda935067df1fb5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTE1LTEtMS0w_627f817e-3bdd-4791-a5c7-e3cadc7b437a"
      unitRef="usd">447000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i389e5536e60c49a5a0ceee0886fca045_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzI4LTE3LTEtMS0w_ee866cdd-becb-4cad-81a9-20d1f7e5f0cc"
      unitRef="usd">455000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i40c7854b1a4640c3819cb580a9f6f419_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTEtMS0xLTA_ec736f73-90c7-46ac-8c10-607259c735c4"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66a5487bfd8f452284fbe7d3ff2c5ff9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTMtMS0xLTA_7ef25106-f32b-4c76-a352-5205f3c83c64"
      unitRef="usd">483000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id65b72cf07aa47b1973dfb9bb3a28323_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTUtMS0xLTA_68274a6f-5811-4a24-85a4-cf42e15d09a3"
      unitRef="usd">482000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i358a98553f7943209f20f57502c434c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTctMS0xLTA_f7555492-0e33-4e41-bc09-34a5ec03a0ec"
      unitRef="usd">14000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b0fbc9b5596453f8b88b17db85f5aa9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTktMS0xLTA_162454ea-b7db-4237-8e6e-712700f655d6"
      unitRef="usd">575000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbddcf663e174f7d911abb1df12ce84f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTExLTEtMS0w_c9017e6d-7a25-4313-ab3b-be8df65e2fd6"
      unitRef="usd">590000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3f563f809894d48ab7c89d2ee8f18f2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTEzLTEtMS0w_f702df1c-c944-4b4f-8d15-a27cf729ea83"
      unitRef="usd">45000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3769c8c30b424f33a150c2196196a059_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTE1LTEtMS0w_6a25aeea-9bb7-4d72-8ca4-297d0c6000df"
      unitRef="usd">813000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a9bf768836345a986b10235dda945a9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMwLTE3LTEtMS0w_0c2e8f7e-213d-43ee-98c5-4c1e8df8edd3"
      unitRef="usd">857000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic330260f1af24c978c806b2a3416c5e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTEtMS0xLTA_a16682f9-e601-4a0b-b4ad-2a5f5634cf55"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0ef50a789254301a24d80d4157ed09b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTMtMS0xLTA_5f93f91d-30d1-4ecb-8e5a-f32ffb5409f8"
      unitRef="usd">171000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie65bb28cfb3444cabded850e87bf4e90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTUtMS0xLTA_8df6ff31-10d0-484d-8f12-81ebaf3d23ae"
      unitRef="usd">182000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9aff7abd7c74f4681631afcc4ec4dea_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTctMS0xLTA_18a5cbb6-f9ec-4f14-8510-fdf815288afb"
      unitRef="usd">16000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5aa6da700c404dd8a7694bfe82d5c830_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTktMS0xLTA_90839c7c-6c92-4bab-8fd4-78a49c751126"
      unitRef="usd">269000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60d3bb6b88b54cdd855c97a8e84eaaec_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTExLTEtMS0w_7ff4d22a-cca2-4887-bf0b-94c69e17d3a2"
      unitRef="usd">285000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bbfae44be544a3289c07e6254ad7066_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTEzLTEtMS0w_ca5b3a88-b7e4-4d44-a538-d05effb10379"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58961068953643e9a0d7276345f42e0c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTE1LTEtMS0w_209fe889-5f04-4a5c-8a9e-5604b76bd4bd"
      unitRef="usd">487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26dff7caf3b24a61bb9d9d43432b1342_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMxLTE3LTEtMS0w_80657d61-f90f-43d7-afe2-5b08e1b5811d"
      unitRef="usd">497000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02da2130a9c547e1b8cfd90b9810c602_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTEtMS0xLTA_bc36f5a0-46cf-450f-999f-6580a7775f60"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e9473f3032842009abc88dcbd4241bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTMtMS0xLTA_2cd2c7b8-51ea-408e-a18d-63dff8d34efa"
      unitRef="usd">453000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9850a5dd51c243e993ed526a423fca5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTUtMS0xLTA_964d7954-dc9e-4aa4-a5bb-9490902df4b6"
      unitRef="usd">453000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95ebce7e3847428bac65d9577590ffba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTctMS0xLTA_9ceec3ca-5c95-4375-a3e8-81e311c98c4d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2992f734d65487ea3350732210cf724_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTktMS0xLTA_a1125d16-882b-446a-9d7a-0eb66f3a07ba"
      unitRef="usd">391000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a61b67189614b05922be71c8c421962_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTExLTEtMS0w_6a56538a-9b5e-42ef-8336-def1f9012579"
      unitRef="usd">391000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i808dbd3f3e6e43ed9399f61bbb7b4055_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTEzLTEtMS0w_b3eeceb5-7d59-4d17-81da-0cac2f911e63"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i164de0f742494c9b8cd2d3f94f2923b9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTE1LTEtMS0w_be2ae58e-d2cf-4398-89c6-941ac9eb9036"
      unitRef="usd">347000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e5ffb4bcbf94ae0abcf664e4c6e1872_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMyLTE3LTEtMS0w_bfb518d3-b53a-4ea4-a553-73922edff96f"
      unitRef="usd">347000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i765e235347ca4df1873ed1248b331df8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTEtMS0xLTMwODQ_92fc6fe5-e114-4d62-a784-8b4615c62dca"
      unitRef="usd">259000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i817e3b1fea9f458fac0f6055c49641a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTMtMS0xLTMwODQ_147b0431-f24f-4bae-82c3-2c5833186029"
      unitRef="usd">22000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0433bcc5a7d7432f9bb4a1eb7ce37fd3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTUtMS0xLTMwODQ_67f1e05d-4e0d-4074-b9b1-f307e15276f7"
      unitRef="usd">281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic50b4573044e4647ac213a16ebc379d6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTctMS0xLTMwODQ_00d8ce18-ffc3-4beb-9989-2eeb2bcbd520"
      unitRef="usd">194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec6cea25192742dab7d8f55c6193e913_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTktMS0xLTMwODQ_dde3cf4a-9003-4b15-8b8f-12e97af8b7f6"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic118b67ceccb466faa220eb7ba62f56e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTExLTEtMS0zMDg0_f28ac939-8a8c-4e16-be03-ce2bc2f61536"
      unitRef="usd">204000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93a086b497c64ebbb2509e91e103680e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTEzLTEtMS0zMDg0_85b2286b-dff1-49eb-99e8-99aca9eb31f9"
      unitRef="usd">134000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8db350f249ba416299a4392f33c42f88_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTE1LTEtMS0zMDg0_68c9617c-f6ef-461c-9ed9-e922a641fff5"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifaaf6f8150b84a25a8315a1b493d2252_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTE3LTEtMS0zMDg0_973f98e6-f9e7-4c1a-b957-e1faaa32e7ea"
      unitRef="usd">139000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74ba25329bb24f2ebc68cfb217f3876e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTEtMS0xLTA_11372927-5b27-45a8-902b-3e2f7d66925a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieff1a0642517447883a7677e44f19609_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTMtMS0xLTA_2b7a6919-9844-4288-a5ff-922cd51240d7"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65dbfd32d29c4a1298cc6b005e57d0b0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTUtMS0xLTA_8d3723de-8b8f-4e4c-afeb-350e20b90e9d"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe5e33fbfd9e47729ed353ad56f6955b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTctMS0xLTA_48984506-ac64-4df6-a3d7-d92ac37bc698"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i428851a5d25042ebb249a9a84028610d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTktMS0xLTA_2e42fb83-0908-477c-a635-b546278fa5c5"
      unitRef="usd">215000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i471a2257c4e044cbb9b7a564c9ac71c3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTExLTEtMS0w_4d7b423f-d464-4772-8a02-3d6b4ff46fbb"
      unitRef="usd">215000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09a09f1a3abd48109fbe59b3fb93d141_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTEzLTEtMS0w_30382672-4735-48f4-9872-dddc9a14c92f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1404f852ad8849619c48eee49eecb017_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTE1LTEtMS0w_44342b35-462f-4900-91be-70495b21646f"
      unitRef="usd">190000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c819bf8048847f3984282adbf7f9562_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzMzLTE3LTEtMS0w_a60f0d7b-2290-4e36-8c88-ea0f75a5c867"
      unitRef="usd">190000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib453c2cf19634dcb9f7c38e577527fce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTEtMS0xLTA_f6f2e973-8a27-4881-9e41-d02de87b0fa4"
      unitRef="usd">1470000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a03414556c84b1f80a00b809a8ce3fc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTMtMS0xLTA_b9ce3773-bf8a-4688-ba0c-0d3e7cd34232"
      unitRef="usd">1836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b493f99d5764db3a3587eb876ab87f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTUtMS0xLTA_a05a3c65-912d-479a-a7fa-6f5b974dc63d"
      unitRef="usd">3306000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7650b81f2f948028475c26edc5c16eb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTctMS0xLTA_15647f23-7d01-4878-924d-09dd083a0dd8"
      unitRef="usd">1724000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifddd89c3eb0447f3be23aa56aa560afa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTktMS0xLTA_d8c7a49d-29cc-4f39-a41e-a5cbc65bc3da"
      unitRef="usd">1758000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i350c3286a7fe4a509add74cc2448733b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTExLTEtMS0w_c422ad2c-75f5-492f-b5b0-7c4d1e101074"
      unitRef="usd">3482000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifea6a755e6024199aadd27d792902ca8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTEzLTEtMS0w_ab91640d-97a7-4291-90f5-350faddbbc73"
      unitRef="usd">1969000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d8c9e4810f4401bb73a64a044563400_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTE1LTEtMS0w_ab2a737c-7fd1-4b22-8620-317ac6af6625"
      unitRef="usd">1718000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdc2a0905fa54560be844a4a5613db12_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM1LTE3LTEtMS0w_78ae010d-3fa1-4c15-bd36-cf9c776be358"
      unitRef="usd">3686000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08dc5fac7cd845a6bd3b00791e7e5b2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTEtMS0xLTA_154d9579-33b8-4339-a169-bbf45cf95e3b"
      unitRef="usd">477000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2950cbfe843d45e68f856f33961cba31_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTMtMS0xLTA_e8897f7d-c9df-4869-b434-5cd2518dfe05"
      unitRef="usd">1494000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icebba189d4a3458198db7346f2a6e713_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTUtMS0xLTA_ccce2c80-fc94-4bb1-804b-db2ae67fe1c9"
      unitRef="usd">1971000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id24f803edfbc4167bb3299a898ee2e13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTctMS0xLTA_aaa56e09-a44e-4033-9f40-8d81540eb9ce"
      unitRef="usd">589000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ddb314823aa47c6954a1f2feca8eebc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTktMS0xLTA_7c157a59-8c62-456d-acc9-33901bb7d3bf"
      unitRef="usd">1452000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8ae0bf62de4457894eb884499173f85_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTExLTEtMS0w_7f30def5-10c5-42e9-987a-b8a0044c0e76"
      unitRef="usd">2041000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9cb86dc9c584485fb7a5049e10ba046b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTEzLTEtMS0w_af13dddd-81e4-467e-a95f-1918758da564"
      unitRef="usd">811000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b7f8648b2f44883844130f1d90b85ca_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTE1LTEtMS0w_6592b7fc-a22d-458c-a3d8-36e2852a666d"
      unitRef="usd">1417000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5e1ba5291ab459dabb27adb7b97387a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM2LTE3LTEtMS0w_2b7b0532-1a84-4669-8c52-8dfc5566fa64"
      unitRef="usd">2228000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26737262a3c3462b96de8ebe023d1021_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTEtMS0xLTg2MzQ_a695b61c-6ce6-4515-aaf1-743aff8013d9"
      unitRef="usd">488000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3daaadb2da99469f970536fbd9f589ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTMtMS0xLTg2MzQ_c0fe8103-ffe2-4475-8710-74f9db4c100d"
      unitRef="usd">192000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia40a7732f3a44955b312d4698d4c6026_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTUtMS0xLTg2MzQ_80dc2139-fa63-481f-a889-dfaab86bfa4a"
      unitRef="usd">680000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83be474e89ab4750bd00aebc5eb6ad68_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTctMS0xLTg2MzQ_d9f44bc9-5bce-490a-8f7e-fcbc0c027a89"
      unitRef="usd">568000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id315307ab2cb4c808c77a47abdcb132c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTktMS0xLTg2MzQ_0f92bb6f-8e25-46e1-9fb2-debb0b27b1f2"
      unitRef="usd">219000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2d95952196a41059a02aa8be7602540_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTExLTEtMS04NjM0_1cbf2331-08db-46f0-8ecc-d813cd988689"
      unitRef="usd">787000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id961d5e81bdf4ce5b89fc5130610e285_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTEzLTEtMS04NjM0_d4f9486d-1337-4f3d-a0e2-70bac49899df"
      unitRef="usd">495000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia103de5e6cbe4fb2a104961a19138f6d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTE1LTEtMS04NjM0_44a15485-f1eb-42d3-a03e-e1436254291a"
      unitRef="usd">208000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie39a5cbe975a499289e9b0481f88571c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTE3LTEtMS04NjM0_fdaf50a1-83d1-4e78-aa44-e122a386fb73"
      unitRef="usd">703000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id37ee02873134a16a7d2ac745f1f3efb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTEtMS0xLTA_d2e1d4f8-15fb-4152-9153-14f88b0cf2c0"
      unitRef="usd">110000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e9f2daaae4745d2ae55c4ff7963f472_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTMtMS0xLTA_6d60a926-c58f-4c71-acdb-30def4a59f6b"
      unitRef="usd">127000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f2a922a9abe43d5a57491ba600cf3d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTUtMS0xLTA_e8dd353a-dac9-4992-ba62-112c3ed3b870"
      unitRef="usd">236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bbaa3f0d655424f8b54cbdd948628ac_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTctMS0xLTA_81bb9f85-9927-463c-a045-6909240e8622"
      unitRef="usd">742000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d42283095d74b78ad5e947157ee6849_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTktMS0xLTA_3f03de13-c205-413b-ae59-2620c8055354"
      unitRef="usd">136000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i509aa0b5030e4f4e8b6a1b0424b3b2b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTExLTEtMS0w_c1c2b013-dfa3-4c70-9bc4-f45a07256e39"
      unitRef="usd">879000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e10e6c25c3b4557a099fe326409b993_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTEzLTEtMS0w_99716498-c1dc-4683-b292-fe1fb4a47a8f"
      unitRef="usd">722000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd7a07462ffa4e17bc9007b49e82bb59_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTE1LTEtMS0w_8d700d3c-1727-4665-b64d-a3a4af5d0b3a"
      unitRef="usd">180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2aa9ecb4f9e4493aa7973a44ec374287_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzM4LTE3LTEtMS0w_a8b59d4d-6d2e-4eb4-a37d-92b5dd54ffb9"
      unitRef="usd">902000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i218d611e83f64fffadaf940a7b0b4fb6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTEtMS0xLTA_8d63fb8d-93ed-474e-9bc3-2b0b72a9652d"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id76b73811b3549068b674f9ad76a7123_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTMtMS0xLTA_58b3bc8d-59c2-4d96-9085-cdd86142dfd8"
      unitRef="usd">444000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95423e666a3b4e49b40bfdea87560d09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTUtMS0xLTA_7e3d7aba-c606-4c5f-b5cc-1c8b5d38d934"
      unitRef="usd">462000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7f702272ab94a368cb9cf9ce09c4a23_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTctMS0xLTA_6937644a-2dad-411a-8777-de10279448f7"
      unitRef="usd">29000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5266d257b030492988eccda7eea5b5de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTktMS0xLTA_b9dc5db3-ff60-482e-ae7f-44b145343d71"
      unitRef="usd">669000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9cdce5f66d1e44a484b2b6697296c809_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTExLTEtMS0w_ff4af05f-a686-4820-921e-9e887691a3d9"
      unitRef="usd">698000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief1b7ba9d9fb403ab62cdc18b6eb0b30_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTEzLTEtMS0w_e5c43cdd-93d3-4b7f-a1a4-48b43919002e"
      unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e9d8e4e0a1e40b5989ef83e9ec5eec8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTE1LTEtMS0w_eff49f75-866d-4142-95e0-25b84221f0e6"
      unitRef="usd">688000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11fc958fd5eb46b88f87a1d5fd077ea1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQxLTE3LTEtMS0w_92d9a8f4-d767-42e1-adc2-b3b7dc255cc8"
      unitRef="usd">708000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7eafdbc1aa0149d59422d69d95d29318_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTEtMS0xLTA_e4d7263c-cace-49b0-bb2f-69945df5932e"
      unitRef="usd">21000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i925822b570a24b5ca88a9c40184078f4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTMtMS0xLTA_3a187870-7ffa-4253-b0e5-c8503c121d99"
      unitRef="usd">365000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1df1b6b114284f41a95dbc2dad95ed8e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTUtMS0xLTA_65413ce9-b1b3-4253-a4d5-2ff86c3c23de"
      unitRef="usd">386000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i966a056f15d24b6d807f7b9fcf634f8a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTctMS0xLTA_255acc25-81cf-4d5f-9a0a-96d42b79d767"
      unitRef="usd">24000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83c7ec1f79b043b5b18d5e72d1499fdb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTktMS0xLTA_cee7a834-d6a9-4c99-bbdb-b72ac8ae2c2e"
      unitRef="usd">418000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8352fe1a5ba54b86949f5c412a8f6d84_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTExLTEtMS0w_ae8b45d6-4a14-4367-a2ed-7098a7b79db0"
      unitRef="usd">442000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fcf3dfb4b9a4b46a7e562cb5174729e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTEzLTEtMS0w_d520c61b-6311-47cb-8ad8-2a25d6bd16ba"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b3b6478297d44108e0c4b7a552445ed_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTE1LTEtMS0w_6e231732-b512-475b-9132-26981143ff45"
      unitRef="usd">431000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ba005e9d4424eb3975bed7e80cec408_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQyLTE3LTEtMS0w_fa421cdd-5145-4b2b-b445-df69679816c8"
      unitRef="usd">453000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id46eaf3fcf0744889088ffbbc1e457c5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTEtMS0xLTg2NDM_da711246-3868-4f02-8316-9dbd310ffbc5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2213ab4b32ee478b9b62e4101ed98e0d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTMtMS0xLTg2NDM_addfc9c0-e69e-41af-9c0d-492d52d10a79"
      unitRef="usd">258000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3be092e6e874de493898709ec58bcd6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTUtMS0xLTg2NDM_3a4e276e-e9d6-4e71-9396-da42a0a09b32"
      unitRef="usd">258000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i574e546b62164a8a9f5caddcf3c862e0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTctMS0xLTg2NDM_d9b80d41-ff41-42dd-b45d-c065441dfb1d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i976d902516444c31a4ac366db6d832da_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTktMS0xLTg2NDM_eecf5302-c8ae-4278-b6a0-99990ba92bb2"
      unitRef="usd">288000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccebb2ddc10e443c8537cc870f8ba888_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTExLTEtMS04NjQz_f4a9506e-cfa7-486c-bb0d-5a7d27b5a3fc"
      unitRef="usd">288000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2839ccfa8fb44d8fa8ebd57a2d4c45a6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTEzLTEtMS04NjQz_f1026b36-fc5d-405c-ab3d-3143c59eafe7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ca98a5ab938484c825c7201cf25965b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTE1LTEtMS04NjQz_eb19b14f-68a4-4e89-a6c0-ccd333f1d180"
      unitRef="usd">335000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8d15a37330f4dd78bdfeef167d3a769_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTE3LTEtMS04NjQz_88b31743-5e77-4f13-af48-84e0d28ffb58"
      unitRef="usd">335000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i512a98056064477d978b1b7f932b53ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTEtMS0xLTA_02444081-8ef2-47c9-9699-70c9ca256c54"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifae8562aa19d49e0880f0646e4267477_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTMtMS0xLTA_f8afa91a-b444-422a-a50d-ebe92f5e21a6"
      unitRef="usd">206000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6de3ad1081d5496086b75ba3dfaa828e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTUtMS0xLTA_46c185b2-5493-4a77-8de3-85f8674ee20f"
      unitRef="usd">218000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i220331bcd9ca417b9f8990a1d20fde9e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTctMS0xLTA_b40c9280-2575-4e89-94ca-d2741f1b7585"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibce7dbd95b264cac956659757d0b8dcb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTktMS0xLTA_adbf07f4-5c65-4cac-846b-2ab90a46d50b"
      unitRef="usd">284000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8c7919a2fdb48038043cef3080be5a6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTExLTEtMS0w_60663b35-f8df-40d1-bbcf-5a0cc953a6d3"
      unitRef="usd">293000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc3e04a9593148d0a9fbc6099bd71fcb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTEzLTEtMS0w_d187aecd-26dd-43d4-98ac-073ff711f7ce"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic63b0377678244a6b0daa177fa91da22_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTE1LTEtMS0w_29956701-d577-4642-a876-e8487e7af230"
      unitRef="usd">353000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51cccff8d27547a1a031e6d2ddfe47e1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQzLTE3LTEtMS0w_cdcd32cc-070c-496d-b824-96a933411594"
      unitRef="usd">376000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0395da8cb60645ceb3126a26ed0ca226_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTEtMS0xLTA_0239f5a1-c003-46ba-9e5b-4bda6519d448"
      unitRef="usd">84000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45440e929de74f10b63f714199cbcbe9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTMtMS0xLTA_4520e2da-525f-4130-8629-c1612fd9b817"
      unitRef="usd">109000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1082609c81ca485f837033633e3ff2ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTUtMS0xLTA_3e13df4b-741a-48e5-82c9-718fdd07da7a"
      unitRef="usd">193000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bb74f29937f40e19f43e122a3376b3f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTctMS0xLTA_b4bb1b05-a972-476f-9b9a-21149ed381f4"
      unitRef="usd">103000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3193b9aa442a468b835ac9e65c53542f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTktMS0xLTA_cfc04558-ef4f-40c2-bc62-b0c5e91db59f"
      unitRef="usd">138000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3ffea7f6f1e4e4983ca7cd6779d45a7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTExLTEtMS0w_ca2bc995-7b70-4101-9b11-3eb42205166d"
      unitRef="usd">241000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ef571096a444eea921f01711727d9bc_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTEzLTEtMS0w_b6198917-d39d-4bed-a016-9a7bb9dc2bac"
      unitRef="usd">115000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14375f6d274a48d9b9b162940b4d25dc_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTE1LTEtMS0w_b8479d15-6661-453e-ade3-a659e69e60a9"
      unitRef="usd">153000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94fd88fa633844479351964383e1f158_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ1LTE3LTEtMS0w_9065bc2a-170e-4741-9000-e8201cad0b8d"
      unitRef="usd">268000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i962fd40d3ee6484299bd3c87f64af7d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTEtMS0xLTA_f12cdc90-f3be-43e0-8267-688134ade01c"
      unitRef="usd">1555000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic416aba94535424bbb9d655ecaf8bf86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTMtMS0xLTA_0df4d5c9-ebb1-44c6-a8d3-e6f27845da13"
      unitRef="usd">3152000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i462d9a562b7d44599cf894438401f0f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTUtMS0xLTA_c92f4539-2da5-4417-9c55-9587d9d828ba"
      unitRef="usd">4709000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab7af0cf69df426784f6ec3b33bf0fc2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTctMS0xLTA_b6df3080-d7cc-4e28-a6af-ac2645c95464"
      unitRef="usd">1416000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14dca43e6ead40a69e7edfc8b772ec1c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTktMS0xLTA_c5556428-1d76-4d74-9685-092614f7032f"
      unitRef="usd">3204000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4054ed0640d4d4eb44198419c1c1fcb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTExLTEtMS0w_179a8d27-4da0-424b-b29c-b99a5734925e"
      unitRef="usd">4615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80e5cfb7bf144a1b85dbe4460106c525_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTEzLTEtMS0w_a1315fc4-86de-458f-8bcb-cd6098838d68"
      unitRef="usd">1231000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib55dcf9079e34da1816b08c7ce38d62e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTE1LTEtMS0w_ba359726-9674-4cae-8895-2849fdeedfe7"
      unitRef="usd">3308000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i576b22bb76944f53a3d4648c3b0410c6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ2LTE3LTEtMS0w_7c1ae496-e3d1-4d81-88b9-9a558814d7ef"
      unitRef="usd">4546000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64789569b5264809a363eb25117c7863_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTEtMS0xLTA_a3bacbd4-89cf-4615-8d2b-79769478ce40"
      unitRef="usd">19449000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86793e8a3a894c159132ce9f8e6c1bb8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTMtMS0xLTA_75bb7018-8493-4e4a-8e18-d273c21595bc"
      unitRef="usd">23572000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTUtMS0xLTA_427ba0f6-c3f2-4ae6-b741-2866c25bbad0"
      unitRef="usd">43021000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4c9e4693f50403c8339af126a90a689_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTctMS0xLTA_320ea6b7-5b1c-47ba-8a6e-e04f182b3d5d"
      unitRef="usd">18953000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e48594fc2d243a0a8f39b754d4d89c1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTktMS0xLTA_cb353b09-1153-4312-b060-49a02e2b7079"
      unitRef="usd">22798000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTExLTEtMS0w_6ef67bfd-6f69-4d9a-af4c-5bd1fea1bcab"
      unitRef="usd">41751000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49bc3f554ac349838de0563f48fcffe4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTEzLTEtMS0w_8f5c20e3-a82a-4ecb-98e0-382bfaeeebe6"
      unitRef="usd">16742000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2ed8c22a5e8422ab95386f092f05a22_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTE1LTEtMS0w_04cc32b8-e5fb-48ca-ba96-049b882edcd0"
      unitRef="usd">20947000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ3LTE3LTEtMS0w_a19e1fb6-b029-4e04-8cc5-2eb6244099d6"
      unitRef="usd">37689000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf30c9ce3ea34204891eeb2f7d539507_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTEtMS0xLTA_26501b89-dba3-4bb4-87fc-2036169b2758"
      unitRef="usd">612000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72ec6b2d07874cabb0d1efdbf4e854df_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTMtMS0xLTA_57a0f159-dccc-4997-9289-699c06467f0a"
      unitRef="usd">2327000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0ccff3c21c3473e96622780327f8b12_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTUtMS0xLTA_c1cda7fd-8e93-45ac-b9ef-95485362bc02"
      unitRef="usd">2939000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9210f70f2d443e5889ab66abde4d50f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTctMS0xLTA_16df4880-0a9a-48fd-a5d5-7ee43ed71fde"
      unitRef="usd">582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia72cf7144b3a4b4b8c1e9ca00c55b8f4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTktMS0xLTA_424ecbd7-d796-46d0-9717-5bf676bbecfc"
      unitRef="usd">2201000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09dc1fc46d8f403fbb3dee2b1027efac_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTExLTEtMS0w_95cf13da-c4f4-4351-80d2-b08a8b03ef2c"
      unitRef="usd">2784000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib820ec90c26a48c1b63f85dba3250264_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTEzLTEtMS0w_f22c68be-6ffc-4265-92dd-ecd8ef45a0cf"
      unitRef="usd">528000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d198392ab6443c6b3cd53afafd9c428_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTE1LTEtMS0w_ae07abf2-cda1-4770-8547-95b5c2f34f26"
      unitRef="usd">2102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iacae1b4908084fab9344e4706e647c20_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzQ5LTE3LTEtMS0w_2b8daa0d-6e5c-43b5-86c6-48ce89c8fb9c"
      unitRef="usd">2630000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f8aa3dff7c84cbd81161181b2b08825_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTEtMS0xLTA_715b036c-a958-46b3-a77f-7254de8adedb"
      unitRef="usd">872000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6859c10e69f430d9106fa8705843e30_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTMtMS0xLTA_d04ffef3-6599-47e5-929c-4ff85ebd9516"
      unitRef="usd">892000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b389087e5b6434f8d9e6fddb68235bc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTUtMS0xLTA_db64ad21-f9e7-4d4b-8294-3143b52f5620"
      unitRef="usd">1764000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13e7a6ff124a4cdabf9930385a1ebb81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTctMS0xLTA_0f09d386-add3-49cb-8278-e5f97a8f1a28"
      unitRef="usd">724000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i531cef5b6df84d26b7bf2ea92797ba73_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTktMS0xLTA_a130e469-9ddd-405b-8716-4b601db650a0"
      unitRef="usd">885000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa6bd27f83f148fa904f54b109976d82_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTExLTEtMS0w_3965e26d-2146-40cc-b073-75c7a2fba244"
      unitRef="usd">1609000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37a62c431e03427790bd62d76d11d85a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTEzLTEtMS0w_7c80d958-8bde-4e51-a7bc-205a048892ae"
      unitRef="usd">710000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5f63110b9c74d60afa7701608b4e568_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTE1LTEtMS0w_19291237-2602-49c0-9be6-ab0182c9a31c"
      unitRef="usd">872000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99ae00b7d39b4af0b551da02254dc1fc_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUwLTE3LTEtMS0w_bd800aad-c8ab-4ebf-8bb1-56a664cc38d3"
      unitRef="usd">1582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3d960b8f6d74e02b74dbdf263f7040a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTEtMS0xLTA_0df90ff9-2b60-4568-85c5-b9980c50c633"
      unitRef="usd">1484000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebadcf45558049f9945a6997f511f459_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTMtMS0xLTA_c027c91b-14bf-4d0f-8b55-4bdde5a0c2ad"
      unitRef="usd">3219000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTUtMS0xLTA_dda9cbb9-160d-4247-9ac2-050acf36ccf8"
      unitRef="usd">4703000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72d58d6fc48c42c586a14d29d0057c85_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTctMS0xLTA_ff5f066a-eca9-4906-9369-955b3602e1fa"
      unitRef="usd">1306000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i383680c7a3bf42a8acc1ed3448266a57_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTktMS0xLTA_14d26005-cc67-49cc-83ae-ff7e3c74ee31"
      unitRef="usd">3086000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTExLTEtMS0w_04452d4f-42b2-43cb-8b90-b62081084573"
      unitRef="usd">4393000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6da7dfe4fb3a43148b28617382d7d627_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTEzLTEtMS0w_b0706861-2728-4c8b-bded-f28ec85da9eb"
      unitRef="usd">1238000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic14adb31336c4a369b484fe90e397510_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTE1LTEtMS0w_4d9e7640-4766-4ace-9e5d-fa361e184a81"
      unitRef="usd">2974000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUxLTE3LTEtMS0w_2dc07705-676c-4734-bca1-c5cfe3c2c8a3"
      unitRef="usd">4212000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45187d95cd0942edb66dab8c766886f8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTEtMS0xLTA_aaa73f3b-a611-4a48-bff4-c4cc89327825"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0bd2491b77054229931de28963068e3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTMtMS0xLTA_952c200a-de9f-4795-b85b-0837634e85f6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id33fa4b2aac9444684437df21be88b83_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTUtMS0xLTA_18a579af-21b3-41a7-aa48-142612f7e9bd"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e19eadf02e2447689f31531525302de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTctMS0xLTA_09ef41de-d951-4571-913e-5e5085697ae2"
      unitRef="usd">174000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90a2e88969d1400e802b86560797eb1f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTktMS0xLTA_f18f4304-548b-40cb-8de2-3ac556476f70"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb55cd05c52044ecac300d08fac63719_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTExLTEtMS0w_e0b43c3b-0e8a-45fe-8d9e-828d12f7bdeb"
      unitRef="usd">175000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19b5c015e07a4757829cb06ce4b2aa8b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTEzLTEtMS0w_973b23f5-a3b6-4f33-ae2c-43839b51f228"
      unitRef="usd">248000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i058927efa4b7468ba0ad2de228285af8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTE1LTEtMS0w_eb16b031-b242-4f90-bdf8-5ca16ee0d392"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUyLTE3LTEtMS0w_decf781e-2a2b-4e5d-a759-aad2e2bdb3d0"
      unitRef="usd">250000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78b124f26fbc4ed6bfea843c38aef53c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTEtMS0xLTA_3327907d-87a8-46a5-827b-306a173ae5a0"
      unitRef="usd">20956000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c11152ee28442a6a313d7ee0d121638_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTMtMS0xLTA_868f47bf-9a5e-42b4-ae83-08c842936502"
      unitRef="usd">26791000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTUtMS0xLTA_dd9210c7-0cc8-4949-aa06-095ff795048d"
      unitRef="usd">47747000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8b8a326cbb045a2adba2e477e561ffb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTctMS0xLTA_cc349eb7-f357-4ff6-a4a6-236f41fd68f4"
      unitRef="usd">20433000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic75220e6ebf14568819bd9a9b6188619_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTktMS0xLTA_c31820b1-2364-445a-b0df-7110b72cbb62"
      unitRef="usd">25885000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTExLTEtMS0w_c522715d-df7f-402c-b369-cb987c9b1372"
      unitRef="usd">46319000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia318474dcd744baa89624395a2172f09_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTEzLTEtMS0w_ee154d9f-2f73-4fe8-a7ef-4bdc19fb092d"
      unitRef="usd">18228000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54197fbcf9eb44bfb6b566fc98512a15_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTE1LTEtMS0w_a8c5b300-40ff-43cb-aceb-dc644c7fd563"
      unitRef="usd">23923000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzUzLTE3LTEtMS0w_cfffc731-836c-42f2-95c0-aea4be694d51"
      unitRef="usd">42151000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a981d56b4f645fe9eeeed274c7cba3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTEtMS0xLTA_f68ff27b-46fe-4558-83f2-bd2be7758846"
      unitRef="usd">71000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d10a58948e44c138c7d0466ca49b76c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTMtMS0xLTA_b87c5792-9abe-4496-a79c-c788326c29b2"
      unitRef="usd">176000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ed37ac5584840178c946fee09f7a1c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTUtMS0xLTA_8b9d4b62-395b-4f40-8570-fc8d2c18b767"
      unitRef="usd">247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9d9ba332d224e66a279d66f036bb8d5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTctMS0xLTA_17a6a682-7caf-4017-8e94-0c41248cc3a1"
      unitRef="usd">86000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30c943b762ec4138807d933021b95604_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTktMS0xLTA_972444a1-ab5e-4715-9883-d30581382e3d"
      unitRef="usd">436000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i729d5aea6d6f496f88811f7efeda63ca_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTExLTEtMS0w_b49cc878-a45a-4ac9-acf6-06158ecbcd32"
      unitRef="usd">521000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9b0fceaafb44bd1aa406949729a0241_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTEzLTEtMS0w_7c49bdd9-3c95-4d8e-add2-c53d0ec125b2"
      unitRef="usd">118000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62d5bac46f7047728d72dfe5c070cbbf_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTE1LTEtMS0w_7cb17a86-711f-4472-ad89-ac3619c17440"
      unitRef="usd">26000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b957d86897d4ded98362051c9b71b26_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU0LTE3LTEtMS0w_70ad4daa-06cf-4e5f-8948-fa3705ad3950"
      unitRef="usd">143000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5949335831d149739ca8f936d4b7a57c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTEtMS0xLTA_1f38626d-9a62-4882-ae38-4afb05ae7cab"
      unitRef="usd">21027000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaad2b34e87e0423a9ea15f4ae64ee1bf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTMtMS0xLTA_46700fd2-c625-4827-b27c-fd6fc3127e5f"
      unitRef="usd">26967000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTUtMS0xLTA_c160d4bf-3176-4dba-b1be-9e562bce9529"
      unitRef="usd">47994000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia16d15f92eef46998d5ead2a1b1771a9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTctMS0xLTA_f50f55eb-1a81-4e53-9a67-b0f6854bae7d"
      unitRef="usd">20519000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0dd811805a64591b10c10d7d8c3a94e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTktMS0xLTA_51cb2f39-9613-49b7-9cce-c6eb9dcfcd4b"
      unitRef="usd">26321000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTExLTEtMS0w_adb152c2-6a38-45f3-b7e0-b012ce51a9f2"
      unitRef="usd">46840000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5401793db14442e29e91d912fc6f3de8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTEzLTEtMS0w_1b5cb1de-aa04-4655-8a7b-0b27c2fe5e8c"
      unitRef="usd">18346000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id687c9edba674c009de90ff41d9177bb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTE1LTEtMS0w_c0276c5d-127e-40cc-9ba2-ce18763f3613"
      unitRef="usd">23949000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo1ZWZkNzllNDc5ZTQ0NDUwOTJhMjQ0MzQ1ZWRkNWU0NC90YWJsZXJhbmdlOjVlZmQ3OWU0NzllNDQ0NTA5MmEyNDQzNDVlZGQ1ZTQ0XzU1LTE3LTEtMS0w_f19ba06d-769b-4774-ac18-69e2469ff5c4"
      unitRef="usd">42294000000</us-gaap:Revenues>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3NDQ_8d448d05-3fc5-475d-affb-56f290b8b45d">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,624&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,376&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,864&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,274&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="i5949335831d149739ca8f936d4b7a57c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzEtMS0xLTEtMA_9c87ae20-3d33-498c-be0c-48b915b0dfb8"
      unitRef="usd">21027000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia16d15f92eef46998d5ead2a1b1771a9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzEtMy0xLTEtMA_0564f54a-6ba6-4481-8e37-5ad95f0ee3ab"
      unitRef="usd">20519000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5401793db14442e29e91d912fc6f3de8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzEtNS0xLTEtMA_5c3dac65-f0ac-4aac-83c5-bcb078db75ad"
      unitRef="usd">18346000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9717f9d6b3c445492a8c653a191c33e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzItMS0xLTEtMA_5f47f993-d38e-4371-aa25-eed2666e84aa"
      unitRef="usd">13600000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if83be0173217465a96cf353e15212445_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzItMy0xLTEtMA_9ad3b09b-6a1f-4127-8637-41f68e62da4f"
      unitRef="usd">12707000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b092f6738974424a865248091f7861b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzItNS0xLTEtMA_577cdec1-ecf5-4478-ad4e-19faf1412ef5"
      unitRef="usd">12213000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0fa67cf15634c3098a5ad2740b26a0e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtMS0xLTEtMTMwOTI_b393c0b8-1bed-4ae1-ae6d-20767473055a"
      unitRef="usd">3624000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8db75135b55642678e951aa56e432e6d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtMy0xLTEtMTMwOTI_cca62d5d-8f2f-418f-b9b8-c3ef4ed19e49"
      unitRef="usd">3207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36735be07e1646a08e5d2a7ed37255c9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtNS0xLTEtMTMwOTI_e49f4018-714f-4013-9137-10a1713e3150"
      unitRef="usd">2184000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37fd9b761d8b4af6bff239e1d9eb1a83_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtMS0xLTEtMA_080e95b5-d673-4198-985c-8356acc4123f"
      unitRef="usd">3376000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8e3f46fa37d451a8e35adb77e7ff6bc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtMy0xLTEtMA_2b67ab42-d43c-4198-8d9b-a2092db07a5f"
      unitRef="usd">3583000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ba30e2338734c24914a82cefe965a84_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzMtNS0xLTEtMA_888d1b47-0603-4d97-9bf5-e0ae9d5e6f72"
      unitRef="usd">3212000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8df174afc3444428bb70e46b35047e30_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzUtMS0xLTEtMA_e63e07aa-6665-4f4c-beef-2a7e11f9caa5"
      unitRef="usd">2864000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i716b88505d1e48bf95997e445c69d7e8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzUtMy0xLTEtMA_1d7dde77-53b5-42fe-8f51-3905d66ef62d"
      unitRef="usd">2943000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2bbf21a381224062a3ec08810f278afd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzUtNS0xLTEtMA_68e37e48-9c95-4da1-b788-ff36ccd29fa5"
      unitRef="usd">2909000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1e5d06897a04de68392658f8d0f8904_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzYtMS0xLTEtMA_b174ffea-0c78-4252-9404-256cb1c78941"
      unitRef="usd">2274000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3310a35e6b0403a81733f2e2057d4ab_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzYtMy0xLTEtMA_0b3a6d18-55ca-403e-b7c9-02d04f24d131"
      unitRef="usd">2469000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba4a6cec336e42db876f0c5690a9b6d4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzYtNS0xLTEtMA_0f6f893b-53b3-49f1-a968-969744acd487"
      unitRef="usd">2415000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c03523e781649d89f6ad179f060154a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzctMS0xLTEtMA_e4ed6335-c06e-44ac-b44a-940af0626eb3"
      unitRef="usd">1229000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7262343d9a65444c927cc6b62cffc5f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzctMy0xLTEtMA_d8c12a8a-9ec6-4eb5-a9e6-29fd431cb53a"
      unitRef="usd">1412000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4370b43741f1402a91671b54edbf2db7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzctNS0xLTEtMA_d6cc6b2f-7e40-4b11-9ca6-c8bac5eb8aab"
      unitRef="usd">1015000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzgtMS0xLTEtMA_621b406b-9ed5-479d-b646-5b2ce48dd627"
      unitRef="usd">47994000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzgtMy0xLTEtMA_704f72e2-ac4b-4c87-b33e-61c0e6abd149"
      unitRef="usd">46840000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTo2ZTM2NTNkNGM2MjU0NDI4YWQyYmI3NjQzODA2MzI1NC90YWJsZXJhbmdlOjZlMzY1M2Q0YzYyNTQ0MjhhZDJiYjc2NDM4MDYzMjU0XzgtNS0xLTEtMA_7ecfba94-b007-43e4-8444-c903c7d5dee9"
      unitRef="usd">42294000000</us-gaap:Revenues>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3MjU_8a972910-1388-44f0-8f02-89a4f5f14d31">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income before taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,722&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge related to the termination of a collaboration with Samsung&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income Before Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,791&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzItMS0xLTEtMA_631e19ae-fe31-4b7c-b66e-e5bf340c7439"
      unitRef="usd">29722000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzItMy0xLTEtMA_2428036f-778d-48cc-b982-683104475d49"
      unitRef="usd">28324000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzItNS0xLTEtMA_8e7906e3-7924-405b-8745-0d095dbcb5f7"
      unitRef="usd">24871000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzMtMS0xLTEtMA_a19c18cb-64c8-4850-8af9-df01a8ebe377"
      unitRef="usd">1650000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzMtMy0xLTEtMA_535ae1c2-3b5f-4c83-9390-8e774ace842e"
      unitRef="usd">1609000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzMtNS0xLTEtMA_c738b0ff-36f8-4720-9a42-1cdf3b3925eb"
      unitRef="usd">1659000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id33fa4b2aac9444684437df21be88b83_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzQtMS0xLTEtMA_843271b8-dc48-4799-a759-024a2d84a1fa"
      unitRef="usd">1000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idb55cd05c52044ecac300d08fac63719_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzQtMy0xLTEtMA_27d53615-0e4c-4443-955f-1cacd0323268"
      unitRef="usd">-7000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzQtNS0xLTEtMA_c7491e1e-2e05-48e7-805d-95fcb4b8cd76"
      unitRef="usd">103000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzUtMS0xLTEtMA_af4e48b5-d4fc-4476-92b5-342cc417b07e"
      unitRef="usd">31373000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzUtMy0xLTEtMA_d4fb8ef2-f708-49f7-a7d4-493eadbe75ae"
      unitRef="usd">29926000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzUtNS0xLTEtMA_7bda5347-b555-473b-b9e4-8a532e8775b6"
      unitRef="usd">26633000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8ed37ac5584840178c946fee09f7a1c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzYtMS0xLTEtMA_db1131cd-663b-439e-a90e-9d99c4f17e04"
      unitRef="usd">140000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i729d5aea6d6f496f88811f7efeda63ca_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzYtMy0xLTEtMA_cc41ed7b-b828-4059-893c-5f8fab029835"
      unitRef="usd">363000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3b957d86897d4ded98362051c9b71b26_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzYtNS0xLTEtMA_ffd091e0-d4e7-4372-ac07-b0998fa3aae8"
      unitRef="usd">6000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzgtMS0xLTEtMA_d242569f-2512-4d45-8380-7e5071b343d1"
      unitRef="usd">59000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzgtMy0xLTEtMA_f67012ec-778c-4861-bf05-6f2ab60cd9c9"
      unitRef="usd">274000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzgtNS0xLTEtMA_29d25a0e-8f6b-4544-a498-0d05ec03c656"
      unitRef="usd">343000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzktMS0xLTEtMA_f4478931-0f91-47a7-9ab6-aa757bc70ac7"
      unitRef="usd">831000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzktMy0xLTEtMA_6fb27083-21b1-4f58-a6cd-604d04641b25"
      unitRef="usd">893000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzktNS0xLTEtMA_8895cf79-22ed-4df2-be8b-ba7969bf2b12"
      unitRef="usd">772000000</us-gaap:InterestExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEwLTEtMS0xLTA_953203e7-016e-4101-aba6-711ea26f66f2"
      unitRef="usd">1602000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEwLTMtMS0xLTA_9b10636d-ffcd-438f-814e-f164b58578f8"
      unitRef="usd">1593000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEwLTUtMS0xLTA_aca97e7d-3b38-4be3-9a5f-de7f6e62b5c0"
      unitRef="usd">1352000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzExLTEtMS0xLTA_2366eb8c-0db1-4599-bba2-31564283cede"
      unitRef="usd">13072000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzExLTMtMS0xLTA_76f450c7-ec46-48c1-adc5-31b47b8773a9"
      unitRef="usd">9499000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzExLTUtMS0xLTA_4a8f8b45-a4a8-43e0-af4f-81e80e3c5d12"
      unitRef="usd">9432000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:AmortizationOfPurchaseAccountingAdjustments
      contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEyLTEtMS0xLTA_2e30db45-ba46-48ed-970b-3d800600dd45"
      unitRef="usd">1168000000</mrk:AmortizationOfPurchaseAccountingAdjustments>
    <mrk:AmortizationOfPurchaseAccountingAdjustments
      contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEyLTMtMS0xLTA_43ab7723-54b8-4802-94bb-38cc990013c4"
      unitRef="usd">1406000000</mrk:AmortizationOfPurchaseAccountingAdjustments>
    <mrk:AmortizationOfPurchaseAccountingAdjustments
      contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEyLTUtMS0xLTA_d27ec4c3-b935-4750-805a-02ee77a81a8f"
      unitRef="usd">2664000000</mrk:AmortizationOfPurchaseAccountingAdjustments>
    <us-gaap:RestructuringCharges
      contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEzLTEtMS0xLTA_21da1bb8-8880-429f-9bb0-8e1466822841"
      unitRef="usd">578000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEzLTMtMS0xLTA_092d7b47-270a-4c97-8892-68e1a747ce21"
      unitRef="usd">638000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzEzLTUtMS0xLTA_0e705dd6-694f-4760-8fc4-451f8a42dbaf"
      unitRef="usd">632000000</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnContractTermination
      contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE0LTEtMS0xLTA_88ffe264-9704-4fb1-a4c9-b56da7800ae9"
      unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE0LTMtMS0xLTA_601713cc-af3f-4a7e-8466-8cec6d08e0f1"
      unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE0LTUtMS0xLTA_091ee08d-bb2b-4bd5-b829-4643af9a9f8a"
      unitRef="usd">423000000</us-gaap:GainLossOnContractTermination>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="iaac14dc59a7447f3898dd54fb665907d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE2LTEtMS0xLTA_6f5a5836-de4a-4bdb-8074-165f2fc006bf"
      unitRef="usd">5530000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i87b8442f973f429c9f17ca02b8bc2328_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE2LTMtMS0xLTA_f66b5818-618f-493d-a783-9d31938ba4c2"
      unitRef="usd">5070000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i48337f9d410f4331865ea7985ef7b977_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE2LTUtMS0xLTA_048a3124-8578-4c98-ab0c-d22fb4fa15f6"
      unitRef="usd">3006000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE3LTEtMS0xLTA_1b2605f8-c067-406c-bcbc-d929ad366c71"
      unitRef="usd">8791000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE3LTMtMS0xLTA_51c9aa61-2e02-4a54-9321-4a39a8b8b25b"
      unitRef="usd">11464000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZToyODIxMmRhOGI0Y2E0ZTJlYjkxMjUwOTVmNjg0Yjc1Mi90YWJsZXJhbmdlOjI4MjEyZGE4YjRjYTRlMmViOTEyNTA5NWY2ODRiNzUyXzE3LTUtMS0xLTA_d0f50a45-30d5-45aa-8571-16f031b5b4f3"
      unitRef="usd">8701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3MzY_2655e83a-070b-40e0-bc01-22b47c51b130">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity (income) loss from affiliates and depreciation and amortization included in segment profits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity (income) loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;690&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity (income) loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity (income) loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzMtMS0xLTEtMA_ecbb5f03-3b43-430e-b0c8-b0df2412e42e"
      unitRef="usd">-6000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzMtMy0xLTEtMA_f8e756f3-f623-4408-9d0e-aca69188bc08"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id33fa4b2aac9444684437df21be88b83_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzMtNS0xLTEtMA_e3b5a0f1-a065-485e-8288-74febeea0cfc"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzMtNy0xLTEtMA_d60feefc-7a0c-4ee9-9275-d9f6eab5b3e2"
      unitRef="usd">-6000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7153d96119be480bb9f7eb5845d3acf6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzQtMS0xLTEtMA_1aaa351f-5afb-403e-82eb-68176e98cd50"
      unitRef="usd">690000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4e678d8a0d5c4318ba5bcaff38eed133_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzQtMy0xLTEtMA_170d930e-4a5b-4ae2-af15-245ade74cf8d"
      unitRef="usd">164000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id33fa4b2aac9444684437df21be88b83_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzQtNS0xLTEtMA_37bac231-3c81-4c74-9da8-6c318696a472"
      unitRef="usd">1000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzQtNy0xLTEtMA_aee54fea-069c-4616-965f-3af0490ced63"
      unitRef="usd">855000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzctMS0xLTEtMA_36bdad60-6436-4fd6-80ba-465f6532e589"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzctMy0xLTEtMA_165935c2-ac57-49a2-8176-765fad20c2e1"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idb55cd05c52044ecac300d08fac63719_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzctNS0xLTEtMA_bade4662-e980-49bc-9fa1-88a88cac53de"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzctNy0xLTEtMA_aa2a7479-9af9-4e70-86ae-d76969c3c25c"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iad9f5bdf9bf949dfb54c999a1722bd21_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzgtMS0xLTEtMA_4c067151-ae50-4a37-a50e-53986bf454a0"
      unitRef="usd">534000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if5e5240123ec46b49886e3aaec3f1b4e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzgtMy0xLTEtMA_fc4d47f8-1e96-4da7-bf2a-09323f6a2ff0"
      unitRef="usd">109000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idb55cd05c52044ecac300d08fac63719_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzgtNS0xLTEtMA_0c079a07-c804-477d-83b3-d0f36c5a3f7b"
      unitRef="usd">10000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie89cf83a7865410bb2bfa2e3ff8f5366_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzgtNy0xLTEtMA_fc236d52-f659-4bdf-848b-9e3f8e02b613"
      unitRef="usd">653000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzExLTEtMS0xLTA_db0e1202-0da8-4598-ad14-7e95b9351502"
      unitRef="usd">-4000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzExLTMtMS0xLTA_ad912165-1940-41b4-b266-584620e2eccf"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzExLTUtMS0xLTA_120de255-4df6-47b1-a361-f44c20ca4873"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzExLTctMS0xLTA_e045325b-0294-437a-a83d-00887ecdc506"
      unitRef="usd">-4000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3c0da2395f9b465285fb453474fe164f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzEyLTEtMS0xLTA_a1acc387-ea5d-468a-8157-c4ff537f1bf3"
      unitRef="usd">411000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie73167ac59814e28b8fcb4b5970496cd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzEyLTMtMS0xLTA_b352f47d-918e-43d1-85f2-b48ae5bd4fb0"
      unitRef="usd">82000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic3dbec799b744590984e625ad0b04be8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzEyLTUtMS0xLTA_dc7d1516-97c7-49c1-acaf-8ad4e0656b5d"
      unitRef="usd">10000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1177eb21fd4543d49c4265ea1062b1b7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTplYmZmYTM4OWQ0MGE0YjE3YmJkZWUzYjhmOTU0MGRmYy90YWJsZXJhbmdlOmViZmZhMzg5ZDQwYTRiMTdiYmRlZTNiOGY5NTQwZGZjXzEyLTctMS0xLTA_705e77b8-0430-49e3-9b4f-ec20213e7dee"
      unitRef="usd">503000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
      contextRef="i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90ZXh0cmVnaW9uOmZiMzY2MGFmMTNkODRmYTg4ODk0YjcxOTgwY2UwNTk4XzU3NDY_9cc134d0-6b24-466e-9d51-931477ecafbc">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, by geographic area where located is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i129f29a2040140c08baabf19b38dddd3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzEtMS0xLTEtMA_bc81f7e1-c802-4e86-88d8-e315e1998d66"
      unitRef="usd">10526000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i184871e21ba348d1b81fad633a38d169_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzEtMy0xLTEtMA_079e2942-1da8-401d-bd1c-61c44c0429ab"
      unitRef="usd">8974000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib70ed1d184c44bd8ba1ed708cad91d61_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzEtNS0xLTEtMA_fc1b8648-bc6f-4a24-a949-8829548dc813"
      unitRef="usd">8306000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3e575aafa15847fba6a21907ae53dd63_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzItMS0xLTEtMA_1ac8b3bb-89e2-49b4-b9d7-cc657a6a92a5"
      unitRef="usd">6059000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie08c0043b99c4e2ba8e47c65a339ceb1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzItMy0xLTEtMA_e0720867-9b9e-45da-8ac9-5a8604d5eeda"
      unitRef="usd">4767000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8c346b2768fb40dd91ac6ebba9fb94d7_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzItNS0xLTEtMA_89360585-8a8f-4a4f-8e3a-abb816dfc006"
      unitRef="usd">3706000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if2f235c0c07d4506bd10df5031278985_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzMtMS0xLTEtMA_a61e88f9-824d-4909-96a0-5363489ba3e8"
      unitRef="usd">761000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8d1c311fbe544e15a962f0cdcb5479e3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzMtMy0xLTEtMA_17b24c18-ccdd-4979-bc9c-2efd78ec926b"
      unitRef="usd">714000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if6a7538040e541f19698e90ed9663cbf_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzMtNS0xLTEtMA_4b7e4c3d-601c-49d9-bb4a-c2659d646ffe"
      unitRef="usd">684000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2f4efdd418f74b408cf00135e5d118c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzQtMS0xLTEtMA_8ea9af88-4798-407f-bac0-6d951004e777"
      unitRef="usd">252000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5b72e0433646475693a6cb7d2df40022_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzQtMy0xLTEtMA_688b3c43-1f7d-4cbc-bc88-8b5f65282822"
      unitRef="usd">266000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6390040a02294303a155f1923472865c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzQtNS0xLTEtMA_3c6d65d3-4ec6-4468-87d0-42212af26aaf"
      unitRef="usd">264000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iee4add6d698c44de8cd75978f383e97c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzUtMS0xLTEtMA_332eda68-2cd9-4b67-8f55-0b87e6867d1b"
      unitRef="usd">217000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie2cad22821de46f29ac5d2e479eed81b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzUtMy0xLTEtMA_60b87b5c-8f1a-4d89-a2d6-543fe003880f"
      unitRef="usd">174000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i52040186e8344d189b9e280fb7fe1b2e_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzUtNS0xLTEtMA_bc3b9164-b7a9-4480-9474-f92e5d8b2294"
      unitRef="usd">167000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i88687f58720d4395a2d6dfdd03bea675_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzYtMS0xLTEtMA_6bf556ae-91b0-4465-8158-6915f0e4c6f2"
      unitRef="usd">166000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3d0b0e5a61604c6e866e7abdc8b2f909_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzYtMy0xLTEtMA_2945e94c-dc9a-4421-ad0b-e59ef062c3bd"
      unitRef="usd">152000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4dbc20679af844698cd41359e5fd718f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzYtNS0xLTEtMA_19ddccab-88b3-4e8e-a264-19b1375e433b"
      unitRef="usd">159000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i78313bb854a147e5a42efbba390205fc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzctMS0xLTEtMA_84c27e02-c503-4e31-8194-149e4df4ae4c"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8ef9755b84b746e88b21161ca9f7a0f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzctMy0xLTEtMA_a8b990ce-be56-4d92-809d-1cb6c830f740"
      unitRef="usd">6000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i265675dad9e342e9b47878356a5b781d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzctNS0xLTEtMA_c53f21ab-9113-48db-867f-4d54a5dbc49a"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i16ad2dca7dc9466c926cfba76668c892_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzgtMS0xLTEtMA_e95d5e98-fabb-400f-ae67-25193311dee2"
      unitRef="usd">17986000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if65645d9ce3443819f0f193e3bf67acc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzgtMy0xLTEtMA_304f8a60-ada5-4b0e-8d98-93005f30e9ca"
      unitRef="usd">15053000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0ef6045954534437abb1993aa1937f07_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8yMjkvZnJhZzpmYjM2NjBhZjEzZDg0ZmE4ODg5NGI3MTk4MGNlMDU5OC90YWJsZTpiMTRkOWJiNjg2YzY0NDRlOWEzZDE1NGFjN2U5YjEwOC90YWJsZXJhbmdlOmIxNGQ5YmI2ODZjNjQ0NGU5YTNkMTU0YWM3ZTliMTA4XzgtNS0xLTEtMA_f5a56274-707e-4f3f-a657-90fddfd4290a"
      unitRef="usd">13291000000</us-gaap:PropertyPlantAndEquipmentNet>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300421942664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-6571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merck&#160;& Co., Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">740-4000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1918501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 Galloping Hill Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Kenilworth<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock ($0.50&#160;par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,530,315,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,461,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000310158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;25, 2021, to be filed with the <br/>Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.125Notesdue2021Member', window );">1.125% Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member', window );">0.500% Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member', window );">1.875% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.875% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member', window );">2.500% Notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.500% Notes due 2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member', window );">1.375% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 36A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.125Notesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.125Notesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300415191464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 47,994<span></span>
</td>
<td class="nump">$ 46,840<span></span>
</td>
<td class="nump">$ 42,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">15,485<span></span>
</td>
<td class="nump">14,112<span></span>
</td>
<td class="nump">13,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">10,468<span></span>
</td>
<td class="nump">10,615<span></span>
</td>
<td class="nump">10,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,558<span></span>
</td>
<td class="nump">9,872<span></span>
</td>
<td class="nump">9,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(886)<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="num">(402)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CostsExpensesAndOther', window );">Total costs, expenses and other</a></td>
<td class="nump">39,203<span></span>
</td>
<td class="nump">35,376<span></span>
</td>
<td class="nump">33,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">8,791<span></span>
</td>
<td class="nump">11,464<span></span>
</td>
<td class="nump">8,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on Income</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">7,082<span></span>
</td>
<td class="nump">9,777<span></span>
</td>
<td class="nump">6,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net Income (Loss) Attributable to Noncontrolling Interests</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 7,067<span></span>
</td>
<td class="nump">$ 9,843<span></span>
</td>
<td class="nump">$ 6,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders (in dollars per share)</a></td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CostsExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of cost of sales, operating expenses and nonoperating income or expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CostsExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429965704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 7,067<span></span>
</td>
<td class="nump">$ 9,843<span></span>
</td>
<td class="nump">$ 6,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive Loss Net of Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized (loss) gain on derivatives, net of reclassifications</a></td>
<td class="num">(297)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized (loss) gain on investments, net of reclassifications</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
<td class="num">(425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(648)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 6,626<span></span>
</td>
<td class="nump">$ 9,195<span></span>
</td>
<td class="nump">$ 5,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300417600200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,062<span></span>
</td>
<td class="nump">$ 9,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable (net of allowance for doubtful accounts of $85 in 2020 and $86 in 2019)</a></td>
<td class="nump">7,851<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (excludes inventories of $2,197 in 2020 and $1,480 in 2019 classified in Other assets - see Note&#160;7)</a></td>
<td class="nump">6,310<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">5,541<span></span>
</td>
<td class="nump">4,277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">27,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property, Plant and Equipment (at cost)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">12,645<span></span>
</td>
<td class="nump">11,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery, equipment and office furnishings</a></td>
<td class="nump">16,649<span></span>
</td>
<td class="nump">15,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">7,324<span></span>
</td>
<td class="nump">5,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment (at cost)</a></td>
<td class="nump">36,968<span></span>
</td>
<td class="nump">32,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="nump">18,982<span></span>
</td>
<td class="nump">17,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">17,986<span></span>
</td>
<td class="nump">15,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">20,238<span></span>
</td>
<td class="nump">19,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other Intangibles, Net</a></td>
<td class="nump">14,604<span></span>
</td>
<td class="nump">14,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">10,211<span></span>
</td>
<td class="nump">6,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">91,588<span></span>
</td>
<td class="nump">84,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">6,431<span></span>
</td>
<td class="nump">3,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="nump">4,594<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">13,053<span></span>
</td>
<td class="nump">12,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,327<span></span>
</td>
<td class="nump">22,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">25,360<span></span>
</td>
<td class="nump">22,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Taxes</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="nump">12,482<span></span>
</td>
<td class="nump">11,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Other paid-in capital</a></td>
<td class="nump">39,588<span></span>
</td>
<td class="nump">39,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">47,362<span></span>
</td>
<td class="nump">46,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,634)<span></span>
</td>
<td class="num">(6,193)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' equity before deduction for treasury stock</a></td>
<td class="nump">82,104<span></span>
</td>
<td class="nump">81,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury stock, at cost: 1,046,877,695 shares in 2020 and 1,038,087,496 shares in 2019</a></td>
<td class="nump">56,787<span></span>
</td>
<td class="nump">55,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</a></td>
<td class="nump">25,317<span></span>
</td>
<td class="nump">25,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interests</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">25,404<span></span>
</td>
<td class="nump">26,001<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">$ 91,588<span></span>
</td>
<td class="nump">$ 84,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300418832648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 2,197<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">1,046,877,695<span></span>
</td>
<td class="nump">1,038,087,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300412039736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Other Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Loss </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- controlling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 34,569<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 39,902<span></span>
</td>
<td class="nump">$ 41,350<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="num">$ (4,910)<span></span>
</td>
<td class="num">$ (274)<span></span>
</td>
<td class="num">$ (43,794)<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">6,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018)</a></td>
<td class="num">(5,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(9,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">26,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">38,808<span></span>
</td>
<td class="nump">42,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,929)<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">9,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018)</a></td>
<td class="num">(5,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(4,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">26,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">39,660<span></span>
</td>
<td class="nump">46,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,950)<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">7,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018)</a></td>
<td class="num">(6,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 25,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 39,588<span></span>
</td>
<td class="nump">$ 47,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (56,787)<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429477944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300515233816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 7,082<span></span>
</td>
<td class="nump">$ 9,777<span></span>
</td>
<td class="nump">$ 6,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">1,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Intangible asset impairment charges</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ChargeForAssetAcquisition', window );">Charge for the acquisition of VelosBio Inc.</a></td>
<td class="nump">2,660<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Charge for the acquisition of Peloton Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions', window );">Charge for future payments related to collaboration license options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(668)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,002)<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(855)<span></span>
</td>
<td class="num">(508)<span></span>
</td>
<td class="num">(911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="num">(341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">560<span></span>
</td>
<td class="num">(2,359)<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Noncurrent liabilities</a></td>
<td class="num">(453)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="num">(2,426)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(674)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">10,253<span></span>
</td>
<td class="nump">13,440<span></span>
</td>
<td class="nump">10,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(4,684)<span></span>
</td>
<td class="num">(3,473)<span></span>
</td>
<td class="num">(2,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity', window );">Purchase of Seagen Inc. common stock</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of securities and other investments</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(3,202)<span></span>
</td>
<td class="num">(7,994)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales of securities and other investments</a></td>
<td class="nump">2,812<span></span>
</td>
<td class="nump">8,622<span></span>
</td>
<td class="nump">15,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired', window );">Acquisition of VelosBio Inc., net of cash acquired</a></td>
<td class="num">(2,696)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of ArQule, Inc., net of cash acquired</a></td>
<td class="num">(2,545)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired', window );">Acquisition of Antelliq Corporation, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,620)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired', window );">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Other acquisitions, net of cash acquired</a></td>
<td class="num">(1,365)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash (Used in) Provided by Investing Activities</a></td>
<td class="num">(9,443)<span></span>
</td>
<td class="num">(2,629)<span></span>
</td>
<td class="nump">4,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="nump">2,549<span></span>
</td>
<td class="num">(3,710)<span></span>
</td>
<td class="nump">5,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on debt</a></td>
<td class="num">(1,957)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">4,419<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(4,780)<span></span>
</td>
<td class="num">(9,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid to stockholders</a></td>
<td class="num">(6,215)<span></span>
</td>
<td class="num">(5,695)<span></span>
</td>
<td class="num">(5,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(436)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used in Financing Activities</a></td>
<td class="num">(2,832)<span></span>
</td>
<td class="num">(8,861)<span></span>
</td>
<td class="num">(13,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(1,769)<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6)</a></td>
<td class="nump">9,934<span></span>
</td>
<td class="nump">7,967<span></span>
</td>
<td class="nump">6,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6)</a></td>
<td class="nump">$ 8,165<span></span>
</td>
<td class="nump">$ 9,934<span></span>
</td>
<td class="nump">$ 7,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ChargeForAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge for asset acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ChargeForAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge for future payments related to collaboration license options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Five, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Four, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire equity securities classified as available-for-sale securities, because they are not classified as trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300531894296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300422000104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#8217;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had an Alliances segment that primarily included activity from the Company&#8217;s relationship with AstraZeneca LP related to sales of Nexium and Prilosec, which concluded in 2018. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned Spin-Off of Women&#8217;s Health, Biosimilars and Established Brands into a New Company </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, Merck announced its intention to spin-off products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed late in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women&#8217;s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410098552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Accounting Policies</a></td>
<td class="text">Summary of Accounting Policies<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates </span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the duration and extent to which fair value is less than cost. An other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to other factors is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.1 billion in 2020, $11.8 billion in 2019 and $10.7 billion in 2018. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $249 </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and $2.9 billion, respectively, at December&#160;31, 2020 and were $233 million and $2.2 billion, respectively, at December&#160;31, 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzU2_e83aaddf-6760-4d99-a679-17c8ad2698ac">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic competition, changes in formularies or launch of over-the-counter products, among others. Outside of the United States, returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the United States, payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for disaggregated revenue disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and from 3 to 15&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Depreciation expense was $1.7 billion in 2020, $1.7 billion in 2019 and $1.4 billion in 2018.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion Costs &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.0 billion in 2020, $2.1 billion in 2019 and $2.1 billion in 2018.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, licenses, trade names and patents, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years (see Note&#160;8). The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as an acquisition of a business, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company retrospectively adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#8217;s collaborative arrangements (see Note 4 and Note 18). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard&#160;Not Yet Adopted &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411846200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Research Collaborations and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock', window );">Acquisitions, Divestitures, Research Collaborations and License Agreements</a></td>
<td class="text">Acquisitions, Divestitures, Research Collaborations and License Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million. In addition, OncoImmune shareholders will be eligible to receive up to $255&#160;million of future contingent regulatory approval milestone payments and tiered royalties ranging from 10% to 20%. OncoImmune&#8217;s lead therapeutic candidate MK-7110 (also known as CD24Fc) is being evaluated for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19). The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50&#160;million for a 20% ownership interest in the new entity, which was valued at $33&#160;million resulting in a $17&#160;million premium. Merck also </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized other net liabilities of $22&#160;million. The Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $462&#160;million in 2020 related to this transaction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio&#8217;s lead investigational candidate is MK-2140 (formerly known as VLS-101), an antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180&#160;million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $2.7 billion in 2020 related to the transaction. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $616&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6&#160;billion, including $850&#160;million in development milestones and $1.75&#160;billion in sales-based  milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65&#160;million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;256&#160;million ($302&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289&#160;million and other net assets of $13&#160;million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401&#160;million related to currently marketed products and inventory of $9&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, also known as EIDD-2801), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments of up to $740&#160;million. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $97&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;D of $136&#160;million, cash of $59&#160;million, deferred tax assets of $70&#160;million and other net liabilities of $32&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $230&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;D impairment charge of $90&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. The Company also recorded a reduction in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses resulting from a decrease in the related liability for contingent consideration of $45&#160;million since future contingent milestone payments have been reduced to $450&#160;million in the aggregate, including up to $60&#160;million for development milestones, up to $196&#160;million for regulatory approval milestones, and up to $194&#160;million for commercial milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#8217;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305&#160;million in 2020, of which $260&#160;million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related to fixed-asset and materials write-offs, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining $45&#160;million of costs were reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95&#160;million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. ArQule&#8217;s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as an acquisition of a business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible asset related to IPR&amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#945; (HIF-2&#945;) for the treatment of patients with cancer and other non-oncology diseases. Peloton&#8217;s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2&#945; inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $1.2 billion; additionally, former Peloton shareholders will be eligible to receive $50 million upon U.S. regulatory approval, $50 million upon first commercial sale in the United States, and up to $1.05 billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $52 million, and other net liabilities of $4 million at the acquisition date, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $993 million in 2019 related to the transaction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq&#8217;s debt. The transaction was accounted for as an acquisition of a business. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.721%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from 18-24 years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results for 2019 include eight months of activity for Antelliq, while the Company&#8217;s results in 2020 include 13 months of activity. The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approaches to enable the body&#8217;s immune system to fight disease, for $301 million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company recorded an aggregate charge of $423 million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conjunction with the termination of a collaboration agreement entered into in 2014 with Samsung Bioepis Co., Ltd. (Samsung) for insulin glargine. The charge reflects a termination payment of $155 million, which represents the reimbursement of all fees previously paid by Samsung to Merck under the agreement, plus interest, as well as the release of Merck&#8217;s ongoing obligations under the agreement. The charge also included fixed asset abandonment charges of $137 million, inventory write-offs of $122 million, as well as other related costs of $9 million. The termination of this agreement had no impact on the Company&#8217;s other collaboration with Samsung.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Merck acquired Viralytics Limited (Viralytics), an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers, for AUD 502 million ($378 million). The transaction provided Merck with full rights to V937 (formerly known as CVA21), an investigational oncolytic immunotherapy. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $34 million (primarily cash) at the acquisition date and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $344 million in 2018 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, Merck and Eisai Co., Ltd. (Eisai) entered into a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima, an orally available tyrosine kinase inhibitor discovered by Eisai (see Note 4). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade/Simponi</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1998, a subsidiary of Schering-Plough entered into a licensing agreement with Centocor Ortho Biotech Inc. (Centocor), a Johnson&#160;&amp; Johnson (J&amp;J) company, to market </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is prescribed for the treatment of inflammatory diseases. In 2005, Schering-Plough&#8217;s subsidiary exercised an option under its contract with Centocor for license rights to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fully human monoclonal antibody. The Company has marketing rights to both products throughout Europe, Russia and Turkey. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lost market exclusivity in major European markets in 2015 and the Company no longer has market exclusivity in any of its marketing territories</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to have market exclusivity for </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in all of its marketing territories. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All profits derived from Merck&#8217;s distribution of the two products in these countries are equally divided between Merck and J&amp;J. The Company&#8217;s marketing rights with respect to these products will revert to Janssen Pharmaceuticals, Inc. in the second half of 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to acquisitions, divestitures, research collaborations and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411314536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text">Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below.</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor currently approved for certain types of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#8217;s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, for multiple indications. In April 2020, Koselugo was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options (of which $250 million was paid in December 2017, $400 million was paid in December 2018 and $100 million was paid in December 2019). The upfront payment and license option payments were reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2017. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $400 million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded $400 million of liabilities and corresponding increases to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $550 million, $200 million and $250 million was paid to AstraZeneca in 2020, 2019 and 2018, respectively. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $160&#160;million, $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.3 billion at December&#160;31, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">733</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai of $750 million in 2018 and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). The Company recorded an aggregate charge of $1.4 billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2018 related to the upfront payment and future option payments. In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $400 million from Merck to Eisai. Accordingly, Merck recorded liabilities of $400 million and corresponding increases to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million related to Lenvima, of which $500 million and $50 million&#160;was paid to Eisai in 2020 and 2019, respectively. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $10&#160;million and $250 million, respectively, from Merck to Eisai. Potential future regulatory milestone payments of $125 million remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at December&#160;31, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount for 2018 includes $1.4 billion related to the upfront payment and option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer&#8217;s Verquvo (vericiguat), which was approved by the FDA in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults. Verquvo is under review by regulatory authorities in other territories including the EU and Japan. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck will commercialize in the United States and Bayer will commercialize in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas (and will record sales of Verquvo) in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, Merck accrued $725 million of sales-based milestone payments for this collaboration, of which $375&#160;million and $350 million was paid to Bayer in 2020 and 2018, respectively. Following the 2021 FDA approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone payment. Accordingly, Merck will record a liability of $400&#160;million and a corresponding increase in intangible assets related to this collaboration in the first quarter of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $849 million at December&#160;31, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410186360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, Merck&#160;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program now estimated to be approximately $3.0 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $700 million in 2021 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $883 million in 2020, $927 million in 2019 and $658 million in 2018 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2020, Merck has recorded total pretax accumulated costs of approximately $1.8 billion. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2020, 2019 and 2018 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;13) and share-based compensation. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(809)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">567</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">603</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be substantially completed by the end of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410147272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:35.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020,&#160;five interest rate swaps with notional amounts of&#160;$250&#160;million&#160;each matured. These swaps effectively converted the Company&#8217;s&#160;$1.25&#160;billion,&#160;1.85%&#160;fixed-rate notes due 2020 to variable rate debt. At December&#160;31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% notes due 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These interest rate swaps matured in January 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:43.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,714</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32,784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collateral posted/received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(886)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:41.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company estimates $331 million of pretax net unrealized losses on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2020 were $163 million during 2020. Unrealized net gains recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2019 were $160 million during 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company also had $586 million and $420 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During 2020 and 2019, the Company recognized unrealized gains of $62 million and $20 million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on certain of these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee. In addition, during 2020 and 2019, the Company recognized unrealized losses of $3 million and $13 million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, related to certain of these investments based on unfavorable observable price changes. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values were $169 million and $24 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,058</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include $6.8 billion and $8.9&#160;billion, respectively, of cash equivalents (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Balance at December&#160;31, 2020 includes $148 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At December&#160;31, 2020 and 2019, $711 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows and a risk-adjusted discount rate of 8% to present value the cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additions to contingent consideration in 2020 relate to the acquisition of Themis. The changes in the estimated fair value of liabilities for contingent consideration in 2020 and 2019 were largely attributable to increases in the liabilities recorded in connection with the termination of the Sanofi Pasteur MSD (SPMSD) joint venture in 2016. In 2020, the increase was partially offset by a decline related to the discontinuation of a COVID-19 vaccine program obtained through the acquisition of Themis. The payments of contingent consideration in both years relate to the SPMSD liabilities described above.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2020, was $36.0 billion compared with a carrying value of $31.8 billion and at December&#160;31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the United&#160;States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented, in aggregate, approximately 45% of total accounts receivable at December&#160;31, 2020. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.7 billion of accounts receivable in the fourth quarter of 2020 and 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2020 and 2019, the Company had collected $102 million and $256&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in January 2021 and 2020, respectively. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to counterparties was $36 million at December&#160;31, 2020. Cash collateral received by the Company from various counterparties was $34 million at December&#160;31, 2019. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410138520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,458&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,310</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised approximately $2.9 billion and $2.6 billion at December&#160;31, 2020 and 2019, respectively. Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2020 and 2019, these amounts included $1.9 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $279 million and $168 million at December&#160;31, 2020 and 2019, respectively, of inventories produced in preparation for product launches.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411457464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangibles</a></td>
<td class="text">Goodwill and Other Intangibles<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,238</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other includes cumulative translation adjustments on goodwill balances and certain other adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2020 and 2019. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The additions to goodwill in the Pharmaceutical segment in 2020 were primarily related to the acquisitions of ArQule and Themis (see Note 3). The additions to goodwill within the Animal Health segment in 2019 primarily relate to the acquisition of Antelliq (see Note 3). The impairments of goodwill within other non-reportable segments in 2019 relate to certain businesses within the Healthcare Services segment. The Healthcare Services segment was fully divested in the first quarter of 2020.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,329</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,196&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, licenses, trade names and patents, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. Some of the Company&#8217;s more significant acquired intangibles, on a net basis, related to human health marketed products (included in products and product rights above) at December&#160;31, 2020 include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $551 million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Implanon/Nexplanon,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $354 million; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, $276 million; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dificid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $228 million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $185 million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $154 million; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $132 million. Additionally, the Company had $5.4 billion of net acquired intangibles related to animal health marketed products at December&#160;31, 2020, of which $2.5&#160;billion relate primarily to trade names obtained through the 2019 acquisition of Antelliq (see Note 3). Some of the Company&#8217;s more significant net intangible assets included in licenses above at December&#160;31, 2020 include Lynparza, $1.3 billion and Lenvima, $1.1 billion as a result of collaborations with AstraZeneca and Eisai (see Note 4). At December&#160;31, 2020, IPR&amp;D primarily relates to MK-1026 obtained through the acquisition of ArQule in 2020 (see Note 3) and MK-7264 (gefapixant) obtained through the acquisition of Afferent Pharmaceuticals in 2016. The Company has an intangible asset related to a collaboration with Bayer (see Note 4) that had a carrying value of $849 million at December&#160;31, 2020 reflected in &#8220;Other&#8221; in the table above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company recorded an impairment charge of $1.6&#160;billion within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset for impairment. The Company revised its cash flow forecasts for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120&#160;million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2020 related to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recall. The remaining intangible asset balance related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $551 million at December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company recorded impairment charges related to marketed products and other intangibles of $705 million. Of this amount, $612 million related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a product for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive organisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the Company will make a separate determination as to the then useful life of the asset and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company recorded a $90 million IPR&amp;D impairment charge within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#8217;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45&#160;million (see Note 6).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company recorded $172 million of IPR&amp;D impairment charges. Of this amount, $155 million relates to the write-off of the intangible asset balance for programs obtained in connection with the acquisition of IOmet Pharma Ltd following a review of clinical trial results conducted by Merck, along with external clinical trial results for similar compounds. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $11 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company recorded $152 million of IPR&amp;D impairment charges. Of this amount, $139 million relates to the write-off of the remaining intangible asset balance for a program obtained in connection with the SmartCells acquisition following a decision to terminate the program due to product development issues. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $60 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense primarily recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $1.9 billion in 2020, $2.0 billion in 2019 and $3.1 billion in 2018. The estimated aggregate amortization expense for each of the next five years is as follows: 2021, $1.5 billion; 2022, $1.5 billion; 2023, $1.4 billion; 2024, $1.3 billion; 2025, $1.2 billion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300409860408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loans Payable, Long-Term Debt and Leases</a></td>
<td class="text">Loans Payable, Long-Term Debt and Leases<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans payable at December&#160;31, 2020 included $2.3 billion of notes due in 2021, $4.0 billion of commercial paper and $73 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2019 included $1.9 billion of notes due in 2020, $1.4 billion of commercial paper and $226 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.79% and 2.23% for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,238</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,233</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">991</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90% notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">746</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">719</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875% notes due 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.125% euro-denominated notes due 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes $294 million and $147 million at December&#160;31, 2020 and 2019, respectively, of borrowings at variable rates that resulted in effective interest rates of 0.45% and 2.54% for 2020 and 2019, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#8217;s option at any time, at varying redemption prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued $4.5&#160;billion principal amount of senior unsecured notes consisting of $1.0&#160;billion of 0.75% notes due 2026, $1.25&#160;billion of 1.45% notes due 2030, $1.0&#160;billion of 2.35% notes due 2040 and $1.25&#160;billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s borrowings require that Merck comply with covenants and, at December&#160;31, 2020, the Company was in compliance with these covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2021, $2.3 billion; 2022, $2.3 billion; 2023, $1.7 billion; 2024, $1.4 billion; 2025, $2.5 billion. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of eight years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company does not record short-term leases (leases with an initial term of 12 months or less) on the balance sheet; however, Merck currently has no short-term leases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#8217;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#8217;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost was $346&#160;million in 2020 and $339 million in 2019. Rental expense under operating leases, net of sublease income, was $322&#160;million in 2018. Cash paid for amounts included in the measurement of operating lease liabilities was $340&#160;million in 2020 and $281 million in 2019. Operating lease assets obtained in exchange for lease obligations was $495&#160;million in 2020 and $129 million in 2019. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_50622f13-ac81-4492-afe1-5ad4feaf94c9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_821d9613-2257-47a4-8e9e-6ec850c6c87e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_36307b76-5525-434a-87a2-55d497163500"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_ff6866b2-78de-4484-8932-0849a2e904bc">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_8ad1ce04-1366-42d1-95f3-bf2b967b7e47"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_a770729c-7273-4447-83c4-49a31ce0554f">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes prepaid leases that have no related lease liability.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $475 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300409833000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Environmental Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Environmental Liabilities</a></td>
<td class="text">Contingencies and Environmental Liabilities <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Litigation). As of December&#160;31, 2020, approximately 3,520 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn v. Merck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the jury returned a verdict in Merck&#8217;s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck&#8217;s motion for judgment as a matter of law in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case and held that the plaintiff&#8217;s failure to warn claim was preempted by federal law.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court&#8217;s preemption decision in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#8217;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#8217;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#8217; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, as of December&#160;31, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, approximately 2,270 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are four Femur Fracture cases pending in other state courts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2020, Merck is aware of approximately 1,480 product users alleging that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the development of pancreatic cancer and other injuries. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the MDL and California State Court, in separate opinions, granted summary judgment to defendants on grounds of federal preemption. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment and expert motions. Briefing of those motions is complete and hearings before both the MDL and California State Court judges took place on October 20 and December 8, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#8217;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(relating to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter discussed above). Merck filed </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that preemption presents a legal question to be resolved by the court. In May 2020, the Illinois Appellate Court issued a mandate to the state trial court, which, as of December 31, 2020, had not scheduled a case management conference.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck reached a settlement with the Attorney General of Utah to fully resolve the state&#8217;s previously disclosed civil lawsuit alleging that Merck misrepresented the safety of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As part of the resolution, Merck paid the state $25&#160;million. The settlement does not constitute an admission by Merck of any liability or wrongdoing. This agreement marks the final resolution of litigation involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. There is ongoing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation in certain countries outside the United States.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#8217;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#8217;s information request by seeking information relating to Merck&#8217;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#8217;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#8217;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#8217;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#8217;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#8217;s investigation and intends to produce information and/or documents as necessary in response to the CID.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Company&#8217;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#8217; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#8217; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#8217; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint and, in August 2019, retailer opt-out plaintiffs filed an amended complaint. In December 2019, the district court granted the Merck Defendants&#8217; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On August 21, 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of 35 direct purchasers, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted the Merck Defendants&#8217; motion for permission to appeal the district court&#8217;s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2020, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota against Merck and others (the UHC Action). The UHC Action makes similar allegations as those made in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class action. On September 23, 2020, the United States Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation already in progress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, Humana Inc. filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against Merck and others, alleging defendants violated state antitrust laws in multiple states. Also, on December 11, 2020, Centene Corporation and others filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana. Both lawsuits allege similar anticompetitive acts to those alleged in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class action. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rotavirus Vaccines Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, MSD is a defendant in putative class action lawsuits filed in 2018 on behalf of direct purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, alleging violations of federal antitrust laws. The cases were consolidated in the Eastern District of Pennsylvania. In January 2019, the court denied MSD&#8217;s motions to compel arbitration and to dismiss the consolidated complaint. In February 2019, MSD appealed the court&#8217;s order on arbitration to the Third Circuit. In October 2019, the Third Circuit vacated the district court&#8217;s order and remanded for limited discovery on the issue of arbitrability. On July 6, 2020, MSD filed a renewed motion to compel arbitration, and plaintiffs filed a cross motion for summary judgment as to arbitrability. On November 20, 2020, the district court denied MSD&#8217;s motion and granted plaintiffs&#8217; motion. On December 4, 2020, MSD filed a notice of appeal to the Third Circuit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the United States District Court for the District of New Jersey, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fluralaner) products in the United States or its territories between May 1, 2014 and December 27, 2019. The complaint contends </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">causes neurological events and alleges violations of the New Jersey Consumer </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fraud Act, Breach of Warranty, Product Liability, and related theories. A similar case was filed in Quebec, Canada in May 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;II vaccine, which charge that the Company misrepresented the efficacy of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#8217;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits have proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the Court. The Company continues to defend against these lawsuits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck KGaA Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2016, to protect its long-established brand rights in the United States, the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the United States, alleging it improperly uses the name &#8220;Merck&#8221; in the United States. KGaA has filed suit against the Company in France, the UK, Germany, Switzerland, Mexico, India, Australia, Singapore, Hong Kong, and China alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In the UK, Australia, Singapore, Hong Kong, and India, KGaA also alleges breach of the parties&#8217; coexistence agreement. The litigation is ongoing in the United States with no trial date set, and also ongoing in numerous jurisdictions outside of the United States; the Company is defending those suits in each jurisdiction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The FDA has granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides a further six months of exclusivity in the United States beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Including this exclusivity, key patent protection extends to January 2023. The Company anticipates that sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States will decline significantly after this loss of market exclusivity. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin, which, if determined to be valid, would preclude generic manufacturers from making sitagliptin phosphate salt and polymorphic forms before that patent, inclusive of pediatric exclusivity, expires in 2027 (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation which, inclusive of pediatric exclusivity, expires in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court has scheduled separate one-day trials on infringement issues in November 2021 through January 2022, to the extent such trials are necessary. In the Company&#8217;s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with nine generic companies providing that these generic companies can bring their products to the market in May 2027 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent, which other manufacturers joined. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision is expected in May 2021. If the challenges are successful, the unchallenged claims of the 2027 salt/polymorph patent will remain valid, subject to the court proceedings described above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the generic companies are successful, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could lose market exclusivity in Germany as early as July 2022. Challenges to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPC have also occurred in Portugal and Finland, and could occur in other European countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Microspherix LLC (Microspherix) sued the Company in the U.S District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringed several of Microspherix&#8217;s patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until those patents expire in May 2021. The Company brought</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR proceedings in the USPTO and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against the Company. The Company appealed the decisions finding claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO&#8217;s decisions. The matter is no longer stayed in the district court, and the Company is currently litigating the invalidity and non-infringement of the remaining asserted claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2020 and 2019 of approximately $250 million and $240 million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#8217;s potential liability varies greatly from site to site. For some sites the potential liability is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $67 million at both December&#160;31, 2020 and 2019. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $65 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410191848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merck certificate of incorporation authorizes 6,500,000,000&#160;shares of common stock and 20,000,000&#160;shares of preferred stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Stock</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company&#160;entered into accelerated share repurchase (ASR) agreements with two third-party financial institutions (the Dealers). Under the ASR agreements, Merck agreed to purchase&#160;$5 billion&#160;of Merck&#8217;s common stock, in total, with an initial delivery of 56.7 million&#160;shares of Merck&#8217;s common stock, based on the then-current market price, made by the Dealers to Merck, and payments of&#160;$5 billion&#160;made by Merck to the Dealers, which were funded with existing cash and investments, as well as short-term borrowings. Upon settlement of the ASR agreements in 2019, Merck received an additional 7.7 million shares as determined by the average daily volume weighted-average price of Merck&#8217;s common stock during the term of the ASR program, less a negotiated discount, bringing the total shares received by Merck under this program to 64.4 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410097720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation Plans</a></td>
<td class="text">Share-Based Compensation Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#8217;s shareholders.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, 100 million shares collectively were authorized for future grants under the Company&#8217;s share-based compensation plans. These awards are settled with treasury shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#8217;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#8217;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#8217;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total pretax share-based compensation cost recorded in 2020, 2019 and 2018 was $475 million, $417 million and $348 million, respectively, with related income tax benefits of $65 million, $57 million and $55 million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#8217;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price of options granted in 2020, 2019 and 2018 was $77.67, $80.05 and $58.15 per option, respectively. The weighted average fair value of options granted in 2020, 2019 and 2018 was $9.93, $10.63 and $8.26 per option, respectively, and were determined using the following assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.67</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(301)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.27</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable December 31, 2020</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58.30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.13</span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested January 1, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,627</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.79</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(728)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80.06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $678 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411255288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefit Plans</a></td>
<td class="text">Pension and Other Postretirement Benefit Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic Benefit Cost</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the&#160;following components:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in net periodic benefit cost year over year for pension plans are largely attributable to changes in the discount rate affecting net loss amortization. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;5), termination charges were recorded in 2020, 2019 and 2018 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the table above.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 14), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obligations and Funded Status</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.453%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,908</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">746</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,620&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,083&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial losses (gains) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,613</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,941)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,642)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(485)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(386)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">941</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,859)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,550)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,413)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,268)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(377)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Actuarial losses (gains) primarily reflect changes in discount rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the accumulated benefit obligation was $26.4 billion and $22.8 billion, respectively, for all pension plans, of which $14.4 billion and $12.8 billion, respectively, related to U.S. pension plans.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:63.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,613</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,526</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,484&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan Assets</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160; Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160; Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2020 and 2019, $942 million and $860 million, respectively, or approximately 4% of the Company&#8217;s pension investments were categorized as Level&#160;3 assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"/><td style="width:18.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,884</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,090</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">927</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,096</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,114</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">475</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,516</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,614</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">76</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,012</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,736</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:25.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.629%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.279%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"/><td style="width:18.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">374</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated 30% to 45% in U.S.&#160;equities, 15% to 30% in international equities, 35% to 45% in fixed-income investments, and up to 5% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 11%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Contributions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected contributions during 2021 are approximately $300 million for U.S. pension plans, approximately $170 million for international pension plans and approximately $35 million for other postretirement benefit plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Benefit Payments</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026&#160;&#8212;&#160;2030</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,271&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amounts Recognized in Other Comprehensive Income</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:28.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.990%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) gain arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(448)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(816)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Actuarial Assumptions</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:33.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#8217;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2021, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will range from 6.50% to 6.70%, as compared to a range of 7.00% to 7.30% in 2020. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Savings Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains defined contribution savings plans in the United States. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2020, 2019 and 2018 were $166 million, $149 million and $136 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411478280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text">Other (Income) Expense, Net<div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(886)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net (as presented in the table above) in 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net in 2018 includes a gain of $115 million related to the settlement of certain patent litigation, income of $99 million related to AstraZeneca&#8217;s option exercise in 2014 in connection with the termination of the Company&#8217;s relationship with AstraZeneca LP (AZLP), and a gain of $85 million resulting from the receipt of a milestone payment for an out-licensed migraine clinical development program. Other, net in 2018 also includes $144 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8), as well as $41 million of charges related to the write-down of assets held for sale to fair value in anticipation of the dissolution of the Company&#8217;s joint venture with Supera Farma Laboratorios S.A. in Brazil.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid was $822 million in 2020, $841 million in 2019 and $777 million in 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300431380072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Income</a></td>
<td class="text">Taxes on Income<div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income before taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs, including amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Peloton</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017 and the Company reflected the impact of the TCJA in its 2017 financial statements. However, since application of certain provisions of the TCJA remained subject to further interpretation, in certain instances the Company made reasonable estimates of the effects of the TCJA, which were since finalized and resulted in additional income tax expense in 2018 and 2019. The Company&#8217;s remaining transition tax liability under the TCJA, which has been reduced by payments and the utilization of foreign tax credits, was $3.0 billion at December&#160;31, 2020, of which $390 million is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the remainder of $2.6 billion is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the United States, particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2022), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. Towards the end of 2020, a new reduced tax rate arrangement was agreed to in Switzerland for certain newly active legal entities.  </span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before taxes consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,025&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on income consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(668)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">588</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">834</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,677</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,677</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2020, $464 million of deferred taxes on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $433 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $330 million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards, all of which are expected to be fully utilized prior to expiry.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid in 2020, 2019 and 2018 were $2.7 billion, $4.5 billion and $1.5 billion, respectively. Tax benefits relating to stock option exercises were $55 million in 2020, $65 million in 2019 and $77 million in 2018. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">298</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Amounts in 2019 reflects the settlement with the IRS discussed below. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  Amount in 2019 includes $78 million related to the divestiture of Merck&#8217;s Consumer Care business in 2014.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to recognize the unrecognized tax benefits of $1.5 billion at December&#160;31, 2020, the income tax provision would reflect a favorable net impact of $1.5 billion.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2020 could decrease by up to approximately $160 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#8217;s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $27 million in 2020, $(101) million in 2019 and $51 million in 2018. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $268 million and $243 million as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $364 million net tax benefit in 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS is currently conducting examinations of the Company&#8217;s tax returns for the years 2015 and 2016. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#8217;s income tax returns are open for examination for the period 2003 through 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411206424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,664&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.79</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019 and 2018, 5 million, 2 million and 6 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300409997208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:37.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.903%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1, 2018, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,910)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(716)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption of ASU 2018-02</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption of ASU 2016-01</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(599)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(299)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(488)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(631)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(279)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized (gains) losses on the sales of available-for-sale investments that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 13).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $5.4 billion and $5.1 billion at December 31, 2020 and 2019, respectively, and other postretirement benefit plan net gain of $391 million and $247 million at December 31, 2020 and 2019, respectively, as well as pension plan prior service credit of $255 million and $263 million at December 31, 2020 and 2019, respectively, and other postretirement benefit plan prior service credit of $244 million and $305 million at December 31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411560008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had an Alliances segment that primarily included activity from the Company&#8217;s relationship with AstraZeneca LP related to sales of Nexium and Prilosec, which concluded in 2018. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:30.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">8,352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">6,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">14,380</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">67</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">583</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,836</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">477</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">488</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diversified Brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">386</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,555</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">19,449</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">23,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">43,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">18,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">22,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">41,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">20,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">37,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">872</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,764</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,703</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">20,956</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">26,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">47,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">20,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">46,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">18,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the non-reportable segments of Healthcare Services (fully divested in the first quarter of 2020) and Alliances (which concluded in 2018). </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,376</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,274</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,722</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">140</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,664)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge related to the termination of a collaboration with Samsung</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,070)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,701&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity (income) loss from affiliates and depreciation and amortization included in segment profits is as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,526</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300431151784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates </span>over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the duration and extent to which fair value is less than cost. An other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related </span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to other factors is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.1 billion in 2020, $11.8 billion in 2019 and $10.7 billion in 2018. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $249 </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and $2.9 billion, respectively, at December&#160;31, 2020 and were $233 million and $2.2 billion, respectively, at December&#160;31, 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xNjMvZnJhZzpkMjVlZjU5ZWFhNWI0YzZjOGUxZjkyNjVjNTVkMTMyMi90ZXh0cmVnaW9uOmQyNWVmNTllYWE1YjRjNmM4ZTFmOTI2NWM1NWQxMzIyXzEyNzU2_e83aaddf-6760-4d99-a679-17c8ad2698ac">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic competition, changes in formularies or launch of over-the-counter products, among others. Outside of the United States, returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the United States, payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for disaggregated revenue disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock', window );">Depreciation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and from 3 to 15&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Promotion Costs</a></td>
<td class="text">Advertising and Promotion Costs &#8212; Advertising and promotion costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Software Capitalization</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Acquired Intangibles</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, licenses, trade names and patents, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years (see Note&#160;8). The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted </span>future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as an acquisition of a business, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">Research and Development&#160;&#8212;&#160;Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring Costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies and Legal Defense Costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxes on Income</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company retrospectively adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#8217;s collaborative arrangements (see Note 4 and Note 18). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard&#160;Not Yet Adopted &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Reclassifications&#160;&#8212;&#160;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discussion of the accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300408556856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Research Collaborations and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible asset related to IPR&amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.721%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from 18-24 years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410151496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">733</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount for 2018 includes $1.4 billion related to the upfront payment and option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300408562216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Charges Related to Restructuring Program Activities by Type of Cost</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and Spending Relating to Restructuring Activities by Program</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(809)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">567</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">603</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be substantially completed by the end of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300421940376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Effect of Net Investment Hedges</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:35.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Summary of Interest Rate Derivatives</a></td>
<td class="text">At December&#160;31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: <div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% notes due 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These interest rate swaps matured in January 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:43.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,714</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32,784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock', window );">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</a></td>
<td class="text">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collateral posted/received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Location and Pretax Gain or Loss Amounts for Derivatives</a></td>
<td class="text"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(886)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:41.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Information on Investments in Debt and Equity Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2020 were $163 million during 2020. Unrealized net gains recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2019 were $160 million during 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,058</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summarized Information about the Changes in Liabilities for Contingent Consideration</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Balance at December&#160;31, 2020 includes $148 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At December&#160;31, 2020 and 2019, $711 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows and a risk-adjusted discount rate of 8% to present value the cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OffsettingAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300409860408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,458&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,310</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411255288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill Activity by Segment</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,238</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other includes cumulative translation adjustments on goodwill balances and certain other adjustments.</span></div>(2) Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2020 and 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Other Intangibles</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,329</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,196&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430674504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,238</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,233</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">991</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90% notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">746</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">719</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875% notes due 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.125% euro-denominated notes due 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetsandLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_50622f13-ac81-4492-afe1-5ad4feaf94c9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzItMC0xLTEtMTkxMTc_821d9613-2257-47a4-8e9e-6ec850c6c87e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_36307b76-5525-434a-87a2-55d497163500"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzQtMC0xLTEtMTkxMTk_ff6866b2-78de-4484-8932-0849a2e904bc">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_8ad1ce04-1366-42d1-95f3-bf2b967b7e47"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNjU3N2JlNGMzODQwZmQ4MTgxYmRlZGY0NTdmYmE1L3NlYzphYjY1NzdiZTRjMzg0MGZkODE4MWJkZWRmNDU3ZmJhNV8xOTYvZnJhZzo3NTU1ZjliZGJiMzA0YWM4OTg1YjE3OGNmMDk1OGJhNy90YWJsZTo0NzRmYjc4OTM2MmU0OTQ5YjU5ZDI4OGFkNDNiZTg1Yi90YWJsZXJhbmdlOjQ3NGZiNzg5MzYyZTQ5NDliNTlkMjg4YWQ0M2JlODViXzUtMC0xLTEtMTkxMTk_a770729c-7273-4447-83c4-49a31ce0554f">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes prepaid leases that have no related lease liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetsandLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetsandLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411525496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Summary of Common Stock and Treasury Stock Transactions</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430806584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Weighted-Average Fair Value of Options Granted</a></td>
<td class="text">The weighted average fair value of options granted in 2020, 2019 and 2018 was $9.93, $10.63 and $8.26 per option, respectively, and were determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information Relative to Stock Option Plan Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.67</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(301)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.27</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable December 31, 2020</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58.30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.13</span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock', window );">Additional Information Pertaining to Stock Option Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Nonvested RSU and PSU Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested January 1, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,627</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.79</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(728)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80.06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional information pertaining to stock option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429445896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the&#160;following components:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Obligation and Funded Status</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.453%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,908</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">746</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,620&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,083&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial losses (gains) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,613</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,941)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,642)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(485)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(386)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">941</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,859)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,550)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,413)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,268)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(377)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Actuarial losses (gains) primarily reflect changes in discount rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock', window );">Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:63.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,613</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,526</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,484&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"/><td style="width:18.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,884</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,090</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">927</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,096</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,114</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">475</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,516</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,614</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">76</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,012</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,736</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"/><td style="width:18.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">374</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock', window );">Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:25.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.629%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.279%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Summary of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026&#160;&#8212;&#160;2030</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,271&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Other Comprehensive Income</a></td>
<td class="text">The following amounts were reflected as components of <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:28.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.990%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) gain arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(448)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(816)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:33.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411499928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(886)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)  Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300409923832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Effective Tax Rate and U.S. Statutory Rate</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income before taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs, including amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Peloton</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Income Before Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before taxes consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,025&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Taxes on Income</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on income consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(668)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Income Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">588</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">834</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,677</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,677</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">298</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Amounts in 2019 reflects the settlement with the IRS discussed below. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  Amount in 2019 includes $78 million related to the divestiture of Merck&#8217;s Consumer Care business in 2014.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411281608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculations of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,664&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.79</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410112776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in AOCI by Component</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:37.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.903%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1, 2018, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,910)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(716)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption of ASU 2018-02</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption of ASU 2016-01</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(599)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">284</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(299)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(488)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(631)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(279)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized (gains) losses on the sales of available-for-sale investments that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 13).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $5.4 billion and $5.1 billion at December 31, 2020 and 2019, respectively, and other postretirement benefit plan net gain of $391 million and $247 million at December 31, 2020 and 2019, respectively, as well as pension plan prior service credit of $255 million and $263 million at December 31, 2020 and 2019, respectively, and other postretirement benefit plan prior service credit of $244 million and $305 million at December 31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429696568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Sales of Company's Products</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:30.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">8,352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">6,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">14,380</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">67</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">583</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,836</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">477</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">488</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diversified Brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">386</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,555</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">19,449</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">23,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">43,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">18,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">22,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">41,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">20,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">37,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">872</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,764</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,703</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">20,956</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">26,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">47,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">20,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">46,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">18,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.06pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.18pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the non-reportable segments of Healthcare Services (fully divested in the first quarter of 2020) and Alliances (which concluded in 2018). </span></div>(5)&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Consolidated Revenues by Geographic Area</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,376</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,274</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,840&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Segment Profits to Income Before Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,722</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">140</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,664)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge related to the termination of a collaboration with Samsung</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,070)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,701&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity (income) loss from affiliates and depreciation and amortization included in segment profits is as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity (income) loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock', window );">Property, Plant and Equipment, Net by Geographic Area</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,526</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411464712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300412197480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate', window );">Product return period and expiration</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SalesDiscounts', window );">Customer discounts</a></td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AccrualForChargebacks', window );">Accrual for chargebacks reflected as direct reduction to accounts receivable</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AccrualForRebates', window );">Accrual for rebates included in accrued and other current liabilities</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">1,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising and promotion costs</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Decrease in deferred income taxes</a></td>
<td class="num">(1,015)<span></span>
</td>
<td class="num">(1,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">6,634<span></span>
</td>
<td class="nump">6,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic defined benefit plan (credit) cost other than service cost</a></td>
<td class="num">$ (339)<span></span>
</td>
<td class="num">$ (545)<span></span>
</td>
<td class="num">$ (512)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate', window );">Product return period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Capitalized Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery, equipment and office furnishings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | United States | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">36 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | United States | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate', window );">Product return period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Capitalized Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">45 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery, equipment and office furnishings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AccrualForChargebacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrual for chargebacks reflected as a direction reduction to accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AccrualForChargebacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AccrualForRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrual for rebates recorded as current liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AccrualForRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenuePerformanceObligationPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenuePerformanceObligationPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Goods, Goods Return Period After to Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SalesDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SalesDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300433481912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Research Collaborations and License Agreements - Acquisitions Narrative (Detail)<br> $ / shares in Units, shares in Thousands, &#8364; in Millions, $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,558.0<span></span>
</td>
<td class="nump">$ 9,872.0<span></span>
</td>
<td class="nump">$ 9,752.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,238.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,238.0<span></span>
</td>
<td class="nump">19,425.0<span></span>
</td>
<td class="nump">18,253.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity', window );">Payments to acquire available for sale securities, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,684.0<span></span>
</td>
<td class="nump">3,473.0<span></span>
</td>
<td class="nump">2,615.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841.0<span></span>
</td>
<td class="nump">767.0<span></span>
</td>
<td class="nump">788.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172.0<span></span>
</td>
<td class="nump">152.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83.0)<span></span>
</td>
<td class="num">(64.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PremiumOnSharesAcquired', window );">Premium on shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SentinelMember', window );">Sentinel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SentinelMember', window );">Sentinel | Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Inventory and fixed assets write-offs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ChargesRelatedToProgramDiscontinuation', window );">Charges related to program discontinuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity', window );">Payments to acquire available for sale securities, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interests issued or issuable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SentinelMember', window );">Sentinel | Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible assets, acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_IAVIMember', window );">IAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_OncoImmuneMember', window );">OncoImmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PremiumOnSharesAcquired', window );">Premium on shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_OncoImmuneMember', window );">OncoImmune | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_OncoImmuneMember', window );">OncoImmune | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_VelosBioMember', window );">VelosBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_DunboyneMember', window );">Dunboyne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302.0<span></span>
</td>
<td class="nump">&#8364; 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember', window );">Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember', window );">Themis | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="nump">$ 2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">361.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">512.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="nump">2,280.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">145.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed', window );">Share-based compensation payments to settle equity awards attributable to precombination service</a></td>
<td class="nump">$ 138.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="nump">0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_PelotonMember', window );">Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 993.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember', window );">Immune Design</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ViralyticsMember', window );">Viralytics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378.0<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Seagen | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | OncoImmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialmilestoneMember', window );">Commercial Milestone | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember', window );">Development Milestones | Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember', window );">Development Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ChargesRelatedToProgramDiscontinuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges related to program discontinuation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ChargesRelatedToProgramDiscontinuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PremiumOnSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on shares acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PremiumOnSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments made to partner as part of collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire equity securities classified as available-for-sale securities, because they are not classified as trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SentinelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SentinelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SeagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SeagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_TukysaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_TukysaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SentinelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SentinelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_IAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_IAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_OncoImmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_OncoImmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_VelosBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_VelosBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_DunboyneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_DunboyneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_PelotonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_PelotonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ViralyticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ViralyticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialmilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialmilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429790232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Research Collaborations and License Agreements - Divestitures Narrative (Detail) - Samsung<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations and License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Gain (loss) on contract termination</a></td>
<td class="num">$ (423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_Contractterminationfeepayment', window );">Contract termination fee payment</a></td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_OtherContractTerminationCosts', window );">Other contract termination costs</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss', window );">Fixed asset abandonment costs related to contract termination</a></td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Inventory write-off related to contract termination</a></td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_Contractterminationfeepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract termination fee payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_Contractterminationfeepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OtherContractTerminationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Contract Termination Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OtherContractTerminationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss recognized as a result of the initial and subsequent write-down of a long-lived asset's carrying amount to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SamsungMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SamsungMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300415244536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,425<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets (useful lives ranging from 18-24 years)</a></td>
<td class="nump">2,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="num">(589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="nump">$ 3,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets (useful lives ranging from 18-24 years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300414728136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,558<span></span>
</td>
<td class="nump">$ 9,872<span></span>
</td>
<td class="nump">$ 9,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,482<span></span>
</td>
<td class="nump">11,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,604<span></span>
</td>
<td class="nump">14,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated aggregate amortization expense, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Other Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to acquire intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Lynparza | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable future contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Lynparza | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to acquire intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Lenvima | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable future contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Lenvima | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to acquire intangible assets</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Adempas | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable future contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bayer AG | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable future contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsMadetoCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsMadetoCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProbableContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Probable Contingent Payments Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProbableContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments made to partner as part of collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430052584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementReceivable', window );">Receivables from counterparty</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementPayable', window );">Payables to counterparty</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Total sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts', window );">Total sales</a></td>
<td class="nump">733<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Total sales | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts', window );">Total sales</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Total sales | Alliance revenue - Koselugo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts', window );">Total sales</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementReceivable', window );">Receivables from counterparty</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementPayable', window );">Payables to counterparty</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementPayable', window );">Payables to counterparty</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Total sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts', window );">Total sales</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementReceivable', window );">Receivables from counterparty</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementPayable', window );">Payables to counterparty</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Total sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales of Adempas recorded by Merck</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Merck&#8217;s profit share of sales in marketing territories</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts', window );">Total sales</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementExpenses', window );">Expenses</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profit Sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Revenues, Net of Commercialization Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Sales, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429465496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected costs</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays', window );">Percentage estimate of cumulative pretax costs that will result in cash outlays (primarily from employee separation expense) (as percent)</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash', window );">Percentage estimate of cumulative pretax costs that will be non-cash (primarily from accelerated depreciation of facilities) (as percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring costs, cost incurred to date</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will be noncash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300613703064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Charges Related to Restructuring Program Activities by Type of Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300414136808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Charges and Spending Relating to Restructuring Activities by Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="nump">$ 658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(809)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(508)<span></span>
</td>
<td class="num">(325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveNoncashActivity', window );">Non-cash activity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(268)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(301)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveNoncashActivity', window );">Non-cash activity</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RestructuringReserveNoncashActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash activity affecting the restructuring reserve, including accelerated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RestructuringReserveNoncashActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430332296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 32,784,000,000<span></span>
</td>
<td class="nump">$ 30,666,000,000<span></span>
</td>
<td class="nump">$ 32,784,000,000<span></span>
</td>
<td class="nump">$ 30,666,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Pre tax net unrealized gain (loss) on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(331,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">586,000,000<span></span>
</td>
<td class="nump">420,000,000<span></span>
</td>
<td class="nump">586,000,000<span></span>
</td>
<td class="nump">420,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Unrealized gains based on favorable observable price changes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Unrealized loss related to unfavorable observable price changes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative upward price adjustment</a></td>
<td class="nump">169,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative downward price adjustment</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000,000<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of loans payable and long-term debt, including current portion</a></td>
<td class="nump">36,000,000,000.0<span></span>
</td>
<td class="nump">28,800,000,000<span></span>
</td>
<td class="nump">36,000,000,000.0<span></span>
</td>
<td class="nump">28,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Long term and short term debt</a></td>
<td class="nump">31,800,000,000<span></span>
</td>
<td class="nump">26,300,000,000<span></span>
</td>
<td class="nump">31,800,000,000<span></span>
</td>
<td class="nump">26,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableSale', window );">Accounts receivable factored</a></td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="nump">2,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Funds collected from factoring of receivable, held in restricted cash</a></td>
<td class="nump">102,000,000<span></span>
</td>
<td class="nump">256,000,000<span></span>
</td>
<td class="nump">102,000,000<span></span>
</td>
<td class="nump">256,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received from counterparties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Right to reclaim cash</a></td>
<td class="nump">36,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.85NotesDue2020Member', window );">1.85% Notes Due 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed-rate notes, stated interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of accounts receivable represented by customers with largest balances (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">6,800,000,000<span></span>
</td>
<td class="nump">8,900,000,000<span></span>
</td>
<td class="nump">$ 6,800,000,000<span></span>
</td>
<td class="nump">8,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps held | interest_rate_swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">13,714,000,000<span></span>
</td>
<td class="nump">14,728,000,000<span></span>
</td>
<td class="nump">13,714,000,000<span></span>
</td>
<td class="nump">14,728,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 19,070,000,000<span></span>
</td>
<td class="nump">$ 15,938,000,000<span></span>
</td>
<td class="nump">$ 19,070,000,000<span></span>
</td>
<td class="nump">$ 15,938,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum planning cycle of hedges (no more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum planning cycle of hedges (no more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease from sale of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.85NotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.85NotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430065080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="nump">385<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300423510632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information About Interest Rate Swaps (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">$ 32,784,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,666,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held | interest_rate_swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member', window );">3.875% notes due 2021 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held | interest_rate_swap</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed-rate notes, stated interest rate (as percent)</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member', window );">2.40% notes due 2022 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held | interest_rate_swap</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed-rate notes, stated interest rate (as percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member', window );">2.35% notes due 2022 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held | interest_rate_swap</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed-rate notes, stated interest rate (as percent)</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411661240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember', window );">Loans payable and current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Liabilities</a></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="nump">$ 1,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Liabilities</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300414206680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">32,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">13,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">19,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">2,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">3,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">5,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">7,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="nump">$ 11,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S.&#160;Dollar Notional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429544776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Gross amounts recognized in the consolidated balance sheet, Asset</a></td>
<td class="nump">$ 182,000,000<span></span>
</td>
<td class="nump">$ 288,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Asset</a></td>
<td class="num">(156,000,000)<span></span>
</td>
<td class="num">(84,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received, Asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(34,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, Asset</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Gross amounts recognized in the consolidated balance sheet, Liability</a></td>
<td class="nump">525,000,000<span></span>
</td>
<td class="nump">97,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Liability</a></td>
<td class="num">(156,000,000)<span></span>
</td>
<td class="num">(84,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral received, liability</a></td>
<td class="num">(36,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, Liability</a></td>
<td class="nump">$ 333,000,000<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300545441224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 47,994<span></span>
</td>
<td class="nump">$ 46,840<span></span>
</td>
<td class="nump">$ 42,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(886)<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="num">(402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(648)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of (loss) gain recognized in OCI on derivatives</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of (loss) gain recognized in OCI on derivatives</a></td>
<td class="num">(383)<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">(Decrease) increase in Sales as a result of AOCI reclassifications</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (income) expense, net | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged items</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Derivatives designated as hedging instruments</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of gain recognized in Other (income) expense, net on derivatives</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="num">$ (160)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430371384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Effects of Derivatives Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="num">$ (260)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts [Member] | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300417863976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information on Debt and Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 1,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities, fair value</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI', window );">Total debt and publicly traded equity securities, fair value</a></td>
<td class="nump">1,876<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net gains</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities, fair value</a></td>
<td class="nump">$ 780<span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities and Equity Securities, FV-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DebtSecuritiesandEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300415658312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 1,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,058<span></span>
</td>
<td class="nump">2,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Purchased currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Purchased currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Purchased currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Purchased currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430824264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summarized Information About Changes in Liabilities for Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 767<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additions</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration, liability, current</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember', window );">Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 711<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300431051944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="nump">$ 1,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work in process</a></td>
<td class="nump">6,420<span></span>
</td>
<td class="nump">5,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Supplies</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates current cost)</a></td>
<td class="nump">8,589<span></span>
</td>
<td class="nump">7,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Decrease to LIFO cost</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_InventoryNetAndInventoryNoncurrent', window );">Total current and noncurrent inventories</a></td>
<td class="nump">8,507<span></span>
</td>
<td class="nump">7,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RecognizedAsAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">6,310<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 2,197<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of current and noncurrent inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RecognizedAsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized as.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RecognizedAsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300418016984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LIFOInventoryAmount', window );">LIFO inventory amount</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember', window );">Inventory Not Expected to be Sold Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember', window );">Inventories Produced in Preparation for Product Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LIFOInventoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LIFOInventoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300412135704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 14,604<span></span>
</td>
<td class="nump">$ 14,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge related to marketed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense, 2021</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense, 2022</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense, 2023</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense, 2024</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated aggregate amortization expense, 2025</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember', window );">Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge related to marketed product</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SivextroMember', window );">Sivextro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge related to marketed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AnimalHealthMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_IOmetPharmaLtdMember', window );">IOmet Pharma Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SmartCellsProgramMember', window );">SmartCells Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">7,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Sivextro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Implanon/Nexplanon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Dificid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">$ 2,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">Licenses | Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">Licenses | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq | Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetsExcludingGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Excluding Goodwill [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetsExcludingGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SivextroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SivextroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AnimalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AnimalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_IOmetPharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_IOmetPharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SmartCellsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SmartCellsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_DificidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_DificidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SimponiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SimponiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300418002008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 19,425<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">20,238<span></span>
</td>
<td class="nump">19,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">16,181<span></span>
</td>
<td class="nump">16,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">16,970<span></span>
</td>
<td class="nump">16,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">3,192<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">3,268<span></span>
</td>
<td class="nump">3,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430607736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Other Intangibles (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 57,597<span></span>
</td>
<td class="nump">$ 55,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">42,993<span></span>
</td>
<td class="nump">41,128<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">14,604<span></span>
</td>
<td class="nump">14,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">3,228<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">3,228<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">45,087<span></span>
</td>
<td class="nump">45,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">39,925<span></span>
</td>
<td class="nump">38,852<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">7,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">4,177<span></span>
</td>
<td class="nump">3,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 1,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300542483064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current maturities</a></td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">6,431,000,000<span></span>
</td>
<td class="nump">3,610,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">25,360,000,000<span></span>
</td>
<td class="nump">$ 22,736,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-term debt, maturities, repayments of principal in 2021</a></td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-term debt, maturities, repayments of principal in 2022</a></td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-term debt, maturities, repayments of principal in 2023</a></td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-term debt, maturities, repayments of principal in 2024</a></td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long-term debt, maturities, repayments of principal in 2025</a></td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Available borrowing capacity under credit facility</a></td>
<td class="nump">$ 6,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="nump">$ 346,000,000<span></span>
</td>
<td class="nump">$ 339,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">340,000,000<span></span>
</td>
<td class="nump">281,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount', window );">Lessee, operating lease, lease not yet commenced, amount</a></td>
<td class="nump">475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">495,000,000<span></span>
</td>
<td class="nump">129,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember', window );">Other Variable Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 294,000,000<span></span>
</td>
<td class="nump">$ 147,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Effective interest rate (as percent)</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember', window );">6.30% debentures due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A0.75notesdue2026Member', window );">0.75% notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.45notesdue2030Member', window );">1.45% notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.35notesdue2040Member', window );">2.35% notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.45notesdue2050Member', window );">2.45% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember', window );">Notes Subject To Repayment At Option Of Holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">$ 73,000,000<span></span>
</td>
<td class="nump">226,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">$ 4,000,000,000.0<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Weighted-average interest rate of commercial paper (as percent)</a></td>
<td class="nump">0.79%<span></span>
</td>
<td class="nump">2.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A0.75notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A0.75notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.45notesdue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.45notesdue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.35notesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.35notesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.45notesdue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.45notesdue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300420504168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 25,360<span></span>
</td>
<td class="nump">$ 22,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member', window );">2.75% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 2,493<span></span>
</td>
<td class="nump">2,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member', window );">3.70% notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,976<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member', window );">2.80% notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member', window );">3.40% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,734<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member', window );">4.00% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,469<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member', window );">2.35% notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 982<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member', window );">4.15% notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,238<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member', window );">1.45% notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">1.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member', window );">1.875% euro-denominated notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">1.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member', window );">2.45% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member', window );">2.40% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,032<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member', window );">0.75% notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 991<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member', window );">3.90% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member', window );">2.35% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,269<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member', window );">2.90% notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 746<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember', window );">6.50% notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 719<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member', window );">0.50% euro-denominated notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 611<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member', window );">1.375% euro-denominated notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member', window );">2.50% euro-denominated notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember', window );">3.60% notes due 2042</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember', window );">6.55% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">6.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember', window );">5.75% notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember', window );">5.95% debentures due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember', window );">5.85% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember', window );">6.40% debentures due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember', window );">6.30% debentures due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.875NotesDue2021Member', window );">3.875% notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.125EuroNotesDue2021Member', window );">1.125% euro-denominated notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.875NotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.875NotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.125EuroNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.125EuroNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300421322616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract', window );"><strong>Loans Payable, Long-Term Debt and Leases - Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other assets</a></td>
<td class="nump">$ 1,725<span></span>
</td>
<td class="nump">$ 1,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,662<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherAssets<span></span>
</td>
<td class="text">us-gaap:OtherAssets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loans Payable, Long-Term Debt and Leases - Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300408577736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,662<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300418823944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Environmental Liabilities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>legalmatter</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>legalmatter</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember', window );">Patent litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement, gain (loss) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled, number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember', window );">Commercial Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | Federal Court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Loss contingency, claims dismissed number</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LossContingencyClaimsonAppealNumber', window );">Loss contingency, claims on appeal, number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | New Jersey State Court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | California State Court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | Other State Court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia | Cases Company Agreed To Toll Statute Of Limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia | Other State Court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_VioxxMember', window );">Vioxx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement, gain (loss) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyClaimsonAppealNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims on Appeal, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyClaimsonAppealNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_FosamaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_FosamaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_NewJerseyStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_NewJerseyStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_CaliforniaStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_CaliforniaStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_OtherStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_OtherStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VioxxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VioxxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410163208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and Environmental Liabilities - Legal Defense Reserves - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember', window );">Legal Defense Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Legal defense costs reserve</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300409794136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Environmental Liabilities - Environmental Litigation and Matters - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SiteContingencyLineItems', window );"><strong>Site Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForEnvironmentalLossContingencies', window );">Accrued liabilities for environmental matters</a></td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_TermForPayingOffEnvironmentalLiabilities', window );">Term for paying off environmental liabilities</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss', window );">Aggregate possible expenditure on environmental matters in excess of amounts accrued</a></td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_TermForPayingOffEnvironmentalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term for paying off environmental liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_TermForPayingOffEnvironmentalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForEnvironmentalLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs accrued as of the balance sheet date for environmental loss contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6395460&amp;loc=d3e13647-108346<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13207-110859<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForEnvironmentalLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of reasonably possible loss exposure in excess of amount accrued for remediation, site restoration, postclosure, monitoring commitments, or other exit costs associated with the sale, disposal or abandonment of a particular property resulting from unanticipated contamination of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.Y.Q4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14394-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SiteContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SiteContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300421165928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=mrk_AcceleratedShareRepurchaseAgreementOctober292018Member', window );">Accelerated Share Repurchase Agreement, October 29, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mrk_AcceleratedShareRepurchaseAgreementMember', window );">Accelerated Share Repurchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="nump">64,400,000<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Payment under ASR agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesDateAxis=mrk_AcceleratedShareRepurchaseAgreementOctober292018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesDateAxis=mrk_AcceleratedShareRepurchaseAgreementOctober292018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mrk_AcceleratedShareRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mrk_AcceleratedShareRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300523635624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Shareholders' Equity (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">1,038,000,000<span></span>
</td>
<td class="nump">985,000,000<span></span>
</td>
<td class="nump">880,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">122,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances (in shares)</a></td>
<td class="num">(7,000,000)<span></span>
</td>
<td class="num">(13,000,000)<span></span>
</td>
<td class="num">(17,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">1,047,000,000<span></span>
</td>
<td class="nump">1,038,000,000<span></span>
</td>
<td class="nump">985,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MovementinCommonStockandTreasuryStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Movement in Common Stock and Treasury Stock [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MovementinCommonStockandTreasuryStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300408542664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares collectively authorized for future grants under share-based compensation plans (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Quantity of stock options that vest per year (as percent)</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Period over which share-based payment awards vest</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Pretax share-based compensation cost</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefits related to share-based compensation</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of options granted (in dollars per share)</a></td>
<td class="nump">$ 77.67<span></span>
</td>
<td class="nump">$ 80.05<span></span>
</td>
<td class="nump">$ 58.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
<td class="nump">$ 8.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards</a></td>
<td class="nump">$ 678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Contractual term of options</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Contractual term of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410025400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">22.10%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="nump">19.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429650280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, January 1 (in shares)</a></td>
<td class="nump">17,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted (in shares)</a></td>
<td class="nump">3,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised (in shares)</a></td>
<td class="num">(1,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited (in shares)</a></td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, December 31 (in shares)</a></td>
<td class="nump">19,446<span></span>
</td>
<td class="nump">17,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable (in shares)</a></td>
<td class="nump">13,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)</a></td>
<td class="nump">$ 59.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">77.67<span></span>
</td>
<td class="nump">$ 80.05<span></span>
</td>
<td class="nump">$ 58.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">52.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited (in dollars per share)</a></td>
<td class="nump">67.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)</a></td>
<td class="nump">63.64<span></span>
</td>
<td class="nump">$ 59.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 58.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429744744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300421245672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested January 1 | shares</a></td>
<td class="nump">13,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">6,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(7,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested December 31 | shares</a></td>
<td class="nump">11,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 67.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">77.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">65.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">72.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 74.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested January 1 | shares</a></td>
<td class="nump">1,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested December 31 | shares</a></td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 69.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">77.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">64.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">80.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 75.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300420407832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400<span></span>
</td>
<td class="nump">$ 22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contributions to defined contribution savings plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage', window );">Percentage of Company's pension investments categorized as Level 3 assets (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 942<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">$ 968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests', window );">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets (as percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets (as percent)</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | U.S.&#160;equities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | U.S.&#160;equities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | International equities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | International equities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Fixed Income Investments | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Fixed Income Investments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Cash And Other Investments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
<td class="nump">$ 9,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,049<span></span>
</td>
<td class="nump">$ 10,163<span></span>
</td>
<td class="nump">$ 8,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 851<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company pension investments which are categorized as level three assets percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DefinedBenefitPlanCashandOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DefinedBenefitPlanCashandOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300433274424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(774)<span></span>
</td>
<td class="num">(817)<span></span>
</td>
<td class="num">(851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(415)<span></span>
</td>
<td class="num">(426)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300414877976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="nump">$ 968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">$ 968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">1,673<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="num">(386)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">(377)<span></span>
</td>
<td class="num">(561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">11,361<span></span>
</td>
<td class="nump">9,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">1,908<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(751)<span></span>
</td>
<td class="num">(582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
<td class="nump">9,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">13,003<span></span>
</td>
<td class="nump">10,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="nump">1,594<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(751)<span></span>
</td>
<td class="num">(582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">13,003<span></span>
</td>
<td class="nump">10,620<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="num">(1,941)<span></span>
</td>
<td class="num">(1,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">(1,859)<span></span>
</td>
<td class="num">(1,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">8,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">12,049<span></span>
</td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">8,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">10,612<span></span>
</td>
<td class="nump">9,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="num">(64)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">12,534<span></span>
</td>
<td class="nump">10,612<span></span>
</td>
<td class="nump">$ 9,083<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="num">(485)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">$ (1,413)<span></span>
</td>
<td class="num">$ (1,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in plan assets, not otherwise separately disclosed in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DefinedBenefitPlanOtherChangesPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430108328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</a></td>
<td class="nump">$ 14,613<span></span>
</td>
<td class="nump">$ 13,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</a></td>
<td class="nump">13,489<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">11,685<span></span>
</td>
<td class="nump">10,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</a></td>
<td class="nump">8,951<span></span>
</td>
<td class="nump">7,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">7,526<span></span>
</td>
<td class="nump">6,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</a></td>
<td class="nump">4,288<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">$ 3,033<span></span>
</td>
<td class="nump">$ 1,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300432221976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 942<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
<td class="nump">$ 9,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,090<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Mortgage and Asset-Backed Securities Investment Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">1,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,199<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Mortgage and Asset-Backed Securities Investment Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,352<span></span>
</td>
<td class="nump">3,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Mortgage and Asset-Backed Securities Investment Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">1,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Mortgage and Asset-Backed Securities Investment Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Insurance contracts, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5,114<span></span>
</td>
<td class="nump">4,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Mortgage and Asset-Backed Securities Investment Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">12,049<span></span>
</td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">8,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">4,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">3,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Corporate obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Insurance contracts, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,779<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Corporate obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Insurance contracts, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7,736<span></span>
</td>
<td class="nump">7,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,286<span></span>
</td>
<td class="nump">3,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,614<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Corporate obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Insurance contracts, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">851<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Corporate obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Insurance contracts, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">851<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Corporate obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Insurance contracts, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Other, Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_FixedIncomeObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_FixedIncomeObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300420401224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">$ 860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">11,361<span></span>
</td>
<td class="nump">9,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">8,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">12,049<span></span>
</td>
<td class="nump">10,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers out of Level 3</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers out of Level 3</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(C)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300514186104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) - Other Postretirement Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="nump">$ 968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">428<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Developed markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Emerging markets equities, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Government and agency obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Fixed income obligations, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Developed markets, Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Government and agency obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Corporate obligations, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Mortgage and asset backed-securities, Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_FixedIncomeObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_FixedIncomeObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430179480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2022</a></td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2023</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2024</a></td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2025</a></td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2026&#160;&#8212;&#160;2030</a></td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2021</a></td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2022</a></td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2023</a></td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2024</a></td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2025</a></td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2026&#160;&#8212;&#160;2030</a></td>
<td class="nump">4,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2021</a></td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2022</a></td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2023</a></td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2024</a></td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2025</a></td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2026&#160;&#8212;&#160;2030</a></td>
<td class="nump">$ 1,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300421519432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="num">(448)<span></span>
</td>
<td class="num">(816)<span></span>
</td>
<td class="num">(397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="num">(449)<span></span>
</td>
<td class="num">(820)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="num">(505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="nump">62<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="num">(345)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300431107080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300409794136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) - Other Postretirement Benefits<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Health care cost trend rate assumed for next year</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429917896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Write-down of assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">$ 822<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember', window );">Healthcare Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_CGRPreceptorantagonistsMember', window );">CGRP receptor antagonists</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain (loss) on sale of clinical development programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_PartnershipInterestMember', window );">AstraZeneca LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember', window );">Patent litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement, gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_CGRPreceptorantagonistsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_CGRPreceptorantagonistsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300417620536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (59)<span></span>
</td>
<td class="num">$ (274)<span></span>
</td>
<td class="num">$ (343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange losses</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Income on investments in equity securities, net</a></td>
<td class="num">(1,338)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic defined benefit plan (credit) cost other than service cost</a></td>
<td class="num">(339)<span></span>
</td>
<td class="num">(545)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_OtherNonoperatingIncomeExpenseOther', window );">Other, net</a></td>
<td class="num">(126)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">$ (886)<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="num">$ (402)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income and expense items not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429936504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate applied to income before taxes</a></td>
<td class="nump">$ 1,846<span></span>
</td>
<td class="nump">$ 2,408<span></span>
</td>
<td class="nump">$ 1,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract', window );"><strong>Differential arising from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(1,242)<span></span>
</td>
<td class="num">(1,020)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount', window );">GILTI and the foreign-derived intangible income deduction</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R&amp;D tax credit</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Tax settlements</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo', window );">Acquisition of VelosBio</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Restructuring</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree', window );">Acquisition of OncoImmune</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">67<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments', window );">Acquisition-related costs, including amortization</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination', window );">Acquisition of Peloton</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount', window );">Tax Cuts and Jobs Act of 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">$ 1,709<span></span>
</td>
<td class="nump">$ 1,687<span></span>
</td>
<td class="nump">$ 2,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Tax&#160;Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate applied to income before taxes</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract', window );"><strong>Differential arising from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(14.10%)<span></span>
</td>
<td class="num">(8.90%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent', window );">GILTI and the foreign-derived intangible income deduction</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credit</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax settlements</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent', window );">Acquisition of VelosBio</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges', window );">Restructuring</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent', window );">Acquisition of OncoImmune</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments', window );">Acquisition-related costs, including amortization</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent', window );">Acquisition of Peloton</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">Tax Cuts and Jobs Act of 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.010<span></span>
</td>
<td class="nump">0.033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total, Tax Rate</a></td>
<td class="nump">19.40%<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="nump">28.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to the amortization of purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Three, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to amortization of purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300421583576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Transition tax for accumulated foreign earnings, liability</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax assets on NOL carryforwards relating to foreign jurisdictions</a></td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic', window );">Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards</a></td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefits relating to stock option exercises</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Favorable net impact to income tax provision if unrecognized tax benefits were recognized</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties associated with uncertain tax positions, expense (benefit)</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Liabilities for accrued interest and penalties</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Valuation allowance on foreign NOL carryforwards</a></td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember', window );">Income Taxes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent', window );">Transition tax liability, current</a></td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent', window );">Transition tax liability, noncurrent</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300409964984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Income Before Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (3,492)<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
<td class="nump">$ 3,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">12,283<span></span>
</td>
<td class="nump">11,025<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">$ 8,791<span></span>
</td>
<td class="nump">$ 11,464<span></span>
</td>
<td class="nump">$ 8,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300530269464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">2,377<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="nump">3,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(605)<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision</a></td>
<td class="num">(668)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">$ 1,709<span></span>
</td>
<td class="nump">$ 1,687<span></span>
</td>
<td class="nump">$ 2,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300430951096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income - Deferred Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Product intangibles and licenses, Assets</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory related, Assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Accelerated depreciation, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Equity Method Investments, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Pensions and other postretirement benefits, Assets</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Compensation related, Assets</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Assets</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards', window );">Net operating losses and other tax credit carryforwards, Assets</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, Assets</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal, Assets</a></td>
<td class="nump">2,989<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, Assets</a></td>
<td class="num">(433)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes</a></td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Product intangibles and licenses, Liabilities</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventory related, Liabilities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Accelerated depreciation, Liabilities</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredTaxLiabilitiesEquityMethodInvestment', window );">Equity method investments, Liabilities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans', window );">Pensions and other postretirement benefits, Liabilities</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other, Liabilities</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Subtotal, Liabilities</a></td>
<td class="nump">2,677<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred income taxes, Liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards and other tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxAssetsUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxLiabilitiesEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxLiabilitiesEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300417976104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized tax benefits, reduction resulting from divestiture of Merck's consumer care business</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance January&#160;1</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions related to current year positions</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions related to prior year positions</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance December&#160;31</a></td>
<td class="nump">$ 1,537<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">$ 1,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_ConsumercarebusinessMember', window );">consumer care business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized tax benefits, reduction resulting from divestiture of Merck's consumer care business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_ConsumercarebusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_ConsumercarebusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429568328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 7,067<span></span>
</td>
<td class="nump">$ 9,843<span></span>
</td>
<td class="nump">$ 6,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average common shares outstanding (in shares)</a></td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">2,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common shares issuable (in shares)</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average common shares outstanding assuming dilution (in shares)</a></td>
<td class="nump">2,541<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300411438440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300420589912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 26,001<span></span>
</td>
<td class="nump">$ 26,882<span></span>
</td>
<td class="nump">$ 34,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(915)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="num">(692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(631)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="num">(716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">253<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">190<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(648)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Adoption of ASU 2018-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">25,404<span></span>
</td>
<td class="nump">26,001<span></span>
</td>
<td class="nump">26,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(383)<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">84<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(299)<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(297)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Adoption of ASU 2018-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(266)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivatives | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Adoption of ASU 2018-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Investments | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(4,261)<span></span>
</td>
<td class="num">(3,556)<span></span>
</td>
<td class="num">(2,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="num">(728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(488)<span></span>
</td>
<td class="num">(756)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
<td class="num">(425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Adoption of ASU 2018-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(4,540)<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
<td class="num">(3,556)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember', window );">Pension Plan Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember', window );">Other Postretirement Benefit Plan Net Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember', window );">Pension Plan Prior Service Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="num">(255)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember', window );">Other Postretirement Benefit Plan Prior Service Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Cumulative Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(1,981)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">89<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Adoption of ASU 2018-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(1,828)<span></span>
</td>
<td class="num">(1,981)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Cumulative Translation Adjustment | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(6,193)<span></span>
</td>
<td class="num">(5,545)<span></span>
</td>
<td class="num">(4,910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (6,634)<span></span>
</td>
<td class="num">$ (6,193)<span></span>
</td>
<td class="num">(5,545)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL116659650-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300410090312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300412809528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Sales of Company's Products (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 47,994<span></span>
</td>
<td class="nump">$ 46,840<span></span>
</td>
<td class="nump">$ 42,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">47,747<span></span>
</td>
<td class="nump">46,319<span></span>
</td>
<td class="nump">42,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">43,021<span></span>
</td>
<td class="nump">41,751<span></span>
</td>
<td class="nump">37,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">14,380<span></span>
</td>
<td class="nump">11,084<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Emend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,938<span></span>
</td>
<td class="nump">3,737<span></span>
</td>
<td class="nump">3,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">926<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">797<span></span>
</td>
<td class="nump">791<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Cubicin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Zepatier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Zetia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Vytorin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Atozet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas (2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,306<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
<td class="nump">3,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
<td class="nump">2,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Implanon/Nexplanon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | NuvaRing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Singulair</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Arcoxia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Nasonex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Follistim AQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4,709<span></span>
</td>
<td class="nump">4,615<span></span>
</td>
<td class="nump">4,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4,703<span></span>
</td>
<td class="nump">4,393<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,939<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">1,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">21,027<span></span>
</td>
<td class="nump">20,519<span></span>
</td>
<td class="nump">18,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">20,956<span></span>
</td>
<td class="nump">20,433<span></span>
</td>
<td class="nump">18,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">19,449<span></span>
</td>
<td class="nump">18,953<span></span>
</td>
<td class="nump">16,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">8,352<span></span>
</td>
<td class="nump">6,305<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Emend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
<td class="nump">1,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">727<span></span>
</td>
<td class="nump">679<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Cubicin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Zepatier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Zetia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Vytorin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Atozet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas (2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,724<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Implanon/Nexplanon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | NuvaRing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Singulair</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Arcoxia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Nasonex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Follistim AQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,555<span></span>
</td>
<td class="nump">1,416<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,484<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">26,967<span></span>
</td>
<td class="nump">26,321<span></span>
</td>
<td class="nump">23,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">26,791<span></span>
</td>
<td class="nump">25,885<span></span>
</td>
<td class="nump">23,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">23,572<span></span>
</td>
<td class="nump">22,798<span></span>
</td>
<td class="nump">20,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,028<span></span>
</td>
<td class="nump">4,779<span></span>
</td>
<td class="nump">3,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Emend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Cubicin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Zepatier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Zetia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Vytorin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Atozet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas (2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,836<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">1,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,494<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Implanon/Nexplanon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | NuvaRing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Singulair</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Arcoxia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Nasonex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Follistim AQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,152<span></span>
</td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,219<span></span>
</td>
<td class="nump">3,086<span></span>
</td>
<td class="nump">2,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">885<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_KeytrudaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_KeytrudaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_EmendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_EmendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_Pneumovax23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_Pneumovax23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RotateqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RotateqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VaqtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VaqtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NoxafilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NoxafilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrevymisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrevymisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrimaxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrimaxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CancidasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CancidasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_InvanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_InvanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CubicinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CubicinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SimponiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SimponiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BelsomraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BelsomraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZepatierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZepatierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZetiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZetiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VytorinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VytorinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AtozetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AtozetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanumetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanumetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NuvaringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NuvaringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SingulairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SingulairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ArcoxiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ArcoxiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NasonexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NasonexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_FollistimAqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_FollistimAqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LivestockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LivestockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300433374792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Consolidated Revenues by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 47,994<span></span>
</td>
<td class="nump">$ 46,840<span></span>
</td>
<td class="nump">$ 42,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">21,027<span></span>
</td>
<td class="nump">20,519<span></span>
</td>
<td class="nump">18,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">12,707<span></span>
</td>
<td class="nump">12,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,624<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,376<span></span>
</td>
<td class="nump">3,583<span></span>
</td>
<td class="nump">3,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,274<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 1,229<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300421429480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(831)<span></span>
</td>
<td class="num">(893)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(13,558)<span></span>
</td>
<td class="num">(9,872)<span></span>
</td>
<td class="num">(9,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(578)<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="num">(632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">8,791<span></span>
</td>
<td class="nump">11,464<span></span>
</td>
<td class="nump">8,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(855)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
<td class="num">(503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">31,373<span></span>
</td>
<td class="nump">29,926<span></span>
</td>
<td class="nump">26,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(690)<span></span>
</td>
<td class="num">(534)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">29,722<span></span>
</td>
<td class="nump">28,324<span></span>
</td>
<td class="nump">24,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">1,650<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Unallocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(831)<span></span>
</td>
<td class="num">(893)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(1,602)<span></span>
</td>
<td class="num">(1,593)<span></span>
</td>
<td class="num">(1,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(13,072)<span></span>
</td>
<td class="num">(9,499)<span></span>
</td>
<td class="num">(9,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AmortizationOfPurchaseAccountingAdjustments', window );">Amortization of purchase accounting adjustments</a></td>
<td class="num">(1,168)<span></span>
</td>
<td class="num">(1,406)<span></span>
</td>
<td class="num">(2,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(578)<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="num">(632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Charge related to the termination of a collaboration with Samsung</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SegmentReportingUnallocatedOtherExpensesNet', window );">Other unallocated, net</a></td>
<td class="num">$ (5,530)<span></span>
</td>
<td class="num">$ (5,070)<span></span>
</td>
<td class="num">$ (3,006)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AmortizationOfPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AmortizationOfPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SegmentReportingUnallocatedOtherExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other net expenses not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SegmentReportingUnallocatedOtherExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300429555048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits (Details) - Operating Segments - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity (income) loss from affiliates</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">653<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity (income) loss from affiliates</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity (income) loss from affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity (income) loss from affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140300431910088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 17,986<span></span>
</td>
<td class="nump">$ 15,053<span></span>
</td>
<td class="nump">$ 13,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">10,526<span></span>
</td>
<td class="nump">8,974<span></span>
</td>
<td class="nump">8,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">6,059<span></span>
</td>
<td class="nump">4,767<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>136
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@F\BA=H)K7"U4)-%JR-<Z4)@A@SLW4ZP'Y52ZI5LO7RMIAUPM6PWABM:0F5
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M*1#O]X3PUQO90/L19?D/4$L#!!0    ( %:$65*N+7<BO ,  -P+   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULI59M;]LV$/XKA%84"9!8KY:MU#80
MVQM68&F#IMT^%/M 2V>;"T6Z)&5G_?4E*46U9=I-T2^22#UWQ^<>\GBC'1>/
M<@V@T%-)F1Q[:Z4V-[XO\S646/;X!IC^L^2BQ$H/Q<J7&P&XL$8E]:,@2/T2
M$^9-1G;N7DQ&O%*4,+@72%9EB<7_4Z!\-_9"[WGB UFME9GP)Z,-7L$#J$^;
M>Z%'?NNE("4P23A# I9C[S:\F8?6P"+^)K"3>]_(4%EP_F@&;XNQ%Y@5 85<
M&1=8O[8P TJ-)[V.+XU3KXUI#/>_G[W_8<EK,@LL8<;I/Z10Z[$W]% !2UQ1
M]8'O_H2&4-_XRSF5]HEV#3;P4%Y)Q<O&6*^@)*Q^XZ<F$7L&87K"(&H,HJY!
M<L(@;@SBEQHDC4%B,U-3L7F88X4G(\%W2!BT]F8^;#*MM:9/F-']00G]EV@[
M-9EQ)CDE!590H >E7UI4A?@2S7BI=]+:2+P%]);EO 1TC3X]S-'%JTOT"A&&
M[@BE6CTY\I5>B_'HYTW<:1TW.A$WC- =9VHMT>^L@.+0@:])M$RB9R;3Z*S'
M.>0]%(=7* JBP+&@V8O-P\QA/G^Y^? ,F[C5);;^XA/^?BS%Y]N%5$*?FW_/
MA$O:<(D-EYP(]TY7F,;OK5*"+"J%%Q20XN@.1/[X^K<P#=Z\QN7FC5Y-[\J
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M$*)N)>N!XAO;7"VXTJV:_5SK]AN$ >C_2\[5\\ $:!OZR3=02P,$%     @
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MB+C7Y^3:V-9.;1NJ0]U?4_>-U->]MF98Q5JBY:J(%K("8BA:OQ]':(7:.<T
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M**/;UO%>'G"6YU9& 5">4BNC+HCBR)/1=!=]&HQ^QK5BE,(;?>H&EI+$BAX
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MFIX0;&L%!(L3V\;/0!A./467#?+/PO)_./WX"Y>EV&ZT.GZAAQ',%>?,GH4
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MRF)D2JI/[38SN!Q(!:?F@#Q(NQ1::=;=; L.Z8:/2**_DZ:/$8V <@>$<:X
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M1 V*6X :BA;D1>8BO!(7H2#7@'74L81$5@'A1-179.^-H/: :U;"'M[U _.
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MF,J4D9:SO6*M5C>"E:G(US!<?7E ,N4>93QV8NT83T5$28@>=,=O':8M&\
ML$-+M*?HK@$.IM\HX:>!/4!7O>M]H_8+!8GH1A'86Z.D /YO-!4(  +S4C_+
MV=MO7IQS"1S\Y)%9?&6?^&[RO.0;MRVI*&++_PC;6SW+W_4LN-MSW_T,=.O0
M!\?<])"J(?E)O\M/^CH_*4DP>#@E^#R5[E"\U7,74A-Z.R(?;^&1'S4+FYY!
MLG@IT:93@JQU=T$J$MX%=7N)9(EB:'J.B)6RKH9.AACX,N;^INU.<Z6TQAXK
M]WEA(%;O<*>D\I,EX (!.Q2F++L5NG#"4C,::&75G<'5%S7=*NZ3>W;L\8-,
MKFR]LQRI\AC# 56T'--AX5SW1%G'&-[74LC!<_.'24_$(J5H0Y:9MJ3\P@G=
M'NL46_#/0C&(Y@V.5&8Q'GJEC[0_S/+_,<ZJ?9!^$E8!U-^@BH1J4K$Z)GDZ
M4E%B3 U64K8JMD]HS0\S5"NL7D3R<TE38A:)(R2IYC%?+W4;M"D]EB@/"4[*
M$5$"M:50X.W(B55F)W,<=$)"F"0F$+45]!2D<2^Z#24^,)X9"+:R9:'8HX!!
M,'"WZV!9> 3\EW>M-%QPM65=5N_"^0KE+:7R]VP!UEQ:>%;7GF4/RZ8,85X[
MWX/SSJJIC,$--;/P.D@-87?E9R D+QJBZS3S/27J)[X+T74\PL])<@._^+!;
M)CB7M^18JYR'YP#0>\P#\!MFS@T9,>+.G;/8V,2%=&[:"8F;./>//GJL^,*2
MQ0%"25/$B:?FPM]V.X"2'HW=2A!0G$N5H41/00O1K[@#6O_A^LGE=;&&4)KE
MAIK=5O#GZ\O/\C]??TXO_^'ZZO)/LT\^HU@E[8'9KP@&EU$P$<&F.?FQ&',K
MV%K8#@]@54TU'Z^2&"^MISG(:(D-SY<C^ZQI*8Y5**HI*1J[F'K>+[W&35C
M62M!;<@\!41";%VH_0:\"VXLDL8$\:4IR>3%@:8>"ND6LO")$Q(UL("G'1?Y
MT_*^8H/!SAG&LH(G;YL[BR(78@+E0DG08,$VS+J8HHZ..QOM@ZKHF"YY+CYI
M7 -[RBGSIBC\ZUA49!6*W548,1/04X\E7*FQWR8481M;"5(A@0>ZSB AC<94
MIN(#N+Q%T8'(;NP8UYQUT+^<_0"L5R&N\3/^!8!Y70YC\?(<Z-G"]J,:0#IE
M;"K84"T)I !C013"648<<%IJ 0?SZ%B;U_4:8'W3MK)$1Q7A11IBTR"Z)U.
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M4B"D.%HCSU*=;=\WW<%1$@>7H5;+VZZYS4R([FYZB37QF AHO<'7Z",,V%6
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M7KVZ_-,GC[AY2G\9NYZ^Y'3=C6.WIQ]W#L*C 1^ SS<=2)7\@AO$;[W]^G\
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M"]<RZ.T-M]+41(P[,L[U1FXN^0,P[/9_NQ*S=K2?!OU/F];#CD'_II7N3[4
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M]_6U&2)7YA'H\H5C?)<BI&@J(QL3J;:3EGAX;6P<K6D06<^E&J#E9+N/I]Y
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M ;Z_-4CO_@,=4/VVZ=E_ %!+ P04    " !6A%E29J7RWK((   '%P  &0
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MA3SBXKY[X$? =19?3L5&Y[FF['[N&6WG4<*E?S1M-?US6[%/0=[#*-4EZ ;
M12+=3A#+RH,;4]6"4S4LV69WH_J!#^:@$#J%K@YM04$MG>*,HBMUKOU!N%WM
M7Z5F7X:E4)4#</$+P2$8J.E7A&P<<(3F::$!DN?22$#*EE&F"F:H89J6;2!I
MU:8HR0UO-U:D6-1ASJ.H<I'P:!@R%G6ZDW:+^;2'#5.SFDY!H9P:BB!*9=8/
MUY/5>,E4<6P40+[7IG;/[K%.["2BM%&J?*ITAYX$^ S%P^@@O/#E;+V.'Z&?
MCL795;0:/IU=<6[/EHOUHQ?KOK.G>4%VE'@I/J$[N$54U=]03_>KWUE3;W<"
M[*V*#6+4,GC+3CO>W$]YB'((1:72H[>/,C>[7!^;"FH,%;WEYK2J,I;*;/S(
MH[8*:".IL=?E)N$5FOIW(?:9P8L],Y?<Y*J1IOJK"KMR:^0'XL9;R:%2Y 1Y
M\UI\.C;?7:_RW_/N^9DC\2^P>1!0WP80]>&8D)W,8?Y,,)5%/^%J-H_Q&T=T
MN5I@(02((K%5)=$"UX%,(1HUB1MNVG;R?"YB,5]1-K%VL@O,INXATBL.;#MP
M/1.10.4-TQ[R%*\7W;C952P6JS7AP=,S$2WI.HJG^*7*?=I%%.PS+EZ1F07Y
M&2UF/^1B'(N9B.??=S'"O_E)!Q>KJ!NU7(IES&!6$7M&F&8175,//N/?^CG_
M*#ZS&1G\,>\B<N[[OIW/X@LQ6V#X*?_FJ_B8P,45'"1WZ.D99EX0M/42O[27
M],HX3*;.>BQW2.8!]PY?AY +W)_0<[QW#F2>WV%7/SE,['<:_NR59=;=<%L>
MY0<8 7+00;UL\B.EII>#UAJ02@#[F!^IE0?"E/>/8RP?1;U'2_06LDJ'.#?2
MQ.1,40U9]51T3SRX[X*TB@5_HSE2G66( FW"&RAEXA%^W)_7LGF 0?OKML3N
ME39J;$?/[C5A@FC/ZESD.E,M+B1/^3%_T^)]98)]HJE$5P$C1PH/G<9%R_'?
M4C)=LP;KXI)J5X51V;@ISA.P$:@41&@1:X+@$>/N,Z(/.&CRAJ*'.W"C,Q%;
M@&NA-MQ+ZS+H5E63B2"58;_J2*NQ2D*"DDW^U2B_E,4:C(QAE-*0U;YF.H%W
M7+?$6"3#,I!(: A79QG"UY0&)>28B&X!.J,0I.V5:^E1M^P8?'I*(+T@JYPJ
M3BT%I9=,?C'P;<QEJA.0KQTJQ^$W&W-GZ.&CIJ'@%O(PB"VIX?2_M>NX,J/#
M%Z+1,M HB5>RF%E3X'9+M&_L@>K',!_2HL8"^?ONX^*>%&HG>#J!PQMK\PGF
M@L-";O#&E%2!XU/JEC^9V'#K*S?>8&MJ5,E6ZC(T.R+FO@7/H>;M?*A::49K
MO,M"]\65'\8-@)YGC0N)LAZ+=JK]U0#C-UMMU1R,'7U"PWF US9\MVQ (AF^
M ^GSTXESA^^ WPU*@!B!O\(A;M2KT/TD26&/L_Q#RH@-82K7;2?Y7Z"37J2+
MAIS5'(8X\3=4IT35M/(!E,5*Z$BK5S-6#7/Q2R/WF+6)LXFQB:_//\@#A<E=
M4.,I75$9E*BA\SA:7/3Y<WDASN=+L.'OS;?-,7?=*%C&J#7^1W.,? +WM\)G
M>34]"HPKL0('=XA)1Y&*(@U%"NIIQ(OINH<XGLX(R_3J><1+S(&> ?3I2P%#
MC 95L%BN!N&.621,8W'J]&S2.YPL%*J&CF"=X TTG%-V3[M3WKMPN'D<'HZ(
MWZ'HJ"USE6'J]'*U& D;CEW#C3<5'W5NC/>FX$L2&<K2 +RGTY/VAA;HSKYO
M_P=02P,$%     @ 5H194E$$.I=!'P  T6L  !D   !X;"]W;W)K<VAE971S
M+W-H965T,34N>&ULQ3UI<]O&DG\%Y56VI"J()GC++TF5+,>)WMJQUW+R:FMK
M/X# D(0#8A@<DI5?OWW,B8.4[=3N!YL@"/3T]/3=/:/O'V3Y1[43H@X^[_.B
M^N'9KJX/+YX_KY*=V,?52!Y$ ;]L9+F/:_A:;I]7AU+$*;VTSY]/QN/%\WV<
M%<]^_)[NO2]__%XV=9X5XGT95,U^'Y>/+T4N'WYX%CW3-SYDVUV--Y[_^/TA
MWHH[4?]V>%_"M^<&2IKM15%EL@A*L?GAV77TXN4,GZ<'?L_$0^5<!SB3M91_
MX)?;](=G8T1(Y"*I$4(,'_?B1N0Y @(T_E0PGYDA\47W6D-_37.'N:SC2MS(
M_%]96N]^>+9Z%J1B$S=Y_4$^_"+4?.8(+Y%Y1?\'#_SL AY.FJJ6>_4R8+#/
M"OZ,/RLZ."^LQ@,O3-0+$\*;!R(L7\5U_./WI7P(2GP:H.$%397>!N2R A?E
MKB[AUPS>JW]\G15QD61Q'MP655TV0.^Z^OYY#:#Q@>>) O.2P4P&P$23X*TL
MZET5_%2D(O4!/ ><#&(3C=C+R5&(KT0R"J91&$S&D_$1>%,ST2G!FP["*[/[
M&%G G6D0%VGPBTBW6;$-KI%#LCH35? JJY)<5DTI@O^^7L/CP#W_<P2+F<%B
M1EC,OI7<7P$F^+(I?MR)X$;N#W'Q" Q5@ 1600WW,KB5U('<!"#RP-1%(#XG
MN[C8BJ",:Q'LY;VP@+.B%J6HZO9O(' 9?(BX+&#<*@R2N-H%&] !_-XFSLK@
M/LX;&!6&BJM**(AY%J^SG'&L=Z5LMKL =!# !RF&&>]%7/"3^E?$NJD$PKF/
MRTPV5; Q!,HL)4+XDN1-BH1(+:V<)T;!=5#!E+--EL1%'1QD2;H#(->67/_^
M;ZM)M/Q'!4KI7A0X \1&3Q7@&<K%FPU,!2@#=X$8GP^R$H"W#)B@WK,>E0$3
M7!^Y_B1(;?$0<9+(IJ@1_U+D\!C!ZL-, TV:LA1%\AB46?6'6F:<:7 HY;:,
M]R%0/G@ G8B?N&#^>K;?BBW[Q" :*4A)4^&4UJC=1\%K->R-'O8# GAK ;A,
MMX,A8:1XG6>@OU)-S6#'O!J"MLUA$47 UJF#"Q"D@/M9 >2IZ99Z4T^N0NK
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M69Q8F=#MH##;GWKF;9K!-_$]R#K.5J[1:JM\69985X:K@F[;!4"2^3U.NLH
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M?8 &$$N]UX"V-)< :R<KVKP.EV[&::O/2-.GBNP$.#L[%#"S7T,!.^QBB"6
M$CH\Y%?*]OE_FGW]K/E!E!2+D$M;Z.T/#Z!D=AQ(J'TH?+P\CEE)E>RNJ2AS
M0%I@"9!/ME'SJPZR:!]>S2I2K;\ZP+7G0"5E\3CN5%@'VURNL>%*]\LA]V?J
M(%2K(ZFET!ZZUA9%VB-<Z+/!*R0W]X8Q5!TP.*]QE&S*EI9LNK!&8N )X<<>
MGK/$,VX&^2Y8=>UA1V612*A>!&^3_P# LC Y8G*7KP%<5LFF3,1+46(3I_,S
MLR9U\@*NOQ#KA!CJC+0U*X79=D,M /%6;10-74,'JSI#?QHDB=-C?;+38X:.
M<-YI_H)5-TH._!H<3O$,VD5GUSAP+1Y*T91<T[5+\#+F(V3<4W*H#!SG T=6
M,#!J*:3JE+NWQ10HE9:F4Q7T]B"]6\@><NQN]>JCUP882I9].[\&U'YF6U;X
M$$65DJFH(-<=P4>#A\/M&Q-KAU7OPFAI;J!GV8.L.6FN@?5"G5W6?(Q"*\;T
M@TA.6W&'B#-=9P^294,\920-9%.3(>!M\P-3(D_/-D'H$[6&R.:<\:<"Z&_?
MFG_;TSXT-$,,:,CM1]JFR']5K:77]2NH"Q;Y#3=Q:3&PSGDK)##KZ7BYH168
M&IL8P+U&D=)O]-+GBUK*L)M,88B<%(W;#5GSQ6!" <OVNSC?F%,F>M$Q4Z@<
M!SVNW.PI+;_I5FKM5]7Y2$TM"<[.EG4A'6:SSVH;_RIV>-K6U/:!:7O,?Z<6
MV%$JMX_H4/1%1]WO%OJXX\.XG#B?MP.A5=.[*M42\+F K6,GU/C?>.R$/N+'
M\C3'6SVJX8&.9E'M-=3G9ZL/O;&;.@$?E"CY^Z0C;CV+?*>/"O*V<5PK<XQK
MV=FZJ7V^]H[.]E;:TQ'FP-9:<DET=KE_;Z@^$$AO%44'AHX-1#>MXN0*.DP]
MMH63?':+JG<FN;=!PD_ #Y3TP]YYZNA$G?]C3IUU;]M3,^UVVE%GFR>UB"7"
M),FT5%#NR".;"D.MFNCU$MKPC7)OP2==K_]<2^](LR,C8?\L<DE;)T!\7C!_
M.RAD?H;H23JB[V_]/'?^S-(>'33\8U(*>?Z+2^:N^7M5U_QGFNSC_,>NWH*K
MB%V1N=C J^/1<OZ,=T+K+[4\T!]M6LL:C ==0K@ W((/P.\;*6O]!0<P?\7K
MQ_\%4$L#!!0    ( %:$65*WVQ+C;@,  +P'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;)U5;6_;. S^*X21#RU@Q"]YL5,D =KUBA78L*+==A\.
M]T&QF5B8+/DDN6GVZT?)>7%VUVZX#XDDBGSXD*+)^5;I;Z9"M/!2"VD6065M
M<Q5%IJBP9F:H&I1TLU:Z9I:.>A.91B,KO5$MHC2.IU'-N R6<R][T,NY:JW@
M$A\TF+:NF=[=H%#;19 $!\$CWU36":+EO&$;?$+[I7G0=(J.*"6O41JN)&A<
M+X+KY.IF[/2]PE>.6]/;@XMDI=0W=[@O%T'L"*' PCH$1LLSOD,A'!#1^&>/
M&1Q=.L/^_H!^YV.G6%;,X#LE_N2EK19!'D"):]8*^ZBV[W$?S\3A%4H8_P_;
M3G>4!E"TQJIZ;TP,:BZ[E;WL\] SR.-7#-*]0>IY=XX\RUMFV7*NU1:TTR8T
MM_&A>FLBQZ5[E">KZ9:3G5W>RV>45FF.9AY9 G3BJ-@;WW3&Z2O&20H?E;25
M@3]DB>4Y0$1,CG32 YV;]$W$6RR&,$I"2.,T?@-O= QOY/%&OPAO![?<%$*9
M5B/\=;TR5E,]_/V&A_'1P]A[&/^_!/ZV,?3WS )E NL5:LH&%(H^ F.Q!+6^
M\JFAOV0&=UQR>OH2-DJ5!@:0A+/IR*]9EL(CVU*I6-2<"<*4I?]"@$MHM"K0
M&)B&8\*:A--)#$]MTPCG/(VG],O@L[),P 5K2/N%.R!#%:DUL21&QEY"'D[R
M&63A-)TYOM04#()5\.'^[I-7@8L\O82+)$LNB16I$^R #,:3'!ZQ4!O)OQ-]
M9J[.PA\0L5$2TSH)9UD.GVQ%B6#&H"5Z83++*,)Q'I\9/3/1$E9+E:B!##H6
M-=I*E42F;C0WSM<I'+&#03J<P8H+X3L$98@$TY/@[!FZHO1:+OLA]233H.\J
M8C>$ZUJUDOCI?ESGU!D57X^)J%V** "N'1>U!OW+%^.GB,GEV_S(-;T'V_/B
MLA M?:4P2'Z..1F.#H+SJ$)'JN<2I"+"+^Z>@.BE5PA&":+);44LE438(=-#
M>AE@9<FMAWR-2)K-J*?UB4SSD^#WD_\OFI2MLBW(A<\<-DPS/P-HB.WO+ C6
M2AIQ9OA?32#J==0:]<;/#2I_%T'77(_2XVBZ[CKR2;V;:Q^9WG!I0.":3.-A
M-@E =[.B.UC5^/Z\4I:ZO=]6-%Y1.P6Z7RME#P?GX#BPES\ 4$L#!!0    (
M %:$65*#\C;+7@T  #DE   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;-U:;6\;N1'^*X1K'&Q@+6M7[W$2P$[:7-KDDL9W*7!%/U"[E,3+OB@DUXKS
MZ_O,<+F[LF4GQ16'HA\2:[GD<%Z>>69(Z>FN,I_L1BDGOA1Y:9\=;9S;/CD_
MM^E&%=(.JJTJ\695F4(Z/)KUN=T:)3->5.3GR7 X/2^D+H^>/^6Q]^;YTZIV
MN2[5>R-L7132W%ZIO-H].XJ/PL 'O=XX&CA__G0KU^I:N5^V[PV>SELIF2Y4
M:755"J-6SXXNXR=78YK/$SYJM;.]SX(L65;5)WIXG3T[&I)"*E>I(PD2?V[4
M"Y7G) AJ?&YD'K5;TL+^YR#]+VP[;%E*JUY4^3]TYC;/CN9'(E,K6>?N0[7[
M437V3$A>6N66_Q<[/W<R.A)I;5U5-(NA0:%+_U=^:?S06S ?/K @:18DK+??
MB+5\*9U\_M14.V%H-J31!S:55T,Y75)0KIW!6XUU[OFKJLIV.L^%+#/QSFV4
M$:]+)\NU7N;*/CUWV(-FGJ>-O"LO+WE 7IR(MU7I-E;\N<Q4MB_@',JU&B9!
MPZOD48DO53H0HS@2R3 9/B)OU%H\8GFC[[&XLU5<6JN<%2^U3?/*UD:)?UXN
MK3/ S;\>V7;<;COF;<?_-4?_'GGBYXT2JRI'SNER+9PD"WWBZ:]XO6Y74U9H
M=RN6M\*J-=+-/1'O-Q* 3U7M="IS<5GJ G]^5#)W&W&)57Z_GRN'X2N9RS)5
MXJ^RK)'6@B,5+\2QB*=1/$WH0S2?#?$W26)ZFD?)9"0NT\^UMIIRTPK,CZ-1
MDH@?_C1/XN2"GL:Q>%ULI3:DE&W?A+\GD'W:_._U.8E/[\^:G?*_H"70I(HE
M)H^"GB=83YK.8S&*XD4B)@G4B<;)9%_%V1CCPTDK>3Z> 2PWRCKM@)8#"D[&
MI_Z_3CVL.4D6IR+!W@_IA#>D$_MOP7X;1<ETCK]!,CPYC)+1G$5ZX;I,\SJ#
M%FE=U+DDJA/ ;FGI,[%?]AO(Q'L2CVW\EUX'RS!*E7'@<5&QR-Z2 6MTF3;"
M5=8)T&V(!-+&0M).(7>.)Z,8?)7GO+D32\@\8"CM2E$8,&!EEC7.=E5OAU)
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MI,R^>A%4&3O9$=!52_Y9Z<=::OCC%Z<O1$MEB-]NK:F"O<IM,"OFD^L3,GZ
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MWI+BQ$=JR_PLQD):F$QN2I0 @QQ@<F$!9C"HR3$:.+;1IZ,MYT1QD*/?^#W
MO\Z<MX->["^TZCHZ'I,>U<!YPN^6M!;X+.KWO:V_T8S^6 D"]*I*2D(\7E7!
M<0\X@F[C*M,FQSYWI]5G"E9*Q3D0:+3Q(?8Q*\(N&Z#TA%B"LMDB+XPB==E7
M5K/)J&-PB);RYJ":I#E84%.6._-HV7N1%!G6:>GY&ZRRQQ"<,$5JM=-0V>>N
M4 A;]"MVAP2D$"";-I<*YHO/LZU8&I^'DP3SKXNN$4+R3Z/"^R;H.S(.R)FR
M(W2/6O3N=J3T6+Q5U \FHG*SI!J-=&0]D.F4Y;RL*/1IG+!(2%$HZX?OD#CA
MNI=$+K6[+SNQ1YD8*T_)I4 =1#(YIW'K,<N;);G?&Y'>B#.(3%A+?1+"3^<B
M4)4%YN#@\TXA$HB[[+G4;^R\[7$,R(LD.[:MJS+Q.?!;M?>A"&#R.D(@600M
M 90*:Q/!HH:ZF9L?DT[%]=JTV^+?S&;[;7'1K/DW[?8$R:OS:D[AXYJ"Z]82
M!ME8:NRJR3W-':7JHYF3:!X/49D77&G;N&J,V YC,?#32_6+[R/)C?$Q*J:?
MIFR,H)P^NEF[Q;T[EJ[54@3B'J2<B%'<E.+DRFB@$2.6%$#ED)CB5(# &[<Y
MCS\?$,1(JH]3YS%VTE"=%IGMQ;<1=S-Q6S)%IQXC_# IYO_5H^0A3#(*Z&/2
M*<LU0&%T#X(95@(?A\03JXM,PF>"Z'LB/&0GN&"J*AZK<JZ1EC8K*6[2T9?D
M4Y-K-<B$AEU5B=$J@>N&16R$.<G$=$U516#[CEVABDQ<IZEGSO<-DU5/!Q$1
M[S:LQF2^=(BGU*7(M>K8K_[=-;>W*A[D/P(!L'6IJ!NEXKSK2-E2</F3VCB"
M^;?.K+'ALD=F7TF:J)"GIO9<]6+A=JX*H(S\7P%HXWQKE9%4"KQ96G'>!'(V
M-[#\02>EUHC@AV^-*S/.^-O9"UJ8N"J4C;/#EHUE&C*CDVSW;$X)\TA&LB-\
MIXMJ53Y%$R@(M$V]*AL5-Z<$YX51F/.:; $!APT<@Q)!"#OD?%.Q"8/=<@Z$
M-FS2P\-20VA46<#?Y:))HX[WQ(H_Y0TK5YE?=##0"LDC(R%PYN6E,KQU.^:G
M4)'W_7S;V)KT3-MLDG4(K!7YY5<RBEJ?&Q=,?B<E2.Q='/W^L?CM^OS7XV*;
M99ZOM3Q[]OR;P!!O21D3"U_&JM]50WA1JL$\(PM$& H?G<L^IR]??E4<O;V\
M.C\_+G)[P[F/'739*AK#U)RQEMT6$O=Q75GE-)[=(R/2#4KZP_7OI!K/-;>T
M<NAMTH>)0==N*YT=G!5@/DLY%>@TEMTK[3TIWO2>I>*R7IP41U=O+H_1&D#D
M[,O'[-/,"DZ]$!=3%*D'"90[^O'MAV/V,0$?RR@,G%F@["%:_+RJD-C;2D2-
MD%7]C6^&BHK\:VXM"LE]$"GU2ZGK[[>-9#P;V2Q@#Z[$W%LR)LA&:%$AY*:#
M&HM\YV$3RWO83YE(]IBWC2%O4#5- BFRY9!D;-!P<&_M)TFD3%-TZ%H.R"=M
M!(040F_ +AUQ32S*_5XDYF;9H7J20TN^LYSO-:O0RP$[7G#81/'LY<5QT1,:
M%2T:0E73\&IR==R&D /K!5I NB.KTK3! %U>(%)!0.I3.C^C* <G-=Q^MD3%
M&PHXZ6=B,<^YXI@?  X'_13/AE2T>M62#"'.!27)6H*%U/#""*D[GHL@F5 *
MN3<*%VDQ=B D<R5/GY-T/?Z'6WSBC/JUV..3E,()W,K@[+-KQAO9&4[N59NY
MYSW!LJQ^LN5VZOO140SI22CRR+]9&#>VSV-EFJM)R7J-E)C22(+>8+D4<U*T
M+U&^YQ8LZ2DKB3LD.-CD(< [VJ6/<3C:+2H7>E.$9<;G 4<.V#'C@:'TC-)>
MIH[KKXBY5ZAJ:(@IL1=.ZJ/&*$+WV[BI<[C)UK"+F_>JJ?MT;>IFZ8KKD_.3
M'$8]<0CVQNV9IAOTJMW/6P\AZ1<PFX8L*2V9\1HD=VB)+Y"RZ@)V?^X]+$<2
M<U5Z.*F_00 /7AK2<H#6T-E;-HN>N0FY@I5II1Y)H0).C\2QO5T0>TJO$9(M
M'>I?CP$+,LX-M_<LS4+[VLC^:_-0\''4TQ/*^_^L^&H.._K3LJX=<*@JHW@R
M'+>VZ)N$U7.UVC ?XQ+"WSV4FE*^X%M'\5ZK6:W7:V)=R9DD(A*DZ)2,+K]$
M@E:T!O<D6)\C?6U=F_?V,OT#G; #XH-A^[(V39)=:C8A:^OSY0$ AW25T<:Y
MU!$=W%E)W'"&6>0/B1.*]3=F84E4%ARMX?QC'@HPP0WB_!Y[V,D=8JIROUK\
M_71+W;:IW(*K&9+D$R<D<@5:2_INC0QTZ&87TN_@,@=J,ITY-",E;F I#I)4
M) O==.  ^G/2/?89'IGM)$P@VO]IQ1.EU1$;UL)7 S9%SDW Y<UR/9S2_T-B
M9D>,2OG>R.#C'FI ;DFX 2^KOC+2'HTPJ8:K+D8K^XGH8A2$+41H8:.GIY4G
M3>\V,%7D[/J8.//V8>?/8?($/]EZ^H/66<H%@:8-TELE+<8F#-Z21-Q)EM$7
MJ#W'W$(9",2KT.>H00JY N2QH_^U:J0H)D/PLY5&T%?6E#&;@%L(M:()%0 !
M/,M7LY/8<Q=4XT?]"W;0P5MR2AW>Y. >P*R@,,IV@&H)00H*#>FGTG$&K\11
M/O&:4<+%W4<!(=Z3 !I^93)F_9'_A_C0L'/5M>BIRKZZOW1'?UQ?S(KK!2T(
M.4?VKVF36GY_?55<TQ=FB[QV$*9W[UX71XN&+W5P&EJ+-&P&+F)AY9A+HEFA
M!87!OA-^Y;YZIDH0GVWWF 0C%0IC#0I!3<%UL;6IEJ"0I.K4<.@_R.-:4"@&
M/4A/"$9BFD-\T=!H&'Q79BDIC4348?N!1LRKM9) :MJ[>'N%P.+N#)0*Y=K,
M(K7(2^4WKSK7Y*JXDO7VDKO(K:3."/AM(\V1W'HF\'VN0BA=!1_LW"X6IGB%
MA%)QO8&&56_P1^.[<87P=P?'#57ARU$.?)92@R%//T76T)L2JB$HIDD#F;:M
M2HIQ3)9ITJ=*Q-S!GC%9VKGK6O6V!HV"FCR/*-&D/FI&PBI(C:E3B*9V#6]%
MP,M!-GUC5J(\0\&?+9/65H+T?LG1ZZ)NZL<9[%I]TO8 BERY'*D] )Q$ W2$
MZ+O\LX=O>;A'5-$4LWF,]MC!'>FP1R$A3&C+* R0I@$'%T"EP]N-*$(\;.@G
M;93@K"?S\%I[[#=-VU#"_3PU<F(H^?36#Y-;GM%LD#XG:=6LZQ.VFW#1HBK'
MB4RB6O2$).>NR"JE^.@6A?TGJ9J-(WW-7L$5F:>K@:<5<T![WQP+!\3N2\[7
M)&C8S<I .M2^MB]I6;FZ#O6,^YX2,@46XY(KLP(<?KX#(K+X:Z)\S.;?0[/
MTE,PCHEW8$_1L_*)% KX&:+:LQ?[:XH?T^1(RL&\OQ;_!E^D8OP7,!YK<G@
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MYD-%LWD:U?#;'M73>ZFXWZ?%G[)C>[!IZYIL]QM4<M!W,SM(SEERM3-_7S/
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MNU"^3=<X-_UF*VW!39W=A!N71=X_?O_X0W%Y":4-(S[FUL!\C!AFK:P[.,C
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M/NZ(N,OR)9ER,FA12N;79T/O!V24YP';T'!HZ=C0&$BPA8FVW(>#* 8=/HW
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M01M7RO-3>%S V[JDO3/1;#B^JU6Q2*?2*.J5M+N#0 ^A^*) ;SBP_=;<5$)
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MM]["0AK<:.J.M#?&Z'9=AA-C2]F OXM+D'0OF%9M7=@)??HG6. J1\+P@<J
M(&PQ]%3!Y2 "/.+:YUF8&FZT<;)>]_$9T[:4BK\79E @\ERWM4]>O#SD[V_\
MF&Y:8<!*2JPG#^(D+.%5LAQ8(-3C<&()K6*I-Z@-[(4LE[M '47',:Y4I?SK
M .1KK8LMEB2K1D@3\""/S1JTAI7P@IVFG(V#ZVC96I@?/->K>P/7NC+WZ*^[
M!+.(XCH(&EIF^J ="F7T '@'*[N')4)D/*"C*)KO 1X@\+HL.Z<XB ;E#E,#
M$NPHI,U:^%=OO"MC+^[DY#%I%_[:^XRRR<6//V1QM/C)DF["D\FW;'*)XNY
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MM$3[S,83X'RE$=A^X17L&_+SOP!02P,$%     @ 5H194N10RP*Y#0  _R(
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M%538LL4!\'^A09O=!QKH:_:3_P!02P,$%     @ 5H194EU?VN>!$0  @2L
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MP>I:8K!S @->5T[/HT=T:P:]A;2]&:Q-1@LM:]13-D6J:N4LZ U&A4W+'?S
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MW\;0D""% (Q,M)*,0J@"7$/UN(,#!C (5!+C/XR_@"-I6)1_04.!#X8Q@9-
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MV(]L]'FN"YLVUJ;!&CH_8'2.CI""P!4(=Z:[12. ?JO<G9J0^;A7K.5AV'M
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MP6C\?\"*-B<4Z9#  23= L^*4Q3 #G#\+4 @7U<F+ (0M3U 99'LQGQH&S?
MB?H&_P;&!-NM&N?P01AGRP'NI#/]T-6X4+9N^MTR _8#RS5N=(L)].]VL'#V
M$X#T?7QHEP%F.!B=U]G5Y>6?%K1OX,XPTF1N!^#=-54)CQ.R?/G"'X%![W8P
M69:[[.>FGKI5NG;S^P"GPRN]A:\4F[)\L[&5A:VZ;(:4OO"D],4L*5T7L(JS
MA!53M'/_T9XN7L,>L_7@X%F $>#B&K$,'ED($?@QV=[ !91XUWG@&1T>'*"
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MW>),"L9M8]AF8O\MF_1%\"' 60'.^1Y%S;\,&_X8-K*>-DZ<\G!L1^M2[/S
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MJ]YPU#M\!235)^RD#8PD4&EPDSEND@"L^YRHXAG!&*]:(VOBIPF+'K4OE8Q
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M=(9UA*"FY$X&%5G-T< I4AQQ6*@'2##%C>)9$%] "#:W7$RJK])+8I7^?0R
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M*4)$:<-8RZ7+3*,[?+P(+JC<>M=X:/0I N_V$:A&OY-T./MFB#3V#63;@Q5
M5?(#(ZI 7 43!30)L+Z$A[XTCK<)-XQ*!A_76VD#,X&<R[:D@T(WI<#EG3%<
MRF#.\3IF0X@ETE0;#S'R!F]#D"WD2$B$NK$U;+GAP0#\N]* 4BB N^>*8UE;
MJ2C>7,G)P<J8)- P2NL0Z8SQ*7 XGM"U_H@]Q@8G3B9T8_&&6_\PH%J)CGN
MJJ,2\_'NCOEL%J$4&L=%H\ -KP.%B@J1C:R2Q<MT2@]X)MRV N>+D^>+:[8X
M^9KBZB]"C)\IK_1X]K2\DL'D>'ZPP":#^2PY6& N!/A@=;FNO)#Z.(V@Q:R%
MG1S^B8I;2FVI_*_EEOQ'Y68?'RGDM!)V':"$]U:N&A\U RX23F:RCO*Z!\UV
M'1* [VNT92T7:!?L%- H5JQX;$E:"3]7UDL-T16]9J%\N:WJX5,'OZ*^/_=N
MC_:Z*;PQZ]@S.HJJMHW5;G77EB[;;NQQ>]O3OH$H$HV"X@)'Q\/C68]LVR>V
M$V_JV)NMC$>G%X<E6FNV80.^%\;X[208V#7KYW\#4$L#!!0    ( %:$65)C
M-.19700  & ,   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;-5746_;
M-A#^*P<M&!H@LT1)MN3,,>"D+5:LZ8*DV[ ->Z"ELTU$(C62BNO\^ATIVW%:
M._6 /6P/IB3R[KOC\?ND\VBI]+U9(%KX5%?27 0+:YOS,#3% FMN>JI!22LS
MI6MNZ5'/0]-HY*5WJJLPCJ)!6',A@_'(S]WH\4BUMA(2;S28MJZY7EUBI987
M 0LV$[=BOK!N(AR/&C['.[0_-S>:GL(M2BEJE$8H"1IG%\&$G5^FSMX;_")P
M:7;NP>UDJM2]>WA77@212P@K+*Q#X'1YP"NL*@=$:?RUQ@RV(9WC[OT&_:W?
M.^UER@U>J>I74=K%19 '4.*,MY6]5<L?<+V?OL,K5&7\",O.-AD&4+3&JGKM
M3!G40G97_FE=AQV'/#K@$*\=8I]W%\AG^9I;/AYIM03MK G-W?BM>F]*3DAW
M*'=6TZH@/SNFW51\JC1WQ8&)UES.D8IN#;SZR*<5FM-1:"F0,P^+->AE!QH?
M &4Q7"MI%P;>R!++YP A9;A-,]ZD>1F_B/@:BQXD[ SB*(Y>P$NVVTX\7O+/
MM_W'9&JL)K;\^4*<=!LG]7'2 W'N2$1E6R&H&1R.N:_"7\'U&A*/6,),2"X+
MP2L0LA-IIY>*6UJU"NQ"&"B>@M,J37 #,YI32W,.OR'7Z[,"JC364]14;5]L
M&MC0#3E,JDI0*"3P!Y0MPG?P?B4;KA\YG$ 6]VE,TY1&EF?[K']4),=VKB"'
M;[_)8Q9_O[U^5)9VP#_W(=@D>09[I8QUU32<N FOV"G$:08LS6&8P!VI6\CY
M&<Q1HG: L@1>DFZ$.U-?>#:(@"4YD,<M&MIYL?!F)86L5.,.A-83LLN!]>,#
M!;FE6?'@!0(SK6J8N "_4]B"TT$45>N**23\9!?D6[1:.V!N#!+'3B!FKEHL
MSN&&KSH8.JI#().BT"W=NCS5,T"JUU14P@I7C/@4TCB!?I;YPMPBO:>-)S6O
ME;;BL3M]JE[!&T$%]P2J!46W2B(T?.7YV/-0[[H$R'D=?9_A?X:(*!]$[7C8
MSR-'F,@3)AWN(TSF$ >0#(\B3)9 [BASF"ZN6BSOTV\(["RE\4C2O!&&BV/H
MPOJ9'Z-G=/G2_4BB)*>0)'W(HJ_A=>E\4'(#\WX7)CV% 4'T2?G_ M\FM6HI
M E&G.V6QX=\)ZZ5 4:LO^(30-E1(\EI#=1MO?-@=].1%-CN?66M;C7M<T_^9
M$"8EU@WWKYB<N;$3 G'] [5XG0CH0#9F&@NE793I"JY1%_<0NPCT=F+#:/U6
M[IQ(69$#3"GX"23Q/F4QYT=*B=G@*&D-&,$!,?&@M ;T(HX'],N.U=0E7Y'-
M$9H:^._5\)D"#CD?4@#1=O,%2[).!4]L^4P#0EKZX@L*M<ZAH_VN:@[QJ[>O
M%0EWNKX:]=SWMHY7I**N =S.;MOG2=<U/IEWO?<UUW,A#50X(]>HE_4#T%T_
MVSU8U?@><JHL=:3^=D%_ 5 [ UJ?*64W#R[ ]D_%^&]02P,$%     @ 5H19
M4MTK/A$&!   U@H  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULI59_
M;Z-&$/TJ(QI5L90&V 6,4]M2DKNJK71ME*2MJJI_K&%MT '+[:[CI)^^,PO&
M]C7VY519QLLR/]YCYXUGNE'ZHRFDM/!<5XV9>86U[97OFZR0M3"7JI4-/EDJ
M70N+MWKEFU9+D3NGNO)9$"1^+<K&FT_=WIV>3]7:5F4C[S28=5T+_7(C*[69
M>:&WW;@O5X6E#7\^;<5*/DC[6WNG\<X?HN1E+1M3J@:T7,Z\Z_#J)B9[9_![
M*3=F;PW$9*'41[KY*9]Y 0&2E<PL11#X\R1O9551((3QJ8_I#2G)<7^]C?Z#
MXXY<%L+(6U7]4>:VF'FI![E<BG5E[]7F1]GS<0 S51EWA4UGFTP\R-;&JKIW
M1@1UV72_XKE_#WL.:7#$@?4.S.'N$CF4[X05\ZE6&]!DC=%HX:@Z;P17-G0H
M#U;CTQ+][/Q>&JO7F5WKLEG!^:-85-*,IK[%V&3A9WV<FRX..Q(G9/!!-;8P
M\+[)97X8P$=0 S*V17;#3D9\)[-+X.$%L( %)^+Q@2EW\?B;F(HFAWM9"2MS
MN*;**&TI#?QUO4 K+)6_3V2,AHR1RQ@=R7A;"+W"H-L\5L$AB#NM5EK4^P 6
M+_#XTDI02[A5QKYV$">3DHBO3"LR.?-0I4;J)^G-'PL)2U6A BFMI4/N95C^
M@TDM/LYZL'H'5A^ ;7NPX@"L[<%F"/8*'F0KM'!RN\XRE)YVL7[%!!H>E145
M_"F%[FH$\(1EO< GVU-VE"F:$5B%< ;??I.RD'V/JS#B>.6,EN,8$U5(?'4!
M*]E@DLJ=I\A1("6='RE]<(XBX!"-Z=UC[JQPMKE\PH;48GNQ@V$: H.4?W9(
MQ,P 3^/!+IQPB,<IX<'=,V )K1D/\)JB_W&*X>04Q0F%B8DGB\.OHL@YA,"C
M+U-D^(E>)1B/V6"5))!P!V;,'#/"%#):3]CX%+_T%#]Z/V%( ;^.'2-R7^9V
M'O(1A#&:O\8O&O/= <83)$AT:/<,/4<$+4WPFL0IG-!^/&@_?I/V">P#_H/F
MA,0U J? SSO!80?H^\)KXC^9]7^+G]":+5J]A_9+K>!-TC^DW.,S\+-HUC@/
MP%8A>"I.[+O*F81.&!&\?T9P1G;52F5)14DE>7XG7J@8S CC9K)LK;F !F>:
M<\[BT7Z))",XCQ(\\%]4\UTF3+%E\;*SPLAHE>*716AY!/=_M9U,@IV&)C#&
M,AL04ZN@1D%M@IK$<<1QD.XAYD%(6(+):<0)^J!D$7KP5L#8;[O"CY/QP>OF
M3@<!?U4'_MZL44NL&IJH#(ILW=AN[!AVAZ'MNIM5=N;=Q/<!BZYL#%1RB:[!
MY1B+6W=35'=C5>LFEX6R. >Y98&#I]1D@,^72MGM#2481MGYOU!+ P04
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MQYP;PI5/7)4H%Z*D!/"R*)!8C8%,*>#>ZFRI=01DU#'M(X?7YV<&D3P<H"W
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M&A^1K<$XH)%P(SXHX#MF$,N!0&!;TH]%HWL;"K L&840-$5VVIW6J3@LHQ6
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MYNATK+!&(3+;=Z9^0. L84/#3)K]O'!K?QU5IED&QB)+=G1$'_/J"L:I-PW
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M -\7$K(>\X(+-/__].:_4$L#!!0    ( %:$65+/&.;?MP(  (D%   9
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M:#"8CCU0-1O5BI&E8X"M-,@G3LR1P*FR!]"?26E:Q2;H_A(6?P!02P,$%
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MPS4=YU'Q GJ_E-(<)PS0_D&X_1=02P,$%     @ 5H194JM+YHFR#P  [#4
M !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL[5MMC]NX$?XKQ/;:>@'5
M*^I=N23 9I/T4EQRBVQRAZ+H!UGFVFIDR2?)^W*_OL\,)5FR9*VWO4]%D:Q>
M*')(SLLS,R3]\CXOOI5KI2KQL$FS\M79NJJV+RXNRGBM-E$YS[<JPY?;O-A$
M%5Z+U46Y+52TY$:;],(R3>]B$R79V>N77'9=O'Z9[ZHTR=1U(<K=9A,5CV]4
MFM^_.I-G3<'G9+6NJ.#B]<MMM%(WJOJZO2[P=M%2628;E95)GHE"W;XZNY0O
MWDB+&G"-GQ-U7W:>!4UED>??Z.7#\M6922-2J8HK(A'A=J>N5)H2)8SCUYKH
M6=LG->P^-]3?\^0QF454JJL\_2595NM79\&96*K;:)=6G_/['U0](9?HQ7E:
M\E7<UW7-,Q'ORBK?U(TQ@DV2Z7OT4#/BE 96W8 9<:$[XE&^C:KH]<LBOQ<%
MU08U>N"I<FL,+LE(*C=5@:\)VE6OKVL&1]E2_%2M52&N\[(J5)44"LROQ!N5
MJ=ND$M=IE)5B]B5:I*H\?WE1H7,B<1'7';W1'5E'.I*6^)AGU;H4[[*E6O8)
M7&#4[="M9NAOK$F*;U4\%[8TA&5:Y@0]NV6%S?3L(_0^#R9=BG]<+L -J,X_
M)SIPV@X<[L YTL%5OMGF&>B7(K\5GV!RUZI(\F42MUR^ O/'>#M-^,M:B0SD
MM@VY14TN!CDQBPNU3*IS 1M&E;V\<Y;WMB_OINF6Y1WGJ%Y6:DDC1G702&'(
M2;;"IV8V+T2C12W?OLYOYN)#5JDBB\CZHG12NTKQ=Q45M6H("%9M%JAL2Y8M
M+C*D2_#$ZXTJ[I)8Z6E_)VS/Q-4*;7JV/+J:DDKLH+VZ%BX./_EZP*JL^>:@
M>\<-<+>$M'TA??H+J*(7TO]W#UM@"P:,">V*3( !Q#41E:7"E&:^[YR+62!]
MNKH25T>Z=+4\NMI4XE.!;U$-^UQ<;O*B2GYCEA''=UFAXGR5);^AERV$"SSM
MSG'FA.?UQ35QD0%=B)JTB2Y?J"S 2$CATKS$P%9 ZW,1=3NS35M(%_RFR5J8
MH2,"IR$(TE)\407P1]=>-&*3)@D)_+<%I(%_+IZN=D45)>F&-1TUI$/7/_TA
ML*3UO?! :T:,D31_T ?R5ZFJ:]MM/1?C0=5.R>']T],J3R)W< U([M(B39 N
M:85+ZN"3\&=N2/68BW1SSR=,W6U-W9VTR)\6:;+2O")+>[]CQ;ZIHFI7CMGW
M-+4;=IFL!$FF/3%37L#-LE7&ZRA;J1)?>QI(73=\R=L1E8:V9#VFDL?$5:D4
M2K$C09#>%?0]JGKVF*!J6:/ F.%K*Q\Q_ZZI#I_>1TDA[J)TITCMNW/X6Y3M
M$"X(%J T;(\>0L-CFY6F(3T2:F"X 8E5&M(DH89>("[C:H>.QXU3&J$)C45S
M*)EA AVDX9IX]EV,"#H,=(NR1P+ JD@6.V8<%#V$0D+G U]8GD6*#^5^=WL+
M'&!05P]:%**(JKU8#A77=SSBY6%QR\1ME"P)&LA W(#,V6+@L&PR\M!FFW3Z
MED.*VU*";?DU$AQVH@5T6.I"&$ W<$1.R**K"&1.AL<6U(H%):83=N4B#<N2
MK5S>#'2Q+U[;,$U;-_<LLWZ0+$_###0]SZ_O0(<>WA/:$]83QA.V ]FA(^.0
MWL"YAG)6E"*!KA \JAH@2V+@.:E%Z.P5Q29%L0%*LQ#0A;D]6VC/UQ;T#RBV
M"82O61J0^%)+_;#NS'.HVF%Q'Y$E"9J0U^89-I4F %ZCN_M[*IQ;*QS^CZC%
M@:8Y$+?=TQ#+<&VGJR'0"--O->1]#]SZU&:P?4>>ZR?/L33L!ZZ^UV[ #CR^
MNSYJ?MX[X0B@IV=TJ6WBNW9*W2=T0*AD^Z/?+^.XV!&Q-@B+=T5!\5":1(LD
M3:J$M)"5*&R].?OBL/;'>@R?\JQI^6.WI30"EVL:KHX+#$>3,"R/J-@^2<OU
MI-;QHP: D(,<3_I("1@E4EU/LTS*F)P%:V\YG_":7NLUO6D_AYQSN4L9=\"C
MW6:71E7-I^LB_Y>.MAIUV?M8'LZ[AUB5;%8,8#\W ,8FHX4UYGDG1T0Y\8MR
M&\7JU1F27HJ]U-GK#QT?7"@]Q"H?<:KH7>>?%+W5GE+'U=->]43W>=TC>9]4
M:Q%!9 V?AIZ?V*1:-G61_7JJU9@!!D;HDHK[AC/I,FHG4;L(WW#A:3U#VN[H
MZ"E+WXO].1.XG&['(W>"L'92)CTXAA5P(F XOC<U!:!$X!+2. B)P0#;YF!!
MB@F5]UN5]T]7>8@_;F/_)_1VFBQEA+?MC,HF>ZNC&L8A__NRIY1MT-A7S<6C
M_B P,K7*X:JC0O6TM6-N'U54[HK:07PM*4V<_OJCNE,I'):^6_7=%I\N?V9D
M^I)74/[3:NT-@^VGT2^]<'$5E6O&D9@>U*^[!)SA@2 7. +B-FNZ;9*2V$?J
M6+;'UQ#V>H<X@[-:0@'R.AAEOH5" D._$6NI6P9HR_0&'M$V JB78Y@AS<(=
M^>XZ%JZ^XXMW&U6LB'\#RA+QS&'+D#PMZ")T\89T?61% 0SA([+!581@A+C$
M(O_+(HJ_$9HI.!E-OFD4#'L9*3IV_VM^!VAC5G%G*Y7%C]T,Y61*Q^X2,0#]
MO2.^/'9G,)2*903R^-CU5V"$.PRK]G7HZ_OD@1.T.-^H,9Z=/FO+(+4:]M(M
M!8HA+AS6H=*KO-CF'%..44?X,]*R7PI\"ZR1.E3Z+$6QA^E[IXB64X:B"^KH
M)FDM:B0H'GEJ];WS=-U'MCTFDDT;E,^1([!Y&8B"-=>0TNDF-Y"_Y7#EP*6[
M;N#YSC[QZ7OJTW%'2LYQ^GC"11RG^L.ODJ J\)Z%-0XR6G)U>]61B+D=(_!#
MX5(B:OC>7K4!$H[A /B>UE9H@_3 'T]V] 8\ SN1ZSE(CW60WNHFXG/;H.1Z
M K[<H6:&((1Q>AX-KBT$2$)HXYH.9VWUAB0!3BXE/FTA(@!IN;6BW78MMTLH
M[+9!%NB@9&B8D,IG!<DK"OO4OKA;07HCY?N24W#*'7$*;3J%;^X(N+??\>T8
M/CTM:1N9]'[\>(-(D&C[(TX,2C4N$R2=?D<7]&JJH$!PP V@W+,PQC<'-#I%
MWI#?*!HBS(<,P4F4\7)"QFO^R(,Z^2QF&]J\(FF8'?4"8X..:P@A:$U;BN'4
M]@S;?R,;DI,X91F^'W*L[7.T0<, 4H5--*N77 S?\KF2R6 6<'CNVO9^.89"
MI2M%*P%9;^;5&CW>*X1U&QVA\:H?;2CHR$^/8X9HZYS66T6YIA P!_MJT]60
M)M;1G1)93GL(*A-QBM;);<(ZIY.C_:36B2JB(EX_S@6%JA3(-2N/G&=E5=,,
MJ5%%>TX<=B8HYP0+Z=:6EBLJ7JC,8F2^;>!\K*LV1SL:Z?=#7[VQQ!I(4>6<
MM8%&RQE+'4.WL6B7H<S?H3;1#&!<&$Z*C)I'L!0[CH,CH5>LZ9E-AV42;9'-
M/2 %1WY=PT"]G*D7;'6?U!VEG47Z2,T[!G*_SDO5-*PS 1K$+LL7E,MJOH+0
M4E6\^-..!XE_S "=+U5:&FVNKVI'=HO0']I2K?-EGN8K=&:00I3))DFC0E0J
M7F?)K^A/R_>$5.3)S:C_H?QD*BBP^QZ_$QGP)E78[%F-5N$HQGE6># 2^MJN
M"R!W1C_!!=K.I <?.@5.GB5YP0$>>K0S<T*H<3S0'W.G2'3\9^8SPT&?G&L,
M?7?S9237<(_3I6^6==R'T[?_W(?OJ0P9UBV3X4B @[(G<HHCK=IG9ZA+5/:\
M7&*HCITH;R21F([^+?*B#IO5WH0<+^AL6]B\M&Q[?8/3;?26QO]]ZG_E4R=6
MT()V!2TX87/TD?J]VB].]]> :V?SY[*%YFZ6-K'*-MGU^.HP\5YS=T%GGFA!
M]BY9DN=MCCXU#.VLI>_Y9Y!UI[LE@2OBAJR\5057 <\NH!_YKC*( &((Y"T9
M0@Q:MZ^9W=6UCDBT3R^350;=B2.H52\"2++MCH+=FC?ZH,B)RX4O.FYM'T%S
M.J3#8.W[)CZ-+-:]B5*NV]T<'/-W8?TW]JU>KI[<!7Z!T:01!UW0XYJ'996
MM6N5#O:^#P%F1MM[[G#':Q;H@PUCQ'.070+8J!0<?E31R-[82.80X-_U#B87
MT?X,V4\)@$#419 R& #O/HX,C(Y=X*_A;W]?;(R+?OUWG/M3BQ]C<M1YR1@]
M_260LE[VT&^_JP2E.?0A5#:RZH"BH_R>T6;G@+EZ!]316VKZST/LU]HP'=:
MX38(-"J@D;+#^[CP=$XX*B;^,LWV"1@.6Q@.3X7A]EQ4>W8P>F2O.(:PDU3'
M$;:EWZ8'-?U!Z-_#EG:G?EQE-28!S;3>\;(^K_(%="($H;4?(%/W?5I_P[N-
M=XF@W!%T%L1$7.S[%MY=6@C'NXOO].Z+D$^Q=59N3=ND%3F?EA*\(! .NIF0
M@#3W9SG-9QPPU!.BLD*M:9*()#YPY#AZ>G.:])?>V;\FKN  I]X:YLWQSJE
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M7@MIH,85N<8GXU$ NITL[<:JC>_FI;(T&[Q:T3!&[0SH?J64W6]<@'Z\S_\
M4$L#!!0    ( %:$65+EV>P.D@<  %82   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;)U8:V_;.!;]*X2W,T@ CRU1[S0)D$=G-X-V)TC:+A:+_4!+
M=$)4$CTDU;3SZ_=<ZF$G=3S ?K!$\7'?]]Q+GSYI\\4^2NG8MZ9N[=GLT;G-
MR7)IRT?9"+O0&]EB9:U-(QP^S</2;HP4E3_4U$L>!.FR$:J=G9_ZN5MS?JH[
M5ZM6WAIFNZ81YONEK/73V2R<C1-WZN'1T<3R_'0C'N2]=)\VMP9?RXE*I1K9
M6J5;9N3Z;'81GESFM-]O^*SDD]T9,])DI?47^KBISF8!"21K63JB(/#Z*J]D
M71,AB/''0',VL:2#N^.1^J]>=^BR$E9>Z?I?JG*/9[-\QBJY%EWM[O33/^2@
M3T+T2EU;_V1/_=XTG;&RLTXWPV%(T*BV?XMO@QUV#N3!*P?X<(![N7M&7LIK
MX<3YJ=%/S-!N4*.!5]6?AG"J):?<.X-5A7/N_*/X)BV#>6[:4C>2'7T4JUK:
MX].E W7:LRP'2I<])?X*I9"S#[IUCY:]:RM9/2>PA%B3;'R4[9(?I'@MRP6+
MPCGC 0\.T(LF72-/+WJ%WJ B5&;7RI:UMIV1[#\7*^L,HN._!UC$$XO8LXA?
M87$G2]V6JE;"Q]RE=$]2MNS=>BU]^'GF=\)))MJ*?5K<+]B]$ZYSVGSW\_OL
M?ICE!7+C&=/5P-0]2B8GQ@Z,S<B8ECQS.S'W:\HR8=E:U\A5>^+MCD=8T"-G
M%XWN6K=5X:^^]W$0FTVM)"303/7N6$E BY</@?B&A?,\3AD/%P'["9]\'@?Y
M]A.K/!L_KQ6T,[)U2M1,&&55^\#61C<G#!F+?&R9%*;%K&5'X9S'_!CO>!'2
M:P[=\,X7!9X\3NBYR(_9WV_>?[R9C+3NZ?Q220,C5I#9B?9!(45&\1'J70\P
M41HS$&=1!/D7!>@1T6 1';.[GT6S>7OMG5 :62D'"4+B'](RQKD?TTR1^B&$
M)$-:Z5PM@8*.=(@\05(C#F@<+;S<?.1S4?[1P0Q>'+UFGX&Y]E)IEB0%2Q<1
M^_EO.0_YVU??=Q*I '4Z0Z8,@X2%"\ZB@H$Z2U*\TI<\?H<9;IJF:R4K,FP/
M_Y()!?SH[S0#S1PJ'$_+"#68+]KE\XN1-<Y4K-36V3F9ONXJ$E$TVCCU9Q_X
M,0F8L"+Q-#EH1Q#GLZB[?EU06(NV!-^8^ZUA&#&*)9X6?N\+W6YA/X?A2PUX
M4.!8_L,\.>RJ@Z<H?'[3*PN"C@A!I^R'W6&8]<QS8AZQWQ%PAATEO3?)L7GF
MA_0<7(^HH"3(2(!B$0\YD>:@%"^R(6,2RI@<\OUT -&2"=&2@_ R@.9EGZ6^
M7.S#J(-$J+,XL1M1RK,96@<KS5<Y&RD_RW\ F5667*W7)^S?2-^AG# 4 ]FL
M8* H?(E+UR!CG2JA_%$TCPM.1HH1M6]8-,]@Y1$-0C[G.3Q.R9^P>%[D,?;D
M\ZP(R8[A/$Z'"<3@ =NED^W2@[9[45SWV>T@@?UVFZ@."/1_V>RJ,X2<;&/T
M5^4[K%\E0 Y ^H85*<<S"<D6"<!L,M\\P@H@. # P9+AD,I)Q(XR!"D:0<Q'
M64:K<03C4]A?2X T,&\/JZ,TH#"/HL C&OPVLL*7AV5ZIO'QP.B((PL@UE%,
MV9"F!)I)0GB9!,4V,\:4&'/A@">SR9/904].2FQ[B/UY<)#,?G].M =_]ID@
MW#/W/7?RUID7%A7"LO=*K-  .(63>Z9NC:8JM5.^>HRJ58G^NJ^[L<^!.4\"
MRIZ8]^;,<JC\%9'B*_@ P^3;*&$12D,2 ^-*--G&KU02>I5#(S("79)OH3(I
M8O8.(.N^0YBO2-N^M$V8F"4_X.1M?P7H)=8>)#>H T8Z97QE!(2T<JU )H]B
MQN.<93FP'4E]I1O<7FPOSB@]3_A$.^+;\:>6&JF'5OU)_0F@?"(;[J!WB  ;
MQ__$I0G7(ZA.M0BUULI=*7>J?2F,^0Z<>Q*FLBR#$48:>;&EW5> '"&+W,J
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M\$D(?-S'1%[#]<%('[.IDP:4E]6ZE)Z9J'5GU6=Q>Q:TG=)P9Y#=E8+P%]K
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MCH*/"4N2"V.'."I%P&(MS!\B08ZZY@LZK=%:<#:/T9IP*8_QGL8)MX+4T<P
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M<P'>SQL,9\,-&8Q_\[[Z+U!+ P04    " !6A%E2;XT@FB,"  ""!   &0
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M;,V=6V_;.!;'OXJ0G1VT0!+KZ*Z9-$!BIY.DS663MONPV ?%IF-A),O5)6F
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M,!Q*9$=Q F37[,+A;&1XHLTDAY+8D:-OF_2B,M5H@BML D6FHT#F+O.ZT]V
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MAE)2 /]]GF#?JC?D-Q<VO_=R^C]02P,$%     @ 5H194J)X+SC5 @  3P<
M !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULG95=3]LP%(;_RE&T"Y"
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M/-%5^:X:5BU]R9PK2P78?^;TXJ%V 32>*66W#3=!_8:.?@-02P,$%     @
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M7\P36?P%VVKL: #B7"J>5L9:0<JR\C]YJA+1,$"PQP!5!NA0 UP9X$,-O,K
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MMR:N3[18EIOU[H36(BL/%YQ-N2P YO>9$'IS4MQ@NT'T[']02P,$%     @
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M5MQ':X!H?26=M :(I35@[#/G%DSCR;)@6C8_1$LV<4NV@[4WE U$:RSIHVM
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MGXG8'UK97\AT4QSC>$RE3./BXYJS)1<Y0'W_E*;R<)$/4!T=FOT/4$L#!!0
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MR*!;#"!_-L:]]P7L_30=:5,=[<+ C8;%&% >"4:(]LZ"[=9RDI:T.0['UEK
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MT4>RJKA"%1,CU_DM9"$-WFGRX0JOG:"L :ZG4IJ7B;W85!?9\1]02P,$%
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MOK8 WVT!^W56^TFHKZ7=/]I.C:_5V6^IS@W=TRS(-1#KG"/0DARX)7F_[OG
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M5'*\NJ.KCF2EN>863*I+TS37ZK\&<6V@OB\9D_N.OCF;/Z71/U!+ P04
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M*/,H'CY<$"P$$HTCB_[2/@&P$GC:MX?7[=R/!:YS&L"6P+&%>WVNHS!"62$
M4**_A%  H00>5.WA;T<J.'8=,0&K?)Q53ZU[R3)+(V2D/E#)I[WYZP.A?#QN
MVMU?OVO?W+&3Y@.K?)Q5?VH9*I+*9#MC>-P>L,?W^G,1V./CT=$>+K8/0IG@
MVP=E7:7\L<OLQH$I#JOWT:PX@D"=!O+X07]. X5\/$S:P^F.T\9@TG)ZW,KM
M&?<=X;(/V/)Q;#TX;1GQ7J5W-BM%1A\ C8+^4L  R!0<*@4,.@[]G(>W 4 J
MP"'5=/-GNI3Z%VHGP"?H+Y4+ %'!H5*YH)W*N8\J Z!5@-/J+#4JCJ,?UL[=
M\!L 88+^<K>@\8;%H7*W34./'O?V<?FP\<)7HO1<55NPLVR5FNI=J?IN_7+>
M6?E*VM;]<_IZ6KUB!\U4;_Q]D'H>I3F)U:UM<O2JF#)=O417?3#9LGRM["8S
M)DO*RX6RDZ6+ O;[VRPS#Q^*#NI7&4__ U!+ P04    " !6A%E2GKOK)I,$
M  #;%   &0   'AL+W=O<FMS:&5E=',O<VAE970V."YX;6RMF%MOXR@8AO\*
MBN9B1IK6!G*LDDA)NKO3BVJK5K-[L=H+:I,$#3890YKIOU_LN,8V&*?:WB0^
M?(>7#W@,S$\B^R'WE"KP*^&I7 SV2AUN@D!&>YH0>2T.--5OMB)+B-*WV2Z0
MAXR2N'!*>(#"<!PDA*6#Y;QX]I MY^*H.$OI0P;D,4E(]KJF7)P6 SAX>_#(
M=GN5/PB6\P/9T2>JOA\>,GT75%%BEM!4,I&"C&X7@Q6\V>!A[E!8_,7H2=:N
M0=Z49R%^Y#=W\6(0YHHHIY'*0Q#]]T(WE/,\DM;QLPPZJ'+FCO7KM^B_%XW7
MC7DFDFX$_YO%:K\83 <@IEMRY.I1G+[1LD&C/%XDN"Q^P:FT#0<@.DHEDM)9
M*TA8>OXGO\I"U!S@N,,!E0ZH[3#L<,"E RX:>E96-.N6*+*<9^($LMQ:1\LO
MBMH4WKHU+,V[\4EE^BW3?FKYAQ#QB7$.2!J#/]6>9N N523=L6=.);@"E<$J
M+SA3K^#Y%3S1G>Y*!3[?4D48EU^TX?>G6_#YTQ?P"; 4W&L/W4MR'B@M,D\5
M1*6@]5D0ZA $$;@7J=I+\%L:T[@9(-"MJYJ(WIJX1MZ(MS2Z!AA^!2A$H4/0
MYF)W.//(P57%<1$/]U7\GT>A?_5@/)$L_M<3>5A%'A:1ASV1OX(UW;$T9>D.
MK DG:41=_7 .-BZ"Y;/]90EG0S2:!R_UXCBLIFB$*ZN&TE&E=.15NHI^'IED
MJFN(G+U'M:33X:0ES+:!> C=NL:5KK%7UZU&BE1,'3/JU#6V<EZ-ANZ4DRKE
MQ)OR+CD0EN6SR95Q,[$SPC%RIYQ6*:?>E,4T=S5O:B7+)TRCZK;)U<2M9E:I
MF5TX:O6$[QFR,X= A*<MC;95<V W9,+0D#+L&;31,3ERHF@,=F^3F%7=![B0
MTCULRL!U12,,6ZI[C)JB:WB'7M$/>Z(_=A$]*A81[H$,1"8D^F" 0<-&B#\2
M866T1E>/X=0JK=.L:QI!PUOH!VX?QDKW>M[)$+7%V4;Y=\:IS/ 5^@';!S)H
MTS/LR&G8"?WP["$9M.'9E=*P$_KAV4DR:'/3^H X;+H$&;)"/UK? S-HLQ2.
M9Y,V<9UF]3'>E&JP"_W<7:4L(1Q\HX2KO6^990")P@\& S(<0WZ.O1,,9;1Z
MT3"<M:>>PPI.)QV# !E (O2_L%"Z-]*&[767RPBC#F0A UCD!VP?&)"-RJYZ
M&$PB/R9[P(!L ':E-/Q#?OYU@@'9X+M"LW;M+Z8C,G1$?CJ^APS(1B5&X_8R
MQV55'^--H8:IR,_4E9ZZCO(UHQD@HNE',\$0#%VZ<KR,"?:Z<&01P;'"1!VH
MQ0:,N&_EZ <"MI=^[:^ UZ0IRS 5^YG:QP)LX[%SNX,-';&?CCTTP#;WNG<\
MN+;I]G.O$PC8!EY[4#A,NC8]V$ 17[I9[^<!MC?AUOBP34;MH@6U8Z*$9KOB
M]$R"2!Q3=3Y.J9Y6)W2KXERJ]7P-;S;G<S83YGSL=T\R/1,EX'2K0X;7$UVT
M['R2=KY1XE <1CT+I4127.XIB6F6&^CW6R'4VTV>H#K/7/X'4$L#!!0    (
M %:$65)*HQ'X_@,  ' 2   9    >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM
M;+V8:X^C-A2&_XJ%5M6NU [X$&[;)-)LTLM(NVTTTVT_5/W@ 2=!"SBUS62V
MO[XV88 !@V9'4;XD7-YS_/KX\'"9'QG_(O:42O289X586'LI#^]M6\1[FA-Q
MQ0ZT4&>VC.=$JEV^L\6!4Y)407EF@^/X=D[2PEK.JV,;OIRS4F9I03<<B3+/
M"?_Z@6;LN+"P]73@-MWMI3Y@+^<'LJ-W5'X^;+C:LYLL29K30J2L0)QN%]8U
M?K^"2 =4BC]3>A2=;:2G<L_8%[USDRPL1SNB&8VE3D'4WP-=T2S3F92/?^ND
M5C.F#NQN/V7_N9J\FLP]$73%LK_21.X75FBAA&Y)F<E;=OR5UA/R=+Z89:+Z
M1<=:ZU@H+H5D>1VL'.1I<?HGCW4A.@%X-A( =0"\-,"M ]QJHB=GU;361)+E
MG+,CXEJMLNF-JC95M)I-6NAEO)-<G4U5G%S^PEAR3+,,D2)!O\L]Y>BFD*38
MI?<9%>@'P[&W:RI)FHEWZNSGNS5Z^^8=>H/2 GU2>=32B+DME3.=WXYK%Q].
M+F#$Q9K&5\C%WR-PP#&$KUX<CJ/GX;:J1U,4:(H"53YW)%\[6W0M!)4"_?08
M9V62%CO4%.SOCRH*W4B:BW\FQG2;,=UJS-G80G F!%H1SK_J8:YS5A;25,E3
M&K]*HR_2AZ47>%$PMQ^Z!3.H/!=FC>J9QUGC<3;I\3J.R[S,B*2)-LAE^A_1
M%Z/)YBF3US$P@RAR>S8-*HPA--OT&IO>I,W?J+%PWF L//.=6<^1284CW^S(
M;QSYDXYN-K??D?SPXWJB48(F5W"QY@R;,</S-&<XJ)X+G>4\E7@HPHX+Y@I'
MC</H-6L>O<3/4#3N!SLM6)U)1QO.DC)6RZ/)>CCM(*[O*F)B17 'W/AB?8!;
M,F(X3R?4>9Y=VIX3]CEEE$6S8*3Z+4WQ-$Z_!55UJF==$D7@]:T:9&'HC35*
M"U4\3=61UL5#-GK8A[ZIH2IP(F_$4TM0/(W0CVFL'M7H9*>V\,/^Y3JUQ20.
MSM2I@>$F% P:=:AR<3A6Z!:L>)JLW]2G!G"ZPRMJJ K';ORXQ2M^%5_QD)T0
M1$[?DD'E^MCL"5K"PC1A_^ DH:@@^62?0DM4N!Q1H?.L>2:BPA"5$(9](!A5
M4312ZY:G<#Z>@@&4WL#G4 1X!/O0LA1>Q5(84A(\M]^F)I4?CO =6I;"-$NK
M-ZBI5FE!"I<#*;0@A3.!%(:(!(#^([]1-0J#%J1P/I""":00]8T:5.".$!]:
MDL*K2%I'==_8PJC_<F(080?Z+R=VYW. _A;SB?!=6@B4T:T*<ZX"-25^^KQQ
MVI'L4'TAN&=2LKS:W%/%5JX%ZOR6,?FTHS\Z-!^9EO\#4$L#!!0    ( %:$
M65*F]R*X\@8  +HC   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;+5:
M6W/:.!3^*QIF,]/.)( E&4,GR4QSZ;0[:9-)>GG8V0=A"_#6%U86(?GW>V0,
M BR.23;TH<%&Y^@[%WWG2.ATGJO?Q41*39[2)"O.6A.MIQ\ZG2*<R%04[7PJ
M,_AFE*M4:'A4XTXQ55)$I5":=&BWV^ND(LY:YZ?ENSMU?IK/=!)G\DZ18I:F
M0CU?R"2?G[6\UO+%?3R>:/.B<WXZ%6/Y(/6/Z9V"I\Y*2Q2G,BOB/"-*CLY:
M'[T/UWY@!,H1/V,Y+]8^$V/*,,]_FX<OT5FK:Q#)1(;:J!#PYU%>RB0QF@#'
MOY72UFI.([C^>:G]4VD\&#,4A;S,DU]QI"=GK7Z+1'(D9HF^S^>?9660;_2%
M>5*4_Y/Y8FS 6B2<%3I/*V% D,;9XJ]XJARQ)N %.P1H)4"W!*B_0X!5 FQ[
M!KY#@%<"?%](?B50FMY9V%XZ[DIH<7ZJ\CE19C1H,Q]*[Y?2X*\X,XGRH!5\
M&X.</K_)15:0._$LAHD\)C=Y-C[Y+E5*KN10$Y%%Y$9"' IR0KX)I80)*WEW
M);6(D^(]O/WQ<$7>_?'^M*,!C='9":N9+Q8STQTS>Y1\S3,]*<AU%LEH4T$'
MS%C90I>V7%!4XY4,VX1YQX1V:=<!Z')O<6_@$+_:7[SO$+_&Q?^<92#>=8'?
M< 9;!9:5^MA..!"_+UFAU0S6M29_W<  \D7+M/@;4<]7ZGFIGN_,&T@4;1(E
M@HF.(565,M/ TIVI6,>R<&7$0F>OU&DH[/&<LF[U[[3SN!ZK^E!O4!NZ =U?
M0?<;H)N4GRY2ODSQ)?AIKDKVRD<DV;#/9<MB$G\-8(\SSVE+?2CK>:@MO94M
MO1>$P06S5YN;^JSG]GFO'AX:+ >[@08KH $*]),(P==I/@,W@WMWH+T.:@BX
MCT>]OP+0?U'"VD0]AH('V6!626&P356<A?%4)"3.S&KT7&[MU]U:S^0-H(,5
MT,&!@%(7T,&+@7I=6SNZ!X+*G/6B6\/J!0U8U^J<=R"LW(G5JV/E#5BIQ4H/
MA-5W8J4.#FC :LN,QU"L'Q^A$RB9=)@KD(ZS,0G%5(2Q?B8SJ.R*A$I&L28C
M>)? 6R=$5EOX2X[:"=&6*@^O5;=3:1H7 ):87N:8S,OV449$/,(W8PE.-3WU
M:@0QOG?"Q"?JDV<IE*OR739(!@M)PDFZZ(DH)Y%X+I!*[=EZY^$%KV9_F!?.
M6E'I68\"X]OT7]GC&,H&:+QL3?/PHE;#N\QX)^9Z@6-\.W$JS(Y:V-^NV)N8
M;7GS\/IV(XM" M1\&_LBH;)<0X0U>#X%2T(9'5?%T&E24,/) Q_%::N@AY?!
M<B=XDH].9H!* &8HQT-HYC-8#4 A\BF<B Q6!&Q!MVTA22R&NU=PO2+RP3;H
M*@[UH1[%<\<63P^OGENY4Q(FM!SR"7;6A71U]97"C4RF%$-#;8&D>(&\U1/@
MOY]"Q25#W@LMRXT5MMFQ%8UZA^CPJ2U#]"5ER!7T2L%&QSC@SJ [AGH\0-UL
M:Q#%:]#U:"3+ P=(8< K"TV4<?4[ 7V^5"%XQ[E!;5#;;7/_R+F/Q.5HV^='
M6 1LY:)X6>BU6??(>!\LF(%=))I)4^9[F'9;%ZA_D 2R1$[_[^Z$UK<<'G.S
MQEY#-X%:]J8X>S]HH4L"?%'VX#K+V&%NM)Q-<<[NM@/_R)20/1/ DB4='"(!
MF.4_AO/?:_QZW:"S] :&SA(HP[<$>^Y)*RT;B=?0FS++L0SG6,]PS$9L&7KZ
MLW;\<Y#S'V:YB>'<]+K8XCJ].N-NHK/<QO">=]_8UMM8;[4WVA%;2W\,IS_:
M9ENQY6AL+5VQX""QM8S#<,9Y76QQG:4W,'26MAC>X^T;VWICU[1NN64VCK,0
MK:U;'XLMMZ3$#]+5<<LX'&><5\6V02=M6+?<TA;'>Z<]8\OKYP5-ZY:O'6WC
M+/2MC.K#;/@/=)7D>T[NEV<NY*,FM]/RC/AV1#[G22059K:E*WZ05HQ;+N)-
MK=B;''KS>A,6,&>[QAV;;8H>)7/+?QQOK2[-+EJ%L4C HBD> LMYO'^0$%C:
MXDT'NV\3@CJM\3JM54%P4&##*:5O*=#'*?!7=8IVLCQ%VZ04,";<BE-C2]TP
M([1^ ^>&K$&.MBG#Z,FW[.SC+>/%+$ZB.!MC!W.^I6*?'B+E?,NF/LZF;W?R
MV3"1\^1S$[2E7[_AI\5=1VFP5N0<<FDG1EPO;\:X]A,BWE[^E),X3+9_Y-Q4
M9KG9[QTD#2Q?^CA?OF$:X!,A+NZLW5$ 4AB7ET,*H BH](N?^%=O5Q=0/I;7
M+K;>7W@?KA;72*R:Q:V6KT*-8Z#81(Y I=DGMHA:7!19/.A\6MZ$&.9:YVGY
M<2(%U' S +X?Y5#YJP<SP>JZSOE_4$L#!!0    ( %:$65)[:]&M* @  #4]
M   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;+6;;6_;-A#'OXI@;$ +
MK#:?*19)@+7!L (=5JSK]F+8"R5F$J.VE$E*LWW[2;+CHTGIF%7CF\0/Y/EX
M)_[UH\@[>ZSJS\V=M6WV]VY;-N>+N[:]?[U:-==W=E<TR^K>EMTW-U6]*]KN
M;7V[:NYK6ZR'3KOMBA&B5KMB4RXNSH;//M079]5#N]V4]D.=-0^[75'_\\9N
MJ\?S!5T\??#+YO:N[3]879S=%[?VHVT_W7^HNW>KHY7U9F?+9E.566UOSA??
MT]=O*<W['D.3WS;VL7%>9_U8KJKJ<__FW?I\07J7[-9>M[V-HOOWQ;ZUVVUO
MJG/DKX/5Q?%'^X[NZR?K/PRC[T9S533V;;7]?;-N[\X7^2);VYOB8=O^4CW^
M: \CDKV]ZVK;#'^SQT-;LLBN'YJVVATZ=Q[L-N7^?_'W(1).!RHF.K!#!_;<
M#OS0@0\#W7LV#.NR:(N+L[IZS.J^=6>M?S'$9NC=C693]GG\V-;=MYNN7WOQ
MOBK*)OM0_%-<;>UWV?NJO'WUJZUWV:6]:K.B7&?O;1>E)GOE?_?BTK;%9MN\
M[+[Z]/$R>_'-R^R;;%-F/VVVVRY#S=FJ[1SL?V9U?7#FS=X9-N',I;U>9IQ^
MES'"R$CWM\_N3LUI]U47EF-LV#$V;+#')^UUPWQ7-FW]T%VY;?;'^ZY!]JZU
MN^9/Q#P_FN>#>3$9>C>>8]':]U=#_WY"?KE@DJLN,E_<H(RT8IJK8ZL3Y\31
M.8$ZQY9:?IN55=NE?OU@^XQ(9,SR:%:F"*DZFE>HUQ_;HK7K[B)L;6V;-JN[
MM]F+HLGN;7W=_=[+L2CC)H= (*[IHVMZ9K9UF$=AN)?L?2-YVHB-YSH_NI:C
MKO&E)J>Y%EBNS=&L29%K2D"ZR/^?[8C-(1:8=XZPTID)/QAP,TZ-5E[&#ZWD
M:2LYGG(*VD99Y+K.O:0SCHT;5(WR)&D'9:*X-'U=VF-RE^-I!X&C<F[:99AV
M+7(_[3),NQ9Z(NT@D!27,[X4?MJQ6R4%>:,Z2=I!I"BN4E^7]ICR"3SMH'74
MS$V[&4D[%W[:S4C:^83 ,Y!*ALN:6!)?XE%" I5C-$7:F<-@N$Y]5=HC-H=H
M8-Z!V+&Y#,="/*-"&2_MAU;RM%4^D7:02A:3->Y1G"#8N$'E6!*.8Z!3+ ')
M16P.T<"\ [%C<V&.A31G<N9G/:0Y,I%RD$F&2YI84C_EV'V=@<*Q)#C'0:-X
M IR+V!RB@7D'0L?GXAP?P3G&_?LZ'\$YM]6I>R"3')<TNA1>VCDVT[FS2$V"
M<QPTBB? N8C-(1J8=R!T?"[.\1&<8]Q?M_$0YR:F.@>-Y+B>T67>+]+M0UV]
M6MNRVFW*(90G=*>P,(#@\21TQT&V> *ZB]C<QP=S#\2/S\4[/H)WC :S?P3O
M*)F@>@'2*7"98\'LE]CL%Z!Z(@G>"= MD0#O(C999/8+$#\Q%^_$"-XQ2KVT
MBQ#O)F:_<![0Q=@N6,DQ;- @>2()VPG0+9& [2(V660E)T#JQ%RV$R';4<)]
MN!,AW%%"I](.0BEP42/A@UE,X@5(G$C"=Q)$2B;@NXA-$GDZ*T'IY%R^DR'?
M&>//=!GBW43*)6BDQ/6,+XTWTSFV>)<@;S()VTG0*)F [2(VAVA@WCE[$7/9
M3H9L9W(?[62(=NY2[]0Y$$GYC,7J\^5=@K[))"@G0:%D I2+V(PMW27(G)Q+
M<G*,Y((G-G*$Y)B86,<I$$D5(SE_KC.!;8R!OJDD)*= I50"DHO89)&YKD#J
MU%R24R'):>%OQJ@0Y+28V(M1(),*ES2UE+[ 8\]L%"B<2K/=ZNRWIMAPQ6T.
MT<"\ ZE3<U%.A2BGJ3_554ARFDT(O *95#&0ZY..+][1J0^2IY*0G0;1T@G(
M+F*31*X"#<JGYY*=#LE.!6LX'9*=E!-37X-JZMAS.QY]AL,QP-<@@3H)[6F0
M,9V ]B(V]_'!W ,QU'-Q3X>XIXA_"] A[DE))ZX#$%(=P[VH&G!,#;1S#B4)
M_VD0-IV _R(V64P-0 SU7/[3(?\I(OVK(,0_*2=6>CD(:1X[?:+\;5H,^G/0
MP#P)_>6@8WD"^HO8'**!>0?2E\^EOSRD/Q$L[O.0_H292CK(9AZE/W_K1F.C
M!L'+D]!?#J*5)Z"_B,TA&IAW('3Y7/K+0_H3P7T_#^E/T*D3=\Z1.US09/ 8
M#[W+YZ!O>1+8,Z!1)@'L16S*R&,\ T)GYL*>"6&/![NT)H0]/K5):T D#2YH
M<FFZI*_M51>FAQHP/\>&#B)GDO"= :$R"?@N8G,(">8=J)V9BW<FQ#L>X)T)
M\<YM=.H<**7!54TN<W^Z8X]P#8B<24)S!H3*)*"YB,TA&IAWSA'CN31G0IIC
MVM=X$]*<V\@[G^P>4,9U30U[=/]MPE/B'#$F2;".$N>8,$D =C&C*G;NDCC'
MC<E<MGNR<%I(X9=1/+62$ZT\!YWCRB3&=WST(L#N]Y0X!XY)$LRCQ#DT3!*
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MU*0GLO;BMO14P?^\7R@M\<C].F$S;FS&UF:GQ29&%KH24ZE2JS*W[VT4Q^G
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MH&P"QDLIS=ZP5V!\\=)_4$L#!!0    ( %:$65)S6F$^E@(  !X&   9
M>&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;'U5VV[:0!#]E9&5AT1J8V."4T6
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M_%#H!?1]Q;G:#[2!NI4<_@502P,$%     @ 5H194G<38E9\ P  VPX  !D
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M*+I/3"5 O%\0PK<#&:#L9\>_ 5!+ P04    " !6A%E2&MQ5798$   Y$
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MD!D'D<8QYKM;0MGVIH=ZKQ,/T6HM]80Q'FWPBLR)?-S,N!H9I94PBDDB(I8
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MU7-S\#IJ3^6VJGYKW_RT/IO%K2-5J)5NI\C,?T_J2A5%.Y/Q\9]^TMG^F.W
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MA@+)>9X3\?<2&%_V'>RL']S3R529!^Z@-R,3> #U-!L*/7(K+V.:0R$I+Y"
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M!%DXU>4!#!!U4UU*P-#9Z*#J6NN=Y2JK2M]""')R2@C*F1HE8D 0@E-='J0
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MN:B)PAR5P&[;/( !XF\L=%*+5,G1G,)2Z?P'(R SQT)FSJW25\/AD)'C-@^
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MU[,V>.L[:#4X]MF^P=N8# _OE&@O.D)%?\D2I:/E40DE2Z03XKV_^-+A1V>
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M_O0I*S>%R.92SP@S5>@I._:<R #U++PXV0#A#$?X662+C.&8]4<,,^E*ALS
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M.8_.02[, 2M\#IW:'(.$?NQ,J8<RIC=.R6QG:GK.,K'S40/DLAVPPND@5^R
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M!G-_(X2^7]AQOOX:F_T&4$L#!!0    ( %:$65)RDH_?O 0  &\6   9
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MQ48!I%M+NNS 7$$IJ_8K=ET?]@##\1% W 'B<P&C#C#R0MO*O*R5(#&?&MV
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M%?QU1R!PZS"S?[=0Z%44>@6%W@D*W[1.MB0PB"SGPF2>3)QRL\(FO6<EV*
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MR[5LOX$I@'R^I%3L;U2!MJ&?_0-02P,$%     @ 5H194H/8D/2I!   9A,
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M/U(^IIU,K>%T'7IUK1UU?MA6-,S1^  Z+[5VO>$O&/X>LG]02P,$%     @
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M,>8(;<@FANN;!^O&$CJ(#ZSH/\,-^Y98W_EH!\7:N!<(:$9BW1T(B@EA,6]
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MQK95!P1-W03]B-R2(G4BM2TA8'3J+A3WIY84J_=TJEP@*)US$P1#;,DQA92
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MI<'!6FD G!JX.?6B/PW=>LG[I]K(K8DNDX"C@DE4TP#8)'"SR8-I:MUX93>
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M<'8%/,_(O5;86O)155#]#:!.Y20U.TO=9"\2MU#.R&+^AF1IEMJH^P7L8JK
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M4057@-B7<(R7\-,,V]U0_OVFO;KXZ9N?OGD]>?GRXI=V/?O0?HJ=QKXH8YG
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M=E'TQ;DX9Z;P9K:X7BUGL3/65]<B0:90]#6U&)@I%#()J$2JJHK\+0V:J*:
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M6@=SF1&<$E$"]/TUY^J]43Z@^?HQ^Q]02P,$%     @ 5H194IN,1 7!!0
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MVJ-'^^^JZK)!X[H_?M%P=*5X*?_T#!8.@X7M8.'(8%>5XC672KNT<3[DS<Y
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MS^#=N"-XY(7CEG5=4!!'<<NZ+LB/3UD'O7JY\ :KFDN*P1*OZ4;W_2NN4B*
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M_Y?D^E=E5_!>C<W[\]A%SD]!Y.(41)Y$3UX=O\C9]5%J=)KW]^"2L'5%Z*+
M7,4"^,U<[&A?%*Q*0A7AC9>1.,;\V4U!XQ5:Z:O^%E_/CW&"2JJ673* O?T5
MQZ1DU]VL>W,0S:S>_F*VYR[J@OW_B? O4$L#!!0    ( %:$65*7BKL<P
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MZXY7[LX\ML+_Z:\5)ZG?YSM=U;6_:7]M+HR</#WHY^DA11]^ 5!+ P04
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M[K W0.^J>E> WDWU;@"]F^K= 'HWU;L!]&ZJ=P/HW53O!M"[J=X-H'=3O1M
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M!%!+ 0(4 Q0    ( %:$65('04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 5H194DU*CV?O    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ 5H194IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !6A%E2BZ9;_&4'  #4)0  &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ 5H194F&K3#3!!   4!$  !@              ("!J0\  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %:$65*N+7<BO ,  -P+   8
M              " @: 4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " !6A%E2L;)SAI8'  "V'@  &               @(&2&   >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 5H194D""]<?K @
M'@@  !@              ("!7B   'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( %:$65)XN'37J@8  '4@   8              " @7\C
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !6A%E2CL1O
M.VD"  #7!0  &               @(%?*@  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ 5H194MX[P/$H"0  _RD  !@
M ("!_BP  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %:$
M65(7"]<>" (  '@$   8              " @5PV  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " !6A%E2Y\"2KJ\'  #5$@  &0
M        @(&:.   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( %:$65*";L<A7"0   %W   9              " @8!   !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 5H194G5^Q_&J&0  /5$
M !D              ("!$V4  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " !6A%E2#K*9!4</  #G-   &0              @('T?@
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %:$65)FI?+>
ML@@   <7   9              " @7*.  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ 5H194E$$.I=!'P  T6L  !D
M ("!6Y<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !6
MA%E2M]L2XVX#  "\!P  &0              @('3M@  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( %:$65*#\C;+7@T  #DE   9
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M970R,2YX;6Q02P$"% ,4    " !6A%E2\;8@>LT6   \2P  &0
M    @($U# $ >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M %:$65(PLR:S @4  )P+   9              " @3DC 0!X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ 5H194N10RP*Y#0  _R(  !D
M             ("!<B@! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " !6A%E2)<APG$4#  #B!P  &0              @(%B-@$ >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %:$65*:F>']D04
M +\/   9              " @=XY 0!X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ 5H194EU?VN>!$0  @2L  !D              ("!
MIC\! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !6A%E2
M@Z"S@A E  #T?P  &0              @(%>40$ >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( %:$65(3E_MJQ00  +@+   9
M      " @:5V 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ 5H194F,TY%E=!   8 P  !D              ("!H7L! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !6A%E2W2L^$08$  #6"@
M&0              @($U@ $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( %:$65)($&U[L@\   LU   9              " @7*$ 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 5H194L\8YM^W
M @  B04  !D              ("!6Y0! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " !6A%E282G%@1L$  #_"   &0
M@(%)EP$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %:$
M65(GUXT/^P0  &X,   9              " @9N; 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ 5H194G<2MVNY @  '@8  !D
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M=#0P+GAM;%!+ 0(4 Q0    ( %:$65+>H8]$\@(  -P&   9
M  " @:+# 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M5H194F\QS*&<!0  H0\  !D              ("!R\8! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " !6A%E2H=[U$)P,  #R'0  &0
M            @(&>S $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( %:$65)OC2":(P(  (($   9              " @7'9 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 5H194@HV EQ-!@
MR2   !D              ("!R]L! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " !6A%E2?.W:MM<.  #[90  &0              @(%/
MX@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( %:$65*B
M>"\XU0(  $\'   9              " @5WQ 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ 5H194J_W\1VF!0  W1L  !D
M     ("!:?0! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %:$65+G5'7%FP0  'L5   9              "
M@=82 @!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 5H19
M4MZK*ERW!P  R2(  !D              ("!J!<" 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " !6A%E2"]8V'X8#  "D#   &0
M        @(&6'P( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( %:$65)^Q6&ES ,  &(1   9              " @5,C @!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 5H194L%<[M3. @  -P@
M !D              ("!5B<" 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " !6A%E2AXENH=$%  "O(P  &0              @(%;*@(
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %:$65*!FR=0
M1P,  -0*   9              " @6,P @!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ 5H194K1_'NN4!   D1$  !D
M ("!X3," 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !6
MA%E2-[L,.V,#  "D"P  &0              @(&L. ( >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( %:$65)M1+-4\@4  '\C   9
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M970V-BYX;6Q02P$"% ,4    " !6A%E2'Z<K8N4&  #6*   &0
M    @(&+60( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M %:$65*>N^LFDP0  -L4   9              " @:=@ @!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ 5H194DJC$?C^ P  <!(  !D
M             ("!<64" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " !6A%E2IO<BN/(&  "Z(P  &0              @(&F:0( >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( %:$65)[:]&M* @
M #4]   9              " @<]P @!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ 5H194K6'T^^! P  +PP  !D              ("!
M+GD" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " !6A%E2
MT\Q02,,"   4"   &0              @('F? ( >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( %:$65)XM_C-GP0  *45   9
M      " @>!_ @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ 5H194GTX"88O @  _00  !D              ("!MH0" 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " !6A%E2<UIA/I8"   >!@
M&0              @($<AP( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    ( %:$65(IB?LY)0,  %8*   9              " @>F) @!X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ 5H194G<38E9\
M P  VPX  !D              ("!18T" 'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    " !6A%E2&MQ5798$   Y$   &0
M@('XD ( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( %:$
M65*)M\'6_@(  %<)   9              " @<65 @!X;"]W;W)K<VAE971S
M+W-H965T.# N>&UL4$L! A0#%     @ 5H194NX(0;AV!   9!$  !D
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M=#@U+GAM;%!+ 0(4 Q0    ( %:$65*$EPFSF0D  &XZ   9
M  " @=NR @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @
M5H194O55'Z13 P  =PT  !D              ("!J[P" 'AL+W=O<FMS:&5E
M=',O<VAE970X-RYX;6Q02P$"% ,4    " !6A%E2T<I,TO<4  !+U0  &0
M            @($UP ( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4
M Q0    ( %:$65*0N&5.-@@   8]   9              " @6/5 @!X;"]W
M;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ 5H194EM#<'M'"0
MO5$  !D              ("!T-T" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX
M;6Q02P$"% ,4    " !6A%E2HHZK3V\#  "9#0  &0              @(%.
MYP( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( %:$65)R
MDH_?O 0  &\6   9              " @?3J @!X;"]W;W)K<VAE971S+W-H
M965T.3(N>&UL4$L! A0#%     @ 5H194J)22P(@!   *A4  !D
M     ("!Y^\" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %:$65*GR ^*9@4   X4   9              "
M@0<% P!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ 5H19
M4E\=[\J: @  )P<  !D              ("!I H# 'AL+W=O<FMS:&5E=',O
M<VAE970Y.2YX;6Q02P$"% ,4    " !6A%E2V>,),T0#  #<"P  &@
M        @(%U#0, >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4
M    " !6A%E2@]B0]*D$  !F$P  &@              @('Q$ , >&PO=V]R
M:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " !6A%E2+%F'4!$$  #0
M#@  &@              @('2%0, >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX
M;6Q02P$"% ,4    " !6A%E2\D:K^V4#  #Y"@  &@              @($;
M&@, >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " !6A%E2
M#2NH)(@"   J!@  &@              @(&X'0, >&PO=V]R:W-H965T<R]S
M:&5E=#$P-"YX;6Q02P$"% ,4    " !6A%E2=A_MVP@*  !=1@  &@
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M:&5E=#$P.2YX;6Q02P$"% ,4    " !6A%E2C5N<8Y(#   1#@  &@
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M P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !6A%E2?M8R)AX#   N00
M&@              @ %49 , >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !6A%E24'Y NGP"  "Q/@  $P              @ &J9P,
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     =P!W ,0@  !7:@,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1489</ContextCount>
  <ElementCount>679</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>252</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010002 - Statement - Consolidated Statement of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofIncome</Role>
      <ShortName>Consolidated Statement of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020003 - Statement - Consolidated Statement of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome</Role>
      <ShortName>Consolidated Statement of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030004 - Statement - Consolidated Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040005 - Statement - Consolidated Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>Consolidated Balance Sheet (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050006 - Statement - Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofEquity</Role>
      <ShortName>Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060007 - Statement - Consolidated Statement of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical</Role>
      <ShortName>Consolidated Statement of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070008 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080009 - Statement - Consolidated Statement of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statement of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210031002 - Disclosure - Summary of Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPolicies</Role>
      <ShortName>Summary of Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210061003 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements</Role>
      <ShortName>Acquisitions, Divestitures, Research Collaborations and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210111004 - Disclosure - Collaborative Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangements</Role>
      <ShortName>Collaborative Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210151005 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210201006 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210331007 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210371008 - Disclosure - Goodwill and Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangibles</Role>
      <ShortName>Goodwill and Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210421009 - Disclosure - Loans Payable, Long-Term Debt and Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeases</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210481010 - Disclosure - Contingencies and Environmental Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities</Role>
      <ShortName>Contingencies and Environmental Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210521011 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210561012 - Disclosure - Share-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlans</Role>
      <ShortName>Share-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210631013 - Disclosure - Pension and Other Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210761014 - Disclosure - Other (Income) Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNet</Role>
      <ShortName>Other (Income) Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210801015 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210881016 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210921017 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>210951018 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>220042001 - Disclosure - Summary of Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.merck.com/role/SummaryofAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>230073001 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables</Role>
      <ShortName>Acquisitions, Divestitures, Research Collaborations and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>230123002 - Disclosure - Collaborative Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsTables</Role>
      <ShortName>Collaborative Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/CollaborativeArrangements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>230163003 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Restructuring</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>230213004 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/FinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230343005 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Inventories</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230383006 - Disclosure - Goodwill and Other Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesTables</Role>
      <ShortName>Goodwill and Other Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/GoodwillandOtherIntangibles</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230433007 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/LoansPayableLongTermDebtandLeases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230533008 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Equity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230573009 - Disclosure - Share-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansTables</Role>
      <ShortName>Share-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/ShareBasedCompensationPlans</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230643010 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230773011 - Disclosure - Other (Income) Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetTables</Role>
      <ShortName>Other (Income) Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNet</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230813012 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/TaxesonIncome</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230893013 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/EarningsperShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230933014 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230963015 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SegmentReporting</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>240024001 - Disclosure - Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/NatureofOperationsDetails</Role>
      <ShortName>Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/NatureofOperations</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>240054002 - Disclosure - Summary of Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPoliciesDetails</Role>
      <ShortName>Summary of Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/SummaryofAccountingPoliciesPolicies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>240084003 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Acquisitions Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail</Role>
      <ShortName>Acquisitions, Divestitures, Research Collaborations and License Agreements - Acquisitions Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>240094004 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Divestitures Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail</Role>
      <ShortName>Acquisitions, Divestitures, Research Collaborations and License Agreements - Divestitures Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>240104005 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions, Divestitures, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>240134006 - Disclosure - Collaborative Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails</Role>
      <ShortName>Collaborative Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240144007 - Disclosure - Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails</Role>
      <ShortName>Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240174008 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240184009 - Disclosure - Restructuring - Charges Related to Restructuring Program Activities by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails</Role>
      <ShortName>Restructuring - Charges Related to Restructuring Program Activities by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240194010 - Disclosure - Restructuring - Charges and Spending Relating to Restructuring Activities by Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails</Role>
      <ShortName>Restructuring - Charges and Spending Relating to Restructuring Activities by Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240224011 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240234012 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Financial Instruments - Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240244013 - Disclosure - Financial Instruments - Information About Interest Rate Swaps (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails</Role>
      <ShortName>Financial Instruments - Information About Interest Rate Swaps (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240254014 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240264015 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240274016 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails</Role>
      <ShortName>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240284017 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails</Role>
      <ShortName>Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240294018 - Disclosure - Financial Instruments - Effects of Derivatives Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Effects of Derivatives Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240304019 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Information on Debt and Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240314020 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240324021 - Disclosure - Financial Instruments - Summarized Information About Changes in Liabilities for Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails</Role>
      <ShortName>Financial Instruments - Summarized Information About Changes in Liabilities for Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240354022 - Disclosure - Inventories - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesInventoriesDetails</Role>
      <ShortName>Inventories - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240364023 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240394024 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240404025 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240414026 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Other Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240444027 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240454028 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240464029 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240474030 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240494031 - Disclosure - Contingencies and Environmental Liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails</Role>
      <ShortName>Contingencies and Environmental Liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240504032 - Disclosure - Contingencies and Environmental Liabilities - Legal Defense Reserves - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails</Role>
      <ShortName>Contingencies and Environmental Liabilities - Legal Defense Reserves - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240514033 - Disclosure - Contingencies and Environmental Liabilities - Environmental Litigation and Matters - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails</Role>
      <ShortName>Contingencies and Environmental Liabilities - Environmental Litigation and Matters - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240544034 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240554035 - Disclosure - Equity - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityShareholdersEquityDetails</Role>
      <ShortName>Equity - Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240584036 - Disclosure - Share-Based Compensation Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Share-Based Compensation Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240594037 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240604038 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails</Role>
      <ShortName>Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240614039 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails</Role>
      <ShortName>Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240624040 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails</Role>
      <ShortName>Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240654041 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240664042 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240674043 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240684044 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240694045 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240704046 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240714047 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240724048 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240734049 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240744050 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240754051 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240784052 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails</Role>
      <ShortName>Other (Income) Expense, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240794053 - Disclosure - Other (Income) Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetDetails</Role>
      <ShortName>Other (Income) Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240824054 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails</Role>
      <ShortName>Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240834055 - Disclosure - Taxes on Income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeNarrativeDetails</Role>
      <ShortName>Taxes on Income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240844056 - Disclosure - Taxes on Income - Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails</Role>
      <ShortName>Taxes on Income - Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240854057 - Disclosure - Taxes on Income - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income - Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240864058 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails</Role>
      <ShortName>Taxes on Income - Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240874059 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Taxes on Income - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240904060 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Calculations of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240914061 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240944062 - Disclosure - Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240974063 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240984064 - Disclosure - Segment Reporting - Sales of Company's Products (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails</Role>
      <ShortName>Segment Reporting - Sales of Company's Products (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240994065 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Consolidated Revenues by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>241004066 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>241014067 - Disclosure - Segment Reporting - Schedule of Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails</Role>
      <ShortName>Segment Reporting - Schedule of Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="mrk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>241024068 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mrk-20201231.htm">mrk-20201231.htm</File>
    <File>ex10-24x2021annualrsuterms.htm</File>
    <File>ex1023-2021annualnqsoterms.htm</File>
    <File>ex21-subsidiarylistasof12x.htm</File>
    <File>ex23-consentofindependentr.htm</File>
    <File>ex241-powerofattorney.htm</File>
    <File>ex242-certificationofboard.htm</File>
    <File>ex311-rule13ax14a15dx14ace.htm</File>
    <File>ex312-rule13ax14a15dx14ace.htm</File>
    <File>ex321-section1350certifica.htm</File>
    <File>ex322-section1350certifica.htm</File>
    <File>exhibit410-merckdescriptio.htm</File>
    <File>exhibit411-merckdescriptio.htm</File>
    <File>exhibit412-merckdescriptio.htm</File>
    <File>mrk-20201231.xsd</File>
    <File>mrk-20201231_cal.xml</File>
    <File>mrk-20201231_def.xml</File>
    <File>mrk-20201231_lab.xml</File>
    <File>mrk-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrk-20201231_g1.jpg</File>
    <File>mrk-20201231_g2.jpg</File>
    <File>mrk-20201231_g3.jpg</File>
    <File>mrk-20201231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>142
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrk-20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 49,
   "contextCount": 1489,
   "dts": {
    "calculationLink": {
     "local": [
      "mrk-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrk-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mrk-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrk-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrk-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrk-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 1089,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 7,
    "http://www.merck.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 12
   },
   "keyCustom": 63,
   "keyStandard": 616,
   "memberCustom": 154,
   "memberStandard": 88,
   "nsprefix": "mrk",
   "nsuri": "http://www.merck.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover Page",
     "role": "http://www.merck.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Nature of Operations",
     "role": "http://www.merck.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854057 - Disclosure - Taxes on Income - Taxes on Income (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails",
     "shortName": "Taxes on Income - Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864058 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
     "shortName": "Taxes on Income - Deferred Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874059 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails",
     "shortName": "Taxes on Income - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240904060 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
     "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914061 - Disclosure - Earnings Per Share - Narrative (Details)",
     "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "if65645d9ce3443819f0f193e3bf67acc_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240944062 - Disclosure - Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240974063 - Disclosure - Segment Reporting - Narrative (Details)",
     "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984064 - Disclosure - Segment Reporting - Sales of Company's Products (Details)",
     "role": "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
     "shortName": "Segment Reporting - Sales of Company's Products (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994065 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)",
     "role": "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Consolidated Revenues by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "id9717f9d6b3c445492a8c653a191c33e_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241004066 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)",
     "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210031002 - Disclosure - Summary of Accounting Policies",
     "role": "http://www.merck.com/role/SummaryofAccountingPolicies",
     "shortName": "Summary of Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241014067 - Disclosure - Segment Reporting - Schedule of Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits (Details)",
     "role": "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails",
     "shortName": "Segment Reporting - Schedule of Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ie9abe8118228461cbfc4c5c43bacd69d_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241024068 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)",
     "role": "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i0ef6045954534437abb1993aa1937f07_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210061003 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements",
     "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements",
     "shortName": "Acquisitions, Divestitures, Research Collaborations and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210111004 - Disclosure - Collaborative Arrangements",
     "role": "http://www.merck.com/role/CollaborativeArrangements",
     "shortName": "Collaborative Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210151005 - Disclosure - Restructuring",
     "role": "http://www.merck.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210201006 - Disclosure - Financial Instruments",
     "role": "http://www.merck.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210331007 - Disclosure - Inventories",
     "role": "http://www.merck.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210371008 - Disclosure - Goodwill and Other Intangibles",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangibles",
     "shortName": "Goodwill and Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210421009 - Disclosure - Loans Payable, Long-Term Debt and Leases",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeases",
     "shortName": "Loans Payable, Long-Term Debt and Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210481010 - Disclosure - Contingencies and Environmental Liabilities",
     "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities",
     "shortName": "Contingencies and Environmental Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010002 - Statement - Consolidated Statement of Income",
     "role": "http://www.merck.com/role/ConsolidatedStatementofIncome",
     "shortName": "Consolidated Statement of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210521011 - Disclosure - Equity",
     "role": "http://www.merck.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210561012 - Disclosure - Share-Based Compensation Plans",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlans",
     "shortName": "Share-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210631013 - Disclosure - Pension and Other Postretirement Benefit Plans",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans",
     "shortName": "Pension and Other Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210761014 - Disclosure - Other (Income) Expense, Net",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNet",
     "shortName": "Other (Income) Expense, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210801015 - Disclosure - Taxes on Income",
     "role": "http://www.merck.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210881016 - Disclosure - Earnings per Share",
     "role": "http://www.merck.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210921017 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210951018 - Disclosure - Segment Reporting",
     "role": "http://www.merck.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220042001 - Disclosure - Summary of Accounting Policies (Policies)",
     "role": "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies",
     "shortName": "Summary of Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230073001 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements (Tables)",
     "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables",
     "shortName": "Acquisitions, Divestitures, Research Collaborations and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020003 - Statement - Consolidated Statement of Comprehensive Income",
     "role": "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
     "shortName": "Consolidated Statement of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230123002 - Disclosure - Collaborative Arrangements (Tables)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsTables",
     "shortName": "Collaborative Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230163003 - Disclosure - Restructuring (Tables)",
     "role": "http://www.merck.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230213004 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.merck.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230343005 - Disclosure - Inventories (Tables)",
     "role": "http://www.merck.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230383006 - Disclosure - Goodwill and Other Intangibles (Tables)",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesTables",
     "shortName": "Goodwill and Other Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230433007 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables",
     "shortName": "Loans Payable, Long-Term Debt and Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230533008 - Disclosure - Equity (Tables)",
     "role": "http://www.merck.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230573009 - Disclosure - Share-Based Compensation Plans (Tables)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansTables",
     "shortName": "Share-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230643010 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables",
     "shortName": "Pension and Other Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230773011 - Disclosure - Other (Income) Expense, Net (Tables)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables",
     "shortName": "Other (Income) Expense, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030004 - Statement - Consolidated Balance Sheet",
     "role": "http://www.merck.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230813012 - Disclosure - Taxes on Income (Tables)",
     "role": "http://www.merck.com/role/TaxesonIncomeTables",
     "shortName": "Taxes on Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230893013 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.merck.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230933014 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230963015 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.merck.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240024001 - Disclosure - Nature of Operations (Details)",
     "role": "http://www.merck.com/role/NatureofOperationsDetails",
     "shortName": "Nature of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240054002 - Disclosure - Summary of Accounting Policies (Details)",
     "role": "http://www.merck.com/role/SummaryofAccountingPoliciesDetails",
     "shortName": "Summary of Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240084003 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Acquisitions Narrative (Detail)",
     "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
     "shortName": "Acquisitions, Divestitures, Research Collaborations and License Agreements - Acquisitions Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia34ed105cdff4df1a7d378c513d91380_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrk:PremiumOnSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnContractTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094004 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Divestitures Narrative (Detail)",
     "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail",
     "shortName": "Acquisitions, Divestitures, Research Collaborations and License Agreements - Divestitures Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i95e7c98c9507428f817f7f277fea1fa3_D20190101-20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnContractTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104005 - Disclosure - Acquisitions, Divestitures, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions, Divestitures, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i29f6fdbabce3486cb4cfe03f8f281390_I20190401",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134006 - Disclosure - Collaborative Arrangements - Narrative (Details)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
     "shortName": "Collaborative Arrangements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i22a33fa403504dada396f58875c9157c_D20170701-20170731",
      "decimals": "-8",
      "lang": "en-US",
      "name": "mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040005 - Statement - Consolidated Balance Sheet (Parenthetical)",
     "role": "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
     "shortName": "Consolidated Balance Sheet (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i0326de13695545ddb2210521908c117c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrk:CollaborativeArrangementReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144007 - Disclosure - Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
     "shortName": "Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i0326de13695545ddb2210521908c117c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrk:CollaborativeArrangementReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174008 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.merck.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184009 - Disclosure - Restructuring - Charges Related to Restructuring Program Activities by Type of Cost (Details)",
     "role": "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
     "shortName": "Restructuring - Charges Related to Restructuring Program Activities by Type of Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "id5a50fbb06094261ad5ce78fa80bfdca_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "if65645d9ce3443819f0f193e3bf67acc_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240194010 - Disclosure - Restructuring - Charges and Spending Relating to Restructuring Activities by Program (Details)",
     "role": "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails",
     "shortName": "Restructuring - Charges and Spending Relating to Restructuring Activities by Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240224011 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i74f699b1657a4cecb4b718174538872b_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234012 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
     "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i74f699b1657a4cecb4b718174538872b_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia25c4a8026c741e390c5f222dcb409cf_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240244013 - Disclosure - Financial Instruments - Information About Interest Rate Swaps (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
     "shortName": "Financial Instruments - Information About Interest Rate Swaps (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia88f884909c041e5a8334a8a11ec5b1d_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i425ef8de5ab24cb2ae98743e10aff911_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254014 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
     "shortName": "Financial Instruments - Fair Value of Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i425ef8de5ab24cb2ae98743e10aff911_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240264015 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ie3c27f7451db44bf808afb15b4e436ff_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240274016 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
     "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i2e100303069b40878e0e19c66282b95b_I20171231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050006 - Statement - Consolidated Statement of Equity",
     "role": "http://www.merck.com/role/ConsolidatedStatementofEquity",
     "shortName": "Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i530838b57a7f40aea997c3c0d8eafce0_I20171231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240284017 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
     "shortName": "Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i34a833d327f8451596b0800e5d644c7a_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i02369c098d4b43f2a421a2218e9d32f1_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294018 - Disclosure - Financial Instruments - Effects of Derivatives Not Designated as Hedging Instruments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Effects of Derivatives Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i02369c098d4b43f2a421a2218e9d32f1_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304019 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails",
     "shortName": "Financial Instruments - Information on Debt and Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314020 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i9a7496836c554c4c8e7d708f7cc69249_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "if65645d9ce3443819f0f193e3bf67acc_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324021 - Disclosure - Financial Instruments - Summarized Information About Changes in Liabilities for Contingent Consideration (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
     "shortName": "Financial Instruments - Summarized Information About Changes in Liabilities for Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354022 - Disclosure - Inventories - Inventories (Details)",
     "role": "http://www.merck.com/role/InventoriesInventoriesDetails",
     "shortName": "Inventories - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LIFOInventoryAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364023 - Disclosure - Inventories - Narrative (Details)",
     "role": "http://www.merck.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LIFOInventoryAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394024 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
     "shortName": "Goodwill and Other Intangibles - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "if65645d9ce3443819f0f193e3bf67acc_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240404025 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
     "shortName": "Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240414026 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
     "shortName": "Goodwill and Other Intangibles - Other Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060007 - Statement - Consolidated Statement of Equity (Parenthetical)",
     "role": "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical",
     "shortName": "Consolidated Statement of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444027 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454028 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "iaba347791c48433e925479fecdd16a54_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:AssetsandLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464029 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:AssetsandLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240474030 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i0fdabe48bf6945578d95ee1057e5b49e_D20180101-20181231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494031 - Disclosure - Contingencies and Environmental Liabilities - Narrative (Details)",
     "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails",
     "shortName": "Contingencies and Environmental Liabilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ie6c8d1063fa24db98c2859bbb23cc25a_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyClaimsSettledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "legalmatter",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ie6d206d30ad44f5780586176e7331c05_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240504032 - Disclosure - Contingencies and Environmental Liabilities - Legal Defense Reserves - Narrative (Details)",
     "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails",
     "shortName": "Contingencies and Environmental Liabilities - Legal Defense Reserves - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ie6d206d30ad44f5780586176e7331c05_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccrualForEnvironmentalLossContingencies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514033 - Disclosure - Contingencies and Environmental Liabilities - Environmental Litigation and Matters - Narrative (Details)",
     "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails",
     "shortName": "Contingencies and Environmental Liabilities - Environmental Litigation and Matters - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccrualForEnvironmentalLossContingencies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "if65645d9ce3443819f0f193e3bf67acc_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240544034 - Disclosure - Equity - Narrative (Details)",
     "role": "http://www.merck.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "if65645d9ce3443819f0f193e3bf67acc_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240554035 - Disclosure - Equity - Shareholders' Equity (Details)",
     "role": "http://www.merck.com/role/EquityShareholdersEquityDetails",
     "shortName": "Equity - Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i530838b57a7f40aea997c3c0d8eafce0_I20171231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584036 - Disclosure - Share-Based Compensation Plans - Narrative (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
     "shortName": "Share-Based Compensation Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070008 - Statement - Consolidated Statement of Cash Flows",
     "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594037 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails",
     "shortName": "Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "if65645d9ce3443819f0f193e3bf67acc_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604038 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails",
     "shortName": "Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614039 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails",
     "shortName": "Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ic34f1f7cd09744c996b65b7244c26c66_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240624040 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails",
     "shortName": "Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ic34f1f7cd09744c996b65b7244c26c66_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654041 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240664042 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i7b329e4def234bf9be62b33165383a04_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240674043 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i04ec46d52043488489055d11d93409d1_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684044 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i04ec46d52043488489055d11d93409d1_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i87b8ce0948a842ed9ef92b8f8846b1e7_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694045 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i3c8164d243514c2d8cc997890ef95cab_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i89ad1d90c9eb49c08404e53143774bb6_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240704046 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia94af3faf76e48268f7b0e512c7e2317_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080009 - Statement - Consolidated Statement of Cash Flows (Parenthetical)",
     "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical",
     "shortName": "Consolidated Statement of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "id8290bb9fd604f50bbd5b1c20107b822_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714047 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i15952b0805294332b2734607d6a255b8_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "id8290bb9fd604f50bbd5b1c20107b822_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724048 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "id8290bb9fd604f50bbd5b1c20107b822_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734049 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "ia0a266388faa4b4099b085bfa7cdc6a2_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744050 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i626c43e45e7f4662beccc195c3b0010c_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "id8290bb9fd604f50bbd5b1c20107b822_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754051 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "id8290bb9fd604f50bbd5b1c20107b822_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i9ba81e0ed1ed4cac8b38566fd7a5b8c9_D20190101-20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784052 - Disclosure - Other (Income) Expense, Net - Narrative (Details)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
     "shortName": "Other (Income) Expense, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i570b68e110f0450c8e9b7bb3c7d7d6ab_D20180101-20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794053 - Disclosure - Other (Income) Expense, Net (Details)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
     "shortName": "Other (Income) Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824054 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails",
     "shortName": "Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834055 - Disclosure - Taxes on Income - Narrative (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
     "shortName": "Taxes on Income - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i16ad2dca7dc9466c926cfba76668c892_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844056 - Disclosure - Taxes on Income - Income Before Taxes (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails",
     "shortName": "Taxes on Income - Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20201231.htm",
      "contextRef": "i4b5e3be1c47c46be9753feb4fd206982_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 252,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r885",
      "r886",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r883"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r885",
      "r886",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrk_A0.500Notesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2024 [Member]",
        "label": "0.500% Notes due 2024 [Member]",
        "terseLabel": "0.500% Notes due 2024"
       }
      }
     },
     "localname": "A0.500Notesdue2024Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A0.50eurodenominatednotesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.50% euro-denominated notes due 2024 [Member]",
        "label": "0.50% euro-denominated notes due 2024 [Member]",
        "terseLabel": "0.50% euro-denominated notes due 2024"
       }
      }
     },
     "localname": "A0.50eurodenominatednotesdue2024Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A0.75notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% notes due 2026",
        "label": "0.75% notes due 2026 [Member]",
        "terseLabel": "0.75% notes due 2026"
       }
      }
     },
     "localname": "A0.75notesdue2026Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A075NotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Notes due 2026",
        "label": "0.75% Notes due 2026 [Member]",
        "terseLabel": "0.75% notes due 2026"
       }
      }
     },
     "localname": "A075NotesDue2026Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.125EuroNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Euro Notes Due 2021 [Member]",
        "label": "1.125% Euro Notes Due 2021 [Member]",
        "terseLabel": "1.125% euro-denominated notes due 2021"
       }
      }
     },
     "localname": "A1.125EuroNotesDue2021Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.125Notesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes due 2021 [Member]",
        "label": "1.125% Notes due 2021 [Member]",
        "terseLabel": "1.125% Notes due 2021"
       }
      }
     },
     "localname": "A1.125Notesdue2021Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2036 [Member]",
        "label": "1.375% Notes due 2036 [Member]",
        "terseLabel": "1.375% Notes due 2036"
       }
      }
     },
     "localname": "A1.375Notesdue2036Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375eurodenominatednotesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% euro-denominated notes due 2036 [Member]",
        "label": "1.375% euro-denominated notes due 2036 [Member]",
        "terseLabel": "1.375% euro-denominated notes due 2036"
       }
      }
     },
     "localname": "A1.375eurodenominatednotesdue2036Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.45notesdue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.45% notes due 2030 [Member]",
        "label": "1.45% notes due 2030 [Member]",
        "terseLabel": "1.45% notes due 2030"
       }
      }
     },
     "localname": "A1.45notesdue2030Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.85NotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.85% Notes Due 2020 [Member]",
        "label": "1.85% Notes Due 2020 [Member]",
        "terseLabel": "1.85% Notes Due 2020 [Member]"
       }
      }
     },
     "localname": "A1.85NotesDue2020Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875EuroNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.875% Euro Notes Due 2026 [Member]",
        "label": "1.875% Euro Notes Due 2026 [Member]",
        "terseLabel": "1.875% euro-denominated notes due 2026"
       }
      }
     },
     "localname": "A1.875EuroNotesDue2026Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.875% Notes due 2026 [Member]",
        "label": "1.875% Notes due 2026 [Member]",
        "terseLabel": "1.875% Notes due 2026"
       }
      }
     },
     "localname": "A1.875Notesdue2026Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A145NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.45% Notes Due 2030",
        "label": "1.45% Notes Due 2030 [Member]",
        "terseLabel": "1.45% notes due 2030"
       }
      }
     },
     "localname": "A145NotesDue2030Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.35NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2022 [Member]",
        "label": "2.35% Notes Due 2022 [Member]",
        "terseLabel": "2.35% notes due 2022",
        "verboseLabel": "2.35% notes due 2022"
       }
      }
     },
     "localname": "A2.35NotesDue2022Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.35notesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% notes due 2040 [Member]",
        "label": "2.35% notes due 2040 [Member]",
        "terseLabel": "2.35% notes due 2040"
       }
      }
     },
     "localname": "A2.35notesdue2040Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.40NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.40% Notes Due 2022 [Member]",
        "label": "2.40% Notes Due 2022 [Member]",
        "terseLabel": "2.40% notes due 2022",
        "verboseLabel": "2.40% notes due 2022"
       }
      }
     },
     "localname": "A2.40NotesDue2022Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.45notesdue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% notes due 2050 [Member]",
        "label": "2.45% notes due 2050 [Member]",
        "terseLabel": "2.45% notes due 2050"
       }
      }
     },
     "localname": "A2.45notesdue2050Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.500Notesdue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.500% Notes due 2034 [Member]",
        "label": "2.500% Notes due 2034 [Member]",
        "terseLabel": "2.500% Notes due 2034"
       }
      }
     },
     "localname": "A2.500Notesdue2034Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.5EuroNotesDue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.5% Euro Notes Due 2034 [Member]",
        "label": "2.5% Euro Notes Due 2034 [Member]",
        "terseLabel": "2.50% euro-denominated notes due 2034"
       }
      }
     },
     "localname": "A2.5EuroNotesDue2034Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.75NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.75% Notes Due 2025 [Member]",
        "label": "2.75% Notes Due 2025 [Member]",
        "terseLabel": "2.75% notes due 2025"
       }
      }
     },
     "localname": "A2.75NotesDue2025Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.90NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.90% Notes Due 2024",
        "label": "2.90% Notes Due 2024 [Member]",
        "terseLabel": "2.90% notes due 2024"
       }
      }
     },
     "localname": "A2.90NotesDue2024Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A235NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2040",
        "label": "2.35% Notes Due 2040 [Member]",
        "terseLabel": "2.35% notes due 2040"
       }
      }
     },
     "localname": "A235NotesDue2040Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A245NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes Due 2050",
        "label": "2.45% Notes Due 2050 [Member]",
        "terseLabel": "2.45% notes due 2050"
       }
      }
     },
     "localname": "A245NotesDue2050Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A280NotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Notes Due 2023 [Member]",
        "label": "2.80% Notes Due 2023 [Member]",
        "terseLabel": "2.80% notes due 2023"
       }
      }
     },
     "localname": "A280NotesDue2023Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.40NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.40% Notes Due 2029",
        "label": "3.40% Notes Due 2029 [Member]",
        "terseLabel": "3.40% notes due 2029"
       }
      }
     },
     "localname": "A3.40NotesDue2029Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.70NotesDue2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes Due 2045 [Member]",
        "label": "3.70% Notes Due 2045 [Member]",
        "terseLabel": "3.70% notes due 2045"
       }
      }
     },
     "localname": "A3.70NotesDue2045Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.875NotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.875% Notes Due 2021",
        "label": "3.875% Notes Due 2021 [Member]",
        "verboseLabel": "3.875% notes due 2021"
       }
      }
     },
     "localname": "A3.875NotesDue2021Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.90NotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.90% Notes Due 2039",
        "label": "3.90% Notes Due 2039 [Member]",
        "terseLabel": "3.90% notes due 2039"
       }
      }
     },
     "localname": "A3.90NotesDue2039Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A4.00NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.00% Notes Due 2049",
        "label": "4.00% Notes Due 2049 [Member]",
        "terseLabel": "4.00% notes due 2049"
       }
      }
     },
     "localname": "A4.00NotesDue2049Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A415NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Notes Due 2043 [Member]",
        "label": "4.15% Notes Due 2043 [Member]",
        "terseLabel": "4.15% notes due 2043"
       }
      }
     },
     "localname": "A415NotesDue2043Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleratedDepreciationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Depreciation [Member]",
        "label": "Accelerated Depreciation [Member]",
        "terseLabel": "Accelerated Depreciation"
       }
      }
     },
     "localname": "AcceleratedDepreciationMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleratedShareRepurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchase Agreement [Member]",
        "label": "Accelerated Share Repurchase Agreement [Member]",
        "terseLabel": "Accelerated Share Repurchase Agreement"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseAgreementMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleratedShareRepurchaseAgreementOctober292018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchase Agreement, October 29, 2018 [Member]",
        "label": "Accelerated Share Repurchase Agreement, October 29, 2018 [Member]",
        "terseLabel": "Accelerated Share Repurchase Agreement, October 29, 2018"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseAgreementOctober292018Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AccrualForChargebacks": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for chargebacks reflected as a direction reduction to accounts receivable.",
        "label": "Accrual For Chargebacks",
        "terseLabel": "Accrual for chargebacks reflected as direct reduction to accounts receivable"
       }
      }
     },
     "localname": "AccrualForChargebacks",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AccrualForRebates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for rebates recorded as current liability.",
        "label": "Accrual For Rebates",
        "terseLabel": "Accrual for rebates included in accrued and other current liabilities"
       }
      }
     },
     "localname": "AccrualForRebates",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements.",
        "label": "Acquisitions Divestitures Research Collaborations And License Agreements [Text Block]",
        "terseLabel": "Acquisitions, Divestitures, Research Collaborations and License Agreements"
       }
      }
     },
     "localname": "AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AdempasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adempas",
        "label": "Adempas [Member]",
        "terseLabel": "Adempas"
       }
      }
     },
     "localname": "AdempasMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueAdempasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Adempas",
        "label": "Alliance revenue - Adempas [Member]",
        "terseLabel": "Alliance revenue - Adempas (2)"
       }
      }
     },
     "localname": "AllianceRevenueAdempasMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueKoselugoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Koselugo",
        "label": "Alliance revenue - Koselugo [Member]",
        "terseLabel": "Alliance revenue - Koselugo"
       }
      }
     },
     "localname": "AllianceRevenueKoselugoMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AlliancerevenueLynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Lynparza [Member]",
        "label": "Alliance revenue - Lynparza [Member]",
        "terseLabel": "Alliance revenue - Lynparza"
       }
      }
     },
     "localname": "AlliancerevenueLynparzaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AmortizationOfPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of purchase accounting adjustments.",
        "label": "Amortization Of Purchase Accounting Adjustments",
        "negatedLabel": "Amortization of purchase accounting adjustments"
       }
      }
     },
     "localname": "AmortizationOfPurchaseAccountingAdjustments",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AnimalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animal Health [Member]",
        "label": "Animal Health [Member]",
        "terseLabel": "Animal Health"
       }
      }
     },
     "localname": "AnimalHealthMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AnimalHealthsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animal Health segment [Member]",
        "label": "Animal Health segment [Member]",
        "terseLabel": "Animal Health"
       }
      }
     },
     "localname": "AnimalHealthsegmentMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AntelliqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antelliq [Member]",
        "label": "Antelliq [Member]",
        "terseLabel": "Antelliq"
       }
      }
     },
     "localname": "AntelliqMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArQuleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ArQule [Member]",
        "label": "ArQule [Member]",
        "terseLabel": "ArQule"
       }
      }
     },
     "localname": "ArQuleMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArcoxiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcoxia [Member].",
        "label": "Arcoxia [Member]",
        "terseLabel": "Arcoxia"
       }
      }
     },
     "localname": "ArcoxiaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AssetsandLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee [Table Text Block]",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsandLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AtozetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Atozet [Member]",
        "label": "Atozet [Member]",
        "terseLabel": "Atozet"
       }
      }
     },
     "localname": "AtozetMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG [Member]",
        "label": "Bayer AG [Member]",
        "terseLabel": "Bayer AG"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BelsomraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Belsomra [Member]",
        "label": "Belsomra [Member]",
        "terseLabel": "Belsomra"
       }
      }
     },
     "localname": "BelsomraMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BridionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridion [Member].",
        "label": "Bridion [Member]",
        "terseLabel": "Bridion"
       }
      }
     },
     "localname": "BridionMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CGRPreceptorantagonistsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CGRP receptor antagonists [Member]",
        "label": "CGRP receptor antagonists [Member]",
        "terseLabel": "CGRP receptor antagonists"
       }
      }
     },
     "localname": "CGRPreceptorantagonistsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CaliforniaStateCourtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California state court.",
        "label": "California State Court [Member]",
        "terseLabel": "California State Court"
       }
      }
     },
     "localname": "CaliforniaStateCourtMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CancidasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancidas [Member].",
        "label": "Cancidas [Member]",
        "terseLabel": "Cancidas"
       }
      }
     },
     "localname": "CancidasMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cases Company Agreed To Toll Statute Of Limitations[Member]",
        "label": "Cases Company Agreed ToToll Statute Of Limitations [Member]",
        "terseLabel": "Cases Company Agreed To Toll Statute Of Limitations"
       }
      }
     },
     "localname": "CasesCompanyAgreedToTollStatuteOfLimitationsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ChargeForAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge for asset acquisition",
        "label": "Charge for asset acquisition",
        "terseLabel": "Charge for the acquisition of VelosBio Inc."
       }
      }
     },
     "localname": "ChargeForAssetAcquisition",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge for future payments related to collaboration license options",
        "label": "Charge for future payments related to collaboration license options",
        "terseLabel": "Charge for future payments related to collaboration license options"
       }
      }
     },
     "localname": "ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ChargesRelatedToProgramDiscontinuation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges related to program discontinuation",
        "label": "Charges related to program discontinuation",
        "terseLabel": "Charges related to program discontinuation"
       }
      }
     },
     "localname": "ChargesRelatedToProgramDiscontinuation",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Expenses",
        "label": "Collaborative Arrangement, Expenses",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CollaborativeArrangementExpenses",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Payable",
        "label": "Collaborative Arrangement, Payable",
        "terseLabel": "Payables to counterparty"
       }
      }
     },
     "localname": "CollaborativeArrangementPayable",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementProfitSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails": {
       "order": 2.0,
       "parentTag": "mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Profit Sharing",
        "label": "Collaborative Arrangement, Profit Sharing",
        "terseLabel": "Merck\u2019s profit share of sales in marketing territories"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitSharing",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Receivable",
        "label": "Collaborative Arrangement, Receivable",
        "terseLabel": "Receivables from counterparty"
       }
      }
     },
     "localname": "CollaborativeArrangementReceivable",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenues, Net of Commercialization Costs",
        "label": "Collaborative Arrangement, Revenues, Net of Commercialization Costs",
        "totalLabel": "Total sales"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesNetofCommercializationCosts",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementSalesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails": {
       "order": 1.0,
       "parentTag": "mrk_CollaborativeArrangementRevenuesNetofCommercializationCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Sales, Net",
        "label": "Collaborative Arrangement, Sales, Net",
        "terseLabel": "Net sales of Adempas recorded by Merck"
       }
      }
     },
     "localname": "CollaborativeArrangementSalesNet",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Abstract]",
        "label": "Collaborative Arrangements [Abstract]",
        "terseLabel": "Collaborative Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.merck.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mrk_CommercialandOtherLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial and Other Litigation [Member]",
        "label": "Commercial and Other Litigation [Member]",
        "terseLabel": "Commercial Litigation"
       }
      }
     },
     "localname": "CommercialandOtherLitigationMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CommercialmilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "commercial milestone [Member]",
        "label": "commercial milestone [Member]",
        "terseLabel": "Commercial Milestone"
       }
      }
     },
     "localname": "CommercialmilestoneMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CompanionAnimalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Companion Animals [Member]",
        "label": "Companion Animals [Member]",
        "terseLabel": "Companion Animals"
       }
      }
     },
     "localname": "CompanionAnimalsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company pension investments which are categorized as level three assets percentage.",
        "label": "Company Pension Investments Which Are Categorized As Level Three Assets Percentage",
        "terseLabel": "Percentage of Company's pension investments categorized as Level 3 assets (as percent)"
       }
      }
     },
     "localname": "CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Line Items]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Table]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ConsumercarebusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "consumer care business [Member]",
        "label": "consumer care business [Member]",
        "terseLabel": "consumer care business"
       }
      }
     },
     "localname": "ConsumercarebusinessMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discussion of the accounting policy for contingent consideration.",
        "label": "Contingent Consideration [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_ContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.",
        "label": "Contingent Payments Collaborative Arrangement",
        "terseLabel": "Contingent payments collaborative arrangement"
       }
      }
     },
     "localname": "ContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_Contractterminationfeepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract termination fee payment",
        "label": "Contract termination fee payment",
        "terseLabel": "Contract termination fee payment"
       }
      }
     },
     "localname": "Contractterminationfeepayment",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CorporateObligationsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate obligations fixed income securities.",
        "label": "Corporate Obligations Fixed Income Securities [Member]",
        "terseLabel": "Corporate obligations, Fixed income securities"
       }
      }
     },
     "localname": "CorporateObligationsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CorporateObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate obligations investment funds.",
        "label": "Corporate Obligations Investment Funds [Member]",
        "terseLabel": "Corporate obligations, Investment funds"
       }
      }
     },
     "localname": "CorporateObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CostsExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.",
        "label": "Costs Expenses And Other",
        "totalLabel": "Total costs, expenses and other"
       }
      }
     },
     "localname": "CostsExpensesAndOther",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CozaarHyzaarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cozaar/Hyzaar [Member].",
        "label": "Cozaar Hyzaar [Member]",
        "terseLabel": "Cozaar/Hyzaar"
       }
      }
     },
     "localname": "CozaarHyzaarMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CubicinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cubicin [Member]",
        "label": "Cubicin [Member]",
        "terseLabel": "Cubicin"
       }
      }
     },
     "localname": "CubicinMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DebtSecuritiesandEquitySecuritiesFVNI": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities and Equity Securities, FV-NI",
        "label": "Debt Securities and Equity Securities, FV-NI",
        "totalLabel": "Total debt and publicly traded equity securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesandEquitySecuritiesFVNI",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Taxes Assets And Liabilities Net [Table]",
        "label": "Deferred Income Taxes Assets And Liabilities Net [Table]",
        "terseLabel": "Deferred Income Taxes Assets And Liabilities Net [Table]"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAssetsAndLiabilitiesNetTable",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carryforwards and other tax credit carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards",
        "terseLabel": "Net operating losses and other tax credit carryforwards, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxAssetsUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets unrecognized tax benefits.",
        "label": "Deferred Tax Assets Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrecognizedTaxBenefits",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxLiabilitiesEquityMethodInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Equity Method Investment",
        "label": "Deferred Tax Liabilities, Equity Method Investment",
        "terseLabel": "Equity method investments, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesEquityMethodInvestment",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.",
        "label": "Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans",
        "terseLabel": "Pensions and other postretirement benefits, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic",
        "label": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic",
        "terseLabel": "Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards"
       }
      }
     },
     "localname": "DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DefinedBenefitPlanCashandOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Cash and Other Investments [Member]",
        "label": "Defined Benefit Plan, Cash and Other Investments [Member]",
        "terseLabel": "Cash And Other Investments"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashandOtherInvestmentsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DefinedBenefitPlanOtherChangesPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in plan assets, not otherwise separately disclosed in the financial statements.",
        "label": "Defined Benefit Plan Other Changes Plan Assets",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherChangesPlanAssets",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DevelopedMarketsEquitiesInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed markets equities investment funds.",
        "label": "Developed Markets Equities Investment Funds [Member]",
        "terseLabel": "Developed markets equities, Investment funds"
       }
      }
     },
     "localname": "DevelopedMarketsEquitiesInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DevelopedMarketsEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed markets equity securities.",
        "label": "Developed Markets Equity Securities [Member]",
        "terseLabel": "Developed markets, Equity securities"
       }
      }
     },
     "localname": "DevelopedMarketsEquitySecuritiesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DificidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dificid [Member]",
        "label": "Dificid [Member]",
        "terseLabel": "Dificid"
       }
      }
     },
     "localname": "DificidMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DunboyneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dunboyne",
        "label": "Dunboyne [Member]",
        "terseLabel": "Dunboyne"
       }
      }
     },
     "localname": "DunboyneMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to the amortization of purchase accounting adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Amortization Of Purchase Accounting Adjustments",
        "terseLabel": "Acquisition-related costs, including amortization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination",
        "terseLabel": "Acquisition of Peloton"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombination",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination, Percent",
        "terseLabel": "Acquisition of Peloton"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Three",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Three",
        "terseLabel": "Acquisition of OncoImmune"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationThree",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Three, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Three, Percent",
        "terseLabel": "Acquisition of OncoImmune"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Two",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Two",
        "terseLabel": "Acquisition of VelosBio"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Two, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Two, Percent",
        "terseLabel": "Acquisition of VelosBio"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]",
        "terseLabel": "Differential arising from:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]",
        "terseLabel": "Differential arising from:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount",
        "terseLabel": "GILTI and the foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent",
        "terseLabel": "GILTI and the foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EmendMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emend [Member].",
        "label": "Emend [Member]",
        "terseLabel": "Emend"
       }
      }
     },
     "localname": "EmendMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EmergingMarketsEquitiesInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging markets equities investment funds.",
        "label": "Emerging Markets Equities Investment Funds [Member]",
        "terseLabel": "Emerging markets equities, Investment funds"
       }
      }
     },
     "localname": "EmergingMarketsEquitiesInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will be noncash.",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash",
        "terseLabel": "Percentage estimate of cumulative pretax costs that will be non-cash (primarily from accelerated depreciation of facilities) (as percent)"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays",
        "terseLabel": "Percentage estimate of cumulative pretax costs that will result in cash outlays (primarily from employee separation expense) (as percent)"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EurodominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro-dominated Notes [Member]",
        "label": "Euro-dominated Notes [Member]",
        "terseLabel": "Euro-denominated notes"
       }
      }
     },
     "localname": "EurodominatedNotesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.",
        "label": "Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests",
        "terseLabel": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests (as percent)"
       }
      }
     },
     "localname": "ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_FederalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal.",
        "label": "Federal [Member]",
        "terseLabel": "Federal Court"
       }
      }
     },
     "localname": "FederalMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point eight five percentage notes due on two thousand and thirty nine.",
        "label": "Five Point Eight Five Percentage Notes Due On Two Thousand And Thirty Nine [Member]",
        "terseLabel": "5.85% notes due 2039"
       }
      }
     },
     "localname": "FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point nine five percentage debentures due on two thousand and twenty eight.",
        "label": "Five Point Nine Five Percentage Debentures Due On Two Thousand And Twenty Eight [Member]",
        "terseLabel": "5.95% debentures due 2028"
       }
      }
     },
     "localname": "FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point seven five percentage notes due on two thousand and thirty six.",
        "label": "Five Point Seven Five Percentage Notes Due On Two Thousand And Thirty Six [Member]",
        "terseLabel": "5.75% notes due 2036"
       }
      }
     },
     "localname": "FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FixedIncomeObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed income obligations investment funds.",
        "label": "Fixed Income Obligations Investment Funds [Member]",
        "terseLabel": "Fixed income obligations, Investment funds"
       }
      }
     },
     "localname": "FixedIncomeObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FollistimAqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follistim AQ [Member].",
        "label": "Follistim Aq [Member]",
        "terseLabel": "Follistim AQ"
       }
      }
     },
     "localname": "FollistimAqMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FosamaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fosamax [Member].",
        "label": "Fosamax [Member]",
        "terseLabel": "Fosamax"
       }
      }
     },
     "localname": "FosamaxMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GardasilGardasil9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gardasil/Gardasil 9 [Member].",
        "label": "Gardasil/Gardasil 9 [Member]",
        "terseLabel": "Gardasil/Gardasil 9"
       }
      }
     },
     "localname": "GardasilGardasil9Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and agency obligations fixed income securities.",
        "label": "Government And Agency Obligations Fixed Income Securities [Member]",
        "terseLabel": "Government and agency obligations, Fixed income securities"
       }
      }
     },
     "localname": "GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GovernmentAndAgencyObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and agency obligations investment funds.",
        "label": "Government And Agency Obligations Investment Funds [Member]",
        "terseLabel": "Government and agency obligations, Investment funds"
       }
      }
     },
     "localname": "GovernmentAndAgencyObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_HealthcareServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Services segment [Member]",
        "label": "Healthcare Services Segment [Member]",
        "terseLabel": "Healthcare Services"
       }
      }
     },
     "localname": "HealthcareServicesSegmentMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IAVI [Member]",
        "label": "IAVI [Member]",
        "terseLabel": "IAVI"
       }
      }
     },
     "localname": "IAVIMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IOmetPharmaLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IOmet Pharma Ltd [Member]",
        "label": "IOmet Pharma Ltd [Member]",
        "terseLabel": "IOmet Pharma Ltd"
       }
      }
     },
     "localname": "IOmetPharmaLtdMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ImmuneDesignMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immune Design [Member]",
        "label": "Immune Design [Member]",
        "terseLabel": "Immune Design"
       }
      }
     },
     "localname": "ImmuneDesignMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ImplanonNexplanonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implanon/Nexplanon [Member].",
        "label": "Implanon/Nexplanon [Member]",
        "terseLabel": "Implanon/Nexplanon"
       }
      }
     },
     "localname": "ImplanonNexplanonMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to amortization of purchase accounting adjustments.",
        "label": "Income Tax Reconciliation Amortization Of Purchase Accounting Adjustments",
        "terseLabel": "Acquisition-related costs, including amortization"
       }
      }
     },
     "localname": "IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IncomeTaxesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Payable [Member]",
        "label": "Income Taxes Payable [Member]",
        "terseLabel": "Income Taxes Payable"
       }
      }
     },
     "localname": "IncomeTaxesPayableMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InsuranceContractsOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance contracts other investments.",
        "label": "Insurance Contracts Other Investments [Member]",
        "terseLabel": "Insurance contracts, Other investments",
        "verboseLabel": "Insurance Contracts"
       }
      }
     },
     "localname": "InsuranceContractsOtherInvestmentsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Measurement Input",
        "label": "Intangible Asset, Measurement Input",
        "terseLabel": "Present value discount rate"
       }
      }
     },
     "localname": "IntangibleAssetMeasurementInput",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "mrk_IntangibleAssetsExcludingGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Excluding Goodwill [Line Items]",
        "label": "Intangible Assets Excluding Goodwill [Line Items]",
        "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillLineItems",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International [Member]",
        "label": "International [Member]",
        "terseLabel": "Int\u2019l"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InvanzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invanz [Member].",
        "label": "Invanz [Member]",
        "terseLabel": "Invanz"
       }
      }
     },
     "localname": "InvanzMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoriesProducedinPreparationforProductLaunchesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories Produced in Preparation for Product Launches [Member]",
        "label": "Inventories Produced in Preparation for Product Launches [Member]",
        "terseLabel": "Inventories Produced in Preparation for Product Launches"
       }
      }
     },
     "localname": "InventoriesProducedinPreparationforProductLaunchesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of current and noncurrent inventories.",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total current and noncurrent inventories"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Not Expected to be Sold Within One Year [Member]",
        "label": "Inventory Not Expected to be Sold Within One Year [Member]",
        "terseLabel": "Inventory Not Expected to be Sold Within One Year"
       }
      }
     },
     "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory [Table]",
        "label": "Inventory [Table]",
        "terseLabel": "Inventory [Table]"
       }
      }
     },
     "localname": "InventoryTable",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IsentressIsentressHDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Isentress/Isentress HD [Member].",
        "label": "Isentress/Isentress HD [Member]",
        "terseLabel": "Isentress/Isentress HD"
       }
      }
     },
     "localname": "IsentressIsentressHDMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanumetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janumet [Member].",
        "label": "Janumet [Member]",
        "terseLabel": "Janumet"
       }
      }
     },
     "localname": "JanumetMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanuviaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Januvia [Member] .",
        "label": "Januvia [Member]",
        "terseLabel": "Januvia"
       }
      }
     },
     "localname": "JanuviaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_KeytrudaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Keytruda [Member]",
        "label": "Keytruda [Member]",
        "terseLabel": "Keytruda"
       }
      }
     },
     "localname": "KeytrudaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LegalDefenseCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Defense Costs [Member]",
        "label": "Legal Defense Costs [Member]",
        "terseLabel": "Legal Defense Costs"
       }
      }
     },
     "localname": "LegalDefenseCostsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LenvimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lenvima [Member]",
        "label": "Lenvima [Member]",
        "terseLabel": "Lenvima",
        "verboseLabel": "Alliance revenue - Lenvima (1)"
       }
      }
     },
     "localname": "LenvimaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "terseLabel": "Lessee, operating lease, lease not yet commenced, amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotyetCommencedAmount",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LivestockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Livestock [Member]",
        "label": "Livestock [Member]",
        "terseLabel": "Livestock"
       }
      }
     },
     "localname": "LivestockMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loans Payable, Long-Term Debt and Leases - Balance Sheet Information [Abstract]",
        "label": "Loans Payable, Long-Term Debt and Leases - Balance Sheet Information [Abstract]",
        "terseLabel": "Loans Payable, Long-Term Debt and Leases - Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "LoansPayableLongTermDebtandLeasesBalanceSheetInformationAbstract",
     "nsuri": "http://www.merck.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mrk_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Current Maturities [Member]",
        "label": "Long Term Debt, Current Maturities [Member]",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtExcludingCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Excluding Current Maturities [Member]",
        "label": "Long Term Debt Excluding Current Maturities [Member]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtExcludingCurrentMaturitiesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LossContingencyClaimsonAppealNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims on Appeal, Number",
        "label": "Loss Contingency, Claims on Appeal, Number",
        "terseLabel": "Loss contingency, claims on appeal, number"
       }
      }
     },
     "localname": "LossContingencyClaimsonAppealNumber",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_LynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lynparza [Member]",
        "label": "Lynparza [Member]",
        "terseLabel": "Lynparza"
       }
      }
     },
     "localname": "LynparzaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc. [Member]",
        "label": "McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc. [Member]",
        "terseLabel": "McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc."
       }
      }
     },
     "localname": "McKessonCorporationAmerisourceBergenCorporationandCardinalHealthInc.Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MilestonePaymentsMadetoCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Made to Collaborative Partner",
        "label": "Milestone Payments Made to Collaborative Partner",
        "terseLabel": "Milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "MilestonePaymentsMadetoCollaborativePartner",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and asset backed securities fixed income securities.",
        "label": "Mortgage And Asset Backed Securities Fixed Income Securities [Member]",
        "verboseLabel": "Mortgage and asset backed-securities, Fixed income securities"
       }
      }
     },
     "localname": "MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and Asset-Backed Securities Investment Funds",
        "label": "Mortgage and Asset-Backed Securities Investment Funds [Member]",
        "terseLabel": "Mortgage and Asset-Backed Securities Investment Funds"
       }
      }
     },
     "localname": "MortgageAndAssetBackedSecuritiesInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MovementinCommonStockandTreasuryStockRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Movement in Common Stock and Treasury Stock [Roll Forward]",
        "label": "Movement in Common Stock and Treasury Stock [Roll Forward]",
        "terseLabel": "Movement in Common Stock and Treasury Stock [Roll Forward]"
       }
      }
     },
     "localname": "MovementinCommonStockandTreasuryStockRollForward",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_NasonexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nasonex [Member].",
        "label": "Nasonex [Member]",
        "terseLabel": "Nasonex"
       }
      }
     },
     "localname": "NasonexMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NewJerseyStateCourtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Jersey state court member.",
        "label": "New Jersey State Court [Member]",
        "terseLabel": "New Jersey State Court"
       }
      }
     },
     "localname": "NewJerseyStateCourtMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NotesSubjectToRepaymentAtOptionOfHolderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Subject To Repayment At Option Of Holder [Member]",
        "label": "Notes Subject To Repayment At Option Of Holder [Member]",
        "terseLabel": "Notes Subject To Repayment At Option Of Holder"
       }
      }
     },
     "localname": "NotesSubjectToRepaymentAtOptionOfHolderMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NoxafilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noxafil [Member].",
        "label": "Noxafil [Member]",
        "terseLabel": "Noxafil"
       }
      }
     },
     "localname": "NoxafilMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NuvaringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NuvaRing [Member].",
        "label": "Nuvaring [Member]",
        "terseLabel": "NuvaRing"
       }
      }
     },
     "localname": "NuvaringMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.",
        "label": "Offsetting Assets And Liabilities [Table Text Block]",
        "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis"
       }
      }
     },
     "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_OncoImmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OncoImmune",
        "label": "OncoImmune [Member]",
        "terseLabel": "OncoImmune"
       }
      }
     },
     "localname": "OncoImmuneMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherContractTerminationCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Contract Termination Costs",
        "label": "Other Contract Termination Costs",
        "terseLabel": "Other contract termination costs"
       }
      }
     },
     "localname": "OtherContractTerminationCosts",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other long term debt.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income and expense items not separately disclosed.",
        "label": "Other Nonoperating Income Expense, Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_OtherPharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other pharmaceutical.",
        "label": "Other Pharmaceutical [Member]",
        "terseLabel": "Other pharmaceutical"
       }
      }
     },
     "localname": "OtherPharmaceuticalMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherPostretirementBenefitPlanNetLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Postretirement Benefit Plan Net Loss [Member]",
        "label": "Other Postretirement Benefit Plan Net Loss [Member]",
        "terseLabel": "Other Postretirement Benefit Plan Net Gain"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlanNetLossMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherPostretirementBenefitPlanPriorServiceCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Postretirement Benefit Plan Prior Service Cost [Member]",
        "label": "Other Postretirement Benefit Plan Prior Service Cost [Member]",
        "terseLabel": "Other Postretirement Benefit Plan Prior Service Credit"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlanPriorServiceCostMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherStateCourtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other state court.",
        "label": "Other State Court [Member]",
        "terseLabel": "Other State Court"
       }
      }
     },
     "localname": "OtherStateCourtMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherVariableRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Variable Rate Debt [Member]",
        "label": "Other Variable Rate Debt [Member]",
        "terseLabel": "Other Variable Rate Debt"
       }
      }
     },
     "localname": "OtherVariableRateDebtMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PatentlitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent litigation [Member]",
        "label": "Patent litigation [Member]",
        "terseLabel": "Patent litigation"
       }
      }
     },
     "localname": "PatentlitigationMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Business Five, Net of Cash Acquired",
        "label": "Payments to Acquire Business Five, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Peloton Therapeutics, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessFiveNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Business Four, Net of Cash Acquired",
        "label": "Payments to Acquire Business Four, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Antelliq Corporation, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessFourNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PelotonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Peloton [Member]",
        "label": "Peloton [Member]",
        "terseLabel": "Peloton"
       }
      }
     },
     "localname": "PelotonMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PensionPlanNetLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension Plan Net Loss [Member]",
        "label": "Pension Plan Net Loss [Member]",
        "terseLabel": "Pension Plan Net Loss"
       }
      }
     },
     "localname": "PensionPlanNetLossMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PensionPlanPriorServiceCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension Plan Prior Service Cost [Member]",
        "label": "Pension Plan Prior Service Cost [Member]",
        "terseLabel": "Pension Plan Prior Service Credit"
       }
      }
     },
     "localname": "PensionPlanPriorServiceCostMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PharmaceuticalsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical segment.",
        "label": "Pharmaceutical segment [Member]",
        "terseLabel": "Pharmaceutical segment",
        "verboseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalsegmentMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_Pneumovax23Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumovax 23[Member].",
        "label": "Pneumovax 23 [Member]",
        "terseLabel": "Pneumovax 23"
       }
      }
     },
     "localname": "Pneumovax23Member",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PremiumOnSharesAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on shares acquired",
        "label": "Premium on shares acquired",
        "terseLabel": "Premium on shares acquired"
       }
      }
     },
     "localname": "PremiumOnSharesAcquired",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PrevymisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevymis",
        "label": "Prevymis [Member]",
        "terseLabel": "Prevymis"
       }
      }
     },
     "localname": "PrevymisMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PrimaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primaxin [Member].",
        "label": "Primaxin [Member]",
        "terseLabel": "Primaxin"
       }
      }
     },
     "localname": "PrimaxinMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProQuadMMRIIVarivaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQuad/M-M-R II/Varivax [Member].",
        "label": "ProQuad MMR II Varivax [Member]",
        "terseLabel": "ProQuad/M-M-R II/Varivax"
       }
      }
     },
     "localname": "ProQuadMMRIIVarivaxMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProbableContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable Contingent Payments Collaborative Arrangement",
        "label": "Probable Contingent Payments Collaborative Arrangement",
        "terseLabel": "Probable future contingent payments collaborative arrangement"
       }
      }
     },
     "localname": "ProbableContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RealEstateInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate investment funds.",
        "label": "Real Estate Investment Funds [Member]",
        "terseLabel": "Real estate, Investment funds",
        "verboseLabel": "Real Estate"
       }
      }
     },
     "localname": "RealEstateInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RecognizedAsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized as.",
        "label": "Recognized As [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "RecognizedAsAbstract",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member].",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RestructuringReserveNoncashActivity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.",
        "label": "Restructuring Reserve Noncash Activity",
        "negatedLabel": "Non-cash activity"
       }
      }
     },
     "localname": "RestructuringReserveNoncashActivity",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RevenuePerformanceObligationPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms",
        "label": "Revenue, Performance Obligation, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTerms",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date",
        "label": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date",
        "terseLabel": "Product return period and expiration"
       }
      }
     },
     "localname": "RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date",
        "label": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date",
        "terseLabel": "Product return period"
       }
      }
     },
     "localname": "RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RotateqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RotaTeq [Member]",
        "label": "Rotateq [Member]",
        "terseLabel": "RotaTeq"
       }
      }
     },
     "localname": "RotateqMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RoyaltyRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Percentage",
        "label": "Royalty Rate, Percentage",
        "terseLabel": "Royalty rate, percentage"
       }
      }
     },
     "localname": "RoyaltyRatePercentage",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestones [Member]",
        "label": "Sales-Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SalesDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Discounts",
        "label": "Sales Discounts",
        "terseLabel": "Customer discounts"
       }
      }
     },
     "localname": "SalesDiscounts",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SamsungMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung [Member]",
        "label": "Samsung [Member]",
        "terseLabel": "Samsung"
       }
      }
     },
     "localname": "SamsungMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SanofiPasteurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Pasteur [Member]",
        "label": "Sanofi Pasteur [Member]",
        "terseLabel": "Sanofi Pasteur"
       }
      }
     },
     "localname": "SanofiPasteurMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ScheduleOfOtherIntangiblesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Intangibles [Table]",
        "label": "Schedule Of Other Intangibles [Table]",
        "terseLabel": "Schedule Of Other Intangibles [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIntangiblesTable",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.",
        "label": "Schedule of Accumulated and Projected Benefit Obligation in Excess of Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_SeagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seagen",
        "label": "Seagen [Member]",
        "terseLabel": "Seagen"
       }
      }
     },
     "localname": "SeagenMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SegmentReportingUnallocatedOtherExpensesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other net expenses not allocated to segments.",
        "label": "Segment Reporting Unallocated Other Expenses Net",
        "negatedLabel": "Other unallocated, net"
       }
      }
     },
     "localname": "SegmentReportingUnallocatedOtherExpensesNet",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SentinelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sentinel [Member]",
        "label": "Sentinel [Member]",
        "terseLabel": "Sentinel"
       }
      }
     },
     "localname": "SentinelMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional information pertaining to stock option plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block]",
        "terseLabel": "Additional Information Pertaining to Stock Option Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_SimponiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi [Member].",
        "label": "Simponi [Member]",
        "terseLabel": "Simponi"
       }
      }
     },
     "localname": "SimponiMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SingulairMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Singulair [Member].",
        "label": "Singulair [Member]",
        "terseLabel": "Singulair"
       }
      }
     },
     "localname": "SingulairMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SivextroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sivextro [Member]",
        "label": "Sivextro [Member]",
        "terseLabel": "Sivextro"
       }
      }
     },
     "localname": "SivextroMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point five five percentage notes due on two thousand and thirty seven.",
        "label": "Six Point Five Five Percentage Notes Due On Two Thousand And Thirty Seven [Member]",
        "terseLabel": "6.55% notes due 2037"
       }
      }
     },
     "localname": "SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point five zero percentage notes due on two thousand and thirty three.",
        "label": "Six Point Five Zero Percentage Notes Due On Two Thousand And Thirty Three [Member]",
        "terseLabel": "6.50% notes due 2033"
       }
      }
     },
     "localname": "SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point four percentage debentures due on two thousand and twenty eight.",
        "label": "Six Point Four Percentage Debentures Due On Two Thousand And Twenty Eight [Member]",
        "terseLabel": "6.40% debentures due 2028"
       }
      }
     },
     "localname": "SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point three percentage debentures due on two thousand and twenty six.",
        "label": "Six Point Three Percentage Debentures Due On Two Thousand And Twenty Six [Member]",
        "terseLabel": "6.30% debentures due 2026"
       }
      }
     },
     "localname": "SixPointThreePercentageDebenturesDueOnTwoThousandAndTwentySixMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SmartCellsProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SmartCells Program [Member]",
        "label": "SmartCells Program [Member]",
        "terseLabel": "SmartCells Program"
       }
      }
     },
     "localname": "SmartCellsProgramMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_TermForPayingOffEnvironmentalLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term for paying off environmental liabilities.",
        "label": "Term For Paying Off Environmental Liabilities",
        "terseLabel": "Term for paying off environmental liabilities"
       }
      }
     },
     "localname": "TermForPayingOffEnvironmentalLiabilities",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_ThemisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Themis [Member]",
        "label": "Themis [Member]",
        "terseLabel": "Themis"
       }
      }
     },
     "localname": "ThemisMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]",
        "label": "Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]",
        "terseLabel": "3.60% notes due 2042"
       }
      }
     },
     "localname": "ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_TukysaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tukysa",
        "label": "Tukysa [Member]",
        "terseLabel": "Tukysa"
       }
      }
     },
     "localname": "TukysaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments made to partner as part of collaborative arrangement.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_VaqtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaqta [Member]",
        "label": "Vaqta [Member]",
        "terseLabel": "Vaqta"
       }
      }
     },
     "localname": "VaqtaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VelosBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VelosBio",
        "label": "VelosBio [Member]",
        "terseLabel": "VelosBio"
       }
      }
     },
     "localname": "VelosBioMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VioxxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vioxx",
        "label": "Vioxx [Member]",
        "terseLabel": "Vioxx"
       }
      }
     },
     "localname": "VioxxMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ViralyticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viralytics [Member]",
        "label": "Viralytics [Member]",
        "terseLabel": "Viralytics"
       }
      }
     },
     "localname": "ViralyticsMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VytorinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vytorin [Member] .",
        "label": "Vytorin [Member]",
        "terseLabel": "Vytorin"
       }
      }
     },
     "localname": "VytorinMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZepatierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zepatier [Member]",
        "label": "Zepatier [Member]",
        "terseLabel": "Zepatier"
       }
      }
     },
     "localname": "ZepatierMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZerbaxaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zerbaxa [Member]",
        "label": "Zerbaxa [Member]",
        "terseLabel": "Zerbaxa"
       }
      }
     },
     "localname": "ZerbaxaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZetiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zetia [Member] .",
        "label": "Zetia [Member]",
        "terseLabel": "Zetia"
       }
      }
     },
     "localname": "ZetiaMember",
     "nsuri": "http://www.merck.com/20201231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific (other than China and Japan)"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r643",
      "r644",
      "r651",
      "r652",
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r643",
      "r644",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r222",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r242",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r222",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r242",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r89",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r175",
      "r182",
      "r285",
      "r552",
      "r553",
      "r554",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r175",
      "r182",
      "r285",
      "r552",
      "r553",
      "r554",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r175",
      "r182",
      "r285",
      "r552",
      "r553",
      "r554",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r253",
      "r412",
      "r415",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r508",
      "r514",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r775",
      "r833",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r508",
      "r514",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r775",
      "r833",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r253",
      "r412",
      "r415",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PartnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partnership Interest [Member]",
        "terseLabel": "AstraZeneca LP"
       }
      }
     },
     "localname": "PartnershipInterestMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r249",
      "r412",
      "r413",
      "r779",
      "r832",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r249",
      "r412",
      "r413",
      "r779",
      "r832",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r447",
      "r508",
      "r514",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r775",
      "r833",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r447",
      "r508",
      "r514",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r775",
      "r833",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r250",
      "r251",
      "r412",
      "r414",
      "r835",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r250",
      "r251",
      "r412",
      "r414",
      "r835",
      "r867",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r372",
      "r509",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesDateAxis": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date of execution of accelerated share repurchases.",
        "label": "Accelerated Share Repurchases, Date [Axis]",
        "terseLabel": "Accelerated Share Repurchases, Date [Axis]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesDateDomain": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date upon which the accelerated share repurchase agreement was executed.",
        "label": "Accelerated Share Repurchases, Date [Domain]",
        "terseLabel": "Accelerated Share Repurchases, Date [Domain]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accelerated Share Repurchases [Line Items]",
        "terseLabel": "Accelerated Share Repurchases [Line Items]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt",
        "negatedLabel": "Payment under ASR agreement"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesTable": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table reflecting activity in an accelerated share repurchase (ASR) program.",
        "label": "Accelerated Share Repurchases [Table]",
        "terseLabel": "Accelerated Share Repurchases [Table]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r39",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $85 in 2020 and $86 in 2019)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableSale": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease from sale of accounts receivable.",
        "label": "Accounts Receivable, Sale",
        "terseLabel": "Accounts receivable factored"
       }
      }
     },
     "localname": "AccountsReceivableSale",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForEnvironmentalLossContingencies": {
     "auth_ref": [
      "r347",
      "r370",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.",
        "label": "Accrual for Environmental Loss Contingencies",
        "terseLabel": "Accrued liabilities for environmental matters"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r32",
      "r791",
      "r815"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r97",
      "r105",
      "r108",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53",
      "r337"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r105",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r105",
      "r116",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r105",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": {
     "auth_ref": [
      "r98",
      "r105",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax",
        "terseLabel": "Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r42",
      "r101",
      "r104",
      "r105",
      "r817",
      "r845",
      "r849"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "negatedTerseLabel": "Accumulated other comprehensive loss",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r100",
      "r105",
      "r108",
      "r172",
      "r173",
      "r174",
      "r650",
      "r840",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r91",
      "r105",
      "r108",
      "r650",
      "r717",
      "r718",
      "r719",
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Cumulative Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of intangible assets, acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Other paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Other Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r148",
      "r326"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r596",
      "r597",
      "r598",
      "r599",
      "r781",
      "r782",
      "r783",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Promotion Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising and promotion costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r217",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other segments",
        "verboseLabel": "All Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r46",
      "r257",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r148",
      "r317",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense for intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r267",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r158",
      "r230",
      "r237",
      "r244",
      "r281",
      "r643",
      "r651",
      "r709",
      "r789",
      "r814"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r82",
      "r158",
      "r281",
      "r643",
      "r651",
      "r709"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r261",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r259",
      "r262",
      "r295",
      "r796"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Investments, debt securities",
        "verboseLabel": "Debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r517",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r662",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r20",
      "r336"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r504",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r504",
      "r510",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity interests issued or issuable (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r621",
      "r623",
      "r624",
      "r628"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r147",
      "r633"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedTerseLabel": "Business combination, contingent consideration arrangements, change in amount of contingent consideration liability",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Potential future milestone payments, maximum"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r622",
      "r625",
      "r630"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Contingent consideration",
        "periodStartLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r622",
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration, liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business Combination, Contingent Consideration, Liability, Measurement Input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r617"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "verboseLabel": "Other net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "terseLabel": "Debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r617"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income tax liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r617"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "verboseLabel": "In-process research and development (IPR&amp;D)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Identifiable intangible assets (useful lives ranging from 18-24 years)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r616",
      "r617"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r616",
      "r617"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r616",
      "r617"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed": {
     "auth_ref": [
      "r613"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed",
        "terseLabel": "Share-based compensation payments to settle equity awards attributable to precombination service"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r154",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r13",
      "r50",
      "r150"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r25",
      "r151",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r144",
      "r150",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6)",
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r144",
      "r715"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Hedged items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "terseLabel": "Obligation and Funded Status"
       }
      }
     },
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r634",
      "r635",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Environmental Liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r384",
      "r868",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies and Legal Defense Costs"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance December\u00a031 (in shares)",
        "periodStartLabel": "Balance January\u00a01 (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r111",
      "r113",
      "r114",
      "r123",
      "r802",
      "r826"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r122",
      "r131",
      "r801",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r253",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r253",
      "r707",
      "r708",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r253",
      "r707",
      "r708",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r211",
      "r212",
      "r253",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of accounts receivable represented by customers with largest balances (as percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r253",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r448",
      "r497",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other profits"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r127",
      "r779"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r356",
      "r357",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r592",
      "r602"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r163",
      "r592"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r592",
      "r602",
      "r604"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r592",
      "r602"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r210",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Loans Payable, Long-Term Debt and Leases"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r32",
      "r33",
      "r790",
      "r793",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r727",
      "r729"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Par Value of Debt",
        "verboseLabel": "Face amount of debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r706"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of loans payable and long-term debt, including current portion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Fixed-rate notes, stated interest rate (as percent)",
        "verboseLabel": "Stated interest rate (as percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r66",
      "r161",
      "r393",
      "r396",
      "r397",
      "r398",
      "r726",
      "r727",
      "r729",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "terseLabel": "Long term and short term debt"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r593",
      "r602"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r593",
      "r602"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r148",
      "r159",
      "r593",
      "r602",
      "r603",
      "r604"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Total deferred provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r35",
      "r36",
      "r584",
      "r792",
      "r810"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Subtotal, Liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedLabel": "Decrease in deferred income taxes",
        "terseLabel": "Deferred income taxes",
        "verboseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r593",
      "r602"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Equity Method Investments, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Product intangibles and licenses, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory related, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred tax assets on NOL carryforwards relating to foreign jurisdictions"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Accelerated depreciation, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Pensions and other postretirement benefits, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Compensation related, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r567",
      "r587"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Deferred income taxes, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.",
        "label": "Deferred Tax Liabilities, Inventory",
        "terseLabel": "Inventory related, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Product intangibles and licenses, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "terseLabel": "Accelerated depreciation, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r437",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]",
        "terseLabel": "Actual return on plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod": {
     "auth_ref": [
      "r452",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold",
        "terseLabel": "Relating to assets sold during the year"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": {
     "auth_ref": [
      "r452",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held",
        "terseLabel": "Relating to assets still held at December 31"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedLabel": "Actuarial (gains) losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r422",
      "r463",
      "r491",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Net loss (gain) amortization"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r422",
      "r464",
      "r492",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of unrecognized prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r29",
      "r420",
      "r421",
      "r445",
      "r497",
      "r788",
      "r813"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Salary growth rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r472",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Expected rate of return on plan assets",
        "verboseLabel": "Expected rate of return on plan assets (as percent)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Salary growth rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation December\u00a031",
        "periodStartLabel": "Benefit obligation January\u00a01"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r431",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r475",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r439",
      "r448",
      "r450",
      "r495",
      "r497",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "terseLabel": "Termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCurtailments": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": {
     "auth_ref": [
      "r448",
      "r450",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]",
        "terseLabel": "International equities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": {
     "auth_ref": [
      "r448",
      "r450",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, US [Member]",
        "terseLabel": "U.S.\u00a0equities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2026\u00a0\u2014\u00a02030"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r458",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r422",
      "r462",
      "r490",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r436",
      "r448",
      "r450",
      "r451",
      "r497"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value of plan assets December\u00a031",
        "periodStartLabel": "Fair value of plan assets January\u00a01",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Plan assets at fair value"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effects of exchange rate changes"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r420",
      "r445",
      "r497"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status December\u00a031"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Health care cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r422",
      "r427",
      "r461",
      "r489",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r459",
      "r487",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanOtherChanges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherChanges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r483",
      "r484",
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r483",
      "r484",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Plan amendments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r441",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effects of exchange rate changes"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r447",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Target allocation (as percent)"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": {
     "auth_ref": [
      "r453",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement",
        "terseLabel": "Purchases and sales, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r423",
      "r466",
      "r494"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r423",
      "r466",
      "r494"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r425",
      "r460",
      "r488",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": {
     "auth_ref": [
      "r454",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3",
        "terseLabel": "Transfers out of Level 3"
       }
      }
     },
     "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r481",
      "r482",
      "r485",
      "r486",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer contributions to defined contribution savings plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r148",
      "r335"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r148",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "negatedLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.",
        "label": "Depreciation, Depletion, and Amortization [Policy Text Block]",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, Asset"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r84",
      "r88"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.",
        "label": "Derivative Asset, Not Offset, Policy Election Deduction",
        "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Asset"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r83",
      "r87",
      "r706"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "netLabel": "Derivative assets",
        "terseLabel": "Gross amounts recognized in the consolidated balance sheet, Asset",
        "verboseLabel": "Fair Value of Derivative, Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAverageRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Average Remaining Maturity",
        "terseLabel": "Maximum planning cycle of hedges (no more than)"
       }
      }
     },
     "localname": "DerivativeAverageRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r85",
      "r88",
      "r686"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative, Collateral, Obligation to Return Cash",
        "negatedTerseLabel": "Cash collateral received, Asset",
        "terseLabel": "Cash collateral received from counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r85",
      "r88",
      "r686"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative, Collateral, Right to Reclaim Cash",
        "negatedLabel": "Cash collateral received, liability",
        "terseLabel": "Right to reclaim cash"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r663",
      "r666",
      "r672",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r660",
      "r663",
      "r672",
      "r681",
      "r682",
      "r688",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r692"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Pre tax net unrealized gain (loss) on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r671",
      "r673"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r83",
      "r87",
      "r706"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "netLabel": "Derivative liabilities",
        "terseLabel": "Gross amounts recognized in the consolidated balance sheet, Liability",
        "verboseLabel": "Fair Value of Derivative, Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, Liability"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r84",
      "r88"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.",
        "label": "Derivative Liability, Not Offset, Policy Election Deduction",
        "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Liability"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r657",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "U.S.\u00a0Dollar Notional",
        "verboseLabel": "Notional amount of derivative"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r668",
      "r672",
      "r685",
      "r687",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Designated as Hedging Instruments"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Products and product rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r504",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018)"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r63"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "Europe, Middle East and Africa"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r124",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r188",
      "r190",
      "r192",
      "r193",
      "r194",
      "r198",
      "r199",
      "r803",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders (in dollars per share)",
        "verboseLabel": "Basic Earnings per Common Share Attributable to Merck\u00a0&amp; Co., Inc. Common Shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r124",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r190",
      "r192",
      "r193",
      "r194",
      "r198",
      "r199",
      "r803",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders (in dollars per share)",
        "verboseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total, Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Tax\u00a0Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r569",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory rate applied to income before taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r569",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowances"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r569",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r569",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r569",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r569",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r569",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "R&amp;D tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount",
        "terseLabel": "Tax Cuts and Jobs Act of 2017"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent",
        "terseLabel": "Tax Cuts and Jobs Act of 2017"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r569",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Tax settlements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Income tax benefits related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefits relating to stock option exercises"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss": {
     "auth_ref": [
      "r373",
      "r375",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of reasonably possible loss exposure in excess of amount accrued for remediation, site restoration, postclosure, monitoring commitments, or other exit costs associated with the sale, disposal or abandonment of a particular property resulting from unanticipated contamination of the assets.",
        "label": "Environmental Exit Costs, Reasonably Possible Additional Loss",
        "terseLabel": "Aggregate possible expenditure on environmental matters in excess of amounts accrued"
       }
      }
     },
     "localname": "EnvironmentalExitCostsReasonablyPossibleAdditionalLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EnvironmentalRemediationSiteAxis": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location or named area designated for environmental remediation.",
        "label": "Environmental Remediation Site [Axis]",
        "terseLabel": "Environmental Remediation Site [Axis]"
       }
      }
     },
     "localname": "EnvironmentalRemediationSiteAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EnvironmentalRemediationSiteDomain": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location or named area designated for environmental remediation.",
        "label": "Environmental Remediation Site [Domain]",
        "terseLabel": "Environmental Remediation Site [Domain]"
       }
      }
     },
     "localname": "EnvironmentalRemediationSiteDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r177",
      "r185",
      "r187",
      "r202",
      "r285",
      "r392",
      "r399",
      "r552",
      "r553",
      "r554",
      "r598",
      "r599",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r722",
      "r840",
      "r841",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r705"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Publicly traded equity securities",
        "verboseLabel": "Publicly traded equity securities, fair value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Income on investments in equity securities, net"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r277",
      "r829"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized net gains"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r26",
      "r31",
      "r273",
      "r812",
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized loss related to unfavorable observable price changes"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative downward price adjustment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized gains based on favorable observable price changes"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative upward price adjustment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r694",
      "r695",
      "r696",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r497",
      "r695",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r694",
      "r695",
      "r698",
      "r699",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r448",
      "r450",
      "r455",
      "r497",
      "r695",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r448",
      "r450",
      "r455",
      "r497",
      "r695",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r497",
      "r695",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r700",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summarized Information about the Changes in Liabilities for Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r450",
      "r693",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "NAV"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r701"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments",
        "terseLabel": "Payments of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r497",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r662",
      "r668",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Estimated aggregate amortization expense, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated aggregate amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated aggregate amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated aggregate amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r318",
      "r322",
      "r325",
      "r329",
      "r780",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r318",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r325",
      "r780"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedIncomeInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments that regularly generate a fixed amount of interest income. Examples include, but are not limited to, bonds, certificates of deposit, notes and debt securities.",
        "label": "Fixed Income Investments [Member]",
        "terseLabel": "Fixed Income Investments"
       }
      }
     },
     "localname": "FixedIncomeInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Jurisdiction"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r711",
      "r712",
      "r713",
      "r714"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Exchange losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r448",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).",
        "label": "Foreign Exchange Option [Member]",
        "terseLabel": "Purchased currency options"
       }
      }
     },
     "localname": "ForeignExchangeOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r448",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Foreign government bonds"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r503",
      "r507",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward Contracts [Member]"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnContractTermination": {
     "auth_ref": [
      "r149",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.",
        "label": "Gain (Loss) on Contract Termination",
        "negatedTerseLabel": "Charge related to the termination of a collaboration with Samsung",
        "terseLabel": "Gain (loss) on contract termination"
       }
      }
     },
     "localname": "GainLossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "terseLabel": "Gain (loss) on sale of clinical development programs"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Litigation settlement, gain (loss)"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r304",
      "r306",
      "r787"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Intangible asset impairment charges"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangibles"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r154",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r307",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r148",
      "r305",
      "r310",
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairments",
        "terseLabel": "Goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r684"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r660",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss recognized as a result of the initial and subsequent write-down of a long-lived asset's carrying amount to fair value.",
        "label": "Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss",
        "terseLabel": "Fixed asset abandonment costs related to contract termination"
       }
      }
     },
     "localname": "ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r148",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Intangible asset impairment charge related to marketed product"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r148",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "verboseLabel": "IPR&amp;D impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r148",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Write-down of assets held for sale"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r54",
      "r154",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r162",
      "r605"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r119",
      "r230",
      "r236",
      "r240",
      "r243",
      "r246",
      "r785",
      "r799",
      "r805",
      "r830"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income Before Taxes",
        "totalLabel": "Income Before Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r162",
      "r605"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r120",
      "r148",
      "r227",
      "r278",
      "r798",
      "r823"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity (income) loss from affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r504",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]",
        "verboseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Acquisitions Divestitures Research Collaborations and License Agreements Transactions [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r574",
      "r581",
      "r583",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r570",
      "r582",
      "r589",
      "r600",
      "r607",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r186",
      "r187",
      "r228",
      "r568",
      "r601",
      "r608",
      "r831"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on Income",
        "totalLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails",
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r154",
      "r564",
      "r565",
      "r582",
      "r583",
      "r588",
      "r594",
      "r870"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowances"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. statutory rate applied to income before taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "R&amp;D tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount",
        "terseLabel": "Tax settlements"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r145",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r321",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r321",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r154",
      "r324",
      "r776",
      "r777",
      "r778",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Acquired Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r316",
      "r323"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other Intangibles, Net",
        "totalLabel": "Net",
        "verboseLabel": "Other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r117",
      "r224",
      "r725",
      "r728",
      "r804"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r448",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap",
        "verboseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r154",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Software Capitalization"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates current cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedLabel": "Decrease to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r14",
      "r77"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories (excludes inventories of $2,197 in 2020 and $1,480 in 2019 classified in Other assets - see Note\u00a07)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/InventoriesInventoriesDetails",
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r24",
      "r78",
      "r154",
      "r201",
      "r300",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials",
        "terseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory Write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r129",
      "r223"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r280",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r822"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LIFOInventoryAmount": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.",
        "label": "LIFO Inventory Amount",
        "terseLabel": "LIFO inventory amount"
       }
      }
     },
     "localname": "LIFOInventoryAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r19",
      "r52"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r61",
      "r158",
      "r238",
      "r281",
      "r644",
      "r651",
      "r652",
      "r709"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r45",
      "r158",
      "r281",
      "r709",
      "r795",
      "r820"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r64",
      "r158",
      "r281",
      "r644",
      "r651",
      "r652",
      "r709"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Available borrowing capacity under credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r68",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Legal defense costs reserve"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Long-term debt, current maturities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r165",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r165",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r165",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r165",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r165",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-Term Debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Effective interest rate (as percent)"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r66",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails",
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails",
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Loss contingency, claims dismissed number"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss contingency, claims settled, number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss contingency, number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss contingency, pending claims number"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r20",
      "r336"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery, equipment and office furnishings"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery, equipment and office furnishings"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r16",
      "r62"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "verboseLabel": "Unallocated"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r73",
      "r158",
      "r281",
      "r709",
      "r794",
      "r819"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r205",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Used in Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash (Used in) Provided by Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r144",
      "r146",
      "r149"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r109",
      "r112",
      "r121",
      "r149",
      "r158",
      "r176",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r191",
      "r230",
      "r236",
      "r240",
      "r243",
      "r246",
      "r281",
      "r709",
      "r800",
      "r824"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income Attributable to Merck\u00a0&amp; Co., Inc.",
        "totalLabel": "Net Income Attributable to Merck\u00a0&amp; Co., Inc.",
        "verboseLabel": "Net income attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r109",
      "r112",
      "r186",
      "r187",
      "r647",
      "r654"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net Income (Loss) Attributable to Noncontrolling Interests",
        "verboseLabel": "Net income (loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside of the United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r399",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r657",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of Interest Rate Swaps Held",
        "verboseLabel": "Number of interest rate swaps held"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/NatureofOperationsDetails",
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.",
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "Separation Costs"
       }
      }
     },
     "localname": "OneTimeTerminationBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r736",
      "r742"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease, cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r732"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liability",
        "verboseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r732"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r732"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r734",
      "r737"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r731"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r740",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r739",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term",
        "verboseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r730"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Operating leases, rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Valuation allowance on foreign NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "verboseLabel": "Total segment profits"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r662",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r99",
      "r101",
      "r467"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedTerseLabel": "Prior service (cost) credit arising during the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r101",
      "r106",
      "r107",
      "r467"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Prior service credit amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r93",
      "r94",
      "r101"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized (loss) gain on investments, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": {
     "auth_ref": [
      "r105",
      "r716",
      "r718",
      "r722"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r105",
      "r116",
      "r716",
      "r718",
      "r722"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedTerseLabel": "Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r92",
      "r101"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized (loss) gain on derivatives, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r92",
      "r101",
      "r665",
      "r670",
      "r689"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of (loss) gain recognized in OCI on derivatives"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r101",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "(Decrease) increase in Sales as a result of AOCI reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r674"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r675"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r110",
      "r113",
      "r116",
      "r122",
      "r392",
      "r716",
      "r721",
      "r722",
      "r801",
      "r825"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other Comprehensive Loss Net of Taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r110",
      "r113",
      "r641",
      "r642",
      "r649"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax": {
     "auth_ref": [
      "r98",
      "r101"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r98",
      "r101"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Benefit plan net (loss) gain and prior service (cost) credit, net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r96",
      "r101",
      "r467"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Net loss (gain) amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax": {
     "auth_ref": [
      "r101",
      "r106",
      "r107",
      "r467"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r101",
      "r106",
      "r107",
      "r467"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "negatedTerseLabel": "Net loss (gain) amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r662",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "verboseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r417",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other Intangible Assets, Net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other investments.",
        "label": "Other Investments [Member]",
        "terseLabel": "Other, Other investments",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r63"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other Noncurrent Liabilities",
        "verboseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncome": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNoncashIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities",
        "verboseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 5.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "negatedTotalLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r419",
      "r420",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r472",
      "r473",
      "r475",
      "r478",
      "r482",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other Postretirement Benefits"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r132",
      "r135",
      "r164"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r142",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "(Payments) receipts, net"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid to stockholders"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r133",
      "r260"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire equity securities classified as available-for-sale securities, because they are not classified as trading securities.",
        "label": "Payments to Acquire Available-for-sale Securities, Equity",
        "negatedTerseLabel": "Purchase of Seagen Inc. common stock",
        "terseLabel": "Payments to acquire available for sale securities, equity"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Three, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of VelosBio Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessThreeNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of ArQule, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r133",
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid for acquisition of business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Other acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "terseLabel": "Payments to acquire intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Payments to Acquire Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of securities and other investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures",
        "terseLabel": "Payments to acquire productive assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r447",
      "r449",
      "r455",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r497",
      "r499",
      "r500",
      "r502",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r32",
      "r420",
      "r421",
      "r445",
      "r497"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34",
      "r420",
      "r421",
      "r445",
      "r497"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r418",
      "r420",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r472",
      "r473",
      "r475",
      "r478",
      "r482",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r502",
      "r503",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefits"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r475",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r138",
      "r141",
      "r164"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales of securities and other investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r136",
      "r547"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Cash received from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductionRelatedImpairmentsOrCharges": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.",
        "label": "Production Related Impairments or Charges",
        "terseLabel": "Inventory write-off related to contract termination",
        "verboseLabel": "Inventory and fixed assets write-offs"
       }
      }
     },
     "localname": "ProductionRelatedImpairmentsOrCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsDivestituresNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r109",
      "r112",
      "r143",
      "r158",
      "r176",
      "r186",
      "r187",
      "r230",
      "r236",
      "r240",
      "r243",
      "r246",
      "r281",
      "r641",
      "r646",
      "r648",
      "r654",
      "r655",
      "r709",
      "r805"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net Income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r53",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r52",
      "r336"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment (at cost)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross [Abstract]",
        "terseLabel": "Property, Plant and Equipment (at cost)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r27",
      "r28",
      "r338",
      "r821"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r27",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r105",
      "r108",
      "r716",
      "r720",
      "r722"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "negatedTerseLabel": "Reclassification adjustments, pretax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r105",
      "r108",
      "r116",
      "r716",
      "r720",
      "r722"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTotalLabel": "Reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r102",
      "r107"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Tax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r236",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Segment Profits to Income Before Taxes"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Payments on debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r561",
      "r881"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 3.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r154",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Charge for the acquisition of Peloton Therapeutics, Inc."
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r153",
      "r786",
      "r816"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r13",
      "r25",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Funds collected from factoring of receivable, held in restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r350",
      "r353",
      "r360",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring costs, cost incurred to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r350",
      "r353",
      "r360",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r350",
      "r353",
      "r360",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Expenses",
        "verboseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r148",
      "r349",
      "r356",
      "r362"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 4.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Restructuring costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r352",
      "r356",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r351",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending balance",
        "periodStartLabel": "Restructuring reserve, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r41",
      "r399",
      "r555",
      "r818",
      "r844",
      "r849"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r177",
      "r185",
      "r187",
      "r285",
      "r552",
      "r553",
      "r554",
      "r598",
      "r599",
      "r840",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r478",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r503",
      "r507",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r478",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r503",
      "r507",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r472",
      "r473",
      "r475",
      "r478",
      "r482",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r472",
      "r473",
      "r475",
      "r478",
      "r482",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r118",
      "r158",
      "r221",
      "r222",
      "r235",
      "r241",
      "r242",
      "r249",
      "r250",
      "r253",
      "r281",
      "r709",
      "r805"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r738",
      "r742"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales",
        "verboseLabel": "Total sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectsofDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r105",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Changes in AOCI by Component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Information on Investments in Debt and Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r265",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummarizedInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r66",
      "r161",
      "r393",
      "r396",
      "r397",
      "r398",
      "r726",
      "r727",
      "r729",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.",
        "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r481",
      "r482",
      "r485",
      "r486",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r663",
      "r672",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Location and Pretax Gain or Loss Amounts for Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Calculations of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.",
        "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Effective Tax Rate and U.S. Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.",
        "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Sales of Company's Products"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Summary of Expected Benefit Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r318",
      "r324",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r313",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r313",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Goodwill Activity by Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Income Before Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Other Intangibles"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Summary of Interest Rate Derivatives"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r24",
      "r47",
      "r48",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Effect of Net Investment Hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r671",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r354",
      "r355",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r354",
      "r355",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r351",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r125",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Consolidated Revenues by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r118",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r230",
      "r233",
      "r239",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r230",
      "r233",
      "r239",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Equity Income from Affiliates and Depreciation and Amortization Included in Segment Profits"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r529",
      "r534",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Nonvested RSU and PSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r517",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r522",
      "r534",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summarized Information Relative to Stock Option Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Determine Weighted-Average Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r69",
      "r156",
      "r203",
      "r204",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Summary of Common Stock and Treasury Stock Transactions"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r581",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r217",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r253",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r219",
      "r220",
      "r230",
      "r234",
      "r240",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails",
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Pretax share-based compensation cost",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Period over which share-based payment awards vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Contractual term of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Nonvested December 31",
        "periodStartLabel": "Number of Shares, Nonvested January 1"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share)",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares collectively authorized for future grants under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Number of Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r524",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding, December 31 (in shares)",
        "periodStartLabel": "Number of Options, Outstanding, January 1 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r516",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price of options granted (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r154",
      "r517",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Quantity of stock options that vest per year (as percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r540",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.",
        "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted-average interest rate of commercial paper (as percent)"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SiteContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Site Contingency [Line Items]",
        "terseLabel": "Site Contingency [Line Items]"
       }
      }
     },
     "localname": "SiteContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SiteContingencyTable": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from an environmental remediation obligation.",
        "label": "Site Contingency [Table]",
        "terseLabel": "Site Contingency [Table]"
       }
      }
     },
     "localname": "SiteContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesEnvironmentalLitigationandMattersNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Capitalized Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r2",
      "r217",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r253",
      "r313",
      "r341",
      "r353",
      "r364",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SegmentReportingScheduleofEquityIncomefromAffiliatesandDepreciationandAmortizationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r71",
      "r172",
      "r173",
      "r174",
      "r177",
      "r185",
      "r187",
      "r202",
      "r285",
      "r392",
      "r399",
      "r552",
      "r553",
      "r554",
      "r598",
      "r599",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r722",
      "r840",
      "r841",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r202",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r37",
      "r38",
      "r392",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "negatedTerseLabel": "Issuances (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r38",
      "r392",
      "r399",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r38",
      "r43",
      "r44",
      "r158",
      "r258",
      "r281",
      "r709"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Merck\u00a0&amp; Co., Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Merck\u00a0&amp; Co., Inc. Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' equity before deduction for treasury stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r158",
      "r172",
      "r173",
      "r174",
      "r177",
      "r185",
      "r281",
      "r285",
      "r399",
      "r552",
      "r553",
      "r554",
      "r598",
      "r599",
      "r639",
      "r640",
      "r653",
      "r709",
      "r716",
      "r717",
      "r722",
      "r841",
      "r842"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r399",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Share-based compensation plans and other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r723",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r723",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r723",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicenseAgreementsAcquisitionsNarrativeDetail",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect",
        "terseLabel": "Adoption of ASU 2018-02"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Transition tax for accumulated foreign earnings, liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current",
        "terseLabel": "Transition tax liability, current"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as noncurrent.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent",
        "terseLabel": "Transition tax liability, noncurrent"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "totalLabel": "Investments"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r267",
      "r268",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r70",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r70",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r38",
      "r392",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchases of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r70",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "terseLabel": "Less treasury stock, at cost: 1,046,877,695 shares in 2020 and 1,038,087,496 shares in 2019"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r392",
      "r399",
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Treasury stock shares purchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r596",
      "r597",
      "r598",
      "r599",
      "r781",
      "r782",
      "r783",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofCollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesRelatedtoRestructuringProgramActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringChargesandSpendingRelatingtoRestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r448",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r563",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance December\u00a031",
        "periodStartLabel": "Balance January\u00a01",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements",
        "terseLabel": "Unrecognized tax benefits from adjustments related to examination"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Liabilities for accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties associated with uncertain tax positions, expense (benefit)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions related to current year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions related to prior year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapse of statute of limitations",
        "negatedTerseLabel": "Unrecognized tax benefits, reduction resulting from divestiture of Merck's consumer care business"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Favorable net impact to income tax provision if unrecognized tax benefits were recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesLegalDefenseReservesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Common shares issuable (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r189",
      "r194"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Average common shares outstanding assuming dilution (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r188",
      "r194"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL116659650-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13283-110859"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13296-110859"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6395460&loc=d3e13647-108346"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB TOPIC 5.Y.Q2)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB TOPIC 5.Y.Q4)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(b)(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117332851&loc=SL7495116-110257"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL75039408-165497"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r882": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r883": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r884": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r885": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r886": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r887": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r888": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r889": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r890": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>143
<FILENAME>0000310158-21-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000310158-21-000004-xbrl.zip
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MH,;IZ=,3>%$D234<<YB>-M&@_C[VPV9D.&@]M.(H'<!QN_64=ORN?]&_[GP
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M$E\%J/7MLBQ; ?B6,]"8:>EJ[G1)\/X1ZE<PR3Q-H9PR(YJGC0GGF_N)(U4
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MUZ4[E>&$WGT7!@"^V)[S/\]P6NW93VH"YEZ18JW&KLP2Y4;W$BJ++(7CBEB
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M^\]9!".L.&],D#*ZD3)12]&3U/G=H%@DOG]Z'[7X"_'NJK>*W>7@7 (9PV(
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M'Z;_7L2R([BXQU^R-QQX3J9A7K+6-5^*<;B\9U);DP>FJ2=OZBD46TM\-M4
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MS5+E17MW#Y?<_]CO75V<G1[W1+?7ZY]?=4][_<<J)4K5!W*  A-T!SYAY"S
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MF8JNU1;7170S554RPI1B[Q(R48.\:CM-3VTN$IT%+\,'!C=LJ)=0FSCI-DK
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M'B?[]RRF'N2Q%W4.!8"1Y\*):IO[[?M[*?48':U3T>4^1CM*CJ\+F"ZS/#M
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MA .,!+U R(!(B0AT1TE$)71'20N,'$LG:GW:\@[@@9"'_6P?AH%8E;]S/\Z
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ME8(=90=@@_JH@BL^1F&:N%B$DHGL^2TS@>9!*6@#.T$*!!"@5P,(D"(P.XE
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M[0ES)8;Z AXT!1!2YX44*C@*=\MOP)NF5PG>=")H](5IL-V:A.4(4@ &2AC
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M2/)\KQZ;?.?6;]?F 5(_A::? 5!+ P04    " !6A%E2IK+25+D&  !?.0
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M&^Z(78<'C+A-)ANQ>PS=UZ;2FU"Z&6)LM.WM:!M7#/8-.&*2.5X4K+>X76#
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MI=L]9=>M[<[+ZNHW7)W[2_SS7P%02P,$%     @ 5H194E2Z9ZA1!   J@\
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M=1O9>6_<O,TM5M^GQ[\!4$L#!!0    ( %:$65(_GY0E< 0  -$.   >
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M;<-U\_H@]/Z+!VM5EMZ+3)UY2G]4"H3MD"#\!X'@AH5;MHIY O-R$S?^;^(
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M5Y>D=X.4@@(#DBX%6W-UA6A4@M&1QUBUL9JP 6NEA2JAIG.EA$*:\"G;DCE
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M@Q86A<EFTM+[Z*'.:?!@+K)KJM+V$RKD\J9; @=0P9_91-3J#\%((2LS70L
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M3(@+T#Z17#U3$)@=!Z;B.G!WOE1U .Z%EO$,GS#5Q"R4>#NGO@31I:+#/CG
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M]S"*?!)-?01H"JR$(:;LSBO.U#(P63E=IA?XCOM8KFXMM 87E@ "R7>9(?Q
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M9R _V6X@WY]4V9K^F;>+XOO_#U!+ P04    " !6A%E2P<IR7=9&  "_K $
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M<!8@TM?#86I&:28S0/ +V17O"NYD7E_"V9E=XNR$17 3XQ.2%&.^CTK&K"B
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MY^3FF84=[M^LGE4QQ3A]PB?BC'3*XR.IH(WN%<<L_Y'WW%"&$^\2W>(6.+@
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M@C.MA+0D6D#JVN8&!HG3.4 ZPAE8N'NIZT0Q,(G;O$': AJ*#9-15:ISG1F
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M6S-0UU$#RHVAI8Y4)%@($)&921LXK6XSE?ZV-&7T:U*?F3;ZO:M)56WV+I.
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MRQY\+-_@<M"BW^.%?GUV^=6;YZ<X?^_\>3_'1XD17*A:$!L]"%)0DE)<;M3
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M0 0!DA13&\9*&(VUIVL<M@O5S2<)-P*T,:1!$WL@#^(R(H6&>RUM^%;FLH5
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M=A%QU7" FC"5T*M)Q+"SK)"4$ACEK8%F RFR-<($WB=RW$RB74WO=DWCQ:0
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M,?LQM5B_ "=OS?OF._^CO'_T;&+D,!GI:LT1K:^1+#3U@:[O$\Z48LZD"4;
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ME_;*XEC+]S.6V?[L:+:%B8)+L8V9O3*E7%UST-461!MR-A@@@DJ&R39.M-R
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MQ)O9WA)25K6U[R (*1FFQMWL<@I&$E,8;H'+<-<=;RM;+Z6X)GB+6F+CH:T
MP6%(WD2?&5T B=NSH&DBX#"7,D7BG,AZ;,P#3;%S+:DW:#7X6-/66, -K*C;
M?B*NL\RP[U,(TG=10@@V,[L<D]A:,(EQNC66<"+BP"VBBR7GD"VY!+%/9R&
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M@!UYX\6R@D'(V3)5#Z2K+H@FUBFGM%4U3QN*Z$5<\:&OOP2-S7Y(;PL<;9:
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MJWN'\WS]Z+K.[*D8$TOC9^ ,Q5MFL.B<IYRR1IQDZD37(5E7];GO0@G-\0N
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MX+$D*YU&G[!2;/862 DC%T1?+5JUE*=E'P,B\% X4Z(-%K(H)P6MEEHT;8J
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M.,G/H5,8_W_VWFT[KN/(%OVBULA+9$9$OU$7=VL?V=*PU'W&V2][Q"TI;),
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M=+/0C]L;WE+EY2-L]\;Z]&7,7Z(=Y4P+(:SS^#(H,RJ89UJ:;BAY:KIM3CS
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MIAW9^F'<A91VOX.Q*&70T3@X\HAM90<65+\@=[$G6S^,D!G&6 AG9!#0><A
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ML=2=5Z?\\=ES0-]SE![YTC,,P>Q!!,DJYPXYC3 *L&ZK>N7X['D<R86]$(J
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MM&^>;%%L07CG$/:6>[9*)3!!)U:?01=C35U">E_5!0O"NXBZCE)34*R'^1A
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MN7>G 86DL-CKNBG:,V&6JUG,^?7,H?/E&R51@FI]:W4:)),_*;A,\@PJ-0[
MG(>'YW(UCX@P58)2V_K1<X8257DR9>A6=]BVF;Z+,+N#YZK)?2"N!/8$Y,!=
MIEOI*A:1RJ1*3N@A:7%E=UQY3/ T\*FBJ=MH",B#C&V^3<@H7-'^SZ?;U6Z:
MH/JWO5<-+/FP*/0+%)HT.=U].J'PNF!A@CK]0*(?/_<#O/W'A_X=W]Y\YC?=
MO^6@#BDI$;@62=UK8ZB9'23I@?CV\*!>HF/1[&?JB\L '3TT!H,4G4ZM-V)K
MJ#5%\T6S_8)Z294C,&RJ&1EUR, >0*730)W,RL4P)IMP,6R_#%N@_KE+QZ[-
MA]>2&8 ;<AK%R&B[6MEBM W4F;\'];YO'Y<:6GQ[![YE_M5\^^F=Y>]20T6D
MUU'$%,2,B@LKH>$VUI2.Q+>'!_520XMF/U.B+ES<$^;)+JA4R$<M&IVLBH3"
MHME^0;W4T!$8-H:4XFPM#]@J/77+.0S@.KU:DBR+8?MEV +USU7?#[%H59I3
MAM0*)YOJOI<HF/K(:?^-I$L$+9K]ZEO5,W:P$G-5](I6.]2>J4UY ^1:$01C
M#0Q8<F81YN\2 8S>K$[9CQE:@ 8IM9YX\F?DQONODEFNYO<QYU%W3)ZQW,Q*
MXZ@C>DG;LBUU46R#MTVFU/(JS=P]6O?G]QX5?YH$2!L&TQ%YS32\Y>H%TN@1
MR19_+HH_CS1A]GZH$X&C61\X*MQO_BWAQHHP O (#6B/G3J/":W),X:7K3PL
MP1"6&#QHBI#<3*8#.%#]RI(>BU%'J[3QX90]9YY!%3"93M(!!@7$1D<Y$/T>
M.\:78#D,ZWH!&*R)>0Q@0!%GRD*E37'3<!5M7BCK'JG,>7C"1>L562KT^9_5
M0IX30N(:16K*JP_A.(1;&/\Y)=5DZB8'[4A02I4.O6 1B%ZE"1ZH]F4IJ46_
MHU7IX+;M:]LLB1W!J!'DWBM/1U-CF^EZ(/H]=HPO)748UL&DEZ3*HMV@):6H
MPXM7"6/-_4A.;[%N*:G]$ZX I482$91!/"N:1: 0BS5R6X0[#.$6QG\N/6<9
MS&PPRE1/3!H^'0P3>._%Y ";>W[36?J)W'[[Y-JWOS[[GY=7W\FS#RF<[D_R
MKVYN[TX_//"M'W]O0]D/N.NO&8:VE"!2AQI#)/G4*L.)<AZM+50_$(#.MI[^
M0U)L+Z@&M3PDL%4-P&CJ8&7B#K=B_SYDH7KG0#IZN/*>]K*.*CS?&B+HUH+/
M +T(04T\#^O]HWKOZTX>.>OV O3<N!5-M+4U0JU%"U;H";>=;:WI 180+R#M
M D@51Z^]0G+KD !9VDBMU1+HJ:'M?T_)(P?2Y6BV,RX3J=S:/ MK\L';"E;J
MPXL.L,HVJ/6%ZJ79/M!9?494=^9P*\:="0B3>H<<)26L][-P%JIW#J3+T6QG
M1+4B9^>B?0HTH&@3W8B1:U64W-,!4+TTVZY9MQ>@6XPRC^TNB!VTJ8Q63#"5
M[7XD^@JU%Y!^Y7@6%1Z=1Q$&J,W9DV"II8QMLQ$=0/Q?K-/])8'T?JBVU5)]
MNCW]S8OP/\KI+W%WNW'M;C[BW2JK]I*62,$N27'4XJ"@G%"DSFA7 TP1]P_Q
M1ZN6%L1_Y5U%-<L"S"430 ENB=)@LL[6BQ_@KF*7J/H0TFE!_%<F+)(.5F]B
M0R'E(0A*G+1UA5)'V3_$]R[M=DG!1X[ZX#Z576M= J [R ;YWO,VL+I_OX]W
MWZA?J-HAJF8T/&-B<XD,(P<CFHRD>73HENK^LP>[1-42??O):\1HG1J,*E(@
M3_G'0\!]V(CF\7I@\[XAOD3?@OB_ONSH)6R#N6F",;+, ]W*2#C?C-"R?XCO
M$E5+].T'XN&)I)01V,M4>:&)6M7$8U@GE;9_B"_1MU#_KJBWAM&'UAF<S_"\
M((="4%7GU+3G USN+53M#U78FNDVU+%: :/,M8Y>S/L$ETLYP$W?.QOPL^=Q
M>GIU_?1WV>_8H-]]I>8Y4\22B1MP*7E %+A/#'NECMG9&RR$[P!,AY2D>T&X
MI'+?J@$>#%T[0<9*#32&0TH'6*:S<X1?[!E^E*X[=<U:-")M77<@0IXZ:\JZ
M_2L?X"9[YPA?@G1_H(\>@SP7UQXP3W>2*IVER1A%<O "_0+5.X,*J@"CF-@8
M,+"I],)@0P!<FX[]9Q$6J"Y0[YTS.YR;8 ;+17G&!J(UB1M1SU6AQ0'R9#M'
M^-)[#XQP<.^UE(:^'>:J8HE'GF^MZ-!^:;VGZPP_AMX[YQE>9 H]R-DY06Y;
M:@,U2A6=1WOM>2%\Z;V+.]:1M(LGB;P--/S_V7N_-KMNX]SS$\WS *@"4'7N
M%"=Q/.,X'OLD%^=FGOIK<PY%*DU2Q\ZG'RQ2DA7/L:68%/=:O4"INW?O;G:S
M&[\7>*L 5+F29U9H7#LD:[_ X:230W]+J+I-+LU[:6M"'2%,=?+L' 9=:!\5
M_DR[QC]__74\O3K^<5^\\B]^%Z_LC_^B+U_\[GU!V=/-\A?<YG/J45)I4A',
M,5:\5RIV5:;H@_S\H-\VKKJ&ZLX">@,/*2#AWE!RKOAO>66>.*,9X@5.;&RV
MGF\0^"E3U:91%M%U*""G,G-;L"_^'>JXPJ;?CK*N)L2SL#]DM%%5<R"@U535
M4J<5 C%J(\_/_F;KK&P5YA43TH1"B!V782Z]8)46#9D#SY]GV&P]WY#P$^8^
M6*;R9*5*%6<UU9;H P_^)^ISOB>R0\+3S^B?$O0!W477RU!T&I(5!144 KQ>
MH<3R9NOYAH2?\@X4BYEVD4J)R[EHQZ)I#5HI[E>X [5#PJL)\2SLU^*SCR*@
M 5B6!K ORTX\NL_E="[@9C9;9V6+N3HX3>XQL:\ $53$AUCMV+1=X ;)*=FZ
M=NF7?WSQA_!?O++77\;E<QX:C%DXE10QJ%,"5ST.A(Z0A>+Y =^AX ;\KR7U
MP"T3)F@S7#,V<[+:FM%]UJ0KE+,])5/7+OORG  7K*.Z=>!.2&$\89&M;;V5
M8?F<9_ =^MV4^8KD=M1B'#@0U#@RIG+E<%B^_ )GFC939V.JJ)<&:\[, 0@^
MF+KUTGPYX\SL%[@ >$JF=JAWEES&9"2$49#[0%Y!7\68M<TN"_*>\_R [U!O
M _[7DG6]S5&R",=$.XJ_.9+8H![+#E_A<M0IF=JAWED IQ'%JR!:,VR+/05N
M.0BSUYQT@8M0.]3;S/\7)W6/,*Y@@8&-G<IT9^=,Y2)#S\_\9NIL3-59";*7
MA"04J-S6/,ID@J4H\P529I^F..L??QOV[NG]S=)G/8&>_FSG)TQCD#K;.'K>
MU.5^1])8-J&+<N?T5-EL/Q2C2X:?9V%;9P?1H0T+(H/J5(48S6L+=]ML7P.G
M4T6>9V%[9,:,YIU:Q0HN,-50 WCT!FZ;[<^/T3,,.L^"NS)V+S$]!8ZCRC33
M6&&L)T(;7*#\QFEQOR-.5 >4@3H#5Q#7D)V&CZ%C@C68?OXLP<;I645TGS+K
M6RR<*1D;("J)@AW[&CE&+S@OD/4]+=L[HGOTGK2PLG3$ 1/+>JQ0-7VVRBT&
M7.#*]6G9?K;S]E7NY$DMJ5)YK)@.&U4V*<5,:GAWUNU)=D3WG*9RB:DZ0*!5
M05>3ECE\>F<47@+8N&^<_BME"Z'7O@QOH'4D7K:WET[IB*+B\P+=R4ZY '_B
M6YW?VQ4^T2Q_P6T[J]':Y.)E!7=YX!X<HQ3-Z4?%SO/C?MM8ZDK:.PON,,7*
M:+G"O(JM@_"$K!_ZJ\[6]ZV\RQ+V?$+!3UF:=GCK%;6'*6:9G-&']@FN59;1
M.3_N.^*ZIAS/HH#248NC3;=$%V=8,WT;E:%YM7:!HQN;L',3EJ00@8TH*P*F
MRI16I)@QT_QP..C<^8=-V DLQ55V!55CR-3(YH2MNE#J<9@Y2RCE%2X[[8#Q
M MH["^XL['661!N)9+YL]/1F!^MU&E]@HW 3=H+9_2I[APRIO24/5$.,9"JS
M)V%HRYX)Y\=]!XS7E.-9% ":U4:$E:+8M1)WL^$ 0=J7*,ZO@$W8N0E+&TA-
MK"%,G,R\8L644FHK,"?I3DE\'L)^]OKIJ]=/ZP-7,A)7V5<$9)68A 4(H5:"
MLB;3P;2L!01<X*KK#A-/J[BS0-X'&8EF$#".Y/6*);BH<FB77:7Y8EP]GY#P
M$T(>P:,J\U'3"%NT!7DI&>%0ALF\ .0[)+R2",_"O74?XNE0@["/PB&I3"V%
M9BE]'P3<7/UMUZJ$)SIR+:UA\<F5:J*U,;S.A+U?>#&NGD_X]RD/Y8-5[U2P
M%SAV3'A2;RVB01MMX*[YN1W"]1-YCGWY@]J[+\@-70RF%RX1E:#V"URTVEP]
MS_#O4^Z'S++L+L><,W%$H38E67!%@PEC/N?S'CO\N_'DOH*]5H;4V:<@-53V
MY5SB*-6O)>T"U0\V5V?DRC-JK>A:O*%#IVYM.89N, C!+Y!.>QY<_?/KI[>_
MD]_%L;M\?,[?B?W/\#_A='H#<96=0'<H2L-M'/LC-KG/3LM5'!T H\,%\F@[
M%+R$^LX"?"[,8ZQ(4(?AG*C&"<G1:F7(!N<'?C-VBAG^*CN$6:!@:1ZL@<!#
M7&:T;*U7TLD7.-"T0\2K"O(L&I@T&M<5&B[D49;+8>T\I[_W^CXNX'(V8V=G
MK I$FUDU.R%+(Y""'!I$6A$ND(K;C)W"6%QE%W'AWJD0,"BA*2EUHBS:5-8;
MOL!6^0X=+Z&^LP!O02,:2DEU[.G:D6T264L);!< ?C-VBAG^*KN+#"M>K%F7
M51:L)EJX+4>#K=9T+_W\P._0\:J"/(L&VBS5R:B.UK&C$K<E "ODK64K^QC)
M9NRC&5L\I7.S"EYQ:A6)+*,O&*:,'A=H>W)*QDX?C'W*1E%EP,SC((0!<CFX
M$<60E"9)C<^/T&V#L;,@U'P$]:ZEEH(51;LIDPQI!U2YJV\^TX#A4];S\\&T
MG)$1=UQ! [M+7Z-<WQ=KT#P_0CM@."%5NN:A7GJ5$EC:6M#Z\MX3O$R/CK8M
M^/.T1Y^RJL>8)69K:WWK6  5ZZ@>$@*5)ES@O.BV1X\^&JH$G:MW242M?A30
M -$I7@._::%];H2>[2QTE7QJM19MH#OHBLV.XS<^!:3U,ALGQ/D1VO;H?%1Q
M">=@[QJ)44A]/1YJ"AG3_0)EY/]+R<"__)?^O-'2O_Y$K99^^]7K5V]>/_WR
MM;V_\/#AGV6OW[UZ^_3'__:OO_W;O]V;I[?_[3?RZG??0'N\^\\O7KWX\MV7
M%W'JNM9&, @.Z-BA4U$>.LQ@M#[R OUJ3HOB_XX-^<./8.,S0WX6%+/75D9I
M51:3QD.:YZS96N-2ZKC L=>?",5?O7ZU)\;/GIY?H+7HI1H(=G?.M%ZCRM1*
MXPH%]\Y,XYX;_VLTBL"*7QMV SB:+!,4 E0?Z6EZA:)A?Q.-W]LB_L6KK^/-
MV^.;[JGP,\.'X+J6XI*0=/0T5"K%C;6I36)YKN'*3P/?GOG^BQD8J=2I-9GI
M6+CIT7BJ.847T%(NL$W^-[0C_O._\#-Y\WMYY>]S(9O%QZW"&39JJ)0CH=R9
MZD0/2\85+7M<@,7G-1ZC#4,([''4TAE-P\PJ+Y.T9H9:[/_Y^^/;K4?U_]@#
M\Q<&9OWRG][^_9J%/@S-^E65[X;F3Q_[[I?F?_K4_S2*WW[D;QA%F&Z64_N*
MJ]!BB-7DPI4D2EE/'*-8^9M1/'>R_12C6/E'C^*?Y[0_8A2)'%P0)Z7@K*B)
MT@E[&T>_=WNOQ4K?CB+M4?RA4:0?/XKTR4:Q.5J)TD@A<4J7B62MS^%>(93.
MO]]U@A7N4UY@$J-961CGP#4["FM6KW)4NJW]0SOY+:8?&@_Z=-?2L9:E!N$Z
M8D4AJ'8<WM4Q*6AZ&^\=1_W6<=3G/S!_4XSQH[(?/^HK__;MFNB.G^&W%J]D
M#>.?OLNWS_SCZZ<P>?,3[ W_)^M4?[QUJI]LNL;2U80F=BA(E7E:3.9&ODQ4
MK7X!'*\2@VX<?T0\MA@TS1[KJZX .<2E1QVI%-6FZ^WBL9]N=KQFI*>LE30A
MFR)4Y,#!6GH#B;"1%^#C*M/5)?F0L:#PO@:,&@8*B1I:FR4'H$RY4";@NY7@
M[]Z]>?$JWKSY[8<O\;TT[S^%O'S[>Y.G^&T\??W"XMO/^6FE_YCT0$D7#5SB
M'XR]3W+N$8>9CJYK(KA0>N"7K]^\^=GZV5Z\.KIHOH@W?_?'7\G;=T_Q+_FG
MI__XIW'^]?J5O7K[\L7;;\KM_L3#^Y"\0>_@! ;68:W\?!0D5=>H-5';\CL7
M&-YC*O_9,=F^?.'KM^#_</RSOMN7.3[ZZ_6;?!5/;W[_XJM?K)_]*7YJ%_>8
ML5P#Z>E3JBHM959M%5366(Z)4<J5,GG?W"[_;BZ6M:):_/;W$>^[X+J_. 0I
M+__^Q1M[^?HX[KS$O-[YZO4;>?GSI]?OOGJSOL3+=[Y$?7S.>WF_"_^7]>O\
M4#K[>X6U?_Z;7R]K'U^]??TDK][*[UZ_>O'F!_?H+DD(=84Q)QS7O-#GU+(F
M=9E@H[9AIA<BY,3K]$.&MF@G 3% %\R@I7O)1%J!W')D_0+G@;\O\O]LFX_!
M_# C_'?Y0[SYM?Q1].4/760XRUYGMA#2.@8T1ZS!&:#$/8',8ES@!-A?'IC_
M=-?C5Z]?V;NGI_6U?_E"],7+*U64].R]16AQ;#A*%^6@&3J!>@:V9S-([\^N
M7&54C)HG.R9//(X+4)>LK",[=*%V@:NDIQF53[BUI<:1RT\.C$ KR- F+:O9
MFPU;SN+\6OEN+?GBW=O?OWY:_[0_.T#X^BE>_.[5SSYD:RXB%@E"\E84UIA
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M9UZA2.!]B+VAT7E(FC-=H95!*PI G 79A]91;.D!&@5L45Q#%+<P.@]1B#7
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M:9DUM&.Z4C.BK8_-ZYEX3>"!,614ZRC45J0*D\:LWKITO$)F_BZ\WM#B/*8
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MO7C$JF]JVLL_U;8W-<M\\<=:F^J2E;PO6P#6=./<SJE&<RJ1I(0:F)4$?D+
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MD"8"W: (()F@2.'D"/Q!&H,3(JVC%HTIOC%U#82FX6W7<QSHEQSP;G& SW#
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MB,@;YLN+_)(3..US:7X24LI[ QA5R3%X53^'UP"[<,U>&LY?C,R_(I3"@\>
MDFY*7Q^X8WP52$F4!@7:H"R2H;A"/'$H9 3U32(]A+6.!/_ -2$()UA$)GDC
MO"BE23!$_>Q(?IS@8Z0LX203XX?G%B-G02K,ZNV!W1[W[(AF1C#D+"!9$M".
M1%@,$D_QZ3A,PO(P&S\&QCA5(,(&002/X@GH$,F !J,T  R-X-E^0$'4I1U
M#Q)$Y?2G@[@.0.$B\5F1WQQ-T-Q/ /7[H)>%OA+X) [#^#K]V#C%.8SP3;U1
M/57F2?AZ]PS;*@@JK0_YP$O 6[P!&?<V.@LEB(!(RT>[L@J7)W$O(6#;F<1
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M0?&O0.F74^4 W?V!!YP6^E-H=I\/YA!AP#.0!H+6>Z)"0JE0'<8?"/GO+/=
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M.9VRS!7<8[A-N"*WRS6E83S,0])09W>')"R(KTB1B7X32",.7ZE8<F]@#(/
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MBF[A$%<B9@=K@79H/7'<RYLG&1)U: M1?MF  X@< <4R@%D(%(=FF!_]]&T
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M5*Z/,-5:_2=JZF0G!">%7+:+:&YU\:(LH$(7? I+N#I7B(PBPB89=S4/F<_
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M$P92F$!:SQ/[5'@J^8XS!3!(&82*#9DPF.!+5NRRC18W+JH??)=9>^GA MW
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MI;FZ4-;/\M7_D2[$YQ@,@,W#/(CG&,&6/ R+97C=>(V+OKE2*+)E0KN@/YE
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M4EI=Q>$=Y-@F+/[&I0X.!H</9)V#![+.XR[\UZ,'LMCZH7XVJQK3_ZW3@K^
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M\Z ,H].Z;V<G"]9#%FS<K3G$O,_#!U%&88E%;(NU=G,2R"*=A_F?VY(%<OH
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M#UEU61IL:":HV7,6)>5=]'4/.@(APGOI*\DAQLX+V3"8.5!#+NJPVYJ/0&[
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MU!U)=FRT0=N)A3N97RHE<B.J#_4R=Q>#PJ"4!D]Q-I<4ZP)MK9KK#3B<VV4
M0R8U "N!Q5YP&6M[]QH9X(_;)1*\0)HVD$I,$?<\ICKJ_(H6#M0)AAG"CR@7
M'9>'@5)T*EQG^4?7&D>Z('+G4'P45H)12LHEA=7,;1-K!3E)]U.I76VP4IJ[
M9O7:?DOWK:A%/RVA8^\_[>B7VKX6T^5&J<I<O.,GCPNVHN@$KYZ?770/#@:=
MFC&X9 #NE*W/4[:HO,-*I[DE;[@.5!/:%;"CL-DUMFN%XX1+F* %QX0BN57
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M4BI$?WMT[_C^R9.M?[YS?++U;Q<^]OC>DWM[]-0'5WJJ G*V86]VA$3B\CS
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M>3Y-NJCZNF_+-?AL"R9 9,;$'*O?VC''>SJ5/8U8 )3OA@:Q%EXG7_$_X?>
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M^II1AQDO!^EE.J_(@5)5!_X[2]I7U=51G67]*M534Y0ES@0F#':S?Y%3"EO
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MQ\]%(9K9#("D.@(9;+2%X(P=:69.N/$!B5Z.(T3+IOV-277W9>=<KU7:HE5
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M=&>,!@_E+$(,L/5<WN-8P'4_?16:]/B@,\R%$AIG/VSIM4(>E.&/:?(DRRW
M%'@P8:D/QY5M#9"QL-Q&RJZ8:HRN>:!8^5>'3?VZF_HF)J'RJ:K4Y27(S7!'
M%%1V4IMLH*/3C(DA20]?H3KIL'-_Z,Z]-<JLP_9PT>1'X$Y8>R*Z1;'2BKJ^
MX_IQJ79J</["@-]%2+>+G-;#AG_=#?]% [,V$6WI#:IBZ5LS*2_1^LJNE/K^
M!^]IAW?^AX)>/@<E?$33G-%A7CO*::EVI;_[S(&0"[ [_CF>]4%$=E]$8)R%
MY-E.#XSV/[#M;R0.PT$\FQJ$/3<UDS"1JZP8DNRQ9&R#*N5TYW+ZW\JN;P.@
MAEYP"/F(F#O)S%//3&QX _7!I<^A@UY/H4Y:10&08N%_!00HS,%SEI:'_?^Z
M^Q_P[+9!_<#(SK 3OF'>.>S.14CFPZ9>JY\=%:^<@<BDXZ(0KGIU#G1E.ZV,
M\68>8.$>%O[H  O?@;$<8.$[!0O_MM6J.:O+,]\_ !U5/B1=^H%UJ76@<'^*
M!P0C*DAHA@R%CM-0[]>#R[3# O%&[!NW@?"5VKY);4=59S0K2:62HT\$3$5_
M7113[@B!<&A?N>+PPSY>Z\'VWBIG@0-\<UNO%D4+?Y5#V?6L.V>N!:$@MV6[
M]"1M<57-FI1\:*0RM$U/5M9][OJ=NP95S!-R]\[)HSBO&>8T4]NG),G64],<
MI5V'/B>"C]?NG0'C8] B0&G60H2%=^RB?.@DKCY0X]Y];]@>2TM)4U)U#5H%
MTBLUTA,.\6#^?V5Q?E?SM<!\N^#F[ "3:@<,J"R,BQ0-#>>'I-EU:!PZ_)+_
M?+>B!?YU-L/Y^16-C8"Z]AEOL2>XM%O;6AML9RTL<7B?;<U22I,UM,-(I?1[
M!GJ7% T\)?(B#TVSA:5.];GSJZ*P#Y+PATN"$ 1WM=MJV[]F(!\<9B6)".!S
M%Q!,J='A(9YVVUOF.A9><HW<6&[);&!:.D"%;5(IXM*&CW/L-"-R?)"FKXR2
M<Q&\<$,FEO]#B+R8:FAKT Y0-Y@Z74W6!63(0C$BN2O'2(A<[..PD7^ 6FB,
M-[%"P"S9;CC [%YZQV,V.(*-P[;9QI)TQ*O6\>0V1CAMEX7V$I_R(UE7P'?A
MX.#,Y""7"%^YZAMHI9M )<LT?E/TQRJ+UK5 ,!\6*<:)/GW#6EDINPA<=V]!
M2<24BQ03Q^]H6?^14!-0J6MC$2C?D".L)3,:9;X+2;O1F$;)_KJ([2?D\YG0
M1M(#L+N9MM&J%0?'88?M7<5;QW]XDPBK0J*JSVB7N$LR*P;\U-#N:YLL@=G4
M%7HR5Z;=E-GCY'0 H)>F*LYN?%_5Y]6@TX T\XC[WUDO@CUCLP2CL<,"<-@*
M33%0Q%$T,?'0%B]RI)#E8YI=.):%B WKBBQ'J&+TY\'R?6MWNYAE5>;%3;V0
MN*0#AE;N1V5=<]O0@'%3#*4* <&MD(KQ%;!3W,!4 <U,&B-@ZT%--*B\E.9:
M1G_!H)C"7&./(*75F\&IC%BQR*C!.\CJ+C=MUA13AM>RR*%14-F:<UQ1H$UU
MO+;/TIY%K%F[$\?+\9H$XU3BF2\E/O!6YFKY;_G!-TWKM#1+O7G'^V=84O&K
MS/O)CFBE<1;&O>8RVWVE_V;(?(%%MI:$D:9449^BB1IT=-:==K;4\]G6MNT1
M/<.BIV%;0)#46H4HP1 /,M(,@Y/*R1)A[F7Z+W NDTE"*^N0]XG,J95^Z!'"
MQ+J:@!B1ON1?TZ,KV$@E\S\+9_(8,YID6HJ0:-^V&PMX*?Q$;91S6  RUJ5U
M-1RQ(0]X^$4N,]#?AXP^K"RYT182D-*:MT7'4_7T/3>+?')I4G3482J4L=V_
M>JY@]\7[!9UNZ\"X)1=R&Z&88? 0R\AP"^*B'08QVP9P4!Z>FR"AJVE1*[TW
M#!5GN7.%*FVPVLFJ>V+5$Z@JV23=DS#P3V9_-RYY6_LFT1MS,S.^V;'X"%+C
M%.K%L)'[B-P[OJAQ\2U@-H'M6\T2/IOZ@KQH5WUG;/=Q<1<"K\;R>.C<L2IE
M6I#=-UT/EWO&^8ZBLNW1YC"5(N-QT'.%I]Y&S^>6.&"A*"H'/!_MMQ/:+%-F
M>.=R+AG;MJ$,&@3"<@%_L)+@'ULSYJ4S0-_%3.KOT#R+_PT3YWG:I1-KP?Q"
MA].:B^Y!SQ@1.3?T,$LJ'[4!_-DG?F-+"$$]'F;6EVDS"9(T2@SNB!BV%%^(
MK5@L1=?CO^# )V]WBI8S?+?^\ORT]0VK7SX_Y5.@$J R9E\C"81+4%X(,-6.
M-]Y\6!5B%TGW/VTM[03IO)+[G<X/. QR$:@MHN)TOS2^R5G\1'Z<%N 'CXL%
MLO ]$[.16,^](CETT?6HIL<'5-,.C.6 :MK#+KKA76,-VP1J?>YQ[G+UQ!?K
MJ#*U1D8C:2$X,AP^4'X.UR06-@SY64VA>3P7LYEM,Q!2?3AS=PEPI6[8=^"$
M4):VQMI06@AF!X-WT?O9$HI"2[AE!L8TV;3\LWL';O+@,J,[Q;4I1..L&V"_
M^M!:22Z("ZZHQQ/R8W'U# U8 232K11PD;(%U%KO0A:.<.W)DZ,EJWRTAS>+
M2?0L:)=+F]70@#%HB1G%AFW9[QN4\N0%*>JB77 M)J!)%>=X&//!-JZRF09Q
M)_(N'?[L:BQ?HW&[X^2E=- #6(9^XE@U]_J,S%"= 3]1321F,I*5F01]2W&K
MMUI58ALKCGNEP]VQ_EGX7O>"%%U20$\3E2H4Z-G&4V^'F#[R>.G<*B4W?1=<
M:>I/P^\KT9:H%SN-%J-;?PR9Y>Z?@U<S1)\A3KP,WA&*&<U'_-E*A8VUFV[)
M)*PM""G*63>6Q7M('GM0&6,@HN3D,.)I#5D$AZ1AZ,93IW2'+5EU.=?ZPC!M
MC,C48SH>9(8HEHB%R(RT/D;T>E>4&U069=I7:-IT.0$K:Q#+HQJ_9H ,(/\Z
M_M:YAAE [L=-VV>(V9/_VRM235I'<T,+(7:M=+O8:6".V%8)!#U.+:;>4&VE
M%Q*_=E-MV(LB9$P>XAC0ZIVV]S]!>]^JKH[X*Y)M8$=/VF>U&U24>)S,;&/?
MCV] 4NA4FD9Q&M,&\3=/V2S("6]QY5P)EX^I0!0X%[SE@>@^E;-ZI<>^6>!>
MNH=FV=Q[+6* !63:93<E[TI?\0[XB?.;7;=-'MC=IS98.$E^:]+<8)1R?'[6
M"_-8W>?]CZ3O5T^(O3DA<=QIQ7$G;H9GS2QFP)/X6M&)_K#+:P(35^-QPW@;
M_X*M:"QWS>W:N(5K\K,N[OCIX>ORDJA*MUYI&T.PP0ORZFH[:=.W5L'B9F$N
M3T8"Y5LN1?I"WO1SN0]->!N^BFW/^#I!;K0IIOT0)K3-T>$Q3NR=U6[Q6T B
M\FDEYSZ?'+11VI)%'NNNI!:P;:_T$D;RAQ3PO$FH7\/(K"K*+>[7+C79^]-?
M?^G/TK<DT=?:*8]CA&)>G)),EMSNG%?>BF;(;#HERX%MQ><F,]R!"RW3XT!A
M#)B74\%N:< D;@U&>A+OUV%C-C9&% CWGT=W^MB69E32R 8-#,[=6M:_I55_
M5J37WAAR]U9E:;IK714&-6\Q:\:SR_1+#!PY&)+/>[MV@G=!U*ZRJ"]^QT_O
MS*JSVO3N7;KH"HUC,9STS;/HAFOWXW+;!;'VBRRW7!O><A#:\-KR>*[61SUV
M;TVO6ZH/"G2[I+4!U@2'WX7%O.7#(1?T2[_8Z+Z2N[?;7O2AE=?'5(7OE?L^
M1MOL=CC<-=]?Q(.$K>M?(DQ(^\4A /9I:]_61@+1\O MTO$^D*^)-/I.VQU3
M370&NJ;/TTGR8]KD:5N4W]L?OO1(+QS7DX-KL#&$75R2:[[6)KNU(M=Z9';/
M[OFA*7*Z6JYS439 <AJNF(QJ[+K"N.:DMNNFF]5E44^8-6&ZWK&5=6K[6FW*
MQFB=C\DU>6:1W!?<BHP0Z8%5J,^[Q7%R.HP;;7[%5@H("7%\K3HS:]S*:N/:
M'6=7*>@VM+_&/Q@98)%EN-%Y9[N]Y6U#]NA:QZTK3Q<THK>V-]( $\LVPMG>
MEFMU6O W8.4Y#3$@Z+"!-V0/:)A'-*FC#)8L:@HE5G^AZ>*A/S1K%[T[<^LB
MQR<O6L98KR70;\Z*NF]A,%52*,:@7+%1VRBLOD+S.$<9V,&F;>,Y#EI520&D
MH/PM6K0RYQ/!$,@K&..$;D$>BLL#9)M-,:8-C6+)+W6/5==&%\).W H$!H2@
MY3M8;]&F7<TF=WZZPM475\B7?7NPTB<'6.D.C.4 *[T:K'2WHQI;T$B';M%_
M3+?HW0^#O,(]!_( 7@[P*(<W>+2"$T;(Z7I+"=Z@5L3A*NFJI6E&]-T"0(M:
M-!\G+RQ3D(86>4/=;GB)N4*(D<O;-FK+AW3QV[I,,_*B6 GUT48G:5\ $O[>
M514*;EK:DG2+IN[GP,.69#;5H5WWKYJ,D@16 ?>^531 _"B4X:EP2HF:>Z "
M>=G(\C@YLA!Q6ICD![A;)%)CL<<1PNS"=+4<Y DM"B)7'DM.PT)+#D$+;U,#
M$XN%E7$54GE#G[ 09/\4.>GR.9 $D\$W7!BM%@JJOMCH!=83ICZ:L'$/'B:"
MTWYM184/,&V)%)=O4UBTO+S;L,^P<P"AQ.T*(H^"%RY^,Y@>>&]DJ83T8J.R
M*&%*%!T$O73>I$N-F4/CN%BBCZ0VAH2@LL0 _!J.$I9&ZG"7JQK7DWL1K'4K
MW$6@HA><2"]K9@:TC:F2;)TQU+1.IHTBYS</*E[@#5MOG:\8<.<+MB#=Z- ,
M*D"3I;E'XW)P6/<$J)HZR_J&V<% ZL#2KCND&Q&>))2Q-X._ZT$/'2=9=S:?
MT1O [< -4+TOV5\2*@3'KW@5>9Z@K.YJ*,>WX:,"8G9;&\B82=+#*"^6C<<8
MC& ^T3NVX":("E4W@GS)>U^KK-+BSTVH9_SQ"0\+GPNZG]7#Q.I!,=3X7E9*
ML8$[.Y81#&IF7I/GI^H!8/O-^SV=TOCJ*BX5T0)N6_VM)S@<I^1M6@NQ4Z9R
MU6+DSC&YV2P@LG"C]^43ERHAZ[='/#M_@2=\Y+"M=N7A K+&<@<5LUL7AFLL
M6G*&<;J"1N=/[:T=IH/X<-OK.JSV%/ASJAUX]9S/BJ;MGGJ<K3C:?BB,X N,
M*&\K/=WR">]I0V.D:SG&T$0PL$)_?]L3Q.OW:M"53/@DF!2_HT5$:Y[:VUB_
M3LYM6\37J:U8TO(E^U*4@*S]TLQZ48&L$B404"RG?2.B'EH!3[G6V_GMX9\L
M@#_:L!N@MT*4@;;J8%X8N<LM)\T:K ,<1*'_L@QJR"P"N5;U><)^6'1D+"FA
MVWX4]6H!PU/WO"+XH&ZR/F026DM\ ,X+4-QXKX(/%>I]7*& PYP'),M/A\/W
M)B'ZR[DQ3=Q MC@L,32#;6/;LH1#9FPF0PD*[U#DB$0F9QH5]O/?M/:+K:D9
M0TH5LN^^U/:HGRBPLF*Z6<$>VH5;=9B&$:M\TVN20&JC92*I37/SCEP&,6=C
MMN$3PH_D<SZBR"3^"N@EU''0MC>O$W!#:?1L048M,YFRO, FXG^<?T96W$-^
M+V.+N@KD=_]1$&/Q@FT^U8 A)90GJ38-J&%B?TMN[)3]-4>(/S0L;D(-P9O(
M_R-U9U+6/LNB%;+O:-68.3-%<5>]>7V#$$?_9N,R[/;TI(^@620VO4',Y2V1
MJZ[F@8KS\ZDX9P6S3"BMB+.31-.T/5=\-&-]3<&TMJ$?)_C(F%G%\3!KS_&]
MMFEK7JG Z;#O?]"^^ZNK,9FQA?:5@9($^'BD259T9'W3<2;GLDFQ@0;58NK(
M-IC8+&9(]%>F4X2\YI--0D&XAKTX;NP3-8:-ISRPI<<&ZZ*[2O/\/?N 4-QY
MVB#8!'HCN>C#K]LZ<]9X0B&+Z5K;"X"L)A5V)'G/06RO06RA3K3:T^;"0VE0
M%TDM1C*$N7.)=0PX?(O;3)1>1=OH3"2GE%1J$@\54,_/NEN';?]ZVUZB&0AM
MEB%[EDR2+)FAA8EB ?)>@X0!E$#]!.MT63+0I]CCP\9]O8VCT\,^E@5$>*^T
M^(\<.G^J5NC=QU>/U*'"O\'F'2 '?IOOW3E #G9@+ ?(P><P6>V*SZLEWY*0
M91(1:U.X!*Q+H:626<I <\-1P &E)ZQ7<V:C4/27H@F47<#>[1-(9,*"^_6S
M^4"D%%XY#62T?S@'2L"N$:=-;T#H(XCB14RE-I'N0T2Q:W,(]ET+!;?PMH<U
M+>1$<@R"%@S[..3'B;AC]U]</VHMYF4]E=JXBA2-!Y27C!0@J<2''">54MY5
M9#Y(6P^2Z'E:J:E&'P@IAT/FUUCQ"-#T:A1J0T:V1/:A=80< V)<@3G;#.:M
MXK8DGE<->K]D1B$YP0SF3=VO+&DW;637*ZD<,S&X^4!']TV&'#)Z!MPJ[).C
M5C%CW:-]"YHZ><W0$P4DR#^*?!CH=!]ZTP09]^=(.+Y:<IK)1:9?U_1>N_[)
M:<9XW[MW[MQSP8W39Z<2,J$1%[<U_86U.!,VZ)1$CY6_[_NHO9*X8PY)!&WC
M>@@LDGER&PU\.Z0S2DX"!F /=[;C^4D8U)]A?@$?L.4P2IXMTI A4@G7>3G:
M=8OGFRIE(!82..!] EU[\"E.N"]':^<C3CN/RM9]Y9DS0PP<R:H+6M*2J-9@
MO6.<_M0LTI+;?-F-F@1;*9):G#&;H(%3J9$"TL -X\U$^CUOWDS8 #?.Y@:'
MV>B,N)B/+E_20?42:6&^4#1DES,J@N%24\D85HHL"N(C"IP(T?! 1\WK9MBL
M0]*!V@P$GS;*M*\I,>'U64)_%",G+=(50-19SX_3T0ZA#AV3N@<)"P[J1R44
M*73X?4N/]01K6UYR Y1Y"'IT%$U!QR0?^MPL=;#BI)HOMB/3JNJEH8 $0@18
M>&ZF9-$IES=^\4:?\EN@#)*W!G5$CN$]DD@1F$8^X8@3Q@9(<MI@%V4DTH5*
M-(_$A.V_[$&E;V0-0)5C#Q.2-EO=E.12^SKE'K$UJ'+N:)/9;252<WXT/T:N
M'+:.K;Q-U\G]!\</OANRP>BYF@@HK;?U&18SM__R]^MV"GJ7KQ. K3,2XLOL
MQ>^3Y&\I1HZ%>;8@8U14%!FK9RD3C 5&@W+TZ\\,J<.#0OW.ADJA^%DT_&AR
MV+@?-$HDXBJ;$$9Y =*-D84!N#+ ^3ZSH.RN7.M[/")@<(;B-NC!-"RC*WWM
MO1W.M,_G$KZR7>@NM$,AK;QN2K@5CYT$@^2DV3Z$HR72&!R5+DQ5B8N)T\02
MW5G"LVT,^B%9K >@*F_MT@':@BDSJI(U56..[#8P,1Q-#Q#)P"\"LL;WW],[
MMA=$7UA+I/B[#YPBML/I%K1DB[K,D<.?<?\^@>5H.PK$4H(A-'UIE5)%1VIT
MB08K(Z\5B&A(6W(B1F+KN\9VM2V36T(>?)>P&^E,V.ZG&X:*P'040%^$09.]
M6H'MKJ5/-[);)$Z33S8XOQHK,9<\H"#,4 _HY4IC+6#;9?4(@F3&$:EHAV39
M'^,C>;*'J[8QWJ5E'Q>\WR]><J')JU<UF.:S,+:Q24O=EO5Y'C3XBYZU#EW2
M"];8M:WA=##MJ*.:;=BM]-21YZ2<#&R(QAD#:5&RUTA7"8?4+O"4K3$;7GEJ
M1C6>:)D#QH(]=K3=ZZTM=T)TVG#X()2M\DN_&I.GXXR3@1.*I^K!BUWXB"S\
M.ADM]_I\G#P0JES8G'W;A@[XQSO>KH>//15:.=?5:*<8B2&TF>T"J9ES7S1E
M/IBF\W&ENG*7>&B3:9@T%1C>>=V4^3E)]O'0[6<[?,3WO]#GWPWWGHU;SP>;
MB^<6WYALW;7F3-L+TT%PK0R<H;G-4.&E5 M.?7WQ4501!7SOOE<7ZM;@]V]O
MF+[!8T#GB=W,BETPX<(\1\AG>"6)>V3;%8Q?>.ZJ"Z\X7\WEVVX4(@/"U#L4
MOG8[;YQO*-P:NSS*5^5;O]IE*^*\#IM[H2QOWKHCBW)(.OND\\DAZ;P#8SDD
MG6]$TGF69.AV) '^,1^#KLW6J/86"XAKW$+36%I;9]8L\S!,J[$M*([M:)L#
M^@-(^6YD+I$+MUJS2=\BUQ3;1:XGX<WQ_<E4T%X*<=C++HK+%XVOR]'XNO 5
M/M[@$UP%<=$51_1GJ,A>2U-ODNIYMVAM<:=K/CI(E$A/+P1DQ2@;[2(;,_5S
MOR+N&5"-$R_7K@;XQ>_CV4=G:R/HZ5U39Q2[! :"8A+99#LYR/))=H;;X(CI
M&#9W\@:3-ZRP=%SCR;%TO%P#::$1."W(IB )29M@'T[)MM*Z>*S&J/='<\C6
M0G.A!E&T37%C:\>*?GF?-\="A;APPQ5O4HL- /=DR+NQT1_.%DZ&;=EL#[!H
M\I%D#MO$[O\)O;B_AL^I^2X:1:MU-$+VN5Q!]*=KMV!<NH0<N&%L21 H&/?J
M;=,,?1-)U8"%:^3!6X,-(OQ<'3TDE2VZBWA?74A@H D &JU;8/U%.D8ZPV[M
MX&T=&M4A/.CP,-(#;.8V/G^&T1.^+TE8^F!70YVQTX \BP>J[!JM2W+3U0-"
MDG.]F^7J%V:%L,K,>BR77-(N$A.TC^,T1W<= 98;8P;87]#FN#9]-T?)C!52
M^L+]E,,#G[ PPB<2?@4'WX9M&%P2@NG8OPVJ""6$PMS#E1#8B9%RP2MM]!3%
M:HVC!G$E;4JZ1Q)-3^,29#IZ=)E.+"2S$QH05(K@FN'"Y%1:J,>Y1JX=D6BK
M&;RD7/LV8UPA79>YV!P7W9-\64N0"(]P6!#;C&CDNAOF89TY,-#/(^LUI?GE
M41LT>L#:KI[YM^ &L(KBHCCNA)@CB,-VF!Y^'C"Q!YV8KC3[D/EF *Q%Q4\K
M]1U:IEYT@5R=,;>"BW<55Z<Y_..5XL[W)-0@_C7W)+P9=X?&TY_]^H]7SX].
MGI"-1L."?UYPW%8BXB-LJQ<G/[82WH>1R2A*6J#EIF6=T#[*&O[DY'JGFD[R
M._SVC2$K::@RD]E?3Q)#]HW]@',P^BDY#39VBVQ]JHE\;]3I;.,3-GZ6@GEM
M/7G?%O6_RT3&T[9KPUIDXTS[\L2Z[S@(R[$_N],:X!?)\7!AZV%K<VO:OI!;
M=TRR7:9\(M8OHDI([=@$D%-&@33*6W,S;XSQDNC'IB&L"Z)..OX3V_P#WC6C
M$45@ V8"DI:I6==;_$O0^Y+?+7<ZYW#J,KA(Z;M]QXXG&D9+;D<9@^U"Z=K8
M11;3VJ[<)"2:8-2C)B0D/:(H"NY0VD2^[5G1],(MPJ>)R81X543V%_5Y0KH_
M>Z]^!Z\AX@)RN"N<GT'N/.@/X0.+\,:QHLO]PFULC5X%:+]-6;7'XL)D/VV%
M@[DA6<&FB(7_3/A6*\95]J)?HGNC:,&P7$,228-,6GA(;3Y/DZ2TF>-8@#EH
M&!*FRRZ1"T:7<VRHC0W9E/U8PL[BWE@4+#F\ZWOGRP#D:()^8<D)2#9YR\#?
MM/?6-I7 F/<F>[^17K0Q +Z%UB 3<1E&=I@_\!MIS'^^>_P@F0+H */)]BY)
M.\FOVHL-CWH3@]E:,Q<22+&.XH<^N),LY9FCCSJM"AP9S9GKDVY"L^2WB/BA
M+^EY?<19UU8RW>$6C:^CVSGUVA"URP5#N&Z1_JZ.TAQD"*V0S0V0(Q/0!Y+]
M:A#$10V4Y'K60A6QY)B$+WT+,\L72?C,P(_@G/\9;%\-##OJ"5.J:T*?GQN.
MXV@U^*BX6A9[O7(B0(%B?= #P-9;A#?HBGXE6>UN_+Q.;+8>-Y98\.ZDZ[KY
M.V3I2?LOUBPA\VMP;EVPTX(W0W=PMUH^V+8\U]KQX4FTU;O7T\_VQ3@TH(OO
M^.6J3,GM_/Z Q7!8C+L'+,8.C.6 Q?@<+,:7.SL?J6!^(5N?-<RU]WKR<<.0
M@'[$OADS]P= W]U2XCO13>NG^AQ.^F17&]"^J4R/!C\?KM4"N'M/C%@/KE5K
M6CYF4(R3GJ-*4 ,<*QYV5F=P),06E<K,&^!*L=,TX/70H*\:YP):;BT.5_P#
M7D#GQN;I2C'".*,VU!4X%A)S&JV?;-M^N;)@%GX]^56UEH$4>9]N^.G*]+\B
M=X3<C4&]OW*ELU,.@NW$XJ!=Z=,2@)ZJAJ>\WHCHVY "'Z"))U+3"$%8,V6S
M8FE&%M5H!OXX>;D1']"13,1;E>ES-IM<R5EZ1O<6;E%;AU [?Q5QMLCYO_O=
MA4[@Q(*))7PBU?L<A]GB&/.,!TIZ,[SAAC^6"AD9A,S2UERE7! [#+N TLX%
M\O#1JM4J]Q!@)-K?D[,JL[5[)[)R9T4C]7]"TS H<M,2/)[0<*7I:9+-<Z]T
MG6Y2*(E+'.[G&A48DW!?BZ!E,9;=P;KG'=/H(+6%K;4CDF0#JM2#2+#PNWU&
M\'<TSNLF)!':P(>,F",$SV0Q[NLKQ7TY<$S_2$$ Q&%?'PGFPTB2-N=9 ],4
M)5TBX*@2K [D\_/2.9)"5>9#]U%I.+ %\G6 EVR'EP#N%W82T5LD7!+1170F
MD2DM^.0'A0V\\KX]M\MEGTF5SJ'5]L?DVS1KLB7Z%BQ#O:TV?@ N/4[>\LD(
MFP%AT5 DPRUO=+^#K .SUQQXKK\B$66F!6A@/>)JKW( ZF$L[ :?D=:#96IU
M=?2CJS%Z;RS8Y\ !_#6W<@F#8%4&/5C6EA-:"L^"BE^[9^,6ML*D(O)8H\EP
MNN8CJ/IAPZ]MP[L&O;X"]+.#QS-APY*Y:+C?"/\D'5?DQ'JI&)IZ^)H$?_DJ
MX%?0P"UWAK>0HF.O((N-R@$QB(/JQX. ?$U6</(V:;G@Q[":)_.3SJPT3S[L
MQ-?<B;S@5.="$L3VO#+->@?J5.P*^Z%D9@GS0US*<R#H_LH;YAJ3V0IUF_QF
M)_.#T'+?(+:UJ#B>N2\9]9S%_ 078O*"RB][@PAF61H/@F52+0OF#6OZE6WB
MGN,JT=IYH2X)O4(#FW-%CB ,&QZBT%^5&FS-4D:K^VOL/&TFX)IM:G(0E_3Q
MHN[(_R[.BE)P[(T]?XU%6?05KK.G0L$&]D]IQT(K>[3$#8@.<0!X1-<E]J*B
M-Y-37S,9%ZKJ3=ITBW_WZ7OZN>UJ8;^EKR-NO%_AWW$'/F %!H((@2?']N)(
M%8&5I_V#MJ,U V"[O)QJ)C [M_(-ASSY'PF=WI5EO3KB-6C;90/G&RV1/6@U
M6+ZK;$S+[>9PR'!6LD7ER.$DYBC.G]V]""?B]Y1CNHRY[XK61,V,MC<GCD*$
MGC!V8W\U8Q*2NB"\/"9;MDGM=K8XK=6),>+:&Y%;938FL2V>AST+1Y:3!T&+
M[8? @6^-5FJ3C5F2<UJBK7VW5!N(*GW-SPV(ZFE5\"IMN[AD B$^7Y.1QT49
M,69MT*=$N<$&[2A#]>L(^O;_]$O2@Q;+E3C)4FY=NL]:+TXRF0_I<E7RO2D0
MU'#;BK9EE>)*8NC&1'9H][+H_Z]IINF'ZP6(N0Y]XD#GJE==QL0N(@P(T=&\
MOD.2X=07N%F*GJ"<23SI*Y^?6 BD8+#UO."V7U0<[;4%+RI$9W35('D$,ZGG
MKF"-<AZ2Y&@F]!DS;G3)CV0"):^C(;QQW..^KC@BJ_14X?B 5:E(<$JEX;RG
MM2P]5:98$)83^8!]<]BW>P?LVPZ,Y8!]VTWLVX5G)]::[:+O0)D9])WF-B;I
M?$/=^A;BP0.>!@T2]*-!%P0Q#2OOZVI32/HZKH7"V#[*T/LT)_V(:Q?M/Q<'
M;3DW:INLL_>T$J)R6P9V):K+I[Y=@DQ@V)>>817LRTKA2"%DAR3'RS883YA1
MBKZK+\+70+8N"\H596V<:N"GI"N:K>]BMR6G,0E?UZU7@F%SR0GY 25+0!AP
MP093KM,[]>8)+A:%402]OOG66V\G#]0O;BLZYLC&Y=>S!#"XYL.&'H)P@[VZ
M%W31(B "LR&^9Z-WVEHVH1O=$.()7Y_*G<K]P$.6TE7?63Y&>%*#J,\-\%,&
M]E:BWI]U].ARY+B"'D$MQ9&&EZVUBHKJS+2=9-0 107#"E?G2 ;L!G@C0XP&
MER9U0NE.4KGBX^H8*QBP8TOH-E;#(TQ=(+"JR;)+T2S6&.\S7P""8FV8^Y<(
M&LI2N;%KK0VUCY-W4=C<5BH.A^5('9BEG;WQL[X$YY<M&$=_9RD24Y2"!WX$
M@4R)$:X%94*S7+L*63J#==]D$CIM+1PKJ)!BK2+,\0/-O!$ *^"H+2TX:F,N
M7$!EYLQGHZU*M@0LXJC)AOLAX+%IW$DXVF>ZS HVS1DW$P"[YGP<=+4Y,*LA
M'\^Y-U"C0:E7&^Z8\,@*CY]CJK5Y*S/@TY"F",J>'WR)7N[H([K-@$\]F[6F
MLP!!^J2%&XT)XFA-OIVJO-@-7NX#:)0!D1.)YHW2"Z,EP[;+!7<5.:]<)7P0
MTD#E(N-"6\]V)HGJ5"G,Y"%;\@VV#G=[2XM@1-MQ2HN(*)F^2.>03A2N^F<N
MGHHYT%G=@H?:G'?1!M'9?@7;36') Q!J&H!)C6>DEMI%[;I\MA',C'I4^/+&
MED0DY6X06C>]S<R3T]&%1#P^/F"W@EQ>2R4GF7_:&Y,7<MDA.*#H.0O]4;BH
MU(</FF)]!B?W1KNV2+B"G5-VA 76(FK+L?7:4B)"CM"&5K33L<.^*]I7B]50
MP$_(JT4K7AJ/C-W@?&-%=\[WGO(/E4;[\9P\FFP;>[\2UFO\^9>WSW_VH&J&
MIUOZ-CZ9<I:.DW\NBE(D?6E@$1?MDK\FU'+2=X%TKQ\[MQTRW'7&KD-KR:A4
M_7/X#TQ%EB><*7=".GS/?4]GK:SK]P.>'>Z#PK4ZL*- K]0&[8AD;,S;$0V-
MY]PM&B9IS.N>%NTH+^:%;8SD6[G8>6_("S9*PAOB/4G=,8O09&QW8[%BNJ10
M]IA[/<!S7V7CW0R8A<KMKCN/__CAC87369%XLM%=QDFEBD/P)?=\4I90.M;%
M<DI FQ@ZO2$[Q]?K&#FAL 4D/^J?_D>C<>@+A 4$J>X+=U4Z<C_X(O%K]*"
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M2Q\7<PR+R/U:Z23;D); 1I0D_F\0&C$V]H=!EH64+,GY0/5,W\!L5;^B7BU
M89#Q9S9Y7D+V%ZTH"XXQ:['*P*A.&QKWNY(+GTCW%BY^L)8B*U=]M*$0VIBX
M#RTPX0&7*?J8X*=5FKU/Y_PC6/O0=(&'OBA6*ZO/AV-DQ\)[\>O K\"^*M@^
MX)+0_"T3ZJSJHJ2W &@!25,6@Y2=M-Q5&FV9RM#<']3L:IKK OW*:K1=>-8B
M3IYI@XLK2!*BD")(-FSG@I)3J0K@& 0L7:V1E0D>M.%7U(9;8GZ0L5G#<)J.
M8^F,-AN0?4^-P(:"N#D]'Y <![MB6!8./5![JN4TZ@3Q*%'38EW4B6^DL\40
M\EQ\+/_MNB*IZD3E<'# Q[DFR7MC^%3V*]]P)TA(N(?JV?#=MX,B/E7NVME;
MYOE)M'('4?UCK&F]47UTB.\:D;%0]I#TLADN >(IJ=H%VE_#JF%RC)YO;#Z<
M7@OC-BH(KF;&DY[CP\V<*6A=L89$Q</'G-ND8D.7DSGGHDU;I(DD3TY6JZ(7
M-14?ERC& \Q* 9L&#'+!E:R2['B*.26V='W&3D-V!4V$#(-?8>KIDJC.]=,W
MC:4U+@I-2.^1MQQX$A35CSZF^#9F'?V9=K!,WF K##:_W:?,P_9RLK#0V7.A
MCOAGKEQ^X@N7;!&I%-9.0B=5<93222!:2$\!+:?DXP3J6O,U)P]HU4XYGYSU
M;>N8##Z#QB"TTN)^>=VVW1E9^BNL? #V\QL <BV6:]D*Q@3:UE<.,LPA!R4X
MB(<D,"2^Z)'Z!VI*@ @<B_A@LIZ='E3UH\OYLQH:6A5M"ZG"VXNVY)KJFX!G
MDQK].Y.1XV.JE%,(R_1?B#)L\@O8I5""<\99,S6XV,ZGSTZ/DW]H43@SE+-?
M9 L_^1G*C)/F9RG3P?IU9JO'Y(A5!%^V]0G*L%"F/>V3%#K2-.Y+(3V]..(]
MX-M37+G7W VHP'TQY7H&6'DG#XY/OH/0W+U'/TR4F4F_JA^DO[KO"I5T+FM!
M F/SF1/%\8=O=NQM1AWQA([,G.\V1X"AL[QW_\X/3!_!IY4+I2V5PO[+F=V7
M$(C>#H-O@:DNG*PKLG0?W?G.2A2N<_QL2\&CT%M1NRYW(2RYTGVCK7H#PHOG
M2GV6%:G4FWL/>_C!K!;BAF2>KI);Q;$YEF/2UD>PXVB'58WF==5WR:(NC2K)
MVP$AR#A"2+I9GJ>M@R(!#15UMOPSW8')$DX]G2]GXOOH'[2R115=N)!R9 -'
M&@4!4/A,)U'5)#_I!S)*V26:EF;LK,^,&9\3W']43^7)GQ\_<,/EH@+0A;O8
MB;X-S]E_:::%>&FF30^4&>F=A[HBG+"3.3M9^M_I<O74ZXYW@MEMDUO/7K^[
M;2FIO?0%JHFAZ$U?6@KWJ.2D/BM::^2KLE6P"NZOTU53E,G)A <G2I$?I"&4
MEMW$QBPT_.PJ;S0=2R*4V6N8GG^JQ^!U(%5D5Q8:Y/H!!2?\3S(.SH'?1:ZW
M5<TH(I<;*8PQ@4YM1=E=+JM(.O.=X);(=FP[3E[7_(6,O7Y@K+L%NR:TNMQ\
M$Y</>US<9EO',L- SL4WJ1Q7C.<%UV.-;]@@?5U9^^=6T'44P^HY7<$/94/J
M]H1?[LC&P87*BT^+^9P&R@#,N[PWS$]N25P"9%:YMNR $@*PC[:;C;6\>) I
M"\;?:&DAHO*RNVIK2>$0V3@U>62,[0_91:,:"1O](B7 O<GI=YB.C:#1AW.R
MN.9R[[<3ET%P=$V:A"!WL9-K,,VY95#7J$?WVT)H(>3"#:;*:^)JFS!KCUT5
MCJ7 @DP90FF:X2$Z3EZX,Q$OQKV)J*7@E/'5Y%K#+*"=UQ8F'HHH1ZWM$3&!
M^$\$>Z$'AXO2%'$D9"4.,&_%-UQKNO!7D0/>UH/HZZ#6ZX!5<%B%AP>LP@Z,
MY8!5V$.F\#'K=*!$M:/#L/C=9^T#:X0MZ5BM#H'S ;_>];,G[;:9.1*X^3P*
M2OKV+_04,4&<)?_<( MAT>H_^;;C/S&RP)FLOR+?P(?V5<5K3';NCP(G2&[]
M^NK'V][H><G[_]89KQQ#G@06ZL9M;,I"6(L42]\51W\OLO?3-'O/ 8D>- ;I
M#,1<S52*#YP=N8*P.@_=.W#(U@C[?)V\^>$U@^:G9I&6,X<VY(^,U85KYL:3
MX E7@O1?EU- <JYL"9I\@<%0= $IJ2NL5FN#>?'IYC?G=?->3T9L]W'9>?BP
MO [97SDOI+-[4V)S8#2@A ?[=?$<]_\\_!J)[T1%&-8VFTNA,_7R%Y8^1QF0
MME$S@:G9*HOTOVPGJU^@%KRM$]$ (J3/X\E-FS6%%!&)::IEG()X"*JSSFRX
M,9;4'W P9:#N#^>:UM"NU> 79[B3 S:I&N#L(U/OFESY%H1ETAWZI4DKFQ G
MC0IS56@H)9&=YKS+"K@X(Y-O:10B/5,> -;K<U*LI(]0K-+Y64U<&(O$AY3R
MK%O;.;FQQX7BF*5Z(>V.M5WZNUEW39]?:]^E24)6MP0T[]+6L:Q[=D1U ']]
M\>SY!.P<"U86-,I>G235/<YG?\=5@^*LWU*1.7WWQL:ICH30@[QL(6MVNBD2
M<&XQ4:35D?7>6(Q9U(^35S8ND88NJCV ?TA%[,$>\$%4QO-)$%6"'E;MP=A:
M"B]T&G;N"H![RDEN]^D"!<9Q\6=IE>:IR_;2FX^4SO4_H'( E=&1+;JP+BT@
M0+B01,VUKF7V+X(F.UT:J>]$LQ6NK,EJNOX0)6+C6\)#K+B%!;]RH]0L3U8T
M6;]LF5F]=8'/HM6:]'-$85$JVZC9NKE>&J2 F2)FJ@M_"5>Y)JURM!@H8_"E
M8Y_>#%5K8W)>) MZVUC828 #F-BBJ&GAU';(-GPNI2T!!#.5D UCD-P^.)(F
MOMJ8FSIE"A],3SMEB_Y86S"MQC@FVLAV;0L$W8TX.9S:/Y+7T3"_?R(HR?_8
MJ0>]CLYK)::G.[9?\2)9:P =%+FX3:Z"B>S)K$#VH>UA;"Z0BJCF]KA;Q8O-
M!K-NF9[C<SAJ4C*LU+O*C+UJU/#F)/J_^DI04?063JJ ]\ S7M...]:P#.7)
M8-^5D8>3"ZV9P?@1=>P!=,28G#70VE'Q@;?Y,&G)Q+V+^F9SHEOT&I3'#1":
MWS9=D9 ZJBS>T[XMT)[0.>0ATIU/-%;*6[FD&3CD'11 694:-)NZ &"AR/&)
M)=;8VI<V1K5Q(+?.R# AX0W:YGA%=- V7X9Q>:,9VFALOZCBBH\0LJ@\3WU5
M"IHK(%>9=J[^T9)NMQ%%B^72WZ<EO7J'&%]J&"ZJK42<Q"!E!Z>.*T%\$><E
M539QV]-!<8VO(HG+;"IP80%ZH?IT$@ KA +Z J+^L6J7L#F?5O"PG[MV=D:X
M_?YQ,?[0%:W^+5UI43=S_'-V>>2MG;7AG.L1)<#5J[:C<BMMQ6^B'&=![$FT
M1;3D'C._N?B1$1?K/*GO78J.;L/11B-DQ1;#0M(EXSN@NPMUMY=TN:Y]28!D
M*H6:3@(0 ?/2U$YX&5"IC^W:<0@*W-XZ2,,G ='CK,YZ+=!E>U>9XKAL*5Q(
M9Z:'J^#[6^B8+'!#749GEPNR^>JR,Y 9M89"Q"?BI8VQ"3C7\\7?>4Y">'W+
ME%'_,(86-<=;YBXY.1 %5T3%AU;+Q\X+1I,;2:I&3213;>XFS9%T^VZ -GR!
M_@]%7"->A$2NP8UB$\;!!=3YKO%!*;>*L.N>5K=![85>/\++T!4E'@)LI]Q!
M<('H@0XT,'('21,_5":%Y?7:PX@[\  YJ.QC,A).. <C/TY^98"$OG)0K(*,
ML&L]X06E94H*_!<OX6!T<%R[-C[8%XPQ+."S$XV:QGA*$M\+0\8::L*@+8=O
MX<GJR#[?U>(HI=M8:PT_F(HW+!XO-G?%^"9,40()K>'*I+BBAE]-]FC<B""T
M>R4$NJ6;I4*H+,(( C-<S<W!V0WGH#H>+#;GI:;*MY=2?W1(J>_ 6 XI]2_!
M+__7_YHVW_]UGV[B<5?O>4 /36K0!GU'+D#A@!YRUSE&P3&_VEU\^[1.%U@L
MFNP*JE;IKE6@E]S($Q=JSC]N84G<!95UQ9[D0U?*O>' '?45B_-LC CA*G)/
MCMR6OEE@+^];']UQ2+==#TJ*IY^Y28<=V;8C @T^DC+#J..]XR%-2S!^^FZO
MG[L9.W=B[CRZ]OVA(5RT/RA]P*$H 0= ,<:FA_QM;MTN'RV.M&./ @HZ6[LK
M[*O]M 2E*7<&T"2")Z0)8FC<)<!1)[ @V-"9AO.?PE,_;.[7V]PV:WHZ@&O!
MU]/^=D5K0YET#I?U#>$=?>4[KH^'TOD>]_JH[9LS4Y2E;<)NS3N7UQ"L0VP
M"ZYUQA4R@%<"6Z<M6?$IE^7BR$&3%JVP2$O/#-\F6!MJC_6V"%N.N[/C%&F
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MST&/GWOT-O/\H,9:\+C*52O!X7989V45E9I(!3?,L8;1R,.5J_V2L IG0L8
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M*D]].<M6 N:-*4C4 MV>X-QSE+?LK>_/H1SZAHTRQT?,&5%SNC([:;:M=1D
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MU<L. WFG=#%*("4*3?INS"Z&N^&:JD$0& %6>[*6&_J$WH00-;WI(H:/DMJ
MX!D^T!G2Y2AAB@![W95EK_WM%U)D%G'RZ&/"3N]@BX3OT\(&5V45]!>-S+^H
M);14@2H=BP-KVM][?[0)7,CP5G) \XUICE?17^B68]O@@/.W@V67J/X59Z=T
ML7:*[L*?2.O!26"B,<BM[RRR&'BZP:[)V@?I(B#D<FGR_1']29_L#OCZ7<W6
M#\\"K$:=-/)#\1A.9F @*&/GC?&_2!!02T/NC1+I?3\,5&D8P!;AM>%2.:B^
MR)QTHD:GR9S$=LD66!.=C)(L ?UUW$-7.F#" _31SZ /O#U0[**L.+HBH4M!
M,6/0FV4'&M0!]I3C,+-"VJ:'(9@(4N#@V#SJ% 2?6)65 +P;2<]Y1$5X))1<
MRM<@"5>3KI8:[YQ><](E"Z#K-.YFV7,XT44MEK;?_;RN<RC>N)QO$. "E%RK
MH/791^,*:TN,$V-F.*^+:@5E&Q^X_F"+)-AMC?:^1LPV='V"XB1]F%U./9"O
M^=EO:IJ!]JT"L;4)HJ^\T($$NTB>8ML=XM;*<22_&_LXL05#$@CCBPS5))R2
M@SLD$7EN9MB:S/HR[IJ-1$N$;NT8X\B#Z&SC3*#-V\%A"IT/;9;&>EO5D'"K
M7:2!+@3S[7P^$"O_1FCK\N3=BE3HKS/N^/$KB)CKZJ/NE)W-$JXNF*&3LJEQ
M@I9;'QZY>[$@:$C<(B]NRH(CD7*ZI9BA<(S$9*)\C_+0-%L F28&'SO?QH85
M;\)M%C>P'+;T! -PSQ'=HFM]S@=RYS;"*6^^;B2,2_K>J4,!\T^"OJP:[R)#
MB)1LBZZ]K*=]3)U5B!0IF7/<:"X'.-'B2P3KD%C(M1QP;<&HMM5W4J6D'YR(
M2//-9_5Q<DM_=3OQS>OC"D8G6+Y6<_#.MJL1S:X]B(7L/0/>4-=M('JD=#;4
MTO9:*#-FK,JZ],/1K#%FS%;DJ&SP8'9]N$K'MT-F? L0=:N^8>9*>3M74Z39
MV,NC0\)]"]7F)<6,;I8TN*83%!-ZX!SSD$H3) 3]UGL?9K2N3$%;-D8D]H*'
ME(X[:$$+\0BV$C _VO''@QD>>/MO>^ZEET+:>J$.SOQQ\GOE.SSE,?&7FAP@
MRIPX2DM[MS/QZVB=V8;.BKH4TPT*]6+;9B!R%CA@ 5,"L) NTJBT!'XU8_^7
M7DEK)//WQ)X>I62QN"&!62603$^1"I.-+!'9C8&M)X6SRS _/**;><-L>;*T
MUG"40%N]O!]J9!WHF<_I6RPX^]6I:OOE):6.0\'=LFPX3AY^>#EZMZ_LL; W
M%3-X6$RT;!$S&1OTH(H#UPZ$IK!K'U[VCW,;-G+U[M<.79Y/L[UF^YA- JM2
MJ6&;(5)N*6Z[1;0RE^S6@, VM"P <+OB+@$K$BITC4]L;)/<!*%2&T(.W8;B
MD0XR'VIP:.6E39N(7,V"J@])?.$6:G!D]TL:QL_KRSILF>0UMYQ8[7K(M_)6
MPDSXNX JL9& 99J5P!7AJAT B_=IN3ZI.XGMV#$;OZK)FK*%O8-U+;IX'7T=
MBMZ 4C5ZX7<<@MZ61DP25(QP.H[4HRV><'WT/N+)-.+:99LO./UN9MS_9KN$
M3!6DK!Q$=&R9#<@9,,,5O)KH[+Q;U]BN</&E%]JU 9YZ*$2^+YWCX?!FKW*[
M!-AM-GWID:Q^KV1*WZSCZ3/':><%.-MNW5N&?O1+DZKG!$3^+E2/4\%K*+5-
M/=V0RNL%2C%NZSA14C'!=J$2?\[(/S7P0XLBL%;0G@(%]= -UH'3P\B]7=%*
MZI!2MGM\_\XAI;P#8SFDE/<PI1R%5SA,<=&-PMIP2_!&M-)HV$;Z6;XS^I1[
M#Q[PY^X]?&P5'FO15S::_U8RJ"0;N2&3Y4-F5IVU-13OI0!>YJ]1]<RYR[(P
M/4=>&ADS/<U;,5:5AM;'<7**\!7ROU:W*R!N6H@"5EMM8W3:##RY]>KMN]OT
MF(SD*&?$_B0HMQNI[Q7D$%[#Q#O\\+?OM,05;4_D]FAUR>-BLNC6<.Z0;5 <
M>$'A0X3AW25W=:**#-19ZTU7KC%AUVE4.G9'7E!C-+$0(,%XASLFW=,PJ!<'
MN^J>*BY*.UM\H98-N&(PY3BSZ6Q= ES#09#4DZAHH;!&03FPQ18-AQLFWD7C
M MX:U&]=T<X*J2ME$+UK-QZNG(WP<(Y]7IP)SZ@7EAM@(KW:%L2RI=G<6'>K
M)6GCSJ/"7G#+(J[WF\2BZ\S>CKV0'.HD==8IK2-RK[E3+,YS^.AXL#A.%SS$
MXAZ&,8]M#XZ*"R.'1V3>MBO7=K[!K("H'>@Q9PG.TJ+9<,#&%!;K0Y.W@REA
M9((/0K(=$BJ?5NT%].55?*@B_^\_77[I/7C\IT]QO*[)SWK&U*#<U_6E!N1Y
MV5^3PCT5__RE**&WDM7:_S-]*YAS4%/]NVLL_08\7!TN,1)[*2']V;/QOA42
MME/1QR=/GCRXO?]K\MN"J4"X-[6_-\YI]B PEC_HC8(3W_IE6Z* 1RY6A")P
M@O'?&/W ]S<2JH)V.0(/"*DU+4^G]3RGV^^HK.OWRI>F3W<5[>K_*>UG&)"4
MPCA\>J,2/6*IY\Q_W!+30Y"0\.%+7:K-7 A3P#>6C8:S,+ E'':[7%N; HW%
M6E)/P/PM7-+,301]X22AI;"9M>*DM\]=E[!H7-%0#1)^6T6F:^<CN'ZQ]$_J
MT@]_S0WFAK^$@;/Q_5:NN(T/@WR#C,N11S<UUM:1" 22Q&-'V$QK,5 'R.!#
MY@Q1B! 24)YY):#'Q1L9+.[74:I*@L5<6IF#7>;NCC4@Y[!IQ&9/I,Q?JCE0
M*UHW%G9HI8;-.ML#/=@."(]6YP>%[V,AWGE3GX.J4@+VZY G4D7),U6XQ)K_
ME4O83<)$(_X\;U(%*5JRR&!\38SZ<$D 7P#!8_WU'Z^>'YT\20"%,<LBDQ7E
MUH1@U+.U]$(Q+G@KN3#U10)47/ ]SI8M!V,2K;&GC]N\;@A?2Z6B[RH'::17
MX=8C8G?)OM*N2H S"ZQS40%H+9[F8264$O6-*X,P*\LI#N=6"*<SKT;T>Q*V
MX^27>ONP;5[;$2+DRD_):Q1!9X7GY0PWE5^IN)C#]2CDF8I?54]+>UO14O>K
M7'"(Z^UC&M1-R@79)NNZYV<#JLR0+=KQ'H-32E8QH"Y48P$ZK>BL^^@JDA@#
M+1D!H/WL<8:Z9[%SS"Y\E+$8=H]%+7QL1ZS=O8%WK&G(W7O2-.29]K=P<5T&
M'D@2$@A1C]L)6@^/JT7W]Y+;MJ:=:C6EV+X!WN*.[N$K1UVD]S0#JNPEG04[
M+'9+DZZ8ZQ7J3$I(08I:=0,8DMM8=*\]@@,<E#V;AE&;U<>2AA_V]>K[*D@R
MU)XC&F'&3-FB6DCHBSL4N'X.H6&AD2YIB&+-!*!ANX5E;Q;"#$7P#EI#1#9*
MX=_(315T*'0'""USAKP-WT:X \%'P @K&!F=UA8&6&&Q'RN&JW "% ;.D7S2
MOMT]T1H<_%!IJ6.";O=A-\9CWI21)S!'D+31 +^^M$>*&STR-,N_(]7@C@8G
MID;L'>"17<>;QO;ZL+UT)-I#1HKF+GT39M_6?:P]M86CZXY+8YT/^ 8FRJQ3
MW(#9%O>XV@-YW0S5/F*! ,G/^E>YPL=8K1M(7^L,)-^; 5LA0W%->*)6(1[[
M(;&PO&AI"@!J6Q[+>/U"$ I(&LJ;D%O=497Q1EC2&?[.Y?^39%I[AS6FD6>K
ME,WEJ U(7^K?5H[^G=M2,4&-T'*C7=&*GNUXW /&=BZT",C<1\GP V<&]0IX
MZ$1_*L1<WN3%GPR)RB,2>!VQ3-\#* ^B]B5OI]CW5"[X#1=4! WNB?@^]O>3
MQ*P*_0E:U-J94GVC B!%G5NK\GT[AZWU^0=;Y6OX$9XO]I(&(*&NX;_+Y^78
MCM(#6?!7T"=!$.0((KD&$1=)QX&3WP-&3@Z D1T8RP$P\B4X^0_*F-?BQ7;?
M9 -3L=%N%#EMPR%3BQ9@(E;.#"..*UO X %4K&H[4.MM;>MT2H)32A4*.Q6'
MB_A+[7W8!R @<<]H\>HE-ZS1>WA1K*3:)V!Z7Z"OY"(]*YAF(P>CE>" 5HPP
MD;S-JF_H.ZWT/QUVZ]$(8>6X,Z/[GJN2F,N-3?U2(@&Y."JB5ZSWDC6%L,/)
M1QW^AEY@;_L9BHPL*]]JL6[ABU3<[T['X/)*T3 WJ8D/XOBEQ/%GYBAP87XO
M"MM(TB<<+^@:)*SBAKJQ6UE49TA@SC>-2J!!\J)=]=Q_(.X6Y=L=2U]CF)+V
MLZ(:.7:J*1L;"P^:0$]LVE(I'CDF1?(J20O/15[\)VSEZ'JL;K;AU'C8K.@"
M3G/S 32W?I4.^O++.2X1:]PV[K=+:& OXQH.A44+/<??XVEY#AO^I302XJ@:
MSZU72'WTE73SM62AG ?3 MJQD#MOG2MI#<+F^/U+;1AM.YB$@=Z@_\UA>[]X
M,LRUXK9]%Z4?N)1Q:M/,L-2*^6>'_)";$5/\]L7ODE49M 4,-[L$IT&6KFQ?
M%QF"L/QP+TC?>K@..4S0#\J$5?*.T\ WI.8X.S?Z8;CW<)YC+]&YNZ+5@#6M
MME=1SJ77Y3BOC0^TA1VC,\D$F2K-A%% FE:E=,#^!5'GVZR5Q1N-04N=./L%
M@L9;)U-)&Y#KX7BO#\?E*\3M@JYC=H.M;S# '@'3:ZT;J^=,RC&\@V;[&EL5
M-)^E,RZ$%H(20UZS+^>IMO&RK6EI'!U_O(Y:ED[K?("!XBO,A<Y/_7O>V2:W
M2M5@5>&[%\\F'ARE5!@#),%!)KY8I(<NCQHI%@N1XR8YFT4)VC8(5TU3EY.1
M(\[=CV>E4J<QN1@HIAMW[]F#+CC*#"6E\EWYS&&/OV2B;;- 98EO<?H=AJKT
M">FVTHUL?HT!%V')!U?"6U3I57?S.N'L)5J?*%+5$8 )KI7]=YK,(H6$G04X
M6EML[.V?+<!0:=:F@"KPKMGZ"0=^GM)9&UFGJU61/#RY0A5)) XX&-%).;K&
M\GUN8G?RP_'7.2NC-'G1XCP^OL?2^'O%K33/Q,"<,96YP%2O(M##%;Y&7?1+
M77V&<-W??^&ZNS.R=?+@^,Y= ==P1OIFN.^_C?AX6=VL:H;5+TR:*Q<<%S)Z
MVL2RENY;9"_\W51%>8Z"F F/ZF\P_0;P=1@>($T#\5@94@I:SBFF%<SUQJKH
M[ I^$!%\_\PD2Y>K/F &Y.Y@9MN >8R*=WV;+L[!W!8\3.M(4&(I/'?WXC%S
MZ<D2]P"Z@/B@G-21H#Q3Z5'C5=JV($^3UVE>M#"K@D'@POE]!5K>'\_7E<GS
M2?+&5%6[+L_2JDB/4:56 3972C&F(_$F2\\V/N22%;\?,E5^\K:1_!,VW1M@
M]>+7/26KONVXCC-M6W*_>S@,[=/D7=UWB^0=R>=+I$R*-JLGR3,4P=<-?X^[
MC9;O%_1/O&K:I.W[-+EU6A5+&OI/G':Y'<YF;"+@_"@4]#^(N,13##[P=Q*!
MO%Y.DG?G1?<?TY2",LJ39POR7XX'):(1)7J$%6I"4M!@1^6%_US0R\C&()_F
MG>45WB;K+#<B\!RU9TR]GR3B0(N>!F*343Y=UB452 JMW&Z)E6!R;WK20'7R
MMLCJX^37;<L&CTSH+4$Y7N0%JF':F).L/A?^P$7JZ82--).+%PL%99*]D$J:
ME5.#^.S?TA6XE=[1)],5(T=%9$YGJ+R:!#5B/NB&=:57F:9*7O1X&HD4^'V5
M@E@?L#3^":<MCL1IW&37CL(RYS%=P\PTC40J; &QKN7'L2?MMO)^EJX*I+.8
MFBXO.F[T=(YHX9_O'S]*IK0@JOZ$U?7/Y$K$OSUYPNOZY[O'#P=_>,R%W:,B
MA4H@B3O*"M.WQUYV<OQD_&4G&Z.@EYTJ I7K@:()#5YU9_15P^$_F=AWG6R\
MZX "<RBPNP<4V Z,Y8 "NPDHL,@&L!Q P;V+JU9+O5?.# K-."8<'[ERA3NH
M*[HR($8.JG>E_D+87#@X,3!( MZ=M+.]%NRM*4@8;HI@[2&$ UTS,U?U*QUE
M,K*JC#(&(V<CU3+<3(6S4^>F+)W1;/)+!R(SG&G4*BQJ^?_9>Q?GQ)%D;_1?
M4?3.G+ W@.9IH'MW(MSNGFG/],-K]_3<LS=NG"BD C0M)$8/NYF__F9F5>D!
M$@8,1D"=^+X=-PBIE)7ORLQ?NF1"=/1C;80<VR?(*((&+%J3@TX29!<3_!$S
MH:ML6:?&!?5%M@Q%Q295B0,A+E7F%=C"IJ,UT?DN4]WQ3&H+9TJ&8FFJP3S[
M6)?FE0RIE4<6=2BJQ,4=X/%,XI7'3?&21#8>_\FMN8>]$SCIB)<+M\"[<RN#
M$5M1R7<Y@GFBP.1<_H#3;# #C$!N5GH"T9(ZDQ53#MW-4P[%0KWW+$2K?%D(
M45%U@U4'W#J2$[<OXRRVBIP?@E(C8*\#@[9#H(.KH!^;A'P0#;P&; ^V)9IT
M]$37@FLIL[?)>59J' P%&M%4HJ=B2]Y;1$I4V=U/7LC_YQ^-B_KK1CV^T16=
MU(_@,4J]O,M4EWU(IB/)^VPL3]WZX:?PVN43GH\89M^)DNBW,>[/ 6:'0^-2
MH-Z#8=1Q31+7M(KCFC6$K_5"!T/E#B!.+1@J'"A7@%SUZ.^>VR*\^\[-B,YB
M/V-WBNP>0#_U%HOH,'<7&F<,2Q$8?:6 B:05KA @S1&,8KND46>2!'B&3=@,
MCO= '1/<D#,1P3%A"I,._YT'D/*)AB<H3//XI@ASPQT1?A HNYSM0?&I[[-X
M2H"?FO!$L#0\?,!8CF8,B;O%O;LR]TM0<6?!^:,64QJ1N;V(C8.(Z&*#X\,R
MJHA/R*8!?Z7^>(VE^0Z;O;)=HB/]Z#4&0=@\(F\).YYHV5I=:-K0A_]OJ?O+
MKVOTU<O06ORNV:]UZKW"K^NU1N%WRV[;J?4[Q;_<]*X7C5JSO=IM7Q(A!#&
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M;GRH&;]P'S2RI?5,2L]TM)[9M<<@M,T-2#1^(O5+Q;@3<%RV25F'R$V&1LI
MY$;,%;\!BLDA23?>5$ZEGG,WI#Y8'H5@=>IV'II2.IUJ\FRM?O)CEI 9ES7C
M-^9CGZK.:<;12E?KGEWY.#+1P(VJ$FRL._0]Q\EQ;=I:<G,I^Y;#,S_86F /
M.+VP#SHMI ANU0B!#VR M;<>==DMG"PT&\4Q!A;_XZRLF7%G4A&/"%R^8 NY
MHX(% J2!Y3SRW$]P(Y6;Z*8BB&8])QS)?X)Q%FN/;C5S/SH<P3>@KBX61UMW
M\53V.,02C?*!9]K8DC;_X-]=&V>SR0:SWT,V5OZ'HH"N8YJS!"&_YRZ6,7V$
M7SE.MM+ZU+771?WPM%<)W8W'CE#?T\00T#Q>Y*.66E+2M"Q:J<S?"'0:Q"D,
MQ^FH?M2SRVB$8]<QQ5K-WE@[-,L2KE]JQB?$QM"Z01*FK=,@SZ$;/M(4<RR+
M6K>ZXBLST>U(\A1".ZB$1.:XY:(Z=[N/" 4HBK%$*TIE;B83>2+7V&?H6@5/
M2-VR7<T^;G-E(S>LD%N.6AG]REW71LSU_S(\U%U#&6V;; >EJ5K/1:?GT&3/
MU"6Q=B6(P.($1R-R ZZ.7]3HOCMN^IPZ\!<CN/IC92#SMT[*/WKSD=@-\T,7
M,\57WCW0-/1<XW_89/K:>!-AT^;(^/#A)J.86LG!4JJX+%9'+ZD=[9!;$:_=
MN,N2PF45Y\Y-:5SLYZC@V&BJP!<(TF2->+Q/GLK)TYP4V%P;1X,'Q==Q@>)X
MCYEW"(9;=='M"8&7'S]3W$R!)6 X+/HE81NSH_X6.R7QV<E3S;AY #/X3(R-
M$S-OL*/'LQ2N,4?,<QQFHR9&#O#.8K*-(%3.HW"<7N0RUYZ(B9>J$7.N#*\R
MMV@U/"99)A9-$1*6%"*)KJI@M5*$3Z!.8X(N(S8+Q+ >G/MG3+@:J!>_8'8[
MX!4:Z=V@U:L!. 0I'J\1[T)OE;Z#D$=YBPIVM\KIY,#(RS!P$"U,UGH+F)WF
MZ[0'4<G6B52R9>*BUFQ)TD;>4;X&2"MP*4+!2#2[^$7U:(5DM$)[SB_;;+3"
MA1ZM\/QKT:,55ANM\$P"EC\AX>;R]HL8=G!]O:!VMKRD_DHB+U:S\0BC_E&.
M!.N4<*J10#-#=R89IA$;5*Q, -_FW5^1C6C:MQ++YR[TS&]CS\%!@A\)WE/X
M%->(%.4;-Q+EDV9QB-^BIQX=#7Z9@-50XQ@G"0F!>C0-0_I$\_Z))">1#P>2
MX36XI/_U_&_RTW<*&>7LT__>O3M7<QSAPF V&7B.\?'VMR5CB%>GV=K#7\I"
M_$MB*QEK"373BGU$@7M&XXP)9>\[.'HA0F8VZNU*OUXW@C'SN6!=NH^/=L):
M9<.*^?8$B"XE>YJ6;"XD.X@E.Q[)&8*=19@8-QP'AIBV&9\)R+VJRTW"'SF.
M]Q"\6G$J3 O66ZPH]F6%N^V$2,O5WW$-OVEW:A>MXJ^7C:E9_EVGW]WZ\)L&
MW+;=U(O=_F*;%[5VO[.-L4(J:UG'G&7J?J=WZ9[GV_162MR>_2 LL.V*_T[$
MV/P@)^?Y^)[O-5.]VOO>4)9OA;S_=C9\Z>L_9QRZ&G6^>"%S!"-\(K2-53R=
M?2X8#/0=.H2K6N5<>=P3)THOP]I)2-FI-=4JZ):O<*BY;3ZZKIQ\)GIIU68-
MWVJ>DV'Y(M]UEMN7=UJJ]!+6PD9R<O2-;YN<@H4;9EL&J!WZ!S'K=K7/3LX0
MRR?IETDT*"C\%GUE7_S]E3F1_-@;BO\^HA9*\E9?\(SM(YL9_\M#XPTW%I3"
MX>BSW^-$QXW#!+S4C>^-?#8)CE?#/5:;PLQO(T*9K\KW-4W.A\/C.?A7(UD:
MACQ6,]0GK94&9A41:!T%N&TB[W4*93Z9)7$U1;=&T1\P9:+IN3UZ=BJ]7N_@
MHL85WRYNRTCT7/Q1:Q4V.CRG=^N:Z6A)L*HJ.5X"K"W[CVK50U *\9%(HA12
MIR3[MBV'Q4(E<7 .BVBE\&$.C&3KJZHE!> 'I:XHN?O$BO>U.&9#PI60:];0
M3IIX&VLI3;I5M=4J[0>M^0J[_@H%=OWM%ZALE*=K;B-/MYLDZ)HOD=Z!9JW?
M1@*GX7$MX$S7"^/*' )<HB*GP+#$W/.5*W*26C/$CQ4%5/=)"T-.QX+M&JFA
MRCVL?X\7$DT)?+V1P5X7=?5R?5@NA("^H4]X5;.<NK:5RJ968---ZZ]6^]W6
M%G!ZG0&=N:RX!I,O?6&\+O+?4Y$_]PGF&/L<?_'9='P<A=2B_A,-U0A?RF!!
M$.$C&-J..AB->QZ$ G30C8U6NNZWT1$]6XCGG%P[-)CC4!\8O*1%P.T&9^;X
ML5)?,DU42&S<48_GC=&!95P#K;Z+YS#P&B>D:L%0<C!]&-=.\;X3]B>8M-]K
M=S6!\!SYWI0SMXKNA65,X=839O*(/ ^Z"7,)4UZTM<&#7QF7@\%7F\/CS%K%
MN)R,N*O^QM+\_W*7FPS,LUDQWOAV$'I.]>,,2YGO_HKLP4"]5<7XU1N[@2>K
MLD2OJORH8KQS;.,#V.19/,R4?O*+P[Y[=Q,['/^&.R6>\LF[9^ J!<;E+Q7C
M9@A[Z\L%W7HFT.B]YU#%.WY-N-C,]8:V<7>Y29G_7L6+Z  T!29 "%$PN-7_
MY<PWKJ))) RP02&P<<O#R'?_N;_:@!6%2W:))@QPY=4J<O.N8@Z^00[^A3B8
M]F^>YU>O5RY?=?)%M];O;E:=O+0T%V*(#4MSE]X6W/OV;A:[VFVW7YI;MC Y
M'Z/QG8MAC:BVHOK.5%70:9S+Y-,%@\*7:%^)-%>7O]S^<Q^'-'L<TO3N]NJW
MIR3(C^F OM';^UG!$9&ST?SQ:;(TI/\['%FZ>??NUOCE]J;VSW]NQ$:/OV\9
M=WFUP<J/O>Q&,G.0!.L_42H.S<*DW.UM*-?#V.1F?:7)6?K4.5$C.6)1>(B3
M%W_:DY$1^"9$;?ZW*OIUC6:K\7^C1NW/Z>B%P9RPX)ML7KK9JT^_O\X&?IW%
MTQ1:@/A:QG 7S?;T.Z9K2]3UVNW4+MJ-3<+*9K?6;;1VT?'9O=A! *AON]O;
MKM9.N_N9MZN?;3_+"-D]FYC&UN;('@D]M@9;?"3TV!KDR9'08VN($D="C_Z3
MZ+%L=.LVQ]_NF4K-^E;BM5,8LKRM9.+Q"Q^=^&A*K4*I1J?VI$Z!$Z)4J[82
M:KNF5*=76\GV:4KUV[4G9;).W'UH].ISVFO34Y!3\!_B Q3MIV_@*IP*0?H7
MJRGO4Z%'HW&QFH=T,@1IMC5!,@1I=VM-'>NO<)0]1Z8G!OLGC;BTI7/?_9"R
MC-RYI92!IF2CT=24W XE6Q=;23EH2C9:=4W)[5"RV]@=)4\]G]&LMVHYYR&%
MA3I91([>"OW5>-'.QC/2#5?M3'[QTS]E:\G"_U)O282 XJX;,0>;2Q["L7'+
MPJ2:_LA(44B+FZ0_C(GYKL8# JPQQXP$EHKG(I2:@! QV=00#\*N:Q;8P6E#
M?7P9VX&QT/8H$.2PZ9V0]OB$*]@]VS45-"1UK?M\R'W$IX=OX ILC1_:A->8
MM+HGR S&I4E]@XU^JV5X"]_&R"S)9>V*P;^;''06W!TO![)A\R%!'Z::#(U@
MRDU[B'K*F:57&1AVF%EHS;@&?@!9P*96T86XQOMC,V.S_AH5J&D3(!W.N_5M
M',H-WS1>TVNE+P5R<$M]^6"#F-);O[O"*X-H\"<WZ>5N^8B:X(!;&^U+_++1
MOJH8'N*MX.NZB.2!XP)L'"U@N^D?W%5_J\@'X\T=FPU@$XBF0,8 P?[PMCW5
MF;D+FOO\KX@'.&L +PLB<PR+)++2PX$@.(0 V0;>(X=^1(Y5-U%RV^.\)CY-
MOZ0&#4Q& UQD:;$9:&"O\T+/$WCVM>AY DOF"13@UI4%I*Y;1I Z%R06^_KC
M=OVW=F!& 4*\4MORI<N<&?A+HG5;8=H"0PE+2M?<\B!R0KKDLP"*]=QC0:-+
MAB@H>TK&% CR,Q@YHU&O_F:,!-ZU@T.#B'BP!)K[@\3!@C>P8()"^,&,,PS)
MJOA?,:N >N,#L)7A ^=N]J>U](; HVD:T)JW@P7(V_6$F68^)S<';*T32;]B
M[IU,1L9[2/$&?"W=FATRC'*6X&&("FY<7U<,(3=%DR5D&'1+*,'H[R?+5X!I
M0U@<7$+$R4YGR@RZZ!ODK]$]8O#M"S&]*8>15[20O1?+N7]_^N@M#TS?GBI^
MGL/JC@+X0? H=$OY!;AX4(-Q)@9F23:1G'6.V)%,H7J/"<4:) &DQ92^+XF/
MQ1UP#6E*E^O=BPD6\F)R 9&;<3"8%XW&-(<+T;AC>D-4 4ZPB^-)[IDI_QK8
M0)*1;1+.(IO:$DN<"3QM>7,( ZS(# .!=EZ T8W/QA7',)J@EB8DM3(D5G<1
M<3 ]1NH!(WSP4E#? 1^AH*?'J(BX*3MN10A]"O<[]4/PDFDN3'(# >DMNH[D
M94M"\:RPE)C3OBS21;Z>(FY@C DJ7>WE(A$E-Z2V^?V27\3;:,*.VT$HE20P
M#UU!=P2^NX<E('_"_M..)+8*6)5B^31S5A*D28S:U, ?L7(P;I1/S/(?O*?C
M$.)JP)>^8KQ@X$S85]@###0M/QH!>W@.#YBCX&Y]'C(;_U4QQEXPQ701+MT#
MH7-I3?@VIA(2Q=UI>941,]R/0E*(/>6W$V:C+TQ!O^>/0,#^%D)34>N=@=US
M^1!"3W%CN281D=LNL%TH1'QN?^:W+[TQJ8V8@OBST+?-BL$L?&V37@B%W0*C
MF-()"9V8!2$3W JB8+@LA)6"A06[BLH;XF:^ZHZH>V>W(+X;27J\$Y748RS$
M+[8'$<TFQ+6F]@+?B^"'CT2,<W49>7;XSD 6"_;2\:;P%SPO&C(SC/R8%3'=
MB#8$8EI0=I1]@/V_YYCM<-&M6$'P*\BO#[")&;Y5CE?*QN"/X4WOD042T57,
M1GFN6(SQ6N#(T/<<7!&\#\=ADN!MX3@O,6 +S5I :,GB:IJC13X;D83R-//,
M!J+I(1L*.1%)HP 9/8AP"A(]:H02#,P&SW?!BT:'$W>:<CYJG4 2D;X2P[,F
MGFL#MZ$=RC5[DLF%=94"![P<$UJP\P+?RC<1/R%5=AQ,JZB">V][40#$'C.<
MJ";8F'3BG>24F*?)F8ESBXJ1!%?%/#;TP+L7O@-W1Y('*XHM&7K[P,GB5R8L
M3MH^>2_8$GM"TTZ)->]Q\@_R!"U(^E$BRSH%3A#>0'8**W(D7C%&WP&U-[+$
M0+JH/(A#E\3<2L??!]7[%WCRP! B<,IUY0_-I5VVV:YQZ3@VFK:%/5;J/H[X
M0&O9]RAL0]^;Y$97(@4*+#"VIR*#G9Z4]^%&7" V#RT&A7.?^'<[FA SW, #
M/0B:E?L(PI]$FQB+KB9[.YA\G)!ZS>,H!%!SX07NIK"XS\,AOO$?'M Y)IH0
MMXKQQO8"&];$I-YY%Z#/:P=C^/4;, M6H'+9N%BUH:O0HU5J]KQ.!] @<14Y
MF!CHYD7 F!9I;'+!*!A"WD%B@@%)]#BQ)%[WD*'M6-)V,$=;GJ+M0- VHQ^(
MS"Y_P$F5%I]R(A)X-Q'\R$07R&?(E2K$<QF>^WQ&WQ 6&,>-QIG\Z#P.[5AB
M7V0@+2^)ESS_#&%<84&Q%<.IF.!S)6YUYI:@U_CWJ3"9\"M09PYL-KH%(?M>
M'>+H:7E8$YMC5Y X?6/R#&AXYI!;Z/W3(<N$XTUPK/04Q%0^/8>6V2011@;
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M=<_(;^$0;8^Y@TX%K DQ."O&$%/94P21#2/$1/+EL? ,:SOLT'-YK'(1?99
MHL6J14[>\U.'.\$4E H5:*?6/,6H%HQZ%2M>K(S6%([A4I;.>Z&4C3$9><=
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MB6?ENJ=-.]1<IVVZMNG+)ZHUGC91;7<6_<2Q[3YYW]DP:;$\.I2* @SV9O^
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MG/<DSFMJSM.<MP^:]^OKYH2?T>P=75MQ25MVBDM,]D$NA 8*$-&55WWJEQT
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M3KBY7%"&?9^M4AW./XTKYB!J%I4CN5YH3#AS@1K#R%FIJFCO170KEAFIDOC
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MWR.D=/HM#?Z*#>!AQV&&'>'#N-#$??O;OS[\> DT('N^VR5VB+%IZL_W' =
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M?\?T-" DG0]+JU) V^0#D#<(C$C2: 2H(5)CI,U%J&PH1QU3\2]@?::QW_
M5ZP>C 5J+ID,*]%NDYA61BMXT]DUO;>OMB;X!SU5,KJ!^H2K7@#VJ1+8A$&H
M^I@R/Q:9^$[]X]TXS$ %6GX7QH1+>JFBA9H)&#1;'#20;=_D^O+G)OU4*IGF
MWWJ]YM5@_<^M9GOM;YN6;7>:PZO.7LMN_JW?VN_-T]KLU5;+/M '\,"&IFW/
MKN7P7K8(/J8)V!3K9TNLGG>+IIV'^:C$9RGRRD+EU3?WZH\^U/7R"9M7'MA5
M.#]# 2KE<;;2<O0)@<&!]Y<!Q_56/=%0.WFJ V_3S?<( 5=--*BHU8#;#W!#
M!W#[-MQ?"Y(#Z*6[96>>CS,_G?N!*&@[VDNWJ);)3P.00VOF]-@.NKL=_E Z
M-:WAQM>-0:=S1)U$=[V*+]%<_N'-;-U([:@OUF.[I!WGQ5HC=(:-;N>J)NZ:
MN$^1N*\:P\&>TUJ?E[A/?DJG6QCR@/ZV2Q/:@^XCNZ8%>J/?:QV1[E(/_7MA
M_ "!M':=450CZ>61U'M%)+V1Z7MQ$E]R+@Z'LYY <!S#H*<U@N.(A,8!STP[
M=N)8XYP?G,2$QM-$3KNU:UOQ QC3=ERBXHT9$>>=3J,WW&'N7ZT@OC1#;@\;
M5_T:0X>,H4'CNOLZ&'ID,.]89V=NB1E.CO1^$-@SSOO=_RKV#?*=WE"7IXT#
MGM!0EVK #!N#ZR,TG%Y]GLQK\*4]0S*G=\>?-FIS0G=\C7G5!DWK<5'+^J+5
M%ZV^: \!!H1IZW$!U",8D';8Y9F;4^%6^Q"J![AU;X2=6K#P?.RG5:6[JUV,
M*[L74A=D7KCI;8SM/K"A!N\(NSXXDS6J-X6E9RLM<A[>X$_4,"?'6IX(NWCX
M/#G(%/EZLB+=:HTV"\7$:D0Q%@$W7YS[7T0JVY68YAFJ$E@VVI_[8:R*A<VP
M$*O+!I7"KD *SB*R( U'JK-?8WTW2*MC4:FI)!QV0X-RT] [ECWXU"9E!1(W
M/\F$5:VGZ^.%U981SYC[7$^^P&Y!(RX5M\?/U$W<^BT7%G43M\-O?%8W<3N,
M)F[S) [S1#=;(L9MV-/*# .GY;U5Q3D)OXJQFKL!4I,[4[*,R&R.!A^A#F4I
M>9WHGTL27P\P;MEC0WR53^@VRF-AM[.P1)\K&TL3!M:W4D!N;C5,)9% O?M#
M[.YY66K(82!3-9MO48!4\8G-4Z,1^M88$2Z'ZFTQTJZA^L<^5^.Y<C/=,OS&
M">%&SAB0S4"T9"0\P 5:)"2Z) U9+;Q(\K%XL&?KS<.,VJ+& AOZR%+B1"],
M5?29V_\CS,4\6YUW@.TQ.JUW%)^B?[??Z1[#*-\]TD8K>K14O8BKNULS9U,
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M_;9TL]*8O]T>5#;F1W()3>M/0D!*RA9V,ID6W-P]T]NB-OB\*_QZ56LO.//
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M+_JE1D*[L\18EK)@L :^<,&_<.1E!Z=>93-:U!4E?-B#11M2?JK2-I$$,[A
M(9A;/CG<= \[>-\E!#4O/J.A749-<W!X_'ZA[>\NT!*6(M%H015/9->F4;'E
MM<&@68S-]YV 8R 0MV N@'S,9]'2(4#CJ%-7C8A6.@:SU3TUO5_,XC0.CB^
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MJS[R%G3;V0Q=X/571V<SU!T*7P@]G49_N*<J4./HA7#4;;3Z_:-O(TG?'I#
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M&MQ(K7?=X8UAYHU%+M(YK#3V1DO/7RRB)7KO:(8)$$&1)]C,%Y93S7H3T-Z
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M9MQ^!U'?F@))LBV!O<K5,"S$'',*6!2M.[25!!@X9.DVO8]DF"G&(CF&N@)
M4GZ6LT(5(Y]7C"*&FR@M7?8YKW*%</RW;Q[V(;1;_6\V\Y)G" >N\(F59&/E
M&19^BA8AQGJ,RK8-!ZP.=!Z,<::/]C%<4-#R)$PSS<*!O/$^1TMO!FPM0_4+
MQ!A8/6.2;9EL6R"510IEBKL0]B'#,7_$(?*XSSD]C.BGQI&L;3#O=@)"'O)$
MP $8$EX 6T,&;ROY<,-)5T#-D/BM$BMRP_J&RXV3ADCX64C\X'> =_PD1FGA
MITOVP'<Z#>(3M$/%F-'^*#)R/X1X]AP%% @ V"4:X?QFN^GA-SNM=S](N? L
M >N]Z5.V&7O&GLA;4I6WC@D0^-KO/)!;=V*K9(@#9PD4W$Z!@#[$EQ_3)$!=
MX3$<\+"YQ8<M-217-9SYEC9-MH^)UI)DOUQ(R)D+G";_1L^-=S\+@QGP#78-
MYW"8DJK5@.59D5H*Y !^@&9A+H)9#$"9$D^9@#$04A1X"3PE!YP$8CX2*=^7
M;IOX08LW/?(C'UW/\)4/'S]1R[X?O7LXP5FWV=%IEL8,V#Z#[22L )07!BX:
M3>0] W.+]/O8\=2@DRHK1OB< E48SP0S[##[PI*BB*5Y0)$$7"(MINXZ*$]R
MY,Y@+V2D"-)75XP0I 70PE0#QJP(D+8F!0@@M2#'[^&E2$A'OW,F\BS1,_ ?
MDQ"]#4M\? YZ98AN%'Z'HS^4X0//C0LXH!&6%+QE@F4U,>,0<2#(,;E D]./
M,E;E<;6??KQQG/!:R**?+4"HE"!I0 94_=ER48Y!IBUUDH3ZE"<O64,%+<I2
M%&YEA'H[+)V,.!5%O8JNT2AJ>/=)$8UY?5QE@2Z:V$4!G0>NH8QHT!.%,.?,
MA (6:O#C<6B4@]#8B-)VJ, *[A*_37YDCFF@^.;HAT4O=)OC:NK@[3$2I5,6
M-/:9-XF2^PR)##F622YA/4'R+_C%[(K5BSJPK@/KW3JP?@![J0/KVP76JT7M
M*]V=LBL4I4C3^S#A\&H0ID$Q!V4"F#[:4))/!V#Z-*JY^9I@$\@QY.$H(,?H
M7Q<@VOS)1'JSXK'#,>?^TCC(UF7L\?[D'_3JR#I3$)9;*?F'K?-\B*5^B&$<
M=B^3=]^&E)8/1CA4@ LUYC!^GH*0QWLU.%UAQ5QY%0-29DJ0?#V[;JD*@89W
MUAZ8.AS<\5F[US$_ Y5CR!?D*]#UF]72C5YE3*H2=BUOI;1@1V*2H%(5ZP1T
M5NBE?LOJ%QE8F\RKWV<J,Y+\GY:*76'<X1;& C ]1K?K_4R0[BLC,OP,ZGFC
M-"G@<!*'8#M2--,CSQ%12-E.H#A^Q/H;T $HS?,PM^(]J&N##KE>U:;$!*G]
M;D<0Q^"GT-:YOO*W3@R!8/<S!0R$=Z-"@2>0@$(! 9GZ70AIB9&Q.DF"@M*U
M8HQ$9042>[+ R%,1RZPV-#)G_AT3\2+)*>01X1KC%&TYT-=G7@SPO)1AA'AZ
MB6%6;YHF]_FLZ:F<'C3^T%JR<RG8IIL#)"D4,@(ROG_G^>;^C@7F5&4R'UT5
MG,2[AD6;'!2AB+1BC_,DQGH3Y56-8/=9X"\X,LN;KX+%7(B\4N7(<LSP Y[@
M!6E(TO\TA/\__1B]QU()8#CZRN]WD_Z?(A(8UEX4([B+ %<  R)I%"8+)YF$
MV"'9R(;HO@"N,O*(  ?-*;4P"S")<;G"L%7$U FJ+N#F"@X^ ;8"5 ]3RXT
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M%VFR$#NRMA)? V*>PG-3=J.?==HNAU/\F'SR=IBPYBX[<Y<].<AF79&C&J%
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MPT:,Q(Z=5_NM!N#T$M02_+_>6)6AJJ-*SDG0G!IHED^ SX$YM#"!<?.P-AJ
MHL; 9@)*4$K0^S)-@-. (IU$47*O8O#BJP@*(P+0#"[#1*O'$R'&%,%QX,M]
M+*S\ 3_WL4ARF<C</M;U@7-C#C:S?-O(NU<)?#$LS[=-T8YO93\ 8JF_I52Z
MF]X/RIZF7>-.U/[4QDWI*-[W@.-<$C=5<"9R5KAPHA4S/YJ84,5J8L-]DGY!
MB-(*!)0$09)BB0G3&=*K*1]#)]BV+8:/E(LH>UZU UFUYG<TYL\ZS:%))E#+
M;IE.@-@"S';:5RTKH4#;R__Z^3/<2AF>?3@L@C=B@7D$)=?D911^P4:2<(S8
M/-3VSC_]]JE]P3=E8WQOB^#N3  SX4PX)R&!&8\37MDW0T&KD*60!JHD4MNC
M#()A29DZYWABB+4K?C:[H"W5VLANVHB5,E.MB(C3TT,<IXL=-?V(]Q< \;MQ
M?JD&.>?RMXN2?@)8G9!*<6>)=UE(S-J[E/3HUI%<2GV'$T3*3&DU1411#EY>
MRD*RO7,83,+^38PO6PH4(&9R$G.9<Z^C\$X+#[_(DY"-+I5*)=E?WXHV4G8(
M%A#I1G:L>MCZ!GP=(U0R[*F+'\_:S6'/\%$%891FXSMD);B0J6?&?6([.2Y4
MYHW-DS'[-S.+)V(&'C%M^1#Z0],$RY_&FQ)$[!86)<4#(S64AXLAH6*4A>,0
M:*3!F&.M$4[IPX*T=H+=(0CD$JD81,*X38Y'5*8E?5D>6N8.N^:CLQI69IOZ
M-V7\HBJC$ENMCE7VR^IC+GYRE%(8<0+._6]06G.=^,RXB@N2HV:')M-1[YW*
M"B]I/!^WH-/QZ894Z#"3Q#;J[_V0/B^;1Q0:$__PT_SR<Y#D^>6G!,Z0>#=H
MYJ; '[P/<\I.84_U39!;,;$ ?D]DWH@"Q*JPP>0=TKIDIR_,J=J@5.W?F.+Z
M8!M3W/J<@_,>^?N8.R\?/[]6IQ+6J=B/?G:U*KL:6,;<<__:ON8ZBHXS1H9*
M7)H.L*K[//"W*N0DUFHTKZN_U5[9Q)!I%BYPRD&'H.I@NO,=U^!<J\X0I3P2
M]!&I]W4E@<JZ-6H1?9R^AQ?2-1SA=3] EH#<W@T!?A%+JX9UEUVS:XEW+)L?
M<3]URD1U-Z![=,+;/Q;Q*%FB>?8!E8_8,<N*!; =NP@Y\HLXF(D]^V>Y;BQN
MM2G[N@.7F&.)2(X*]1D<R$)A-<C1,L6C7\+_7)V =O1C53=7Z@[07G,!!NLN
MP%7Y C20"E@G@I\[E:MUUJW66EW-4E.C)) 5'E57&&.).>6U5AQNY<;I(H2U
MC<9);^X/W2JM3K=;7:756.D#N]KH]HZ=KH]HI;ZW0&MWMA9HW_]UE'[[?1U1
MU!'%7AU1/("]U!'%[2**KZ>9WJBT#(#[SR&82V.4^\@VE7;W260)Z JGH+"Z
MNA1P^@25'<VT*7,?2%#$/K4]#,G6FQ24N%_M+6JP:N>1U**&8Q%:FR'5RC>T
MG@30(1M:J6[<)]0'\QQS'[46I;4G$,61; W*!JO58D5:^R"B6#NRXZ0/JCF2
MI?<)!325TS![F@1*">B+3'RG_O$.V\I'_O*[,": TDL5(^L-6VRVF#7BY$\S
MHE3^W*2?2N-+^;=>KWDU6/]SJ]E>^]NF9=N=YO"JL]>RFW_KM_9[\[0V>[75
MLC0&5A)$Q=#ETJ39UYE1O(\KF2C]LY =67_T<SU5=,.(Z77#H(_FT0>PN<M0
MX2-#]?D96B72F,@NMD#VOL!@]?FEP;%.5Z##HS'V5"?>@O2.$G+59(/6:PVY
M/2$W="#W$.]Y8!+ZDS E6.25P/%_97J!='?M.0[^82"TO /ASQL9TMGSG7_[
M,?>O<?"K[N"5XM0MT^SWV8"/O^Z(A$W,\%'[*7/;D[UAU9A^ S>L^N"]1J??
MK>F\IO,3I_-NH]^_/E ZWUG5F]#_.QYM3L6^1MQ?CO[+SO2GH=24M;/6>.CL
M!H[*VWAX^DWWJGE,"DXUW>U*\Z\!Z+]L8Y4^=-ZU%NFQ$^<:EMEN=DZ00*H/
M6Q/('@32:EZ]40)YI'=&AJ<ZQ^N@N<7H' ?NN,!%=L%..%B7:XF_U[UZ/+0.
M3P2UFMWOVB\!C6T<IR<&\6H:;35[-<1?&.)7)8@3H_R6@NG'G%'Q.]5T!I3<
M$,:Z^DUE8ZH,/JJ62%62G1I);+)AK7Q!D\^:S9(TYW;&9"+)9 J588]Y&3);
M7P^"<IIQF^0]ZIE7D1U["KT&UPD<-WV1\T1;5@O9:M2<M;LKV:'7#7L(W@R^
M+5+3NV;M#&^[ \M9IYR-O?KE8:NGTS;EAYO>=J=SNFN/1&6':-7ADI.9N'XB
MYLE(G %D#ZR@RIQ&)<TTS.AJ[@6H$JDS-7D5MHH++_QPO)*?<RH$5\C>/++,
MLH+8KLMTM(KQU:S_:S>GG5:B3N>QQ2R "J+D'FD0ITIA"96N0N9.6EATHP>F
M6N4JUFS5AJ+C@C/@>083UD':,VSQ5?E<-2G@_-V0VG,FDPE.;C1[TU2QQ6Y.
M(#O=H0J94E=!%5;E[EH^L%JXP53!@+41MNE3563#H^0U=86Q+6. <:54#9^M
MV1F_#=)NX]N&:5IM@BMHPN4BU:14YK78E1<E(26C4[_^B\;:NQ!F6:'&":Z^
M)9?>S*[D4('J]<57[-[(V&!.F"RX NSXJ=DN0YF96NE,=D"@O$DLE^$)!KI<
M419FFXS2,*8IW+K^P=0-PFIIR (K(R*I^(*IH>GO6T/#FQ1CMWV\K+DR]2$T
MUW)U ZI(#T0F',MMU&S*,LHU%;JL,'. 9(T 5]US8&,%MA>Q:S,K]B&K,SGO
M576@4&2X#MB9G.(N;R\.]JM2'4(UI\^"ZV<%34I&Q\_^A-/YN.V0,R5PPPE1
MF A57S6>AW%(,RJH!F5E,B!J3EB8Q065:]0K.JW"IX&.AF:8\]Q!["G$'2[6
MPV?#+%)3;I,[MV"L=HG49,T,D-34ZY=:D[I$ <^-A*KS7+\ONZ\2G<.<?8ZX
MLN9AM.5&L3S)_A93"[)J:["B-0)2GD*/0-%D I^LE"8[D<B6"=@XLV9O;E@7
M^Y2*??IUL<\![*4N]GFXV.<IKO\K*D-6WR+07[!>&!MQC2+99R>34VG7"19L
MQ8#%T-AV*OONU6M5KJ^;_<'U/J4JW4[S>MA]CH**7K_W+-4?S[#9=K/#T#N.
MS0[Z^VZHWNR&S5XWA]WMJ."D:X ^*H7]QT*@Z?Z16JR\A6*@8WKTZ N7KNNZ
MI2IH/)QE5U??[ $YM+)KP.T'N [IRIUW\,]N#</]8'AE8-BK8;@/ZYN)5)"W
MX^!JZ#18-CE5GA,V'W4#+,M^?9:DXUYSV-M+;E>X[Q#VE]UF&Q<L0Q0.PTZA
M\_9%R1UQ8E4=VV'X](HZMCMWMW'5&QYH34==NU13^=.<^WHPJ&F\IO&3IO%V
MH]/=M=:DIO*:RH^+ROO]6ENI:?RT:;PW;!\HC;]HE;45Y97O7^+#!$0[W'WY
M#!TQMT/4SPEVG5[X2PHX4^6 G'Q-Q0><+(?#A$QE0K6M?:Q%CEOR[,;5SIK)
MTQ0YUH6H-8Y.!T?2PUUCJ<92C:5CQ]*^<977KV[?5C>J5'MV(:Z*$Q\'<75Z
M($WW]#B^@BGZ* YPM$C:CP/46'I9+%WAS-L:1P>-HVYCN&__PQI'+Q4=&#1Z
M@UT[#3TADHZW/]]V\/U XT2SW"["HTI:*V/D5!KS;4EQK<9@L&N[R-H,>EDD
M#7HUA@X;0VTP)78-!]0X>O'0>^]UNOC5.-J:TS6ZW=[)NWM>/5/VCS@503*-
MX0W0@?ROWDC$8H(]!DXD7;:S)EWVM,V';FO7NU,;>#6&:@S5#L<:2S663A!+
M=2:46SR6PKND3Y'25^I$)6(_R%4')/S#[[?_O#D5A;#[&(7P:,VI;J/5ZM<F
M[V'CZ'K7R%F-H1=V2G3K.W38&&HWAL/Z%ATVCMY6+M=K>?9^"2.1Y4DLMNGG
M?B*ZW=6;=/9UZHR;&D,UAH[;05%CJ<92C:7C=/:]3L*^H'$3)Z*Y]=ZD5Z[=
M& QVK8^OK=47]LJ]9AI*C:$M,-3KU EWAXVA[E5=JWS8&.J]IM?TN28+/V5/
MRU>K5'A4:Y''@^:D.\\\ 7@.^U:W&]WK/?/,GO)RO6"#IL?M=\\&3O4U>]/7
M[!INV>/:G-6WK+YE]2U[J"+DNK-G&*6^9?4MJV_95G 9-EJMQS5?KF]9?<OJ
M6_9 0D"_T1H<JS C=\VW-(#Q^XV#P'$49G4"/"];-0SS.7+BKYK#P>[AK,[Z
M<%:GV>]L#&>U+SQ&[NK_/DO ;M#<(U[7X488052,X1.3(B]2G M^!VA(TJ4U
MTCXOC4P/DKD9WTPCS^.8QR[SD'0U2!NH0M#\YU1L,3[Y;5.,J5-]MH,\P[:/
MA<IO-LRN=6:VZRFXSDCP'_S(CP/A?9X)@2UC)CAE//.BT!^%$4\2QYGPQ;IB
MZ@;<$KQF0-;P+]EY!OL/+T3L1_A^ _=WUFX.O9$:LFY>.>NV>GHDN_PZ#S7W
M=0=CM9=ED\94RDJ>&<# &XMI*F@@<Q'+JYDO89VIG]+R^& >SO&?\(SD S1@
M/2ERGK&.?9&W/2S\8YG V3#U="G\M &[3(6?)3&U74:., >HJMJB!4W3Q/^B
M3V8BSR,>OXY?P07TBC09/O#C.,GA3][<'XMFS56V*W8Z*J[R[)M^$>@?"6_\
ML"K UQ8!.KS2"S&E_#]%F+(FL/"7<-43',X-6_9RI\:PX=W/PF"VHDL(R<SD
M^PE $Q8Q3(%V*ME /@-]&!@:S@Q$[@=/23VDP.GNIE3Q/ -^]VL"3*;=4ZPP
ML!GZ)(R!H8=^!/"'/U!Z_$7-2[9,KJ]Y2<U+JGG))Z4:Z9H3OIE6N<F=\'S4
M1_AGE/&9'XGL$L\Z1BV'JU;PMONY=P^ZDN<'LU#<P:]@4Z#&YIVC[I3C $QX
M7X"" ZL1"QG1/0?.$^0%7&ZKF=^%-RIR#S6'A1\BP\C#B!4*PRRN7HQ7G!1C
MZ%UXWO-<LT<H_/.D0/H27\F\-0KH4ENG$2;0P@^QN/<C26XS'\@3B60I4,44
M,2P@@@+)P)#)]1.32?]A"7+5>WI":;>V8+MK9JGZ*2H(</D"H6>I1&!01 #?
M$>R9; GK>;SFQI\ 8GV:)..,7H-MW84!_-78.V"*A/-B;ODBU*4&.PEL)U &
M0)/ E\? %J)D06H*_K<_)C+-8)6FIVA@G!!*>7UF$/ [OC+?MD8.F58*^LQ4
MLBTXCA^ YL,7)D-E! AB27#!;R%EA,#XQ'@=/Y(<",DH*P(X?S8I(L7IE-IE
M'<^/\.C3 G:' /$7BS2YPR53<L>(E$C/L$\X?KZ-P4M*F&7)E<T\"UJ5?'J;
MZD+2*6\R ,/_P&T+?$+5^S#S0U *D<'+-6").=S,#" R^C>($77/2E#!/ZF/
MT9ZLW?C3*1JV.9G-[69+F=-[<GGO/?,/^#U-YNMIKWPW%O A@!NL)LWI2<&7
M@EUGDHC (%_@9@B97\DJAOMSUNMH8Q\Q@+<@DZ^$L=D#W@VVU!?(%ND3@/8]
MAAP9C\;9H*N_K1YC^ !5*YF,![0PE J%/O@-X9HLU&?(!9%$<!%@8Y^4J:!@
M4680)(U9]J!7(JGTRRP$W"Q8'0^6H H QP+*$CDL39N0;@AO$?D2&7@AQ=>%
MMC/(=0"'!_0TO7\D]X#'U+T3$F* #!^P&(0+'P]/-SD$-0*W5\)9M]72@$.G
M*,#RC^;GIMXN[:8!)#E8>8X<0C'! ;#HO$"G/.OVRJ]L<?!QD>(V$:8G((3
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M&!%E ?=%IMUIO;L7473Y)4Z FV;D%D//*JHD:49/M-_)6 TP5P%2.2#_!PL
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MJFWY)U2(CI_[W6!A/G*R.RYN5GAT$G(XQFYTAM40>1)O#BI;BF'#*>]!]#[
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MLO7%+1[IGMK#N52C"VN(G/UQ7CQ,+2^/XTVAVQ,!_2&A<@-S'GIVL^5VPG6
M4 9Q"/*+1)FC?9#A9GR65@L5W[8"Z>8ZDW%CO HCV\ECD;D]BVSI3L3 UK%
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MV^-?!1]MG[&QSK+<EV4:M@-BA63D3;1(OMI =UU1FR_A1O++W@#I;8K2"B<
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MBZ+<!M:IF9C''1.T[6*_@Q/=5)]MN^8</NG+J<@S$4VX?2QY8M)P2C7VU(M
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M[4SM@HFWRNV0EJHTV3LD_&&O7)R[DCSS\NI)+;=QM2_;C5Q[QQ<V<0HQ#>.
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M>YP^U=/37X;CC__7N[?^U["4B4RSF/G)RX6U>S)R 6?R\7NCX_>HZ_B!/!S
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M2<4I 486+K8WE](HY*V*O?OZ3&QS3_/LB=E![27#P[>"AT[Y#K>$>FL M[8
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M^[Y<F/_49^<_]9Z.]_O1V[7?>S4;V_>GXV%XR>E__H?$2/QT%QK<M9BRV_F
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M"$AL,4"Z4((XS*G 0?=7N]$S/#-&/DH%)F/(-\"05J6AHK#$6 2X(P%#A-!
M"JB XD12%Y $FR)A"%]1E9N));^Y,+[T,QW^Z'I>3T9AY+EIQP/J,_5B/*O6
MXHFU%V<7PYA&<.B+@1WDC,4;8M%<_P[F)"X8(D!C$UN1*0NT1!8HJXE5# D<
M]1DJ^H3O0!)U=L@\2GTF8\@WP)!.63\3W$2?KO*%!M1@# RU#"@)L38.6NUC
M.T/>YW 90[*/YCX:D]7;O6Y,-CX[G_A3/YH./OC><#R]4]'^)L/3:A7G^WO1
M<:;A-<-/-VOR4:]4<JP][:Y361_[6UBL8S][49SH3QFU;H9:<ZT_E'4<QT1'
M[)$)5IAB0 L5^W\HB&A8<$MT3*OA9)E=^X?L2'EPR5Z-=3>1[-MK'EFR-T^R
MNUT[F"K"R@+KI )4%@883F'L\1.;*WO$"A<E.ZSU9DCV-RUI?Y0UF-O@V>@6
MD)6%8S_[\&5_,O%Z>C&YS([66P#!7 ,-XJDAD!D@N-4Q+=L#Z3P%U N# RXX
MPL7>@<1]!'>@@T:N$-\6=-H&GTE&IV^#3JV:(KDF4'@+B([-Q:C"0$/* =-A
M(8NPFE8& T2BOF3KZM.QL<7BMZH'W[@ZWM_\=-J;50)2E_/J69B)Z>S'32^U
MV+P*BSFH>56-(B?!WP1PV-5)\.>G+T["NQW^^_WQX5_OCP[#?/SZ_#*,X2S>
M]\6O_SX[.GF.7N,_X8M?EJJ2Z#\2$1'PRP+.L0#4,@4T@S@V<2Z$HIAPE_+R
M J+UI1!]KI:)#U?EO&]>/4;>AINZ#9]=_J.,Q$3$6@P<BWRHED#IL"L=1 86
MAA"&2]Y-(OM0BCY5R\S"<]OP3A476^ VVP;+>$[B<@KU[02NTUO)%H(['8G2
MO(DIU!)H2ST0)E+36A-7;>^ \;Y8T1!N>\S@[&K?$(7Q0>S5C!EKP(R.<5IX
MYB4EP"I! "5& .TL!M 8JI5RTI*(&:RO5K"!;%^.XDZ0E95-)+] 639=05GF
MOTQ9MLMNN&U0A9;=<!G6;@1K?\PU1*)6>1NY&0VE01621@?#01J +64&<LLE
MY65#)+3-JE"."&P9%&V#AI6A: U0U.&*-19K)PPH>,P_"@<)T,(P(#EAIA#>
M$&(2%"FX\^[_G5"_(H=RN&@R'H;/W@:-:^8G?CK+_9#N6;>:1ZVCP6@\"5A5
M+T?&K)MAUER7(Z^PTD86@"$6JT4* U0D'.4*,JH%9LC9O8-=\")MC.J46QQM
MKNJ4D6;-2--I7%0@R1R'0!/$ #40 \4Y!HYQZ(4IL(LYG&HY;6M#Q3T[IK*G
M:=L\3<]'=G@1Y_3W\20.\,EL-AF8BYDV0W\RGE=W,^C=#O3F.AI)IQQA-)J$
MW :3D#%@;-"VK'0:4>\$UZ5WBN9\U>R=>A0J5H:O38>OCD=+"F0()8#*Z%PG
MR@/EM0)&,\V,Q0H2&."+]R%$C\2C5=XLC&!Q;#NAU]U)U[[[U*R$R2]V_GD
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MHN""<:]=H(Q1A<$GCF"X!FK!:S9?LCB*H=%[".DDGD$?V%3%BG6R-)2ID*K
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M-F1NTR,IZ'$3]#A91X\8F9+4&D2Y%XA5WB.E-4<4_H I9DPYD=!#R+/QC"+
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M+!$"^X"$H1@QYRNDM3"(<D^(MQ78AJE!FIZU+(H,/PP9OLW$19'AS<EPQSL
M656<1R1PC(A5$3Q['S2*'DON$BY'!C(L;G+\3LE?E/F[O?4#;A!K7$>DQ^9X
M.#>C_5#.%;HB(/&N8R"EJ2)C"CG*+&*""&2QLT@' 13%7/&8C(IM1LJ)8/T4
MZUZX!D5V;TUV.^5,Q%;!&8$J+ -B. 2D@HP@P#39AY[!OUL[M P[>ZB">PM)
M@B*X&Q/<3J.U(I6)"MC56P%*5\MTA#<H7<*$H%X+J]/9N?)LF^.]FIAD)U,?
MI@@L^I_2HV>3T= /6A$ZM; >NP5ICN]C,SL<O)Q./@Q]\ -[,EB*Q& 7*//A
MQBF$2^]5_W"L#X50EW8K@)B)EBTI?SGY<Y92H$MRKJA9$.Y*"/=\[?! &D0(
MJM)(<NT1\P$CXR)!VC/OI=318T X7&V3<U(.]ZE*ZAI0=QO1U$NMYR:AUGN,
M5WUH_"AXU0>\6KE2W(+F\:%"FH:(&.4,*6LMDLXQ%FCEA6. 5W2;L1NWHA;(
M^/X@8P.>6H&,/D!&IW5=>U5%SI&(A"%&E$*&PW<^"J^KZ*UV)ILXFIR-P/04
M,JZ;[[EWGM[Y/DOV\IZ-)A]G@SB=' W28+G999V\36W3M0Y *0_X=@_84'5D
M+_C^?$76A/4&(1W+Y8?SQ;340_8E8/'2G!R%\7SV:K+K_KL83@/H=;](<!1V
M\XE218E?38F?K(UQ "U=!5PAPIE"+ :!M%0,.4>Q%])JIM)1I=OBG,,/2U55
M'Z2Y%^G/(LUW*,TK+UY%+84E!G&9VC&%Y.G@88$8-D)S$B2C<FL'G'A9ZIP?
MJC3?IJ==I'GSTKQRL"MC06ZM15AJBY@W#JD(7R()E#(!5I?.I4D"]^2HAPU5
M2_;847BYF+I#,PN#21S\$<S;, 8?V3V"MSTZFJ3E3-S[4D#94\=A]X,9CE)_
MY[/)] ] I3^"6TQS3.,I_'U^4L#J:F#5.97F*7GQQ.$#I9RSWE'$0K(Z@*!(
M"5,AB8UC(08F6:P/H#R;1"@U67T0\;[E!C\'L"C,[+ (]^T+]]ZZ<'NCN?"!
MH9B/LF$&(VV9 ^<B&EM%KR53J7Q $4Q^[E%S=Y'QGB?SBHS?G8S_N2[C511!
M,"E1, JT>%2IF%I52! B*R^8BFFR4_]D_.&G*%K/8Y9<C]F2\3MCJ8<Y69<E
MIN0N;G'JW!F8VC/3]V&><&H%4 6:K@9-Z^?:1Q)\".F<2YL:OPFX%:F8TA$A
MI:,&_N5;.[HG49 2TWQ8&8HBSAL1Y\YT-TF\TK9"7%<$,6LYLB3"%U]13RRG
M,O6 TVV WR+1#U2B[S1+421Z(Q*]RE00PBM.O4$8JS2+VAJD>?K1N4IS%U5E
M04'+;:U[4D7P'60JIA/8+M\4\LV M;^=YW OHA[WJDNKI=XS(%Z*=.R9>2+;
MR>[8/YZ,1B$O=O8B/E]1K@#8M;,7NP=8AR"QXVF65(48]A1I,#51.A)#IS/T
M=)4'SH(BNM?=6B6LVN.PZJUZ.05@;C&#LGM@HZ/. :)HE^HLI6;(4.%1B$8S
M(+#T5&WMJ&UQ\UZ)(N,]EO%;]7N*C-]B!F7WH&*!>^IL&D>#$0-3$6G##;*>
M*1:JR$),/=]\F_ ^"?G#SYUDMW\VS+()/M!?8329_3*<Y-*M[<$XS--O7>I]
M,G6 P)<$2D_\H-.AFU\6,UC\;/;J<!K"?IB_B*EGK?FC+_!U-?C"G0JNZL4K
MQP^BDI(;PI# 7H"=0BTRWBF -&5,U)62@>6:4]V3"9TE-MMS-^32U1U%M#<I
MVG2]?NOUIP.LJ;*5(,@QEII# D&*NH!8P,PP+H/V9F.U'47">RSA=U6_521\
MPQ+>K=YZC0^ @(P1%1%.H05&64#*BPHQ!H#N;8C,A#Y*^,//QISR0':GORU&
M87O3#LB]"*$\% ?DXZ0@V ;=#[[W\8!4G.) TM%A)/60<(Z4(14*AL58"6F%
M],GYX.PFI5XE/MICT^3.G8\BUIL0Z[VN6',7@Y$A95.U0JRB!!D1#:*LLI4D
M&D>%^UA47J3[P3D>1;HW(=U_=J7;&K#H%,@T#L:D(\!Y"BMHQ(D5F$8A'"=]
ME.[O+NVQ"X(X&@W_.W@\F1Y/TBC$R;AD/^ZV".PT@AU-WU^,7L\FBVF!K\WY
M'+L'5"<BVHB<!((Q2B)2C!M$(@F".Q,K_(60Z'TJ_"KQV#Y7P]]&Y5>!EEOT
M>]*Y8E4EO>=(^'18J<44*1D9,H1YA[4PWJC4Y"+(349A%+'^?KV=(M"WZ.KL
M'BBO-8V$HBIB\'.,UD@;S)&IO*+<,:QY+,F5'O@Y+\-H,H=O7QV&J3D."UCE
MK*1:[I^W,_Q0<L0W13#2]79B8)8H;Q''.*0V>H>T-@IQXEU%?="<NH?A[90@
M</%V"K1\<VA9>3M$4JXIU8A3<'08L119D_(\6!E+F.8AS0;#V]4YIP>5S&U_
MQ?J^>#M%H#<BT"MOQWE::1S!QR'"(C#X/#+2$*2(-:$B5,K8RV%_#S^KDP\D
MKIV7VN>9E23.O:P@"[,"63<O@>WT\ <J*D,54L%$Q(RSR("IB4#[*,R8U-;;
M9(-040:%]5.P>^%:%.F]@Q:5W0,059>GA@,08\1T)9"- NP/85/MNHC2Q:T=
MTI<!0D5V^S@2K,CN'32?[!Y$:YT(+"#II$" NPH9:AA2,<(_.F*/0789Q?V0
MW8>?$<D^0LEK?$O[?P8O#-]=A#G/)M/N^(U,D.5IJN4 XNO"#NL:_(0[%BL2
MD =]@9C"#BDA+)**>P'_P]RD XCIV9!CR664H&=?VE4*D-P1D*Q\#\8#8:G1
M##/NP7Y)@WO2---*\4@C =>#ZJT=*E6/ IU%EGN8P"BR?$>RW!G"I9DPS@H$
MM!,I<<&1D4XCJRKAK.4^6 I&P3FCQ>]?TN)21[GWWUL!9WR0?/'!#W_.@A\,
MQS\.0$P^##W\8$\&2PD9K$3D)LF-2^]:_S"N%YF/)<A=.@4"!$[T;8GZRTFB
M\_-Q@;X;0Q_O^D/>X\IIZE!TL0)_R'ND(P?/2'M9!1ZX,V)K1V\SMH'3GZ^"
M/;<18;W4>FX2?KW'L-&+O$J!C5[!QLK[\3):+GA$-J39Y\IHL)B$0K:JP/PE
M,5$[C_PCNL!&@8V>#CLN8/$-P6+E7C'-F<#"("V404S0@ Q1 2F!M5344% (
M6SMLF^*SB=KK]<!\<\2X;CKHWGE?YWL/V?-Z-II\;(Z*>38<F[&[I+NUJ6VZ
M$&'+ ^[F 0^_CC)%'=RA&;\-@R$\_7 RG:-YF!X-8+.FDX_P$M_=,:I]K:#L
MQ$Q_#\=-,/5%_"/1[!60[$FP\Z+5KZ35]SZM=8;I:,!6H\AJXQ'(BT/@U&%D
M-",^"N<YK^K!>V==@/N42RT%8"7(4,#E5L"E,PG#5L0:G";_A0HQYQPR*K62
M8&-QU : 1J9)&!*721CW2;1[&@@H OUM!+ISVJME@0N/$:7M:!O-?$ A&!M,
M8!6@]]8.W\9D4S& 4O5YJ2-?&UX?@#!Z8/+OK0"TKQU@713ZSV3\MH#0]4#H
MI.NR"&X8J:A!),B(F)0<&8H-$DY%HH@CPKC4[:6Y+!WGO13B/A1?7F::<!'?
MC8GORBD0A%=,.X&\HA2QU.EE& NH8F ?*.5H)%4?^\N+%/>Q[ZNHXMN7Y<YD
M/.V=#J" ,0T&O'PBD.8\(&8J;.!O 7N<<H)$]405/_SD1NL$URF]X6RV,&,7
MTHR(:SL&]R)2<6_S&L\;$A58N@DL?>YZ"(89)I0/2'L&L*2$0LI6,368$QPE
M45K*!$L,EZ1&B7S>#Q^EX,EMX\G*95&1!(X=1MA(B9BT$1EC4F=)Q"&==F(T
M37BB^8W[Q(I(]UBD;^L0HR+-FY?FE=-B,(X.*W!5B*W2Q$J"M-0$!26K9!TX
M%G09YWTGOLMBZ@[-#.X([LI\&LQL,3V!54S<^Y+1Z(GGLFIH_3T<-_1Z$1]/
MCHXFXS\2I0HV70V;JJ[G$BKM11 >@<U($6.$ S9AB3@V+O@01>"IAW6;J)M,
MU"E1T3Y'16_5<2CBO'EQWNM45_(069#(DL@0TUP@ ^1$U'NP+B@F2I'D.$A5
MAF,_5'&^U0JH(LZ;%^?.:&PA.&/1(4QY&HTMTFALJI$B6FMBM(UI4J7>KG1/
MM//#3W<\&::FO[&?#8[-T _FD]I=.)R,?)A^=VT<??<:7L0EO0HF71N3U@XR
MK;CQP0N,7&4"8A4 $]#0(LX(B4#22CNSM2.V"2ZSK_LIRO?38RBBO"%1[J09
MO& V$(J")6!>& Y^@P-K0U$9!8L1G 65JJN%+J+\4$7Y+KR%(LH;$N7.7.P(
M0"R=3>T1'$29" 2(;!%10$7II';I1 J^C>79:71E,O8M%$:%3V'JAK-<&)4]
MAL'D.!^I\[TE&F[78[@XT9DQYT5-@Z<-<<IL_BMBT-JAGY5UQ ;)$(E,(0:$
M0L8PB0BFU%K+G/!Q:T?=[Q*H$OOL<;W$YL_D*8"Q<<!8^1]66Z89C@A@0R"&
MI4:&,HZB-4P!TAMFP&BAXFQPLPCMPQ':S1_&4X1VXT*[\C2$3.->C45"B8"8
M%A(I33UH>>XIUH$H&\#3."<C<?^F7M\?9^/ZQ_#<BSA'+[(/%XW<[\!-)Q^:
M*;*<<%=F0EX7?-8.WJ0,:X4M1S+$U&A!)=*2 !9I,!XH9\Q7)AW_)?H1Y"CQ
MRGMEX1?I_1;2N]<)$'@P$B1#U+B(6(@":<P,<E9%)SC&D2?3H4<ET$6 ^YAP
M*(KXCD1YY0503KR3RB%MTCE66'%DM+,(W/<J"&N\2T,5*.E)XO"[&;S\E6-O
MFE-OKC9Y^1(ABGL\>KY?KL5-A] 7G+LQSJT=_&DLY]A("FP&8,=L)9&)FB!K
M.*ZDM$(ZE<;5*GJ3O.HUT.8V@I??[L2*^P\;O2BB*K#1*]CHS)P*5%31!!0I
M2T<#4HRLE@1A33CFK@J,R*T=M:W.R6T4V"BP<4O^4X&-/L#&RJN2G%">@IJ5
MJ<#:,*Q"QAJ&/!@>7@LG@X[IF/%M+#;0O]6_XVX>UF&C3V,,;IX*OIY^:H[_
M^-W,P^!Q_C[/SDU"M5V[9D__NQA^ ,E)4W7-V ]^#[/Y=.CFX+"EOY=C2'M2
M0U93]45L:9I(^F*<2)3^ZU!Q1<#TA]VQ7_]%YY,%,Z^&F6M'D3(C*E9Y@X@F
MZ4 1'9'14B/ET_G+. JF'7AH_.Q!I/>I[*R<:7COH*M_N:X"77V KI67Z' T
MFKN0NF[28'%, +H(14QAX375@3L,YM[94:8%/+Y/\.A'GJW 2!]@I#-?S((E
MRZ5%3%<!,6XQTH$21(A6OI*":):.5*LVD(OKG\OX\!)U/SP)+HTB"S\.GH_K
M[U+*[AN[BO<_M'9/$WDWPLV7L"L3W[))RSCP\VB1*-5%Z!JU"]!>"6A_^[CF
M:@+IF=,5XIH*Q)AWR!*O4-#>2<MYC+A*P]*DN,GQ]26J?^^@IP^N7@&<AP(X
M>]VN;N6ICPA[F@8T&(ZL9AQYC T/P"M@MN>3I\2-?<2".M\?ZMSF[(>".CU'
MG4YMIXR2ZJA01328.41ZI'2E$+.>!$I=L$0GU%%R4SU>_7,K;]( YH<?VALW
MUZ/TX9]T>X/AV -7_X1T1JT[08G+>Y,#,Q_\$MX.Q^-4+CJ)@]?!3 <_#+/P
MP8K^<07 B8(+QKUV@3)&%=:QBEA3<+JBD,:Y@^>7"V2O T41]JL)>Q+R5M@_
M^%__8OY?_QZ](:,/]MT$O_[[3_[F:._D]:L]\N+O/ZN]SWOT];N]ZO6KI^SU
MWWN?]H[^_6[_">S52'W.SWJU5[UX\O8S["LY ,N51E81Y)4!>X5)@;2N#%*L
M<D3;($QD*1=W]M2*Q%C3%>.YAO'^;<8+,ST9X.U!\K@'#=?E&N9<US_8G<T"
M,"X:S$(8[$_F82!6KA9(XD-LPKAQ4OSZ<G@[^KY(])4E>A6EL)P88H-&CE,#
MZEO%U".ID%94&(:9LTJFH;&:GCTS^QZFQ$N;5Q]=BRI$ 3Z%YHPGB)'&6JPU
M-09@1L9*9H2Y0X^B(,R5$:8SM\5@RT%](!)T1$P1CS0S:<J\9A75@1@&"",W
M$98H0MYC(2<!+J'P/Z$MJY14H0I8.R&((E9SFX5<%B&_1T*^B@)@H94,-J#*
M8/#](Y-(>6F1B,Q*%HCB0J8YSY4^.VSA_IU9U40@ZIO!"DX'(3:?7WYX48*G
M\.N;Q0>P,)YX9Z1WF@GA-!$N6B.%$,HI31*@7*9&M\0';@(#)U^(#]#71_OO
M]YZ\)OM'?WZ$*ZM]\@;6_^?):WC__7>'1R]^_8WO?W[/]Y^=C@^XZH 8D<[H
M9H DA*1S+3&R$3M4<4.X-$I1[[=V<'6V5O>"^,"3X,*1#=,!W42$X-9 XEQ;
MX#RHN-N(PC^N&<?=P ;UQDBZ<:SE^IA6C*2>HN,JUN)C99E7 N$HP1/2&"--
MB$&$Z\HQPZ)@N<\3B[/%=_<IUO(-K*1;S![?;+VG'<#O5TN<STI%2VS E2X1
M^0>G)5;Q,N^L\$)21$DE$ L<#&!:160JIR-3.$:M+XK(%Z N0%V NC] 71(;
M#PZH.YTT526J-.@I*DL0X]PB19Q!.G)K,%5:.K:AQ$9?@#H'3/\Y-W84VG!(
M)S)Y9*9OA^/\>+T.;PZ8+4PW+;"Z%==\PY^&<WB8^[( DR3 KP[# *RDR1$L
MYB35*8TG<WB<F<*OQX,A+/7MU(P&QV::YS',#X>S)-9Y.TT**,5ZD@E\9C:'
M7Z39D8_6@T2=76D>+8%</Q]/9L-$_Y^F863FPP_AYX]#/S]L@:5S54/C:G6)
ML;" Q?SB2[[Y?N/J:_B8MU>14P&SSM>TW PTQ@HNI0W,4<6JZ!7 H/7!1\9E
MM(8?8"ZWVJL.IZO@]]N [#28]\A$>,6?S.BC.9EM_7.=$8$+N]M^>L<NW)<8
MO]F^U.( (#Z9FDQ/$.\P39^"-9G>K&5P.$V:ZW^^3B @SZL$!$E$'B>E-Y[_
MWS_-O7V765[\.8S[)7[9D!R="1MF.=K/J#2?I-U=8<^S)?;\T6+/[ SVW(W@
M[X6I>U]KMO\U1\<_P\(?;:>VQ$<Y"?3'PLZ&?FBFW?&AWWS%5]0-/_PCY0+@
M4:-T",@@?'(!=.5Q  0ZS KB"/3R?/;C6;B_)*R):NO+JA,G*W0MR8?5Z2Q?
M^LTW1_?SN1(_:BA\YFMC%^\OCN#.;@/-DJ>FBIGY8AI>Q!= C"SIL[NV6=_M
M-C;KA+[^[#[#,S[!->SUN]WJ]>??#U_\^@QLS]_(FW=^^/KSX;N]HW\?O?A#
M5V_^WV'ECOX:F[_U NS/=_N?]^#S3V%]A\.])[^_V_\U%<_N'X'->01K?_?B
MU[V3UT>O>3I;!>S> \T]T\X;9*R7B F63F\,"CECM,.5U-J&V@\9CA?![R8O
M0BO&''Q *2,9&*:*&$:4-)@+Y21W6X, GL!QLB*F"]!(]68G:%]M=VO$-@0^
M!9;PM^:1^=,U:;[ZV(N$@*_;C^\6L_DPGJP) >.W( -7!KH?\M\&DRF8C0%^
MGVW,'P=@09K!V]'$ FX?!C.:'PY<@I/&"(4/FSEX@",P":<S0*#QY$.V#]L/
M9],O(]+\$#R#MX>#X7PV.)X"U:;#?&#1X"CXH8.ESK8''\"ZK;^S0]B2MR"-
M*;EICH>ASL>;<7(EVYL?3R=^X>:S1X-7JS7_[_\H@N7/L\%DR0#90CZ>#D']
M')O1Z&0 &PGVF$^SR<SR+@-K9L/Z,4UZ=7"AQSP+;Y,"VVQG]?/]9VO^,U#9
M)1_Z(WA'LS ^@RN+E!->XLKX[1_UHE;.<?7] <W)WF\'PF## N5(8,D04Q(C
M#3H! <AP"B*L71+@^<?).?GW=B\'#86!%3\>#MUA9J$D&2]!FQX9%Q;9V<S<
MLELSY;\:CE]>"*[084*BU0VFX7@RS5[H\F./!A<Z8/<&5EZ=W9?F]0;+ IG#
M!3QF*;AG-[$1_8Y,_^L+5RQE-KFWPUGC[B:DR)_(=P20^0!+2& $PIXI O_
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M$X8_-\R>D]!)6A:S1D22-UK?&U8U/LE\/UN*TO%B"B2:M13Z(><^?1/,7U(
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MG+4X(*NM1>!;>&NCL2Y7B9 SU*Z9H$F*MD"\PM-F#M5IF^%THK-6 \M$9\X
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MW2 Q.J$PC4)C9JE21 K.C9;".1TD*U*U<:EZY>B!I!YV6F)D*$UEYTX@I4Q
MG"JB<30@<F1K1Y\O55\S6-;U\^415AJB0*)553G":-!&&RZ<A6^=%!077M@\
M+[S[K3IPKN(@?@XQ%0(@K/#(5, 03'*F544(U^%BA/V*?%MI@K0F4ALIDU+J
M2D@F226CU\807VBZ>9K^B0^BH9)R:5#%#/B/T6($8LT1T=S)H%1DCE\HWYV>
MPU8[MB.\+D3_!^!D_!'"8'\"3C%6]>B\X6Q9,NJ7G;K):QQ-<N_V5R?LW'07
MONV$GB<I3)XBW"G6$IJY(KMCOUN/):YEJ8SI>?7;QP-F#?:"&F0XU8B%9(2"
M!D4A HRI-,:3D--%+8!Z'MOHK":2:0 [2F((\-D0*F^#ZNGY#%VNZ-E\G>[2
M4G!J66Y]SOGABUF(B]%@E-N\UTX'V%Z-OEEKOY[-IR8]#*4'+\_2R>=$=H[N
M26='NS *]73!])?ZD[6=DSJPUR-LIU8"CP8D&.9V_C0)(_LG7[2)E,7$&$&X
M8XQ5W%:>ZO^?O6]_;B)9TOU7%-S=#8AP<;H>W5U]9B\1'LS,^AQL&# S%WYQ
MU--ND"6O6@+,7W\SJ_HIR4]@$*#=. /84C^JLC*_?'WI7%YPI[R@^4WM)S;+
M+BN YYB&G,TOGH_59 X''Z>XA9'7K\(C/RW]3QA__?3LZ ]^;)&I-P]G78#7
MF60) 6?3$9^"Z92I\W">[SUBZ8K]O 8..9IPSFEA &6+-"T*3D%!)%(Q:C*;
MW#B[LMW.FV_GJT_'S+,\S1DC1<IR(M*$$Y4S#KMK$FT0D1I][Y%8V<ZH\W"Q
M8YQQLP("OR[*,<8IOFFA?NP_N5:/I9)FX%P6UF5<&&8T,Z#)G-06ZY>R;"OX
M7U[P3]BQ84[!"DML*@=EYG,+?D &;G_F<^=20462@V]W6S7FO6"IY50)DPE>
M,)F[+*%YP;A* '[>V*O;[N;-=_/=Q;$M!'>)2(GA%MQU)T&A%5XB*DTX> +*
MIO[>(_J=J;$#94[AA[.+G4#]>MX2YDV]QSB^7\PF977:5W3+S2+?0O&M+TF_
M%O4C+^NRHS@:(-N:0'8C*3S6^8X_<VUH<K!GZ'$JK!:ZD(2J#."%MJ!@"Y$1
MHX1U#E/VV 1%KVWOWT0.C^V.K^SX"3TVMN"<99QD0L".6VX)*%]+A&!>\CR5
M0M*;[/B&DGAL-WUET]^)8S"X1:HS2YC*8=,%&&*=&$;@[*<R$8"$,H6;+JYG
M\;A)M/1[(VC^RN'*7?L>8&&)\9K'TVI>;4.3AWOOTF,NM::ZH"0O:$( CSL0
M2ID3#F+F/4LX+]QR:%+JC&7"IMQJ(PKD'!+!@MG,<<MLNAR:["U]4%< T<^F
M04^%G1C5$<+5'MYOYY:N1V?7OOBCT?*[GK?O:L*[!J*(B-!LI/>(<P[7P;IE
M,MXXTN+2&]27#?'*305^O>5Y$A_WY[8+<(]C+%K0DJ<DXUB$74A*)$L=$6G*
M,ZS!%C:T!B7?,?S;[OO2OK_^=)S*-$VT<<3EB0<0:#V1TG,"ZI=;SYV#W^.^
M7T?=M^$@<+OU2UMO/AQ3DVE1*#"S-(>#+A*$@FE"C "5:VB6.76SK?_24/#K
M8K# TSY1XU>5>SGU\P]@#",,^^GD -'7R8=CF1OP^[@B!HXCP30QD52@,R@M
MSXW,<F8V--';;.#HL3H/7_JTB3G?P=3LYD'A\EWA>S7O0-@HTB1/:F[AT)PP
MU?-Z,F\8A_C>C:=QF$8MRV2![.C-8G3%GS@5>Q8)Y68XJ#K>"?F,FSD@H7FM
MYER/:9!S=3&;X@R0\-DPS.KL?#R]<(& &2\SO@@UJ./W@[;"YN[UX[6C'"K7
M0YV;R[?5A.QW H]>#-ZVH=QO/9>N1UH]OYTPS:<X &Y<3W 9F?%T$4?P+&+'
M26^^2VB5' Z,42WE?DN2V*?;WMS=C//,=D.QQ+?=O%8S87=O<T:Z Z%=V(9V
MBGHH XF-/U6HKP@S.:[+3/(TI[DJ<I_85,A$*P.NH3"%<HER8.,_)Y?U&W)F
MNJ<EG'8PG?A$>NS"RO[,R2QZ .;S6!;64.H8F$X%Z#D#'"4]0"@I4T&M%("O
MTCND)G,NK4RM<C)Q@BFE54*IA)\EA<REOG$?XW8[;[.=XECP/!.IIL1;K)AA
M3@$B9IZDS!:*:6=S5R#'\16YR9W.(M8EIK%HJN,:7N[)=W&23%DY\@'KT<]G
MT[<.N_Q:O=VHA;/%>%["S\+4@.IA';AJ53UL>%,'=CYSV#XW02;D^GI(N7D2
M&XK.X7NDO7H,+87?#CA?^R2?@6)A5D.0H+QVK@HBK4]P?@_. 7;T?@#G9G>R
M?#JJYE<_L;-P\.$X=4Y0R2Q)0!%AFUM!< H\48E7*E59FGN^H<Y"LX$;YATT
MC]51?E0U@40S**3F4.ZQS/0GNK6%H[T!T/ E'&/2C)[V[<P@I"0QD>#DX:B]
M<QF80N#@1< 81V;C4<?H3:2NZ7B%P^SA=J9PZ-6=C\8.9]HI)'.98!MU:-H-
MQ#)GV+CO9Y$< ST'W_\VG.W2J-!$[3Z6."197XQ\.:OBPU?U:&[8X7FD]VU:
MK@<DTTV#=!GP:[AC/5\(,.TD3(@*X'9UE=32R^+WQ[CLX8N![1T@\D6-T1;H
MTNS[Y6[P (*KO^/N.Y'2&8?F-<O17F_NJG"!>G0B;G#]J.U%KKPQ 'P56<CK
M>W?7QMN>M,+2[5YD51Z%'^O>")TU=/;W8QO=^L=IKOW@N[8=RP:CA[1^8INQ
M#[ JTTQZ"K#8)XP("0!+@\="K$UYQITKC$^6TWMIGLDDY8EWG(+>% 56BWL+
MGHU0J72K X(WP\;LULIUU E#M6'VIGW$LGO$QI/OC1R-6;W 3A%&>B&_5VE"
M;F\'[8]U0?SK3ZIY'#G?CPTTTRJZK.%\J%,:DS,@R6I;#;R+\:C.-^X:#P)!
MQ+#9(?+;-\80[G))]\*-?>J<::E _+R30IB$*9U3R97FTL"/DF+KA'UI)XP=
M'ITDQ]+;3.4L)RXWB@AC<W#">$*8+_(<?B-H:%NXK4_]I3BAMMMYB^U\]^&X
MX#P%MYH1ACD%80L&9@!=A\+1@F8"_H%9)G%5O>_]JFYKC#^4#X8C0F*XK&[.
M;H!JU:+"9BJ #Y.Y<1A$.3.+,QP6'H>;!@CJ.I V!"A5,T=<K5.<2!V("*^&
M/SB"4X=!@SZR @WO%>/C[6AEG (24>\:#L3%I"'W<]WDA?6X:,LS/^"9S[8\
M\QOP+%N>^1OQS%_+&[\$C!.O6*8SG^6."EVD4AB9"TYS1HVW17$I7_QZ-^D;
MG='U:W$MZ']4TYX:59V.?"#UC-JRZCICD6'U'* KH,4P8PA_#,[M=($94Z3&
MJ<=TU]FQ-1[IVM@".L6=YQO4=M5ZV/$F<.6A<L>)K^$[2,X60\)5H*2K)Z?W
M2&:OF/ZVZB_C3SLC5-\=L?*RVQ[A^/"Y!K?$*%%#--M>OL=8N[S<:RH$OZ_:
MC^>S*8;57L KJYDYW9W8O2Y?_=.ZZ?!,Z;'+<N; 'R>.98:(U('#GO.,.*,!
M=V?"Y'Q3&_Y[;C>I=WC4;'$X&+U-WC!W?/_YB_]29^>_['7XLR61CF]5U14A
M;Q>37DE(4#OX@0C/8E2O'0V_%$ONA0G[@5[P^J>8!IHC>*U7JTT_!=VQLSQ&
MNW?+FD<+T2_ *(,SM^?.G$Y@X4X">Z$'+5>&05P7]=2VLVY0G>GEQ8.;/W/-
M$.UFUEW YG%FHR/HO=L5K8>,70L=\ENQTJ%1T!@-C='->3D>U:\9U@DNK.&&
MTSC KR,/#6_]</0*>4(!NJ,,8=2@_U50C:I;HIU1H'2,X<\S]0XYW1L]&XV:
M:H?8P?\FI!?:N$R+[_02A7V='6?QU<S3( Y1L8>ZFX5&[P)C+? 0;Z<S6.TV
M:="9R29;UQM&'N\T1]N$&Z#="1)=]XA3AEY6YUAU(KN4"^@E C +@,2I=\L
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M<$*-PK&S+%,LV5 - 9L8B^GBGFZ8+D ]%><*A,=<LLX-[V=ME.$S(^=]8!-
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MK;I70C?(EJT6Z)G,NA5S'*Z(Z=@ZA!K/W<[HU-F36'$TCE;SM#RO<SPQ736
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MGNN3R[63SQH^T8N=(87-3CO\)I;%-)RB;JD!<-THGJF)YLFX0<%FK#NO)Y'
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M19HP70@#.M^X1#KJN)&2&4;7H\O]P]^6-_M)R(L>A+1HM\_//B"OZ&EYOK4
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M:IM&DMX^ <]5@H.:9"3CR%2?II[H@G' 8JE@-%,^TUBG=HVNB9*!-JE&G8@
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MN?OB)7D\_9.PT?W0%J46560=42>U#F^'Y720.DP8C9@<K8>'*]D@?PV?S@^
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M^^=^*!R$98S5[J-06S@/5*"SQ@^<SD[4I/P4_26+19Y-C$U9VXQ[6\Q.0E/
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MGVEE59:2-,.QIBK+B$R]!>%3A18^=3K'(1$/5\-P#<O4+SB[H.9F&E_LC*+
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M:=-NA-I5786#Y^8G(VKZWE58]&#C)U^TF[A59+=39/M]1588G3!N-*&94$2
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MJL*D>9HJ;EV@!Y+%UG/>SHOX+N9%;*+S_(-VV?R]FNMU7W-Y0Y4M=$$XXY:
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M2LMN8^)1M77&C4">(2:LFX=56VFI&!J(C'P("\8F#\F0MFJY1-JZP.2ZF2Q
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MX[F&\V4P[)&/W#L>#'?3<3]E^I[-9)\W#Z"/XOFZ956O_S?O_TF,I/?#+OU
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M@HRN(B$*S"85;KEV':%]\)I=QXVQ:DCMFRT%QGF='%,A*U9[>1"9Y9G5EJ@
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M5N.9\PD9.A.#B=HY&1[X=//U&-J=SC4^?NV1FXSGVE66.CA^F7 L0>3@((.
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MLM91S#HQBTXQ$"$Q5#XQ4TI20@>NFAY!_N)V98=\'?)UR#=F@RIZ$Q.W4 !
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MXRE$%PSS&34CXF>8RYHSKJP* #[K2OR[))GGKM)."2NRX" 4@@_"N>*E4E$
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M@$8F)8VCI0_>**LU.*EXX=YWWM;R*.\TSH2\1&.B9$K73&T9$W.T-@QB-"J
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MNEB??P"O"Y^*S#ZNS#8[5$2?"S 8E)QAB"L+G@6.$4FI3=3>AH1]SD,MZKU
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M@WC>)P1FZYP-VA=\PGK#Y<B",AN>A(F'.GYH_6[G(X_U[TW_\*(#.-:?YYW
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M%ZPJ6'4-5G&&HW1&*4\\CTE9JDET@;- @I>JRN C>HQ5NF#5"F!5HQ&>"U(
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M7XKO]10 T2PI#;ZS#C[E'MT$<2Q5[BHDD.2*4&%]\%2L;0I63)<"3"_)="G
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M-Y8VAN PT8XI(D1TG&)A'(7_,2>"-5;@=-LRE,74G%?8__47K4@RR25D/>8
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M*%;_HK5*(^(JJ0LIVH!($@)Q)B72)$1D'07GC07E4LA)&40_@X[O!3>6+UJ
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MG8+BP2;C2OAU<=K\[>D?NY^:VEQ)H26"A8B(TV"0Q@HC$@+C@L;())Y5WJO
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MSW_L!M;U#*SWRW&!5C,-"GJA?"TMV< )A.J%KC'(DI)R7K6X0/!G*^@\G+C
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M_G)N&%1V>WCI'$[_^A=\L.\RF3W\.4OPE(#/0S>^%(H2%=GL@8AB]#(3H-<
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M'=61KHK7WBC3('N BTM!.+8$T9W*CZCR(2Y%&=$7*,OPV2]' F/N22(H$JL
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M&'P!=P!TK%M&CQC1>1YA.3S+@;_QR"J[=JO@Z.IO5HTGY\3.-^L)A*.?:Q\
M&A2Q#M;7@'4#1\Q;0+'(NR9UX^-BU/.XC)VY<C6[1O7MXH+Y/UXQZ0Q7E@IN
M/3=>&2&)C=P8JU6J 8;@FPK"+.(/OQX]P?O+!_@3I.$E^[]\]\W.^1&Q7+FD
M)8I*L1P<D<@Z'Y#3-AIJI-,^@/_[#?=WX;0O&PS $,/8"<LI%1:+%#RU03AP
MQ!FNZX.,EOV>89!FV><MNSCBT9I@M$524(FX201I#K9'*DDB=][[%/.R7S_L
M=KGL>0-V#O",@Q6 ^  VX*P5@^P)IJLYH[,)8E4_S/S%<@:ZIHK,3<@.^"@
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MVZ]XRPN+G_SP! &42W#)DYY;JQ>?8P,Q"T',AQEZDI3"FFMD$GA&W#B.C/4
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MXC)YI!D BU"&)<43\<EN;)--MMY9/ VFO&A,:;RF!T"1J:W.E,M>*0 0*ZU
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M&\-8($\36 CO,;(B2 16(A FHZ,8@RK,"9*N*F_ZI6@'&-;ZJ(+F3% KP1B
M\&-G+18&2)+%6(?<WKI1A8=7A;V#G2.GG)2)*01^0T <K  "ZF21 V--,/QI
M&5@%HJ\?XUQ55?BS_1FDK.BOCRY(,,9&A$2B=#R:X&)(G%L<M16<IR9#[C%T
M 1@2P5A9$1.*5"7$G1!(!Q(1F&;0!LJ))P)TX9N.0XY*K99"_-GNGO5[[352
M!^;!9R9)A2@YX=*20)SF1&L1.?.A48>'5X?]-[M'7/ $DZY0!(<-<2PQ<@(3
M9*QD,>G,DW+6YYPN;F-UV&J]#J&=7\HQ[<WIZ''KQ(;%W$@>O+::&.,$!\2T
MUC)EI*$A"!;D3=Q9/Y14F)<G%?"O/^+!!)U3OVS$$O$H@2OP$)$(T87(*1$$
MN+/8F@.2KI:*O(^0]P'F;1-,[PK87EZDF[<%;@SS;^8[U)LJBTB8"(ZXY PW
MW/(4J571Q("C!=\ ).O1*>G+D[#=\_V#8[)[\4[L'KR]V,T1;C# X)X%1#T!
MDRP9S=*&40)OP4@:;:H\M:V;JHR,1:X6JZG-,)"OZ?VXOAO8=MY6&YP4_>'Q
M2055>8>]EM*R K$L5J]!8."2_VG]4,;8VNO#1=F/"^Z/9>&?R'S>T@-1:$UO
M<HTW#>L=K5ML:/W[O'=FBPN[F*6E!D=,I 8L#4#]G7/4$!N9UM[ +ZR1^$>4
M^#>?X/</1\0'Q8/EB"62FQ<"OAH9$K)&^JBPTI8HL+I;UX_<7>)KYJ#_CKW/
ML!Z+R8/GG#-P0K2BB3NK#194P9\"+#ZGL9&'A[>Q..]@4*X]YM(@9=2H@ZXE
MX)1'">9)$ T>NLPR,&=?[U(& #L ]<IA9Y!Q"9A^!["DJ%(LR]:7-EC4USD7
MX&/L16\KD7G;+FU["M<XX-KKFVWLSA_O_Z_MGOW\9@I5:Y@M,[KN_C]$,)7S
MD?4JJ!;OAIV<_5"#VC2T5B.#:RDJ>>N'XYCL6?LK@.B/M[MP2K&( +E_G%@0
M4!^'5>9*6=^*R*W6P0PES5D%UZ!YAI/,SF0]D;_8\UC,3!R,!3 [4USX@BV*
M<Y#N.H,CCVHA4H*)(I)@)J3F4E+C@N$1W"*ON7;Z@4LP@W:^9#>([1WL'FEG
MJ_*T"%,ELC("(+,(T)P28?!><-1N;&M^O6+RV WZAOTN8NI$/ZBM?F8,%/]<
M-3>H?B<_YY>S7%<)534;V+J,+]3I5>N83K73&X'(M$<X27D"'827VD4WJZX'
MU3U>7&^24#Q:2@QGG!&;NXYC)X/SP4>MW=&;/ !,P)^]OTV['.Q^NJI!M7+E
M+*KP@LW:)<WA^P=>9#<R<2:MI!@YQW4N#&J0=4XCD#L20@)F'WTV<3<E1H[M
M7 9@T)'5"KG]VB\KJUO"<I=/NE<_9;I6:XI6(.<M*SC@ZVFLY&JSLNU=U^[5
MEATX1MN!R,&U;:=B(2X.+.K 2[9KR\Q63MJN/8!KY.M4(%U$.Z@P*S.N6&1^
MTII<H]U+]:W*K18 X-@BS$'"0>R> <.H*%4Y+,]B+\-B)4WYTLU*7HLOY_4I
MAZZ,_QG"_,.TM<MRF$W))$44:&ZGLPF+U>GTOV0^EF>\G2UAY9>/*>/X\V5>
MM4Y[,+I465/%^BK9U( ]'0P'U2T&1?OX&#X-UXR?\_(7,4>VQO>(F?A=7C^_
MTBS@556\QKDKW;RTJ[,\O8B?VV6F3(,2V'5YTDJPHOD;L#@EO):_VTSQU2D&
MUZ?3OLA".88FF.EA]ZSV"&UUFJ"2SB(.AD4OFXPZYMH:P#BJ=/$JLQSTQ;?/
MZASQLX']5/EM-39EXAIM LVI%JR,ETLU;YF AF:]JSPX8,B-8MQ*,6HO\@NX
MJKT^J,EP?%C@<RPJ'Z$R7<",0[OTL*2#Z<DOZ]S[66VJY0(^-EKM,UO4*YPS
M^:<D!.0A1%C:;I:$K'HN LL9'Q@80]ODK,+XE6^YT\UZ7UWOK KY1$CL938"
M:P$35049\HR/9VXVI+ YBO/43F0UY=>\)Y"5;*IJ_W%Z]<';Z;>^%/ VZJ<$
M%\@&K%^<K[2_-1[DWP7X5F_Z7];_T/#=72M/]P\."8P'[Y["]0]VCV 9!)?$
M(9F2 -<JE_(DW".BDF$VD.!]CB#3Z_WG:]=J'+58.?U<';=J'*F<@K+&?,WW
M/S-?'G/G+K".#%O73(*S'=OSL3$-WYK+;/.;4UKKA,W3NWOOON2=G?N?V)H.
M)K?&<>2M9Q(2)N:&D/ U1C.3*3(G-P0\E7YV1V:22Q;D-,9932*.@<3 O?7:
M,2VD3$%9X;0WF=,0,^(T]SV,OV ,^>4ITUM0(G\DM.(V"8$PUT!NB'+()DN1
MCUY:9YBQN8.EPC?G*V^U]K-CTB[S(6EPD!8\S>0P]8:[D+CC1CN 5Y(B]<HX
M&(S5C4P\KDSLO3D^BL!NL3,<&:TU@"H(!G@A$5F-G36)2QGQQK8D-R<JKB[Q
M6(UL]DD8=6ZLV_KA($Y%NLM/[3H+I?JE'!3PS6%5WF < 0<7=ICC0NX<E"/G
M1E6S7PY+'\\&%3'\O;!==-;/>_F?8ZM?'-M>N^R66ZW7916BJ.X+ZU:_<S$.
MV@=XZ:QH]\$S'+\('VQ7X28872^/KHI5P8/X.&MMNCD?++^0];$<N4 ^YF _
M/'ZW/[Y:(R'S'*(\<1^V_MP:QY%@::OH=[;$J;+MV0T V+V<W>FP11%!O&8"
MA3#EIV-I6;V([BK,^KARR,H'4E=ALII(ZDM;\$<(I<ZZ79E=9++8[M7;?3..
MV&ALBL+@:[/6[[VJ1@%S]?.7=AB<C*N$37UK5,@)3[YB7=GO@+F]\2M3+IZ/
MV>8]D4-'L+HR/5,_3XKQ<,[L<40.V,0G5.T<O;*=+_:\W/AIUHT%'W9Z!J\^
M_(V/F-*#/6+M.8?LHE;+_0J@(A;Y4S FNS)C:9T4V7/YK[9U4BCE(O=,<YR"
M)IJXD,\:"I6<%4=J8_N@1KX$F-;+U:G^]9-=VV<IJ\'/$<$K:EH[35@%;%6P
MD27,%0W&Q2"X,]0J$;&0&VL:5KG,TKWD!I=;/_7YF_(R@=8-2_A^64[GP905
MGXYEKE1VU2Q=UB(#^]/N98SM@%G+$!IM ;QDQ.#*FJ9LMD;WS]O)M==PF:N[
MV3JQGRMHA6];?Y*O&?U)#R;I."?LMA*P\+:K\C'  ZC\]NQ#G%46*9M<L.*3
M1\VEU*P?&^U,'FVUW1Q3Y36CRFV^?@1C,Z>0Y!%7#S0!_D$VS6 BX'+M3FOT
MG)4O !=VX'/T>V-/*#_?^+&W6A_.X$/ET'N8U%Q,;?JKJ94?=/SA64<DATV!
M1'R*N6!;!,N5:<&8,HP\G7*\Z3#(!FZJ -QX&#5%J!.7CK,_-E5D]P7DD"X4
MU6&>@;(+:@6Q/'EJB ^!,DXI2THQ]EC9HCN7,EJ):!-+GQ]+WSG?O7A]Y(B*
M.DJ,).$\GT]U**,W @QWU'L>!*8;V^;Z-N=EU&>"&-=IWDHFEKX?0VM6ZQ _
MQT[_K%N9Z2?DV?'K67U8;>:<Q'0,I?*@*H,[CJ]<CCP#X'%ANQ5*_[K_U\X;
M1 S8%^^S<^3A.=LAH]]?PI"IW+W=6/A/ER?L<I81/ P 7\J^<.^X;*6BWX51
M_'&2HS>DY6'<E2$I!\-P?AG%&MVGRL?,?U?O;OY_]MZ\J:UC6Q_^*BK?>WZ5
M5+E)ST-R7U>10'Q)1>(XP?$1_U ]@D!"7 G,\.G?M?:60("8C1'V/J<",MI#
M#VMXUMCUR] PW,[[8 RB87B<020?#OL997%Z"[KR<&(?#([V*YT'LAX7X3A/
M'%WHA*IE]!"&,,X@I2_&#U+\:#2;$UKM:'TI*%R0U!/%50<Q_E[^ZV_RV_ ?
MPG^ZND83&_1BB6<R#2MGR_6EKG(^9@T=]*.!U3N& 4V4QW0K^X"TZBQ('$S]
MANV*2V"VO91'YV_[RN(6D0=\>H#<_76";GZ[ #>_G<_GM]GI+(]&()4SKMGX
MMQW\N+9?8X[U<L,M?T[7B34BNA+1<-_*QRW+><F..I*ERD0&64B@7!,F+4W:
M%,MC>/-.WE2].Y73%Z55^L=O/M3Y&B.4#6ZY5^G+LNRL=+=$2,(4D\'$#8)(
MD'W$QZR)$\:FG), 8^?-.V9N"5>!O+T%NXR?%N+4.EE5<F&Y:%F\#,9'FD3F
MEFL:<VZ(ZL6)Z@-M;ZQN49H,BS816K@CDBM!')>,L&!*TB4+D9"0U,VQ\-F"
M711&QYA0626"WN1RGF9J(1R8X(F9[@D]=+7N[T\@3>5LG5.5N[8^R-.2W-:?
MAVD&%_D9+'>.V0ZKH&(-6- YL8^1R#IX6.' MX!HAG!S]3X@XSK,=\/M./!Q
M#^;O1Y4]CFGO=V"H\R<M))CZ NS:@*D%9'$8>W<K^F(S=P"@G A$>A&)=<#B
MFCK!''<Q:K!QV<WI8M^,IX?9+X"7E*%!V\P8+50J&FUVP80@HDDF:5]EJ3,[
MY17;J+87QTNHYH2A (DRT2D5(E5QQ%N=2!':"X:]UE75EN_%\%(*+H$E6ZB+
MTBCI0PG!*$Y#U#)RV1#5BQ,5$M/>EA5*1>D$429+(@V3Q',!P-N7G*(%N1 I
M-K2[I9/#77CI'CGN53CB'#[<!9W^!BE]^%ON]\>74-0L8IKUM$U#!'D:B:A>
MDM#O-CS/X9J%,;/%K:\4_SR=_1K\LW@L^_&T _C'J0*<R1BQ1=CZ+(>0J":!
M6BV-D"8&^^:=OMG'_RW@'^3-V6Y+DZAJ%="M!0[RW2QS8@!T)I996W([=2ND
M46^\5R?('^U/*H$/>]5I5JTT.MJ^_)Q]K+(&(=$Z&(['E3"[%D:N@I48N0W8
MH*9?29J+F&?_=/K ZF'G0>+#JW.J+<G)H4ZEAPUO3O'R 5AXO2K(6]U3YP)4
M&3M3<78>)!A_ [[!V7RR@:]A[O8^SMZ?MU*%U=XG52K:G+*(2=Y2.:HR;F="
M,G4DX7JI!!KRO8.ZP/O2/L F[IP_-@Z/^AA);F&*&AK4W\!:+V]OC_(V*LO9
MV/@TGG6IK=G$UEC(H.#BE$4^M$)-!I5% -@%<ESJD)U1HN0@2^)4.\OOB@,]
MI+GO[!G#U['S=]R;*9ZNKVQO21%Y,8(38Q0HVD@="2HXHK1F%LPLS_!8=[8T
M!QM/6S'UI@D97S."T9# ER&!C>TM'Y0&=O2$:RV(=+80:PI@K>2D-U8'&PSV
MVIT#MBZ1 #;-W?^Z?IF&"KX$%9QA4$&88*C+A91("U!!#"2$Z(B4R@A1C*,^
MOGDG;NL]6E.!K8W*BQ-%_>WJ%FW"*B5N8C7N W6T"A;_G&8_&B,(]>.)X3O^
M&44->^"IE=HGGJ(W*3JI=71<QQ*\T7@:KW4W';/Q$-JZ[;C[F3FOUE/NP- V
MCG/_<V[#.'>^:]JCV!0P@[F>G(VD:"Z)5%(0RX#V5 2KWN682\8#D^=T^Y[2
MWB](%_R5TT47Z'WC>/A]D\/N1TSPDPPT 5&9*1!%/A%0"X: )91T,"Y1Q^]!
M#N);((>=$9#^=TT09^VM[$$S.2L)['T$D!H*@8V11,N<*2!49RU#@KCY[(F*
M(.0W0!"_#X]&WS4]=%8 JR0MJ0N,%,7!:'$8'97%$6W@_YI'KW2\O5=^10_J
M6Z 'N/8[IX>]+<FUY#8:@ X"\ .>;NI+H20G+;QA,3*&"3%+<R*%$WJX5T5?
MM;9W5B QAS5#MWG'F,):0/3K[6^3?BZ'/S,[=9A-O&,$__+L[C$SUYWCENHL
MS.L_)\S2.1K D^,7\.E<IOZ5' Y7>N/8'XZ/1GD#'OUK?QCW7IRHNQ.B'HK.
MQD>VN=OO;;[_H]<^6Z;=3VV)8>ON[JI PFRO[+'U]W#?Z16BWHVLL_'/8!V>
MWQVLG;57_MKIGFVK]95_>@" 99=WC]<W/DH8H_C/69?#6+:B<9RE3(E.+A'I
M0?T%P3U)+E@9..>@%-^TIOGU:1GE2^0T&F$-YPHX(FN')K5F0)DNP;WR#9AE
MT1]@M>CH""#UGT.@D]:__2DZ\-^V_AP"06[DT:"%6S$Y3\2/T;MX:>>O5-?-
MK:N[>RB7ATZ-M90:Q:,(4@/Z4RH"3PN ?$ J_J%U>,_'.P_TTEY:XOOXSL5"
M^\[KZ1S4T[G[@**'N8.^@H9%$D<*1P+_[6B$D;$%4I]?6]*LGK27 5W;;(K/
MA,4,YI;A@83$%<@=G:-P3)I<^?]N.7D(3W8;8GX$9AS4_N '.FGPK*'$A',E
M*XGM1%,6,LNJ;1T>]O4%MK[9\FK+SSH?$# %CMVTM**PY84&XIVB)"J6..AK
M#2;5FW?R-I=O=;C0-$H+ N$@CQ[L_@V4!JM*DLD9Z8VRB06G06FP[(VG[ MT
M*IRWZ2^?5/'5-YVWM[<*[&LR3!!NE"<276T^)$TB+'LQ0 [9@-5DYK#Y3#H=
M)ER35/EU:XZO\@*NY!V,,BB(.I&@SAD8'LRVP=\9]E,>C9=:]U(FS#U.F10-
MP$,E%T&02&&9*[0P)P"D%FU\K(YU?&)@J5$FLT1V*8/SI+VRO:50HT3,M O8
MM,]$C>>9*3S*T7"KP"X(=P47YVB6!T8:LPZ!J^ %$+BTR=G"N0S!*<#7$6RW
M+T 'S?[C_J_)]0];*E";LS3$YRJ>S!-QP@4B!%@#,B59%+W=5?=%-$N)#LP)
M)7S)3!83'"O.>LU"],*J=!/S-YKEP4Q_TMG>$M0R9DPB%HPU(I-P!-"Z(1Q9
M7%LJB\#36OGU0YV>3;5@"+(V9'(B'EM[;>>Z%2#VW!I-^FU=H[,P'(VJ_-IQ
ME=1R(\4!98":^B(85EXEK+]WAJ/#J5KY-)G#<CV%M<D,_H()G%,=X=\=V7W@
M(&NDM8ZR)(F&10= 4Q2Q(7(P7'@,J3!FM7OSCBZ9Z_KE7Y5$>=CV/DZ1--O[
MF.T5(%6REI0;:XDK ?"JRH*$".:**JP(G10/K*!=RJ\CUG^==WJH<PCJ@[1N
M<%4@)=1UV=C- 1/Q/^?^Z4-ZO-W?7?/N?\+HIW<WNH%N]&/=<=]WV&3.-DWF
M%F L39.Y>S:9N\.Y?<49SB7J%L,!+UL)<-II14'O! =:S7-E;V3*Q?-^ST84
MKH4-GC&8]#=VDSOJY_6";U[;QV[453'.]QU7BEM<"2JD8<1Y%HG,&FPUYS2A
MFB;F7)3"Y:MQHKM"%8L0EP!"PRHX@%[A<)XOJ:XV&Z-Y,2P_WQ6)F>A&74VH
M/H7Y7&N.0&*0ZCSP@W'^>?KAE]0;'_3]Z<^]_6IXU4V_ *ZKCAZ?\">LVH5Z
M6:*UBCD<P7]I^OS)UTO55S\=INO?&;?$K+WQ:[K$;OSNML?:):'4HYYZ^W>:
M/N[.N\:J[_74GZK5K5<8M@IW_?][(]Y<((0J#/\S;;%JJZ?/N^52?G""%_]R
M#0M=W>R:AKY^%+^B*I2+YT1^]Z1>\?RO"83)_)F[-/\[""'XN+=='89))D.,
M,6= (A-^KQ(W#@Y; )![J34=_RUK@HD=<]C_#DCYK&OR,'O7@ZDKC7&@A:T4
M(CNNI'$EQY28]DK.=V>L=7Z?YRF[4,"S-N[?A^CN^7<>(0$!5G_]-F_WTQ_C
MS8V# :8WK:_\!=]]E)W!1[HY^ O^_>M>=Z._M[G1Z6,:5'O0ENV_)_?\YX^=
M,$C]]<$FIC?)SOON<6=CF\-8!YOP[_;[OW;6/_W5;_./F 9U"EK^Y#]GJX?M
MW^C)GQOX^VH:%<S_;(UUSW9V8,QL<^/#&:S+3H=O[L%\U/K[CZK]?O6L\^G#
MV277_4K[K(,IV9K)J HEM&"$,!E)+&98<9> EJ@1"E.R^9*YGH3[KQF//6;9
M74')EP7VT]F.MN[)?"\JCO_[JBS^<O.?G?<(7[E0$W^ T_YQ N=!3OO9B%UG
MN!^_$?_]5Y<Z?T^DSO)6*B)IY0Q)3EHBBS'$9:S=D%QD+QQ/RH.@>"O==3?=
M"Q6M5G0YR6A\+J[$;Q_(G;= KZ>-YRJV^V9%[_R=_@Y$[P/AWIP@>?;6"!YM
ME%QZ[FRA1GJ:J JRV"R_0+RT$;U?1O2>GHM>:XUE1C#B!);-1<N(ESX2K8S6
MU"7M#:]%[_7$]P45?P\VTDKUOV_:#A-2^A"9CS85F54)L.4F>,^55T;$Q@Y[
M>;9<N]D.V^WRSJ"S"W;5<7OWKUYWXX."]^^T/ZVRSON/)YV-WW?781Z;&W_T
MY]EAW/)L&$LD%Z.)=$D0ZYTE7GC!N,U9.X%EV>9ZJN9E.TS>8(>=<QE_&)?-
MU?VOVOQX')\U.O %F.W"_,@VP*9(2I()8'Y8[HF-PH,.3)XIEI*6Z<T[]M:9
MZ\E'K\C\F*_FGM7"N/+*&QW$KUUN/!D[:\DT'NL>!$]2)>,,SQ&L7IL#-B-,
M#79>&+DQ@YT3\T8$0U34GLA4.,'^D80S)2EGH'6]K>7&38=4O 3O/C:&\2W#
M8PM(*!8:I/%1%LZ"-M*(!)L8C18Y-O#XQ3FO?4N8XB/M?/IG#^[;[>Y^Y!BF
MZ)S!7 <?8 TBP./JWV)]Y2.=!X^=2J#C&=;'ND"DEIYXKRAQ-CF/0C=C(1-?
MLG?!8TPB?#0\GL-E"Z?FG@R/'\=GC9I[ 6:[@,<E&K 352$Q1T$DCXP$I2D0
MDS'4^I*IK>"QD?8UP^/Y:NYK.."?!(]?@]QX,CP&:SK*++T5)LD@DI.9JF(E
M8TY&);Y$*4XC-[Z,W+B QU%YIBVF!F8+\+AP31P#"<*U#3*%7 33M=PP7\BU
MW'B/GP<>2SR'SRF#V1R2"NZ #46(7&@35-"-]_CE.>_#;5D\QYOOV[2S F/>
MZ*/W6'0^==7F^]7C]LKJ6??3FMK<_2"[NWMR'CSV+@$N%ISDA*T=7'8$$+,@
MRIN<5,E:^X+>8WDG/':-]_B.GM:/XK-&S;T LUW 8YV9X=%2DBUVFM0A$Q=D
M(%[+D+4R3%<%ZF^-N%ZO_(K@<>,]7A05/:<1>HS>.,9$QAA=4D%F(XHP5N9B
M*><-/%X8N7$!CPM(=YV<)<Q01Z1GCMA@$I%969.T=IS%6FX\.?.B\1X_+SQ6
M67*7 S"=DM'RP+B#YU+O&-;FV08>OSCG?;PEN>+77GOP4<*SQ.;N*NL /.[R
MMNQ^^LCAO6QS8_FD\^G#"4#DT[G)%3J7Z((BAIE 0.5'8GW6V#Q48+_A8G.L
MVF#=F5SQ%'C\&KQ 3X?'C^*S1LV] +-=P&,I@HI8^A$"FH^"<Q*D]T0:H:T"
M5!)I%225^GJ'C5<$CQOO\:*HZ#DM J-S&L\Y9TQ)Q0!E&<.\!:M:60N"HX''
M"R,W+N QRU910,B$63QP-8I  A[A*&W!^G(KA3&UW+@>=6J\QXL$CT-2-NK(
MF,E>"N8#3>@UQ$:*@L$.-_#XQ3FO>PZ/.RL?Z/KU!(OC[FX\:9_%X_65CR>=
MW0\G;9C'^L8:;V_L]#IGD6^^W]QMKZ2Y^<<6^%@4L'2U0@]9<(P ^S(2HC'*
M QT4+:OFP'?6@?+&@WR'JGL4KS6J[@48;@J1SZ+L;&]I'WFBB1'AN$!O4";6
M9$-BM-F#)BS%XD'U;_GKALF-%WE15/6<^KU@9:&)4UN49-993XU+64IJ2HBR
M2;)8'-EQ>DEV2&LC"P"5@XP< '(TF, 8B=)@XU A9>:RDAUS$K0:3_(B064O
M?> B)O@_("0/%JL)(7IN-05C598&*K\X]\5;$BU6*;P?QML][7Q:/0,(?-K=
M6%7K&ZML?65;M3?:IS VU5GY?2Y,-JPX@\P;J4,V#H5X 1" XI;+3&5*'#W)
M["Z8+)L\Y+NZA#R*SQI5]P+,-E.F5V2@0A?BJ 6('$PDSH#6*PZ <W$QN5 %
M3+EH\I ;3_*S0&1>BK-XO(S,00;K0XZF<,>Q>8*/R380>6'DQDP>LLZ2!B$(
MS4(3*04EEB>0(%&'+$005JJ;Y$;C25XD>&QL*DI0+8T5DF?0X=R55#P/JA2I
M0P./7YSS]B[@\<:R!"C\.;W_1Z;__:._R?N?P^[!SOI*EZ]_6CO=_/3AK/W^
M ZS)'_#\KNIR6,V5[6-8-PH0>6_]=WO6WMV3G8TVP.IM@-,?Q99/AJN$R98J
M)"*!LXDW6)K$4Y ><'/2ICH:YBZ,+&CC2KY=USV.V1I=]P(<]_<ECMM2"N"(
M$X88(0THO"!(L-*1%,"\%*#0*+;30X7WJMOI-;[D15'6\X0'Y[Q$"A+#R^B<
M3QH/\Q74*V-85O<#RF=Y-$Q^O-/(C>>1&Z=7Y$:@*M@ <L-&2B2CAO@D.0E8
M;)EYLE$EY%++&?^E\20O"O?-A<HPPQB9]Y&E+$.DWEG'8DQ,@NI6T310^<49
M</7XSXWEB?)>O@*3AZ*]L<HV/W5/NF=KK,,!$I^MJO7WO^]T!IM[7;XYZ RZ
M'-9+=?M787+D6SI%4Y3)Z$H&DY?F0H)W  .T"]+(Q(MU")/MW-;;^6@T)"GO
M#P>]_9FC]"8Y&+IQ+M^N^Q['>@UP?@G^F[:A7M[R1<9 )2,F,U!^F4D29&!$
M26VL _572JA ,VN\RXUW^5E <P0J,]PSG7*1+"A/J3."2:$2$)^[Z93A1G"\
M@.!HGPN.8+6('E SLP*[P'D0'"(H@H<.A 2Z-^8J^P+@=.->7A3FF^]>5M([
M!<9-MJ"KG7(\L)BBHR9*IJ5J,//+L][I!69>/5Y?63[[4_S5S__[U^GFIW00
MN-0=>&?G_1^[G4_P?AAS9V7O;'-W3VU^^GC2/H-G;L![^(>3]D:_M,_6U/K*
MQ[/.RC88P&VVOKSE\%1YRABQD5DB3;+$&BG )-8E)"NMX0QSE>]T,*O&P7R7
MC^A1[-:HNY?@N=5+/+?E,!Q0BB4T.M!YS&=B+5B:Q?HH!.!FJ29@F;UFL-QX
MF!=%7\^1'@*PLJ@:$'D)&,P&ZX1103KX6[+W!,N-A_F9!4?[LN#0+K'DO0/-
M*B61EBKB.9X+5[RS*F7\W;B87P=<9J"FN?<8(BY2\^RD+C1Y77ARG*G4P.67
MY\"36US,L!:1=0=_['5W,3%YC:Y_6L7,C+/N65MUSU959Z,#X]GC[6LNYH]B
MR^E 8TR49 ?:'W!Q(@X,8:)#TI(;KR-VA>7W: OWE**^U^ 7>C)0?ARC-4#Y
M);CMPJ',&=B1WC$\U- 0J;@@OG!/N'-)!%!V5G#$R'1.?Z=7A)$;A_*B*.EY
M&%D'Y;2T"4_BI=F9PHU15DICN#1-NO(""8X+A[+E3GML!T>YH=@WF9*0!.A8
M%DIF63@ M97@8-=5:^-07BB$K)2*UH.IPYC,*@50"%H&H:U1DC6GGR\"ZYU=
M=BBOR:L.91B;:.,ZK0 "QK&LP"J>]?LPOY/V>W@_7Z.=P3\]^.^:0[ESO,6$
MIR'%0I3SP,TI%^*9 IPL#),^".6$?/..WN,0]*<D7KP&E]#3<?*CV W57:/3
MGH6Q5B\QUI9U5"3.*'$>C_DVP9#@@B<E"H\MQI,U^<T[YQJ?<>,S?IY3]D 0
M>)U+MAF$1"E6<B5I#)+)8HOUC<]X(<1&^[+8$%';(I,AU%-,L B4V" E\:$$
M6IRR$0WIQF>\8.PW%Q'37"*8,85)*Z02/"B18/LT5]Y:ZYL*O@7@P-.;?<8'
M\)XUWGZ_=M(]6S[IG+5I]PS'](%W>5=V^-KI^ON/K/OIG_[F/W-\QIJ#<%6*
M$4LC<#(W%C@Y8I9R5-Q%4QBW>)2(N\MG+)I>R7>HNL<Q6H.%GSV#8GE+6J#
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M +M,@;$6A<7VF?"# C_8F#DV'',\T *<D-Z\8^)5MQEK/+N+HHRORP;@?^<
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M<-88[8-PUDK]38#GQH^\*+K[NN105*NL)/?&4J#'Y)S5"22YC<XD:6YI;]:
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MU%Q:SK0* 4P^NB3G94@A(3ULGQ\G4.;DY#4[_:"=[AQON623S(P28[(BT@7
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M5$2N0,*]DTLWE12'"4X%,M^/O0/?;_EJD5'J@LW: RXZVA]G, C.4Z^!$,;
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MW!E=-#[:SB2,LM\COL!H?_;]8W\Z?O/3928"#II=P:N3OW&*I3S;%&M63GB
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M(9QV*.)8L-(\ZF$HI5)F 63JT2YV=%7P^V#P%4,[?IRX2]]KW'LS^ K:HK=
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M81O''U<E6L>]:;FQY<85V;B6&UMN;+EQ53:.WTM!?XQ!T\_0BN1NN^$3'&W
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M;)2!D:CH4_/8!O;>Y?XTL/<8[(N=76B+*D=10X.9P!X9>",*Y.+02,>QU*/
M^YSLWVBFMYIB"RVL&LWLCF8ZN42),YI3SH )80&5X+6H%T+,(:4D=-89#XZ6
M YD-Z_<%ZUOH>M6POD-G02?GB&D7.6<9?%2U1':QX'C0$%)T5B5A>*W@M_;9
M@0;VWMH/6\@X:F#?)=@7.4J)2YX%X3RP0&!G,A+L@P(G4F&1>RM1K0)[,R :
MSZPM*K:0(=5X9I<\L\BIDAEC<3(!336KN9 2'.H"BA6K70HQ.GUPM-S KX']
MOH!]"[W &MAW"?9% E8V,J;,!-3 ,J / H+#""IPJ;S*3J6PRBNY.[#?]V)(
MWY^/IWYX<IK/;IEXM0>9GWU(O+IVYN>"=9[F:4W\K'F?C\_S\U%WJAH+W8B%
M7G63JS(Z@XGF*J'5@*0RP;EB02./1$"L=OS:\^2JED7>6[6SS4)(C4ONADL6
M8=82?61>)=#19T!> GA1JR)Q@4)+E2361,UV#//^ GJ;19$:H.\$T)TDJ:*,
ML"P9\&@#D%)08*.S4(+*6>@HZ3<KQ4$#=$\ W8<DJ3(:G_HI7>O/Z</W>3Q*
M?G+<T+TK="^V:]+ZTB;CP4E4@#3!X'2@?QKMB,.CM,Q6L6U)HWW7]']CEU[F
M1C6YL%M"Z>0_%9$YQFR@\$3Z7P@)P0L#4FKAF,XF1I(+NJF%>XOG;992:GB^
M&WN^D^.D,K)HA0.N$I)"H&D+VEO@G"5F;,JTHOMU1+P!>O_**C4@WQ&0%_E+
M'J64R@2(R0M E Z"([O>">9U9#;G0$!>I^5*P_!776*I8?B.,+S(#4HH:<-%
M!BJ2S8XN9[ E($3:B)6(.J*N]5J6=^,&XOL XBTD!C40WQ&(%SD_@8R@ZDZ%
M(C&1HI810N02M&,JL\3)>G:KC@CM!,/WO=[2+WDZ/<FWS_;9@WS$>Y+MTYDI
MWOCG1OSSP]M_="SZNF&8VOB,YDX"QB(@R*)!"5ZB*8HKH58V.-\?=W]+;NZM
M>W #Z3Z;#B8V9EF+618N!E3,*"X3:%VSF7FP0$O9 ]F:BF7!5"CBZFABP_A]
MP7@_,H :K->"=:?*<Q R2(&0I"/!4#"#*UY!]%J3,BSHO&@GDGH,Z#YD #5
M[QK0"P^$8I@\LPB&3(':\,B!S;4)(C."64U8-Z:V+FT60".3^YKPT\AD+3)Y
M]8%,=&!%V8(@9:Z%4JTA=5 \9*RM(:3(3(<-) @T0/<6T/W(^&F 7L\_^.>%
MC_#M[UI'Z\RLCE$UX[.V],I:2"H$ENB?SN-*!V&#=$\@W8>Z1LU+UR]\O_^
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M.=:M@]J-\[8:XEC$L#-3.;I:Z-OY1/(..5BT'K2+'EE"H[T[.%)F'R(<&SA
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MNX9G@SRSQZKJKA\C1;VJ!]G&1_-6G>3:%[0ON/H+-EED<F;3]@+IJZGOI\^
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M5O)C47)L(FB^'(,AC!Y9/$Q#3\J+6)^O; 8[ACZF9@_N1H^:1HW1(^<;0Q2
M!(DUANZ7SZ.JT<7:^47+[SPF:.OU9/7:L#+[*ILB1*A3>)06:[=:_>ISO6/E
MW7I]/WH]&!A[BEFHS]#6MAC$O'+>UD-JRU@^@:/2^071#Z<F'D^O]]35\97L
M^ T^QN^[$M]G*^ [1?CI\ZOKS^5S.Y-GXTS6W1_6IS4_[]9?7GW7L_B!6Z[I
M_MV*4JIU$TL-6+/,'BW+F"JZFGYM_\!)PNK;S7S_>[_Y9?]=(<IUJ ;U]20
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M"RUE&IT=MR-JB8@%]PR8TP3PH>*;8NH(ZRE)710N+0<6P- &B!6:99;Q&&;
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M+I;'-YRZ4Z/9.S\/:)J+F".L^6*&$]6((M0<=4UOCG=8'C?-CDNS^!TW9/7
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MM?W; K(AQ,E(D,\O:MS^D)WE/D33*J8\M NU.5<;).9,79/>D,)OO6U'/4V
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MEB5SPK F0WCRP!I8B */-HW*E%3D_ +?N1?QUNO)ZK6WFJ(L)UGVI9>30(Y
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MS\4/.!^I-2ZJ18L]7;A1*<GT'),8\F2B-PN,'QC"7EEA+RU^8 A[D0[[7,R
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MT[,P 5URPNJ"<M&A@D1>94!03,6SIEI<O<1"&-/TNLA[:<D&AKSO8+EP%D%
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M[&_F"8PI8#%3P+.Y0@1.7#7G5,D1%$3-*H>8%2.CCM*;T5^2*71, V,:&-/
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MG% ;KF148V@*= &5G+:*/"7/)F,)]YW%;U!X4'A0^%H4KLU1DJ\E1LB:T22
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M%4-]*'DUE3R+78PY!*1@E-8H2M89E)A1144.E#-F2\$/):^_DDNB4K(G,MA
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MZ.Q7C29QQ*-Q\50?=T^CKDLP^*AY&9]R%@E<7!KG5NGI<YNX=ESU+IX['-8
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MW&FRJVD<[</NRO9:Q_8>B"J5[;4#,C8+7#2P\6J7A9R1LU.(W+B2UD]*GE\
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MWH5C<JT92V=_6(#^;UWGE=3:)Q&X$21'@VCN8T*XD#I[)W=U*<.)Y[N4W2R
MC:?GW_]R2SN743/X:X[@)3&=Z![%=33<"QI#%DQD9W*V0NM4T#1+-U&;^)D4
M7Q6R+5A4)K+L U5"1V<8CS)8H82,W*9X42@/W' /CW#!QI*#/$5#*";=2WN1
M4)0@O&X^F?RJBU/OXS+)AOT\A1CO[*?.]<59_['SP\^O_MDY=J-.ZJ-F2;'3
M[7=>IY *S6@*MS8?&.,3?A@<X-A/.KA]O=2\M?RVB[^<5'DM_RJ/*T_HXA<U
M'\[=ONN'KNOAG)%#-)&)ZYW_'1PG5!,O.J-N/Z2..SSLH<8X[9$74($X?,CA
M</"Y.RHTX\+CA^D 7\6O'QWYCSB0SGC0R4?#$OZ(7XWP<SA,X^9A+\I03I_6
M[>,(\-M&%R9SX&+")[K1H-^(3<*-0TLLG7UE:KC0A1&\Z!SO=\-^YS@-TW0&
M99H]W)'8K-8PC8YZT[4LIZ2,!5>@V["ISAAW(DVLM_*&PLB:3Y6;P?7.SOG@
MFOI\^KO1=,9XV#KC(1Z#23/!\I@>"E&WUQV?=!KYNC+"?=Q7GU(?GQ"/ @[(
MGW0.W4FS"V?[>C3&1WPY6WTT1?'L3)X?\'.XE2^: _(_=S")J7*1Q>!T+.*D
M@F4JH$QKI90)QK+=M]?&/YD[6,(WU)G8.5LA?,./@^&K$(X.CE!%I_CC9&9O
MW+"LY>B7T\4[([%V23GLA__NDW#P1]_]:8^V/_:0K_YZO+U3QKGU$<?X96OG
M1QS']Y_>?^DA5WW/MW_ZN?<!Q_G?+V^_X-AWN<TRF8C6@4?;5UANP3 2F_AU
M'7,R-,125>)J":@.KF"OG 4W/D.-"3/E]$6G[/&+<J8FI_$N!XAX:1QW@8OH
M!([ )>IR%L;))!+:.#<<H+M<I<SO /UP-!RF%2A9]*!S]"7L9D&I<4% M(FA
M.1,4H'IGX"2Q(DL1E#=XCNPUY^A@>HZZHP*3O:,X0<\%!Y@T3WS9'2-VAUOH
MT;=G ([?@CA:-,83A< TXSF#\(F"*!H A>TN8I99<L93I3B+0M!D<^+>6)FY
M"2&IU"J<WAKTPR5)>XZ(O;T3$+&]$3QQ\$9G$#Y9\-$RT$XZGF5V,OBU#;:N
M;D;L5DM:D\S2.=_PSNDAZ*;14TK<>N<5$J<IP3OEA)=(V64J-DLW<='[@TYO
MT-]KR&I,2!R[X]0KK+K;_XSL$W?CN#O>+U]Q."6WA4SC0[NC\;#KC\H[TE0T
M.GDX.#AC;,B'1]W8=4-<I 8:"OUK2'398X<"/.G*?HDZXL?/'E&^>G_0BPW7
M;&!NO(^J_7APU(L-33^YP%"GP#.ZTU2N,0DZWHV:\XC$&!GZA&WC(">_QG\T
MG[MFFK@?."WD_ ?3?BNG>W+#7"^/9[R/SY]\2^PBT\>SAFR^V:4Q+EV1F5!0
M?KUST0B]V2QLMQ5XNH9G!Z@L#YKHZ6SZ8]R89B>:DWWZZO!"JEG'^<'GA.N#
M>#_L]LY,PAF#L-FUP=D]<7G@QZ-A=Q2[8?*+9B?.OO3LFYH#-_GR=^4XQ<[O
MY9"@"7+HRK4B:H@A?N';<NO6GUA;O^.COJ1A^?>+#I[XX]3KE;]_QPFZ0YQP
M\Z[_'*$=..C\U@V#*1V=C"Z=RBL.H)AR_7*7U]E#D<8Y_&/R3I_VRH(,BMG6
M'4ZM-L;^V<CV,*%1==)-$Z%QG>P^#X:-+7EJ&O=G#,GR\+-5#46*AJ=BTLQY
M_??U1BR.QH/AR>1=I8$*_3O*W>#8#>/$?$TXHZ:Q2B'8KM/'$W)JXIT]W0UQ
M$GL3^2KVF]L;IO+ZH(Q_9M$: #BUDO%)N+QN,M!>VD,I+4LR;F3MDA!<N#J=
M0RSX1=[P>]C'&?72=I[0KN]3.;QG'HG7^!>*5T!>,>4+S;W7#@[A^]X@?'IV
MQ"#(S==[NPK5O_(\0A;,@B!,@6TL.\60FGMKC4+REI ^'99[YN%1NO:2:WIG
MS1%89O#M[);KZ<%L2L5]<RBFJ@I/( )YP8Q!?ODMO)[.4#4S:%P"Y_?UC0\$
M9])SAZ/T\O2'[U #'_;<R<MNOQE/\Z%K<AS/+[;7R>1R>YJ7.7W^].7UYJ5+
MCIO):\JL6\YN?)FLTQM?^]ICS3J7\EY/_?IKBMSODZLT5G6KIWXC2_>.^;2+
M]JS=GK,WQ_P]DHI1YTV_D,W+=T&W" /[RN0G/K!6Y544K76'2=T8^]#^^5^_
MV>6R^IG/WUSU+=^CRFW+$^QON1RG;.RNI0^6-IKRH3GT=YY_6^(LVE4 ^(YQ
MD[\,1J,?AX.#ZT*9+MD7:71ZII?^6G\2XC2@[[]L?7S/?M[?_.G'3^]W]LC6
MZ]^ZVZ_?R_+WAX/?/FU^_/%@Z^#]7UL_7 IQ^OC'QTVT/W#<Q^___&T?YT6V
M?GHKMCY^PK]_/OCPTZ\GFW^^9Q\^OB'__7*:3=_T:":*$I&%!YX(FB/,>_#2
M&6"XV=)F:KTIGJ47PLZA8G!KHB;O,IY;QZ<O.V(^-/Y\:1&S#>F-%0R?# Q/
MSL PA^1=Z=80B!<@DBFUXHR'IL>2XMRPTI5%\ =W9:EX6/%PA?'P\?-M*E0^
M!E1NG?-&::EH<C*)=AZA,FNP,0K(G'&1M7&H$@MOU ]O-_E88#G?N[^G,_6G
MWI9;=+AI==[-$M9ZNQ,*3;>I@M"=0.CMK/'JK)1:,PJ<>@;"E>X8ECB@3G&6
M<)N]CR5'X@4S5ZOZMK8TTN*(WQT2_5H-#6TPV"HTM! :SDTYHZD(.1*$AE(S
MS4D'7A,%/$27#<\N4U::8;\@[&KOG"J>U7ZHXCEW\9PQ'Y+3**')@DDRH_G@
M\:><&<@<M+?X!_YO;4.\L.9J3<.%2^<#/86U5/<"EZ9MET3S=3.N4-&653??
MWOPU'CK<E6[?#4_>CM/!J 3#XR>'@Q[.>^]MB8A(H^7/.7I<+;$Y:]]%EJFC
ME(%5R.2$1E5A@S# E0J<*\$5\VL;YH6V5YL\M-:\>Q3U\8C>@D>J_K7JBF2^
MWH854B2K;NQ71;(H17)^&^"M=(X("TE*#L(R@N:&I$"Y5)KP1+4VS6V 4'>T
M-RJ:5S2O:%[OABJ:+QC-9RZ/<'NY4P$QG)4P'>4#>"8%&!Z]=2SX1$QC%I"K
M9L&2@ODM"J,]5K)?R2P>]$N!FM/$ORO%3I][HI_8^O)V5SN/8*<8:!X#".8,
M.)=X*6*=O0HJAR!6(=&O@;V20SNMGE23_%8K<6Z9QEJ3_&J2WS-+<JM)?L\J
MR>^.:# M?'9>J?%>[1X>$AY>O^")O^!NVJZQ3O2ZED]\SK\>X9IP#5SO%B$
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MS^N33#M;1=2VW/2]Y)XK<RMSO\W<.Z>,YW \9SI]A<F5T:LR>JY7%G7)^FQ
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MH_*IL-?8ZT4_E7^5?Y5_Y_QC"7^%X_^4]8(8-&A(HC8HQ0SS5C;%C%17_K6
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MG,\4A* $C&()+ ^$:$N"9>7\S?6,>8WF/GV?I0KE0PKE7+L"ZG@FTD&V,H!
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M58"[0H'(3((EP4/T5!*F@S2Z1,N^/J"[O07*=8^LMD=>?RHGQ165)O($7*L
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MTP[QN\-)B^:A[E^,3=_=>TOW__A=O-E[?;K[\RNRL_?OHL+)_M&_\;U>HPF
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MAI6^#S8ICC).N;/E_%FUNCLCPEV-[5517J7!P_9!ED9[*PTH;2D(D5"4@Y*
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M2ZO RI4'XLHLE,RLCD93 JSI9^$,<D40 ]9KKV3(BG]MIDJ%2X7+ZG9*FR+
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M?V8H]Q!H(""XB>")IV"%(#D8M-BR0*.L=@6NK&A%0+VRXJ%9,8NA\T@42S8
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MD(C89UZRJLTL7OA4:XG46V?T'*6"S4+Q\73_AQO8C?>^MN"VQ@L;O> 3C=0
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MN.!YB^'94'W3HIB5H,9J'[@55 H!+8"NNDG;7))[96OYT=Y#>M )F#-5%YJ
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ML$5BV+ABJ/I"!:M+/74'I:=9G8^<!D@H!)":+&)8Q/ )ES08F06,#^K<6!_
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M4XBYV7@ 6=Q,OBQPWF)P0F.-(7O-A6#4C#%JS[UEW[V.L^+3RPJQ)7!NC(2
MD,E"I&MU% =QUL9K4%QOF+&78%DOF*A=V+S-V$PI>L\*J:@":C/ME%H4:8;1
M%G$L;&X1FQL/80\#2O/#:2C5TLR*#GW-K@VLG5L<-9BJ#66IVML,3L&>HY86
MF!I4PRE6ZF64; F.R:JTP+E%<&X\A-R38.#F2N^S;8/66;D"7<V^MA:IA*B6
M<I8KEY)='L*/P-7?#H^/?G:GSYO@0UK76-=8U[AYU_BE^P?_<*)/GAWKR<FO
M7G^U]Y^_6V["#Y_K:A5[JR38%#@!U3 /]V5)R)TI+G/ EF1?NN@F'.I'1\X.
M:^D.F-!Q!E-]'(;D.#+P+$L4WUTO6>: E0]>"S$$#J%FKIY'@"P#&7VWA##Y
MH!EI=?';(C%L[(1- &L8T;4HT8@A%$>EJ2./+5LJ*'[:C'-:/N-%#)_J_($Q
MP6CH?5$$&L)0F71$@MA%TEC$L#UBV-@)C9VK[R.Y4G&V'/+#H0HY9=5N/,Z-
M^OX!YF4G7,3PJ7P1"3SC-$:(0/.1.BM;.E%+$XU]E43;(C%L[(2S8R/-'IY=
M01T,"$XR@!M"Q@UUE,C14@EZM^_OPN;MP28,'V/E/J!%B%1,U]=6?>+D@5M8
MGJ4M8G/C)V2B,#!5%_,L)SI,R&.7YEI6;.)[:]&"=J[+%G&;L5EQ&I9J@> [
ME! PYIY#;M[KJ$2\L+G%);B-GS 4'CW%ZJKEVJ:H,SH.@=WL7EXCUEK8P$DU
M+W#>8G!2(2YC2.LPBVEY M]J2-C+;.,:5L.Q;8)SXR>LI"T5#<ZRV^1 4!QA
MJTYS%9N5N87.%CG#E1N.+7#N,#B'H%8C8B^=(&ICU-&@*PTMJ+C,OML$Y\90
MB*%"5ADNX5R+*LR.6TUN#!LK"3TGT?V#\IZCK0N<MP><4GID;BEQG]N5F3J5
M2%6E4>T0+U,Q]&*AWR?/'_>C9^<_7[B]/MQNO(98;5A"ME!*N9OBC=%1@&B)
M:=4H,:"&O'\0[@2XA6[#&VMY^5J?\K-#/?Y9)I<;T37XREM6C1,"YR@:&&)%
M"?-(K?0\,B89?FU9;8EOX(V263E;4.CLM,5B=*/#21KD)%IZ3?9_F:M?[W$V
MWZ0=J]5-?(=Y84"NZ&?K)K X9REC8(;9?$NIYB:T>&%[O+#QN,3:LU(<CIAG
M*;V$3CQUQ\$^C3Y"TV@RQ-_LK>Q%##M,#$D*@1>)4!F@)NF^ :1>,.="?;EB
MMT@,&X^+2N0T&KJ1.CG(:7I<4G)UA(J4@C3E>5!Q$<,BAD^UJ!$:U=)K'<K0
M4D%JS7LR$9&8>RQKKVY[Q+#QN$1@;EZBB[-W[R1NA\%WY]G((+%*:LF((5S9
MX[*PN</8U%2]R7<?RFR?.Y#\:(-]@-(LQT]I87-[V/SN8@'<QBU5EY+%:]"0
M'87A76[8E8<%\5GG,N8KU[-;V-QA;!H.4^E^E%I-3V>FH6"Y'$7[E NLEIS;
M7(';>%RJ#0O(W*F+T1LX:YTM.=DQ\8@QQ8%]%J&M5U[O7^#<87!RJBR:>XTY
M0>^>DHDIXM"!(5!;[<.V"<Z-Q\6G;FEM3FY(; [:B([ 8FBTQ&.,DFNH\TC'
M@N8MAB90E!C%A)(GT%Y0.U/*OM0^YE'@!<TM0G/C<"FQ#@Q579+>'50*CO.T
MGZ7&O54!8]3] WA/5X<%SML#SH2D.:>BQ3<@SNSMMM4CEM'8PP+G-L&YL;&H
M8BG-<"G:9M-J[@X#DXU!#Z-J'KXU V>^LG'[&L%Y375;=KADUF_YN!\>?<\G
M[?DC_K!9Y3J\=^L:ZQKK&NL:'W.-Y2)\=OCSNF[>"*WW?D? OWQ,)N9;Q0P2
M&(I]G3!0DXR>:90!X3)>H1.[8_MJJ;YK47WW7EPT$VJKJ8R:'-DXS3,'S6$+
MWA5?Y^':FG*#_8-WR^+\ZTK%=A:>'X'.4F9]M"JCXX <(\(0K3V-$5L>8SGY
MM@C*C9.OZH@Y^.)&FD=H6RV.4XXN1Y]':IA:,5 "OGM*;QEV%C%<"S'TDJ7&
M-GQEABJ!ZFR'22*)(Z:8%C%LCQ@V3KZ"L0*7X3*&X( C.,P,K@V(&G+WQ&D2
MP[NF@$4,BQBN9_$V(Q/FG$8E2-'3B'[DFGULD*#1<B1LCQ@V3KY1<\Y T?EI
M[ 6=U:J:)Y> LS:?V&LS&7_E5B0+FCL,S2I^2"/)F<IT>:,@2JA=,(_,O*"Y
M16ANC'RA1,B@[,1&PD%,U:$6=35$4VFCY#S[TN:KU\-9V-QA; [IO8U2DH8*
MHW8*@45"'R$VM:Q[87.+JU\;(]_L;UFU=%<Y9@<I),>2Q(EB-VAJ'*?@I&7D
MN\W@Y#1RL7CI"0DZ($MM2#VJX@@XXC(D;!&<&R/?J#[.8ZNN$8 #@>&PA^PX
MUC9J)&6<V>X*G+<9FZD6:MB2%X@P4N*0?8N!BOW//M/"YA:Q><')9_&2U50M
MB9PVO_S_V7O7YKIR(TOTKR@T-VZT(X1J/!*)S/(-1:C;W=/=,54][K9GQOU%
MD0DD+-IZU.CA<M6OOPFJRH>RI+)4)(\.*538E$B*F^?LC;60"UA8F0-U@9"Y
MC=C1Q\^8=^_3Y8/D-CA/&9S".AL2%2Q0A0DUQ5SJ&,+K\PW.(X+SX.1S@O3*
MI5G(J0RO:LU6RJ/7MSVMNI9LC/+NI@8WWLEW8XTD_^N[E\^>GSW=+=?>GT95
M2LP89Y*9H7.C3A%7M $D[-7JWI(Z$MG\^:*!1!(BY<G!,*XMJ>CB&62$+'6)
M*NBSKO"[F[TCM0,S3Y@79K19HS3B7-<Q=LDP* Y(M=F(K)L7CL<+!P]+G5PF
MIQ%*',X+ZT@!695E:9E3*T2>Y+S0=L>U30S7U:,5JVJF/K4 0!<=-JA&6WXW
M,-[QE4<DAH.'92VLSUE22''$  0CT$PY4#*5648N8DX,-]S#LHGAA)<MC&7.
MYGS0>H,)2 F+JXK>?9J"8;MSS!&)X>!A222UJV*8;*NK4UKFMA3#')-2S40R
M=<74G5"&]H;F54.SBN 0G_H[1!B#I"&#3J,\:J>RFR$>$9H'#PM'*MQ;#]@Y
M!U#Q8GX."(T$_.LUI8QW[V?DC<U;C$V,HS@_+U=9A>[@K+5S$S("$['=#/&8
M"W 7PJCFA)&SA-[%P4G4@LZH@:$C6VJCK$ZEF7;#M=L,3D?F% -0JP!2,G&/
MS3!7D-$BXMZ*.R(X#QZ6+E6+$ 5M!@$&0)!:*(Q8;4Y-L31>H>P;F[<8FY48
M4\052H907'W&T7);6^;KW$[L&YM'Q.;!P[(.KQ@1ASJC8]/59R!A"Q4C:$,=
MH&.=IMK]UFXS.#...5N7632#8%+EP0,*E*RIP#9_'A.<%YJJ1:QM8 J3XPQ0
M1@LR+8>JD2SI.@"YP,FG!,[//0SEP<MGW]O+SRT-Y2.X)N8A.94HW"LT'\;4
MY^"H3&F9)C^D/\K%WH[?V_-G0UX\V@QT-0STW45CB_:"LTH,@-T)J#H+,?,,
MN,)K6FMU8ES;0I13_N6-WJO:%ML3I@PTAE9FB2[IP;F!13O1Z%Z=9D@Z]B;V
M\<CA0J^U/G)O2J$FDP!>D@1)- (6+R9I%+"Y@FSK3FC9Q'!-Q,!4H]0Q:NIY
M+2IPL5$S"N0RN]2YB>%XQ'!PMS#":%PAC,X60&2M]^E:C.?(ZS@;*&YBV,1P
MC0L:7$V[-2L$#3+Y;< ZN'K%ZDIZZH>X6[;(N%:Z.'A>V$=D+UU"[;S.G[<:
MI!@M,UQ)J3-U&.\7&1NUMP>U,S/GV0H,7(F,)J74V$K.*:[#SKO3TQ'Q^<<+
MIUM2KB-A(%I)C( 2>#0)T11Q%HE-O<XO_+:+?6/S]F"3U[8 MK2V\4!CY=5:
MIJ7N[+Q.HN>-S2,NT/WYPAGTBK70.H->O=;.-@.5@F'83-,?1ZYK;WV#\W:#
MDR(-'6460W,=/+@PS[6-ITTAU@_I)K/+W>N%[,$.H\7K7=,:VJ@<8*3FI>[P
M^;1+SY-3,BR[WOT<8)L0AL7I"A48.BOUD1W%#%X(YZ([.N*8 #UX8M2R6"4+
M(Z]=K\*N1;EC8$C2V91C09]3=X>VVPU.JW,J:%<'I%@47=F%8-#1$K7MB3DF
M. ^>&)U:$XT2M!8)8.>+R[6$5ER1V)B3<9X:.(_:H6V<_>G'"__P\V']XR]3
M.C?3?"KD/7C\^$R>=KOS_#4,[H0[#X8]^49>W+F657_X(N>?9>'YY3?/7IRM
M ?/E<WLL+\_^9+_T&_MER%_D]LW;#UI>V+K"W?M_EP_]8/P9W$:?X:7WZ]J*
M$RW5T=D%QG0:=;&2,I"6DL:DO5]W)$Y-!Y?/5]_Z/7C(>7:<5H.EM#SZF(,T
M@D *F&K'/+K<O9_KVZ?;;M*>W38AGS YK*;(1=,TX0F5IO0X,=;:@=$K[]V'
MZ8CD\-4;Y)"@:822PLPPU]%7"Y1[";E7<N(FC)F=''9:Q>:&ZS(-0RG:>Y4V
M&I0\614DF;9NI<VQ6S$=D1M^^P8W8)O)8ATNQ:)_B V"LCI5E-@LU=QPMG7R
M=F=<;7*XII6:7J-";24"&" TZ3D526C:2^.!>VOR>.30WR"'& =U2Q3F]'(!
MU#0P$X=LIEF[CIKCW?N)+]V3:>/SA/%I';M)KHES@SQ$VZ#I=3TF+L:I;'P>
M#Y]_? .?8UCI$R1PC N?J;K@IQE2-FXR2=O$?3+_EL.SIT2*7DGWKH X17*.
M7EJK8)X5;</SB(MR/SI[OO_*7]O#F4DZ%PXDU+W"3AC4'*G=?/;,$U-=.Y$Y
M[OGS-@.4BT1"!6X=P50UU\@^<5J*!2G:WHD\(D"_?P.@5#5G?S9AS)D"\'F!
M:^0?I(M_5M)<T39E _0V Y2&EAIG!E:!A-F?/A3.LY0.>1)M@!X1H.D-@")U
MQM1ZF&@S *8>V 8'XYP%(?GHK'?O[UBXVPQ/KV@GKOS<J 2K9Q>55"7YA%I&
MSG4[>8X)S_(&/+F5R63G><=M]6:2H%Q;L.0/34JV9K+FSU,*5;UU"3<_[=MY
M;=+9@3;O-[6 .JF4S%Z8P\RF'5>_A9S:+-1>Z^<=://)2.?[BX$V*966.;?@
M=;OSC4\%@6/64"S/-A#99X<=:+.]Q=?=E<75HD2$7%,#:$1%&K9F #,QQFUU
M.2(Y7 BTT2;(B0/3ZK6<B8+4.8-+A3YJRA#'VLK.;R^';V+8Q' U25=UZ!PE
MC\P=)&6FWE%CK%;;B+K;-1V1&"ZV:_*JH0Q[O3FVCH"L'$ZO&FJT')6C\=C$
ML(GA&M<PU*J5,IT<V*!Y#6NCU"*CXD2N57>@S:>FBT.@#9 7$#5BD([+2S_]
M;RN[=W"67IKK0Z9]P/=S0.VJ(6N2.G*-D&TM$+"P$,1,F.+86^O'P^<AT"8;
MY*E40N1(P=G4IW,L-6@%S(VFU%Y].D^7WA78V#QE;+8D.=?6P2) 5V67?Q6A
ML_26^G:E'7.![A!H Z/IBN\, ];DZ:5.((DYE($*<P).U0W.VP[.R!)Y)BFB
M RCYW[T 9O4"F,M(D':@S2>'["'0IL1"&1VHT'P6!9H0F/S3,8:3:7)&S7/7
MNY\#;!-$F%2S#")@3-R!S S8K&M,;>^T'Q&@AT ;@ )9%S8QSP <8^"D%EH$
MKIH3PLK,\&)G@_,6@[-T2JR3(C@XVRQ,+D\=JCK;Y(K;!G-,<!X";03CC%[T
MAIPY!K""@3I1,(FS5=>BA.W4P'G40)M/@JM?G8G:2WN_[^4JK'G[&OL:^QK[
M&A]SC5OG/ORH<*Z[]_]-GK[ZTYEL/^+[MPJAEI[[<A(5&%UYME[(5O.+W&;_
M6#_BTU=/QK.7/WQ_EX!7GK_UX.'$N<[;ED"R3(E$*;!!"B/F8=0T3@&O .]!
MVP:#K0ZOB36RQ ():L5.H,EEHL2H%%FH6YE]L\9)L,;!K:B\LH^<-5S22P!T
MR:@2>XBC6.NC0"YYL085W*RQ6>.:<KG6(:K)/&I#&%JD5&JFU%#\P_S89KZ;
M-:XWLNO!0XE52L<:..41H+$$:5,"SJK<O%S$,N[>+_=*W*RQ6>.Z#F0V7&<Q
MT\R3@6(F:+5GM-%K7[%='VEFW*QQO5E>#QZFBN!L7D(;_DR &@7.,$+D,2(5
MB6/0JC5:OG30P0;N*0-W^(/F7DPCK"TDM5Q$*J[_1YD?VU9S _=Z0[X>/!S4
MFP"/D+GW +-P$$@6I';U*D![&7(.W$H;N+<8N*7&7C*AUWH&4EW5C]&@]PQ.
MYJ7L&?<T@'O!!]DA9QFYAU9G#<!Y!JT:0^LP5O)3B@U6H0[T=NSV1N[M0>XT
M<=36:A@S)&;QMYO;:)PYYBX?DBVTD7O$7+!O'XIR0H@C<),6(',*'!W#*R+*
M'YYJ;V7-N8R73C79R#UAY*[L8[;E7IX ,:FV(@CBE7/%XE??R#T-Y*8+R,W2
M2O,Y=PZ7N9IS(,PQE-2DHTS$7,^KY;2KY=N,W#YZELBQ3JD.UJA& .)U,Z8R
M-'V(4W(C]XA98M\^;"3FSV.$,B6M'+$:=!0,?7)O#=5*I54M([V]K'WC;90W
MVLOSQ%[^+"_/C8@NO/S^&HWN+-1;'P15T >UQM@X6;.J>>X\D"/137XC1:S"
MX-HXE*(4H*Q5M80<5"=4IYQJ1>_>A_9V#]*;M(6V,TU/F!@RU]AU>F%2!E1#
MFE1Q^DC$U%5*VAOO)\$9![N.$7&;S8<ICQF %EU @5#[R*NA\;1XKBW@'<UP
M-FMLUK@2UNBF*HEX@!2HE)B&M@(XLZ"U]"%M]#9K7#]K'.PZW=5&[A3#[ P!
M5%.@"!J&9C%LTU+G\[7$MOOK;=:XIN60D6%2+#:F=DC85,MJ<4!,9MEV_ZYC
M4L/!DR/+=&%Q;>B#!8BE!)X0 PUR?1)M^8/OWJ]T2M'I&YM7WWID:$E RX<#
MK2-7D.6KLRZ.3NU[8_\D8'MPY+2>:I/*@3KF !5'D-[74@*?[Q&-HO-<!]1+
M[^MOX)XP<,=:L=:)>1A ;<1@2@3 G%IQ,;^!>Q+ O>#(:;/$8;.&%'L-D&T%
MA3<)2A)7@ERTMIKQW8OP=BV^D7M[D,M="4?G7AVN5.>*#8S EJ)*!-2=HW)$
M>%ZPW<Q4AO\7*)E+96P6A.L,SIW4*HV5[7CW/J4-SML,SJ)M$@)IG@Y.*@[1
M5.),@Z-2[;*W[D\#MP?3#5;._M!ZD+Q.I%7J*RV;0D'+*TH.$<=Y09S>WD[;
MR+T]R-5J2:5F3J)0>8AJ;C*T*;?B==9&[FD@]V"Z<=AJK"6')+1F7%RBMN9
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M0JP]B)812G)ZK6PRK>W:]W. ;NK")%64"P%!IUQ[<Y#VF2MCU;TG?T20IC=
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M30R;&*Z$&%*DC)$[I2ZP;!*EQ5*P%"MS9I5-#,<CAH./I5@J8X*&!DD"D-5
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M3VHC]Q8C5VL=?7)L;,5)W+&)&JFW;FL(9-O(/0WD7O <2:G<,GJ-[(4R=+%
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MZJ>$"ESP>_93#=K33_7(*N;(!/LGEYHBK)&BD](:Y]8C:[WJB>LW;#\9)OE
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M)) VQ4WC,0_LD!#)W2 -@M35I;$>@E#&SM=B\6$+LKWAY]WR\\<9/\?$";Q
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M6(7L8U4K:YQ;XYZTQK(89,.I*X'C<O5YG.MZ<-9E-NY97_B@G POIAL)$SY
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M,R>D-@G\U$T3QPGB],5;O^-[-]N.& -I"UBZ%3X,P]([9^F9CI &0>PSPNR
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MW];CR5!L7J +%';TLR=<&WBW(>Z\_=^X>/UV)056NQR"O/?#*"\5&+U1:P2
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MJ#"SPX@D%,3'$KEA@J4M$H*-+E.;<4&E$_A![(LMAF@;5'B&J+ %FXA!A2=
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M?FS7BXC:Q)C/JH)G1>U8J+),57'=TD*>R(9W[F$E?NE$=-7\:B:8J89;V/2
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M;2,:JVHH,NNO@G&XF"\RUQMO%F>L:^%A8+Y !(UECW_/\N) H''5*:G"M7&
ML^#5NM/,TJ+B-[^?<3;6ZYSF]VWC>-1-**NSK!9NJ_>6NSX@U]6#@@/0@TC[
M]*"9\H,[+X?E^I;&]G-KDTFGG#LG_">-26^!X\J:Y9J+J>K03&:]4H^&O'^-
MK1-KUJNEV,E@@,7%YGZK+$F+=QZ!)*&MP\U[ZYO&6KRN[OVYX%7:UJ<^']HZ
MDNE(I2LN_\'99#S-P#B&-1M?WWZ[JDB)2G219.54_$*!_#>)M5Z7_^P35J"&
MW_VH"S2O>/AI/OP/P R JFK+7O6?OWO2GW*TNB&8?M)5DDOK5ZS4?=XH%XQ'
MIZ6+#>'9. V?5<];%,^6;GHYB1?W_<LT8+H>&"Y'312++YON:Z,:-DJ):9Z/
MA_EXGH"KF".L29]/2CUA#!PRBLW6[![;AH-ZXVMCQU+*U8V7=77AZGY5M/]+
MTI-BHLW(TP?\U#BQQ]-DT.;/;GW7N+9+&Y)Y",FLB?NX-36^-8)05<1^'P!2
M8^6)+FVNS$W3ZDW+T&.-1^L\G_K'ZQ'PWI'!*M?QL_4K4F<[?L7(^!5;[HM[
M;G[%]?2[U:BQ>Y7/;9_*5]GIKQL&<Z2HRI*F3Q4=TZ.NZQKV\P4Z/E?RBI+S
M]0E0MZD[@'._Z2I29K$J\QG/N+)>O+RY>+49,IXM7CY;O,%<RNIS]'E$\_N]
MTQB!2J>=$Z=0-6ZNX#WFU#(:5E4#9@9G':>L# SPD').FN7QM)3)J,I& 7U?
MFPV4<H*/;98;D'H%YY2E&9TNDMNRN[&;5-FH]ZDM_/"/J0$;S28K"KOAU/2$
MIIT+ZZI'2Z;%KZR9"4&_5R5T5]70M7U==?'XPK\K41Z)8;]3+\*NY[CW"@._
M_5I$V-:#RPGMNIZ_+X/UNM0+]F6P8=<-O1V$[3].=#.["]T5LR@D?P='VT5>
M7&\0N#V7"++Q*N@#K4WK<#I1+2#S5"G+Y30T0X/I.-=_QU)=KM)FL9FA^K>L
MC+GUS_.925C_NSHG]$/JPV(:&ZX/#/7/E_S5,]Z$W]4_I+ Y=K.ZD/.+JWNJ
MW;'$UJVK&S_GU;V=Q LYT&5?],+5 0[Z(D@)U0<55#!E G2-ZPM*GM$?M0"C
M[KDIQ.A]D%>5LV!A*.J?E?,</2'XN*R*G8)5F@RJS\ FK_23DE<W4RA6 W/,
MDV\710Z#M:M%3Q(I0?FOA!!5J'4TME3/-*O>D?O">4,*FM<LV:*G%;_946+3
M\6IQ$PL'?M=*UU2-J[2;1U'2_:Y[KX2<)69+W$C;[;*;&9)8IT8;M5Z25POF
ME-6,OI)P-@"+G1%?XR<*#'=$:23J4!IT/"=\%.H)NOY6J<?K+LFO;5"/^XC4
MLS6*<:R69-C=2AG_O7@J;V_^/RP2?ZLF'GC=@"YD/&Q["?#JADOQ*$#H;A$(
MEY)U^[87_NQXOM<)F-/23=Y87DK5?YN>2CHQ?<_EH:%N,G6G3'2/XV!A5>_%
M0TMV9D_89*[XWMHLLIP2'Q7JS#:9;3+;M/4S9?ZPJSP%[HWS[E'4I%WLT'D.
MFLD:AJC'7:DM"&H/WZH]X:F9ZOH@.6XKI/T4PORC$-ANB:IU*'!?I7<+Z]-N
M9GNX4OR\^<P ^>-KY+NCL+6*[N'KW<4 P*=1L^]EQ'>W8<1_')?:AI.86W#2
MC537OQ,=;E/6 4.J \&D2'H<^YQAT%C9[(.&\>GYL$H*FH4157%%L\BA6;Q2
M.0L\LZ<F"F6U>-.(VOD?/AC] $_O=BP841=K/COJ^? APJ\P!^B[K%Z,D0%5
M'Z#I(ZIR6\N><YH/[>,Z[796K:(*NQM-P\;6BG][)K3K[@'M'E]5M*OHZDJU
MO.M?6X1T(D([-"*:)F94C)T"BTSUF"C5YD^&614.YW:<*.J$7E2W!E6IU>JG
MU5TOL0O'0!>JAG=-!M:(7Z.OO]DJ1%,S!EN.F@3Y/N\-Y#I$W;6.L*N>K&=&
M(J\3TJ#!B:,>'P+F5A,0=2)=8PA?WELS:E?7,7FNZMN$K_<#VG&=:*.'+N52
M%:&#,:?3?+XJ1V^N+$P5/GA75NJ:J0V!NVGVL$\7&=3?5</3.I3<:T\H>52%
MDM=!XRH>'$^"7C8JYR+$SPMX)T^J8!:\,DU0.YG6SMYB826GV\)\,<S>;*Q#
M'52N5TAWNKMWE:4EH>'UVG]23Y[;@O:%AN_SID[S1K,&*6]Q(YL<<@,=]Z!H
M0^ ?0-$&VA[8K3-X/DU+_ASIDC_8H153@W7R?56L]P R<586<= 4C9R&>_3
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M#%=7='P=Y^(:_NJ-!_VW_Q]02P,$%     @ 5H194LK@L3,R)0  D+(! !
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M 12 ;/.<%H'F@Z[KJHI/U ._XU'P?\F <1+,G>],6?#IS<5BF8,;PF!?[L>
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MH(T$*VXBW27PJKAEF;J)T4MN \E<& QK T4_)BFB='9>:!<R;[+$'J6J5\F
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M$4^.62&4V'V,]JQL&E8\.?KZBPWY^M P[5G[Y.1:<_=7CTYXA$]G4.IP7R>
M-&3T$R.VY_DN4ZX4:+S_LLB2&9\N*+A)L],@HX,0B3<:333- G\+F42E()7[
M/,HTV?#?0,_!AW0//_;%:H-6^PQ*!$6HD\4AX8HX+TM2, V>::L,;[*C_3A9
M?0H?:N#DWNE=/:'4.\U]F*;US7R:??9!$"85)3A[2YS!4,;EA!$,C\';)B'G
MDY3UX4#D"'#94S1'=/1_]Z4!SOSRJHEE0Y.V::CVMFRK258R8F\!XS_8@ \D
M<EE#Y@(&!E5&YC:07%HI2Z]$.3UCQ' G=99>NS95-[8E\."[((^-\\<X#6>Q
MU$."A#$Y7%5'&@0J+*Y'6Q0M<D6R15$$3;+F5OB8).K?SKFRB=H^&<4FN+NK
M]MK+M+7Q'$1PI0*E(F"T1ZWOY*H1*7-:,2.48TTNXF[E3![YJD07$*HAE_[9
MRP'KT&+B8$>SF7<GVK75E#('H.BOV9P"D=FC6Y6L)M;2H*QAB:;PPUK-M7'^
M#_CIZ^%70#_3!(VK@RCG<2V&X(@#(PCH  &8$)XVJ3N]*Z'/TE;N@K:=;.6A
MDJQW8W<7*B<7TX$5269''='>+'0_)59Y121HJE%'6R.;;,;L2NBS-*R=X6U7
M27:.MW=H6#Y_@]%7^'TRGI_-!MIS$#%($G*I**Y*/KU,@D1J(@7NJ>1-$@SV
M);A/6>Z]PM]!DNT<AR=Y#M-K%<V$HU'+C#@I6T8@44676GO&<6:,43SK)K>P
M]J)V&P3*OR("]Y?I4<SNYV^3<ILH1ZD=,31E] TBAM  )=]:"FER-%*Z8UM=
MI',;R*F_(N3VD>-QP(;H@8'*PG-A/5&"A5))E!,K OZ)$;Y5W ENFS1EV9G2
M;0"G_[* VUF6[396KNLAQ%5%W/'7X70R+N3ZT7KID-VW4;9^],&;)OM-XL#D
MA&T'K9!6L_=0G7&V:9+-MD2\A5,_>@D9QC-8W87KDOM;#=^91'9G1D=2NO/Z
M?-64#K_QNY^C ]BER':GI3/Y'<BF X6Y+-VZ!^=77SR830\14&5.>R>'WOIZ
MI?DU2/-</KC"&MKPH$HS[P"]G\[\%,XF(W0V9\M7#F7&YB=6XLJ6)!_(GL4H
MOZ*#FEY,SK^@@5@0^V'DQ_NPYK&G'<R6K4EMQY*]%<;3SVS)G@:JY9'1*NB;
M79[>DG%--=,CXY[,,*#]4OZ<_8'OSR<X/DS/AV/XYR)*AG3R%:/+4[AI,9'?
M+S__V]27Y(XFO*]'5DNA-6)>.VDO"Q=>3O):#O='&"V -Y]\FD_BGTOZRJ>O
MKNLV$?!!E+24:3T6-5RT*0T7;OEHC<@/,$4BQNCEWR/S@)O.+:AHNB2KL*:#
M%?AN,L;8&%7 QT]_E/Z0G_[H9KT]/6XGJVO'Z1\HD ](Q#*,75R5_S"9S:<P
M'TX7[5M_A3'DX7Q?3W3[9Q_,V#VGT17S]O99=QVA.T8V\&>W'KN"=[O_6-VQ
MN*GGNS4515--QN6X!'43S-%B#"=I&%<?>8'?ZT *VQ/1G7CV9$RE3-"7.,@8
MTAI!#],PB-H&KXT@%IPFDDE.G+>:!*ELSMI;(9ID@FY+X.%U_N^.\PFF7X<1
M%K.GU&;%(R,L2DMD,D!P\I(HQ*#5#I I33)1'J6J3SF>37!TOP- +1E5; ]Q
MEZ0W&'9.8;:<K4Y<4.\3@45WJ.P,"2HP0H7*'J0-+C1)HWN<K#XE:QX).'M+
MJ2%R7GW_ K%X[#"_F([?+P/@97LA*Z5--@MBO*1$2H2U=582+QA5P1AF9*-^
M(]L3N6,*9MMB-$>"5241-@39>GF<]_D#,F2ZID1?3 '#^T&2.B<; >%@<^EF
M94EPMK1IH='GR++Q'1G[;<CM4^;ED7!77:J=(? W/QS/WDYPC<P&"6D00 51
MTA>>,$Y\-I0$:AF^!2'&)I<==J!QQY3+'U+)U1%@0X25.9=5,/DZ7/3M1)T\
M]*/WBRY!4Q_G%W[T>7&,L)C"ZHL?(4Y.QZ7GT,N+TMY[R<=!MLXS9R/ZDA;5
M=E"2!(8*/#').+>EF7R3"U]-9]6G/,XC@?A8&&D(^QOJD(-E6995^?("/D]>
M7)3]^=$B6W7@@ ;T.0(!QP.: 5KHYIID<$@I%YJ[1EU"]R-X&[":'USE-A#M
M48#X">;ST6(+;,8&QDA<)A[]8 S B/20B8L6309W6@H&1O..S/UV!&\#1/N7
M!>+>HFV7!;_U'NS[,+I)Q'Q]4?95/\W]_.* <]UZ8W>W%;T;&YKM0*^/C"8:
M7QG8@);5F$RTB(E(;0SQ2:)VHXD9ZHQ4L4E+I6V(:Q A+7M63Z;EC]7KZ]W&
M.0^11Y,(!G,"U;R5N*251JT?F$K&!:LZ\DF?H+3?.]0'XFR+0*FB'*N9ZY4V
M.'E0&]R?PVQ5DV^]YRX+EGK+* 'IT,T =#,"RH18XW-(*CCFFJS&PTGO5<'L
MYHCL6-1'@^CZC:6;U96C-%(*080N39.$4B3D[(@*$< @PKQH$N=4H;[GF^E'
M!NKA G\&3N=>1:YJCMX?Q[-1&:RM<!TTU:"#12!'A:%,#L2C@284C;;F/!G1
MYG+V<5S/ZT3JY0!79U>,<ZVU($X (S(F2KQ$1D1<4Z"!4@--"M]N2=^S<S-W
MP=33;N;A,FNX%[3Z]6:%#U)*.NF(YL%+221/Z/]R$8@1WF7PAJ7<T8*Z1]OS
M<P_K(NDP8?7 IJ[U@2E)S]/)?RZ.X^_-:SA>EDR=K*V8#O9Z:I#7G56NSLRN
M<DVO%6(A:?FE3L6\U?C=R7%W=G0EJ.O;"B_._/@49L/QVD6NDACKQY>SM_ 5
M1N(8<JQ!7G=BKL[,8RS7QS]ZE!6\"TG'6=1[,ZWS=7Z5'W?UYE4%I0[7\A,D
M'&&][L*48US76'RTO#"%L_+]K_!FC$_LXMK,+F0<Y\K&3LRIU;EIPYCE+/;1
MK;1;WEWZSXO9?/EJGDP107'D9[-A'L9ER'/]_@P?]ME_'QA+LXHND<R]*UUY
M@ 0I$I%*46\\RR(WN01QG.D>W!&A!M7O8/['V"_S[2!=G;>?3(=HW4_7<Y"6
MDRI2TH8%D1,0S3A&;)IZXB.&A<HF;ZPRRL0F+3V.--\=]W[:ANS/8&'>:Q#Q
M#&!:KTO)1F7]4#+-@UG4CTXJJB0U%Y((Q<J>6Y3$LR2)X4(%X?!_VJ9!6-MY
M]>F^T ^TQ(Z!NN9+J<AA,SM?HSQ/WK]XL[6D;F;IO4PR.4>,";H45M7$*9^(
M,$Z$*(%2+KNV:RTF^DP$\WHR7<L O!&3%30[:1P)$=?(X@J =0Y_0UQ&[VD,
MOG,GL?VTGXT7<O2EN8O_T3.X=J([UR_7'#S?AXW)FN"$,U$R1<!J57K@6.(B
M*!*HHQZ8";%-(E=?&/!<')MGM6I[B^ >G$]>[_G=J5]WI]#=<'Q5Z&[A[EUO
MUN, ?WS:=K JG=.?R\R.L&W; Q%VOG__[^!'\[,7?KI8C)^G./I'/U^?.Q+\
MQ,.Z!&-->H\ L6;L/A XBR&7&K\<7HQG@*IZ#X$^_)R#&;T%>2T8L'=YML>>
MUH89#<JN/3A.A1)KVSVW#9N:EDY[<,3*?&K+GN9G7.\FX\E5[YU;@P\H<QK]
M5TXT!T,D"$.<,Y88)RV%S+EH4RKB<;(.#0S?+&IV%@V^?.Q5E:*!<%I%Q1FQ
M7%N<+@:LUN9$*$TT.B^]8$WN,FPBJ$\9MQ61<C?,J2*/:ML&5Z-?S2R CAJ$
M)5RJ1*2C@EA-#0G@G!!4&6V;7 .\0T>ODF:;@F%_]E?# $;%R,?Q\J96O/P\
M10_/Q\*8^WM;/ 3'&,HOT-+A6(9$?!:<(%I]I"+D8)H4G]N!QCZU;6T(G592
MJP:K59\2B*4)_1!FK[^^&UZ1-C!!2Q=0Q5&6RLQ5();Z2(3F(D4 G4,36_L8
M47VJ^=40.-7D4@TI:U4F;I]?SE;S_0A?83KSH_=Y]<*K[W%TL:BQL[:-=Y5!
M-9"<ZQ@\:E%(:$DML\2'H(BB07J.;^381$E5GD>OZH(U!.0QQ7\PAC%F>H(W
MBW<'W&LK3:3$"P%$<L:) XZ6G:K,%=4Q.GH;D_>BL2V'ZE,AK@:H:<'P=KOX
M:'UA-ADOZ=LC K_]_8-#[D?(.7#GX=:3]]ZU>N@I=2?=8)?JUO-+,:-Q'(Z&
MJQIO\V\ XU<Y0^F449RQLMFZV+!?W+E#I7)97ME_CZ;FZ'5979,5E7: KC#P
M?:4J5H9FH&S643!!,OK#1$832,!(C'#'>-(\<NN:) )MH.?PJ'[UV-LBV##:
MR?PUH%7PHVLQW'P?Y3&($+E'RTDR=8[(X&QI/ZV(9Y*IP%+DT*1R;]59]&EW
MJ08*[^\D'$OD%?>B'IS"*M"]1>#+(:J14J!CZ$<#;20 ,HH8;TJ-#NF)1[>"
M4"F29(+FF$2'^'R*WCXEB'2(Q*IBK.*V7YNB6S3=IOJWT224MF1S/SX=HN?P
M=O*MV+BT_,IJ3B\Q>OE:7KOZU%4N;KI8;,B<G$\N,"X1PJBL*2=6,UQ4T9>2
MKLGC?"&$Q U/P6T1 G1,=I^VTVK"M>\(:*U6\86U\IJ#D(3AHI"FM"#214Z\
MTH!+4#.3HI.X!CM4HK>IZ]/.7(<J\P 1=8">9=K<["/, ,<Y&_C$A+"!$\Y+
M[I\&]!FDCR2D'(/GDIO49-=M:PI[M9_6+8P.D55K*!47%$[&Z2T^8'3]&9@-
M7  GE1<$:46'(*32?"DJA#]HD\%385R'@-I$9Y_VVSI$516Q=>;'_7HQ&XYA
M5JY9AU7]_8$!I5A&-]-(7@I*NTR\PS\SXS:9:$$E5LD?>V#X'4O0/QO8="61
M>N>46Q!;5.C%XN+>_YJ$V4F<O\^( K-RZZ1A&+D81:B@B/@H'+$\9Y($0_O,
M,U6FB>]T,.4[5I]_-A@\CFA;&\IE#9XW&&Q@T(P&'3^PK,-2:K8LQ38:3;[Y
M<82!IUPF"N7$O]1P0X&0$',B2H&(R2@*IDESM\-)WP:3[AECLF/A5K&P&VB^
MTR'L CU+/X.3&,O2&8Y/UZX\#Z1B%B@N)"0T$\FU)QX#&N*RDXZY&%2.6QC;
MPRG9:B.8/D. '4%0K37>NTDY\RE;*&$$U\D L_D47UI<6\=5,SU%GU-02$+Q
MXFY2C_P"0QP-F3#CI-$L!A:Z/*+8ENZML/@#GDHTD6MK,"[2"M972F#*>*\C
M88KC2LD< YW"G:291@V--++<(>CNTK<5N'[ @X:#Y-0XJBB=X(;C"T3X^V7J
MRF1<]O5R4C%0G#3P4OW#$QND)C11%I/,&8U]=^'#0R1V$6+MX@ 5@8IH+.&\
MM((RS&"<F-%)3QS_"U*%-FT8*L^C3V?2C?"Z3T36"@G'W&SZC#"$#S"-)4%1
M,.^<0"J#HX;(Y#7^YDK[M&"YDZ@%9=C"%ZY 2I_.HALC\!C"ZW2/ZLD#=AE=
MB,I(8D6Q@ZK4)4'K5_KI2:92RMXW27*J07R?3J%[I"JKRKQ3M-[STH021CIN
M"<VEDWA$=] EZPA52D@!DKDV_>'W(;9/Y]$]0N-!,NT4?4_EOSD&5'(;B,FR
MU+%) I5\,H1*+P5-GD%H$MI5H'W'4^Z_"C9K2KSSHZ<[I_<<%+,:% %/:4D$
M8<@K7%::4\,4BS[Q)B5!]R-WQ_/QMFD7/4+D@8+M&H3KF4@I^)B3*9G!A34Q
MN=(1*J"383R-T5MCCV:K=\\<Z^J4O5_8VU>>1XVBOTVNPC",])72PA.0I4B;
MDIE8QB.Q5"0P,IEHGKHY4X60/AVA]SB"WD]P?<CQN*);&Z30FT0X+[4\F<?E
MX8-!A];I'!CHZ)K4P#^<]#Z=J/=+!]:2=V<Z<9>#7 48845OB''1$&D,1OTN
M:HS_L]8J!"&<J*0AG^OQ>T\49BNI'M-47V^7>@W1LK(!A3\D<I%X(QTQ22=<
M10'7DFYGIW?0@)V=L_<$=)5DUJF)WCIOP%(:DA(:E7<69>/)ED *,*077 05
MK(Y-TM]J3J)7Y_<]LMM-0- IC#>FSK.<O>2:$@!9=NME*3J=52F?K2 Z:K,Z
MV@G-(=<?V%_P:*:*D)_7/=<K^P%EPU2$2 )&=F@_@BR'I9D$"3(8PZ2BII+-
MKTGW5DC^08YU>H^+CDKR5"@F_/CSZI94:5H\^-9(RY_7)03A@!+KVSVW+J.V
M([]J59E2/Z]TI'AHC2X)6;,"K[[/IQYU"GK>T\LWJ EFZ-;@PIOC5$:+@E:K
MJK"2R1!H,&BR<]F?-918@[]!$)0!KF['&]ZJ;3*G.OFY.Y'V$G^9S8=Q$+5E
M0:M$LA&!2!L8L51RHK2CZ""JY$*CHL=[T]RG+,&^(/WA5.#VD*B<8[X3P2MC
M.] ,8N0)(YHL,#H/Z#]:@:"SB3H!5!FC&J:=[T-RG[(,?R $[P.(CMRJ6W]4
M\AP>?&;MXH!/D5W)8[A*;=YT+4*P9#R%4MNC)$XEADZRM8E(85U463G462W6
M^!-T':KUKAZ_2L79>"DD^>A#%"39LHY*X6J752;,)Y#2F)1=D_2"[<CKDSVN
MB:.[&JF!L*J9SVO:[N2_WJ&-:LF9SX'86$I14!6)5Z4,>F9*4]35%)J<V6Y'
M7I_,8B= JB>LZD!Z>+?N#H7>L"AE9L0X7YHBJU)2.*+)S=(+$,%JK5O":1LB
M^Y0HWP6HJ@NN_C72.\1P'32-G)'(!"52422F7+!6X*4WR0A@;>MDU;7IRP84
M\TVS-<RY*)4DW$9 R>+2=HYYDKUW4B=)/30YTGB<K#[9\!HXN;LZ*@JENJK=
MN$A3B#+$<CX7RE4^34D A=//03GJ=#"B25R[D\_;A^"U+E1JBJ4:5I[ +W60
M:2E]J##V1</!2R7$2(G.P+)U7+K0I$O5+DIE[TFO_.W[LPXL:C#"DFS*.0\O
M,O$6_XP^@[8 IJDJW417GW1I1=QL4*E5I%-[G:P\Z_M$1:^UL-80Z4NRK2T%
MU0"GSA+/QGO!?9O3@R?HZI-.[0 R-:13&S*W_.;[I"7KDZ/9$F%*FF%T&(SE
MY-!35TE9U/V0FYR3;$5=GV*<]O"I**F.=G_ON1353H\?>7+=G>!MIU!Y/Q@'
M>COT83A:=&8;E+95EJ(EB5;ITH8!_3K/@5@,C:-EF@;6Y*+?P^34"@ ^7]7S
M> ?S0=92A6B!"&I+U7]&B?48J7ONA0'KC6!-,C4?(F9'3Z;M3<4*D-CDZN\M
M@':QX/H4N5&&!R&) 6?1D\)@P[J4B4XAA2QHDFUZC#Y&5)\\EH;(.%@>W2"$
MQ0PV.DE8\+JT2L:8E.= DN7"BNQ+98OC(J26"?AM,DG?AJ,1VO^;]+KEXKW[
M]R )DXV5C'#A&'+%2N(PZB B4B^=5RZTV5@\F/(^19#5</>(\NU OM77X6VR
MKUY=^:(O_)?AW(^&_U7X]A5]ULGTLO3DG V,D5$$)-<H&DJIVEBB8D6$RTE2
MF4,238]R]R.[C]J^(T VD6QC-'Z8ED:@\\L/(S^>XTHJ'8Z_E.MR@R"T3! 4
ML9 QPD[:$F<]KANJN0,(7-V])=X2?AOI[%- VS'>ZLBNRCV)#03B,BCI5TC;
MHK[1!T3_%.;#Z:)VPBH*+]3/!CF@PT6S(-Z94LR4(\74!HS'34Y!<(9A^A;W
M'@ZEHT_5J:JCJ7-!-=9=RV;%.0HF=?2$^N2(-,X3FR00R )0D4HF>(=Z:NLV
MTEW5D>I8)^TNDQ8@67I]OTTGL]D@)L5]N22F(>(<*63B/2!!PBEKDZ"<-VF%
M]# Y]2>YV0L>).^5\,C\I*4H2;6X3!7SZ/5J"4JA+:"MHYHGB>QC ', @I[<
M-ZHEKW;+YMI9'7  "1@9$>$!=7U@D7A><LLXA6BD%D8T.2O>3%(?HXN6:-E/
M%NVPL=GE!&:<SDX3H!KI2X!^@1! %%4LZ9@YBTTJL6]/8A\CA9;8J2.K=EC"
M7^Y&S)/S\N]2*..T\CMGK\Z_C":7<'5L5ZH32&H"=21JSXG,#N/GZ -Q+@B3
M?%2R38G1>E/H8YS1$HO=R+I'6%U_>U *OP26*(F*&2)%9,0+FPGW+M*HL_!M
M&@37G48?HYI>879OF=?>@EG2_\=X"G%R.BX;D/CB]8IBWNH02UZ%<NAE"NU)
M,#25WO$A4:XXOWL)\JFMED?'ZU./UXJP:<;R-F!8W84<GY9KDB_\='J9)]-O
M?IJN]WP^7]74O?7N('AFN1&4:)DED>AXDJ DQ1]1:Q&T9FJ;4GC5".I35=K6
M<.I$:.V,YFHOB(ODM/2EX%XFI70]<5D4*YZ4#=DR7 B=&+^MM^:ZJCG;A1';
M70;M\%!29KA1/G+@A.O25,-83:PI%ZY%CEP9XY-H>@]L<\Y2M0W'$'PPY28Y
MT]J5GFF<V.0"L2HK8!H8N@7'VG#LV?[:KHAX>G=M9PFT@_L#+;>XTMFD#,1:
MCGK9)T5<H(% H-1SZKAJGF9R2$,U?H0$OD9 .5 X'64#;_ G*V4$/_'TNEG!
MNTSEP&)<K_QTC$[3#+VG3V=^"GOPZ=XC#F;&XT15GO%G'T:P#SXV/*CZ[!\B
ML!(//JR&>'%#Z&R2[[Z[_Q+:;YQJ'#Q@>I42[O^Y, &03KYB='(*[R[. TS?
MYY?#T06^NAA^]OYB/IO[<4*:!I[;J*(TQ$65B+0"75G++ F<"\%S$H(V.8#=
MD<Y#[?^&X>Z-\ZN?#>. 6I]IRIX( 8Q(EC$X8[9<L$?^&.%EMDV.UG:BLD^^
M8TO4W?46VHFRFK?Y((F;F'%3!'\0F1 R2B#)2TMDLIP@@9IXQZPTU".SFFQ%
M[TEOG\Y[CX[ RN)MY\/>M485*L4^^<CJ!K9IO=C%MDPY+YC"6<F]NRHD7#;Z
M]N#.HX\[F#/;$]N0*WN[M%L\M"F'&KBZCPVW_Q+;YJE-.=72:7ULW'<P?Y\Q
M)OU06LF4=I?SZ3!<S(O</D\^^'*1>)"C3,;'3&@2:-K1X),@:-&S,3+4KB[G
M)IMZ!])]J)OQV/#+HIH?(8[\;#;,P[@,1JZH&B@CN:+@B>2E.*Q2EMAHT4V2
MU,3,P7#=Y ;N 33WR>'M$K%WW8^NQ%[-';Y+3BD$>Q+CQ7F1'Z1-\UF5"4"3
M/YRDZQEP8ZQG2'PH#9<E$XZ$&#2)/ ME34K FUR\JCF)7FWG'A/*1T-&/[$=
M@J>FK$GEC""26DE\SHQDYH**SK&LFFS&M,/V<1AZW1YAX*Q*R99 BPI>SE8!
M SX,OD+*WE '7,<F9J[J+/ID^(Z&]Q:J8S^<M-4=DSB\1>."NLQ06)(3%J&T
M[%2I$"9) .%]0.VK?)-]H6T)[)4]ZS="#Q5O-? =XD4&8(:&K-'0E_JVT2-7
M2H-M9Z/*,D-PMO-X:Z?@H1-VK6D79)<MG>]9N<XG2^=['UC!$]->L6!3;))7
M<PC1?3(Z76&U0J2UG]"/N:H+K93);&7B) 27B/11$(MFCVB:A3,QE,:I/0%H
MW\S-,\+FKI)N=P;Q"4[+B<A'^%("R_'I'ANB]QYQ\.[GXT0=N"M\]^%[[YAO
M>%#UV3?8&;\[1(63IR<?69TO34^>[@[VR:,,)KDL<S^^+)<&2^?) XX1=AR@
M.O=VF5!E7KXHN3BC82I!P$?X"N,+F(7+WV!R.O5?SH;Q9 J^'F-W&:TZE_>>
M:F66WVZY.LFK]U'J);MP/EE:K"J].*L-75T8=9A06['$,T@7(YCD<O%X?KDD
MHG@W)SDO:(69'Z>7@.Y%7%*.?YZ<EV__U^)/_,;H @D:CF]/J*)N:DYC??76
M+5LK@^+6G72_=B<='=9VFG*?4:L+[N"IKXMBY2B7'\'/X-_^Y?\!4$L#!!0
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MWT2@W(<0B0A6$IF=)TXK19(7QIA@N-/R_S_]F_0A:NHL82 RD49:$BS+)-D
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M'LS^>OCHO[Y*./)^[L]/.A="99"2XK$,.J:RK?,D4)J(B1&\P1U?=JR:$C:
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MH&EF2M!\?Q97PWRY$CCZ^V#T95*/ANM'MDJY78]Y-=&6XIR="EQEI<LI:.9
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M^\=%,>K;/)_NYG_:4T&S%&PF(I82;@SG.8NK&:&I#"\:YFAJ(:XZ\(](>8_
MYQI9[GW4?-U-8<V )L\O;_QJWE,A9Y>3R(I0E=!2B7*"+E,F.B2=<-L=P#6Y
M&MX6:$6I^<'@$036E)EU9>V>%0.DZ=_*^1FD7W^:CB_@^C?1A8:OT]\&L[WW
MKS\M6@7N+;^+,(%_7I0:525>XJHWE'>.29\MCJ"8RW!!O#.<"!J9\I%&[YI4
M0-F Y_%[G;30P*K@*G#1H@W 75C+FO4=@#5MR[P)V2.U:*[!W\.:V,/X!U4'
M6-2\Q!F7!5<2_&QQ_80B$O>#RF1<;E=[]WZ3JGBH@?-!1;&-S=N+8=%TPF:;
MN0^!:,LC+L(EPTHR0[+C0@MN [0)MUR+YA':!-=AZWX-[&#J!K6E-]QOW^@Y
M2956X)@G-D=1:L=)XJ.-A/G$("0EC&]RW_8@LN_"PZC+3X/BM1L WOAFN@!L
MZ7,\B/!Q?(_*S';3S9ZT-%B .@!U IQ5C&A.\?.)PA'/K"!<X]QHDE1.-CD@
M?B3=/."=/+ILMF"CHEQF68%P>C$H?WYY58I@V24KXDII*!4D*!U+#UO GP6-
M/PBNJ;.6AI7-[_J<RHUO.+P34IF*474[5O1&YKG?YZ6'3M\/SI>H%J"8""5O
MB1-&.3I=SJ#C+4PBZ'$;(1R.5G>)_MCX@F/BMHX5*W^XI93#Y+F?0+HC./R+
M26:!\Q0.#QUJQTFP0A*AF(L17>I@30=N-[_AF,BM9,>*7F!!=:-J_AU8SBF3
M2M?H%'2Y0BKY")9%XM$)#CJP%$R77/=[7G%,_-:R9,-&!#<V-S-G WQ@+&E.
M4J*42"T%L:)D5%&O:+F1,;Y)A_8->+Z+/6$-+@XDD7G R=7I20> +7>"#R)\
MG)U@%3X[:&1_,AJV=MH,-('7WA8V'2!0H)98SC@1^/O,FB@8.]@4<P"U/+#_
M>QRQ;,-!9>?Q[3".7IV?7UPYLC8Y<#EK(A5(=&1QH^) 1:*I,#&&J'';TL&G
M6'WNDPBTV,?LHTHVJ[RO^P>Z-)/G_=$"B6 "4O2>9%VZ6">9<.$SB"1;RZFT
M OVF#NS=?NHQ<;>'O2I_>2\OAF%T>:6A9!C^'XHF9ELB,W@@5I=Z-#2"-GI-
MA<3UOORMIQX3<WO8J_*6[.,9G/>OSG2X\D8G29B-GDCC<6L(RA*5$D0JDDNK
ME2G6\G;SF<?$VLZVJNA"%QPGX_^%&X@%CA"-HLR@6P+XK<N<@3A'43L)<+)F
M*7-G.W!V\YG'Q-G.MJK8]&P67X]S-6[2E^+1+*L4%1'*XB*+GA?QI?RMRT%(
M*I1+MDL&RJV''A-KNUNK8D^RF7R&4Q@,^O]<.D<.;)99%"H EUA+B;>XXE)M
MN4;Y:&J[G"_??NHQ$;>'O2KWV)H[M2]ATC]=ZLA8P+75&.)3\O-T1D^=([G\
MJ+7VU(<.[-U]\C$QN*?=*O:;FKFX_;$?7$[[<;GL!@H !EU;;A(.*_!,@N6*
M<.^H,<HKK;H<$Z\^]Y@8W,MF%7M*3<;3WHM2&P/&G_QX>OF'/Y]?.ZLH)"[$
MDN!/<!GFZ/,ZG T(>)FY"@;W*5VJ]^#S;QS1X*]6CV<V 3CJH]\J5J_H_!0\
M[^'3Q3B>^0F<G**^SV<7(K<A+C3?!>06Y[Z=)-(9W6'/?.L0.3H4"Q5/%+8#
M*QG@3(C+$8VQ./5.$UL^EURZ(7I\JG'59I-'ELJ& ]]'5,HVQJ\=*@#^%)8N
MBJ7*XA9.$]S3:5SB)*Z5)1]120Y42*=8[)+C??.9AW,)&II\5,%>E4]Y/Y3"
MA4,8+)#D6 H$1$IL3)Q( P:WXPP(S3[*:#DUN<LI[^VG'A]W.]NL\E?WZN0?
MKQ8HJ&92F\!)UK9<%P1*G,39Q1H1DS8NNTX1&]=//#;6=K15Q1/>,LY%V9:W
MXP\P_MR/\Y7!9NZ\](PD$7!+ASLY$LHD8)R@*C.EK.M2,Z?3HKD.P-&[X'M;
MO>)!U@T\I9OT M%DH>XNH&J[W!O1'-[%WI^HNZQ7LG)EEWHS. @Z&8N0LBQY
M\D%3XG$=(=JYF*3A/*T63?MFJ+_'93X0\]L8M_)B_?'BK\N)7SH-6@9F'/)A
M53E.PD$Y;@0Q@H;H1"PW(UTN]VX\\[ +=B43CRK8IZU++'*TAF?T[*(41-+H
MB T22-04MV\.EQS>Y1KV,5WB^ESM8:/*7]6+M_]X]9*Y!1 9C:0)0NDNQTJN
M+Y"@-?H+)F@C<8Q4=?FL;CWT6^=J=PLU2#M\">/^YUE3P%?#R71\41S]]_W)
M7[/IWBD;->>&<+"H):X0&V.>\$BUB30P;9ITZ+X/U%'[QM59J7AM>!=;"> ?
M^W@SK[L+MI:1R?>!>YR@Y'I4;M1()1X:!"7?BY$K&;R1 9<F_$ID*%W>4[;$
M.NJI4J A-&E3<7B-/!"*_#@2V<;\#:3Q^VC\Q8_3$MCR-C9YBBL?%X1Y$]!S
MX9G8")$(34WD8 P":R&*]7 .?_%=C[+5IG?[V[M!V8Q7PS@ZAP]3/YT=,;XN
M_V 9B>^-"YS9T@'"IT7$KJ">Y)A]Z6!J4VY2S/(>3-^%\U&+DXK!+@] 6]:%
MZ@"NI?-Q+[K'\3ZJ<=E-(WL0T6")N1\DY0(D#YEPJ3QNE(&18"0G%&=9KK4#
MSINT%7\$E3S@?SR.2+:Q?P-QO(<)X //<%]_(UUXT:AE&5KK36*!92*E%T0*
M*HG/TA'M8\S6:LYBDXRY#M@.[YE49'/4EHJ*?LKL*K1TLIH??Z?(0"I)1(JA
M] 1FQ)8<(BM-E!( 07:IZ]<MF&;YUJ/V.7:W;^50S!F(JR2_AV%4#[.[?O_A
M;_EV9&"5PSW,5SL^[@:<:$)T.$<0QRG"X:A-W$0!8<:RX'0VBG<I6_XT6+SG
MPJXNB=M8K3)Y;]!2YQ?GRWH=60C.DB<\^)+>4@+MJ60(1"(R98*(U6Y?;[WY
MP/$VN]I^5,-PE5?,-_[K#2!:6YZ4H\1#1B#<&6(M>@HFV<#*50E?S3/?@\&;
M;_X&&=S9<"U.Z&9]:E^7/K6K;6R?7[[Q_S4:OQAX] IFIY3"&&D"(\J6; SA
M(PF4>Z*2\8KGD#A738[MNF,\:C^J-6=WY;5S,ZH.4*^!WH@S[ *WY>G.EG@?
MY[RG&?_==5:-O,-.:6MA:\,S8RD0;JDN!<@4L2([8J.1+@9I4CSTM'8XK3UP
M:O14I;8-9TVN/&<G&) ^0CP;C@:CT\OW_=.SJPL7U#B;Y6=+\+S4GU,DH%=
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M_.+B/8,OU@$7PF9G'=HV.?$G0+ G3)N3X]<NJFK)J^NJD(4$Q/(HCCR@SJ(
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M4^_PF0T&/[X8YV79[HM$OUJ,I/AU-*L]RJZF.'MSTTDM6J:"0-JV2BVVMD9
M*+XVMR.+-SK'0FC<F7(/U(<>;N_FG^L]XI>O4_Q<=_P*HDX\K/,1'^II-3GQ
M)9;)%-?G)Q+FC^'O"QNE1A:J3<@B*%[GSGCZ3MO",3K!O&LRO;O_I1RS$JPU
M@]</WB,3H8$#M]^*UM=RO<*Z'!>$9U;5L4F*_%%+)/2<9^#".[3,EMRF!VG/
MZ_A)ZF$H,%!;AJ<$>>VGZYRXMM:"CZQVAO<*8L) E%-22R]BLDV&;.Z->/B6
MJD-S<QAE'KM-ZV.KO2EWY](EX[F%0H<$J))J/;(2BXKG[(ID7#?)!SKMCB)-
M:;%+[Y%=U#-T/XDNV'[V'ME/E;LTEMA'#T-SQ9 .N3(&-*\SVGUM]&DDG=Z>
M/'3ZC=*BB6/RO'J/-*/(+N)O485+-MSHT_BWO]/GVO)U!7#5::TX+C%[8#Z1
MK^)5 5>L!A21?JPU'>==;HIWYL:CJ$ZL$\E."EPOO.U-^CUZBC5&^=O5=$+"
M&2VZKRUBE4M,J@3EZO ]NVCFK$*!:*-:#->RVAAC^9K)O#&ZN^WY9Z#;WL37
MI--0]?,^S E6W=W>3-)M3T_G=9&<'#C.BP!5\^^#S0&"B8$[*[(534I7'L'T
M8UF;?2FG0?OD+=!6R4X=P+6T-A]%=QQSLS===N/( 8H8;I=979OQY 4R";:F
M5BLI' 1= A2):%V*O&"3ENM'8,D3!N=Q2+*+_!N08Q%\?#L93V@_)EBUO6]%
M^]O?7TEJJ[1HQ8QW&#@DQU.=J,3!F6Q)I5BLMTZZW.ZRY EPPYLH/>IS4R2X
M3V4<Z5[Z];A,IE^NWYXXN9JO=_CK^7:Z\\>UN*/>;ZUK-]7!,>NXSB6XJ)1,
M4652KG4V6%1)V8TWU9T_N:]HQ6U(V9&WXZP64((IM2L6V<V!*\@VJ!2R#IK9
MMD&*WNZ6UX=<)US.+>9D*$IN$:(*Y&S0NL"S.KR8B1AK<\LLFXV/W@3H-.;W
M[:+YI^:)[R7J%AWDKZH<WI6[+]#MVF?_Q,M\X:QB:(T"9^O,\U(07"*P+O%0
M:,\O7C;I/](!V_,G1M\*:!JS?3M9Y(1?+KD;0O;<U?'F)7(Z[W6":&JEHG1)
MTKG,4#9.R+D/Z/FSH1=1-_"Z[V]?]T[;:@OFVR'G%U+Y'!1WH)V11%9N(*9H
MP"J;G X"A6YT/G:%> XT::*.IG,)KJ-2QL04A.+@7?2@O(_T'5.@9>9))290
M-;[B.?I V'[VA]W%>2J9!F\FXT]$V"^5Q#>=>'AT(65IP4M+-,64(=B2H396
MUU+2ETZS*'?FQ28PQX_U[J'<2<]";F!'K&-:W4QW0-4R9KL9UG&"M8>K[0D>
M'"#SX1@11=!!Y@@A&?*)HA(0>;80#$%+C(XSWJ0%Q)!,>"(@.Q01=A%UWU4[
M\A<Z!N]4G_#5](N@#<O:0#$BT@&9!(1@Z;S43)*]4GB1:Q;DYK*=+<\?WOSK
M0_:3G@77\RW]"_&+8G<@K7IV>U:LT\X!%EU;V*@ $5,M0LW.HB[)8Y?Z[2V/
M?_ZJ[$%L?;^6XA>I-T R/G"R51F$R&N^@"O@A) @/ O1291*=4FWV/+X<]#D
MP6)KXK@_-L6*Y>2R$( ABAI*()99'4 43>>)8%ZUR:DZ[;3>PXWOWH3>E!";
M!M1UP/8S67<_5>XT*' //0R=K,MXTMXF!.NC!L5M 8^$T3F5BZ2-+<2?R;KM
M*+*+^)LDUFP<7!>=S61\*N"BUE\QH>G@M F8\)D)*2)C3:92/XM!@3NIK-N@
MP%WD?:2$B)N)/I/2HCQ_Z^-;)#QT6\M:@@-7+JNL%.K(E#4LJIB%3\BSHDU
ME(T)#EL_J?^$!DYH3/4U#'>UDQ3S$&1!X*8(Z;4C:C:^Q7O35T+#0E3YS2C$
MT>5H?F>X6?WY!5IAO:U%SEE7DPY]G1W"($FA(IGIW,HFZ7Z/HCJ-RZA=.+"^
M-?4G] ;Y#8^">W7UY>IR>7*G*889_HK7_[R()L00K0=A:KJ]UA$<>@YH910N
M<L-EDUKR/?&>.8MZ4E13$_G:;4Q,%I%9@EQ< I5MI ,YV-I%-XL8; FZ2>G"
M"=UO'L*"0\1Y*O>;+\,E'>?XX3/B_41J,OYL##I#]*740=&"%D,[HW*.,\^U
M5&VN-;8!.I50RTY*7A_LU8>P&^P+FW"MG/L.R)K."-P*[4C# 7M180=>'"#_
M81F2HTQ6"#*7=+;DU2D'D7L/)G)TF*61I4EH96AF/#4(<&!B["+VGB]=ZF7$
MQ^5EQ*NKZ92.H3_"_&JZ*.U;W>YIF:W3 = %.E<KT!!* (V1\X)U:E#I< '3
MX:.&MR;[TLJDG4A[OC"]"^^WO]/E51Z-/VW#B2HK2^83(&*=4R8-1)$+.&Z$
M02^U,VY'U3_UF6?'@5Z%O/7U'RR6=B='_ -^FN*GFO?Y$N=_(8X_?I[,[B:1
M?_P<YF%*/YF-/BWJP,-L63]\Y]EAG!?_WO(OOYW,'__[S<)X)[.RQA'$DUGG
M8\%+Z0T&95)-1E#&"V=L;?K.E:RU?L4]%;P\F47VY>;?+N[6XRV*!:X<AV1K
M(WR5'?A4:IQ?:)1<E9@;E4L]@JJ_R,:+V0SGLXN@;,X^:,A"9EHEUQ!USI"3
M9%YQA18;7_A= SEFK.M0[6^/=^PAY"8S%6[C.=>1.#H?+U0RC$M:%XN2S"3,
M9&_71!95O,TR,U5$\QN"&S3GJ?Y]Q3UDN5>4S@4O)1A;-.'B J*I<T<2H^/!
M,*9-XRZ IU/NU8X)!PB]0;K0S3)G=]:^R5)_^7WSW??+[\LS>75,T]^]#OM)
MRXW5Y,6+:F4K57*=N\R(ZT64X(/EMZ-)>NWHU6Q)PT?=^Z;AB:C[5$+YC_?A
M"Y$,86>!B]I@B24.OF@-+&%$<AJC2(.U[#UV]N2I\&:GKJD[Z&_PKJD=L/U,
MQ-Q/E3MU3=U##T-S13!;&_87(,\\DI%H%'AO$G#T7B3G'1--<NZ>5R)F,XKL
M(O[&B9AK33MU8-9)4IPKRH**28&3PD+(*J'P*?,V;MMV2">6D+F3ZAY)R#Q
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M8,D3EM-Q2+*+_%NE,6]-LEZ>J\%YYG4VP%-M),,EP1..5:"HI>92Z28#MKN
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M\A;&DDE6%E<4>";K;%@DGXOS.HM)6LZS]8W\T9-._3S<'>U+Y WVA,<SA+J
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MWYXM\QLXU]&7@(R9F!($'0B)<0&<C IDY$S(1/];S_?>:)3??^I0]\$]:>I
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M#80[.))\'Q=Y]N/Y;W]_K37=;W%>^W3Y((L$'A2=D*H8B,8C.&M1>DZN&1_
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MTF;+R0&62G-049'K$C#1EZAUR2H9#"V(<NH], \A10^B;AY27(;2O5-T,'/
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M2 _BO:.&!W9H'Y3-2*\*I_F1M,^UV""QF&1FBI:Q;+E!D;N<K1\@ZH^XLV.
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MW+M97.>]<%4)0M8N[MQPYJU-S$=$+YT,1N_>,?ED+:.UQ@>,41[JW?O BB8
M<KWS5U9QIJ%2VRFR8I5<*EX+C.M'^YW[(Y^L,;31[H"EOU7(.PUWGQ13E!QK
M$_A:6N28UD:10RT+<Q9-)JR!"]7!"'J\\A3,H)6&[QN"&=R/_'ZO"3./)3@D
M4S79DZDJ7UC,EB3D(AG'4]'K]0/='<A[;SL%^!OH]3[RMIV;\&A';I6RR4DS
MA%I?"IJVKI@-2UH(G8*P9IWJ=PMGX4@ZHK=Q&8;2_GV3<4,[#H^)ZHW6/!ED
MM,M9"HC ,O!U@Y,**[>=<E9OZ3Z<N'FTU/1]H_"[&,6?L_GR,WS&:L=5![]
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MI\MWN/RQD*W^T^SFYH_K7K#71*"QM"\QD[5@N@C.@I2*<:F<2K1_\=@E8GX
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M'CR2)Q'IRY"/U?V'GCM5QTMH#U>CXA?_P'F$W[8>A"';$ZP3C [06L)A@8$
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MV"SQ=S^$E\_Z[43ZK*GP&^=W/D:TN3D<@JEUFN]38$Z?Y=N"J&=Y'R'E4VE
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MZ[ %7]W<K*[V=KQ-+*58 8ZYI&IG4H(6:+LAT]5*FVHM8^AR!;8?SCFRWE#
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MQ<!'.L8]]R$FRTT9<DG]JD=/'<%8$WD=.GIJ\\?U2X0%_M__]?\!4$L#!!0
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MMK05V9A"/8 I$((DN[$!E5(BAIGLSP;F=>RK[:/^'>7_F^K_[^6BSG[UX*N
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M%'[Z?G>8*C!"/46VQ(#GQ:Y7;E-]6\F,<].\([0-W-.B],&LPC3MLI1I0&#
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M.;MQ^R6.C4;"Y]M+%?P*\#H%$I*MRX,PES";U)F0WS_50SB+^OK+CR%P>QI
M:15"]&?:HE./>^=I +EL2QH@F:[V8A["OH+W;P-WUR?@1])ML;E?4!/:/#3
M1Q8@45J4'(L8_PS?VP;2R;;85V4046)X2Q[=ZCS6I<G7+D67#KF\QIJFF.Z0
MXB G7;8W15C;<U\Y]Y'PW+C]%QH65JDEURZ<,36=3U9(Q-8=F3;6:2J[SD]U
MRQ L6*[F-@_^O1#]G5"]I)1JJSZF#L%KD DPE;FFTSAJC#+!37(V;3TF'2)
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M;^56CPPMGM.!L#DH&FF]XM$KD7P%OF8+;]>&N\+Y]O"65)8;>&.RVO&O%J5
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MR;$RR,.R4O6/:(!KHBF6/G99H)PA)>8?92Q^<V66QV+'XKEM:I0$X$()L(:
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M5"\FJS8R#&PYK6 ,RG5)_\OYEVV;2>$.';4\O> BKS,2^#XC;F-D$UPGCYW
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M-#W?O9'8K72.Y3BV^=9RE/3ROO^EE\A^\LW%WXM*/<^N*X676)=GW_<U3%,
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M\%#*R;BK2,>UO\\5FDH<Q'>BU;8.%@R1L7 !<F 1,52G%F,X<.3=BKO_1EG
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M!$B7>VQ+PT^J, 3FOE9AQIH>C-;VIKQ[JCV\G36)H1U1'AYH20&78I8\"+)
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MF[W"',UC3WB2,]^SC#0::@V)J#L!AY"OIU!28GV>'[_AG ZUC!QE6US[C,E
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MA Q/ECP^X.'27:; O7S" ]QHDVQQM?3!6:,VG=,_XL8,NK256_MZ/64N57;
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M'H3/FZQ5W#K;7V_6T6 @T7#<C]U;,E*]%VU"PY)7EP3((XP#32Q>5 ,<Q$Y
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MC:L4VFLE85;G\]I>17O>G8W0YVBX0Z,8MYMS_^&\Q?S!^;;'@4>Q&:W;KU?
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MY-4:APG>+FZ(>2#IQ=YY%L?XPL3OE.1S,EH*3)V?ZX7U&O=4>[^TK>+Q?D1
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MGOFE!><2&K7%.T9ZZKR %', $WJMSB]N1F@FC8<H+7B=2M-[4!MH=X')[,&
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M#7QVL->W^7[\X?'FR-&IK[ROZ!854]JQ6SBZ1DAWJ20]HU3U7D-!\GN(N6U
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M"/$*".33]47X(?Q#0_B@,E(R?+9(?_> B!  )@.54Y%15(')\T&A*N"?G#(
MD-^$?*N?2 2 FV0_ZB%[?)/\9YVCP+= !2'_+BO5K^V!'/ZC/1"I7]M#!OE1
M!D2![&?9; S?RS/X7C[I2?Q5I[LTD$J<H;,SU-9V.6YAIF=X3!> @-QT!L>0
M_@%D^P# SS\TV$)?B\_.WH&/NA>L;P\H%Q0 7.$A@2:6>E:[51CJ:O.%@$S
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MGH*VEK:NC)R"C*:"GLR/O#H!\+!=C?W(Z[Z;5_D_R_O-X^?J^[\K8]<"=HL
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M("GOKB3@2%:0 +M4 C0#"04)10DE"64)4#50J 04)@&5E8#*28!=##)!%25
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ME/KUSA7CG[_J_X<M^@_"+W?GK+[?G>O[J[MS?]R+ B!DL@#PBS>41"2. ]H
M%04%!24%%24EU1XJ,-+24%'1T-+MW4N[=R_=OF_^RGW_QIE)2P.,DCV&0)@
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MC;J1.%/,Q<0Y7FD'+RX)*EI:W9DSESP]#E<+)AWETG?K)@++,0=M$T3-YHE
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M^*-(:_^9Y)%3Z9<:..^V//=M5^=3KU[SK!JNT!)?=8K[IP'X?0+OCO9,UUB
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MNP:51^BR4+WP.&>=1I6(O+OP! &6'6-KJZ/<W<4ML#J ?"UP31F5.)-(J['
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MIX7NZB7$&G*X!\PO'(F;.I4Q19$@=YE5_^!1":];"6RZ !!._NY%"$^\*A$
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MBEDB/Q:A5>S]4$'F1C[J[;-L(#!X"@QWL!, ._8>ME;A"KSR\F_TN-+GCE2
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MBN8\Z%8V-VI!M'X+02BFW&,PC)G4+>E#F.+0@T'B!\1C'N(TM+'T'<DUM[W
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MO?^16.8C[DP/2DFLYB2"4L@(HC1.8>IQ"CW)4L(%YU1:^9>'3LX4!GQO:BY
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M%Y+ENDW1?D/?CTKRG@ES^^[F?M4T-?I05MF3_MEG437-('77R-JA*451"+Y
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MSU/-P;L&!LBJVVYEW=-FS9H\A?:D3@C!/1SX,(ZB%")&(X@#)J'Z<81\A%"
M JM@V6,CS8TYZE.\E00[H@X\"3T.KQF+. %M9 (9B)=]J.TY+)R&W1X=;-H0
MW',ZOPK'/7N#'4^41;7XHB,QZC#PR$MXR/1!9YH0B#CGD B&88Q1FK X\'!J
M9%+L/'5NW[_>CV=EE3&R!/TS?ILH^EW83G_K@\&8P.TS  ?C[_J@WB>^875]
M[_M5_]K_=G<?.,EW>E"'[IL\_,MAZ_3/ZU(9 67Y;O5$L[PI B78ZB'7V8<W
M7,U+)C.]IVCK5K!_K-4&A*L]25>K+A.E^MWZ2?"V:%US9;UE61 <!:&GUOD
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MK?QV[&\W#V:,/AJZ([-T)R/8"GD%=M%^5PB>54#G2UZ!5@-WC#P(.)<L:R?
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M\MF1&/1$!EIF\%LCM>4^U@!Y,T)RB^?(C'0IE-;L8XZ.2_HQ&'52_C%'89^
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M6M]7\5"WSNN.+G&$@S1.%.U% 4188DAPC&#*?4^0B%-N>]Q[>*#YG?PJ.<&
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MLVK&G!/-U<@\VM>B3A'M]+@"O;S1N^W\Y7R;HM2JXXY8'6#JDF8O$6=2TG6
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M O!.'8L*V!._'>>/^V<\YR,3ZD;S?J*'5A[L:J_XMM8?;%4#"@%00]#=VX(
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M. X$@9&0&411I"U=CC-HPHA4$%*9QF,F.,_1SKTF9];1!3UDQNPH;^1Y&)D
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M<<":B7F_%C.:EE::_Q<GI=_"G0CFD2W95GK0$7\!.I@?:;#8USQ_\A?&< 6
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M2#F,PH (&@4XH-:=B8^>/#=R:H1S2:WJXG39'!VL_<@LTL@U*+FLBX!+;ME
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M:X<QY\:H[V21_ZBJH)7@(#Z@)6C3]@X:.&<379X!NT,WS[B.S+R78/1('@,
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M6]791/\IZ6K[_:W>L9J]ZS<]EOBJ_QPN18 20@(% V7LCTQ;(A1''"8JB\.
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M]#P8H\6,GACR]<)'S^O?&TG:<]LP-OGS9B/^R%>K)0T0"1(IH21*TX;4>.*
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M@/1K5_)S#[5(@B#F/H$)]M0RG(9J_Z9K*,9Q$H58)G'L2=N($V= OUY5/_=
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M\V2$8^&+U"AGQ$ ?2^,(+>6_@[SGDA#$%OX;)X \?^GJ )Z)J> 8,F-<7$Y
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M14YCX#:5R)%^9DX><EK3PW0A \^.F_G-/>_6P=1'81Q':K:GB80HB3R8HC2
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M:9Q0JV-STYZ7QE Z,ICDSX#UQ;4\(3=&W?!,? HLI[9LCF<AT/&)VS3Z?24
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M9S,>1ZK:-R#'-C&Z5*\H2YUFHBT"W-JGK;/52@:)'R0(PXAS!)$72)@2[,&
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M^9S'IWB\<-C-5HQ7&<R)5XN9Q_&2E)-N,)\H0>6%PKU6.DLWF XDOW34P<C
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MVC/>$%T*] 470<:037/I<[[[5[K@,<;E]&6.>1/V3DM_RXJ?/[?5^ *,_51
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MHK$-D?>.,C?V[LKGY"GHQ[*?.KPA-#)?N(!CS0Y6RO=0@KZ_0P?Z;\=4T#_
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M\C&ODZ&JQ%Y)$XQ"H6#"31790!)(0LIA(O1[+4RYB\S))NT9:VY<VJ2S[!V
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MDPQBG(:0I0D/ LQP(IW2Y#O/GMVG_K@M5Z)*>-2X@C],>TT!OND-MG2T)[L
MVGWT V$9^3O74NG_CO!IGU#7Y]?<??RD'_ )O8Z_V5.7N'N6_X]\T':!;$\I
MJ&29R*2$B4@%1/K#A#B2D?Z#A32+6)PHJ[YPSQ\]MX^TE<[>(7@$U66_['
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M-?;9=6K$"?':IFH,.:?M:S4BTL\:88TYEMOB4Q;;Y4?]H+NZL3@MZ^ 9EJ
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M*D*FDMAML9Y.]+DMT%4G/UI+[K:(3CC==@OG/"=QY,7R5#.<!>C$7'05;U;
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M3->NZ5&SZ+ZT1_TFRB!- J'VM0%'BO50(F":4F7?8FWFQB)-L/'IF\%X<V/
MCVNR*L 3>2[W<_KP@]5VS%.]X5,VS/*@6I'YUV^"?S]9.D9U9.+4TH)6$:'&
M+-R+/(!&38 TIU3'@$Y$KRZ M6)="Y@Z&-CD*9.QL85*;6:VN6V8C^);3K27
M:1]VL?"('XL0(\BH'T+D11ZD)$DAHHE0UJB4,J4V'MJ3$>;FJ+7.F[V,G=DN
M_BI$1F;1H\"H&U +>S-RB%0O-BYWRZ>#3+KEO:CC\;[U\H5#XJ'^24C^7\_Z
MSV;A\E@<A2&%3-EANLVPA!2K+YWX*)68$.8E1DTUSC]^;@97)>'?*A%M8G1.
M<.NWG*Y#8^1/O!(.5-(-BEHZ?9,LHI2N06:RJ*36J^*Z:=!E!#J#CDYNFC#(
MZ)+ AT%%%Z\:&$1TP2NG#V9>"[G.Q;%;K_YG[4Z/2$)8DF+H2YV %Q,?IC$7
M.HX(4T0]G,:)5>#0%<+,C0@K7SH[\*5G]>GC4I\^ EJ*#O+.@Q-U]\:T6YN3
M.34SKJ::J9%)^O*!Q^Z(N)ZE$W5VOW%Z N("5Z<!/]?(,VV0CP/D3@)[7#QS
M>''R3;TG_:8>\7;]2++5(DD2+^4202YTWR,1,4AUU_<HI(E'_3CT&;6M.GXZ
MS-RX=%].O/*-:$G!GY6LEO&3%W U8[WKT9K .V</U*#JWI=Q<%VV^\Q(D]?C
MOJSMN4+;'5>[;,*^4"86PLP+(0]$HL/\!,1<"DBP%\4BH20(O,5WD=/U=;W3
M;=[P]G#CO>CMCMBL):F+GN<+DH2A3P,&4]]C$$G%M"FE,8QX*/W(9QY#WO4-
MZ>=&LI]+2Q,4%Y!5?^D(>[.!UXQKKP=M9*X]VY1]7[3FI@P=U&75=(/KE<N2
MV]W0C-\P?0Y=SB_1;\_5@R.KF1"\T!$M[98)7Q_6^:8Y.5B$88Q0G*8P3B(*
M48@22!(A((JB6#+" H\*RSCB_E'GQB(Z+(P]Z(] -W0IM*B504+7>;[^D:WN
M+=W_9MB;<8IS1$>FF$;>*E+OU9=VYYQ?P-<]N&^[SJV'A"2;P^0X6ME@X*D#
MF<VQ.!/C;''S0&ZJG_IM7;9]S84:E&_+1EI57:X%%;''F2 0T4#G-Y 48I8&
M,/*]D$8R]GFXBVDV9*:^,8V^H<,8Y;'/)<A3I@MI"+T8\VRSS6T#D?N!EGZ"
MF*>,<!'Z"FW]$_:H/M/UTI3PQ M2NP7 "<Q3FI -/6W6@%0B@Z>=S("40KM&
MW9#Z76(Y-NVW8*RE!7MQZSJ6#NG>%!JG5-\[Z+0T;XK!"<4;WSC4#Z@;T:YT
M=J%8L><W2Y(]%F^SXC%33^>?MN7!8(*('ZK-*:2<J TKB3U(XC2!:@^;I!)Y
M,4V->BC8##HW[M$R [87^@:P4FQ=A;22&ZQ*P6W]A0;XFWH/W:(ZNB^Q['C=
M K22&.Q$5EO<;D0'.!;-(7+K9C08=V*GHSD2IRY(BWO='QNK+> ^V.N_!+\7
MOY%LI7]S?%K2.DD6<> E"89,,JELU 1!BCP.I2<B["$FJ11V-JIC">=GT=X^
MKK=5?8+:<_=**_$+*+];W3;W?I7]4[&>VH97QYROJN/G7RH;6%<^T%EY2C]0
M/:H [W[J=%AU3[G?W#7DU<W0P3<%EWJAW)U$#WE-KC^<'FOJ9W->764Y-QJ"
M4L4;H)7<77*LZ?1'V5?,PE2GVT-$G,V!]Q7XVIR!7S.,?6SEU^SGYW6VVKQ7
M,NC_/@OU5:TVY%XT635WJV\_UM\>UEM=Z>YVQ;\]9+DN=J<HK FAHY)AM1^'
MG 811&'J04I) F-"9.(QW\?F28 .Y)F;$1W_&D5'"8.)><BBBPGJ9O@7@'WL
M4Z3L)RC5 5J7ZH^]1JUTN[L54%J!1JVRC46E&"@U&Q!BZN2#,HY)G7C>)@IB
MU?/W5,Z?U%-7_O&TG[_]I[1>@8V:OTTS?_J_335_A=;04=RK0Y0[ F5=C#)9
M9*U#2-JAN"X?.[BONLASP76-_=+7]#E?JW=O\ZP;16UNJV*O3_HC6'"42M^/
M0L@3G?PN.(*I;N^7QB'F04 3R8TZ-MD//;<E[I8QL=3UNM0VAPMEU;"L-H)[
M_*K73H'9WF4<8$=>Q!JAJVX;I=@WH!'\IFPQM]EE-I7".^T_;@F8XY;BIJ-/
MW27<$I4SC;]MGW!]<$7C37^_SLM]1UTP;W5_JQT15?9?D"0LH4@9[C$B$"4Z
MWHV3& KMZJ9^@%)A%9UE.?[<^*R4<WA(A0GB]L$5CG&<-LQB=_RFMJR_U+ZS
MG0)@K\$X 1<6T(T5>F$BPHL%85C@TQ6.8?.8 1W.U]]%?DN+34[89B%H+*47
MQQ C+X&(2&5\L9#"*!4\3:* $K/ L),GSXV+2N' GXUXAEO14\"Z"><J&$:F
M$F,$[#J=G]/VFE;G!\^;KM?Y.34.FIV?O6"86?&[(+KSI/[(/ZR>MF4L?MG?
M+DPE$Y1)Z(6,0D1I +%/,&0H)HG:" F2,AO[X=) <_LX6W*"4M Z.V1 Y\"+
MV)I9"BX0&_D['@:6]<+?AX3+%?[B6),NY7T:'Z_9O==/EO:\*R)*<2 "(@,8
M$-UV, U32),(P4 PB:($^Y'$-J5;KI#%BF,F*/+B*.EY>+78:^;U^L-EA[/U
M\@?)EQ.?QRC]Z@#6%\Y[?IG"K@YP<Y#U?&79UKW/J6D1_F&EC,#R_*9HCI1?
M/^L39K5#^R*6U:@/V=/KYTJV79.%C^OZP/GYW,.^9,5?96?J11#**!3* $Q"
MR2$*0P&I[X40,QI1&B=^2B,[A_A4HL_-KMP+"UJJ'X2<@#]+R2VMS G?!E/?
M_!SG>'3?_O73.\"I/S72;@\%)I-^XD.%J6?E]%!B<@D&)NRS!\&W2W$GJ^&K
M=7/7$OVM^K]BD[';%7^O_CV[7Y6#?A,_-Z\5XG^IY4GP($D(##'5?2@DAJE(
M=2H101A[/HJY54NV*^69VYI3FZJO=V&+MON$:^?';,&8$/615X%&$VWWU^#7
M^X/Z;TJ=&] H5)[UUBK5BP/06H%2+8?KA". G:;,7RG2M+GU;O [2<)W]%C[
M&-'/>L.R7NDS:K4GT:M"':>6$!'Z$J<PHLR#B/E2!WYZ$$LFTA"%,69&7M^N
M0>;&DK6<9?Q%N6G7HIJ'!U[$LIO\7"$T]J'O.7 &!%%>1,D\,M(%6A.%.PY$
MS2J$L0^.CKC$B[=.%FS8)WP[@K#WVFN]*+??14[NQ1>A2U IP[BN:O[L+WPA
MO8CB6)%@C""*:0*)\!GD*!0QD1[BL57/0X,QY\:.OY.?V>/V$3RI?]6" O;,
M*@/G06<R%.#5:@T>M8FS>2"K7X;Z+B[/@:W3P0FRDWD+;D M+]@)W/0R>![#
M4="+SC@[_,O#OM#6O!>'RWOJ_EN'$5*K]/^"<\^C2'<[8#IZCZ!$45 BH8QD
M3&/UOS2UBMYK/7MN!#.XXT$;+S.2&(C"R&1@ H#U%W]&59=?=OOQDW[!9_0Z
M_E+/73(X<R!;"?Y:K-0/&VV ?!7Y]XR)-^MBLTA)P ,41]"/$Q^BB/H08Q+#
M!#.!<2 #/PPMDP4NCS:WK[86;4"YPVY035=[1U"-OLZ7<H):T'(_< ,:[-YT
M83<DPK\?$\=!_1T#3AW'WZ_[F=!]@YNN")RI/#FWJZJG9UW?\FU6L.5:!^OL
MW:0T%<B+90I3GQ'M=>&0Z'Y':N\1AXSP4(96;FRKT>?&+'45A@]U%89W314&
MM?<;$.1B/ =FQ#,:LB,3405J[836;N?J'VK9P5YX\.<H'NA!N#F/5#$68/K8
M%%MLSD:C6#]D&+F]T7JM-GGI1--'@:^?%8FRAT>2_U7&M^( \4!G'&&! X@"
M/X:$)_H/K B.(LJD5<.3O@'G1F$'\@(M,-C).RB2N!=Q,_9RB>/(A'4-A-;L
M9(J+2T+J'7-2#C)%X)AVC.\;RC3%YD[^ME[S0K%:;9X57]=+OD I0EZ(.&01
MTBT^_ AB7YE0D11QB#"/@MBH1$G_4/-CEZ(,+"W(TO8\OP-/4P9Q@=+HW%$!
M5(I96CN-H$!+ZI(W^M!PRQ@71YN8*_JT/F6)WCL&Q@\UX4I5+U =C;M>:<=/
MN2BF22JP1Q(H68 @BK#:5J$T5']0$41>&F%FUZ"B:[2YL43='74OY"##HQM@
M,\YP!MO(M&&-F'T<C@D23J-L.@><-H;&1/>3"!FCF]SG-KTAQ</[Y?K'0;&V
M6ZF^V^.8?EVOAOQ<)#&3J8@%])*$082)A)@G"":4IKH;#N>ILQ:/ML+-C9ET
M/,1VE0NR+ MOUAE/]SI06IGZ?'?.ML]P.DZ#<ICM9#W3%GZB%YB_2=Q(G?E0
M6CN@U3M;4Y-H-4^2I4H;;;(\J:'X3Y4X92W?;#*IAB)KDUHU> PGA>4_ZZX8
MJ_NJ5G1=UIS1E(J($!B35.U$(ZD379F$J6)]P:(H]4*KG6C_D'-C]-.B\D^5
MT$UQ>0<EY<\A;\;%;O$<F6%/R\G7\M9EY4<O)M\!SXBEY,^-^I*%Y#M0Z"DC
MWW7G@&*^VL=3]FG[/5,_;93UVP3.1D&*!(Z0VLX2#Z(DH3!%B:?+Y> @D"(F
M 3*NT7MQF+E132DI+$4%>UDMBKE>!K2;3=S!-#*#G$=H2-W;RU!9E+-U ME4
M56H'0F=7>K87D:Z*LI=OGJY0;*\"!_5?^Z\>&IQ%-_N,Q$]J6NLFU4$:\A"E
M,51V6:KL,9VSCI& 88(%3XB( V99Q/7\0'.C1BUG*_E860KJXH']OR^":V9R
MN8!L9)H<B-: L*QN*-Q&9%T8:^)@K&Z-3^.P>JYW5/;YMUQ9:@M&D) 1"Z"@
MHBQ+A"'&2,(D")GG)\2/D+0I2W1^&"MNF*#BT-<M+8=Q5+ZY@M*4"ZX%:'0F
M.%.6N11RQ/++!R",6FJY&NEERRH?:-M;0OGP:KNOO\@WB\\DWZS4@ON0/7U8
MJ95761W-GLF/TH $!/I(^!!YDD*" PYED@I&F(]]SRB?JW.4N=D%M[I0Y/\K
M5DI#\/&SV9??#6/WA^\,G)&_^Y:,H!'2H:UO!$/'EZ_N;WWUZF_'7WSW )-\
M\$8Z-M^[V<7VG_OOV4IG*-;OIL^0C+@N4>4'L5K?J8 X"@,8A&I]%PF1TLSZ
M/WGRW#[K6CCS[_D0I_YO>+#V(W^WM5R./]6SVE[[>1X^=+)/\JPN[<_P_ 7#
M[.S71,T.$U\?A-A5#:HWBSP,A4A#A0KV)$3J+Y!PFD O2 D)28*EL-J)7QYJ
M;A]G+2DH106-K ,WXQT(FYG@;G ;^;,>"IFU+=Z/ADM[O&.T26WR?JV/[7*#
M.URE5;9*/!3_R#8/MXQM'[=+W7VHONJ.+K/[*OCCP^K=3R:*XD[JZZLMP^W]
M?5ZVD^VZ<Q%1E@342V L?5)%Z9!4$"@\YK' IQZQBQE^*47FQG9-N1-=(Z(
M/Y3>@*P V6L :)T N=[IH!ONBE)]'>&C[P2DWGMWWWAMMNE$[YJQ<V3V;]#X
M[I<S.;)EY9SR36JIL;OF[N U>K=[C<J[&A=.]XUC)MY..X?CYO1.I,L+IPM/
M.V/]F<@3RS.T8$E=J>YVNWE8ZQ(H[5.XB/O(%[I@DM#Y.2F!*?(9I)*&Q!<R
MI*E53G/78'-;#_?%'L%.VJN.XSJ1-EMI7.$W\FIP#70#BJ3T8^*V:DK'>!.7
M4>G7_+2NBL$] VI1*FI:;9;9IB:EQE7O);YN$P)QPB5$W$LAEA&%,A"4^KY
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MS#422>K[ @I,&40>09"B""M.)\P+8I2DTK@$_N&CYT8DC73FW]015/V$,AR
MD4FE$6P L1R!8$XNP\&8B&#,0;$BF?-Z=Q#-T0V3D<UY0=N$<^&*89NW.I/O
M_3H7V?WJ&_E9QWS609X+KC9IB? D)+JX(2)"Y^>R&$8"IV'((B_UC/)S#<>;
M&SW5<MKMP?HP-=MO.41J9!ZK)06UJ&68>BTL>%6+ZS!CSA 8ESNGOB$GW249
MZG^\(S*];6@23YY]+_W'I6]ID:K]3BAY"CE7<"+F$TB83*$G_8AP23B*K.J
M'#U_;CRQ%Z_VQ5IVK#B&SXPBK@!E9$JPP&- ULE9K=VFC1P.,7'>QUG]3A,W
MSE\V-#B ;$I/V)T\/>S;A>,@'J0XIA[$(DV5-1 +B&4<P3CRB!>2($ 4V04&
M&(PZMV]])[2._#][TFT0GG/%)!BZ:UU#.[:#U@6J Z(%+%!R&RE@,O#$40(6
M6)Q&"-C<?%VB\*Z4X\>,T&Q9QD@M1$I8&,0Q](C@$$6ZG1:2 A+.8AI3BJ@^
M][>J$7)Q,"M&FJ NR-<M+8>Y 2TAAV7OGL76U!IQ@]CHIDDKL[8EX@WX+5\7
MEV$;G!W;A<<8N:YGQWN1S-4NS2_EH7;>XZK.D-[ZL(W@[[>;;=[L@.ICP>*3
M^+GY]D,LOXO?UZO-0[$(J4]Q'',HXQA!9>(D,,7(@PS1A$K$!(D\RXH"U\@S
M-WM(O8[^M76'[";$F(^F@GE\RCI3I:C1!E3J['];*70#_A]!<G"W<I@IY C2
M<6L8V8GTPJ6-!N'77_%HV&,'EH/EWT6^R0I=+'M=;.K3]'T$7^P3E-*40U^W
M6U'TR2'F8:0KQ 9>*$F$@]"J)&SW>'.CQY:X976.S^JM6)>!E:7TEN5A>[ V
M8T:'"([,?&WPR@)LH\;I&.+BM%QLSY#3EHPUT_^D;*SA;?;'XF_6CX\Z+9 L
M'[.E*#;K5=-^,HS3E/E!"'W.)$0D9)!XO@>CF!&UX5.D0HP\49VCS(U*]H*"
MWQM)S<^,+X/9S1K.(!J9*]@>G9V0 X[6+\-D?LKN!*Z)#MR'P69U^-X+1\<Y
M_.5[)SN2[Q6_?3K??[$]#=YM'D3^=Y)GVM&O6]Z\%713OY0,ISSUL0>E8+$N
MN$\A%4D*HP@E/"92QL2X[W/'.'.CPE)4T,A:]0'2TII_YUV@]A.B(ZA&IL1+
M* V@Q2ZXS(G1$6P34>-P^*SHT0"4#H+LNGLRBC10H4V2)I</[7>W43.HFSE5
MU9I*G^Z[GVRYY<H\_6V]YC^RY7*!B4\XBA/(0EWN 24$$D0BR*.4L(CQV$NL
M,IS-AIT;B992@C<DSY_+ @/=G="NP=ML7^H>Q9'Y=2_PKD9GA>FKG=2@$=MA
M!)0=3FX[R1F-/''#.!LT3OO"6=T]C)5VO0OW7>@4Z1UVHE/_^&:[*6Y7_+_7
M5&?JW4G%]$GU42X2S@5->0AQE(0011A#*DF@K#Z)F,2^"(55/-75$LV-R_1I
MGI:V]+%I>75VK(XET"+;<=KULV5&=Y/.P<A,:-Z=\^Q$N6_#Z0Q<E_1YO5"3
M,JLS#(])U]V#A_@4E^K'=5Z&SK520-7H(OM>1E^&&*51*KD.'A$0Z5J95'T
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M+R83C&A?7OG=:I-MGM]G2_%I6T4;>X&Z2%GL4DBF+/84P322"4P91UX:1S+
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M+/BMLAK)O?@B=,I=\\OJ$!<S(KRRN2TF*404Z2+'U(.""^0C*5,OLBKD9RO
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MI"@H2IDD*4G\U*;(9]^ 5A0T6=7.=GE''?Y7R6J;X=<#M1D?N01P9#ZR1&U
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M4XA9+"!.];0_33(L66 ;_7WPY*E]_C4X^T#B0YZZO^J;K!_X*ZYQ]0BE/F3
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MNS[]NOI>:E^^U/.MQ]7RRV;%_Z!+\=4$76[7S^6_/^L&?UFM_Z1K,<^RB*L
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M<Z:=/17$6'<;8Q#% 8$$FUS;*14DRCB/,W); )\GI%/3Q]HL\*1_6X _M66
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M1(EQEH,HAC&.8T81#2ASB@KO:FQJ F% EA-^;GZ0>[B.E?^Z^+5S+GVQ-K!
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MZOL_E_I+_)8_[3.8SN-(R2Q.8IAE!$/$0@F)2:=$,!$RS3(9,:<#I-8M3TY
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M"4D4D)C)(,J8U7[&U9:FILB5]\MKM&"SAUON23@<>^\FN%MOO=(VL'16C#5
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MY.7N1A,"$83,>%<!I$Q/>)%@%%(J(OW/) HPCA.4NE4BL&AT:@*TPVQFO_N
MK0:V31A%_PZP$R/?M XL1QX8=<_P[$"1U_3,-NV.FUO9@8F3Q,@N]U[2I7:G
M?M __??_TOQ&_Y_)#O[?_\O_ U!+ P04    " !7A%E2$R$(D(9A 0"_?A
M%    &UR:RTR,#(P,3(S,5]P<F4N>&ULY+U9=QO)<B[Z[E_1=]_7F]TY#UZV
MSZ*F;2UWMW0E;?O<^X*50R0)-PC(&-2B?_V)+(#SH")0B4IN[T$B*; JAB\C
M(R(C(_[I?WT_G_WT#9:KZ6+^SW]A/].__ 3SN$C3^>D__^5O7]X1^Y?_]2__
M\ __]'\1\K]???KUIS>+N#F'^?JGUTOP:T@__3E=G_WT'PE6?_R4EXOSG_YC
ML?QC^LT3\B_=+[U>?+U83D_/UC]QRMG=?UW^HPB4^Q B$<%*(K/SQ&FE2/+"
M&!,,=UK^/Z?_*'V(FCI+&(A,I)&6!,LR23: I<H HZQ[Z&PZ_^,?RQ_!K^ G
M9&Z^ZK[]Y[^<K==?__&77_[\\\^?OX?E[.?%\O073JGXY?+3?]E]_/N]S_\I
MND\SY]POW;]>?70U?>B#^%CVR__^[=?/\0S./9G.5VL_C^4%J^D_KKH?_KJ(
M?MW)_(=T_?3H)\IWY/)CI/R(,$X$^_G[*OWE7_[AIY^VXE@N9O )\D_E[[]]
M>G_KE>>PC'_\'!?GOY1__>7U K'PT9\66KO?75]\A7_^RVIZ_G5V];.S)>1_
M_LOY\@]\):>,;U_X?U__[B_7[_ZZA!7"I>/U5_S![A'E97O0 =_7,$^P9>[R
M%;-%O/6A61'M8GGYFS,?8-;]=))@.NF>?!)6ZZ6/ZPE3@2KM(N%14"*#"\1"
M$L0'$1Q+P"'<8;O0O$*B.TVL(/Y\NOCV"S[XER*+\D4G%()PW(GEWDNWXMF/
M^LOE]WZ>%\OS3JI??)C!Q$LKG<V"A$P3D508XK+U)$GNO& F!L8&8.2Q]]_F
MZ:;23Y;QI\4RP1*MRR4!?AGO > VLG>?^.6K7^*#2#R;SM+E;Q<S,X0^UXN!
MY;I5()+^EY]0 AF62TB_;O7W**,=EVNTO]!]<E]L;%;DU/NODS<0D <41L?-
MR??I:N*3MV@T/3%4(P>":N(X4R0Z)946VC#M[R/C$AC9KT)'[>X-6W3 ;+VZ
M_,E=F#Q.RG@@&4:]BT%EW1Q:?O?G\&9Q[J?SB:403%2!T.@8D4YP$H*WQ(%W
M/(()*J;ZF+DF:!SD#*7H)W&SI]1'1 ]N_),3]C/CZO?%&E9I \6U^PW. RPG
M'&2PBJ-GIG)  XQKR68TP-)0Z[D15/'P S_BJ>>W!(1]-;<86(QC0X'^K"B]
MP8/<\1"-MS(+(#XE7"/,X5?4T"(9(;S*!G?J/E!XY/F]H,!?#A2&$./84& _
M6W,3SGK' V!,YR!FDI.V1'*?B8L"K:?P I$<8J0_BBZ>>GXO*(B7 X4AQ#@V
M%/AM.(M+.#.?O;#!$NY9\= 9>NA.8&"?T5D'IBGWJ0\4'GE^+RC(EP.%(<0X
M-A38S^(FG,4EG&-6+C.KB<7MCDAM&;$)W2F@*3'C06EO^UF%!Y_?"PKJY4!A
M"#&."(5'XK!?IW-XOX;SU21[*U@$19P+FDAE,PE.>72LE11:<\:4O V'H5(8
M5S2,XU,,'J$.*NI&(/,%/SM)07G%J2$I)'2+N\P.M?B5M\KGF *30T*DO+.I
MI,6>&GP %L\69R,P.)G/-W[V";XNENN)=PD239EP:0&I=I)XZRPQ/D$T)@E[
MUZT\" XWW]V4I1@.%GN+MQ%X?%GZ^6I:9'+) ]*>.)6$6\:)3$P12Y4BD!3U
M,G*A,Q_28MQY_SB127WK<8B81X;*V_EZNKYX-YW![YO.?[*&,:F"(%(:%(;@
M0&P.B>3LHG0Y.0 [ $3NOG><2*4:- X2:Q.0^ 2GTW*,M/76)YX*KKC,):<;
MD7Z92$A9DZ1DLM$)H6P<#!:WWSU.Y%(9&@>(=V1XO$;J3Y;@7R\23)2RRFG%
M"8+8$<DPY@X>.>"0 ],Q))'<$"?&-][9"P[ZQ<!A;W&.#(-2LC'[>+:87UHX
MS4(VGCO"6"H6CF8,O*,F&,53EAQN@GP(W^+N>WO!P;P8.!PDUB8VCO?SN%BB
M&]0)Y#.J EXO-O/U\J)#.*)8,I<5T=(R(D.VQ= Y0H/.AMFL)1>#[2-/DM(+
M./;% &=HX3>!I2_^^_N$DIKFZ;9 ;+<H&*2D>"Q"BJF$ZIX$2A,Q,8(W&,5G
M-T1]SY-$],*/>V'X&4+@32#G)"74R&KW5Q$/FTAO9 9G")1B26GQ*V<X)T%0
M9AA(D=T0SLJC!/1+GM$7!IE#)=T27(HS]F'Y9?'G?&*4##;F0!2H8BN9(3X5
M[&=(CDHCK!@N#K[W^GY0>3F)UB&DW!)0NJWUP_+C<O%M.H\PH4EGJ00E$"TZ
M[N"!!(L[:S+<")6BLY0.C98[-/2#S,M)P@XF[Y9P\W&Q6OO9_S_]N@WWDDE:
M2448MXCY("EQ002BD1=MDG11ZZ%1<XN"?IAY.1G9@60],F(^0]PLD0_&PY?I
M>@:3R$565"4"&.^5\ZB ?KOT1'*6LL)E$/D0.+G[WG[H>#E)V8/D.C(FOBQ]
MN87T^>(\+&83!"W&<5(2"P8)C\(1E[,G-$JKDLQ<&34 (&Z]M!\:7DX>=G^)
M-F(>WGZ/9WY^"ET"V2)B$;6*&.E2.7(2)&A5S!M8#TEY)X:(;1YZ=S]@O)R,
M[,'R;<+A>+TX/R\IH$7\X_,9"G+U8;,N%^\*YB?.">89U81)L$12%%)PQA*3
M,*#G%H4SX"'?4Y3TP\[+2=\.+/LFD/1Q$V;3^&ZV\.L)."NXT9X 1#238'$9
MT,S1J1+.I\2DAB%J3.Z]N!].7EJV=E_)-@&+_X#9[-_F&,1_!K]:S"&]7ZTV
ML)QXRE7*,1 4BR&2!4>L\YHD1D..T1KIAX/((T3T@\M+2\X.(?$FH//OB]D&
M];'L"B26JXE&2AF:0^)$!&2 *>*UXX1G$T(0BO$TW'9TY^7]2M=>6E+V$ DW
M 9'7FV41W[:@JKCIJ)/-:F)=S)HQ1Y+@@:!-E"1D],7 4,D3!F_&AN$<EP=I
MZ >8EY::'4#>3>#F_1R?YN-Z^@W>^+7?L35)$B!+:PD7'(4#@1$'AN-RH"",
M#SFKX2S,PS3TP\U+R\\.(.\F<-/9R==^#:>+Y<7$2\:=-YXD8SV1.2'Y.64B
M"NBY4)#C$+4L#[RZ'TI>6D9V?^DV 8[/YWXV>[59H316JPFS5%(E+$DZ*"+1
M.2=694N8S\SC;DJ='J[XX-:K^X'CY21D#Y5N$^!X>P[+4]PQ_[I<_+D^P]#_
MJY]?3'#/= ;=<L)41#:LC^4$/)=PSICDM4!^!@/)@R3T \O+R=<.)>V10?,^
MYN7))DWQ$R?K-:RV*GDW\Z<3ET &*C-)CJ-=5$X0;V@BRF<;8@)&Y0.]:9Z-
MF<<IZ >9EY/)'4C639B9SV<8_5_B71G/A)21!.M*42B*QCNM,:9+PJE$N8U#
MG/_<?W,_A+RT?.W>LAT9&2<HCU1DTD':,&:TLHH(#.W+!;6(D(Z) (]11AM\
MX$-L.;=>V@\/+R<ON[]$&[GR]Q&6TT5Z.T\8C<$$E$,4 R6*&TG0KPK$,H'N
M=F#60M9)#5(G^^#+^T'CY>1@#Y=P(Q!Y-UU%/_O_P"_?X4]6$VV3C-DXA#4"
M7!J4BD<>4#0,(8[A.@9H X+DSNO[W0E].?G7(:3<%%"V>-\RD<!FY (=:Y&*
M052.!.. <$!>F&-!F"'2:(\2T \L+R?W.HRDF_!/7R,;2S][/T_P_=_@8A)2
M3#%K2[Q@74B6M_5VT4O#T8?2C@UW8?3.R_O!Y*6E6@^1\-AW1K=IX6N;>+5]
M2D:U095J+A#F"'&"OC8G$(40+$7<2H?8>QY[?S^@O)QLZR!R;F3W65W?98/T
MZN)3H03F$;[ ]_4K_/ ?$VZYX@PC]W*Z66Z9B%($[LN=-I62]2;D!_JR[KT;
M_9"@?FAZ.>G9.IH8#%[_],L].2//?^S9Z7V^6LRFJ7#8W34H?"]R8?Q\O^[O
M3SUOB([PO>D]L$O\90>W[:.OWG758SQ)SU/BDB33]?XMG=<BY1@/48N(<%+X
M!PI/#V^._ @]AS:!_@3?8+Z!U<08Y,HD3K(PW:*1Q',3" ^>!JJ8,_R!,J;#
M^;HD8-S>OD-H^VZGY[U$VT!?\->+U7IU,D]OOW^%^0I6U\+ V#\(YHD/"JT>
MQ;C.,<&)IEQ$;QP/#S7<.APBCQ$T;@_@&I 91/2-0.A#_NMBD0HWGV'Y;1IA
M]7DQ2Q.KE,O.*F)BZ?S",BZ&,M!%!W35(.I$S0,>\# @>IBD<2W/,"I_ $<#
MR+\!)'V&V:P<?\(<,!9$9D[2^73>M1(J-3@[J4T8< :,&Q(3E$,,%S!*],B?
M5<GG:)1@#Q2P'(ZJ?N2-:ZBJ(*R"7AI VR?4#!)PAOR\P=U[MOA:3/LE,Q$E
MI#T$$D0Y*7,QE$,R-/3,9YNC8TY5<?V>I&K<[N=5L#6<%MJ U'JYB>O-$I?+
MZS._/$6/$+1W,@9#:-2!2)D=1JC!$ZH=1$N-M?2!3K:#(.D>,>/V3*\%H,-D
MW@!N/JS/8/G[8K[X"L6DSD^W_N;E*L@FQ9R8)@&*.<T1Q8/FE03OHM5 M4H/
MI)L/1]#39(W;=+T*E@;4P_-1Y;:HFL-I27P<A*O21+X3T)5TYJGC;9*SH3&*
M0 RC"CU"F4G@FA&%QC2(+&U,?68R//CP<9H75@'$, +<W[(LUGXVB&79 OC7
MQ6KU#B7V>C%'5&\0V!^V"%_,5Z\@+Y:P_=P7_QV0990;:FLZ]\N++LF**R+B
M;R)ILVY-H.%#HSM1.@09&$?+4<K,G&'$.Q:(5EQ9(R6*^H%"K:&R8U5X&M?!
MJI%E: 4 S:P%9'&WJ%]A/).GZPG$TOY-)**Y1+,N(Z"3:8 8Y;1E/EB7'NAO
M-!2.[]$SKH]6#X.'";X!+^WC<H%4EZ4T21P2DR'A+M %N.ADN@!E6I/%WTM2
MJ%@%,M<DC.M]U4#)GN)MP+#\#NMK,WNR7B^G8;,N(UV^+!ZQG$$EYWGF1/#2
M"SD$C&NS13E9(27/(>F'NC4>CI]G4SJN3U<#9G65U8"9NL7@I-Q_C@888:FT
MQ:5(O)7:$NN@U()KD-I41]HX?:R/AJ)G";D!>_76+^<(\-5'6'8M7%[YU31.
M/+-4, 8D.@]$1EVFE:%?1X/DPAL.63QP_?QPI#Q(S3@-K&LBYG"A[XV<;[ ,
MBX&LRUTVWDQGFS6D26;1&>\Q LA&E"$/&;]";K@  ,$<]7>'/=9!SXZ><1I8
M'Q,_^PA^0 0=H4"I7%I:PAE&#--O,'2UTD,/KU:Z]$-.!JICNGKEAUVUU,D\
M/?#N*SQ2XU/D*A(CN"U5MI8X9RC)-(GH@4N:JQQ-/)/.83VBG*7VS"2B:.1$
MJF1*%M?CWIW1$%M)O:I2E/!\CZA:'4)-G#SM*3U'^ WXTEW.]P')%%Z0L0_Y
MB_^^O=F /U^"7\$;V/Y])3OK& 3- P:OI2#,>$5LN9$;/9IFSBC^\<"UDH$.
M;PXB?=Q*AF-B],AJ;AS8K_WJ[-UL\>>_0CJ%O_KIO(N4,[[\$\297ZVN!FB@
M2E R$Q^L#MEE$F6@1+IL2\\31E04(=!,F355MI$AF1C7(!\;@,_ ?U4T-+X2
M3K[YZ:SDAMXMEI_]#';=<Z>P.DG_N5FMNWG?._5,C%:0&7K>5 8T0!$H0;.#
MS+,H<L9_JY1I&8J!<<U]PRN@&@H:1__'\H-N67>?*B,'EK">+KM=>7>&\W'F
MYP^)(>K(1"ICS"6(H@M& C>6E!)XS:FPW%:IT:S$S[CGP@VOC6-A9-1RFCZ"
M0-L T]/Y]I)BO.C&)I?6@=MML7PWV^+EOAQ2RE%(-!0ZXJZ)(5 D3EA*N#%E
M2J8V4M8K[QJ<G7&/KQM>*D="2..;RI422BM69/;6 =S'3L<3$\"&G (!JVT9
M6,*(I_BMYRJ;++P-#TT .5+(_#C=XQ[)-XS\H77>P!': YQ>K5:?& =GR^C1
MB/L:%4"<I99$SK*QRDA05>SY$S2-Z[\<,Y4SE&(&PUBM@Y)7'MVJ")_/ -8'
M'HO<>M2PAR"/4SG\D<>[Z1S?-?4S]$*G';8O 244Y2X8CC:M3, J;<YLDD"X
MEAJB2][# ]WC!CWG>)2X0RW1R6H%Z^MJ9Z0D:)\H8<HBQJ5 .ZHS)\F#!T>3
MM[3**?YM,IHYWA@&$W>-S $R;\ ]VU*_:Z=R;72M3E2)LMN7KN8F&92'R(1S
MSX*U#D2=:TH/4C,N?@Y1[X-(.436#0"FI(#+EHU_O?VOS?2;GY7&*2?KUWZY
MO)C.3__=SS: WJ.VGJ.8HI(8I&"H0BR3I23<<*:48RY7J6GL15T+@#H(!7?=
MG,%5T@#.?O/+/Z +"ZY3K)=#%[3(+C-G,.:E >,#:TAP69<V^]8I7(0R5ZFX
M?H*F<1/FPV-J*/$W@*23&!<;7!"?( (N#F0)@X!+7@QPX,8IPH6.1";C<$&@
MM*AWB2N3E+Q[!VZ@G>X)HL8-T(;'TF *: !,[^??2A77\@)9F+@0LBZ5=MF6
MTTTC)?&*&:)H:>YCJ>;7(Z6'O2QT3<2X*=;AP;*W@)NHB.TR7[>$,O$VAZ#+
MV&5A%9$A!F*]+U,Q;0Q HTZV7D;_%BGCYB2'A\J!PF[ FMPFWN6D=40KB'X:
MHEVK1(+,%NVA$-PI4,;4V8N>#9)JEWPJ;#Y[B[B!S/)#7EBYF+3C!@0XP74F
M *K,\K:,A-+<B6OM,T#0MDXJZVFR6G"%!XG7!Y1^ [;FX[)TLEA?E!/X=>F-
M@*%BUU_GK\M2UW(I,)5+$U-<7,D"*_=P(W+E XDI4(MP4&A':V"J'WDMN,:#
M8*N"-AK V*]^GB8\T"RM\R2C--#&HM/F7'9$&^6 YAPKM60K+Q\WM5-#J8L#
M)=P *EYM4&KENA**Y/WYU^7B6Y>07W52F23'E3?E]I-AND@#S:A4'O=Z(Q)G
MG@E1Q> \2=6X>]@1<#2<3AH V&\>!3J'Y<4]64V,=":HX(@PU!"9/<I(,TO
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MK]V*^8O__O;[U\+.*YA#GJXG,:('$9DE/'E;)NT"\:6UM7#4"94,575*OWY
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M1"G]2XLG$&0.BC&"9MX2R:(B/E!T2JS.PG&FG1OY[LJXT<J1J[0K:6Y_"[G
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MSR>UD=&\1SKW'DIG+:0E;VP G^#K;F?XD#^?+99K]&G/WT!83Q0R(X5-1/J
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M!=#H95:RSG]MXSCW230Q_,:P]X\Q=(3R^T/1MH>81Q54H&@YE\1 %:X!C?*
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M25F 29YE=D%[TWB0YG/B#:LI?S%O&@UL\F(&XOY:2HY7B_(N4^K[+6^NI>N
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MQOA?.3U92C"!&]I?-?6CB,=;A( 4]B3);13>1*V;="(_(].TG37=H'$LJW4
MP&VW[-WNVKVKDLFYDIA+'0,H)@TX7\=F)^]+0JU*;O(",DBZ:0D7NP'E^);L
M )Z/ZX^VJQ#1R2B,!B]DJ:3FO/*,2>!&T]J$<)B:G-J[Q9F6#K$; (Y@JPX0
M-^3N[.UM!69B%%W4%P M'2TN24GZHE\<$Y2<:<PB-BEF/4C*:4_M\UQ&MC-;
M!YA\O*2'GOW5U\IM_J^<WBQ6%)6L9JL+7SDM"N5H7-+&4TI533H-/$C)0F;%
M-0H=#Q2T_\*K(S'S.&!L:<#^ 7IO3O5RL5H])([>4.=6"E'C5!9*DX8-G3M*
M^PB^4DAF'J)E7%NKFER>CR)]_R439X%R U._8'S?44/71;-8!/,NUQ$3](O3
M% DY%H&A=LFDJ%$TR:)&D;[_%\UI\7V\J?NANM^OVX=:N,C<H5(!(:;B084Z
M+9E;"4FY(#-J$])9XHM] O8?\;8!ZR@&ZV*4YN-D\K=O[V87W%G*0S&"BPQI
M5W$+01L!DO0G:!U1LB:PVR7,M+=.YX/8R8:8%$Y?E_]U\7 K[&AJ^^W_O/O]
MPJ''PE% XK5G6UE.$;="T"DD[HU6AC]JI7_2UC?XRZ:],&J/G39:/SX.7%SA
M93.O]'0,SH4NQ6M?*'LSWM4RT0"^*LZ)'(MFD<?4A)9AF'B]4%J=M]NN@>E>
MS&2!VS];/US5S?AVAF%VN;VF71>')KRZK1==S&^K1-?7$>-V.H\E39LNZ":Z
MZJ!#VFDEI38&R&%31N*-!;0Z0/:U+4<$4<5KX),F[)"^M='&E*]VFO+]G?WH
M'[Q;D$NX;\XMZ8?345KR-*&D6H15V=*$MY!SS!PC6MZ&*76T%?32,-86MWL+
MX,\*@ [NJX;TLM!IR851&7@1O$XEJU<444.BN-X7EKE@309QC-5^UKXMX[RH
M.:(][1 3]H3*9_I=E$V!U3L*JQ7%7X:"O<"Y!R,8%I31JC;S$7^*]K2#\'!$
M>]HAQND4;T_[GPI/T68Z55RL'$J*\MM$B84TRAJ?49DV8]Y^CO:T@Q!Q5'O:
M >;I"7*OO]^-PIWE964,_/ZV\@6N-VH2F44O3>7**G42;@*?DP0K R:KUDRF
MC<_>9\2;]H*@N^-W+$/V!,_[6^[I^FY[3Y/6"DEAF#THGC2$RI_J5>91T#JS
M:\(;=9"4G?C($6$RQ$V.8K.> /G[_,_KJ]5:8WSK^DDBP21WM>F)E*;(ZP='
MZ\ETYCB;D,#39JC$?IDZ =OX2-B'N1/-TBG"Q'8I/D5A9.$0;1VE:+P'%Z('
M;:,M);F8VI"Y/R-3)V?O) @[QBR=(DS>;):LF%*8*0_+M&.XHXPL:0FY>*-D
M4M&*)B_6S\@T;2'/M @[QBP](&Q/3WR(1F(MF Y%8V7@C>"R9*!81)6-B+'-
MG7Z7I!>=Y TCF*H#Q(W:5%*B%*IDA&*<!25J\5%&#[*$Y)Q"DT,3RJF?GQ3C
M(%2U),4XQ,0=P/OY7O<@ N?6F3J:C4X=03^A0 <F\)*9*0Y]$S+ITUD*7@9)
MQD%@.8BEX!#+=0##Y_J(O3("(_?@8ZY7!MJ"U\(#R]H:E74(MDTSQ(G=WR^#
M*.,4"(YEM0X .)A6(5E!>X@49%.=G21- "RI@+"9:2],2;%)Z\)_0YJ,4Z#9
MQ)X=X'18;[L*CK-B ZC $]11JI7*VE<J$!LH7[3<M)RR/@)+P<N@SC@%H>-;
ML@-X[NE\UX)[(WP$&>MS/$\4EW"G(*AB91 :M6CR?G("2\'+H,DX!8 CV*H#
MQ/T^_Y975U4G55OK7#"G8),O'(Q*K+8,&_#!>C!9:&^-89&;%FA[*LJTKJZ/
M>Z 3#=0=Q-Y0RO5YL9S]:VW'[::QCB>N$H)/GM71P:Y.U*S,<#$[9K0+JHF#
M^[%H4X_"/<WXSV+I9$MT@*W=5)>Y*"Z2*V!YB*!2$J0CB9"<1"E,](PWB=\Z
M)"4=V^2#J$8/T7\'('IVK$U4ED56A]G4"9T*98$0#,62JI"^HLS1-RD>.'G,
M5+,(K(]S<32C=07 '7-P='0VF,K@XFJO&J>H$BEF!1E<L#';'&*3$K\7.H;J
M(-,?,H;J$#MT@*EG1B )H5E@=?B(CJ08[@O01JSYCY&BQ%)"&_J0%SF&ZB"S
M#Q]#=8@-.D#3]K;EU[_B%YQ_?KP8I:PPG"? P&@QCG)>'[T"ZV5A)@7I;).,
M\5FI>NE.'AE3XUFB/UB]__->6(K":Z<ILY$<*[.3HZ5D'B!*5C +A_2W9P#5
M?9EZ&2#?%E)'6Z$'0(T0F[Z]I:Q0/)=0<VU,(E:N>@;.! $\.^M\Y$ZU(>4<
M=173<H3TD2Q,!XL.]L1FS;<JV-$:C3PQ;FJ3G\P*E$D>O+4:T#G/A+0A\"8X
M_Z%DG93)GQ\UNRH%1C-A#Y@<RC?&8A+%! LV,]*:KSS2B &8KV-<D[2&-R'H
M'I4@KAE"1\;%L:1PAQBI _#M9"+32H;"M(8D)8*RI4XN- 9"8-P5E8TO37S@
MT91PS5*7MJ Z6?D= .C3$A,Y^'L[(& R1C.$$FK5K$1)83(FX-P)5Z()+C49
M@_9$DFE3E+;0.4WM';"^O;_ZDI<;'5&@4,,$TND%&IEXHNS*4P@+*LM RE$)
MA"E*(_>LZ"87O#NEF?;)O2U^3E=_![[G[A9@LY(+EKP2)B5 2H- U7<VGUT=
M696*]5&@]HWYN#:"3/LHU18Y)RG]!%KFJ[8)X$4I,JED$ *)7<O<5:TW)NP[
M@V0#:XIL<L>V5Z)I+RL:A].CF*&#8^Q>%OR<KF2(G-.& "=\+0WV"(Z%""84
MGW,,WIDFW5K#Q.ND/WKRJX4&QNS@E'Q]O2+MK%9O%E_#;+XV:[TT)]61<>BG
MU8SLNV7YW*S_^T7*/MJ42(M2NNUD4D/K1.,D4SS27S=Y%CU"UFEO'5I 9G%>
M^W4 T;N8XIX^+[A PPNSD"63I+0B 8.EWQ9#*T =:5EMH[E[TDSK(\\ L]-M
M,'EP][R6*$.6%$H$"=8S#8I"B5KA'J%D02&LDQ3#EO,?PM/>4IP!6"-:9;2
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M"%PW<=:/H+D;-L_J;N)4&AP!6!^RL22?<?7KWU_KD/6WN*IS;GR010(/BIP
M50Q$XVL;"XO2<XJ8^0EBQRVJNN4*G]6%0W]:.,\VU?>_V;!3]:[7G*!9]8O<
MM>U7+3E9I#J^SV+ME2=3!$\;)] 6&I4P(7$\]W[5WBDD( !&41LJ)5H@O @@
M+S,YGW) TV2 Z;GTJ]X' 9WZ5>\A[Q'L<3M:IL3,LD2=0!>WGC00ZT&;J0FF
M,6<A1"Q-KM@/;$-TVF[4^VCWY39$^XAZ=&"Y5Z#J@DA.T]YK>:D5%=[4L1&2
M]F.N2^*I:&Q2['(V;8CV4G37-D3[2'WX<FZKUYT ?UEWJ-";2F2F7?08 L@Z
M)U))H\ G9X S;IQ%PY.++W@VSSQ^3# X5&_S?H4X- [D3Y;=L:!N6,":G\92
MK4C/=4B@H  AY0S,"^,B3UYN!U.[<;#[\6.JH.P#!ST(<6@<"'>/ R$W'*AH
M",PFT,Y*%E)QA>"SS^"8,"F:@D)UZ_*QZ^ECJGCLQ1H<+<*A02!_4O=9\#<L
M&.,E\@#)&&+!:@:.IT3[/\9@<N;"F6[&8-?CQU2IV(\Q.%J(0^- _<3NV[,;
M%@PO4:;:OBKK.DI(U4G2LN9!%<ZE1Q*/ZX*#W8\?4_%@'SCH08A#XT#(>^[-
M;=<B5'6FE"2/V0620U$. FUI("T+5A5GI'[I].OIIX^IA*^73>%H$0X- N+P
M'@<WVYJ5EDL6.(A486PIBG(NU2IL;:222!:M2Q_VW4\?4\%=+Z;@:!$.#0*N
M[G%PV\>.(IG$"XO )"%8>50411L&W&89778Y^TX;PLZGCZG,K0\0'"_"P4'P
MD[/ZUZO%_)Y[<]/:DC:XC(5[X**V,-.FMK:J0^8%8J#_664Z10K/O&-,=66]
M *(G<0X-"W$?V+<][1+C7AJE@*7,H68_T&970IUJDEE&<GYLMY.D74\?51U7
M+V["T3(<' 4/PQYQ$_:D*&34O(J@MAJS$:(6"!@94R4&10Y2MP/%78\?5<U4
M/R>*1TMQT++\Z^['#TY%;TQ:$5B#7 1>TZ-4R0C>QYIQ$JU0DB79+7K<^?11
M52CU 83C93BT09 _^7M0EC?QK^0V%$U13["Y@&+D];AD,O"0&/,^%9$[-8S=
M_?A1%0CU<YITM!2'!D)M?KS#IFD>H]%1@&9(GB_3M+G%HD 4DHG.,0G19=K%
M$X\?585./SO#T5(<?F<0#] LU,WV)IC)U<4QN1Z'D'<##E4$KJSA,4AIF.\&
MA5V/'U4)33]0.%J*(YEX4HMJ_Q\NYG=MK&[X>C12X\MTL?J^[EUP:P*3MH%+
M**5V,/#$;G#! MK@M"H&M>IR1=D#*:,JLND!8*?6SM ;%/N)C"?%X1EG\\OI
MK/95NS>\XV9Y&1-31%5;J_DZ$=A["$8&\,SG'#FR1PUDGYJ TN%MHZJ^Z<6?
M[5W&0Z.&_R2M?I(E>>.RZ^"=KQ,0I:I6F;9K\,X6\N M^BRUH?V[V\%8E]>-
MJOBFGT.RWJ4\-'#$3UNG?O(&_EH'I650P)2D->!\! KM ^0B# 9C=':=ABP]
M^891U;_TXPKU(<N!$7$]6JSNN+3S=MMP?YO7_?:O^<U!83T7MK& RX*D)KD!
MCUAK\3%$D:.@CQV <S0AHRIWZ0%?I]7,B)SR^F]7M^\C?L/9S40C&:PMD8&Q
MM0EM9 P"K3C(&I-@3@6QW5#S1:?\0%*Z0?%\CH9/K9V!P;AF<;WP*OU[,7P[
M=C'6^D;$!$YH>7U:&@M'^C*5%'1@IM.LNAY(Z0;&\SF>/K5VQ@+&M]/9UN+K
M, ?TUUJA>[,"E8G9(H,HZG&=+?094FQ<\WZ\]D(DWB5WJC>"N@'S?,[+A]'4
M6."YIG^?U5BE=,-O\$*K8" KK4"%DHE?+2"A<!YYS3GH<E';!RW=0'D^9_<G
MU\]8',GYU>+@]1>%<VP=PCOO00DD?I.2P(4+R")3OM-Q6Q^T=,/C^5P@G%P_
M(\'C,2.\67"E:*Y!2%$3LGP&+SB'@))V"6E2MFD/.#:?KWY^MPVGTL[0QW^R
MIOW=N[[C-T/B#?D5Q$=MP<W('T:2'R-N+,LL&.UBU)TN09]X?C?8G-&-0A]R
M'/Y&G/_$Q782Z TG)(L<N+0@8B87M,XW\RIRL"&&E&S*2G0Z#G[F'=U0<5;W
M!?W(<V K\6[U!1</>E1O+LA$/<1&!(.TX9(GF" Z'0 +SPJSIN"YRY'&$X_O
MAH;SN1[H0XJC:_/PYK:+4RPZ%\80T-4.O))[\%Z8VOPBQ.@95]MUF2VZ/-S2
M,Z:J[KZ[@QPF]-%AY]D!<EYS:]$Z,%$46ELDMZC(1D:%29"DG'!-^H_V/-_O
MY!,R]D+$X?/]]E'/Z$:SW1O8:A-FRRW!0-6$]J@L^(")/D2M2U;)8&@!LR/F
MY)Y\LL4QD.I![.?9F._G<!%F"3]^022AEOGB<OW"ACWZ7GCC"=KU[</SD9W[
MULUP#Z3GMKM;-(6<*ZEJH,YKNC(!$)T'1GZY]T%ZWBG3]U@Z^NU$NM6"=>(3
MN1<N"5!6YKIZ.<49@9CTV6:EC='L!.W?MZ@:9N\\.6B>[U9ZC*9&L:<^T<GW
M]<;(9Q31UZDP(5*,I- 4"");D)9<!Q52Y*= WC99P^RQ(X/>4;H:02#Q!#?W
M/(SBF37::XC(ZV(2&H(*D;C24H>2G=NN[&H*OCU]O-[ON,>*OP,U-EX(3KQ%
M'HD7\+Q61:IB@0C/@,@H*D(O<FH241S39+[WV^NQPFTO[1P.LODJ7#0 68<Y
M6,'FX"4!)-B2R)%0=?B,0!#!9&.X%<*<8&Q+3S/+>K_$'ADL>];G"'W"+0YK
MA^TZF*0>*6T.DR9<66>=4Y""( Z+"."\$>!3,B9(8Q6>'K$["!VF%]BX$7NL
M/D>WC6^%9.MCSWH8]J[\-IV1C*?AXOU\.:W2_;4>8"RG52?3Y6J",KBB> &L
MG7%4Q  A)>(]L%RT]:2 $VS[!],_3).SD:'[--H?'>BW@\$]^#;"!,TD!^YD
MK72KK62-<Z!20A=M=EZ=TMG=FX%AVKJ-#/8GTO]X<7\7A.[!>@K&R>(YI&+K
MK8ATX&V.()1T6%1@,H@30O\0'H;I83=6]#='P7E>9&WFT7__F+Y@OKK AC=8
M3[WJ!%=7G;CL:=K4]1MOH5PLZAPHL//)U\;L-7>9G.CJ-1.RK(FNS92IAV2T
MF&A]N[1NIIO^<H5O28B?_L*+;_C'?+;ZLIP@8R&AH77#DZ4(-WF(J799,/1]
MKS*6U(C]PP@>-NWC".QTF7S=N\9&L.EWY?._,"P^_36?,!T9#UI =M%3 &LI
M=N52@PPHB$/%=6@RNG%/.H?-%1D AX?HY]S@5ZL.)C$Q[Y13@+6D2EFA( :7
M@6E!GZ-4>KO8:   5DJ'G9DR% 3WUM&9@; 68DUH,:G@"H5S,9%?JP/)-?A$
M<C4Z<6&SM8-CL!(Z[+R6@2"XMX;.#8'3;SAQ)#EET(#62,(T]3I8% 2NN$>=
M/-G]-#@"B=!A)\4,A<!]-71&"'Q5Z)VW3&I.S/DB(2C&0&' 6L<G:R\O)85+
M0N0V"<*'4#OLO)H!L'BXKLX(D)-H,J+2&ECVMLYF*N""-9"##"&45(1M4EK3
ME<!A)^0, +N]-#*"-))G^?ISEC?7N)A__3O1K[ZZK%]-8F%)!">!65$+W;*!
MD*6 8 QJ;X3QH9P<=D]1.^R GE-AL!==C<#T/96>)8J(S#D'DM66JR:3+0]1
M@DF1""6++DH3I^^8Y+EF%:@]@JH/>?>87C2&"XS)5C)ITRN,"1_P$F.;T]MK
MC/]SD,!?SV<523A+4ZP=,'Z=?9LNYK.Z-])VM8$6_>@ \79^]/'"/(R+GFZ
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MU>:>P(T^3/JCP]'W]SC+].GKBS"]7+Z]NCY^D$0S)@3:.6M&%,G(ZSJY3NO
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M.@)+]$P4)9+(A1D.EJ.NU^\):ND4. Q*:LM9.L45TMY7DJ<N*SIF=^M)^F/
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M?D$K;WG]Y+=SBBUV=(*W)6 H6A,XC25[:C/XD@P49-G&+*1.MHF#WI7"@>/
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M(+C #=B J*1!Q]I,3VW"S5D'LX-L(KUA8PP+Y*4@YTX<RZ?D<9W?'!GRY*6
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MA[FNZ8_'3JO'_H"K9ZPX.H<E=HQDUC^L#=]_"]-%S>G'"<,48F "Y+JR6:E
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M5ZL?*5QW;YB(F$6214 VTH$R3D,0JD#AWFL18I1M9I#VSLF99A7W",]V*^8
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MOV.];3HZT?Z:+6.UOB\5<OR, &>Y!]3<Y:0L"M-NK,DI.#S3578"F)]^11Z
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MI4G =@"M8W*W>D)@:XV- )2WJ9$_?[_]]#^FN""BOGQ_@]_P8KTW&.=X#D6
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M34I9GUUQ]BG'X?BNZA)_/[X5?[5X&:[2]17Y=_&^OKENZP#G:?<#ZK/KUYO
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M'O6F:0$Z>T[8(5:.7D&?<1678U5>#%'Q=?AX&R!;YF*JW;4ZJ5C?R6CSD<8
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M:IATT6D)NH1Z *TC!\-:D,%Q%R.=(M,&70^I&,DX]=.E^WRAP!&L'GIRXL=
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M15+,='D^V5FTF[ O)-YV/+N&OK?#8C;%;:U:3&1TBJ*!K<:D2J'!98F0U*I
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M;FYU86QR<W5T97)M<RYH=&U02P$"% ,4    " !6A%E2CNB38X@<   DE0
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M87@Q-&$Q-61X,31A8V4N:'1M4$L! A0#%     @ 5H194ED0Y4G,!P  'R
M !X              ( !KX$  &5X,S$R+7)U;&4Q,V%X,31A,35D>#$T86-E
M+FAT;5!+ 0(4 Q0    ( %:$65)4NF>H400  *H/   >              "
M ;>)  !E>#,R,2US96-T:6]N,3,U,&-E<G1I9FEC82YH=&U02P$"% ,4
M" !6A%E2/Y^4)7 $  #1#@  '@              @ %$C@  97@S,C(M<V5C
M=&EO;C$S-3!C97)T:69I8V$N:'1M4$L! A0#%     @ 5H194E2F@/,&$
MGT\  !X              ( !\)(  &5X:&EB:70T,3 M;65R8VMD97-C<FEP
M=&EO+FAT;5!+ 0(4 Q0    ( %:$65+V@%J9!$@  !6V 0 >
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M+3(P,C Q,C,Q+GAS9%!+ 0(4 Q0    ( %:$65)3KIP(X$$  +K@ @ 4
M          "  ;9>"0!M<FLM,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M %:$65*17*&!TQ<! +=B#  4              "  <B@"0!M<FLM,C R,#$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( %:$65+V2=*> M$  /,R 0 3
M      "  <VX"@!M<FLM,C R,#$R,S%?9S$N:G!G4$L! A0#%     @ 5H19
M4G>BE@L-1P  -&,  !,              ( ! (H+ &UR:RTR,#(P,3(S,5]G
M,BYJ<&=02P$"% ,4    " !6A%E2G+7C\J48  !I&P  $P
M@ $^T0L ;7)K+3(P,C Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( %:$65*';.01
M\$H  /UZ   3              "  13J"P!M<FLM,C R,#$R,S%?9S0N:G!G
M4$L! A0#%     @ 5H194J](%78>'0( T/\5 !0              ( !-34,
M &UR:RTR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @ 5X194A,A")"&80$
MOWX0 !0              ( !A5(. &UR:RTR,#(P,3(S,5]P<F4N>&UL4$L%
3!@     7 !< 7P8  #VT#P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
